[
    {
        "id": "5bc844fc-e852-4270-bfaf-36ea9eface3d",
        "primaryId": "NCT01928186",
        "secondaryId": "NCT00684983",
        "label": "Contradiction",
        "statement_text": "All the primary trial participants do not receive any oral capecitabine  oral lapatinib ditosylate or cixutumumab IV  in conrast all the secondary trial subjects receive these ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Diagnostic (FLT PET) Patients with early stage  ER positive primary breast cancer undergo FLT PET scan at baseline and 1-6 weeks after the start of standard endocrine treatment  The surgery follows 1-7 days after the second FLT PET scan  Tracer used in the FLT PET (positron emission tomography) scanning procedure: [F18] fluorothymidine  Positron Emission Tomography: Undergo FLT PET Laboratory Biomarker Analysis: Correlative studies - Ki67 staining of the tumor tissue in the biopsy and surgical specimen  INTERVENTION 1: Arm A ",
        "premise_nums": [
            "67 staining of",
            "1-6 weeks",
            "1-7 days",
            "6 weeks after",
            "Ki67 staining",
            "[F18] fluorothymidine",
            "7 days after"
        ]
    },
    {
        "id": "5bc844fc-e852-4270-bfaf-36ea9eface3d",
        "primaryId": "NCT01928186",
        "secondaryId": "NCT00684983",
        "label": "Contradiction",
        "statement_text": "All the primary trial participants do not receive any oral capecitabine  oral lapatinib ditosylate or cixutumumab IV  in conrast all the secondary trial subjects receive these ",
        "statement_nums": [],
        "premise_text": "Patients receive oral capecitabine twice daily on days 1-14 and oral lapatinib ditosylate once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity  lapatinib ditosylate: Given PO and capecitabine: Given POINTERVENTION 2: Arm B ",
        "premise_nums": [
            "1-14 and",
            "14 and oral",
            "1-21. Courses",
            "21 days in"
        ]
    },
    {
        "id": "5bc844fc-e852-4270-bfaf-36ea9eface3d",
        "primaryId": "NCT01928186",
        "secondaryId": "NCT00684983",
        "label": "Contradiction",
        "statement_text": "All the primary trial participants do not receive any oral capecitabine  oral lapatinib ditosylate or cixutumumab IV  in conrast all the secondary trial subjects receive these ",
        "statement_nums": [],
        "premise_text": "Patients receive capecitabine and lapatinib ditosylate as in arm I  Patients also receive cixutumumab IV over 1-1½ hours on days 1, 8, and 15. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity  cixutumumab: Given IV  lapatinib ditosylate: Given PO and capecitabine: Given PO",
        "premise_nums": [
            "1-1½ hours",
            "21 days in"
        ]
    },
    {
        "id": "86b7cb3d-6186-4a04-9aa6-b174ab764eed",
        "primaryId": "NCT00662129",
        "statement_text": "Patients with Platelet count over 100,000/mm¬¨‚â•, ANC smaller than 1,700/mm¬¨‚â• and Hemoglobin between 4 to 5 grams per deciliter are eligible for the primary trial ",
        "statement_nums": [
            "100,000/mm¬¨‚â•, ANC",
            "1,700/mm¬¨‚â• and",
            "4 to 5"
        ],
        "label": "Contradiction",
        "premise_text": "PATIENT CHARACTERISTICS: ANC 1,500/mm³ Platelet count 100,000/mm³ Hemoglobin 9.0 g/dL ",
        "premise_nums": [
            "100,000/mm³ Hemoglobin",
            "Hemoglobin 9.0 g/dL",
            "1,500/mm³ Platelet"
        ]
    },
    {
        "id": "dbed5471-c2fc-45b5-b26f-430c9fa37a37",
        "primaryId": "NCT00093145",
        "secondaryId": "NCT00703326",
        "label": "Entailment",
        "statement_text": "Heart-related adverse events were recorded in both the primary trial and the secondary trial ",
        "statement_nums": [],
        "premise_text": "Adverse Events 1: Supraventricular tachycardia 1/32 (3.13%) Adverse Events 1: Atrial fibrillation 1/752 (0.13%) Atrial flutter 0/752 (0.00%) Cardiac failure congestive 1/752 (0.13%) Left ventricular dysfunction 0/752 (0.00%) ",
        "premise_nums": [
            "1/32 (3.13%)",
            "1/752 (0.13%)",
            "0/752 (0.00%)"
        ]
    },
    {
        "id": "20c35c89-8d23-4be3-b603-ac0ee0f3b4de",
        "primaryId": "NCT01097642",
        "statement_text": "Adult Patients with histologic confirmation of invasive bilateral breast carcinoma (T1 N1 M1) are eligible for the primary trial ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria: Patients with histologic confirmation of invasive breast carcinoma  Patients greater than or equal to 18 years  Patients should have T1N1-3M0 or T2-4 N0-3M0. Patients with bilateral breast cancer are eligible  ",
        "premise_nums": [
            "1-3M0 or",
            "2-4 N0-3M0"
        ]
    },
    {
        "id": "f17cb242-419d-4f5d-bfa4-41494ed5ac0e",
        "primaryId": "NCT00852930",
        "secondaryId": "NCT02308020",
        "label": "Contradiction",
        "statement_text": "Laser Therapy is in each cohort of the primary trial and the secondary trial  along with neoadjuvant chemotherapy ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Laser Therapy Alone therapist administered laser treatment laser: therapist administered laser INTERVENTION 2: Mld Alone therapist administered manual lymphatic drainage manual lymphatic drainage: therapist administered massage therapy INTERVENTION 1: Part A Abemaciclib: HR+  HER2+ Breast Cancer Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle when administered as a single agent or in combination with endocrine therapy (ET)  Participants with hormone receptor positive HR+  HER2+ breast cancer receiving concurrent trastuzumab  150 mg abemaciclib was given orally once every 12 hours on days 1-21 of a 21-day cycle  Participants may continue to receive treatment until discontinuation criteria are met  INTERVENTION 2: ",
        "premise_nums": [
            "1-21 of",
            "12 hours on",
            "21 of a",
            "150 mg abemaciclib",
            "200 mg was",
            "21-day cycle"
        ]
    },
    {
        "id": "f17cb242-419d-4f5d-bfa4-41494ed5ac0e",
        "primaryId": "NCT00852930",
        "secondaryId": "NCT02308020",
        "label": "Contradiction",
        "statement_text": "Laser Therapy is in each cohort of the primary trial and the secondary trial  along with neoadjuvant chemotherapy ",
        "statement_nums": [],
        "premise_text": "Part B Abemaciclib: HR+  HER2- Breast CancerAbemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle when administered as a single agent or for in combination with endocrine therapy (ET)  Participants may continue to receive treatment until discontinuation criteria are met  ",
        "premise_nums": [
            "1-21 of",
            "12 hours on",
            "21 of a",
            "200 mg was",
            "21-day cycle"
        ]
    },
    {
        "id": "fc5c4554-7ce9-4c16-b374-a3cd9d15b021",
        "primaryId": "NCT00971945",
        "secondaryId": "NCT01027416",
        "label": "Contradiction",
        "statement_text": "Patients must have already participated in a specific clinical study to participate in the primary trial or the secondary trial ",
        "statement_nums": [],
        "premise_text": "Inclusion Criteria: Subjects who were confirmed to have a response after receiving at least two courses of weekly paclitaxel therapy and considered to need to continue the therapy by the investigator/subinvestigator among the patients with advanced or recurrent breast cancer who had met the selection criteria and participated in the preceding phase II clinical study Inclusion Criteria: The patient must consent to be in the study and must have signed an approved consent form conforming to institutional guidelines The patient must be 18 years or older  Core biopsy should definitively demonstrate invasive carcinoma  Invasive carcinoma should be ER-apha receptor positive ",
        "premise_nums": [
            "18 years or"
        ]
    },
    {
        "id": "fc5c4554-7ce9-4c16-b374-a3cd9d15b021",
        "primaryId": "NCT00971945",
        "secondaryId": "NCT01027416",
        "label": "Contradiction",
        "statement_text": "Patients must have already participated in a specific clinical study to participate in the primary trial or the secondary trial ",
        "statement_nums": [],
        "premise_text": "The tumor should be approximately at least 1 cm  to account for variability in imaging and imaging occult disease (physical exam  mammography  ultrasound)  We recognize that from time to time because of this variation  there might not be enough tissue available for analysis after surgical excision but this will allow the greatest opportunity to capture as many eligible patients as possible Patients in whom surgical excision of the tumor is part of standard of care management ECOG score of 0 or 1 Negative serum or urine beta-hCG pregnancy test at screening for patients of child-bearing potential (this is routinely done if the patient is premenopausal and having surgery) Consent to participate in DBBR (RPCI only) Exclusion Criteria: Male patients are not eligible for this study ",
        "premise_nums": [
            "0 or 1"
        ]
    },
    {
        "id": "fc5c4554-7ce9-4c16-b374-a3cd9d15b021",
        "primaryId": "NCT00971945",
        "secondaryId": "NCT01027416",
        "label": "Contradiction",
        "statement_text": "Patients must have already participated in a specific clinical study to participate in the primary trial or the secondary trial ",
        "statement_nums": [],
        "premise_text": "Female patients with inoperable tumors or women with stage 4 disease diagnosed on CT  PET  PET/CT or bone scan Patients with diagnosis by FNA cytology only Pregnant or lactating women Prior therapy for breast cancer  including irradiation  chemo- immuno- and/or hormonal therapy Patients receiving any hormonal therapy  e.g  ovarian hormonal replacement therapy  infertility medications etc.  are not eligible Nonmalignant systemic disease (cardiovascular  renal  hepatic  etc.) that would preclude the patient from being subjected to surgical excision Psychiatric or addictive disorders that would preclude obtaining informed consent Patients known or suspected to have hypercoagulable syndrome or with history of venous or arterial thrombosis  stroke  TIA  or pulmonary embolism ",
        "premise_nums": [
            "4 disease diagnosed"
        ]
    },
    {
        "id": "fc5c4554-7ce9-4c16-b374-a3cd9d15b021",
        "primaryId": "NCT00971945",
        "secondaryId": "NCT01027416",
        "label": "Contradiction",
        "statement_text": "Patients must have already participated in a specific clinical study to participate in the primary trial or the secondary trial ",
        "statement_nums": [],
        "premise_text": "Women with non-invasive disease or microinvasion are not eligible Women undergoing neoadjuvant chemotherapy are not eligible women currently on tamoxifen and raloxifene for prevention are not eligible Patients shall not receive any herbal/alternative therapies such as flaxseed or soy products or black cohosh  Patients with a known mutation in p53 (Li Fraumeni Syndrome) ",
        "premise_nums": []
    },
    {
        "id": "96b77cdd-aa9f-4770-8447-8a04d9ca5da7",
        "primaryId": "NCT00633750",
        "statement_text": "Patients with Clinical stage II (T2 N1) invasive mammary carcinoma are not eligible for the primary trial ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria: Clinical stage I or II (T1 or T2, N0 or N1) invasive mammary carcinoma Exclusion Criteria: Fixed axillary lymph node metastases (N2) ",
        "premise_nums": [
            "1 or T2,",
            "0 or N1)"
        ]
    },
    {
        "id": "c73faed2-371b-4238-bf7d-293fae380203",
        "primaryId": "NCT00003404",
        "secondaryId": "NCT00711529",
        "label": "Contradiction",
        "statement_text": "the primary trial and the secondary trial have Hypnotherapy based interventions  the secondary trial also used pain medication in its intervention ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Adjuvant Radiotherapy Adjuvant radiation was started within 12 weeks of local excision or breast re-excision  Adjuvant Radiotherapy: Adjuvant radiation therapy INTERVENTION 1: Hypnotherapy Patients randomized to the hypnosis arm of the study will undergo individually three one-hour sessions with a certified hypnotherapist  These sessions will be one week apart  Patients will also be instructed on the use of self-hypnosis techniques to use at home  INTERVENTION 2: Gabapentin Patients randomized to the gabapentin arm will be prescribed 900mg of the drug daily (300 mg by mouth three times daily)  ",
        "premise_nums": [
            "12 weeks of",
            "300 mg by"
        ]
    },
    {
        "id": "8765009d-ffc4-4395-ab7a-11ecdfd43a40",
        "primaryId": "NCT00201773",
        "statement_text": "Adele is an 85 year old woman with Stage II histologically confirmed ER+ breast cancer with an ECOG of 0, she is eligible for the primary trial",
        "statement_nums": [
            "85 year old"
        ],
        "label": "Entailment",
        "premise_text": "Inclusion Criteria: Must be female with histologically confirmed breast cancer Stage II-IV disease ER and/or PR positive ECOG Performance Status 0-1 Postmenopausal ",
        "premise_nums": [
            "0-1 Postmenopausal"
        ]
    },
    {
        "id": "0ad7293d-df35-42e8-881d-f2afc3f7d3fd",
        "primaryId": "NCT02606708",
        "secondaryId": "NCT02504424",
        "label": "Contradiction",
        "statement_text": "Only patients in the primary trial receive 40.5 Gy of brachytherapy  patients in the secondary trial receive no radiotherapy whatsoever ",
        "statement_nums": [
            "receive 40.5 Gy of"
        ],
        "premise_text": "INTERVENTION 1: Accelerated Intensity Modulated Radiation Therapy (AIMRT) All patients shall receive a total of 40.5 Gy to the entire breast in 2.7 Gy/fraction x 15 fractions  Monday to Friday for 3 weeks delivered prone in uniform daily doses through IMRT tangent fields  A concurrent boost to the original tumor bed of 0.50 Gy will be delivered  Accelerated intensity modulated radiation therapy (AIMRT) INTERVENTION 1: AeroForm Tissue Expander AeroForm Tissue Expansion inflation with carbon dioxide by remote control AeroForm Tissue Expander: The AeroForm Tissue Expander is a breast tissue expander implanted following mastectomy and activated by remote control to release small doses of carbon dioxide from an internal reservoir to fill and inflate the expander  ",
        "premise_nums": [
            "of 40.5 Gy to",
            "3 weeks delivered",
            "in 2.7 Gy/fraction",
            "of 0.50 Gy will"
        ]
    },
    {
        "id": "2bc1e094-41a1-46d9-9b0c-b5a47f23323d",
        "primaryId": "NCT00895414",
        "statement_text": "Certain drinks are banned for patients undertaking the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Inclusion Criteria: Agrees not to consume grapefruit juice while on the study ",
        "premise_nums": []
    },
    {
        "id": "83b83400-1439-462d-bba3-42817b5b1fa1",
        "primaryId": "NCT00777049",
        "statement_text": "Most of the cases of CHF in the primary trial  were in cohort 1.",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Cardiac failure congestive 1/32 (3.13%) Adverse Events 2: Cardiac failure congestive 0/20 (0.00%) ",
        "premise_nums": [
            "1/32 (3.13%)",
            "0/20 (0.00%)"
        ]
    },
    {
        "id": "c3257f7b-f5b4-4a9c-8a8f-b037f27caa8f",
        "primaryId": "NCT00058058",
        "statement_text": "Candidates for the primary trial must have a life expectancy over 6 months ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Life expectancy Not specified ",
        "premise_nums": []
    },
    {
        "id": "17a821f8-5e68-4bf7-ac01-3f96ddfc5187",
        "primaryId": "NCT02964234",
        "statement_text": "Patients eligible for the primary trial must live in the USA ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Inclusion Criteria: Age 52-75 years old; Identification as Latina/Hispanic/Chicana female; Residence in Pilsen  Little Village  East Side or South Chicago; ",
        "premise_nums": [
            "52-75 years",
            "75 years old;"
        ]
    },
    {
        "id": "d76d6c7f-ba39-483c-a89e-152af5ae2878",
        "primaryId": "NCT02525718",
        "secondaryId": "NCT02606708",
        "label": "Entailment",
        "statement_text": "Patients in group 1 of the secondary trial and the primary trial do not receive the same dosage of AIMRT ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "INTERVENTION 1: Placebo Subjects will be randomly selected to receive saline (placebo)  administered to the breast area to cover the intercostal nerves supplying the breast tissue during surgery  Saline: If randomized to this arm  subjects will receive an intraoperative injection of saline  (2.5 mg/ml) INTERVENTION 1: Accelerated Intensity Modulated Radiation Therapy (AIMRT) All patients shall receive a total of 40.5 Gy to the entire breast in 2.7 Gy/fraction x 15 fractions  Monday to Friday for 3 weeks delivered prone in uniform daily doses through IMRT tangent fields  A concurrent boost to the original tumor bed of 0.50 Gy will be delivered  Accelerated intensity modulated radiation therapy (AIMRT) ",
        "premise_nums": [
            "of 40.5 Gy to",
            "3 weeks delivered",
            "in 2.7 Gy/fraction",
            "of 0.50 Gy will",
            "(2.5 mg/ml"
        ]
    },
    {
        "id": "65f3e755-3e23-4e84-a218-87922759094d",
        "primaryId": "NCT01669343",
        "secondaryId": "NCT00146172",
        "label": "Contradiction",
        "statement_text": "the primary trial administers letrozole for 28 days  whereas the secondary trial administers is intervention over 4 cycles of 21 days ",
        "statement_nums": [
            "4 cycles of"
        ],
        "premise_text": "INTERVENTION 1: Post-menopausal Women Using Adjuvant Letrozole Part A Routine Care Letrozole; Part B Double Dose Letrozole in overweight/obese participants Letrozole: Part A Monitor standard of care letrozole use for 28 days; measure blood levels of estrogens and vitamin D at start and end of period  Part B In overweight/obese participants who completed Part A  provide a double dose of letrozole and monitor use for 28 days; measure blood levels of estrogens and vitamin D at start and end of period  INTERVENTION 1: Neratinib 40 mg Neratinb 40 mg qd INTERVENTION 2: Neratinib 80 mg Neratinib 80 mg qd ",
        "premise_nums": [
            "80 mg Neratinib",
            "80 mg qd",
            "40 mg Neratinb",
            "40 mg qd"
        ]
    },
    {
        "id": "d3590771-806b-4754-a455-38113bfedfca",
        "primaryId": "NCT00952692",
        "statement_text": "Candidates for the primary trial must have adequate colon and liver function  and must not be currently receiving amiodarone or have received amiodarone in the last 28 day  Renal function is not relevant for inclusion ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria: The following criteria are to be checked at the time of study entry  The patients may only be included in the study if ALL of the following statements are FULLFILLED: The patient (male or female) is at least 18 years old at the time of signature of the informed consent form  Written informed consent has been obtained from the patient prior to the performance of any protocol-specific procedure  The patient is diagnosed with confirmed invasive breast cancer with stage IV disease  Note: If the metastatic disease is restricted to a solitary lesion  its neoplastic nature should be confirmed by cytology or histology  ",
        "premise_nums": [
            "18 years old"
        ]
    },
    {
        "id": "d3590771-806b-4754-a455-38113bfedfca",
        "primaryId": "NCT00952692",
        "statement_text": "Candidates for the primary trial must have adequate colon and liver function  and must not be currently receiving amiodarone or have received amiodarone in the last 28 day  Renal function is not relevant for inclusion ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "The patient has documented disease progression or relapse following at least one prior standard therapy with trastuzumab (alone or in combination with chemotherapy) Patients with prior lapatinib use are eligible  Furthermore  The administration of the chemotherapeutic agent(s) should have been stopped for at least 28 days by the time of the first ASCI administration  The administration of trastuzumab alone could be maintained after chemotherapy  but the last dose of trastuzumab should not have been given less than three weeks before the first ASCI administration  The patient will not be given trastuzumab during the trial  ",
        "premise_nums": [
            "28 days by"
        ]
    },
    {
        "id": "d3590771-806b-4754-a455-38113bfedfca",
        "primaryId": "NCT00952692",
        "statement_text": "Candidates for the primary trial must have adequate colon and liver function  and must not be currently receiving amiodarone or have received amiodarone in the last 28 day  Renal function is not relevant for inclusion ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "For metastatic patients whose disease is ER+ and/or PR+ the following criteria should be met:Patients with visceral disease that requires chemotherapy (eg.  patients with liver or lung metastases)  Rapidly progressing or life threatening disease  as determined by the investigator  Patients who received hormonal therapy and are no longer benefiting from this therapy  A tumor lesion from the patient biopsied before or during screening shows either: Overexpression of the HER2 protein  as determined by immunohistochemistry (IHC  with result IHC 3+) or Amplification of the HER2 gene as determined by FISH (at least 4 fold i.e  at least 8 copies)  ",
        "premise_nums": [
            "4 fold i.e",
            "2 gene as",
            "3+) or"
        ]
    },
    {
        "id": "d3590771-806b-4754-a455-38113bfedfca",
        "primaryId": "NCT00952692",
        "statement_text": "Candidates for the primary trial must have adequate colon and liver function  and must not be currently receiving amiodarone or have received amiodarone in the last 28 day  Renal function is not relevant for inclusion ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Note: Overexpression/amplification measurements must be performed on a metastatic lesion in all cases where such a lesion is sufficiently easily accessible  If however such a biopsy is not possible  then these measurements can be performed on the primary tumor  Use of the primary tumor is to be documented and justified Ten FFPE tissue sections of the tumor on which the HER2 overexpression/amplification has been done -if available-may be requested  These may be used to retrospectively carry out part of the translational research (i.e  analysis of EGF receptor activity and of the presence of immune effector cells  refer to Section 7). The patient has at least one measurable lesion according to RECIST criteria  ",
        "premise_nums": []
    },
    {
        "id": "d3590771-806b-4754-a455-38113bfedfca",
        "primaryId": "NCT00952692",
        "statement_text": "Candidates for the primary trial must have adequate colon and liver function  and must not be currently receiving amiodarone or have received amiodarone in the last 28 day  Renal function is not relevant for inclusion ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "The patient has ECOG status of 0 or 1.The patient has adequate bone marrow reserve as indicated by: White blood cell count greater than /= 3,000/mm3. Neutrophil count greater than /= 1,500/mm3. Platelet count greater than /= 100,000/mm3. Hemoglobin levels greater than /= 10.0 g/dl  The patient has adequate renal function as shown by the creatinine levels (i.e  within the normal range)  The patient has adequate hepatic function as shown by serum bilirubin levels i.e: Serum bilirubin levels within the normal limits  ",
        "premise_nums": [
            "100,000/mm3. Hemoglobin",
            "1,500/mm3. Platelet",
            "10.0 g/dl",
            "3,000/mm3. Neutrophil",
            "0 or 1.The"
        ]
    },
    {
        "id": "d3590771-806b-4754-a455-38113bfedfca",
        "primaryId": "NCT00952692",
        "statement_text": "Candidates for the primary trial must have adequate colon and liver function  and must not be currently receiving amiodarone or have received amiodarone in the last 28 day  Renal function is not relevant for inclusion ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Both AST and ALT levels smaller than 1.5 times the ULN  Note: However  for patients with liver metastasis  a serum bilirubin level smaller than 1.5 times the ULN and both AST and ALT levels smaller than 3 times the ULN will be accepted The patient has a baseline Left Ventricular Ejection Fraction (LVEF) measured by MUGA scan equal to or greater than the LLN for the radiology facility  ",
        "premise_nums": [
            "3 times the",
            "than 1.5 times the"
        ]
    },
    {
        "id": "d3590771-806b-4754-a455-38113bfedfca",
        "primaryId": "NCT00952692",
        "statement_text": "Candidates for the primary trial must have adequate colon and liver function  and must not be currently receiving amiodarone or have received amiodarone in the last 28 day  Renal function is not relevant for inclusion ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "If the patient is female  she must be of non-childbearing potential  i.e  have a current tubal ligation  hysterectomy  ovariectomy or be post-menopausal  or if she is of childbearing potential  she must practice adequate contraception for 30 days prior to treatment  have a negative pregnancy test and continue such precautions for two months after completion of the study treatment ",
        "premise_nums": [
            "30 days prior"
        ]
    },
    {
        "id": "d3590771-806b-4754-a455-38113bfedfca",
        "primaryId": "NCT00952692",
        "statement_text": "Candidates for the primary trial must have adequate colon and liver function  and must not be currently receiving amiodarone or have received amiodarone in the last 28 day  Renal function is not relevant for inclusion ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Adequate contraception is defined as a contraceptive method with failure rate of less than 1% per year when used consistently and correctly (when applicable  as mentioned in the product label) for example abstinence  combined or progestogen oral contraceptives  injectable progestogen  implants of levonorgestrel  oestrogenic vaginal ring  percutaneous contraceptive patches or intrauterine device (IUD) or intrauterine system (IUS)  vasectomy with documented azoospermia of the sole male partner or double barrier method (condom or occlusive cap plus spermicidal agent) ",
        "premise_nums": [
            "1% per"
        ]
    },
    {
        "id": "d3590771-806b-4754-a455-38113bfedfca",
        "primaryId": "NCT00952692",
        "statement_text": "Candidates for the primary trial must have adequate colon and liver function  and must not be currently receiving amiodarone or have received amiodarone in the last 28 day  Renal function is not relevant for inclusion ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "For azoospermia  \"documented\" refers to the outcome of the investigator's/ designee's medical examination of the subject or review of the subject's medical history for study eligibility  as obtained via a verbal interview with the subject or from the subject's medical records Post-menopause: Menopause is the age associated with complete cessation of menstrual cycles  menses  and implies the loss of reproductive potential by ovarian failure  A practical definition accepts menopause after 1 year without menses with an appropriate clinical profile at the appropriate age e.g  greater than 45 years  Able to swallow and retain oral medication  In the view of the investigator  the patient can and will comply with the requirements of the protocol  ",
        "premise_nums": [
            "1 year without"
        ]
    },
    {
        "id": "d3590771-806b-4754-a455-38113bfedfca",
        "primaryId": "NCT00952692",
        "statement_text": "Candidates for the primary trial must have adequate colon and liver function  and must not be currently receiving amiodarone or have received amiodarone in the last 28 day  Renal function is not relevant for inclusion ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Exclusion Criteria:The following criteria should be checked at the time of study entry  If any apply  the patient must not be included in the study: The patient has received greater than 300 mg/m2 doxorubicin (cumulative dose) or greater than 600 mg/m2 epirubicin (cumulative dose)  The patient is receiving treatment with bisphosphonate UNLESS the biphosphonate treatment was initiated more than three weeks before the first ASCI administration  (See also section 5.3.2.). The patient has received any investigational or non-registered product (drug or vaccine) other than the study treatment(s) within 30 days preceding the first dose of study treatment  or planned use during the study period  ",
        "premise_nums": [
            "600 mg/m2 epirubicin",
            "2 doxorubicin (cumulative",
            "2 epirubicin (cumulative",
            "30 days preceding",
            "300 mg/m2 doxorubicin"
        ]
    },
    {
        "id": "d3590771-806b-4754-a455-38113bfedfca",
        "primaryId": "NCT00952692",
        "statement_text": "Candidates for the primary trial must have adequate colon and liver function  and must not be currently receiving amiodarone or have received amiodarone in the last 28 day  Renal function is not relevant for inclusion ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "The patient is currently receiving amiodarone or has received amiodarone in the 6 months prior to screening The patient requires concomitant treatment with systemic corticosteroids or any immunosuppressive agents  The use of prednisone  or equivalent  smaller than 0.5 mg/kg/day (absolute maximum 40 mg/day)  or inhaled corticosteroids or topical steroids is permitted  The patient has a malabsorption syndrome  disease significantly affecting gastrointestinal function  or resection of the stomach or small bowel  Patients with ulcerative colitis  ",
        "premise_nums": [
            "6 months prior",
            "40 mg/day)",
            "than 0.5 mg/kg"
        ]
    },
    {
        "id": "d3590771-806b-4754-a455-38113bfedfca",
        "primaryId": "NCT00952692",
        "statement_text": "Candidates for the primary trial must have adequate colon and liver function  and must not be currently receiving amiodarone or have received amiodarone in the last 28 day  Renal function is not relevant for inclusion ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "The patient has known coronary artery disease  arrhythmia requiring treatment  clinically significant valvular disease  cardiomegaly on chest X-ray  ventricular hypertrophy (found by ECG) or previous myocardial infarction The patient has any acute or chronic  clinically significant pulmonary  cardiovascular  hepatic or renal functional abnormality  as determined by physical examination or laboratory screening tests  The patient has current active hepatic or biliary's disease (with exception of patients with Gilbert's syndrome  asymptomatic gallstones  liver metastases or stable chronic liver disease per investigator assessment)  ",
        "premise_nums": []
    },
    {
        "id": "d3590771-806b-4754-a455-38113bfedfca",
        "primaryId": "NCT00952692",
        "statement_text": "Candidates for the primary trial must have adequate colon and liver function  and must not be currently receiving amiodarone or have received amiodarone in the last 28 day  Renal function is not relevant for inclusion ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "The patient presents with autoimmune disease (vitiligo and autoimmune thyroid disease is not an exclusion criterion) The patient has a known family history of congenital or hereditary immunodeficiency  The patient has any uncontrolled bleeding disorder or coagulation disorder or thrombocytopenia or pro-thrombotic disorder  The patient has a history of anaphylaxis or severe allergic reaction to vaccines or unknown allergens  ",
        "premise_nums": []
    },
    {
        "id": "d3590771-806b-4754-a455-38113bfedfca",
        "primaryId": "NCT00952692",
        "statement_text": "Candidates for the primary trial must have adequate colon and liver function  and must not be currently receiving amiodarone or have received amiodarone in the last 28 day  Renal function is not relevant for inclusion ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "The patient has a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to Lapatinib  These include other anilinoquinazolines  such as gefitinib (Iressa)  erlotinib (Tarceva)  or other chemically related compounds or excipients The patient is known to be positive for the Human Immunodeficiency Virus (HIV)  The patient has (or has had) previous or concomitant malignancies at other sites except effectively treated: Non-melanoma skin cancers or carcinoma in situ of the cervix ",
        "premise_nums": []
    },
    {
        "id": "d3590771-806b-4754-a455-38113bfedfca",
        "primaryId": "NCT00952692",
        "statement_text": "Candidates for the primary trial must have adequate colon and liver function  and must not be currently receiving amiodarone or have received amiodarone in the last 28 day  Renal function is not relevant for inclusion ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Malignancy that has been in remission for greater than 2 years and is considered highly likely to have been cured The patient has any psychiatric or addictive disorder that may compromise her ability to give informed consent  or to comply with the trial procedures  The patient has any other condition that in the opinion of the investigator might jeopardize the patient's safety or ability to comply with the requirements of the study  The patient is pregnant or lactating  ",
        "premise_nums": [
            "2 years and"
        ]
    },
    {
        "id": "941b960f-8d57-4830-9d4c-8e96765ba76c",
        "primaryId": "NCT00994279",
        "secondaryId": "NCT00545077",
        "label": "Contradiction",
        "statement_text": "both the primary trial and the secondary trial administer Bevacizumab to every single HER2+ patient ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Arm 1: Yoga Intervention Yoga Intervention Yoga: Yoga sessions INTERVENTION 2: Arm 2: Educational Wellness Group Educational Wellness Group Education: Educational Wellness Group INTERVENTION 1: Arm A: Endocrine Therapy (ET) Endocrine treatment consisting of either letrozole or fulvestrant  Patients will be randomized to receive bevacizumab 15mg/kg every 3 weeks plus endocrine treatment or endocrine treatment as a single agent  The patients will receive the assigned treatment until the progression of the disease  unacceptable toxicity or withdrawal of the consent  Letrozole Fulvestrant INTERVENTION 2: Arm B: ET With Bevacizumab (ET-B) ",
        "premise_nums": [
            "3 weeks plus",
            "15mg/kg every"
        ]
    },
    {
        "id": "941b960f-8d57-4830-9d4c-8e96765ba76c",
        "primaryId": "NCT00994279",
        "secondaryId": "NCT00545077",
        "label": "Contradiction",
        "statement_text": "both the primary trial and the secondary trial administer Bevacizumab to every single HER2+ patient ",
        "statement_nums": [],
        "premise_text": "Endocrine treatment consisting of either letrozole or fulvestrant  Patients will be randomized to receive bevacizumab 15mg/kg i.v  on day 1 every 3 weeks plus endocrine treatment or endocrine treatment as a single agent  The patients will receive the assigned treatment until the progression of the disease  unacceptable toxicity or withdrawal of the consent Letrozole Bevacizumab Fulvestrant ",
        "premise_nums": [
            "15mg/kg i",
            "1 every 3"
        ]
    },
    {
        "id": "f79a9011-0a68-4255-a40f-5d73af412bf0",
        "primaryId": "NCT01425268",
        "secondaryId": "NCT01373671",
        "label": "Entailment",
        "statement_text": "CO2 is utilised as part of the intervention in a single one of the study groups in the primary trial  and not used in either of the study groups in the secondary trial ",
        "statement_nums": [
            "2 is utilised"
        ],
        "premise_text": "INTERVENTION 1: AeroForm Tissue Expansion AeroForm Tissue Expansion inflation with carbon dioxide by remote control AeroForm Tissue Expansion: The AeroForm Patient Controlled Tissue Expander is a breast tissue expander implanted following mastectomy and activated by remote control to release small doses of carbon dioxide from an internal reservoir to fill and inflate the expander  INTERVENTION 1: FFDM and DBT FFDM exam and DBT scan on Siemens MAMMOMAT Inspiration INTERVENTION 2: FFDM Only FFDM exam only ",
        "premise_nums": []
    },
    {
        "id": "1b4f8828-cc7f-4831-a1c0-cc14e6ad23af",
        "primaryId": "NCT00777101",
        "secondaryId": "NCT00559845",
        "label": "Entailment",
        "statement_text": "There were no completed suicides in either the primary trial or the secondary trial  however there was one attempt in cohort 1 of the secondary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Adverse Events 1: Total: 31/116 (26.72%) Neutropenia 1/116 (0.86%) Thrombocytopenia 1/116 (0.86%) Acute myocardial infarction 1/116 (0.86%) Myocardial infarction 0/116 (0.00%) Pericardial effusion 0/116 (0.00%) Abdominal pain 3/116 (2.59%) Ascites 1/116 (0.86%) Diarrhoea 3/116 (2.59%) Gingival bleeding 1/116 (0.86%) Intestinal haemorrhage 1/116 (0.86%) ",
        "premise_nums": [
            "1/116 (0.86%)",
            "31/116 (26.72%)",
            "3/116 (2.59%)",
            "0/116 (0.00%)"
        ]
    },
    {
        "id": "1b4f8828-cc7f-4831-a1c0-cc14e6ad23af",
        "primaryId": "NCT00777101",
        "secondaryId": "NCT00559845",
        "label": "Entailment",
        "statement_text": "There were no completed suicides in either the primary trial or the secondary trial  however there was one attempt in cohort 1 of the secondary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Nausea 2/116 (1.72%)Adverse Events 2: Total: 24/115 (20.87%) Neutropenia 1/115 (0.87%) Thrombocytopenia 0/115 (0.00%) Acute myocardial infarction 0/115 (0.00%) Myocardial infarction 1/115 (0.87%) Pericardial effusion 1/115 (0.87%) Abdominal pain 0/115 (0.00%) Ascites 0/115 (0.00%) Diarrhoea 4/115 (3.48%) Gingival bleeding 0/115 (0.00%) ",
        "premise_nums": [
            "24/115 (20.87%)",
            "1/115 (0.87%)",
            "2/116 (1.72%)Adverse",
            "4/115 (3.48%)",
            "0/115 (0.00%)"
        ]
    },
    {
        "id": "1b4f8828-cc7f-4831-a1c0-cc14e6ad23af",
        "primaryId": "NCT00777101",
        "secondaryId": "NCT00559845",
        "label": "Entailment",
        "statement_text": "There were no completed suicides in either the primary trial or the secondary trial  however there was one attempt in cohort 1 of the secondary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Intestinal haemorrhage 0/115 (0.00%)Nausea 3/115 (2.61%) Adverse Events 1: Total: 8/54 (14.81%) Anaemia 1/54 (1.85%) Febrile Neutropenia 1/54 (1.85%) Retinopathy Hypertensive 1/54 (1.85%) Febrile Infection 1/54 (1.85%) Postoperative Wound Complication 1/54 (1.85%) Cardiac Imaging Procedure Abnormal 1/54 (1.85%) Malignant Melanoma In Situ 1/54 (1.85%) Suicide Attempt 1/54 (1.85%) ",
        "premise_nums": [
            "3/115 (2.61%)",
            "8/54 (14.81%)",
            "1/54 (1.85%)",
            "0/115 (0.00%)Nausea"
        ]
    },
    {
        "id": "1b4f8828-cc7f-4831-a1c0-cc14e6ad23af",
        "primaryId": "NCT00777101",
        "secondaryId": "NCT00559845",
        "label": "Entailment",
        "statement_text": "There were no completed suicides in either the primary trial or the secondary trial  however there was one attempt in cohort 1 of the secondary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Dyspnoea 1/54 (1.85%)",
        "premise_nums": [
            "1/54 (1.85%)"
        ]
    },
    {
        "id": "57f3a264-9119-4931-9f9c-9cb20e945973",
        "primaryId": "NCT00075270",
        "secondaryId": "NCT01781299",
        "label": "Contradiction",
        "statement_text": "the primary trial is testing a chemotherapy treatment whereas the secondary trial is testing a physcotherapy course ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Lapatinib With Paclitaxel Participants received lapatinib 1500 milligrams (mg) orally once daily (OD) with paclitaxel 175 mg/meters squared (m^2) intravenously (IV) over the course of 3 hours  every 3 weeks  The treatment group was stratified by sites of metastatic disease and stage of disease  Participants were treated until disease progression  unacceptable toxicity  or consent withdrawal  INTERVENTION 2: Placebo With Paclitaxel Participants received matching placebo orally OD with paclitaxel (175 mg/m^2 IV) over the course of 3 hours  every 3 weeks  The treatment group was stratified by sites of metastatic disease and stage of disease  Participants were treated until disease progression  unacceptable toxicity  or consent withdrawal  ",
        "premise_nums": [
            "1500 milligrams (mg)",
            "175 mg/meters squared"
        ]
    },
    {
        "id": "57f3a264-9119-4931-9f9c-9cb20e945973",
        "primaryId": "NCT00075270",
        "secondaryId": "NCT01781299",
        "label": "Contradiction",
        "statement_text": "the primary trial is testing a chemotherapy treatment whereas the secondary trial is testing a physcotherapy course ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1:AlloDerm RTU Participants within this arm will have the acellular dermal matrix AlloDerm RTU implanted at the time of tissue expander placement  AlloDerm RTU INTERVENTION 2: SurgiMend PRS Participants within this arm will have the acellular dermal matrix SurgiMend PRS implanted at the time of tissue expander placement  SurgiMend PRS ",
        "premise_nums": [
            "1:AlloDerm RTU"
        ]
    },
    {
        "id": "589e2f5b-9286-465b-8162-bb1549cd5ece",
        "primaryId": "NCT00305448",
        "statement_text": "At least 4 patients in both cohorts of the primary trial achieved either complete response (CR) or partial response (PR) ",
        "statement_nums": [
            "4 patients in"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Objective Response Rate (ORR) An objective response (OR) is defined as a patient having a best overall response of either complete response (CR) or partial response (PR)  A patient has best overall response of CR if she had overall response of CR or PR on one visit and met the confirmation criteria per RECIST  ORR is defined as percentage of patients with objective response  Each patient with measurable disease at baseline was assessed for OR from the sequence of Response Evaluation Criteria in Solid Tumors (RECIST) scan data up to data cut-off  RECIST scans were performed every 12 weeks (+/- 2weeks) from randomization ",
        "premise_nums": []
    },
    {
        "id": "589e2f5b-9286-465b-8162-bb1549cd5ece",
        "primaryId": "NCT00305448",
        "statement_text": "At least 4 patients in both cohorts of the primary trial achieved either complete response (CR) or partial response (PR) ",
        "statement_nums": [
            "4 patients in"
        ],
        "label": "Entailment",
        "premise_text": "Time frame: baseline and every 12 weeks (+/- 2weeks) from randomization data up to data cut-off (19th march 2008)Results 1: Arm/Group Title: Fulvestrant 250 mg Arm/Group Description: Fulvestrant 250 mg Overall Number of Participants Analyzed: 45 Measure Type: Number Unit of Measure: percentage of participants 11.1 Results 2: Arm/Group Title: Fulvestrant 250 mg + Loading Dose Arm/Group Description: Fulvestrant 250 mg + Loading Dose Overall Number of Participants Analyzed: 51 Measure Type: Number Unit of Measure: percentage of participants 17.6 ",
        "premise_nums": [
            "45 Measure Type:",
            "1 Results 2:",
            "250 mg Overall",
            "participants 11.1 Results 2",
            "51 Measure Type:",
            "250 mg Arm"
        ]
    },
    {
        "id": "8275f846-59b6-404d-a6d8-e01335279f1a",
        "primaryId": "NCT03066947",
        "statement_text": "Less than 1/4 patients in the primary trial experienced adverse events ",
        "statement_nums": [
            "4 patients in",
            "1/4 patients"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 8/24 (33.33%) ",
        "premise_nums": [
            "8/24 (33.33%)"
        ]
    },
    {
        "id": "b3c1f5d1-6f7f-4bab-a4e8-5d1dab597cc7",
        "primaryId": "NCT01390064",
        "statement_text": "The both Cohorts of the primary trial receive their treatment via Subcutaneous administration ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "INTERVENTION 1: Initial Cohort Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG Subcutaneous administration 5 doses of 300 micrograms Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG: All research participants will receive the Mimotope P10s-PADRE/MONTANIDE ISA 51 VG vaccine via subcutaneous (SC) injection following the schedule INTERVENTION 2: Escalation Cohort Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG Subcutaneous administration of 5 doses of 500 micrograms ",
        "premise_nums": [
            "300 micrograms Vaccination",
            "5 doses of",
            "51 VG vaccine",
            "51 VG Subcutaneous"
        ]
    },
    {
        "id": "b3c1f5d1-6f7f-4bab-a4e8-5d1dab597cc7",
        "primaryId": "NCT01390064",
        "statement_text": "The both Cohorts of the primary trial receive their treatment via Subcutaneous administration ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG: All research participants will receive the Mimotope P10s-PADRE/MONTANIDE ISA 51 VG vaccine via subcutaneous (SC) injection following the schedule",
        "premise_nums": [
            "51 VG vaccine"
        ]
    },
    {
        "id": "18d9991c-ca96-4bab-93af-77654857a07f",
        "primaryId": "NCT01142661",
        "statement_text": "the primary trial does not accept patients with grade 1 alopecia ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Exclusion Criteria Subjects who meet any of the following criteria will be excluded from participation in the treatment protocol: Existing anti-cancer therapy-related toxicities of Grade greater than /= 2, except that alopecia and Grade 2 neuropathy are acceptable  ",
        "premise_nums": [
            "2 neuropathy are"
        ]
    },
    {
        "id": "6fb9056d-277c-4dc2-9b45-d7661bb41831",
        "primaryId": "NCT01925170",
        "secondaryId": "NCT00324259",
        "label": "Contradiction",
        "statement_text": "Participant in cohort 1 of the primary trial undergo a Mammography  whereas patients in cohort 1 of the secondary trial receive 6 mg Estradiol as supplementation for the Mammography ",
        "statement_nums": [
            "6 mg Estradiol",
            "1 of the"
        ],
        "premise_text": "INTERVENTION 1: Mammography Only For this reporting arm  the interpretation and analysis was done with mammography only  INTERVENTION 1: Arm 1 (6 mg Estradiol) 6 mg of estradiol daily (2 mg tid)  ",
        "premise_nums": [
            "2 mg tid)",
            "6 mg Estradiol)",
            "6 mg of"
        ]
    },
    {
        "id": "52b23601-2276-4634-96c7-8b6e55596085",
        "primaryId": "NCT00129376",
        "statement_text": "A single patient in the primary trial experienced a clinically significant inflammation of the back of the throat ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Acute Pharyngitis * 1/63 (1.59%) ",
        "premise_nums": [
            "1/63 (1.59%)"
        ]
    },
    {
        "id": "95e05332-4926-4381-90a4-87941269e7bf",
        "primaryId": "NCT00431067",
        "statement_text": "More than 5% of the primary trial participants achieved partial response (PR) ",
        "statement_nums": [
            "5% of"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Objective Response (OR) Objective response (OR) including complete response (CR) and partial response (PR) according to the Response Evaluation Criteria in Solid Tumours (RECIST) criteria   Time frame: From first dose of study medication to response measurement  up to 34 month Results 1: Arm/Group Title: Afatinib 50 mg Arm/Group Description: Patients received continuous daily dosing with Afatinib 50 mg therapy over 28-day treatment cycles until further disease progression or undue toxicity  Overall Number of Participants Analyzed: 41 Measure Type: Number Unit of Measure: Participants 4 ",
        "premise_nums": [
            "50 mg therapy",
            "41 Measure Type:",
            "34 month Results",
            "50 mg Arm",
            "28-day treatment"
        ]
    },
    {
        "id": "20d51467-b059-4f39-b636-d32f2dc692da",
        "primaryId": "NCT00054028",
        "secondaryId": "NCT02162719",
        "label": "Contradiction",
        "statement_text": "Both the primary trial and the secondary trial at least partly administer their interventions orally ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Suramin and Paclitaxel Suramin will be infused weekly over 30 minutes  Four hours after the completion of the suramin infusion the 1 hour infusion of paclitaxel will begin  INTERVENTION 1: Ipatasertib and Paclitaxel Participants randomised to receive paclitaxel 80 mg/m^2, intravenously on Days 1, 8, and 15 along with ipatasertib 400 mg  orally  once daily from Days 1-21 in each cycle of 28 days until disease progression  intolerable toxicity  elective withdrawal from the study  or study completion or termination  ",
        "premise_nums": [
            "80 mg/m^2,",
            "1-21 in",
            "1 hour infusion",
            "28 days until",
            "15 along with",
            "21 in each"
        ]
    },
    {
        "id": "15c83d26-f9ba-44cc-a920-6941781cdd8b",
        "primaryId": "NCT01427933",
        "statement_text": "Neutropenia affected the majority of patients in cohort 1 of the primary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Neutropenia 4/69 (5.80%) ",
        "premise_nums": [
            "4/69 (5.80%)"
        ]
    },
    {
        "id": "e100212f-5bef-4f84-a3c1-d18a6b3e8355",
        "primaryId": "NCT01648322",
        "secondaryId": "NCT00436566",
        "label": "Contradiction",
        "statement_text": "the primary trial has a shorter time frame than the secondary trial  both of these studies employ the same units of measure in their evaluation ",
        "statement_nums": [],
        "premise_text": "Outcome Measurement: Duration of Moderate Neurtopenia Post First Chemotherapy Administration Number of days In which the patient has had an absolute neutrophil count (ANC) Level smaller than 2.0 x 10^9/L after first cycle of chemotherapy Time frame: The first of 4, 21 Day Chemotherapy Cycles Unit of Measure: days 0.6 (1.26) Outcome Measurement: Number of Patients With Congestive Heart Failure (CHF) While on Active Treatment [Not Specified] Time frame: 6 months Unit of Measure: participants 0 ",
        "premise_nums": [
            "9/L after",
            "6 months Unit",
            "than 2.0 x 10",
            "21 Day Chemotherapy"
        ]
    },
    {
        "id": "56d2a387-49dd-49b9-93bb-bcb092bf2714",
        "primaryId": "NCT02286843",
        "statement_text": "the primary trial is testing a novel radiotracer called 89Zr-trastuzumab to evaluate its use for visualization of HER2+ lesions ",
        "statement_nums": [
            "89Zr-trastuzumab to"
        ],
        "label": "Entailment",
        "premise_text": "INTERVENTION 1: HER2-targeted PET/CT Pts with confirmed HER2- breast cancer will undergo HER2-targeted PET/CT  89Zr-trastuzumab is a novel radiotracer which allows excellent visualization of HER2+ lesions  89Zr-pertuzumab is a novel radiotracer which may allow for specific visualization of HER2+ lesions  PET/CT imaging with these novel radiotracers will allow evaluation of all identifiable malignant lesions  rather than evaluation of only single lesions by biopsy  ",
        "premise_nums": [
            "89Zr-pertuzumab is",
            "2-targeted PET/CT",
            "89Zr-trastuzumab is"
        ]
    },
    {
        "id": "2485a3e1-7520-47d2-b941-32ebf91e5b65",
        "primaryId": "NCT00300781",
        "statement_text": "Participants of the primary trial are assigned an intervention depending on their prior treatments ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "INTERVENTION 1: Neratinib 240, Prior Trastuzumab Neratinib: 80mg capsules and 40mg coated tablets taken orally in prescribed dose of 240mg daily  as long as tolerated and disease does not worsen in participants with prior trastuzumab treatment  INTERVENTION 2: Neratinib 240, No Prior Trastuzumab Neratinib: 80mg capsules and 40mg coated tablets taken orally in prescribed dose of 240mg daily  as long as tolerated and disease does not worsen in participants with no prior trastuzumab treatment  ",
        "premise_nums": []
    },
    {
        "id": "b97d9465-db14-43af-9451-4b824e67abb8",
        "primaryId": "NCT00899574",
        "secondaryId": "NCT01007942",
        "label": "Contradiction",
        "statement_text": "the primary trial and the secondary trial use different inclusion criteria for their cohorts  so patients may be eligible for one cohort  but not the other ",
        "statement_nums": [],
        "premise_text": "Inclusion Criteria: (Cohort 1) Concurrent systemic cancer therapy (hormones  biologics or chemotherapy) is allowed if distant metastases have been non-progressing (stable or responding) on that regimen for greater than or = 12 weeks and skin metastases are non-responsive (stable or progressing) as assessed by the investigator  (Cohort 2) Any concurrent systemic therapy is allowed Inclusion Criteria: Histologically or cytologically confirmed invasive breast carcinoma with locally recurrent or radiological evidence of metastatic disease  Locally recurrent disease must not be amenable to resection with curative intent  HER2+ status defined as IHC 3+ staining or in situ hybridization positive Patients with resistance to trastuzumab ",
        "premise_nums": [
            "12 weeks and"
        ]
    },
    {
        "id": "b97d9465-db14-43af-9451-4b824e67abb8",
        "primaryId": "NCT00899574",
        "secondaryId": "NCT01007942",
        "label": "Contradiction",
        "statement_text": "the primary trial and the secondary trial use different inclusion criteria for their cohorts  so patients may be eligible for one cohort  but not the other ",
        "statement_nums": [],
        "premise_text": "Prior taxane therapyPatients with an ECOG performance status of 0 - 2 Patients with measurable disease as per RECIST criteria Documentation of negative pregnancy test for patients of child bearing potential prior to enrollment within 7 days prior to randomization  Sexually active pre-menopausal women must use adequate contraceptive measures  excluding estrogen containing contraceptives  while on study; Patients must meet laboratory criteria defined in the study within 21 days prior to randomization Exclusion Criteria: Prior mTOR inhibitors or vinca alkaloid agents for the treatment of cancer More than three prior chemotherapy lines for advanced disease  ",
        "premise_nums": [
            "7 days prior",
            "2 Patients with",
            "21 days prior"
        ]
    },
    {
        "id": "b97d9465-db14-43af-9451-4b824e67abb8",
        "primaryId": "NCT00899574",
        "secondaryId": "NCT01007942",
        "label": "Contradiction",
        "statement_text": "the primary trial and the secondary trial use different inclusion criteria for their cohorts  so patients may be eligible for one cohort  but not the other ",
        "statement_nums": [],
        "premise_text": "Symptomatic CNS metastases or evidence of leptomeningeal disease  Previously treated asymptomatic CNS metastases are allowed provided that the last treatment for CNS metastases was completed greater than 8 weeks prior to randomizationImpairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral everolimus Peripheral neuropathy grade 2 at randomization Active cardiac disease History of cardiac dysfunction Any malignancy within 5 years prior to randomization  with the exception of adequately treated in-situ carcinoma of the cervix uteri  basal or squamous cell carcinoma or non-melanomatous skin cancer Known hypersensitivity to any study medication ",
        "premise_nums": [
            "8 weeks prior",
            "2 at randomization",
            "5 years prior"
        ]
    },
    {
        "id": "b97d9465-db14-43af-9451-4b824e67abb8",
        "primaryId": "NCT00899574",
        "secondaryId": "NCT01007942",
        "label": "Contradiction",
        "statement_text": "the primary trial and the secondary trial use different inclusion criteria for their cohorts  so patients may be eligible for one cohort  but not the other ",
        "statement_nums": [],
        "premise_text": "Breastfeeding or pregnant",
        "premise_nums": []
    },
    {
        "id": "798c0983-5265-47ea-bfcd-735738793482",
        "primaryId": "NCT02010021",
        "statement_text": "A patient has recently been receiving Tamoxifen to treat breast cancer  they are excluded from the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Exclusion Criteria: Prior endocrine therapy for any histologically confirmed cancer is not allowed  Prior endocrine therapy that was administered 5 years ago for the prevention of breast cancer in patients with no history of breast cancer is allowed  ",
        "premise_nums": [
            "5 years ago"
        ]
    },
    {
        "id": "127e9179-6781-4b9a-abe9-080d2ffad591",
        "primaryId": "NCT02176083",
        "secondaryId": "NCT03061175",
        "label": "Entailment",
        "statement_text": "Neither the primary trial or NCT0306117 use chemotherapy or radiotherapy in their intervention ",
        "statement_nums": [
            "0306117 use chemotherapy",
            "NCT0306117 use"
        ],
        "premise_text": "INTERVENTION 1: Intervention Text message management prompts: YBCS will receive text message prompts on how to manage hot flashes and vaginal dryness Text message management prompts INTERVENTION 2: Control Control YBCS will not receive text message prompts on managing hot flashes and vaginal dryness INTERVENTION 1: Arm I (Web-Based CPM-DA) Patients receive a website address  a secure username and password  and instructions for using the web-based CPM-DA  Internet-Based Intervention: Receive web-based CPM-DA Survey Administration: Ancillary studies INTERVENTION 2: Arm II (Usual Care) Patients undergo usual care available to patients considering CPM and receive information from a medical oncologist about CPM  Survey Administration: Ancillary studies ",
        "premise_nums": []
    },
    {
        "id": "a54e1dfa-3975-4dc6-8530-c0adc79b1b0d",
        "primaryId": "NCT00089479",
        "secondaryId": "NCT02964234",
        "label": "Entailment",
        "statement_text": "Agatha had her 50th birthday last week  she has a histologically confirmed adenocarcinoma of the breast  with no evidence of metastatic disease  She is eligible for the primary trial but not the secondary trial ",
        "statement_nums": [],
        "premise_text": "Inclusion Criteria: female patients 18-70 years of age; Inclusion Criteria: Age 52-75 years old; ",
        "premise_nums": [
            "18-70 years",
            "52-75 years",
            "70 years of",
            "75 years old;"
        ]
    },
    {
        "id": "16dc5a77-5758-4d19-9801-6e9932d9fbc9",
        "primaryId": "NCT01401166",
        "statement_text": "several patients in cohort 1 of the primary trial Preferred oral tablets as a Method of Drug Administration ",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Percentage of Participants by Preferred Method of Drug Administration The preferred method of drug administration (IV or SC Herceptin) was assessed in trial-specific telephone interviews with each study participant  Participants were asked  \"All things considered  which method of administration did you prefer?\" at the end of the crossover period (Week 24). The percentage of participants who preferred each method of drug administration was reported  Time frame: Week 24 Results 1: Arm/Group Title: Cohort 1: SC (SID) Then IV Herceptin ",
        "premise_nums": [
            "24 Results 1:"
        ]
    },
    {
        "id": "16dc5a77-5758-4d19-9801-6e9932d9fbc9",
        "primaryId": "NCT01401166",
        "statement_text": "several patients in cohort 1 of the primary trial Preferred oral tablets as a Method of Drug Administration ",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Arm/Group Description: Participants received Herceptin on Day 1 of each 3-week cycle for 18 cycles  During Cycles 1 to 4 of the crossover period  SC Herceptin was administered via SID  and during Cycles 5 to 8, IV Herceptin was given  In the continuation period  participants received IV Herceptin for up to 10 remaining cycles  Administration was performed by HCP  Those with at least 2 treatment cycles remaining of the 18-cycle treatment course after the crossover period were offered the opportunity to self-administer SC Herceptin via SID under the direction of a trained HCP  The SC dose was 600 mg for all cycles where SC Herceptin was given  and the IV dose was 6 mg/kg for all cycles where IV Herceptin was given Overall Number of Participants Analyzed: 117 ",
        "premise_nums": [
            "5 to 8,",
            "1 of each",
            "1 to 4",
            "10 remaining cycles",
            "3-week cycle",
            "600 mg for",
            "2 treatment cycles",
            "6 mg/kg for",
            "18-cycle treatment"
        ]
    },
    {
        "id": "16dc5a77-5758-4d19-9801-6e9932d9fbc9",
        "primaryId": "NCT01401166",
        "statement_text": "several patients in cohort 1 of the primary trial Preferred oral tablets as a Method of Drug Administration ",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Measure Type: NumberUnit of Measure: percentage of participants SC Herceptin: 95.7 IV Herceptin: 4.3 No Preference: 0.0 ",
        "premise_nums": [
            "7 IV Herceptin:",
            "3 No Preference:"
        ]
    },
    {
        "id": "2ed770a0-fe98-4029-9511-ad04a94a1a69",
        "primaryId": "NCT00190671",
        "secondaryId": "NCT00455533",
        "label": "Contradiction",
        "statement_text": "In the primary trial cohort 2 had more patients with Leukopenia than cohort 1, whereas in the secondary trial cohort 1 had more than cohort 2. Cohort 1 of the primary trial had the highest proportion of patients with leukopenia ",
        "statement_nums": [
            "1 had more",
            "2 had more",
            "1 of the"
        ],
        "premise_text": "Adverse Events 1: Leukopenia 0/42 (0.00%) Adverse Events 2: Leukopenia 2/61 (3.28%) Adverse Events 1: LEUKOPENIA 2/145 (1.38%) Adverse Events 2: LEUKOPENIA 0/144 (0.00%) ",
        "premise_nums": [
            "2/61 (3.28%)",
            "0/42 (0.00%)",
            "2/145 (1.38%)",
            "0/144 (0.00%)"
        ]
    },
    {
        "id": "b4c97206-66fd-468b-8388-fac076222c10",
        "primaryId": "NCT00863655",
        "statement_text": "There were 7 more cases of Anaemia and 1 more case of Disseminated intravascular coagulation in cohort 1 of the primary trial compared to cohort 2.",
        "statement_nums": [
            "7 more cases",
            "1 of the",
            "1 more case"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 158/482 (32.78%) Anaemia 7/482 (1.45%) Disseminated intravascular coagulation 1/482 (0.21%) Adverse Events 2: Total: 37/238 (15.55%) Anaemia 2/238 (0.84%) Disseminated intravascular coagulation 0/238 (0.00%) ",
        "premise_nums": [
            "37/238 (15.55%)",
            "1/482 (0.21%)",
            "2/238 (0.84%)",
            "158/482 (32.78%)",
            "0/238 (0.00%)",
            "7/482 (1.45%)"
        ]
    },
    {
        "id": "6e22d118-af77-41bd-bd47-9385779f33aa",
        "primaryId": "NCT00450723",
        "statement_text": "There are several types of surgical and therapeutic treatments which are banned for patients wanting to take part in the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "PRIOR CONCURRENT THERAPY: No prior thoracic or cardiac surgery No prior ipsilateral chest tube placement Contralateral chest tube placement allowed No prior neoadjuvant chemotherapy No prior radiotherapy to the mediastinum ",
        "premise_nums": []
    },
    {
        "id": "ccc5362a-33d0-4f1b-be46-d31729ba9194",
        "primaryId": "NCT01945775",
        "statement_text": "The shortest PFS in the Talazoparib group of the primary trial was over a month shorter than the Median PFS for that group ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Progression-Free Survival (PFS): Independent Radiological Facility (IRF) Assessment ",
        "premise_nums": []
    },
    {
        "id": "fa530b28-9142-49f2-aa80-4d04fa532910",
        "primaryId": "NCT03765996",
        "statement_text": "Participants in group 2 of the primary trial receive taping to anastomosis regions.  but no Complex Decongestive Physiotherapy ",
        "statement_nums": [
            "2 of the"
        ],
        "label": "Contradiction",
        "premise_text": "INTERVENTION 1: Decongestive Physiotherapy This group received Complex Decongestive Physiotherapy  ",
        "premise_nums": []
    },
    {
        "id": "7cbe445f-2df6-4a87-be6b-7ecc1e80b08b",
        "primaryId": "NCT00063570",
        "statement_text": "None of the patients in cohort 1 of the primary trial had a platlet deficiency  and none of the patients in cohort 2 had Pyrexia ",
        "statement_nums": [
            "2 had Pyrexia",
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 17 Anaemia 2/52 (3.85%) Febrile neutropenia 4/52 (7.69%) Pancytopenia 1/52 (1.92%) Thrombocytopenia 0/52 (0.00%) Abdominal pain 1/52 (1.92%) Constipation 1/52 (1.92%) Pyrexia 2/52 (3.85%) Hepatic failure 1/52 (1.92%) Hyperbilirubinaemia 1/52 (1.92%) Device related infection 1/52 (1.92%) Pneumonia 2/52 (3.85%) Sepsis 1/52 (1.92%) ",
        "premise_nums": [
            "0/52 (0.00%)",
            "4/52 (7.69%)",
            "17 Anaemia 2",
            "1/52 (1.92%)",
            "2/52 (3.85%)"
        ]
    },
    {
        "id": "7cbe445f-2df6-4a87-be6b-7ecc1e80b08b",
        "primaryId": "NCT00063570",
        "statement_text": "None of the patients in cohort 1 of the primary trial had a platlet deficiency  and none of the patients in cohort 2 had Pyrexia ",
        "statement_nums": [
            "2 had Pyrexia",
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 2:Total: 7 Anaemia 0/21 (0.00%) Febrile neutropenia 1/21 (4.76%) Pancytopenia 0/21 (0.00%) Thrombocytopenia 1/21 (4.76%) Abdominal pain 0/21 (0.00%) Constipation 0/21 (0.00%) Pyrexia 1/21 (4.76%) Hepatic failure 0/21 (0.00%) Hyperbilirubinaemia 0/21 (0.00%) Device related infection 0/21 (0.00%) Pneumonia 0/21 (0.00%) Sepsis 0/21 (0.00%) ",
        "premise_nums": [
            "7 Anaemia 0",
            "2:Total: 7",
            "0/21 (0.00%)",
            "1/21 (4.76%)"
        ]
    },
    {
        "id": "41cf791e-ed7a-48e5-af84-eefc9fa41ba7",
        "primaryId": "NCT00503906",
        "secondaryId": "NCT01142661",
        "label": "Contradiction",
        "statement_text": "The adverse events in the primary trial where all equally prevalent  whereas in the secondary trial  alcohol poisoning was reported as the most common event ",
        "statement_nums": [],
        "premise_text": "Adverse Events 1: Total: 8/29 (27.59%) Leukopenia [1]1/29 (3.45%) Thrombocytopenia [1]1/29 (3.45%) Abscess [1]1/29 (3.45%) Breast Abscess 1/29 (3.45%) Fever/Sepsis [1]1/29 (3.45%) Neutropenic Fever [2]1/29 (3.45%) Peripheral Neuropathy [1]1/29 (3.45%) Seizure/Syncope [1]1/29 (3.45%) Hematuria [1]1/29 (3.45%) ",
        "premise_nums": [
            "1/29 (3.45%)",
            "8/29 (27.59%)"
        ]
    },
    {
        "id": "41cf791e-ed7a-48e5-af84-eefc9fa41ba7",
        "primaryId": "NCT00503906",
        "secondaryId": "NCT01142661",
        "label": "Contradiction",
        "statement_text": "The adverse events in the primary trial where all equally prevalent  whereas in the secondary trial  alcohol poisoning was reported as the most common event ",
        "statement_nums": [],
        "premise_text": "UTI [1]1/29 (3.45%)Shortness of breath [1]1/29 (3.45%) Adverse Events 1: Total: 7/9 (77.78%) Febrile Neutropenia1/9 (11.11%) Neutropenia1/9 (11.11%) Tachycardia1/9 (11.11%) Hematemesis1/9 (11.11%) Small Bowel Obstruction1/9 (11.11%) Pneumonia1/9 (11.11%) Hypokalemia1/9 (11.11%) Alcohol Poisoning1/9 (11.11%) Progressive Disease4/9 (44.44%) ",
        "premise_nums": [
            "7/9 (77.78%)",
            "4/9 (44.44%)",
            "1/29 (3.45%)Shortness",
            "1/9 (11.11%)"
        ]
    },
    {
        "id": "d417aa7b-6d2c-46f8-812c-426ea60e0328",
        "primaryId": "NCT00894504",
        "statement_text": "There were only 3 adverse events in the primary trial which occurred more than twice ",
        "statement_nums": [
            "3 adverse events"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 10/71 (14.08%) ATRIAL FIBRILLATION 1/71 (1.41%) CARDIAC TAMPONADE 1/71 (1.41%) PERICARDIAL EFFUSION 1/71 (1.41%) SUPRAVENTRICULAR TACHYCARDIA 1/71 (1.41%) DIARRHOEA 1/71 (1.41%) NAUSEA 1/71 (1.41%) VOMITING 1/71 (1.41%) CHEST PAIN 1/71 (1.41%) PNEUMONIA 1/71 (1.41%) MALIGNANT PLEURAL EFFUSION 1/71 (1.41%) HEPATIC ENCEPHALOPATHY 1/71 (1.41%) ",
        "premise_nums": [
            "1/71 (1.41%)",
            "10/71 (14.08%)"
        ]
    },
    {
        "id": "2744cc0a-86e9-4764-ae1c-f10f635dc283",
        "primaryId": "NCT00171704",
        "statement_text": "Most patients in the Letrozole group of the primary trial had a decreased Bone Mineral Density of the Lumbar Spine after 24 months ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Percent Change From Baseline of Bone Mineral Density of the Lumbar Spine (L2-l4) Lumbar spine (L2-L4) BMD measurements by dual energy X-ray absorptiometry (DXA) were performed after surgery and within 2 weeks prior to randomization and repeated every 6 months for the first 2 years and annually thereafter until 5 years after enrollment  The primary scanning site was the lumbar spine (L2 to L4) and the secondary scanning site was the total hip  All DXA scans were evaluated by a central reader  Time frame: Baseline  24 months Results 1: Arm/Group Title: Letrozole Arm/Group Description: 2.5 mg once daily (q.d.)orally for 5 years ",
        "premise_nums": [
            "2 years and",
            "2-l4) Lumbar",
            "5 years after",
            "6 months for",
            "2-L4) BMD",
            "2 to L4)",
            "2 weeks prior",
            "24 months Results",
            "5 mg once"
        ]
    },
    {
        "id": "2744cc0a-86e9-4764-ae1c-f10f635dc283",
        "primaryId": "NCT00171704",
        "statement_text": "Most patients in the Letrozole group of the primary trial had a decreased Bone Mineral Density of the Lumbar Spine after 24 months ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Overall Number of Participants Analyzed: 63Median (Full Range) Unit of Measure: Percent Change -4.63 (-14.21 to 4.32) Results 2: Arm/Group Title: Tam-Let Arm/Group Description: 20 mg Tamoxifen once daily (q.d.) orally for 2 years followed by Letrozole 2.5 mg q.d  orally for 3 years  Overall Number of Participants Analyzed: 68 Median (Full Range) Unit of Measure: Percent Change 0.37 (-6.98 to 15.21) ",
        "premise_nums": [
            "Letrozole 2.5 mg q",
            "2 years followed",
            "21 to 4.32)",
            "68 Median (Full",
            "98 to 15.21)",
            "20 mg Tamoxifen",
            "5 mg q.d"
        ]
    },
    {
        "id": "2e4717fd-b349-48a3-b751-88674dfaaa18",
        "primaryId": "NCT02392611",
        "statement_text": "In the primary trial cohort 1 patients must have failed or be intolerant to standard therapy  or have no standard therapy available  and cohort 2 patients must respond well to standard therapy ",
        "statement_nums": [
            "1 patients must",
            "2 patients must"
        ],
        "label": "Contradiction",
        "premise_text": "INTERVENTION 1: Monotherapy: Alobresib 0.6 mg Participants with advanced solid tumors and lymphomas who had failed or were intolerant to standard therapy  or for whom no standard therapy existed received alobresib tablets at a dose of 0.6 mg orally once daily on Study Day 1 through C1D28 of 28 days cycle to determine the MTD  INTERVENTION 2: Monotherapy: Alobresib 1.4 mg Participants with advanced solid tumors and lymphomas who had failed or were intolerant to standard therapy  or for whom no standard therapy existed received alobresib tablets at a dose of 1.4 mg orally once daily on Study Day 1 through C1D28 of 28 days cycle to determine the MTD  ",
        "premise_nums": [
            "of 0.6 mg orally",
            "Alobresib 0.6 mg Participants",
            "Alobresib 1.4 mg Participants",
            "28 days cycle",
            "D28 of",
            "of 1.4 mg orally",
            "1 through C1D28"
        ]
    },
    {
        "id": "b0c65cd7-8cad-404d-8704-ee074e480f57",
        "primaryId": "NCT01237327",
        "secondaryId": "NCT00030823",
        "label": "Contradiction",
        "statement_text": "the primary trial and the secondary trial do not have any overlapping inclusion criteria  apart from the mimimum age limit of 18.",
        "statement_nums": [],
        "premise_text": "Inclusion Criteria: Previous participation in study 971-ONC-0028-080. Exclusion Criteria: Subjects who had not previously participated in study 971-ONC-0028-080. DISEASE CHARACTERISTICS: Diagnosis of breast cancer at high risk for recurrence  defined by one of the following: Stage IV that is free of all known disease after eradication by surgery  radiotherapy  or chemotherapy May or may not have elevated CA 15-3 or CEA levels Stage I  II  or III previously treated with adjuvant chemotherapy and clinically free of identifiable disease  but have rising CA 15-3 or CEA levels Rising CA 15-3 and CEA defined as a prior normal level increased on 2 consecutive occasions at least 2 weeks apart ",
        "premise_nums": [
            "2 weeks apart",
            "3 or CEA",
            "971-ONC-0028-080. DISEASE",
            "3 and CEA",
            "2 consecutive occasions",
            "971-ONC-0028-080. Exclusion",
            "15-3 and",
            "15-3 or"
        ]
    },
    {
        "id": "b0c65cd7-8cad-404d-8704-ee074e480f57",
        "primaryId": "NCT01237327",
        "secondaryId": "NCT00030823",
        "label": "Contradiction",
        "statement_text": "the primary trial and the secondary trial do not have any overlapping inclusion criteria  apart from the mimimum age limit of 18.",
        "statement_nums": [],
        "premise_text": "For patients with a significant history of smoking who have a chronically elevated CEA (less than 15), CEA must be increased at least 1.5 times the uppermost chronic value on 2 consecutive occasions at least 2 weeks apartStage III and completed adjuvant therapy no more than 24 months ago Recurrence in the ipsilateral axilla after lumpectomy and/or axillary dissection or modified radical mastectomy Recurrence in the ipsilateral breast after lumpectomy and/or axillary dissection Stage II with at least 4 positive axillary nodes and completed adjuvant therapy no more than 24 months ago Stage IV that is stable on hormonal therapy Hormone receptor status: Not specified PATIENT CHARACTERISTICS: Age: 18 and over ",
        "premise_nums": [
            "4 positive axillary",
            "24 months ago",
            "2 weeks apartStage",
            "18 and over",
            "2 consecutive occasions",
            "least 1.5 times the"
        ]
    },
    {
        "id": "b0c65cd7-8cad-404d-8704-ee074e480f57",
        "primaryId": "NCT01237327",
        "secondaryId": "NCT00030823",
        "label": "Contradiction",
        "statement_text": "the primary trial and the secondary trial do not have any overlapping inclusion criteria  apart from the mimimum age limit of 18.",
        "statement_nums": [],
        "premise_text": "Sex:Male or female Menopausal status: Not specified Performance status: Karnofsky 80-100% Life expectancy: Not specified Hematopoietic: Lymphocyte count at least 500/mm^3 WBC at least 3,000/mm^3 Hepatic: AST no greater than 1.5 times upper limit of normal (ULN) Alkaline phosphatase no greater than 1.5 times ULN Renal: Creatinine no greater than 1.5 times ULN Cardiovascular: No clinically significant New York Heart Association class III or IV cardiac disease Other: Not pregnant Negative pregnancy test Fertile patients must use effective contraception No prior seafood allergy No known prior immunodeficiency or autoimmune disease ",
        "premise_nums": [
            "3,000/mm^3 Hepatic:",
            "3 WBC at",
            "80-100% Life",
            "500/mm^3 WBC",
            "than 1.5 times ULN",
            "than 1.5 times upper"
        ]
    },
    {
        "id": "b0c65cd7-8cad-404d-8704-ee074e480f57",
        "primaryId": "NCT01237327",
        "secondaryId": "NCT00030823",
        "label": "Contradiction",
        "statement_text": "the primary trial and the secondary trial do not have any overlapping inclusion criteria  apart from the mimimum age limit of 18.",
        "statement_nums": [],
        "premise_text": "No other active cancer except basal cell or squamous cell skin cancerPRIOR CONCURRENT THERAPY: Biologic therapy: At least 6 weeks since prior immunotherapy No prior vaccine with any of the antigens in this study Chemotherapy: See Disease Characteristics At least 4 weeks since prior chemotherapy No concurrent chemotherapy Endocrine therapy: See Disease Characteristics Radiotherapy: See Disease Characteristics At least 4 weeks since prior radiotherapy No concurrent radiotherapy Surgery: See Disease Characteristics At least 4 weeks since prior surgery Concurrent surgery for local recurrence allowed if patient remains disease free ",
        "premise_nums": [
            "6 weeks since",
            "4 weeks since"
        ]
    },
    {
        "id": "28e20650-e100-4e30-a319-5eceb69a979d",
        "primaryId": "NCT00509769",
        "statement_text": "1 patient in the primary trial had toxic hepatitis ",
        "statement_nums": [
            "1 patient in"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Hepatotoxicity 1/112 (0.89%) ",
        "premise_nums": [
            "1/112 (0.89%)"
        ]
    },
    {
        "id": "8cf0c320-9486-4531-9212-bb3284b734f1",
        "primaryId": "NCT02336737",
        "secondaryId": "NCT01432886",
        "label": "Entailment",
        "statement_text": "the secondary trial is testing for the DLT of its interventions  whereas the primary trial is evaluating the efficacy of lymph node detection through the use of SentiMag and SiennaXP ",
        "statement_nums": [],
        "premise_text": "Outcome Measurement: Number of Participants With Detected Lymph Nodes The proportion of lymph nodes detected intraoperatively by SentiMag and SiennaXP in relation the proportion of lymph nodes detected by the combination of Technetium Sulfur Colloid and Isosulfan blue dye Outcome Measurement: Number of Participants With Dose Limiting Toxicity (DLT) ",
        "premise_nums": []
    },
    {
        "id": "34a75478-e7cc-495e-86c3-d0accdaf1ddd",
        "primaryId": "NCT00317603",
        "statement_text": "Participants of the primary trial must be older than 18, have histologically confirmed stage 4 breast cancer  ECOGsmaller than 2 and a life expectancy exceeding 6 months ",
        "statement_nums": [
            "2 and a",
            "4 breast cancer"
        ],
        "label": "Entailment",
        "premise_text": "Inclusion Criteria: Histologically confirmed Stage IV breast cancer ECOG performance status 0 or 1 Estimated life expectancy of greater than or equal to 6 months 18 years of age or older ",
        "premise_nums": [
            "6 months 18",
            "0 or 1"
        ]
    },
    {
        "id": "47780450-1202-4934-8e50-b29416b124f5",
        "primaryId": "NCT00332709",
        "secondaryId": "NCT00659373",
        "label": "Contradiction",
        "statement_text": "All the primary trial participants receive the same dose of Letrozole  and all patients in the secondary trial are administered the same dose of Tamoxifen ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Letrozole Letrozole 2.5 mg/day for 3 years INTERVENTION 2: Letrozole + Zoledronic Acid Letrozole 2.5mg/day for 3 years plus Zoledronic acid 4mg every 6 months INTERVENTION 1: Tamoxifen Tamoxifen 20mg orally daily for 5 years INTERVENTION 2: Ovarian Function Suppression Tamoxifen 20mg orally daily or Exemestane 25mg orally daily for 5 years plus ovarian function suppression (OFS; triptorelin (GnRH analogue) 3.75 mg by im injection q28 days for 5 years; or surgical oophorectomy; or ovarian irradiation) ",
        "premise_nums": [
            "3 years INTERVENTION",
            "5 years INTERVENTION",
            "q28 days",
            "Letrozole 2.5 mg/day",
            "3 years plus",
            "75 mg by",
            "Letrozole 2.5mg/day",
            "5 years plus",
            "28 days for",
            "6 months INTERVENTION"
        ]
    },
    {
        "id": "47780450-1202-4934-8e50-b29416b124f5",
        "primaryId": "NCT00332709",
        "secondaryId": "NCT00659373",
        "label": "Contradiction",
        "statement_text": "All the primary trial participants receive the same dose of Letrozole  and all patients in the secondary trial are administered the same dose of Tamoxifen ",
        "statement_nums": [],
        "premise_text": "Note: Data were collected separately for the T+OFS and E+OFS participants in the parent study  IBCSG 24-02 (SOFT)  The sample size for this Co-SOFT substudy was small  so the analysis plan was revised to pre-specify collective analysis for all patients receiving OFS ",
        "premise_nums": []
    },
    {
        "id": "27421e64-e9f0-42a9-8070-bdfb0ce4ce7c",
        "primaryId": "NCT00179309",
        "statement_text": "There were 2 cases of severe back pain observed in the primary trial ",
        "statement_nums": [
            "2 cases of"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 3/25 (12.00%) Anemia 0/25 (0.00%) Sinus tachycardia 0/25 (0.00%) Pericardial effusion 1/25 (4.00%) Gastrointestinal disorders - Other  specify -stomatitis) 0/25 (0.00%) Vomiting 1/25 (4.00%) Fever 0/25 (0.00%) Injection site reaction 1/25 (4.00%) Catheter related infection 0/25 (0.00%) Activated partial thromboplastin time prolonged 0/25 (0.00%) Adverse Events 2: Total: 2/23 (8.70%) Anemia 1/23 (4.35%) ",
        "premise_nums": [
            "1/25 (4.00%)",
            "0/25 (0.00%)",
            "3/25 (12.00%)",
            "1/23 (4.35%)",
            "2/23 (8.70%)"
        ]
    },
    {
        "id": "27421e64-e9f0-42a9-8070-bdfb0ce4ce7c",
        "primaryId": "NCT00179309",
        "statement_text": "There were 2 cases of severe back pain observed in the primary trial ",
        "statement_nums": [
            "2 cases of"
        ],
        "label": "Contradiction",
        "premise_text": "Sinus tachycardia 1/23 (4.35%)Pericardial effusion 0/23 (0.00%) Gastrointestinal disorders - Other  specify -stomatitis) 1/23 (4.35%) Vomiting 0/23 (0.00%) Fever 1/23 (4.35%) Injection site reaction 1/23 (4.35%) Catheter related infection 1/23 (4.35%) Activated partial thromboplastin time prolonged 1/23 (4.35%) ",
        "premise_nums": [
            "0/23 (0.00%)",
            "1/23 (4.35%)Pericardial"
        ]
    },
    {
        "id": "c5e6497a-2e2f-4663-97fd-e73ba8904b0c",
        "primaryId": "NCT01856543",
        "secondaryId": "NCT00365599",
        "label": "Contradiction",
        "statement_text": "Across all cohorts of the secondary trial and the primary trial there was only a single recorded case of Myocarditis and Thrombosis ",
        "statement_nums": [],
        "premise_text": "Adverse Events 1: Total: 3/73 (4.11%) Chest Pain - cardiac 1/73 (1.37%) Myocarditis 1/73 (1.37%) Pericarditis 1/73 (1.37%) Ventricular tachycardia 1/73 (1.37%) Skin infection 0/73 (0.00%) Dermatitis radiation 0/73 (0.00%) Dyspnea 1/73 (1.37%) Adverse Events 2: Total: 3/70 (4.29%) Chest Pain - cardiac 0/70 (0.00%) Myocarditis 0/70 (0.00%) Pericarditis 0/70 (0.00%) ",
        "premise_nums": [
            "0/73 (0.00%)",
            "0/70 (0.00%)",
            "3/70 (4.29%)",
            "3/73 (4.11%)",
            "1/73 (1.37%)"
        ]
    },
    {
        "id": "c5e6497a-2e2f-4663-97fd-e73ba8904b0c",
        "primaryId": "NCT01856543",
        "secondaryId": "NCT00365599",
        "label": "Contradiction",
        "statement_text": "Across all cohorts of the secondary trial and the primary trial there was only a single recorded case of Myocarditis and Thrombosis ",
        "statement_nums": [],
        "premise_text": "Ventricular tachycardia 0/70 (0.00%)Skin infection 2/70 (2.86%) Dermatitis radiation 1/70 (1.43%) Dyspnea 0/70 (0.00%) Adverse Events 1: Total: 4/43 (9.30%) Hemoglobin [1]1/43 (2.33%) Hemorrhage/Bleeding [2]1/43 (2.33%) Neutrophils/granulocytes (ANC/AGC) [3]1/43 (2.33%) Platelets [4]1/43 (2.33%) Anorexia [5]1/43 (2.33%) ",
        "premise_nums": [
            "1/70 (1.43%)",
            "2/70 (2.86%)",
            "1/43 (2.33%)",
            "0/70 (0.00%)Skin",
            "4/43 (9.30%)"
        ]
    },
    {
        "id": "c5e6497a-2e2f-4663-97fd-e73ba8904b0c",
        "primaryId": "NCT01856543",
        "secondaryId": "NCT00365599",
        "label": "Contradiction",
        "statement_text": "Across all cohorts of the secondary trial and the primary trial there was only a single recorded case of Myocarditis and Thrombosis ",
        "statement_nums": [],
        "premise_text": "Sodium  serum-low (hyponatremia) [1]1/43 (2.33%)Thrombosis/thrombus/embolism [6]2/43 (4.65%) ",
        "premise_nums": [
            "2/43 (4.65%)",
            "1/43 (2.33%)Thrombosis/thrombus/embolism"
        ]
    },
    {
        "id": "c4dd814d-f525-465f-abe1-a7975771d57e",
        "primaryId": "NCT01105650",
        "statement_text": "Participants in cohort 1 of the primary trial weighing less than 45 kg receive 5 million units/m^2 less of IL-2, than participants over 45 kg  but all participants will be administered Methylprednisolone 3 times per week for 6 doses ",
        "statement_nums": [
            "3 times per",
            "45 kg receive",
            "5 million units",
            "1 of the",
            "2 less of"
        ],
        "label": "Contradiction",
        "premise_text": "INTERVENTION 1: Arm 1: CsA Fludarabine: Administered intravenously  25 mg/m^2, days -6 through -2 (5 days)  Cyclophosphamide: Administered intravenously  60 mg/kg  days -5 and -4. Cyclosporine (CsA): Administered intravenously  1.5 mg/kg for target dose range of 150-250 ng/mL day -3 through day +14 Natural Killer cells: Administered by infusion over less than 1 hour; no more than 8.0 x 10^7 cells/kg will be given  ",
        "premise_nums": [
            "10^7 cells",
            "60 mg/kg",
            "25 mg/m^2,",
            "14 Natural Killer",
            "1.5 mg/kg",
            "150-250 ng/mL",
            "than 8.0 x 10",
            "3 through day"
        ]
    },
    {
        "id": "c4dd814d-f525-465f-abe1-a7975771d57e",
        "primaryId": "NCT01105650",
        "statement_text": "Participants in cohort 1 of the primary trial weighing less than 45 kg receive 5 million units/m^2 less of IL-2, than participants over 45 kg  but all participants will be administered Methylprednisolone 3 times per week for 6 doses ",
        "statement_nums": [
            "3 times per",
            "45 kg receive",
            "5 million units",
            "1 of the",
            "2 less of"
        ],
        "label": "Contradiction",
        "premise_text": "Interleukin- 2 (IL-2): Given subcutaneously at 9 million units 3 times a week for a total of 6 doses  beginning 4 hours after NK cell infusion  (For patients weighing less than 45 kilograms  IL-2 will be given at 5 million units/m^2 3 times per week for 6 doses) ",
        "premise_nums": [
            "3 times per",
            "2 will be",
            "3 times a",
            "9 million units",
            "5 million units",
            "4 hours after"
        ]
    },
    {
        "id": "cfd93077-87c5-458b-8712-e1896929309d",
        "primaryId": "NCT00924352",
        "statement_text": "One patient in the primary trial had abnormally low red blood cells  white blood cells  and platelets ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Pancytopenia * 1/56 (1.79%) ",
        "premise_nums": [
            "1/56 (1.79%)"
        ]
    },
    {
        "id": "a3faaf85-62c6-430f-acf2-9c5992ee5221",
        "primaryId": "NCT00503906",
        "secondaryId": "NCT01142661",
        "label": "Entailment",
        "statement_text": "The adverse events in the primary trial where all equally prevalent  whereas in the secondary trial  progression of disease was reported as the most common event ",
        "statement_nums": [],
        "premise_text": "Adverse Events 1: Total: 8/29 (27.59%) Leukopenia [1]1/29 (3.45%) Thrombocytopenia [1]1/29 (3.45%) Abscess [1]1/29 (3.45%) Breast Abscess 1/29 (3.45%) Fever/Sepsis [1]1/29 (3.45%) Neutropenic Fever [2]1/29 (3.45%) Peripheral Neuropathy [1]1/29 (3.45%) Seizure/Syncope [1]1/29 (3.45%) Hematuria [1]1/29 (3.45%) ",
        "premise_nums": [
            "1/29 (3.45%)",
            "8/29 (27.59%)"
        ]
    },
    {
        "id": "a3faaf85-62c6-430f-acf2-9c5992ee5221",
        "primaryId": "NCT00503906",
        "secondaryId": "NCT01142661",
        "label": "Entailment",
        "statement_text": "The adverse events in the primary trial where all equally prevalent  whereas in the secondary trial  progression of disease was reported as the most common event ",
        "statement_nums": [],
        "premise_text": "UTI [1]1/29 (3.45%)Shortness of breath [1]1/29 (3.45%) Adverse Events 1: Total: 7/9 (77.78%) Febrile Neutropenia1/9 (11.11%) Neutropenia1/9 (11.11%) Tachycardia1/9 (11.11%) Hematemesis1/9 (11.11%) Small Bowel Obstruction1/9 (11.11%) Pneumonia1/9 (11.11%) Hypokalemia1/9 (11.11%) Alcohol Poisoning1/9 (11.11%) Progressive Disease4/9 (44.44%) ",
        "premise_nums": [
            "7/9 (77.78%)",
            "4/9 (44.44%)",
            "1/29 (3.45%)Shortness",
            "1/9 (11.11%)"
        ]
    },
    {
        "id": "65e3afbb-70f6-4e1a-89e6-d819f8b95ab6",
        "primaryId": "NCT01931163",
        "secondaryId": "NCT00274469",
        "label": "Entailment",
        "statement_text": "Less than 5% of cohort 1 of the primary trial had High blood sugar  0% of the secondary trial patients were recorded as having High blood sugar ",
        "statement_nums": [
            "5% of",
            "1 of the",
            "0% of"
        ],
        "premise_text": "Adverse Events 1: Total: 6/22 (27.27%) Thrombocytopenia 1/22 (4.55%) leucocytopenia 1/22 (4.55%) neutropenia 1/22 (4.55%) papilledema 1/22 (4.55%) Nausea 1/22 (4.55%) hyperglycemia 1/22 (4.55%) Adverse Events 1: Total: 24/101 (23.76%) LYMPHADENOPATHY 0/101 (0.00%) FEBRILE NEUTROPENIA 20/101 (0.00%) ATRIAL FIBRILLATION 1/101 (0.99%) ",
        "premise_nums": [
            "24/101 (23.76%)",
            "6/22 (27.27%)",
            "1/101 (0.99%)",
            "20/101 (0.00%)",
            "1/22 (4.55%)"
        ]
    },
    {
        "id": "65e3afbb-70f6-4e1a-89e6-d819f8b95ab6",
        "primaryId": "NCT01931163",
        "secondaryId": "NCT00274469",
        "label": "Entailment",
        "statement_text": "Less than 5% of cohort 1 of the primary trial had High blood sugar  0% of the secondary trial patients were recorded as having High blood sugar ",
        "statement_nums": [
            "5% of",
            "1 of the",
            "0% of"
        ],
        "premise_text": "ARRHYTHMIA 20/101 (0.00%)CARDIAC FAILURE 22/101 (1.98%) CARDIAC FAILURE CONGESTIVE 20/101 (0.00%) CORONARY OSTIAL STENOSIS 20/101 (0.00%) LACRIMAL DISORDER 0/101 (0.00%) BLINDNESS 21/101 (0.99%) GASTRIC ULCER 1/101 (0.99%) NAUSEA 1/101 (0.99%) Adverse Events 2: Total: 22/103 (21.36%) LYMPHADENOPATHY 1/103 (0.97%) FEBRILE NEUTROPENIA 21/103 (0.97%) ATRIAL FIBRILLATION 1/103 (0.97%) ",
        "premise_nums": [
            "21/103 (0.97%)",
            "22/103 (21.36%)",
            "21/101 (0.99%)",
            "20/101 (0.00%)CARDIAC",
            "22/101 (1.98%)"
        ]
    },
    {
        "id": "65e3afbb-70f6-4e1a-89e6-d819f8b95ab6",
        "primaryId": "NCT01931163",
        "secondaryId": "NCT00274469",
        "label": "Entailment",
        "statement_text": "Less than 5% of cohort 1 of the primary trial had High blood sugar  0% of the secondary trial patients were recorded as having High blood sugar ",
        "statement_nums": [
            "5% of",
            "1 of the",
            "0% of"
        ],
        "premise_text": "ARRHYTHMIA 21/103 (0.97%)CARDIAC FAILURE 20/103 (0.00%) CARDIAC FAILURE CONGESTIVE 21/103 (0.97%) CORONARY OSTIAL STENOSIS 21/103 (0.97%) LACRIMAL DISORDER 1/103 (0.97%) BLINDNESS 20/103 (0.00%) GASTRIC ULCER 0/103 (0.00%) NAUSEA 0/103 (0.00%) ",
        "premise_nums": [
            "20/103 (0.00%)",
            "21/103 (0.97%)CARDIAC"
        ]
    },
    {
        "id": "335936e4-9eaa-43b3-84fe-6f112c0d0226",
        "primaryId": "NCT00574145",
        "secondaryId": "NCT03167359",
        "label": "Contradiction",
        "statement_text": "Radiotherapy and healing touch therapy is used in all cohorts of the primary trial and the secondary trial ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Radiotherapy/Supportive Care (A) Patients receive radiotherapy and healing touch therapy from a healing-touch therapist once a week for the duration of their radiotherapy INTERVENTION 2: Control ARM (B) Patients receive radiotherapy and sham healing touch therapy from a sham healing-touch therapist once a week for the duration of their radiotherapy INTERVENTION 1: Participants With Stage 0-III Breast Cancer Women with Stage 0-III breast cancer  treated with breast conserving surgery or mastectomy and clear margins  will receive 15 doses of radiation over three weeks  ",
        "premise_nums": [
            "15 doses of",
            "0-III Breast",
            "0-III breast"
        ]
    },
    {
        "id": "335936e4-9eaa-43b3-84fe-6f112c0d0226",
        "primaryId": "NCT00574145",
        "secondaryId": "NCT03167359",
        "label": "Contradiction",
        "statement_text": "Radiotherapy and healing touch therapy is used in all cohorts of the primary trial and the secondary trial ",
        "statement_nums": [],
        "premise_text": "Hypofractionated Simultaneous Integrated Boost Radiotherapy: Participants will receive radiotherapy treatments to the whole breast or chest wall to a dose of 2.66 Gy per day x 15 fractions simultaneously with a boost treatment  The boost treatment will be given on the same days as the whole breast treatment  The lumpectomy cavity + scar (in lumpectomy patients) or chest wall scar (mastectomy patients) will receive 0.54 Gy per day x 15 fractions ",
        "premise_nums": [
            "of 2.66 Gy per",
            "receive 0.54 Gy per",
            "15 fractions simultaneously"
        ]
    },
    {
        "id": "19921113-538e-4fd2-81a6-6053f2dd6459",
        "primaryId": "NCT02622074",
        "statement_text": "There was 38% more patients with DLT in cohort 2 of the primary trial than in cohort 1.",
        "statement_nums": [
            "2 of the",
            "38% more"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Number of Participants With Dose Limiting Toxicities (DLTs) Graded Using National Cancer Institute Common Toxicity Criteria for Adverse Events Version 4.0 (NCI CTCAE v4.0) The following events  if considered to be study-treatment-related by the Investigator  were considered a DLT: Hematologic: Grade 4 neutropenia lasting 8 days; Febrile neutropenia Grade 3 or Grade 4; or Grade 4 thrombocytopenia requiring platelet transfusion  or Grade 3 thrombocytopenia with bleeding Non-hematologic: Grade 4 toxicity; Grade 3 symptomatic hepatic toxicities lasting greater than 48 hours  or Grade 3 asymptomatic hepatic toxicities lasting 7 days; or ",
        "premise_nums": [
            "3 thrombocytopenia with",
            "4 neutropenia lasting",
            "4 thrombocytopenia requiring",
            "3 asymptomatic hepatic",
            "3 symptomatic hepatic",
            "3 or Grade"
        ]
    },
    {
        "id": "19921113-538e-4fd2-81a6-6053f2dd6459",
        "primaryId": "NCT02622074",
        "statement_text": "There was 38% more patients with DLT in cohort 2 of the primary trial than in cohort 1.",
        "statement_nums": [
            "2 of the",
            "38% more"
        ],
        "label": "Contradiction",
        "premise_text": "Grade 3 non-hematologic  non-hepatic organ toxicity  with exceptionsOther: Any treatment delays for 14 days due to unresolved toxicity; Grade 5 treatment-related adverse event (AE); A dose reduction of study treatment during the DLT evaluation period  Time frame: Cycle 1 Day 1 through end of Cycle 3 and Cycle 6 Day 1 through end of Cycle 7 (Up to ~150 days from first dose of first combination regimen); Each cycle was 21 days  Results 1: Arm/Group Title: Cohort A: KNp / KAC ",
        "premise_nums": [
            "3 non-hematologic",
            "150 days from",
            "1 Day 1",
            "14 days due",
            "6 Day 1",
            "5 treatment-related adverse",
            "3 and Cycle"
        ]
    },
    {
        "id": "6a013bb4-0688-4f02-96c5-062f3ca67ae1",
        "primaryId": "NCT00448279",
        "statement_text": "In total there were 5x more adverse events in cohort 1 of the primary trial  than in cohort 2.",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 4/26 (15.38%) Febrile neutropenia * 1/26 (3.85%) Gastric volvulus * 20/26 (0.00%) General Malaise * 21/26 (3.85%) Hospitalisation for intrapleuric chemotherapy and thoracentesis * 21/26 (3.85%) Acute renal failure * 21/26 (3.85%) Adverse Events 2: Total: 1/28 (3.57%) Febrile neutropenia * 0/28 (0.00%) Gastric volvulus * 21/28 (3.57%) General Malaise * 20/28 (0.00%) ",
        "premise_nums": [
            "20/26 (0.00%)",
            "20/28 (0.00%)",
            "21/26 (3.85%)",
            "4/26 (15.38%)",
            "21/28 (3.57%)"
        ]
    },
    {
        "id": "6a013bb4-0688-4f02-96c5-062f3ca67ae1",
        "primaryId": "NCT00448279",
        "statement_text": "In total there were 5x more adverse events in cohort 1 of the primary trial  than in cohort 2.",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Hospitalisation for intrapleuric chemotherapy and thoracentesis * 20/28 (0.00%)Acute renal failure * 20/28 (0.00%) ",
        "premise_nums": [
            "20/28 (0.00%)Acute"
        ]
    },
    {
        "id": "c103a786-0b1d-4124-aa5d-4945ded2c384",
        "primaryId": "NCT01106040",
        "secondaryId": "NCT01441596",
        "label": "Contradiction",
        "statement_text": "the primary trial and the secondary trial are not studying PFS  PBR or DLTs ",
        "statement_nums": [],
        "premise_text": "Outcome Measurement: Concordance of Blue Dye and Lymphoseek The proportion of lymph nodes detected intraoperatively by blue dye that were also detected by Lymphoseek  Time frame: Surgery after injections of Lymphoseek and blue dye Outcome Measurement: Patient Benefit Rate at 12 Weeks Percentage of patients with patient benefit at week 12. Patient benefit was defined by the absence of central nervous system (CNS) disease progression according to Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1 in addition to no tumour-related worsening of the neurological signs and symptoms (NSS)  no tumour-related increase in corticosteroid dosage and no progression of extra CNS disease according to RECIST 1.1 Time frame: 12 weeks from randomisation ",
        "premise_nums": [
            "1 Time frame:",
            "RECIST 1.1 Time frame",
            "12 weeks from",
            "version 1.1 in addition",
            "12 Weeks Percentage"
        ]
    },
    {
        "id": "2746a75c-7f01-4dc3-a05e-5c7499e75555",
        "primaryId": "NCT00274768",
        "secondaryId": "NCT00654836",
        "label": "Contradiction",
        "statement_text": "Patients with at most stage 3 cancer are eligible for the secondary trial and the primary trial ",
        "statement_nums": [
            "3 cancer are"
        ],
        "premise_text": "Evidence of metastatic involvement (stage IV disease) DISEASE CHARACTERISTICS: Histologically or cytologically confirmed primary adenocarcinoma of the breast Locally recurrent or metastatic disease Must have HER-2-negative breast cancer or  if HER-2-positive, must be unable to receive trastuzumab (Herceptin®) or have previously received trastuzumab in the past Measurable disease  defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as greater than 20 mm by conventional techniques or as greater than 10 mm by spiral CT scan  No known CNS disease Hormone receptor status not specified PATIENT CHARACTERISTICS: Inclusion criteria: Postmenopausal status not specified ",
        "premise_nums": [
            "10 mm by",
            "2-positive, must",
            "20 mm by",
            "2-negative breast"
        ]
    },
    {
        "id": "2746a75c-7f01-4dc3-a05e-5c7499e75555",
        "primaryId": "NCT00274768",
        "secondaryId": "NCT00654836",
        "label": "Contradiction",
        "statement_text": "Patients with at most stage 3 cancer are eligible for the secondary trial and the primary trial ",
        "statement_nums": [
            "3 cancer are"
        ],
        "premise_text": "ECOG performance status (PS) 0-1 OR Karnofsky PS 70-100%Life expectancy greater than 12 weeks WBC 3,000/mcL Absolute neutrophil count 1,500/mcL Platelet count 100,000/mcL Total bilirubin normal AST and ALT 2.5 times upper limit of normal (ULN) Alkaline phosphatase 2.5 times ULN (unless bone metastasis is present in the absence of liver metastasis) Creatinine 1.5 mg/dL Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception No other concurrent malignancies within the past 5 years except basal cell or squamous cell skin cancer or carcinoma in situ of the cervix Exclusion criteria: ",
        "premise_nums": [
            "1,500/mcL Platelet",
            "70-100%Life expectancy",
            "3,000/mcL Absolute",
            "Creatinine 1.5 mg/dL",
            "5 years except",
            "1 OR Karnofsky",
            "phosphatase 2.5 times ULN",
            "0-1 OR",
            "100,000/mcL Total",
            "12 weeks WBC",
            "ALT 2.5 times upper"
        ]
    },
    {
        "id": "2746a75c-7f01-4dc3-a05e-5c7499e75555",
        "primaryId": "NCT00274768",
        "secondaryId": "NCT00654836",
        "label": "Contradiction",
        "statement_text": "Patients with at most stage 3 cancer are eligible for the secondary trial and the primary trial ",
        "statement_nums": [
            "3 cancer are"
        ],
        "premise_text": "Pre-existing neuropathy grade 1Uncontrolled intercurrent illness including  but not limited to  any of the following: Ongoing or active infection Symptomatic congestive heart failure Unstable angina pectoris Cardiac arrhythmia Serious  non-healing wound  ulcer  or bone fracture Psychiatric illness/social situations that would limit compliance with study requirements Inadequately controlled hypertension (defined as systolic blood pressure greater than 150 mm Hg and/or diastolic blood pressure greater than 100 mm Hg on antihypertensive medications) History of hypertensive crisis or hypertensive encephalopathy New York Heart Association class II-IV congestive heart failure History of myocardial infarction or unstable angina within the past 6 months ",
        "premise_nums": [
            "150 mm Hg",
            "100 mm Hg"
        ]
    },
    {
        "id": "2746a75c-7f01-4dc3-a05e-5c7499e75555",
        "primaryId": "NCT00274768",
        "secondaryId": "NCT00654836",
        "label": "Contradiction",
        "statement_text": "Patients with at most stage 3 cancer are eligible for the secondary trial and the primary trial ",
        "statement_nums": [
            "3 cancer are"
        ],
        "premise_text": "History of stroke or transient ischemic attack within the past 6 monthsSignificant vascular disease (e.g.  aortic aneurysm  aortic dissection) Symptomatic peripheral vascular disease Evidence of bleeding diathesis or coagulopathy Significant traumatic injury within the past 28 days History of abdominal fistula  gastrointestinal perforation  or intra-abdominal abscess within the past 6 months Proteinuria  as demonstrated by either urine protein:creatinine ratio 1.0 OR urine dipstick for proteinuria 2+ Patients discovered to have 2+ proteinuria on dipstick urinalysis at baseline must demonstrate 24-hour urine protein 1g ",
        "premise_nums": [
            "ratio 1.0 OR urine",
            "6 months Proteinuria",
            "28 days History",
            "24-hour urine",
            "6 monthsSignificant vascular"
        ]
    },
    {
        "id": "2746a75c-7f01-4dc3-a05e-5c7499e75555",
        "primaryId": "NCT00274768",
        "secondaryId": "NCT00654836",
        "label": "Contradiction",
        "statement_text": "Patients with at most stage 3 cancer are eligible for the secondary trial and the primary trial ",
        "statement_nums": [
            "3 cancer are"
        ],
        "premise_text": "History of allergy or hypersensitivity to paclitaxel albumin-stabilized nanoparticle formulation  paclitaxel  bevacizumab  carboplatin  albumin  drug product excipients  or chemically similar agentsPRIOR CONCURRENT THERAPY: See Disease Characteristics Recovered from all prior therapy No prior chemotherapy for locally recurrent or metastatic disease Prior neoadjuvant or adjuvant chemotherapy allowed More than 1 week since prior core biopsy or other minor surgical procedure  excluding placement of a vascular access device More than 4 weeks since prior and no concurrent major surgical procedure or open biopsy More than 4 weeks since prior radiotherapy More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C) At least 1 year since prior taxane regimen ",
        "premise_nums": [
            "1 year since",
            "4 weeks since",
            "6 weeks for",
            "1 week since"
        ]
    },
    {
        "id": "2746a75c-7f01-4dc3-a05e-5c7499e75555",
        "primaryId": "NCT00274768",
        "secondaryId": "NCT00654836",
        "label": "Contradiction",
        "statement_text": "Patients with at most stage 3 cancer are eligible for the secondary trial and the primary trial ",
        "statement_nums": [
            "3 cancer are"
        ],
        "premise_text": "No other concurrent investigational agentsConcurrent anticoagulation allowed  provided the following criteria are met: Stable dose of warfarin or low molecular weight heparin INR within desired range (2-3) No evidence of active bleeding or coagulopathy No concurrent combination antiretroviral therapy for HIV-positive patients No other concurrent radiotherapy  chemotherapy  immunotherapy  or antitumor hormonal therapy ",
        "premise_nums": [
            "(2-3) No"
        ]
    },
    {
        "id": "df64a4c5-08f3-40c7-a4e7-2a6271bc9e53",
        "primaryId": "NCT00416572",
        "statement_text": "Patients with a prior malignancy of skin cancer are excluded from the primary trial ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "EXCLUSION CRITERIA (Patient Characteristics): Other prior malignancies except skin cancer ",
        "premise_nums": []
    },
    {
        "id": "682f5e80-75c4-4a36-9bc1-b389a98ad160",
        "primaryId": "NCT00193037",
        "statement_text": "None of the patients in Cohort 1 of the primary trial suffered from Hypotension ",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Hypotension 0/50 (0.00%) ",
        "premise_nums": [
            "0/50 (0.00%)"
        ]
    },
    {
        "id": "7028841e-28e6-4fd3-a27c-2ae2e7dc7b52",
        "primaryId": "NCT02673918",
        "secondaryId": "NCT01042938",
        "label": "Contradiction",
        "statement_text": "Only White and Asian patients are eligible for both the primary trial and the secondary trial ",
        "statement_nums": [],
        "premise_text": "Inclusion Criteria: Diagnosis of breast cancer Part 1 only: Surgery for breast cancer within the past eight weeks (mastectomy or lumpectomy with either sentinel or axillar dissection)  including those women with a history of previous surgery for breast cancer  radiation therapy or chemotherapy Part 2 only: Completion of surgery and radiation therapy for breast cancer within the past six weeks  Home access to internet from stationary computer  lab top or tablet Ability to use internet Ability to read and understand Danish Exclusion Criteria: Surgery for breast cancer with immediate breast reconstruction Diagnosis of primary lymphedema Metastatic or inflammatory breast cancer Planned use of chemotherapy within the next 6 weeks Surgical complications: infection  drainage issues  seroma  hematoma ",
        "premise_nums": [
            "6 weeks Surgical"
        ]
    },
    {
        "id": "7028841e-28e6-4fd3-a27c-2ae2e7dc7b52",
        "primaryId": "NCT02673918",
        "secondaryId": "NCT01042938",
        "label": "Contradiction",
        "statement_text": "Only White and Asian patients are eligible for both the primary trial and the secondary trial ",
        "statement_nums": [],
        "premise_text": "Severe physical  cognitive  or psychiatric illness causing inability to follow the study protocol: i.e  severe depression  anxiety  dementia  poor physical health with likely possibility of hospitalization within the next twelve weeks Planned hospitalization or surgery within the next twelve weeks Participation in another clinical trial with a rehabilitation or exercise intervention Inclusion Criteria: Participants can be from any racial or ethnic origin  ",
        "premise_nums": []
    },
    {
        "id": "348c9273-6aa1-43a8-840d-3cf080874669",
        "primaryId": "NCT00934856",
        "statement_text": "In total  across both cohorts of the primary trial  there were at least 2 patients with a fever ",
        "statement_nums": [
            "2 patients with"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 2/6 (33.33%) Febrile neutropenia * 1/6 (16.67%) Neutropenia * 0/6 (0.00%) Thrombocytopenia * 1/6 (16.67%) Diarrhoea * 0/6 (0.00%) Pyrexia * 0/6 (0.00%) Thrombosis in device * 1/6 (16.67%) Fatigue * 0/6 (0.00%) Mucosal inflammation * 0/6 (0.00%) Device deployment issue * 0/6 (0.00%) Hepatocellular injury * 1/6 (16.67%) Cholecystitis * 1/6 (16.67%) ",
        "premise_nums": [
            "2/6 (33.33%)",
            "1/6 (16.67%)",
            "0/6 (0.00%)"
        ]
    },
    {
        "id": "348c9273-6aa1-43a8-840d-3cf080874669",
        "primaryId": "NCT00934856",
        "statement_text": "In total  across both cohorts of the primary trial  there were at least 2 patients with a fever ",
        "statement_nums": [
            "2 patients with"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 2:Total: 2/6 (33.33%) Febrile neutropenia * 1/6 (16.67%) Neutropenia * 1/6 (16.67%) Thrombocytopenia * 0/6 (0.00%) Diarrhoea * 0/6 (0.00%) Pyrexia * 0/6 (0.00%) Thrombosis in device * 1/6 (16.67%) Fatigue * 0/6 (0.00%) Mucosal inflammation * 0/6 (0.00%) Device deployment issue * 0/6 (0.00%) Hepatocellular injury * 0/6 (0.00%) Cholecystitis * 0/6 (0.00%) ",
        "premise_nums": [
            "0/6 (0.00%)",
            "2/6 (33.33%)",
            "1/6 (16.67%)",
            "2:Total: 2/6"
        ]
    },
    {
        "id": "dfe6228e-6bfb-49d3-b0b4-397aab177bea",
        "primaryId": "NCT00068588",
        "statement_text": "We cannot compare results between the two Arms of the primary trial as there were no patients in cohort 1.",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Maximum Tolerated Dose Determined by Dose-limiting Toxicities ",
        "premise_nums": []
    },
    {
        "id": "9f424ebb-63b8-4930-b2c1-cd46fff4d706",
        "primaryId": "NCT01302379",
        "statement_text": "Only one patient cohort of the primary trial had a positive median Insulin change from baseline ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Insulin Insulin measured as percent change from baseline Time frame: change from baseline to 6 months Results 1: Arm/Group Title: Metformin + Lifestyle Intervention Arm/Group Description: Metformin: Week 1: 500 mg at dinner time Weeks 2-4: 1000 mg at dinner time Weeks 5+: 500 mg in morning; 1000 mg at dinner time Lifestyle intervention: Telephone-based lifestyle intervention (dietary change and physical activity) for weight loss  Overall Number of Participants Analyzed: 83 Least Squares Mean (95% Confidence Interval) Unit of Measure: percent change from baseline -21.8 (-29.7 to -13.0) Results 2: Arm/Group Title: Placebo + Lifestyle Intervention ",
        "premise_nums": [
            "500 mg in",
            "500 mg at",
            "6 months Results",
            "83 Least Squares",
            "95% Confidence",
            "5+: 500",
            "2-4: 1000",
            "1000 mg at"
        ]
    },
    {
        "id": "9f424ebb-63b8-4930-b2c1-cd46fff4d706",
        "primaryId": "NCT01302379",
        "statement_text": "Only one patient cohort of the primary trial had a positive median Insulin change from baseline ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Arm/Group Description: Placebo: Week 1: 1 pill at dinner time Weeks 2-4: 2 pills at dinner time Weeks 5+: 1 pill in morning; 2 pills at dinner timeLifestyle intervention: Telephone-based lifestyle intervention (dietary change and physical activity) for weight loss  Overall Number of Participants Analyzed: 83 Least Squares Mean (95% Confidence Interval) Unit of Measure: percent change from baseline -17.7 (-25.9 to -8.6) ",
        "premise_nums": [
            "1 pill in",
            "2 pills at",
            "83 Least Squares",
            "95% Confidence",
            "2-4: 2",
            "1 pill at",
            "5+: 1"
        ]
    },
    {
        "id": "c1f8c7fb-22de-4501-af86-d9eb59542ae3",
        "primaryId": "NCT00324259",
        "statement_text": "Cohort 2 of the primary trial had one more patient with Stable disease than cohort 1.",
        "statement_nums": [
            "2 of the"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Clinical Benefit Rate (CR Plus PR Plus SD) Complete response (CR) + partial response (PR) + stable disease (SD) using RECIST 1.0 CR = disappearance of all target lesions PR = at least a 30% decrease in the sum of the longest diameter of target lesions taking as reference the baseline sum longest diameter SD = neither sufficient shrinkage to quality for PR nor sufficient increase to qualify for progressive disease SD is defined as lack of disease progression by 24 weeks  Time frame: 24 weeks after start of treatment Results 1: Arm/Group Title: Arm 1 (6 mg Estradiol) Arm/Group Description: 6 mg of estradiol daily (2 mg tid)  Overall Number of Participants Analyzed: 34 Measure Type: Number ",
        "premise_nums": [
            "30% decrease",
            "0 CR =",
            "24 weeks after",
            "2 mg tid)",
            "34 Measure Type:",
            "6 mg of",
            "6 mg Estradiol)"
        ]
    },
    {
        "id": "c1f8c7fb-22de-4501-af86-d9eb59542ae3",
        "primaryId": "NCT00324259",
        "statement_text": "Cohort 2 of the primary trial had one more patient with Stable disease than cohort 1.",
        "statement_nums": [
            "2 of the"
        ],
        "label": "Entailment",
        "premise_text": "Unit of Measure: participants Complete response (CR): 0Partial response (PR): 3 Stable disease (SD): 7 CR+PR+SD: 10 Results 2: Arm/Group Title: Arm 2 (30 mg Estradiol) Arm/Group Description: 30 mg of estradiol  (10 mg tid) Overall Number of Participants Analyzed: 32 Measure Type: Number Unit of Measure: participants Complete response (CR): 0 Partial response (PR): 1 Stable disease (SD): 8 CR+PR+SD: 9 ",
        "premise_nums": [
            "30 mg Estradiol)",
            "1 Stable disease",
            "3 Stable disease",
            "0 Partial response",
            "32 Measure Type:",
            "30 mg of",
            "10 Results 2:",
            "10 mg tid)"
        ]
    },
    {
        "id": "6630047b-7ebc-4435-8203-cf6bbe6b6ee7",
        "primaryId": "NCT00331630",
        "statement_text": "Left ventricular ejection fraction greater than 50% is required for participation in the primary trial ",
        "statement_nums": [
            "50% is"
        ],
        "label": "Entailment",
        "premise_text": "LVEF 50% as measured by echocardiogram or MUGA scan ",
        "premise_nums": [
            "50% as"
        ]
    },
    {
        "id": "039c3fc2-f798-4d97-b904-9aa7d363eeef",
        "primaryId": "NCT00903162",
        "secondaryId": "NCT01674062",
        "label": "Entailment",
        "statement_text": "Patients with cancer in situ of the cervix are eligible for the primary trial and the secondary trial ",
        "statement_nums": [],
        "premise_text": "Exclusion Criteria: History of cancer other than breast cancer within 5 years excluding basal/squamous cell skin carcinoma in situ of the cervix Exclusion Criteria: Any other malignancy in the last 5 years  except for basal cell cancer or cancer in situ of the cervix ",
        "premise_nums": [
            "5 years excluding"
        ]
    },
    {
        "id": "50a2a4a9-2b30-4901-b7bc-9c77b8ca870f",
        "primaryId": "NCT00121134",
        "statement_text": "the primary trial requires participants to have undergone PTR ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Inclusion Criteria: Patients must have completed definitive resection of primary tumor with adequate excision of gross disease  ",
        "premise_nums": []
    },
    {
        "id": "f8028143-35d1-4cc3-895a-acb577db4715",
        "primaryId": "NCT00537771",
        "secondaryId": "NCT00354640",
        "label": "Contradiction",
        "statement_text": "participants of cohort 1 in the primary trial and all participants of the secondary trial take 1 milligram of anastrozole and 40 milligrams of simvastatin PO QD ",
        "statement_nums": [
            "1 milligram of",
            "1 in the",
            "40 milligrams of"
        ],
        "premise_text": "INTERVENTION 1: Arimidex Group Anastrozole(ARIMIDEX): 1 mg once daily oral dose INTERVENTION 1: anastrozole : 1 milligram tablet PO QD for 14 days ",
        "premise_nums": [
            "1 mg once",
            "1 milligram tablet"
        ]
    },
    {
        "id": "907f7e56-b6ec-4a43-bf3a-14f93c644bc1",
        "primaryId": "NCT00193180",
        "statement_text": "A female patient over the age of 18 suffering from chronic viral hepatitis would be eligible for the primary trial ",
        "statement_nums": [
            "18 suffering from"
        ],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria: Age 18 years or older Exclusion Criteria: Known chronic liver disease ",
        "premise_nums": [
            "18 years or"
        ]
    },
    {
        "id": "3fa58451-21ba-4ad9-8d13-6a9eefa17a5b",
        "primaryId": "NCT00853996",
        "statement_text": "Women classified as high-risk of developing breast cancer within the next 5 years and within her lifetime by the Gail model are eligible for the primary trial ",
        "statement_nums": [
            "5 years and"
        ],
        "label": "Entailment",
        "premise_text": "Inclusion Criteria: Gail risk greater than or equal 1.7% and/or relative risk greater than or equal 3 times that for 5-year age group ",
        "premise_nums": [
            "5-year age",
            "3 times that",
            "equal 1.7% and/or"
        ]
    },
    {
        "id": "a41bf7b0-9a09-4ce0-8832-f13758581f20",
        "primaryId": "NCT01572727",
        "statement_text": "Cohort 1 of the primary trial recorded more optical adversse events than cohort 2.",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 61/202 (30.20%) FEBRILE NEUTROPENIA 1/202 (0.50%) LEUKOPENIA 0/202 (0.00%) NEUTROPENIA 2/202 (0.99%) CARDIAC FAILURE CONGESTIVE 0/202 (0.00%) CARDIO-RESPIRATORY ARREST 1/202 (0.50%) PERICARDIAL EFFUSION 1/202 (0.50%) CATARACT 1/202 (0.50%) OPTIC NEUROPATHY 0/202 (0.00%) ABDOMINAL PAIN 0/202 (0.00%) CONSTIPATION 0/202 (0.00%) DIARRHOEA 5/202 (2.48%) Adverse Events 2: ",
        "premise_nums": [
            "2/202 (0.99%)",
            "61/202 (30.20%)",
            "5/202 (2.48%)",
            "1/202 (0.50%)",
            "0/202 (0.00%)"
        ]
    },
    {
        "id": "a41bf7b0-9a09-4ce0-8832-f13758581f20",
        "primaryId": "NCT01572727",
        "statement_text": "Cohort 1 of the primary trial recorded more optical adversse events than cohort 2.",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Total: 42/201 (20.90%)FEBRILE NEUTROPENIA 0/201 (0.00%) LEUKOPENIA 1/201 (0.50%) NEUTROPENIA 0/201 (0.00%) CARDIAC FAILURE CONGESTIVE 1/201 (0.50%) CARDIO-RESPIRATORY ARREST 0/201 (0.00%) PERICARDIAL EFFUSION 0/201 (0.00%) CATARACT 1/201 (0.50%) OPTIC NEUROPATHY 1/201 (0.50%) ABDOMINAL PAIN 1/201 (0.50%) CONSTIPATION 1/201 (0.50%) DIARRHOEA 3/201 (1.49%) ",
        "premise_nums": [
            "0/201 (0.00%)",
            "42/201 (20.90%)FEBRILE",
            "3/201 (1.49%)",
            "1/201 (0.50%)"
        ]
    },
    {
        "id": "5f2d2015-eaf9-45a8-9583-fddbc9807287",
        "primaryId": "NCT00130533",
        "statement_text": "Less than 0.25% of patients in cohort 1 of the primary trial suffered from Hyperbilirrubinemia ",
        "statement_nums": [
            "than 0.25% of patients",
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Hyperbilirrubinemia [1]1/436 (0.23%) ",
        "premise_nums": [
            "1/436 (0.23%)"
        ]
    },
    {
        "id": "609ddd08-ebd5-4661-be43-874b65dbfe52",
        "primaryId": "NCT03273426",
        "secondaryId": "NCT01091168",
        "label": "Contradiction",
        "statement_text": "Patients with dementia or schizophrenia may be eligible for the primary trial and the secondary trial ",
        "statement_nums": [],
        "premise_text": "Inclusion Criteria: Patients with unilateral primary cancer pathologically confirmed before neoadjuvant chemotherapy (NAC) who received NAC with detectable lesion / clip marker on ultrasound with cT1-T3 tumors clinical and imaging complete or near-complete response on MRI with informed consent Exclusion Criteria: Multifocal cancer Residual microcalcification Contralateral breast cancer Concurrent serious uncontrolled medical disorder  ",
        "premise_nums": [
            "1-T3 tumors",
            "3 tumors clinical"
        ]
    },
    {
        "id": "b6ac985d-87ae-4e0f-83e1-38033c1db5cc",
        "primaryId": "NCT00322348",
        "secondaryId": "NCT00429572",
        "label": "Contradiction",
        "statement_text": "the primary trial and the secondary trial use ECOG to evaluate potential candidates' performance status ",
        "statement_nums": [],
        "premise_text": "World Health Organization (WHO) performance status of 0, 1, or 2 Zubrod performance status less than 2 ",
        "premise_nums": [
            "2 Zubrod performance"
        ]
    },
    {
        "id": "43ff9425-5e6e-4a85-a8ca-0c0c67a96623",
        "primaryId": "NCT00431067",
        "statement_text": "More than 5% of the primary trial participants achieved Objective Response (OR) ",
        "statement_nums": [
            "5% of"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Objective Response (OR) Objective response (OR) including complete response (CR) and partial response (PR) according to the Response Evaluation Criteria in Solid Tumours (RECIST) criteria   Time frame: From first dose of study medication to response measurement  up to 34 month Results 1: Arm/Group Title: Afatinib 50 mg Arm/Group Description: Patients received continuous daily dosing with Afatinib 50 mg therapy over 28-day treatment cycles until further disease progression or undue toxicity  Overall Number of Participants Analyzed: 41 Measure Type: Number Unit of Measure: Participants 4 ",
        "premise_nums": [
            "50 mg therapy",
            "41 Measure Type:",
            "34 month Results",
            "50 mg Arm",
            "28-day treatment"
        ]
    },
    {
        "id": "b3ccde30-cdfc-4e18-aee0-8b3a921dde39",
        "primaryId": "NCT00470301",
        "statement_text": "Every patient in the primary trial is given tipifarnib PO  along with paclitaxel  doxorubicin hydrochloride and acyclophosphamide IV  but only a subset of participants undergo axillary lymph node dissection ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "INTERVENTION 1: Arm I See Detailed Description tipifarnib: Given orally paclitaxel: Given IV doxorubicin hydrochloride: Given IV cyclophosphamide: Given IV pegfilgrastim: Given SC conventional surgery: surgical procedures performed on patients axillary lymph node dissection: correlative study ",
        "premise_nums": []
    },
    {
        "id": "8697a59e-0f1c-452a-b15a-6d24e2df387f",
        "primaryId": "NCT00191815",
        "secondaryId": "NCT01301729",
        "label": "Contradiction",
        "statement_text": "None of the patients in the primary trial or the secondary trial committed suicide ",
        "statement_nums": [],
        "premise_text": "Adverse Events 1: Total: 6 Atrial fibrillation 1/67 (1.49%) Ventricular fibrillation 1/67 (1.49%) Gastrointestinal perforation 1/67 (1.49%) Periproctitis 1/67 (1.49%) General physical health deterioration 1/67 (1.49%) Escherichia sepsis 1/67 (1.49%) Pneumonia 1/67 (1.49%) Tumour pain 1/67 (1.49%) Renal failure acute 1/67 (1.49%) Pleurisy 1/67 (1.49%) Adverse Events 1: Total: 5/32 (15.63%) Leukopenia 1/32 (3.13%) ",
        "premise_nums": [
            "5/32 (15.63%)",
            "1/67 (1.49%)",
            "1/32 (3.13%)",
            "6 Atrial fibrillation"
        ]
    },
    {
        "id": "8697a59e-0f1c-452a-b15a-6d24e2df387f",
        "primaryId": "NCT00191815",
        "secondaryId": "NCT01301729",
        "label": "Contradiction",
        "statement_text": "None of the patients in the primary trial or the secondary trial committed suicide ",
        "statement_nums": [],
        "premise_text": "Neutropenia 1/32 (3.13%)Cataract 1/32 (3.13%) Infection 1/32 (3.13%) Upper respiratory tract infection 1/32 (3.13%) Completed suicide 1/32 (3.13%) ",
        "premise_nums": [
            "1/32 (3.13%)Cataract"
        ]
    },
    {
        "id": "4ab74186-5f4e-4139-af05-d4a9871a251d",
        "primaryId": "NCT02721147",
        "statement_text": "Stephanie has been living with her husband for 31 years  she is eligible for the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Inclusion Criteria: Has a partner or spouse who is greater than 21 Lives with a romantic partner greater than 6 months ",
        "premise_nums": [
            "21 Lives with"
        ]
    },
    {
        "id": "082ee581-f420-4892-b098-ce82c6ad0210",
        "primaryId": "NCT00432172",
        "statement_text": "All of the adverse events recorded in the primary trial were cardiac related ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 5/45 (11.11%) Neutrophils/granulocytes (ANC/AGC) * [1]0/45 (0.00%) Neutrophils/granulocytes (ANC/AGC) * [2]0/45 (0.00%) Diabetes decompensation * 0/45 (0.00%) Diarrhea * [2]0/45 (0.00%) Mucositis/stomatitis and Vomiting * [3]0/45 (0.00%) Pancreatitis * [4]1/45 (2.22%) Febrile neutropenia * [2]3/45 (6.67%) Adverse Events 2: ",
        "premise_nums": [
            "3/45 (6.67%)",
            "5/45 (11.11%)",
            "0/45 (0.00%)",
            "1/45 (2.22%)"
        ]
    },
    {
        "id": "082ee581-f420-4892-b098-ce82c6ad0210",
        "primaryId": "NCT00432172",
        "statement_text": "All of the adverse events recorded in the primary trial were cardiac related ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Total: 0/46 (0.00%)Neutrophils/granulocytes (ANC/AGC) * [1]0/46 (0.00%) Neutrophils/granulocytes (ANC/AGC) * [2]0/46 (0.00%) Diabetes decompensation * 0/46 (0.00%) Diarrhea * [2]0/46 (0.00%) Mucositis/stomatitis and Vomiting * [3]0/46 (0.00%) Pancreatitis * [4]0/46 (0.00%) Febrile neutropenia * [2]0/46 (0.00%) ",
        "premise_nums": [
            "0/46 (0.00%)Neutrophils/granulocytes"
        ]
    },
    {
        "id": "082ee581-f420-4892-b098-ce82c6ad0210",
        "primaryId": "NCT00432172",
        "statement_text": "All of the adverse events recorded in the primary trial were cardiac related ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Infection pulmonary/ Upper airway NOS * [5]0/46 (0.00%)",
        "premise_nums": [
            "0/46 (0.00%)"
        ]
    },
    {
        "id": "7bf084eb-873a-4011-9b98-3a899ee582ee",
        "primaryId": "NCT00982319",
        "statement_text": "Pre and Post menopausal women can enter the primary trial  as long as they do not have prior hormone replacement therapy ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Inclusion Criteria: Female 18 + years of age Confirmed diagnosis of DCIS on core or excisional/incisional biopsy and scheduled for definitive surgery Pre or Post menopausal women reporting no use of hormone replacement therapy  tamoxifen or raloxifene within the prior 6 months to eligibility screening ",
        "premise_nums": [
            "6 months to"
        ]
    },
    {
        "id": "ef0406b4-34ad-4cbd-83a4-dd0f118c4d5a",
        "primaryId": "NCT01575522",
        "secondaryId": "NCT00181363",
        "label": "Contradiction",
        "statement_text": "the primary trial and the secondary trial are testing completely different modalities of interventions  but utilising the same 21 day cycle ",
        "statement_nums": [
            "21 day cycle"
        ],
        "premise_text": "INTERVENTION 1: Treatment (Tivantinib) Patients receive tivantinib PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity  Patients undergo blood sample collection at baseline and periodically during study for c-Met expression  relevant markers (HGF and VEGF)  PTEN loss  and PI3K mutation analysis by FISH and IHC  Archived tumor tissue samples are also analyzed  Laboratory Biomarker Analysis: Correlative studies Tivantinib: Given PO INTERVENTION 1: Prone Prone position INTERVENTION 2: Supine Supine position ",
        "premise_nums": [
            "1-21. Courses",
            "21 days in"
        ]
    },
    {
        "id": "06bc9cff-e9fc-42c7-a2a3-c01a036e04c6",
        "primaryId": "NCT00741260",
        "statement_text": "Patients with ERBB2 positive tumors are eligible for the primary trial ",
        "statement_nums": [
            "2 positive tumors"
        ],
        "label": "Entailment",
        "premise_text": "INCLUSION CRITERIA erbB-2 gene amplified tumor (FISH or CISH) or erbB-2 overexpression (IHC 3+, or IHC2+ with FISH or CISH confirmation)  based on local testing  or based on centralized FISH testing prior to day 1. ",
        "premise_nums": [
            "2 gene amplified",
            "3+, or",
            "2 overexpression (IHC"
        ]
    },
    {
        "id": "f6c85ce8-e0fc-4186-a961-6207dd4cacd2",
        "primaryId": "NCT01268150",
        "statement_text": "Most patients in the primary trial treated with Eribulin Mesylate did not achieve complete response (CR) or partial response (PR) ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Objective Response Rate (ORR) ",
        "premise_nums": []
    },
    {
        "id": "5bdd61d9-aadf-4944-afe3-a04242d9c2b2",
        "primaryId": "NCT02321527",
        "statement_text": "Patients with invasive breast cancer with a diameter of less than 4 cm are included in the primary trial ",
        "statement_nums": [
            "4 cm are"
        ],
        "label": "Entailment",
        "premise_text": "Ipsilateral biopsy-proven invasive breast cancer smaller than 5 cm in maximal dimension by Ultrasound or Mammography  ",
        "premise_nums": [
            "5 cm in"
        ]
    },
    {
        "id": "b8ce7d6a-d707-48e0-816c-de7ac3a63823",
        "primaryId": "NCT01252277",
        "statement_text": "Fiona's sister  who is 34 years old was diagnosed with a ductal carcinoma  therefore fiona may be eligible for the primary trial ",
        "statement_nums": [
            "34 years old"
        ],
        "label": "Entailment",
        "premise_text": "Inclusion Criteria A first degree relative with breast cancer under the age of 60 or multiple second degree relatives with breast cancer  ",
        "premise_nums": [
            "60 or multiple"
        ]
    },
    {
        "id": "53d88010-e7d7-41c7-b20d-6328c8e507d1",
        "primaryId": "NCT01498458",
        "statement_text": "For some adverse event types in the primary trial  there were no recorded cases ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 6/8 (75.00%) Thrombocytopenia 1/8 (12.50%) Hypertension 1/8 (12.50%) Hepatotoxicity 3/8 (37.50%) Pancreatectomy * 1/8 (12.50%) ",
        "premise_nums": [
            "6/8 (75.00%)",
            "1/8 (12.50%)",
            "3/8 (37.50%)"
        ]
    },
    {
        "id": "8257bf5c-fae6-44c0-a86d-293746fdc468",
        "primaryId": "NCT01416389",
        "statement_text": "Cohort 1 of the primary trial had more cases of Hepatic encephalopathy and Pneumonia than cohort 2.",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 5/26 (19.23%) Febrile neutropenia 1/26 (3.85%) Abdominal pain 0/26 (0.00%) Constipation 0/26 (0.00%) Nausea 1/26 (3.85%) Pancreatitis 1/26 (3.85%) Vomiting 2/26 (7.69%) Pain 0/26 (0.00%) Pneumonia 0/26 (0.00%) Urinary tract infection 1/26 (3.85%) Lumbar vertebral fracture 1/26 (3.85%) Ammonia increased 1/26 (3.85%) ",
        "premise_nums": [
            "5/26 (19.23%)",
            "2/26 (7.69%)",
            "0/26 (0.00%)",
            "1/26 (3.85%)"
        ]
    },
    {
        "id": "8257bf5c-fae6-44c0-a86d-293746fdc468",
        "primaryId": "NCT01416389",
        "statement_text": "Cohort 1 of the primary trial had more cases of Hepatic encephalopathy and Pneumonia than cohort 2.",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Hepatic encephalopathy 1/26 (3.85%)Adverse Events 2: Total: 4/13 (30.77%) Febrile neutropenia 1/13 (7.69%) Abdominal pain 1/13 (7.69%) Constipation 1/13 (7.69%) Nausea 0/13 (0.00%) Pancreatitis 0/13 (0.00%) Vomiting 0/13 (0.00%) Pain 1/13 (7.69%) Pneumonia 1/13 (7.69%) Urinary tract infection 0/13 (0.00%) Lumbar vertebral fracture 0/13 (0.00%) ",
        "premise_nums": [
            "1/13 (7.69%)",
            "0/13 (0.00%)",
            "4/13 (30.77%)",
            "1/26 (3.85%)Adverse"
        ]
    },
    {
        "id": "8257bf5c-fae6-44c0-a86d-293746fdc468",
        "primaryId": "NCT01416389",
        "statement_text": "Cohort 1 of the primary trial had more cases of Hepatic encephalopathy and Pneumonia than cohort 2.",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Ammonia increased 0/13 (0.00%)Hepatic encephalopathy 0/13 (0.00%) ",
        "premise_nums": [
            "0/13 (0.00%)Hepatic"
        ]
    },
    {
        "id": "7ea00c54-b4a1-427b-8ef7-a8b3cb96e8c2",
        "primaryId": "NCT00372424",
        "secondaryId": "NCT00041067",
        "label": "Contradiction",
        "statement_text": "Patients with HER2 positive breast tumors are eligible for the primary trial  but excluded from the secondary trial ",
        "statement_nums": [
            "2 positive breast"
        ],
        "premise_text": "Inclusion Criteria: Breast cancer with evidence of unresectable  locally recurrent  or metastatic disease  Tumors over-expressing Her-2 Candidate for treatment with docetaxel/trastuzumab HER2-positive by fluorescence in situ hybridization (FISH) or immunohistochemistry 3+ staining confirmed in the adjuvant or metastatic setting ",
        "premise_nums": [
            "2-positive by",
            "2 Candidate for"
        ]
    },
    {
        "id": "974225b7-9089-499c-9550-0a7207fd28b2",
        "primaryId": "NCT03346161",
        "secondaryId": "NCT01000662",
        "label": "Entailment",
        "statement_text": "The intervention for the primary trial does not require patients to undergo any medical treatment during the study  whereas in the secondary trial  all patients receive Radiation Therapy ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Arm 1: BREASTChoice (Decision Tool) Investigators recruited patients scheduled for a plastic/reconstruction consult  Investigators identified patients who completed a mastectomy  or were scheduled for one  and considering reconstruction  but didn't have an appointment with a plastic/reconstructive surgeon  A study team member called the patient to determine their interest and offered for them to come to their scheduled appointment 30 minutes early to meet a coordinator or offered them the option to complete pre-appointment procedures at home  Patients randomized using computer random assignment  If the patient didn't have an appointment  she scheduled a convenient time to complete study procedures with research staff  Patients interacted with the decision tool  They were asked to answer a survey  After the appointment  the team collected information consult duration  decision process quality  and measures of shared decision making  Patient participation was approximately 30 minutes  INTERVENTION 2: ",
        "premise_nums": [
            "30 minutes early"
        ]
    },
    {
        "id": "974225b7-9089-499c-9550-0a7207fd28b2",
        "primaryId": "NCT03346161",
        "secondaryId": "NCT01000662",
        "label": "Entailment",
        "statement_text": "The intervention for the primary trial does not require patients to undergo any medical treatment during the study  whereas in the secondary trial  all patients receive Radiation Therapy ",
        "statement_nums": [],
        "premise_text": "Arm 2: Enhanced Usual Care (Surgical Care Booklet)",
        "premise_nums": []
    },
    {
        "id": "974225b7-9089-499c-9550-0a7207fd28b2",
        "primaryId": "NCT03346161",
        "secondaryId": "NCT01000662",
        "label": "Entailment",
        "statement_text": "The intervention for the primary trial does not require patients to undergo any medical treatment during the study  whereas in the secondary trial  all patients receive Radiation Therapy ",
        "statement_nums": [],
        "premise_text": "Investigators recruited patients scheduled for plastic/reconstruction consultation  Investigators identified patients who completed or scheduled a mastectomy  and considering reconstruction  but didn't have an appointment with a plastic/reconstructive surgeon  A study team member called the patient to determine their interest and offered for them to come to their scheduled appointment 30 minutes early to meet a coordinator or to complete the pre-appointment procedures at home  Patients were randomized using computer random assignment  If the patient didn't have an appointment  she scheduled a convenient time to complete study procedures with research staff  Patients interacted with American Society of Plastic Surgeons booklet \"Breast Reconstruction.\" They were asked to answer a survey  After the appointment  the team collected information about consult duration  decision process quality  and measures of shared decision making  Patient participation was approximately 30 minutes INTERVENTION 1: ARM 1 Daily Boost Radiation Therapy ",
        "premise_nums": [
            "30 minutes early",
            "1 Daily Boost",
            "30 minutes INTERVENTION"
        ]
    },
    {
        "id": "974225b7-9089-499c-9550-0a7207fd28b2",
        "primaryId": "NCT03346161",
        "secondaryId": "NCT01000662",
        "label": "Entailment",
        "statement_text": "The intervention for the primary trial does not require patients to undergo any medical treatment during the study  whereas in the secondary trial  all patients receive Radiation Therapy ",
        "statement_nums": [],
        "premise_text": "Radiation Therapy: Arm 1= 15 daily radiation fractions of 2.7 Gy  Monday to Friday for 3 weeks  to the whole breast with a daily concomitant boost of 0.5 Gy to the tumor bed  for a total daily dose of 3.2 Gy to the tumor bed (2.7Gy+0.5 Gy)  The overall dose will be 40.5 Gy to the breast and 48.0 Gy to the tumor bed ",
        "premise_nums": [
            "of 3.2 Gy to",
            "and 48.0 Gy to",
            "of 0.5 Gy to",
            "be 40.5 Gy to",
            "15 daily radiation"
        ]
    },
    {
        "id": "974225b7-9089-499c-9550-0a7207fd28b2",
        "primaryId": "NCT03346161",
        "secondaryId": "NCT01000662",
        "label": "Entailment",
        "statement_text": "The intervention for the primary trial does not require patients to undergo any medical treatment during the study  whereas in the secondary trial  all patients receive Radiation Therapy ",
        "statement_nums": [],
        "premise_text": "Arm 2= 15 daily radiation fractions of 2.7 Gy Monday to friday for three weeks to the entire breast with a Friday boost of 2.0 Gy to the tumor bed  for a total dose to the tumor bed on each friday of 4.7 Gy (2.7 Gy+ 2.0 Gy)  The overall dose will be 40.5 Gy to the breast and 46.5 gy to the tumor bed INTERVENTION 2: ARM 2 Weekly Boost Radiation Therapy ",
        "premise_nums": [
            "7 Gy (2.7",
            "of 2.7 Gy Monday",
            "15 daily radiation",
            "2 Weekly Boost",
            "be 40.5 Gy to",
            "and 46.5 gy to",
            "of 2.0 Gy to"
        ]
    },
    {
        "id": "974225b7-9089-499c-9550-0a7207fd28b2",
        "primaryId": "NCT03346161",
        "secondaryId": "NCT01000662",
        "label": "Entailment",
        "statement_text": "The intervention for the primary trial does not require patients to undergo any medical treatment during the study  whereas in the secondary trial  all patients receive Radiation Therapy ",
        "statement_nums": [],
        "premise_text": "Radiation Therapy: Arm 1= 15 daily radiation fractions of 2.7 Gy  Monday to Friday for 3 weeks  to the whole breast with a daily concomitant boost of 0.5 Gy to the tumor bed  for a total daily dose of 3.2 Gy to the tumor bed (2.7Gy+0.5 Gy)  The overall dose will be 40.5 Gy to the breast and 48.0 Gy to the tumor bed ",
        "premise_nums": [
            "of 3.2 Gy to",
            "and 48.0 Gy to",
            "of 0.5 Gy to",
            "be 40.5 Gy to",
            "15 daily radiation"
        ]
    },
    {
        "id": "974225b7-9089-499c-9550-0a7207fd28b2",
        "primaryId": "NCT03346161",
        "secondaryId": "NCT01000662",
        "label": "Entailment",
        "statement_text": "The intervention for the primary trial does not require patients to undergo any medical treatment during the study  whereas in the secondary trial  all patients receive Radiation Therapy ",
        "statement_nums": [],
        "premise_text": "Arm 2= 15 daily radiation fractions of 2.7 Gy Monday to friday for three weeks to the entire breast with a Friday boost of 2.0 Gy to the tumor bed  for a total dose to the tumor bed on each friday of 4.7 Gy (2.7 Gy+ 2.0 Gy)  The overall dose will be 40.5 Gy to the breast and 46.5 gy to the tumor bed ",
        "premise_nums": [
            "7 Gy (2.7",
            "of 2.7 Gy Monday",
            "15 daily radiation",
            "be 40.5 Gy to",
            "and 46.5 gy to",
            "of 2.0 Gy to"
        ]
    },
    {
        "id": "6f533f52-c8e4-4983-8968-69af03a9e34a",
        "primaryId": "NCT01506609",
        "statement_text": "Patients with cytologically confirmed breast cancer  who's Locally recurrent disease is amenable to radiation with curative intent are not eligible for the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Inclusion Criteria: Histologically or cytologically confirmed breast cancer that is either locally recurrent or metastatic  Locally recurrent disease must not be amenable to surgical resection or radiation with curative intent  ",
        "premise_nums": []
    },
    {
        "id": "690b8562-7d68-4642-bacb-601f227bb763",
        "primaryId": "NCT00591864",
        "statement_text": "the primary trial does not have an intervention section ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "INTERVENTION 1: Study Participants There are no arms or subgroups in this study  ",
        "premise_nums": []
    },
    {
        "id": "75f94edd-dbde-4a19-be18-e67c767f6d8f",
        "primaryId": "NCT03618017",
        "statement_text": "the primary trial's intervention section does not describe the intervention dosage  frequency or duration for cohort 2, however cohort 1 recieves placebo twice daily for two months ",
        "statement_nums": [
            "1 recieves placebo"
        ],
        "label": "Contradiction",
        "premise_text": "INTERVENTION 1: Recruitment Population Pre-randomization recruitment and enrollment ",
        "premise_nums": []
    },
    {
        "id": "e37ed9ee-b312-4ea3-a6eb-3785fa94ccc4",
        "primaryId": "NCT00687440",
        "secondaryId": "NCT01307891",
        "label": "Entailment",
        "statement_text": "the primary trial had a higher percentage of patients with at least partial response than either cohort of the secondary trial ",
        "statement_nums": [],
        "premise_text": "Outcome Measurement: Number of Participants Who Had a Tumor Response  According to Standard RECIST (Response Evaluation Criteria in Solid Tumors) Criteria Those who achieved either complete (disappearance of all target lesions) or partial (at least 30% decrease in the sum of the longest diameter (LD) of target lesions  taking as reference the baseline sum LD) response  Time frame: Week 09, Week 18, at the end of each patient's treatment  and at 3, 6, 9, and 12 months after end of treatment  Results 1: Arm/Group Title: Caelyx  Docetaxel  Trastuzumab ",
        "premise_nums": [
            "30% decrease",
            "12 months after"
        ]
    },
    {
        "id": "e37ed9ee-b312-4ea3-a6eb-3785fa94ccc4",
        "primaryId": "NCT00687440",
        "secondaryId": "NCT01307891",
        "label": "Entailment",
        "statement_text": "the primary trial had a higher percentage of patients with at least partial response than either cohort of the secondary trial ",
        "statement_nums": [],
        "premise_text": "Arm/Group Description: Stage 1: subjects will receive Caelyx one day every 3 weeks in combination with docetaxel one day every 3 weeks and trastuzumab once weekly during 6 cycles  At the end of this stage  based on the number of cardiac events  subjects will proceed to a second stage or restart with a lower dose of Caelyx Stage 2: subjects will be treated with the recommended dose of Caelyx (defined in the first stage) in combination with docetaxel and trastuzumab  Overall Number of Participants Analyzed: 26 Measure Type: Number Unit of Measure: Participants Participants who had a complete tumor response: 2 Participants who had a partial tumor response: 13 Participants who did not have a tumor response: 11 Outcome Measurement: Objective Response Rate ",
        "premise_nums": [
            "26 Measure Type:",
            "11 Outcome Measurement:",
            "2 Participants who",
            "3 weeks and",
            "13 Participants who",
            "3 weeks in"
        ]
    },
    {
        "id": "e37ed9ee-b312-4ea3-a6eb-3785fa94ccc4",
        "primaryId": "NCT00687440",
        "secondaryId": "NCT01307891",
        "label": "Entailment",
        "statement_text": "the primary trial had a higher percentage of patients with at least partial response than either cohort of the secondary trial ",
        "statement_nums": [],
        "premise_text": "Patient response rates will be measured by the Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI  Responses include the following: Complete Response (CR) disappearance of all target lesions; Partial Response (PR) at least a 30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) best response from the start of treatment until disease progression Time frame: Baseline to 6 months Results 1: Arm/Group Title: Abraxane + Tigatuzumab ",
        "premise_nums": [
            "30% decrease",
            "6 months Results"
        ]
    },
    {
        "id": "e37ed9ee-b312-4ea3-a6eb-3785fa94ccc4",
        "primaryId": "NCT00687440",
        "secondaryId": "NCT01307891",
        "label": "Entailment",
        "statement_text": "the primary trial had a higher percentage of patients with at least partial response than either cohort of the secondary trial ",
        "statement_nums": [],
        "premise_text": "Arm/Group Description: Patients will receive Abraxane at 100 mg/m2 X 3 doses on Days 1, 8, and 15 at 28-day intervals and tigatuzumab to be administered as a 10 mg/kg loading dose followed by 5 mg/kg for the first cycle and then every other week on Days 1 and 15 for subsequent cycles  Patients will be evaluated for response every 8 weeks  Patients with disease progression will be taken off the study Overall Number of Participants Analyzed: 39 Measure Type: Number Unit of Measure: percentage of patients 28 (14.9 to 45.0) Results 2: Arm/Group Title: Abraxane Alone ",
        "premise_nums": [
            "100 mg/m2 X",
            "9 to 45.0)",
            "2 X 3",
            "15 at 28",
            "1 and 15",
            "39 Measure Type:",
            "5 mg/kg for",
            "10 mg/kg loading",
            "3 doses on",
            "28-day intervals"
        ]
    },
    {
        "id": "e37ed9ee-b312-4ea3-a6eb-3785fa94ccc4",
        "primaryId": "NCT00687440",
        "secondaryId": "NCT01307891",
        "label": "Entailment",
        "statement_text": "the primary trial had a higher percentage of patients with at least partial response than either cohort of the secondary trial ",
        "statement_nums": [],
        "premise_text": "Arm/Group Description: Patients will receive Abraxane at 100 mg/m2 weekly X 3 doses on Days 1, 8, and 15 at 28-day intervals  Abraxane will be administered on an outpatient basis by an IV infusion over 30 minutes  Patients will be evaluated for response every 2 cycles (every 8 weeks) Overall Number of Participants Analyzed: 21 Measure Type: Number Unit of Measure: percentage of patients 38 (18 to 61.1) ",
        "premise_nums": [
            "2 weekly X",
            "18 to 61.1)",
            "2 cycles (every",
            "21 Measure Type:",
            "15 at 28",
            "100 mg/m2 weekly",
            "3 doses on",
            "28-day intervals"
        ]
    },
    {
        "id": "34ee4f66-e6f7-458c-964c-12fa730a9d56",
        "primaryId": "NCT02556632",
        "statement_text": "Both cohorts the primary trial apply the topical intervention for approximately every 4-6 hours every day for a week of the study ",
        "statement_nums": [
            "4-6 hours",
            "6 hours every"
        ],
        "label": "Entailment",
        "premise_text": "INTERVENTION 1: Arm I (Curcumin-based Gel) Patients apply curcumin-based gel topically TID approximately every 4-6 hours beginning on the first day of radiation therapy and continuing until 1 week after completion of radiation therapy  Curcumin-based Gel: Applied topically Laboratory Biomarker Analysis: Correlative studies Questionnaire Administration: Ancillary studies INTERVENTION 2: Arm II (HPR Plus) Patients apply HPR Plus™ topically TID approximately every 4-6 hours beginning on the first day of radiation therapy and continuing until 1 week after completion of radiation therapy  Dermatologic Complications Management: Apply HPR Plus topically Laboratory Biomarker Analysis: Correlative studies Questionnaire Administration: Ancillary studies ",
        "premise_nums": [
            "1 week after",
            "6 hours beginning",
            "4-6 hours"
        ]
    },
    {
        "id": "9b0451fe-f760-46d3-b555-0a9b83546e73",
        "primaryId": "NCT00087152",
        "secondaryId": "NCT00203502",
        "label": "Contradiction",
        "statement_text": "the primary trial recorded half as many patients vomiting as the secondary trial ",
        "statement_nums": [],
        "premise_text": "Adverse Events 1: Nausea 1/20 (5.00%) Adverse Events 1: Nausea/vomiting 4/39 (10.26%) ",
        "premise_nums": [
            "4/39 (10.26%)",
            "1/20 (5.00%)"
        ]
    },
    {
        "id": "b9304415-073d-476e-a056-cb2a747d56fa",
        "primaryId": "NCT00021255",
        "statement_text": "Cohort 2 of the primary trial recieves Doxorubicin only during cycles 1-4, and then Doxorubicin  cyclophosphamide  Herceptin and docetaxel during Cycle 5 of the study ",
        "statement_nums": [
            "1-4, and",
            "2 of the",
            "5 of the"
        ],
        "label": "Contradiction",
        "premise_text": "INTERVENTION 2: AC Followed by Docetaxel + Herceptin (AC→TH) ",
        "premise_nums": []
    },
    {
        "id": "6e365e33-16b8-43e1-99b5-49dfed6f7b13",
        "primaryId": "NCT00316199",
        "statement_text": "Only Chinese women with stage 4 or Unresectable  locally recurrent cancer breast cancer are eligible for the primary trial ",
        "statement_nums": [
            "4 or Unresectable"
        ],
        "label": "Entailment",
        "premise_text": "Inclusion Criteria: Female patients of Chinese origin with histologically or cytologically proven diagnosis of breast cancer  Unresectable  locally recurrent breast cancer or stage IV disease  ",
        "premise_nums": []
    },
    {
        "id": "7c2dd3c3-8e72-451e-9fe7-c442f659bfc3",
        "primaryId": "NCT01306942",
        "statement_text": "Participants of cohort 1 in the primary trial received more Dasatinib and Paclitaxel than those in cohort 2.",
        "statement_nums": [
            "1 in the"
        ],
        "label": "Contradiction",
        "premise_text": "INTERVENTION 1: Phase I: Dasatinib 100mg/Trastuzumab 2mg/kg/Paclitaxel 80mg/m2 Cohort 1: Eligible patients were enrolled and treated with 4-week cycles of trastuzumab 2 mg/kg IV weekly (following a loading dose of 4 mg/kg in cycle 1) and paclitaxel 80 mg/m2 weekly x 3 weeks followed by a rest period of 7 days  Dasatinib 100mg was administered orally once daily (QD)  Treatment was repeated on Day 1 of a 28-day cycle until radiographic or symptomatic progression or unacceptable toxicity occured  Only in the phase I  the first cycle lasted 38 days  INTERVENTION 2: ",
        "premise_nums": [
            "1 of a",
            "2mg/kg/Paclitaxel",
            "2 Cohort 1:",
            "3 weeks followed",
            "2 weekly x",
            "4-week cycles",
            "2 mg/kg IV",
            "80 mg/m2 weekly",
            "4 mg/kg in",
            "28-day cycle",
            "100mg/Trastuzumab",
            "80mg/m2 Cohort"
        ]
    },
    {
        "id": "7c2dd3c3-8e72-451e-9fe7-c442f659bfc3",
        "primaryId": "NCT01306942",
        "statement_text": "Participants of cohort 1 in the primary trial received more Dasatinib and Paclitaxel than those in cohort 2.",
        "statement_nums": [
            "1 in the"
        ],
        "label": "Contradiction",
        "premise_text": "Phase I: Dasatinib 140mg/Trastuzumab 2mg/kg/Paclitaxel 80mg/m2Cohort 2: Eligible patients were enrolled and treated with 4-week cycles of trastuzumab 2 mg/kg IV weekly (following a loading dose of 4 mg/kg in cycle 1) and paclitaxel 80 mg/m2 weekly x 3 weeks followed by a rest period of 7 days  Dasatinib 140mg was administered orally once daily (QD)  Treatment was repeated on Day 1 of a 28-day cycle until radiographic or symptomatic progression or unacceptable toxicity occured  Only in the phase I  the first cycle lasted 38 days  ",
        "premise_nums": [
            "1 of a",
            "2mg/kg/Paclitaxel",
            "80mg/m2Cohort",
            "3 weeks followed",
            "2 weekly x",
            "4-week cycles",
            "2 mg/kg IV",
            "80 mg/m2 weekly",
            "4 mg/kg in",
            "140mg/Trastuzumab",
            "28-day cycle"
        ]
    },
    {
        "id": "27acc6d7-c12d-4a38-9133-a5c8429dd264",
        "primaryId": "NCT00656669",
        "statement_text": "the primary trial recorded 23 adverse events ",
        "statement_nums": [
            "23 adverse events"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 0/23 (0.00%) ",
        "premise_nums": [
            "0/23 (0.00%)"
        ]
    },
    {
        "id": "5919a080-2f0d-4c3b-9b03-10df80b2e680",
        "primaryId": "NCT01007942",
        "statement_text": "There were no adverse event in the primary trial which affected more than 10% of a particular patient cohort ",
        "statement_nums": [
            "10% of"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Febrile neutropenia 30/280 (10.71%) ",
        "premise_nums": [
            "30/280 (10.71%)"
        ]
    },
    {
        "id": "91f6e62a-97e7-49fa-8509-7ff8c1f0155e",
        "primaryId": "NCT00671918",
        "secondaryId": "NCT00571987",
        "label": "Contradiction",
        "statement_text": "Patients with pure ductal carcinoma in situ (DCIS) or Melanoma are eligible for both the secondary trial and the primary trial  and are able to participate in these trials alongside other drug trials  up to a maximum of 3.",
        "statement_nums": [],
        "premise_text": "Inclusion Criteria: The patient is currently not participating in another investigational drug study  Patients with pure ductal carcinoma in situ (DCIS) or non-invasive carcinoma if lymph node biopsy is part of the surgical plan  Inclusion Criteria: Ductal or Infiltrating Ductal Carcinoma ",
        "premise_nums": []
    },
    {
        "id": "b351a091-d5fb-49f9-a864-5c89c6316b1b",
        "primaryId": "NCT01688609",
        "statement_text": "Patients must have histologically or cytologically confirmed PR+ invasive breast cancer  with Primary tumor greater than 2 cm in diameter TO PARTICIPATE in the primary trial ",
        "statement_nums": [
            "2 cm in"
        ],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria: Patients must have histologically or cytologically confirmed primary invasive breast cancer Primary tumor is larger than 2 cm in diameter (T2) as measured by caliper or ultrasound Overexpression and/or amplification of HER2 is confirmed by immunohistochemistry (IHC) 3+ or fluorescence in situ hybridization (FISH) + when IHC 2+ ",
        "premise_nums": [
            "2 is confirmed",
            "2 cm in",
            "(T2) as"
        ]
    },
    {
        "id": "d5ca2086-8404-42d1-bf45-5370f3d4e8e8",
        "primaryId": "NCT02139358",
        "secondaryId": "NCT02574455",
        "label": "Contradiction",
        "statement_text": "There was 16.67% more cases of hemorrhaging in the primary trial than in the secondary trial ",
        "statement_nums": [
            "was 16.67% more cases"
        ],
        "premise_text": "Adverse Events 1: Total: 7/15 (46.67%) Cardiac arrest * 1/15 (6.67%) Chest pain - cardiac * 1/15 (6.67%) Diarrhea * 1/15 (6.67%) Duodenal hemorrhage * 1/15 (6.67%) Fatigue * 1/15 (6.67%) Fever * 1/15 (6.67%) Sudden death NOS * 1/15 (6.67%) Sepsis * 1/15 (6.67%) Skin infection * 1/15 (6.67%) Neutrophil count decreased * 1/15 (6.67%) Platelet count decreased * 1/15 (6.67%) Adverse Events 1: ",
        "premise_nums": [
            "7/15 (46.67%)",
            "1/15 (6.67%)"
        ]
    },
    {
        "id": "d5ca2086-8404-42d1-bf45-5370f3d4e8e8",
        "primaryId": "NCT02139358",
        "secondaryId": "NCT02574455",
        "label": "Contradiction",
        "statement_text": "There was 16.67% more cases of hemorrhaging in the primary trial than in the secondary trial ",
        "statement_nums": [
            "was 16.67% more cases"
        ],
        "premise_text": "Total: 69/258 (26.74%)Anaemia 3/258 (1.16%) Febrile neutropenia 13/258 (5.04%) Neutropenia 5/258 (1.94%) Thrombocytopenia 1/258 (0.39%) Atrial fibrillation 0/258 (0.00%) Mitral valve incompetence 1/258 (0.39%) Pericardial effusion 0/258 (0.00%) Sinus tachycardia 0/258 (0.00%) Abdominal pain 3/258 (1.16%) Abdominal pain upper 1/258 (0.39%) Colitis 1/258 (0.39%) Adverse Events 2: ",
        "premise_nums": [
            "1/258 (0.39%)",
            "13/258 (5.04%)",
            "3/258 (1.16%)",
            "0/258 (0.00%)",
            "5/258 (1.94%)",
            "69/258 (26.74%)Anaemia"
        ]
    },
    {
        "id": "d5ca2086-8404-42d1-bf45-5370f3d4e8e8",
        "primaryId": "NCT02139358",
        "secondaryId": "NCT02574455",
        "label": "Contradiction",
        "statement_text": "There was 16.67% more cases of hemorrhaging in the primary trial than in the secondary trial ",
        "statement_nums": [
            "was 16.67% more cases"
        ],
        "premise_text": "Total: 64/224 (28.57%)Anaemia 2/224 (0.89%) Febrile neutropenia 4/224 (1.79%) Neutropenia 1/224 (0.45%) Thrombocytopenia 0/224 (0.00%) Atrial fibrillation 1/224 (0.45%) Mitral valve incompetence 0/224 (0.00%) Pericardial effusion 2/224 (0.89%) Sinus tachycardia 1/224 (0.45%) Abdominal pain 3/224 (1.34%) Abdominal pain upper 0/224 (0.00%) Colitis 0/224 (0.00%) ",
        "premise_nums": [
            "2/224 (0.89%)",
            "1/224 (0.45%)",
            "4/224 (1.79%)",
            "64/224 (28.57%)Anaemia",
            "3/224 (1.34%)",
            "0/224 (0.00%)"
        ]
    },
    {
        "id": "4c038972-20a9-4031-a1cd-ba00e9dd0908",
        "primaryId": "NCT00410813",
        "secondaryId": "NCT00617539",
        "label": "Contradiction",
        "statement_text": "In the primary trial  Dasatinib  70 mg  Twice Daily results in a better median PFS than Dasatinib  100 mg  Daily  The opposite was true in the secondary trial ",
        "statement_nums": [],
        "premise_text": "Outcome Measurement: Progression-free Survival RECIST progression defined as 20% increase in the sum of longest diameters of target measurable lesions over the smallest sum observed  unequivocal progression of non-measurable disease  the appearance of any new lesion/site  death due to disease without prior documentation of progression and without symptomatic deterioration  development of one or more new bone lesions from baseline  or symptomatic deterioration related to disease progression  Time from date of registration to date of first documentation of progression or symptomatic deterioration  or death due to any cause  Patients last known to be alive and progression-free are censored at last date of contact  Time frame: Up to 2 years Results 1: ",
        "premise_nums": [
            "2 years Results",
            "20% increase"
        ]
    },
    {
        "id": "4c038972-20a9-4031-a1cd-ba00e9dd0908",
        "primaryId": "NCT00410813",
        "secondaryId": "NCT00617539",
        "label": "Contradiction",
        "statement_text": "In the primary trial  Dasatinib  70 mg  Twice Daily results in a better median PFS than Dasatinib  100 mg  Daily  The opposite was true in the secondary trial ",
        "statement_nums": [],
        "premise_text": "Arm/Group Title: Dasatinib  100 mg  DailyArm/Group Description: Dasatinib  100 mg PO daily until progression of disease Overall Number of Participants Analyzed: 41 Median (95% Confidence Interval) Unit of Measure: weeks 10.3 (8.4 to 16.7) Results 2: Arm/Group Title: Dasatinib  70 mg  Twice Daily Arm/Group Description: Dasatinib  70 mg PO twice daily until progression of disease Overall Number of Participants Analyzed: 38 Median (95% Confidence Interval) Unit of Measure: weeks 15.3 (8.7 to 20.1) Outcome Measurement: Number of Patients With Objective Treatment Response (Complete or Partial) in the CNS ",
        "premise_nums": [
            "7 to 20.1)",
            "100 mg PO",
            "95% Confidence",
            "4 to 16.7)",
            "70 mg PO"
        ]
    },
    {
        "id": "82d6275a-97e6-4d13-84eb-5f7c2585db8b",
        "primaryId": "NCT02132949",
        "secondaryId": "NCT01111825",
        "label": "Contradiction",
        "statement_text": "Between both of the patient cohorst of the primary trial and the secondary trial there was only a single patient who suffered heart failure ",
        "statement_nums": [],
        "premise_text": "Adverse Events 1: Total: 56/199 (28.14%) AGRANULOCYTOSIS 1/199 (0.50%) ANAEMIA 1/199 (0.50%) BONE MARROW FAILURE 1/199 (0.50%) FEBRILE NEUTROPENIA 11/199 (5.53%) LEUKOPENIA 1/199 (0.50%) NEUTROPENIA 1/199 (0.50%) PANCYTOPENIA 1/199 (0.50%) ACUTE MYOCARDIAL INFARCTION 1/199 (0.50%) ATRIAL FLUTTER 1/199 (0.50%) ATRIAL THROMBOSIS 0/199 (0.00%) CARDIAC FAILURE 3/199 (1.51%) Adverse Events 2: ",
        "premise_nums": [
            "56/199 (28.14%)",
            "1/199 (0.50%)",
            "11/199 (5.53%)",
            "0/199 (0.00%)",
            "3/199 (1.51%)"
        ]
    },
    {
        "id": "82d6275a-97e6-4d13-84eb-5f7c2585db8b",
        "primaryId": "NCT02132949",
        "secondaryId": "NCT01111825",
        "label": "Contradiction",
        "statement_text": "Between both of the patient cohorst of the primary trial and the secondary trial there was only a single patient who suffered heart failure ",
        "statement_nums": [],
        "premise_text": "Total: 66/198 (33.33%)AGRANULOCYTOSIS 0/198 (0.00%) ANAEMIA 0/198 (0.00%) BONE MARROW FAILURE 0/198 (0.00%) FEBRILE NEUTROPENIA 27/198 (13.64%) LEUKOPENIA 0/198 (0.00%) NEUTROPENIA 2/198 (1.01%) PANCYTOPENIA 1/198 (0.51%) ACUTE MYOCARDIAL INFARCTION 0/198 (0.00%) ATRIAL FLUTTER 0/198 (0.00%) ATRIAL THROMBOSIS 1/198 (0.51%) CARDIAC FAILURE 4/198 (2.02%) Adverse Events 1: ",
        "premise_nums": [
            "0/198 (0.00%)",
            "1/198 (0.51%)",
            "27/198 (13.64%)",
            "66/198 (33.33%)AGRANULOCYTOSIS",
            "2/198 (1.01%)",
            "4/198 (2.02%)"
        ]
    },
    {
        "id": "82d6275a-97e6-4d13-84eb-5f7c2585db8b",
        "primaryId": "NCT02132949",
        "secondaryId": "NCT01111825",
        "label": "Contradiction",
        "statement_text": "Between both of the patient cohorst of the primary trial and the secondary trial there was only a single patient who suffered heart failure ",
        "statement_nums": [],
        "premise_text": "Total: 3/8 (37.50%)Anaemia 0/8 (0.00%) Febrile neutropenia 0/8 (0.00%) Polycythaemia 0/8 (0.00%) Acute coronary syndrome 0/8 (0.00%) Vertigo 0/8 (0.00%) Eyelid oedema 1/8 (12.50%) Constipation 0/8 (0.00%) Diarrhoea 0/8 (0.00%) Nausea 0/8 (0.00%) Stomatitis 0/8 (0.00%) Upper gastrointestinal haemorrhage 0/8 (0.00%) ",
        "premise_nums": [
            "0/8 (0.00%)",
            "3/8 (37.50%)Anaemia",
            "1/8 (12.50%)"
        ]
    },
    {
        "id": "82d6275a-97e6-4d13-84eb-5f7c2585db8b",
        "primaryId": "NCT02132949",
        "secondaryId": "NCT01111825",
        "label": "Contradiction",
        "statement_text": "Between both of the patient cohorst of the primary trial and the secondary trial there was only a single patient who suffered heart failure ",
        "statement_nums": [],
        "premise_text": "Vomiting 0/8 (0.00%)Chest pain 0/8 (0.00%) Adverse Events 2: Total: 2/6 (33.33%) Anaemia 0/6 (0.00%) Febrile neutropenia 0/6 (0.00%) Polycythaemia 0/6 (0.00%) Acute coronary syndrome 0/6 (0.00%) Vertigo 0/6 (0.00%) Eyelid oedema 0/6 (0.00%) Constipation 0/6 (0.00%) Diarrhoea 0/6 (0.00%) Nausea 0/6 (0.00%) Stomatitis 0/6 (0.00%) ",
        "premise_nums": [
            "2/6 (33.33%)",
            "0/8 (0.00%)Chest",
            "0/6 (0.00%)"
        ]
    },
    {
        "id": "82d6275a-97e6-4d13-84eb-5f7c2585db8b",
        "primaryId": "NCT02132949",
        "secondaryId": "NCT01111825",
        "label": "Contradiction",
        "statement_text": "Between both of the patient cohorst of the primary trial and the secondary trial there was only a single patient who suffered heart failure ",
        "statement_nums": [],
        "premise_text": "Upper gastrointestinal haemorrhage 0/6 (0.00%)Vomiting 0/6 (0.00%) Chest pain 1/6 (16.67%) ",
        "premise_nums": [
            "0/6 (0.00%)Vomiting",
            "1/6 (16.67%)"
        ]
    },
    {
        "id": "286e74e5-74ed-4d42-b32d-f1398c514d37",
        "primaryId": "NCT01125566",
        "statement_text": "At least one participant in the primary trial receiving an oral treatment of film-coated Afatinib tablet at a starting dose of 40 milligram (mg) once daily and weekly 10 minutes intravenous infusions of Vinorelbine 25 mg/meter^2 (meter=m) had a PFS over 9 months ",
        "statement_nums": [
            "25 mg/meter^2",
            "40 milligram (mg)",
            "10 minutes intravenous"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Progression-free Survival (PFS) PFS is defined as time from randomisation to disease progression or death whichever occurs first  Assessed by investigator according to the Response Evaluation Criteria in Solid Tumours (RECIST 1.1). RECIST is a set of published rules that define when tumors in cancer patients improve (\"respond\")  stay the same (\"stabilize\") or worsen (\"progress\") during treatment  Only data collected until the cut-off date for RECIST 1.1 based endpoints (08Jun2013) were considered  ",
        "premise_nums": [
            "(08Jun2013) were",
            "RECIST 1.1 based endpoints"
        ]
    },
    {
        "id": "286e74e5-74ed-4d42-b32d-f1398c514d37",
        "primaryId": "NCT01125566",
        "statement_text": "At least one participant in the primary trial receiving an oral treatment of film-coated Afatinib tablet at a starting dose of 40 milligram (mg) once daily and weekly 10 minutes intravenous infusions of Vinorelbine 25 mg/meter^2 (meter=m) had a PFS over 9 months ",
        "statement_nums": [
            "25 mg/meter^2",
            "40 milligram (mg)",
            "10 minutes intravenous"
        ],
        "label": "Entailment",
        "premise_text": "Progression of disease was determined if at least 1 of the following criteria applied:At least a 20% increase in the sum of the diameters (SoD) of target lesions taking as reference the smallest SoD recorded since the treatment started  together with an absolute increase in the SoD of at least 5 mm Appearance of 1 or more new lesions Unequivocal progression of existing non-target lesions Time frame: From randomization (07Sep2010) until disease progression  death or data cut-off (08Jun2013); Up to 34 months Results 1: ",
        "premise_nums": [
            "(07Sep2010) until",
            "5 mm Appearance",
            "34 months Results",
            "1 or more",
            "1 of the",
            "20% increase"
        ]
    },
    {
        "id": "286e74e5-74ed-4d42-b32d-f1398c514d37",
        "primaryId": "NCT01125566",
        "statement_text": "At least one participant in the primary trial receiving an oral treatment of film-coated Afatinib tablet at a starting dose of 40 milligram (mg) once daily and weekly 10 minutes intravenous infusions of Vinorelbine 25 mg/meter^2 (meter=m) had a PFS over 9 months ",
        "statement_nums": [
            "25 mg/meter^2",
            "40 milligram (mg)",
            "10 minutes intravenous"
        ],
        "label": "Entailment",
        "premise_text": "Arm/Group Title: Afatinib + Vinorelbine (AV)",
        "premise_nums": []
    },
    {
        "id": "634642da-db6d-49cc-a999-67f46e91dbca",
        "primaryId": "NCT01237327",
        "secondaryId": "NCT00030823",
        "label": "Entailment",
        "statement_text": "the primary trial and the secondary trial do not have any overlapping inclusion or exclusion criteria ",
        "statement_nums": [],
        "premise_text": "Inclusion Criteria: Previous participation in study 971-ONC-0028-080. Exclusion Criteria: Subjects who had not previously participated in study 971-ONC-0028-080. DISEASE CHARACTERISTICS: Diagnosis of breast cancer at high risk for recurrence  defined by one of the following: Stage IV that is free of all known disease after eradication by surgery  radiotherapy  or chemotherapy May or may not have elevated CA 15-3 or CEA levels Stage I  II  or III previously treated with adjuvant chemotherapy and clinically free of identifiable disease  but have rising CA 15-3 or CEA levels Rising CA 15-3 and CEA defined as a prior normal level increased on 2 consecutive occasions at least 2 weeks apart ",
        "premise_nums": [
            "2 weeks apart",
            "3 or CEA",
            "971-ONC-0028-080. DISEASE",
            "3 and CEA",
            "2 consecutive occasions",
            "971-ONC-0028-080. Exclusion",
            "15-3 and",
            "15-3 or"
        ]
    },
    {
        "id": "634642da-db6d-49cc-a999-67f46e91dbca",
        "primaryId": "NCT01237327",
        "secondaryId": "NCT00030823",
        "label": "Entailment",
        "statement_text": "the primary trial and the secondary trial do not have any overlapping inclusion or exclusion criteria ",
        "statement_nums": [],
        "premise_text": "For patients with a significant history of smoking who have a chronically elevated CEA (less than 15), CEA must be increased at least 1.5 times the uppermost chronic value on 2 consecutive occasions at least 2 weeks apartStage III and completed adjuvant therapy no more than 24 months ago Recurrence in the ipsilateral axilla after lumpectomy and/or axillary dissection or modified radical mastectomy Recurrence in the ipsilateral breast after lumpectomy and/or axillary dissection Stage II with at least 4 positive axillary nodes and completed adjuvant therapy no more than 24 months ago Stage IV that is stable on hormonal therapy Hormone receptor status: Not specified PATIENT CHARACTERISTICS: Age: 18 and over Sex: Male or female ",
        "premise_nums": [
            "4 positive axillary",
            "24 months ago",
            "2 weeks apartStage",
            "18 and over",
            "2 consecutive occasions",
            "least 1.5 times the"
        ]
    },
    {
        "id": "634642da-db6d-49cc-a999-67f46e91dbca",
        "primaryId": "NCT01237327",
        "secondaryId": "NCT00030823",
        "label": "Entailment",
        "statement_text": "the primary trial and the secondary trial do not have any overlapping inclusion or exclusion criteria ",
        "statement_nums": [],
        "premise_text": "Menopausal status:Not specified Performance status: Karnofsky 80-100% Life expectancy: Not specified Hematopoietic: Lymphocyte count at least 500/mm^3 WBC at least 3,000/mm^3 Hepatic: AST no greater than 1.5 times upper limit of normal (ULN) Alkaline phosphatase no greater than 1.5 times ULN Renal: Creatinine no greater than 1.5 times ULN Cardiovascular: No clinically significant New York Heart Association class III or IV cardiac disease Other: Not pregnant Negative pregnancy test Fertile patients must use effective contraception No prior seafood allergy No known prior immunodeficiency or autoimmune disease No other active cancer except basal cell or squamous cell skin cancer ",
        "premise_nums": [
            "3,000/mm^3 Hepatic:",
            "3 WBC at",
            "80-100% Life",
            "500/mm^3 WBC",
            "than 1.5 times ULN",
            "than 1.5 times upper"
        ]
    },
    {
        "id": "634642da-db6d-49cc-a999-67f46e91dbca",
        "primaryId": "NCT01237327",
        "secondaryId": "NCT00030823",
        "label": "Entailment",
        "statement_text": "the primary trial and the secondary trial do not have any overlapping inclusion or exclusion criteria ",
        "statement_nums": [],
        "premise_text": "PRIOR CONCURRENT THERAPY:Biologic therapy: At least 6 weeks since prior immunotherapy No prior vaccine with any of the antigens in this study Chemotherapy: See Disease Characteristics At least 4 weeks since prior chemotherapy No concurrent chemotherapy Endocrine therapy: See Disease Characteristics Radiotherapy: See Disease Characteristics At least 4 weeks since prior radiotherapy No concurrent radiotherapy Surgery: See Disease Characteristics At least 4 weeks since prior surgery Concurrent surgery for local recurrence allowed if patient remains disease free ",
        "premise_nums": [
            "6 weeks since",
            "4 weeks since"
        ]
    },
    {
        "id": "a529e364-2da7-4067-acb6-9fb2f0adf08b",
        "primaryId": "NCT01401062",
        "statement_text": "A patient who underwent T-cell transfer therapy in the past 2 weeks would be excluded from the primary trial ",
        "statement_nums": [
            "2 weeks would"
        ],
        "label": "Entailment",
        "premise_text": "Must be 4 weeks since all of the following treatments (recovered from toxicity of prior treatment to Grade 1, excluding alopecia): immunotherapy; ",
        "premise_nums": [
            "4 weeks since"
        ]
    },
    {
        "id": "317e00ae-9d17-4f85-8787-602cc2548fdb",
        "primaryId": "NCT00004092",
        "statement_text": "Patients with Cancer that has spread from a breast tumor to their bone marrow are excluded from the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "No histologically proven bone marrow metastasis ",
        "premise_nums": []
    },
    {
        "id": "de955acc-ce0e-4416-9884-644a06971603",
        "primaryId": "NCT00195013",
        "secondaryId": "NCT00620373",
        "label": "Contradiction",
        "statement_text": "Cohort 2 of the primary trial and the secondary trial are test groups ",
        "statement_nums": [
            "2 of the"
        ],
        "premise_text": "INTERVENTION 1: Glutamine 10 grams three times a day (orally) for four days and then stop glutamine: 10 grams three times a day (orally) for four days and then stop INTERVENTION 2: Placebo 10 grams three times a day (orally) for four days and then stop Placebo: 10 grams three times a day (orally) for four days and then stop INTERVENTION 1: Mammography Only For this reporting arm  the interpretation and analysis was done with mammography only  INTERVENTION 2: Gamma Imaging For this reporting arm  the interpretation and analysis was done with gamma imaging only  ",
        "premise_nums": [
            "10 grams three"
        ]
    },
    {
        "id": "4956f0d0-4df4-4de3-9a46-6073927485c3",
        "primaryId": "NCT01017549",
        "secondaryId": "NCT01390064",
        "label": "Entailment",
        "statement_text": "the secondary trial has more patients cohorts than the primary trial ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Electronic Brachytherapy Radiation therapy was delivered using the 510(k) cleared Xoft Axxent System  Accelerated partial breast irradiation is the method of radiation therapy administration that has been commonly used by physicians using Iridium-192, but was FDA cleared for use prior to commencing study enrollment using an electronic source  INTERVENTION 1: Initial Cohort Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG Subcutaneous administration 5 doses of 300 micrograms Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG: All research participants will receive the Mimotope P10s-PADRE/MONTANIDE ISA 51 VG vaccine via subcutaneous (SC) injection following the schedule INTERVENTION 2: Escalation Cohort ",
        "premise_nums": [
            "300 micrograms Vaccination",
            "5 doses of",
            "51 VG vaccine",
            "51 VG Subcutaneous"
        ]
    },
    {
        "id": "4956f0d0-4df4-4de3-9a46-6073927485c3",
        "primaryId": "NCT01017549",
        "secondaryId": "NCT01390064",
        "label": "Entailment",
        "statement_text": "the secondary trial has more patients cohorts than the primary trial ",
        "statement_nums": [],
        "premise_text": "Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG Subcutaneous administration of 5 doses of 500 microgramsVaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG: All research participants will receive the Mimotope P10s-PADRE/MONTANIDE ISA 51 VG vaccine via subcutaneous (SC) injection following the schedule ",
        "premise_nums": [
            "5 doses of",
            "51 VG vaccine",
            "500 microgramsVaccination with",
            "51 VG Subcutaneous"
        ]
    },
    {
        "id": "9ca0cc75-58b3-451d-abcc-378526744ca4",
        "primaryId": "NCT01985971",
        "secondaryId": "NCT03273426",
        "label": "Entailment",
        "statement_text": "Patients will have to undergo an MRI scan for before entry for both the secondary trial and the primary trial  for the primary trial patients will also need to have a brain MR and PET imaging  after study entry ",
        "statement_nums": [],
        "premise_text": "Inclusion Criteria: Ability to undergo brain MR and PET imaging Subjects with prior resection of brain metastases with progressions on brain MRI  Inclusion Criteria: clinical and imaging complete or near-complete response on MRI ",
        "premise_nums": []
    },
    {
        "id": "6efb001b-5ed3-470b-a206-7768a1adf597",
        "primaryId": "NCT01581619",
        "statement_text": "histologically confirmed invasive ductal breast cancer would result in exclusion from the primary trial  but not from the secondary trial ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Exclusion Criteria: No histologic evidence of EIC ",
        "premise_nums": []
    },
    {
        "id": "70dd1a42-6e40-4880-80a8-45dfd4941ce4",
        "primaryId": "NCT00089973",
        "statement_text": "the primary trial uses a 3 week cycle for SB-715992 administration ",
        "statement_nums": [
            "3 week cycle"
        ],
        "label": "Entailment",
        "premise_text": "INTERVENTION 1: SB-715992 The eligible participants were administered Ispinesib  intravenously as a one-hour infusion on Day 1 of every 21-day treatment cycle  at a dose of 18 mg/m^2. The dosing was repeated for up to multiple cycles  until disease progression or removal from treatment due to an unacceptable toxicity or withdrawal of consent  ",
        "premise_nums": [
            "21-day treatment",
            "715992 The eligible",
            "1 of every",
            "18 mg/m^2."
        ]
    },
    {
        "id": "85f43677-b680-4127-b1da-7e1cc966e4b2",
        "primaryId": "NCT01943916",
        "secondaryId": "NCT01653964",
        "label": "Entailment",
        "statement_text": "Not all subjects in the primary trial and the secondary trial will be adminstered 4-8 mCi Tc-99m sestamibi ",
        "statement_nums": [
            "4-8 mCi"
        ],
        "premise_text": "INTERVENTION 1: Overall Population Each subject served as her own control  with imaging of each mass by both the test and control modalities  Specificity difference is a single measure for the overall ITD population  INTERVENTION 1: Molecular Breast Imaging Molecular breast imaging performed after injection of 4 mCi Tc-99m sestamibi and again after 8 mCi Tc-99m sestamibi  ",
        "premise_nums": [
            "4 mCi Tc",
            "8 mCi Tc"
        ]
    },
    {
        "id": "4cccea8a-22ae-4813-96df-b902850f4991",
        "primaryId": "NCT01783444",
        "secondaryId": "NCT03136367",
        "label": "Contradiction",
        "statement_text": "Women of any age can participate in the primary trial or the secondary trial ",
        "statement_nums": [],
        "premise_text": "Key Inclusion Criteria: - Women with locally advanced  recurrent  or metastatic breast cancer along with confirmation of estrogen-receptor positive (ER+)  Measurable disease defined as at least one lesion 10 mm by CT or MRI that can be accurately measured in at least one dimension (CT scan slice thickness 5 mm) OR Bone lesions: lytic or mixed (lytic + blastic) in the absence of measurable disease as defined above  Key Exclusion Criteria: - Patients who received more than one chemotherapy line  Patients with only non-measurable lesions other than lytic or mixed (lytic and blastic) bone metastasis.Previous treatment with exemestane  mTOR inhibitors  PI3K inhibitors or AKT inhibitors  Inclusion Criteria: Assigned female at birth; 18 years and older; ",
        "premise_nums": [
            "10 mm by",
            "18 years and"
        ]
    },
    {
        "id": "8574ecd7-4da7-49b0-a273-de495bc1fee7",
        "primaryId": "NCT00951665",
        "statement_text": "Nausea and Death are two of the most common adverse events for patients in cohort 1 of the primary trial",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 7/26 (26.92%) Febrile neutropenia 1/26 (3.85%) Neutropenia 0/26 (0.00%) Thrombocytopenia 0/26 (0.00%) Cardiac failure congestive 0/26 (0.00%) Extrasystoles 0/26 (0.00%) Nausea 1/26 (3.85%) Abdominal pain 0/26 (0.00%) Constipation 0/26 (0.00%) Gastrointestinal haemorrhage 0/26 (0.00%) Death - unknown cause 1/26 (3.85%) Thrombosis in device 0/26 (0.00%) ",
        "premise_nums": [
            "0/26 (0.00%)",
            "1/26 (3.85%)",
            "7/26 (26.92%)"
        ]
    },
    {
        "id": "01b82c51-dd3d-430b-9523-0e93a9eb9c1a",
        "primaryId": "NCT00950300",
        "secondaryId": "NCT00615901",
        "label": "Contradiction",
        "statement_text": "the primary trial recorded a multitude of patients with chest pain  whereas the secondary trial observed only one patient with abdominal pain ",
        "statement_nums": [],
        "premise_text": "Adverse Events 1: Angina pectoris * 1/298 (0.34%) Adverse Events 1: Abdominal pain 1/38 (2.63%) ",
        "premise_nums": [
            "1/38 (2.63%)",
            "1/298 (0.34%)"
        ]
    },
    {
        "id": "93149dfc-667b-48d3-a46d-ad48b15e701f",
        "primaryId": "NCT00451555",
        "statement_text": "Cohort 1 and 2 of the primary trial recorded exactly the same number of each type of adverse events ",
        "statement_nums": [
            "1 and 2"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 17/94 (18.09%) Anaemia 2/94 (2.13%) Lymphadenopathy 0/94 (0.00%) Angina pectoris 0/94 (0.00%) Ischaemic cardiomyopathy 0/94 (0.00%) Myocardial infarction 1/94 (1.06%) Haemorrhoids 1/94 (1.06%) Ileus 1/94 (1.06%) Nausea 1/94 (1.06%) Vomiting 1/94 (1.06%) Asthenia 1/94 (1.06%) Disease progression 0/94 (0.00%) Oedema peripheral 1/94 (1.06%) ",
        "premise_nums": [
            "1/94 (1.06%)",
            "17/94 (18.09%)",
            "0/94 (0.00%)",
            "2/94 (2.13%)"
        ]
    },
    {
        "id": "93149dfc-667b-48d3-a46d-ad48b15e701f",
        "primaryId": "NCT00451555",
        "statement_text": "Cohort 1 and 2 of the primary trial recorded exactly the same number of each type of adverse events ",
        "statement_nums": [
            "1 and 2"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 2:Total: 9/39 (23.08%) Anaemia 2/39 (5.13%) Lymphadenopathy 0/39 (0.00%) Angina pectoris 0/39 (0.00%) Ischaemic cardiomyopathy 0/39 (0.00%) Myocardial infarction 1/39 (2.56%) Haemorrhoids 1/39 (2.56%) Ileus 1/39 (2.56%) Nausea 1/39 (2.56%) Vomiting 1/39 (2.56%) Asthenia 1/39 (2.56%) Disease progression 0/39 (0.00%) Oedema peripheral 1/39 (2.56%) ",
        "premise_nums": [
            "2/39 (5.13%)",
            "1/39 (2.56%)",
            "0/39 (0.00%)",
            "9/39 (23.08%)",
            "2:Total: 9/39"
        ]
    },
    {
        "id": "d080eec7-412f-4a44-8c56-91e0ec459acc",
        "primaryId": "NCT01422408",
        "statement_text": "the primary trial is a phase II trial in which all participants will recieve topical fluocinonide 0.05% cream to apply to their genitalia twice daily for two weeks ",
        "statement_nums": [
            "fluocinonide 0.05% cream to"
        ],
        "label": "Entailment",
        "premise_text": "INTERVENTION 1: Supportive Care (Fluocinonide Cream) This is a single-arm  single-stage  open-label phase II trial of topical fluocinonide 0.05% cream to improve vaginal symptoms  All subjects will receive topical fluocinonide 0.05% cream to apply twice daily for two weeks and then once daily for two weeks to the vagina  The duration of treatment will be 4 weeks  ",
        "premise_nums": [
            "fluocinonide 0.05% cream to"
        ]
    },
    {
        "id": "fd18a599-f94a-478a-975f-854a4210ccad",
        "primaryId": "NCT00659373",
        "secondaryId": "NCT02202252",
        "label": "Contradiction",
        "statement_text": "the primary trial has a 5 year long intervention  the duration of the secondary trial is only a single day after removal of the drains ",
        "statement_nums": [
            "5 year long"
        ],
        "premise_text": "INTERVENTION 1: Tamoxifen Tamoxifen 20mg orally daily for 5 years INTERVENTION 2: Ovarian Function Suppression Tamoxifen 20mg orally daily or Exemestane 25mg orally daily for 5 years plus ovarian function suppression (OFS; triptorelin (GnRH analogue) 3.75 mg by im injection q28 days for 5 years; or surgical oophorectomy; or ovarian irradiation) Note: Data were collected separately for the T+OFS and E+OFS participants in the parent study  IBCSG 24-02 (SOFT)  The sample size for this Co-SOFT substudy was small  so the analysis plan was revised to pre-specify collective analysis for all patients receiving OFS  INTERVENTION 1: Single Drain ",
        "premise_nums": [
            "5 years INTERVENTION",
            "q28 days",
            "75 mg by",
            "5 years plus",
            "28 days for"
        ]
    },
    {
        "id": "fd18a599-f94a-478a-975f-854a4210ccad",
        "primaryId": "NCT00659373",
        "secondaryId": "NCT02202252",
        "label": "Contradiction",
        "statement_text": "the primary trial has a 5 year long intervention  the duration of the secondary trial is only a single day after removal of the drains ",
        "statement_nums": [
            "5 year long"
        ],
        "premise_text": "Insertion of a single drain: A negative pressure drain will be inserted below the lower flap directing to the axilla in the single drain group Ultrasonography after removal of the drains: One day after removal of the drains seroma under the flaps and in the axilla will be examined by ultrasonography  Insertion of a single drain: A negative pressure drain will be inserted below the lower flap directing to the axilla  Ultrasonography after removal of the drains: One day after removal of the drains seroma under the flaps and in the axilla will be examined by ultrasonography  INTERVENTION 2: Double Drain Insertion of double drains: Two negative pressure drains will be inserted into the axilla and below the lower flap in the double drains group  ",
        "premise_nums": []
    },
    {
        "id": "fd18a599-f94a-478a-975f-854a4210ccad",
        "primaryId": "NCT00659373",
        "secondaryId": "NCT02202252",
        "label": "Contradiction",
        "statement_text": "the primary trial has a 5 year long intervention  the duration of the secondary trial is only a single day after removal of the drains ",
        "statement_nums": [
            "5 year long"
        ],
        "premise_text": "Ultrasonography after removal of the drains: One day after removal of the drains seroma under the flaps and in the axilla will be examined by ultrasonography Insertion of double drains: Two drains will be inserted into the axilla and below the lower flap in the double drains group  Ultrasonography after removal of the drains: One day after removal of the drains seroma under the flaps and in the axilla will be examined by ultrasonography  ",
        "premise_nums": []
    },
    {
        "id": "ac9ca070-80b2-4913-97d8-06d1b90fcfce",
        "primaryId": "NCT01797120",
        "secondaryId": "NCT02005887",
        "label": "Contradiction",
        "statement_text": "the secondary trial and the primary trial both have a placebo arm and a test arm ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 2: Fulvestrant & Placebo Fulvestrant Day 1 & 15 of Cycle 1, then Day 1 of all subsequent cycles (every 28 days for 12 cycles) plus placebo daily x 12 cycles  Fulvestrant: Fulvestrant 500 mg Day 1 & 15 of Cycle 1, then 500 mg Day 1 of all subsequent cycles (every 28 days for 12 cycles)  If no evidence of disease progression after 12 cycles  unblind and continue same dose and schedule until progression or unacceptable toxicity  Placebo: Placebo for Everolimus (2 tablets) daily x 12 cycles  Placebo manufactured to mimic everolimus tablet  INTERVENTION 1: Arm A: Triptorelin + Letrozol ",
        "premise_nums": [
            "15 of Cycle",
            "500 mg Day",
            "28 days for",
            "1 of all"
        ]
    },
    {
        "id": "ac9ca070-80b2-4913-97d8-06d1b90fcfce",
        "primaryId": "NCT01797120",
        "secondaryId": "NCT02005887",
        "label": "Contradiction",
        "statement_text": "the secondary trial and the primary trial both have a placebo arm and a test arm ",
        "statement_nums": [],
        "premise_text": "Arm A: Triptorelin 3.75 mg i.m  on day 1 every 28 days for 6 cycles + letrozole 2.5 mg/day orally for 6 cyclesTriptorelin: Triptorelin 3.75 mg injected into the muscle on day 1 every 28 days for 6 cycles (1 cycle= 28 days) Letrozole: Letrozole 2.5 mg orally every day for 6 cycles INTERVENTION 2: Arm B: Degarelix + Letrozol Arm B: Degarelix 240 mg s.c  on day 1 of cycle 1, followed by 80 mg s.c  on day 1 of cycles 2 to 6 + letrozole 2.5 mg every day orally for 6 cycles ",
        "premise_nums": [
            "letrozole 2.5 mg/day",
            "80 mg s.c",
            "2 to 6",
            "75 mg i.m",
            "6 cycles (1",
            "6 cycles INTERVENTION",
            "1 of cycles",
            "letrozole 2.5 mg every",
            "1 every 28",
            "Triptorelin 3.75 mg injected",
            "240 mg s.c",
            "Letrozole 2.5 mg orally"
        ]
    },
    {
        "id": "ac9ca070-80b2-4913-97d8-06d1b90fcfce",
        "primaryId": "NCT01797120",
        "secondaryId": "NCT02005887",
        "label": "Contradiction",
        "statement_text": "the secondary trial and the primary trial both have a placebo arm and a test arm ",
        "statement_nums": [],
        "premise_text": "Degarelix: Degarelix 240 mg injected under the skin given as two injections of 120 mg on the first day of treatment  followed by injection of 80 mg on day 1 of cycles 2 to 6 (1 cycle=28 days)Letrozole: Letrozole 2.5 mg orally every day for 6 cycles ",
        "premise_nums": [
            "80 mg on",
            "240 mg injected",
            "2 to 6",
            "120 mg on",
            "1 of cycles",
            "Letrozole 2.5 mg orally"
        ]
    },
    {
        "id": "19f5ff0d-3419-4f27-a7e5-6c7291c3cd21",
        "primaryId": "NCT00082810",
        "statement_text": "Throughout the duration of the primary trial  pariticpants receive increasing doses of Fulvestrant ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "INTERVENTION 1: Fulvestrant 250 mg + Tipifarnib 300 mg Patients receive fulvestrant 250 mg intramuscularly on day 1 and oral tipifarnib 300 mg twice daily on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity ",
        "premise_nums": [
            "250 mg intramuscularly",
            "28 days in",
            "1-21. Courses",
            "300 mg Patients",
            "1 and oral",
            "300 mg twice"
        ]
    },
    {
        "id": "009d23bb-2179-4ce3-927d-4dedca6b32a8",
        "primaryId": "NCT00479674",
        "statement_text": "Patients that have previously been trated with bevacizumab are not eligible for the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Exclusion Criteria: Prior treatment with Abraxane®  carboplatin or bevacizumab  or any taxane for metastatic breast cancer; ",
        "premise_nums": []
    },
    {
        "id": "5152d810-7669-4fb2-a66b-a0a1d6026af5",
        "primaryId": "NCT00577122",
        "secondaryId": "NCT01923168",
        "label": "Contradiction",
        "statement_text": "the secondary trial and the primary trial both use Pathologic complete response (pCR) as their outcome measure  and use a 6 month time frame ",
        "statement_nums": [
            "6 month time"
        ],
        "premise_text": "Outcome Measurement: Clinical Benefit Rate (CR + PR + SD greater than 6 Months)  To determine the clinical benefit rate (Complete Response + Partial Response + Stable Disease greater than 6 months) per Response Evaluation Criteria in Solid tumors (RECIST version 1.0). of MPA monotherapy and MPA + low dose oral cyclophosphamide and methotrexate (ldoCM) in patients with refractory hormone receptor negative metastatic breast cancer  This will show the percent of patients who had Clinical Benefit and the Exact 95% Confidence Interval  Time frame: baseline through end of study  up to 3 years Outcome Measurement: Pathological Complete Response (pCR) Per Investigator Assessment for Alpelisib vs  Placebo for PIK3CA Mutant Cohort ",
        "premise_nums": [
            "3 years Outcome",
            "95% Confidence"
        ]
    },
    {
        "id": "5152d810-7669-4fb2-a66b-a0a1d6026af5",
        "primaryId": "NCT00577122",
        "secondaryId": "NCT01923168",
        "label": "Contradiction",
        "statement_text": "the secondary trial and the primary trial both use Pathologic complete response (pCR) as their outcome measure  and use a 6 month time frame ",
        "statement_nums": [
            "6 month time"
        ],
        "premise_text": "Pathologic complete response (pCR) defined as absence of any residual invasive cancer on hematoxylin and eosin evaluation of the resected breast specimen and all sampled ipsilateral lymph nodes following completion of 24 weeks of treatment by local assessment (ypT0/Tis ypN0). Patients who experienced progression of disease while undergoing neoadjuvant therapy  or who did not receive surgery for any reason  or received antineoplastic treatment other than study drug(s) before surgery were considered as non-responders for the calculation of pCR rate Time frame: After 24 weeks of treatment ",
        "premise_nums": [
            "0/Tis ypN0",
            "24 weeks of"
        ]
    },
    {
        "id": "e8f4a600-0296-47d4-903b-2fa840ebcf28",
        "primaryId": "NCT02005549",
        "statement_text": "Patients with stage 3 Cervical carcinoma are excluded from the primary trial ",
        "statement_nums": [
            "3 Cervical carcinoma"
        ],
        "label": "Entailment",
        "premise_text": "Inclusion Criteria: no prior or current neoplasm except for non-melanoma skin cancer  or in situ cancer of the cervix; ",
        "premise_nums": []
    },
    {
        "id": "3fa8b747-b48d-4fb4-995d-38a23c64ccb3",
        "primaryId": "NCT02069093",
        "statement_text": "2 of the patients in the primary trial were either symptomatic  but able to swallow a modified diet; symptomatic and unable to aliment or hydrate orally or had symptoms associated with life-threatening consequences ",
        "statement_nums": [
            "2 of the"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Number of Participants With Stomatitis Grade 2 The incidence of grade 2 stomatitis was reported  Grade 1 = minimal symptoms  normal diet; grade 2 = symptomatic  but able to swallow a modified diet; grade 3 = symptomatic and unable to aliment or hydrate orally; and grade 4 = symptoms associated with life-threatening consequences  Time frame: 56 days Results 1: Arm/Group Title: Dexamethasone Based Mouthwash ",
        "premise_nums": [
            "2 The incidence",
            "2 stomatitis was",
            "56 days Results"
        ]
    },
    {
        "id": "3fa8b747-b48d-4fb4-995d-38a23c64ccb3",
        "primaryId": "NCT02069093",
        "statement_text": "2 of the patients in the primary trial were either symptomatic  but able to swallow a modified diet; symptomatic and unable to aliment or hydrate orally or had symptoms associated with life-threatening consequences ",
        "statement_nums": [
            "2 of the"
        ],
        "label": "Entailment",
        "premise_text": "Arm/Group Description: Participants swished and spat 10mL of 0.5mg/5mL dexamethasone steroid mouthwash (investigational treatment) 4 times daily (qid) orally for 2 minutes each for 8 weeks  Participants remained without food or drink (NPO) for one hour after administration of the mouthwash  Also  participants received everolimus 10 mg and exemstane 25 mg (study treatments) according to local regulations Overall Number of Participants Analyzed: 86 Measure Type: Number Unit of Measure: Participants Stomatitis grade greater than or equal 2: Yes: 2 Stomatitis grade greater than or equal 2: No: 83 ",
        "premise_nums": [
            "2 Stomatitis grade",
            "10 mg and",
            "4 times daily",
            "of 0.5mg/5mL",
            "2 minutes each",
            "86 Measure Type:",
            "25 mg (study"
        ]
    },
    {
        "id": "3fa8b747-b48d-4fb4-995d-38a23c64ccb3",
        "primaryId": "NCT02069093",
        "statement_text": "2 of the patients in the primary trial were either symptomatic  but able to swallow a modified diet; symptomatic and unable to aliment or hydrate orally or had symptoms associated with life-threatening consequences ",
        "statement_nums": [
            "2 of the"
        ],
        "label": "Entailment",
        "premise_text": "Stomatitis grade greater than or equal 2: Not evaluable: 1",
        "premise_nums": []
    },
    {
        "id": "b9c294c3-93b7-4681-be02-285f9e5cd867",
        "primaryId": "NCT03167359",
        "secondaryId": "NCT01385137",
        "label": "Entailment",
        "statement_text": "Between all cohorts in the primary trial and the secondary trial Omega-3-fatty Acids are only used in one cohort ",
        "statement_nums": [
            "3-fatty Acids"
        ],
        "premise_text": "INTERVENTION 1: Participants With Stage 0-III Breast Cancer Women with Stage 0-III breast cancer  treated with breast conserving surgery or mastectomy and clear margins  will receive 15 doses of radiation over three weeks  Hypofractionated Simultaneous Integrated Boost Radiotherapy: Participants will receive radiotherapy treatments to the whole breast or chest wall to a dose of 2.66 Gy per day x 15 fractions simultaneously with a boost treatment  The boost treatment will be given on the same days as the whole breast treatment  The lumpectomy cavity + scar (in lumpectomy patients) or chest wall scar (mastectomy patients) will receive 0.54 Gy per day x 15 fractions  INTERVENTION 1: Arm I (Omega-3-fatty Acid) ",
        "premise_nums": [
            "of 2.66 Gy per",
            "0-III Breast",
            "15 doses of",
            "receive 0.54 Gy per",
            "3-fatty Acid",
            "15 fractions simultaneously",
            "0-III breast"
        ]
    },
    {
        "id": "b9c294c3-93b7-4681-be02-285f9e5cd867",
        "primaryId": "NCT03167359",
        "secondaryId": "NCT01385137",
        "label": "Entailment",
        "statement_text": "Between all cohorts in the primary trial and the secondary trial Omega-3-fatty Acids are only used in one cohort ",
        "statement_nums": [
            "3-fatty Acids"
        ],
        "premise_text": "Patients receive oral omega-3-fatty acid twice daily (BID) or three times daily (TID) for 24 weeks in the absence of disease progression or unacceptable toxicityINTERVENTION 2: Arm II (Placebo) Patients receive oral placebo BID or TID for 24 weeks in the absence of disease progression or unacceptable toxicity ",
        "premise_nums": [
            "3-fatty acid",
            "24 weeks in"
        ]
    },
    {
        "id": "9df90d78-d857-4e1d-a650-e47f7b6b68d6",
        "primaryId": "NCT00322374",
        "statement_text": "Cohort 2 of the primary trial receive a higher dose of Ixabepilone  at a higher frequency  than cohort 1,",
        "statement_nums": [
            "2 of the"
        ],
        "label": "Contradiction",
        "premise_text": "INTERVENTION 1: Ixabepilone 25 mg^m2 + Epirubicin 75 mg^m2 Participants received 25 mg/m^2 Ixabepilone as a 3-hour IV infusion following a 3- to 5-minute IV infusion of 75 mg/m^2 epirubicin every 21 days  INTERVENTION 2: Ixabepilone 30 mg^m2 + Epirubicin 75 mg^m2 Participants received 30 mg/m^2 Ixabepilone as a 3-hour IV infusion following a 3- to 5-minute IV infusion of 75 mg/m^2 epirubicin every 21 days  ",
        "premise_nums": [
            "30 mg/m^2",
            "2 Ixabepilone as",
            "25 mg/m^2",
            "75 mg^m2 Participants",
            "30 mg^m2",
            "2 Participants received",
            "25 mg^m2",
            "2 epirubicin every",
            "3-hour IV",
            "5-minute IV",
            "75 mg/m^2"
        ]
    },
    {
        "id": "4923ff4f-b2a8-48ad-bf4b-1e193deb0dfe",
        "primaryId": "NCT03098550",
        "statement_text": "There results section indicates there were no patients in the primary trial with 0 adverse events ",
        "statement_nums": [
            "0 adverse events"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Number of Participants With Adverse Events (AEs) Number of participants with any grade of adverse events (AEs) graded by Common Terminology Criteria for Adverse Events (CTCAE v4.0) to determine the safety and tolerability of Nivolumab and Daratumumab Time frame: From first dose to 30 days post last dose (up to 34 months) Results 1: Arm/Group Title: Nivolumab + Daratumumab (TNBC) ",
        "premise_nums": [
            "30 days post"
        ]
    },
    {
        "id": "4923ff4f-b2a8-48ad-bf4b-1e193deb0dfe",
        "primaryId": "NCT03098550",
        "statement_text": "There results section indicates there were no patients in the primary trial with 0 adverse events ",
        "statement_nums": [
            "0 adverse events"
        ],
        "label": "Entailment",
        "premise_text": "Arm/Group Description: Triple-negative breast cancer (TNBC) treated with Triple-negative breast cancer (TNBC) treated with Nivolumab IV 240 mg Q2W (weeks 3 to 24) + Daratumumab IV 16 mg/kg Q1W (weeks 1 to 8), Daratumumab IV 16 mg/kg Q2W (weeks 9-24)Overall Number of Participants Analyzed: 41 Measure Type: Count of Participants Unit of Measure: Participants 41 100.0% Results 2: Arm/Group Title: Nivolumab + Daratumumab (NSCLC) ",
        "premise_nums": [
            "1 to 8),",
            "41 100.0% Results 2",
            "16 mg/kg Q",
            "41 Measure Type:",
            "3 to 24)",
            "240 mg Q2W",
            "9-24)Overall Number"
        ]
    },
    {
        "id": "4923ff4f-b2a8-48ad-bf4b-1e193deb0dfe",
        "primaryId": "NCT03098550",
        "statement_text": "There results section indicates there were no patients in the primary trial with 0 adverse events ",
        "statement_nums": [
            "0 adverse events"
        ],
        "label": "Entailment",
        "premise_text": "Arm/Group Description: Non-small cell lung cancer (NSCLC) treated with Nivolumab IV 240 mg Q2W (weeks 3 to 24) + Daratumumab IV 16 mg/kg Q1W (weeks 1 to 8), Daratumumab IV 16 mg/kg Q2W (weeks 9-24)Overall Number of Participants Analyzed: 21 Measure Type: Count of Participants Unit of Measure: Participants 21 100.0% ",
        "premise_nums": [
            "1 to 8),",
            "16 mg/kg Q",
            "3 to 24)",
            "240 mg Q2W",
            "21 Measure Type:",
            "9-24)Overall Number"
        ]
    },
    {
        "id": "92ac6e0c-8427-454d-9218-36eda1c580a7",
        "primaryId": "NCT01653964",
        "secondaryId": "NCT02660788",
        "label": "Entailment",
        "statement_text": "The interventions in the primary trial and the secondary trial are so different that it is not possible or useful to compare them ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Molecular Breast Imaging Molecular breast imaging performed after injection of 4 mCi Tc-99m sestamibi and again after 8 mCi Tc-99m sestamibi  INTERVENTION 1: Control Arm Mail Standard Reminder Postcard INTERVENTION 2: Family Physician Reminder Letter Arm Mail Standard Reminder Postcard Family Physician Reminder Letter ",
        "premise_nums": [
            "4 mCi Tc",
            "8 mCi Tc"
        ]
    },
    {
        "id": "f0aff1fc-4a67-4b28-a974-a4a67a5c930f",
        "primaryId": "NCT00733408",
        "statement_text": "There was over 14 weeks difference in Progression-free Survival between the minimum and maximum PFS in the primary trial ",
        "statement_nums": [
            "14 weeks difference"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Progression-free Survival (PFS) ",
        "premise_nums": []
    },
    {
        "id": "f0aff1fc-4a67-4b28-a974-a4a67a5c930f",
        "primaryId": "NCT00733408",
        "statement_text": "There was over 14 weeks difference in Progression-free Survival between the minimum and maximum PFS in the primary trial ",
        "statement_nums": [
            "14 weeks difference"
        ],
        "label": "Entailment",
        "premise_text": "Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions  or a measurable increase in a non-target lesion  or the appearance of new lesions  Kaplan-Meier survival curves will be used  A 95% confidence interval for the median PFS will be calculated  A lower bound greater than 8 months would be strong evidence that Nab-Paclitaxel- bevacizumab induction therapy followed by bevacizumab-erlotinib hydrochloride maintenance therapy is superior to paclitaxel and bevacizumab  However  a median PFS of 13 months or greater (regardless of whether the 95% confidence interval for the median extends below 8 months) could also indicate promising results ",
        "premise_nums": [
            "95% confidence",
            "8 months would",
            "13 months or",
            "20% increase"
        ]
    },
    {
        "id": "f0aff1fc-4a67-4b28-a974-a4a67a5c930f",
        "primaryId": "NCT00733408",
        "statement_text": "There was over 14 weeks difference in Progression-free Survival between the minimum and maximum PFS in the primary trial ",
        "statement_nums": [
            "14 weeks difference"
        ],
        "label": "Entailment",
        "premise_text": "Time frame: Time from date of registration to date of first documentation of progression or symptomatic deterioration or death due to any cause  assessed up to 8 yearsResults 1: Arm/Group Title: Tx (Chemo  MoAb  and Enzyme Inhibitor) Arm/Group Description: INDUCTION THERAPY: Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV on days 1, 8, and 15 and bevacizumab IV over 30-90 minutes on days 1 and 15. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity  ",
        "premise_nums": [
            "8 yearsResults 1:",
            "6 courses in",
            "30-90 minutes",
            "15 and bevacizumab",
            "90 minutes on",
            "28 days for",
            "1 and 15."
        ]
    },
    {
        "id": "f0aff1fc-4a67-4b28-a974-a4a67a5c930f",
        "primaryId": "NCT00733408",
        "statement_text": "There was over 14 weeks difference in Progression-free Survival between the minimum and maximum PFS in the primary trial ",
        "statement_nums": [
            "14 weeks difference"
        ],
        "label": "Entailment",
        "premise_text": "MAINTENANCE THERAPY: Patients achieving complete response  partial response  or stable disease after completion of induction therapy will receive bevacizumab IV over 30-90 minutes once every 14 or 21 days and erlotinib hydrochloride PO QD in the absence of disease progression or unacceptable toxicity paclitaxel albumin-stabilized nanoparticle formulation: Given IV bevacizumab: Given IV erlotinib hydrochloride: Given PO Overall Number of Participants Analyzed: 55 Median (95% Confidence Interval) Unit of Measure: Months 9.1 (7.2 to 11.1) ",
        "premise_nums": [
            "14 or 21",
            "30-90 minutes",
            "90 minutes once",
            "95% Confidence",
            "2 to 11.1)"
        ]
    },
    {
        "id": "2e0c241f-0a3b-4b39-87fe-ee2e5c7768d6",
        "primaryId": "NCT00121836",
        "secondaryId": "NCT00256243",
        "label": "Entailment",
        "statement_text": "Patients that are not willing to sign and give written informed consent for participation of the primary trial or the secondary trial will not be made to take part ",
        "statement_nums": [],
        "premise_text": "Inclusion Criteria: Women greater than or equal 18 years of age HER2-negative metastatic breast cancer Previous adjuvant chemotherapy or hormonal treatment greater than or equal 1 measurable target lesion Exclusion Criteria: Previous treatment with chemotherapy  an anti-angiogenic agent  or a biologic therapy for advanced or metastatic cancer Radiation therapy within 4 weeks of study treatment start or insufficient recovery from the effects of prior radiation therapy Central nervous system metastases Other malignancy within last 5 years  except cured basal cell carcinoma of skin and carcinoma in situ of uterine cervix Serious concurrent infection All patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines  ",
        "premise_nums": [
            "1 measurable target",
            "4 weeks of",
            "18 years of",
            "2-negative metastatic"
        ]
    },
    {
        "id": "96ab702d-cfe1-48fb-b348-a7c7b8db3f16",
        "primaryId": "NCT00684983",
        "statement_text": "The Median length of time that a patient in Arm A of the primary trial survived after receiving a TNBC diagnosis was 6 months ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Progression-free Survival (PFS) Analysis of the primary endpoint  PFS  will be performed using Cox regression with treatment group as a single covariate  Time frame: From randomization to the earliest date of documentation of disease progression  up to 5 years Results 1: Arm/Group Title: Arm A Arm/Group Description: Patients receive oral capecitabine twice daily on days 1-14 and oral lapatinib ditosylate once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity  lapatinib ditosylate: Given PO and capecitabine: Given PO Overall Number of Participants Analyzed: 19 Median (95% Confidence Interval) ",
        "premise_nums": [
            "14 and oral",
            "21 days in",
            "1-14 and",
            "1-21. Courses",
            "95% Confidence",
            "5 years Results"
        ]
    },
    {
        "id": "96ab702d-cfe1-48fb-b348-a7c7b8db3f16",
        "primaryId": "NCT00684983",
        "statement_text": "The Median length of time that a patient in Arm A of the primary trial survived after receiving a TNBC diagnosis was 6 months ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Unit of Measure: Median survival and CI in months 6.0 (4.3 to 8.6)",
        "premise_nums": []
    },
    {
        "id": "6224d2de-c62b-4b43-8517-475eaa565491",
        "primaryId": "NCT00811135",
        "statement_text": "The majority of patients in the primary trial experienced at least one adverse event ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 20/88 (22.73%) ",
        "premise_nums": [
            "20/88 (22.73%)"
        ]
    },
    {
        "id": "95154c62-9f79-4d80-90fd-2f61612285b0",
        "primaryId": "NCT01095003",
        "secondaryId": "NCT01702571",
        "label": "Contradiction",
        "statement_text": "In total more than 5 patients in the primary trial and the secondary trial experienced Earache ",
        "statement_nums": [
            "5 patients in"
        ],
        "premise_text": "Adverse Events 1: Total: 107/383 (27.94%) Anaemia 4/383 (1.04%) Febrile neutropenia 7/383 (1.83%) Haemoytique anaemia 0/383 (0.00%) Leukopenia 1/383 (0.26%) Neutropenia 6/383 (1.57%) Thrombocytopenia 2/383 (0.52%) Anginal pectoris 1/383 (0.26%) Cardiomyopathy 0/383 (0.00%) Ear pain 0/383 (0.00%) Abdominal distension 1/383 (0.26%) Abdominal pain 6/383 (1.57%) ",
        "premise_nums": [
            "6/383 (1.57%)",
            "0/383 (0.00%)",
            "107/383 (27.94%)",
            "1/383 (0.26%)",
            "7/383 (1.83%)",
            "2/383 (0.52%)",
            "4/383 (1.04%)"
        ]
    },
    {
        "id": "95154c62-9f79-4d80-90fd-2f61612285b0",
        "primaryId": "NCT01095003",
        "secondaryId": "NCT01702571",
        "label": "Contradiction",
        "statement_text": "In total more than 5 patients in the primary trial and the secondary trial experienced Earache ",
        "statement_nums": [
            "5 patients in"
        ],
        "premise_text": "Adverse Events 2:Total: 85/383 (22.19%) Anaemia 3/383 (0.78%) Febrile neutropenia 2/383 (0.52%) Haemoytique anaemia 0/383 (0.00%) Leukopenia 0/383 (0.00%) Neutropenia 1/383 (0.26%) Thrombocytopenia 1/383 (0.26%) Anginal pectoris 0/383 (0.00%) Cardiomyopathy 1/383 (0.26%) Ear pain 1/383 (0.26%) Abdominal distension 0/383 (0.00%) Abdominal pain 3/383 (0.78%) ",
        "premise_nums": [
            "0/383 (0.00%)",
            "1/383 (0.26%)",
            "2/383 (0.52%)",
            "3/383 (0.78%)",
            "2:Total: 85/383",
            "85/383 (22.19%)"
        ]
    },
    {
        "id": "95154c62-9f79-4d80-90fd-2f61612285b0",
        "primaryId": "NCT01095003",
        "secondaryId": "NCT01702571",
        "label": "Contradiction",
        "statement_text": "In total more than 5 patients in the primary trial and the secondary trial experienced Earache ",
        "statement_nums": [
            "5 patients in"
        ],
        "premise_text": "Adverse Events 1:Total: 427/2002 (21.33%) ANAEMIA 13/2002 (0.65%) BONE MARROW FAILURE 1/2002 (0.05%) DISSEMINATED INTRAVASCULAR COAGULATION 1/2002 (0.05%) FEBRILE NEUTROPENIA 1/2002 (0.05%) THROMBOCYTOPENIA 11/2002 (0.55%) ACUTE CORONARY SYNDROME 3/2002 (0.15%) ANGINA PECTORIS 1/2002 (0.05%) CARDIAC ARREST 1/2002 (0.05%) CARDIAC FAILURE 1/2002 (0.05%) CARDIAC TAMPONADE 1/2002 (0.05%) Adverse Events 2: Total: 36/181 (19.89%) ",
        "premise_nums": [
            "13/2002 (0.65%)",
            "11/2002 (0.55%)",
            "1/2002 (0.05%)",
            "36/181 (19.89%)",
            "1:Total: 427/2002",
            "3/2002 (0.15%)",
            "427/2002 (21.33%)"
        ]
    },
    {
        "id": "95154c62-9f79-4d80-90fd-2f61612285b0",
        "primaryId": "NCT01095003",
        "secondaryId": "NCT01702571",
        "label": "Contradiction",
        "statement_text": "In total more than 5 patients in the primary trial and the secondary trial experienced Earache ",
        "statement_nums": [
            "5 patients in"
        ],
        "premise_text": "ANAEMIA 0/181 (0.00%)BONE MARROW FAILURE 0/181 (0.00%) DISSEMINATED INTRAVASCULAR COAGULATION 0/181 (0.00%) FEBRILE NEUTROPENIA 0/181 (0.00%) THROMBOCYTOPENIA 10/181 (5.52%) ACUTE CORONARY SYNDROME 1/181 (0.55%) ANGINA PECTORIS 0/181 (0.00%) CARDIAC ARREST 0/181 (0.00%) CARDIAC FAILURE 0/181 (0.00%) CARDIAC TAMPONADE 0/181 (0.00%) ",
        "premise_nums": [
            "10/181 (5.52%)",
            "0/181 (0.00%)BONE",
            "1/181 (0.55%)"
        ]
    },
    {
        "id": "2f6243a9-af40-426d-9a6a-a5c5708cf1b4",
        "primaryId": "NCT00721630",
        "secondaryId": "NCT00364611",
        "label": "Entailment",
        "statement_text": "the primary trial and the secondary trial recorded the exact same number of cases of nausea ",
        "statement_nums": [],
        "premise_text": "Adverse Events 1: Nausea 1/23 (4.35%) Adverse Events 1: Nausea * 1/52 (1.92%) ",
        "premise_nums": [
            "1/23 (4.35%)",
            "1/52 (1.92%)"
        ]
    },
    {
        "id": "837f0588-22fc-4069-b2bc-297b3f6aabf7",
        "primaryId": "NCT00058058",
        "statement_text": "Candidates for the primary trial do not need to meet a specific life expectancy criteria ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Life expectancy Not specified ",
        "premise_nums": []
    },
    {
        "id": "01ef1af2-bac4-4ff9-9f0e-bb39276a9d78",
        "primaryId": "NCT00572728",
        "secondaryId": "NCT02472964",
        "label": "Entailment",
        "statement_text": "Patients in the primary trial will not be made to take Herceptin¬¨¬© (trastuzumab) or paclitaxel intravenously like those in the secondary trial ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Diagnostic (18F-FLT) Patients undergo 18F-FLT PET/CT at baseline (prior to chemotherapy  FLT-1), early therapy (5-10 days after the initiation of the first course of chemotherapy  FLT-2), and post therapy (within 3 weeks prior to surgery  FLT-3). Patients undergo standard surgical resection of residual tumor following completion of neoadjuvant chemotherapy  Fluorothymidine F-18: Undergo 18F-FLT PET/CT Positron Emission Tomography: Undergo 18F-FLT PET/CT Computed Tomography: Undergo 18F-FLT PET/CT ",
        "premise_nums": [
            "(5-10 days",
            "10 days after",
            "3 weeks prior",
            "18F-FLT PET"
        ]
    },
    {
        "id": "01ef1af2-bac4-4ff9-9f0e-bb39276a9d78",
        "primaryId": "NCT00572728",
        "secondaryId": "NCT02472964",
        "label": "Entailment",
        "statement_text": "Patients in the primary trial will not be made to take Herceptin¬¨¬© (trastuzumab) or paclitaxel intravenously like those in the secondary trial ",
        "statement_nums": [],
        "premise_text": "Laboratory Biomarker Analysis: Correlative studiesINTERVENTION 1: Herceptin© + Taxane Part 1: Herceptin© (trastuzumab) intravenously+ paclitaxel 80 mg/m2 weekly intravenously or docetaxel 75 mg/m2 intravenously once every three weeks (investigators choice) for 8 cycles then evaluate for primary endpoint  Part 2: If SD or PR  CR at cycle 9 (week 24) proceed to Herceptin© (trastuzumab) alone once every 3 weeks until DP or subject withdrawal   INTERVENTION 2: ",
        "premise_nums": [
            "3 weeks until",
            "75 mg/m2 intravenously",
            "8 cycles then",
            "80 mg/m2 weekly",
            "2 intravenously once",
            "2 weekly intravenously"
        ]
    },
    {
        "id": "01ef1af2-bac4-4ff9-9f0e-bb39276a9d78",
        "primaryId": "NCT00572728",
        "secondaryId": "NCT02472964",
        "label": "Entailment",
        "statement_text": "Patients in the primary trial will not be made to take Herceptin¬¨¬© (trastuzumab) or paclitaxel intravenously like those in the secondary trial ",
        "statement_nums": [],
        "premise_text": "MYL-1401O Trastuzumab + TaxanePart 1:Myl 1401OTrastuzumab Intravenously + paclitaxel 80 mg/m2 weekly intravenously or docetaxel 75 mg/m2 intravenously once every three weeks (investigators choice) for 8 cycles then evaluate for primary endpoint  Part 2: If SD or PR  CR at cycle 9 (week 24) proceed to Myl 1401O( Mylan Trastuzumab) alone once every 3 weeks until DP or subject withdrawal  ",
        "premise_nums": [
            "3 weeks until",
            "75 mg/m2 intravenously",
            "8 cycles then",
            "1:Myl 1401OTrastuzumab",
            "80 mg/m2 weekly",
            "2 intravenously once",
            "2 weekly intravenously"
        ]
    },
    {
        "id": "e7b47e19-9cd0-4121-a79a-ee223e7f3ab7",
        "primaryId": "NCT03511378",
        "statement_text": "Patients must have a life expectancy over half a year to participate in the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Inclusion Criteria: Patient who have estimated life expectancy of more than six months ",
        "premise_nums": []
    },
    {
        "id": "21cf4dfe-2cd7-4e60-943d-2f7e1266a80d",
        "primaryId": "NCT02630693",
        "statement_text": "A 30% of patients in the primary trial suffered a life-threatening reaction to an infection ",
        "statement_nums": [
            "30% of"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 9/90 (10.00%) Febrile neutropenia 2/90 (2.22%) Ascites 0/90 (0.00%) Nausea 0/90 (0.00%) Vomiting 0/90 (0.00%) Death NOS 1/90 (1.11%) Fever 0/90 (0.00%) Other general disorders  administration site conditions 0/90 (0.00%) Other hepatobiliary disorders 1/90 (1.11%) Lung infection 2/90 (2.22%) Sepsis 2/90 (2.22%) Spinal fracture 0/90 (0.00%) Adverse Events 2: Total: 12/89 (13.48%) ",
        "premise_nums": [
            "2/90 (2.22%)",
            "1/90 (1.11%)",
            "0/90 (0.00%)",
            "9/90 (10.00%)",
            "12/89 (13.48%)"
        ]
    },
    {
        "id": "21cf4dfe-2cd7-4e60-943d-2f7e1266a80d",
        "primaryId": "NCT02630693",
        "statement_text": "A 30% of patients in the primary trial suffered a life-threatening reaction to an infection ",
        "statement_nums": [
            "30% of"
        ],
        "label": "Contradiction",
        "premise_text": "Febrile neutropenia 0/89 (0.00%)Ascites 1/89 (1.12%) Nausea 1/89 (1.12%) Vomiting 1/89 (1.12%) Death NOS 2/89 (2.25%) Fever 1/89 (1.12%) Other general disorders  administration site conditions 1/89 (1.12%) Other hepatobiliary disorders 0/89 (0.00%) Lung infection 0/89 (0.00%) Sepsis 1/89 (1.12%) Spinal fracture 1/89 (1.12%) ",
        "premise_nums": [
            "1/89 (1.12%)",
            "2/89 (2.25%)",
            "0/89 (0.00%)Ascites"
        ]
    },
    {
        "id": "d72ecaae-c132-480c-af5e-87c58dd26082",
        "primaryId": "NCT00679341",
        "secondaryId": "NCT00201851",
        "label": "Contradiction",
        "statement_text": "The only adverse event observed in Patients from both the secondary trial and the primary trial  was Endocervical cancer ",
        "statement_nums": [],
        "premise_text": "Adverse Events 1: Total: 14/69 (20.29%) Febrile neutropenia 0/69 (0.00%) Anaemia 0/69 (0.00%) Atrial fibrillation 1/69 (1.45%) Cardiopulmonary failure 0/69 (0.00%) Supraventricular extrasystoles 1/69 (1.45%) Abdominal pain 1/69 (1.45%) Intestinal obstruction 0/69 (0.00%) Vomiting 1/69 (1.45%) Chills 1/69 (1.45%) Oedema peripheral 0/69 (0.00%) Pyrexia 1/69 (1.45%) Adverse Events 2: ",
        "premise_nums": [
            "14/69 (20.29%)",
            "1/69 (1.45%)",
            "0/69 (0.00%)"
        ]
    },
    {
        "id": "d72ecaae-c132-480c-af5e-87c58dd26082",
        "primaryId": "NCT00679341",
        "secondaryId": "NCT00201851",
        "label": "Contradiction",
        "statement_text": "The only adverse event observed in Patients from both the secondary trial and the primary trial  was Endocervical cancer ",
        "statement_nums": [],
        "premise_text": "Total: 17/66 (25.76%)Febrile neutropenia 6/66 (9.09%) Anaemia 1/66 (1.52%) Atrial fibrillation 1/66 (1.52%) Cardiopulmonary failure 1/66 (1.52%) Supraventricular extrasystoles 0/66 (0.00%) Abdominal pain 0/66 (0.00%) Intestinal obstruction 1/66 (1.52%) Vomiting 0/66 (0.00%) Chills 0/66 (0.00%) Oedema peripheral 1/66 (1.52%) Pyrexia 0/66 (0.00%) Adverse Events 1: ",
        "premise_nums": [
            "6/66 (9.09%)",
            "17/66 (25.76%)Febrile",
            "1/66 (1.52%)",
            "0/66 (0.00%)"
        ]
    },
    {
        "id": "d72ecaae-c132-480c-af5e-87c58dd26082",
        "primaryId": "NCT00679341",
        "secondaryId": "NCT00201851",
        "label": "Contradiction",
        "statement_text": "The only adverse event observed in Patients from both the secondary trial and the primary trial  was Endocervical cancer ",
        "statement_nums": [],
        "premise_text": "Total: 0/244 (0.00%)Pregnancy *0/244 (0.00%) Endocervical cancer *0/244 (0.00%) Nosocomial pneumonia *0/244 (0.00%) Venous thrombosis *0/244 (0.00%) ",
        "premise_nums": [
            "0/244 (0.00%)Pregnancy"
        ]
    },
    {
        "id": "80245791-4a95-4682-bd5f-856694c9f52f",
        "primaryId": "NCT00721409",
        "secondaryId": "NCT02413320",
        "label": "Contradiction",
        "statement_text": "Patients with HER2 negative tumours are eligible for the primary trial but not for the secondary trial",
        "statement_nums": [
            "2 negative tumours"
        ],
        "premise_text": "Inclusion Criteria: Inoperable estrogen receptor positive and HER2 negative breast cancer  Inclusion Criteria: Patients with newly diagnosed stage I (Tgreater than 1cm), II or III triple negative breast cancer who have not had definitive breast surgery or received systemic chemotherapy ",
        "premise_nums": [
            "2 negative breast"
        ]
    },
    {
        "id": "be7a2ed3-49a3-45e0-ba0a-ee5ee95e6138",
        "primaryId": "NCT01325428",
        "secondaryId": "NCT00073073",
        "label": "Entailment",
        "statement_text": "the secondary trial and the primary trial do not require participants to be of a particular ethnicity  to be able to speak a specific language or to be above a certain height threshold ",
        "statement_nums": [],
        "premise_text": "Inclusion criteria: Female patients greater than or equal 18 years with proven diagnosis of HER2-overexpressing, histologically confirmed breast cancer Locally advanced or metastatic disease Must have disease that can be evaluated according to RECIST 1.1 (Response Evaluation Criteria for Solid Tumours version 1.1) For trastuzumab pre-treated patients  must have failed prior trastuzumab treatment Investigator-confirmed diagnosis of Inflammatory Breast Cancer Must have biopsiable disease Exclusion criteria: Prior treatment with HER2-targeted small molecules or antibodies other than trastuzumab (which must have been given in the trastuzumab-failure study population) Must not have received prior vinorelbine treatment INCLUSION CRITERIA: Postmenopausal female  ",
        "premise_nums": [
            "2-targeted small",
            "18 years with",
            "2-overexpressing, histologically"
        ]
    },
    {
        "id": "be7a2ed3-49a3-45e0-ba0a-ee5ee95e6138",
        "primaryId": "NCT01325428",
        "secondaryId": "NCT00073073",
        "label": "Entailment",
        "statement_text": "the secondary trial and the primary trial do not require participants to be of a particular ethnicity  to be able to speak a specific language or to be above a certain height threshold ",
        "statement_nums": [],
        "premise_text": "Postmenopausal defined as no menses for at least 12 months or bilateral oophorectomy  In unclear cases  (e.g  50 year old who has had hysterectomy) chemical confirmation of postmenopausal status may be confirmed with follicle stimulating hormone (FSH) greater than 35 U/L Elevated risk for developing invasive breast cancer by virtue of one of the following criteria: Gail Model risk of greater than or equal to 1.7% over 5 years from study entry  (This is the same minimum level of risk required for a subject to be eligible for the recently completed NSABP-P1 tamoxifen breast cancer prevention trial)  Lobular neoplasia  Atypical ductal hyperplasia  ",
        "premise_nums": [
            "1 tamoxifen breast",
            "to 1.7% over 5",
            "5 years from",
            "50 year old",
            "12 months or",
            "35 U/L Elevated"
        ]
    },
    {
        "id": "be7a2ed3-49a3-45e0-ba0a-ee5ee95e6138",
        "primaryId": "NCT01325428",
        "secondaryId": "NCT00073073",
        "label": "Entailment",
        "statement_text": "the secondary trial and the primary trial do not require participants to be of a particular ethnicity  to be able to speak a specific language or to be above a certain height threshold ",
        "statement_nums": [],
        "premise_text": "DCIS (ductal carcinoma in situ) that has been previously treated with mastectomy or lumpectomy and radiation  +/- tamoxifen Deleterious mutations in BRCA1 or 2 OR A priori risk assessment of 20% chance or greater of carrying BRCA1/2 gene mutation  The BRCAPRO and Couch model will both be used to asses this risk  If a woman has a 20% risk of carrying a BRCA1/2 mutation by either model  she will meet eligibility criteria  Prior stage I or II breast cancer at least 2 years out from treatment for invasive disease and no prior use of aromatase inhibitors  ",
        "premise_nums": [
            "2 mutation by",
            "20% chance",
            "20% risk",
            "2 years out",
            "1 or 2",
            "2 OR A",
            "2 gene mutation",
            "BRCA1/2 mutation",
            "BRCA1/2 gene"
        ]
    },
    {
        "id": "be7a2ed3-49a3-45e0-ba0a-ee5ee95e6138",
        "primaryId": "NCT01325428",
        "secondaryId": "NCT00073073",
        "label": "Entailment",
        "statement_text": "the secondary trial and the primary trial do not require participants to be of a particular ethnicity  to be able to speak a specific language or to be above a certain height threshold ",
        "statement_nums": [],
        "premise_text": "Subjects should be willing to abstain from use of hormonal therapies (e.g  tamoxifen  hormone replacement therapy  oral contraceptive pills  hormone-containing intrauterine devices (IUDs)  E-string is acceptable)  Venlafaxine will be offered as supportive care for women with menopausal symptoms Eastern Cooperative Oncology Group (ECOG) performance status 0-1. Subject has been counseled regarding her options and has signed the informed consent document  Baseline dual-emission x-ray absorptiometry (DEXA) scan with bone mineral density (BMD) T-score greater than or equal to 2.5 at antero posterior (AP) spine  ",
        "premise_nums": [
            "to 2.5 at antero",
            "0-1. Subject"
        ]
    },
    {
        "id": "be7a2ed3-49a3-45e0-ba0a-ee5ee95e6138",
        "primaryId": "NCT01325428",
        "secondaryId": "NCT00073073",
        "label": "Entailment",
        "statement_text": "the secondary trial and the primary trial do not require participants to be of a particular ethnicity  to be able to speak a specific language or to be above a certain height threshold ",
        "statement_nums": [],
        "premise_text": "Hemoglobin greater than or equal to 11 g/dl Creatinine less than 1.5 times the upper limits of normal  Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) less than 2.5 times upper limit of normal  No investigational agent for the past 30 days  If history of cancer (other than squamous or basal cell skin cancers)  subject must have no evidence of disease at time of enrollment AND no history of cancer directed treatment in the 2 years preceding enrollment  EXCLUSION CRITERIA: ",
        "premise_nums": [
            "2 years preceding",
            "than 2.5 times upper",
            "11 g/dl Creatinine",
            "than 1.5 times the"
        ]
    },
    {
        "id": "be7a2ed3-49a3-45e0-ba0a-ee5ee95e6138",
        "primaryId": "NCT01325428",
        "secondaryId": "NCT00073073",
        "label": "Entailment",
        "statement_text": "the secondary trial and the primary trial do not require participants to be of a particular ethnicity  to be able to speak a specific language or to be above a certain height threshold ",
        "statement_nums": [],
        "premise_text": "Current or recent chronic use (within 3 months) of hormonal medications  e.g  oral contraceptive pills  hormone replacement therapy  tamoxifen  raloxifene  IUD with progestins or corticosteroids  (Subjects on chronic topical or inhaled steroids will be eligible for the study.) Current use of phenytoin  carbamazepine  rifampin due to increased estrogen metabolism History of clotting or bleeding disorder  History of allergic reactions attributed to compounds of similar chemical or biologic composition to exemestane (e.g  anastrozole  letrozole  formestane)  ",
        "premise_nums": []
    },
    {
        "id": "be7a2ed3-49a3-45e0-ba0a-ee5ee95e6138",
        "primaryId": "NCT01325428",
        "secondaryId": "NCT00073073",
        "label": "Entailment",
        "statement_text": "the secondary trial and the primary trial do not require participants to be of a particular ethnicity  to be able to speak a specific language or to be above a certain height threshold ",
        "statement_nums": [],
        "premise_text": "Uncontrolled intercurrent illness including  but not limited to  ongoing or active infection  symptomatic congestive heart failure  unstable angina pectoris  cardiac arrhythmia  or psychiatric illness/social situations that would limit compliance with study requirements ",
        "premise_nums": []
    },
    {
        "id": "f0da58e6-e937-41ac-b53a-d46ec8a28d11",
        "primaryId": "NCT01923168",
        "statement_text": "Intervention 1 of the primary trial require participants to take 300 mg alpelisib once daily ",
        "statement_nums": [
            "300 mg alpelisib",
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "INTERVENTION 1: Alpelisib + Letrozole Participants took alpelisib 300 mg once daily plus letrozole 2.5 mg once daily  ",
        "premise_nums": [
            "300 mg once",
            "letrozole 2.5 mg once"
        ]
    },
    {
        "id": "5a74a63a-3912-44f0-9e83-4e6b678cbe90",
        "primaryId": "NCT02685566",
        "secondaryId": "NCT03076190",
        "label": "Contradiction",
        "statement_text": "the primary trial and the secondary trial have the same number of study groups  and are both testing the effectiveness of Full-Field Digital Mammography ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: FFDM Plus DBT Breast Images with FFDM and DBT FFDM Plus DBT: FujiFilm Aspire Cristalle System  This endpoint will be evaluated qualitatively  The Pass Criteria require adequate performance in non-cancer cases (recall rate) and in cancer cases (detection rate)  INTERVENTION 2: Full-Field Digital Mammography (FFDM) Breast Images with FFDM alone FFDM: FujiFilm Aspire Cristalle System  This endpoint will be evaluated qualitatively  The Pass Criteria require adequate performance in non-cancer cases (recall rate) and in cancer cases (detection rate)  INTERVENTION 1: Active Control Group Health Education Active Control Group INTERVENTION 2: My Surgical Success Treatment Group My Surgical Success Intervention Group ",
        "premise_nums": []
    },
    {
        "id": "43f03ba4-ef03-4f57-b059-3d9267f0dcf8",
        "primaryId": "NCT00325234",
        "statement_text": "Patients under the age of 18, wanting to participate in the primary trial  must discontinue any Antitumoral hormonal treatment prior to study entry  and have a life expectancy of more than 3 months ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria: Antitumoral hormonal treatment must be discontinued prior to enrollment  Estimated life expectancy of at least 3 months  Female participants must be at least 18 years of age  ",
        "premise_nums": [
            "18 years of"
        ]
    },
    {
        "id": "6e106caf-2522-4022-898d-64b82093d77a",
        "primaryId": "NCT02413320",
        "statement_text": "Females over the age of 20 with no prior chemotherapy with therapeutic intent for current cancer  are eligible for the primary trial ",
        "statement_nums": [
            "20 with no"
        ],
        "label": "Entailment",
        "premise_text": "Inclusion Criteria: No prior chemotherapy  endocrine therapy or radiation therapy with therapeutic intent for this cancer Female subjects age 18 - 70 years ",
        "premise_nums": []
    },
    {
        "id": "7f8a918c-fab8-4129-8178-0cda7d0441e1",
        "primaryId": "NCT00021255",
        "statement_text": "Cohort 2 of the primary trial recieves Doxorubicin  cyclophosphamide  Herceptin and docetaxel throughout the cycles of the study ",
        "statement_nums": [
            "2 of the"
        ],
        "label": "Entailment",
        "premise_text": "INTERVENTION 2: AC Followed by Docetaxel + Herceptin (AC→TH) ",
        "premise_nums": []
    },
    {
        "id": "84aa1194-c081-4acf-9ed6-8cf0d1a08f5d",
        "primaryId": "NCT01125566",
        "statement_text": "At least 400 participants in the primary trial receiving an oral treatment of film-coated Afatinib tablet at a starting dose of 40 milligram (mg) once daily and weekly 10 minutes intravenous infusions of Vinorelbine 25 mg/meter^2 (meter=m) had a PFS over 9 months ",
        "statement_nums": [
            "10 minutes intravenous",
            "25 mg/meter^2",
            "40 milligram (mg)",
            "400 participants in"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Progression-free Survival (PFS) PFS is defined as time from randomisation to disease progression or death whichever occurs first  Assessed by investigator according to the Response Evaluation Criteria in Solid Tumours (RECIST 1.1). RECIST is a set of published rules that define when tumors in cancer patients improve (\"respond\")  stay the same (\"stabilize\") or worsen (\"progress\") during treatment  Only data collected until the cut-off date for RECIST 1.1 based endpoints (08Jun2013) were considered  ",
        "premise_nums": [
            "(08Jun2013) were",
            "RECIST 1.1 based endpoints"
        ]
    },
    {
        "id": "84aa1194-c081-4acf-9ed6-8cf0d1a08f5d",
        "primaryId": "NCT01125566",
        "statement_text": "At least 400 participants in the primary trial receiving an oral treatment of film-coated Afatinib tablet at a starting dose of 40 milligram (mg) once daily and weekly 10 minutes intravenous infusions of Vinorelbine 25 mg/meter^2 (meter=m) had a PFS over 9 months ",
        "statement_nums": [
            "10 minutes intravenous",
            "25 mg/meter^2",
            "40 milligram (mg)",
            "400 participants in"
        ],
        "label": "Contradiction",
        "premise_text": "Progression of disease was determined if at least 1 of the following criteria applied:At least a 20% increase in the sum of the diameters (SoD) of target lesions taking as reference the smallest SoD recorded since the treatment started  together with an absolute increase in the SoD of at least 5 mm Appearance of 1 or more new lesions Unequivocal progression of existing non-target lesions Time frame: From randomization (07Sep2010) until disease progression  death or data cut-off (08Jun2013); Up to 34 months Results 1: ",
        "premise_nums": [
            "(07Sep2010) until",
            "5 mm Appearance",
            "34 months Results",
            "1 or more",
            "1 of the",
            "20% increase"
        ]
    },
    {
        "id": "84aa1194-c081-4acf-9ed6-8cf0d1a08f5d",
        "primaryId": "NCT01125566",
        "statement_text": "At least 400 participants in the primary trial receiving an oral treatment of film-coated Afatinib tablet at a starting dose of 40 milligram (mg) once daily and weekly 10 minutes intravenous infusions of Vinorelbine 25 mg/meter^2 (meter=m) had a PFS over 9 months ",
        "statement_nums": [
            "10 minutes intravenous",
            "25 mg/meter^2",
            "40 milligram (mg)",
            "400 participants in"
        ],
        "label": "Contradiction",
        "premise_text": "Arm/Group Title: Afatinib + Vinorelbine (AV)",
        "premise_nums": []
    },
    {
        "id": "2bd65df6-4f1d-461c-93f5-f2ddbfde57b6",
        "primaryId": "NCT02018458",
        "secondaryId": "NCT00895414",
        "label": "Contradiction",
        "statement_text": "Patients with unexplained fever below thirty eight degrees Celsius may be included in the secondary trial and the primary trial ",
        "statement_nums": [],
        "premise_text": "Exclusion Criteria: Active infection or unexplained fever greater than 38.5°C during screening  Inclusion Criteria: Tissue diagnosis of a breast carcinoma The oncologist must have prescribed doxorubicin as part of the planned chemotherapy regimen Have acceptable organ function within 14 days of enrollment defined as: liver function: total bilirubin  AST and ALT within normal institutional limits kidney function: estimated Creatinine Clearance greater than 60 ml/min calculated creatinine clearance (for females) - formula: (140 - age) x weight x .85 divided by (sCr x 72) At least 18 years old Patient must have given written informed consent indicating an understanding of the investigational nature of the study Agrees not to consume grapefruit juice while on the study Exclusion Criteria: ",
        "premise_nums": [
            "14 days of",
            "60 ml/min calculated",
            "85 divided by",
            "18 years old"
        ]
    },
    {
        "id": "2bd65df6-4f1d-461c-93f5-f2ddbfde57b6",
        "primaryId": "NCT02018458",
        "secondaryId": "NCT00895414",
        "label": "Contradiction",
        "statement_text": "Patients with unexplained fever below thirty eight degrees Celsius may be included in the secondary trial and the primary trial ",
        "statement_nums": [],
        "premise_text": "Known allergy to enalaprilTaking any known P450 cytochrome inducers or inhibitors Taking any herbal supplements while on the study or the week prior to receiving doxorubicin Taking an ace-inhibitor or angiotensin receptor blocker Pregnant or lactating  Enalapril is Pregnancy Categories C (first trimester) and D (second and third trimesters) ",
        "premise_nums": [
            "450 cytochrome inducers",
            "P450 cytochrome"
        ]
    },
    {
        "id": "0290bc2d-9cd3-44ab-9b04-385f19527c42",
        "primaryId": "NCT02550210",
        "statement_text": "Patients must have ductal carcinoma  that can be felt by touch to be eligible for the primary trial ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria: Histologic diagnosis of palpable invasive breast cancer or ductal carcinoma in situ ",
        "premise_nums": []
    },
    {
        "id": "505afbf8-b2b4-4b12-99c5-e0feef473248",
        "primaryId": "NCT00577122",
        "secondaryId": "NCT01923168",
        "label": "Entailment",
        "statement_text": "the secondary trial and the primary trial do not both use Clinical Benefit Rate as their outcome measure  and they do not use the same time frame ",
        "statement_nums": [],
        "premise_text": "Outcome Measurement: Clinical Benefit Rate (CR + PR + SD greater than 6 Months)  To determine the clinical benefit rate (Complete Response + Partial Response + Stable Disease greater than 6 months) per Response Evaluation Criteria in Solid tumors (RECIST version 1.0). of MPA monotherapy and MPA + low dose oral cyclophosphamide and methotrexate (ldoCM) in patients with refractory hormone receptor negative metastatic breast cancer  This will show the percent of patients who had Clinical Benefit and the Exact 95% Confidence Interval  Time frame: baseline through end of study  up to 3 years Outcome Measurement: Pathological Complete Response (pCR) Per Investigator Assessment for Alpelisib vs  Placebo for PIK3CA Mutant Cohort ",
        "premise_nums": [
            "3 years Outcome",
            "95% Confidence"
        ]
    },
    {
        "id": "505afbf8-b2b4-4b12-99c5-e0feef473248",
        "primaryId": "NCT00577122",
        "secondaryId": "NCT01923168",
        "label": "Entailment",
        "statement_text": "the secondary trial and the primary trial do not both use Clinical Benefit Rate as their outcome measure  and they do not use the same time frame ",
        "statement_nums": [],
        "premise_text": "Pathologic complete response (pCR) defined as absence of any residual invasive cancer on hematoxylin and eosin evaluation of the resected breast specimen and all sampled ipsilateral lymph nodes following completion of 24 weeks of treatment by local assessment (ypT0/Tis ypN0). Patients who experienced progression of disease while undergoing neoadjuvant therapy  or who did not receive surgery for any reason  or received antineoplastic treatment other than study drug(s) before surgery were considered as non-responders for the calculation of pCR rate Time frame: After 24 weeks of treatment ",
        "premise_nums": [
            "0/Tis ypN0",
            "24 weeks of"
        ]
    },
    {
        "id": "19e7469d-8a6f-4bbd-9c8c-ad6b127ce7a5",
        "primaryId": "NCT01816594",
        "secondaryId": "NCT02222337",
        "label": "Entailment",
        "statement_text": "Patients with histologically confirmed  newly diagnosed stage 0 bilateral breast cancer cannot take part in the primary trial  but may still be eligible for the secondary trial ",
        "statement_nums": [
            "0 bilateral breast"
        ],
        "premise_text": "Patient has bilateral breast cancer or metastatic disease or inflammatory breast cancer Inclusion Criteria: Survivors: Latina  has been diagnosed with breast cancer  speaks English or Spanish  has a Caregiver who is willing to participate  Caregivers: a primary caregiver for a Latina breast cancer survivor  speak English or Spanish Exclusion Criteria: Inability to understand spoken English and/or Spanish and/or Cognitive impairment that precludes informed consent (determined by the PIs or Co-Investigators who are mental health professionals)  ",
        "premise_nums": []
    },
    {
        "id": "2e540abd-06e3-483d-bd69-6eb5d2275e9e",
        "primaryId": "NCT01830933",
        "secondaryId": "NCT01224678",
        "label": "Contradiction",
        "statement_text": "Patients in the primary trial and the secondary trial are administered daily oral medication ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Usual Care Usual Care is the comparison Clinic Patients  where there is no change in their standard or usual care  INTERVENTION 2: BreastCARE Intervention Intervention Clinic Patients: The participants will answer questions on the tablet-PC to calculate their breast cancer risk  Intervention Patient Report  Once the patient completes the BreastCare Computer survey  the program will immediately generate a personal feedback report containing information about her risk factors and recommendations to reduce her risk  This report will be printed and given to the patients before she meets with her doctor  BreastCARE : The physician will receive a physician report that contains information similar to the patient report  Patients receive oral vitamin D (2000 IU) once daily for 12 months  ",
        "premise_nums": []
    },
    {
        "id": "d905f4cb-32aa-41b8-8f61-40578d8ea9ae",
        "primaryId": "NCT00274469",
        "statement_text": "No less than 2 patients from either cohorts of the primary trial felt nauseous ",
        "statement_nums": [
            "2 patients from"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: NAUSEA 1/101 (0.99%) Adverse Events 2: NAUSEA 0/103 (0.00%) ",
        "premise_nums": [
            "0/103 (0.00%)",
            "1/101 (0.99%)"
        ]
    },
    {
        "id": "45510043-7931-493b-8251-41b0be9aabbd",
        "primaryId": "NCT00232505",
        "statement_text": "There were 2 instances of patients with Atrial tachycardia in the primary trial ",
        "statement_nums": [
            "2 instances of"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 3/31 (9.68%) Edema: limb * 2/31 (6.45%) Neutrophils/granulocytes (ANC/AGC) * 0/31 (0.00%) Cardiac General - Other (Specify  __) * [1]0/31 (0.00%) Cardiac General - Other (Specify  __) * [2]0/31 (0.00%) Left ventricular diastolic dysfunction * 0/31 (0.00%) Supraventricular and nodal arrhythmia - Atrial tachycardia/Paroxysmal Atrial Tachycardia * 0/31 (0.00%) Adverse Events 2: Total: 8/25 (32.00%) ",
        "premise_nums": [
            "2/31 (6.45%)",
            "3/31 (9.68%)",
            "8/25 (32.00%)",
            "0/31 (0.00%)"
        ]
    },
    {
        "id": "45510043-7931-493b-8251-41b0be9aabbd",
        "primaryId": "NCT00232505",
        "statement_text": "There were 2 instances of patients with Atrial tachycardia in the primary trial ",
        "statement_nums": [
            "2 instances of"
        ],
        "label": "Contradiction",
        "premise_text": "Edema: limb * 1/25 (4.00%)Neutrophils/granulocytes (ANC/AGC) * 0/25 (0.00%) Cardiac General - Other (Specify  __) * [1]1/25 (4.00%) Cardiac General - Other (Specify  __) * [2]0/25 (0.00%) Left ventricular diastolic dysfunction * 1/25 (4.00%) Supraventricular and nodal arrhythmia - Atrial tachycardia/Paroxysmal Atrial Tachycardia * 0/25 (0.00%) ",
        "premise_nums": [
            "0/25 (0.00%)",
            "1/25 (4.00%)Neutrophils/granulocytes"
        ]
    },
    {
        "id": "e7037f34-bd2e-402e-a19c-48073781885a",
        "primaryId": "NCT00193037",
        "statement_text": "10 of the patients in Cohort 1 of the primary trial suffered from Hypotension ",
        "statement_nums": [
            "10 of the",
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Hypotension 0/50 (0.00%) ",
        "premise_nums": [
            "0/50 (0.00%)"
        ]
    },
    {
        "id": "5275a332-46c1-4941-8850-26a8033012e3",
        "primaryId": "NCT00981305",
        "statement_text": "Only people who have previously been diagnosed with cancer and have no signs of cancer after finishing treatment are eliglbe for the primary trial  as long as they are over the age of 20.",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Inclusion Criteria: breast cancer survivors over 20 years-old ",
        "premise_nums": [
            "20 years-old"
        ]
    },
    {
        "id": "1ec6aca8-6e67-4535-aeb7-a250e1d7b6c0",
        "primaryId": "NCT01129622",
        "secondaryId": "NCT01156987",
        "label": "Contradiction",
        "statement_text": "the secondary trial and the primary trial both used MRI and Letrozole for their interventions ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Letrozole  Breast Enhancement  Safety Single arm of healthy postmenopausal women to have two breast MRI (baseline and post-treatment)  Letrozole of 12.5 mg/day is given for three successive days just prior to the second MRI  INTERVENTION 1: Healthy Volunteers Healthy women will be screened for Magnetic Resonance Imaging (MRI) contraindications  and then undergo contrast injection  and SWIFT acquisition  Magnetic resonance imaging: Patients and healthy volunteers will be first screened for MRI contraindications  The SWIFT MRI workflow will be performed as follows: ",
        "premise_nums": [
            "of 12.5 mg/day"
        ]
    },
    {
        "id": "b02f43d7-44bb-4219-9a08-fd70e7cc9b87",
        "primaryId": "NCT01004744",
        "statement_text": "Patients must have a confirmed Postmenopausal status  defined as a lack of menses for over a year  if they are to take part in the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Postmenopausal status defined as cessation of menses for greater than 1 year or FSH greater than 20 mIU/mL (within the past month) ",
        "premise_nums": [
            "20 mIU/mL",
            "1 year or"
        ]
    },
    {
        "id": "1a6661e0-343f-4056-b568-611e7cc7750c",
        "primaryId": "NCT01827163",
        "statement_text": "Any patients with breast cancer above stage  currently receiving radiation therapy or biotherapy are excluded from the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Exclusion Criteria: Patients with stage IV breast cancer or undergoing chemotherapy  radiation therapy  immunotherapy  or biotherapy for current breast cancer  ",
        "premise_nums": []
    },
    {
        "id": "ec97c90e-f904-4cf2-9567-8525edf747cf",
        "primaryId": "NCT03196635",
        "secondaryId": "NCT01943916",
        "label": "Contradiction",
        "statement_text": "the primary trial and the secondary trial are both evaluating patient assisted imaging interventions ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: All Study Participants  PA Compression Image Sets All image sets (30 patient-assisted compression image sets) were evaluated for acceptability of overall clinical image quality by two (2) readers  INTERVENTION 2: All Study Participants  TC Compression Image Sets All image sets (30 TC compression image sets) were evaluated for acceptability of overall clinical image quality by two (2) readers  INTERVENTION 1: Overall Population Each subject served as her own control  with imaging of each mass by both the test and control modalities  Specificity difference is a single measure for the overall ITD population  ",
        "premise_nums": [
            "30 TC compression",
            "(2) readers"
        ]
    },
    {
        "id": "7a129a1e-20d9-4f5a-a921-d30957460e27",
        "primaryId": "NCT00820222",
        "secondaryId": "NCT01819233",
        "label": "Entailment",
        "statement_text": "the secondary trial and the primary trial do not test the same modalities of cancer treatments ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Lapatinib Plus Capecitabine Participants received a daily dose of 5 tablets of lapatinib (1250 mg) at approximately the same time every day  either 1 hour (or more) before breakfast or 1 hour (or more) after breakfast  Participants also received capecitabine 2000 mg/m^2) per day (divided and administered orally twice daily  12 hours apart)  for 14 days  every 21 days  Capecitabine was taken with food or within 30 minutes after food  Participants received study medication until disease progression  unacceptable toxicity  or participant withdrawal  INTERVENTION 2: Trastuzumab Plus Capecitabine ",
        "premise_nums": [
            "5 tablets of",
            "2000 mg/m^2)",
            "12 hours apart)",
            "30 minutes after",
            "1 hour (or"
        ]
    },
    {
        "id": "7a129a1e-20d9-4f5a-a921-d30957460e27",
        "primaryId": "NCT00820222",
        "secondaryId": "NCT01819233",
        "label": "Entailment",
        "statement_text": "the secondary trial and the primary trial do not test the same modalities of cancer treatments ",
        "statement_nums": [],
        "premise_text": "Participants received an IV infusion of trastuzumab 8 mg/kg on Day 1, followed by a 6 mg/kg infusion every 3 weeks  Participants also received capecitabine 2500 mg/m^2 per day (divided and administered orally twice daily  12 hours apart)  for 14 days  every 21 days  Capecitabine was taken with food or within 30 minutes after food  Participants received study medication until disease progression  unacceptable toxicity  or participant withdrawal INTERVENTION 1: Behavioral Dietary Intervention ",
        "premise_nums": [
            "2 per day",
            "6 mg/kg infusion",
            "12 hours apart)",
            "30 minutes after",
            "2500 mg/m^2",
            "8 mg/kg on"
        ]
    },
    {
        "id": "7a129a1e-20d9-4f5a-a921-d30957460e27",
        "primaryId": "NCT00820222",
        "secondaryId": "NCT01819233",
        "label": "Entailment",
        "statement_text": "the secondary trial and the primary trial do not test the same modalities of cancer treatments ",
        "statement_nums": [],
        "premise_text": "Beginning 2-4 weeks after completion of lumpectomy  patients receive food diaries to complete for 7-10 days  Dietary counselors then give patients guidelines for dietary modifications to reduce caloric intake by 25% of their normal diet  Patients follow caloric restricted diet for 10 weeks (2 weeks prior to radiation therapy  during 6 weeks of radiation therapy  and at least 2 weeks after radiation therapy)  Patients undergo radiation therapy QD 5 days a week for 6 weeks Behavioral dietary intervention: Receive caloric restricted dietary intervention Therapeutic conventional surgery: Undergo definitive lumpectomy Radiation therapy: Undergo radiation therapy Counseling intervention: Receive dietary counseling Quality-of-life assessment: Ancillary studies ",
        "premise_nums": [
            "25% of",
            "2-4 weeks",
            "6 weeks Behavioral",
            "5 days a",
            "4 weeks after",
            "7-10 days",
            "10 weeks (2",
            "6 weeks of",
            "2 weeks after"
        ]
    },
    {
        "id": "fa9bd6ab-bd69-43f9-a0c0-f8c80bad9da4",
        "primaryId": "NCT01566721",
        "statement_text": "The difference in Percentage of Participants With At Least 1 Adverse Event (AE) During the Treatment Period in both cohorts of the primary trial is less than 1%.",
        "statement_nums": [
            "1 Adverse Event"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Percentage of Participants With At Least 1 Adverse Event (AE) During the Treatment Period Participants were planned to receive a total of 18 cycles of SC Herceptin  An AE was defined as any untoward medical occurrence in a participant administered SC Herceptin  Examples included unfavorable/unintended signs and symptoms  new or exacerbated disease  recurrence of intermittent condition  deterioration in laboratory value or other clinical test  or adverse procedure-related events  The percentage of participants with at least 1 AE during the treatment period (regardless of severity or seriousness) was reported  Time frame: From Day 1 up to 19 cycles (cycle length 3 weeks) (approximately 1 year) Results 1: ",
        "premise_nums": [
            "19 cycles (cycle",
            "1 AE during",
            "18 cycles of",
            "1 up to",
            "1 Adverse Event"
        ]
    },
    {
        "id": "fa9bd6ab-bd69-43f9-a0c0-f8c80bad9da4",
        "primaryId": "NCT01566721",
        "statement_text": "The difference in Percentage of Participants With At Least 1 Adverse Event (AE) During the Treatment Period in both cohorts of the primary trial is less than 1%.",
        "statement_nums": [
            "1 Adverse Event"
        ],
        "label": "Entailment",
        "premise_text": "Arm/Group Title: Cohort A: SC Herceptin by Needle/SyringeArm/Group Description: Participants received SC Herceptin by an assisted administration as 600 mg every 3 weeks for a total of 18 doses/cycles  Each dose of SC Herceptin was taken from a single-use vial and injected by needle/syringe  Overall Number of Participants Analyzed: 1864 Measure Type: Number Unit of Measure: percentage of participants 88.6 Results 2: Arm/Group Title: Cohort B: SC Herceptin by SID ",
        "premise_nums": [
            "1864 Measure Type:",
            "18 doses/cycles",
            "3 weeks for",
            "6 Results 2:",
            "600 mg every",
            "participants 88.6 Results 2"
        ]
    },
    {
        "id": "fa9bd6ab-bd69-43f9-a0c0-f8c80bad9da4",
        "primaryId": "NCT01566721",
        "statement_text": "The difference in Percentage of Participants With At Least 1 Adverse Event (AE) During the Treatment Period in both cohorts of the primary trial is less than 1%.",
        "statement_nums": [
            "1 Adverse Event"
        ],
        "label": "Entailment",
        "premise_text": "Arm/Group Description: Participants received SC Herceptin as 600 mg every 3 weeks for a total of 18 doses/cycles  Each dose of SC Herceptin was administered from a pre-filled SID  The first administration was performed by an HCP  Subsequent doses were self-administered by participants who were willing and judged competent by the HCP Overall Number of Participants Analyzed: 709 Measure Type: Number Unit of Measure: percentage of participants 89.0 ",
        "premise_nums": [
            "18 doses/cycles",
            "3 weeks for",
            "600 mg every",
            "709 Measure Type:"
        ]
    },
    {
        "id": "a1c99d5b-d53a-4195-ad5f-5e1b48c22078",
        "primaryId": "NCT03176238",
        "secondaryId": "NCT01498458",
        "label": "Entailment",
        "statement_text": "Although there is a much higher percentage of patients with Thrombocytopenia in the secondary trial than in cohort 1 of the primary trial  no robust comparisons can be made due to the significant differences in cohort sizes ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Adverse Events 1: Total: 59/199 (29.65%) Anaemia 7/199 (3.52%) Thrombocytopenia 2/199 (1.01%) Adverse Events 1: Total: 6/8 (75.00%) Thrombocytopenia 1/8 (12.50%) ",
        "premise_nums": [
            "2/199 (1.01%)",
            "6/8 (75.00%)",
            "7/199 (3.52%)",
            "1/8 (12.50%)",
            "59/199 (29.65%)"
        ]
    },
    {
        "id": "0203435e-03a0-4c41-afdf-6c497d8908c1",
        "primaryId": "NCT00331630",
        "statement_text": "Men with Left ventricular ejection fraction greater than 50% are excluded from participating in the primary trial ",
        "statement_nums": [
            "50% are"
        ],
        "label": "Contradiction",
        "premise_text": "LVEF 50% as measured by echocardiogram or MUGA scan Male or female ",
        "premise_nums": [
            "50% as"
        ]
    },
    {
        "id": "e6388dc2-b096-467d-8b70-fd5346dd581a",
        "primaryId": "NCT00083174",
        "secondaryId": "NCT00190671",
        "label": "Entailment",
        "statement_text": "The highest number of occurences for any adverse event in both the primary trial and the secondary trial was 2.",
        "statement_nums": [],
        "premise_text": "Adverse Events 1: Total: 39/2240 (1.74%) Supraven.arrhyth  Atrial fibrillation 1/2240 (0.04%) Cardiac ischemia/infarction 2/2240 (0.09%) Valvular heart disease 1/2240 (0.04%) Cardiac General - Other 2/2240 (0.09%) Endocrine - Other 1/2240 (0.04%) Ocular - Other 1/2240 (0.04%) Colitis 2/2240 (0.09%) Diarrhea 1/2240 (0.04%) Dysphagia 1/2240 (0.04%) Gastritis 1/2240 (0.04%) ",
        "premise_nums": [
            "2/2240 (0.09%)",
            "1/2240 (0.04%)",
            "39/2240 (1.74%)"
        ]
    },
    {
        "id": "e6388dc2-b096-467d-8b70-fd5346dd581a",
        "primaryId": "NCT00083174",
        "secondaryId": "NCT00190671",
        "label": "Entailment",
        "statement_text": "The highest number of occurences for any adverse event in both the primary trial and the secondary trial was 2.",
        "statement_nums": [],
        "premise_text": "Adverse Events 1:Total: 6 Agranulocytosis 0/42 (0.00%) Anaemia 2/42 (4.76%) Febrile neutropenia 1/42 (2.38%) Leukopenia 0/42 (0.00%) Neutropenia 1/42 (2.38%) Thrombocytopenia 1/42 (2.38%) Cardio-respiratory arrest 0/42 (0.00%) Pericardial effusion 1/42 (2.38%) Gastric ulcer haemorrhage 0/42 (0.00%) Melaena 0/42 (0.00%) Fatigue 1/42 (2.38%) ",
        "premise_nums": [
            "2/42 (4.76%)",
            "6 Agranulocytosis 0",
            "1:Total: 6",
            "0/42 (0.00%)",
            "1/42 (2.38%)"
        ]
    },
    {
        "id": "e6388dc2-b096-467d-8b70-fd5346dd581a",
        "primaryId": "NCT00083174",
        "secondaryId": "NCT00190671",
        "label": "Entailment",
        "statement_text": "The highest number of occurences for any adverse event in both the primary trial and the secondary trial was 2.",
        "statement_nums": [],
        "premise_text": "Multi-organ failure 0/42 (0.00%)Adverse Events 2: Total: 13 Agranulocytosis 1/61 (1.64%) Anaemia 1/61 (1.64%) Febrile neutropenia 0/61 (0.00%) Leukopenia 2/61 (3.28%) Neutropenia 2/61 (3.28%) Thrombocytopenia 1/61 (1.64%) Cardio-respiratory arrest 1/61 (1.64%) Pericardial effusion 0/61 (0.00%) Gastric ulcer haemorrhage 1/61 (1.64%) Melaena 1/61 (1.64%) ",
        "premise_nums": [
            "1/61 (1.64%)",
            "0/61 (0.00%)",
            "0/42 (0.00%)Adverse",
            "13 Agranulocytosis 1",
            "2/61 (3.28%)"
        ]
    },
    {
        "id": "e6388dc2-b096-467d-8b70-fd5346dd581a",
        "primaryId": "NCT00083174",
        "secondaryId": "NCT00190671",
        "label": "Entailment",
        "statement_text": "The highest number of occurences for any adverse event in both the primary trial and the secondary trial was 2.",
        "statement_nums": [],
        "premise_text": "Fatigue 1/61 (1.64%)Multi-organ failure 1/61 (1.64%) ",
        "premise_nums": [
            "1/61 (1.64%)Multi-organ"
        ]
    },
    {
        "id": "93511e52-1c12-4dee-858e-13b10793e2a6",
        "primaryId": "NCT00429182",
        "secondaryId": "NCT00429507",
        "label": "Contradiction",
        "statement_text": "the secondary trial exclusively uses radiotherapy in its intervention  whereas the primary trial gives its patient cohorts Stem Cell Transplants on the first day of the study ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: High-dose Chemotherapy Carboplatin + Cyclophosphamide + Thiotepa Carboplatin : Target AUC of 20, then divided into 4 doses given by vein (IV) days -6, -5, -4, -3 prior to stem cell infusion  Thiotepa : 120 mg/m^2 by vein days -6, -5, -4, -3 prior to stem cell infusion  Stem Cell Transplant : Stem Cell Transplant on Day 0. Cyclophosphamide : 1.5 gm/m^2 by vein days -6, -5, -4, -3 prior to stem cell infusion  INTERVENTION 1: ",
        "premise_nums": [
            "3 prior to",
            "4 doses given",
            "120 mg/m^2",
            "2 by vein",
            "1.5 gm/m"
        ]
    },
    {
        "id": "93511e52-1c12-4dee-858e-13b10793e2a6",
        "primaryId": "NCT00429182",
        "secondaryId": "NCT00429507",
        "label": "Contradiction",
        "statement_text": "the secondary trial exclusively uses radiotherapy in its intervention  whereas the primary trial gives its patient cohorts Stem Cell Transplants on the first day of the study ",
        "statement_nums": [],
        "premise_text": "Samarium 153-EDTMP + Stem Cell TransplantSamarium 153-EDTMP tracer dose = 30 millicurie (mCi) intravenous Day 1; or with study drug to bones  receive higher therapy dose of 153 Sm-EDTMP 7-14 days after tracer dose  Stem Cell Transplant Day 0, about 14-21 days after Samarium 153-EDTMP. ",
        "premise_nums": [
            "30 millicurie (mCi)",
            "153 Sm-EDTMP",
            "14 days after",
            "14-21 days",
            "21 days after",
            "7-14 days",
            "153-EDTMP +",
            "153-EDTMP tracer"
        ]
    },
    {
        "id": "cb932dbf-4c98-4488-b189-1286442968b6",
        "primaryId": "NCT02005549",
        "statement_text": "Patients with Cervical carcinoma in situ are excluded from the primary trial ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria: no prior or current neoplasm except for non-melanoma skin cancer  or in situ cancer of the cervix; ",
        "premise_nums": []
    },
    {
        "id": "0b9aa7e8-5912-44db-b9b0-6a84df769e19",
        "primaryId": "NCT00545688",
        "statement_text": "There were no patients with paranasal sinus reactions in the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 21/107 (19.63%) Febrile neutropenia * 10/107 (9.35%) Neutropenia * 1/107 (0.93%) Left ventricular dysfunction * 0/107 (0.00%) Angina pectoris * 0/107 (0.00%) Cardiac failure congestive * 0/107 (0.00%) Diarrhoea * 2/107 (1.87%) Abdominal strangulated hernia * 0/107 (0.00%) Duodenal ulcer haemorrhage * 0/107 (0.00%) Pyrexia * 1/107 (0.93%) Adverse Events 2: Total: 22/107 (20.56%) ",
        "premise_nums": [
            "2/107 (1.87%)",
            "22/107 (20.56%)",
            "1/107 (0.93%)",
            "10/107 (9.35%)",
            "21/107 (19.63%)",
            "0/107 (0.00%)"
        ]
    },
    {
        "id": "0b9aa7e8-5912-44db-b9b0-6a84df769e19",
        "primaryId": "NCT00545688",
        "statement_text": "There were no patients with paranasal sinus reactions in the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Febrile neutropenia * 8/107 (7.48%)Neutropenia * 6/107 (5.61%) Left ventricular dysfunction * 3/107 (2.80%) Angina pectoris * 1/107 (0.93%) Cardiac failure congestive * 0/107 (0.00%) Diarrhoea * 0/107 (0.00%) Abdominal strangulated hernia * 1/107 (0.93%) Duodenal ulcer haemorrhage * 0/107 (0.00%) Pyrexia * 1/107 (0.93%) ",
        "premise_nums": [
            "8/107 (7.48%)Neutropenia",
            "1/107 (0.93%)",
            "3/107 (2.80%)",
            "6/107 (5.61%)",
            "0/107 (0.00%)"
        ]
    },
    {
        "id": "570ab6bb-b23c-4955-b6b0-d756d1b69c0e",
        "primaryId": "NCT00756717",
        "statement_text": "Patients with cytologically confirmed  metastatic  early stage invasive breast cancer with an Allred score of 3 are eligible for the primary trial ",
        "statement_nums": [
            "3 are eligible"
        ],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria: Patients must have histologically or cytologically confirmed early stage  ER-positive (Allred score 3), invasive breast cancer that is not either locally advanced by criteria other than size or inflammatory  and is not metastatic  - Patients must be candidates for surgical removal of the tumor by lumpectomy or mastectomy  ",
        "premise_nums": []
    },
    {
        "id": "daf105f8-58e8-47d7-b0a2-5949620b0a2b",
        "primaryId": "NCT00296036",
        "statement_text": "the primary trial administers the placebo and Urea/Lactic Acid Cream in the same frequency and on the same areas of the skin ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "INTERVENTION 1: Urea/Lactic Acid Cream Patients receive topical urea/lactic acid-based cream applied to palms and soles twice daily  INTERVENTION 2: Placebo Cream Patients receive placebo cream applied to palms and soles twice daily  ",
        "premise_nums": []
    },
    {
        "id": "c4b671ae-4701-43a3-ada1-659c265d1f3a",
        "primaryId": "NCT01582971",
        "statement_text": "In order to participate in the primary trial  participants must be aware of where they are  and what day it is ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Inclusion Criteria: Cognitively oriented to time  place  and person (determined via nurse recruiter) ",
        "premise_nums": []
    },
    {
        "id": "0a17a404-ed1d-4c31-a192-509b68198ea8",
        "primaryId": "NCT00717405",
        "statement_text": "There was a dental adverse event in the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 20/52 (38.46%) Febrile bone marrow aplasia * 5/52 (9.62%) Febrile neutropenia * 6/52 (11.54%) Leukopenia * 6/52 (11.54%) Atrial tachycardia * 1/52 (1.92%) Vomiting * 1/52 (1.92%) Tooth loss * 1/52 (1.92%) Hyperthermia * 1/52 (1.92%) Malaise * 1/52 (1.92%) Pyrexia * 1/52 (1.92%) Impaired healing * 3/52 (5.77%) Inflammation * 1/52 (1.92%) ",
        "premise_nums": [
            "3/52 (5.77%)",
            "5/52 (9.62%)",
            "20/52 (38.46%)",
            "1/52 (1.92%)",
            "6/52 (11.54%)"
        ]
    },
    {
        "id": "9661db11-0c91-48c6-a8e8-6cb7cc2b06fd",
        "primaryId": "NCT02699983",
        "secondaryId": "NCT00994279",
        "label": "Entailment",
        "statement_text": "Neither the primary trial or the secondary trial require participants to practice yoga while Wearing a Fitbit activity monitoring device ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Group I (SparkPeople Program) Participants receive training on how to use the SparkPeople website  self-monitor their diet using the SparkPeople tool  and to self-monitor their activity daily using the Fitbit monitoring device  Participants receive weekly motivational reminders to log into the website for 3 months via email  text  or phone  based on patient preference (active phase)  Participants then enter the maintenance phase for 3 months without reminders  Behavioral Dietary Intervention: Use SparkPeople web-based program Exercise Intervention: Use Fitbit monitor and SparkPeople web-based program Activity Monitoring Device: Wear Fitbit activity monitoring device INTERVENTION 2: Group II (Wait List) Participants receive the weight loss handout and a Fitbit activity monitor  After 6 months  participants receive the SparkPeople treatment  Exercise Intervention: Use Fitbit monitor Activity Monitoring Device: Wear Fitbit activity monitoring device INTERVENTION 1: ",
        "premise_nums": [
            "3 months via",
            "3 months without"
        ]
    },
    {
        "id": "9661db11-0c91-48c6-a8e8-6cb7cc2b06fd",
        "primaryId": "NCT02699983",
        "secondaryId": "NCT00994279",
        "label": "Entailment",
        "statement_text": "Neither the primary trial or the secondary trial require participants to practice yoga while Wearing a Fitbit activity monitoring device ",
        "statement_nums": [],
        "premise_text": "Arm 1: Yoga InterventionYoga Intervention Yoga: Yoga sessions INTERVENTION 2: Arm 2: Educational Wellness Group Educational Wellness Group Education: Educational Wellness Group ",
        "premise_nums": []
    },
    {
        "id": "e8b86ef4-3ce8-4d81-a632-f30672c80ff5",
        "primaryId": "NCT02115607",
        "secondaryId": "NCT01823107",
        "label": "Entailment",
        "statement_text": "Patients in the primary trial receive an Infusion of Perflutren Lipid Microspheres  whereas in the secondary trial subjects are implanted with a Meso BioMatrix Acellular Peritoneum Matrix ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Definity Infusion Infusion of Definity (Perflutren Lipid Microspheres) Definity infusion: 3 ml of Perflutren Lipid Microspheres (Definity) mixed in 50 ml of saline is infused at a rate of approximately 4ml/min INTERVENTION 1: Meso BioMatrix Acellular Peritoneum Matrix All subjects had the Meso BioMatrix Acellular Peritoneum Matrix implanted along with a tissue expander during the first stage of breast reconstruction  After tissue expansion  the tissue expander was replaced with a breast implant during the second stage of reconstruction  ",
        "premise_nums": [
            "3 ml of",
            "50 ml of",
            "4ml/min INTERVENTION"
        ]
    },
    {
        "id": "879f2f14-38a8-419a-bae0-e62ed81eb9dd",
        "primaryId": "NCT00146172",
        "statement_text": "Cohort 1 of the primary trial recieves less than 60% of cohort 2's dose of LA-EP2006.",
        "statement_nums": [
            "60% of",
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "INTERVENTION 1: Neratinib 40 mg Neratinb 40 mg qd INTERVENTION 2: Neratinib 80 mg Neratinib 80 mg qd ",
        "premise_nums": [
            "80 mg Neratinib",
            "80 mg qd",
            "40 mg Neratinb",
            "40 mg qd"
        ]
    },
    {
        "id": "2ec46285-dd0c-4420-b9f6-e44a1ac74f20",
        "primaryId": "NCT01752907",
        "secondaryId": "NCT01940497",
        "label": "Contradiction",
        "statement_text": "There were 0 observed cases of Tibia or Fibula fractures in the primary trial or the secondary trial ",
        "statement_nums": [
            "0 observed cases"
        ],
        "premise_text": "Adverse Events 1: Total: 16/149 (10.74%) Anaemia 0/149 (0.00%) Febrile neutropenia 7/149 (4.70%) Neutropenia 1/149 (0.67%) Pancytopenia 1/149 (0.67%) Atrial fibrillation 2/149 (1.34%) Cardiac failure congestive 0/149 (0.00%) Abdominal pain 0/149 (0.00%) Diarrhoea 2/149 (1.34%) Dyspepsia 0/149 (0.00%) Gastritis haemorrhagic 0/149 (0.00%) Nausea 2/149 (1.34%) Adverse Events 2: ",
        "premise_nums": [
            "16/149 (10.74%)",
            "7/149 (4.70%)",
            "0/149 (0.00%)",
            "1/149 (0.67%)",
            "2/149 (1.34%)"
        ]
    },
    {
        "id": "2ec46285-dd0c-4420-b9f6-e44a1ac74f20",
        "primaryId": "NCT01752907",
        "secondaryId": "NCT01940497",
        "label": "Contradiction",
        "statement_text": "There were 0 observed cases of Tibia or Fibula fractures in the primary trial or the secondary trial ",
        "statement_nums": [
            "0 observed cases"
        ],
        "premise_text": "Total: 20/151 (13.25%)Anaemia 1/151 (0.66%) Febrile neutropenia 4/151 (2.65%) Neutropenia 2/151 (1.32%) Pancytopenia 0/151 (0.00%) Atrial fibrillation 0/151 (0.00%) Cardiac failure congestive 1/151 (0.66%) Abdominal pain 1/151 (0.66%) Diarrhoea 3/151 (1.99%) Dyspepsia 1/151 (0.66%) Gastritis haemorrhagic 1/151 (0.66%) Nausea 1/151 (0.66%) Adverse Events 1: ",
        "premise_nums": [
            "1/151 (0.66%)",
            "2/151 (1.32%)",
            "4/151 (2.65%)",
            "3/151 (1.99%)",
            "20/151 (13.25%)Anaemia",
            "0/151 (0.00%)"
        ]
    },
    {
        "id": "2ec46285-dd0c-4420-b9f6-e44a1ac74f20",
        "primaryId": "NCT01752907",
        "secondaryId": "NCT01940497",
        "label": "Contradiction",
        "statement_text": "There were 0 observed cases of Tibia or Fibula fractures in the primary trial or the secondary trial ",
        "statement_nums": [
            "0 observed cases"
        ],
        "premise_text": "Total: 5/95 (5.26%)Febrile neutropenia 0/95 (0.00%) Neutropenia 0/95 (0.00%) Atrial fibrillation 0/95 (0.00%) Pleuropericarditis 0/95 (0.00%) Vomiting 0/95 (0.00%) Pryexia 0/95 (0.00%) Anaphylactic shock 1/95 (1.05%) Gastroenteritis 0/95 (0.00%) Fibula fracture 1/95 (1.05%) Tibia fracture 1/95 (1.05%) Intervertebral disc protrusion 0/95 (0.00%) Adverse Events 2: ",
        "premise_nums": [
            "5/95 (5.26%)Febrile",
            "1/95 (1.05%)",
            "0/95 (0.00%)"
        ]
    },
    {
        "id": "2ec46285-dd0c-4420-b9f6-e44a1ac74f20",
        "primaryId": "NCT01752907",
        "secondaryId": "NCT01940497",
        "label": "Contradiction",
        "statement_text": "There were 0 observed cases of Tibia or Fibula fractures in the primary trial or the secondary trial ",
        "statement_nums": [
            "0 observed cases"
        ],
        "premise_text": "Total: 3/20 (15.00%)Febrile neutropenia 0/20 (0.00%) Neutropenia 0/20 (0.00%) Atrial fibrillation 1/20 (5.00%) Pleuropericarditis 1/20 (5.00%) Vomiting 0/20 (0.00%) Pryexia 0/20 (0.00%) Anaphylactic shock 0/20 (0.00%) Gastroenteritis 1/20 (5.00%) Fibula fracture 0/20 (0.00%) Tibia fracture 0/20 (0.00%) Intervertebral disc protrusion 1/20 (5.00%) ",
        "premise_nums": [
            "3/20 (15.00%)Febrile",
            "0/20 (0.00%)",
            "1/20 (5.00%)"
        ]
    },
    {
        "id": "f8afffdc-649b-4921-942a-66b804a3717f",
        "primaryId": "NCT00121992",
        "statement_text": "In order to be eligible for the primary trial  patients must not have prior radiation  anthracycline or systemic anticancer therapy   and must have T1-4, N1 and M1 bilateral breast cancer ",
        "statement_nums": [
            "1 and M1",
            "1-4, N1"
        ],
        "label": "Contradiction",
        "premise_text": "Exclusion Criteria: Prior systemic anticancer therapy for breast cancer (immunotherapy  hormonotherapy  chemotherapy)  Prior anthracycline therapy or taxoids (paclitaxel  docetaxel) for any malignancy  Prior radiation therapy for breast cancer  Any T4 or N1-3 or M1 breast cancer  ",
        "premise_nums": [
            "N1-3 or",
            "3 or M1"
        ]
    },
    {
        "id": "65f22210-47dd-4865-99e2-ddd414dddb08",
        "primaryId": "NCT01806259",
        "statement_text": "In total Over 82% patient in the primary trial achieve Recurrence-free Survival after 5 years ",
        "statement_nums": [
            "82% patient"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Recurrence-free Survival 2 years for the primary analysis + 3 additional years for secondary analysis (From date of randomization until the date of first documented progression or date of death from any cause  whichever came first  assessed up to 5 years) Time frame: 5 years Results 1: Arm/Group Title: Ketorolac 30 mg Arm/Group Description: Active drug to be compared with placebo Ketorolac 30 mg IV Overall Number of Participants Analyzed: 96 Measure Type: Count of Participants Unit of Measure: Participants 80 83.3% Results 2: Arm/Group Title: NaCl 0.9% 3mL Arm/Group Description: Ketorolac 30 mg IV Overall Number of Participants Analyzed: 107 Measure Type: Count of Participants Unit of Measure: Participants 96 89.7% ",
        "premise_nums": [
            "96 Measure Type:",
            "30 mg Arm",
            "80 83.3% Results 2",
            "3 additional years",
            "2 years for",
            "30 mg IV",
            "107 Measure Type:",
            "5 years Results"
        ]
    },
    {
        "id": "ff8a1e0d-d2ee-4687-b429-5b3b6081edc6",
        "primaryId": "NCT00915603",
        "secondaryId": "NCT02511730",
        "label": "Contradiction",
        "statement_text": "INR of 1.35 is enough for participation in the primary trial and the secondary trial ",
        "statement_nums": [
            "of 1.35 is enough"
        ],
        "premise_text": "Inclusion Criteria: International normalized ratio (INR) smaller than =1.5 or prothrombin time (PT)/partial Inclusion Criteria: Female subjects participating in FMSU004A protocol with known clinical status Exclusion Criteria: Subjects with unknown clinical status not participating in FMSU004A protocol  ",
        "premise_nums": [
            "5 or prothrombin"
        ]
    },
    {
        "id": "b86f0f3c-7905-470d-ae5d-e1867eb8bd3b",
        "primaryId": "NCT00917735",
        "statement_text": "One patient in cohort 2 of the primary trial crashed their motorbike ",
        "statement_nums": [
            "2 of the"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 2: Total: 8/537 (1.49%) Hypertension 1/537 (0.19%) Acoustic Neuroma 0/537 (0.00%) Diarrhea 1/537 (0.19%) Colitis 0/537 (0.00%) Elevated ALT or AST enzyme 0/537 (0.00%) Diagnosis of Uterine Cancer 2/537 (0.37%) Motorcycle accident 1/537 (0.19%) Fall 1/537 (0.19%) Surgery 2/537 (0.37%) ",
        "premise_nums": [
            "8/537 (1.49%)",
            "1/537 (0.19%)",
            "2/537 (0.37%)",
            "0/537 (0.00%)"
        ]
    },
    {
        "id": "0aa3c085-b9c6-4918-a5d0-eabc55bdd177",
        "primaryId": "NCT01560416",
        "statement_text": "There was over 10 more cases of adverse events in cohort 2 than in cohort 1 of the primary trial ",
        "statement_nums": [
            "10 more cases",
            "2 than in",
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 2/15 (13.33%) Adverse Events 2: Total: 11/35 (31.43%) ",
        "premise_nums": [
            "11/35 (31.43%)",
            "2/15 (13.33%)"
        ]
    },
    {
        "id": "333c2723-e2e8-4c68-9591-36b7f169ff26",
        "primaryId": "NCT00828074",
        "statement_text": "A higher percentage of cohort 1 of the primary trial showed signs of fever  compared to cohort 2.",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Fever * 2/41 (4.88%) Adverse Events 2: Fever * 0/5 (0.00%) ",
        "premise_nums": [
            "2/41 (4.88%)",
            "0/5 (0.00%)"
        ]
    },
    {
        "id": "1fa01b9a-1288-404c-ad58-8dcf3db3264c",
        "primaryId": "NCT00477464",
        "statement_text": "59% of Arm A of the primary trial achieved a best overall response  classified as a complete or partial (confirmed) tumor response or stable disease for at least 6 months ",
        "statement_nums": [
            "59% of"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Clinical Benefit Response (Independent Reviewer-assessed) CBR is defined as the percentage of participants receiving at least one dose of study medication who achieved a best overall response classified as a complete or partial (confirmed) tumor response or stable disease for at least 6 months (24 weeks)  A \"complete response\" is defined as the disappearance of all target or non-target lesions  \"partial response\" and \"disease progression\" as at least a 30% decrease and at least a 20% increase  respectively  in the sum of the longest diameter of target lesions  and \"stable disease\" as neither \"partial response\" nor \"disease progression.\" Time frame: Baseline  every 6 weeks until Week 24 and then every 12 weeks until disease progression (up to Week 119) Results 1: ",
        "premise_nums": [
            "30% decrease",
            "6 weeks until",
            "6 months (24",
            "12 weeks until",
            "24 and then",
            "20% increase"
        ]
    },
    {
        "id": "1fa01b9a-1288-404c-ad58-8dcf3db3264c",
        "primaryId": "NCT00477464",
        "statement_text": "59% of Arm A of the primary trial achieved a best overall response  classified as a complete or partial (confirmed) tumor response or stable disease for at least 6 months ",
        "statement_nums": [
            "59% of"
        ],
        "label": "Entailment",
        "premise_text": "Arm/Group Title: Lapatinib 1250 mg and Capecitabine 2000 mg/m^2Arm/Group Description: Participants took lapatinib and capecitabine  Lapatinib was orally administered at 1250 milligrams (mg) once daily  Capecitabine was orally administered at 1000 mg per square meter (mg/m^2) twice daily on the first day through the fourteenth day of each 21-day cycle  Overall Number of Participants Analyzed: 51 Measure Type: Number Unit of Measure: percentage of participants 59 ",
        "premise_nums": [
            "1250 milligrams (mg)",
            "1250 mg and",
            "1000 mg per",
            "2000 mg/m^2Arm/Group",
            "51 Measure Type:",
            "21-day cycle"
        ]
    },
    {
        "id": "ed272c3f-37a1-4db7-8990-bf226f8c9822",
        "primaryId": "NCT02049957",
        "secondaryId": "NCT01506609",
        "label": "Entailment",
        "statement_text": "There is the same number of cases of Diplopia in the primary trial as anemia in the secondary trial ",
        "statement_nums": [],
        "premise_text": "Adverse Events 1: Total: 1/6 (16.67%) Angina pectoris 0/6 (0.00%) Pericardial effusion 0/6 (0.00%) Diplopia 0/6 (0.00%) Abdominal pain 0/6 (0.00%) Colitis 0/6 (0.00%) Gastritis 0/6 (0.00%) Nausea 0/6 (0.00%) Vomiting 0/6 (0.00%) Fatigue 0/6 (0.00%) General physical health deterioration 0/6 (0.00%) Generalised oedema 0/6 (0.00%) Hepatic failure [1]0/6 (0.00%) Adverse Events 2: ",
        "premise_nums": [
            "1/6 (16.67%)",
            "0/6 (0.00%)"
        ]
    },
    {
        "id": "ed272c3f-37a1-4db7-8990-bf226f8c9822",
        "primaryId": "NCT02049957",
        "secondaryId": "NCT01506609",
        "label": "Entailment",
        "statement_text": "There is the same number of cases of Diplopia in the primary trial as anemia in the secondary trial ",
        "statement_nums": [],
        "premise_text": "Total: 2/6 (33.33%)Angina pectoris 0/6 (0.00%) Pericardial effusion 0/6 (0.00%) Diplopia 0/6 (0.00%) Abdominal pain 0/6 (0.00%) Colitis 0/6 (0.00%) Gastritis 0/6 (0.00%) Nausea 0/6 (0.00%) Vomiting 0/6 (0.00%) Fatigue 0/6 (0.00%) General physical health deterioration 0/6 (0.00%) Generalised oedema 0/6 (0.00%) Hepatic failure [1]0/6 (0.00%) Adverse Events 1: ",
        "premise_nums": [
            "0/6 (0.00%)",
            "2/6 (33.33%)Angina"
        ]
    },
    {
        "id": "ed272c3f-37a1-4db7-8990-bf226f8c9822",
        "primaryId": "NCT02049957",
        "secondaryId": "NCT01506609",
        "label": "Entailment",
        "statement_text": "There is the same number of cases of Diplopia in the primary trial as anemia in the secondary trial ",
        "statement_nums": [],
        "premise_text": "Total: 0/2 (0.00%)ANAEMIA 0/2 (0.00%) FEBRILE NEUTROPENIA 0/2 (0.00%) LYMPHADENOPATHY 0/2 (0.00%) NEUTROPENIA 0/2 (0.00%) PANCYTOPENIA 0/2 (0.00%) THROMBOCYTOPENIA 0/2 (0.00%) ATRIAL FIBRILLATION 0/2 (0.00%) CARDIAC TAMPONADE 0/2 (0.00%) PERICARDIAL EFFUSION 0/2 (0.00%) TACHYCARDIA 0/2 (0.00%) ABDOMINAL PAIN 0/2 (0.00%) ",
        "premise_nums": [
            "0/2 (0.00%)ANAEMIA"
        ]
    },
    {
        "id": "ed272c3f-37a1-4db7-8990-bf226f8c9822",
        "primaryId": "NCT02049957",
        "secondaryId": "NCT01506609",
        "label": "Entailment",
        "statement_text": "There is the same number of cases of Diplopia in the primary trial as anemia in the secondary trial ",
        "statement_nums": [],
        "premise_text": "ABDOMINAL PAIN UPPER 0/2 (0.00%)Adverse Events 2: Total: 0/1 (0.00%) ANAEMIA 0/1 (0.00%) FEBRILE NEUTROPENIA 0/1 (0.00%) LYMPHADENOPATHY 0/1 (0.00%) NEUTROPENIA 0/1 (0.00%) PANCYTOPENIA 0/1 (0.00%) THROMBOCYTOPENIA 0/1 (0.00%) ATRIAL FIBRILLATION 0/1 (0.00%) CARDIAC TAMPONADE 0/1 (0.00%) PERICARDIAL EFFUSION 0/1 (0.00%) TACHYCARDIA 0/1 (0.00%) ",
        "premise_nums": [
            "0/1 (0.00%)",
            "0/2 (0.00%)Adverse"
        ]
    },
    {
        "id": "ed272c3f-37a1-4db7-8990-bf226f8c9822",
        "primaryId": "NCT02049957",
        "secondaryId": "NCT01506609",
        "label": "Entailment",
        "statement_text": "There is the same number of cases of Diplopia in the primary trial as anemia in the secondary trial ",
        "statement_nums": [],
        "premise_text": "ABDOMINAL PAIN 0/1 (0.00%)ABDOMINAL PAIN UPPER 0/1 (0.00%) ",
        "premise_nums": [
            "0/1 (0.00%)ABDOMINAL"
        ]
    },
    {
        "id": "b1497cf4-6b06-4227-b679-19e2ac5fb5c3",
        "primaryId": "NCT01421017",
        "statement_text": "the primary trial studies the effects of CTX/IMQ/RT and Epothilone on Central Nervous System (CNS) Progression-free Survival(PFS)  9 weeks after the start of treatment ",
        "statement_nums": [
            "9 weeks after"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Systemic Tumor Response Rates (Complete Response+Partial Response) The systemic tumor response refers to the response at the time of best overall response  The response criteria are specially adapted from Response Evaluation Criteria in Solid Tumor for Immunotherapies (Wolchok  et al.  2009). Time frame: 9 weeks from the start of the treatment of RT ",
        "premise_nums": [
            "9 weeks from"
        ]
    },
    {
        "id": "186d5a67-1309-4abc-b31a-de026c5b8bda",
        "primaryId": "NCT00405938",
        "statement_text": "Patients diagnosed with intradural tumors are excluded from the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Exclusion Criteria: No metastatic disease to the Central Nervous System ",
        "premise_nums": []
    },
    {
        "id": "6b86f306-f989-4676-8f5e-c4c8a6aa4258",
        "primaryId": "NCT00470847",
        "statement_text": "the primary trial participants will receive either Lapatinib  WBRT or Herceptin ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "INTERVENTION 1: Lapatinib,Whole Brain Radiation,Herceptin Lapatinib before and during Whole Brain Radiation Therapy (WBRT)  then Herceptin 4mg/kg IV weekly ",
        "premise_nums": [
            "4mg/kg IV"
        ]
    },
    {
        "id": "0e8e4a92-b104-4192-ad36-33b683f94216",
        "primaryId": "NCT02463032",
        "statement_text": "There was less than a 5% difference in the results from the 9 mg and 18 mg group in the primary trial ",
        "statement_nums": [
            "18 mg group",
            "5% difference",
            "9 mg and"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Clinical Benefit Rate  in Centrally Confirmed Androgen Receptor (AR)+ Subjects To estimate the clinical benefit rate (defined as complete response  partial response  or stable disease) according to RECIST 1.1, in subjects with estrogen receptor positive/androgen receptor positive (ER+/AR+) BC who have centrally confirmed AR+ status  Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions assessed by CT or MRI: Complete Response (CR)  Disappearance of all target lesions; Partial Response (PR)  greater than or equal 30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR; Clinical Benefit Rate (CBR)= CR + PR + SD  Time frame: 24 weeks ",
        "premise_nums": [
            "30% decrease"
        ]
    },
    {
        "id": "0e8e4a92-b104-4192-ad36-33b683f94216",
        "primaryId": "NCT02463032",
        "statement_text": "There was less than a 5% difference in the results from the 9 mg and 18 mg group in the primary trial ",
        "statement_nums": [
            "18 mg group",
            "5% difference",
            "9 mg and"
        ],
        "label": "Entailment",
        "premise_text": "Results 1:Arm/Group Title: GTx-024 9 mg Arm/Group Description: Drug: GTx-024 GTx-024 softgel capsules will be administered once daily to a total dose of 9 mg GTx-024: To determine whether either or both doses result in an acceptable clinical benefit rate  Overall Number of Participants Analyzed: 50 Measure Type: Number Unit of Measure: participants 16 Results 2: Arm/Group Title: GTx-024 18 mg Arm/Group Description: Drug: GTx-024 GTx-024 softgel capsules will be administered once daily to a total dose of 18 mg GTx-024: To determine whether either or both doses result in an acceptable clinical benefit rate  Overall Number of Participants Analyzed: 52 Measure Type: Number ",
        "premise_nums": [
            "50 Measure Type:",
            "16 Results 2:",
            "18 mg GTx",
            "1:Arm/Group Title:",
            "18 mg Arm",
            "52 Measure Type:",
            "9 mg Arm",
            "9 mg GTx",
            "024 softgel capsules"
        ]
    },
    {
        "id": "0e8e4a92-b104-4192-ad36-33b683f94216",
        "primaryId": "NCT02463032",
        "statement_text": "There was less than a 5% difference in the results from the 9 mg and 18 mg group in the primary trial ",
        "statement_nums": [
            "18 mg group",
            "5% difference",
            "9 mg and"
        ],
        "label": "Entailment",
        "premise_text": "Unit of Measure: participants 15",
        "premise_nums": []
    },
    {
        "id": "47ea6e1a-c9dd-4fc6-82b6-7af46dec7a12",
        "primaryId": "NCT00438659",
        "secondaryId": "NCT01271725",
        "label": "Entailment",
        "statement_text": "the primary trial has a topical intervention  whereas the secondary trial has both oral and IV interventions ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Mometasone Patients apply 2.5 mL mometasone furoate cream once daily to the treatment area (breast or chest wall) for the duration of planned radiotherapy  INTERVENTION 2: Placebo Patients apply 2.5 mL of an identical-appearing placebo cream to the treatment area as in arm A  INTERVENTION 1: Afatinib Monotherapy Patient received Afatinib monotherapy orally once daily at a dose of 40 milligram (mg) film-coated tablets until progression of their disease  unacceptable adverse events or other reason necessitating withdrawal  Patients could have dose reduced if 40 mg was not tolerated  INTERVENTION 2: Afatinib and Paclitaxel or Vinorelbine Combination Therapy ",
        "premise_nums": [
            "apply 2.5 mL of",
            "40 mg was",
            "apply 2.5 mL mometasone",
            "40 milligram (mg)"
        ]
    },
    {
        "id": "47ea6e1a-c9dd-4fc6-82b6-7af46dec7a12",
        "primaryId": "NCT00438659",
        "secondaryId": "NCT01271725",
        "label": "Entailment",
        "statement_text": "the primary trial has a topical intervention  whereas the secondary trial has both oral and IV interventions ",
        "statement_nums": [],
        "premise_text": "Patient received Afatinib monotherapy orally once daily at a dose of 40 mg film-coated tablets until progression of their disease  unacceptable adverse events or other reason necessitating withdrawal (Patients could have dose reduced if 40 mg was not tolerated) and 80 mg/square meter (m2) Paclitaxel concentrate for intravenous infusion or 25 mg/m2 Vinorelbine concentrate for intravenous infusion once weekly starting after treatment failure on afatinib monotherapy",
        "premise_nums": [
            "40 mg film",
            "(m2) Paclitaxel",
            "80 mg/square meter",
            "25 mg/m2 Vinorelbine",
            "2 Vinorelbine concentrate",
            "40 mg was"
        ]
    },
    {
        "id": "03a8a787-2bf3-43e5-9c9e-7bd9c3278751",
        "primaryId": "NCT00171704",
        "statement_text": "All patients in the Letrozole group of the primary trial had a decreased Bone Mineral Density of the Lumbar Spine after 3 years ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Percent Change From Baseline of Bone Mineral Density of the Lumbar Spine (L2-l4) Lumbar spine (L2-L4) BMD measurements by dual energy X-ray absorptiometry (DXA) were performed after surgery and within 2 weeks prior to randomization and repeated every 6 months for the first 2 years and annually thereafter until 5 years after enrollment  The primary scanning site was the lumbar spine (L2 to L4) and the secondary scanning site was the total hip  All DXA scans were evaluated by a central reader  Time frame: Baseline  24 months Results 1: Arm/Group Title: Letrozole Arm/Group Description: 2.5 mg once daily (q.d.)orally for 5 years ",
        "premise_nums": [
            "2 years and",
            "2-l4) Lumbar",
            "5 years after",
            "6 months for",
            "2-L4) BMD",
            "2 to L4)",
            "2 weeks prior",
            "24 months Results",
            "5 mg once"
        ]
    },
    {
        "id": "03a8a787-2bf3-43e5-9c9e-7bd9c3278751",
        "primaryId": "NCT00171704",
        "statement_text": "All patients in the Letrozole group of the primary trial had a decreased Bone Mineral Density of the Lumbar Spine after 3 years ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Overall Number of Participants Analyzed: 63Median (Full Range) Unit of Measure: Percent Change -4.63 (-14.21 to 4.32) Results 2: Arm/Group Title: Tam-Let Arm/Group Description: 20 mg Tamoxifen once daily (q.d.) orally for 2 years followed by Letrozole 2.5 mg q.d  orally for 3 years  Overall Number of Participants Analyzed: 68 Median (Full Range) Unit of Measure: Percent Change 0.37 (-6.98 to 15.21) ",
        "premise_nums": [
            "Letrozole 2.5 mg q",
            "2 years followed",
            "21 to 4.32)",
            "68 Median (Full",
            "98 to 15.21)",
            "20 mg Tamoxifen",
            "5 mg q.d"
        ]
    },
    {
        "id": "7d7a9a69-533a-4480-b2e7-aa59eb8a738b",
        "primaryId": "NCT02260531",
        "statement_text": "the percentage of participants achieving complete response (CR) or partial response (PR) was 6x higher in the HER2-positive group in the primary trial  than in the ER+ and/or PR+ group ",
        "statement_nums": [
            "2-positive group"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: CNS Objective Response Rate (ORR) The central nervous system (CNS) ORR was defined as the percentage of participants achieving complete response (CR) or partial response (PR) based on RECIST 1.1 criteria in the evaluation CNS lesions on treatment: CR is complete disappearance of all target lesions and PR is at least a 30% decrease in the sum of longest diameter (LD) of target lesions  taking as reference baseline sum LD  PR or better overall response assumes at a minimum incomplete response/stable disease (SD) for the evaluation of non-target lesions and absence of new lesions  ",
        "premise_nums": [
            "30% decrease",
            "RECIST 1.1 criteria in"
        ]
    },
    {
        "id": "7d7a9a69-533a-4480-b2e7-aa59eb8a738b",
        "primaryId": "NCT02260531",
        "statement_text": "the percentage of participants achieving complete response (CR) or partial response (PR) was 6x higher in the HER2-positive group in the primary trial  than in the ER+ and/or PR+ group ",
        "statement_nums": [
            "2-positive group"
        ],
        "label": "Contradiction",
        "premise_text": "Time frame: Disease assessments occurred every 6 cycles  Patients with stable or responsive disease after completion of 6 cycles could reduce frequency of assessments to every 3 cycles  Response was evaluated up to 25 months Results 1: Arm/Group Title: Cohort 1 - Cabozantinib  Trastuzumab for HER2+ Arm/Group Description: HER2-positive Cabozantinib- orally administered daily per treatment cycle Trastuzumab- IV administered once per cycle MRI- Baseline  Cycle 2 Day 1, and every 2 cycles Magnetic Resonance Angiography (MRA )  Baseline  Cycle 2 Day 1, ",
        "premise_nums": [
            "6 cycles could",
            "2 Day 1,",
            "2 cycles Magnetic",
            "2-positive Cabozantinib-",
            "25 months Results"
        ]
    },
    {
        "id": "7d7a9a69-533a-4480-b2e7-aa59eb8a738b",
        "primaryId": "NCT02260531",
        "statement_text": "the percentage of participants achieving complete response (CR) or partial response (PR) was 6x higher in the HER2-positive group in the primary trial  than in the ER+ and/or PR+ group ",
        "statement_nums": [
            "2-positive group"
        ],
        "label": "Contradiction",
        "premise_text": "Cabozantinib: One  60 mg tablet daily of each 21 day cycle  Number of Cycles: until progression or unacceptable toxicity develops Trastuzumab: For HER2-Positive participants only  Administered by IV on day 1 of each 21 day cycle  Number of Cycles: until progression or unacceptable toxicity develops  Overall Number of Participants Analyzed: 21 Measure Type: Number Unit of Measure: percentage of participants 5 (.2 to 24) Results 2: Arm/Group Title: Cohort 2 - Cabozantinib for ER+ and/or PR+ Arm/Group Description: Hormone receptor-positive (ER+ and/or PR+) Cabozantinib- orally administered daily per treatment cycle ",
        "premise_nums": [
            "60 mg tablet",
            "1 of each",
            "2-Positive participants",
            "2 to 24)",
            "21 Measure Type:",
            "21 day cycle"
        ]
    },
    {
        "id": "7d7a9a69-533a-4480-b2e7-aa59eb8a738b",
        "primaryId": "NCT02260531",
        "statement_text": "the percentage of participants achieving complete response (CR) or partial response (PR) was 6x higher in the HER2-positive group in the primary trial  than in the ER+ and/or PR+ group ",
        "statement_nums": [
            "2-positive group"
        ],
        "label": "Contradiction",
        "premise_text": "MRI- Baseline  Cycle 2 Day 1, and every 2 cyclesMagnetic Resonance Angiography (MRA )  Baseline  Cycle 2 Day 1, Cabozantinib: One  60 mg tablet daily of each 21 day cycle  Number of Cycles: until progression or unacceptable toxicity develops  Overall Number of Participants Analyzed: 7 Measure Type: Number Unit of Measure: percentage of participants 14 (.4 to 58) ",
        "premise_nums": [
            "2 Day 1,",
            "4 to 58)",
            "60 mg tablet",
            "2 cyclesMagnetic Resonance",
            "7 Measure Type:",
            "21 day cycle"
        ]
    },
    {
        "id": "c6fc8336-7c74-443e-9548-3bbafe21fc37",
        "primaryId": "NCT00036270",
        "statement_text": "In total Less than 10% of patients in the primary trial either had a disease relapse or died ",
        "statement_nums": [
            "10% of"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Disease Free Survival (DFS): Number of Events (Disease Relapse or Death) From Baseline up to 2.75 Years Number of events (disease relapse or death) to time of observation for DFS  DFS defined as time from randomization to earliest documentation of disease relapse or death from any cause in postmenopausal  receptor positive  node negative or node positive breast cancer patients for adjuvant treatment with exemestane compared with adjuvant tamoxifen therapy at 2.75 years  Disease relapse: primary tumor recurrence (locoregional or distant) and ipsilateral or contralateral breast cancer (CBC)  Intercurrent death: death without disease relapse  Time frame: Baseline (Month 0) up to 2.75 years Results 1: ",
        "premise_nums": [
            "to 2.75 years Results",
            "to 2.75 Years Number"
        ]
    },
    {
        "id": "c6fc8336-7c74-443e-9548-3bbafe21fc37",
        "primaryId": "NCT00036270",
        "statement_text": "In total Less than 10% of patients in the primary trial either had a disease relapse or died ",
        "statement_nums": [
            "10% of"
        ],
        "label": "Entailment",
        "premise_text": "Arm/Group Title: ExemestaneArm/Group Description: Exemestane (Aromasin ) 25 mg QD for 5 years  Overall Number of Participants Analyzed: 4898 Measure Type: Number Unit of Measure: Events (disease relapse or death) 352 Results 2: Arm/Group Title: Tamoxifen Followed by Exemestane Arm/Group Description: Tamoxifen 20 mg QD; upon completing 2.5 years to 3 years of tamoxifen  participants were to be switched to exemestane 25 mg QD and then were to complete a total of 5 years endocrine therapy  Overall Number of Participants Analyzed: 4868 Measure Type: Number Unit of Measure: Events (disease relapse or death) 388 ",
        "premise_nums": [
            "4868 Measure Type:",
            "completing 2.5 years to",
            "5 years endocrine",
            "20 mg QD;",
            "25 mg QD",
            "352 Results 2:",
            "4898 Measure Type:",
            "3 years of"
        ]
    },
    {
        "id": "9035000f-d87b-439f-882a-e6e30694e391",
        "primaryId": "NCT01351376",
        "statement_text": "Patients currently prescribed Diuretics are excluded from the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Exclusion Criteria: medication(s) known to affect body fluid balance ",
        "premise_nums": []
    },
    {
        "id": "522ca0ec-aeb0-4083-a274-ab58c2cddb8a",
        "primaryId": "NCT03210220",
        "secondaryId": "NCT00290745",
        "label": "Contradiction",
        "statement_text": "Unlike the primary trial  the secondary trial does not test Gonadotrophin-releasing Hormone Analogues or medical devices ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Pecs Group Ultrasound guided pectoral nerve block is performed right after induction  before surgery  The needle is advanced to the tissue plane between the pectoralis major and pectoralis minor muscle at the vicinity of the pectoral branch of the acromiothoracic artery  and 10 mL of 0.5% ropivacaine deposited  In a similar manner  20 mL is deposited at the level of the third rib between the pectoralis minor muscle and the serratus anterior muscle   INTERVENTION 2: Control Group There is no block  INTERVENTION 1: Tamoxifen or Letrozole tamoxifen or letrozole work in treating women with ductal carcinoma in situ letrozole tamoxifen citrate conventional surgery neoadjuvant therapy ",
        "premise_nums": [
            "of 0.5% ropivacaine deposited",
            "10 mL of",
            "20 mL is"
        ]
    },
    {
        "id": "46d65581-7a0a-423b-907e-662c1f5843cc",
        "primaryId": "NCT01127763",
        "statement_text": "There were 4% more cases (1 more case) of Dyspnea than Dehydration in the primary trial ",
        "statement_nums": [
            "1 more case)",
            "4% more"
        ],
        "label": "Entailment",
        "premise_text": "Dehydration 1/25 (4.00%) Dyspnea (Shortness Of Breath) 2/25 (8.00%) ",
        "premise_nums": [
            "1/25 (4.00%)",
            "2/25 (8.00%)"
        ]
    },
    {
        "id": "f4ea6e98-75e1-43a0-8202-548bb7ceb66c",
        "primaryId": "NCT02413008",
        "secondaryId": "NCT02725801",
        "label": "Entailment",
        "statement_text": "The intervention in the primary trial requires patients to receive multiple applications of treatment over a period of several weeks  whereas the interventions for the secondary trial are only apllied once ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: 0.005% Estriol Vaginal Gel Route: Vaginal  Administration by an applicator inserted deep inside the vagina Dose: 1 g of gel  containing 50 Mcg of estriol Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: twice weekly administration INTERVENTION 1: One-port intervention is placement of one-port tissue expander at time of reconstruction Allergen one-port tissue expander placement: patients will be randomized to receive a one port or two port tissue expander for breast reconstruction ",
        "premise_nums": [
            "1-3: single",
            "0.005% Estriol",
            "4-12: twice",
            "1 g of",
            "50 Mcg of"
        ]
    },
    {
        "id": "c3a618d6-2c2e-4ed6-bfe7-88d28ec18240",
        "primaryId": "NCT00534417",
        "statement_text": "The median TTP for patients in cohort one of the primary trial is NA ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Time to Progression (TTP) Time to progression is defined as the time from treatment start until objective tumor progression  Progression is defined per Response Evaluation Criteria in Solid Tumors (RECIST)v1.0 guidelines as a measurable increase in the smallest diameter of any target lesion  progression of existing non-target lesions  or the appearance of 1 or more new lesions  The median time to progression is the parameter used to describe TTP  Time frame: TTP was measured from day 1 of treatment until time of progression (assessed every 8 weeks)  up to 29 months  Results 1: Arm/Group Title: Capecitabine and Fulvestrant ",
        "premise_nums": [
            "v1.0 guidelines",
            "1 or more",
            "1 of treatment",
            "0 guidelines as"
        ]
    },
    {
        "id": "c3a618d6-2c2e-4ed6-bfe7-88d28ec18240",
        "primaryId": "NCT00534417",
        "statement_text": "The median TTP for patients in cohort one of the primary trial is NA ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Arm/Group Description: Capecitabine will be given on a continuous basis at a total dose of 1500 mg  given as 1000 mg po AM and 500 mg po PM in patients of body weight smaller than 80 kg  and at a total dose of 2000 mg given as 1000 mg po bid in patients with a body weight of 80 kg Fulvestrant will be given at 500 mg on Day 1 followed by 250 mg on Days 15 and 29, then 250 mg every 28 days  Overall Number of Participants Analyzed: 41 Median (95% Confidence Interval) Unit of Measure: Months 26.94 [1] (7.26 to NA) ",
        "premise_nums": [
            "80 kg Fulvestrant",
            "500 mg po",
            "1000 mg po",
            "500 mg on",
            "26 to NA)",
            "250 mg on",
            "95% Confidence",
            "1 followed by",
            "2000 mg given",
            "250 mg every",
            "15 and 29,"
        ]
    },
    {
        "id": "932728c5-2e7f-401f-be64-e90597ff2ce2",
        "primaryId": "NCT00129935",
        "statement_text": "There were more cases of embolisms in cohort 2 of the primary trial than cohort 1.",
        "statement_nums": [
            "2 of the"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 111/669 (16.59%) Leukocytes * [1]1/669 (0.15%) Hemoglobin * [1]1/669 (0.15%) Hemoglobin * [2]0/669 (0.00%) CNS cerebrovascular ischemia * [1]0/669 (0.00%) CNS cerebrovascular ischemia * [3]0/669 (0.00%) Heart Failure * [1]3/669 (0.45%) Thrombosis/embolism * [1]1/669 (0.15%) ",
        "premise_nums": [
            "0/669 (0.00%)",
            "3/669 (0.45%)",
            "111/669 (16.59%)",
            "1/669 (0.15%)"
        ]
    },
    {
        "id": "932728c5-2e7f-401f-be64-e90597ff2ce2",
        "primaryId": "NCT00129935",
        "statement_text": "There were more cases of embolisms in cohort 2 of the primary trial than cohort 1.",
        "statement_nums": [
            "2 of the"
        ],
        "label": "Entailment",
        "premise_text": "Thrombosis/embolism * [3]0/669 (0.00%)Adverse Events 2: Total: 138/715 (19.30%) Leukocytes * [1]0/715 (0.00%) Hemoglobin * [1]0/715 (0.00%) Hemoglobin * [2]1/715 (0.14%) CNS cerebrovascular ischemia * [1]1/715 (0.14%) CNS cerebrovascular ischemia * [3]1/715 (0.14%) Heart Failure * [1]1/715 (0.14%) ",
        "premise_nums": [
            "0/669 (0.00%)Adverse",
            "0/715 (0.00%)",
            "138/715 (19.30%)",
            "1/715 (0.14%)"
        ]
    },
    {
        "id": "932728c5-2e7f-401f-be64-e90597ff2ce2",
        "primaryId": "NCT00129935",
        "statement_text": "There were more cases of embolisms in cohort 2 of the primary trial than cohort 1.",
        "statement_nums": [
            "2 of the"
        ],
        "label": "Entailment",
        "premise_text": "Thrombosis/embolism * [1]3/715 (0.42%)Thrombosis/embolism * [3]2/715 (0.28%) ",
        "premise_nums": [
            "3/715 (0.42%)Thrombosis/embolism",
            "2/715 (0.28%)"
        ]
    },
    {
        "id": "54ad9406-852c-40fc-bd0e-8e7e81eacc71",
        "primaryId": "NCT00291577",
        "statement_text": "It is not possible for a participant of the primary trial to have a Time to Reach Maximum Plasma Concentration of 16, 17 or 20 hours",
        "statement_nums": [
            "17 or 20"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Time to Reach Maximum Plasma Concentration (Tmax): Sunitinib (SU011248), Sunitinib Metabolite (SU012662), and Total Drug PK Parameters Median Tmax = time for maximum plasma concentration (Cmax) for SU011248, SU012662, and combined SU011248 and SU012662 (total drug); collected C1D2, C2D3. Paired observation  Time frame: 1, 2, 4, 6, 8, 12, 24 hours postdose ",
        "premise_nums": [
            "011248 and SU012662",
            "SU011248 and",
            "24 hours postdose"
        ]
    },
    {
        "id": "7021a4a9-b474-4568-a3b8-015a50c9d9cc",
        "primaryId": "NCT00201760",
        "secondaryId": "NCT00127933",
        "label": "Contradiction",
        "statement_text": "Patients must have a triple negative infiltrating breast carcinoma to participate in the secondary trial or the primary trial ",
        "statement_nums": [],
        "premise_text": "Eligibility Criteria: Must have invasive metastatic breast cancer Tumor must be Her 2/neu 3+ by IHC (must be confirmed by Ohio State University pathology)or positive FISH Inclusion Criteria: infiltrating (invasive) HER2-neu-negative or HER2-neu-positive breast cancer  ",
        "premise_nums": [
            "2-neu-negative or",
            "2/neu 3+",
            "2-neu-positive breast"
        ]
    },
    {
        "id": "24eced44-40b2-4365-abd3-42eb13220cf0",
        "primaryId": "NCT00290745",
        "statement_text": "There is no radiotherapy or educational part of the intervention used in the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "INTERVENTION 1: Tamoxifen or Letrozole tamoxifen or letrozole work in treating women with ductal carcinoma in situ letrozole tamoxifen citrate conventional surgery neoadjuvant therapy ",
        "premise_nums": []
    },
    {
        "id": "3e2dda3a-815f-4681-a470-009d9f9b30d6",
        "primaryId": "NCT01448447",
        "secondaryId": "NCT03252145",
        "label": "Entailment",
        "statement_text": "the primary trial is testing a radiotherapy intervention whereas the secondary trial is testing a novel hand-held medical device",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Sole Method patients will be treated with HDR brachytherapy using Mammosite ML as the sole method for radiation delivery after lumpectomy for breast cancer or DCIS Mammosite ML: 34 Gy / 10 fractions (3.4 Gy per fraction) 2 fractions / day (separated by at least 6 hours) Delivered in 5 consecutive working days INTERVENTION 2: Boost patients will be treated with HDR brachytherapy using Mammosite ML as a boost technique prior to standard external beam radiation after lumpectomy for breast cancer or DCIS ",
        "premise_nums": [
            "5 consecutive working",
            "10 fractions (3.4"
        ]
    },
    {
        "id": "3e2dda3a-815f-4681-a470-009d9f9b30d6",
        "primaryId": "NCT01448447",
        "secondaryId": "NCT03252145",
        "label": "Entailment",
        "statement_text": "the primary trial is testing a radiotherapy intervention whereas the secondary trial is testing a novel hand-held medical device",
        "statement_nums": [],
        "premise_text": "Mammosite ML: 5-10.2 Gy / 2-3 fractions (3.4 Gy per fraction) 2 fractions / day (separated by at least 6 hours) Delivered in 1-2 days Followed by whole breast radiation (25-28 daily tx)INTERVENTION 1: Manual Lymph Drainage Manual lymph drainage (MLD) treatment 3 times a week for 4 weeks to the lymphedematous upper limb Manual Lymph Drainage (MLD): MLD is a practitioner-applied manual massage technique designed to decrease limb volume in patients with lymphedema by enhancing movement of lymph fluid  resulting in reductions in interstitial fluid  INTERVENTION 2: Negative Pressure ",
        "premise_nums": [
            "2-3 fractions",
            "2 days Followed",
            "3 fractions (3.4",
            "3 times a",
            "4 weeks to",
            "5-10.2 Gy",
            "28 daily tx)INTERVENTION",
            "(25-28 daily",
            "1-2 days"
        ]
    },
    {
        "id": "3e2dda3a-815f-4681-a470-009d9f9b30d6",
        "primaryId": "NCT01448447",
        "secondaryId": "NCT03252145",
        "label": "Entailment",
        "statement_text": "the primary trial is testing a radiotherapy intervention whereas the secondary trial is testing a novel hand-held medical device",
        "statement_nums": [],
        "premise_text": "PhysioTouch (negative pressure massage) treatment 3 times a week for 4 weeks to the lymphedematous upper limbPhysioTouch: The PhysioTouch is a hand-held device that administers negative pressure under the treatment head  and gently pulls the underlying skin and subcutaneous tissue into the suction cup  This suction produces a stretch to the skin and in the subcutaneous tissue space  This action is thought to facilitate lymphatic flow from the interstitium into the lymphatic vessels  and mobilizes the superficial fascia  ",
        "premise_nums": [
            "3 times a",
            "4 weeks to"
        ]
    },
    {
        "id": "1a293e7c-691f-4f93-bab8-6bf5d9b3f904",
        "primaryId": "NCT01653964",
        "secondaryId": "NCT02660788",
        "label": "Contradiction",
        "statement_text": "The interventions in the primary trial and the secondary trial are similar  as they are testing the same medication  however they are not using the same doses ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Molecular Breast Imaging Molecular breast imaging performed after injection of 4 mCi Tc-99m sestamibi and again after 8 mCi Tc-99m sestamibi  INTERVENTION 1: Control Arm Mail Standard Reminder Postcard INTERVENTION 2: Family Physician Reminder Letter Arm Mail Standard Reminder Postcard Family Physician Reminder Letter ",
        "premise_nums": [
            "4 mCi Tc",
            "8 mCi Tc"
        ]
    },
    {
        "id": "a87e6e20-c7d0-4941-9933-204fab99b299",
        "primaryId": "NCT00444535",
        "statement_text": "Less than 1/3 participants in the primary trial treated with Lapatinib achieved Progression-free Survival Rate After 6 months of Study Treatment ",
        "statement_nums": [
            "6 months of",
            "1/3 participants",
            "3 participants in"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Investigator-evaluated Crude Progression-free Survival Rate After 12 Weeks of Study Treatment The PFS rate is defined as the percentage of subjects who have shown no evidence of disease progression or death from any cause following 12 weeks of treatment  Disease progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions  or a measurable increase in a non-target lesion  or the appearance of new lesions  Since there is no independent reviewer  only the investigator response was reported  Time frame: up to week 12 Results 1: Arm/Group Title: Lapatinib + Bevacizumab ",
        "premise_nums": [
            "12 Weeks of",
            "12 Results 1:",
            "12 weeks of",
            "20% increase"
        ]
    },
    {
        "id": "a87e6e20-c7d0-4941-9933-204fab99b299",
        "primaryId": "NCT00444535",
        "statement_text": "Less than 1/3 participants in the primary trial treated with Lapatinib achieved Progression-free Survival Rate After 6 months of Study Treatment ",
        "statement_nums": [
            "6 months of",
            "1/3 participants",
            "3 participants in"
        ],
        "label": "Contradiction",
        "premise_text": "Arm/Group Description: Lapatinib (1500 mg once daily taken orally) and bevacizumab (10 mg/kg intravenously [IV] every two weeks)Overall Number of Participants Analyzed: 52 Measure Type: Count of Participants Unit of Measure: Participants No disease progression by Week 12: 36 69.2% Disease progression or death by Week 12: 16 30.8% ",
        "premise_nums": [
            "36 69.2% Disease progression",
            "1500 mg once",
            "52 Measure Type:"
        ]
    },
    {
        "id": "6c3427a8-27a1-459c-9fbc-175649210868",
        "primaryId": "NCT01940497",
        "statement_text": "There were more allergic reactions observed in cohort 1 of the primary trial than cohort 2.",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 5/95 (5.26%) Febrile neutropenia 0/95 (0.00%) Neutropenia 0/95 (0.00%) Atrial fibrillation 0/95 (0.00%) Pleuropericarditis 0/95 (0.00%) Vomiting 0/95 (0.00%) Pryexia 0/95 (0.00%) Anaphylactic shock 1/95 (1.05%) Gastroenteritis 0/95 (0.00%) Fibula fracture 1/95 (1.05%) Tibia fracture 1/95 (1.05%) Intervertebral disc protrusion 0/95 (0.00%) Adverse Events 2: ",
        "premise_nums": [
            "0/95 (0.00%)",
            "5/95 (5.26%)",
            "1/95 (1.05%)"
        ]
    },
    {
        "id": "6c3427a8-27a1-459c-9fbc-175649210868",
        "primaryId": "NCT01940497",
        "statement_text": "There were more allergic reactions observed in cohort 1 of the primary trial than cohort 2.",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Total: 3/20 (15.00%)Febrile neutropenia 0/20 (0.00%) Neutropenia 0/20 (0.00%) Atrial fibrillation 1/20 (5.00%) Pleuropericarditis 1/20 (5.00%) Vomiting 0/20 (0.00%) Pryexia 0/20 (0.00%) Anaphylactic shock 0/20 (0.00%) Gastroenteritis 1/20 (5.00%) Fibula fracture 0/20 (0.00%) Tibia fracture 0/20 (0.00%) ",
        "premise_nums": [
            "3/20 (15.00%)Febrile",
            "0/20 (0.00%)",
            "1/20 (5.00%)"
        ]
    },
    {
        "id": "883bec6a-bce2-4e60-9304-49a056e66df7",
        "primaryId": "NCT00101400",
        "statement_text": "A female with Hemoglobin greater than 10.0 g/dl  Absolute neutrophil count 1,733/mm3, platelet count = 100,000/¬¨¬µl and total bilirubin smaller than 1.2 x ULN are eligilbe for the primary trial ",
        "statement_nums": [
            "than 10.0 g/dl",
            "than 1.2 x ULN",
            "1,733/mm3, platelet",
            "100,000/¬¨¬µl and"
        ],
        "label": "Contradiction",
        "premise_text": "Hemoglobin greater than 9.0 g/dl Absolute neutrophil count (ANC) greater than 1,500/mm3 Platelet count = 100,000/µl Total bilirubin =1.5 x the upper limit of normal  ",
        "premise_nums": [
            "3 Platelet count",
            "than 9.0 g/dl",
            "1,500/mm3 Platelet",
            "100,000/µl Total",
            "5 x the"
        ]
    },
    {
        "id": "8720143a-2611-4502-a5ee-da4e641df918",
        "primaryId": "NCT02402764",
        "secondaryId": "NCT00490646",
        "label": "Contradiction",
        "statement_text": "There were no cases of extravasation in either the primary trial or the secondary trial ",
        "statement_nums": [],
        "premise_text": "Adverse Events 1: Total: 3/10 (30.00%) Sinus tachycardia * 1/10 (10.00%) Blurred vision * 1/10 (10.00%) Memory impairment * 1/10 (10.00%) Dyspnea * 2/10 (20.00%) Adverse Events 1: Total: 13/24 (54.17%) FEBRILE NEUTROPENIA 5/24 (20.83%) HAEMATOTOXICITY 0/24 (0.00%) NEUTROPENIA 3/24 (12.50%) LYMPHADENOPATHY 0/24 (0.00%) PERICARDIAL EFFUSION 1/24 (4.17%) ATRIAL FIBRILLATION 1/24 (4.17%) ",
        "premise_nums": [
            "3/24 (12.50%)",
            "1/24 (4.17%)",
            "3/10 (30.00%)",
            "1/10 (10.00%)",
            "13/24 (54.17%)",
            "5/24 (20.83%)",
            "2/10 (20.00%)",
            "0/24 (0.00%)"
        ]
    },
    {
        "id": "8720143a-2611-4502-a5ee-da4e641df918",
        "primaryId": "NCT02402764",
        "secondaryId": "NCT00490646",
        "label": "Contradiction",
        "statement_text": "There were no cases of extravasation in either the primary trial or the secondary trial ",
        "statement_nums": [],
        "premise_text": "APLASIA 0/24 (0.00%)NAUSEA 0/24 (0.00%) PYREXIA 1/24 (4.17%) EXTRAVASATION 0/24 (0.00%) CHOLECYSTITIS 1/24 (4.17%) PATHOLOGICAL FRACTURE 1/24 (4.17%) Adverse Events 2: Total: 6/24 (25.00%) FEBRILE NEUTROPENIA 0/24 (0.00%) HAEMATOTOXICITY 1/24 (4.17%) NEUTROPENIA 0/24 (0.00%) LYMPHADENOPATHY 1/24 (4.17%) PERICARDIAL EFFUSION 0/24 (0.00%) ATRIAL FIBRILLATION 0/24 (0.00%) ",
        "premise_nums": [
            "6/24 (25.00%)",
            "0/24 (0.00%)NAUSEA",
            "1/24 (4.17%)"
        ]
    },
    {
        "id": "8720143a-2611-4502-a5ee-da4e641df918",
        "primaryId": "NCT02402764",
        "secondaryId": "NCT00490646",
        "label": "Contradiction",
        "statement_text": "There were no cases of extravasation in either the primary trial or the secondary trial ",
        "statement_nums": [],
        "premise_text": "APLASIA 1/24 (4.17%)NAUSEA 1/24 (4.17%) PYREXIA 0/24 (0.00%) EXTRAVASATION 1/24 (4.17%) CHOLECYSTITIS 0/24 (0.00%) PATHOLOGICAL FRACTURE 0/24 (0.00%) ",
        "premise_nums": [
            "1/24 (4.17%)NAUSEA",
            "0/24 (0.00%)"
        ]
    },
    {
        "id": "0fdda7a2-4119-40a7-84f3-6c5c6077df49",
        "primaryId": "NCT02186015",
        "statement_text": "Women in cohort A and B of the primary trial with serum 25 (OH)D greater than or equal to 30 ng/ml did not receive weekly supplementation of cholecalciferol ",
        "statement_nums": [
            "30 ng/ml did"
        ],
        "label": "Contradiction",
        "premise_text": "INTERVENTION 1: Cholecalciferol Enrolled women received 50,000 IUs weekly supplementation of cholecalciferol for 8 weeks  INTERVENTION 2: No Cholecalciferol Enrolled women with serum 25 (OH)D greater than or equal to 30 ng/ml received no intervention  ",
        "premise_nums": [
            "received 50,000 IUs weekly",
            "30 ng/ml received"
        ]
    },
    {
        "id": "e7eae332-6b6a-41e0-aa31-86a781fd373f",
        "primaryId": "NCT01273896",
        "statement_text": "There was twice as many Cardiac adverse events as cases of Dyspnea in cohort 1 of the primary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Cardiac General  other1/22 (4.55%) Dyspnea (shortness of breath)2/22 (9.09%) ",
        "premise_nums": [
            "2/22 (9.09%)",
            "1/22 (4.55%)"
        ]
    },
    {
        "id": "9a52d5d4-ff71-42ee-8672-ec4ac3cfd591",
        "primaryId": "NCT01439945",
        "statement_text": "In the primary trial Low Dose Magnesium Oxide is 400 mg/day less than high dose Magnesium Oxide ",
        "statement_nums": [
            "400 mg/day less"
        ],
        "label": "Entailment",
        "premise_text": "INTERVENTION 1: Low Dose Magnesium Oxide (800 mg/Day) Week 2: Patients take one 400 mg tablet of magnesium oxide orally (PO) daily (QD)  Week 3: Patients take two 400 mg tablet of magnesium oxide orally (PO) daily (QD)  Weeks 4-9: Patients take two 400 mg tablet of magnesium oxide orally (PO) daily (QD)  INTERVENTION 2: High Dose Magnesium Oxide (1200 mg/Day) Week 2: Patients take one 400 mg tablet of magnesium oxide orally (PO) daily (QD)  Week 3: Patients take two 400 mg tablet of magnesium oxide orally (PO) daily (QD)  Weeks 4-9: ",
        "premise_nums": [
            "400 mg tablet",
            "4-9: Patients"
        ]
    },
    {
        "id": "9a52d5d4-ff71-42ee-8672-ec4ac3cfd591",
        "primaryId": "NCT01439945",
        "statement_text": "In the primary trial Low Dose Magnesium Oxide is 400 mg/day less than high dose Magnesium Oxide ",
        "statement_nums": [
            "400 mg/day less"
        ],
        "label": "Entailment",
        "premise_text": "Patients take three 400 mg tablet of magnesium oxide orally (PO) daily (QD) ",
        "premise_nums": [
            "400 mg tablet"
        ]
    },
    {
        "id": "c09b9f7c-2d22-4c44-a79d-32929530dd9e",
        "primaryId": "NCT01735175",
        "secondaryId": "NCT01216319",
        "label": "Contradiction",
        "statement_text": "the secondary trial and the primary trial are both testing Biodesign interventions ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: LA-EP2006 During each chemotherapy cycle eligible patients receive LA-EP2006 s.c  post chemotherapy application  LA-EP2006: Eligible patients are scheduled to receive six cycles of chemotherapy every three weeks  During each chemotherapy cycle pegfilgrastim is injected s.c  post chemotherapy application  INTERVENTION 2: Neulasta® During each chemotherapy cycle eligible patients receive Neulasta® s.c  post chemotherapy application  Neulasta®: Eligible patients are scheduled to receive six cycles of chemotherapy every three weeks  During each chemotherapy cycle pegfilgrastim is injected s.c  post chemotherapy application  INTERVENTION 1: Nipple Reconstruction Cylinder Nipple reconstruction: Biodesign® Nipple Reconstruction Cylinder ",
        "premise_nums": [
            "EP2006 During",
            "2006 During each"
        ]
    },
    {
        "id": "6f143256-52e4-40b7-950c-5c892f8632b9",
        "primaryId": "NCT00003199",
        "statement_text": "The patient group with the highest percent of PFS at 5 months in the primary trial was Stage IIIB patients  and the worst was Stage IV Disease patients ",
        "statement_nums": [
            "5 months in"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Event-free Survival Event-free survival of patients treated for inflammatory (Stage IIIb) and responsive stage IV breast cancer with BUMELTT and PBSC support and low dose immunotherapy with IL2 and GM-CSF  Time frame: 11 years Results 1: Arm/Group Title: TX/Maintenance Therapy for Stage IIIB/IV Breast Cancer Arm/Group Description: See Detailed Description  tamoxifen citrate: Given orally busulfan: Given orally thiotepa: Given IV melphalan: Given IV aldesleukin: Given SC sargramostim: Given SC peripheral blood stem cell transplantation: Undergo autologous peripheral blood stem cell infusion ",
        "premise_nums": [
            "11 years Results"
        ]
    },
    {
        "id": "6f143256-52e4-40b7-950c-5c892f8632b9",
        "primaryId": "NCT00003199",
        "statement_text": "The patient group with the highest percent of PFS at 5 months in the primary trial was Stage IIIB patients  and the worst was Stage IV Disease patients ",
        "statement_nums": [
            "5 months in"
        ],
        "label": "Contradiction",
        "premise_text": "radiation therapy: May undergo radiotherapy after completion of IL-2/GM-CSFOverall Number of Participants Analyzed: 50 Measure Type: Count of Participants Unit of Measure: Participants Stage IIIB Disease: 18 participants 11 61.1% Stage IV Disease: 32 participants 9 28.1% ",
        "premise_nums": [
            "32 participants 9",
            "50 Measure Type:",
            "18 participants 11",
            "11 61.1% Stage IV",
            "2/GM-CSFOverall Number"
        ]
    },
    {
        "id": "d2718f05-1d35-4c84-a054-06a3fe4a0a9c",
        "primaryId": "NCT00217399",
        "statement_text": "To be included in the primary trial  patients must have at least 1 unidimensionally measurable lesion  and must meet some specific size conditions ",
        "statement_nums": [
            "1 unidimensionally measurable"
        ],
        "label": "Entailment",
        "premise_text": "Measurable disease  defined as greater than or equal 1 unidimensionally measurable lesion  including greater than or equal 1 of the following: Lesion greater than or equal 10 mm on CT scan (5 mm sections) Lesion greater than or equal 20 mm on CT scan or MRI (10 mm sections) Lesion greater than or equal 10 mm on physical exam ",
        "premise_nums": [
            "1 unidimensionally measurable",
            "10 mm on",
            "10 mm sections)",
            "20 mm on",
            "5 mm sections)",
            "1 of the"
        ]
    },
    {
        "id": "7f49cafd-3a27-4fc8-872d-914b9176442e",
        "primaryId": "NCT01427933",
        "statement_text": "Neutropenia was the most common adverse event for patients in cohort 1 of the primary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 26/69 (37.68%) Anaemia 2/69 (2.90%) Febrile neutropenia 3/69 (4.35%) Neutropenia 4/69 (5.80%) Cardiac arrest 1/69 (1.45%) Cardiac failure congestive 1/69 (1.45%) Cardiac tamponade 1/69 (1.45%) Pericardial effusion 1/69 (1.45%) Abdominal pain 1/69 (1.45%) Ascites 2/69 (2.90%) Colitis 1/69 (1.45%) Gastritis 1/69 (1.45%) Gastritis erosive 1/69 (1.45%) ",
        "premise_nums": [
            "2/69 (2.90%)",
            "3/69 (4.35%)",
            "1/69 (1.45%)",
            "26/69 (37.68%)",
            "4/69 (5.80%)"
        ]
    },
    {
        "id": "2e84c5ba-2de9-42a1-8e75-44f6d5e9ef25",
        "primaryId": "NCT01998906",
        "statement_text": "The same number of cases of Neutropenia and Pancytopenia are observed in patients from cohort 1 of the primary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Neutropenia * 1/115 (0.87%) Pancytopenia * 1/115 (0.87%) ",
        "premise_nums": [
            "1/115 (0.87%)"
        ]
    },
    {
        "id": "3bf314d0-2cd6-4331-ad4e-6aa7961d6cd8",
        "primaryId": "NCT00428922",
        "secondaryId": "NCT00499083",
        "label": "Contradiction",
        "statement_text": "Patients with prior radiotherapy for the treatment of stage 4 cancer over 5 years ago  are not eligible for either the primary trial or the secondary trial ",
        "statement_nums": [
            "4 cancer over",
            "5 years ago"
        ],
        "premise_text": "Inclusion Criteria: Histologically confirmed breast cancer with evidence of metastatic disease HER2 3+ or FISH (fluorescent in situ hybridization)+ Age 18 years No prior trastuzumab  except as given in the adjuvant or neoadjuvant setting  No prior chemotherapy in the metastatic setting  Exclusion Criteria: CNS (central nervous system) metastases Prior radiation therapy within the last 4 weeks Pregnant (positive pregnancy test) or lactating women Major surgical procedure  open biopsy  non-healing wounds  or significant traumatic injury within 28 days prior to starting study or anticipation of need for major surgical procedure during the study Minor surgical procedures such as fine needle aspirations or core biopsies within 7 days prior to start of study  No prior chemotherapy or radiotherapy ",
        "premise_nums": [
            "4 weeks Pregnant",
            "18 years No",
            "7 days prior",
            "28 days prior"
        ]
    },
    {
        "id": "4ab00376-83a4-467e-8a1e-6b8b1643a8f0",
        "primaryId": "NCT00365599",
        "secondaryId": "NCT01771666",
        "label": "Entailment",
        "statement_text": "Black men with and ECOG smaller than =2, with ANC greater than 1.5 x 10^9/L, PLT greater than 100 x 10^9/L and no prior history of blood clots are eligible for the primary trial but excluded from the secondary trial",
        "statement_nums": [
            "100 x 10",
            "than 1.5 x 10",
            "9/L and",
            "9/L, PLT"
        ],
        "premise_text": "Inclusion Criteria: Patients must have Eastern Cooperative Oncology Group (ECOG) performance status 0-2. ",
        "premise_nums": []
    },
    {
        "id": "e2d8e4b2-d5dc-404c-98a5-2a6799dd29c1",
        "primaryId": "NCT01565499",
        "secondaryId": "NCT01234402",
        "label": "Entailment",
        "statement_text": "None of the patients in the primary trial were recorded as having heart related adverse events  whereas many patients in the secondary trial experienced several different heart related issues ",
        "statement_nums": [],
        "premise_text": "Adverse Events 1: Total: 6/81 (7.41%) Colitis [1]1/81 (1.23%) Multiple Sclerosis Relapse 1/81 (1.23%) Neurotoxicity [2]2/81 (2.47%) Community-acquired pneumonia 1/81 (1.23%) Local Infection Reservoir Area 1/81 (1.23%) Adverse Events 1: Total: 20/52 (38.46%) Anaemia 0/52 (0.00%) Pancytopenia 1/52 (1.92%) Acute myocardial infarction 0/52 (0.00%) Atrial fibrillation 0/52 (0.00%) ",
        "premise_nums": [
            "0/52 (0.00%)",
            "2/81 (2.47%)",
            "20/52 (38.46%)",
            "1/81 (1.23%)",
            "1/52 (1.92%)",
            "6/81 (7.41%)"
        ]
    },
    {
        "id": "e2d8e4b2-d5dc-404c-98a5-2a6799dd29c1",
        "primaryId": "NCT01565499",
        "secondaryId": "NCT01234402",
        "label": "Entailment",
        "statement_text": "None of the patients in the primary trial were recorded as having heart related adverse events  whereas many patients in the secondary trial experienced several different heart related issues ",
        "statement_nums": [],
        "premise_text": "Cardiac failure 1/52 (1.92%)Cardiogenic shock 1/52 (1.92%) Palpitations 0/52 (0.00%) Pericardial effusion 0/52 (0.00%) Right ventricular failure 1/52 (1.92%) Abdominal pain 0/52 (0.00%) Ascites 3/52 (5.77%) Adverse Events 2: Total: 25/49 (51.02%) Anaemia 2/49 (4.08%) Pancytopenia 0/49 (0.00%) Acute myocardial infarction 1/49 (2.04%) Atrial fibrillation 1/49 (2.04%) ",
        "premise_nums": [
            "3/52 (5.77%)",
            "0/52 (0.00%)",
            "0/49 (0.00%)",
            "1/52 (1.92%)Cardiogenic",
            "25/49 (51.02%)",
            "1/49 (2.04%)",
            "2/49 (4.08%)"
        ]
    },
    {
        "id": "e2d8e4b2-d5dc-404c-98a5-2a6799dd29c1",
        "primaryId": "NCT01565499",
        "secondaryId": "NCT01234402",
        "label": "Entailment",
        "statement_text": "None of the patients in the primary trial were recorded as having heart related adverse events  whereas many patients in the secondary trial experienced several different heart related issues ",
        "statement_nums": [],
        "premise_text": "Cardiac failure 0/49 (0.00%)Cardiogenic shock 0/49 (0.00%) Palpitations 1/49 (2.04%) Pericardial effusion 4/49 (8.16%) Right ventricular failure 0/49 (0.00%) Abdominal pain 1/49 (2.04%) Ascites 0/49 (0.00%) ",
        "premise_nums": [
            "1/49 (2.04%)",
            "0/49 (0.00%)Cardiogenic",
            "4/49 (8.16%)"
        ]
    },
    {
        "id": "407369fa-92ba-4994-8a0f-d372995f3241",
        "primaryId": "NCT02699983",
        "secondaryId": "NCT00994279",
        "label": "Contradiction",
        "statement_text": "Neither the primary trial or the secondary trial require participants to practice yoga ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Group I (SparkPeople Program) Participants receive training on how to use the SparkPeople website  self-monitor their diet using the SparkPeople tool  and to self-monitor their activity daily using the Fitbit monitoring device  Participants receive weekly motivational reminders to log into the website for 3 months via email  text  or phone  based on patient preference (active phase)  Participants then enter the maintenance phase for 3 months without reminders  Behavioral Dietary Intervention: Use SparkPeople web-based program Exercise Intervention: Use Fitbit monitor and SparkPeople web-based program Activity Monitoring Device: Wear Fitbit activity monitoring device INTERVENTION 2: Group II (Wait List) Participants receive the weight loss handout and a Fitbit activity monitor  After 6 months  participants receive the SparkPeople treatment  Exercise Intervention: Use Fitbit monitor Activity Monitoring Device: Wear Fitbit activity monitoring device INTERVENTION 1: Arm 1: Yoga Intervention Yoga Intervention Yoga: Yoga sessions ",
        "premise_nums": [
            "3 months via",
            "3 months without"
        ]
    },
    {
        "id": "407369fa-92ba-4994-8a0f-d372995f3241",
        "primaryId": "NCT02699983",
        "secondaryId": "NCT00994279",
        "label": "Contradiction",
        "statement_text": "Neither the primary trial or the secondary trial require participants to practice yoga ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 2:Arm 2: Educational Wellness Group Educational Wellness Group Education: Educational Wellness Group ",
        "premise_nums": [
            "2:Arm 2:"
        ]
    },
    {
        "id": "05e50a3d-d5b2-4fe6-9709-c884c89c5f71",
        "primaryId": "NCT01004172",
        "secondaryId": "NCT00802945",
        "label": "Entailment",
        "statement_text": "the primary trial and the secondary trial both evaluate response rates  however the primary trial studies CNS response  whereas the secondary trial studies tumor response  additionally  they test different treatments ",
        "statement_nums": [],
        "premise_text": "Outcome Measurement: Central Nervous System (CNS) Objective Response Rate Outcome Measurement: Objective Response Rate (ORR) ",
        "premise_nums": []
    },
    {
        "id": "59fd53e4-b38c-4018-bafc-6fd7f7becebe",
        "primaryId": "NCT00546104",
        "statement_text": "1 patient in the primary trial suffered from a blood clot blocking their blood vessels ",
        "statement_nums": [
            "1 patient in"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 10/31 (32.26%) Edema  limb 1/31 (3.23%) Thrombosis1/31 (3.23%) diarrhea1/31 (3.23%) Pain 2/31 (6.45%) Pain  back1/31 (3.23%) Pain  extrimity limb 1/31 (3.23%) Syncope 1/31 (3.23%) Pain  chest/thorax1/31 (3.23%) hyponatremia 1/31 (3.23%) fever1/31 (3.23%) AST 1/31 (3.23%) infection1/31 (3.23%) Anorexia 1/31 (3.23%) ",
        "premise_nums": [
            "2/31 (6.45%)",
            "10/31 (32.26%)",
            "1/31 (3.23%)"
        ]
    },
    {
        "id": "59fd53e4-b38c-4018-bafc-6fd7f7becebe",
        "primaryId": "NCT00546104",
        "statement_text": "1 patient in the primary trial suffered from a blood clot blocking their blood vessels ",
        "statement_nums": [
            "1 patient in"
        ],
        "label": "Entailment",
        "premise_text": "Dyspnea 2/31 (6.45%)",
        "premise_nums": [
            "2/31 (6.45%)"
        ]
    },
    {
        "id": "c17eaeab-4e99-4cc4-8681-ae6ccddba572",
        "primaryId": "NCT01926886",
        "statement_text": "There were no cases of Cellulitis  Nausea or Anaemia in the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 8/101 (7.92%) Vertigo * 1/101 (0.99%) Infected lymphocele * 1/101 (0.99%) Ejection fraction decreased * 5/101 (4.95%) Lymphoedema * 1/101 (0.99%) ",
        "premise_nums": [
            "8/101 (7.92%)",
            "5/101 (4.95%)",
            "1/101 (0.99%)"
        ]
    },
    {
        "id": "621d06ac-12dd-42c2-a012-15c1d94a4f0b",
        "primaryId": "NCT00952692",
        "statement_text": "Candidates for the primary trial must have adequate renal and hepatic function  and must not be currently receiving amiodarone or have received amiodarone in the 6 months",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Inclusion Criteria: The patient has adequate renal function as shown by the creatinine levels (i.e  within the normal range)  The patient has adequate hepatic function as shown by serum bilirubin levels i.e: Exclusion Criteria: The patient is currently receiving amiodarone or has received amiodarone in the 6 months prior to screening  ",
        "premise_nums": [
            "6 months prior"
        ]
    },
    {
        "id": "021e79d2-ce70-43cf-aac9-fa8d4c8d3770",
        "primaryId": "NCT00193063",
        "statement_text": "In the primary trial patient cohort  3 different types of infections are observed  these are pneumonia  urinary tract and Athlete's foot ",
        "statement_nums": [
            "3 different types"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 14/41 (34.15%) Cardiac ischemia/infarction 2/41 (4.88%) Duodenal ulcer 1/41 (2.44%) Vomiting 2/41 (4.88%) Fever 2/41 (4.88%) Death NOS 1/41 (2.44%) Liver failure 1/41 (2.44%) Infection - pneumonia 2/41 (4.88%) Infection - port site 2/41 (4.88%) Infection - urinary tract 1/41 (2.44%) Disease progression 3/41 (7.32%) Confusion 1/41 (2.44%) ",
        "premise_nums": [
            "2/41 (4.88%)",
            "14/41 (34.15%)",
            "1/41 (2.44%)",
            "3/41 (7.32%)"
        ]
    },
    {
        "id": "06aa0fbc-fe49-4715-88cc-507646f6323f",
        "primaryId": "NCT00486525",
        "statement_text": "The difference between the two cohorts of the primary trial is that cohort 1 participated in a Hatha yoga  whereas cohort 2 abstained from yoga ",
        "statement_nums": [
            "1 participated in",
            "2 abstained from"
        ],
        "label": "Entailment",
        "premise_text": "INTERVENTION 1: Arm I: Yoga Therapy Patients participated in a Hatha yoga session over 90 minutes twice weekly for 12 weeks  Patients were also encouraged to practice yoga at home  Patients recorded their total home/class practice time in weekly logs  INTERVENTION 2: Arm II: Wait-List Wait-listed women were told to continue performing their usual activities  and to refrain from beginning any yoga practice  After their final assessment they were offered the yoga classes  ",
        "premise_nums": [
            "90 minutes twice"
        ]
    },
    {
        "id": "21947261-bbef-4d3a-adda-02bb4a91a3ca",
        "primaryId": "NCT00754325",
        "secondaryId": "NCT00399529",
        "label": "Contradiction",
        "statement_text": "the secondary trial and the primary trial both accept patients with progesterone receptors(PgR+) adenocarcinoma of the breast ",
        "statement_nums": [],
        "premise_text": "Inclusion Criteria: Histologically confirmed hormone receptor positive (HR+) [(estrogen receptor (ER+) and/or progesterone receptors(PgR+)] breast cancer according to immunohistochemistry (IHC) Inclusion Criteria: Patients with histologically confirmed HER-2/neu-overexpressing adenocarcinoma of the breast; this is defined as HER-2+ by immunohistochemistry (IHC) 3+ staining or Fluorescence In-Situ Hybridization (FISH)  Prior adjuvant Trastuzumab therapy is permitted  Patients must not be eligible for therapy of known curative potential for metastatic breast cancer if it is identified during the course of the study  ",
        "premise_nums": [
            "2/neu-overexpressing adenocarcinoma"
        ]
    },
    {
        "id": "71daae7c-3ee5-4451-91e2-273d8ff55aae",
        "primaryId": "NCT00617942",
        "secondaryId": "NCT00388726",
        "label": "Contradiction",
        "statement_text": "the secondary trial had a lower total number of patients experiencing adverse events compared to the primary trial ",
        "statement_nums": [],
        "premise_text": "Adverse Events 1: Total: 7/37 (18.92%) Adverse Events 1: Total: 130/503 (25.84%) ",
        "premise_nums": [
            "130/503 (25.84%)",
            "7/37 (18.92%)"
        ]
    },
    {
        "id": "4a14a8f4-c9c2-4aa2-85bc-caa1f9820e37",
        "primaryId": "NCT00203502",
        "statement_text": "Every single patient in the primary trial experienced at least 1 adverse event ",
        "statement_nums": [
            "1 adverse event"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 39/39 (100.00%) ",
        "premise_nums": [
            "39/39 (100.00%)"
        ]
    },
    {
        "id": "7d22937b-9823-45fa-a914-261f993e4d64",
        "primaryId": "NCT01644890",
        "statement_text": "Throughout the primary trial  one patient developed issues with their vision ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 34/214 (15.89%) Leukocytosis 0/214 (0.00%) Atrial fibrillation 0/214 (0.00%) Cardiac failure congestive 0/214 (0.00%) Pericardial effusion 1/214 (0.47%) Cataract 0/214 (0.00%) Macular fibrosis 0/214 (0.00%) Constipation 2/214 (0.93%) Diarrhoea 2/214 (0.93%) Enterocolitis 0/214 (0.00%) Ileus 1/214 (0.47%) Nausea 3/214 (1.40%) Adverse Events 2: Total: 27/213 (12.68%) ",
        "premise_nums": [
            "27/213 (12.68%)",
            "2/214 (0.93%)",
            "1/214 (0.47%)",
            "34/214 (15.89%)",
            "3/214 (1.40%)",
            "0/214 (0.00%)"
        ]
    },
    {
        "id": "7d22937b-9823-45fa-a914-261f993e4d64",
        "primaryId": "NCT01644890",
        "statement_text": "Throughout the primary trial  one patient developed issues with their vision ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Leukocytosis 1/213 (0.47%)Atrial fibrillation 1/213 (0.47%) Cardiac failure congestive 1/213 (0.47%) Pericardial effusion 0/213 (0.00%) Cataract 1/213 (0.47%) Macular fibrosis 1/213 (0.47%) Constipation 1/213 (0.47%) Diarrhoea 1/213 (0.47%) Enterocolitis 1/213 (0.47%) Ileus 0/213 (0.00%) Nausea 0/213 (0.00%) ",
        "premise_nums": [
            "0/213 (0.00%)",
            "1/213 (0.47%)Atrial"
        ]
    },
    {
        "id": "507a4189-4905-4752-8348-d715a5ce3962",
        "primaryId": "NCT01940497",
        "statement_text": "There were 3 more allergic reactions observed in cohort 1 of the primary trial than cohort 2.",
        "statement_nums": [
            "3 more allergic",
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 5/95 (5.26%) Febrile neutropenia 0/95 (0.00%) Neutropenia 0/95 (0.00%) Atrial fibrillation 0/95 (0.00%) Pleuropericarditis 0/95 (0.00%) Vomiting 0/95 (0.00%) Pryexia 0/95 (0.00%) Anaphylactic shock 1/95 (1.05%) Gastroenteritis 0/95 (0.00%) Fibula fracture 1/95 (1.05%) Tibia fracture 1/95 (1.05%) Intervertebral disc protrusion 0/95 (0.00%) Adverse Events 2: ",
        "premise_nums": [
            "0/95 (0.00%)",
            "5/95 (5.26%)",
            "1/95 (1.05%)"
        ]
    },
    {
        "id": "507a4189-4905-4752-8348-d715a5ce3962",
        "primaryId": "NCT01940497",
        "statement_text": "There were 3 more allergic reactions observed in cohort 1 of the primary trial than cohort 2.",
        "statement_nums": [
            "3 more allergic",
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Total: 3/20 (15.00%)Febrile neutropenia 0/20 (0.00%) Neutropenia 0/20 (0.00%) Atrial fibrillation 1/20 (5.00%) Pleuropericarditis 1/20 (5.00%) Vomiting 0/20 (0.00%) Pryexia 0/20 (0.00%) Anaphylactic shock 0/20 (0.00%) Gastroenteritis 1/20 (5.00%) Fibula fracture 0/20 (0.00%) Tibia fracture 0/20 (0.00%) ",
        "premise_nums": [
            "3/20 (15.00%)Febrile",
            "0/20 (0.00%)",
            "1/20 (5.00%)"
        ]
    },
    {
        "id": "24001e83-6a8c-4f67-9c24-55dc285c4cc2",
        "primaryId": "NCT00096356",
        "statement_text": "the primary trial results indicate that CoQ10 reduces the level of fatigue experienced by patients compared to a placebo ",
        "statement_nums": [
            "10 reduces the",
            "CoQ10 reduces"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Effects of Coenzyme Q10 on Fatigue (as Measured by POMS-F) 24 Weeks Following Randomization POMS-F is the Profile of Mood States - fatigue scale  It ranges from 0 to 28; higher values indicate greater fatigue  Time frame: 24 weeks Results 1: Arm/Group Title: Arm 1 - CoQ10 & Vitamin E Arm/Group Description: CoQ10 100mg capsule combined with Vitamin E 100 IU taken orally three times per day  Overall Number of Participants Analyzed: 122 Least Squares Mean (Standard Error) Unit of Measure: units on a scale 6.96 (0.71) Results 2: Arm/Group Title: Arm 2 - Placebo & Vitamin E Arm/Group Description: Placebo-Vitamin E 100 mg/day in 3 doses Overall Number of Participants Analyzed: 114 ",
        "premise_nums": [
            "24 Weeks Following",
            "10 on Fatigue",
            "3 doses Overall",
            "100 IU taken",
            "Q10 on",
            "100 mg/day in",
            "122 Least Squares",
            "24 weeks Results",
            "0 to 28;"
        ]
    },
    {
        "id": "24001e83-6a8c-4f67-9c24-55dc285c4cc2",
        "primaryId": "NCT00096356",
        "statement_text": "the primary trial results indicate that CoQ10 reduces the level of fatigue experienced by patients compared to a placebo ",
        "statement_nums": [
            "10 reduces the",
            "CoQ10 reduces"
        ],
        "label": "Entailment",
        "premise_text": "Least Squares Mean (Standard Error)Unit of Measure: units on a scale 8.33 (0.79) ",
        "premise_nums": []
    },
    {
        "id": "d179396d-94fe-465f-a4f1-e7c3291a0a9a",
        "primaryId": "NCT00513695",
        "statement_text": "filgrastim is the only drug in the primary trial given by subcutaneous injection ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "INTERVENTION 1: Treatment (Neoadjuvant Chemotherapy Before Surgery) Patients receive neoadjuvant chemotherapy comprising sunitinib malate PO once daily and paclitaxel IV over 1 hour once weekly for 8-12 weeks in the absence of disease progression or unacceptable toxicity  Beginning within 3 weeks of completion of sunitinib malate and paclitaxel  patients receive doxorubicin IV once weekly for 15 weeks  cyclophosphamide PO once daily for 15 weeks  and filgrastim SC on days 2-7 for 16 weeks in the absence of disease progression or unacceptable toxicity  Beginning 3-6 weeks after completion of chemotherapy  patients undergo surgery  sunitinib malate: Given PO paclitaxel: Given IV ",
        "premise_nums": [
            "3 weeks of",
            "2-7 for",
            "3-6 weeks",
            "12 weeks in",
            "6 weeks after",
            "8-12 weeks",
            "1 hour once",
            "16 weeks in",
            "7 for 16"
        ]
    },
    {
        "id": "d179396d-94fe-465f-a4f1-e7c3291a0a9a",
        "primaryId": "NCT00513695",
        "statement_text": "filgrastim is the only drug in the primary trial given by subcutaneous injection ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "doxorubicin hydrochloride: Given IVcyclophosphamide: Given PO filgrastim: Given SC therapeutic conventional surgery: Undergo surgery laboratory biomarker analysis: Correlative studies flow cytometry: Correlative studies ",
        "premise_nums": []
    },
    {
        "id": "4b893eeb-80a4-4a83-8df5-b5c668ce55b1",
        "primaryId": "NCT00796978",
        "secondaryId": "NCT01276041",
        "label": "Entailment",
        "statement_text": "More patients in the secondary trial suffered from oedema in their limbs  compared to patients in the primary trial ",
        "statement_nums": [],
        "premise_text": "Adverse Events 1: Total: 8/56 (14.29%) Platelets * 1/56 (1.79%) Heart failure * 1/56 (1.79%) Left ventricular systolic dysfunction * 1/56 (1.79%) Dehydration * 1/56 (1.79%) Diarrhea * 1/56 (1.79%) Infection with normal ANC or Grade 1 or 2 neutrophils - Bladder (urinary) * 1/56 (1.79%) Sodium  serum-low (hyponatremia) * 1/56 (1.79%) Fracture * 2/56 (3.57%) Adverse Events 1: Total: 18/70 (25.71%) ",
        "premise_nums": [
            "8/56 (14.29%)",
            "1 or 2",
            "18/70 (25.71%)",
            "1/56 (1.79%)",
            "2/56 (3.57%)"
        ]
    },
    {
        "id": "4b893eeb-80a4-4a83-8df5-b5c668ce55b1",
        "primaryId": "NCT00796978",
        "secondaryId": "NCT01276041",
        "label": "Entailment",
        "statement_text": "More patients in the secondary trial suffered from oedema in their limbs  compared to patients in the primary trial ",
        "statement_nums": [],
        "premise_text": "Cardiac arrest 1/70 (1.43%)Pericardial effusion 1/70 (1.43%) Ear pain 1/70 (1.43%) Blurred vision 1/70 (1.43%) Eye disorders - Other  specify 2/70 (2.86%) Abdominal Pain 5/70 (7.14%) Colitis 1/70 (1.43%) Diarrhea 2/70 (2.86%) Nausea 2/70 (2.86%) Death NOS 1/70 (1.43%) Edema limbs 1/70 (1.43%) Fatigue 3/70 (4.29%) ",
        "premise_nums": [
            "5/70 (7.14%)",
            "2/70 (2.86%)",
            "1/70 (1.43%)Pericardial",
            "3/70 (4.29%)"
        ]
    },
    {
        "id": "44cd16f5-6638-4d82-9121-1941eb8ce4b5",
        "primaryId": "NCT00448279",
        "statement_text": "In total there were more adverse events in cohort 1 of the primary trial  than in cohort 2.",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 4/26 (15.38%) Febrile neutropenia * 1/26 (3.85%) Gastric volvulus * 20/26 (0.00%) General Malaise * 21/26 (3.85%) Hospitalisation for intrapleuric chemotherapy and thoracentesis * 21/26 (3.85%) Acute renal failure * 21/26 (3.85%) Adverse Events 2: Total: 1/28 (3.57%) Febrile neutropenia * 0/28 (0.00%) Gastric volvulus * 21/28 (3.57%) General Malaise * 20/28 (0.00%) ",
        "premise_nums": [
            "20/26 (0.00%)",
            "20/28 (0.00%)",
            "21/26 (3.85%)",
            "4/26 (15.38%)",
            "21/28 (3.57%)"
        ]
    },
    {
        "id": "44cd16f5-6638-4d82-9121-1941eb8ce4b5",
        "primaryId": "NCT00448279",
        "statement_text": "In total there were more adverse events in cohort 1 of the primary trial  than in cohort 2.",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Hospitalisation for intrapleuric chemotherapy and thoracentesis * 20/28 (0.00%)Acute renal failure * 20/28 (0.00%) ",
        "premise_nums": [
            "20/28 (0.00%)Acute"
        ]
    },
    {
        "id": "50ac2c53-3b63-4507-8712-41f8c257b4da",
        "primaryId": "NCT01697345",
        "secondaryId": "NCT00513292",
        "label": "Entailment",
        "statement_text": "Fluorouracil  epirubicin  and cyclophosphamide (FEC) are used in both cohorts of the secondary trial  but not in cohort 1 of the primary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "INTERVENTION 1: FSFI Total Score (Pretest) Administered to participants prior to starting vaginal testosterone therapy  INTERVENTION 1: FEC-75 Then Paclitaxel/Trastuzumab ",
        "premise_nums": []
    },
    {
        "id": "14607d45-9aef-458d-89cc-d47c62c23322",
        "primaryId": "NCT02322814",
        "secondaryId": "NCT00356148",
        "label": "Entailment",
        "statement_text": "A patient with Histologically confirmed triple-negative breast cancer  with no known Brain metastases and no prior history of either autoimmune disease or cardiac dysfunction  could be eligible for both the secondary trial and the primary trial ",
        "statement_nums": [],
        "premise_text": "Inclusion Criteria: Histologically confirmed estrogen receptor (ER)-negative  progesterone receptor (PR)-negative  and human epidermal growth factor 2 (HER2)-negative adenocarcinoma of the breast with measurable metastatic or locally advanced disease History of autoimmune disease Brain metastases (symptomatic or nonsymptomatic) that have not been treated previously  are progressive  or require any type of therapy (e.g.  radiation  surgery  or steroids) to control symptoms from brain metastases within 30 days prior to first study treatment dose History of clinically significant cardiac dysfunction Inclusion Criteria: ",
        "premise_nums": [
            "30 days prior"
        ]
    },
    {
        "id": "14607d45-9aef-458d-89cc-d47c62c23322",
        "primaryId": "NCT02322814",
        "secondaryId": "NCT00356148",
        "label": "Entailment",
        "statement_text": "A patient with Histologically confirmed triple-negative breast cancer  with no known Brain metastases and no prior history of either autoimmune disease or cardiac dysfunction  could be eligible for both the secondary trial and the primary trial ",
        "statement_nums": [],
        "premise_text": "Women at any age with early stage breast cancer (stage I-II) and American Society of Anesthesiologists (ASA) score of I-II Exclusion Criteria: Ductal carcinoma in situ (DCIS; stage 0 cancer)  Advanced or distant metastatic stage  Receiving any neoadjuvant therapy  History of receiving any antibiotics within prior 3 months  History of immunodeficiency  Having a remote infection  History of reaction to study antibiotics  Denial of signing the consent form  ",
        "premise_nums": []
    },
    {
        "id": "d2961e96-bd3b-4994-aa7e-2b310eb6204e",
        "primaryId": "NCT01300351",
        "statement_text": "At least 1 participant in the primary trial showed signs of poor liver function ",
        "statement_nums": [
            "1 participant in"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Hepatic function abnormal * 1/109 (0.92%) ",
        "premise_nums": [
            "1/109 (0.92%)"
        ]
    },
    {
        "id": "8a5d7285-f4be-4e50-9057-19f74bcc410b",
        "primaryId": "NCT03106077",
        "statement_text": "Patients in the primary trial receive at most 200mg of IMGN853 by IV every 3 weeks ",
        "statement_nums": [
            "IMGN853 by",
            "853 by IV"
        ],
        "label": "Contradiction",
        "premise_text": "INTERVENTION 1: Cohort A: Advanced Triple-Negative Breast Cancer (TNBC) 6 mg/kg IMGN853 IV Q3W ",
        "premise_nums": [
            "6 mg/kg IMGN",
            "853 IV Q3W",
            "IMGN853 IV"
        ]
    },
    {
        "id": "512990dd-45d2-4b31-b571-66735ff02308",
        "primaryId": "NCT00394251",
        "statement_text": "There were 4 different adverse events  for which 0 cases were recorded in cohort 1.",
        "statement_nums": [
            "0 cases were",
            "4 different adverse"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 30/98 (30.61%) Coagulopathy 1/98 (1.02%) Febrile neutropenia 7/98 (7.14%) Pancytopenia 2/98 (2.04%) Cardiac failure 0/98 (0.00%) Cardiac failure congestive 0/98 (0.00%) Pericardial effusion 0/98 (0.00%) Appendicitis perforated 1/98 (1.02%) Colitis 1/98 (1.02%) Ileus 1/98 (1.02%) Abdominal pain upper 1/98 (1.02%) Gastrointestinal haemorrhage 0/98 (0.00%) ",
        "premise_nums": [
            "1/98 (1.02%)",
            "7/98 (7.14%)",
            "0/98 (0.00%)",
            "30/98 (30.61%)",
            "2/98 (2.04%)"
        ]
    },
    {
        "id": "383db144-4bcd-4ebc-989c-b6ae7d282026",
        "primaryId": "NCT00471276",
        "secondaryId": "NCT00951665",
        "label": "Contradiction",
        "statement_text": "Gastrointestinal haemorrhage was more common in patients from cohort 2 of the secondary trial  than cohort 1 of the primary trial  ",
        "statement_nums": [
            "2 of the",
            "1 of the"
        ],
        "premise_text": "Adverse Events 1: Total: 13/83 (15.66%) Cardiac failure congestive 1/83 (1.20%) Hypothyroidism 1/83 (1.20%) Nausea 2/83 (2.41%) Vomiting 2/83 (2.41%) Diarrhea 1/83 (1.20%) Gastrointestinal Haemorrhage 1/83 (1.20%) Asthenia 1/83 (1.20%) Hyperbilirubinaemia 1/83 (1.20%) Anal abscess 1/83 (1.20%) Dehydration 3/83 (3.61%) Decreased appetite 1/83 (1.20%) ",
        "premise_nums": [
            "2/83 (2.41%)",
            "13/83 (15.66%)",
            "3/83 (3.61%)",
            "1/83 (1.20%)"
        ]
    },
    {
        "id": "383db144-4bcd-4ebc-989c-b6ae7d282026",
        "primaryId": "NCT00471276",
        "secondaryId": "NCT00951665",
        "label": "Contradiction",
        "statement_text": "Gastrointestinal haemorrhage was more common in patients from cohort 2 of the secondary trial  than cohort 1 of the primary trial  ",
        "statement_nums": [
            "2 of the",
            "1 of the"
        ],
        "premise_text": "Adverse Events 2:Total: 5/10 (50.00%) Febrile neutropenia 0/10 (0.00%) Neutropenia 0/10 (0.00%) Thrombocytopenia 1/10 (10.00%) Cardiac failure congestive 0/10 (0.00%) Extrasystoles 0/10 (0.00%) Nausea 0/10 (0.00%) Abdominal pain 0/10 (0.00%) Constipation 0/10 (0.00%) Gastrointestinal haemorrhage 0/10 (0.00%) Death - unknown cause 0/10 (0.00%) ",
        "premise_nums": [
            "5/10 (50.00%)",
            "2:Total: 5/10",
            "1/10 (10.00%)",
            "0/10 (0.00%)"
        ]
    },
    {
        "id": "383db144-4bcd-4ebc-989c-b6ae7d282026",
        "primaryId": "NCT00471276",
        "secondaryId": "NCT00951665",
        "label": "Contradiction",
        "statement_text": "Gastrointestinal haemorrhage was more common in patients from cohort 2 of the secondary trial  than cohort 1 of the primary trial  ",
        "statement_nums": [
            "2 of the",
            "1 of the"
        ],
        "premise_text": "Thrombosis in device 0/10 (0.00%)",
        "premise_nums": [
            "0/10 (0.00%)"
        ]
    },
    {
        "id": "bfa07fb7-f8cb-4215-9bca-ddee8b3bea73",
        "primaryId": "NCT00951665",
        "statement_text": "Most patients in cohort 1 of the primary trial died of unknown causes ",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 7/26 (26.92%) Febrile neutropenia 1/26 (3.85%) Neutropenia 0/26 (0.00%) Thrombocytopenia 0/26 (0.00%) Cardiac failure congestive 0/26 (0.00%) Extrasystoles 0/26 (0.00%) Nausea 1/26 (3.85%) Abdominal pain 0/26 (0.00%) Constipation 0/26 (0.00%) Gastrointestinal haemorrhage 0/26 (0.00%) Death - unknown cause 1/26 (3.85%) Thrombosis in device 0/26 (0.00%) ",
        "premise_nums": [
            "0/26 (0.00%)",
            "1/26 (3.85%)",
            "7/26 (26.92%)"
        ]
    },
    {
        "id": "228e80ab-84d6-4b60-9960-dcdcbd78c03c",
        "primaryId": "NCT00328783",
        "statement_text": "Patients with an FEV1 of 80% to 120% are ineligible for the primary trial ",
        "statement_nums": [
            "120% are",
            "80% to"
        ],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria: Adequate pulmonary function ",
        "premise_nums": []
    },
    {
        "id": "b7caad28-5fb2-4eb6-845e-8315cff97318",
        "primaryId": "NCT00896649",
        "statement_text": "prior hormonal treatment(s) in the metastatic or adjuvant setting is not necessary for patients in the primary trial  neither is Adequate organ function or a particular racial or ethnic background ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Inclusion criteria: DISEASE CHARACTERISTICS: Scheduled to undergo screening mammogram at one of the Boston Medical Center-affiliated primary care clinics and meets 1 of the following criteria: Dense breast tissue At high-risk for breast cancer PATIENT CHARACTERISTICS: Has 1 of the following racial or ethnic backgrounds based on the patient's country of birth or the mother and father's country of birth: Hispanic Haitian Creole African American Caucasian PRIOR CONCURRENT THERAPY: None specified Exclusion criteria: No history of breast cancer  palpable breast mass  abnormal nipple discharge  or other focal complaints warranting diagnostic mammogram ",
        "premise_nums": [
            "1 of the"
        ]
    },
    {
        "id": "73c37b9c-e7ba-4c90-b26e-23b7a65509c4",
        "primaryId": "NCT00005957",
        "statement_text": "T2 N1 M0 adenocarcinoma of the breast are eligible for the primary trial ",
        "statement_nums": [
            "0 adenocarcinoma of"
        ],
        "label": "Entailment",
        "premise_text": "DISEASE CHARACTERISTICS: Histologically proven invasive carcinoma of the breast No evidence of T4, N2-3, or M1 disease prior to surgery Node positive or high-risk node negative ",
        "premise_nums": [
            "2-3, or",
            "1 disease prior"
        ]
    },
    {
        "id": "d5b81f6c-821a-4db5-8810-9cc47a952913",
        "primaryId": "NCT02287675",
        "statement_text": "Informed consent is obligatory for entry in the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Inclusion Criteria: The subject must provide written informed consent with Health Insurance Portability and Accountability Act (HIPAA) authorization before participating in the study ",
        "premise_nums": []
    },
    {
        "id": "cdba382e-894b-4f79-a8e2-ff818746adc5",
        "primaryId": "NCT01202591",
        "statement_text": "100% of patients in the primary trial suffered adverse events ",
        "statement_nums": [
            "100% of"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Safety and Tolerability in Terms of Number of Patients With Adverse Events (Serious and Non-serious) [Not Specified] Time frame: 3 years  10 months (Adverse events recorded from patient screening to discontinuation plus 28 days safety follow-up)  Results 1: Arm/Group Title: AZD4547 80mg bd Cont + Ex 25mg Arm/Group Description: 80 mg AZD4547 BD continuous + 25 mg exemestane Overall Number of Participants Analyzed: 5 Measure Type: Number Unit of Measure: Participants 5 Results 2: Arm/Group Title: AZD4547 40mg Cont + Ex 25mg Arm/Group Description: 40 mg AZD4547 BD continuous + 25 mg exemestane Overall Number of Participants Analyzed: 5 Measure Type: Number Unit of Measure: Participants 5 ",
        "premise_nums": [
            "28 days safety",
            "5 Results 2:",
            "5 Measure Type:",
            "AZD4547 BD",
            "80 mg AZD4547",
            "10 months (Adverse",
            "25 mg exemestane",
            "40 mg AZD4547"
        ]
    },
    {
        "id": "0093175a-38cb-4f63-b391-709ac48158b8",
        "primaryId": "NCT00971737",
        "secondaryId": "NCT00392392",
        "label": "Contradiction",
        "statement_text": "Patients with tumors overexpressing HER-2 are eligible for the secondary trial  but not for the primary trial ",
        "statement_nums": [
            "2 are eligible"
        ],
        "premise_text": "DISEASE CHARACTERISTICS: Histologically confirmed adenocarcinoma of the breast Does not overexpress HER-2/neu, defined as FISH negative or 0, 1+, or 2+ by IHC Stage IV disease Inclusion Criteria: FISH+ HER2 gene amplified breast cancer ",
        "premise_nums": [
            "1+, or",
            "2 gene amplified",
            "2/neu, defined"
        ]
    },
    {
        "id": "19106207-4fa2-4cc4-8e22-6e5330bf05ce",
        "primaryId": "NCT00846027",
        "statement_text": "None of the adverse events recorded for the primary trial occurred more than once ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 21/82 (25.61%) Neutrophils count decreased 1/82 (1.22%) Cardiac ischemia/infarction 1/82 (1.22%) Left ventricular systolic dysfunction 1/82 (1.22%) Hypertension 1/82 (1.22%) Supraventricular and nodal arrhythmia 1/82 (1.22%) Anorexia 1/82 (1.22%) Gastrointestinal perforation 1/82 (1.22%) Vomiting 1/82 (1.22%) Dehydration 1/82 (1.22%) Diarrhoea 1/82 (1.22%) ",
        "premise_nums": [
            "1/82 (1.22%)",
            "21/82 (25.61%)"
        ]
    },
    {
        "id": "a015685e-f744-4bb2-a6d3-893f081d6dcc",
        "primaryId": "NCT02597452",
        "secondaryId": "NCT01929395",
        "label": "Contradiction",
        "statement_text": "the primary trial and the secondary trial both use 21 day cycles for their interventions up to a maximum of 10 and 4 cycles respectively ",
        "statement_nums": [
            "10 and 4",
            "21 day cycles"
        ],
        "premise_text": "INTERVENTION 1: Intelligent Breast Exam  iBE Single Arm: Additional breast exam by a FDA approved hand-held intelligent breast exam device and a clinical breast exam during their scheduled breast screening appointment  No return visit required for participation  intelligent Breast Exam  iBE: A bilateral iBE exam will be performed on the entire breast in addition to a clinical breast exam administered by a trained individual  If the patient is selected to participate in the inter-rater reliability portion of the study  the subject will undergo both the iBE and the clinical breast exams twice sequentially performed by two different separately trained individuals during the same visit  INTERVENTION 1: Phase 1: Addition of Supine MRI to Conventional Imaging Pre-operative supine MRI with intraoperative optical scanning and tracking (group MRI) ",
        "premise_nums": []
    },
    {
        "id": "b9578bae-6640-4ef1-ba2c-899b45c602ee",
        "primaryId": "NCT01487954",
        "statement_text": "All patients in the primary trial had to drink 4 cups of water  either Alkaline Water or Distilled  depending on which cohort they are in ",
        "statement_nums": [
            "4 cups of"
        ],
        "label": "Contradiction",
        "premise_text": "INTERVENTION 1: Arm I: Alkaline Water Patients undergo external beam radiation therapy QD  5 days a week for 6 weeks  Patients drink 8 ounces of alkaline water within 30 minutes immediately prior to and after undergoing radiation therapy  alkaline water: Patients drink 8 ounces of alkaline water within 30 minutes immediately prior to and after undergoing radiation therapy  external beam radiation therapy (EBRT): Patients undergo external beam radiation therapy QD  5 days a week for 6 weeks  INTERVENTION 2: Arm II: Distilled Water Patients undergo external beam radiation therapy as in arm I  Patients also drink 8 ounces of distilled water within 30 minutes immediately prior to and after undergoing radiation therapy ",
        "premise_nums": [
            "30 minutes immediately",
            "5 days a",
            "8 ounces of"
        ]
    },
    {
        "id": "b9578bae-6640-4ef1-ba2c-899b45c602ee",
        "primaryId": "NCT01487954",
        "statement_text": "All patients in the primary trial had to drink 4 cups of water  either Alkaline Water or Distilled  depending on which cohort they are in ",
        "statement_nums": [
            "4 cups of"
        ],
        "label": "Contradiction",
        "premise_text": "distilled water: Patients also drink 8 ounces of distilled water within 30 minutes immediately prior to and after undergoing radiation therapy external beam radiation therapy (EBRT): Patients undergo external beam radiation therapy QD  5 days a week for 6 weeks  ",
        "premise_nums": [
            "30 minutes immediately",
            "5 days a",
            "8 ounces of"
        ]
    },
    {
        "id": "405369ef-d216-4d81-a04f-46f36f466a19",
        "primaryId": "NCT01416389",
        "statement_text": "Cohort 1 of the primary trial had more cases of urinary infections and lumbar fractures than cohort 2.",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Urinary tract infection 1/26 (3.85%) Lumbar vertebral fracture 1/26 (3.85%) Adverse Events 2: Urinary tract infection 0/13 (0.00%) Lumbar vertebral fracture 0/13 (0.00%) ",
        "premise_nums": [
            "0/13 (0.00%)",
            "1/26 (3.85%)"
        ]
    },
    {
        "id": "e424c65e-7c6f-43a4-95e4-6beb705d9903",
        "primaryId": "NCT00559754",
        "secondaryId": "NCT02924883",
        "label": "Contradiction",
        "statement_text": "A higher percent of patients in cohort 1 of the secondary trial experienced stomatitis  than in cohort 1 of the primary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Adverse Events 1: Total: 13/72 (18.06%) Adverse Events 1: Total: 52/133 (39.10%) ",
        "premise_nums": [
            "13/72 (18.06%)",
            "52/133 (39.10%)"
        ]
    },
    {
        "id": "f2bd0a9c-74c4-443e-b666-0a0b3aa125e1",
        "primaryId": "NCT01466270",
        "statement_text": "The the primary trial placebo group had a better mean retention than the donepezil hydrochloride PO QD group ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Retention Retention is the percentage of participants who stay in the study for 24 weeks  Time frame: 24 Weeks Results 1: Arm/Group Title: Arm I Arm/Group Description: Patients receive donepezil hydrochloride PO QD  donepezil hydrochloride: Given PO Overall Number of Participants Analyzed: 31 Mean (Standard Error) Unit of Measure: percentage of participants 71.0 (8.3) Results 2: Arm/Group Title: Arm II Arm/Group Description: Patients receive placebo PO QD  Placebo: Given PO Overall Number of Participants Analyzed: 31 Mean (Standard Error) Unit of Measure: percentage of participants 80.7 (7.2) ",
        "premise_nums": [
            "24 Weeks Results",
            "31 Mean (Standard"
        ]
    },
    {
        "id": "0bf293c5-f4fc-40f1-9bd2-8f1f781c7e4a",
        "primaryId": "NCT00072293",
        "statement_text": "Patients with a nonpalpable breast lesion and 0 palpable axillary lymph nodes are eligible for the primary trial ",
        "statement_nums": [
            "0 palpable axillary"
        ],
        "label": "Entailment",
        "premise_text": "Palpable or nonpalpable breast lesion No palpable axillary lymph node(s) ",
        "premise_nums": []
    },
    {
        "id": "6843daf8-8136-4973-9bf2-62a622d5a890",
        "primaryId": "NCT01156987",
        "secondaryId": "NCT02234479",
        "label": "Contradiction",
        "statement_text": "Participants in the primary trial are assigned an intervention depending on their HIV diagnosis  whereas in the secondary trial the interventions are randomly assigned ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Healthy Volunteers Healthy women will be screened for Magnetic Resonance Imaging (MRI) contraindications  and then undergo contrast injection  and SWIFT acquisition  Magnetic resonance imaging: Patients and healthy volunteers will be first screened for MRI contraindications  The SWIFT MRI workflow will be performed as follows: INTERVENTION 2: Breast Cancer Patients Breast cancer patients who have suspected breast lesion that will be biopsied will be screened for Magnetic Resonance Imaging (MRI) contraindications  and then undergo contrast injection and SWIFT acquisition  Magnetic resonance imaging: Patients and healthy volunteers will be first screened for MRI contraindications  The SWIFT MRI workflow will be performed as follows: INTERVENTION 1: Hydrophor (Group A) ",
        "premise_nums": []
    },
    {
        "id": "6843daf8-8136-4973-9bf2-62a622d5a890",
        "primaryId": "NCT01156987",
        "secondaryId": "NCT02234479",
        "label": "Contradiction",
        "statement_text": "Participants in the primary trial are assigned an intervention depending on their HIV diagnosis  whereas in the secondary trial the interventions are randomly assigned ",
        "statement_nums": [],
        "premise_text": "Group A (current standard of care): Patients will be instructed (by nurses and with printed study materials) to apply a thin layer of the Hydrophor daily  starting at the onset of radiation therapy (RT) and continuing until 2 weeks after the final RT session or until the RT site is healed (whichever is first)  Hydrophor application should include the entire treatment area  including the axillae and shoulder/back area in patients treated with modified radical mastectomy  To avoid possible build-up effects  patients should not apply the Hydrophor within 4 hours of receiving RT  Patients should wash the application area daily with perfume-free soap and tap water  Patients will be asked to refrain from using other topical agents in the irradiated area INTERVENTION 2: MediHoney (Group B) ",
        "premise_nums": [
            "4 hours of",
            "2 weeks after"
        ]
    },
    {
        "id": "6843daf8-8136-4973-9bf2-62a622d5a890",
        "primaryId": "NCT01156987",
        "secondaryId": "NCT02234479",
        "label": "Contradiction",
        "statement_text": "Participants in the primary trial are assigned an intervention depending on their HIV diagnosis  whereas in the secondary trial the interventions are randomly assigned ",
        "statement_nums": [],
        "premise_text": "Group B (study target): Patients will be instructed (by nurses and with printed study materials) to apply a thin layer of the Medihoney daily  starting at the onset of RT and continuing until 2 weeks after the final RT session or until the RT site is healed (whichever is first)  Medihoney application should include the entire treatment area  including the axillae and shoulder/back area in patients treated with modified radical mastectomy  To avoid possible build-up effects  patients should not apply the Medihoney within 4 hours of receiving RT  Patients should wash the application area daily with perfume-free soap and tap water  Patients will be asked to refrain from using other topical agents in the irradiated area ",
        "premise_nums": [
            "4 hours of",
            "2 weeks after"
        ]
    },
    {
        "id": "2687b547-c225-4838-bbcd-99212a74d815",
        "primaryId": "NCT01828021",
        "secondaryId": "NCT01326481",
        "label": "Entailment",
        "statement_text": "Patients in the primary trial and the secondary trial did not have any of the same adverse events ",
        "statement_nums": [],
        "premise_text": "Adverse Events 1: Total: 6/25 (24.00%) Supraventricular extrasystoles 1/25 (4.00%) Ventricular extrasystoles 1/25 (4.00%) Ascites 2/25 (8.00%) Diarrhea 1/25 (4.00%) Nausea 1/25 (4.00%) Pancreatitis 1/25 (4.00%) Small intestinal obstruction 1/25 (4.00%) Vomiting 1/25 (4.00%) Bile duct obstruction 1/25 (4.00%) Portal hypertension 1/25 (4.00%) Adverse Events 1: Total: 6/19 (31.58%) ",
        "premise_nums": [
            "6/19 (31.58%)",
            "6/25 (24.00%)",
            "1/25 (4.00%)",
            "2/25 (8.00%)"
        ]
    },
    {
        "id": "2687b547-c225-4838-bbcd-99212a74d815",
        "primaryId": "NCT01828021",
        "secondaryId": "NCT01326481",
        "label": "Entailment",
        "statement_text": "Patients in the primary trial and the secondary trial did not have any of the same adverse events ",
        "statement_nums": [],
        "premise_text": "Febrile neutropenia [1]1/19 (5.26%)Fatigue [1]1/19 (5.26%) Pyrexia [1]1/19 (5.26%) Fracture [1]1/19 (5.26%) Hip Fracture [1]1/19 (5.26%) Headache [2]1/19 (5.26%) ",
        "premise_nums": [
            "1/19 (5.26%)Fatigue"
        ]
    },
    {
        "id": "fadf7710-6e4d-49d6-82fc-4f3137b5e26b",
        "primaryId": "NCT00759785",
        "statement_text": "Only one adverse event is observed in patients from cohort 1 of the primary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 1/25 (4.00%) Diarrhoea 0/25 (0.00%) Breast abscess 0/25 (0.00%) Breast cellulitis 0/25 (0.00%) Syncope 1/25 (4.00%) ",
        "premise_nums": [
            "0/25 (0.00%)",
            "1/25 (4.00%)"
        ]
    },
    {
        "id": "8c4e6f36-37b4-4bde-b518-08a6dc55f7a5",
        "primaryId": "NCT00074152",
        "statement_text": "All of the adverse event cases in the primary trial occurred in patients from cohort 2.",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 0/77 (0.00%) Neutropenia [1]0/77 (0.00%) Left ventricular dysfunction 0/77 (0.00%) Cardiac ischemia 0/77 (0.00%) Gastrointestinal pain 0/77 (0.00%) Colitis 0/77 (0.00%) Febrile neutropenia 0/77 (0.00%) Pulmonary/upper respiratory infection 0/77 (0.00%) Diverticulitis 0/77 (0.00%) Motor neuropathy 0/77 (0.00%) Endometrial mucosa thinkening 0/77 (0.00%) Adverse Events 2: Total: 12/85 (14.12%) ",
        "premise_nums": [
            "0/77 (0.00%)",
            "12/85 (14.12%)"
        ]
    },
    {
        "id": "8c4e6f36-37b4-4bde-b518-08a6dc55f7a5",
        "primaryId": "NCT00074152",
        "statement_text": "All of the adverse event cases in the primary trial occurred in patients from cohort 2.",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Neutropenia [1]1/85 (1.18%)Left ventricular dysfunction 1/85 (1.18%) Cardiac ischemia 2/85 (2.35%) Gastrointestinal pain 1/85 (1.18%) Colitis 1/85 (1.18%) Febrile neutropenia 3/85 (3.53%) Pulmonary/upper respiratory infection 1/85 (1.18%) Diverticulitis 1/85 (1.18%) Motor neuropathy 1/85 (1.18%) Endometrial mucosa thinkening 1/85 (1.18%) ",
        "premise_nums": [
            "2/85 (2.35%)",
            "3/85 (3.53%)",
            "1/85 (1.18%)Left"
        ]
    },
    {
        "id": "6c0896ac-db42-45b4-a6e2-620a27fd321a",
        "primaryId": "NCT01439945",
        "statement_text": "In the primary trial Low Dose Magnesium Oxide is 5% less than high dose Magnesium Oxide ",
        "statement_nums": [
            "5% less"
        ],
        "label": "Contradiction",
        "premise_text": "INTERVENTION 1: Low Dose Magnesium Oxide (800 mg/Day) Week 2: Patients take one 400 mg tablet of magnesium oxide orally (PO) daily (QD)  Week 3: Patients take two 400 mg tablet of magnesium oxide orally (PO) daily (QD)  Weeks 4-9: Patients take two 400 mg tablet of magnesium oxide orally (PO) daily (QD)  INTERVENTION 2: High Dose Magnesium Oxide (1200 mg/Day) Week 2: Patients take one 400 mg tablet of magnesium oxide orally (PO) daily (QD)  Week 3: Patients take two 400 mg tablet of magnesium oxide orally (PO) daily (QD)  Weeks 4-9: Patients take three 400 mg tablet of magnesium oxide orally (PO) daily (QD)  ",
        "premise_nums": [
            "400 mg tablet",
            "4-9: Patients"
        ]
    },
    {
        "id": "3a80ba8a-265f-4931-a9a8-b7e00e372599",
        "primaryId": "NCT00432172",
        "statement_text": "All of the adverse events recorded in the primary trial occurred in patients from cohort 1.",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 5/45 (11.11%) Neutrophils/granulocytes (ANC/AGC) * [1]0/45 (0.00%) Neutrophils/granulocytes (ANC/AGC) * [2]0/45 (0.00%) Diabetes decompensation * 0/45 (0.00%) Diarrhea * [2]0/45 (0.00%) Mucositis/stomatitis and Vomiting * [3]0/45 (0.00%) Pancreatitis * [4]1/45 (2.22%) Febrile neutropenia * [2]3/45 (6.67%) ",
        "premise_nums": [
            "3/45 (6.67%)",
            "5/45 (11.11%)",
            "0/45 (0.00%)",
            "1/45 (2.22%)"
        ]
    },
    {
        "id": "3a80ba8a-265f-4931-a9a8-b7e00e372599",
        "primaryId": "NCT00432172",
        "statement_text": "All of the adverse events recorded in the primary trial occurred in patients from cohort 1.",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Adverse Events 2:Total: 0/46 (0.00%) Neutrophils/granulocytes (ANC/AGC) * [1]0/46 (0.00%) Neutrophils/granulocytes (ANC/AGC) * [2]0/46 (0.00%) Diabetes decompensation * 0/46 (0.00%) Diarrhea * [2]0/46 (0.00%) Mucositis/stomatitis and Vomiting * [3]0/46 (0.00%) Pancreatitis * [4]0/46 (0.00%) Febrile neutropenia * [2]0/46 (0.00%) ",
        "premise_nums": [
            "2:Total: 0/46",
            "0/46 (0.00%)"
        ]
    },
    {
        "id": "3a80ba8a-265f-4931-a9a8-b7e00e372599",
        "primaryId": "NCT00432172",
        "statement_text": "All of the adverse events recorded in the primary trial occurred in patients from cohort 1.",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Infection pulmonary/ Upper airway NOS * [5]0/46 (0.00%)",
        "premise_nums": [
            "0/46 (0.00%)"
        ]
    },
    {
        "id": "df4b98f2-7ca9-4855-8d94-d62407ff8535",
        "primaryId": "NCT01929395",
        "secondaryId": "NCT01857882",
        "label": "Entailment",
        "statement_text": "the primary trial only has one test cohort whereas the secondary trial has both a test and control group ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Phase 1: Addition of Supine MRI to Conventional Imaging Pre-operative supine MRI with intraoperative optical scanning and tracking (group MRI) INTERVENTION 1: Decision Support Workshop The decision support workshop will be 2 hours in duration on the morning of the consultation and will be facilitated by a dedicated social worker from psycho-oncology  Decision Support Workshop: Incorporates the key components of shared decision-making and decision support with the philosophy of delivering supportive care to cancer patients  Surgeon (30 mins): treatment options for breast reconstruction with indications/ contraindications  advantages / disadvantages  expected post-operative course  aesthetic result and complications with probabilities Registered nurse (30 mins): preparing for surgery  postoperative recovery and how to navigate the health care system Social worker (30 mins): values clarification exercise ",
        "premise_nums": [
            "2 hours in"
        ]
    },
    {
        "id": "df4b98f2-7ca9-4855-8d94-d62407ff8535",
        "primaryId": "NCT01929395",
        "secondaryId": "NCT01857882",
        "label": "Entailment",
        "statement_text": "the primary trial only has one test cohort whereas the secondary trial has both a test and control group ",
        "statement_nums": [],
        "premise_text": "Breast reconstruction patient volunteer (30 mins) questions and answers about her personal experienceINTERVENTION 2: Standard Care Routine pre-consultation education ",
        "premise_nums": []
    },
    {
        "id": "5d2542fa-5482-4aff-af29-80875a0a9dcc",
        "primaryId": "NCT01015131",
        "secondaryId": "NCT00312208",
        "label": "Entailment",
        "statement_text": "the primary trial records instances of Rectal Hemorrhage within its patient cohort  whereas the secondary trial records Vaginal hemorrhages ",
        "statement_nums": [],
        "premise_text": "Adverse Events 1: Total: 8/44 (18.18%) Febrile neutropenia4/44 (9.09%) Rectal bleeding1/44 (2.27%) Chest pain2/44 (4.55%) Fever1/44 (2.27%) Catheter site infection1/44 (2.27%) Neutrophil count decreased1/44 (2.27%) Dizziness1/44 (2.27%) Adverse Events 1: Total: 331/1634 (20.26%) Anemia 3/1634 (0.18%) Coagulation disorders 1/1634 (0.06%) ",
        "premise_nums": [
            "1/1634 (0.06%)",
            "1/44 (2.27%)",
            "2/44 (4.55%)",
            "3/1634 (0.18%)",
            "331/1634 (20.26%)",
            "8/44 (18.18%)",
            "4/44 (9.09%)"
        ]
    },
    {
        "id": "5d2542fa-5482-4aff-af29-80875a0a9dcc",
        "primaryId": "NCT01015131",
        "secondaryId": "NCT00312208",
        "label": "Entailment",
        "statement_text": "the primary trial records instances of Rectal Hemorrhage within its patient cohort  whereas the secondary trial records Vaginal hemorrhages ",
        "statement_nums": [],
        "premise_text": "Hemorrhage Vaginal 1/1634 (0.06%)Leukopenia 18/1634 (1.10%) Lymphadenopathy 0/1634 (0.00%) Lymphedema 0/1634 (0.00%) Pancytopenia 0/1634 (0.00%) Thrombocytopenia 0/1634 (0.00%) Arrhythmia 3/1634 (0.18%) Arrhythmia Ventricular 0/1634 (0.00%) Cardiomyopathy 1/1634 (0.06%) ",
        "premise_nums": [
            "3/1634 (0.18%)",
            "1/1634 (0.06%)Leukopenia",
            "0/1634 (0.00%)",
            "18/1634 (1.10%)"
        ]
    },
    {
        "id": "5deb8ebd-fbd2-4d84-8ad2-a1248426908b",
        "primaryId": "NCT00880464",
        "secondaryId": "NCT00458237",
        "label": "Entailment",
        "statement_text": "HIV+ Patients are excluded from both the secondary trial and the primary trial ",
        "statement_nums": [],
        "premise_text": "Exclusion Criteria: Evidence of HIV infection Exclusion Criteria: HIV positive patients ",
        "premise_nums": []
    },
    {
        "id": "5f4880ac-1ce2-4b89-841b-a9918720b6ea",
        "primaryId": "NCT00365417",
        "secondaryId": "NCT00853996",
        "label": "Entailment",
        "statement_text": "To be eligible for both the secondary trial and the primary trial patients must satisfy all the following conditions; alkaline phosphatase smaller than 2 x ULN  aspartate aminotransferase smaller than = 1.5 x ULN and Hemoglobin greater than 10 g/dL ",
        "statement_nums": [
            "2 x ULN",
            "10 g/dL",
            "5 x ULN"
        ],
        "premise_text": "The following criteria for evidence of adequate hepatic function must be met: alkaline phosphatase must be less than 2.5 x ULN for the lab; and aspartate aminotransferase (AST) must be less than/equal to 1.5 x ULN for the lab  Platelet count must be greater than/equal to 100,000/mm^3. Hemoglobin must be greater than/equal to 10 g/dL  Platelets greater than 100,000/mm^3 Hemoglobin greater than 10 g/dL ",
        "premise_nums": [
            "100,000/mm^3 Hemoglobin",
            "than 2.5 x ULN",
            "100,000/mm^3. Hemoglobin",
            "10 g/dL",
            "3 Hemoglobin greater",
            "to 1.5 x ULN"
        ]
    },
    {
        "id": "5f4880ac-1ce2-4b89-841b-a9918720b6ea",
        "primaryId": "NCT00365417",
        "secondaryId": "NCT00853996",
        "label": "Entailment",
        "statement_text": "To be eligible for both the secondary trial and the primary trial patients must satisfy all the following conditions; alkaline phosphatase smaller than 2 x ULN  aspartate aminotransferase smaller than = 1.5 x ULN and Hemoglobin greater than 10 g/dL ",
        "statement_nums": [
            "2 x ULN",
            "10 g/dL",
            "5 x ULN"
        ],
        "premise_text": "AST smaller than 2 times upper limit of normal (ULN)Alkaline phosphatase smaller than 2 times ULN ",
        "premise_nums": [
            "2 times upper",
            "2 times ULN"
        ]
    },
    {
        "id": "b3aabfaa-23cb-4a75-8416-761d8574f0a4",
        "primaryId": "NCT01441596",
        "statement_text": "Patients in cohort 1 of the primary trial may receive gradually increasing doses of Afatinib monotherapy from 40mg PO to 50mg PO ",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "INTERVENTION 1: Afatinib Mono Afatinib monotherapy administered orally: starting dose 40 mg per day  continuous treatment in a 3-weekly course  If well tolerated  the dose may be escalated to 50 mg  ",
        "premise_nums": [
            "40 mg per",
            "3-weekly course"
        ]
    },
    {
        "id": "f697c2d8-e0dd-476e-8ff4-dffe053076f8",
        "primaryId": "NCT00524303",
        "statement_text": "The Trastuzumab arm of the primary trial reported a pCR rate of 54%, significantly worse results than the Lapatinib arm which achieved a pCR rate of 45%.",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Percentage of Participants With Overall Pathological Complete Response (pCR) After 26 Weeks of Therapy ",
        "premise_nums": [
            "26 Weeks of"
        ]
    },
    {
        "id": "f697c2d8-e0dd-476e-8ff4-dffe053076f8",
        "primaryId": "NCT00524303",
        "statement_text": "The Trastuzumab arm of the primary trial reported a pCR rate of 54%, significantly worse results than the Lapatinib arm which achieved a pCR rate of 45%.",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "A pCR in the breast was defined as no pathologic evidence of invasive disease (residual ductal carcinoma in situ [DCIS] or lobular carcinoma in situ [LCIS] was allowed)  A pCR in the axillary lymph node(s) was defined as no evidence of breast cancer cells in the lymph node (including subcapsular sinus)  Overall pCR was defined as the sum of pCR in the breast and pCR in the lymph nodes  26 weeks of therapy comprised the 2-week run-in phase  12 weeks of treatment with FEC  and 12 weeks of treatment with Paclitaxel Time frame: Week 26 Results 1: ",
        "premise_nums": [
            "12 weeks of",
            "26 Results 1:",
            "2-week run-in",
            "26 weeks of"
        ]
    },
    {
        "id": "f697c2d8-e0dd-476e-8ff4-dffe053076f8",
        "primaryId": "NCT00524303",
        "statement_text": "The Trastuzumab arm of the primary trial reported a pCR rate of 54%, significantly worse results than the Lapatinib arm which achieved a pCR rate of 45%.",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Arm/Group Title: Trastuzumab",
        "premise_nums": []
    },
    {
        "id": "f2c0f753-1775-42af-94f0-b87b20156e65",
        "primaryId": "NCT02835625",
        "secondaryId": "NCT00486525",
        "label": "Contradiction",
        "statement_text": "the primary trial and the secondary trial do not use chemotherapy  radiotherapy or mammography in their interventions",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Digital Breast Tomosynthesis Digital Breast Tomosynthesis + Synthetic Mammography (DBT) The DBT was independently read by two radiologists  A consensus meeting decided whether to recall the woman or not  Women selected for further assessment (positive screening exam) was recalled  Digital Breast Tomosynthesis + Synthetic Mammography: Two-view tomosynthesis performed with GE SenoClaire 3D Breast Tomosynthesis  INTERVENTION 2: Digital Mammography The digital mammograms was independently read by two radiologists  A consensus meeting decided whether to recall the woman or not  Women selected for further assessment (positive screening exam) was recalled  Digital mammography: Two-view digital mammography performed with GE SenoClaire 3D Breast Tomosynthesis  INTERVENTION 1: Arm I: Yoga Therapy ",
        "premise_nums": []
    },
    {
        "id": "f2c0f753-1775-42af-94f0-b87b20156e65",
        "primaryId": "NCT02835625",
        "secondaryId": "NCT00486525",
        "label": "Contradiction",
        "statement_text": "the primary trial and the secondary trial do not use chemotherapy  radiotherapy or mammography in their interventions",
        "statement_nums": [],
        "premise_text": "Patients participated in a Hatha yoga session over 90 minutes twice weekly for 12 weeks  Patients were also encouraged to practice yoga at home  Patients recorded their total home/class practice time in weekly logs INTERVENTION 2: Arm II: Wait-List Wait-listed women were told to continue performing their usual activities  and to refrain from beginning any yoga practice  After their final assessment they were offered the yoga classes  ",
        "premise_nums": [
            "90 minutes twice"
        ]
    },
    {
        "id": "17b31c1d-db62-4628-b390-02da22512079",
        "primaryId": "NCT01028352",
        "statement_text": "Patients with aromatase inhibitor associated musculoskeletal symptoms  such as Grade 1 or above musculoskeletal pain or sensory neuropathy  are eligible for the primary trial ",
        "statement_nums": [
            "1 or above"
        ],
        "label": "Entailment",
        "premise_text": "Inclusion Criteria: AI-associated musculoskeletal symptoms  defined as: Grade 1 or higher musculoskeletal pain that developed or worsened (6 or 7 on CGICS) during AI therapy or Grade 1 or higher sensory neuropathy that developed or worsened (6 or 7 on CGICS) during AI therapy; ",
        "premise_nums": [
            "6 or 7",
            "7 on CGICS",
            "1 or higher"
        ]
    },
    {
        "id": "2e6e1044-8b4a-41f7-8319-85fc5bba4482",
        "primaryId": "NCT00574145",
        "secondaryId": "NCT03167359",
        "label": "Entailment",
        "statement_text": "Radiotherapy is used in all cohorts of the primary trial and the secondary trial ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Radiotherapy/Supportive Care (A) Patients receive radiotherapy and healing touch therapy from a healing-touch therapist once a week for the duration of their radiotherapy INTERVENTION 2: Control ARM (B) Patients receive radiotherapy and sham healing touch therapy from a sham healing-touch therapist once a week for the duration of their radiotherapy INTERVENTION 1: Participants With Stage 0-III Breast Cancer Women with Stage 0-III breast cancer  treated with breast conserving surgery or mastectomy and clear margins  will receive 15 doses of radiation over three weeks  ",
        "premise_nums": [
            "15 doses of",
            "0-III Breast",
            "0-III breast"
        ]
    },
    {
        "id": "2e6e1044-8b4a-41f7-8319-85fc5bba4482",
        "primaryId": "NCT00574145",
        "secondaryId": "NCT03167359",
        "label": "Entailment",
        "statement_text": "Radiotherapy is used in all cohorts of the primary trial and the secondary trial ",
        "statement_nums": [],
        "premise_text": "Hypofractionated Simultaneous Integrated Boost Radiotherapy: Participants will receive radiotherapy treatments to the whole breast or chest wall to a dose of 2.66 Gy per day x 15 fractions simultaneously with a boost treatment  The boost treatment will be given on the same days as the whole breast treatment  The lumpectomy cavity + scar (in lumpectomy patients) or chest wall scar (mastectomy patients) will receive 0.54 Gy per day x 15 fractions ",
        "premise_nums": [
            "of 2.66 Gy per",
            "receive 0.54 Gy per",
            "15 fractions simultaneously"
        ]
    },
    {
        "id": "456c6011-52bb-4c8b-9e82-e5a85cbbe0e3",
        "primaryId": "NCT00493649",
        "secondaryId": "NCT01201265",
        "label": "Contradiction",
        "statement_text": "There was 1 MRSA infection in cohort 1 of the secondary trial and 4 in cohort 2 of the primary trial ",
        "statement_nums": [
            "2 of the",
            "1 MRSA infection",
            "4 in cohort",
            "1 of the"
        ],
        "premise_text": "Adverse Events 1: Total: 51/486 (10.49%) ANEMIA 1/486 (0.21%) NEUTROPENIA 4/486 (0.82%) FIBRILLATION ATRIAL 1/486 (0.21%) ABDOMINAL PAIN 2/486 (0.41%) BLOATING 1/486 (0.21%) BOWEL PERFORATION 1/486 (0.21%) COLITIS 1/486 (0.21%) DEHYDRATION 5/486 (1.03%) DIARRHEA 5/486 (1.03%) GASTRIC INFLAMMATION 1/486 (0.21%) NAUSEA 3/486 (0.62%) ",
        "premise_nums": [
            "51/486 (10.49%)",
            "2/486 (0.41%)",
            "4/486 (0.82%)",
            "1/486 (0.21%)",
            "5/486 (1.03%)",
            "3/486 (0.62%)"
        ]
    },
    {
        "id": "456c6011-52bb-4c8b-9e82-e5a85cbbe0e3",
        "primaryId": "NCT00493649",
        "secondaryId": "NCT01201265",
        "label": "Contradiction",
        "statement_text": "There was 1 MRSA infection in cohort 1 of the secondary trial and 4 in cohort 2 of the primary trial ",
        "statement_nums": [
            "2 of the",
            "1 MRSA infection",
            "4 in cohort",
            "1 of the"
        ],
        "premise_text": "NAUSEA AND VOMITING 1/486 (0.21%)Adverse Events 1: Total: 17/40 (42.50%) Anaemia 2/40 (5.00%) Febrile Neutropenia 3/40 (7.50%) Neutropenia 2/40 (5.00%) Thrombocytopenia 5/40 (12.50%) Pericardial Effusion 1/40 (2.50%) Abdominal Pain Lower 1/40 (2.50%) Disease Progression 6/40 (15.00%) Fatigue 1/40 (2.50%) Pyrexia 3/40 (7.50%) Septic Shock 1/40 (2.50%) ",
        "premise_nums": [
            "2/40 (5.00%)",
            "3/40 (7.50%)",
            "1/40 (2.50%)",
            "1/486 (0.21%)Adverse",
            "17/40 (42.50%)",
            "5/40 (12.50%)",
            "6/40 (15.00%)"
        ]
    },
    {
        "id": "456c6011-52bb-4c8b-9e82-e5a85cbbe0e3",
        "primaryId": "NCT00493649",
        "secondaryId": "NCT01201265",
        "label": "Contradiction",
        "statement_text": "There was 1 MRSA infection in cohort 1 of the secondary trial and 4 in cohort 2 of the primary trial ",
        "statement_nums": [
            "2 of the",
            "1 MRSA infection",
            "4 in cohort",
            "1 of the"
        ],
        "premise_text": "Streptococcal Infection 1/40 (2.50%)",
        "premise_nums": [
            "1/40 (2.50%)"
        ]
    },
    {
        "id": "0c0324d2-0672-45cb-b715-e51e48786afb",
        "primaryId": "NCT03618017",
        "statement_text": "the primary trial's intervention section does not describe the intervention dosage  frequency or duration ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "INTERVENTION 1: Recruitment Population Pre-randomization recruitment and enrollment ",
        "premise_nums": []
    },
    {
        "id": "b3bd3522-8731-448a-bade-a5a350697a98",
        "primaryId": "NCT01421472",
        "statement_text": "Over 9 patients in the primary trial suffered from adverse events associated with a low number of white blood cells present in the bloodstream ",
        "statement_nums": [
            "9 patients in"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Febrile Neutropenia * 5/67 (7.46%) ",
        "premise_nums": [
            "5/67 (7.46%)"
        ]
    },
    {
        "id": "8607e8c1-6e99-49be-a63e-e707856c805a",
        "primaryId": "NCT01572038",
        "secondaryId": "NCT00826267",
        "label": "Contradiction",
        "statement_text": "Each patient in the primary trial receives 3 different drugs  whereas in the secondary trial patients are given supportive-expressive group psychotherapy instead ",
        "statement_nums": [
            "3 different drugs"
        ],
        "premise_text": "INTERVENTION 1: Pertuzumab + Trastuzumab + Taxane Participants received pertuzumab and trastuzumab intravenously (IV) plus taxane chemotherapy once of every 3 weeks per treatment cycle until predefined study end  unacceptable toxicity  withdrawal of consent  disease progression  or death  whichever occurred first  Taxane chemotherapy was docetaxel  paclitaxel  or nab-paclitaxel  per the investigator's choice  INTERVENTION 1: Afatinib 50 mg Patients received continuous daily dosing with Afatinib 50 mg orally from Day 1 to Day 21 of each treatment course  2 treatment courses were to be given in the trial  INTERVENTION 2: Lapatinib 1500 mg ",
        "premise_nums": [
            "50 mg orally",
            "50 mg Patients",
            "21 of each",
            "3 weeks per",
            "2 treatment courses",
            "1 to Day"
        ]
    },
    {
        "id": "8607e8c1-6e99-49be-a63e-e707856c805a",
        "primaryId": "NCT01572038",
        "secondaryId": "NCT00826267",
        "label": "Contradiction",
        "statement_text": "Each patient in the primary trial receives 3 different drugs  whereas in the secondary trial patients are given supportive-expressive group psychotherapy instead ",
        "statement_nums": [
            "3 different drugs"
        ],
        "premise_text": "Patients received continuous daily dosing with Lapatinib 1500 mg orally from Day 1 to Day 21 of each treatment course  2 treatment courses were to be given in the trial ",
        "premise_nums": [
            "21 of each",
            "1500 mg orally",
            "2 treatment courses",
            "1 to Day"
        ]
    },
    {
        "id": "1c26e1a7-9d77-46ff-b1c6-179ece7c190f",
        "primaryId": "NCT03252431",
        "statement_text": "On average patients from both arms of the primary trial experienced Grade 4 Neutropenia for the same amount of time ",
        "statement_nums": [
            "4 Neutropenia for"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Duration in Days of Grade 4 Neutropenia in Chemotherapy Cycle 1 ",
        "premise_nums": [
            "4 Neutropenia in"
        ]
    },
    {
        "id": "1c26e1a7-9d77-46ff-b1c6-179ece7c190f",
        "primaryId": "NCT03252431",
        "statement_text": "On average patients from both arms of the primary trial experienced Grade 4 Neutropenia for the same amount of time ",
        "statement_nums": [
            "4 Neutropenia for"
        ],
        "label": "Entailment",
        "premise_text": "Eligible subjects were randomized in a 1:1 ratio  Subjects were dosed with either the F 627 20 mg/dose PFS or Neulasta® 6 mg/dose as the study drug in each chemotherapy cycle  Subjects remained in their assigned treatment arm throughout the study  Subjects were dosed subcutaneously (SC) 24 to 28 hours after receiving TC chemotherapy (75 mg/m2 docetaxel + 600 mg/m2 cyclophosphamide) on Day 2 of each chemotherapy cycle that the subject underwent (up to 4 cycles)  Grade 4 (severe) neutropenia was defined as ANC smaller than 0.5 × 109/L within the first 12 days of chemotherapy ",
        "premise_nums": [
            "6 mg/dose as",
            "109/L within",
            "1:1 ratio",
            "12 days of",
            "24 to 28",
            "600 mg/m2 cyclophosphamide",
            "20 mg/dose PFS",
            "2 of each"
        ]
    },
    {
        "id": "1c26e1a7-9d77-46ff-b1c6-179ece7c190f",
        "primaryId": "NCT03252431",
        "statement_text": "On average patients from both arms of the primary trial experienced Grade 4 Neutropenia for the same amount of time ",
        "statement_nums": [
            "4 Neutropenia for"
        ],
        "label": "Entailment",
        "premise_text": "Time frame: The first of 4, 21-day chemotherapy cycles (average 3 weeks)Results 1: Arm/Group Title: F-627 Arm/Group Description: F-627, 20 mg fixed dose pre-filled syringe  administered on Day 2 of each of 4 chemotherapy cycles  F-627: single dose pre-filled syringe Overall Number of Participants Analyzed: 197 Mean (Standard Deviation) Unit of Measure: days 0.2 (0.51) Results 2: Arm/Group Title: Neulasta Arm/Group Description: 6 mg fixed dose Neulasta   administered on Day 2 of each of 4 chemotherapy cycles Neulasta: single dose pre-filled syringe Overall Number of Participants Analyzed: 196 Mean (Standard Deviation) ",
        "premise_nums": [
            "20 mg fixed",
            "197 Mean (Standard",
            "196 Mean (Standard",
            "6 mg fixed",
            "21-day chemotherapy",
            "4 chemotherapy cycles",
            "2 of each"
        ]
    },
    {
        "id": "1c26e1a7-9d77-46ff-b1c6-179ece7c190f",
        "primaryId": "NCT03252431",
        "statement_text": "On average patients from both arms of the primary trial experienced Grade 4 Neutropenia for the same amount of time ",
        "statement_nums": [
            "4 Neutropenia for"
        ],
        "label": "Entailment",
        "premise_text": "Unit of Measure: days 0.2 (0.45)",
        "premise_nums": []
    },
    {
        "id": "0a156ee2-eb90-40d2-9802-27b9b4a42ff3",
        "primaryId": "NCT00191789",
        "statement_text": "In cohort 2 and 3 of the primary trial there was only case 1 of jaundice ",
        "statement_nums": [
            "2 and 3",
            "1 of jaundice"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 17/65 (26.15%) Febrile neutropenia 3/65 (4.62%) Neutropenia 2/65 (3.08%) Pancytopenia 1/65 (1.54%) Thrombocytopenia 1/65 (1.54%) Cardiac arrest 2/65 (3.08%) Myocardial infarction 1/65 (1.54%) Diarrhoea 5/65 (7.69%) Stomatitis 1/65 (1.54%) Vomiting 2/65 (3.08%) Fatigue 1/65 (1.54%) Jaundice 1/65 (1.54%) ",
        "premise_nums": [
            "17/65 (26.15%)",
            "3/65 (4.62%)",
            "5/65 (7.69%)",
            "2/65 (3.08%)",
            "1/65 (1.54%)"
        ]
    },
    {
        "id": "0a156ee2-eb90-40d2-9802-27b9b4a42ff3",
        "primaryId": "NCT00191789",
        "statement_text": "In cohort 2 and 3 of the primary trial there was only case 1 of jaundice ",
        "statement_nums": [
            "2 and 3",
            "1 of jaundice"
        ],
        "label": "Contradiction",
        "premise_text": "Neutropenic infection 2/65 (3.08%)",
        "premise_nums": [
            "2/65 (3.08%)"
        ]
    },
    {
        "id": "82895f11-37bf-4d03-8de2-84818d93cce0",
        "primaryId": "NCT00266110",
        "secondaryId": "NCT00879086",
        "label": "Entailment",
        "statement_text": "the primary trial and the secondary trial have entirely different adverse event reports ",
        "statement_nums": [],
        "premise_text": "Adverse Events 1: Total: 2/17 (11.76%) Nausea * 1/17 (5.88%) Pain - Abdomen NOS * 1/17 (5.88%) Constipation * 1/17 (5.88%) Adverse Events 1: Total: 19/51 (37.25%) Febrile neutropenia 6/51 (11.76%) Anaemia 1/51 (1.96%) Leukopenia 1/51 (1.96%) Neutropenia 1/51 (1.96%) Thrombocytopenia 0/51 (0.00%) Pericarditis 1/51 (1.96%) Atrial flutter 0/51 (0.00%) Cardiac failure congestive 0/51 (0.00%) ",
        "premise_nums": [
            "6/51 (11.76%)",
            "1/51 (1.96%)",
            "0/51 (0.00%)",
            "19/51 (37.25%)",
            "1/17 (5.88%)",
            "2/17 (11.76%)"
        ]
    },
    {
        "id": "82895f11-37bf-4d03-8de2-84818d93cce0",
        "primaryId": "NCT00266110",
        "secondaryId": "NCT00879086",
        "label": "Entailment",
        "statement_text": "the primary trial and the secondary trial have entirely different adverse event reports ",
        "statement_nums": [],
        "premise_text": "Visual impairment 0/51 (0.00%)Dysphagia 1/51 (1.96%) Abdominal pain 0/51 (0.00%) Chills 1/51 (1.96%) Adverse Events 2: Total: 17/50 (34.00%) Febrile neutropenia 0/50 (0.00%) Anaemia 1/50 (2.00%) Leukopenia 0/50 (0.00%) Neutropenia 1/50 (2.00%) Thrombocytopenia 1/50 (2.00%) Pericarditis 0/50 (0.00%) Atrial flutter 1/50 (2.00%) Cardiac failure congestive 1/50 (2.00%) ",
        "premise_nums": [
            "1/51 (1.96%)",
            "1/50 (2.00%)",
            "0/50 (0.00%)",
            "0/51 (0.00%)Dysphagia",
            "17/50 (34.00%)"
        ]
    },
    {
        "id": "82895f11-37bf-4d03-8de2-84818d93cce0",
        "primaryId": "NCT00266110",
        "secondaryId": "NCT00879086",
        "label": "Entailment",
        "statement_text": "the primary trial and the secondary trial have entirely different adverse event reports ",
        "statement_nums": [],
        "premise_text": "Visual impairment 1/50 (2.00%)Dysphagia 0/50 (0.00%) Abdominal pain 1/50 (2.00%) Chills 0/50 (0.00%) ",
        "premise_nums": [
            "0/50 (0.00%)",
            "1/50 (2.00%)Dysphagia"
        ]
    },
    {
        "id": "f94643de-7122-4a58-972d-b0bb7e59d441",
        "primaryId": "NCT00878709",
        "secondaryId": "NCT02447003",
        "label": "Contradiction",
        "statement_text": "the primary trial had a total of 3 patients experiencing Pancreatic Cancer  the secondary trial had 0.",
        "statement_nums": [
            "3 patients experiencing"
        ],
        "premise_text": "Adverse Events 1: Total: 103/1408 (7.32%) Anaemia 1/1408 (0.07%) Angina pectoris 1/1408 (0.07%) Myocardial infarction 1/1408 (0.07%) Atrial fibrillation 0/1408 (0.00%) Sinus tachycardia 0/1408 (0.00%) Tachycardia 0/1408 (0.00%) Vertigo 0/1408 (0.00%) Diarrhoea 22/1408 (1.56%) Vomiting 12/1408 (0.85%) Nausea 4/1408 (0.28%) Abdominal pain 2/1408 (0.14%) ",
        "premise_nums": [
            "12/1408 (0.85%)",
            "2/1408 (0.14%)",
            "0/1408 (0.00%)",
            "103/1408 (7.32%)",
            "22/1408 (1.56%)",
            "4/1408 (0.28%)",
            "1/1408 (0.07%)"
        ]
    },
    {
        "id": "f94643de-7122-4a58-972d-b0bb7e59d441",
        "primaryId": "NCT00878709",
        "secondaryId": "NCT02447003",
        "label": "Contradiction",
        "statement_text": "the primary trial had a total of 3 patients experiencing Pancreatic Cancer  the secondary trial had 0.",
        "statement_nums": [
            "3 patients experiencing"
        ],
        "premise_text": "Pancreatitis 2/1408 (0.14%)Adverse Events 2: Total: 85/1408 (6.04%) Anaemia 1/1408 (0.07%) Angina pectoris 0/1408 (0.00%) Myocardial infarction 1/1408 (0.07%) Atrial fibrillation 1/1408 (0.07%) Sinus tachycardia 1/1408 (0.07%) Tachycardia 1/1408 (0.07%) Vertigo 1/1408 (0.07%) Diarrhoea 1/1408 (0.07%) Vomiting 1/1408 (0.07%) Nausea 1/1408 (0.07%) ",
        "premise_nums": [
            "0/1408 (0.00%)",
            "2/1408 (0.14%)Adverse",
            "1/1408 (0.07%)",
            "85/1408 (6.04%)"
        ]
    },
    {
        "id": "f94643de-7122-4a58-972d-b0bb7e59d441",
        "primaryId": "NCT00878709",
        "secondaryId": "NCT02447003",
        "label": "Contradiction",
        "statement_text": "the primary trial had a total of 3 patients experiencing Pancreatic Cancer  the secondary trial had 0.",
        "statement_nums": [
            "3 patients experiencing"
        ],
        "premise_text": "Abdominal pain 0/1408 (0.00%)Pancreatitis 1/1408 (0.07%) Adverse Events 1: Total: 46/170 (27.06%) Anaemia 1/170 (0.59%) Febrile neutropenia 1/170 (0.59%) Cardiac tamponade 1/170 (0.59%) Myocarditis 1/170 (0.59%) Pericardial effusion 2/170 (1.18%) Pericarditis 1/170 (0.59%) Colitis 1/170 (0.59%) Constipation 1/170 (0.59%) Diarrhoea 0/170 (0.00%) ",
        "premise_nums": [
            "0/1408 (0.00%)Pancreatitis",
            "0/170 (0.00%)",
            "46/170 (27.06%)",
            "1/170 (0.59%)",
            "2/170 (1.18%)",
            "1/1408 (0.07%)"
        ]
    },
    {
        "id": "f94643de-7122-4a58-972d-b0bb7e59d441",
        "primaryId": "NCT00878709",
        "secondaryId": "NCT02447003",
        "label": "Contradiction",
        "statement_text": "the primary trial had a total of 3 patients experiencing Pancreatic Cancer  the secondary trial had 0.",
        "statement_nums": [
            "3 patients experiencing"
        ],
        "premise_text": "Gastroenteritis eosinophilic 0/170 (0.00%)Intestinal obstruction 0/170 (0.00%) Adverse Events 2: Total: 0/1 (0.00%) Anaemia 0/1 (0.00%) Febrile neutropenia 0/1 (0.00%) Cardiac tamponade 0/1 (0.00%) Myocarditis 0/1 (0.00%) Pericardial effusion 0/1 (0.00%) Pericarditis 0/1 (0.00%) Colitis 0/1 (0.00%) Constipation 0/1 (0.00%) Diarrhoea 0/1 (0.00%) ",
        "premise_nums": [
            "0/1 (0.00%)",
            "0/170 (0.00%)Intestinal"
        ]
    },
    {
        "id": "f94643de-7122-4a58-972d-b0bb7e59d441",
        "primaryId": "NCT00878709",
        "secondaryId": "NCT02447003",
        "label": "Contradiction",
        "statement_text": "the primary trial had a total of 3 patients experiencing Pancreatic Cancer  the secondary trial had 0.",
        "statement_nums": [
            "3 patients experiencing"
        ],
        "premise_text": "Gastroenteritis eosinophilic 0/1 (0.00%)Intestinal obstruction 0/1 (0.00%) Nausea 0/1 (0.00%) ",
        "premise_nums": [
            "0/1 (0.00%)Intestinal"
        ]
    },
    {
        "id": "1485315b-3169-42a3-a672-6f7963d49a51",
        "primaryId": "NCT01869764",
        "secondaryId": "NCT02556632",
        "label": "Entailment",
        "statement_text": "Every participant in the secondary trial and the primary trial undergoes Laboratory Biomarker Analysis ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Arm I (Omega-3 Fatty Acid) Patients receive omega-3 fatty acid PO daily for 7-14 days  omega-3 fatty acid: Given PO laboratory biomarker analysis: Correlative studies INTERVENTION 2: Arm II (Placebo) Patients receive placebo PO daily for 7-14 days  placebo: Given PO laboratory biomarker analysis: Correlative studies INTERVENTION 1: Arm I (Curcumin-based Gel) Patients apply curcumin-based gel topically TID approximately every 4-6 hours beginning on the first day of radiation therapy and continuing until 1 week after completion of radiation therapy  Curcumin-based Gel: Applied topically Laboratory Biomarker Analysis: Correlative studies Questionnaire Administration: Ancillary studies INTERVENTION 2: Arm II (HPR Plus) ",
        "premise_nums": [
            "1 week after",
            "7-14 days",
            "6 hours beginning",
            "3 fatty acid:",
            "4-6 hours",
            "3 Fatty Acid)"
        ]
    },
    {
        "id": "1485315b-3169-42a3-a672-6f7963d49a51",
        "primaryId": "NCT01869764",
        "secondaryId": "NCT02556632",
        "label": "Entailment",
        "statement_text": "Every participant in the secondary trial and the primary trial undergoes Laboratory Biomarker Analysis ",
        "statement_nums": [],
        "premise_text": "Patients apply HPR Plus™ topically TID approximately every 4-6 hours beginning on the first day of radiation therapy and continuing until 1 week after completion of radiation therapy Dermatologic Complications Management: Apply HPR Plus topically Laboratory Biomarker Analysis: Correlative studies Questionnaire Administration: Ancillary studies ",
        "premise_nums": [
            "1 week after",
            "6 hours beginning",
            "4-6 hours"
        ]
    },
    {
        "id": "b4ef27ca-52b4-4af3-9b60-e9e0285e0e86",
        "primaryId": "NCT03719677",
        "statement_text": "Potential participants will be considered regardless of the hormone receptivity of their breast cancer ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Will not exclude participants based on hormone receptivity  one exception is that we will exclude HER2 positive BCS ",
        "premise_nums": [
            "2 positive BCS"
        ]
    },
    {
        "id": "769bb3b2-9d2d-4dad-bd59-0042c55ac1ee",
        "primaryId": "NCT03371732",
        "statement_text": "patients with Karnofsky Index = 72 are eligible for the primary trial ",
        "statement_nums": [
            "72 are eligible"
        ],
        "label": "Entailment",
        "premise_text": "Inclusion Criteria : women with primary breast cancer  without ongoing support for substance use  An AUDIT-C score greater than 1 or more than one cigarette smoked per day  Individuals able to consent to benefit of intervention focused on substance use  (Karnofsky Index greater than 70). ",
        "premise_nums": [
            "1 or more"
        ]
    },
    {
        "id": "426196d8-44ab-4c5c-8f81-5cb12345ad69",
        "primaryId": "NCT00899574",
        "secondaryId": "NCT01007942",
        "label": "Entailment",
        "statement_text": "the primary trial uses different inclusion criteria for its cohorts  the secondary trial only uses one set on inclusion criteria for all cohorts ",
        "statement_nums": [],
        "premise_text": "Inclusion Criteria: (Cohort 1) Concurrent systemic cancer therapy (hormones  biologics or chemotherapy) is allowed if distant metastases have been non-progressing (stable or responding) on that regimen for greater than or = 12 weeks and skin metastases are non-responsive (stable or progressing) as assessed by the investigator  (Cohort 2) Any concurrent systemic therapy is allowed Inclusion Criteria: Histologically or cytologically confirmed invasive breast carcinoma with locally recurrent or radiological evidence of metastatic disease  Locally recurrent disease must not be amenable to resection with curative intent  HER2+ status defined as IHC 3+ staining or in situ hybridization positive Patients with resistance to trastuzumab Prior taxane therapy ",
        "premise_nums": [
            "12 weeks and"
        ]
    },
    {
        "id": "426196d8-44ab-4c5c-8f81-5cb12345ad69",
        "primaryId": "NCT00899574",
        "secondaryId": "NCT01007942",
        "label": "Entailment",
        "statement_text": "the primary trial uses different inclusion criteria for its cohorts  the secondary trial only uses one set on inclusion criteria for all cohorts ",
        "statement_nums": [],
        "premise_text": "Patients with an ECOG performance status of 0 - 2Patients with measurable disease as per RECIST criteria Documentation of negative pregnancy test for patients of child bearing potential prior to enrollment within 7 days prior to randomization  Sexually active pre-menopausal women must use adequate contraceptive measures  excluding estrogen containing contraceptives  while on study; Patients must meet laboratory criteria defined in the study within 21 days prior to randomization Exclusion Criteria: Prior mTOR inhibitors or vinca alkaloid agents for the treatment of cancer More than three prior chemotherapy lines for advanced disease  ",
        "premise_nums": [
            "7 days prior",
            "21 days prior"
        ]
    },
    {
        "id": "426196d8-44ab-4c5c-8f81-5cb12345ad69",
        "primaryId": "NCT00899574",
        "secondaryId": "NCT01007942",
        "label": "Entailment",
        "statement_text": "the primary trial uses different inclusion criteria for its cohorts  the secondary trial only uses one set on inclusion criteria for all cohorts ",
        "statement_nums": [],
        "premise_text": "Symptomatic CNS metastases or evidence of leptomeningeal disease  Previously treated asymptomatic CNS metastases are allowed provided that the last treatment for CNS metastases was completed greater than 8 weeks prior to randomizationImpairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral everolimus Peripheral neuropathy grade 2 at randomization Active cardiac disease History of cardiac dysfunction Any malignancy within 5 years prior to randomization  with the exception of adequately treated in-situ carcinoma of the cervix uteri  basal or squamous cell carcinoma or non-melanomatous skin cancer Known hypersensitivity to any study medication ",
        "premise_nums": [
            "8 weeks prior",
            "2 at randomization",
            "5 years prior"
        ]
    },
    {
        "id": "426196d8-44ab-4c5c-8f81-5cb12345ad69",
        "primaryId": "NCT00899574",
        "secondaryId": "NCT01007942",
        "label": "Entailment",
        "statement_text": "the primary trial uses different inclusion criteria for its cohorts  the secondary trial only uses one set on inclusion criteria for all cohorts ",
        "statement_nums": [],
        "premise_text": "Breastfeeding or pregnant",
        "premise_nums": []
    },
    {
        "id": "bcf433b6-4029-4d00-9ccf-d8d94f1722d8",
        "primaryId": "NCT00365365",
        "secondaryId": "NCT00005908",
        "label": "Contradiction",
        "statement_text": "the primary trial and the secondary trial only recorded one type of acute adverse event ",
        "statement_nums": [],
        "premise_text": "Adverse Events 1: Total: 23/78 (29.49%) Febrile neutropenia * 4/78 (5.13%) Neutropenia * 1/78 (1.28%) Thrombocytopenia * 0/78 (0.00%) Acute coronary syndrome * 1/78 (1.28%) Cardiac failure congestive * 1/78 (1.28%) Myocardial infarction * 1/78 (1.28%) Cardiomyopathy * 0/78 (0.00%) Abdominal pain * 1/78 (1.28%) Diarrhoea * 1/78 (1.28%) Upper gastrointestinal haemorrhage * 1/78 (1.28%) Adverse Events 1: ",
        "premise_nums": [
            "23/78 (29.49%)",
            "0/78 (0.00%)",
            "1/78 (1.28%)",
            "4/78 (5.13%)"
        ]
    },
    {
        "id": "bcf433b6-4029-4d00-9ccf-d8d94f1722d8",
        "primaryId": "NCT00365365",
        "secondaryId": "NCT00005908",
        "label": "Contradiction",
        "statement_text": "the primary trial and the secondary trial only recorded one type of acute adverse event ",
        "statement_nums": [],
        "premise_text": "Total: 29/30 (96.67%)Febrile neutropenia [1]3/30 (10.00%) Lymphatics 1/30 (3.33%) Diarrhea (without colostomy) 5/30 (16.67%) Abdominal pain or cramping 2/30 (6.67%) Colitis 1/30 (3.33%) Dehydration 1/30 (3.33%) Nausea 1/30 (3.33%) Stomatitis/pharyngitis (oral/pharyngeal/mucositis) 1/30 (3.33%) Vomiting 1/30 (3.33%) ",
        "premise_nums": [
            "5/30 (16.67%)",
            "3/30 (10.00%)",
            "1/30 (3.33%)",
            "29/30 (96.67%)Febrile",
            "2/30 (6.67%)"
        ]
    },
    {
        "id": "1268edfc-cce2-4f07-9fbb-392341b7f399",
        "primaryId": "NCT01605396",
        "statement_text": "The Ridaforolimus + Dalotuzumab + Exemestane group of the primary trial had a median PFS of over 5 months ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: 1. Progression-free Survival (PFS) According to Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Based on Blinded Independent Central Review (BICR) ",
        "premise_nums": []
    },
    {
        "id": "58ccfd13-aa6d-4604-bf3d-c69270fe50d2",
        "primaryId": "NCT01276041",
        "statement_text": "1 patient in the primary trial died in an event not associated with a specifc CTCAE term ",
        "statement_nums": [
            "1 patient in"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 18/70 (25.71%) Cardiac arrest 1/70 (1.43%) Pericardial effusion 1/70 (1.43%) Ear pain 1/70 (1.43%) Blurred vision 1/70 (1.43%) Eye disorders - Other  specify 2/70 (2.86%) Abdominal Pain 5/70 (7.14%) Colitis 1/70 (1.43%) Diarrhea 2/70 (2.86%) Nausea 2/70 (2.86%) Death NOS 1/70 (1.43%) Edema limbs 1/70 (1.43%) Fatigue 3/70 (4.29%) ",
        "premise_nums": [
            "5/70 (7.14%)",
            "1/70 (1.43%)",
            "2/70 (2.86%)",
            "3/70 (4.29%)",
            "18/70 (25.71%)"
        ]
    },
    {
        "id": "a6e4f4f3-72cc-4617-bf8b-7eac1c8b8249",
        "primaryId": "NCT00182793",
        "secondaryId": "NCT00509769",
        "label": "Contradiction",
        "statement_text": "The majority of patients in the primary trial and the secondary trial experienced an adverse event ",
        "statement_nums": [],
        "premise_text": "Adverse Events 1: Total: 24/32 (75.00%) Adverse Events 1: Total: 30/112 (26.79%) Thrombocytopenia 1/112 (0.89%) Dysphagia 1/112 (0.89%) Haemorrhoidal haemorrhage 1/112 (0.89%) Oesophageal stenosis 1/112 (0.89%) Upper gastrointestinal haemorrhage 1/112 (0.89%) Asthenia 1/112 (0.89%) Disease progression 1/112 (0.89%) Hepatotoxicity 1/112 (0.89%) Cellulitis 3/112 (2.68%) Pneumonia 2/112 (1.79%) ",
        "premise_nums": [
            "30/112 (26.79%)",
            "3/112 (2.68%)",
            "1/112 (0.89%)",
            "24/32 (75.00%)",
            "2/112 (1.79%)"
        ]
    },
    {
        "id": "a6e4f4f3-72cc-4617-bf8b-7eac1c8b8249",
        "primaryId": "NCT00182793",
        "secondaryId": "NCT00509769",
        "label": "Contradiction",
        "statement_text": "The majority of patients in the primary trial and the secondary trial experienced an adverse event ",
        "statement_nums": [],
        "premise_text": "Osteomyelitis 1/112 (0.89%)",
        "premise_nums": [
            "1/112 (0.89%)"
        ]
    },
    {
        "id": "8c84c96f-1635-40dc-839b-fc937ed566a2",
        "primaryId": "NCT01105312",
        "statement_text": "Patients with measurable diseases are only eligible for phase 2 of the primary trial ",
        "statement_nums": [
            "2 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Measurable or non-measurable disease for phase I study (The Phase I portion of this study closed and the Phase II portion of the study opened as per NCCTG Addendum 6, effective January 23, 2012.) Measurable disease only for phase II study ",
        "premise_nums": []
    },
    {
        "id": "7b48355e-3b9c-4cca-b7fa-1cbd612d1523",
        "primaryId": "NCT00320710",
        "statement_text": "There was no adverse event in cohort 2 of the primary trial which occurred in more than 5% of patients ",
        "statement_nums": [
            "5% of",
            "2 of the"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 2: Anaemia 3/202 (1.49%) Febrile neutropenia 2/202 (0.99%) Leukocytosis 0/202 (0.00%) Leukopenia 0/202 (0.00%) Neutropenia 0/202 (0.00%) Pancytopenia 1/202 (0.50%) Atrial fibrillation 1/202 (0.50%) Cardiac failure congestive 1/202 (0.50%) Palpitations 1/202 (0.50%) Pericardial effusion 1/202 (0.50%) Supraventricular tachycardia 1/202 (0.50%) ",
        "premise_nums": [
            "3/202 (1.49%)",
            "2/202 (0.99%)",
            "1/202 (0.50%)",
            "0/202 (0.00%)"
        ]
    },
    {
        "id": "3d188d93-13c6-48f3-b231-dcdeef81080e",
        "primaryId": "NCT00617539",
        "statement_text": "Presence of Extracranial metastases is part of the exclusion critera for the primary trial ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "DISEASE CHARACTERISTICS: Histologically or cytologically confirmed breast cancer with radiographically confirmed metastases to the brain Extracranial metastases allowed ",
        "premise_nums": []
    },
    {
        "id": "d7e81d80-5cbf-4969-be00-4fdf17aa4eb9",
        "primaryId": "NCT01209195",
        "statement_text": "Lower doses of MM-121 and Paclitaxel are utilised in cohort1 of the primary trial than in cohort 2.",
        "statement_nums": [
            "121 and Paclitaxel",
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "INTERVENTION 1: Part 1: Dose Escalation: Cohort 1 MM-121 - 20 mg/kg loading dose followed by 12 mg/kg weekly IV Paclitaxel - 80mg/m2 weekly IV INTERVENTION 2: Part 1: Dose Escalation: Cohort 2 MM-121 - 40 mg/kg loading dose followed by 20 mg/kg weekly IV Paclitaxel - 80mg/m2 weekly IV ",
        "premise_nums": [
            "2 MM-121",
            "80mg/m2 weekly",
            "2 weekly IV",
            "40 mg/kg loading",
            "20 mg/kg weekly",
            "12 mg/kg weekly",
            "1 MM-121",
            "20 mg/kg loading"
        ]
    },
    {
        "id": "2206dc2a-93da-4c11-b110-81f9c39af807",
        "primaryId": "NCT00101400",
        "statement_text": "A female with Hemoglobin greater than 10.0 g/dl  Absolute neutrophil count 1,733/mm3, platelet count = 100,000/¬¨¬µl and total bilirubin greater than 1.6 x ULN are eligilbe for the primary trial ",
        "statement_nums": [
            "than 10.0 g/dl",
            "1,733/mm3, platelet",
            "100,000/¬¨¬µl and",
            "than 1.6 x ULN"
        ],
        "label": "Entailment",
        "premise_text": "Hemoglobin greater than 9.0 g/dl Absolute neutrophil count (ANC) greater than 1,500/mm3 Platelet count = 100,000/µl Total bilirubin =1.5 x the upper limit of normal  ",
        "premise_nums": [
            "3 Platelet count",
            "than 9.0 g/dl",
            "1,500/mm3 Platelet",
            "100,000/µl Total",
            "5 x the"
        ]
    },
    {
        "id": "6173faf3-f845-4cf1-94a9-756d1bff48bb",
        "primaryId": "NCT01419197",
        "statement_text": "There was one patient in the primary trial who suffered from a significant decrease in the number of granulocytes in their blood ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Adverse Events 2: Granulocytopenia 1/184 (0.54%) ",
        "premise_nums": [
            "1/184 (0.54%)"
        ]
    },
    {
        "id": "512c72ab-f1b3-450d-8167-6e0d8d2bf5dd",
        "primaryId": "NCT02006979",
        "statement_text": "Only one cohort of the primary trial needs to receive manual lymph drainage prior to each cycle of anthracyclines ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "INTERVENTION 1: Exercise an acute bout of exercise performed 24 hours prior to each cycle of anthracyclines and no exercise for 48 hours post exercise INTERVENTION 2: Usual Care no exercise for 72 hours prior or 48 hours post each cycle of anthracyclines ",
        "premise_nums": [
            "72 hours prior",
            "24 hours prior",
            "48 hours post"
        ]
    },
    {
        "id": "ee54ca2d-ccd9-4ceb-b6e7-c1ee10de8104",
        "primaryId": "NCT00849472",
        "statement_text": "More than a dozen the primary trial participants are classified as having Pathologic Complete Response (pCR) in the Breast and Nodes ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Number of Participants With Pathologic Complete Response (pCR) in the Breast and Nodes pCR was defined as no histologic evidence of invasive tumor cells in the surgical breast specimen  axillary nodes  or sentinel node identified after neoadjuvant chemotherapy  Time frame: From the start of the study until the time of surgery (average of 221.9 days [standard deviation of 23.65 days] after study entry) Results 1: Arm/Group Title: AC  Followed by Weekly Paclitaxel and Concurrent Pazopanib ",
        "premise_nums": [
            "9 days [standard"
        ]
    },
    {
        "id": "ee54ca2d-ccd9-4ceb-b6e7-c1ee10de8104",
        "primaryId": "NCT00849472",
        "statement_text": "More than a dozen the primary trial participants are classified as having Pathologic Complete Response (pCR) in the Breast and Nodes ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Arm/Group Description: Participants were treated with intravenous (IV) doxorubicin (60 milligrams per meters squared [mg/m^2]) and cyclophosphamide (AC) (600 mg/m^2) every 21 days for 4 cycles  This was followed by weekly paclitaxel (WP) 80 mg/m^2 IV on Days 1, 8, and 15 every 28 days for 4 cycles given concurrently with oral pazopanib 800 mg (2 tablets taken at the same time each day  either 1 hour before or 2 hours after a meal) taken daily and continuing until 7 days before surgery  Pazopanib was resumed at the same oral dose 4-6 weeks after surgery and was continued daily for 6 months ",
        "premise_nums": [
            "21 days for",
            "800 mg (2",
            "2 hours after",
            "80 mg/m^2",
            "1 hour before",
            "6 weeks after",
            "60 milligrams per",
            "4-6 weeks",
            "7 days before",
            "4 cycles given",
            "2 IV on",
            "15 every 28"
        ]
    },
    {
        "id": "ee54ca2d-ccd9-4ceb-b6e7-c1ee10de8104",
        "primaryId": "NCT00849472",
        "statement_text": "More than a dozen the primary trial participants are classified as having Pathologic Complete Response (pCR) in the Breast and Nodes ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Overall Number of Participants Analyzed: 93Measure Type: Number Unit of Measure: Participants 16 ",
        "premise_nums": []
    },
    {
        "id": "87987ebb-6799-4d1d-8529-d33c6b7799f8",
        "primaryId": "NCT00548184",
        "statement_text": "64 of the study participants in the primary trial receiving lapatinib 1000mg daily and trauzumab 4mg/kg loading dose and then 2mg/kg every week experienced at least Near Complete Pathologic Response  or better  after 12 weeks ",
        "statement_nums": [
            "2mg/kg every",
            "4mg/kg loading",
            "64 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Pathologic Assessment After Study Treatment Pathologic Assessment After 12 weeks of lapatinib and trastuzumab with or without endocrine therapy  Pathologic complete response: no invasive cancer in the residual breast  Near pathologic complete response: residual disease of less than 1 cm in breast  Time frame: 12 weeks Results 1: Arm/Group Title: Lapatinib + Trastuzumab Arm/Group Description: All study participants received lapatinib 1000mg daily and trauzumab 4mg/kg loading dose and then 2mg/kg every week Overall Number of Participants Analyzed: 64 Measure Type: Number ",
        "premise_nums": [
            "12 weeks Results",
            "12 weeks of",
            "2mg/kg every",
            "4mg/kg loading",
            "64 Measure Type:",
            "1 cm in"
        ]
    },
    {
        "id": "87987ebb-6799-4d1d-8529-d33c6b7799f8",
        "primaryId": "NCT00548184",
        "statement_text": "64 of the study participants in the primary trial receiving lapatinib 1000mg daily and trauzumab 4mg/kg loading dose and then 2mg/kg every week experienced at least Near Complete Pathologic Response  or better  after 12 weeks ",
        "statement_nums": [
            "2mg/kg every",
            "4mg/kg loading",
            "64 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Unit of Measure: participants Complete Pathologic Response: 18Near Complete Pathologic Response: 16 Not Pathologic response: 30 ",
        "premise_nums": [
            "16 Not Pathologic"
        ]
    },
    {
        "id": "bf94f208-a29b-4d8f-92a7-3cb8241ce344",
        "primaryId": "NCT00097721",
        "secondaryId": "NCT00896649",
        "label": "Contradiction",
        "statement_text": "Black women cannot take part in the secondary trial or the primary trial ",
        "statement_nums": [],
        "premise_text": "Inclusion Criteria: Female patients with histologically or cytologically confirmed carcinoma of the breast Patients with advanced/metastatic disease that is not amenable to curative therapy (either surgery or radiation therapy) Patients must have measurable disease by the RECIST criteria  defined as at least one lesion that can be accurately measured in at least one diameter (at least 10 mm in longest diameter (LD) by spiral computer tomography (CT) scan  or at least 20 mm by standard techniques; If the only measurable lesion is a lymph node  it must measure at least 20 mm in LD  If a single lesion is identified as the target lesion  a cytological or histological confirmation of breast carcinoma is required  ",
        "premise_nums": [
            "20 mm by",
            "20 mm in",
            "10 mm in"
        ]
    },
    {
        "id": "bf94f208-a29b-4d8f-92a7-3cb8241ce344",
        "primaryId": "NCT00097721",
        "secondaryId": "NCT00896649",
        "label": "Contradiction",
        "statement_text": "Black women cannot take part in the secondary trial or the primary trial ",
        "statement_nums": [],
        "premise_text": "Patients must have had prior treatment with an anthracycline and a taxane (either sequential or in combination) and may have had prior treatment with other agents as well Patients must have progressed within six months of the last dose of chemotherapy  or experienced disease progression while receiving chemotherapy for advanced/metastatic disease  Resolution of all chemotherapy or radiation-related toxicities to less than grade 1 severity Age 18 years Eastern Cooperative Oncology Group (ECOG) Performance Status (APPENDIX 4) of 0 or 1 Life expectancy of 3 months Adequate renal function as evidenced by serum creatinine 1.5 mg/dL or calculated creatinine clearance 50 mL/minute (min) per the Cockcroft and Gault formula ",
        "premise_nums": [
            "creatinine 1.5 mg/dL",
            "0 or 1",
            "1 severity Age",
            "18 years Eastern",
            "50 mL/minute",
            "3 months Adequate"
        ]
    },
    {
        "id": "bf94f208-a29b-4d8f-92a7-3cb8241ce344",
        "primaryId": "NCT00097721",
        "secondaryId": "NCT00896649",
        "label": "Contradiction",
        "statement_text": "Black women cannot take part in the secondary trial or the primary trial ",
        "statement_nums": [],
        "premise_text": "Adequate bone marrow function as evidenced by absolute neutrophil count (ANC) 1.5 x 10^9/L, hemoglobin 10.0 g/dL (a hemoglobin smaller than 10.0 g/dL would be acceptable if it can be corrected by growth factor or transfusion)  and platelet count 100 x 10^9/LAdequate liver function as evidenced by bilirubin 1.5 mg/dL and alkaline phosphatase  alanine transaminase (ALT)  and aspartate transaminase (AST) 3 times the upper limits of normal (ULN) (in the case of liver metastases 5 x ULN) ",
        "premise_nums": [
            "than 10.0 g/dL",
            "9/L, hemoglobin",
            "bilirubin 1.5 mg/dL",
            "5 x ULN)",
            "100 x 10",
            "3 times the",
            "hemoglobin 10.0 g/dL",
            "9/LAdequate liver"
        ]
    },
    {
        "id": "bf94f208-a29b-4d8f-92a7-3cb8241ce344",
        "primaryId": "NCT00097721",
        "secondaryId": "NCT00896649",
        "label": "Contradiction",
        "statement_text": "Black women cannot take part in the secondary trial or the primary trial ",
        "statement_nums": [],
        "premise_text": "Patients willing and able to complete the FACT-B questionnaire  Analgesic Diary  Pain VAS  and the tumor-related symptomatic assessmentPatients willing and able to comply with the study protocol for the duration of the study A sample from the diagnostic biopsy (paraffin block) must be available Written informed consent prior to any study-specific screening procedures with the understanding that the patient may withdraw consent at any time without prejudice Exclusion Criteria: Patients who have received chemotherapy  radiation  hormonal therapy  or Herceptin within 2 weeks of E7389 treatment start Radiation therapy encompassing greater than 10% of marrow Failure to recover from any chemotherapy related or other therapy related toxicity at study entry that is deemed to be clinically significant by the study investigator Prior treatment with Mitomycin C or nitrosoureas ",
        "premise_nums": [
            "7389 treatment start",
            "2 weeks of",
            "E7389 treatment",
            "10% of"
        ]
    },
    {
        "id": "bf94f208-a29b-4d8f-92a7-3cb8241ce344",
        "primaryId": "NCT00097721",
        "secondaryId": "NCT00896649",
        "label": "Contradiction",
        "statement_text": "Black women cannot take part in the secondary trial or the primary trial ",
        "statement_nums": [],
        "premise_text": "Prior high dose chemotherapy with hematopoietic stem cell rescue in the past two yearsPulmonary lymphangitic involvement that results in pulmonary dysfunction requiring active treatment  including the use of oxygen Active symptomatic brain metastasis; Patients with central Nervous System (CNS) metastasis are considered eligible if they have completed local therapy and discontinued from corticosteroids for at least two weeks before starting treatment with E7389 Patients with meningeal carcinomatosis Patients who require therapeutic anti-coagulant therapy with Warfarin or related compounds; Mini dose warfarin for catheter related thrombosis prophylaxis is permitted ",
        "premise_nums": [
            "E7389 Patients",
            "7389 Patients with"
        ]
    },
    {
        "id": "bf94f208-a29b-4d8f-92a7-3cb8241ce344",
        "primaryId": "NCT00097721",
        "secondaryId": "NCT00896649",
        "label": "Contradiction",
        "statement_text": "Black women cannot take part in the secondary trial or the primary trial ",
        "statement_nums": [],
        "premise_text": "Women who are pregnant or breast-feeding; Women of childbearing potential with either a positive pregnancy test at Screening or no pregnancy test  Women of childbearing potential unless (1) surgically sterile or (2) using adequate measures of contraception in the opinion of the Investigator  Postmenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential Severe /uncontrolled intercurrent illness/infection Significant cardiovascular impairment (history of congestive heart failure greater than NYHA grade II  unstable angina or myocardial infarction within the past six months  or serious cardiac arrhythmia) Patients with organ allografts Patients with known positive HIV status ",
        "premise_nums": [
            "(1) surgically",
            "(2) using",
            "12 months to"
        ]
    },
    {
        "id": "bf94f208-a29b-4d8f-92a7-3cb8241ce344",
        "primaryId": "NCT00097721",
        "secondaryId": "NCT00896649",
        "label": "Contradiction",
        "statement_text": "Black women cannot take part in the secondary trial or the primary trial ",
        "statement_nums": [],
        "premise_text": "Patients who have had a prior malignancy  other than carcinoma in situ of the cervix  or non-melanoma skin cancer  unless the prior malignancy was diagnosed and definitively treated 5 years previously with no subsequent evidence of recurrencePatients with pre-existing neuropathy greater than Grade 1 Patients with a hypersensitivity to halichondrin B and/or halichondrin B chemical derivative Patients who participated in a prior E7389 clinical trial Patients with other significant disease or disorders that  in the Investigator's opinion  would exclude the patient from the study PATIENT CHARACTERISTICS: Has 1 of the following racial or ethnic backgrounds based on the patient's country of birth or the mother and father's country of birth: Hispanic Haitian Creole African American Caucasian ",
        "premise_nums": [
            "1 Patients with",
            "E7389 clinical",
            "5 years previously",
            "7389 clinical trial",
            "1 of the"
        ]
    },
    {
        "id": "c68f6822-24fa-44b5-bf63-c272a8031fab",
        "primaryId": "NCT02988986",
        "statement_text": "Patients must have either AST or ALT smaller than 1.5 ULN to participate in the primary trial ",
        "statement_nums": [
            "than 1.5 ULN to"
        ],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria: Hepatic status: Serum total bilirubin 1 x upper limit of normal (ULN; in the case of known Gilbert's syndrome  a higher serum total bilirubin [smaller than 1.5 x ULN] is allowed)  aspartate aminotransferase and alanine aminotransferase 1.5 x ULN  and alkaline phosphatase 1.5 x ULN; ",
        "premise_nums": [
            "5 x ULN;",
            "than 1.5 x ULN",
            "1 x upper",
            "phosphatase 1.5 x ULN",
            "aminotransferase 1.5 x ULN",
            "5 x ULN]"
        ]
    },
    {
        "id": "54a459cf-f01a-4abc-a8cf-0efebc01c694",
        "primaryId": "NCT02019277",
        "secondaryId": "NCT00863655",
        "label": "Contradiction",
        "statement_text": "the primary trial and the secondary trial recorded none of the same types of adverse events",
        "statement_nums": [],
        "premise_text": "Adverse Events 1: Total: 27/50 (54.00%) Febrile neutropenia * 4/50 (8.00%) Anaemia * 1/50 (2.00%) Neutropenia * 1/50 (2.00%) Cardiac failure * 1/50 (2.00%) Diarrhoea * 1/50 (2.00%) Gastritis * 1/50 (2.00%) Nausea * 1/50 (2.00%) Oesophagitis * 1/50 (2.00%) Pyrexia * 7/50 (14.00%) Mucosal inflammation * 1/50 (2.00%) Drug hypersensitivity * 1/50 (2.00%) ",
        "premise_nums": [
            "27/50 (54.00%)",
            "4/50 (8.00%)",
            "7/50 (14.00%)",
            "1/50 (2.00%)"
        ]
    },
    {
        "id": "54a459cf-f01a-4abc-a8cf-0efebc01c694",
        "primaryId": "NCT02019277",
        "secondaryId": "NCT00863655",
        "label": "Contradiction",
        "statement_text": "the primary trial and the secondary trial recorded none of the same types of adverse events",
        "statement_nums": [],
        "premise_text": "Cellulitis * 2/50 (4.00%)Adverse Events 1: Total: 158/482 (32.78%) Anaemia 7/482 (1.45%) Disseminated intravascular coagulation 1/482 (0.21%) Lymphadenopathy 0/482 (0.00%) Neutropenia 0/482 (0.00%) Thrombocytopenia 2/482 (0.41%) Anaemia 28/482 (1.66%) Disseminated intravascular coagulation 21/482 (0.21%) Febrile neutropenia 21/482 (0.21%) Lymphadenopathy 20/482 (0.00%) ",
        "premise_nums": [
            "20/482 (0.00%)",
            "21/482 (0.21%)",
            "158/482 (32.78%)",
            "28/482 (1.66%)",
            "2/482 (0.41%)",
            "2/50 (4.00%)Adverse",
            "7/482 (1.45%)"
        ]
    },
    {
        "id": "54a459cf-f01a-4abc-a8cf-0efebc01c694",
        "primaryId": "NCT02019277",
        "secondaryId": "NCT00863655",
        "label": "Contradiction",
        "statement_text": "the primary trial and the secondary trial recorded none of the same types of adverse events",
        "statement_nums": [],
        "premise_text": "Neutropenia 20/482 (0.00%)",
        "premise_nums": [
            "20/482 (0.00%)"
        ]
    },
    {
        "id": "dd4b5a08-c033-4429-81d0-1ad59596edbd",
        "primaryId": "NCT02683083",
        "statement_text": "sufferers of hyperthyroidism and diabetes mellitus are eligible for the primary trial ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Exclusion Criteria: Patients will not be included in the study if one of the following criteria applies: Pregnant patients Breast feeding patients Patients with occupational exposure to ionizing irradiation Patients with previous thyroid disorders ",
        "premise_nums": []
    },
    {
        "id": "d97ebc59-ab4b-462a-9057-12f4fc46df56",
        "primaryId": "NCT01153672",
        "secondaryId": "NCT01432145",
        "label": "Entailment",
        "statement_text": "Patients in the primary trial receive vorinostat at the same frequency and through the same route of administration as the secondary trial receive 6-Mercaptopurine.",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Treatment (Enzyme Inhibitor Therapy  AI Sensitization Therapy) Patients receive vorinostat PO QD for 2 weeks followed by AI therapy comprising anastrozole PO QD  letrozole PO QD  OR exemestane PO QD for 6 weeks  Courses repeat every 8 weeks in the absence of disease progression or unacceptable toxicity  vorinostat: Given PO laboratory biomarker analysis: Correlative studies biopsy: Optional correlative studies F-18 16 alpha-fluoroestradiol: Correlative studies positron emission tomography: Correlative studies anastrozole: Given PO letrozole: Given PO exemestane: Given PO ",
        "premise_nums": [
            "16 alpha-fluoroestradiol:",
            "8 weeks in",
            "2 weeks followed"
        ]
    },
    {
        "id": "d97ebc59-ab4b-462a-9057-12f4fc46df56",
        "primaryId": "NCT01153672",
        "secondaryId": "NCT01432145",
        "label": "Entailment",
        "statement_text": "Patients in the primary trial receive vorinostat at the same frequency and through the same route of administration as the secondary trial receive 6-Mercaptopurine.",
        "statement_nums": [],
        "premise_text": "gene expression analysis: Correlative studiesINTERVENTION 1: 6-Mercaptopurine and Methotrexate (6MP/MTX) 6-Mercaptopurine: 6MP 75mg/m2 body surface area  administered orally (PO) once a day (od) in the morning 1 hour after eating  on a continuous schedule  One cycle is 28 days  Treatment is given continuously until disease progression  Methotrexate: Methotrexate 20mg/m2 will be taken orally  once a week  in the morning  One cycle is 28 days  Treatment is given continuously until disease progression  ",
        "premise_nums": [
            "1 hour after",
            "75mg/m2 body",
            "6-Mercaptopurine: 6MP",
            "2 will be",
            "2 body surface",
            "6-Mercaptopurine and",
            "20mg/m2 will"
        ]
    },
    {
        "id": "d97ebc59-ab4b-462a-9057-12f4fc46df56",
        "primaryId": "NCT01153672",
        "secondaryId": "NCT01432145",
        "label": "Entailment",
        "statement_text": "Patients in the primary trial receive vorinostat at the same frequency and through the same route of administration as the secondary trial receive 6-Mercaptopurine.",
        "statement_nums": [],
        "premise_text": "Update: These original doses were reduced following an Urgent Safety Measure in August 2012 due to a large proportion of patients requiring a dose reduction or treatment delay due to incidences of myelo-suppression The reduced doses were 55mg/m2 of 6MP orally once a day  and 15mg/m2 of Methotrexate orally once a week  ",
        "premise_nums": [
            "2 of 6MP",
            "2 of Methotrexate",
            "2012 due to",
            "15mg/m2 of",
            "55mg/m2 of"
        ]
    },
    {
        "id": "2e4c7d0b-f1a2-4204-bac3-7445852fd916",
        "primaryId": "NCT01727011",
        "secondaryId": "NCT01420146",
        "label": "Contradiction",
        "statement_text": "the primary trial and the secondary trial interventions involve a variety of scans  such as CT  PET  MRI and dosimetry",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: IPAS Once the patient recorded in the trial  and after completion of a post-implant dosimetry scanner to analyze the dose distribution within the target volume and organs at risk  the patient is treated by irradiation and partial accelerated breast brachytherapy using high dose rate  delivering a total dose of 16 Gy in one fraction IPAS INTERVENTION 1: Zr89-trastuzumab PET/CT Zr89-trastuzumab (trastuzumab labelled with zirconium 89) for PET/CT single arm ",
        "premise_nums": [
            "89-trastuzumab PET/CT",
            "16 Gy in"
        ]
    },
    {
        "id": "fafac1e0-1eaa-4a99-8f3f-72b3f71c4691",
        "primaryId": "NCT01928186",
        "secondaryId": "NCT00684983",
        "label": "Entailment",
        "statement_text": "All the primary trial participants and cohort 1 participants in the secondary trial do not receive any oral capecitabine  oral lapatinib ditosylate or cixutumumab IV  however cohort 2 of the secondary trial receive all of these ",
        "statement_nums": [
            "2 of the",
            "1 participants in"
        ],
        "premise_text": "INTERVENTION 1: Diagnostic (FLT PET) Patients with early stage  ER positive primary breast cancer undergo FLT PET scan at baseline and 1-6 weeks after the start of standard endocrine treatment  The surgery follows 1-7 days after the second FLT PET scan  Tracer used in the FLT PET (positron emission tomography) scanning procedure: [F18] fluorothymidine  Positron Emission Tomography: Undergo FLT PET Laboratory Biomarker Analysis: Correlative studies - Ki67 staining of the tumor tissue in the biopsy and surgical specimen  INTERVENTION 1: Arm A ",
        "premise_nums": [
            "67 staining of",
            "1-6 weeks",
            "1-7 days",
            "6 weeks after",
            "Ki67 staining",
            "[F18] fluorothymidine",
            "7 days after"
        ]
    },
    {
        "id": "fafac1e0-1eaa-4a99-8f3f-72b3f71c4691",
        "primaryId": "NCT01928186",
        "secondaryId": "NCT00684983",
        "label": "Entailment",
        "statement_text": "All the primary trial participants and cohort 1 participants in the secondary trial do not receive any oral capecitabine  oral lapatinib ditosylate or cixutumumab IV  however cohort 2 of the secondary trial receive all of these ",
        "statement_nums": [
            "2 of the",
            "1 participants in"
        ],
        "premise_text": "Patients receive oral capecitabine twice daily on days 1-14 and oral lapatinib ditosylate once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity  lapatinib ditosylate: Given PO and capecitabine: Given POINTERVENTION 2: Arm B ",
        "premise_nums": [
            "1-14 and",
            "14 and oral",
            "1-21. Courses",
            "21 days in"
        ]
    },
    {
        "id": "fafac1e0-1eaa-4a99-8f3f-72b3f71c4691",
        "primaryId": "NCT01928186",
        "secondaryId": "NCT00684983",
        "label": "Entailment",
        "statement_text": "All the primary trial participants and cohort 1 participants in the secondary trial do not receive any oral capecitabine  oral lapatinib ditosylate or cixutumumab IV  however cohort 2 of the secondary trial receive all of these ",
        "statement_nums": [
            "2 of the",
            "1 participants in"
        ],
        "premise_text": "Patients receive capecitabine and lapatinib ditosylate as in arm I  Patients also receive cixutumumab IV over 1-1½ hours on days 1, 8, and 15. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity  cixutumumab: Given IV  lapatinib ditosylate: Given PO and capecitabine: Given PO",
        "premise_nums": [
            "1-1½ hours",
            "21 days in"
        ]
    },
    {
        "id": "4546c169-cc5c-4e03-bcce-31d491ed18e0",
        "primaryId": "NCT01989676",
        "statement_text": "the primary trial only records cardiovasuclar adverse events ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 67/349 (19.20%) Anaemia * 3/349 (0.86%) Leukopenia * 1/349 (0.29%) Neutropenia * 3/349 (0.86%) Thrombocytopenia * 1/349 (0.29%) Atrial fibrillation * 2/349 (0.57%) Cardiac arrest * 1/349 (0.29%) Cardiac failure * 0/349 (0.00%) Cardiac failure acute * 0/349 (0.00%) Cardio-respiratory arrest * 2/349 (0.57%) Cardiovascular insufficiency * 0/349 (0.00%) ",
        "premise_nums": [
            "0/349 (0.00%)",
            "2/349 (0.57%)",
            "1/349 (0.29%)",
            "67/349 (19.20%)",
            "3/349 (0.86%)"
        ]
    },
    {
        "id": "1bb3badf-41c6-4741-90f0-367473ce254d",
        "primaryId": "NCT00612560",
        "statement_text": "children and illiterate adults are not able to take part in the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Inclusion Criteria: Age 18 and 85 years Exclusion Criteria: Inability to read and write English ",
        "premise_nums": [
            "18 and 85"
        ]
    },
    {
        "id": "87953ba3-3e94-421c-b426-b716562b8b5d",
        "primaryId": "NCT02806544",
        "secondaryId": "NCT00605267",
        "label": "Contradiction",
        "statement_text": "A patient with stage 2B   pathologically confirmed PR positive breast cancer is elgible for both the primary trial and the secondary trial ",
        "statement_nums": [],
        "premise_text": "Inclusion Criteria: Clinical locally advance breast cancer (Stage IIB or III) Pathologically confirmed diagnosis of estrogen receptor (ER)-positive or progesterone receptor (PR)-positive breast cancer with ER or PR Allred Score greater than 4 Inclusion Criteria: Premenopausal  estrogen receptor positive women  aged 20 years and over  with operable and measurable breast cancer who have provided written informed consent Exclusion Criteria: Medical history of chemotherapy or endocrine therapy for breast cancer  or with treatment history of radiotherapy  Unwillingness to stop taking any drug known to affect sex hormone status (including hormone replacement therapy (HRT)  ",
        "premise_nums": [
            "4 Inclusion Criteria:",
            "20 years and"
        ]
    },
    {
        "id": "847b4dbe-428f-431c-8916-2a9c0c80cce4",
        "primaryId": "NCT00686127",
        "secondaryId": "NCT01129622",
        "label": "Contradiction",
        "statement_text": "dosages are specified in the intervention section of the secondary trial and the primary trial",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Lidocaine Patch Lidocaine patch 5% (Lidoderm®  Endo Pharmaceuticals Inc.): 1 patch was applied topically to the affected site(s) for 12 hours each day  INTERVENTION 2: Placebo Patch Placebo patch: 1 patch was applied topically to the affected site(s) for 12 hours each day  INTERVENTION 1: Letrozole  Breast Enhancement  Safety Single arm of healthy postmenopausal women to have two breast MRI (baseline and post-treatment)  Letrozole of 12.5 mg/day is given for three successive days just prior to the second MRI  ",
        "premise_nums": [
            "of 12.5 mg/day",
            "1 patch was",
            "12 hours each"
        ]
    },
    {
        "id": "9c00b318-0a3a-43c9-a6cd-2983c07be393",
        "primaryId": "NCT00232505",
        "statement_text": "There were no instances of patients with abnormal heart rates in the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 3/31 (9.68%) Edema: limb * 2/31 (6.45%) Neutrophils/granulocytes (ANC/AGC) * 0/31 (0.00%) Cardiac General - Other (Specify  __) * [1]0/31 (0.00%) Cardiac General - Other (Specify  __) * [2]0/31 (0.00%) Left ventricular diastolic dysfunction * 0/31 (0.00%) Supraventricular and nodal arrhythmia - Atrial tachycardia/Paroxysmal Atrial Tachycardia * 0/31 (0.00%) Adverse Events 2: Total: 8/25 (32.00%) ",
        "premise_nums": [
            "2/31 (6.45%)",
            "3/31 (9.68%)",
            "8/25 (32.00%)",
            "0/31 (0.00%)"
        ]
    },
    {
        "id": "9c00b318-0a3a-43c9-a6cd-2983c07be393",
        "primaryId": "NCT00232505",
        "statement_text": "There were no instances of patients with abnormal heart rates in the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Edema: limb * 1/25 (4.00%)Neutrophils/granulocytes (ANC/AGC) * 0/25 (0.00%) Cardiac General - Other (Specify  __) * [1]1/25 (4.00%) Cardiac General - Other (Specify  __) * [2]0/25 (0.00%) Left ventricular diastolic dysfunction * 1/25 (4.00%) Supraventricular and nodal arrhythmia - Atrial tachycardia/Paroxysmal Atrial Tachycardia * 0/25 (0.00%) ",
        "premise_nums": [
            "0/25 (0.00%)",
            "1/25 (4.00%)Neutrophils/granulocytes"
        ]
    },
    {
        "id": "cbfe14a5-5169-4de3-b69f-13b489be949a",
        "primaryId": "NCT02597452",
        "secondaryId": "NCT01929395",
        "label": "Entailment",
        "statement_text": "the primary trial and the secondary trial do not use cyclical interventions ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Intelligent Breast Exam  iBE Single Arm: Additional breast exam by a FDA approved hand-held intelligent breast exam device and a clinical breast exam during their scheduled breast screening appointment  No return visit required for participation  intelligent Breast Exam  iBE: A bilateral iBE exam will be performed on the entire breast in addition to a clinical breast exam administered by a trained individual  If the patient is selected to participate in the inter-rater reliability portion of the study  the subject will undergo both the iBE and the clinical breast exams twice sequentially performed by two different separately trained individuals during the same visit  INTERVENTION 1: Phase 1: Addition of Supine MRI to Conventional Imaging Pre-operative supine MRI with intraoperative optical scanning and tracking (group MRI) ",
        "premise_nums": []
    },
    {
        "id": "bd6bf811-e9a8-4e1e-ace1-703aa8f5374b",
        "primaryId": "NCT00325598",
        "statement_text": "There is a significant difference in the Percentage of Participants Achieving a Dosimetrically Satisfactory Treatment Plan between cohort 1 and 2 of the primary trial  the increase in Gy has a huge effect ",
        "statement_nums": [
            "1 and 2"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Feasibility of PBI Directed External Radiotherapy as Measured by Percentage of Participants Achieving a Dosimetrically Satisfactory Treatment Plan -The study will be deemed infeasible if more than 4 patients cannot be given treatment because her tumor is such that a dosimetrically satisfactory treatment plan cannot be devised for her  Time frame: Within 1 year of protocol registration Results 1: Arm/Group Title: Cohort 1 (36 Gy) Arm/Group Description: 36 Gy in 9 fractions BID x 4 1/2 treatment days Partial Breast Irradiation (PBI) Overall Number of Participants Analyzed: 50 Measure Type: Number Unit of Measure: percentage of participants 100 Results 2: ",
        "premise_nums": [
            "9 fractions BID",
            "50 Measure Type:",
            "36 Gy in",
            "1 year of",
            "100 Results 2:",
            "4 patients cannot",
            "4 1/2 treatment",
            "2 treatment days"
        ]
    },
    {
        "id": "bd6bf811-e9a8-4e1e-ace1-703aa8f5374b",
        "primaryId": "NCT00325598",
        "statement_text": "There is a significant difference in the Percentage of Participants Achieving a Dosimetrically Satisfactory Treatment Plan between cohort 1 and 2 of the primary trial  the increase in Gy has a huge effect ",
        "statement_nums": [
            "1 and 2"
        ],
        "label": "Contradiction",
        "premise_text": "Arm/Group Title: Cohort 2 (40 Gy)Arm/Group Description: 40 Gy in 10 fractions BID over 5 treatment days Partial Breast Irradiation (PBI) Overall Number of Participants Analyzed: 50 Measure Type: Number Unit of Measure: percentage of participants 100 ",
        "premise_nums": [
            "5 treatment days",
            "40 Gy in",
            "50 Measure Type:",
            "10 fractions BID"
        ]
    },
    {
        "id": "3c4d9ab0-5e16-48b3-96d4-ae9d337b2822",
        "primaryId": "NCT01332630",
        "secondaryId": "NCT00121134",
        "label": "Contradiction",
        "statement_text": "There were more patients with hypotension in cohort 1 of the primary trial  than in cohort 1 of the secondary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Adverse Events 1: Total: 6/21 (28.57%) Hypertension 3/21 (14.29%) Edema 3/21 (14.29%) Nausea 2/21 (9.52%) Fracture 1/21 (4.76%) Dizziness 3/21 (14.29%) Syncope 2/21 (9.52%) Headache 2/21 (9.52%) Dyspnea 2/21 (9.52%) Hypoxia 3/21 (14.29%) Adverse Events 1: Total: 1/40 (2.50%) Hypertension 0/40 (0.00%) Lower GI bleed 1/40 (2.50%) ",
        "premise_nums": [
            "6/21 (28.57%)",
            "1/21 (4.76%)",
            "1/40 (2.50%)",
            "2/21 (9.52%)",
            "3/21 (14.29%)",
            "0/40 (0.00%)"
        ]
    },
    {
        "id": "3c4d9ab0-5e16-48b3-96d4-ae9d337b2822",
        "primaryId": "NCT01332630",
        "secondaryId": "NCT00121134",
        "label": "Contradiction",
        "statement_text": "There were more patients with hypotension in cohort 1 of the primary trial  than in cohort 1 of the secondary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Death 0/40 (0.00%)Headache 0/40 (0.00%) Dyspnea 0/40 (0.00%) Sinusitis 0/40 (0.00%) Wound Dehiscence 0/40 (0.00%) ",
        "premise_nums": [
            "0/40 (0.00%)Headache"
        ]
    },
    {
        "id": "eae76b80-107c-4469-b06f-73d5f7a4c1d5",
        "primaryId": "NCT02073487",
        "secondaryId": "NCT03371732",
        "label": "Entailment",
        "statement_text": "Heavy smokers (more than 5 cigarettes smoked per day) are eligible for the secondary trial and the primary trial ",
        "statement_nums": [
            "5 cigarettes smoked"
        ],
        "premise_text": "Inclusion Criteria: Female gender; Age 18 years; Performance Status- Eastern Cooperative Oncology Group (ECOG) 0-1 Histologically confirmed invasive breast cancer: Primary tumor greater than 1 cm diameter  measured by clinical examination and mammography or ultrasound  Any N  No evidence of metastasis (M0) (isolated supra-clavicular node involvement allowed); Over expression and/or amplification of HER2 in the invasive component of the primary tumor and confirmed by a certified laboratory prior to randomization  Known hormone receptor status  Hematopoietic status: CBC not less than .75 of institutional lower limit  Absolute neutrophil count 1,5 x 10^9/L, Platelet count 100 x 10^9/L, Hemoglobin at least 9 g/dl  Hepatic status: ",
        "premise_nums": [
            "75 of institutional",
            "1 cm diameter",
            "count 1,5 x 10",
            "0-1 Histologically",
            "1 Histologically confirmed",
            "2 in the",
            "100 x 10",
            "9/L, Hemoglobin",
            "9/L, Platelet",
            "9 g/dl"
        ]
    },
    {
        "id": "eae76b80-107c-4469-b06f-73d5f7a4c1d5",
        "primaryId": "NCT02073487",
        "secondaryId": "NCT03371732",
        "label": "Entailment",
        "statement_text": "Heavy smokers (more than 5 cigarettes smoked per day) are eligible for the secondary trial and the primary trial ",
        "statement_nums": [
            "5 cigarettes smoked"
        ],
        "premise_text": "Serum total bilirubin 2 x upper limit of normal (ULN)  In the case of known Gilbert's syndrome  a higher serum total bilirubin (smaller than 1.5 x ULN) is allowed  Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) 3.5 times ULN  Alkaline phosphatase 2.5 times ULN  Renal status: Creatinine 1.5mg/dL,Cardiovascular: Baseline left ventricular ejection fraction (LVEF) ³ 50% measured by echocardiography (ECHO) or Multiple Gate Acquisition (MUGA) scan  ",
        "premise_nums": [
            "50% measured",
            "than 1.5 x ULN",
            "Creatinine 1.5mg/dL",
            "5 x ULN)",
            "phosphatase 2.5 times ULN",
            "2 x upper"
        ]
    },
    {
        "id": "eae76b80-107c-4469-b06f-73d5f7a4c1d5",
        "primaryId": "NCT02073487",
        "secondaryId": "NCT03371732",
        "label": "Entailment",
        "statement_text": "Heavy smokers (more than 5 cigarettes smoked per day) are eligible for the secondary trial and the primary trial ",
        "statement_nums": [
            "5 cigarettes smoked"
        ],
        "premise_text": "Negative serum or urine β-hCG pregnancy test at screening for patients of childbearing potential within 2-weeks (preferably 7 days) prior to randomization Fertile patients must use effective contraception (barrier method - condoms  diaphragm - also in conjunction with spermicidal jelly  or total abstinence  Oral  injectable  or implant hormonal contraceptives are not allowed) Signed informed consent form (ICF) Patient accepts to make available tumor samples for submission to central laboratory to conduct translational studies as part of this protocol  Exclusion Criteria: Previous (less than 5 years) or current history of malignant neoplasms  except for curatively treated: Basal and squamous cell carcinoma of the skin; Carcinoma in situ of the cervix  ",
        "premise_nums": []
    },
    {
        "id": "eae76b80-107c-4469-b06f-73d5f7a4c1d5",
        "primaryId": "NCT02073487",
        "secondaryId": "NCT03371732",
        "label": "Entailment",
        "statement_text": "Heavy smokers (more than 5 cigarettes smoked per day) are eligible for the secondary trial and the primary trial ",
        "statement_nums": [
            "5 cigarettes smoked"
        ],
        "premise_text": "Patients with a prior malignancy diagnosed more than 5 years prior to randomization may enter the study Preexisting peripheral neuropathy grade 2 Known history of uncontrolled or symptomatic angina  clinically significant arrhythmias  congestive heart failure  transmural myocardial infarction  uncontrolled hypertension ( 180/110), unstable diabetes mellitus  dyspnea at rest  or chronic therapy with oxygen; Concurrent disease or condition that would make the subject inappropriate for study participation or any serious medical disorder that would interfere with the subject's safety; Unresolved or unstable  serious adverse events from prior administration of another investigational drug; Dementia  altered mental status  or any psychiatric condition that would prevent the understanding or rendering of ICF; ",
        "premise_nums": [
            "180/110), unstable",
            "2 Known history",
            "5 years prior"
        ]
    },
    {
        "id": "eae76b80-107c-4469-b06f-73d5f7a4c1d5",
        "primaryId": "NCT02073487",
        "secondaryId": "NCT03371732",
        "label": "Entailment",
        "statement_text": "Heavy smokers (more than 5 cigarettes smoked per day) are eligible for the secondary trial and the primary trial ",
        "statement_nums": [
            "5 cigarettes smoked"
        ],
        "premise_text": "Malabsorption syndrome  disease significantly affecting gastrointestinal function  or resection of the stomach or small bowel  Subjects with ulcerative colitis are also excluded;Concurrent neoadjuvant cancer therapy (chemotherapy  radiation therapy  immunotherapy  biologic therapy other than the trial therapies); Concurrent treatment with an investigational agent or participation in another therapeutic clinical trial; Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to trastuzumab Emtansine  trastuzumab  lapatinib  paclitaxel  abraxane or their components; Pregnant or lactating women; Concomitant use of CYP3A4 inhibitors or inducers ",
        "premise_nums": [
            "4 inhibitors or"
        ]
    },
    {
        "id": "eae76b80-107c-4469-b06f-73d5f7a4c1d5",
        "primaryId": "NCT02073487",
        "secondaryId": "NCT03371732",
        "label": "Entailment",
        "statement_text": "Heavy smokers (more than 5 cigarettes smoked per day) are eligible for the secondary trial and the primary trial ",
        "statement_nums": [
            "5 cigarettes smoked"
        ],
        "premise_text": "Other concurrent severe and/or uncontrolled concomitant medical conditions (e.g  active or uncontrolled infection  uncontrolled diabetes) that could cause unacceptable safety risks or compromise compliance with the protocolPatients have an active infection and require IV or oral antibiotics  Pregnant or breast-feeding women Patients unwilling or unable to comply with the protocol Inclusion Criteria : women with primary breast cancer  without ongoing support for substance use  An AUDIT-C score greater than 1 or more than one cigarette smoked per day  Individuals able to consent to benefit of intervention focused on substance use  (Karnofsky Index greater than 70). Exclusion Criteria : Patients who currently use substances for which a second-line care is already committed  Patients with a Karnofsky index smaller than 70. ",
        "premise_nums": [
            "1 or more"
        ]
    },
    {
        "id": "6cf7d10e-902e-4f78-85f6-e06d63e1cd0e",
        "primaryId": "NCT00347919",
        "statement_text": "less than 50% of the primary trial subjects treated with Lapatinib 1500 mg had no progressive Disease at Week 12.",
        "statement_nums": [
            "1500 mg had",
            "50% of"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Percentage of Participants With Progressive Disease at Week 12 in Cohort 1 The percentage of participants with progressive disease (PD) 12 weeks after randomization was measured  Per Response Evaluation Criteria In Solid Tumors (RECIST)  a response of PD is defined as a greater than or equal 20% increase in target lesions  Participants were also classified as having PD if their response at Week 12 was unknown or missing  Response was determined by an independent radiologist and by an investigator  Time frame: Week 12 Results 1: Arm/Group Title: Cohort 1: Lapatinib 1500 mg Arm/Group Description: Lapatinib 1500 milligrams (mg) administered orally once a day Overall Number of Participants Analyzed: 72 Measure Type: Number Unit of Measure: percentage of participants Independently Evaluated: 38.9 Investigator Evaluated: 43.1 ",
        "premise_nums": [
            "1500 milligrams (mg)",
            "72 Measure Type:",
            "12 Results 1:",
            "9 Investigator Evaluated:",
            "12 was unknown",
            "12 weeks after",
            "1500 mg Arm",
            "12 in Cohort",
            "1 The percentage",
            "20% increase"
        ]
    },
    {
        "id": "91ad45ae-6714-4c27-ac1a-d8ff8e89684f",
        "primaryId": "NCT00334542",
        "statement_text": "A Female patients with a bilateral mastectomy would be excluded from the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "At least 1 healthy intact breast ",
        "premise_nums": [
            "1 healthy intact"
        ]
    },
    {
        "id": "91cf53f9-7233-49ee-a619-c027f6db67ac",
        "primaryId": "NCT00605267",
        "statement_text": "Only men can be eligible for the primary trial ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria: Premenopausal  estrogen receptor positive women  aged 20 years and over  with operable and measurable breast cancer who have provided written informed consent Exclusion Criteria: Medical history of chemotherapy or endocrine therapy for breast cancer  or with treatment history of radiotherapy  Unwillingness to stop taking any drug known to affect sex hormone status (including hormone replacement therapy (HRT)  ",
        "premise_nums": [
            "20 years and"
        ]
    },
    {
        "id": "78894316-fc7d-4d61-a2d4-9ea369bfce20",
        "primaryId": "NCT02273973",
        "statement_text": "Twice as many patients in cohort 1 of the primary trial suffered from Erysipelas than Bacterial diarrhoea ",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Erysipelas 2/167 (1.20%) Bacterial diarrhoea 1/167 (0.60%) ",
        "premise_nums": [
            "2/167 (1.20%)",
            "1/167 (0.60%)"
        ]
    },
    {
        "id": "889e6622-1614-4f6c-a47c-e7caad6e154f",
        "primaryId": "NCT00879086",
        "statement_text": "Cohort 1 and 2 of the primary trial had the same number of patients with anaemia and Neutropenia  but Cohort 1 had 1 more case of Leukopenia than cohort 2.",
        "statement_nums": [
            "1 and 2",
            "1 had 1"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Anaemia 1/51 (1.96%) Leukopenia 1/51 (1.96%) Neutropenia 1/51 (1.96%) Adverse Events 2: Anaemia 1/50 (2.00%) Leukopenia 0/50 (0.00%) Neutropenia 1/50 (2.00%) ",
        "premise_nums": [
            "0/50 (0.00%)",
            "1/51 (1.96%)",
            "1/50 (2.00%)"
        ]
    },
    {
        "id": "4577d986-d7e5-4b5d-9852-b944a6f7f252",
        "primaryId": "NCT01740323",
        "secondaryId": "NCT00127205",
        "label": "Entailment",
        "statement_text": "the secondary trial and the primary trial accept patients in the same age range ",
        "statement_nums": [],
        "premise_text": "Inclusion Criteria: Female breast cancer patients over the age of 18 will be recruited for this study  Patients enrolled in the study will meet standard criteria for whole breast XRT  PATIENT CHARACTERISTICS: Age 18 and over ",
        "premise_nums": [
            "18 and over",
            "18 will be"
        ]
    },
    {
        "id": "e83b56ba-d129-4cde-976d-2865e67ef4a3",
        "primaryId": "NCT02472964",
        "secondaryId": "NCT00089661",
        "label": "Entailment",
        "statement_text": "the primary trial studies tumours response  whereas the secondary trial investigates changes in Bone Mineral Density ",
        "statement_nums": [],
        "premise_text": "Outcome Measurement: Primary Endpoint : Compare Best Overall Response Rate (ORR) (According to Response Evaluation Criteria in Solid Tumor [RECIST] 1.1 Criteria) at Week 24 of MYL-1401O Plus Taxane Versus Herceptin® Plus Taxane in the ITT1 Population Tumor measurements were perform by centralized blinded reviewers using RECIST 1.1 criteria  Per RECIST 1.1: Complete Response (CR): Disappearance of all target lesions  Any pathological lymph node must have reduction in short axis to smaller than 10 mm.Partial Response (PR): greater than /= 30% decrease sum of the diameters of target lesions from baseline sum diameters  ",
        "premise_nums": [
            "30% decrease",
            "24 of MYL",
            "1 Population Tumor"
        ]
    },
    {
        "id": "e83b56ba-d129-4cde-976d-2865e67ef4a3",
        "primaryId": "NCT02472964",
        "secondaryId": "NCT00089661",
        "label": "Entailment",
        "statement_text": "the primary trial studies tumours response  whereas the secondary trial investigates changes in Bone Mineral Density ",
        "statement_nums": [],
        "premise_text": "Progressive Disease (PD): smaller than /= 20% increase in the sum of the diameters of target lesions  from the smallest sum on study with at least a 5 mm absolute increase in the sum of all lesions  The appearance of one or more new lesions* denotes disease progression Stable Disease (SD): Neither sufficient decrease or increase  Evaluation of Non-Target Lesions Complete Response (CR): Disappearance of all non-target lesions  Non-complete Response/Non-Progressive Disease: Persistence of one or more non-target lesions  Progressive Disease (PD): Substantial  unequivocal progression of existing non-target lesions  Time frame: from time of First treatment to week 24 Outcome Measurement: Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 12 Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry  Time frame: 12 months ",
        "premise_nums": [
            "12 Bone Mineral",
            "5 mm absolute",
            "24 Outcome Measurement:",
            "20% increase"
        ]
    },
    {
        "id": "eee75423-9a61-4a57-8baf-8f91b9562486",
        "primaryId": "NCT01705691",
        "statement_text": "The majority of patients in the primary trial suffered from Kidney stones ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 3/19 (15.79%) Febrile neutropenia 1/19 (5.26%) Colitis 1/19 (5.26%) Pain in extremity 0/19 (0.00%) Nephrolithiasis 0/19 (0.00%) Pulmonary embolism 1/19 (5.26%) Dyspnoea 0/19 (0.00%) Haematoma 0/19 (0.00%) Adverse Events 2: Total: 4/30 (13.33%) Febrile neutropenia 1/30 (3.33%) Colitis 0/30 (0.00%) Pain in extremity 1/30 (3.33%) ",
        "premise_nums": [
            "0/30 (0.00%)",
            "3/19 (15.79%)",
            "1/19 (5.26%)",
            "1/30 (3.33%)",
            "4/30 (13.33%)",
            "0/19 (0.00%)"
        ]
    },
    {
        "id": "eee75423-9a61-4a57-8baf-8f91b9562486",
        "primaryId": "NCT01705691",
        "statement_text": "The majority of patients in the primary trial suffered from Kidney stones ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Nephrolithiasis 1/30 (3.33%)Pulmonary embolism 0/30 (0.00%) Dyspnoea 1/30 (3.33%) Haematoma 1/30 (3.33%) ",
        "premise_nums": [
            "0/30 (0.00%)",
            "1/30 (3.33%)Pulmonary"
        ]
    },
    {
        "id": "9e046221-7d4b-4681-a374-96793350927d",
        "primaryId": "NCT00802945",
        "secondaryId": "NCT01231659",
        "label": "Contradiction",
        "statement_text": "Group 1 of the secondary trial has a higher ORR than both the Everolimus + Letrozole cohort of the primary trial and the trastuzumab cohort ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Outcome Measurement: Objective Response Rate (ORR) Per Response Evaluation Criteria In Solid Tumors (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR)  Disappearance of all target lesions; Partial Response (PR)  at least a 30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR  Time frame: Up to 2 years  Results 1: Arm/Group Title: NKTR-102 14 Day Arm/Group Description: NKTR-102: NKTR-102 given on a q14 day schedule Overall Number of Participants Analyzed: 35 Measure Type: Number Unit of Measure: percentage of subjects 28.6 (14.6 to 46.3) ",
        "premise_nums": [
            "30% decrease",
            "102 given on",
            "q14 day",
            "35 Measure Type:",
            "6 to 46.3)",
            "14 Day Arm",
            "14 day schedule"
        ]
    },
    {
        "id": "9e046221-7d4b-4681-a374-96793350927d",
        "primaryId": "NCT00802945",
        "secondaryId": "NCT01231659",
        "label": "Contradiction",
        "statement_text": "Group 1 of the secondary trial has a higher ORR than both the Everolimus + Letrozole cohort of the primary trial and the trastuzumab cohort ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Results 2:Arm/Group Title: NKTR-102 21 Days Arm/Group Description: NKTR-102: NKTR-102 given on a q21 day schedule Overall Number of Participants Analyzed: 35 Measure Type: Number Unit of Measure: percentage of subjects 35 (14.6 to 46.3) Outcome Measurement: Percentage of Participants With Overall Response Rate (ORR) ",
        "premise_nums": [
            "102 given on",
            "21 Days Arm",
            "2:Arm/Group Title:",
            "q21 day",
            "35 Measure Type:",
            "21 day schedule",
            "6 to 46.3)"
        ]
    },
    {
        "id": "9e046221-7d4b-4681-a374-96793350927d",
        "primaryId": "NCT00802945",
        "secondaryId": "NCT01231659",
        "label": "Contradiction",
        "statement_text": "Group 1 of the secondary trial has a higher ORR than both the Everolimus + Letrozole cohort of the primary trial and the trastuzumab cohort ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Overall Response Rate (ORR) was defined as the proportion of patients whose best overall response was either complete response (CR) or partial response (PR) according to RECIST 1.0 for target lesions and assessed by CT: Complete Response (CR)  disappearance of all target lesions for a period of at least one month; Partial Response (PR)  greater than or equal 30% decrease in the sum of the longest diameter of target lesions; Overall Response (ORR) = CR + PR  Only descriptive statistics Time frame: From the date of randomization until the date of the first documented disease progression or date of death from any cause whichever came first  assessed for approximately 15 months Results 1: ",
        "premise_nums": [
            "30% decrease",
            "15 months Results",
            "RECIST 1.0 for target"
        ]
    },
    {
        "id": "9e046221-7d4b-4681-a374-96793350927d",
        "primaryId": "NCT00802945",
        "secondaryId": "NCT01231659",
        "label": "Contradiction",
        "statement_text": "Group 1 of the secondary trial has a higher ORR than both the Everolimus + Letrozole cohort of the primary trial and the trastuzumab cohort ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Arm/Group Title: Everolimus + LetrozoleArm/Group Description: All patients received 2 tablets (5 mg each) of Everolimus (a total of 10 mg) + 1 tablet of Letrozole (2.5 mg) daily until disease progression or as described in the protocol  Overall Number of Participants Analyzed: 43 Measure Type: Number Unit of Measure: Percentage of Participants 37.2 ",
        "premise_nums": [
            "2 tablets (5",
            "43 Measure Type:",
            "1 tablet of"
        ]
    },
    {
        "id": "5448c6b8-244c-4a42-bbef-e1a1a2e254e2",
        "primaryId": "NCT01738438",
        "secondaryId": "NCT00331552",
        "label": "Entailment",
        "statement_text": "Cyclophosphamide  Doxil and Trastuzumab were used in the secondary trial intervention  but not in the primary trial ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Cabozantinib Cabozantinib was given at a dose of 60 mg orally once per day for 21 day cycles  Treatment continued in the absence of disease progression or unacceptable toxicity  INTERVENTION 1: Phase I: Cyclophosphamide  Doxil  Trastuzumab Patients receive oral cyclophosphamide once daily on days 1-28 and pegylated doxorubicin HCl liposome IV over 90 minutes on day 1. Treatment repeats every 4-6 weeks in the absence of disease progression or unacceptable toxicity  Some patients with HER2/neu 3+ disease may also receive trastuzumab IV over 30-90 minutes weekly or every 3 weeks at the discretion of the treating physician  ",
        "premise_nums": [
            "90 minutes weekly",
            "2/neu 3+",
            "30-90 minutes",
            "3 weeks at",
            "28 and pegylated",
            "60 mg orally",
            "1-28 and",
            "6 weeks in",
            "4-6 weeks",
            "90 minutes on",
            "21 day cycles"
        ]
    },
    {
        "id": "5448c6b8-244c-4a42-bbef-e1a1a2e254e2",
        "primaryId": "NCT01738438",
        "secondaryId": "NCT00331552",
        "label": "Entailment",
        "statement_text": "Cyclophosphamide  Doxil and Trastuzumab were used in the secondary trial intervention  but not in the primary trial ",
        "statement_nums": [],
        "premise_text": "pegylated liposomal doxorubicin hydrochloride: Given IVcyclophosphamide: Given orally trastuzumab: Given IV ",
        "premise_nums": []
    },
    {
        "id": "135a7d7b-b5d1-4fe6-9a41-4b303d6fb9b2",
        "primaryId": "NCT00429572",
        "secondaryId": "NCT02455453",
        "label": "Entailment",
        "statement_text": "pre-menopausal patients are excluded from the secondary trial  but eligible for the primary trial ",
        "statement_nums": [],
        "premise_text": "Inclusion Criteria: Recurrent or residual metastatic breast carcinoma Zubrod performance status less than 2 18-60 years old Related donor human leukocyte antigen (HLA)-compatible for allogeneic transplantation or unrelated HLA-compatible donor  No major organ dysfunction or active infection Exclusion Criteria: None Inclusion Criteria: Patient must be postmenopausal defined as meeting one or more of the following: ",
        "premise_nums": [
            "60 years old",
            "2 18-60 years"
        ]
    },
    {
        "id": "8d450d42-4eb1-4edb-be76-b2885964aa90",
        "primaryId": "NCT01506609",
        "secondaryId": "NCT00656019",
        "label": "Contradiction",
        "statement_text": "Patients with cytologically confirmed breast cancer  who's Locally recurrent disease is amenable to radiation with curative intent are not eligible for the secondary trial  but are eligible for the primary trial ",
        "statement_nums": [],
        "premise_text": "Inclusion Criteria: Histologically or cytologically confirmed breast cancer that is either locally recurrent or metastatic  Locally recurrent disease must not be amenable to surgical resection or radiation with curative intent  INCLUSION CRITERIA: Undergoing core needle biopsy for a breast abnormality suspicious for breast cancer  Has undergone a core needle biopsy demonstrating breast cancer and has not yet had any further therapy  provided the core needle biopsy is available for analysis  No prior therapy for breast cancer within the past 5 years  18 years of age or older  Ability to understand and the willingness to sign a written informed consent document  EXCLUSION CRITERIA: History of parathyroid disease  hypercalcemia  or kidney stones  ",
        "premise_nums": [
            "18 years of"
        ]
    },
    {
        "id": "8d450d42-4eb1-4edb-be76-b2885964aa90",
        "primaryId": "NCT01506609",
        "secondaryId": "NCT00656019",
        "label": "Contradiction",
        "statement_text": "Patients with cytologically confirmed breast cancer  who's Locally recurrent disease is amenable to radiation with curative intent are not eligible for the secondary trial  but are eligible for the primary trial ",
        "statement_nums": [],
        "premise_text": "Supplemental vitamin D other than from a standard multiple vitamin or from standard formulations of calcium and vitamin D (eg  calcium citrate with vitamin D) within the prior 6 months History of renal failure requiring dialysis or kidney transplantation  Pregnant or nursing Receiving supplemental calcium greater than 1200 mg calcium per day during study  Initial treatment of breast cancer will not be with breast-conserving surgery or mastectomy  Locally-advanced breast cancer Plans for neoadjuvant chemotherapy  hormonal therapy  or other systemic therapy Plans for preoperative radiation therapy Plans for breast cancer surgery  and does not allow for at least 10 days of vitamin D intervention  Any condition potentially interfering with subjects ability to comply with taking study medication  ",
        "premise_nums": [
            "6 months History",
            "10 days of",
            "1200 mg calcium"
        ]
    },
    {
        "id": "8d450d42-4eb1-4edb-be76-b2885964aa90",
        "primaryId": "NCT01506609",
        "secondaryId": "NCT00656019",
        "label": "Contradiction",
        "statement_text": "Patients with cytologically confirmed breast cancer  who's Locally recurrent disease is amenable to radiation with curative intent are not eligible for the secondary trial  but are eligible for the primary trial ",
        "statement_nums": [],
        "premise_text": "Any medical condition that would potentially interfere with vitamin D absorption  such as celiac sprue  ulcerative colitis Current participation in another research study that would increase risk to subject  in the opinion of the investigators ",
        "premise_nums": []
    },
    {
        "id": "2674e194-3113-4a11-b2cc-f089d960d194",
        "primaryId": "NCT01104584",
        "statement_text": "the primary trial does not use trastuzumab  Tamoxifen or Exemestane in its intervention ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "INTERVENTION 1: CMRM Versus UMRM [Not Specified] ",
        "premise_nums": []
    },
    {
        "id": "a7232387-b266-4bfb-8df8-ca9789188500",
        "primaryId": "NCT00490646",
        "statement_text": "Cohort 1 of the primary trial had 25% more patients experiencing adverse events than cohort 2.",
        "statement_nums": [
            "25% more",
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 13/24 (54.17%) FEBRILE NEUTROPENIA 5/24 (20.83%) HAEMATOTOXICITY 0/24 (0.00%) NEUTROPENIA 3/24 (12.50%) LYMPHADENOPATHY 0/24 (0.00%) PERICARDIAL EFFUSION 1/24 (4.17%) ATRIAL FIBRILLATION 1/24 (4.17%) APLASIA 0/24 (0.00%) NAUSEA 0/24 (0.00%) PYREXIA 1/24 (4.17%) EXTRAVASATION 0/24 (0.00%) CHOLECYSTITIS 1/24 (4.17%) ",
        "premise_nums": [
            "3/24 (12.50%)",
            "1/24 (4.17%)",
            "13/24 (54.17%)",
            "5/24 (20.83%)",
            "0/24 (0.00%)"
        ]
    },
    {
        "id": "a7232387-b266-4bfb-8df8-ca9789188500",
        "primaryId": "NCT00490646",
        "statement_text": "Cohort 1 of the primary trial had 25% more patients experiencing adverse events than cohort 2.",
        "statement_nums": [
            "25% more",
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "PATHOLOGICAL FRACTURE 1/24 (4.17%)Adverse Events 2: Total: 6/24 (25.00%) FEBRILE NEUTROPENIA 0/24 (0.00%) HAEMATOTOXICITY 1/24 (4.17%) NEUTROPENIA 0/24 (0.00%) LYMPHADENOPATHY 1/24 (4.17%) PERICARDIAL EFFUSION 0/24 (0.00%) ATRIAL FIBRILLATION 0/24 (0.00%) APLASIA 1/24 (4.17%) NAUSEA 1/24 (4.17%) PYREXIA 0/24 (0.00%) EXTRAVASATION 1/24 (4.17%) ",
        "premise_nums": [
            "1/24 (4.17%)Adverse",
            "6/24 (25.00%)",
            "0/24 (0.00%)"
        ]
    },
    {
        "id": "a7232387-b266-4bfb-8df8-ca9789188500",
        "primaryId": "NCT00490646",
        "statement_text": "Cohort 1 of the primary trial had 25% more patients experiencing adverse events than cohort 2.",
        "statement_nums": [
            "25% more",
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "CHOLECYSTITIS 0/24 (0.00%)PATHOLOGICAL FRACTURE 0/24 (0.00%) ",
        "premise_nums": [
            "0/24 (0.00%)PATHOLOGICAL"
        ]
    },
    {
        "id": "2e317381-2704-4d06-a793-1d2b29139969",
        "primaryId": "NCT01959490",
        "statement_text": "In total only one participant of the primary trial did not achieve Pathological Complete Response ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Number of Patients With a Pathological Complete Response (pCR) Who Received Targeted Therapy With Trastuzumab and Pertuzumab or Bevacizumab Predicted by Genomically-derived Molecular Subtypes  Number of patients with a pathological complete response (pCR) who received targeted therapy with trastuzumab and pertuzumab or bevacizumab predicted by genomically-derived molecular subtypes (HER2 positive or HER2 negative  pCR is defined as absence of invasive cancer in breast or lymph nodes after neoadjuvant chemotherapy  Time frame: Up to 30 days after last cycle of treatment Results 1: Arm/Group Title: Cohort 1P (HER2 Positive) ",
        "premise_nums": [
            "30 days after",
            "2 positive or"
        ]
    },
    {
        "id": "2e317381-2704-4d06-a793-1d2b29139969",
        "primaryId": "NCT01959490",
        "statement_text": "In total only one participant of the primary trial did not achieve Pathological Complete Response ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Arm/Group Description: Patients receive a run-in Pertuzumab treatment of 840 mg IV over 60 minutes on day -14 followed by Trastuzumab IV over 30-60 minutes and Pertuzumab IV over 30-60 minutes  docetaxel IV  and carboplatin IV on day 1. Treatment repeats very 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity Overall Number of Participants Analyzed: 5 Measure Type: Count of Participants Unit of Measure: Participants 4 80.0% Results 2: Arm/Group Title: Cohort 1T (HER2 Positive) ",
        "premise_nums": [
            "840 mg IV",
            "4 80.0% Results 2",
            "60 minutes on",
            "6 courses in",
            "60 minutes and",
            "3 weeks for",
            "5 Measure Type:",
            "14 followed by",
            "30-60 minutes"
        ]
    },
    {
        "id": "2e317381-2704-4d06-a793-1d2b29139969",
        "primaryId": "NCT01959490",
        "statement_text": "In total only one participant of the primary trial did not achieve Pathological Complete Response ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Arm/Group Description: Patients receive a run-in Trastuzumab treatment of 8 mg/kg IV over 90 minutes on day -14 followed by Trastuzumab IV over 30-60 minutes and Pertuzumab IV over 30-60 minutes  Docetaxel IV  and Carboplatin IV on day 1. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity Overall Number of Participants Analyzed: 6 Measure Type: Count of Participants Unit of Measure: Participants 6 100.0% ",
        "premise_nums": [
            "6 courses in",
            "60 minutes and",
            "3 weeks for",
            "8 mg/kg IV",
            "14 followed by",
            "6 Measure Type:",
            "30-60 minutes",
            "90 minutes on"
        ]
    },
    {
        "id": "030316a2-fb48-469d-9c55-04cdc9a37fb6",
        "primaryId": "NCT00559507",
        "statement_text": "the primary trial participants are given saracatinib PO every single day of the study duration ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "INTERVENTION 1: Treatment (Enzyme Inhibitor Therapy) Patients receive saracatinib PO on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity  ",
        "premise_nums": [
            "1-28. Treatment",
            "28 days in"
        ]
    },
    {
        "id": "2c723e02-14d8-4a80-a95f-517e904bbbad",
        "primaryId": "NCT00338286",
        "statement_text": "No participants of the primary trial had a Progression Free Survival over 1 year  but several patients had a PFS of less than 1 month ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Progression Free Survival Progression free survival was based in investigator-determined progressive disease (PD) and calculated from the date of randomization to the date of PD or the date of death  whichever occurred first  Participants who had not progressed and were still alive at the time of clinical cut off were censored at the last disease assessment prior to the clinical cutoff  For PD or death with a missing interval immediately preceding the event  progression-free survival (PFS) was censored at the last disease assessment prior to the missing interval  Participants who withdrew from the study (withdrawal of consent or lost to follow-up) without progression were censored at the time of the last disease assessment  ",
        "premise_nums": []
    },
    {
        "id": "2c723e02-14d8-4a80-a95f-517e904bbbad",
        "primaryId": "NCT00338286",
        "statement_text": "No participants of the primary trial had a Progression Free Survival over 1 year  but several patients had a PFS of less than 1 month ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Time frame: From the date of randomization to the date of disease progression (PD) or death  whichever occurred first (up to 8.4 years)Results 1: Arm/Group Title: Standard of Care (SOC) Arm/Group Description: Participants received standard supportive care as packed red blood cells (RBC) transfusion as per Investigator's discretion  Overall Number of Participants Analyzed: 1048 Median (95% Confidence Interval) Unit of Measure: Months 7.4 (7.1 to 7.6) Results 2: Arm/Group Title: Epoetin Alfa Arm/Group Description: Participants received SOC plus epoetin alfa 40,000 international units (IU) subcutaneously (SC) once a week  Overall Number of Participants Analyzed: 1050 ",
        "premise_nums": [
            "alfa 40,000 international units",
            "95% Confidence",
            "1 to 7.6)"
        ]
    },
    {
        "id": "2c723e02-14d8-4a80-a95f-517e904bbbad",
        "primaryId": "NCT00338286",
        "statement_text": "No participants of the primary trial had a Progression Free Survival over 1 year  but several patients had a PFS of less than 1 month ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Median (95% Confidence Interval)Unit of Measure: Months 7.4 (6.9 to 7.6) ",
        "premise_nums": [
            "95% Confidence",
            "9 to 7.6)"
        ]
    },
    {
        "id": "8befa03f-c3da-4950-8d27-491ea06b51ed",
        "primaryId": "NCT00885755",
        "secondaryId": "NCT01075100",
        "label": "Entailment",
        "statement_text": "Patients' appetites were not affected in the primary trial  but at least one was affected in the secondary trial ",
        "statement_nums": [],
        "premise_text": "Adverse Events 1: Total: 9/33 (27.27%) Febrile neutropenia * 1/33 (3.03%) Cardiac failure * 1/33 (3.03%) Pyrexia * 2/33 (6.06%) Chest pain * 1/33 (3.03%) Medical device complication * 1/33 (3.03%) Cellulitis * 1/33 (3.03%) Sepsis * 1/33 (3.03%) Hip fracture * 1/33 (3.03%) Back pain * 1/33 (3.03%) Menorrhagia * 1/33 (3.03%) Thrombosis * 1/33 (3.03%) Adverse Events 1: ",
        "premise_nums": [
            "9/33 (27.27%)",
            "1/33 (3.03%)",
            "2/33 (6.06%)"
        ]
    },
    {
        "id": "8befa03f-c3da-4950-8d27-491ea06b51ed",
        "primaryId": "NCT00885755",
        "secondaryId": "NCT01075100",
        "label": "Entailment",
        "statement_text": "Patients' appetites were not affected in the primary trial  but at least one was affected in the secondary trial ",
        "statement_nums": [],
        "premise_text": "Total: 10/48 (20.83%)NEUTROPENIA 1/48 (2.08%) THROMBOCYTOPENIA 0/48 (0.00%) VOLUME BLOOD DECREASED 1/48 (2.08%) FIBRILLATION ATRIAL 1/48 (2.08%) HYPOTENSION 1/48 (2.08%) ABDOMINAL PAIN 1/48 (2.08%) APPETITE DECREASED 0/48 (0.00%) DEHYDRATION 4/48 (8.33%) DIARRHEA 4/48 (8.33%) NAUSEA 3/48 (6.25%) VOMITING 2/48 (4.17%) FEVER 1/48 (2.08%) RIGORS 0/48 (0.00%) Adverse Events 2: ",
        "premise_nums": [
            "3/48 (6.25%)",
            "4/48 (8.33%)",
            "10/48 (20.83%)NEUTROPENIA",
            "2/48 (4.17%)",
            "0/48 (0.00%)",
            "1/48 (2.08%)"
        ]
    },
    {
        "id": "8befa03f-c3da-4950-8d27-491ea06b51ed",
        "primaryId": "NCT00885755",
        "secondaryId": "NCT01075100",
        "label": "Entailment",
        "statement_text": "Patients' appetites were not affected in the primary trial  but at least one was affected in the secondary trial ",
        "statement_nums": [],
        "premise_text": "Total: 5/53 (9.43%)NEUTROPENIA 1/53 (1.89%) THROMBOCYTOPENIA 1/53 (1.89%) VOLUME BLOOD DECREASED 0/53 (0.00%) FIBRILLATION ATRIAL 0/53 (0.00%) HYPOTENSION 0/53 (0.00%) ABDOMINAL PAIN 0/53 (0.00%) APPETITE DECREASED 1/53 (1.89%) DEHYDRATION 0/53 (0.00%) DIARRHEA 0/53 (0.00%) NAUSEA 1/53 (1.89%) VOMITING 1/53 (1.89%) FEVER 1/53 (1.89%) RIGORS 1/53 (1.89%) ",
        "premise_nums": [
            "1/53 (1.89%)",
            "5/53 (9.43%)NEUTROPENIA",
            "0/53 (0.00%)"
        ]
    },
    {
        "id": "32424458-a3e2-440a-9693-6a2f8d4aaddb",
        "primaryId": "NCT01307891",
        "statement_text": "Abraxane + Capecitabine group of the primary trial has 61 more patients with either Complete Response (CR) disappearance of all target lesions; Partial Response (PR) at least a 30% decrease in the sum of the longest diameter of target lesions than the Abraxane Alone group ",
        "statement_nums": [
            "30% decrease",
            "61 more patients"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Objective Response Rate Patient response rates will be measured by the Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI  Responses include the following: Complete Response (CR) disappearance of all target lesions; Partial Response (PR) at least a 30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) best response from the start of treatment until disease progression  Time frame: Baseline to 6 months Results 1: Arm/Group Title: Abraxane + Tigatuzumab ",
        "premise_nums": [
            "30% decrease",
            "6 months Results"
        ]
    },
    {
        "id": "32424458-a3e2-440a-9693-6a2f8d4aaddb",
        "primaryId": "NCT01307891",
        "statement_text": "Abraxane + Capecitabine group of the primary trial has 61 more patients with either Complete Response (CR) disappearance of all target lesions; Partial Response (PR) at least a 30% decrease in the sum of the longest diameter of target lesions than the Abraxane Alone group ",
        "statement_nums": [
            "30% decrease",
            "61 more patients"
        ],
        "label": "Contradiction",
        "premise_text": "Arm/Group Description: Patients will receive Abraxane at 100 mg/m2 X 3 doses on Days 1, 8, and 15 at 28-day intervals and tigatuzumab to be administered as a 10 mg/kg loading dose followed by 5 mg/kg for the first cycle and then every other week on Days 1 and 15 for subsequent cycles  Patients will be evaluated for response every 8 weeks  Patients with disease progression will be taken off the study Overall Number of Participants Analyzed: 39 Measure Type: Number Unit of Measure: percentage of patients 28 (14.9 to 45.0) Results 2: ",
        "premise_nums": [
            "100 mg/m2 X",
            "9 to 45.0)",
            "2 X 3",
            "15 at 28",
            "1 and 15",
            "39 Measure Type:",
            "5 mg/kg for",
            "10 mg/kg loading",
            "3 doses on",
            "28-day intervals"
        ]
    },
    {
        "id": "32424458-a3e2-440a-9693-6a2f8d4aaddb",
        "primaryId": "NCT01307891",
        "statement_text": "Abraxane + Capecitabine group of the primary trial has 61 more patients with either Complete Response (CR) disappearance of all target lesions; Partial Response (PR) at least a 30% decrease in the sum of the longest diameter of target lesions than the Abraxane Alone group ",
        "statement_nums": [
            "30% decrease",
            "61 more patients"
        ],
        "label": "Contradiction",
        "premise_text": "Arm/Group Title: Abraxane AloneArm/Group Description: Patients will receive Abraxane at 100 mg/m2 weekly X 3 doses on Days 1, 8, and 15 at 28-day intervals  Abraxane will be administered on an outpatient basis by an IV infusion over 30 minutes  Patients will be evaluated for response every 2 cycles (every 8 weeks)  Overall Number of Participants Analyzed: 21 Measure Type: Number Unit of Measure: percentage of patients 38 (18 to 61.1) ",
        "premise_nums": [
            "2 weekly X",
            "18 to 61.1)",
            "2 cycles (every",
            "21 Measure Type:",
            "15 at 28",
            "100 mg/m2 weekly",
            "3 doses on",
            "28-day intervals"
        ]
    },
    {
        "id": "a2b25229-c003-49c3-8b0b-94b68f756d3c",
        "primaryId": "NCT00468585",
        "statement_text": "the primary trial did not record any skin infections in their patients ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 2/4 (50.00%) Atrial fibrillation 0/4 (0.00%) Dehydration 1/4 (25.00%) Fatigue (asthenia  lethargy  malaise) 1/4 (25.00%) Pain - Back 1/4 (25.00%) Urinary tract infection 0/4 (0.00%) Dyspnea (shortness of breath) 0/4 (0.00%) Pericardial effusion 0/4 (0.00%) Thrombosis 0/4 (0.00%) Skin infection 0/4 (0.00%) Rash: hand-foot skin reaction 0/4 (0.00%) Adverse Events 2: Total: 0/3 (0.00%) ",
        "premise_nums": [
            "0/4 (0.00%)",
            "2/4 (50.00%)",
            "1/4 (25.00%)",
            "0/3 (0.00%)"
        ]
    },
    {
        "id": "a2b25229-c003-49c3-8b0b-94b68f756d3c",
        "primaryId": "NCT00468585",
        "statement_text": "the primary trial did not record any skin infections in their patients ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Atrial fibrillation 0/3 (0.00%)Dehydration 0/3 (0.00%) Fatigue (asthenia  lethargy  malaise) 0/3 (0.00%) Pain - Back 0/3 (0.00%) Urinary tract infection 0/3 (0.00%) Dyspnea (shortness of breath) 0/3 (0.00%) Pericardial effusion 0/3 (0.00%) Thrombosis 0/3 (0.00%) Skin infection 0/3 (0.00%) Rash: hand-foot skin reaction 0/3 (0.00%) ",
        "premise_nums": [
            "0/3 (0.00%)Dehydration"
        ]
    },
    {
        "id": "728721c4-6376-4ab8-9e4a-af8596bd1ab3",
        "primaryId": "NCT00852930",
        "secondaryId": "NCT02308020",
        "label": "Entailment",
        "statement_text": "Laser Therapy is only used in cohort 1 of the primary trial  neither cohort of the secondary trial make use of this ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "INTERVENTION 1: Laser Therapy Alone therapist administered laser treatment laser: therapist administered laser INTERVENTION 2: Mld Alone therapist administered manual lymphatic drainage manual lymphatic drainage: therapist administered massage therapy INTERVENTION 1: Part A Abemaciclib: HR+  HER2+ Breast Cancer Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle when administered as a single agent or in combination with endocrine therapy (ET)  Participants with hormone receptor positive HR+  HER2+ breast cancer receiving concurrent trastuzumab  150 mg abemaciclib was given orally once every 12 hours on days 1-21 of a 21-day cycle  Participants may continue to receive treatment until discontinuation criteria are met  INTERVENTION 2: ",
        "premise_nums": [
            "1-21 of",
            "12 hours on",
            "21 of a",
            "150 mg abemaciclib",
            "200 mg was",
            "21-day cycle"
        ]
    },
    {
        "id": "728721c4-6376-4ab8-9e4a-af8596bd1ab3",
        "primaryId": "NCT00852930",
        "secondaryId": "NCT02308020",
        "label": "Entailment",
        "statement_text": "Laser Therapy is only used in cohort 1 of the primary trial  neither cohort of the secondary trial make use of this ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Part B Abemaciclib: HR+  HER2- Breast CancerAbemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle when administered as a single agent or for in combination with endocrine therapy (ET)  Participants may continue to receive treatment until discontinuation criteria are met  ",
        "premise_nums": [
            "1-21 of",
            "12 hours on",
            "21 of a",
            "200 mg was",
            "21-day cycle"
        ]
    },
    {
        "id": "c7151ad6-bcac-48e1-ba1e-e6f56a043804",
        "primaryId": "NCT01086605",
        "secondaryId": "NCT00570921",
        "label": "Contradiction",
        "statement_text": "the primary trial and the secondary trial both record cases of Cholecystitis ",
        "statement_nums": [],
        "premise_text": "Adverse Events 1: Total: 3/24 (12.50%) Disseminated intravascular coagulation 0/24 (0.00%) Death NOS 0/24 (0.00%) Edema limbs 0/24 (0.00%) Fatigue 0/24 (0.00%) Hepatic failure 1/24 (4.17%) Alanine aminotransferase increased 1/24 (4.17%) Aspartate aminotransferase increased 1/24 (4.17%) Blood bilirubin increased 0/24 (0.00%) Ejection fraction decreased 1/24 (4.17%) Adverse Events 2: Total: 9/22 (40.91%) Disseminated intravascular coagulation 1/22 (4.55%) ",
        "premise_nums": [
            "3/24 (12.50%)",
            "1/24 (4.17%)",
            "9/22 (40.91%)",
            "0/24 (0.00%)",
            "1/22 (4.55%)"
        ]
    },
    {
        "id": "c7151ad6-bcac-48e1-ba1e-e6f56a043804",
        "primaryId": "NCT01086605",
        "secondaryId": "NCT00570921",
        "label": "Contradiction",
        "statement_text": "the primary trial and the secondary trial both record cases of Cholecystitis ",
        "statement_nums": [],
        "premise_text": "Death NOS 1/22 (4.55%)Edema limbs 1/22 (4.55%) Fatigue 1/22 (4.55%) Hepatic failure 0/22 (0.00%) Alanine aminotransferase increased 0/22 (0.00%) Aspartate aminotransferase increased 1/22 (4.55%) Blood bilirubin increased 1/22 (4.55%) Ejection fraction decreased 1/22 (4.55%) Adverse Events 1: Total: 5/33 (15.15%) Left Ventricular Thrombus * 1/33 (3.03%) Nausea * 1/33 (3.03%) Acute Cholecystitis * 1/33 (3.03%) ",
        "premise_nums": [
            "5/33 (15.15%)",
            "1/33 (3.03%)",
            "1/22 (4.55%)Edema",
            "0/22 (0.00%)"
        ]
    },
    {
        "id": "c7151ad6-bcac-48e1-ba1e-e6f56a043804",
        "primaryId": "NCT01086605",
        "secondaryId": "NCT00570921",
        "label": "Contradiction",
        "statement_text": "the primary trial and the secondary trial both record cases of Cholecystitis ",
        "statement_nums": [],
        "premise_text": "Renal Failure * 1/33 (3.03%)Pneumonia * 1/33 (3.03%) ",
        "premise_nums": [
            "1/33 (3.03%)Pneumonia"
        ]
    },
    {
        "id": "4f71e33c-4f0f-4952-bb03-52402be5f9f4",
        "primaryId": "NCT02015676",
        "statement_text": "There is 1 case (1.45%) of thrombocytopenia in the primary trial ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 26/69 (37.68%) Thrombophlebitis * 1/69 (1.45%) Anaemia NOS * 1/69 (1.45%) Acute febrile neutrophilic dermatosis * 1/69 (1.45%) Cardiac failure NOS * 2/69 (2.90%) Ejection fraction decreased * 1/69 (1.45%) Intestinal obstruction NOS * 1/69 (1.45%) Diarrhoea NOS * 2/69 (2.90%) Febrile neutropenia * 12/69 (17.39%) Mucosal inflammation NOS * 1/69 (1.45%) ",
        "premise_nums": [
            "26/69 (37.68%)",
            "12/69 (17.39%)",
            "1/69 (1.45%)",
            "2/69 (2.90%)"
        ]
    },
    {
        "id": "ef675459-a7d9-4ea1-8963-c95682c38d15",
        "primaryId": "NCT03004534",
        "statement_text": "Participants with T4 N1 M0 breast carcinoma are eligible for the primary trial ",
        "statement_nums": [
            "0 breast carcinoma"
        ],
        "label": "Contradiction",
        "premise_text": "Tumor must be confined to either the breast or to the breast and ipsilateral axilla (Note: patinets with multifocal/multicentric tumors are eligible)  Patient must have (according to TNM 7th edition rules): T1 with T 1.0cm, T2 or T3 by at least one radiographic or clinical measurement Either clinically positive (N1 only) or clinically negative axillary nodes (N0) M0 ",
        "premise_nums": [
            "2 or T3",
            "1 with T",
            "(N0) M"
        ]
    },
    {
        "id": "f9df9e45-eb68-4257-801e-b086a89374b8",
        "primaryId": "NCT02658734",
        "secondaryId": "NCT02073487",
        "label": "Contradiction",
        "statement_text": "Female Patients with LVEF greater than 50%, who have previously undergone treatment with any of the following drugs; trastuzumab emtansine  paclitaxel  abraxane or lapatinib are still eligible for the primary trial but are excluded from the secondary trial ",
        "statement_nums": [],
        "premise_text": "Inclusion Criteria: Prospectively confirmed HER2-positive (i.e.  IHC 3+ or IHC 2+ and gene amplified by fluorescence in situ hybridization [FISH] positive) as assessed on primary tumor and/or metastatic site Documented progression of unresectable  locally advanced  or mBC  determined by the investigator Left ventricular ejection fraction (LVEF) greater than /= 50% by echocardiogram (ECHO) Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 ",
        "premise_nums": [
            "0 or 1",
            "50% by"
        ]
    },
    {
        "id": "f9df9e45-eb68-4257-801e-b086a89374b8",
        "primaryId": "NCT02658734",
        "secondaryId": "NCT02073487",
        "label": "Contradiction",
        "statement_text": "Female Patients with LVEF greater than 50%, who have previously undergone treatment with any of the following drugs; trastuzumab emtansine  paclitaxel  abraxane or lapatinib are still eligible for the primary trial but are excluded from the secondary trial ",
        "statement_nums": [],
        "premise_text": "A negative serum Beta-Human Chorionic Gonadotropin (Beta-HCG) test for women of childbearing potential (premenopausal or not meeting the definition of postmenopausal i.e  greater than /= 12 months of amenorrhea)  and women who have not undergone surgical sterilization (i.e.  absence of ovaries and/or uterus)",
        "premise_nums": [
            "12 months of"
        ]
    },
    {
        "id": "f9df9e45-eb68-4257-801e-b086a89374b8",
        "primaryId": "NCT02658734",
        "secondaryId": "NCT02073487",
        "label": "Contradiction",
        "statement_text": "Female Patients with LVEF greater than 50%, who have previously undergone treatment with any of the following drugs; trastuzumab emtansine  paclitaxel  abraxane or lapatinib are still eligible for the primary trial but are excluded from the secondary trial ",
        "statement_nums": [],
        "premise_text": "For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use two adequate non-hormonal methods of contraception  including at least one method with a failure rate of smaller than 1% per year  during the treatment period and for at least 7 months after the last dose of study drug",
        "premise_nums": [
            "7 months after",
            "1% per"
        ]
    },
    {
        "id": "94fc10ff-65e1-4b0a-8ff3-1cc48db3433e",
        "primaryId": "NCT00319254",
        "statement_text": "the primary trial did not use overall response rate  tumour response rate or progression-free survival rate as its outcome measurement ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Progression-Free Survival (PFS) Rate PFS was based on Kaplan-Meier estimates  PFS was defined as time in weeks from start of study treatment to first documentation of objective tumor progression or death due to any cause  PFS was calculated as (first event date minus the date of first dose of study medication plus 1) divided by 7. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease [PD])  or from death case report forms (CRFs)  Percentage of participants who had not experienced progression or death by Week 16 is reported  ",
        "premise_nums": [
            "16 is reported"
        ]
    },
    {
        "id": "958721dc-e374-4fd1-abb9-071add70bde3",
        "primaryId": "NCT00820170",
        "statement_text": "According to the results of the primary trial the MTD of paclitaxel is approximately is 120 mg ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Phase I Portion: Maximum Tolerated Dose/MTD of Dasatinib When Administered in Combination With a Fixed Dose of Weekly Paclitaxel  [Not Specified] Time frame: Through completion of Phase I  up to 1 year Results 1: Arm/Group Title: Dasatinib and Paclitaxel Arm/Group Description: The phase I portion is a standard  three-patient per cohort  dose escalation schedule will be used  Between 6 and 54 patients will likely be necessary to determine the MTD of dasatinib in combination with weekly paclitaxel  The phase II portion of this trial has a Simon two-stage design to determine the efficacy of dasatinib when administered in combination with paclitaxel  ",
        "premise_nums": [
            "6 and 54",
            "1 year Results"
        ]
    },
    {
        "id": "958721dc-e374-4fd1-abb9-071add70bde3",
        "primaryId": "NCT00820170",
        "statement_text": "According to the results of the primary trial the MTD of paclitaxel is approximately is 120 mg ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Dasatinib and Paclitaxel: A treatment cycle will consist of 28 days  according to the following schedule:Dasatinib 120MG PO once daily  Weekly paclitaxel 80 mg/m2 given intravenously over 1 hour on day 1, 8, and 15 of a 28 day cycle  The trial will initially test the combination of weekly paclitaxel and dasatinib given PO  once daily   continuously  In case of 2 dose-limiting toxicities (DLT) in the first cohort (0), the next cohort will test dasatinib given with a different schedule  5 days on and 2 days off  omitting dasatinib the day prior and the day of administration of paclitaxel  Overall Number of Participants Analyzed: 15 Measure Type: Number ",
        "premise_nums": [
            "15 Measure Type:",
            "5 days on",
            "2 dose-limiting toxicities",
            "28 day cycle",
            "1 hour on",
            "15 of a",
            "2 given intravenously",
            "2 days off",
            "80 mg/m2 given"
        ]
    },
    {
        "id": "958721dc-e374-4fd1-abb9-071add70bde3",
        "primaryId": "NCT00820170",
        "statement_text": "According to the results of the primary trial the MTD of paclitaxel is approximately is 120 mg ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Unit of Measure: mg of dasatinib 120",
        "premise_nums": []
    },
    {
        "id": "19c0b2c7-e45c-4740-b25d-f6e738b59893",
        "primaryId": "NCT01764022",
        "statement_text": "Cohort 2 of the primary trial recorded 1 incident of thrombocytopenia ",
        "statement_nums": [
            "2 of the",
            "1 incident of"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 2: Anemia with trombocytopenia 1/110 (0.91%) ",
        "premise_nums": [
            "1/110 (0.91%)"
        ]
    },
    {
        "id": "7bcfca9e-1b09-45d4-8165-cb6ac96b8815",
        "primaryId": "NCT02896855",
        "secondaryId": "NCT00171314",
        "label": "Contradiction",
        "statement_text": "the secondary trial recorded more total occurences of gastrointestinal adverse events than the primary trial ",
        "statement_nums": [],
        "premise_text": "Adverse Events 1: Total: 23/120 (19.17%) Febrile neutropenia 4/120 (3.33%) Leukopenia 2/120 (1.67%) Neutropenia 8/120 (6.67%) Cardiac tamponade 0/120 (0.00%) Ventricular arrhythmia 1/120 (0.83%) Ascites 0/120 (0.00%) Oesophagitis 0/120 (0.00%) Large intestine polyp 0/120 (0.00%) Death 1/120 (0.83%) Liver injury 1/120 (0.83%) Pneumonia 3/120 (2.50%) Adverse Events 2: ",
        "premise_nums": [
            "23/120 (19.17%)",
            "0/120 (0.00%)",
            "3/120 (2.50%)",
            "8/120 (6.67%)",
            "2/120 (1.67%)",
            "4/120 (3.33%)",
            "1/120 (0.83%)"
        ]
    },
    {
        "id": "7bcfca9e-1b09-45d4-8165-cb6ac96b8815",
        "primaryId": "NCT02896855",
        "secondaryId": "NCT00171314",
        "label": "Contradiction",
        "statement_text": "the secondary trial recorded more total occurences of gastrointestinal adverse events than the primary trial ",
        "statement_nums": [],
        "premise_text": "Total: 30/122 (24.59%)Febrile neutropenia 3/122 (2.46%) Leukopenia 3/122 (2.46%) Neutropenia 9/122 (7.38%) Cardiac tamponade 2/122 (1.64%) Ventricular arrhythmia 0/122 (0.00%) Ascites 1/122 (0.82%) Oesophagitis 1/122 (0.82%) Large intestine polyp 0/122 (0.00%) Death 1/122 (0.82%) Liver injury 0/122 (0.00%) Pneumonia 5/122 (4.10%) Adverse Events 1: Total: 47/254 (18.50%) ",
        "premise_nums": [
            "5/122 (4.10%)",
            "3/122 (2.46%)",
            "0/122 (0.00%)",
            "47/254 (18.50%)",
            "30/122 (24.59%)Febrile",
            "9/122 (7.38%)",
            "1/122 (0.82%)",
            "2/122 (1.64%)"
        ]
    },
    {
        "id": "7bcfca9e-1b09-45d4-8165-cb6ac96b8815",
        "primaryId": "NCT02896855",
        "secondaryId": "NCT00171314",
        "label": "Contradiction",
        "statement_text": "the secondary trial recorded more total occurences of gastrointestinal adverse events than the primary trial ",
        "statement_nums": [],
        "premise_text": "Anaemia 1/254 (0.39%)Febrile neutropenia 1/254 (0.39%) Lymphadenopathy 1/254 (0.39%) Acute myocardial infarction 1/254 (0.39%) Angina pectoris 0/254 (0.00%) Angina unstable 0/254 (0.00%) Bundle branch block left 0/254 (0.00%) Cardiac failure 4/254 (1.57%) Coronary artery disease 0/254 (0.00%) Coronary artery stenosis 1/254 (0.39%) Adverse Events 2: Total: 56/269 (20.82%) Anaemia 1/269 (0.37%) ",
        "premise_nums": [
            "56/269 (20.82%)",
            "1/269 (0.37%)",
            "0/254 (0.00%)",
            "4/254 (1.57%)",
            "1/254 (0.39%)Febrile"
        ]
    },
    {
        "id": "7bcfca9e-1b09-45d4-8165-cb6ac96b8815",
        "primaryId": "NCT02896855",
        "secondaryId": "NCT00171314",
        "label": "Contradiction",
        "statement_text": "the secondary trial recorded more total occurences of gastrointestinal adverse events than the primary trial ",
        "statement_nums": [],
        "premise_text": "Febrile neutropenia 0/269 (0.00%)Lymphadenopathy 0/269 (0.00%) Acute myocardial infarction 0/269 (0.00%) Angina pectoris 3/269 (1.12%) Angina unstable 1/269 (0.37%) Bundle branch block left 1/269 (0.37%) Cardiac failure 1/269 (0.37%) Coronary artery disease 1/269 (0.37%) Coronary artery stenosis 0/269 (0.00%) ",
        "premise_nums": [
            "3/269 (1.12%)",
            "1/269 (0.37%)",
            "0/269 (0.00%)Lymphadenopathy"
        ]
    },
    {
        "id": "e3a8be03-20e4-460d-9ebc-f958a515ac45",
        "primaryId": "NCT01095003",
        "statement_text": "Less than 5 patients in the primary trial experienced Earache ",
        "statement_nums": [
            "5 patients in"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 107/383 (27.94%) Anaemia 4/383 (1.04%) Febrile neutropenia 7/383 (1.83%) Haemoytique anaemia 0/383 (0.00%) Leukopenia 1/383 (0.26%) Neutropenia 6/383 (1.57%) Thrombocytopenia 2/383 (0.52%) Anginal pectoris 1/383 (0.26%) Cardiomyopathy 0/383 (0.00%) Ear pain 0/383 (0.00%) Abdominal distension 1/383 (0.26%) Abdominal pain 6/383 (1.57%) Adverse Events 2: ",
        "premise_nums": [
            "6/383 (1.57%)",
            "0/383 (0.00%)",
            "107/383 (27.94%)",
            "1/383 (0.26%)",
            "7/383 (1.83%)",
            "2/383 (0.52%)",
            "4/383 (1.04%)"
        ]
    },
    {
        "id": "e3a8be03-20e4-460d-9ebc-f958a515ac45",
        "primaryId": "NCT01095003",
        "statement_text": "Less than 5 patients in the primary trial experienced Earache ",
        "statement_nums": [
            "5 patients in"
        ],
        "label": "Entailment",
        "premise_text": "Total: 85/383 (22.19%)Anaemia 3/383 (0.78%) Febrile neutropenia 2/383 (0.52%) Haemoytique anaemia 0/383 (0.00%) Leukopenia 0/383 (0.00%) Neutropenia 1/383 (0.26%) Thrombocytopenia 1/383 (0.26%) Anginal pectoris 0/383 (0.00%) Cardiomyopathy 1/383 (0.26%) Ear pain 1/383 (0.26%) Abdominal distension 0/383 (0.00%) Abdominal pain 3/383 (0.78%) ",
        "premise_nums": [
            "0/383 (0.00%)",
            "85/383 (22.19%)Anaemia",
            "1/383 (0.26%)",
            "2/383 (0.52%)",
            "3/383 (0.78%)"
        ]
    },
    {
        "id": "f1096271-3160-4483-9246-ba0d96735efb",
        "primaryId": "NCT01118624",
        "statement_text": "Less than 5% of the primary trial participants achieved CR or PR ",
        "statement_nums": [
            "5% of"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Objective Response Rate (ORR) Tumor response evaluation was performed using RECIST 1.0 using CT/MRI  Proportion of patients achieving a CR or PR is considered in the overall response  Time frame: Assessed at the end of each even-numbered cycle (every 8 weeks)  or per standard of care but no less than 4 weeks and nor more than every 12 weeks (+/- 1 week) if treatment has ended  Results 1: Arm/Group Title: Pralatrexate Arm/Group Description: Study drug 190 mg/m^2 for 2 to 4 weeks  Overall Number of Participants Analyzed: 22 Measure Type: Number Unit of Measure: participants 1 ",
        "premise_nums": [
            "4 weeks and",
            "2 for 2",
            "22 Measure Type:",
            "RECIST 1.0 using CT",
            "190 mg/m^2",
            "2 to 4"
        ]
    },
    {
        "id": "329b6871-2edc-4142-a4af-e7f8cef118ee",
        "primaryId": "NCT00004888",
        "statement_text": "More the primary trial participants suffered Grade 1 Cardiotoxicity Events After Cycle 8 than Grade 3 events ",
        "statement_nums": [
            "1 Cardiotoxicity Events",
            "8 than Grade"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Grades of Cardiotoxicity Events in the Subset of Patients Reporting a Cardiotoxicity Event This table summarizes the cardiotoxicity events of different grades  Grade 1 is a decline of left ventricular ejection fraction(LVEF) greater than or equal 10% but smaller than 20% of baseline value  Grade 2 is LVEF below LLN (50%) or decline of LVEF greater than or equal 20% of baseline value  Grade 3 is congestive heart failure responsive to treatment  Please note that only a subset of patients reported cardiotoxic events so the totals will not add up to the total number of participants  Time frame: Baseline  after cycle 4 (~84 days)  after cycle 8 (~168 days)  and 30 or more days after last cycle of induction therapy ",
        "premise_nums": [
            "10% but",
            "30 or more",
            "2 is LVEF",
            "1 is a",
            "3 is congestive",
            "(50%) or",
            "20% of"
        ]
    },
    {
        "id": "329b6871-2edc-4142-a4af-e7f8cef118ee",
        "primaryId": "NCT00004888",
        "statement_text": "More the primary trial participants suffered Grade 1 Cardiotoxicity Events After Cycle 8 than Grade 3 events ",
        "statement_nums": [
            "1 Cardiotoxicity Events",
            "8 than Grade"
        ],
        "label": "Entailment",
        "premise_text": "Results 1:Arm/Group Title: Arm I: Doxorubicin and Taxotere Arm/Group Description: Patients received PLD 30 mg/m^2 IV followed by docetaxel 60 mg/m^2 IV  one hour after PLD completion  every 3 weeks for a total of 8 cycles  Dexamthasone 8 mg orally twice a day was administered the day before  the day of  and the day following docetaxel  The maximum allowed cumulative dose of PLD was 240 mg/m^2. Pyridoxine 200 mg PO daily started on Day 1 of Cycle 1 and continued daily while the patient was on PLD  Overall Number of Participants Analyzed: 16 Measure Type: Number Unit of Measure: participants Grade 1 After Cycle 4 (approx  84 days): 2 ",
        "premise_nums": [
            "200 mg PO",
            "60 mg/m^2",
            "30 mg/m^2",
            "3 weeks for",
            "1:Arm/Group Title:",
            "1 and continued",
            "1 of Cycle",
            "1 After Cycle",
            "16 Measure Type:",
            "240 mg/m^2.",
            "2 IV followed",
            "8 mg orally"
        ]
    },
    {
        "id": "329b6871-2edc-4142-a4af-e7f8cef118ee",
        "primaryId": "NCT00004888",
        "statement_text": "More the primary trial participants suffered Grade 1 Cardiotoxicity Events After Cycle 8 than Grade 3 events ",
        "statement_nums": [
            "1 Cardiotoxicity Events",
            "8 than Grade"
        ],
        "label": "Entailment",
        "premise_text": "Grade 1 After Cycle 8 (approx  168 days): 4Grade 1 After 30 days or more after last cycle: 1 Grade 2 After Cycle 4 (approx 84 days): 3 Grade 2 After Cycle 8 (approx 168 days): 4 Grade 2 After 30 days or more after last cycle: 1 Grade 3 After Cycle 4 (approx 84 days): 1 Grade 3 After Cycle 8 (approx 168 days): 0 Grade 3 After 30 days or more after last cycle: 0 ",
        "premise_nums": [
            "4 Grade 2",
            "30 days or",
            "1 Grade 2",
            "1 After 30",
            "1 After Cycle",
            "3 Grade 2",
            "1 Grade 3",
            "0 Grade 3"
        ]
    },
    {
        "id": "67522762-9423-4e3d-bf75-247f84ba7f05",
        "primaryId": "NCT00365417",
        "secondaryId": "NCT00853996",
        "label": "Contradiction",
        "statement_text": "To be eligible for both the secondary trial and the primary trial patients must satisfy all the following conditions; alkaline phosphatase smaller than 2.5 x ULN  aspartate aminotransferase smaller than = 1.5 x ULN and Hemoglobin greater than 10 g/dL ",
        "statement_nums": [
            "than 2.5 x ULN",
            "10 g/dL"
        ],
        "premise_text": "The following criteria for evidence of adequate hepatic function must be met: alkaline phosphatase must be less than 2.5 x ULN for the lab; and aspartate aminotransferase (AST) must be less than/equal to 1.5 x ULN for the lab  Platelet count must be greater than/equal to 100,000/mm^3. Hemoglobin must be greater than/equal to 10 g/dL  Platelets greater than 100,000/mm^3 Hemoglobin greater than 10 g/dL ",
        "premise_nums": [
            "100,000/mm^3 Hemoglobin",
            "than 2.5 x ULN",
            "100,000/mm^3. Hemoglobin",
            "10 g/dL",
            "3 Hemoglobin greater",
            "to 1.5 x ULN"
        ]
    },
    {
        "id": "67522762-9423-4e3d-bf75-247f84ba7f05",
        "primaryId": "NCT00365417",
        "secondaryId": "NCT00853996",
        "label": "Contradiction",
        "statement_text": "To be eligible for both the secondary trial and the primary trial patients must satisfy all the following conditions; alkaline phosphatase smaller than 2.5 x ULN  aspartate aminotransferase smaller than = 1.5 x ULN and Hemoglobin greater than 10 g/dL ",
        "statement_nums": [
            "than 2.5 x ULN",
            "10 g/dL"
        ],
        "premise_text": "AST smaller than 2 times upper limit of normal (ULN)Alkaline phosphatase smaller than 2 times ULN ",
        "premise_nums": [
            "2 times upper",
            "2 times ULN"
        ]
    },
    {
        "id": "efd37946-54f3-4813-b63d-6d7df6123677",
        "primaryId": "NCT02630693",
        "statement_text": "A total of 3 patients in the primary trial suffered a life-threatening reaction to an infection ",
        "statement_nums": [
            "3 patients in"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 9/90 (10.00%) Febrile neutropenia 2/90 (2.22%) Ascites 0/90 (0.00%) Nausea 0/90 (0.00%) Vomiting 0/90 (0.00%) Death NOS 1/90 (1.11%) Fever 0/90 (0.00%) Other general disorders  administration site conditions 0/90 (0.00%) Other hepatobiliary disorders 1/90 (1.11%) Lung infection 2/90 (2.22%) Sepsis 2/90 (2.22%) Spinal fracture 0/90 (0.00%) Adverse Events 2: Total: 12/89 (13.48%) ",
        "premise_nums": [
            "2/90 (2.22%)",
            "1/90 (1.11%)",
            "0/90 (0.00%)",
            "9/90 (10.00%)",
            "12/89 (13.48%)"
        ]
    },
    {
        "id": "efd37946-54f3-4813-b63d-6d7df6123677",
        "primaryId": "NCT02630693",
        "statement_text": "A total of 3 patients in the primary trial suffered a life-threatening reaction to an infection ",
        "statement_nums": [
            "3 patients in"
        ],
        "label": "Entailment",
        "premise_text": "Febrile neutropenia 0/89 (0.00%)Ascites 1/89 (1.12%) Nausea 1/89 (1.12%) Vomiting 1/89 (1.12%) Death NOS 2/89 (2.25%) Fever 1/89 (1.12%) Other general disorders  administration site conditions 1/89 (1.12%) Other hepatobiliary disorders 0/89 (0.00%) Lung infection 0/89 (0.00%) Sepsis 1/89 (1.12%) Spinal fracture 1/89 (1.12%) ",
        "premise_nums": [
            "1/89 (1.12%)",
            "2/89 (2.25%)",
            "0/89 (0.00%)Ascites"
        ]
    },
    {
        "id": "dcf62f43-04b7-4acb-b444-2d805238a8b1",
        "primaryId": "NCT02162667",
        "statement_text": "The Herceptin group in the primary trial had a higher percentage of Patients Achieving partial Pathological Response than the CT-P6 and ZA group ",
        "statement_nums": [
            "6 and ZA"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: The Percentage of Patients Achieving Pathological Complete Response Defined as the Absence of Invasion Tumor Cells in the Breast and in Axillary Lymph Nodes  Regardless of Ductal Carcinoma in Situ (DCIS) Subject who went through Neoadjuvant period completely (24 weeks)  will receive surgery within 3-6 weeks after last treatment of neoadjuvant period  The primary endpoint  Pathological complete response  will be assessed using resected bio-specimens collected in breast and axilla during a surgery  Time frame: After Neo-adjuvant therapy and Surgery (up to 30 weeks) Results 1: Arm/Group Title: CT-P6 ",
        "premise_nums": [
            "3-6 weeks",
            "6 weeks after"
        ]
    },
    {
        "id": "dcf62f43-04b7-4acb-b444-2d805238a8b1",
        "primaryId": "NCT02162667",
        "statement_text": "The Herceptin group in the primary trial had a higher percentage of Patients Achieving partial Pathological Response than the CT-P6 and ZA group ",
        "statement_nums": [
            "6 and ZA"
        ],
        "label": "Contradiction",
        "premise_text": "Arm/Group Description: Patient received CT-P6 at an initial dose of 8 mg/kg administered by a single IV infusion on Day 1 of Cycle 1, followed by 6 mg/kg on Day 1 of Cycles 2 through 8 (3-week cycles)  Patients also received docetaxel 75 mg/m^2 during cycles 1 through 4 and FEC (fluorouracil 500mg/m^2, epirubicin 75mg/m^2, and cyclophosphamide 500mg/m^2) during Cycles 5 through 8. After a total of 8 treatment cycles of the neoadjuvant treatment  surgery was performed within 3 to 6 weeks from the last dose of study Overall Number of Participants Analyzed: 248 ",
        "premise_nums": [
            "75mg/m^2,",
            "3 to 6",
            "500mg/m^2,",
            "2 through 8",
            "2 during cycles",
            "6 mg/kg on",
            "1 of Cycles",
            "500mg/m^2)",
            "75 mg/m^2",
            "1 through 4",
            "5 through 8.",
            "6 at an",
            "8 treatment cycles",
            "8 mg/kg administered",
            "(3-week cycles"
        ]
    },
    {
        "id": "dcf62f43-04b7-4acb-b444-2d805238a8b1",
        "primaryId": "NCT02162667",
        "statement_text": "The Herceptin group in the primary trial had a higher percentage of Patients Achieving partial Pathological Response than the CT-P6 and ZA group ",
        "statement_nums": [
            "6 and ZA"
        ],
        "label": "Contradiction",
        "premise_text": "Measure Type: NumberUnit of Measure: percentage of responders 46.77 (40.43 to 53.19) Results 2: Arm/Group Title: Herceptin ",
        "premise_nums": [
            "43 to 53.19)"
        ]
    },
    {
        "id": "dcf62f43-04b7-4acb-b444-2d805238a8b1",
        "primaryId": "NCT02162667",
        "statement_text": "The Herceptin group in the primary trial had a higher percentage of Patients Achieving partial Pathological Response than the CT-P6 and ZA group ",
        "statement_nums": [
            "6 and ZA"
        ],
        "label": "Contradiction",
        "premise_text": "Arm/Group Description: Patient received Herceptin at an initial dose of 8 mg/kg administered by a single IV infusion on Day 1 of Cycle 1, followed by 6 mg/kg on Day 1 of Cycles 2 through 8 (3-week cycles)  Patients also received docetaxel 75 mg/m^2 during cycles 1 through 4 and FEC (fluorouracil 500mg/m^2, epirubicin 75mg/m^2, and cyclophosphamide 500mg/m^2) during Cycles 5 through 8. After a total of 8 treatment cycles of the neoadjuvant treatment  surgery was performed within 3 to 6 weeks from the last dose of study Overall Number of Participants Analyzed: 256 ",
        "premise_nums": [
            "8 treatment cycles",
            "75mg/m^2,",
            "3 to 6",
            "(3-week cycles",
            "1 through 4",
            "5 through 8.",
            "500mg/m^2,",
            "1 of Cycles",
            "2 through 8",
            "8 mg/kg administered",
            "2 during cycles",
            "6 mg/kg on",
            "500mg/m^2)",
            "75 mg/m^2"
        ]
    },
    {
        "id": "dcf62f43-04b7-4acb-b444-2d805238a8b1",
        "primaryId": "NCT02162667",
        "statement_text": "The Herceptin group in the primary trial had a higher percentage of Patients Achieving partial Pathological Response than the CT-P6 and ZA group ",
        "statement_nums": [
            "6 and ZA"
        ],
        "label": "Contradiction",
        "premise_text": "Measure Type: NumberUnit of Measure: percentage of responders 50.39 (44.10 to 56.68) ",
        "premise_nums": [
            "10 to 56.68)"
        ]
    },
    {
        "id": "83dc7b9a-b863-4f81-88fb-763afc3b79e8",
        "primaryId": "NCT03252145",
        "secondaryId": "NCT00904033",
        "label": "Contradiction",
        "statement_text": "None of the subjects in the primary trial are required to injest any pills  and half the subjects in the secondary trial must take a weekly tablet ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Manual Lymph Drainage Manual lymph drainage (MLD) treatment 3 times a week for 4 weeks to the lymphedematous upper limb Manual Lymph Drainage (MLD): MLD is a practitioner-applied manual massage technique designed to decrease limb volume in patients with lymphedema by enhancing movement of lymph fluid  resulting in reductions in interstitial fluid  INTERVENTION 2: Negative Pressure PhysioTouch (negative pressure massage) treatment 3 times a week for 4 weeks to the lymphedematous upper limb ",
        "premise_nums": [
            "3 times a",
            "4 weeks to"
        ]
    },
    {
        "id": "83dc7b9a-b863-4f81-88fb-763afc3b79e8",
        "primaryId": "NCT03252145",
        "secondaryId": "NCT00904033",
        "label": "Contradiction",
        "statement_text": "None of the subjects in the primary trial are required to injest any pills  and half the subjects in the secondary trial must take a weekly tablet ",
        "statement_nums": [],
        "premise_text": "PhysioTouch: The PhysioTouch is a hand-held device that administers negative pressure under the treatment head  and gently pulls the underlying skin and subcutaneous tissue into the suction cup  This suction produces a stretch to the skin and in the subcutaneous tissue space  This action is thought to facilitate lymphatic flow from the interstitium into the lymphatic vessels  and mobilizes the superficial fascia INTERVENTION 1: No Exercise Multivitamin Arm + Calcitriol Arm:Calcitriol pill taken once per week INTERVENTION 2: Exercise Exercise Arm: Exercise consisting of progressive walking and resistance band training Calcitriol+ Exercise Arm: Calcitriol pill taken once per week + Exercise ",
        "premise_nums": []
    },
    {
        "id": "d446920a-2b8e-4452-b9f2-17d2771dbb07",
        "primaryId": "NCT00075764",
        "statement_text": "The most common adverse event in cohort 1 of the primary trial is Neutropenia ",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 21/337 (6.23%) Blood/Bone Marrow-Other 0/337 (0.00%) Febrile neutropenia 0/337 (0.00%) Hemoglobin 2/337 (0.59%) Atrioventricular block - 2nd degree Mobitz Type II 0/337 (0.00%) Cardiac-ischemia/infarction 1/337 (0.30%) Left ventricular diastolic dysfunction 0/337 (0.00%) Left ventricular systolic dysfunction 1/337 (0.30%) Restrictive cardiomyopathy 1/337 (0.30%) ",
        "premise_nums": [
            "0/337 (0.00%)",
            "1/337 (0.30%)",
            "2/337 (0.59%)",
            "21/337 (6.23%)"
        ]
    },
    {
        "id": "aa710138-bf2a-4a7f-8014-4513fa1f448b",
        "primaryId": "NCT01269346",
        "secondaryId": "NCT01597193",
        "label": "Entailment",
        "statement_text": "Cohort 1 of the primary trial and Cohort 1 of the secondary trial both have less than 30% occurrence of adverse events ",
        "statement_nums": [
            "30% occurrence",
            "1 of the"
        ],
        "premise_text": "Adverse Events 1: Total: 15/52 (28.85%) Adverse Events 1: Total: 2/7 (28.57%) ",
        "premise_nums": [
            "15/52 (28.85%)",
            "2/7 (28.57%)"
        ]
    },
    {
        "id": "aa38a1cc-35d6-4194-9e9e-3bcc0298a95c",
        "primaryId": "NCT01340300",
        "secondaryId": "NCT00671918",
        "label": "Entailment",
        "statement_text": "Patients must be doing less than 2 hours of physical exercise per week to participate in the primary trial  however  this is not a requirement for the secondary trial ",
        "statement_nums": [
            "2 hours of"
        ],
        "premise_text": "Inclusion Criteria: Less than 120 minutes of exercise per week Inclusion Criteria: The patient has provided written informed consent with HIPAA authorization before participating in the study  as has his/her responsible caregiver  if applicable  The patient is a candidate for surgical intervention  with lymph node mapping being a part of the surgical plan  The patient is at least 18 years of age at the time of consent  The patient has an ECOG performance status of Grade 0 - 2 [8]. The patient has a clinical negative node status at the time of study entry  If of child bearing potential  the patient has a negative pregnancy test within 72 hours prior to administration of Lymphoseek  has been surgically sterilized  or has been postmenopausal for at least 1 year  The patient is currently not participating in another investigational drug study  Melanoma Patients ",
        "premise_nums": [
            "120 minutes of",
            "72 hours prior",
            "18 years of"
        ]
    },
    {
        "id": "aa38a1cc-35d6-4194-9e9e-3bcc0298a95c",
        "primaryId": "NCT01340300",
        "secondaryId": "NCT00671918",
        "label": "Entailment",
        "statement_text": "Patients must be doing less than 2 hours of physical exercise per week to participate in the primary trial  however  this is not a requirement for the secondary trial ",
        "statement_nums": [
            "2 hours of"
        ],
        "premise_text": "The patient has a diagnosis of primary melanoma Breast Cancer Patients The patient has a diagnosis of primary breast cancer  Patients with pure ductal carcinoma in situ (DCIS) or non-invasive carcinoma if lymph node biopsy is part of the surgical plan  Exclusion Criteria: The patient is pregnant or lactating; The patient has clinical or radiological evidence of metastatic cancer including palpably abnormal or enlarged lymph nodes (i.e.  all patients should be any T,N0,M0); The patient has a known hypersensitivity to Lymphazurin or Patent Bleu V  Melanoma Patients The patient has a tumor with a Breslow depth less than 0.75mm.; ",
        "premise_nums": [
            "0,M0); The"
        ]
    },
    {
        "id": "aa38a1cc-35d6-4194-9e9e-3bcc0298a95c",
        "primaryId": "NCT01340300",
        "secondaryId": "NCT00671918",
        "label": "Entailment",
        "statement_text": "Patients must be doing less than 2 hours of physical exercise per week to participate in the primary trial  however  this is not a requirement for the secondary trial ",
        "statement_nums": [
            "2 hours of"
        ],
        "premise_text": "Patients that have had preoperative chemotherapy  immunotherapy or radiation therapy;Patients diagnosed with a prior invasive melanoma that would occur on the same body region or potentially draining to the same nodal basin or patients with truncal or extremity primary melanoma who has had a prior breast cancer potentially draining to the same axillary nodal basin; Patients who have undergone node basin surgery of any type or radiation to the nodal basin(s) potentially draining the primary melanoma; Patients who have undergone a wide excision for their primary melanoma (greater than 1 cm in dimension) or complex reconstruction (rotation  free flap or skin graft of any type)  Breast Cancer Patients The patient has bilateral primary breast cancers or multiple tumors within their breast; ",
        "premise_nums": [
            "1 cm in"
        ]
    },
    {
        "id": "aa38a1cc-35d6-4194-9e9e-3bcc0298a95c",
        "primaryId": "NCT01340300",
        "secondaryId": "NCT00671918",
        "label": "Entailment",
        "statement_text": "Patients must be doing less than 2 hours of physical exercise per week to participate in the primary trial  however  this is not a requirement for the secondary trial ",
        "statement_nums": [
            "2 hours of"
        ],
        "premise_text": "Patients that have had prior surgical procedures such as breast implants  reduction mammoplasty or axillary surgery;Patients scheduled for bilateral mastectomy for any reason; Patients that have had preoperative radiation therapy to the affected breast or axilla ",
        "premise_nums": []
    },
    {
        "id": "6a71c114-2e38-4d57-8f8b-8252d9c62cbe",
        "primaryId": "NCT01491737",
        "statement_text": "There were 4 cases of Febrile neutropenia in cohort 1 of the primary trial  and 0 cases of heart failure ",
        "statement_nums": [
            "4 cases of",
            "1 of the",
            "0 cases of"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Febrile neutropenia 4/127 (3.15%) Cardiac failure 0/127 (0.00%) ",
        "premise_nums": [
            "0/127 (0.00%)",
            "4/127 (3.15%)"
        ]
    },
    {
        "id": "4333aaa3-dbe4-4275-a982-881fe25c96c0",
        "primaryId": "NCT00407888",
        "statement_text": "Arm 2 of the primary trial receive dose-intensive chemotherapy on a21 day cycle up to 3 times in the absence of disease progression or unacceptable toxicity ",
        "statement_nums": [
            "2 of the",
            "3 times in",
            "a21 day",
            "21 day cycle"
        ],
        "label": "Contradiction",
        "premise_text": "INTERVENTION 1: Arm I ",
        "premise_nums": []
    },
    {
        "id": "4333aaa3-dbe4-4275-a982-881fe25c96c0",
        "primaryId": "NCT00407888",
        "statement_text": "Arm 2 of the primary trial receive dose-intensive chemotherapy on a21 day cycle up to 3 times in the absence of disease progression or unacceptable toxicity ",
        "statement_nums": [
            "2 of the",
            "3 times in",
            "a21 day",
            "21 day cycle"
        ],
        "label": "Contradiction",
        "premise_text": "Patients receive dose-intensive chemotherapy comprising doxorubicin hydrochloride IV over 10-15 minutes on day 1, oral cyclophosphamide once daily on days 1-7, and filgrastim subcutaneously on days 2-7. Courses repeat every 7 days for up to 12 weeks in the absence of disease progression or unacceptable toxicity  Beginning 1 week later  patients then receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes once a week for 12 weeks in the absence of disease progression or unacceptable toxicity  Patients with HER-2/neu positive disease also receive trastuzumab IV over 30-90 minutes once a week for 1 year in the absence of disease progression or unacceptable toxicity ",
        "premise_nums": [
            "1 week later",
            "30 minutes once",
            "30-90 minutes",
            "7 days for",
            "90 minutes once",
            "15 minutes on",
            "12 weeks in",
            "2/neu positive",
            "2-7. Courses",
            "10-15 minutes",
            "1 year in",
            "1-7, and"
        ]
    },
    {
        "id": "4333aaa3-dbe4-4275-a982-881fe25c96c0",
        "primaryId": "NCT00407888",
        "statement_text": "Arm 2 of the primary trial receive dose-intensive chemotherapy on a21 day cycle up to 3 times in the absence of disease progression or unacceptable toxicity ",
        "statement_nums": [
            "2 of the",
            "3 times in",
            "a21 day",
            "21 day cycle"
        ],
        "label": "Contradiction",
        "premise_text": "doxorubicin hydrochloride: Given IVcyclophosphamide: Given orally filgrastim: Given SC paclitaxel albumin-stabilized nanoparticle formulation: Given IV trastuzumab: Given IV laboratory biomarker analysis: Correlative studies quality-of-life assessment: Ancillary studies ",
        "premise_nums": []
    },
    {
        "id": "d605b820-2915-4b19-b9cd-ca7850645f83",
        "primaryId": "NCT00357110",
        "statement_text": "Only 6 patients in cohort 1 of the primary trial had Varicose Veins ",
        "statement_nums": [
            "6 patients in",
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Varicose Vein 1/6 (16.67%) ",
        "premise_nums": [
            "1/6 (16.67%)"
        ]
    },
    {
        "id": "d6de70df-d113-4bc8-9d3b-b71f31937ebe",
        "primaryId": "NCT01525589",
        "statement_text": "People who inherit harmful variants of the BReast CAncer gene 1 or 2 are eligible for the primary trial ",
        "statement_nums": [
            "1 or 2"
        ],
        "label": "Entailment",
        "premise_text": "Inclusion Criteria: Known deleterious germline mutation of BRCA1/2 (Patients in Cohorts A and A1) ",
        "premise_nums": [
            "1/2 (Patients"
        ]
    },
    {
        "id": "9f897b29-7cfa-414c-8cf6-212a68ec2216",
        "primaryId": "NCT03346161",
        "secondaryId": "NCT01000662",
        "label": "Contradiction",
        "statement_text": "Neither the secondary trial or the primary trial require patients to undergo any kind of medical treatment during their interventions  they are only testing effectiveness of consultations ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Arm 1: BREASTChoice (Decision Tool) Investigators recruited patients scheduled for a plastic/reconstruction consult  Investigators identified patients who completed a mastectomy  or were scheduled for one  and considering reconstruction  but didn't have an appointment with a plastic/reconstructive surgeon  A study team member called the patient to determine their interest and offered for them to come to their scheduled appointment 30 minutes early to meet a coordinator or offered them the option to complete pre-appointment procedures at home  Patients randomized using computer random assignment  If the patient didn't have an appointment  she scheduled a convenient time to complete study procedures with research staff  Patients interacted with the decision tool  They were asked to answer a survey  After the appointment  the team collected information consult duration  decision process quality  and measures of shared decision making  Patient participation was approximately 30 minutes  INTERVENTION 2: ",
        "premise_nums": [
            "30 minutes early"
        ]
    },
    {
        "id": "9f897b29-7cfa-414c-8cf6-212a68ec2216",
        "primaryId": "NCT03346161",
        "secondaryId": "NCT01000662",
        "label": "Contradiction",
        "statement_text": "Neither the secondary trial or the primary trial require patients to undergo any kind of medical treatment during their interventions  they are only testing effectiveness of consultations ",
        "statement_nums": [],
        "premise_text": "Arm 2: Enhanced Usual Care (Surgical Care Booklet)",
        "premise_nums": []
    },
    {
        "id": "9f897b29-7cfa-414c-8cf6-212a68ec2216",
        "primaryId": "NCT03346161",
        "secondaryId": "NCT01000662",
        "label": "Contradiction",
        "statement_text": "Neither the secondary trial or the primary trial require patients to undergo any kind of medical treatment during their interventions  they are only testing effectiveness of consultations ",
        "statement_nums": [],
        "premise_text": "Investigators recruited patients scheduled for plastic/reconstruction consultation  Investigators identified patients who completed or scheduled a mastectomy  and considering reconstruction  but didn't have an appointment with a plastic/reconstructive surgeon  A study team member called the patient to determine their interest and offered for them to come to their scheduled appointment 30 minutes early to meet a coordinator or to complete the pre-appointment procedures at home  Patients were randomized using computer random assignment  If the patient didn't have an appointment  she scheduled a convenient time to complete study procedures with research staff  Patients interacted with American Society of Plastic Surgeons booklet \"Breast Reconstruction.\" They were asked to answer a survey  After the appointment  the team collected information about consult duration  decision process quality  and measures of shared decision making  Patient participation was approximately 30 minutes INTERVENTION 1: ARM 1 Daily Boost Radiation Therapy ",
        "premise_nums": [
            "30 minutes early",
            "1 Daily Boost",
            "30 minutes INTERVENTION"
        ]
    },
    {
        "id": "9f897b29-7cfa-414c-8cf6-212a68ec2216",
        "primaryId": "NCT03346161",
        "secondaryId": "NCT01000662",
        "label": "Contradiction",
        "statement_text": "Neither the secondary trial or the primary trial require patients to undergo any kind of medical treatment during their interventions  they are only testing effectiveness of consultations ",
        "statement_nums": [],
        "premise_text": "Radiation Therapy: Arm 1= 15 daily radiation fractions of 2.7 Gy  Monday to Friday for 3 weeks  to the whole breast with a daily concomitant boost of 0.5 Gy to the tumor bed  for a total daily dose of 3.2 Gy to the tumor bed (2.7Gy+0.5 Gy)  The overall dose will be 40.5 Gy to the breast and 48.0 Gy to the tumor bed ",
        "premise_nums": [
            "of 3.2 Gy to",
            "and 48.0 Gy to",
            "of 0.5 Gy to",
            "be 40.5 Gy to",
            "15 daily radiation"
        ]
    },
    {
        "id": "9f897b29-7cfa-414c-8cf6-212a68ec2216",
        "primaryId": "NCT03346161",
        "secondaryId": "NCT01000662",
        "label": "Contradiction",
        "statement_text": "Neither the secondary trial or the primary trial require patients to undergo any kind of medical treatment during their interventions  they are only testing effectiveness of consultations ",
        "statement_nums": [],
        "premise_text": "Arm 2= 15 daily radiation fractions of 2.7 Gy Monday to friday for three weeks to the entire breast with a Friday boost of 2.0 Gy to the tumor bed  for a total dose to the tumor bed on each friday of 4.7 Gy (2.7 Gy+ 2.0 Gy)  The overall dose will be 40.5 Gy to the breast and 46.5 gy to the tumor bed INTERVENTION 2: ARM 2 Weekly Boost Radiation Therapy ",
        "premise_nums": [
            "7 Gy (2.7",
            "of 2.7 Gy Monday",
            "15 daily radiation",
            "2 Weekly Boost",
            "be 40.5 Gy to",
            "and 46.5 gy to",
            "of 2.0 Gy to"
        ]
    },
    {
        "id": "9f897b29-7cfa-414c-8cf6-212a68ec2216",
        "primaryId": "NCT03346161",
        "secondaryId": "NCT01000662",
        "label": "Contradiction",
        "statement_text": "Neither the secondary trial or the primary trial require patients to undergo any kind of medical treatment during their interventions  they are only testing effectiveness of consultations ",
        "statement_nums": [],
        "premise_text": "Radiation Therapy: Arm 1= 15 daily radiation fractions of 2.7 Gy  Monday to Friday for 3 weeks  to the whole breast with a daily concomitant boost of 0.5 Gy to the tumor bed  for a total daily dose of 3.2 Gy to the tumor bed (2.7Gy+0.5 Gy)  The overall dose will be 40.5 Gy to the breast and 48.0 Gy to the tumor bed ",
        "premise_nums": [
            "of 3.2 Gy to",
            "and 48.0 Gy to",
            "of 0.5 Gy to",
            "be 40.5 Gy to",
            "15 daily radiation"
        ]
    },
    {
        "id": "9f897b29-7cfa-414c-8cf6-212a68ec2216",
        "primaryId": "NCT03346161",
        "secondaryId": "NCT01000662",
        "label": "Contradiction",
        "statement_text": "Neither the secondary trial or the primary trial require patients to undergo any kind of medical treatment during their interventions  they are only testing effectiveness of consultations ",
        "statement_nums": [],
        "premise_text": "Arm 2= 15 daily radiation fractions of 2.7 Gy Monday to friday for three weeks to the entire breast with a Friday boost of 2.0 Gy to the tumor bed  for a total dose to the tumor bed on each friday of 4.7 Gy (2.7 Gy+ 2.0 Gy)  The overall dose will be 40.5 Gy to the breast and 46.5 gy to the tumor bed ",
        "premise_nums": [
            "7 Gy (2.7",
            "of 2.7 Gy Monday",
            "15 daily radiation",
            "be 40.5 Gy to",
            "and 46.5 gy to",
            "of 2.0 Gy to"
        ]
    },
    {
        "id": "0d0deba5-c7bd-489b-a49d-c6af9a5cd92a",
        "primaryId": "NCT00676663",
        "statement_text": "The the primary trial placebo group performed much better than the test group  as a lower PFS is ideal ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Progression-free Survival (PFS) PFS is defined as the number of months from the date of randomization to the earlier of progressive disease (PD) or death due to any cause  Time frame: From date of randomization to discontinuation due to disease progression or death up to primary completion date (Median follow-up 6 months) Results 1: Arm/Group Title: Exemestane 25 mg + Placebo Arm/Group Description: Exemestane (Aromasin ) 25 mg tablets orally once daily plus a placebo-matching entinostat tablet orally once per week on Days 1, 8, 15 and 22 of each 28-day treatment cycle until development of progressive disease (PD) or unacceptable toxicity or closure of the study by the Sponsor  whichever occurred first  Overall Number of Participants Analyzed: 66 ",
        "premise_nums": [
            "15 and 22",
            "25 mg tablets",
            "28-day treatment"
        ]
    },
    {
        "id": "0d0deba5-c7bd-489b-a49d-c6af9a5cd92a",
        "primaryId": "NCT00676663",
        "statement_text": "The the primary trial placebo group performed much better than the test group  as a lower PFS is ideal ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Median (95% Confidence Interval)Unit of Measure: months 2.27 (1.81 to 3.68) Results 2: Arm/Group Title: Exemestane 25 mg + Entinostat 5 mg Arm/Group Description: Exemestane (Aromasin ) 25 mg tablets orally once daily plus an entinostat 5 mg tablet orally once per week on Days 1, 8, 15 and 22 of each 28-day treatment cycle until development of progressive disease (PD) or unacceptable toxicity or closure of the study by the Sponsor  whichever occurred first  Overall Number of Participants Analyzed: 64 Median (95% Confidence Interval) Unit of Measure: months 4.28 (3.26 to 5.36) ",
        "premise_nums": [
            "81 to 3.68)",
            "95% Confidence",
            "26 to 5.36)",
            "15 and 22",
            "5 mg Arm",
            "25 mg tablets",
            "28-day treatment"
        ]
    },
    {
        "id": "4606f64f-64cc-4d73-a8be-75701c97008d",
        "primaryId": "NCT00024102",
        "statement_text": "A patient in cohort 2 of the primary trial received a Plasma transfusion ",
        "statement_nums": [
            "2 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 2: Total: 17/181 (9.39%) Disseminated intravascular coagulation 0/181 (0.00%) Febrile neutropenia 1/181 (0.55%) Hemoglobin decreased 13/181 (7.18%) Lymphatics 0/181 (0.00%) Transfusion: pRBCs 1/181 (0.55%) Arrhythmia supraventricular 1/181 (0.55%) Cardiac disorder 0/181 (0.00%) Edema 0/181 (0.00%) Left ventricular failure 1/181 (0.55%) Myocardial ischemia 0/181 (0.00%) ",
        "premise_nums": [
            "13/181 (7.18%)",
            "17/181 (9.39%)",
            "0/181 (0.00%)",
            "1/181 (0.55%)"
        ]
    },
    {
        "id": "40bef815-18ed-4db5-8108-9a1cdbdd0a13",
        "primaryId": "NCT00478257",
        "statement_text": "Adequate Hematologic  Hepatic and renal function is not necessary for participating in the primary trial  However  being pregnant is required ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria: stage I-III breast cancer adjuvant or neoadjuvant anthracycline-based chemotherapy Exclusion Criteria: under age 18 pregnancy metastatic or inoperable (including inflammatory) breast cancer confounding underlying medical illnesses history of mania history of other axis-I psychiatric disorder other physical or psychological impairments - ",
        "premise_nums": [
            "18 pregnancy metastatic"
        ]
    },
    {
        "id": "5c676007-9ea4-4f80-82dd-89293237cb07",
        "primaryId": "NCT00319254",
        "statement_text": "the primary trial did not use overall response rate  tumour response rate or preference score as its outcome measurement ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Progression-Free Survival (PFS) Rate PFS was based on Kaplan-Meier estimates  PFS was defined as time in weeks from start of study treatment to first documentation of objective tumor progression or death due to any cause  PFS was calculated as (first event date minus the date of first dose of study medication plus 1) divided by 7. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease [PD])  or from death case report forms (CRFs)  Percentage of participants who had not experienced progression or death by Week 16 is reported  ",
        "premise_nums": [
            "16 is reported"
        ]
    },
    {
        "id": "a6682883-ace7-4d83-a35c-956928fdc75a",
        "primaryId": "NCT01325428",
        "secondaryId": "NCT00073073",
        "label": "Contradiction",
        "statement_text": "the secondary trial and the primary trial do not require participants to be of a particular ethnicity  sex  height or to be able to speak a specific language ",
        "statement_nums": [],
        "premise_text": "Inclusion criteria: Female patients greater than or equal 18 years with proven diagnosis of HER2-overexpressing, histologically confirmed breast cancer Locally advanced or metastatic disease Must have disease that can be evaluated according to RECIST 1.1 (Response Evaluation Criteria for Solid Tumours version 1.1) For trastuzumab pre-treated patients  must have failed prior trastuzumab treatment Investigator-confirmed diagnosis of Inflammatory Breast Cancer Must have biopsiable disease Exclusion criteria: Prior treatment with HER2-targeted small molecules or antibodies other than trastuzumab (which must have been given in the trastuzumab-failure study population) Must not have received prior vinorelbine treatment INCLUSION CRITERIA: Postmenopausal female  ",
        "premise_nums": [
            "2-targeted small",
            "18 years with",
            "2-overexpressing, histologically"
        ]
    },
    {
        "id": "a6682883-ace7-4d83-a35c-956928fdc75a",
        "primaryId": "NCT01325428",
        "secondaryId": "NCT00073073",
        "label": "Contradiction",
        "statement_text": "the secondary trial and the primary trial do not require participants to be of a particular ethnicity  sex  height or to be able to speak a specific language ",
        "statement_nums": [],
        "premise_text": "Postmenopausal defined as no menses for at least 12 months or bilateral oophorectomy  In unclear cases  (e.g  50 year old who has had hysterectomy) chemical confirmation of postmenopausal status may be confirmed with follicle stimulating hormone (FSH) greater than 35 U/L Elevated risk for developing invasive breast cancer by virtue of one of the following criteria: Gail Model risk of greater than or equal to 1.7% over 5 years from study entry  (This is the same minimum level of risk required for a subject to be eligible for the recently completed NSABP-P1 tamoxifen breast cancer prevention trial)  Lobular neoplasia  Atypical ductal hyperplasia  ",
        "premise_nums": [
            "1 tamoxifen breast",
            "to 1.7% over 5",
            "5 years from",
            "50 year old",
            "12 months or",
            "35 U/L Elevated"
        ]
    },
    {
        "id": "a6682883-ace7-4d83-a35c-956928fdc75a",
        "primaryId": "NCT01325428",
        "secondaryId": "NCT00073073",
        "label": "Contradiction",
        "statement_text": "the secondary trial and the primary trial do not require participants to be of a particular ethnicity  sex  height or to be able to speak a specific language ",
        "statement_nums": [],
        "premise_text": "DCIS (ductal carcinoma in situ) that has been previously treated with mastectomy or lumpectomy and radiation  +/- tamoxifen Deleterious mutations in BRCA1 or 2 OR A priori risk assessment of 20% chance or greater of carrying BRCA1/2 gene mutation  The BRCAPRO and Couch model will both be used to asses this risk  If a woman has a 20% risk of carrying a BRCA1/2 mutation by either model  she will meet eligibility criteria  Prior stage I or II breast cancer at least 2 years out from treatment for invasive disease and no prior use of aromatase inhibitors  ",
        "premise_nums": [
            "2 mutation by",
            "20% chance",
            "20% risk",
            "2 years out",
            "1 or 2",
            "2 OR A",
            "2 gene mutation",
            "BRCA1/2 mutation",
            "BRCA1/2 gene"
        ]
    },
    {
        "id": "a6682883-ace7-4d83-a35c-956928fdc75a",
        "primaryId": "NCT01325428",
        "secondaryId": "NCT00073073",
        "label": "Contradiction",
        "statement_text": "the secondary trial and the primary trial do not require participants to be of a particular ethnicity  sex  height or to be able to speak a specific language ",
        "statement_nums": [],
        "premise_text": "Subjects should be willing to abstain from use of hormonal therapies (e.g  tamoxifen  hormone replacement therapy  oral contraceptive pills  hormone-containing intrauterine devices (IUDs)  E-string is acceptable)  Venlafaxine will be offered as supportive care for women with menopausal symptoms Eastern Cooperative Oncology Group (ECOG) performance status 0-1. Subject has been counseled regarding her options and has signed the informed consent document  Baseline dual-emission x-ray absorptiometry (DEXA) scan with bone mineral density (BMD) T-score greater than or equal to 2.5 at antero posterior (AP) spine  Hemoglobin greater than or equal to 11 g/dl  ",
        "premise_nums": [
            "11 g/dl",
            "to 2.5 at antero",
            "0-1. Subject"
        ]
    },
    {
        "id": "a6682883-ace7-4d83-a35c-956928fdc75a",
        "primaryId": "NCT01325428",
        "secondaryId": "NCT00073073",
        "label": "Contradiction",
        "statement_text": "the secondary trial and the primary trial do not require participants to be of a particular ethnicity  sex  height or to be able to speak a specific language ",
        "statement_nums": [],
        "premise_text": "Creatinine less than 1.5 times the upper limits of normal Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) less than 2.5 times upper limit of normal  No investigational agent for the past 30 days  If history of cancer (other than squamous or basal cell skin cancers)  subject must have no evidence of disease at time of enrollment AND no history of cancer directed treatment in the 2 years preceding enrollment  EXCLUSION CRITERIA: ",
        "premise_nums": [
            "2 years preceding",
            "than 2.5 times upper",
            "than 1.5 times the"
        ]
    },
    {
        "id": "a6682883-ace7-4d83-a35c-956928fdc75a",
        "primaryId": "NCT01325428",
        "secondaryId": "NCT00073073",
        "label": "Contradiction",
        "statement_text": "the secondary trial and the primary trial do not require participants to be of a particular ethnicity  sex  height or to be able to speak a specific language ",
        "statement_nums": [],
        "premise_text": "Current or recent chronic use (within 3 months) of hormonal medications  e.g  oral contraceptive pills  hormone replacement therapy  tamoxifen  raloxifene  IUD with progestins or corticosteroids  (Subjects on chronic topical or inhaled steroids will be eligible for the study.) Current use of phenytoin  carbamazepine  rifampin due to increased estrogen metabolism History of clotting or bleeding disorder  History of allergic reactions attributed to compounds of similar chemical or biologic composition to exemestane (e.g  anastrozole  letrozole  formestane)  ",
        "premise_nums": []
    },
    {
        "id": "a6682883-ace7-4d83-a35c-956928fdc75a",
        "primaryId": "NCT01325428",
        "secondaryId": "NCT00073073",
        "label": "Contradiction",
        "statement_text": "the secondary trial and the primary trial do not require participants to be of a particular ethnicity  sex  height or to be able to speak a specific language ",
        "statement_nums": [],
        "premise_text": "Uncontrolled intercurrent illness including  but not limited to  ongoing or active infection  symptomatic congestive heart failure  unstable angina pectoris  cardiac arrhythmia  or psychiatric illness/social situations that would limit compliance with study requirements ",
        "premise_nums": []
    },
    {
        "id": "1a271e29-477b-4819-a472-5c7c7df99e70",
        "primaryId": "NCT00265759",
        "secondaryId": "NCT00866905",
        "label": "Contradiction",
        "statement_text": "2 cases of hematolysis were recorded in the primary trial  none in the secondary trial ",
        "statement_nums": [
            "2 cases of"
        ],
        "premise_text": "Adverse Events 1: Total: 9/157 (5.73%) Blood disorder 1/157 (0.64%) Hemoglobin decreased 1/157 (0.64%) Hemolysis 0/157 (0.00%) Arrhythmia 0/157 (0.00%) Cardiac disorder 0/157 (0.00%) Myocardial ischemia 1/157 (0.64%) Hearing impaired 0/157 (0.00%) Tinnitus 0/157 (0.00%) Cataract 0/157 (0.00%) Diplopia 0/157 (0.00%) Glaucoma 0/157 (0.00%) Vision blurred 0/157 (0.00%) Adverse Events 2: Total: 14/157 (8.92%) ",
        "premise_nums": [
            "14/157 (8.92%)",
            "1/157 (0.64%)",
            "9/157 (5.73%)",
            "0/157 (0.00%)"
        ]
    },
    {
        "id": "1a271e29-477b-4819-a472-5c7c7df99e70",
        "primaryId": "NCT00265759",
        "secondaryId": "NCT00866905",
        "label": "Contradiction",
        "statement_text": "2 cases of hematolysis were recorded in the primary trial  none in the secondary trial ",
        "statement_nums": [
            "2 cases of"
        ],
        "premise_text": "Blood disorder 0/157 (0.00%)Hemoglobin decreased 2/157 (1.27%) Hemolysis 1/157 (0.64%) Arrhythmia 0/157 (0.00%) Cardiac disorder 0/157 (0.00%) Myocardial ischemia 0/157 (0.00%) Hearing impaired 2/157 (1.27%) Tinnitus 1/157 (0.64%) Cataract 1/157 (0.64%) Diplopia 0/157 (0.00%) Glaucoma 1/157 (0.64%) Vision blurred 1/157 (0.64%) Adverse Events 1: Total: 6/168 (3.57%) ",
        "premise_nums": [
            "6/168 (3.57%)",
            "0/157 (0.00%)Hemoglobin",
            "2/157 (1.27%)",
            "1/157 (0.64%)"
        ]
    },
    {
        "id": "1a271e29-477b-4819-a472-5c7c7df99e70",
        "primaryId": "NCT00265759",
        "secondaryId": "NCT00866905",
        "label": "Contradiction",
        "statement_text": "2 cases of hematolysis were recorded in the primary trial  none in the secondary trial ",
        "statement_nums": [
            "2 cases of"
        ],
        "premise_text": "FEBRILE NEUTROPENIA 3/168 (1.79%)ENTERITIS 1/168 (0.60%) PERIPHERAL NEUROPATHY 2/168 (1.19%) DEPRESSION 1/168 (0.60%) ",
        "premise_nums": [
            "3/168 (1.79%)ENTERITIS",
            "1/168 (0.60%)",
            "2/168 (1.19%)"
        ]
    },
    {
        "id": "060e833e-384f-48f0-8e56-ebd95f55f221",
        "primaryId": "NCT01926886",
        "statement_text": "There were no cases of Cellulitis  Vertigo or Anaemia in the primary trial ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 8/101 (7.92%) Vertigo * 1/101 (0.99%) Infected lymphocele * 1/101 (0.99%) Ejection fraction decreased * 5/101 (4.95%) Lymphoedema * 1/101 (0.99%) ",
        "premise_nums": [
            "8/101 (7.92%)",
            "5/101 (4.95%)",
            "1/101 (0.99%)"
        ]
    },
    {
        "id": "ac193d32-156e-48bf-bc6b-d613691f869c",
        "primaryId": "NCT01166763",
        "statement_text": "the primary trial only recorded three types of adverse events ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 3/30 (10.00%) Cholecystitis * [1]1/30 (3.33%) Increase in diarrhea * [2]1/30 (3.33%) Flank pain * [3]1/30 (3.33%) ",
        "premise_nums": [
            "1/30 (3.33%)",
            "3/30 (10.00%)"
        ]
    },
    {
        "id": "d79173da-5e59-4150-99bd-f1c20118dddc",
        "primaryId": "NCT00503750",
        "statement_text": "All participants of the primary trial must have recently undergone either an echocardiography ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria: Normal (greater than 50%) left ventricular ejection fraction (LVEF) by MUGA scan or echocardiography  ",
        "premise_nums": []
    },
    {
        "id": "50559f15-636d-4265-8f8c-4aad016c6c50",
        "primaryId": "NCT01176916",
        "secondaryId": "NCT00186121",
        "label": "Entailment",
        "statement_text": "postmenopausal women are eligible for the primary trial  and Premenopausal women are eligible for the secondary trial ",
        "statement_nums": [],
        "premise_text": "Inclusion Criteria: The patient must be postmenopausal woman  INCLUSION CRITERIA Premenopausal  defined as any of: ",
        "premise_nums": []
    },
    {
        "id": "a5af6d2b-4cea-40aa-acdc-59fab5362b3e",
        "primaryId": "NCT00635050",
        "statement_text": "Patients with Breast cancers that have estrogen receptors are included in the primary trial ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria: Patients with node-negative  ER or PR-positive tumors 4 cm in size whose tumors are low risk (defined as a score of 0-17) on an Oncotype DX profile are not eligible  ",
        "premise_nums": [
            "0-17) on",
            "4 cm in"
        ]
    },
    {
        "id": "7e89b190-b8f7-4281-b0f1-0e65dcebf402",
        "primaryId": "NCT00941330",
        "statement_text": "Patients in cohort 1 of the primary trial receive Exemestane twice as often as cohort 2 patients receive Cytoxan ",
        "statement_nums": [
            "2 patients receive",
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "INTERVENTION 1: A: Exemestane ARM A: Patients will be treated with exemestane  Exemestane: 25 mg daily by mouth for 6 to 12 months  INTERVENTION 2: B: Docetaxel and Cytoxan ARM B: Patients will be treated with docetaxel and cytoxan  Docetaxel: Docetaxel (75 mg/m²) into a vein once every 3 weeks for 6 cycles (6 times in about 24 weeks)  Cytoxan: Cytoxan (600 mg/m²) into a vein once every 3 weeks for 6 cycles (6 times in about 24 weeks)  ",
        "premise_nums": [
            "6 cycles (6",
            "25 mg daily",
            "3 weeks for",
            "6 to 12"
        ]
    },
    {
        "id": "6036d341-9c6a-49fc-a2f4-19c0e2399f4c",
        "primaryId": "NCT01565083",
        "statement_text": "There were significantly more cases of ventricular tachycardia than Supraventricular tachycardia in cohort 2 of the primary trial ",
        "statement_nums": [
            "2 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 2: Supraventricular tachycardia * 1/107 (0.93%) Tachycardia * 1/107 (0.93%) ",
        "premise_nums": [
            "1/107 (0.93%)"
        ]
    },
    {
        "id": "a84afa25-2741-4a08-9e6c-4049f5feca48",
        "primaryId": "NCT01790932",
        "statement_text": "patients with Phosphoinositide 3-kinase inhibitor based treatments are eligible for the primary trial  if this treatment ended over 5 years prior ",
        "statement_nums": [
            "5 years prior",
            "3-kinase inhibitor"
        ],
        "label": "Contradiction",
        "premise_text": "Exclusion Criteria: Have received previous treatment with PI3K inhibitors ",
        "premise_nums": []
    },
    {
        "id": "09e4c746-642a-4a5d-a267-25258a3f2ec0",
        "primaryId": "NCT01669343",
        "secondaryId": "NCT00146172",
        "label": "Entailment",
        "statement_text": "the primary trial and the secondary trial do not have the same duration of intervention administration ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Post-menopausal Women Using Adjuvant Letrozole Part A Routine Care Letrozole; Part B Double Dose Letrozole in overweight/obese participants Letrozole: Part A Monitor standard of care letrozole use for 28 days; measure blood levels of estrogens and vitamin D at start and end of period  Part B In overweight/obese participants who completed Part A  provide a double dose of letrozole and monitor use for 28 days; measure blood levels of estrogens and vitamin D at start and end of period  INTERVENTION 1: Neratinib 40 mg Neratinb 40 mg qd INTERVENTION 2: Neratinib 80 mg Neratinib 80 mg qd ",
        "premise_nums": [
            "80 mg Neratinib",
            "80 mg qd",
            "40 mg Neratinb",
            "40 mg qd"
        ]
    },
    {
        "id": "99855d11-e2e4-4a0e-b40e-2264ff128ac5",
        "primaryId": "NCT02502864",
        "statement_text": "the primary trial recorded the same number of occurences for every type of adverse event ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 3/9 (33.33%) Fatigue * 1/9 (11.11%) Non-cardiac chest pain * 1/9 (11.11%) Sepsis * 1/9 (11.11%) Urinary tract infection * 1/9 (11.11%) Syncope * 1/9 (11.11%) Anxiety * 1/9 (11.11%) Thromboembolic event * 1/9 (11.11%) ",
        "premise_nums": [
            "1/9 (11.11%)",
            "3/9 (33.33%)"
        ]
    },
    {
        "id": "54fe69c7-5a67-49b1-8bc5-c975133e2bb7",
        "primaryId": "NCT00712985",
        "secondaryId": "NCT02038010",
        "label": "Entailment",
        "statement_text": "Patients in the primary trial receive a lower dose of Zometa by IV than the secondary trial patients receive of ado-trastuzumab emtansine ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Zoledronic Acid 5 mg IV Zometa (Zoledronic Acid) 5 mg IV given over 15 minutes as a one time dose  Follow-up at month 1 & every 2 months to month 12 for serum & urine markers of bone destruction (NTx & CTx)  INTERVENTION 1: Cohort -1 (250mg BYL719, 3.6mg/kg T-DM1) ",
        "premise_nums": [
            "12 for serum",
            "5 mg IV",
            "2 months to",
            "15 minutes as",
            "3.6mg/kg"
        ]
    },
    {
        "id": "54fe69c7-5a67-49b1-8bc5-c975133e2bb7",
        "primaryId": "NCT00712985",
        "secondaryId": "NCT02038010",
        "label": "Entailment",
        "statement_text": "Patients in the primary trial receive a lower dose of Zometa by IV than the secondary trial patients receive of ado-trastuzumab emtansine ",
        "statement_nums": [],
        "premise_text": "Patients receive 250 mg PO daily PI3K inhibitor BYL719 on days 1-21 and 3.6mg/kg IV over 30-90 minutes on day 1 ado-trastuzumab emtansine (T-DM1). Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity PI3K inhibitor BYL719: Given PO Ado-trastuzumab emtansine: Given IV Pharmacological study: Correlative studies Laboratory biomarker analysis: Optional correlative studies ",
        "premise_nums": [
            "1-21 and",
            "250 mg PO",
            "21 days in",
            "30-90 minutes",
            "1 ado-trastuzumab emtansine",
            "and 3.6mg/kg",
            "719 on days",
            "BYL719 on",
            "90 minutes on"
        ]
    },
    {
        "id": "76362fd3-3a07-4aa3-a072-b9075d2ea791",
        "primaryId": "NCT00436566",
        "statement_text": "Not a single patient in the primary trial suffered from Congestive Heart Failure (during active treatment) ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Number of Patients With Congestive Heart Failure (CHF) While on Active Treatment [Not Specified] Time frame: 6 months Results 1: Arm/Group Title: AC/PTL Arm/Group Description: Standard doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (80 mg/m^2) x 12 with concurrent standard dose trastuzumab (weekly x 12, then repeat 3 weeks for an additional 9 months) plus daily lapatinib (modified to 750 mg during Paclitaxel + Trastuzumab + Lapatinib (PTL) and 1000 mg during trastuzumab + lapatinib (TL)) for a total of 12 months  Overall Number of Participants Analyzed: 109 ",
        "premise_nums": [
            "1000 mg during",
            "6 months Results",
            "3 weeks for",
            "12 with concurrent",
            "750 mg during"
        ]
    },
    {
        "id": "76362fd3-3a07-4aa3-a072-b9075d2ea791",
        "primaryId": "NCT00436566",
        "statement_text": "Not a single patient in the primary trial suffered from Congestive Heart Failure (during active treatment) ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Measure Type: NumberUnit of Measure: participants 0 ",
        "premise_nums": []
    },
    {
        "id": "064b39e9-e9d8-4c51-a76a-ad150bb127f1",
        "primaryId": "NCT00878709",
        "secondaryId": "NCT02447003",
        "label": "Entailment",
        "statement_text": "the primary trial had a total of 3 patients experiencing pancreas related adverse events  the secondary trial had 0.",
        "statement_nums": [
            "3 patients experiencing"
        ],
        "premise_text": "Adverse Events 1: Total: 103/1408 (7.32%) Anaemia 1/1408 (0.07%) Angina pectoris 1/1408 (0.07%) Myocardial infarction 1/1408 (0.07%) Atrial fibrillation 0/1408 (0.00%) Sinus tachycardia 0/1408 (0.00%) Tachycardia 0/1408 (0.00%) Vertigo 0/1408 (0.00%) Diarrhoea 22/1408 (1.56%) Vomiting 12/1408 (0.85%) Nausea 4/1408 (0.28%) Abdominal pain 2/1408 (0.14%) ",
        "premise_nums": [
            "12/1408 (0.85%)",
            "2/1408 (0.14%)",
            "0/1408 (0.00%)",
            "103/1408 (7.32%)",
            "22/1408 (1.56%)",
            "4/1408 (0.28%)",
            "1/1408 (0.07%)"
        ]
    },
    {
        "id": "064b39e9-e9d8-4c51-a76a-ad150bb127f1",
        "primaryId": "NCT00878709",
        "secondaryId": "NCT02447003",
        "label": "Entailment",
        "statement_text": "the primary trial had a total of 3 patients experiencing pancreas related adverse events  the secondary trial had 0.",
        "statement_nums": [
            "3 patients experiencing"
        ],
        "premise_text": "Pancreatitis 2/1408 (0.14%)Adverse Events 2: Total: 85/1408 (6.04%) Anaemia 1/1408 (0.07%) Angina pectoris 0/1408 (0.00%) Myocardial infarction 1/1408 (0.07%) Atrial fibrillation 1/1408 (0.07%) Sinus tachycardia 1/1408 (0.07%) Tachycardia 1/1408 (0.07%) Vertigo 1/1408 (0.07%) Diarrhoea 1/1408 (0.07%) Vomiting 1/1408 (0.07%) Nausea 1/1408 (0.07%) ",
        "premise_nums": [
            "0/1408 (0.00%)",
            "2/1408 (0.14%)Adverse",
            "1/1408 (0.07%)",
            "85/1408 (6.04%)"
        ]
    },
    {
        "id": "064b39e9-e9d8-4c51-a76a-ad150bb127f1",
        "primaryId": "NCT00878709",
        "secondaryId": "NCT02447003",
        "label": "Entailment",
        "statement_text": "the primary trial had a total of 3 patients experiencing pancreas related adverse events  the secondary trial had 0.",
        "statement_nums": [
            "3 patients experiencing"
        ],
        "premise_text": "Abdominal pain 0/1408 (0.00%)Pancreatitis 1/1408 (0.07%) Adverse Events 1: Total: 46/170 (27.06%) Anaemia 1/170 (0.59%) Febrile neutropenia 1/170 (0.59%) Cardiac tamponade 1/170 (0.59%) Myocarditis 1/170 (0.59%) Pericardial effusion 2/170 (1.18%) Pericarditis 1/170 (0.59%) Colitis 1/170 (0.59%) Constipation 1/170 (0.59%) Diarrhoea 0/170 (0.00%) ",
        "premise_nums": [
            "0/1408 (0.00%)Pancreatitis",
            "0/170 (0.00%)",
            "46/170 (27.06%)",
            "1/170 (0.59%)",
            "2/170 (1.18%)",
            "1/1408 (0.07%)"
        ]
    },
    {
        "id": "064b39e9-e9d8-4c51-a76a-ad150bb127f1",
        "primaryId": "NCT00878709",
        "secondaryId": "NCT02447003",
        "label": "Entailment",
        "statement_text": "the primary trial had a total of 3 patients experiencing pancreas related adverse events  the secondary trial had 0.",
        "statement_nums": [
            "3 patients experiencing"
        ],
        "premise_text": "Gastroenteritis eosinophilic 0/170 (0.00%)Intestinal obstruction 0/170 (0.00%) Adverse Events 2: Total: 0/1 (0.00%) Anaemia 0/1 (0.00%) Febrile neutropenia 0/1 (0.00%) Cardiac tamponade 0/1 (0.00%) Myocarditis 0/1 (0.00%) Pericardial effusion 0/1 (0.00%) Pericarditis 0/1 (0.00%) Colitis 0/1 (0.00%) Constipation 0/1 (0.00%) Diarrhoea 0/1 (0.00%) ",
        "premise_nums": [
            "0/1 (0.00%)",
            "0/170 (0.00%)Intestinal"
        ]
    },
    {
        "id": "064b39e9-e9d8-4c51-a76a-ad150bb127f1",
        "primaryId": "NCT00878709",
        "secondaryId": "NCT02447003",
        "label": "Entailment",
        "statement_text": "the primary trial had a total of 3 patients experiencing pancreas related adverse events  the secondary trial had 0.",
        "statement_nums": [
            "3 patients experiencing"
        ],
        "premise_text": "Gastroenteritis eosinophilic 0/1 (0.00%)Intestinal obstruction 0/1 (0.00%) Nausea 0/1 (0.00%) ",
        "premise_nums": [
            "0/1 (0.00%)Intestinal"
        ]
    },
    {
        "id": "67a628d7-d883-44b9-b351-901f20fd5d0a",
        "primaryId": "NCT00429182",
        "secondaryId": "NCT00429507",
        "label": "Entailment",
        "statement_text": "the secondary trial and the primary trial give their patient cohorts Stem Cell Transplants on the first day of the study ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: High-dose Chemotherapy Carboplatin + Cyclophosphamide + Thiotepa Carboplatin : Target AUC of 20, then divided into 4 doses given by vein (IV) days -6, -5, -4, -3 prior to stem cell infusion  Thiotepa : 120 mg/m^2 by vein days -6, -5, -4, -3 prior to stem cell infusion  Stem Cell Transplant : Stem Cell Transplant on Day 0. Cyclophosphamide : 1.5 gm/m^2 by vein days -6, -5, -4, -3 prior to stem cell infusion  INTERVENTION 1: Samarium 153-EDTMP + Stem Cell Transplant ",
        "premise_nums": [
            "3 prior to",
            "4 doses given",
            "153-EDTMP +",
            "120 mg/m^2",
            "2 by vein",
            "1.5 gm/m"
        ]
    },
    {
        "id": "67a628d7-d883-44b9-b351-901f20fd5d0a",
        "primaryId": "NCT00429182",
        "secondaryId": "NCT00429507",
        "label": "Entailment",
        "statement_text": "the secondary trial and the primary trial give their patient cohorts Stem Cell Transplants on the first day of the study ",
        "statement_nums": [],
        "premise_text": "Samarium 153-EDTMP tracer dose = 30 millicurie (mCi) intravenous Day 1; or with study drug to bones  receive higher therapy dose of 153 Sm-EDTMP 7-14 days after tracer dose  Stem Cell Transplant Day 0, about 14-21 days after Samarium 153-EDTMP.",
        "premise_nums": [
            "30 millicurie (mCi)",
            "153 Sm-EDTMP",
            "14 days after",
            "14-21 days",
            "21 days after",
            "7-14 days",
            "153-EDTMP tracer"
        ]
    },
    {
        "id": "78c60212-28f7-4306-9f63-549be04687b2",
        "primaryId": "NCT00448591",
        "statement_text": "Only two types of adverse events  Leukopenia and Anaemia  occurred in more than 1% of patient in cohort 1 of the primary trial ",
        "statement_nums": [
            "1% of",
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Total: 672/2264 (29.68%) Febrile neutropenia * 117/2264 (5.17%) Neutropenia * 98/2264 (4.33%) Febrile bone marrow aplasia * 14/2264 (0.62%) Anaemia * 8/2264 (0.35%) Leukopenia * 8/2264 (0.35%) Thrombocytopenia * 6/2264 (0.27%) Disseminated intravascular coagulation * 3/2264 (0.13%) Agranulocytosis * 1/2264 (0.04%) ",
        "premise_nums": [
            "14/2264 (0.62%)",
            "6/2264 (0.27%)",
            "117/2264 (5.17%)",
            "1/2264 (0.04%)",
            "8/2264 (0.35%)",
            "98/2264 (4.33%)",
            "3/2264 (0.13%)",
            "672/2264 (29.68%)"
        ]
    },
    {
        "id": "78c60212-28f7-4306-9f63-549be04687b2",
        "primaryId": "NCT00448591",
        "statement_text": "Only two types of adverse events  Leukopenia and Anaemia  occurred in more than 1% of patient in cohort 1 of the primary trial ",
        "statement_nums": [
            "1% of",
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Bone marrow failure * 1/2264 (0.04%)",
        "premise_nums": [
            "1/2264 (0.04%)"
        ]
    },
    {
        "id": "a72e1259-50be-48e5-bdf8-296040cbf7ce",
        "primaryId": "NCT01593020",
        "secondaryId": "NCT00834678",
        "label": "Contradiction",
        "statement_text": "Patients with aspartate aminotransferase more than 2 times the upper limit of normal are excluded from both the secondary trial but eligible for the primary trial ",
        "statement_nums": [
            "2 times the"
        ],
        "premise_text": "Exclusion Criteria: AST or ALT greater than 2.5 times the upper limit of normal (ULN) ALT and AST 2.5 times ULN ( 5 times ULN in the presence of documented liver metastases) ",
        "premise_nums": [
            "than 2.5 times the",
            "AST 2.5 times ULN"
        ]
    },
    {
        "id": "19cfd511-8582-4116-8d51-7ec4a6221022",
        "primaryId": "NCT03366428",
        "statement_text": "0/49 the primary trial Participants With HER2-expressing Metastatic and/or Unresectable Breast Cancer had a Maximum change from baseline in QTcF of smaller than 60ms.",
        "statement_nums": [
            "2-expressing Metastatic",
            "49 the primary",
            "0/49 the"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Changes in QTcF After Treatment With DS-8201a in Participants With HER2-expressing Metastatic and/or Unresectable Breast Cancer The number of participants with notable electrocardiogram changes meeting predefined criteria is being reported  Time frame: Screening (within 7 days before enrollment) up to Cycle 3 Day 15 (each cycle is 21 days) Results 1: Arm/Group Title: DS-8201a Arm/Group Description: Participants who received 6.4 mg/kg of DS-8201a as an intravenous (IV) infusion once every 3 weeks on Day 1 of each 21-day cycle  Overall Number of Participants Analyzed: 49 Measure Type: Count of Participants ",
        "premise_nums": [
            "1 of each",
            "3 Day 15",
            "2-expressing Metastatic",
            "received 6.4 mg/kg",
            "7 days before",
            "3 weeks on",
            "49 Measure Type:",
            "21-day cycle"
        ]
    },
    {
        "id": "19cfd511-8582-4116-8d51-7ec4a6221022",
        "primaryId": "NCT03366428",
        "statement_text": "0/49 the primary trial Participants With HER2-expressing Metastatic and/or Unresectable Breast Cancer had a Maximum change from baseline in QTcF of smaller than 60ms.",
        "statement_nums": [
            "2-expressing Metastatic",
            "49 the primary",
            "0/49 the"
        ],
        "label": "Contradiction",
        "premise_text": "Unit of Measure: Participants Maximum change from baseline in QTcF: greater than 30 ms: 3 6.1%Maximum change from baseline in QTcF: greater than 60 ms: 0 0.0% ",
        "premise_nums": [
            "3 6.1%Maximum change"
        ]
    },
    {
        "id": "3f012bd3-bb89-414b-9dd9-35cef524a69a",
        "primaryId": "NCT00820170",
        "statement_text": "According to the results of the primary trial the MTD of dasatinib in combination with weekly paclitaxel is approximately is 120 mg ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Phase I Portion: Maximum Tolerated Dose/MTD of Dasatinib When Administered in Combination With a Fixed Dose of Weekly Paclitaxel  [Not Specified] Time frame: Through completion of Phase I  up to 1 year Results 1: Arm/Group Title: Dasatinib and Paclitaxel Arm/Group Description: The phase I portion is a standard  three-patient per cohort  dose escalation schedule will be used  Between 6 and 54 patients will likely be necessary to determine the MTD of dasatinib in combination with weekly paclitaxel  The phase II portion of this trial has a Simon two-stage design to determine the efficacy of dasatinib when administered in combination with paclitaxel  ",
        "premise_nums": [
            "6 and 54",
            "1 year Results"
        ]
    },
    {
        "id": "3f012bd3-bb89-414b-9dd9-35cef524a69a",
        "primaryId": "NCT00820170",
        "statement_text": "According to the results of the primary trial the MTD of dasatinib in combination with weekly paclitaxel is approximately is 120 mg ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Dasatinib and Paclitaxel: A treatment cycle will consist of 28 days  according to the following schedule:Dasatinib 120MG PO once daily  Weekly paclitaxel 80 mg/m2 given intravenously over 1 hour on day 1, 8, and 15 of a 28 day cycle  The trial will initially test the combination of weekly paclitaxel and dasatinib given PO  once daily   continuously  In case of 2 dose-limiting toxicities (DLT) in the first cohort (0), the next cohort will test dasatinib given with a different schedule  5 days on and 2 days off  omitting dasatinib the day prior and the day of administration of paclitaxel  ",
        "premise_nums": [
            "5 days on",
            "2 dose-limiting toxicities",
            "28 day cycle",
            "1 hour on",
            "15 of a",
            "2 given intravenously",
            "2 days off",
            "80 mg/m2 given"
        ]
    },
    {
        "id": "3f012bd3-bb89-414b-9dd9-35cef524a69a",
        "primaryId": "NCT00820170",
        "statement_text": "According to the results of the primary trial the MTD of dasatinib in combination with weekly paclitaxel is approximately is 120 mg ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Overall Number of Participants Analyzed: 15Measure Type: Number Unit of Measure: mg of dasatinib 120 ",
        "premise_nums": []
    },
    {
        "id": "5eafb3a1-473a-4270-848d-173e5dca9466",
        "primaryId": "NCT02600923",
        "statement_text": "Patients with Leukemia  Hepatitis or Cataracts cannot be included in the primary trial ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria: Adult women with proven diagnosis of advanced adenocarcinoma of the breast (locoregional recurrent or metastatic disease)  Women who are not of childbearing potential  ER-positive and/or Progesterone receptor (PgR)-positive tumor based on local laboratory results (test as per local practice)  HER2-negative breast cancer based on local laboratory results (test as per local practice or local guidelines)  Patients must be appropriate candidates for letrozole therapy  Eastern Cooperative Oncology Group (ECOG) performance status 0-2. Adequate bone marrow function  Adequate liver function Adequate renal function  Exclusion Criteria: Known hypersensitivity to letrozole  or any of its excipients  or to any palbociclib excipients  ",
        "premise_nums": [
            "2-negative breast",
            "0-2. Adequate"
        ]
    },
    {
        "id": "5eafb3a1-473a-4270-848d-173e5dca9466",
        "primaryId": "NCT02600923",
        "statement_text": "Patients with Leukemia  Hepatitis or Cataracts cannot be included in the primary trial ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Current use of food or drugs known to be potent inhibitors or inducers of CYP3A4 isoenzymes within 7 days prior to study entry Prior treatment with any CDK inhibitor  Previous participation in a palbociclib clinical study  Participation in other studies involving investigational drug(s) within 2 weeks prior to study entry and/or during study participation  QTc greater than 480 msec; history of QT syndrome  Brugada syndrome or known history of QTc prolongation  or Torsade de Pointes  High cardiovascular risk  including  but not limited to recent myocardial infarction  severe/unstable angina and severe cardiac dysrhythmias in the past 6 months prior to enrollment  ",
        "premise_nums": [
            "7 days prior",
            "2 weeks prior",
            "4 isoenzymes within",
            "6 months prior"
        ]
    },
    {
        "id": "5eafb3a1-473a-4270-848d-173e5dca9466",
        "primaryId": "NCT02600923",
        "statement_text": "Patients with Leukemia  Hepatitis or Cataracts cannot be included in the primary trial ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Diagnosis of any second invasive malignancy within the last 3 years prior to enrollment  Note: patients with adequately treated basal cell or squamous cell skin cancer  a history of intraepithelial neoplasia or in situ disease (eg  carcinoma in situ of the cervix or melanoma in situ) may enter Active uncontrolled or symptomatic brain metastases  Previously treated and clinically stable  brain metastases are permitted  Other severe acute or chronic medical or psychiatric conditions  Patients who are investigational site staff members directly involved in the conduct of the study and their family members  site staff members otherwise supervised by the investigator  or patients who are Pfizer employees directly involved in the conduct of the study  ",
        "premise_nums": [
            "3 years prior"
        ]
    },
    {
        "id": "ed956644-5228-4915-b706-1cedb0462577",
        "primaryId": "NCT00711529",
        "secondaryId": "NCT02835625",
        "label": "Entailment",
        "statement_text": "the primary trial participants are treated with hypnosis  this is not used at all in the secondary trial ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Hypnotherapy Patients randomized to the hypnosis arm of the study will undergo individually three one-hour sessions with a certified hypnotherapist  These sessions will be one week apart  Patients will also be instructed on the use of self-hypnosis techniques to use at home  INTERVENTION 2: Gabapentin Patients randomized to the gabapentin arm will be prescribed 900mg of the drug daily (300 mg by mouth three times daily)  INTERVENTION 1: Digital Breast Tomosynthesis Digital Breast Tomosynthesis + Synthetic Mammography (DBT) The DBT was independently read by two radiologists  A consensus meeting decided whether to recall the woman or not  Women selected for further assessment (positive screening exam) was recalled  ",
        "premise_nums": [
            "300 mg by"
        ]
    },
    {
        "id": "ed956644-5228-4915-b706-1cedb0462577",
        "primaryId": "NCT00711529",
        "secondaryId": "NCT02835625",
        "label": "Entailment",
        "statement_text": "the primary trial participants are treated with hypnosis  this is not used at all in the secondary trial ",
        "statement_nums": [],
        "premise_text": "Digital Breast Tomosynthesis + Synthetic Mammography: Two-view tomosynthesis performed with GE SenoClaire 3D Breast Tomosynthesis INTERVENTION 2: Digital Mammography The digital mammograms was independently read by two radiologists  A consensus meeting decided whether to recall the woman or not  Women selected for further assessment (positive screening exam) was recalled  Digital mammography: Two-view digital mammography performed with GE SenoClaire 3D Breast Tomosynthesis  ",
        "premise_nums": []
    },
    {
        "id": "02158762-9490-46a1-b494-0589885fd4ce",
        "primaryId": "NCT00281697",
        "statement_text": "the primary trial does not record any cardiac related adverse events ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 112/458 (24.45%) Febrile neutropenia 8/458 (1.75%) Neutropenia 6/458 (1.31%) Anaemia 3/458 (0.66%) Thrombocytopenia 3/458 (0.66%) Pancytopenia 2/458 (0.44%) Myocardial infarction 0/458 (0.00%) Pericardial effusion 0/458 (0.00%) Tachycardia 0/458 (0.00%) Acute myocardial infarction 1/458 (0.22%) Atrial fibrillation 0/458 (0.00%) Adverse Events 2: ",
        "premise_nums": [
            "112/458 (24.45%)",
            "3/458 (0.66%)",
            "0/458 (0.00%)",
            "8/458 (1.75%)",
            "6/458 (1.31%)",
            "2/458 (0.44%)",
            "1/458 (0.22%)"
        ]
    },
    {
        "id": "02158762-9490-46a1-b494-0589885fd4ce",
        "primaryId": "NCT00281697",
        "statement_text": "the primary trial does not record any cardiac related adverse events ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Total: 39/221 (17.65%)Febrile neutropenia 5/221 (2.26%) Neutropenia 1/221 (0.45%) Anaemia 2/221 (0.90%) Thrombocytopenia 0/221 (0.00%) Pancytopenia 0/221 (0.00%) Myocardial infarction 2/221 (0.90%) Pericardial effusion 2/221 (0.90%) Tachycardia 2/221 (0.90%) Acute myocardial infarction 0/221 (0.00%) Atrial fibrillation 1/221 (0.45%) ",
        "premise_nums": [
            "5/221 (2.26%)",
            "0/221 (0.00%)",
            "1/221 (0.45%)",
            "2/221 (0.90%)",
            "39/221 (17.65%)Febrile"
        ]
    },
    {
        "id": "c0a8e1a0-cbe6-4240-b578-59afa4d6cf23",
        "primaryId": "NCT00217672",
        "secondaryId": "NCT00110084",
        "label": "Entailment",
        "statement_text": "the primary trial had a higher occurrence rate of fistula enterovesical than the secondary trial ",
        "statement_nums": [],
        "premise_text": "Adverse Events 1: fistula enterovesical 1/74 (1.35%) Adverse Events 1: Total: 11/50 (22.00%) Anemia 3/50 (6.00%) Febrile neutropenia 1/50 (2.00%) Arrythmia 1/50 (2.00%) Ileus 1/50 (2.00%) Nausea 1/50 (2.00%) Pain-Abdominal 1/50 (2.00%) Vomiting 1/50 (2.00%) Bronchial infection 1/50 (2.00%) Sepsis 1/50 (2.00%) Neutropenia 2/50 (4.00%) Platelet count decreased 1/50 (2.00%) ",
        "premise_nums": [
            "1/74 (1.35%)",
            "1/50 (2.00%)",
            "11/50 (22.00%)",
            "3/50 (6.00%)",
            "2/50 (4.00%)"
        ]
    },
    {
        "id": "c0a8e1a0-cbe6-4240-b578-59afa4d6cf23",
        "primaryId": "NCT00217672",
        "secondaryId": "NCT00110084",
        "label": "Entailment",
        "statement_text": "the primary trial had a higher occurrence rate of fistula enterovesical than the secondary trial ",
        "statement_nums": [],
        "premise_text": "Dehydration 1/50 (2.00%)Arthralgia 1/50 (2.00%) ",
        "premise_nums": [
            "1/50 (2.00%)Arthralgia"
        ]
    },
    {
        "id": "7ec286e9-f519-41da-848d-a0bc5a50c0ee",
        "primaryId": "NCT00686127",
        "secondaryId": "NCT01129622",
        "label": "Entailment",
        "statement_text": "dosages are specified in the intervention section of the secondary trial  whereas for the primary trial these are not made clear ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Lidocaine Patch Lidocaine patch 5% (Lidoderm®  Endo Pharmaceuticals Inc.): 1 patch was applied topically to the affected site(s) for 12 hours each day  INTERVENTION 2: Placebo Patch Placebo patch: 1 patch was applied topically to the affected site(s) for 12 hours each day  INTERVENTION 1: Letrozole  Breast Enhancement  Safety Single arm of healthy postmenopausal women to have two breast MRI (baseline and post-treatment)  Letrozole of 12.5 mg/day is given for three successive days just prior to the second MRI  ",
        "premise_nums": [
            "of 12.5 mg/day",
            "1 patch was",
            "12 hours each"
        ]
    },
    {
        "id": "d0af59a9-04ae-4922-97eb-dc29f5bc44e3",
        "primaryId": "NCT00256698",
        "secondaryId": "NCT03573804",
        "label": "Contradiction",
        "statement_text": "the primary trial and the secondary trial use completely different drugs and techniques for their interventions  however they both require trained Radiologists on site for evaluation ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Fulvestrant + Anastrozole Fulvestrant 250 mg Loading Dose Regimen + Anastrozole 1 mg INTERVENTION 2: Anastrozole Anastrozole 1 mg INTERVENTION 1: Prone to Supine MRI Evaluated by Radiologist A Radiologist A  number of participants successfully segmented INTERVENTION 2: Prone to Supine MRI Evaluated by Radiologist B Radiologist B  number of participants successfully segmented ",
        "premise_nums": [
            "1 mg INTERVENTION",
            "250 mg Loading"
        ]
    },
    {
        "id": "5d4cbb15-ea50-4394-b1b9-ab4553b5b275",
        "primaryId": "NCT00509587",
        "statement_text": "Patients in the primary trial receive oral pazopanib once daily every day  continuing until disease progression or unacceptable toxicity ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "INTERVENTION 1: Treatment (Pazopanib Hydrochloride) Patients receive oral pazopanib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity  pazopanib hydrochloride: Given orally pharmacological study: Correlative studies laboratory biomarker analysis: Correlative studies ",
        "premise_nums": [
            "28 days in",
            "1-28. Courses"
        ]
    },
    {
        "id": "bd51e2f7-05a6-4d1a-b6eb-4f6426eec3d8",
        "primaryId": "NCT00777049",
        "statement_text": "All 4 of the CHF cases in the primary trial  were in cohort 1.",
        "statement_nums": [
            "4 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Cardiac failure congestive 1/32 (3.13%) Adverse Events 2: Cardiac failure congestive 0/20 (0.00%) ",
        "premise_nums": [
            "1/32 (3.13%)",
            "0/20 (0.00%)"
        ]
    },
    {
        "id": "78a5162d-140a-4631-b776-5c284446b5ec",
        "primaryId": "NCT02366130",
        "secondaryId": "NCT01262027",
        "label": "Entailment",
        "statement_text": "the primary trial and the secondary trial have entirely different adverse event profiles ",
        "statement_nums": [],
        "premise_text": "Adverse Events 1: Total: 28/36 (77.78%) Lymphocytopenia 210/36 (27.78%) Neutropenia 29/36 (25.00%) Anemia 26/36 (16.67%) Thrombocytopenia 24/36 (11.11%) Hyperglycemia 27/36 (19.44%) Nausea 213/36 (36.11%) Diarrhea 211/36 (30.56%) Fatigue 215/36 (41.67%) Flu-like symptoms 26/36 (16.67%) Hot Flashes 25/36 (13.89%) AST/ALT elevation 211/36 (30.56%) Arthralgia 24/36 (11.11%) Adverse Events 1: Total: 1/22 (4.55%) ",
        "premise_nums": [
            "26/36 (16.67%)",
            "27/36 (19.44%)",
            "28/36 (77.78%)",
            "29/36 (25.00%)",
            "24/36 (11.11%)",
            "213/36 (36.11%)",
            "25/36 (13.89%)",
            "215/36 (41.67%)",
            "211/36 (30.56%)",
            "210/36 (27.78%)",
            "1/22 (4.55%)"
        ]
    },
    {
        "id": "78a5162d-140a-4631-b776-5c284446b5ec",
        "primaryId": "NCT02366130",
        "secondaryId": "NCT01262027",
        "label": "Entailment",
        "statement_text": "the primary trial and the secondary trial have entirely different adverse event profiles ",
        "statement_nums": [],
        "premise_text": "Blood bilirubin increased 1/22 (4.55%)Alkaline phosphatase increased 1/22 (4.55%) ",
        "premise_nums": [
            "1/22 (4.55%)Alkaline"
        ]
    },
    {
        "id": "633ef768-9e9b-4336-9142-8d4ce7ee2342",
        "primaryId": "NCT01026142",
        "secondaryId": "NCT00846027",
        "label": "Entailment",
        "statement_text": "There were 10x more patients with Left ventricular systolic dysfunction in the primary trial than in the secondary trial ",
        "statement_nums": [],
        "premise_text": "Adverse Events 1: Left Ventricular Dysfunction 4/218 (1.83%) Adverse Events 2: Left Ventricular Dysfunction 13/228 (5.70%) Adverse Events 1: Left ventricular systolic dysfunction 1/82 (1.22%) ",
        "premise_nums": [
            "1/82 (1.22%)",
            "13/228 (5.70%)",
            "4/218 (1.83%)"
        ]
    },
    {
        "id": "7c5b29bc-ac37-48bb-abb1-a102174f79ef",
        "primaryId": "NCT00826267",
        "statement_text": "Cohort 1 and 2 of the primary trial receive 50mg of different drugs  administered orally from Day 1 to Day 21",
        "statement_nums": [
            "1 and 2",
            "1 to Day"
        ],
        "label": "Contradiction",
        "premise_text": "INTERVENTION 1: Afatinib 50 mg Patients received continuous daily dosing with Afatinib 50 mg orally from Day 1 to Day 21 of each treatment course  2 treatment courses were to be given in the trial  INTERVENTION 2: Lapatinib 1500 mg Patients received continuous daily dosing with Lapatinib 1500 mg orally from Day 1 to Day 21 of each treatment course  2 treatment courses were to be given in the trial  ",
        "premise_nums": [
            "50 mg orally",
            "50 mg Patients",
            "21 of each",
            "2 treatment courses",
            "1500 mg Patients",
            "1 to Day",
            "1500 mg orally"
        ]
    },
    {
        "id": "b8881e2e-ca25-4c1b-bbd2-281ebdb7514a",
        "primaryId": "NCT00708214",
        "statement_text": "All Progression Free Participants (After 16 Weeks of Treatment) in the primary trial were in the Afatinib 50 mg With Letrozole group ",
        "statement_nums": [
            "50 mg With",
            "16 Weeks of"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Percentage of Progression Free Participants After 16 Weeks of Treatment Progression was defined according to 1 of the following criteria: New bone lesion(s) on bone scan or on magnetic resonance imaging; Progression or occurrence of new lesion(s) according to the Response Evaluation Criteria In Solid Tumours version 1.0 (RECIST); an increase in tumour marker CA 15.3 of more than 20 percent,compared with baseline  at 2 consecutive examinations; occurrence of disease-related skeletal events  If a patient did not fulfil any criteria and was withdrawn because of clinical deterioration amounting to PD according to the Investigator  they were considered as having PD  Time frame: 16 weeks Results 1: Arm/Group Title: Afatinib 50 mg With Letrozole ",
        "premise_nums": [
            "CA 15.3 of more",
            "16 Weeks of",
            "50 mg With",
            "2 consecutive examinations;",
            "1 of the",
            "16 weeks Results"
        ]
    },
    {
        "id": "b8881e2e-ca25-4c1b-bbd2-281ebdb7514a",
        "primaryId": "NCT00708214",
        "statement_text": "All Progression Free Participants (After 16 Weeks of Treatment) in the primary trial were in the Afatinib 50 mg With Letrozole group ",
        "statement_nums": [
            "50 mg With",
            "16 Weeks of"
        ],
        "label": "Entailment",
        "premise_text": "Arm/Group Description: Patients received continuous daily dosing with Afatinib 50 mg therapy with letrozole 2.5 mg over 28-day treatment cycles until further disease progression Overall Number of Participants Analyzed: 7 Measure Type: Number Unit of Measure: Percentage of participants 28.57 (3.67 to 70.96) Results 2: Arm/Group Title: Afatinib 40 mg With Letrozole Arm/Group Description: Patients received continuous daily dosing with Afatinib 40 mg therapy with letrozole 2.5 mg over 28-day treatment cycles until further disease progression  Overall Number of Participants Analyzed: 13 Measure Type: Number Unit of Measure: Percentage of participants 0.00 (0.00 to 24.71) ",
        "premise_nums": [
            "50 mg therapy",
            "40 mg With",
            "13 Measure Type:",
            "67 to 70.96)",
            "letrozole 2.5 mg over",
            "00 to 24.71)",
            "40 mg therapy",
            "7 Measure Type:",
            "28-day treatment"
        ]
    },
    {
        "id": "a70cc8e5-0ef5-4045-8fec-d9e7503b5e6e",
        "primaryId": "NCT00615901",
        "secondaryId": "NCT00829166",
        "label": "Contradiction",
        "statement_text": "the primary trial recorded many more seizures than the secondary trial  despite having less than one tenth the number of patients in its total cohort ",
        "statement_nums": [],
        "premise_text": "Adverse Events 1: Seizure 1/38 (2.63%) Adverse Events 1: Total: 92/490 (18.78%) Anaemia * 1/490 (0.20%) Anaemia of malignant disease * 0/490 (0.00%) Febrile neutropenia * 0/490 (0.00%) Neutropenia * 0/490 (0.00%) Thrombocytopenia * 4/490 (0.82%) Angina pectoris * 0/490 (0.00%) Atrial fibrillation * 1/490 (0.20%) Cardiomyopathy * 1/490 (0.20%) ",
        "premise_nums": [
            "1/490 (0.20%)",
            "92/490 (18.78%)",
            "1/38 (2.63%)",
            "4/490 (0.82%)",
            "0/490 (0.00%)"
        ]
    },
    {
        "id": "a70cc8e5-0ef5-4045-8fec-d9e7503b5e6e",
        "primaryId": "NCT00615901",
        "secondaryId": "NCT00829166",
        "label": "Contradiction",
        "statement_text": "the primary trial recorded many more seizures than the secondary trial  despite having less than one tenth the number of patients in its total cohort ",
        "statement_nums": [],
        "premise_text": "Coronary artery disease * 0/490 (0.00%)Pericardial effusion * 0/490 (0.00%) Adverse Events 2: Total: 99/488 (20.29%) Anaemia * 1/488 (0.20%) Anaemia of malignant disease * 1/488 (0.20%) Febrile neutropenia * 2/488 (0.41%) Neutropenia * 1/488 (0.20%) Thrombocytopenia * 1/488 (0.20%) Angina pectoris * 1/488 (0.20%) Atrial fibrillation * 0/488 (0.00%) ",
        "premise_nums": [
            "99/488 (20.29%)",
            "1/488 (0.20%)",
            "2/488 (0.41%)",
            "0/490 (0.00%)Pericardial",
            "0/488 (0.00%)"
        ]
    },
    {
        "id": "a70cc8e5-0ef5-4045-8fec-d9e7503b5e6e",
        "primaryId": "NCT00615901",
        "secondaryId": "NCT00829166",
        "label": "Contradiction",
        "statement_text": "the primary trial recorded many more seizures than the secondary trial  despite having less than one tenth the number of patients in its total cohort ",
        "statement_nums": [],
        "premise_text": "Cardiomyopathy * 0/488 (0.00%)Coronary artery disease * 1/488 (0.20%) Pericardial effusion * 2/488 (0.41%) ",
        "premise_nums": [
            "2/488 (0.41%)",
            "0/488 (0.00%)Coronary",
            "1/488 (0.20%)"
        ]
    },
    {
        "id": "e852619c-312a-470f-8b77-149e79f69a3f",
        "primaryId": "NCT00390455",
        "secondaryId": "NCT00558103",
        "label": "Entailment",
        "statement_text": "In both the secondary trial and the primary trial the test cohorts produced better results than the control groups ",
        "statement_nums": [],
        "premise_text": "Outcome Measurement: Progression-free Survival (PFS) PFS was defined as the interval from study entry until disease progression or death resulting from any cause  which ever occurred first  Progression is defined as a 20% increase in the sum of longest diameter of target lesions (per RECIST criteria)  Time frame: Interval from randomization until disease progression or death  whichever occurs first  assessed up to 5 years Results 1: Arm/Group Title: Arm I (Lapatinib) Arm/Group Description: Patients receive 1500 mg lapatinib ditosylate PO QD on days 1-28 and fulvestrant IM on days 1 (500 mg) and 15 (250 mg) of course 1 and on day 1 (250 mg)of each subsequent course  Overall Number of Participants Analyzed: 146 Median (95% Confidence Interval) ",
        "premise_nums": [
            "1 and on",
            "1-28 and",
            "28 and fulvestrant",
            "95% Confidence",
            "1500 mg lapatinib",
            "5 years Results",
            "20% increase"
        ]
    },
    {
        "id": "e852619c-312a-470f-8b77-149e79f69a3f",
        "primaryId": "NCT00390455",
        "secondaryId": "NCT00558103",
        "label": "Entailment",
        "statement_text": "In both the secondary trial and the primary trial the test cohorts produced better results than the control groups ",
        "statement_nums": [],
        "premise_text": "Unit of Measure: months 4.7 (3.7 to 5.7)Results 2: Arm/Group Title: Arm II (Placebo) Arm/Group Description: Patients receive placebo PO QD on days 1-28 and fulvestrant IM on days 1 (500 mg) and 15 (250 mg) of course 1 and on day 1 (250 mg) of each subsequent course  Overall Number of Participants Analyzed: 145 Median (95% Confidence Interval) Unit of Measure: months 3.8 (3.8 to 5.6) Outcome Measurement: Number of Participants With Overall Response (OR)  Defined as Those Participants Achieving Complete Response (CR) or Partial Response (PR)  Assessed Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.0 and Cutaneous Lesions ",
        "premise_nums": [
            "Version 1.0 and Cutaneous",
            "8 to 5.6)",
            "1 and on",
            "1-28 and",
            "28 and fulvestrant",
            "7 to 5.7)Results",
            "95% Confidence"
        ]
    },
    {
        "id": "e852619c-312a-470f-8b77-149e79f69a3f",
        "primaryId": "NCT00390455",
        "secondaryId": "NCT00558103",
        "label": "Entailment",
        "statement_text": "In both the secondary trial and the primary trial the test cohorts produced better results than the control groups ",
        "statement_nums": [],
        "premise_text": "RECIST-based response assessment was done at Weeks (Wks) 4 and 8 and every 8 weeks thereafter  Cutaneous disease assessment was done at Wk 4 and every 4 weeks thereafter  OR was evaluated when the skin and RECIST assessments coincided  Per RECIST  CR is the disappearance of all target and non-target lesions; PR is at least a 30 percent (%) decrease in the sum of the longest diameter (LD) of target lesions  taking as a reference the baseline sum LD  Cutaneous disease contained non-measurable and measurable skin disease  which was assessed by skin assessment tools Time frame: Baseline until disease progression/recurrence was documented  assessed for up to 66 weeks Results 1: Arm/Group Title: Cohort 1: Lapatinib 1500 mg + Pazopanib Placebo ",
        "premise_nums": [
            "66 weeks Results",
            "4 and 8",
            "4 weeks thereafter",
            "8 weeks thereafter",
            "4 and every"
        ]
    },
    {
        "id": "e852619c-312a-470f-8b77-149e79f69a3f",
        "primaryId": "NCT00390455",
        "secondaryId": "NCT00558103",
        "label": "Entailment",
        "statement_text": "In both the secondary trial and the primary trial the test cohorts produced better results than the control groups ",
        "statement_nums": [],
        "premise_text": "Arm/Group Description: Participants received oral lapatinib 1500 milligrams (mg) (6 x 250 mg tablets) in combination with placebo (matching to pazopanib; 2 tablets) once daily (QD) Overall Number of Participants Analyzed: 38 Measure Type: Number Unit of Measure: participants 11 Results 2: Arm/Group Title: Cohort 1: Lapatinib 1500 mg + Pazopanib 800 mg Arm/Group Description: Participants received oral lapatinib 1500 mg (6 x 250 mg tablets) in combination with pazopanib 800 mg (2 x 400 mg tablets) QD  Overall Number of Participants Analyzed: 38 Measure Type: Number Unit of Measure: participants 17 ",
        "premise_nums": [
            "800 mg (2",
            "1500 milligrams (mg)",
            "6 x 250",
            "1500 mg (6",
            "250 mg tablets)",
            "11 Results 2:",
            "800 mg Arm",
            "38 Measure Type:",
            "400 mg tablets)"
        ]
    },
    {
        "id": "27160f45-e4cb-48be-8cf2-c23ced4578c0",
        "primaryId": "NCT00003830",
        "statement_text": "The most common adverse event in both cohorts of the primary trial was Anaphylaxis  which affected more than 10 patients in total ",
        "statement_nums": [
            "10 patients in"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 9/2788 (0.32%) Anaphylaxis 5/2788 (0.18%) Infections and infestations - Other  specify 2/2788 (0.07%) Nervous system disorders - Other  specify 0/2788 (0.00%) Respiratory  thoracic and mediastinal disorders - Other  specify 1/2788 (0.04%) Thromboembolic event 1/2788 (0.04%) Adverse Events 2: Total: 8/2800 (0.29%) Anaphylaxis 5/2800 (0.18%) Infections and infestations - Other  specify 0/2800 (0.00%) ",
        "premise_nums": [
            "0/2788 (0.00%)",
            "1/2788 (0.04%)",
            "2/2788 (0.07%)",
            "5/2800 (0.18%)",
            "8/2800 (0.29%)",
            "5/2788 (0.18%)",
            "0/2800 (0.00%)",
            "9/2788 (0.32%)"
        ]
    },
    {
        "id": "27160f45-e4cb-48be-8cf2-c23ced4578c0",
        "primaryId": "NCT00003830",
        "statement_text": "The most common adverse event in both cohorts of the primary trial was Anaphylaxis  which affected more than 10 patients in total ",
        "statement_nums": [
            "10 patients in"
        ],
        "label": "Contradiction",
        "premise_text": "Nervous system disorders - Other  specify 1/2800 (0.04%)Respiratory  thoracic and mediastinal disorders - Other  specify 1/2800 (0.04%) Thromboembolic event 2/2800 (0.07%) ",
        "premise_nums": [
            "2/2800 (0.07%)",
            "1/2800 (0.04%)Respiratory"
        ]
    },
    {
        "id": "e4b65e9f-10f6-4424-95d2-837e29587a63",
        "primaryId": "NCT00754325",
        "secondaryId": "NCT00399529",
        "label": "Entailment",
        "statement_text": "the secondary trial and the primary trial both accept patients with HER-2/neu-overexpressing adenocarcinoma of the breast ",
        "statement_nums": [
            "2/neu-overexpressing adenocarcinoma"
        ],
        "premise_text": "Inclusion Criteria: Histologically confirmed hormone receptor positive (HR+) [(estrogen receptor (ER+) and/or progesterone receptors(PgR+)] breast cancer according to immunohistochemistry (IHC) Inclusion Criteria: Patients with histologically confirmed HER-2/neu-overexpressing adenocarcinoma of the breast; this is defined as HER-2+ by immunohistochemistry (IHC) 3+ staining or Fluorescence In-Situ Hybridization (FISH)  Prior adjuvant Trastuzumab therapy is permitted  Patients must not be eligible for therapy of known curative potential for metastatic breast cancer if it is identified during the course of the study  ",
        "premise_nums": [
            "2/neu-overexpressing adenocarcinoma"
        ]
    },
    {
        "id": "68f6f3db-0bfb-4e03-8e2f-92ae5d0f55a1",
        "primaryId": "NCT01127373",
        "statement_text": "Patients with T1N2M0, T2N1M0, T3N1M1 and TxN1M0 tumors are eliglbe for the primary trial ",
        "statement_nums": [
            "1 and TxN1M0"
        ],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria: Pathologic confirmation of metastatic disease in at least one regional lymph node  Regional lymph nodes are defined as the ipsilateral axillary lymph nodes  ipsilateral supraclavicular lymph nodes  and ipsilateral internal mammary lymph nodes  Thus  any T stage is allowed as long as the N stage is 1 and M stage is 0. ",
        "premise_nums": [
            "1 and M"
        ]
    },
    {
        "id": "7796fe1b-1952-4339-90f3-47b051ebe927",
        "primaryId": "NCT01432886",
        "statement_text": "One of the patients in cohort 2 of the primary trial experienced neutropenia persisting for more than 7 days ",
        "statement_nums": [
            "2 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Results 1: Arm/Group Title: E7389 With Weekly Trastuzumab Arm/Group Description: Eribulin mesylate (E7389) was administered intravenously on Day 1 and Day 8 of each 3 week cycle  Trastuzumab was administered intravenously weekly  with an initial dose of 4 mg/kg followed by 2 mg/kg for the remaining doses  Overall Number of Participants Analyzed: 6 Measure Type: Number Unit of Measure: Participants 0 Results 2: Arm/Group Title: E7389 With Tri-weekly Trastuzumab ",
        "premise_nums": [
            "1 and Day",
            "2 mg/kg for",
            "3 week cycle",
            "E7389 With",
            "(E7389) was",
            "4 mg/kg followed",
            "7389 With Weekly",
            "6 Measure Type:",
            "0 Results 2:",
            "8 of each"
        ]
    },
    {
        "id": "7796fe1b-1952-4339-90f3-47b051ebe927",
        "primaryId": "NCT01432886",
        "statement_text": "One of the patients in cohort 2 of the primary trial experienced neutropenia persisting for more than 7 days ",
        "statement_nums": [
            "2 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Arm/Group Description: Eribulin mesylate (E7389) was administered intravenously on Day 1 and Day 8 of each 3 week cycle  Trastuzumab was administered intravenously tri-weekly  with an initial dose of 8 mg/kg followed by 6 mg/kg for the remaining doses Overall Number of Participants Analyzed: 6 Measure Type: Number Unit of Measure: Participants 0 ",
        "premise_nums": [
            "1 and Day",
            "3 week cycle",
            "(E7389) was",
            "8 mg/kg followed",
            "6 Measure Type:",
            "8 of each",
            "6 mg/kg for"
        ]
    },
    {
        "id": "c7df7b38-068b-48a8-b805-b8ebb3e854e6",
        "primaryId": "NCT01086605",
        "secondaryId": "NCT00570921",
        "label": "Entailment",
        "statement_text": "the primary trial and the secondary trial do not record any of the same adverse events ",
        "statement_nums": [],
        "premise_text": "Adverse Events 1: Total: 3/24 (12.50%) Disseminated intravascular coagulation 0/24 (0.00%) Death NOS 0/24 (0.00%) Edema limbs 0/24 (0.00%) Fatigue 0/24 (0.00%) Hepatic failure 1/24 (4.17%) Alanine aminotransferase increased 1/24 (4.17%) Aspartate aminotransferase increased 1/24 (4.17%) Blood bilirubin increased 0/24 (0.00%) Ejection fraction decreased 1/24 (4.17%) Adverse Events 2: Total: 9/22 (40.91%) Disseminated intravascular coagulation 1/22 (4.55%) ",
        "premise_nums": [
            "3/24 (12.50%)",
            "1/24 (4.17%)",
            "9/22 (40.91%)",
            "0/24 (0.00%)",
            "1/22 (4.55%)"
        ]
    },
    {
        "id": "c7df7b38-068b-48a8-b805-b8ebb3e854e6",
        "primaryId": "NCT01086605",
        "secondaryId": "NCT00570921",
        "label": "Entailment",
        "statement_text": "the primary trial and the secondary trial do not record any of the same adverse events ",
        "statement_nums": [],
        "premise_text": "Death NOS 1/22 (4.55%)Edema limbs 1/22 (4.55%) Fatigue 1/22 (4.55%) Hepatic failure 0/22 (0.00%) Alanine aminotransferase increased 0/22 (0.00%) Aspartate aminotransferase increased 1/22 (4.55%) Blood bilirubin increased 1/22 (4.55%) Ejection fraction decreased 1/22 (4.55%) Adverse Events 1: Total: 5/33 (15.15%) Left Ventricular Thrombus * 1/33 (3.03%) Nausea * 1/33 (3.03%) Acute Cholecystitis * 1/33 (3.03%) ",
        "premise_nums": [
            "5/33 (15.15%)",
            "1/33 (3.03%)",
            "1/22 (4.55%)Edema",
            "0/22 (0.00%)"
        ]
    },
    {
        "id": "c7df7b38-068b-48a8-b805-b8ebb3e854e6",
        "primaryId": "NCT01086605",
        "secondaryId": "NCT00570921",
        "label": "Entailment",
        "statement_text": "the primary trial and the secondary trial do not record any of the same adverse events ",
        "statement_nums": [],
        "premise_text": "Renal Failure * 1/33 (3.03%)Pneumonia * 1/33 (3.03%) ",
        "premise_nums": [
            "1/33 (3.03%)Pneumonia"
        ]
    },
    {
        "id": "39227bbb-0e26-4ba0-94a7-762376541889",
        "primaryId": "NCT00945061",
        "statement_text": "patients with Multi-focal breast cancer cannot be accepted for the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Inclusion Criteria: Unifocal breast cancer recurrence ",
        "premise_nums": []
    },
    {
        "id": "fdb7afc0-ef7e-44bf-bfe3-5252fa8b0106",
        "primaryId": "NCT03283553",
        "secondaryId": "NCT02679755",
        "label": "Contradiction",
        "statement_text": "the primary trial and the secondary trial have a different number of cohorts ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Multicomponent Intervention 1.) A one-page paper-pencil agenda setting checklist completed immediately before a regularly scheduled medical oncology visit to elicit and align patient and companion perspectives regarding issues to discuss with the provider  and to stimulate discussion about the role of the companion in the visit  2.) facilitated registration for the patient portal (for patient and family member  as desired by the patient)  and 3.) education (as relevant) on access to doctor's electronic visit notes  INTERVENTION 2: Usual Care Care as usual with the medical oncologist  INTERVENTION 1: Palbociclib+Letrozole India Cohort ",
        "premise_nums": []
    },
    {
        "id": "fdb7afc0-ef7e-44bf-bfe3-5252fa8b0106",
        "primaryId": "NCT03283553",
        "secondaryId": "NCT02679755",
        "label": "Contradiction",
        "statement_text": "the primary trial and the secondary trial have a different number of cohorts ",
        "statement_nums": [],
        "premise_text": "Participants received Palbociclib orally once a day at 125 mg for 21 days followed by 7 days off treatment ofr each 28-day cycle  Participants received Letrozole orally at 2.5 mg once daily as continuous daily dosing schedule according to product labeling and in compliance with its local prescribing informationINTERVENTION 2: Palbociclib+Letrozole Australia Cohort Participants received Palbociclib orally once a day at 125 mg for 21 days followed by 7 days off treatment for each 28-day cycle  Participants received Letrozole orally at 2.5 mg once daily as continuous daily dosing schedule according to product labeling and in compliance with its local prescribing information ",
        "premise_nums": [
            "at 2.5 mg once",
            "28-day cycle",
            "7 days off",
            "125 mg for",
            "21 days followed"
        ]
    },
    {
        "id": "fd15ddaf-1abc-4551-a5b3-08217b975e36",
        "primaryId": "NCT02321527",
        "statement_text": "Patients with invasive breast cancer with a diameter of more than 70mm are included in the primary trial ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Ipsilateral biopsy-proven invasive breast cancer smaller than 5 cm in maximal dimension by Ultrasound or Mammography  ",
        "premise_nums": [
            "5 cm in"
        ]
    },
    {
        "id": "067f4671-0720-4980-a0fa-8d01d31daa9a",
        "primaryId": "NCT00054132",
        "secondaryId": "NCT01421017",
        "label": "Contradiction",
        "statement_text": "As the primary trial and the secondary trial use very similar outcome metrics  we can easily compare and contrast across their results ",
        "statement_nums": [],
        "premise_text": "Outcome Measurement: Level of EGFR Expression Estimated at the end of the trial Immunoreactivity will be evaluated qualitatively with regard to intensity as follows: Measured on a scale  ranging from 0-3+ 0=negative (no immunoreactivity) 1+ - 3+ = positive: Outcome Measurement: Systemic Tumor Response Rates (Complete Response+Partial Response) The systemic tumor response refers to the response at the time of best overall response  The response criteria are specially adapted from Response Evaluation Criteria in Solid Tumor for Immunotherapies (Wolchok  et al.  2009). Time frame: 9 weeks from the start of the treatment of RT ",
        "premise_nums": [
            "0-3+ 0=negative",
            "9 weeks from"
        ]
    },
    {
        "id": "026e7eb7-37fd-4aae-b74f-dacf905db262",
        "primaryId": "NCT02366130",
        "secondaryId": "NCT01262027",
        "label": "Contradiction",
        "statement_text": "the primary trial reported more than 10 times the number of patients experiencing adverse events as the secondary trial  ",
        "statement_nums": [
            "10 times the"
        ],
        "premise_text": "Adverse Events 1: Total: 28/36 (77.78%) Lymphocytopenia 210/36 (27.78%) Neutropenia 29/36 (25.00%) Anemia 26/36 (16.67%) Thrombocytopenia 24/36 (11.11%) Hyperglycemia 27/36 (19.44%) Nausea 213/36 (36.11%) Diarrhea 211/36 (30.56%) Fatigue 215/36 (41.67%) Flu-like symptoms 26/36 (16.67%) Hot Flashes 25/36 (13.89%) AST/ALT elevation 211/36 (30.56%) Arthralgia 24/36 (11.11%) Adverse Events 1: ",
        "premise_nums": [
            "26/36 (16.67%)",
            "27/36 (19.44%)",
            "28/36 (77.78%)",
            "29/36 (25.00%)",
            "24/36 (11.11%)",
            "213/36 (36.11%)",
            "25/36 (13.89%)",
            "215/36 (41.67%)",
            "211/36 (30.56%)",
            "210/36 (27.78%)"
        ]
    },
    {
        "id": "026e7eb7-37fd-4aae-b74f-dacf905db262",
        "primaryId": "NCT02366130",
        "secondaryId": "NCT01262027",
        "label": "Contradiction",
        "statement_text": "the primary trial reported more than 10 times the number of patients experiencing adverse events as the secondary trial  ",
        "statement_nums": [
            "10 times the"
        ],
        "premise_text": "Total: 1/22 (4.55%)Blood bilirubin increased 1/22 (4.55%) Alkaline phosphatase increased 1/22 (4.55%) ",
        "premise_nums": [
            "1/22 (4.55%)Blood"
        ]
    },
    {
        "id": "a79fc503-215f-40d4-9cc1-e101cec3a9c9",
        "primaryId": "NCT02878057",
        "statement_text": "Patients that are fully active and able to carry on all pre-disease performance without restriction are excluded from the primary trial ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria: Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. ",
        "premise_nums": []
    },
    {
        "id": "ee5f95d0-3824-4ce4-bf58-1ecd3ce4e7ee",
        "primaryId": "NCT00191269",
        "statement_text": "the primary trial measured the Number of Participants With Disease Progression (PD) or Death  to evaluate the performance of its interventions ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Tumor Response Best response recorded from the start of treatment until disease progression/recurrence using Response Evaluation Criteria In Solid Tumors (RECIST) criteria that defines when participants improve (\"respond\")  stay the same (\"stable\")  or worsen (\"progression\") during treatment  Time frame: baseline to measured progressive disease ",
        "premise_nums": []
    },
    {
        "id": "7a9fa9d8-8b71-4df3-918f-0f8e8ecb4b0a",
        "primaryId": "NCT00574587",
        "secondaryId": "NCT00777049",
        "label": "Entailment",
        "statement_text": "There were no cases of cardiac tamponade in the primary trial or the secondary trial ",
        "statement_nums": [],
        "premise_text": "Adverse Events 1: Total: 0/3 (0.00%) cardiac tamponade 0/3 (0.00%) congestive heart failure 0/3 (0.00%) pulmonary emobolism 0/3 (0.00%) Adverse Events 2: Total: 2/23 (8.70%) cardiac tamponade 0/23 (0.00%) congestive heart failure 1/23 (4.35%) pulmonary emobolism 1/23 (4.35%) Adverse Events 1: Total: 12/32 (37.50%) Anaemia 0/32 (0.00%) Neutropenia 1/32 (3.13%) Thrombocytopenia 4/32 (12.50%) ",
        "premise_nums": [
            "0/3 (0.00%)",
            "2/23 (8.70%)",
            "4/32 (12.50%)",
            "1/32 (3.13%)",
            "0/32 (0.00%)",
            "12/32 (37.50%)",
            "1/23 (4.35%)",
            "0/23 (0.00%)"
        ]
    },
    {
        "id": "7a9fa9d8-8b71-4df3-918f-0f8e8ecb4b0a",
        "primaryId": "NCT00574587",
        "secondaryId": "NCT00777049",
        "label": "Entailment",
        "statement_text": "There were no cases of cardiac tamponade in the primary trial or the secondary trial ",
        "statement_nums": [],
        "premise_text": "Atrial fibrillation 1/32 (3.13%)Cardiac failure congestive 1/32 (3.13%) Myocardial ischaemia 1/32 (3.13%) Abdominal discomfort 0/32 (0.00%) Ascites 1/32 (3.13%) Constipation 0/32 (0.00%) Rectal haemorrhage 1/32 (3.13%) Vomiting 1/32 (3.13%) Fatigue 1/32 (3.13%) Adverse Events 2: Total: 8/20 (40.00%) Anaemia 1/20 (5.00%) Neutropenia 0/20 (0.00%) Thrombocytopenia 1/20 (5.00%) ",
        "premise_nums": [
            "8/20 (40.00%)",
            "1/20 (5.00%)",
            "0/32 (0.00%)",
            "0/20 (0.00%)",
            "1/32 (3.13%)Cardiac"
        ]
    },
    {
        "id": "7a9fa9d8-8b71-4df3-918f-0f8e8ecb4b0a",
        "primaryId": "NCT00574587",
        "secondaryId": "NCT00777049",
        "label": "Entailment",
        "statement_text": "There were no cases of cardiac tamponade in the primary trial or the secondary trial ",
        "statement_nums": [],
        "premise_text": "Atrial fibrillation 0/20 (0.00%)Cardiac failure congestive 0/20 (0.00%) Myocardial ischaemia 0/20 (0.00%) Abdominal discomfort 1/20 (5.00%) Ascites 0/20 (0.00%) Constipation 2/20 (10.00%) Rectal haemorrhage 0/20 (0.00%) Vomiting 0/20 (0.00%) Fatigue 0/20 (0.00%) ",
        "premise_nums": [
            "0/20 (0.00%)Cardiac",
            "2/20 (10.00%)",
            "1/20 (5.00%)"
        ]
    },
    {
        "id": "ccb703ea-df18-451b-8db8-ed0e510a4c0f",
        "primaryId": "NCT03592121",
        "secondaryId": "NCT01439711",
        "label": "Entailment",
        "statement_text": "Unlike the secondary trial  the primary trial does not specify a specific dosage or frequency for its intervention ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: AB-101 Apply to both nipple/areola regions approximately 1 hour prior to sexual activity AB-101: Apply approximately 1 hour prior to sexual activity INTERVENTION 2: Placebo Apply to both nipple/areola regions approximately 1 hour prior to sexual activity Placebo: Apply approximately 1 hour prior to sexual activity INTERVENTION 1: Letrozole + MRI Protocol Therapy will consist of 6 months of letrozole  administered orally at a dose of 2.5 mg/day  Patients will have a bilateral MRI for disease evaluation at months 3 and 6. ",
        "premise_nums": [
            "of 2.5 mg/day",
            "6 months of",
            "101 Apply to",
            "1 hour prior",
            "3 and 6."
        ]
    },
    {
        "id": "56cd4492-3884-4b2a-a000-7c859d86f6f5",
        "primaryId": "NCT00284180",
        "statement_text": "Across both cohorts of the primary trial a total of two patients had low levels of oxygen in their body tissues ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 5/11 (45.45%) Diabetes insipidus [1]1/11 (9.09%) Nausea 0/11 (0.00%) Ileus 1/11 (9.09%) Dehydration 1/11 (9.09%) Vomiting 0/11 (0.00%) Pain NOS [2]2/11 (18.18%) Pain - abdomen 0/11 (0.00%) Fracture [3]0/11 (0.00%) Progressive Disease 1/11 (9.09%) CNS Ischemia 1/11 (9.09%) Respiratory Failure 0/11 (0.00%) Hypoxia 1/11 (9.09%) Adverse Events 2: ",
        "premise_nums": [
            "5/11 (45.45%)",
            "1/11 (9.09%)",
            "2/11 (18.18%)",
            "0/11 (0.00%)"
        ]
    },
    {
        "id": "56cd4492-3884-4b2a-a000-7c859d86f6f5",
        "primaryId": "NCT00284180",
        "statement_text": "Across both cohorts of the primary trial a total of two patients had low levels of oxygen in their body tissues ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Total: 8/21 (38.10%)Diabetes insipidus [1]0/21 (0.00%) Nausea 1/21 (4.76%) Ileus 0/21 (0.00%) Dehydration 1/21 (4.76%) Vomiting 1/21 (4.76%) Pain NOS [2]0/21 (0.00%) Pain - abdomen 1/21 (4.76%) Fracture [3]1/21 (4.76%) Progressive Disease 1/21 (4.76%) CNS Ischemia 1/21 (4.76%) Respiratory Failure 1/21 (4.76%) Hypoxia 1/21 (4.76%) ",
        "premise_nums": [
            "0/21 (0.00%)",
            "8/21 (38.10%)Diabetes",
            "1/21 (4.76%)"
        ]
    },
    {
        "id": "08b79e0d-5e97-45fb-ac83-0096b56f714b",
        "primaryId": "NCT01492101",
        "statement_text": "less than 1% of either cohort of the primary trial was effect by either Pancytopenia or Coagulopathy ",
        "statement_nums": [
            "1% of"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Pancytopenia *2/425 (0.47%) Coagulopathy *1/425 (0.24%) Adverse Events 2: Pancytopenia *0/406 (0.00%) Coagulopathy *0/406 (0.00%) ",
        "premise_nums": [
            "2/425 (0.47%)",
            "1/425 (0.24%)",
            "0/406 (0.00%)"
        ]
    },
    {
        "id": "c524ecf2-1ca6-4a9a-bedf-f0709124fa1b",
        "primaryId": "NCT01466270",
        "statement_text": "The the primary trial placebo group had a over 10% higher mean retention than the donepezil hydrochloride PO QD group ",
        "statement_nums": [
            "10% higher"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Retention Retention is the percentage of participants who stay in the study for 24 weeks  Time frame: 24 Weeks Results 1: Arm/Group Title: Arm I Arm/Group Description: Patients receive donepezil hydrochloride PO QD  donepezil hydrochloride: Given PO Overall Number of Participants Analyzed: 31 Mean (Standard Error) Unit of Measure: percentage of participants 71.0 (8.3) Results 2: Arm/Group Title: Arm II Arm/Group Description: Patients receive placebo PO QD  Placebo: Given PO Overall Number of Participants Analyzed: 31 Mean (Standard Error) Unit of Measure: percentage of participants 80.7 (7.2) ",
        "premise_nums": [
            "24 Weeks Results",
            "31 Mean (Standard"
        ]
    },
    {
        "id": "6d549a9b-47bf-4369-962b-2759cfd7051e",
        "primaryId": "NCT00798135",
        "secondaryId": "NCT01209195",
        "label": "Contradiction",
        "statement_text": "the primary trial and the secondary trial both investigate Pharmacokinetics Itraconazole 500mg QD ",
        "statement_nums": [],
        "premise_text": "Outcome Measurement: Pharmacokinetics (PK) of Oral Itraconazole To determine the pharmacokinetics (PK) of oral itraconazole in patients with MBC by measuring mean trough plasma levels at steady state at weeks 2 and 4. Time frame: pre-dose at Weeks 2 and 4 Results 1: Arm/Group Title: Itraconazole Arm/Group Description: oral itraconazole 200mg a day until disease progression or unacceptable toxicities  Overall Number of Participants Analyzed: 12 Mean (Standard Deviation) Unit of Measure: ng/mL Week 2 Intraconazole Concentration: 230.7 (216.8) Week 4 Intraconazole Concentration: 305.8 (334.8) ",
        "premise_nums": [
            "2 Intraconazole Concentration:",
            "12 Mean (Standard",
            "4 Intraconazole Concentration:",
            "2 and 4."
        ]
    },
    {
        "id": "6d549a9b-47bf-4369-962b-2759cfd7051e",
        "primaryId": "NCT00798135",
        "secondaryId": "NCT01209195",
        "label": "Contradiction",
        "statement_text": "the primary trial and the secondary trial both investigate Pharmacokinetics Itraconazole 500mg QD ",
        "statement_nums": [],
        "premise_text": "Week 2 6-OH Itraconazole Concentration: 454.8 (429.3)Week 4 6-OH Itraconazole Concentration: 501.6 (502.6) Outcome Measurement: Dose Escalation: To Evaluate the Safety and Tolerability of Escalating Doses of the MM-121 Plus Paclitaxel Combination Via Reporting of Dose-limiting Toxicity (DLT) To establish the safety of escalating doses of MM-121 in combination with paclitaxel in order to determine the recommended phase 2 dose  Dose-escalation conducted using standard 3+3 model to determine maximum tolerated dose  Reports of Dose-Limiting Toxicities (DLTs) were assessed to determine the MTD  Time frame: From date of first dose to 30 days after termination  the longest 163 weeks ",
        "premise_nums": [
            "3+3 model",
            "2 6-OH Itraconazole",
            "4 6-OH Itraconazole",
            "30 days after",
            "121 Plus Paclitaxel",
            "121 in combination",
            "3 model to"
        ]
    },
    {
        "id": "596f20cf-299d-40a3-881a-cdd49bcb21f6",
        "primaryId": "NCT00703326",
        "secondaryId": "NCT00274768",
        "label": "Entailment",
        "statement_text": "Participants with HER2- primary breast tumors  confirmed by fluorescence in-situ hybridization are eligible for the secondary trial and the primary trial ",
        "statement_nums": [],
        "premise_text": "Inclusion Criteria: Participant has histologically or cytologically confirmed adenocarcinoma of the breast that is now metastatic or locally-recurrent and inoperable with curative intent  Every effort should be made to make paraffin-embedded tissue or slides from the diagnostic biopsy or surgical specimen available for confirmation of diagnosis Participants' primary and/or metastatic tumor is human epidermal growth factor receptor 2 (HER2)-negative by fluorescence in-situ hybridization (FISH) or chromogenic in-situ hybridization (CISH) or 0, 1+ overexpression by immunohistochemistry (IHC) DISEASE CHARACTERISTICS: Histologically or cytologically confirmed diagnosis of adenocarcinoma of the breast ",
        "premise_nums": []
    },
    {
        "id": "596f20cf-299d-40a3-881a-cdd49bcb21f6",
        "primaryId": "NCT00703326",
        "secondaryId": "NCT00274768",
        "label": "Entailment",
        "statement_text": "Participants with HER2- primary breast tumors  confirmed by fluorescence in-situ hybridization are eligible for the secondary trial and the primary trial ",
        "statement_nums": [],
        "premise_text": "Hormone receptor status:Not specified ",
        "premise_nums": []
    },
    {
        "id": "78ae19aa-6e26-4f9a-b381-cd77d92e4ecb",
        "primaryId": "NCT03066947",
        "statement_text": "At least one patient in the primary trial suffered from Gastroesophageal reflux disease ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 8/24 (33.33%) Restrictive Cardiomyopathy * 21/24 (4.17%) Palpitations * 21/24 (4.17%) GERD * 21/24 (4.17%) Fever * 21/24 (4.17%) Sepsis * 1/24 (4.17%) Urinary Tract Infection * 21/24 (4.17%) Influenza A * 21/24 (4.17%) Dehydration * 21/24 (4.17%) Hyponatremia * 21/24 (4.17%) Worsening of Hypercalcemia * 21/24 (4.17%) Bone Pain * 21/24 (4.17%) ",
        "premise_nums": [
            "21/24 (4.17%)",
            "8/24 (33.33%)"
        ]
    },
    {
        "id": "1d4f9f95-6f97-4054-9dd8-fe78aa5fc685",
        "primaryId": "NCT00418028",
        "secondaryId": "NCT00293540",
        "label": "Entailment",
        "statement_text": "Sam has recently received a liver transplant  he is not eligible for the primary trial  but is eligible for the secondary trial ",
        "statement_nums": [],
        "premise_text": "Exclusion criteria: Patients with organ transplants  Inclusion Criteria: Estrogen receptor or progesterone receptor positive breast cancer Premenopausal with regular menstrual cycles Exclusion Criteria: Current oral contraceptives ",
        "premise_nums": []
    },
    {
        "id": "d4b2d877-34af-4944-84f7-046e22c2854e",
        "primaryId": "NCT01781299",
        "statement_text": "all subjects in the primary trial must undergo a minor surgery ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "INTERVENTION 1: AlloDerm RTU Participants within this arm will have the acellular dermal matrix AlloDerm RTU implanted at the time of tissue expander placement  AlloDerm RTU INTERVENTION 2: SurgiMend PRS Participants within this arm will have the acellular dermal matrix SurgiMend PRS implanted at the time of tissue expander placement  SurgiMend PRS ",
        "premise_nums": []
    },
    {
        "id": "d3ca3729-2795-4cd5-9968-666781d17fac",
        "primaryId": "NCT00119262",
        "statement_text": "cohorts 1 and 2 of the primary trial recorded a different number of patients that suffered from Congestive Heart Failure ",
        "statement_nums": [
            "1 and 2"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Congestive Heart Failure Rate Clinical congestive heart failure includes patients with symptomatic decline in LVEF to at or below the lower limit of normal (LLN)  or symptomatic diastolic dysfunction  223 treated patients were included in the analysis  Time frame: assessed on day 1 of cycles 5, 9, 17 and 25, and at end of treatment  then every 3 months for smaller than 2 years and every 6 months for 2-3 years from study entry Results 1: Arm/Group Title: Arm A (ddBAC greater than BT greater than B) ",
        "premise_nums": [
            "3 years from",
            "2 years and",
            "17 and 25,",
            "6 months for",
            "3 months for",
            "223 treated patients",
            "2-3 years",
            "1 of cycles"
        ]
    },
    {
        "id": "d3ca3729-2795-4cd5-9968-666781d17fac",
        "primaryId": "NCT00119262",
        "statement_text": "cohorts 1 and 2 of the primary trial recorded a different number of patients that suffered from Congestive Heart Failure ",
        "statement_nums": [
            "1 and 2"
        ],
        "label": "Contradiction",
        "premise_text": "Arm/Group Description: Dose dense bevacizumab  cyclophosphamide and doxorubicin  followed by paclitaxel and bevacizumab  followed by bevacizumabOverall Number of Participants Analyzed: 103 Measure Type: Number Unit of Measure: percentage of participants 2.9 (0.6 to 8.3) Results 2: Arm/Group Title: Arm B (ddAC greater than BT greater than B) Arm/Group Description: Dose dense doxorubicin and cyclophosphamide  followed by paclitaxel and bevacizumab  followed by bevacizumab Overall Number of Participants Analyzed: 120 Measure Type: Number ",
        "premise_nums": [
            "120 Measure Type:",
            "6 to 8.3)",
            "103 Measure Type:"
        ]
    },
    {
        "id": "d3ca3729-2795-4cd5-9968-666781d17fac",
        "primaryId": "NCT00119262",
        "statement_text": "cohorts 1 and 2 of the primary trial recorded a different number of patients that suffered from Congestive Heart Failure ",
        "statement_nums": [
            "1 and 2"
        ],
        "label": "Contradiction",
        "premise_text": "Unit of Measure: percentage of participants 2.5 (0.5 to 7.1)",
        "premise_nums": []
    },
    {
        "id": "fb85a3a5-b9a1-48f4-84f3-2e2307e2f104",
        "primaryId": "NCT01752907",
        "statement_text": "There were 0 observed cases of Tibia or Fibula fractures in the primary trial ",
        "statement_nums": [
            "0 observed cases"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 16/149 (10.74%) Anaemia 0/149 (0.00%) Febrile neutropenia 7/149 (4.70%) Neutropenia 1/149 (0.67%) Pancytopenia 1/149 (0.67%) Atrial fibrillation 2/149 (1.34%) Cardiac failure congestive 0/149 (0.00%) Abdominal pain 0/149 (0.00%) Diarrhoea 2/149 (1.34%) Dyspepsia 0/149 (0.00%) Gastritis haemorrhagic 0/149 (0.00%) Nausea 2/149 (1.34%) Adverse Events 2: ",
        "premise_nums": [
            "16/149 (10.74%)",
            "7/149 (4.70%)",
            "0/149 (0.00%)",
            "1/149 (0.67%)",
            "2/149 (1.34%)"
        ]
    },
    {
        "id": "fb85a3a5-b9a1-48f4-84f3-2e2307e2f104",
        "primaryId": "NCT01752907",
        "statement_text": "There were 0 observed cases of Tibia or Fibula fractures in the primary trial ",
        "statement_nums": [
            "0 observed cases"
        ],
        "label": "Entailment",
        "premise_text": "Total: 20/151 (13.25%)Anaemia 1/151 (0.66%) Febrile neutropenia 4/151 (2.65%) Neutropenia 2/151 (1.32%) Pancytopenia 0/151 (0.00%) Atrial fibrillation 0/151 (0.00%) Cardiac failure congestive 1/151 (0.66%) Abdominal pain 1/151 (0.66%) Diarrhoea 3/151 (1.99%) Dyspepsia 1/151 (0.66%) Gastritis haemorrhagic 1/151 (0.66%) Nausea 1/151 (0.66%) ",
        "premise_nums": [
            "1/151 (0.66%)",
            "2/151 (1.32%)",
            "4/151 (2.65%)",
            "3/151 (1.99%)",
            "20/151 (13.25%)Anaemia",
            "0/151 (0.00%)"
        ]
    },
    {
        "id": "b98c7a50-ed79-41ff-9733-fff143f630be",
        "primaryId": "NCT01901146",
        "secondaryId": "NCT00209092",
        "label": "Contradiction",
        "statement_text": "Cohort 1 of the primary trial recorded the same number of instances of Neutropenic fever as Cohort 1 of the secondary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Adverse Events 1: Febrile neutropenia 3/364 (0.82%) Adverse Events 1: Febrile Neutropenia *0/25 (0.00%) ",
        "premise_nums": [
            "0/25 (0.00%)",
            "3/364 (0.82%)"
        ]
    },
    {
        "id": "47aa5686-75af-4ed8-b4ff-715b458ce40a",
        "primaryId": "NCT02203565",
        "secondaryId": "NCT00194779",
        "label": "Entailment",
        "statement_text": "laboratory biomarker analysis is used in the secondary trial and the primary trial ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Supportive Care (Dakin's Solution  Radiation Therapy) Patients apply Dakin's solution topically daily over 10 minutes within 60 minutes of radiation therapy for up to 6 weeks  Dakin's solution: Applied topically radiation therapy: Undergo radiation therapy questionnaire administration: Ancillary studies laboratory biomarker analysis: Optional correlative studies INTERVENTION 1: Treatment (Neoadjuvant Therapy  Adjuvant Therapy) See Detailed Description  doxorubicin hydrochloride: Given IV cyclophosphamide: Given PO paclitaxel: Given IV filgrastim: Given SC capecitabine: Given PO methotrexate: Given IV vinorelbine tartrate: Given IV needle biopsy: Correlative studies therapeutic conventional surgery: Undergo definitive breast surgery ",
        "premise_nums": [
            "60 minutes of",
            "10 minutes within"
        ]
    },
    {
        "id": "47aa5686-75af-4ed8-b4ff-715b458ce40a",
        "primaryId": "NCT02203565",
        "secondaryId": "NCT00194779",
        "label": "Entailment",
        "statement_text": "laboratory biomarker analysis is used in the secondary trial and the primary trial ",
        "statement_nums": [],
        "premise_text": "immunohistochemistry staining method: Correlative studiestrastuzumab: Given IV tamoxifen citrate: Given PO letrozole: Given PO laboratory biomarker analysis: Correlative studies ",
        "premise_nums": []
    },
    {
        "id": "e89fdc93-d624-4ba7-aa64-574a278e982b",
        "primaryId": "NCT00077376",
        "secondaryId": "NCT01256008",
        "label": "Entailment",
        "statement_text": "the primary trial investigates a novel chemotherapy treatment  whereas the secondary trial is testing a type of psychological therapy ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Trastuzumab/Ixabepilone/Carboplatin ",
        "premise_nums": []
    },
    {
        "id": "e89fdc93-d624-4ba7-aa64-574a278e982b",
        "primaryId": "NCT00077376",
        "secondaryId": "NCT01256008",
        "label": "Entailment",
        "statement_text": "the primary trial investigates a novel chemotherapy treatment  whereas the secondary trial is testing a type of psychological therapy ",
        "statement_nums": [],
        "premise_text": "During the induction phase  patients were treated with Ixabepilone (BMS-247550) 15mg/m2 intravenously (IV) followed by carboplatin (AUC=2 IV) on days 1, 8 and 15 of a 28-day cycle for a maximum of 6 cycles  Trastuzumab was administered weekly (4mg/kg loading dose then 2mg/kg IV) starting on day 1. Routine premedication included H1 blocker (diphenhydramine 50 mg orally (PO) or IV)  H2 blocker (ranitidine 150 mg PO or 50 mg IV or another equivalent H2 blocker)  and at least a 5-HT3 antagonist and dexamethasone ",
        "premise_nums": [
            "50 mg IV",
            "50 mg orally",
            "2mg/kg IV",
            "15mg/m2 intravenously",
            "150 mg PO",
            "2 intravenously (IV)",
            "2 blocker (ranitidine",
            "5-HT3 antagonist",
            "8 and 15",
            "3 antagonist and",
            "28-day cycle",
            "1 blocker (diphenhydramine"
        ]
    },
    {
        "id": "e89fdc93-d624-4ba7-aa64-574a278e982b",
        "primaryId": "NCT00077376",
        "secondaryId": "NCT01256008",
        "label": "Entailment",
        "statement_text": "the primary trial investigates a novel chemotherapy treatment  whereas the secondary trial is testing a type of psychological therapy ",
        "statement_nums": [],
        "premise_text": "After completion of 24 weekly trastuzumab doses (induction therapy)  trastuzumab were given at a dose of 6 mg/kg IV every 3 weeks (maintenance therapy) beginning one week after the 24th weekly dose  Trastuzumab were repeated every 21 days until disease progression or prohibitive toxicity INTERVENTION 1: Stage 1 Clinical Management The group will receive clinical management treatment only each session  Clinical Management: Clinical management is a clear contrast method of psychological therapy  which is a half-structured interview and lasting for 20-25 minutes each session  Clinical management will be assigned to both experimental group and controlled group in the first stage of intervention  Following are major elements: ",
        "premise_nums": [
            "1 Clinical Management",
            "25 minutes each",
            "21 days until",
            "24 weekly trastuzumab",
            "6 mg/kg IV",
            "3 weeks (maintenance",
            "20-25 minutes"
        ]
    },
    {
        "id": "e89fdc93-d624-4ba7-aa64-574a278e982b",
        "primaryId": "NCT00077376",
        "secondaryId": "NCT01256008",
        "label": "Entailment",
        "statement_text": "the primary trial investigates a novel chemotherapy treatment  whereas the secondary trial is testing a type of psychological therapy ",
        "statement_nums": [],
        "premise_text": "Talk to the subjects to find their main problems; introduce knowledge and medication knowledge about cancer and depression; subjects reporting use of drugs for cancer and depression and a variety of signs and symptoms of the reaction  Encourage patients to adhere to drug treatment and to comply with this research program; The operation of CBT and clinical management should be conducted by the same person as far as possible ",
        "premise_nums": []
    },
    {
        "id": "1739541a-2d3f-4a13-b956-769a1cbed4d7",
        "primaryId": "NCT00871858",
        "statement_text": "1 patient in cohort 1 of the primary trial was diagnosed with a Clear cell renal cell carcinoma ",
        "statement_nums": [
            "1 patient in",
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 2/60 (3.33%) Bronchial infection 0/60 (0.00%) Ankle fracture 1/60 (1.67%) Clear cell kidney cancer 0/60 (0.00%) Programmed peritoneal dialysis 1/60 (1.67%) Endometrial atrophy 0/60 (0.00%) Adverse Events 2: Total: 3/58 (5.17%) Bronchial infection 1/58 (1.72%) Ankle fracture 0/58 (0.00%) Clear cell kidney cancer 1/58 (1.72%) Programmed peritoneal dialysis 0/58 (0.00%) Endometrial atrophy 1/58 (1.72%) ",
        "premise_nums": [
            "2/60 (3.33%)",
            "3/58 (5.17%)",
            "1/60 (1.67%)",
            "0/60 (0.00%)",
            "1/58 (1.72%)",
            "0/58 (0.00%)"
        ]
    },
    {
        "id": "c8f401a0-5e7d-4fd9-b31e-0866c9bee6a9",
        "primaryId": "NCT02187744",
        "statement_text": "One patient in the primary trial suffered from sepsis  due to the presence of an implanted device ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Device related sepsis 1/113 (0.88%) ",
        "premise_nums": [
            "1/113 (0.88%)"
        ]
    },
    {
        "id": "206fc00c-2c34-42bc-8fca-44be696e03c9",
        "primaryId": "NCT02312622",
        "statement_text": "Both cohorts of the primary trial receive identical interventions; Pegylated Irinotecan Administered intravenously (IV) at 145 mg/m¬¨‚â§ as monotherapy once every 21 days   the differences between the cohorts is the type of cancers that patients are diagnosed with  cohort 1 is NSCLC  whereas cohort 2 is mBC and the number of cycles for each cohort  1 for cohort 1 and 4 for cohort 2.",
        "statement_nums": [
            "2 is mBC",
            "1 and 4",
            "1 is NSCLC",
            "145 mg/m¬¨‚â§",
            "1 for cohort"
        ],
        "label": "Contradiction",
        "premise_text": "INTERVENTION 1: Cohort A - Pegylated Irinotecan to Treat NSCLC Patients with non-small cell lung carinoma (NSCLC) will receive pegylated irinotecan intravenously (IV) over 90 minutes every 21 days in the absence of disease progression or unacceptable toxicity  ",
        "premise_nums": [
            "21 days in",
            "90 minutes every"
        ]
    },
    {
        "id": "206fc00c-2c34-42bc-8fca-44be696e03c9",
        "primaryId": "NCT02312622",
        "statement_text": "Both cohorts of the primary trial receive identical interventions; Pegylated Irinotecan Administered intravenously (IV) at 145 mg/m¬¨‚â§ as monotherapy once every 21 days   the differences between the cohorts is the type of cancers that patients are diagnosed with  cohort 1 is NSCLC  whereas cohort 2 is mBC and the number of cycles for each cohort  1 for cohort 1 and 4 for cohort 2.",
        "statement_nums": [
            "2 is mBC",
            "1 and 4",
            "1 is NSCLC",
            "145 mg/m¬¨‚â§",
            "1 for cohort"
        ],
        "label": "Contradiction",
        "premise_text": "Pegylated Irinotecan: Administered intravenously (IV) at 145 mg/m² as monotherapy once every 21 days (1 cycle)INTERVENTION 2: Cohort C - Pegylated Irinotecan to Treat mBC ",
        "premise_nums": [
            "21 days (1",
            "145 mg/m²"
        ]
    },
    {
        "id": "206fc00c-2c34-42bc-8fca-44be696e03c9",
        "primaryId": "NCT02312622",
        "statement_text": "Both cohorts of the primary trial receive identical interventions; Pegylated Irinotecan Administered intravenously (IV) at 145 mg/m¬¨‚â§ as monotherapy once every 21 days   the differences between the cohorts is the type of cancers that patients are diagnosed with  cohort 1 is NSCLC  whereas cohort 2 is mBC and the number of cycles for each cohort  1 for cohort 1 and 4 for cohort 2.",
        "statement_nums": [
            "2 is mBC",
            "1 and 4",
            "1 is NSCLC",
            "145 mg/m¬¨‚â§",
            "1 for cohort"
        ],
        "label": "Contradiction",
        "premise_text": "Patients with metastatic breast cancer (MBC) to brain will receive pegylated irinotecan intravenously (IV) over 90 minutes every 21 days in the absence of disease progression or unacceptable toxicity Pegylated Irinotecan: Administered intravenously (IV) at 145 mg/m² as monotherapy once every 21 days (1 cycle) ",
        "premise_nums": [
            "21 days (1",
            "90 minutes every",
            "21 days in",
            "145 mg/m²"
        ]
    },
    {
        "id": "4a6d7f07-27b5-4281-b59c-f1c77dbd6e2d",
        "primaryId": "NCT00393939",
        "statement_text": "Median (95% Confidence Interval) Progression-Free Survival (PFS) was over a year higher for patients in the Trastuzumab + Sunitinib group of the primary trial than for the Docetaxel group ",
        "statement_nums": [
            "95% Confidence"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Progression-Free Survival (PFS) PFS defined as time from date of randomization to date of the first documentation of objective tumor progression or death due to any cause  whichever occurred first  PFS calculated as (Months) = (first event date minus randomization date plus 1) divided by 30.4. Time frame: Baseline up to Month 33 Results 1: Arm/Group Title: Docetaxel + Sunitinib ",
        "premise_nums": [
            "33 Results 1:"
        ]
    },
    {
        "id": "4a6d7f07-27b5-4281-b59c-f1c77dbd6e2d",
        "primaryId": "NCT00393939",
        "statement_text": "Median (95% Confidence Interval) Progression-Free Survival (PFS) was over a year higher for patients in the Trastuzumab + Sunitinib group of the primary trial than for the Docetaxel group ",
        "statement_nums": [
            "95% Confidence"
        ],
        "label": "Contradiction",
        "premise_text": "Arm/Group Description: Sunitinib 37.5 milligrams (mg) daily by oral capsule for 2 weeks followed by a 1-week off-treatment period (Schedule 2/1) with docetaxel 75 milligrams per square meter (mg/m^2) every 3 weeks  or sunitinib 37.5 mg daily in continuous dosing (in absence of docetaxel)  or docetaxel 100 mg/m^2 every 3 weeks (in absence of sunitinib) Overall Number of Participants Analyzed: 296 Median (95% Confidence Interval) ",
        "premise_nums": [
            "2 every 3",
            "2 weeks followed",
            "75 milligrams per",
            "100 mg/m^2",
            "95% Confidence",
            "2/1) with",
            "sunitinib 37.5 mg daily",
            "1-week off-treatment",
            "5 milligrams (mg)"
        ]
    },
    {
        "id": "4a6d7f07-27b5-4281-b59c-f1c77dbd6e2d",
        "primaryId": "NCT00393939",
        "statement_text": "Median (95% Confidence Interval) Progression-Free Survival (PFS) was over a year higher for patients in the Trastuzumab + Sunitinib group of the primary trial than for the Docetaxel group ",
        "statement_nums": [
            "95% Confidence"
        ],
        "label": "Contradiction",
        "premise_text": "Unit of Measure: months Independent radiology assessment: 8.6 (8.2 to 10.3)Investigator's assessment: 8.2 (7.3 to 8.6) Results 2: Arm/Group Title: Docetaxel Arm/Group Description: Docetaxel 100 mg/m^2 every 3 weeks Overall Number of Participants Analyzed: 297 Median (95% Confidence Interval) Unit of Measure: months Independent radiology assessment: 8.3 (7.7 to 9.6) Investigator's assessment: 6.9 (6.5 to 7.3) ",
        "premise_nums": [
            "2 every 3",
            "3 to 8.6)",
            "3 weeks Overall",
            "5 to 7.3)",
            "7 to 9.6)",
            "100 mg/m^2",
            "95% Confidence"
        ]
    },
    {
        "id": "83cef795-d4a8-486c-8ac1-34a9acee9672",
        "primaryId": "NCT00581256",
        "statement_text": "Patients with left-sided breast cancer and an ECOG between 1-2 are excluded from the primary trial ",
        "statement_nums": [
            "2 are excluded",
            "1-2 are"
        ],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria: All patients must have left-sided breast cancer  Performance status should be 0-2 by ECOG criteria  Exclusion Criteria: Performance status greater than 2 by ECOG criteria ",
        "premise_nums": [
            "0-2 by",
            "2 by ECOG"
        ]
    },
    {
        "id": "b3cee7a6-cec1-4676-974d-7cfb3ccd9919",
        "primaryId": "NCT00127933",
        "secondaryId": "NCT00191789",
        "label": "Entailment",
        "statement_text": "the primary trial recorded one patient with a catheter-related complication  whereas in the secondary trial none where observed ",
        "statement_nums": [],
        "premise_text": "Catheter site cellulitis 1/122 (0.82%) Catheter site cellulitis 0/34 (0.00%) Adverse Events 1: Total: 17/65 (26.15%) Febrile neutropenia 3/65 (4.62%) Neutropenia 2/65 (3.08%) Pancytopenia 1/65 (1.54%) Thrombocytopenia 1/65 (1.54%) Cardiac arrest 2/65 (3.08%) Myocardial infarction 1/65 (1.54%) Diarrhoea 5/65 (7.69%) Stomatitis 1/65 (1.54%) Vomiting 2/65 (3.08%) ",
        "premise_nums": [
            "17/65 (26.15%)",
            "3/65 (4.62%)",
            "0/34 (0.00%)",
            "1/122 (0.82%)",
            "5/65 (7.69%)",
            "2/65 (3.08%)",
            "1/65 (1.54%)"
        ]
    },
    {
        "id": "b3cee7a6-cec1-4676-974d-7cfb3ccd9919",
        "primaryId": "NCT00127933",
        "secondaryId": "NCT00191789",
        "label": "Entailment",
        "statement_text": "the primary trial recorded one patient with a catheter-related complication  whereas in the secondary trial none where observed ",
        "statement_nums": [],
        "premise_text": "Fatigue 1/65 (1.54%)Jaundice 1/65 (1.54%) Neutropenic infection 2/65 (3.08%) ",
        "premise_nums": [
            "1/65 (1.54%)Jaundice",
            "2/65 (3.08%)"
        ]
    },
    {
        "id": "007de11b-4265-4695-b18e-e0d6909a347a",
        "primaryId": "NCT00944047",
        "secondaryId": "NCT00228943",
        "label": "Contradiction",
        "statement_text": "Patients with HER2 positive tumors are excluded from the primary trial  but may be included in the secondary trial ",
        "statement_nums": [
            "2 positive tumors"
        ],
        "premise_text": "Inclusion Criteria: HER-2/neu 1+ or 2+ by immunohistochemistry Inclusion Criteria: At least 18 years of age Willing and able to provide informed consent Reporting daily hot flashes Able to read  write  and speak English Postmenopausal to limit sample variability (greater than 12 months amenorrhea) Greater then 1 month but smaller than 5 years post-treatment (surgery  radiation  chemotherapy) for non-metastatic breast cancer  These criteria allow inclusion of women successfully treated for recurrent breast cancer since there is no known reason to exclude them  Menopausal status is assessed using self-reports due to problems in reliably measuring follicle-stimulating hormone levels and estradiol in tamoxifen users  Exclusion Criteria: ",
        "premise_nums": [
            "1 month but",
            "12 months amenorrhea)",
            "5 years post",
            "2/neu 1+",
            "18 years of"
        ]
    },
    {
        "id": "007de11b-4265-4695-b18e-e0d6909a347a",
        "primaryId": "NCT00944047",
        "secondaryId": "NCT00228943",
        "label": "Contradiction",
        "statement_text": "Patients with HER2 positive tumors are excluded from the primary trial  but may be included in the secondary trial ",
        "statement_nums": [
            "2 positive tumors"
        ],
        "premise_text": "Exclusion criteria are current depression  history of migraines or hepatitis  abnormal chemistry profile (e.g.  sodium  potassium  glucose)  or a positive urine drug screen for illegal substances ",
        "premise_nums": []
    },
    {
        "id": "ce621235-b584-439b-bb11-ab2fa04c3195",
        "primaryId": "NCT01869764",
        "secondaryId": "NCT02556632",
        "label": "Contradiction",
        "statement_text": "Every participant in the secondary trial and the primary trial undergoes Laboratory Biomarker Analysis and completes a Questionnaire ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Arm I (Omega-3 Fatty Acid) Patients receive omega-3 fatty acid PO daily for 7-14 days  omega-3 fatty acid: Given PO laboratory biomarker analysis: Correlative studies INTERVENTION 2: Arm II (Placebo) Patients receive placebo PO daily for 7-14 days  placebo: Given PO laboratory biomarker analysis: Correlative studies INTERVENTION 1: Arm I (Curcumin-based Gel) Patients apply curcumin-based gel topically TID approximately every 4-6 hours beginning on the first day of radiation therapy and continuing until 1 week after completion of radiation therapy  Curcumin-based Gel: Applied topically Laboratory Biomarker Analysis: Correlative studies Questionnaire Administration: Ancillary studies INTERVENTION 2: ",
        "premise_nums": [
            "1 week after",
            "7-14 days",
            "6 hours beginning",
            "3 fatty acid:",
            "4-6 hours",
            "3 Fatty Acid)"
        ]
    },
    {
        "id": "ce621235-b584-439b-bb11-ab2fa04c3195",
        "primaryId": "NCT01869764",
        "secondaryId": "NCT02556632",
        "label": "Contradiction",
        "statement_text": "Every participant in the secondary trial and the primary trial undergoes Laboratory Biomarker Analysis and completes a Questionnaire ",
        "statement_nums": [],
        "premise_text": "Arm II (HPR Plus)Patients apply HPR Plus™ topically TID approximately every 4-6 hours beginning on the first day of radiation therapy and continuing until 1 week after completion of radiation therapy  Dermatologic Complications Management: Apply HPR Plus topically Laboratory Biomarker Analysis: Correlative studies Questionnaire Administration: Ancillary studies ",
        "premise_nums": [
            "1 week after",
            "6 hours beginning",
            "4-6 hours"
        ]
    },
    {
        "id": "f358f023-2393-44eb-9535-3f0e1851318d",
        "primaryId": "NCT01646346",
        "secondaryId": "NCT03283553",
        "label": "Contradiction",
        "statement_text": "the secondary trial and the primary trial both use irradiation techniques in their studies ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: 4D Conformal Image-Guided Partial Breast RT This is a single arm trial designed to look at the results in women treated with partial breast irradiation twice daily for 5 days  4D Conformal Image-Guided Partial Breast RT: External beam partial breast radiation to target a portion of the breast twice a day for 5 days  INTERVENTION 1: Multicomponent Intervention 1.) A one-page paper-pencil agenda setting checklist completed immediately before a regularly scheduled medical oncology visit to elicit and align patient and companion perspectives regarding issues to discuss with the provider  and to stimulate discussion about the role of the companion in the visit  2.) facilitated registration for the patient portal (for patient and family member  as desired by the patient)  and 3.) education (as relevant) on access to doctor's electronic visit notes  INTERVENTION 2: Usual Care ",
        "premise_nums": []
    },
    {
        "id": "f358f023-2393-44eb-9535-3f0e1851318d",
        "primaryId": "NCT01646346",
        "secondaryId": "NCT03283553",
        "label": "Contradiction",
        "statement_text": "the secondary trial and the primary trial both use irradiation techniques in their studies ",
        "statement_nums": [],
        "premise_text": "Care as usual with the medical oncologist ",
        "premise_nums": []
    },
    {
        "id": "0e963b25-0d2b-4fc6-89c6-1eb068bc092e",
        "primaryId": "NCT00470301",
        "statement_text": "Every patient in the primary trial is given tipifarnib PO  along with paclitaxel  doxorubicin hydrochloride and acyclophosphamide IV ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "INTERVENTION 1: Arm I See Detailed Description tipifarnib: Given orally paclitaxel: Given IV doxorubicin hydrochloride: Given IV cyclophosphamide: Given IV pegfilgrastim: Given SC conventional surgery: surgical procedures performed on patients axillary lymph node dissection: correlative study ",
        "premise_nums": []
    },
    {
        "id": "390b08d3-e147-47f9-82d7-0643b8d5c8ae",
        "primaryId": "NCT00733408",
        "statement_text": "There was just under 8 weeks difference in Progression-free Survival between the minimum and maximum PFS in the primary trial ",
        "statement_nums": [
            "8 weeks difference"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Progression-free Survival (PFS) ",
        "premise_nums": []
    },
    {
        "id": "2570cb04-4edd-48c9-b634-9f2e086469de",
        "primaryId": "NCT00994279",
        "secondaryId": "NCT00545077",
        "label": "Entailment",
        "statement_text": "Between both the primary trial and the secondary trial Bevacizumab is only administered to patients in cohort 2 of the secondary trial ",
        "statement_nums": [
            "2 of the"
        ],
        "premise_text": "INTERVENTION 1: Arm 1: Yoga Intervention Yoga Intervention Yoga: Yoga sessions INTERVENTION 2: Arm 2: Educational Wellness Group Educational Wellness Group Education: Educational Wellness Group INTERVENTION 1: Arm A: Endocrine Therapy (ET) Endocrine treatment consisting of either letrozole or fulvestrant  Patients will be randomized to receive bevacizumab 15mg/kg every 3 weeks plus endocrine treatment or endocrine treatment as a single agent  The patients will receive the assigned treatment until the progression of the disease  unacceptable toxicity or withdrawal of the consent  Letrozole Fulvestrant INTERVENTION 2: Arm B: ET With Bevacizumab (ET-B) ",
        "premise_nums": [
            "3 weeks plus",
            "15mg/kg every"
        ]
    },
    {
        "id": "2570cb04-4edd-48c9-b634-9f2e086469de",
        "primaryId": "NCT00994279",
        "secondaryId": "NCT00545077",
        "label": "Entailment",
        "statement_text": "Between both the primary trial and the secondary trial Bevacizumab is only administered to patients in cohort 2 of the secondary trial ",
        "statement_nums": [
            "2 of the"
        ],
        "premise_text": "Endocrine treatment consisting of either letrozole or fulvestrant  Patients will be randomized to receive bevacizumab 15mg/kg i.v  on day 1 every 3 weeks plus endocrine treatment or endocrine treatment as a single agent  The patients will receive the assigned treatment until the progression of the disease  unacceptable toxicity or withdrawal of the consent Letrozole Bevacizumab Fulvestrant ",
        "premise_nums": [
            "15mg/kg i",
            "1 every 3"
        ]
    },
    {
        "id": "f6a7e279-b923-45e3-8ad5-e81e17c0a682",
        "primaryId": "NCT00270894",
        "statement_text": "60 patients in the primary trial were able to Complete at least 85% of the Planned Dose on Schedule ",
        "statement_nums": [
            "60 patients in",
            "85% of"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Percentage of Subjects Able to Complete greater than 85% of the Planned Dose on Schedule Feasibility will be determined by evaluating the percentage of subjects able to complete the neoadjuvant portion of the study on time with greater than 85% of the protocol-specified dose  Time frame: From the start of treatment through the neoadjuvant treatment period (approximately 20 weeks) Results 1: Arm/Group Title: Neoadjuvant Therapy ",
        "premise_nums": [
            "85% of"
        ]
    },
    {
        "id": "f6a7e279-b923-45e3-8ad5-e81e17c0a682",
        "primaryId": "NCT00270894",
        "statement_text": "60 patients in the primary trial were able to Complete at least 85% of the Planned Dose on Schedule ",
        "statement_nums": [
            "60 patients in",
            "85% of"
        ],
        "label": "Contradiction",
        "premise_text": "Arm/Group Description: Neoadjuvant therapy will consist of epirubicin (100 mg/m^2) + cyclophosphamide (600 mg/m^2) every 2 weeks for 4 cycles; followed by a 3-week break; followed by docetaxel (75 mg/m^2) every 2 weeks for 4 cycles + trastuzumab (6 mg/kg [loading dose] once then 4 mg/kg [maintenance dose]) every 2 weeks for 4 treatments Overall Number of Participants Analyzed: 30 Measure Type: Number Unit of Measure: percentage of participants 60 ",
        "premise_nums": [
            "4 treatments Overall",
            "4 mg/kg",
            "30 Measure Type:",
            "2 weeks for",
            "3-week break"
        ]
    },
    {
        "id": "3d82851c-f302-4988-bd78-232583e04e96",
        "primaryId": "NCT02511730",
        "secondaryId": "NCT00193206",
        "label": "Entailment",
        "statement_text": "Patients with prior chemotherapy are eligible for the primary trial  but excluded from the secondary trial ",
        "statement_nums": [],
        "premise_text": "Inclusion Criteria: Female subjects participating in FMSU004A protocol with known clinical status Exclusion Criteria: Subjects with unknown clinical status not participating in FMSU004A protocol  Inclusion Criteria: No prior chemotherapy for breast cancer ",
        "premise_nums": []
    },
    {
        "id": "5c9f5916-37d3-4f6f-977b-be70204cf57c",
        "primaryId": "NCT01819233",
        "statement_text": "All the primary trial participants have the same number of calories in their diets throughout the duration of the study ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "INTERVENTION 1: Behavioral Dietary Intervention Beginning 2-4 weeks after completion of lumpectomy  patients receive food diaries to complete for 7-10 days  Dietary counselors then give patients guidelines for dietary modifications to reduce caloric intake by 25% of their normal diet  Patients follow caloric restricted diet for 10 weeks (2 weeks prior to radiation therapy  during 6 weeks of radiation therapy  and at least 2 weeks after radiation therapy)  Patients undergo radiation therapy QD 5 days a week for 6 weeks  Behavioral dietary intervention: Receive caloric restricted dietary intervention Therapeutic conventional surgery: Undergo definitive lumpectomy Radiation therapy: Undergo radiation therapy Counseling intervention: Receive dietary counseling Quality-of-life assessment: Ancillary studies ",
        "premise_nums": [
            "25% of",
            "2-4 weeks",
            "5 days a",
            "4 weeks after",
            "7-10 days",
            "10 weeks (2",
            "6 weeks of",
            "2 weeks after"
        ]
    },
    {
        "id": "0c5f2498-4c10-4e51-8915-d86b37b08156",
        "primaryId": "NCT01156987",
        "secondaryId": "NCT02234479",
        "label": "Entailment",
        "statement_text": "Participants in the primary trial are assigned an intervention depending on their cancer diagnosis  whereas in the secondary trial the interventions are randomly assigned ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Healthy Volunteers Healthy women will be screened for Magnetic Resonance Imaging (MRI) contraindications  and then undergo contrast injection  and SWIFT acquisition  Magnetic resonance imaging: Patients and healthy volunteers will be first screened for MRI contraindications  The SWIFT MRI workflow will be performed as follows: INTERVENTION 2: Breast Cancer Patients Breast cancer patients who have suspected breast lesion that will be biopsied will be screened for Magnetic Resonance Imaging (MRI) contraindications  and then undergo contrast injection and SWIFT acquisition  Magnetic resonance imaging: Patients and healthy volunteers will be first screened for MRI contraindications  The SWIFT MRI workflow will be performed as follows: INTERVENTION 1: Hydrophor (Group A) ",
        "premise_nums": []
    },
    {
        "id": "0c5f2498-4c10-4e51-8915-d86b37b08156",
        "primaryId": "NCT01156987",
        "secondaryId": "NCT02234479",
        "label": "Entailment",
        "statement_text": "Participants in the primary trial are assigned an intervention depending on their cancer diagnosis  whereas in the secondary trial the interventions are randomly assigned ",
        "statement_nums": [],
        "premise_text": "Group A (current standard of care): Patients will be instructed (by nurses and with printed study materials) to apply a thin layer of the Hydrophor daily  starting at the onset of radiation therapy (RT) and continuing until 2 weeks after the final RT session or until the RT site is healed (whichever is first)  Hydrophor application should include the entire treatment area  including the axillae and shoulder/back area in patients treated with modified radical mastectomy  To avoid possible build-up effects  patients should not apply the Hydrophor within 4 hours of receiving RT  Patients should wash the application area daily with perfume-free soap and tap water  Patients will be asked to refrain from using other topical agents in the irradiated area INTERVENTION 2: MediHoney (Group B) ",
        "premise_nums": [
            "4 hours of",
            "2 weeks after"
        ]
    },
    {
        "id": "0c5f2498-4c10-4e51-8915-d86b37b08156",
        "primaryId": "NCT01156987",
        "secondaryId": "NCT02234479",
        "label": "Entailment",
        "statement_text": "Participants in the primary trial are assigned an intervention depending on their cancer diagnosis  whereas in the secondary trial the interventions are randomly assigned ",
        "statement_nums": [],
        "premise_text": "Group B (study target): Patients will be instructed (by nurses and with printed study materials) to apply a thin layer of the Medihoney daily  starting at the onset of RT and continuing until 2 weeks after the final RT session or until the RT site is healed (whichever is first)  Medihoney application should include the entire treatment area  including the axillae and shoulder/back area in patients treated with modified radical mastectomy  To avoid possible build-up effects  patients should not apply the Medihoney within 4 hours of receiving RT  Patients should wash the application area daily with perfume-free soap and tap water  Patients will be asked to refrain from using other topical agents in the irradiated area ",
        "premise_nums": [
            "4 hours of",
            "2 weeks after"
        ]
    },
    {
        "id": "c54dc963-671a-4384-8b1f-d8058a832131",
        "primaryId": "NCT00545688",
        "statement_text": "There were no patients with paranasal sinus reactions  or Left ventricular dysfunction in the primary trial ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 21/107 (19.63%) Febrile neutropenia * 10/107 (9.35%) Neutropenia * 1/107 (0.93%) Left ventricular dysfunction * 0/107 (0.00%) Angina pectoris * 0/107 (0.00%) Cardiac failure congestive * 0/107 (0.00%) Diarrhoea * 2/107 (1.87%) Abdominal strangulated hernia * 0/107 (0.00%) Duodenal ulcer haemorrhage * 0/107 (0.00%) Pyrexia * 1/107 (0.93%) Adverse Events 2: ",
        "premise_nums": [
            "2/107 (1.87%)",
            "1/107 (0.93%)",
            "10/107 (9.35%)",
            "21/107 (19.63%)",
            "0/107 (0.00%)"
        ]
    },
    {
        "id": "c54dc963-671a-4384-8b1f-d8058a832131",
        "primaryId": "NCT00545688",
        "statement_text": "There were no patients with paranasal sinus reactions  or Left ventricular dysfunction in the primary trial ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Total: 22/107 (20.56%)Febrile neutropenia * 8/107 (7.48%) Neutropenia * 6/107 (5.61%) Left ventricular dysfunction * 3/107 (2.80%) Angina pectoris * 1/107 (0.93%) Cardiac failure congestive * 0/107 (0.00%) Diarrhoea * 0/107 (0.00%) Abdominal strangulated hernia * 1/107 (0.93%) Duodenal ulcer haemorrhage * 0/107 (0.00%) Pyrexia * 1/107 (0.93%) ",
        "premise_nums": [
            "22/107 (20.56%)Febrile",
            "0/107 (0.00%)",
            "1/107 (0.93%)",
            "6/107 (5.61%)",
            "8/107 (7.48%)",
            "3/107 (2.80%)"
        ]
    },
    {
        "id": "a4c62782-9f4c-4cf5-96b3-eb8e9098a3b4",
        "primaryId": "NCT02340221",
        "statement_text": "A total of 32 patients in the primary trial had Diarrhoea ",
        "statement_nums": [
            "32 patients in"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 19/213 (8.92%) Pancytopenia 0/213 (0.00%) Anaemia 1/213 (0.47%) Atrial fibrillation 0/213 (0.00%) Cardiac failure congestive 0/213 (0.00%) Myocardial infarction 0/213 (0.00%) Supraventricular tachycardia 0/213 (0.00%) Diarrhoea 0/213 (0.00%) Colitis 0/213 (0.00%) Vomiting 1/213 (0.47%) Nausea 1/213 (0.47%) Enterocolitis 0/213 (0.00%) Adverse Events 2: Total: 133/416 (31.97%) ",
        "premise_nums": [
            "0/213 (0.00%)",
            "1/213 (0.47%)",
            "19/213 (8.92%)",
            "133/416 (31.97%)"
        ]
    },
    {
        "id": "a4c62782-9f4c-4cf5-96b3-eb8e9098a3b4",
        "primaryId": "NCT02340221",
        "statement_text": "A total of 32 patients in the primary trial had Diarrhoea ",
        "statement_nums": [
            "32 patients in"
        ],
        "label": "Entailment",
        "premise_text": "Pancytopenia 1/416 (0.24%)Anaemia 0/416 (0.00%) Atrial fibrillation 2/416 (0.48%) Cardiac failure congestive 1/416 (0.24%) Myocardial infarction 1/416 (0.24%) Supraventricular tachycardia 1/416 (0.24%) Diarrhoea 32/416 (7.69%) Colitis 14/416 (3.37%) Vomiting 4/416 (0.96%) Nausea 3/416 (0.72%) Enterocolitis 2/416 (0.48%) ",
        "premise_nums": [
            "0/416 (0.00%)",
            "4/416 (0.96%)",
            "32/416 (7.69%)",
            "1/416 (0.24%)Anaemia",
            "3/416 (0.72%)",
            "2/416 (0.48%)",
            "14/416 (3.37%)"
        ]
    },
    {
        "id": "91adb350-ab20-41a6-944d-c13b55cf33f2",
        "primaryId": "NCT00014222",
        "statement_text": "Cohort one of the primary trial reported 2/680 patients experiecing eye-related adverse events  whereas cohort two recorded none ",
        "statement_nums": [
            "680 patients experiecing",
            "2/680 patients"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 83/680 (12.21%) Hemoglobin 11/680 (1.62%) Transfusion: Platelets 0/680 (0.00%) Transfusion: pRBCs 0/680 (0.00%) Febrile neutropenia 49/680 (7.21%) Edema 1/680 (0.15%) Ischemia/infarction 0/680 (0.00%) Palpitations 0/680 (0.00%) Pericardial effusion 0/680 (0.00%) Keratitis 1/680 (0.15%) Double vision 1/680 (0.15%) Colitis 1/680 (0.15%) ",
        "premise_nums": [
            "49/680 (7.21%)",
            "11/680 (1.62%)",
            "83/680 (12.21%)",
            "0/680 (0.00%)",
            "1/680 (0.15%)"
        ]
    },
    {
        "id": "91adb350-ab20-41a6-944d-c13b55cf33f2",
        "primaryId": "NCT00014222",
        "statement_text": "Cohort one of the primary trial reported 2/680 patients experiecing eye-related adverse events  whereas cohort two recorded none ",
        "statement_nums": [
            "680 patients experiecing",
            "2/680 patients"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 2:Total: 86/688 (12.50%) Hemoglobin 15/688 (2.18%) Transfusion: Platelets 1/688 (0.15%) Transfusion: pRBCs 1/688 (0.15%) Febrile neutropenia 41/688 (5.96%) Edema 0/688 (0.00%) Ischemia/infarction 0/688 (0.00%) Palpitations 1/688 (0.15%) Pericardial effusion 1/688 (0.15%) Keratitis 0/688 (0.00%) Double vision 0/688 (0.00%) ",
        "premise_nums": [
            "1/688 (0.15%)",
            "0/688 (0.00%)",
            "41/688 (5.96%)",
            "86/688 (12.50%)",
            "2:Total: 86/688",
            "15/688 (2.18%)"
        ]
    },
    {
        "id": "91adb350-ab20-41a6-944d-c13b55cf33f2",
        "primaryId": "NCT00014222",
        "statement_text": "Cohort one of the primary trial reported 2/680 patients experiecing eye-related adverse events  whereas cohort two recorded none ",
        "statement_nums": [
            "680 patients experiecing",
            "2/680 patients"
        ],
        "label": "Entailment",
        "premise_text": "Colitis 0/688 (0.00%)",
        "premise_nums": [
            "0/688 (0.00%)"
        ]
    },
    {
        "id": "78949f1f-6738-4220-a233-e7831902e6f3",
        "primaryId": "NCT02038010",
        "secondaryId": "NCT00764322",
        "label": "Contradiction",
        "statement_text": "Neither the primary trial or the secondary trial are measuring Dose Limiting Toxicity of BYL719 in Combination With T-DM1.",
        "statement_nums": [
            "719 in Combination",
            "BYL719 in"
        ],
        "premise_text": "Outcome Measurement: Dose Limiting Toxicity (DLT) of Dose-escalating BYL719 in Combination With T-DM1 DLTs of BYL719 in combination with T-DM1 will be assessed using National Cancer Institute's Common Toxicity Criteria for adverse events version 4.0 (except for hyperglycemia)  A DLT is described any grade 3 or higher  clinically significant toxicity (excluding alopecia) experienced during the first 21 days following first dose of BYL719 that is determined to be at least possibly related to study medication  Lower grades may also be considered DLTs if they lead to a dose interruption of more than 7 consecutive days of BYL719. In general adverse events (AEs) will be graded according to the following: ",
        "premise_nums": [
            "21 days following",
            "719 that is",
            "BYL719 that",
            "719 in Combination",
            "1 will be",
            "719 in combination",
            "BYL719 in",
            "7 consecutive days",
            "3 or higher",
            "1 DLTs of"
        ]
    },
    {
        "id": "78949f1f-6738-4220-a233-e7831902e6f3",
        "primaryId": "NCT02038010",
        "secondaryId": "NCT00764322",
        "label": "Contradiction",
        "statement_text": "Neither the primary trial or the secondary trial are measuring Dose Limiting Toxicity of BYL719 in Combination With T-DM1.",
        "statement_nums": [
            "719 in Combination",
            "BYL719 in"
        ],
        "premise_text": "Grade 1 Mild AE Grade 2 Moderate AE Grade 3 Severe AE Grade 4 Life-threatening or disabling AE Grade 5 Death related to AETime frame: The 1st 21 days (Cycle 1) of treatment Outcome Measurement: Endoxifen Concentrations in Participants Receiving Tamoxifen Citrate Dose of 20 mg or 40 mg Stratified by the Metabolizing CYP2D6 Genotypes ",
        "premise_nums": [
            "4 Life-threatening or",
            "40 mg Stratified",
            "21 days (Cycle",
            "1 Mild AE",
            "3 Severe AE",
            "5 Death related",
            "2 Moderate AE",
            "20 mg or"
        ]
    },
    {
        "id": "78949f1f-6738-4220-a233-e7831902e6f3",
        "primaryId": "NCT02038010",
        "secondaryId": "NCT00764322",
        "label": "Contradiction",
        "statement_text": "Neither the primary trial or the secondary trial are measuring Dose Limiting Toxicity of BYL719 in Combination With T-DM1.",
        "statement_nums": [
            "719 in Combination",
            "BYL719 in"
        ],
        "premise_text": "Measurements of plasma concentrations of the key active metabolite of tamoxifen  endoxifen  were measured at baseline and after 4 months of treatment; The most common CYP2D6 alleles have been grouped by functional activity classifications with descending activity: ultra-rapid (UM)  extensive (EM)  intermediate (IM) or poor (PM) metabolism  A given patient has two alleles  giving them 10 possible allelic combinations  or diplotypes (UM/UM  UM/EM  EM/EM  etc.)  These diplotypes are collapsed into four phenotypes  UM  EM  IM or PM Time frame: 4 months ",
        "premise_nums": [
            "6 alleles have",
            "4 months of",
            "10 possible allelic"
        ]
    },
    {
        "id": "135311d8-c579-4568-913e-937be00dde7e",
        "primaryId": "NCT00390455",
        "secondaryId": "NCT00558103",
        "label": "Contradiction",
        "statement_text": "In both the secondary trial and the primary trial the test cohorts achieved better overall response than the control groups ",
        "statement_nums": [],
        "premise_text": "Outcome Measurement: Progression-free Survival (PFS) PFS was defined as the interval from study entry until disease progression or death resulting from any cause  which ever occurred first  Progression is defined as a 20% increase in the sum of longest diameter of target lesions (per RECIST criteria)  Time frame: Interval from randomization until disease progression or death  whichever occurs first  assessed up to 5 years Results 1: Arm/Group Title: Arm I (Lapatinib) Arm/Group Description: Patients receive 1500 mg lapatinib ditosylate PO QD on days 1-28 and fulvestrant IM on days 1 (500 mg) and 15 (250 mg) of course 1 and on day 1 (250 mg)of each subsequent course  Overall Number of Participants Analyzed: 146 Median (95% Confidence Interval) ",
        "premise_nums": [
            "1 and on",
            "1-28 and",
            "28 and fulvestrant",
            "95% Confidence",
            "1500 mg lapatinib",
            "5 years Results",
            "20% increase"
        ]
    },
    {
        "id": "135311d8-c579-4568-913e-937be00dde7e",
        "primaryId": "NCT00390455",
        "secondaryId": "NCT00558103",
        "label": "Contradiction",
        "statement_text": "In both the secondary trial and the primary trial the test cohorts achieved better overall response than the control groups ",
        "statement_nums": [],
        "premise_text": "Unit of Measure: months 4.7 (3.7 to 5.7)Results 2: Arm/Group Title: Arm II (Placebo) Arm/Group Description: Patients receive placebo PO QD on days 1-28 and fulvestrant IM on days 1 (500 mg) and 15 (250 mg) of course 1 and on day 1 (250 mg) of each subsequent course  Overall Number of Participants Analyzed: 145 Median (95% Confidence Interval) Unit of Measure: months 3.8 (3.8 to 5.6) Outcome Measurement: Number of Participants With Overall Response (OR)  Defined as Those Participants Achieving Complete Response (CR) or Partial Response (PR)  Assessed Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.0 and Cutaneous Lesions ",
        "premise_nums": [
            "Version 1.0 and Cutaneous",
            "8 to 5.6)",
            "1 and on",
            "1-28 and",
            "28 and fulvestrant",
            "7 to 5.7)Results",
            "95% Confidence"
        ]
    },
    {
        "id": "135311d8-c579-4568-913e-937be00dde7e",
        "primaryId": "NCT00390455",
        "secondaryId": "NCT00558103",
        "label": "Contradiction",
        "statement_text": "In both the secondary trial and the primary trial the test cohorts achieved better overall response than the control groups ",
        "statement_nums": [],
        "premise_text": "RECIST-based response assessment was done at Weeks (Wks) 4 and 8 and every 8 weeks thereafter  Cutaneous disease assessment was done at Wk 4 and every 4 weeks thereafter  OR was evaluated when the skin and RECIST assessments coincided  Per RECIST  CR is the disappearance of all target and non-target lesions; PR is at least a 30 percent (%) decrease in the sum of the longest diameter (LD) of target lesions  taking as a reference the baseline sum LD  Cutaneous disease contained non-measurable and measurable skin disease  which was assessed by skin assessment tools Time frame: Baseline until disease progression/recurrence was documented  assessed for up to 66 weeks Results 1: Arm/Group Title: Cohort 1: Lapatinib 1500 mg + Pazopanib Placebo ",
        "premise_nums": [
            "66 weeks Results",
            "4 and 8",
            "4 weeks thereafter",
            "8 weeks thereafter",
            "4 and every"
        ]
    },
    {
        "id": "135311d8-c579-4568-913e-937be00dde7e",
        "primaryId": "NCT00390455",
        "secondaryId": "NCT00558103",
        "label": "Contradiction",
        "statement_text": "In both the secondary trial and the primary trial the test cohorts achieved better overall response than the control groups ",
        "statement_nums": [],
        "premise_text": "Arm/Group Description: Participants received oral lapatinib 1500 milligrams (mg) (6 x 250 mg tablets) in combination with placebo (matching to pazopanib; 2 tablets) once daily (QD) Overall Number of Participants Analyzed: 38 Measure Type: Number Unit of Measure: participants 11 Results 2: Arm/Group Title: Cohort 1: Lapatinib 1500 mg + Pazopanib 800 mg Arm/Group Description: Participants received oral lapatinib 1500 mg (6 x 250 mg tablets) in combination with pazopanib 800 mg (2 x 400 mg tablets) QD  Overall Number of Participants Analyzed: 38 Measure Type: Number Unit of Measure: participants 17 ",
        "premise_nums": [
            "800 mg (2",
            "1500 milligrams (mg)",
            "6 x 250",
            "1500 mg (6",
            "250 mg tablets)",
            "11 Results 2:",
            "800 mg Arm",
            "38 Measure Type:",
            "400 mg tablets)"
        ]
    },
    {
        "id": "0984431d-4997-41dc-9ba4-07134568c3fa",
        "primaryId": "NCT00258349",
        "secondaryId": "NCT01328249",
        "label": "Entailment",
        "statement_text": "Cohort 1 of the primary trial does not receive any Eribulin Mesylate With Prophylactic Filgrastim  whereas both cohorts in the secondary trial receive some ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "INTERVENTION 1: Vorinostat +Trastuzumab Trastuzumab: 6 mg/kg once on Day 1, infused over 90 minutes  every 3 weeks; Vorinostat 200 mg of SAHA orally twice a day  daily for 14 days out of a 21-day cycle INTERVENTION 1: Cohort 1: Eribulin Mesylate With Filgrastim as Needed ",
        "premise_nums": [
            "14 days out",
            "200 mg of",
            "6 mg/kg once",
            "21-day cycle"
        ]
    },
    {
        "id": "d9dc4a6d-a913-46ac-b0aa-d50823ff2305",
        "primaryId": "NCT00662129",
        "statement_text": "Patients with Platelet count over 100,000/mm¬¨‚â•, ANC smaller than 1,700/mm¬¨‚â• and Hemoglobin between 11 to 18 grams per deciliter are eligible for the primary trial ",
        "statement_nums": [
            "100,000/mm¬¨‚â•, ANC",
            "11 to 18",
            "1,700/mm¬¨‚â• and"
        ],
        "label": "Entailment",
        "premise_text": "PATIENT CHARACTERISTICS: ANC 1,500/mm³ Platelet count 100,000/mm³ Hemoglobin 9.0 g/dL ",
        "premise_nums": [
            "100,000/mm³ Hemoglobin",
            "Hemoglobin 9.0 g/dL",
            "1,500/mm³ Platelet"
        ]
    },
    {
        "id": "9d9ab190-cdcf-4320-b69a-12f2dad9dba9",
        "primaryId": "NCT02435680",
        "secondaryId": "NCT01743560",
        "label": "Entailment",
        "statement_text": "the secondary trial and the primary trial use non comparable evaluation metrics  and significantly different time frames ",
        "statement_nums": [],
        "premise_text": "Outcome Measurement: Progression Free Survival (PFS) as Per RECIST v1.1 (by Local Investigator Assessment) PFS Results presented for all MCS110 treated patients (with and without day 8 dose)  in line with phase 2 study design  Time frame: 4 years Outcome Measurement: Best Overall Response of Everolimus and Exemestane Treatment in Postmenopausal Women With Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer ",
        "premise_nums": [
            "MCS110 treated",
            "2 study design",
            "110 treated patients",
            "4 years Outcome"
        ]
    },
    {
        "id": "9d9ab190-cdcf-4320-b69a-12f2dad9dba9",
        "primaryId": "NCT02435680",
        "secondaryId": "NCT01743560",
        "label": "Entailment",
        "statement_text": "the secondary trial and the primary trial use non comparable evaluation metrics  and significantly different time frames ",
        "statement_nums": [],
        "premise_text": "The best Overall Response (OR) for each patient is determined from the sequence of investigator overall lesion responses according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1.). To be assigned a best OR of Complete Responese (CR) at least two determinations of CR at least 4 weeks apart before progression are required  To be assigned a best OR of Partial Response (PR) at least two determinations of PR or better at least 4 weeks apart before progression (and not qualifying for a CR) are required.The Overall Response Rate (ORR) was defined as the proportion of patients with a best OR of confirmed CR or PR by week 48.Time frame: At 48 weeks ",
        "premise_nums": [
            "4 weeks apart"
        ]
    },
    {
        "id": "89fdf182-7474-4e70-baf7-03c8920c4ff3",
        "primaryId": "NCT01385137",
        "secondaryId": "NCT00593346",
        "label": "Contradiction",
        "statement_text": "Placebo treatment is used in cohort 2 of the secondary trial  but there is only a test group in the primary trial ",
        "statement_nums": [
            "2 of the"
        ],
        "premise_text": "INTERVENTION 1: Arm I (Omega-3-fatty Acid) Patients receive oral omega-3-fatty acid twice daily (BID) or three times daily (TID) for 24 weeks in the absence of disease progression or unacceptable toxicity INTERVENTION 2: Arm II (Placebo) Patients receive oral placebo BID or TID for 24 weeks in the absence of disease progression or unacceptable toxicity INTERVENTION 1: Accelerated Partial Breast Brachytherapy Each patient will receive accelerated partial breast brachytherapy with multiple plane implant  Patients will receive 3400 cGy delivered in 10 twice-daily fractions  Treatment is to be given over 5-7 days with a minimum of 6 hours separation between fractions  ",
        "premise_nums": [
            "7 days with",
            "3-fatty acid",
            "10 twice-daily fractions",
            "5-7 days",
            "3400 cGy delivered",
            "3-fatty Acid",
            "6 hours separation",
            "24 weeks in"
        ]
    },
    {
        "id": "9f2fd0cc-af87-433d-9d2f-6235591d6cb1",
        "primaryId": "NCT00422903",
        "statement_text": "Percentage of Participants With Clinical Objective Response (cOR) in the Breast  Evaluated by an Independent Radiological Evaluation Monitoring Committee was highest in cohort 2.",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Percentage of Participants With Clinical Objective Response (cOR) in the Breast  Evaluated by an Independent Radiological Evaluation Monitoring Committee ",
        "premise_nums": []
    },
    {
        "id": "9f2fd0cc-af87-433d-9d2f-6235591d6cb1",
        "primaryId": "NCT00422903",
        "statement_text": "Percentage of Participants With Clinical Objective Response (cOR) in the Breast  Evaluated by an Independent Radiological Evaluation Monitoring Committee was highest in cohort 2.",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "cOR is defined as the documented evidence of complete response (CR) and partial response (PR) as assessed by ultrasound examination using Response Evaluation Criteria In Solid Tumors (RECIST)  CR is defined as the disappearance of all target lesions (TLs) and non-TLs and the appearance of no new lesions (NLs)  PR for TLs is defined as a greater than or equal 30% decrease in the sum of the longest diameter (LD) of TLs  taking as a reference the Baseline sum LD  For non-TLs  it is defined as the persistence of greater than or equal 1 non-TL and no new TLs or non-TLs Time frame: From Baseline (Day 1) up to 6 months  evaluated every 12 weeks Results 1: ",
        "premise_nums": [
            "30% decrease",
            "1 non-TL and",
            "12 weeks Results"
        ]
    },
    {
        "id": "9f2fd0cc-af87-433d-9d2f-6235591d6cb1",
        "primaryId": "NCT00422903",
        "statement_text": "Percentage of Participants With Clinical Objective Response (cOR) in the Breast  Evaluated by an Independent Radiological Evaluation Monitoring Committee was highest in cohort 2.",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Arm/Group Title: Letrozole + PlaceboArm/Group Description: Letrozole tablets in the dose of 2.5 milligrams (mg) plus matching placebo were administered orally once daily for 6 months prior to surgery  Overall Number of Participants Analyzed: 48 Measure Type: Number Unit of Measure: percentage of participants CR: 2 PR: 58 Results 2: Arm/Group Title: Letrozole + Lapatinib Arm/Group Description: Letrozole tablets in the dose of 2.5 mg plus lapatinib ditosylate monohydrate tablets in the dose of 1500 mg were administered orally once daily for 6 months prior to surgery  Overall Number of Participants Analyzed: 41 Measure Type: Number ",
        "premise_nums": [
            "6 months prior",
            "58 Results 2:",
            "41 Measure Type:",
            "of 2.5 mg plus",
            "1500 mg were",
            "48 Measure Type:",
            "5 milligrams (mg)"
        ]
    },
    {
        "id": "9f2fd0cc-af87-433d-9d2f-6235591d6cb1",
        "primaryId": "NCT00422903",
        "statement_text": "Percentage of Participants With Clinical Objective Response (cOR) in the Breast  Evaluated by an Independent Radiological Evaluation Monitoring Committee was highest in cohort 2.",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Unit of Measure: percentage of participants CR: 12PR: 54 ",
        "premise_nums": []
    },
    {
        "id": "90364098-7e9a-47be-ab2e-f66958cfb09d",
        "primaryId": "NCT02413008",
        "secondaryId": "NCT02725801",
        "label": "Contradiction",
        "statement_text": "The interventions in the primary trial and the secondary trial are applied daily for a period of several months ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: 0.005% Estriol Vaginal Gel Route: Vaginal  Administration by an applicator inserted deep inside the vagina Dose: 1 g of gel  containing 50 Mcg of estriol Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: twice weekly administration INTERVENTION 1: One-port intervention is placement of one-port tissue expander at time of reconstruction Allergen one-port tissue expander placement: patients will be randomized to receive a one port or two port tissue expander for breast reconstruction ",
        "premise_nums": [
            "1-3: single",
            "0.005% Estriol",
            "4-12: twice",
            "1 g of",
            "50 Mcg of"
        ]
    },
    {
        "id": "021c3f62-8067-49e3-9d4b-c7641feb2548",
        "primaryId": "NCT00331552",
        "secondaryId": "NCT01306942",
        "label": "Contradiction",
        "statement_text": "The same dose of trastuzumab was used for the interventions in the primary trial and the secondary trial ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Phase I: Cyclophosphamide  Doxil  Trastuzumab Patients receive oral cyclophosphamide once daily on days 1-28 and pegylated doxorubicin HCl liposome IV over 90 minutes on day 1. Treatment repeats every 4-6 weeks in the absence of disease progression or unacceptable toxicity  Some patients with HER2/neu 3+ disease may also receive trastuzumab IV over 30-90 minutes weekly or every 3 weeks at the discretion of the treating physician  pegylated liposomal doxorubicin hydrochloride: Given IV cyclophosphamide: Given orally trastuzumab: Given IV INTERVENTION 1: ",
        "premise_nums": [
            "90 minutes weekly",
            "2/neu 3+",
            "30-90 minutes",
            "3 weeks at",
            "28 and pegylated",
            "1-28 and",
            "6 weeks in",
            "4-6 weeks",
            "90 minutes on"
        ]
    },
    {
        "id": "021c3f62-8067-49e3-9d4b-c7641feb2548",
        "primaryId": "NCT00331552",
        "secondaryId": "NCT01306942",
        "label": "Contradiction",
        "statement_text": "The same dose of trastuzumab was used for the interventions in the primary trial and the secondary trial ",
        "statement_nums": [],
        "premise_text": "Phase I: Dasatinib 100mg/Trastuzumab 2mg/kg/Paclitaxel 80mg/m2Cohort 1: Eligible patients were enrolled and treated with 4-week cycles of trastuzumab 2 mg/kg IV weekly (following a loading dose of 4 mg/kg in cycle 1) and paclitaxel 80 mg/m2 weekly x 3 weeks followed by a rest period of 7 days  Dasatinib 100mg was administered orally once daily (QD)  Treatment was repeated on Day 1 of a 28-day cycle until radiographic or symptomatic progression or unacceptable toxicity occured  Only in the phase I  the first cycle lasted 38 days  ",
        "premise_nums": [
            "1 of a",
            "2mg/kg/Paclitaxel",
            "80mg/m2Cohort",
            "3 weeks followed",
            "2 weekly x",
            "4-week cycles",
            "2 mg/kg IV",
            "80 mg/m2 weekly",
            "4 mg/kg in",
            "28-day cycle",
            "100mg/Trastuzumab"
        ]
    },
    {
        "id": "6893c9b4-d3a3-47a8-ada9-8aef67de2375",
        "primaryId": "NCT01702571",
        "statement_text": "Patients with incurable and unresectable Breast Cancer are eligible for the primary trial  unless it is metastatic ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria: Documented progression of incurable  unresectable  LABC  or mBC  defined by the investigator: progression must occur during or after most recent treatment for LABC/mBC or within 6 months of completing adjuvant therapy ",
        "premise_nums": [
            "6 months of"
        ]
    },
    {
        "id": "b88cde11-ae29-48e8-832b-4b9cb2596c30",
        "primaryId": "NCT00859651",
        "statement_text": "Helen had stage III ovarian cancer 2 years prior  from which she is still recovering  she is excluded from the primary trial ",
        "statement_nums": [
            "2 years prior"
        ],
        "label": "Entailment",
        "premise_text": "Exclusion Criteria: Other prior malignancy  The following is allowed: adequately treated basal cell or squamous cell skin cancer  in situ cervical cancer  adequately treated stage I or II cancer from which the participant is currently in complete remission  or any other cancer (including breast cancer) for which the participant has been disease-free for 5 years  ",
        "premise_nums": []
    },
    {
        "id": "ebe7078c-fd8b-439a-b1f5-7bd482071ead",
        "primaryId": "NCT02472964",
        "secondaryId": "NCT00089661",
        "label": "Contradiction",
        "statement_text": "the primary trial studies changes in tumour diameter  whereas the secondary trial investigates changes in heart failure rate ",
        "statement_nums": [],
        "premise_text": "Outcome Measurement: Primary Endpoint : Compare Best Overall Response Rate (ORR) (According to Response Evaluation Criteria in Solid Tumor [RECIST] 1.1 Criteria) at Week 24 of MYL-1401O Plus Taxane Versus Herceptin® Plus Taxane in the ITT1 Population Tumor measurements were perform by centralized blinded reviewers using RECIST 1.1 criteria  Per RECIST 1.1: Complete Response (CR): Disappearance of all target lesions  Any pathological lymph node must have reduction in short axis to smaller than 10 mm.Partial Response (PR): greater than /= 30% decrease sum of the diameters of target lesions from baseline sum diameters  ",
        "premise_nums": [
            "30% decrease",
            "24 of MYL",
            "1 Population Tumor"
        ]
    },
    {
        "id": "ebe7078c-fd8b-439a-b1f5-7bd482071ead",
        "primaryId": "NCT02472964",
        "secondaryId": "NCT00089661",
        "label": "Contradiction",
        "statement_text": "the primary trial studies changes in tumour diameter  whereas the secondary trial investigates changes in heart failure rate ",
        "statement_nums": [],
        "premise_text": "Progressive Disease (PD): smaller than /= 20% increase in the sum of the diameters of target lesions  from the smallest sum on study with at least a 5 mm absolute increase in the sum of all lesions  The appearance of one or more new lesions* denotes disease progression Stable Disease (SD): Neither sufficient decrease or increase  Evaluation of Non-Target Lesions Complete Response (CR): Disappearance of all non-target lesions  Non-complete Response/Non-Progressive Disease: Persistence of one or more non-target lesions  Progressive Disease (PD): Substantial  unequivocal progression of existing non-target lesions  Time frame: from time of First treatment to week 24 Outcome Measurement: Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 12 Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry  ",
        "premise_nums": [
            "12 Bone Mineral",
            "5 mm absolute",
            "24 Outcome Measurement:",
            "20% increase"
        ]
    },
    {
        "id": "ebe7078c-fd8b-439a-b1f5-7bd482071ead",
        "primaryId": "NCT02472964",
        "secondaryId": "NCT00089661",
        "label": "Contradiction",
        "statement_text": "the primary trial studies changes in tumour diameter  whereas the secondary trial investigates changes in heart failure rate ",
        "statement_nums": [],
        "premise_text": "Time frame: 12 months",
        "premise_nums": []
    },
    {
        "id": "d0b9c11c-50f2-4803-a96c-fff3ca90cf36",
        "primaryId": "NCT02312622",
        "statement_text": "Both cohorts of the primary trial receive identical interventions; Pegylated Irinotecan Administered intravenously (IV) at 145 mg/m¬¨‚â§ as monotherapy once every 21 days (1 cycle)  the difference between the cohorts is the type of cancers that patients are diagnosed with  cohort 1 is NSCLC  whereas cohort 2 is mBC ",
        "statement_nums": [
            "21 days (1",
            "2 is mBC",
            "145 mg/m¬¨‚â§",
            "1 is NSCLC"
        ],
        "label": "Entailment",
        "premise_text": "INTERVENTION 1: Cohort A - Pegylated Irinotecan to Treat NSCLC Patients with non-small cell lung carinoma (NSCLC) will receive pegylated irinotecan intravenously (IV) over 90 minutes every 21 days in the absence of disease progression or unacceptable toxicity  Pegylated Irinotecan: Administered intravenously (IV) at 145 mg/m² as monotherapy once every 21 days (1 cycle) ",
        "premise_nums": [
            "21 days (1",
            "90 minutes every",
            "21 days in",
            "145 mg/m²"
        ]
    },
    {
        "id": "d0b9c11c-50f2-4803-a96c-fff3ca90cf36",
        "primaryId": "NCT02312622",
        "statement_text": "Both cohorts of the primary trial receive identical interventions; Pegylated Irinotecan Administered intravenously (IV) at 145 mg/m¬¨‚â§ as monotherapy once every 21 days (1 cycle)  the difference between the cohorts is the type of cancers that patients are diagnosed with  cohort 1 is NSCLC  whereas cohort 2 is mBC ",
        "statement_nums": [
            "21 days (1",
            "2 is mBC",
            "145 mg/m¬¨‚â§",
            "1 is NSCLC"
        ],
        "label": "Entailment",
        "premise_text": "INTERVENTION 2:Cohort C - Pegylated Irinotecan to Treat mBC Patients with metastatic breast cancer (MBC) to brain will receive pegylated irinotecan intravenously (IV) over 90 minutes every 21 days in the absence of disease progression or unacceptable toxicity  Pegylated Irinotecan: Administered intravenously (IV) at 145 mg/m² as monotherapy once every 21 days (1 cycle) ",
        "premise_nums": [
            "90 minutes every",
            "21 days in",
            "145 mg/m²",
            "21 days (1",
            "2:Cohort C"
        ]
    },
    {
        "id": "b620e1c5-69c4-4c30-9006-faa346200b60",
        "primaryId": "NCT01256008",
        "secondaryId": "NCT00300781",
        "label": "Contradiction",
        "statement_text": "the primary trial is investigating Cognitive behavioural therapy  a type of psychotherapy  in contrast the secondary trial studies Trastuzumab  a type of chemotherapy ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Stage 1 Clinical Management The group will receive clinical management treatment only each session  Clinical Management: Clinical management is a clear contrast method of psychological therapy  which is a half-structured interview and lasting for 20-25 minutes each session  Clinical management will be assigned to both experimental group and controlled group in the first stage of intervention  Following are major elements: Talk to the subjects to find their main problems; introduce knowledge and medication knowledge about cancer and depression; subjects reporting use of drugs for cancer and depression and a variety of signs and symptoms of the reaction  Encourage patients to adhere to drug treatment and to comply with this research program; The operation of CBT and clinical management should be conducted by the same person as far as possible  INTERVENTION 2: Stage 1 CBT The experimental group will receive CBT each session  ",
        "premise_nums": [
            "20-25 minutes",
            "1 Clinical Management",
            "1 CBT The",
            "25 minutes each"
        ]
    },
    {
        "id": "b620e1c5-69c4-4c30-9006-faa346200b60",
        "primaryId": "NCT01256008",
        "secondaryId": "NCT00300781",
        "label": "Contradiction",
        "statement_text": "the primary trial is investigating Cognitive behavioural therapy  a type of psychotherapy  in contrast the secondary trial studies Trastuzumab  a type of chemotherapy ",
        "statement_nums": [],
        "premise_text": "CBT and clinical management: The subjects will receive standardized CBT treatment regularly for 9 sessions(once per week in the first month and once half a month in the second and third months)  and each session will last for about 60 minutes.The treatment includes three steps:Concept stage (the first and second sessions): establishment of therapeutic relationships with the subjects; Skills acquisition and repeat stage (the third session to the 8th session): clarification of sources of stress  patients' cognitive and behavioral response to stress  Application and complete price segment (the 9th session): return visit to test efficacy of psychological intervention INTERVENTION 1: Neratinib 240, Prior Trastuzumab ",
        "premise_nums": []
    },
    {
        "id": "b620e1c5-69c4-4c30-9006-faa346200b60",
        "primaryId": "NCT01256008",
        "secondaryId": "NCT00300781",
        "label": "Contradiction",
        "statement_text": "the primary trial is investigating Cognitive behavioural therapy  a type of psychotherapy  in contrast the secondary trial studies Trastuzumab  a type of chemotherapy ",
        "statement_nums": [],
        "premise_text": "Neratinib: 80mg capsules and 40mg coated tablets taken orally in prescribed dose of 240mg daily  as long as tolerated and disease does not worsen in participants with prior trastuzumab treatment INTERVENTION 2: Neratinib 240, No Prior Trastuzumab Neratinib: 80mg capsules and 40mg coated tablets taken orally in prescribed dose of 240mg daily  as long as tolerated and disease does not worsen in participants with no prior trastuzumab treatment  ",
        "premise_nums": []
    },
    {
        "id": "0900325b-6ecd-46f1-b3f1-a2ce1605d151",
        "primaryId": "NCT00325598",
        "statement_text": "There is no difference in results or cohort size between cohort 1 and 2 of the primary trial  the increase in Gy has no notable effect ",
        "statement_nums": [
            "1 and 2"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Feasibility of PBI Directed External Radiotherapy as Measured by Percentage of Participants Achieving a Dosimetrically Satisfactory Treatment Plan -The study will be deemed infeasible if more than 4 patients cannot be given treatment because her tumor is such that a dosimetrically satisfactory treatment plan cannot be devised for her  Time frame: Within 1 year of protocol registration Results 1: Arm/Group Title: Cohort 1 (36 Gy) Arm/Group Description: 36 Gy in 9 fractions BID x 4 1/2 treatment days Partial Breast Irradiation (PBI) Overall Number of Participants Analyzed: 50 Measure Type: Number Unit of Measure: percentage of participants 100 Results 2: Arm/Group Title: Cohort 2 (40 Gy) ",
        "premise_nums": [
            "9 fractions BID",
            "50 Measure Type:",
            "36 Gy in",
            "1 year of",
            "100 Results 2:",
            "4 patients cannot",
            "4 1/2 treatment",
            "2 treatment days"
        ]
    },
    {
        "id": "0900325b-6ecd-46f1-b3f1-a2ce1605d151",
        "primaryId": "NCT00325598",
        "statement_text": "There is no difference in results or cohort size between cohort 1 and 2 of the primary trial  the increase in Gy has no notable effect ",
        "statement_nums": [
            "1 and 2"
        ],
        "label": "Entailment",
        "premise_text": "Arm/Group Description: 40 Gy in 10 fractions BID over 5 treatment daysPartial Breast Irradiation (PBI) Overall Number of Participants Analyzed: 50 Measure Type: Number Unit of Measure: percentage of participants 100 ",
        "premise_nums": [
            "40 Gy in",
            "50 Measure Type:",
            "10 fractions BID",
            "5 treatment daysPartial"
        ]
    },
    {
        "id": "6f10e1f3-1197-464e-b574-d697fb49331d",
        "primaryId": "NCT02419807",
        "secondaryId": "NCT00777101",
        "label": "Entailment",
        "statement_text": "Patients with HER2 + breast cancer are eligible for both the primary trial and the secondary trial  However  only patients with stage 1-2 breast cancer are eligible for the primary trial  and patients with stage 3-4 are eligilbe for the secondary trial ",
        "statement_nums": [
            "2 breast cancer",
            "3-4 are",
            "4 are eligilbe",
            "1-2 breast"
        ],
        "premise_text": "Inclusion Criteria: Participants with a confirmed diagnosis of clinical stage 1 or 2 breast cancer Inclusion Criteria: Stage IIIB  IIIC  or IV erbB2 (HER2) positive breast cancer ",
        "premise_nums": [
            "1 or 2",
            "(HER2) positive"
        ]
    },
    {
        "id": "cbf91beb-829b-488f-8e80-3b08b891a181",
        "primaryId": "NCT03592121",
        "secondaryId": "NCT01439711",
        "label": "Contradiction",
        "statement_text": "the secondary trial and the primary trial both require their patients to receive their respective interventions on a daily basis ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: AB-101 Apply to both nipple/areola regions approximately 1 hour prior to sexual activity AB-101: Apply approximately 1 hour prior to sexual activity INTERVENTION 2: Placebo Apply to both nipple/areola regions approximately 1 hour prior to sexual activity Placebo: Apply approximately 1 hour prior to sexual activity INTERVENTION 1: Letrozole + MRI Protocol Therapy will consist of 6 months of letrozole  administered orally at a dose of 2.5 mg/day  Patients will have a bilateral MRI for disease evaluation at months 3 and 6. ",
        "premise_nums": [
            "of 2.5 mg/day",
            "6 months of",
            "101 Apply to",
            "1 hour prior",
            "3 and 6."
        ]
    },
    {
        "id": "985df98b-b397-4dbc-8fad-43ada30927d7",
        "primaryId": "NCT00254592",
        "statement_text": "Patients needing active supportive care can participate in the primary trial ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria: Patients must have a performance status of 0-2 by Zubrod criteria ",
        "premise_nums": [
            "0-2 by",
            "2 by Zubrod"
        ]
    },
    {
        "id": "0d4fdeef-89b2-463b-8252-66fa51d9ce8c",
        "primaryId": "NCT00356811",
        "secondaryId": "NCT00296036",
        "label": "Contradiction",
        "statement_text": "The the secondary trial intervention is applied to the palms and soles twice daily  the primary trial participants are not administered any medication on the skin of the hands or feet  but rather onto the breast or chest wall ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Lapatinib Plus Paclitaxel Participants received lapatinib 1500 mg orally OD with paclitaxel  administered as a 1-hour IV infusion at a dose of 80 mg/m^2 on Days 1, 8, and 15 (±2 days) of a 28-day treatment cycle for at least 6 months  Participants were treated until disease progression  unacceptable toxicity  or consent withdrawal  INTERVENTION 1: Urea/Lactic Acid Cream Patients receive topical urea/lactic acid-based cream applied to palms and soles twice daily  INTERVENTION 2: Placebo Cream Patients receive placebo cream applied to palms and soles twice daily  ",
        "premise_nums": [
            "1-hour IV",
            "80 mg/m^2",
            "1500 mg orally",
            "2 on Days",
            "28-day treatment"
        ]
    },
    {
        "id": "2c270b8f-d1a4-4686-a75c-bb3ac4b0c6fe",
        "primaryId": "NCT02595372",
        "statement_text": "27.6% of Patients Who Have Fatty Acid Synthase (FASN) Expression in the primary trial treated with Minocycline Hydrochloride did not have Pathological Complete Response ",
        "statement_nums": [
            "27.6% of"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Percentage of Patients With Pathological Complete Response (pCR) in Patients Who Have Fatty Acid Synthase (FASN) Expression pCR is defined as no invasive disease in the breast of axilla at the time of definitive surgery  A patient is considered to have FASN expression if the positivity was greater than or equal 15% at the baseline or after 4-7 days of Omeprazole monotherapy  FASN expression is evaluated using immunohistochemistry in core biopsy samples  The percent of patients with FASN expression that have pCR will be calculated with an exact 95% confidence interval  Time frame: Up to 6 months Results 1: ",
        "premise_nums": [
            "95% confidence",
            "6 months Results",
            "4-7 days",
            "7 days of",
            "15% at"
        ]
    },
    {
        "id": "2c270b8f-d1a4-4686-a75c-bb3ac4b0c6fe",
        "primaryId": "NCT02595372",
        "statement_text": "27.6% of Patients Who Have Fatty Acid Synthase (FASN) Expression in the primary trial treated with Minocycline Hydrochloride did not have Pathological Complete Response ",
        "statement_nums": [
            "27.6% of"
        ],
        "label": "Contradiction",
        "premise_text": "Arm/Group Title: High Dose Omeprazole TreatmentArm/Group Description: Patients will be treated with omeprazole 80 mg orally BID beginning 4-7 days prior to chemotherapy and continuing until surgery  Overall Number of Participants Analyzed: 29 Measure Type: Number Unit of Measure: percentage of participants 72.4 (52.8 to 87.3) ",
        "premise_nums": [
            "7 days prior",
            "4-7 days",
            "29 Measure Type:",
            "80 mg orally",
            "8 to 87.3)"
        ]
    },
    {
        "id": "494c1f01-5a2d-409e-b614-5871f408fbe6",
        "primaryId": "NCT00450866",
        "statement_text": "In the primary trial group A has a higher percentage of patients with greater than 25% increase in tumor area at 3 months after treatment than group B ",
        "statement_nums": [
            "25% increase",
            "3 months after"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Central Nervous System (CNS) Progression-free Survival(PFS) The number of patients that are documented to have progression free survival at 3 months after treatment  Progression free is define as smaller than 25% increase in tumor area  PFS will be measured from the date of entry into the trial to the date of documented progression of brain metastases or death  Time frame: 3 months after treatment Results 1: Arm/Group Title: Epothilone B: Group A ",
        "premise_nums": [
            "25% increase",
            "3 months after"
        ]
    },
    {
        "id": "494c1f01-5a2d-409e-b614-5871f408fbe6",
        "primaryId": "NCT00450866",
        "statement_text": "In the primary trial group A has a higher percentage of patients with greater than 25% increase in tumor area at 3 months after treatment than group B ",
        "statement_nums": [
            "25% increase",
            "3 months after"
        ],
        "label": "Contradiction",
        "premise_text": "Arm/Group Description: Group A: Patients with progressive  radiographically measurable parenchymal brain metastases after whole brain radiation therapy (WBRT)  Patupilone will be administered as a single intravenous infusion over 20 minutes  once every 3 weeks  Patupilone will be administered at a dose of 10 mg/m2 (q3weeks) with actual body weight Overall Number of Participants Analyzed: 45 Measure Type: Number Unit of Measure: participants 12 Results 2: Arm/Group Title: Epothilone B: Group B ",
        "premise_nums": [
            "45 Measure Type:",
            "(q3weeks) with",
            "10 mg/m2",
            "12 Results 2:"
        ]
    },
    {
        "id": "494c1f01-5a2d-409e-b614-5871f408fbe6",
        "primaryId": "NCT00450866",
        "statement_text": "In the primary trial group A has a higher percentage of patients with greater than 25% increase in tumor area at 3 months after treatment than group B ",
        "statement_nums": [
            "25% increase",
            "3 months after"
        ],
        "label": "Contradiction",
        "premise_text": "Arm/Group Description: Group B: an exploratory cohort of patients  with either leptomeningeal metastases (LMD) or unirradiated  asymptomatic brain metastasis from breast cancer (BCBM).Patupilone will be administered as a single intravenous infusion over 20 minutes  once every 3 weeks  Patupilone will be administered at a dose of 10 mg/m2 (q3weeks) with actual body weight Overall Number of Participants Analyzed: 10 Measure Type: Number Unit of Measure: participants 2 ",
        "premise_nums": [
            "10 mg/m2",
            "(q3weeks) with",
            "10 Measure Type:"
        ]
    },
    {
        "id": "17881072-2517-483f-9c03-1edad21a58cf",
        "primaryId": "NCT01008150",
        "secondaryId": "NCT00375427",
        "label": "Contradiction",
        "statement_text": "In total the secondary trial recorded only 3 more cases of Pyrexia than the primary trial ",
        "statement_nums": [
            "3 more cases"
        ],
        "premise_text": "Adverse Events 1: Total: 7/42 (16.67%) Febrile neutropenia 1/42 (2.38%) Left venrticular dysfunction 1/42 (2.38%) Cardiac valve disease 1/42 (2.38%) Diarrhoea 0/42 (0.00%) Abdominal pain 1/42 (2.38%) Colitis 0/42 (0.00%) Nausea 0/42 (0.00%) Vomiting 0/42 (0.00%) Pyrexia 0/42 (0.00%) Influenza like illness 1/42 (2.38%) Oedema peripheral 1/42 (2.38%) Fatigue 0/42 (0.00%) Adverse Events 2: ",
        "premise_nums": [
            "1/42 (2.38%)",
            "0/42 (0.00%)",
            "7/42 (16.67%)"
        ]
    },
    {
        "id": "17881072-2517-483f-9c03-1edad21a58cf",
        "primaryId": "NCT01008150",
        "secondaryId": "NCT00375427",
        "label": "Contradiction",
        "statement_text": "In total the secondary trial recorded only 3 more cases of Pyrexia than the primary trial ",
        "statement_nums": [
            "3 more cases"
        ],
        "premise_text": "Total: 7/42 (16.67%)Febrile neutropenia 0/42 (0.00%) Left venrticular dysfunction 1/42 (2.38%) Cardiac valve disease 0/42 (0.00%) Diarrhoea 0/42 (0.00%) Abdominal pain 0/42 (0.00%) Colitis 0/42 (0.00%) Nausea 0/42 (0.00%) Vomiting 0/42 (0.00%) Pyrexia 2/42 (4.76%) Influenza like illness 0/42 (0.00%) Oedema peripheral 0/42 (0.00%) Fatigue 0/42 (0.00%) Adverse Events 1: Total: 21/209 (10.05%) ",
        "premise_nums": [
            "2/42 (4.76%)",
            "7/42 (16.67%)Febrile",
            "21/209 (10.05%)",
            "0/42 (0.00%)",
            "1/42 (2.38%)"
        ]
    },
    {
        "id": "17881072-2517-483f-9c03-1edad21a58cf",
        "primaryId": "NCT01008150",
        "secondaryId": "NCT00375427",
        "label": "Contradiction",
        "statement_text": "In total the secondary trial recorded only 3 more cases of Pyrexia than the primary trial ",
        "statement_nums": [
            "3 more cases"
        ],
        "premise_text": "Anaemia 0/209 (0.00%)Febrile neutropenia 0/209 (0.00%) Thrombocytopenia 0/209 (0.00%) Acute myocardial infarction 0/209 (0.00%) Cardiac failure 0/209 (0.00%) Diplopia 0/209 (0.00%) Gastric haemorrhage 0/209 (0.00%) Nausea 0/209 (0.00%) Oral pain 0/209 (0.00%) Vomiting 1/209 (0.48%) Mucosal inflammation 0/209 (0.00%) Pain 1/209 (0.48%) Adverse Events 2: Total: 29/216 (13.43%) ",
        "premise_nums": [
            "29/216 (13.43%)",
            "1/209 (0.48%)",
            "0/209 (0.00%)Febrile"
        ]
    },
    {
        "id": "17881072-2517-483f-9c03-1edad21a58cf",
        "primaryId": "NCT01008150",
        "secondaryId": "NCT00375427",
        "label": "Contradiction",
        "statement_text": "In total the secondary trial recorded only 3 more cases of Pyrexia than the primary trial ",
        "statement_nums": [
            "3 more cases"
        ],
        "premise_text": "Anaemia 2/216 (0.93%)Febrile neutropenia 2/216 (0.93%) Thrombocytopenia 2/216 (0.93%) Acute myocardial infarction 1/216 (0.46%) Cardiac failure 1/216 (0.46%) Diplopia 1/216 (0.46%) Gastric haemorrhage 1/216 (0.46%) Nausea 1/216 (0.46%) Oral pain 2/216 (0.93%) Vomiting 2/216 (0.93%) Mucosal inflammation 1/216 (0.46%) Pain 0/216 (0.00%) ",
        "premise_nums": [
            "0/216 (0.00%)",
            "1/216 (0.46%)",
            "2/216 (0.93%)Febrile"
        ]
    },
    {
        "id": "58ba5dfd-3d8d-42e4-8cff-3c179fcd43a7",
        "primaryId": "NCT00093795",
        "statement_text": "Patients with cancer cells that have metastasised into less than 3 lymph nodes  with at least one larger than 2mm, cannot enter the primary trial ",
        "statement_nums": [
            "3 lymph nodes"
        ],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria: By pathologic evaluation  ipsilateral nodes must be pN1 (pN1mi, pN1a, pN1b, pN1c), pN2a, pN3a, or pN3b (only if due to microscopic involvement of internal mammary node detected by sentinel lymph node dissection and with more than 3 positive axillary lymph nodes)  ",
        "premise_nums": [
            "3 positive axillary"
        ]
    },
    {
        "id": "da6ce3a9-b653-47b2-9271-f831e4de3f19",
        "primaryId": "NCT00912340",
        "statement_text": "Less patients in cohort 2 of the primary trial had an unusual amount of fluid around the lungs than in cohort 1.",
        "statement_nums": [
            "2 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Pleural effusion *0/24 (0.00%) Adverse Events 2: Pleural effusion *2/30 (6.67%) ",
        "premise_nums": [
            "2/30 (6.67%)",
            "0/24 (0.00%)"
        ]
    },
    {
        "id": "66979ae5-a709-4adf-9067-287f0f92b9e2",
        "primaryId": "NCT00828074",
        "statement_text": "A higher number of cohort 2 participants from the primary trial experienced fever  compared to cohort 1.",
        "statement_nums": [
            "2 participants from"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Fever * 2/41 (4.88%) Adverse Events 2: Fever * 0/5 (0.00%) ",
        "premise_nums": [
            "2/41 (4.88%)",
            "0/5 (0.00%)"
        ]
    },
    {
        "id": "0af6799b-655f-4b8b-a192-ce8dcbb2fcff",
        "primaryId": "NCT02692755",
        "statement_text": "Only Black women are eligible for the primary trial  as long as they do not have uncontrolled or symptomatic brain metastases ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Inclusion Criteria: Self-identified Black  African or African American women of 18 years of age with proven diagnosis of advanced adenocarcinoma of the breast (locoregionally recurrent or metastatic disease) Exclusion Criteria: Current use of food or drugs known to be potent inhibitors or inducers of CYP3A4 Active uncontrolled or symptomatic brain metastases  Previously treated and clinically stable  as per Investigator's judgment  brain metastases are permitted  ",
        "premise_nums": [
            "4 Active uncontrolled",
            "18 years of"
        ]
    },
    {
        "id": "3a3e2387-c4c7-48e6-b3ca-1257de7019c2",
        "primaryId": "NCT00072293",
        "statement_text": "Patients with a palpable breast lesions and axillary lymph nodes are eligible for the primary trial ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Palpable or nonpalpable breast lesion No palpable axillary lymph node(s) ",
        "premise_nums": []
    },
    {
        "id": "46ac8a9f-77ab-40cf-9421-64aad4ae6976",
        "primaryId": "NCT00537771",
        "secondaryId": "NCT00354640",
        "label": "Entailment",
        "statement_text": "participants of cohort 1 in the primary trial and all participants of the secondary trial take 1 milligram of anastrozole PO QD ",
        "statement_nums": [
            "1 milligram of",
            "1 in the"
        ],
        "premise_text": "INTERVENTION 1: Arimidex Group Anastrozole(ARIMIDEX): 1 mg once daily oral dose INTERVENTION 1: anastrozole : 1 milligram tablet PO QD for 14 days ",
        "premise_nums": [
            "1 mg once",
            "1 milligram tablet"
        ]
    },
    {
        "id": "d2b7253b-0654-4bb1-a9a4-b203714d64f9",
        "primaryId": "NCT00445458",
        "secondaryId": "NCT00950742",
        "label": "Entailment",
        "statement_text": "the primary trial and the secondary trial measure the DLT of their respective interventions  using the same time frame ",
        "statement_nums": [],
        "premise_text": "Outcome Measurement: Dose Limiting Toxicity Incidence of Neratinib in Combination With Paclitaxel Dose Limiting Toxicity in subjects with solid tumors treated with neratinib  administered daily  in combination with paclitaxel 80 mg/m² IV on days 1, 8, and 15 of a 28 day cycle  Time frame: From first dose date through day 28 Outcome Measurement: Number of Participants With Dose Limiting Toxicities (DLT) Number of participants with DLT in the first cycle (28 days) for the determination of the maximum tolerated dose (MTD)  Important Limitations and Caveats are provided in the respective section  Time frame: 28 days ",
        "premise_nums": [
            "28 Outcome Measurement:",
            "80 mg/m²",
            "28 day cycle",
            "15 of a"
        ]
    },
    {
        "id": "9a896e4a-ae6b-468c-a7c0-32c1514c0b48",
        "primaryId": "NCT00107276",
        "secondaryId": "NCT00232505",
        "label": "Entailment",
        "statement_text": "Less than 5% of patients undergoing the intervention in the primary trial had adverse events  in comparison almost 10% patients in cohort 1 of the secondary trial experienced an adverse event  and more than 30% of those in cohort 2 of the secondary trial had adverse events ",
        "statement_nums": [
            "2 of the",
            "5% of",
            "10% patients",
            "30% of",
            "1 of the"
        ],
        "premise_text": "Adverse Events 1: Total: 4/95 (4.21%) Adverse Events 1: Total: 3/31 (9.68%) Adverse Events 2: Total: 8/25 (32.00%) ",
        "premise_nums": [
            "8/25 (32.00%)",
            "3/31 (9.68%)",
            "4/95 (4.21%)"
        ]
    },
    {
        "id": "41eb4b9a-3b8f-4895-9aa3-cb43dbe27dd4",
        "primaryId": "NCT00356811",
        "secondaryId": "NCT00296036",
        "label": "Entailment",
        "statement_text": "The the secondary trial intervention is applied to the palms and soles twice daily  the primary trial participants are not administered any medication topically ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Lapatinib Plus Paclitaxel Participants received lapatinib 1500 mg orally OD with paclitaxel  administered as a 1-hour IV infusion at a dose of 80 mg/m^2 on Days 1, 8, and 15 (±2 days) of a 28-day treatment cycle for at least 6 months  Participants were treated until disease progression  unacceptable toxicity  or consent withdrawal  INTERVENTION 1: Urea/Lactic Acid Cream Patients receive topical urea/lactic acid-based cream applied to palms and soles twice daily  INTERVENTION 2: Placebo Cream Patients receive placebo cream applied to palms and soles twice daily  ",
        "premise_nums": [
            "1-hour IV",
            "80 mg/m^2",
            "1500 mg orally",
            "2 on Days",
            "28-day treatment"
        ]
    },
    {
        "id": "0931065d-35e4-4f82-8ef6-ac6db900127a",
        "primaryId": "NCT00290732",
        "secondaryId": "NCT02748213",
        "label": "Entailment",
        "statement_text": "Patients whose breast cancer has spread into both the skin and the chest wall are eligible for the secondary trial  but not the primary trial ",
        "statement_nums": [],
        "premise_text": "T1-3, any N disease No inflammatory breast cancer or other T4 features Inclusion Criteria: Histologically confirmed  HER2-positive advanced and/or metastatic breast cancer not amenable to curative therapy ",
        "premise_nums": [
            "4 features Inclusion",
            "2-positive advanced",
            "1-3, any"
        ]
    },
    {
        "id": "70912726-ba1b-47ef-9005-9584c8caf559",
        "primaryId": "NCT00853996",
        "statement_text": "Women classified as low-risk of developing breast cancer within the next 5 years by the Gail model   and no Family history consistent with hereditary breast cancer  are eligible for the primary trial ",
        "statement_nums": [
            "5 years by"
        ],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria: Gail risk greater than or equal 1.7% and/or relative risk greater than or equal 3 times that for 5-year age group Family history consistent with hereditary breast cancer  as indicated by 1 of the following criteria: ",
        "premise_nums": [
            "5-year age",
            "equal 1.7% and/or",
            "3 times that",
            "1 of the"
        ]
    },
    {
        "id": "6743f85c-8318-49cc-acba-94aeb1f57130",
        "primaryId": "NCT00493636",
        "statement_text": "Cohort 1 of the primary trial had a longer PFS than cohort 2. However the patient with the longest PFS was in cohort 2.",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Progression Free Survival [Not Specified] Time frame: From the date of randomization to date of first documented disease progression (i.e.  the date on which a radiologic procedure or clinical evaluation was performed) or the date of death due to any cause  if before progression  assessed up to 39 months  Results 1: Arm/Group Title: A (Sorafenib + Gemcitabine or Capecitabine) ",
        "premise_nums": []
    },
    {
        "id": "6743f85c-8318-49cc-acba-94aeb1f57130",
        "primaryId": "NCT00493636",
        "statement_text": "Cohort 1 of the primary trial had a longer PFS than cohort 2. However the patient with the longest PFS was in cohort 2.",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Arm/Group Description: Sorafenib will be administered (400 mg; 2 tablets x 200 mg) orally twice daily (approximately every 12 hours); Gemcitabine will be administered 1000 mg/m2 pm Days 1 and 8 of a 21 day cycle; Capecitabine will be administered orally at a dose of 1,000 mg/m2 twice daily  within 30 minutes after a meal  for 14 days followed by a 7 day rest period (without capecitabine)Gemcitabine: Gemcitabine will be administered 1000 mg/m2 pm Days 1 and 8 of a 21 day cycle ",
        "premise_nums": [
            "of 1,000 mg/m2",
            "14 days followed",
            "2 pm Days",
            "1000 mg/m2 pm",
            "1 and 8",
            "21 day cycle;",
            "2 tablets x",
            "2 twice daily",
            "30 minutes after",
            "7 day rest"
        ]
    },
    {
        "id": "6743f85c-8318-49cc-acba-94aeb1f57130",
        "primaryId": "NCT00493636",
        "statement_text": "Cohort 1 of the primary trial had a longer PFS than cohort 2. However the patient with the longest PFS was in cohort 2.",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Sorafenib: Sorafenib will be administered (400 mg; 2 tablets x 200 mg) orally twice daily (approximately every 12 hours)Capecitabine: Capecitabine will be administered orally at a dose of 1,000 mg/m2 twice daily  within 30 minutes after a meal  for 14 days followed by a 7 day rest period (without capecitabine)  Overall Number of Participants Analyzed: 81 Median (95% Confidence Interval) Unit of Measure: Days 103 (83 to 128) Results 2: Arm/Group Title: B (Placebo + Gemcitabine or Capecitabine) ",
        "premise_nums": [
            "of 1,000 mg/m2",
            "14 days followed",
            "95% Confidence",
            "2 tablets x",
            "2 twice daily",
            "30 minutes after",
            "7 day rest",
            "83 to 128)"
        ]
    },
    {
        "id": "6743f85c-8318-49cc-acba-94aeb1f57130",
        "primaryId": "NCT00493636",
        "statement_text": "Cohort 1 of the primary trial had a longer PFS than cohort 2. However the patient with the longest PFS was in cohort 2.",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Arm/Group Description: Placebo will be administered ( 2 tablets ) orally twice daily (approximately every 12 hours); Gemcitabine will be administered 1000 mg/m2 pm Days 1 and 8 of a 21 day cycle; Capecitabine will be administered orally at a dose of 1,000 mg/m2 twice daily  within 30 minutes after a meal  for 14 days followed by a 7 day rest period (without capecitabine)Gemcitabine: Gemcitabine will be administered 1000 mg/m2 pm Days 1 and 8 of a 21 day cycle Placebo: Placebo will be administered (400 mg; 2 tablets x 200 mg) orally twice daily (approximately every 12 hours) ",
        "premise_nums": [
            "of 1,000 mg/m2",
            "14 days followed",
            "2 pm Days",
            "1000 mg/m2 pm",
            "1 and 8",
            "21 day cycle;",
            "2 tablets x",
            "2 twice daily",
            "2 tablets )",
            "30 minutes after",
            "7 day rest"
        ]
    },
    {
        "id": "6743f85c-8318-49cc-acba-94aeb1f57130",
        "primaryId": "NCT00493636",
        "statement_text": "Cohort 1 of the primary trial had a longer PFS than cohort 2. However the patient with the longest PFS was in cohort 2.",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Capecitabine: Capecitabine will be administered orally at a dose of 1,000 mg/m2 twice daily  within 30 minutes after a meal  for 14 days followed by a 7 day rest period (without capecitabine) Overall Number of Participants Analyzed: 79 Median (95% Confidence Interval) Unit of Measure: Days 81 (48 to 95) ",
        "premise_nums": [
            "of 1,000 mg/m2",
            "14 days followed",
            "48 to 95)",
            "95% Confidence",
            "2 twice daily",
            "30 minutes after",
            "7 day rest"
        ]
    },
    {
        "id": "ddffa26d-2581-477a-955c-ebf0c2ab0f97",
        "primaryId": "NCT00784849",
        "secondaryId": "NCT02104895",
        "label": "Contradiction",
        "statement_text": "Accelerated partial Breast breast irradiation is used in some form for both cohorts of the secondary trial  but not at all in the primary trial ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Sentinel Lymph Node Biopsy With Radiolabeled Methylene Blue One arm diagnostic using 1 mCi of 125-I Methylene blue dye to find sentinel lymph nodes INTERVENTION 1: Whole Breast Irradiation (WBI) Conventional whole breast irradiation (WBI) Whole breast irradiation (WBI): Conventional whole breast irradiation (WBI) INTERVENTION 2: Partial Breast Irradiation (APBI) Accelerated partial breast irradiation (APBI) Accelerated partial breast irradiation (APBI): Accelerated partial breast irradiation (APBI) using intensity modulated radiotherapy (IMRT) ",
        "premise_nums": [
            "1 mCi of",
            "125-I Methylene"
        ]
    },
    {
        "id": "f1a45b47-498d-45c8-b6d9-6c8f035da30b",
        "primaryId": "NCT01201265",
        "statement_text": "1 patient in the primary trial was affected by Sepsis ",
        "statement_nums": [
            "1 patient in"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 17/40 (42.50%) Anaemia 2/40 (5.00%) Febrile Neutropenia 3/40 (7.50%) Neutropenia 2/40 (5.00%) Thrombocytopenia 5/40 (12.50%) Pericardial Effusion 1/40 (2.50%) Abdominal Pain Lower 1/40 (2.50%) Disease Progression 6/40 (15.00%) Fatigue 1/40 (2.50%) Pyrexia 3/40 (7.50%) Septic Shock 1/40 (2.50%) Streptococcal Infection 1/40 (2.50%) ",
        "premise_nums": [
            "2/40 (5.00%)",
            "3/40 (7.50%)",
            "1/40 (2.50%)",
            "17/40 (42.50%)",
            "5/40 (12.50%)",
            "6/40 (15.00%)"
        ]
    },
    {
        "id": "a5272c37-0e32-42db-a44a-d17df7bd70ff",
        "primaryId": "NCT00179309",
        "statement_text": "There were no pain related adverse events observed in the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 3/25 (12.00%) Anemia 0/25 (0.00%) Sinus tachycardia 0/25 (0.00%) Pericardial effusion 1/25 (4.00%) Gastrointestinal disorders - Other  specify -stomatitis) 0/25 (0.00%) Vomiting 1/25 (4.00%) Fever 0/25 (0.00%) Injection site reaction 1/25 (4.00%) Catheter related infection 0/25 (0.00%) Activated partial thromboplastin time prolonged 0/25 (0.00%) Adverse Events 2: Total: 2/23 (8.70%) Anemia 1/23 (4.35%) ",
        "premise_nums": [
            "1/25 (4.00%)",
            "0/25 (0.00%)",
            "3/25 (12.00%)",
            "1/23 (4.35%)",
            "2/23 (8.70%)"
        ]
    },
    {
        "id": "a5272c37-0e32-42db-a44a-d17df7bd70ff",
        "primaryId": "NCT00179309",
        "statement_text": "There were no pain related adverse events observed in the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Sinus tachycardia 1/23 (4.35%)Pericardial effusion 0/23 (0.00%) Gastrointestinal disorders - Other  specify -stomatitis) 1/23 (4.35%) Vomiting 0/23 (0.00%) Fever 1/23 (4.35%) Injection site reaction 1/23 (4.35%) Catheter related infection 1/23 (4.35%) Activated partial thromboplastin time prolonged 1/23 (4.35%) ",
        "premise_nums": [
            "0/23 (0.00%)",
            "1/23 (4.35%)Pericardial"
        ]
    },
    {
        "id": "4c67a7b4-36fa-4c20-a15a-122609550973",
        "primaryId": "NCT00201773",
        "statement_text": "Adele is an 85 year old woman with Stage IV histologically confirmed ER+ breast cancer with an ECOG of 0, she has a life expectancy below 6 months and a history of thrombotic events  She is eligible for the primary trial",
        "statement_nums": [
            "6 months and",
            "85 year old"
        ],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria: Must be female with histologically confirmed breast cancer Stage II-IV disease ER and/or PR positive ECOG Performance Status 0-1 Postmenopausal ",
        "premise_nums": [
            "0-1 Postmenopausal"
        ]
    },
    {
        "id": "120c6aa7-fcaa-4eaa-b520-6382968a6724",
        "primaryId": "NCT00620373",
        "statement_text": "the primary trial tests two different dental imaging modalities  namely Mammography and gamma imaging ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "INTERVENTION 1: Mammography Only For this reporting arm  the interpretation and analysis was done with mammography only  INTERVENTION 2: Gamma Imaging For this reporting arm  the interpretation and analysis was done with gamma imaging only  ",
        "premise_nums": []
    },
    {
        "id": "e35ebcea-f1ca-4c26-aa3b-2dc5de1a8645",
        "primaryId": "NCT00050011",
        "statement_text": "the primary trial results show that Zoledronic Acid Upfront is a better treatment than Zoledronic Acid Delayed-start for preventing any change in Lumbar Spine (L1-L4) Bone Mineral Density (BMD) ",
        "statement_nums": [
            "1-L4) Bone"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Percent Change From Baseline in Lumbar Spine (L1-L4) Bone Mineral Density (BMD) ",
        "premise_nums": [
            "1-L4) Bone"
        ]
    },
    {
        "id": "e35ebcea-f1ca-4c26-aa3b-2dc5de1a8645",
        "primaryId": "NCT00050011",
        "statement_text": "the primary trial results show that Zoledronic Acid Upfront is a better treatment than Zoledronic Acid Delayed-start for preventing any change in Lumbar Spine (L1-L4) Bone Mineral Density (BMD) ",
        "statement_nums": [
            "1-L4) Bone"
        ],
        "label": "Contradiction",
        "premise_text": "Bone mineral density (BMD) measurements were assessed by dual energy x-ray absorptiometry (DXA)  The DXA devices of participating sites were cross-calibrated and the DXA results were compiled and analyzed by a central reader  Percent change = 100*((BMD at Month 12 - Baseline BMD)/Baseline BMD))  Missing data at month 12 were imputed by using the last observation carried forward (LOCF) method  Post-baseline non-missing data from month 6 were carried forward to month 12. Data prior to month 6 were not carried forward Time frame: Baseline  12 months Results 1: ",
        "premise_nums": [
            "6 were not",
            "12 were imputed",
            "6 were carried",
            "12 months Results"
        ]
    },
    {
        "id": "e35ebcea-f1ca-4c26-aa3b-2dc5de1a8645",
        "primaryId": "NCT00050011",
        "statement_text": "the primary trial results show that Zoledronic Acid Upfront is a better treatment than Zoledronic Acid Delayed-start for preventing any change in Lumbar Spine (L1-L4) Bone Mineral Density (BMD) ",
        "statement_nums": [
            "1-L4) Bone"
        ],
        "label": "Contradiction",
        "premise_text": "Arm/Group Title: Zoledronic Acid UpfrontArm/Group Description: Participants in the upfront arm received Zoledronic Acid 4 mg i.v  on Day 1 and every 6 months until disease progression (recurrence)or the end of study  Participants also received Letrozole 2.5 daily plus calcium (1000-1200 mg) and vitamin D (400-800 IU) daily  Letrozole : Participants received 2.5 mg daily  Zoledronic Acid : Participants received Zoledronic Acid 4 mg IV 15-minute infusion every 6 months  Overall Number of Participants Analyzed: 253 Mean (Standard Deviation) ",
        "premise_nums": [
            "4 mg i.v",
            "(1000-1200 mg",
            "1 and every",
            "15-minute infusion",
            "253 Mean (Standard",
            "(400-800 IU",
            "Letrozole 2.5 daily plus",
            "4 mg IV",
            "6 months until",
            "received 2.5 mg daily"
        ]
    },
    {
        "id": "e35ebcea-f1ca-4c26-aa3b-2dc5de1a8645",
        "primaryId": "NCT00050011",
        "statement_text": "the primary trial results show that Zoledronic Acid Upfront is a better treatment than Zoledronic Acid Delayed-start for preventing any change in Lumbar Spine (L1-L4) Bone Mineral Density (BMD) ",
        "statement_nums": [
            "1-L4) Bone"
        ],
        "label": "Contradiction",
        "premise_text": "Unit of Measure: Percentage of BMD 1.955 (3.3658)Results 2: Arm/Group Title: Zoledronic Acid Delayed-start ",
        "premise_nums": []
    },
    {
        "id": "e35ebcea-f1ca-4c26-aa3b-2dc5de1a8645",
        "primaryId": "NCT00050011",
        "statement_text": "the primary trial results show that Zoledronic Acid Upfront is a better treatment than Zoledronic Acid Delayed-start for preventing any change in Lumbar Spine (L1-L4) Bone Mineral Density (BMD) ",
        "statement_nums": [
            "1-L4) Bone"
        ],
        "label": "Contradiction",
        "premise_text": "Arm/Group Description: In lieu of a placebo arm  which was considered unethical for this trial  a delayed start arm was used  Participants who met certain clinical criteria indicating risk of lumbar spine or total hip fracture  or experienced clinical fracture unrelated to trauma or any asymptomatic fracture discovered at the Month 36 scheduled visit  were started on zoledronic acid 4 mg i.v  and for every 6 months until disease progression (recurrence) or end of study  Participants also received Letrozole 2.5 daily plus calcium (1000-1200 mg) and vitamin D (400-800 IU) daily Letrozole : Participants received 2.5 mg daily  ",
        "premise_nums": [
            "36 scheduled visit",
            "4 mg i.v",
            "(1000-1200 mg",
            "(400-800 IU",
            "Letrozole 2.5 daily plus",
            "6 months until",
            "received 2.5 mg daily"
        ]
    },
    {
        "id": "e35ebcea-f1ca-4c26-aa3b-2dc5de1a8645",
        "primaryId": "NCT00050011",
        "statement_text": "the primary trial results show that Zoledronic Acid Upfront is a better treatment than Zoledronic Acid Delayed-start for preventing any change in Lumbar Spine (L1-L4) Bone Mineral Density (BMD) ",
        "statement_nums": [
            "1-L4) Bone"
        ],
        "label": "Contradiction",
        "premise_text": "Zoledronic Acid : Participants received Zoledronic Acid 4 mg IV 15-minute infusion every 6 months Overall Number of Participants Analyzed: 256 Mean (Standard Deviation) Unit of Measure: Percentage of BMD -2.325 (3.9542) ",
        "premise_nums": [
            "6 months Overall",
            "4 mg IV",
            "256 Mean (Standard",
            "15-minute infusion"
        ]
    },
    {
        "id": "ac997ae1-7e48-48e2-af9e-f7e289622250",
        "primaryId": "NCT00798135",
        "secondaryId": "NCT01209195",
        "label": "Entailment",
        "statement_text": "the primary trial and the secondary trial investigate different outcome measures for different interventions ",
        "statement_nums": [],
        "premise_text": "Outcome Measurement: Pharmacokinetics (PK) of Oral Itraconazole To determine the pharmacokinetics (PK) of oral itraconazole in patients with MBC by measuring mean trough plasma levels at steady state at weeks 2 and 4. Time frame: pre-dose at Weeks 2 and 4 Results 1: Arm/Group Title: Itraconazole Arm/Group Description: oral itraconazole 200mg a day until disease progression or unacceptable toxicities  Overall Number of Participants Analyzed: 12 Mean (Standard Deviation) Unit of Measure: ng/mL Week 2 Intraconazole Concentration: 230.7 (216.8) Week 4 Intraconazole Concentration: 305.8 (334.8) ",
        "premise_nums": [
            "2 Intraconazole Concentration:",
            "12 Mean (Standard",
            "4 Intraconazole Concentration:",
            "2 and 4."
        ]
    },
    {
        "id": "ac997ae1-7e48-48e2-af9e-f7e289622250",
        "primaryId": "NCT00798135",
        "secondaryId": "NCT01209195",
        "label": "Entailment",
        "statement_text": "the primary trial and the secondary trial investigate different outcome measures for different interventions ",
        "statement_nums": [],
        "premise_text": "Week 2 6-OH Itraconazole Concentration: 454.8 (429.3)Week 4 6-OH Itraconazole Concentration: 501.6 (502.6) Outcome Measurement: Dose Escalation: To Evaluate the Safety and Tolerability of Escalating Doses of the MM-121 Plus Paclitaxel Combination Via Reporting of Dose-limiting Toxicity (DLT) To establish the safety of escalating doses of MM-121 in combination with paclitaxel in order to determine the recommended phase 2 dose  Dose-escalation conducted using standard 3+3 model to determine maximum tolerated dose  Reports of Dose-Limiting Toxicities (DLTs) were assessed to determine the MTD  Time frame: From date of first dose to 30 days after termination  the longest 163 weeks ",
        "premise_nums": [
            "3+3 model",
            "2 6-OH Itraconazole",
            "4 6-OH Itraconazole",
            "30 days after",
            "121 Plus Paclitaxel",
            "121 in combination",
            "3 model to"
        ]
    },
    {
        "id": "59328f44-6755-4dcb-b04c-4e0ce2ba3ac8",
        "primaryId": "NCT02915744",
        "statement_text": "The difference in median Overall Survival (OS) of Patients between the two cohort of the primary trial was less than one month  the patient with the longest OS was in cohort 1.",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Overall Survival (OS) of Patients To compare Overall Survival (OS) of patients who receive 145 mg/m2 NKTR-102 given once every 21 days (q21d) with OS of patients who receive Treatment of Physician's Choice (TPC)  Overall survival is defined as the time from the date of randomization to the date of death from any cause  Patients will be followed until their date of death or until final database closure  Patients who are lost-to-follow-up or are alive at the time of analysis will be censored at the time they were last known to be alive or at the date of event cut-off for OS analysis  Time frame: Within 3 years from study start Results 1: ",
        "premise_nums": [
            "3 years from",
            "145 mg/m2 NKTR",
            "102 given once",
            "21 days (q21d)",
            "(q21d) with"
        ]
    },
    {
        "id": "59328f44-6755-4dcb-b04c-4e0ce2ba3ac8",
        "primaryId": "NCT02915744",
        "statement_text": "The difference in median Overall Survival (OS) of Patients between the two cohort of the primary trial was less than one month  the patient with the longest OS was in cohort 1.",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Arm/Group Title: NKTR-102Arm/Group Description: In Group A  NKTR-102 will be administered at a dose level of 145 mg/m2 on a q21d schedule as a 90-minute intravenous (IV) infusion on Day 1 of each treatment cycle  Overall Number of Participants Analyzed: 92 Median (95% Confidence Interval) Unit of Measure: months 7.8 (6.1 to 10.2) Results 2: Arm/Group Title: Treatment of Physician's Choice (TPC) ",
        "premise_nums": [
            "145 mg/m2 on",
            "90-minute intravenous",
            "1 of each",
            "102 will be",
            "2 on a",
            "95% Confidence",
            "1 to 10.2)"
        ]
    },
    {
        "id": "59328f44-6755-4dcb-b04c-4e0ce2ba3ac8",
        "primaryId": "NCT02915744",
        "statement_text": "The difference in median Overall Survival (OS) of Patients between the two cohort of the primary trial was less than one month  the patient with the longest OS was in cohort 1.",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Arm/Group Description: In Group B  TPC will be administered per standard of care  Patients randomized to TPC will receive single-agent IV chemotherapy  limited to choice of one of the following 7 agents: eribulin  ixabepilone  vinorelbine  gemcitabine  paclitaxel  docetaxel  or nab-paclitaxel Overall Number of Participants Analyzed: 86 Median (95% Confidence Interval) Unit of Measure: months 7.5 (5.8 to 10.4) ",
        "premise_nums": [
            "8 to 10.4)",
            "95% Confidence"
        ]
    },
    {
        "id": "441c0760-ca4a-4f1d-864e-a77395fd1f18",
        "primaryId": "NCT00399802",
        "statement_text": "The Lapatinib group of the primary trial had a smaller Percentage Change From Baseline in Urinary N-telopeptide of Type I Collagen than the Odanacatib 5 mg group",
        "statement_nums": [
            "5 mg group"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Percentage Change From Baseline in Urinary N-telopeptide of Type I Collagen (u-NTx) at Week 4 u-NTx is a biochemical index of bone resorption  Participants provided urine specimens on Day 1 (baseline) and at Week 4 for measurement of u-NTx  Time frame: Baseline and Week 4 Results 1: Arm/Group Title: Single IV Infusion of ZA 4 mg Arm/Group Description: Participants received a single IV infusion of ZA 4 mg at the start of treatment and a once-daily odanacatib matching placebo tablet for 4 weeks  Overall Number of Participants Analyzed: 14 Mean (95% Confidence Interval) ",
        "premise_nums": [
            "4 mg at",
            "4 mg Arm",
            "4 u-NTx is",
            "95% Confidence",
            "4 for measurement",
            "4 Results 1:"
        ]
    },
    {
        "id": "441c0760-ca4a-4f1d-864e-a77395fd1f18",
        "primaryId": "NCT00399802",
        "statement_text": "The Lapatinib group of the primary trial had a smaller Percentage Change From Baseline in Urinary N-telopeptide of Type I Collagen than the Odanacatib 5 mg group",
        "statement_nums": [
            "5 mg group"
        ],
        "label": "Contradiction",
        "premise_text": "Unit of Measure: Percentage change -73 (-80 to -62)Results 2: Arm/Group Title: Once-daily Odanacatib 5 mg Arm/Group Description: Participants received a once-daily odanacatib 5 mg tablet for 4 weeks and a single IV infusion of ZA matching placebo at the start of treatment  Overall Number of Participants Analyzed: 27 Mean (95% Confidence Interval) Unit of Measure: Percentage change -77 (-82 to -71) ",
        "premise_nums": [
            "5 mg Arm",
            "95% Confidence",
            "5 mg tablet",
            "4 weeks and"
        ]
    },
    {
        "id": "fbe60029-8944-4e12-b4b2-3413037a10cc",
        "primaryId": "NCT00723125",
        "statement_text": "57% of patients in cohort 1 of the primary trial had Pathological Complete Response Rates at Surgery ",
        "statement_nums": [
            "57% of",
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Pathological Complete Response Rates at Surgery [Not Specified] Time frame: at surgery approximately 5 months after initial treatment Results 1: Arm/Group Title: Cohort 1 ",
        "premise_nums": [
            "5 months after"
        ]
    },
    {
        "id": "fbe60029-8944-4e12-b4b2-3413037a10cc",
        "primaryId": "NCT00723125",
        "statement_text": "57% of patients in cohort 1 of the primary trial had Pathological Complete Response Rates at Surgery ",
        "statement_nums": [
            "57% of",
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Arm/Group Description: Avastin 10 mg/kg IV over 90 minutes day -14 Abraxane 100 mg/m2 IV over 30 minutes weekly x 12 weeks with Carboplatin at AUC 6 over 30 min IV and Avastin 15 mg/kg IV over 30-90 minutes weeks 1,4,7, and 10 Avastin 10 mg/kg IV over 30-60 minutes cycles 1-3 (omit dose with cycle 4) Doxorubicin 60 mg/m2* and Cyclophosphamide 600 mg/m2 IV q2weeks x 4 cycles Definitive surgery Avastin 10 mg/kg IV over 30-60 minutes q2weeks x 34 weeks",
        "premise_nums": [
            "100 mg/m2 IV",
            "60 minutes cycles",
            "2 IV over",
            "10 Avastin 10",
            "30 minutes weekly",
            "14 Abraxane 100",
            "30-90 minutes",
            "12 weeks with",
            "6 over 30",
            "30-60 minutes",
            "10 mg/kg IV",
            "60 minutes q2weeks",
            "90 minutes weeks",
            "60 mg/m2*",
            "15 mg/kg IV",
            "600 mg/m2 IV",
            "4 cycles Definitive",
            "1,4,7, and",
            "90 minutes day",
            "2 IV q2weeks"
        ]
    },
    {
        "id": "fbe60029-8944-4e12-b4b2-3413037a10cc",
        "primaryId": "NCT00723125",
        "statement_text": "57% of patients in cohort 1 of the primary trial had Pathological Complete Response Rates at Surgery ",
        "statement_nums": [
            "57% of",
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Cohort 1 and Cohort 2: Abraxane 100 mg/m2 IV over 30 minutes weekly x 12 weeks with Carboplatin at AUC 6 over 30 min IV and Avastin 15 mg/kg IV over 30-90 minutes weeks 1,4,7, and 10 (in Cohort 2, omit dose of Avastin on week 10)Overall Number of Participants Analyzed: 28 Measure Type: Number Unit of Measure: participants 16 ",
        "premise_nums": [
            "30 minutes weekly",
            "100 mg/m2 IV",
            "1 and Cohort",
            "28 Measure Type:",
            "2 IV over",
            "30-90 minutes",
            "1,4,7, and",
            "12 weeks with",
            "90 minutes weeks",
            "6 over 30",
            "15 mg/kg IV"
        ]
    },
    {
        "id": "fe1782aa-a871-4608-a7cb-8f83b7f76d8a",
        "primaryId": "NCT00278109",
        "secondaryId": "NCT01881230",
        "label": "Contradiction",
        "statement_text": "Gemcitabine is not used in the primary trial  and used only in cohort 2 of the secondary trial ",
        "statement_nums": [
            "2 of the"
        ],
        "premise_text": "INTERVENTION 1: Experimental cyclophosphamide: chemotherapy doxorubicin hydrochloride: chemotherapy adjuvant therapy: chemotherapy radiation therapy: chemotherapy INTERVENTION 1: Arm A: Nab-Paclitaxel + Gemcitabine ",
        "premise_nums": []
    },
    {
        "id": "fe1782aa-a871-4608-a7cb-8f83b7f76d8a",
        "primaryId": "NCT00278109",
        "secondaryId": "NCT01881230",
        "label": "Contradiction",
        "statement_text": "Gemcitabine is not used in the primary trial  and used only in cohort 2 of the secondary trial ",
        "statement_nums": [
            "2 of the"
        ],
        "premise_text": "Participants received nab-Paclitaxel 125 mg/m^2 on Days 1 and 8 by intravenous (IV) administration followed by gemcitabine 1000 mg/m^2 on Days 1 and 8 by IV administration of each 21-day treatment cycle  Participants continued treatment until progressive disease (PD)  unacceptable toxicity  required palliative radiotherapy or surgical intervention of lesion(s)  withdrawal from study treatment  withdrawal of study consent  participant refusal or the investigator felt it was no longer in the best interest of the participant to continue on treatmentINTERVENTION 2: Arm B: Nab-Paclitaxel + Carboplatin ",
        "premise_nums": [
            "1000 mg/m^2",
            "1 and 8",
            "125 mg/m^2",
            "21-day treatment",
            "2 on Days"
        ]
    },
    {
        "id": "fe1782aa-a871-4608-a7cb-8f83b7f76d8a",
        "primaryId": "NCT00278109",
        "secondaryId": "NCT01881230",
        "label": "Contradiction",
        "statement_text": "Gemcitabine is not used in the primary trial  and used only in cohort 2 of the secondary trial ",
        "statement_nums": [
            "2 of the"
        ],
        "premise_text": "Participants received nab-Paclitaxel 125 mg/m^2 on Days 1 and 8 by IV administration followed by carboplatin area under the curve 2 (AUC 2) on Days 1 and 8 in each 21-day treatment cycle  Participants continued treatment until progressive disease (PD)  unacceptable toxicity  required palliative radiotherapy or surgical intervention of lesion(s)  withdrawal from study treatment  withdrawal of study consent  participant refusal or the investigator felt it was no longer in the best interest of the participant to continue on treatment ",
        "premise_nums": [
            "21-day treatment",
            "1 and 8",
            "125 mg/m^2",
            "2 on Days"
        ]
    },
    {
        "id": "a153ecbf-11ac-4c40-a3af-9dbb0e12c49b",
        "primaryId": "NCT02364388",
        "secondaryId": "NCT01425268",
        "label": "Entailment",
        "statement_text": "There is no overlap in treatments used in the primary trial and the secondary trial ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: MAESTRO Baseline INTERVENTION 1: AeroForm Tissue Expansion AeroForm Tissue Expansion inflation with carbon dioxide by remote control AeroForm Tissue Expansion: The AeroForm Patient Controlled Tissue Expander is a breast tissue expander implanted following mastectomy and activated by remote control to release small doses of carbon dioxide from an internal reservoir to fill and inflate the expander  INTERVENTION 2: Saline Tissue Expansion Saline Tissue Expansion inflated by needle injections of saline Saline Tissue Expansion: A saline tissue expander is a breast tissue expander which is implanted following mastectomy and inflated over time using needle injections to fill and inflate the expander with saline  ",
        "premise_nums": []
    },
    {
        "id": "bcd48c1e-bfeb-4f1e-993f-cbbe4fadbf6e",
        "primaryId": "NCT00405938",
        "statement_text": "Patients intracranial metastasis may be eligible for the primary trial ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Exclusion Criteria: No metastatic disease to the Central Nervous System ",
        "premise_nums": []
    },
    {
        "id": "4dc22366-3ff3-41c8-aa4c-7342d7b7085d",
        "primaryId": "NCT00263588",
        "statement_text": "The majority of the primary trial subjects either had Progressive disease or undetermined CNS objective response rate ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: The Number of Participants With Central Nervous System (CNS) Best Overall Response Summary of CNS Objective Response (Lapatinib Monotherapy - MITT Population) Response to lapatinib in patients with progressive brain metastases from ErbB2-overexpressing breast cancer  The primary indicator of drug efficacy was CNS objective response rate  A CNS objective response was defined as either a Complete response (CR) or Partial response (PR)  as assessed by volumetric analysis of brain Magnetic resonance imaging (MRI)  provided there was no progression of systemic disease outside of the CNS  increasing steroid requirements  or worsening of Neurological signs and symptoms (NSS) ",
        "premise_nums": [
            "2-overexpressing breast"
        ]
    },
    {
        "id": "4dc22366-3ff3-41c8-aa4c-7342d7b7085d",
        "primaryId": "NCT00263588",
        "statement_text": "The majority of the primary trial subjects either had Progressive disease or undetermined CNS objective response rate ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "A CNS objective response rate was defined as a 50% volumetric reduction in sum of CNS target lesions  with no new or progressive CNS or non-CNS lesions  no increases in tumor-related steroid requirements and no worsening of neurological signs or symptomsTime frame: time from baseline to data cutoff (25 Sept 2007); approximately 2 years Results 1: Arm/Group Title: Cohort A Arm/Group Description: 750mg lapatinib administered orally twice daily  Cohort A subjects had Eastern Cooperative Oncology Group (ECOG) performance status 0-1, and one or two prior trastuzumab-containing regimens  in total  for treatment of breast cancer in adjuvant and/or metastatic settings Overall Number of Participants Analyzed: 94 Measure Type: Count of Participants ",
        "premise_nums": [
            "94 Measure Type:",
            "50% volumetric",
            "0-1, and",
            "2 years Results",
            "25 Sept 2007);"
        ]
    },
    {
        "id": "4dc22366-3ff3-41c8-aa4c-7342d7b7085d",
        "primaryId": "NCT00263588",
        "statement_text": "The majority of the primary trial subjects either had Progressive disease or undetermined CNS objective response rate ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Unit of Measure: Participants Complete response (CR): 0 0.0%Partial response (PR): 6 6.4% Stable disease (SD): 40 42.6% Progressive disease (PD): 40 42.6% Unknown: 8 8.5% Results 2: Arm/Group Title: Cohort B Arm/Group Description: 750mg lapatinib administered orally twice daily  Cohort B subjects had ECOG performance status 2 and/or more than 2 prior trastuzumab-containing regimens for treatment of breast cancer in the adjuvant and/or metastatic settings  Overall Number of Participants Analyzed: 143 Measure Type: Count of Participants Unit of Measure: Participants Complete response (CR): 0 0.0% Partial response (PR): 9 6.3% ",
        "premise_nums": [
            "2 and/or more",
            "2 prior trastuzumab",
            "0 0.0%Partial response",
            "8 8.5% Results 2",
            "6 6.4% Stable disease",
            "40 42.6% Progressive disease",
            "42.6% Unknown",
            "143 Measure Type:",
            "0 0.0% Partial response"
        ]
    },
    {
        "id": "4dc22366-3ff3-41c8-aa4c-7342d7b7085d",
        "primaryId": "NCT00263588",
        "statement_text": "The majority of the primary trial subjects either had Progressive disease or undetermined CNS objective response rate ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Stable disease (SD): 46 32.2%Progressive disease (PD): 70 49.0% Unknown: 18 12.6% ",
        "premise_nums": [
            "46 32.2%Progressive disease",
            "49.0% Unknown"
        ]
    },
    {
        "id": "196c2132-c735-4b79-bf03-3a830fcaf0fc",
        "primaryId": "NCT00645333",
        "secondaryId": "NCT00006110",
        "label": "Contradiction",
        "statement_text": "the primary trial records several central nervous system related adverse events in its patients  whereas the secondary trial does not ",
        "statement_nums": [],
        "premise_text": "Autoimmune disorder *1/30 (3.33%) Immune system disorder *1/30 (3.33%) Adverse Events 1: Total: 7/52 (13.46%) Febrile neutropenia (fever of unknown origin without clinically or microbiologically documented infe * 0/52 (0.00%) Atrial Fibrillation * 1/52 (1.92%) Sepsis * 1/52 (1.92%) Muscle weakness upper limb * 1/52 (1.92%) Dizziness * 1/52 (1.92%) Seizure * 1/52 (1.92%) Nervous system disorders - Other  specify * [1]1/52 (1.92%) ",
        "premise_nums": [
            "1/52 (1.92%)",
            "1/30 (3.33%)",
            "7/52 (13.46%)",
            "0/52 (0.00%)"
        ]
    },
    {
        "id": "72619b0a-57c2-465c-8428-72019b59f8ae",
        "primaryId": "NCT02924883",
        "statement_text": "In the primary trial  all cases of Enteritis  Vertigo and Cardiac failure occurred in cohort 2.",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 52/133 (39.10%) Thrombocytopenia 2/133 (1.50%) Anaemia 1/133 (0.75%) Disseminated intravascular coagulation 0/133 (0.00%) Atrial thrombosis 1/133 (0.75%) Cardiac failure 0/133 (0.00%) Vertigo 0/133 (0.00%) Vomiting 3/133 (2.26%) Nausea 1/133 (0.75%) Colitis 1/133 (0.75%) Constipation 1/133 (0.75%) Enteritis 0/133 (0.00%) Abdominal pain 0/133 (0.00%) Adverse Events 2: ",
        "premise_nums": [
            "0/133 (0.00%)",
            "52/133 (39.10%)",
            "2/133 (1.50%)",
            "3/133 (2.26%)",
            "1/133 (0.75%)"
        ]
    },
    {
        "id": "72619b0a-57c2-465c-8428-72019b59f8ae",
        "primaryId": "NCT02924883",
        "statement_text": "In the primary trial  all cases of Enteritis  Vertigo and Cardiac failure occurred in cohort 2.",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Total: 16/67 (23.88%)Thrombocytopenia 0/67 (0.00%) Anaemia 0/67 (0.00%) Disseminated intravascular coagulation 1/67 (1.49%) Atrial thrombosis 0/67 (0.00%) Cardiac failure 1/67 (1.49%) Vertigo 1/67 (1.49%) Vomiting 0/67 (0.00%) Nausea 1/67 (1.49%) Colitis 0/67 (0.00%) Constipation 0/67 (0.00%) Enteritis 1/67 (1.49%) Abdominal pain 2/67 (2.99%) ",
        "premise_nums": [
            "2/67 (2.99%)",
            "1/67 (1.49%)",
            "0/67 (0.00%)",
            "16/67 (23.88%)Thrombocytopenia"
        ]
    },
    {
        "id": "b8663fa7-585a-4cd9-afd2-89e8e1a58b82",
        "primaryId": "NCT02732119",
        "statement_text": "Mark complained he had a racing heart twice in the last month and he is therefore excluded from the primary trial ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Exclusion Criteria: Clinically significant  uncontrolled heart disease and/or recent cardiac events  ",
        "premise_nums": []
    },
    {
        "id": "7c92d075-ba9d-45b5-9834-83b09d2753bc",
        "primaryId": "NCT02536794",
        "secondaryId": "NCT00712985",
        "label": "Entailment",
        "statement_text": "the primary trial and the secondary trial both administer treatments to their patients through IV ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Treatment (MEDI4736, Tremelimumab) Patients receive anti-B7H1 monoclonal antibody MEDI4736 IV over 1 hour and tremelimumab IV over 1 hour on day 1. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity  Four weeks after the last combination dose  patients continue to receive anti-B7H1 monoclonal antibody MEDI4736 every 2 weeks for up to 18 additional doses in the absence of disease progression or unacceptable toxicity  Patients achieving PD or clinical benefit (CR  PR  or SD) may be retreated with anti-B7H1 monoclonal antibody MEDI4736 for an additional 52 weeks  Anti-B7H1 Monoclonal Antibody MEDI4736: Given IV ",
        "premise_nums": [
            "MEDI4736 for",
            "1 monoclonal antibody",
            "18 additional doses",
            "2 weeks for",
            "1 hour and",
            "4736 for an",
            "MEDI4736 IV",
            "4736 every 2",
            "1 Monoclonal Antibody",
            "1 hour on",
            "4 courses in",
            "MEDI4736 every",
            "4736 IV over",
            "28 days for"
        ]
    },
    {
        "id": "7c92d075-ba9d-45b5-9834-83b09d2753bc",
        "primaryId": "NCT02536794",
        "secondaryId": "NCT00712985",
        "label": "Entailment",
        "statement_text": "the primary trial and the secondary trial both administer treatments to their patients through IV ",
        "statement_nums": [],
        "premise_text": "Laboratory Biomarker Analysis: Correlative studiesPharmacological Study: Correlative studies Tremelimumab: Given IV INTERVENTION 1: Zoledronic Acid 5 mg IV Zometa (Zoledronic Acid) 5 mg IV given over 15 minutes as a one time dose  Follow-up at month 1 & every 2 months to month 12 for serum & urine markers of bone destruction (NTx & CTx)  ",
        "premise_nums": [
            "2 months to",
            "12 for serum",
            "5 mg IV",
            "15 minutes as"
        ]
    },
    {
        "id": "0e8d1b4f-d6f6-455a-a7e3-07f67a8fbcc8",
        "primaryId": "NCT00411788",
        "statement_text": "If Hannah has been taking ketoconazole to treat athlete's foot for 6 weeks  until today  she will be eligible for the primary trial next Tuesday ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Exclusion Criteria: Use of any of these medications within 4 weeks; cyclosporine  diltiazen  ketoconazole  rifampin  fluconazole  delavirdine  nicardipine  pioglitazone  and sulfonamides  erythromycin  clarithromycin  itraconazole  erythromycin  metoclopramide  nevirapine  phenobarbital  phenytoin  indinavir  fosamprenavir  nefazadone  St Johns Wort  ",
        "premise_nums": []
    },
    {
        "id": "9a346aac-46c2-4a50-8f3a-309b3b7bc295",
        "primaryId": "NCT00382785",
        "secondaryId": "NCT00784849",
        "label": "Contradiction",
        "statement_text": "Neither the primary trial or the secondary trial use Low Dose Magnesium Oxide  Biopsies or Mometasone in their intervention ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Moderated Group one 12-week online support group led by a professional healthcare provider INTERVENTION 2: Non-facilitated (Peer-led) 12-week online support in a peer-led format INTERVENTION 1: Sentinel Lymph Node Biopsy With Radiolabeled Methylene Blue One arm diagnostic using 1 mCi of 125-I Methylene blue dye to find sentinel lymph nodes ",
        "premise_nums": [
            "1 mCi of",
            "12-week online",
            "125-I Methylene"
        ]
    },
    {
        "id": "949d79e0-95db-47a2-802a-6280c0255923",
        "primaryId": "NCT02132949",
        "secondaryId": "NCT01111825",
        "label": "Entailment",
        "statement_text": "Between both of the patient cohorts of the primary trial and the secondary trial there was only a single patient with a deficiency of granulocytes in the blood ",
        "statement_nums": [],
        "premise_text": "Adverse Events 1: Total: 56/199 (28.14%) AGRANULOCYTOSIS 1/199 (0.50%) ANAEMIA 1/199 (0.50%) BONE MARROW FAILURE 1/199 (0.50%) FEBRILE NEUTROPENIA 11/199 (5.53%) LEUKOPENIA 1/199 (0.50%) NEUTROPENIA 1/199 (0.50%) PANCYTOPENIA 1/199 (0.50%) ACUTE MYOCARDIAL INFARCTION 1/199 (0.50%) ATRIAL FLUTTER 1/199 (0.50%) ATRIAL THROMBOSIS 0/199 (0.00%) ",
        "premise_nums": [
            "1/199 (0.50%)",
            "56/199 (28.14%)",
            "11/199 (5.53%)",
            "0/199 (0.00%)"
        ]
    },
    {
        "id": "949d79e0-95db-47a2-802a-6280c0255923",
        "primaryId": "NCT02132949",
        "secondaryId": "NCT01111825",
        "label": "Entailment",
        "statement_text": "Between both of the patient cohorts of the primary trial and the secondary trial there was only a single patient with a deficiency of granulocytes in the blood ",
        "statement_nums": [],
        "premise_text": "CARDIAC FAILURE 3/199 (1.51%)Adverse Events 2: Total: 66/198 (33.33%) AGRANULOCYTOSIS 0/198 (0.00%) ANAEMIA 0/198 (0.00%) BONE MARROW FAILURE 0/198 (0.00%) FEBRILE NEUTROPENIA 27/198 (13.64%) LEUKOPENIA 0/198 (0.00%) NEUTROPENIA 2/198 (1.01%) PANCYTOPENIA 1/198 (0.51%) ACUTE MYOCARDIAL INFARCTION 0/198 (0.00%) ATRIAL FLUTTER 0/198 (0.00%) ",
        "premise_nums": [
            "0/198 (0.00%)",
            "1/198 (0.51%)",
            "66/198 (33.33%)",
            "3/199 (1.51%)Adverse",
            "27/198 (13.64%)",
            "2/198 (1.01%)"
        ]
    },
    {
        "id": "949d79e0-95db-47a2-802a-6280c0255923",
        "primaryId": "NCT02132949",
        "secondaryId": "NCT01111825",
        "label": "Entailment",
        "statement_text": "Between both of the patient cohorts of the primary trial and the secondary trial there was only a single patient with a deficiency of granulocytes in the blood ",
        "statement_nums": [],
        "premise_text": "ATRIAL THROMBOSIS 1/198 (0.51%)CARDIAC FAILURE 4/198 (2.02%) Adverse Events 1: Total: 3/8 (37.50%) Anaemia 0/8 (0.00%) Febrile neutropenia 0/8 (0.00%) Polycythaemia 0/8 (0.00%) Acute coronary syndrome 0/8 (0.00%) Vertigo 0/8 (0.00%) Eyelid oedema 1/8 (12.50%) Constipation 0/8 (0.00%) Diarrhoea 0/8 (0.00%) Nausea 0/8 (0.00%) ",
        "premise_nums": [
            "1/8 (12.50%)",
            "3/8 (37.50%)",
            "0/8 (0.00%)",
            "1/198 (0.51%)CARDIAC",
            "4/198 (2.02%)"
        ]
    },
    {
        "id": "949d79e0-95db-47a2-802a-6280c0255923",
        "primaryId": "NCT02132949",
        "secondaryId": "NCT01111825",
        "label": "Entailment",
        "statement_text": "Between both of the patient cohorts of the primary trial and the secondary trial there was only a single patient with a deficiency of granulocytes in the blood ",
        "statement_nums": [],
        "premise_text": "Stomatitis 0/8 (0.00%)Upper gastrointestinal haemorrhage 0/8 (0.00%) Vomiting 0/8 (0.00%) Chest pain 0/8 (0.00%) Adverse Events 2: Total: 2/6 (33.33%) Anaemia 0/6 (0.00%) Febrile neutropenia 0/6 (0.00%) Polycythaemia 0/6 (0.00%) Acute coronary syndrome 0/6 (0.00%) Vertigo 0/6 (0.00%) Eyelid oedema 0/6 (0.00%) ",
        "premise_nums": [
            "2/6 (33.33%)",
            "0/8 (0.00%)Upper",
            "0/6 (0.00%)"
        ]
    },
    {
        "id": "949d79e0-95db-47a2-802a-6280c0255923",
        "primaryId": "NCT02132949",
        "secondaryId": "NCT01111825",
        "label": "Entailment",
        "statement_text": "Between both of the patient cohorts of the primary trial and the secondary trial there was only a single patient with a deficiency of granulocytes in the blood ",
        "statement_nums": [],
        "premise_text": "Constipation 0/6 (0.00%)Diarrhoea 0/6 (0.00%) Nausea 0/6 (0.00%) Stomatitis 0/6 (0.00%) Upper gastrointestinal haemorrhage 0/6 (0.00%) Vomiting 0/6 (0.00%) Chest pain 1/6 (16.67%) ",
        "premise_nums": [
            "1/6 (16.67%)",
            "0/6 (0.00%)Diarrhoea"
        ]
    },
    {
        "id": "6e080a1e-a03e-4547-a7c4-c9d5a80de977",
        "primaryId": "NCT01325207",
        "secondaryId": "NCT02429427",
        "label": "Contradiction",
        "statement_text": "Patients participating in the primary trial and the secondary trial experienced serious eye disorders ",
        "statement_nums": [],
        "premise_text": "Adverse Events 1: Total: 1/3 (33.33%) Pericardial effusion [1]0/3 (0.00%) Abdominal muscle wall hemorrhage [2]0/3 (0.00%) Dehydration [3]0/3 (0.00%) Gastroenteritis 0/3 (0.00%) Dehydration 0/3 (0.00%) Vomiting [4]0/3 (0.00%) Colonic perforation [5]0/3 (0.00%) Abdominal pain 0/3 (0.00%) Chemical meningitis 0/3 (0.00%) Lung infection 0/3 (0.00%) Wound infection 0/3 (0.00%) Adverse Events 2: ",
        "premise_nums": [
            "0/3 (0.00%)",
            "1/3 (33.33%)"
        ]
    },
    {
        "id": "6e080a1e-a03e-4547-a7c4-c9d5a80de977",
        "primaryId": "NCT01325207",
        "secondaryId": "NCT02429427",
        "label": "Contradiction",
        "statement_text": "Patients participating in the primary trial and the secondary trial experienced serious eye disorders ",
        "statement_nums": [],
        "premise_text": "Total: 2/3 (66.67%)Pericardial effusion [1]0/3 (0.00%) Abdominal muscle wall hemorrhage [2]0/3 (0.00%) Dehydration [3]0/3 (0.00%) Gastroenteritis 0/3 (0.00%) Dehydration 0/3 (0.00%) Vomiting [4]0/3 (0.00%) Colonic perforation [5]0/3 (0.00%) Abdominal pain 0/3 (0.00%) Chemical meningitis 0/3 (0.00%) Lung infection 0/3 (0.00%) Wound infection 1/3 (33.33%) Adverse Events 1: ",
        "premise_nums": [
            "1/3 (33.33%)",
            "0/3 (0.00%)",
            "2/3 (66.67%)Pericardial"
        ]
    },
    {
        "id": "6e080a1e-a03e-4547-a7c4-c9d5a80de977",
        "primaryId": "NCT01325207",
        "secondaryId": "NCT02429427",
        "label": "Contradiction",
        "statement_text": "Patients participating in the primary trial and the secondary trial experienced serious eye disorders ",
        "statement_nums": [],
        "premise_text": "Total: 148/1755 (8.43%)Anaemia * 1/1755 (0.06%) Neutropenia * 0/1755 (0.00%) Thrombocytopenia * 0/1755 (0.00%) Thrombocytopenic purpura * 1/1755 (0.06%) Acute cardiac event * 1/1755 (0.06%) Aortic valve incompetence * 1/1755 (0.06%) Arrhythmia * 1/1755 (0.06%) Atrial fibrillation * 1/1755 (0.06%) Cardiac failure * 0/1755 (0.00%) Cardiac tamponade * 0/1755 (0.00%) Adverse Events 2: Total: 64/868 (7.37%) ",
        "premise_nums": [
            "1/1755 (0.06%)",
            "64/868 (7.37%)",
            "148/1755 (8.43%)Anaemia",
            "0/1755 (0.00%)"
        ]
    },
    {
        "id": "6e080a1e-a03e-4547-a7c4-c9d5a80de977",
        "primaryId": "NCT01325207",
        "secondaryId": "NCT02429427",
        "label": "Contradiction",
        "statement_text": "Patients participating in the primary trial and the secondary trial experienced serious eye disorders ",
        "statement_nums": [],
        "premise_text": "Anaemia * 2/868 (0.23%)Neutropenia * 2/868 (0.23%) Thrombocytopenia * 1/868 (0.12%) Thrombocytopenic purpura * 0/868 (0.00%) Acute cardiac event * 0/868 (0.00%) Aortic valve incompetence * 0/868 (0.00%) Arrhythmia * 1/868 (0.12%) Atrial fibrillation * 0/868 (0.00%) Cardiac failure * 1/868 (0.12%) Cardiac tamponade * 1/868 (0.12%) ",
        "premise_nums": [
            "0/868 (0.00%)",
            "2/868 (0.23%)Neutropenia",
            "1/868 (0.12%)"
        ]
    },
    {
        "id": "63218fb2-3f5b-4738-bea8-11fbbc560949",
        "primaryId": "NCT01730729",
        "statement_text": "Patients with severe malabsorption disorders are ineligible for the primary trial  unless they are able to receive intravenous (IV) alimentation ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Patients with any of the following conditions or complications are NOT eligible for participation: Require intravenous (IV) alimentation Malabsorption syndrome ",
        "premise_nums": []
    },
    {
        "id": "d7fa4f81-e108-491f-9b08-c147a33863e8",
        "primaryId": "NCT01953003",
        "statement_text": "Patients receiving intervention 1 of the primary trial  will be administered medication orally and intraveinously ",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "INTERVENTION 1: Arm A : iv Vinflunine Plus Capecitabine Vinflunine dose 280 mg/m² on day 1 of each cycle every 3 weeks  Capecitabine 825 mg/m² twice daily orally for 14 consecutive days beginning on day 1 of each cycle followed by 1 week of rest  vinflunine: intraveinous administration day 1 once every 3 weeks  280 mg/m² Capecitabine: Arm A : 1650 mg/m² Arm B : 2500 mg/m² INTERVENTION 2: Arm B : Capecitabine 1250 mg/m² twice daily orally for 14 consecutive days beginning on day 1 of each cycle followed by 1 week of rest Capecitabine: Arm A : 1650 mg/m² Arm B : 2500 mg/m² ",
        "premise_nums": [
            "1 once every",
            "1 week of",
            "1 of each",
            "825 mg/m²",
            "2500 mg/m²",
            "14 consecutive days",
            "1650 mg/m²",
            "1250 mg/m²",
            "280 mg/m²"
        ]
    },
    {
        "id": "f24afb09-ea65-457f-9f9b-0db3cc3101ac",
        "primaryId": "NCT00849472",
        "statement_text": "Two dozen the primary trial participants are classified as having Pathologic Complete Response (pCR) in the Breast and Nodes ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Number of Participants With Pathologic Complete Response (pCR) in the Breast and Nodes pCR was defined as no histologic evidence of invasive tumor cells in the surgical breast specimen  axillary nodes  or sentinel node identified after neoadjuvant chemotherapy  Time frame: From the start of the study until the time of surgery (average of 221.9 days [standard deviation of 23.65 days] after study entry) Results 1: Arm/Group Title: AC  Followed by Weekly Paclitaxel and Concurrent Pazopanib ",
        "premise_nums": [
            "9 days [standard"
        ]
    },
    {
        "id": "f24afb09-ea65-457f-9f9b-0db3cc3101ac",
        "primaryId": "NCT00849472",
        "statement_text": "Two dozen the primary trial participants are classified as having Pathologic Complete Response (pCR) in the Breast and Nodes ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Arm/Group Description: Participants were treated with intravenous (IV) doxorubicin (60 milligrams per meters squared [mg/m^2]) and cyclophosphamide (AC) (600 mg/m^2) every 21 days for 4 cycles  This was followed by weekly paclitaxel (WP) 80 mg/m^2 IV on Days 1, 8, and 15 every 28 days for 4 cycles given concurrently with oral pazopanib 800 mg (2 tablets taken at the same time each day  either 1 hour before or 2 hours after a meal) taken daily and continuing until 7 days before surgery  Pazopanib was resumed at the same oral dose 4-6 weeks after surgery and was continued daily for 6 months ",
        "premise_nums": [
            "21 days for",
            "800 mg (2",
            "2 hours after",
            "80 mg/m^2",
            "1 hour before",
            "6 weeks after",
            "60 milligrams per",
            "4-6 weeks",
            "7 days before",
            "4 cycles given",
            "2 IV on",
            "15 every 28"
        ]
    },
    {
        "id": "f24afb09-ea65-457f-9f9b-0db3cc3101ac",
        "primaryId": "NCT00849472",
        "statement_text": "Two dozen the primary trial participants are classified as having Pathologic Complete Response (pCR) in the Breast and Nodes ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Overall Number of Participants Analyzed: 93Measure Type: Number Unit of Measure: Participants 16 ",
        "premise_nums": []
    },
    {
        "id": "3cd79df2-e6dd-41dd-b819-4d993b5f7aed",
        "primaryId": "NCT00403130",
        "statement_text": "There were no cases of Leukopenia  Epitasis or Arrhythmia observed in patients participating in the primary trial ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 18/26 (69.23%) Thrombocytopenia * 4/26 (15.38%) Neutropenia * 3/26 (11.54%) Epitasis * 1/26 (3.85%) Peripheral arterial ischemia * 1/26 (3.85%) Thrombosis * [1]1/26 (3.85%) Weakness * 1/26 (3.85%) Pain * [2]2/26 (7.69%) Febrile neutropenia * 1/26 (3.85%) Aspartate Aminotransferase * [3]1/26 (3.85%) Syncope * 1/26 (3.85%) ",
        "premise_nums": [
            "4/26 (15.38%)",
            "2/26 (7.69%)",
            "3/26 (11.54%)",
            "18/26 (69.23%)",
            "1/26 (3.85%)"
        ]
    },
    {
        "id": "d2d6f646-5881-42a2-b965-0c6f79e89463",
        "primaryId": "NCT00090857",
        "statement_text": "Candidates for the primary trial must have a bone density scan 1 month prior to study entry  if the results from this are more than 2 standard deviations below normal  the study physician can still decide to let them participate ",
        "statement_nums": [
            "2 standard deviations",
            "1 month prior"
        ],
        "label": "Entailment",
        "premise_text": "Bone density scan within 2 standard deviations from normal within the past 30 days Bone density scan 2 standard deviations below normal allowed if approved by the study physician ",
        "premise_nums": [
            "30 days Bone",
            "2 standard deviations"
        ]
    },
    {
        "id": "428d5165-560b-4783-8c4b-5fd3a3289cab",
        "primaryId": "NCT00022672",
        "statement_text": "There were no patients in either cohort of the primary trial with a PFS exceeding one year ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Progression Free Survival (PFS) ",
        "premise_nums": []
    },
    {
        "id": "6e7df2e4-11b3-4183-aefc-760f85809515",
        "primaryId": "NCT02536794",
        "secondaryId": "NCT00712985",
        "label": "Contradiction",
        "statement_text": "the primary trial and the secondary trial both administer Zometa to their patients through IV  although in different doses ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Treatment (MEDI4736, Tremelimumab) Patients receive anti-B7H1 monoclonal antibody MEDI4736 IV over 1 hour and tremelimumab IV over 1 hour on day 1. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity  Four weeks after the last combination dose  patients continue to receive anti-B7H1 monoclonal antibody MEDI4736 every 2 weeks for up to 18 additional doses in the absence of disease progression or unacceptable toxicity  Patients achieving PD or clinical benefit (CR  PR  or SD) may be retreated with anti-B7H1 monoclonal antibody MEDI4736 for an additional 52 weeks  ",
        "premise_nums": [
            "MEDI4736 for",
            "1 monoclonal antibody",
            "18 additional doses",
            "2 weeks for",
            "1 hour and",
            "4736 for an",
            "MEDI4736 IV",
            "4736 every 2",
            "1 hour on",
            "4 courses in",
            "MEDI4736 every",
            "4736 IV over",
            "28 days for"
        ]
    },
    {
        "id": "6e7df2e4-11b3-4183-aefc-760f85809515",
        "primaryId": "NCT02536794",
        "secondaryId": "NCT00712985",
        "label": "Contradiction",
        "statement_text": "the primary trial and the secondary trial both administer Zometa to their patients through IV  although in different doses ",
        "statement_nums": [],
        "premise_text": "Anti-B7H1 Monoclonal Antibody MEDI4736: Given IVLaboratory Biomarker Analysis: Correlative studies Pharmacological Study: Correlative studies Tremelimumab: Given IV INTERVENTION 1: Zoledronic Acid 5 mg IV Zometa (Zoledronic Acid) 5 mg IV given over 15 minutes as a one time dose  Follow-up at month 1 & every 2 months to month 12 for serum & urine markers of bone destruction (NTx & CTx)  ",
        "premise_nums": [
            "12 for serum",
            "5 mg IV",
            "2 months to",
            "15 minutes as",
            "1 Monoclonal Antibody"
        ]
    },
    {
        "id": "45e6b4b6-ca31-4318-936e-5b27cbca47a2",
        "primaryId": "NCT01439711",
        "statement_text": "One patient in the primary trial had a 2.87 cm3 decrease in Total MRI Functional Tumor Volume (FTV) over 3 months ",
        "statement_nums": [
            "3 decrease in"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Mean Total MRI Functional Tumor Volume (FTV) Change From Baseline to Month 3 (V3) Mean total MRI FTV change from baseline to month 3 (V3): For patients with more than one measureable lesion on the MRI  the sum over all measureable lesions on the MRI was calculated at each time point  V3 was calculated by subtracting the total MRI FTV measured (i.e  the sum over all lesions present with MRI FTV measurements) at 3 months from the total MRI FTV measured at baseline  For V3 the raw change in the volume will be calculated for each patient and a mean and 95% confidence interval will be constructed using two-sided t-tests  Time frame: up to 3 months from start of treatment Results 1: ",
        "premise_nums": [
            "3 months from",
            "(V3) Mean",
            "3 was calculated",
            "95% confidence",
            "3 the raw"
        ]
    },
    {
        "id": "45e6b4b6-ca31-4318-936e-5b27cbca47a2",
        "primaryId": "NCT01439711",
        "statement_text": "One patient in the primary trial had a 2.87 cm3 decrease in Total MRI Functional Tumor Volume (FTV) over 3 months ",
        "statement_nums": [
            "3 decrease in"
        ],
        "label": "Entailment",
        "premise_text": "Arm/Group Title: Letrozole + MRIArm/Group Description: Protocol Therapy will consist of 6 months of letrozole  administered orally at a dose of 2.5 mg/day  Patients will have a bilateral MRI for disease evaluation at months 3 and 6. Overall Number of Participants Analyzed: 68 Mean (95% Confidence Interval) Unit of Measure: cubic centimeters -1.93 (-2.87 to -0.98) ",
        "premise_nums": [
            "of 2.5 mg/day",
            "6 months of",
            "95% Confidence",
            "3 and 6."
        ]
    },
    {
        "id": "22a6d10e-55c5-4a8c-8010-3e8252bcb279",
        "primaryId": "NCT00458237",
        "statement_text": "Patient who have recently undergone External beam radiation therapy are eligible for the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Inclusion Criteria: Patients may have received prior radiation therapy ",
        "premise_nums": []
    },
    {
        "id": "7fd1ae1e-bfdb-4c37-aaea-ed97663758e3",
        "primaryId": "NCT00593346",
        "secondaryId": "NCT00902330",
        "label": "Contradiction",
        "statement_text": "the primary trial treament last for a shorter period of time than the secondary trial treatment  but is administered much more often ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Accelerated Partial Breast Brachytherapy Each patient will receive accelerated partial breast brachytherapy with multiple plane implant  Patients will receive 3400 cGy delivered in 10 twice-daily fractions  Treatment is to be given over 5-7 days with a minimum of 6 hours separation between fractions  INTERVENTION 1: Arm I (Cranial Microcurrent Electrical Stimulation [CES]) ",
        "premise_nums": [
            "7 days with",
            "10 twice-daily fractions",
            "5-7 days",
            "3400 cGy delivered",
            "6 hours separation"
        ]
    },
    {
        "id": "7fd1ae1e-bfdb-4c37-aaea-ed97663758e3",
        "primaryId": "NCT00593346",
        "secondaryId": "NCT00902330",
        "label": "Contradiction",
        "statement_text": "the primary trial treament last for a shorter period of time than the secondary trial treatment  but is administered much more often ",
        "statement_nums": [],
        "premise_text": "Patients receive a CES unit (Alpha-Stim® 100 Microcurrent Stimulator) that passes microcurrent levels of biphasic electrical stimulation via ear-lobe electrodes  The CES unit is preset to provide 1 hour of 100 μA (sub-sensory level)  modified square-wave biphasic stimulation on a 50% duty cycle at .05 Hz  and to automatically turn off at the end of 1 hour  Patients use their CES unit once daily in weeks 1-18.energy-based therapy: Given once a day for 18 weeks ",
        "premise_nums": [
            "1 hour of",
            "100 Microcurrent Stimulator)",
            "50% duty",
            "1-18.energy-based therapy:"
        ]
    },
    {
        "id": "50d119f6-a657-4619-918e-7617ac57f052",
        "primaryId": "NCT03078751",
        "statement_text": "Cohort 1 of the primary trial reported one case of AML ",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 4/26 (15.38%) Disseminated intravascular coagulation 1/26 (3.85%) Cardiac failure congestive 1/26 (3.85%) Breast cellulitis 1/26 (3.85%) Cellulitis 1/26 (3.85%) Acute myeloid leukaemia 1/26 (3.85%) Seizure 0/26 (0.00%) Pulmonary embolism 1/26 (3.85%) ",
        "premise_nums": [
            "4/26 (15.38%)",
            "0/26 (0.00%)",
            "1/26 (3.85%)"
        ]
    },
    {
        "id": "e436827b-10db-4179-bf8f-07786ee6145b",
        "primaryId": "NCT01009918",
        "statement_text": "There are no racial criteria for entry into the primary trial  however there are gender criteria ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "INCLUSION CRITERIA Males and Females 18 years old diagnosed with HER2 positive breast cancer Scheduled to receive neoadjuvant or adjuvant trastuzumab (Herceptin®) therapy (anthracycline-containing regimens are permitted)  Patients receiving Herceptin® with their chemotherapy are permitted for eligibility work-up  Taxanes are permitted  Trastuzumab (Herceptin®) therapy may be given with or after primary chemotherapy  Pertuzumab may be used in conjunction with trastuzumab  Left Ventricular Ejection Fraction (LVEF) 50% by MUGA scan or echocardiogram Adequate renal function for administration of trastuzumab-containing chemotherapy regimen  Sitting systolic blood pressure of greater than 90 mm Hg Pulse 60 beats/minute ",
        "premise_nums": [
            "2 positive breast",
            "90 mm Hg",
            "60 beats/minute",
            "18 years old",
            "50% by"
        ]
    },
    {
        "id": "e436827b-10db-4179-bf8f-07786ee6145b",
        "primaryId": "NCT01009918",
        "statement_text": "There are no racial criteria for entry into the primary trial  however there are gender criteria ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Not pregnant or breastfeedingFemale patients of childbearing potential  who are sexually active  must have a negative pregnancy test before starting the study Both men and women must be willing to use effective contraception during the study  Teratogenicity is documented for both active study agents Able to swallow capsules EXCLUSION CRITERIA: Patients with metastatic disease Prior treatment with trastuzumab or anthracyclines prior to this chemotherapy regimen Current treatment with angiotensin converting enzyme (ACE) inhibitors  angiotensin receptor blockers (ARBs)  such as losartan  β-blockers or digoxin Known cardiac history: heart failure  myocardial infarction  radiation-induced cardiac dysfunction Known allergy to either ACE inhibitors or β-blockers ",
        "premise_nums": []
    },
    {
        "id": "e436827b-10db-4179-bf8f-07786ee6145b",
        "primaryId": "NCT01009918",
        "statement_text": "There are no racial criteria for entry into the primary trial  however there are gender criteria ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "History of bronchial asthma or related bronchospastic conditionsHereditary or idiopathic angioedema History of severe hypersensitivity reactions to drugs or other causes  i.e  bee stings This protocol does not exclude patients who are participating on other investigational studies  Refer to the local IRB guidelines  ",
        "premise_nums": []
    },
    {
        "id": "fcc6708a-b0fc-4215-a45f-02b1e0e2d30a",
        "primaryId": "NCT00631852",
        "statement_text": "Patients with hemophilia are excluded from the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Exclusion Criteria: active bleeding or a pathological condition that carries a high risk of bleeding ",
        "premise_nums": []
    },
    {
        "id": "d63706f1-4fb8-488d-8f86-c1a19df341d4",
        "primaryId": "NCT00944047",
        "secondaryId": "NCT00228943",
        "label": "Entailment",
        "statement_text": "Patients with tumors underexpressing HER2 are excluded from the primary trial  but may be included in the secondary trial ",
        "statement_nums": [
            "2 are excluded"
        ],
        "premise_text": "Inclusion Criteria: HER-2/neu 1+ or 2+ by immunohistochemistry Inclusion Criteria: At least 18 years of age Willing and able to provide informed consent Reporting daily hot flashes Able to read  write  and speak English Postmenopausal to limit sample variability (greater than 12 months amenorrhea) Greater then 1 month but smaller than 5 years post-treatment (surgery  radiation  chemotherapy) for non-metastatic breast cancer  These criteria allow inclusion of women successfully treated for recurrent breast cancer since there is no known reason to exclude them  Menopausal status is assessed using self-reports due to problems in reliably measuring follicle-stimulating hormone levels and estradiol in tamoxifen users  Exclusion Criteria: ",
        "premise_nums": [
            "1 month but",
            "12 months amenorrhea)",
            "5 years post",
            "2/neu 1+",
            "18 years of"
        ]
    },
    {
        "id": "d63706f1-4fb8-488d-8f86-c1a19df341d4",
        "primaryId": "NCT00944047",
        "secondaryId": "NCT00228943",
        "label": "Entailment",
        "statement_text": "Patients with tumors underexpressing HER2 are excluded from the primary trial  but may be included in the secondary trial ",
        "statement_nums": [
            "2 are excluded"
        ],
        "premise_text": "Exclusion criteria are current depression  history of migraines or hepatitis  abnormal chemistry profile (e.g.  sodium  potassium  glucose)  or a positive urine drug screen for illegal substances ",
        "premise_nums": []
    },
    {
        "id": "ab357056-67a7-4227-966d-8c96eb1640fd",
        "primaryId": "NCT02694029",
        "statement_text": "Candidates for the primary trial are expected to be capable of holding their breath for half a minute ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Inclusion Criteria: Patient must be able to maintain a 30 second breath hold  ",
        "premise_nums": [
            "30 second breath"
        ]
    },
    {
        "id": "0359eef3-6339-485e-95bc-0cb6fa7bcd12",
        "primaryId": "NCT00635050",
        "statement_text": "Patients with Breast cancers that have estrogen receptors are excluded from the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Inclusion Criteria: Patients with node-negative  ER or PR-positive tumors 4 cm in size whose tumors are low risk (defined as a score of 0-17) on an Oncotype DX profile are not eligible  ",
        "premise_nums": [
            "0-17) on",
            "4 cm in"
        ]
    },
    {
        "id": "57ef3c6c-b4e1-4302-b423-aa9faca21200",
        "primaryId": "NCT00791037",
        "secondaryId": "NCT00606931",
        "label": "Entailment",
        "statement_text": "the primary trial and the secondary trial do not use the same route of administration for their interventions ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Treatment (Vaccine Therapy+ex Vivo-expanded T Cells) Patients receive HER2/neu peptide vaccine admixed with sargramostim (GM-CSF) ID on days 1, 8, and 15. Beginning 2 weeks later  patients undergo leukapheresis to isolate and collect peripheral blood mononuclear cells for T-cell expansion  Patients receive cyclophosphamide IV once on day -1 and autologous ex vivo-expanded HER2-specific T cell IV over 30 minutes on day 1. Treatment repeats every 7-10 days for up to three immunizations  Patients receive a booster HER2/neu peptide vaccine 1 month after the final T-cell infusion  followed by 2 additional booster vaccines at 2-month intervals  ",
        "premise_nums": [
            "2-month intervals",
            "1 month after",
            "1 and autologous",
            "30 minutes on",
            "2 weeks later",
            "2/neu peptide",
            "10 days for",
            "2 additional booster",
            "2-specific T",
            "7-10 days"
        ]
    },
    {
        "id": "57ef3c6c-b4e1-4302-b423-aa9faca21200",
        "primaryId": "NCT00791037",
        "secondaryId": "NCT00606931",
        "label": "Entailment",
        "statement_text": "the primary trial and the secondary trial do not use the same route of administration for their interventions ",
        "statement_nums": [],
        "premise_text": "HER-2/neu peptide vaccine: Given IDleukapheresis: Undergo leukapheresis ex vivo-expanded HER2-specific T cells: Given IV cyclophosphamide: Given IV sargramostim: Given ID laboratory biomarker analysis: Correlative study INTERVENTION 1: PET Guided Biopsy No comparison group  All enrolled participants were expected to undergo PET guided biopsy  ",
        "premise_nums": [
            "2-specific T",
            "2/neu peptide"
        ]
    },
    {
        "id": "29d5779b-c228-4b82-9ca8-075beadae879",
        "primaryId": "NCT00091442",
        "statement_text": "There were more cases of Febrile neutropenia than eukopenia observed in the primary trial  but less cases of Febrile neutropenia than Neutropenia ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Neutropenia 14/373 (3.75%) Febrile neutropenia 10/373 (2.68%) Leukopenia 1/373 (0.27%) ",
        "premise_nums": [
            "10/373 (2.68%)",
            "14/373 (3.75%)",
            "1/373 (0.27%)"
        ]
    },
    {
        "id": "4e124d90-68d7-40bd-a8b1-27cb49d64c64",
        "primaryId": "NCT00591864",
        "statement_text": "the primary trial patients receive Trametinib  Akt Inhibitor GSK2141795 PO QD on days 1-28, up to a maximum of 8 cycles ",
        "statement_nums": [
            "GSK2141795 PO",
            "1-28, up",
            "2141795 PO QD"
        ],
        "label": "Contradiction",
        "premise_text": "INTERVENTION 1: Study Participants There are no arms or subgroups in this study  ",
        "premise_nums": []
    },
    {
        "id": "0a9a7f5b-eb32-4a11-86e3-5a9a6377eea3",
        "primaryId": "NCT00291694",
        "statement_text": "the route of administration for both interventions in the primary trial is a topical skin cream ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "INTERVENTION 1: Celecoxib Randomized to receive celecoxib daily for 12 months INTERVENTION 2: Placebo Randomized to receive placebo daily for 12 months ",
        "premise_nums": [
            "12 months INTERVENTION"
        ]
    },
    {
        "id": "f4c7dae5-012f-4f05-b5ba-da072fe1359c",
        "primaryId": "NCT01674062",
        "statement_text": "One patient in the primary trial was observed suffering from Enteritis ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 12/66 (18.18%) Palpitations * 1/66 (1.52%) Haematemesis * 1/66 (1.52%) Performance status decreased * 1/66 (1.52%) Hepatic failure * 1/66 (1.52%) Cellulitis * 1/66 (1.52%) Device related infection * 1/66 (1.52%) Pneumonia * 1/66 (1.52%) Pneumonia pneumococcal * 1/66 (1.52%) Femur fracture * 0/66 (0.00%) Hypokalaemia * 1/66 (1.52%) Back pain * 2/66 (3.03%) ",
        "premise_nums": [
            "12/66 (18.18%)",
            "2/66 (3.03%)",
            "1/66 (1.52%)",
            "0/66 (0.00%)"
        ]
    },
    {
        "id": "927bbb75-37da-4b75-9483-252d31a0fd98",
        "primaryId": "NCT01067976",
        "secondaryId": "NCT00941330",
        "label": "Entailment",
        "statement_text": "Unlike the secondary trial  the primary trial does not provide a duration of cycles or any dosages in the intervention section ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: CMRM vs UMRM [Not Specified] INTERVENTION 1: A: Exemestane ARM A: Patients will be treated with exemestane  Exemestane: 25 mg daily by mouth for 6 to 12 months  INTERVENTION 2: B: Docetaxel and Cytoxan ARM B: Patients will be treated with docetaxel and cytoxan  Docetaxel: Docetaxel (75 mg/m²) into a vein once every 3 weeks for 6 cycles (6 times in about 24 weeks)  Cytoxan: Cytoxan (600 mg/m²) into a vein once every 3 weeks for 6 cycles (6 times in about 24 weeks)  ",
        "premise_nums": [
            "6 cycles (6",
            "25 mg daily",
            "3 weeks for",
            "6 to 12"
        ]
    },
    {
        "id": "80a5cdbc-0721-41b6-af1a-28e3f46557ce",
        "primaryId": "NCT01610284",
        "statement_text": "1 patient in the primary trial had a cardiac related adverse event ",
        "statement_nums": [
            "1 patient in"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 146/573 (25.48%) Anaemia 4/573 (0.70%) Disseminated intravascular coagulation 0/573 (0.00%) Neutropenia 1/573 (0.17%) Thrombocytopenia 0/573 (0.00%) Acute coronary syndrome 1/573 (0.17%) Angina pectoris 1/573 (0.17%) Atrial fibrillation 2/573 (0.35%) Atrial flutter 0/573 (0.00%) Cardiac arrest 1/573 (0.17%) Cardiac failure 0/573 (0.00%) Adverse Events 2: Total: 101/570 (17.72%) ",
        "premise_nums": [
            "0/573 (0.00%)",
            "1/573 (0.17%)",
            "146/573 (25.48%)",
            "2/573 (0.35%)",
            "101/570 (17.72%)",
            "4/573 (0.70%)"
        ]
    },
    {
        "id": "80a5cdbc-0721-41b6-af1a-28e3f46557ce",
        "primaryId": "NCT01610284",
        "statement_text": "1 patient in the primary trial had a cardiac related adverse event ",
        "statement_nums": [
            "1 patient in"
        ],
        "label": "Contradiction",
        "premise_text": "Anaemia 3/570 (0.53%)Disseminated intravascular coagulation 1/570 (0.18%) Neutropenia 1/570 (0.18%) Thrombocytopenia 1/570 (0.18%) Acute coronary syndrome 0/570 (0.00%) Angina pectoris 1/570 (0.18%) Atrial fibrillation 0/570 (0.00%) Atrial flutter 1/570 (0.18%) Cardiac arrest 0/570 (0.00%) Cardiac failure 1/570 (0.18%) ",
        "premise_nums": [
            "1/570 (0.18%)",
            "3/570 (0.53%)Disseminated",
            "0/570 (0.00%)"
        ]
    },
    {
        "id": "af710d36-8062-4412-8d11-1c57a14b5e5a",
        "primaryId": "NCT00217672",
        "secondaryId": "NCT00110084",
        "label": "Contradiction",
        "statement_text": "the primary trial had three times the occurence rate of fistula enterovesical as the secondary trial ",
        "statement_nums": [],
        "premise_text": "Adverse Events 1: fistula enterovesical 1/74 (1.35%) Adverse Events 1: Total: 11/50 (22.00%) Anemia 3/50 (6.00%) Febrile neutropenia 1/50 (2.00%) Arrythmia 1/50 (2.00%) Ileus 1/50 (2.00%) Nausea 1/50 (2.00%) Pain-Abdominal 1/50 (2.00%) Vomiting 1/50 (2.00%) Bronchial infection 1/50 (2.00%) Sepsis 1/50 (2.00%) Neutropenia 2/50 (4.00%) Platelet count decreased 1/50 (2.00%) ",
        "premise_nums": [
            "1/74 (1.35%)",
            "1/50 (2.00%)",
            "11/50 (22.00%)",
            "3/50 (6.00%)",
            "2/50 (4.00%)"
        ]
    },
    {
        "id": "af710d36-8062-4412-8d11-1c57a14b5e5a",
        "primaryId": "NCT00217672",
        "secondaryId": "NCT00110084",
        "label": "Contradiction",
        "statement_text": "the primary trial had three times the occurence rate of fistula enterovesical as the secondary trial ",
        "statement_nums": [],
        "premise_text": "Dehydration 1/50 (2.00%)Arthralgia 1/50 (2.00%) ",
        "premise_nums": [
            "1/50 (2.00%)Arthralgia"
        ]
    },
    {
        "id": "c91c7dc1-17b7-4475-9aec-38999a18a306",
        "primaryId": "NCT00717405",
        "statement_text": "There were several patients who contracted Pneumonia in the primary trial ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 20/52 (38.46%) Febrile bone marrow aplasia * 5/52 (9.62%) Febrile neutropenia * 6/52 (11.54%) Leukopenia * 6/52 (11.54%) Atrial tachycardia * 1/52 (1.92%) Vomiting * 1/52 (1.92%) Tooth loss * 1/52 (1.92%) Hyperthermia * 1/52 (1.92%) Malaise * 1/52 (1.92%) Pyrexia * 1/52 (1.92%) Impaired healing * 3/52 (5.77%) Inflammation * 1/52 (1.92%) ",
        "premise_nums": [
            "3/52 (5.77%)",
            "5/52 (9.62%)",
            "20/52 (38.46%)",
            "1/52 (1.92%)",
            "6/52 (11.54%)"
        ]
    },
    {
        "id": "5357ce66-7f7b-4ffd-926c-f6116f5a2e20",
        "primaryId": "NCT00243503",
        "secondaryId": "NCT00448279",
        "label": "Entailment",
        "statement_text": "the primary trial and the secondary trial observed a different number of adverse events in their patients ",
        "statement_nums": [],
        "premise_text": "Adverse Events 1: Total: 25/60 (41.67%) Anaemia * 1/60 (1.67%) Febrile neutropenia * 2/60 (3.33%) Idiopathic thrombocytopenic purpura * 1/60 (1.67%) Thrombocytopenia * 3/60 (5.00%) Cardiac failure * 1/60 (1.67%) Cardiac failure acute * 1/60 (1.67%) Cardiogenic shock * 1/60 (1.67%) Left ventricular dysfunction * 1/60 (1.67%) Anal fistula * 1/60 (1.67%) Adverse Events 1: Total: 4/26 (15.38%) ",
        "premise_nums": [
            "3/60 (5.00%)",
            "2/60 (3.33%)",
            "4/26 (15.38%)",
            "1/60 (1.67%)",
            "25/60 (41.67%)"
        ]
    },
    {
        "id": "5357ce66-7f7b-4ffd-926c-f6116f5a2e20",
        "primaryId": "NCT00243503",
        "secondaryId": "NCT00448279",
        "label": "Entailment",
        "statement_text": "the primary trial and the secondary trial observed a different number of adverse events in their patients ",
        "statement_nums": [],
        "premise_text": "Febrile neutropenia * 1/26 (3.85%)Gastric volvulus * 20/26 (0.00%) General Malaise * 21/26 (3.85%) Hospitalisation for intrapleuric chemotherapy and thoracentesis * 21/26 (3.85%) Acute renal failure * 21/26 (3.85%) ",
        "premise_nums": [
            "20/26 (0.00%)",
            "21/26 (3.85%)",
            "1/26 (3.85%)Gastric"
        ]
    },
    {
        "id": "3c7ecca8-5397-41f5-b72b-84217bf3acd2",
        "primaryId": "NCT00399529",
        "statement_text": "Women with chronic obstructive pulmonary disease that do not require systemic corticosteroids  are eligible for the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "No prior or currently active autoimmune disease requiring management with systemic immunosuppression  This includes inflammatory bowel disease  systemic vasculitis  scleroderma  psoriasis  multiple sclerosis  hemolytic anemia or immune-mediated thrombocytopenia  rheumatoid arthritis  systemic lupus erythematosus  Sjogren's syndrome  sarcoidosis  or other rheumatologic disease  Asthma or chronic obstructive pulmonary disease that does not require daily systemic corticosteroids is acceptable  ",
        "premise_nums": []
    },
    {
        "id": "2c53e14a-719c-4994-9090-73f9bddb60ba",
        "primaryId": "NCT00615901",
        "secondaryId": "NCT00829166",
        "label": "Entailment",
        "statement_text": "the primary trial recorded more seizures than the secondary trial  despite having less than one tenth the number of patients in its total cohort ",
        "statement_nums": [],
        "premise_text": "Adverse Events 1: Seizure 1/38 (2.63%) Adverse Events 1: Total: 92/490 (18.78%) Anaemia * 1/490 (0.20%) Anaemia of malignant disease * 0/490 (0.00%) Febrile neutropenia * 0/490 (0.00%) Neutropenia * 0/490 (0.00%) Thrombocytopenia * 4/490 (0.82%) Angina pectoris * 0/490 (0.00%) Atrial fibrillation * 1/490 (0.20%) Cardiomyopathy * 1/490 (0.20%) ",
        "premise_nums": [
            "1/490 (0.20%)",
            "92/490 (18.78%)",
            "1/38 (2.63%)",
            "4/490 (0.82%)",
            "0/490 (0.00%)"
        ]
    },
    {
        "id": "2c53e14a-719c-4994-9090-73f9bddb60ba",
        "primaryId": "NCT00615901",
        "secondaryId": "NCT00829166",
        "label": "Entailment",
        "statement_text": "the primary trial recorded more seizures than the secondary trial  despite having less than one tenth the number of patients in its total cohort ",
        "statement_nums": [],
        "premise_text": "Coronary artery disease * 0/490 (0.00%)Pericardial effusion * 0/490 (0.00%) Adverse Events 2: Total: 99/488 (20.29%) Anaemia * 1/488 (0.20%) Anaemia of malignant disease * 1/488 (0.20%) Febrile neutropenia * 2/488 (0.41%) Neutropenia * 1/488 (0.20%) Thrombocytopenia * 1/488 (0.20%) Angina pectoris * 1/488 (0.20%) Atrial fibrillation * 0/488 (0.00%) ",
        "premise_nums": [
            "99/488 (20.29%)",
            "1/488 (0.20%)",
            "2/488 (0.41%)",
            "0/490 (0.00%)Pericardial",
            "0/488 (0.00%)"
        ]
    },
    {
        "id": "2c53e14a-719c-4994-9090-73f9bddb60ba",
        "primaryId": "NCT00615901",
        "secondaryId": "NCT00829166",
        "label": "Entailment",
        "statement_text": "the primary trial recorded more seizures than the secondary trial  despite having less than one tenth the number of patients in its total cohort ",
        "statement_nums": [],
        "premise_text": "Cardiomyopathy * 0/488 (0.00%)Coronary artery disease * 1/488 (0.20%) Pericardial effusion * 2/488 (0.41%) ",
        "premise_nums": [
            "2/488 (0.41%)",
            "0/488 (0.00%)Coronary",
            "1/488 (0.20%)"
        ]
    },
    {
        "id": "7c1b03bc-d299-4ee8-b9ee-3d253f3fc33a",
        "primaryId": "NCT00089999",
        "statement_text": "In total more participants in the primary trial had no tumor Response  than partial response  and only 3 patients had a complete response ",
        "statement_nums": [
            "3 patients had"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Number of Participants With a Best Overall Response (OR) of Confirmed Complete Response (CR) or Partial Response (PR)  as Assessed by the Independent Review Committee (IRC) ",
        "premise_nums": []
    },
    {
        "id": "bfb617c8-51ae-4ab2-be05-6346daad5437",
        "primaryId": "NCT00820222",
        "secondaryId": "NCT01819233",
        "label": "Contradiction",
        "statement_text": "the secondary trial and the primary trial interventions both require subjects to follow caloric restricted diets or gluten free diets  while completing food diaries ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Lapatinib Plus Capecitabine Participants received a daily dose of 5 tablets of lapatinib (1250 mg) at approximately the same time every day  either 1 hour (or more) before breakfast or 1 hour (or more) after breakfast  Participants also received capecitabine 2000 mg/m^2) per day (divided and administered orally twice daily  12 hours apart)  for 14 days  every 21 days  Capecitabine was taken with food or within 30 minutes after food  Participants received study medication until disease progression  unacceptable toxicity  or participant withdrawal  INTERVENTION 2: Trastuzumab Plus Capecitabine ",
        "premise_nums": [
            "5 tablets of",
            "2000 mg/m^2)",
            "12 hours apart)",
            "30 minutes after",
            "1 hour (or"
        ]
    },
    {
        "id": "bfb617c8-51ae-4ab2-be05-6346daad5437",
        "primaryId": "NCT00820222",
        "secondaryId": "NCT01819233",
        "label": "Contradiction",
        "statement_text": "the secondary trial and the primary trial interventions both require subjects to follow caloric restricted diets or gluten free diets  while completing food diaries ",
        "statement_nums": [],
        "premise_text": "Participants received an IV infusion of trastuzumab 8 mg/kg on Day 1, followed by a 6 mg/kg infusion every 3 weeks  Participants also received capecitabine 2500 mg/m^2 per day (divided and administered orally twice daily  12 hours apart)  for 14 days  every 21 days  Capecitabine was taken with food or within 30 minutes after food  Participants received study medication until disease progression  unacceptable toxicity  or participant withdrawal INTERVENTION 1: Behavioral Dietary Intervention ",
        "premise_nums": [
            "2 per day",
            "6 mg/kg infusion",
            "12 hours apart)",
            "30 minutes after",
            "2500 mg/m^2",
            "8 mg/kg on"
        ]
    },
    {
        "id": "bfb617c8-51ae-4ab2-be05-6346daad5437",
        "primaryId": "NCT00820222",
        "secondaryId": "NCT01819233",
        "label": "Contradiction",
        "statement_text": "the secondary trial and the primary trial interventions both require subjects to follow caloric restricted diets or gluten free diets  while completing food diaries ",
        "statement_nums": [],
        "premise_text": "Beginning 2-4 weeks after completion of lumpectomy  patients receive food diaries to complete for 7-10 days  Dietary counselors then give patients guidelines for dietary modifications to reduce caloric intake by 25% of their normal diet  Patients follow caloric restricted diet for 10 weeks (2 weeks prior to radiation therapy  during 6 weeks of radiation therapy  and at least 2 weeks after radiation therapy)  Patients undergo radiation therapy QD 5 days a week for 6 weeks Behavioral dietary intervention: Receive caloric restricted dietary intervention Therapeutic conventional surgery: Undergo definitive lumpectomy Radiation therapy: Undergo radiation therapy Counseling intervention: Receive dietary counseling Quality-of-life assessment: Ancillary studies ",
        "premise_nums": [
            "25% of",
            "2-4 weeks",
            "6 weeks Behavioral",
            "5 days a",
            "4 weeks after",
            "7-10 days",
            "10 weeks (2",
            "6 weeks of",
            "2 weeks after"
        ]
    },
    {
        "id": "dcc5c3b0-848b-4ef4-afe6-e9c9933e33af",
        "primaryId": "NCT00404066",
        "statement_text": "Abnormal LVEF  Pregnancy or lactating automatically eliminates patients from participating in the primary trial  unless treated with herbal medicines ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "All herbal (alternative) medicines are prohibited  EXCLUSION CRITERIA Congestive heart failure  abnormal left ventricular ejection fraction (LVEF)  angina pectoris  uncontrolled cardiac arrhythmias  or other significant heart disease  or who have had a myocardial infarction within the past year  Pregnant or lactating ",
        "premise_nums": []
    },
    {
        "id": "18fcd396-cb03-4e80-bb2d-ee03c12ba32a",
        "primaryId": "NCT00455533",
        "secondaryId": "NCT00767520",
        "label": "Contradiction",
        "statement_text": "Throughout both the secondary trial and the primary trial there was only one case of pregnancy  in cohort 1 of the secondary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Adverse Events 1: Total: 17/145 (11.72%) ANAEMIA 0/145 (0.00%) LEUKOPENIA 2/145 (1.38%) NEUTROPENIA 1/145 (0.69%) LEUKOCYTOSIS 1/145 (0.69%) THROMBOCYTOPENIA 1/145 (0.69%) FEBRILE NEUTROPENIA 1/145 (0.69%) THROMBOTIC THROMBOCYTOPENIC PURPURA 0/145 (0.00%) DISSEMINATED INTRAVASCULAR COAGULATION 0/145 (0.00%) CARDIAC FAILURE 1/145 (0.69%) ATRIAL FIBRILLATION 1/145 (0.69%) Adverse Events 2: ",
        "premise_nums": [
            "1/145 (0.69%)",
            "2/145 (1.38%)",
            "17/145 (11.72%)",
            "0/145 (0.00%)"
        ]
    },
    {
        "id": "18fcd396-cb03-4e80-bb2d-ee03c12ba32a",
        "primaryId": "NCT00455533",
        "secondaryId": "NCT00767520",
        "label": "Contradiction",
        "statement_text": "Throughout both the secondary trial and the primary trial there was only one case of pregnancy  in cohort 1 of the secondary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Total: 11/144 (7.64%)ANAEMIA 1/144 (0.69%) LEUKOPENIA 0/144 (0.00%) NEUTROPENIA 0/144 (0.00%) LEUKOCYTOSIS 0/144 (0.00%) THROMBOCYTOPENIA 0/144 (0.00%) FEBRILE NEUTROPENIA 1/144 (0.69%) THROMBOTIC THROMBOCYTOPENIC PURPURA 1/144 (0.69%) DISSEMINATED INTRAVASCULAR COAGULATION 1/144 (0.69%) CARDIAC FAILURE 0/144 (0.00%) ATRIAL FIBRILLATION 0/144 (0.00%) Adverse Events 1: ",
        "premise_nums": [
            "11/144 (7.64%)ANAEMIA",
            "0/144 (0.00%)",
            "1/144 (0.69%)"
        ]
    },
    {
        "id": "18fcd396-cb03-4e80-bb2d-ee03c12ba32a",
        "primaryId": "NCT00455533",
        "secondaryId": "NCT00767520",
        "label": "Contradiction",
        "statement_text": "Throughout both the secondary trial and the primary trial there was only one case of pregnancy  in cohort 1 of the secondary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Total: 22/79 (27.85%)Anaemia 0/79 (0.00%) Right ventricular dysfunction 1/79 (1.27%) Diarrhoea 1/79 (1.27%) Vomiting 2/79 (2.53%) Abdominal pain 0/79 (0.00%) Colonic obstruction 0/79 (0.00%) Dysphagia 1/79 (1.27%) Nausea 1/79 (1.27%) Mucosal inflammation 1/79 (1.27%) Performance status decreased 1/79 (1.27%) Sudden death 1/79 (1.27%) Adverse Events 2: Total: 13/76 (17.11%) ",
        "premise_nums": [
            "2/79 (2.53%)",
            "13/76 (17.11%)",
            "0/79 (0.00%)",
            "22/79 (27.85%)Anaemia",
            "1/79 (1.27%)"
        ]
    },
    {
        "id": "18fcd396-cb03-4e80-bb2d-ee03c12ba32a",
        "primaryId": "NCT00455533",
        "secondaryId": "NCT00767520",
        "label": "Contradiction",
        "statement_text": "Throughout both the secondary trial and the primary trial there was only one case of pregnancy  in cohort 1 of the secondary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Anaemia 1/76 (1.32%)Right ventricular dysfunction 0/76 (0.00%) Diarrhoea 0/76 (0.00%) Vomiting 2/76 (2.63%) Abdominal pain 1/76 (1.32%) Colonic obstruction 1/76 (1.32%) Dysphagia 0/76 (0.00%) Nausea 1/76 (1.32%) Mucosal inflammation 0/76 (0.00%) Performance status decreased 0/76 (0.00%) Sudden death 0/76 (0.00%) ",
        "premise_nums": [
            "0/76 (0.00%)",
            "2/76 (2.63%)",
            "1/76 (1.32%)Right"
        ]
    },
    {
        "id": "694c5820-ebb6-4271-8685-a0b51c637f7f",
        "primaryId": "NCT00038103",
        "statement_text": "There is no significant difference in the proportions of Subjects With Clinical Benefit in the Exemestane + Celecoxib cohort and in the Exemestane alone cohort of the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Number of Subjects With Clinical Benefit Clinical benefit was based on objective tumor assessments made according to Response Evaluation Criteria (RECIST) system of unidimensional evaluation  Includes subjects with complete response (CR)  partial response (PR)  and long term disease stabilization (SD) for at least 24 weeks  Time frame: Baseline  Week 8, 16, 24, and every 12 weeks beyond 24 up to Week 108 and every 24 weeks thereafter until 9 months following last subject last visit (LSLV) Results 1: Arm/Group Title: Exemestane (Exemestane Alone) Arm/Group Description: oral dose exemestane taken with food (25 mg tablet once daily) Overall Number of Participants Analyzed: 49 ",
        "premise_nums": [
            "24 weeks thereafter",
            "25 mg tablet",
            "9 months following",
            "108 and every",
            "24 up to",
            "12 weeks beyond"
        ]
    },
    {
        "id": "694c5820-ebb6-4271-8685-a0b51c637f7f",
        "primaryId": "NCT00038103",
        "statement_text": "There is no significant difference in the proportions of Subjects With Clinical Benefit in the Exemestane + Celecoxib cohort and in the Exemestane alone cohort of the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Measure Type: NumberUnit of Measure: participants 24 Results 2: Arm/Group Title: Combination (Exemestane + Celecoxib) Arm/Group Description: oral doses to be taken with food (25 mg tablet exemestane once daily; celecoxib 2 x 200 mg tablets twice daily) Overall Number of Participants Analyzed: 51 Measure Type: Number Unit of Measure: participants 24 ",
        "premise_nums": [
            "25 mg tablet",
            "24 Results 2:",
            "51 Measure Type:",
            "2 x 200"
        ]
    },
    {
        "id": "b87abb47-13b6-4dbe-9cfd-e63075b676aa",
        "primaryId": "NCT00662025",
        "statement_text": "on assessment 0 the primary trial Participants had a confirmed disappearance of all target and non-target lesions ",
        "statement_nums": [
            "0 the primary"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Number of Participants With Objective Response Based on Data Review Committee's Assessment Number of participants with objective response based on assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors version 1.0 (RECIST)  CR is defined as disappearance of all target and non-target lesions  PR is defined as 30% decrease in sum of the longest dimensions (LDs) of the target lesions taking as reference the baseline sum LD according to RECIST  Confirmed responses are those that persist on repeat evaluation 4 weeks after initial documentation of response  Time frame: Day 1 of Cycle 2, every 6 weeks after Cycle 2, and at the end of Cycle 8. Results 1: Arm/Group Title: SUNITINIB+CAPECITABINE ",
        "premise_nums": [
            "30% decrease",
            "6 weeks after",
            "1 of Cycle",
            "4 weeks after"
        ]
    },
    {
        "id": "b87abb47-13b6-4dbe-9cfd-e63075b676aa",
        "primaryId": "NCT00662025",
        "statement_text": "on assessment 0 the primary trial Participants had a confirmed disappearance of all target and non-target lesions ",
        "statement_nums": [
            "0 the primary"
        ],
        "label": "Contradiction",
        "premise_text": "Arm/Group Description: Sunitinib was administered orally from Day 1 at the starting dose of 37.5 mg/day on a continuous daily dosing schedule in 21-day cycles  Capecitabine was administered orally from Days 1 to 14 every 21 days at a starting dose of 2,000 mg/m^2/day. Participants were monitored for toxicity  and sunitinib and/or capecitabine dosing could be interrupted or reduced according to individual tolerance  Participants with progressive disease (PD) or intolerable toxicity were considered for discontinuation from the study Overall Number of Participants Analyzed: 63 Measure Type: Number Unit of Measure: participants Total Number of Participants with CR+PR: 19 Complete Response (CR): 0 Partial Response (PR): 19 ",
        "premise_nums": [
            "of 2,000 mg/m",
            "19 Complete Response",
            "1 to 14",
            "63 Measure Type:",
            "0 Partial Response",
            "21-day cycles",
            "2,000 mg/m^2/day",
            "21 days at",
            "1 at the",
            "of 37.5 mg/day"
        ]
    },
    {
        "id": "eb025223-1b4a-4df7-a85e-2eeeb62a6bf5",
        "primaryId": "NCT00754845",
        "statement_text": "Patients who received over 5 years of anastrozole therapy  completed under a year ago  are eligible for the primary trial ",
        "statement_nums": [
            "5 years of"
        ],
        "label": "Contradiction",
        "premise_text": "Must have received 4½ - 6 years of aromatase inhibitor therapy (e.g.  letrozole  anastrozole  or exemestane)  either as initial therapy or after prior tamoxifen citrate  including treatment received as part of clinical trial CAN-NCIC-MA17 Completed aromatase inhibitor therapy 2 years ago ",
        "premise_nums": [
            "6 years of",
            "17 Completed aromatase",
            "MA17 Completed",
            "2 years ago"
        ]
    },
    {
        "id": "23df2cc2-6aae-4251-a8a7-e2f5a65f176a",
        "primaryId": "NCT02149524",
        "statement_text": "None of the adverse events which occurred in the primary trial were not GI related ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 58/438 (13.24%) Febrile neutropenia 13/438 (2.97%) Neutropenia 5/438 (1.14%) Anaemia 0/438 (0.00%) Thrombocytopenia 0/438 (0.00%) Haemolytic anaemia 1/438 (0.23%) Leukopenia 1/438 (0.23%) Cardiac failure congestive 0/438 (0.00%) Supraventricular tachycardia 0/438 (0.00%) Myocardial infarction 1/438 (0.23%) Vertigo 0/438 (0.00%) Adverse Events 2: ",
        "premise_nums": [
            "58/438 (13.24%)",
            "1/438 (0.23%)",
            "5/438 (1.14%)",
            "0/438 (0.00%)",
            "13/438 (2.97%)"
        ]
    },
    {
        "id": "23df2cc2-6aae-4251-a8a7-e2f5a65f176a",
        "primaryId": "NCT02149524",
        "statement_text": "None of the adverse events which occurred in the primary trial were not GI related ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Total: 56/437 (12.81%)Febrile neutropenia 10/437 (2.29%) Neutropenia 7/437 (1.60%) Anaemia 2/437 (0.46%) Thrombocytopenia 1/437 (0.23%) Haemolytic anaemia 0/437 (0.00%) Leukopenia 0/437 (0.00%) Cardiac failure congestive 3/437 (0.69%) Supraventricular tachycardia 1/437 (0.23%) Myocardial infarction 0/437 (0.00%) Vertigo 1/437 (0.23%) ",
        "premise_nums": [
            "2/437 (0.46%)",
            "7/437 (1.60%)",
            "1/437 (0.23%)",
            "3/437 (0.69%)",
            "10/437 (2.29%)",
            "0/437 (0.00%)",
            "56/437 (12.81%)Febrile"
        ]
    },
    {
        "id": "1bd51c93-d7a8-4da4-825d-ada625033c34",
        "primaryId": "NCT00418028",
        "secondaryId": "NCT00293540",
        "label": "Contradiction",
        "statement_text": "Samantha has recently received a liver transplant  and is taking the combined oral contraceptive pill  she is not eligible for the primary trial  but is eligible for the secondary trial ",
        "statement_nums": [],
        "premise_text": "Exclusion criteria: Patients with organ transplants  Exclusion Criteria: Current oral contraceptives ",
        "premise_nums": []
    },
    {
        "id": "58c58b68-fc9a-438c-8a85-9233dde714c9",
        "primaryId": "NCT01827787",
        "statement_text": "The Triple-Negative Breast Cancer cohort of the primary trial had a much lower ORR than the HR+/HER2- cohort ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Overall Response Rate (ORR) ORR was defined as the percentage of participants achieving complete response (CR) or partial response (PR) based on RECIST 1.1 criteria on treatment  Per RECIST 1.1 for target lesions: CR is complete disappearance of all target lesions and PR is at least a 30% decrease in the sum of longest diameter (LD) of target lesions  taking as reference baseline sum LD  PR or better overall response assumes at a minimum incomplete response/stable disease (SD) for the evaluation of non-target lesions and absence of new lesions  ",
        "premise_nums": [
            "30% decrease",
            "RECIST 1.1 criteria on",
            "RECIST 1.1 for target"
        ]
    },
    {
        "id": "58c58b68-fc9a-438c-8a85-9233dde714c9",
        "primaryId": "NCT01827787",
        "statement_text": "The Triple-Negative Breast Cancer cohort of the primary trial had a much lower ORR than the HR+/HER2- cohort ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Time frame: Disease was evaluated radiologically at baseline and every 9 weeks on treatment; Maximum treatment duration was 38 cycles/26 months (Cohort 1) and 17 cycles/12 months (Cohort 2)Results 1: Arm/Group Title: Cohort 1: HR+/HER2- Arm/Group Description: Eribulin: 1.4 mg/m2 administered intravenously over 2-5 minutes on days 1 and 8 of each 21 day cycle Participants remained on single agent eribulin until disease progression or withdrawal for other reasons  Overall Number of Participants Analyzed: 45 Measure Type: Number Unit of Measure: percentage of participants 35.6 (24 to 49) Results 2: Arm/Group Title: Cohort 2: TNBC ",
        "premise_nums": [
            "2-5 minutes",
            "17 cycles/12 months",
            "12 months (Cohort",
            "26 months (Cohort",
            "45 Measure Type:",
            "2 administered intravenously",
            "21 day cycle",
            "24 to 49)",
            "38 cycles/26 months",
            "1 and 8",
            "5 minutes on",
            "1.4 mg/m",
            "9 weeks on"
        ]
    },
    {
        "id": "58c58b68-fc9a-438c-8a85-9233dde714c9",
        "primaryId": "NCT01827787",
        "statement_text": "The Triple-Negative Breast Cancer cohort of the primary trial had a much lower ORR than the HR+/HER2- cohort ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Arm/Group Description: Eribulin: 1.4 mg/m2 administered intravenously over 2-5 minutes on days 1 and 8 of each 21 day cycleParticipants remained on single agent eribulin until disease progression or withdrawal for other reasons  Overall Number of Participants Analyzed: 38 Measure Type: Number Unit of Measure: percentage of participants 13.2 (5 to 26) ",
        "premise_nums": [
            "2-5 minutes",
            "2 administered intravenously",
            "5 to 26)",
            "1 and 8",
            "5 minutes on",
            "1.4 mg/m",
            "38 Measure Type:",
            "21 day cycleParticipants"
        ]
    },
    {
        "id": "843778c6-a320-49a1-93a0-5dc6239b822a",
        "primaryId": "NCT00965523",
        "statement_text": "The most common adverse events in the primary trial where Infection and Stomatitis ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 14/81 (17.28%) Neutropenia1/81 (1.23%) Cataract1/81 (1.23%) Ascites1/81 (1.23%) Gastritis Hemorrhagic1/81 (1.23%) Nausea1/81 (1.23%) Stomatitis2/81 (2.47%) Malaise1/81 (1.23%) Oedema1/81 (1.23%) Pain1/81 (1.23%) Pyrexia1/81 (1.23%) Infection2/81 (2.47%) Upper Limb Fracture1/81 (1.23%) Dehydration1/81 (1.23%) ",
        "premise_nums": [
            "14/81 (17.28%)",
            "2/81 (2.47%)",
            "1/81 (1.23%)"
        ]
    },
    {
        "id": "843778c6-a320-49a1-93a0-5dc6239b822a",
        "primaryId": "NCT00965523",
        "statement_text": "The most common adverse events in the primary trial where Infection and Stomatitis ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Hypercalcemia1/81 (1.23%)",
        "premise_nums": [
            "1/81 (1.23%)"
        ]
    },
    {
        "id": "a5486f80-69e5-4a5a-8435-f82f39cddf85",
        "primaryId": "NCT00080301",
        "statement_text": "There were 2 more cases of Gastrointestinal Haemorrhage in cohort 2 of the primary trial  than in cohort 1.",
        "statement_nums": [
            "2 more cases",
            "2 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 127/368 (34.51%) ANAEMIA 3/368 (0.82%) LEUKOPENIA 0/368 (0.00%) NEUTROPENIA 0/368 (0.00%) COAGULOPATHY 3/368 (0.82%) LYMPHADENOPATHY 0/368 (0.00%) THROMBOCYTOPENIA 2/368 (0.54%) BONE MARROW FAILURE 0/368 (0.00%) FEBRILE NEUTROPENIA 4/368 (1.09%) DISSEMINATED INTRAVASCULAR COAGULATION 0/368 (0.00%) ",
        "premise_nums": [
            "0/368 (0.00%)",
            "127/368 (34.51%)",
            "4/368 (1.09%)",
            "2/368 (0.54%)",
            "3/368 (0.82%)"
        ]
    },
    {
        "id": "a5486f80-69e5-4a5a-8435-f82f39cddf85",
        "primaryId": "NCT00080301",
        "statement_text": "There were 2 more cases of Gastrointestinal Haemorrhage in cohort 2 of the primary trial  than in cohort 1.",
        "statement_nums": [
            "2 more cases",
            "2 of the"
        ],
        "label": "Contradiction",
        "premise_text": "ATRIAL FLUTTER 0/368 (0.00%)CARDIAC ARREST 0/368 (0.00%) Adverse Events 2: Total: 151/369 (40.92%) ANAEMIA 11/369 (2.98%) LEUKOPENIA 6/369 (1.63%) NEUTROPENIA 18/369 (4.88%) COAGULOPATHY 0/369 (0.00%) LYMPHADENOPATHY 1/369 (0.27%) THROMBOCYTOPENIA 7/369 (1.90%) BONE MARROW FAILURE 1/369 (0.27%) FEBRILE NEUTROPENIA 15/369 (4.07%) ",
        "premise_nums": [
            "0/369 (0.00%)",
            "6/369 (1.63%)",
            "151/369 (40.92%)",
            "15/369 (4.07%)",
            "0/368 (0.00%)CARDIAC",
            "18/369 (4.88%)",
            "11/369 (2.98%)",
            "7/369 (1.90%)",
            "1/369 (0.27%)"
        ]
    },
    {
        "id": "a5486f80-69e5-4a5a-8435-f82f39cddf85",
        "primaryId": "NCT00080301",
        "statement_text": "There were 2 more cases of Gastrointestinal Haemorrhage in cohort 2 of the primary trial  than in cohort 1.",
        "statement_nums": [
            "2 more cases",
            "2 of the"
        ],
        "label": "Contradiction",
        "premise_text": "DISSEMINATED INTRAVASCULAR COAGULATION 1/369 (0.27%)ATRIAL FLUTTER 1/369 (0.27%) CARDIAC ARREST 1/369 (0.27%) ",
        "premise_nums": [
            "1/369 (0.27%)ATRIAL"
        ]
    },
    {
        "id": "c2c60b25-f255-48ba-bcb7-2bcd2de4315d",
        "primaryId": "NCT00171314",
        "statement_text": "There are four types of adverse events in the primary trial  for which no occurences are recorded ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 47/254 (18.50%) Anaemia 1/254 (0.39%) Febrile neutropenia 1/254 (0.39%) Lymphadenopathy 1/254 (0.39%) Acute myocardial infarction 1/254 (0.39%) Angina pectoris 0/254 (0.00%) Angina unstable 0/254 (0.00%) Bundle branch block left 0/254 (0.00%) Cardiac failure 4/254 (1.57%) Coronary artery disease 0/254 (0.00%) Coronary artery stenosis 1/254 (0.39%) ",
        "premise_nums": [
            "1/254 (0.39%)",
            "47/254 (18.50%)",
            "0/254 (0.00%)",
            "4/254 (1.57%)"
        ]
    },
    {
        "id": "a8167a90-8ccf-4024-a4cc-8c1b047fd548",
        "primaryId": "NCT00068601",
        "secondaryId": "NCT01684215",
        "label": "Entailment",
        "statement_text": "the primary trial and the secondary trial do not employ the same route of administration for their interventions ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Standard Chemotherapy Patients receive cyclophosphamide-containing chemotherapy alone  cyclophosphamide: Part of planned chemotherapy regimen INTERVENTION 2: Chemotherapy Plus Goserelin Patients receive goserelin subcutaneously once every 4 weeks beginning 1 week before start of cyclophosphamide-containing chemotherapy  Treatment continues until completion of chemotherapy in the absence of disease progression or unacceptable toxicity  cyclophosphamide: Part of planned chemotherapy regimen goserelin acetate: Given subcutaneously INTERVENTION 1: PD-0332991 100 mg: Dose Escalation Cohort ",
        "premise_nums": [
            "4 weeks beginning",
            "1 week before"
        ]
    },
    {
        "id": "a8167a90-8ccf-4024-a4cc-8c1b047fd548",
        "primaryId": "NCT00068601",
        "secondaryId": "NCT01684215",
        "label": "Entailment",
        "statement_text": "the primary trial and the secondary trial do not employ the same route of administration for their interventions ",
        "statement_nums": [],
        "premise_text": "In Phase 1-Part 1, participants received single oral dose of PD-0332991 100 mg capsule in lead-in period (7 days prior to Cycle 1 Day 1), followed by PD-0332991 100 mg capsule orally once daily continuously for 21 days followed by 7 days off treatment in each cycle of 28 days  unless participants experienced disease progression or unacceptable toxicity or withdrew consent INTERVENTION 2: PD-0332991 125 mg: Dose Escalation Cohort ",
        "premise_nums": [
            "1-Part 1,",
            "7 days prior",
            "7 days off",
            "1 Day 1),",
            "21 days followed",
            "100 mg capsule"
        ]
    },
    {
        "id": "a8167a90-8ccf-4024-a4cc-8c1b047fd548",
        "primaryId": "NCT00068601",
        "secondaryId": "NCT01684215",
        "label": "Entailment",
        "statement_text": "the primary trial and the secondary trial do not employ the same route of administration for their interventions ",
        "statement_nums": [],
        "premise_text": "In Phase 1-Part 1, participants received single oral dose of PD-0332991 125 mg capsule in lead-in period (7 days prior to Cycle 1 Day 1), followed by PD-0332991 125 mg capsule orally once daily continuously for 21 days followed by 7 days off treatment in each cycle of 28 days  unless participants experienced disease progression or unacceptable toxicity or withdrew consent ",
        "premise_nums": [
            "1-Part 1,",
            "125 mg capsule",
            "7 days prior",
            "7 days off",
            "1 Day 1),",
            "21 days followed"
        ]
    },
    {
        "id": "bdca0fa1-a3fa-4dcf-8f58-15d130dbfa75",
        "primaryId": "NCT00106002",
        "statement_text": "the primary trial participants are treated with 600 mg of Pemetrexed orally twice a month until complete response or disease progression ",
        "statement_nums": [
            "600 mg of"
        ],
        "label": "Contradiction",
        "premise_text": "INTERVENTION 1: Pemetrexed 600 mg/m2, intravenous (IV)  every 14 days until complete response or disease progression ",
        "premise_nums": [
            "600 mg/m2,",
            "14 days until"
        ]
    },
    {
        "id": "277f5d17-36cc-44c5-9b94-7e052f2bdb2c",
        "primaryId": "NCT01067976",
        "secondaryId": "NCT00941330",
        "label": "Contradiction",
        "statement_text": "Unlike the secondary trial  the primary trial only provides the duration of cycles and drug doses in the intervention section ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: CMRM vs UMRM [Not Specified] INTERVENTION 1: A: Exemestane ARM A: Patients will be treated with exemestane  Exemestane: 25 mg daily by mouth for 6 to 12 months  INTERVENTION 2: B: Docetaxel and Cytoxan ARM B: Patients will be treated with docetaxel and cytoxan  Docetaxel: Docetaxel (75 mg/m²) into a vein once every 3 weeks for 6 cycles (6 times in about 24 weeks)  Cytoxan: Cytoxan (600 mg/m²) into a vein once every 3 weeks for 6 cycles (6 times in about 24 weeks)  ",
        "premise_nums": [
            "6 cycles (6",
            "25 mg daily",
            "3 weeks for",
            "6 to 12"
        ]
    },
    {
        "id": "fcb195de-2143-44d8-8c46-136104554e2d",
        "primaryId": "NCT01492101",
        "statement_text": "There less than 1% of either cohort of the primary trial was effect by Pancytopenia  but just over 5% of cohort 1 patients suffered from Coagulopathy ",
        "statement_nums": [
            "5% of",
            "1% of",
            "1 patients suffered"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Pancytopenia *2/425 (0.47%) Coagulopathy *1/425 (0.24%) Adverse Events 2: Pancytopenia *0/406 (0.00%) ",
        "premise_nums": [
            "2/425 (0.47%)",
            "1/425 (0.24%)",
            "0/406 (0.00%)"
        ]
    },
    {
        "id": "70337af9-3d4a-44bc-bbfa-0d97ea88553c",
        "primaryId": "NCT00317720",
        "statement_text": "Patients must have at least 3 prior treatments with trastuzumab to be eligible for the primary trial ",
        "statement_nums": [
            "3 prior treatments"
        ],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria: History of trastuzumab resistance  defined as the development of progressive disease after trastuzumab-based therapy for metastatic breast cancer  Patient may not have received more than 2 prior trastuzumab-based regimens and one lapatinib-based regimen (either as single agent or in combination with chemotherapy)for metastatic breast cancer  Patients who develop metastatic disease during or after adjuvant or neoadjuvant trastuzumab are eligible  ",
        "premise_nums": [
            "2 prior trastuzumab"
        ]
    },
    {
        "id": "9cf89221-5801-4709-a098-de763b6e702e",
        "primaryId": "NCT00334542",
        "statement_text": "A Female patients with a mastectomy would be excluded from the primary trial ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "At least 1 healthy intact breast ",
        "premise_nums": [
            "1 healthy intact"
        ]
    },
    {
        "id": "f89883ea-dd60-4d5f-9354-13fbca2aeec8",
        "primaryId": "NCT01031446",
        "statement_text": "Sarah has been experiencing epileptic seizures from a brain tumor  This will not prevent her from participating in the primary trial ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "No symptomatic brain metastases ",
        "premise_nums": []
    },
    {
        "id": "a289f67c-ff56-44a9-b3da-152fb0d20271",
        "primaryId": "NCT01301729",
        "secondaryId": "NCT02129556",
        "label": "Entailment",
        "statement_text": "Only 1 respiratory adverse event was recorded across the duration of both the secondary trial and the primary trial ",
        "statement_nums": [
            "1 respiratory adverse"
        ],
        "premise_text": "Adverse Events 1: Total: 5/32 (15.63%) Leukopenia 1/32 (3.13%) Neutropenia 1/32 (3.13%) Cataract 1/32 (3.13%) Infection 1/32 (3.13%) Upper respiratory tract infection 1/32 (3.13%) Completed suicide 1/32 (3.13%) Adverse Events 1: Total: 4/6 (66.67%) Anemia 0/6 (0.00%) Takotsubo cardiomyopathy 1/6 (16.67%) Pericardial effusion 0/6 (0.00%) Vertigo 1/6 (16.67%) Retinal vein occlusion 0/6 (0.00%) ",
        "premise_nums": [
            "5/32 (15.63%)",
            "1/32 (3.13%)",
            "1/6 (16.67%)",
            "4/6 (66.67%)",
            "0/6 (0.00%)"
        ]
    },
    {
        "id": "a289f67c-ff56-44a9-b3da-152fb0d20271",
        "primaryId": "NCT01301729",
        "secondaryId": "NCT02129556",
        "label": "Entailment",
        "statement_text": "Only 1 respiratory adverse event was recorded across the duration of both the secondary trial and the primary trial ",
        "statement_nums": [
            "1 respiratory adverse"
        ],
        "premise_text": "Gastroenteritis 1/6 (16.67%)Vomiting 1/6 (16.67%) Diarrhea 0/6 (0.00%) Death 2/6 (33.33%) Bile duct dilatation 0/6 (0.00%) Hepatic hemorrhage 0/6 (0.00%) Adverse Events 2: Total: 25/52 (48.08%) Anemia 1/52 (1.92%) Takotsubo cardiomyopathy 0/52 (0.00%) Pericardial effusion 2/52 (3.85%) Vertigo 0/52 (0.00%) Retinal vein occlusion 1/52 (1.92%) ",
        "premise_nums": [
            "0/52 (0.00%)",
            "2/6 (33.33%)",
            "25/52 (48.08%)",
            "1/52 (1.92%)",
            "2/52 (3.85%)",
            "0/6 (0.00%)",
            "1/6 (16.67%)Vomiting"
        ]
    },
    {
        "id": "a289f67c-ff56-44a9-b3da-152fb0d20271",
        "primaryId": "NCT01301729",
        "secondaryId": "NCT02129556",
        "label": "Entailment",
        "statement_text": "Only 1 respiratory adverse event was recorded across the duration of both the secondary trial and the primary trial ",
        "statement_nums": [
            "1 respiratory adverse"
        ],
        "premise_text": "Gastroenteritis 0/52 (0.00%)Vomiting 0/52 (0.00%) Diarrhea 1/52 (1.92%) Death 9/52 (17.31%) Bile duct dilatation 1/52 (1.92%) Hepatic hemorrhage 1/52 (1.92%) ",
        "premise_nums": [
            "0/52 (0.00%)Vomiting",
            "1/52 (1.92%)",
            "9/52 (17.31%)"
        ]
    },
    {
        "id": "10ed1242-c6ab-4ad0-b93c-4738857f543a",
        "primaryId": "NCT02635737",
        "statement_text": "Patients with ICDs may be eligible for the primary trial ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Exclusion Criteria: Patients with a Pacemaker or implanted device; ",
        "premise_nums": []
    },
    {
        "id": "683b9885-4027-4108-b37e-61255611538a",
        "primaryId": "NCT02692755",
        "statement_text": "Asian  white british and white irish women are eligible for the primary trial  as long as they do not have uncontrolled or symptomatic brain metastases ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria: Self-identified Black  African or African American women of 18 years of age with proven diagnosis of advanced adenocarcinoma of the breast (locoregionally recurrent or metastatic disease) Exclusion Criteria: Current use of food or drugs known to be potent inhibitors or inducers of CYP3A4 Active uncontrolled or symptomatic brain metastases  Previously treated and clinically stable  as per Investigator's judgment  brain metastases are permitted  ",
        "premise_nums": [
            "4 Active uncontrolled",
            "18 years of"
        ]
    },
    {
        "id": "a47e048a-56aa-49e0-9903-563f53797b6e",
        "primaryId": "NCT00600340",
        "statement_text": "Cohorts 1 of the primary trial recieves Bevacizumab at a higher frequency and dose than cohort 2.",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "INTERVENTION 1: Bevacizumab Plus Paclitaxel Bevacizumab 10 mg/kg intravenous (i.v.)  days 1 and 15, every 4 weeks  Paclitaxel 90 mg/m2, days 1, 8 and 15, every 4 weeks INTERVENTION 2: Bevacizumab Plus Capecitabine Bevacizumab 15 mg/kg i.v.  day 1, every 3 weeks  Capecitabine 1000 mg/m² twice-daily  days 1-14, every 3 weeks ",
        "premise_nums": [
            "4 weeks INTERVENTION",
            "8 and 15,",
            "1000 mg/m²",
            "10 mg/kg intravenous",
            "1-14, every",
            "90 mg/m2,",
            "1 and 15,",
            "15 mg/kg i"
        ]
    },
    {
        "id": "690de5e2-3d7f-407e-8eb9-783adf58841b",
        "primaryId": "NCT00356148",
        "secondaryId": "NCT01856543",
        "label": "Contradiction",
        "statement_text": "Women of any age can participate in the primary trial and the secondary trial ",
        "statement_nums": [],
        "premise_text": "Inclusion Criteria: Women at any age with early stage breast cancer (stage I-II) and American Society of Anesthesiologists (ASA) score of I-II  Inclusion Criteria: Age 18 years ",
        "premise_nums": []
    },
    {
        "id": "f5477a02-dde7-44c8-80b5-2cdb9fa66f23",
        "primaryId": "NCT01234337",
        "secondaryId": "NCT00217672",
        "label": "Contradiction",
        "statement_text": "More than 2 cases of Anaphylaxis occurred in either the primary trial or the secondary trial ",
        "statement_nums": [
            "2 cases of"
        ],
        "premise_text": "Adverse Events 1: Total: 80/260 (30.77%) Anaemia * 2/260 (0.77%) Febrile neutropenia * 0/260 (0.00%) Neutropenia * 2/260 (0.77%) Thrombocytopenia * 0/260 (0.00%) Bundle branch block right * 0/260 (0.00%) Pericardial effusion * 0/260 (0.00%) Cardiopulmonary failure * 0/260 (0.00%) Aplasia * 0/260 (0.00%) Eye symptom * 1/260 (0.38%) Abdominal discomfort * 0/260 (0.00%) Adverse Events 2: ",
        "premise_nums": [
            "1/260 (0.38%)",
            "80/260 (30.77%)",
            "0/260 (0.00%)",
            "2/260 (0.77%)"
        ]
    },
    {
        "id": "f5477a02-dde7-44c8-80b5-2cdb9fa66f23",
        "primaryId": "NCT01234337",
        "secondaryId": "NCT00217672",
        "label": "Contradiction",
        "statement_text": "More than 2 cases of Anaphylaxis occurred in either the primary trial or the secondary trial ",
        "statement_nums": [
            "2 cases of"
        ],
        "premise_text": "Total: 71/267 (26.59%)Anaemia * 2/267 (0.75%) Febrile neutropenia * 1/267 (0.37%) Neutropenia * 0/267 (0.00%) Thrombocytopenia * 1/267 (0.37%) Bundle branch block right * 1/267 (0.37%) Pericardial effusion * 5/267 (1.87%) Cardiopulmonary failure * 1/267 (0.37%) Aplasia * 1/267 (0.37%) Eye symptom * 0/267 (0.00%) Abdominal discomfort * 1/267 (0.37%) Adverse Events 1: ",
        "premise_nums": [
            "1/267 (0.37%)",
            "2/267 (0.75%)",
            "71/267 (26.59%)Anaemia",
            "5/267 (1.87%)",
            "0/267 (0.00%)"
        ]
    },
    {
        "id": "f5477a02-dde7-44c8-80b5-2cdb9fa66f23",
        "primaryId": "NCT01234337",
        "secondaryId": "NCT00217672",
        "label": "Contradiction",
        "statement_text": "More than 2 cases of Anaphylaxis occurred in either the primary trial or the secondary trial ",
        "statement_nums": [
            "2 cases of"
        ],
        "premise_text": "Total: 13/74 (17.57%)neutropenia 1/74 (1.35%) left ventricular dysfunction 1/74 (1.35%) fistula enterovesical 1/74 (1.35%) constipation and hypokalemia 1/74 (1.35%) nausea  vomiting and burning abdominal pain 2/74 (2.70%) Infection 1/74 (1.35%) febrile neutropenia 3/74 (4.05%) speech impairment 1/74 (1.35%) dyspnea  pain 1/74 (1.35%) hemorrhage/bleeding 2/74 (2.70%) ",
        "premise_nums": [
            "13/74 (17.57%)neutropenia",
            "2/74 (2.70%)",
            "1/74 (1.35%)",
            "3/74 (4.05%)"
        ]
    },
    {
        "id": "dc184dcb-a22d-4cac-bee1-6c182692e522",
        "primaryId": "NCT03511378",
        "statement_text": "Patients must have a life expectancy over a year to participate in the primary trial ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria: Patient who have estimated life expectancy of more than six months ",
        "premise_nums": []
    },
    {
        "id": "4dfbdeba-cae0-48b2-a38d-07338512904e",
        "primaryId": "NCT03076190",
        "secondaryId": "NCT03196635",
        "label": "Entailment",
        "statement_text": "Molecular Breast Imaging is not applied in either the primary trial or the secondary trial interventions ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Active Control Group Health Education Active Control Group INTERVENTION 2: My Surgical Success Treatment Group My Surgical Success Intervention Group INTERVENTION 1: All Study Participants  PA Compression Image Sets All image sets (30 patient-assisted compression image sets) were evaluated for acceptability of overall clinical image quality by two (2) readers  INTERVENTION 2: All Study Participants  TC Compression Image Sets All image sets (30 TC compression image sets) were evaluated for acceptability of overall clinical image quality by two (2) readers  ",
        "premise_nums": [
            "30 TC compression",
            "(2) readers"
        ]
    },
    {
        "id": "62489179-bb30-4b96-a904-ea907dd05e23",
        "primaryId": "NCT01097460",
        "secondaryId": "NCT01009918",
        "label": "Contradiction",
        "statement_text": "Every patient in the primary trial and the secondary trial suffered at least 1 Treatment-emergent adverse event over a span of 2 years ",
        "statement_nums": [
            "1 Treatment-emergent adverse"
        ],
        "premise_text": "Outcome Measurement: Incidence of Treatment-emergent AE's [Not Specified] Time frame: 2 years Results 1: Arm/Group Title: MM-111 + Herceptin Arm/Group Description: MM-111 will be combined with Herceptin MM-111 and Herceptin: For Phase 1: Dose escalation cohorts  MM-111 and Herceptin are administered weekly or bi-weekly via IV Overall Number of Participants Analyzed: 16 Measure Type: Number Unit of Measure: participants 16 Outcome Measurement: Number of Participants With Trastuzumab-Induced Cardiotoxicity After 52 Weeks of Treatment ",
        "premise_nums": [
            "111 and Herceptin:",
            "16 Outcome Measurement:",
            "52 Weeks of",
            "16 Measure Type:",
            "2 years Results",
            "111 will be"
        ]
    },
    {
        "id": "62489179-bb30-4b96-a904-ea907dd05e23",
        "primaryId": "NCT01097460",
        "secondaryId": "NCT01009918",
        "label": "Contradiction",
        "statement_text": "Every patient in the primary trial and the secondary trial suffered at least 1 Treatment-emergent adverse event over a span of 2 years ",
        "statement_nums": [
            "1 Treatment-emergent adverse"
        ],
        "premise_text": "Reduction in incidence of trastuzumab-induced cardiotoxicity after 52 weeks of treatment as measured by preservation of Left Ventricular Ejection Fraction (LVEF)  Number of Patients who experienced a cardiotoxicity Time frame: 2 years Results 1: Arm/Group Title: Arm I Lisinopril Arm/Group Description: Patients receive oral lisinopril once daily  lisinopril: Given orally Overall Number of Participants Analyzed: 152 Measure Type: Count of Participants Unit of Measure: Participants 45 29.6% ",
        "premise_nums": [
            "52 weeks of",
            "2 years Results",
            "152 Measure Type:"
        ]
    },
    {
        "id": "45891239-bb78-4f83-8306-8edceb8247fe",
        "primaryId": "NCT01011946",
        "statement_text": "All patients in the primary trial must have a bilateral breast mammography prior to study entry ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria: Women 18-75 years old with newly diagnosed breast cancer who are considered candidates for breast conserving surgery (i.e  lumpectomy)  Exclusion Criteria: Children (smaller than 18 years old) Pregnant or Lactating women Diabetic patients (Type I or II) Patients who are scheduled for a sentinel node procedure using radioactive Tc-99m within 24 hours of PEM Patients who have NOT undergone a standard of care bilateral breast MRI at UC  ",
        "premise_nums": [
            "18-75 years",
            "75 years old",
            "18 years old)",
            "24 hours of"
        ]
    },
    {
        "id": "9ec1e3f0-64a2-4629-aee8-cdb516fd27f3",
        "primaryId": "NCT00258349",
        "secondaryId": "NCT01328249",
        "label": "Contradiction",
        "statement_text": "Cohort 1 of the primary trial does not receive any Eribulin Mesylate or Vorinostat  whereas both cohorts in the secondary trial receive some of both ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "INTERVENTION 1: Vorinostat +Trastuzumab Trastuzumab: 6 mg/kg once on Day 1, infused over 90 minutes  every 3 weeks; Vorinostat 200 mg of SAHA orally twice a day  daily for 14 days out of a 21-day cycle INTERVENTION 1: Cohort 1: Eribulin Mesylate With Filgrastim as Needed ",
        "premise_nums": [
            "14 days out",
            "200 mg of",
            "6 mg/kg once",
            "21-day cycle"
        ]
    },
    {
        "id": "91f23b55-38b6-41c4-af30-baa15e989aa7",
        "primaryId": "NCT00371254",
        "statement_text": "Patients must have eceptorsestrogen receptor (ER) -  progesterone receptor (PR) - and human epidermal growth factor receptor 2 (HER2) - non metastatic breast cancer  aswell as not having Dysphagia ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria: recurrent or progressive locally advanced  or 'triple negative' metastatic breast cancer Exclusion Criteria: Unable to take oral medication ",
        "premise_nums": []
    },
    {
        "id": "7eea6ac2-ef9a-4c3e-b14d-eb9671dab89d",
        "primaryId": "NCT00374322",
        "statement_text": "the primary trial results show that Participants receiving lapatinib 1500 milligrams (mg) orally were twice as likely to achieve DFS at 5 years than placebo patients ",
        "statement_nums": [
            "5 years than",
            "1500 milligrams (mg)"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Number of Participants (Par.) With Any Recurrence of the Initial Disease  Second Primary Cancer  Contralateral Breast Cancer  or Death (Disease-free Survival [DFS]) ",
        "premise_nums": []
    },
    {
        "id": "a2d489d5-3677-43ef-b03a-33d571c0c3b2",
        "primaryId": "NCT02650193",
        "secondaryId": "NCT00656669",
        "label": "Entailment",
        "statement_text": "Patients with Class III obesity cannot be included in the primary trial  but can be entered into the secondary trial  as long as they do not have uncontrolled Hypertension ",
        "statement_nums": [],
        "premise_text": "Inclusion Criteria: Body mass index (BMI) of 19 to 40 kg/m^2   inclusive Inclusion Criteria: Patients must have histologically-confirmed adenocarcinoma of the breast with operable or inoperable stage 1c (primary tumor greater than 1.0 cm)  II or III disease  Measurable disease by physical examinations or diagnostic breast imaging (mammography  ultrasonography or MR)  Pre-treatment core or incisional biopsy  Patients may not have had definitive primary surgery  Male or female  18 years of age or older  ECOG performance status 0 or 1. Adequate organ function as defined in the protocol  Exclusion Criteria: ",
        "premise_nums": [
            "19 to 40",
            "40 kg/m^2",
            "0 or 1.",
            "18 years of"
        ]
    },
    {
        "id": "a2d489d5-3677-43ef-b03a-33d571c0c3b2",
        "primaryId": "NCT02650193",
        "secondaryId": "NCT00656669",
        "label": "Entailment",
        "statement_text": "Patients with Class III obesity cannot be included in the primary trial  but can be entered into the secondary trial  as long as they do not have uncontrolled Hypertension ",
        "statement_nums": [],
        "premise_text": "Prior radiation therapy  cytotoxic therapy or systemic therapy for breast cancer  Prior use of tamoxifen or raloxifene as chemoprevention is allowed but must be discontinued prior to study entry Metastatic (Stage IV) breast cancer Patients who have had only a pre-treatment fine needle aspiration (FNA) are excluded  Current therapeutic treatment on another clinical trial with an investigational agent  Any of the following within the 6 months prior to starting study treatment: -myocardial infarction -severe/unstable angina -coronary/peripheral artery bypass graft -congestive heart failure -cerebrovascular accident including transient ischemic attack -pulmonary embolus ",
        "premise_nums": [
            "6 months prior"
        ]
    },
    {
        "id": "a2d489d5-3677-43ef-b03a-33d571c0c3b2",
        "primaryId": "NCT02650193",
        "secondaryId": "NCT00656669",
        "label": "Entailment",
        "statement_text": "Patients with Class III obesity cannot be included in the primary trial  but can be entered into the secondary trial  as long as they do not have uncontrolled Hypertension ",
        "statement_nums": [],
        "premise_text": "Ongoing cardiac dysrhythmias of NCI CTCAE grade greater than or equal 2, atrial fibrillation of any grade  or QTc interval greater than 450 msec for males or greater than 470 msec for females Hypertension that cannot be controlled by medications  Current treatment with therapeutic doses of any anti-coagulant  Prophylactic use of anticoagulants is allowed  Known human immunodeficiency virus (HIV) infection  Pregnancy or breastfeeding  All female patients with reproductive potential must have a negative pregnancy test prior to first day of study medication  ",
        "premise_nums": [
            "470 msec for",
            "450 msec for"
        ]
    },
    {
        "id": "a2d489d5-3677-43ef-b03a-33d571c0c3b2",
        "primaryId": "NCT02650193",
        "secondaryId": "NCT00656669",
        "label": "Entailment",
        "statement_text": "Patients with Class III obesity cannot be included in the primary trial  but can be entered into the secondary trial  as long as they do not have uncontrolled Hypertension ",
        "statement_nums": [],
        "premise_text": "Other severe acute or chronic medical or psychiatric condition  or laboratory abnormality that would impart  in the judgment of the investigator  excess risk associated with study participation or study drug administration  or which  in the judgment of the investigator  would make the patient inappropriate for entry into this study ",
        "premise_nums": []
    },
    {
        "id": "943ff737-4edd-4dbd-a3c9-213e3e0234d8",
        "primaryId": "NCT00423917",
        "secondaryId": "NCT00082641",
        "label": "Entailment",
        "statement_text": "the primary trial and the secondary trial both report cases of confusion in their patient cohorts ",
        "statement_nums": [],
        "premise_text": "Adverse Events 1: Confusion 1/33 (3.03%) Adverse Events 1: Confusion 1/11 (9.09%) Adverse Events 2: Confusion 0/12 (0.00%) ",
        "premise_nums": [
            "0/12 (0.00%)",
            "1/11 (9.09%)",
            "1/33 (3.03%)"
        ]
    },
    {
        "id": "be50c45f-ec51-40c8-904f-ffc200d39d9d",
        "primaryId": "NCT01042938",
        "statement_text": "Only patients capable of understanding english are eligible for the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Inclusion Criteria: Participants must be able to understand English and able to complete assessment forms (all assessment forms are in English)  ",
        "premise_nums": []
    },
    {
        "id": "f53c8212-6da8-470f-a392-1bb037ed90e8",
        "primaryId": "NCT04030104",
        "secondaryId": "NCT02525718",
        "label": "Contradiction",
        "statement_text": "Intervention 1 for the secondary trial and the primary trial either include no treatment at all  or a placebo ",
        "statement_nums": [
            "1 for the"
        ],
        "premise_text": "INTERVENTION 1: IUS Alone IUS alone imaging INTERVENTION 2: Imagio (IUS+OA) IUS+OA imaging INTERVENTION 1: Placebo Subjects will be randomly selected to receive saline (placebo)  administered to the breast area to cover the intercostal nerves supplying the breast tissue during surgery  Saline: If randomized to this arm  subjects will receive an intraoperative injection of saline  (2.5 mg/ml) INTERVENTION 2: 0.25 % Bupivacaine w/ Epinephrine & 4mg Dexamethasone ",
        "premise_nums": [
            "0.25 % Bupivacaine",
            "(2.5 mg/ml"
        ]
    },
    {
        "id": "f53c8212-6da8-470f-a392-1bb037ed90e8",
        "primaryId": "NCT04030104",
        "secondaryId": "NCT02525718",
        "label": "Contradiction",
        "statement_text": "Intervention 1 for the secondary trial and the primary trial either include no treatment at all  or a placebo ",
        "statement_nums": [
            "1 for the"
        ],
        "premise_text": "Subjects will be randomly selected to receive selective block with a local anesthetic solution containing 0.25 % bupivacaine (2.5 mg/ml) with 1:100,000 epinephrine and 4 mg dexamethasone  The injection will be performed in certain locations of the breast area to cover the intercostal nerves supplying the breast tissue Subjects will be randomly selected to receive the local anesthetic solution containing 0.25 % bupivacaine (2.5 mg/ml) with 1:100,000 epinephrine and 4 mg dexamethasoneadministered to the breast area to cover the intercostal nerves supplying the breast tissue during surgery  ",
        "premise_nums": [
            "0.25 % bupivacaine",
            "1:100,000 epinephrine",
            "000 epinephrine and",
            "4 mg dexamethasoneadministered",
            "(2.5 mg/ml"
        ]
    },
    {
        "id": "f53c8212-6da8-470f-a392-1bb037ed90e8",
        "primaryId": "NCT04030104",
        "secondaryId": "NCT02525718",
        "label": "Contradiction",
        "statement_text": "Intervention 1 for the secondary trial and the primary trial either include no treatment at all  or a placebo ",
        "statement_nums": [
            "1 for the"
        ],
        "premise_text": "0.25 % bupivacaine (2.5 mg/ml) w/ 1:100,000 epinephrine & 4 mg dexamethasone: If randomized to this arm  subjects will receive a selective block with a local anesthetic solution containing 0.25 % bupivacaine (2.5 mg/ml) with 1:100,000 epinephrine and 4 mg dexamethasone intraoperatively  ",
        "premise_nums": [
            "4 mg dexamethasone:",
            "0.25 % bupivacaine",
            "1:100,000 epinephrine",
            "000 epinephrine and",
            "(2.5 mg/ml"
        ]
    },
    {
        "id": "7b7e6e8b-aa62-4fcd-af1e-c243995243d1",
        "primaryId": "NCT02622074",
        "statement_text": "There were twice as many patients with DLT in cohort 2 of the primary trial than in cohort 1.",
        "statement_nums": [
            "2 of the"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Number of Participants With Dose Limiting Toxicities (DLTs) Graded Using National Cancer Institute Common Toxicity Criteria for Adverse Events Version 4.0 (NCI CTCAE v4.0) The following events  if considered to be study-treatment-related by the Investigator  were considered a DLT: Hematologic: Grade 4 neutropenia lasting 8 days; Febrile neutropenia Grade 3 or Grade 4; or Grade 4 thrombocytopenia requiring platelet transfusion  or Grade 3 thrombocytopenia with bleeding Non-hematologic: Grade 4 toxicity; Grade 3 symptomatic hepatic toxicities lasting greater than 48 hours  or Grade 3 asymptomatic hepatic toxicities lasting 7 days; or ",
        "premise_nums": [
            "3 thrombocytopenia with",
            "4 neutropenia lasting",
            "4 thrombocytopenia requiring",
            "3 asymptomatic hepatic",
            "3 symptomatic hepatic",
            "3 or Grade"
        ]
    },
    {
        "id": "7b7e6e8b-aa62-4fcd-af1e-c243995243d1",
        "primaryId": "NCT02622074",
        "statement_text": "There were twice as many patients with DLT in cohort 2 of the primary trial than in cohort 1.",
        "statement_nums": [
            "2 of the"
        ],
        "label": "Entailment",
        "premise_text": "Grade 3 non-hematologic  non-hepatic organ toxicity  with exceptionsOther: Any treatment delays for 14 days due to unresolved toxicity; Grade 5 treatment-related adverse event (AE); A dose reduction of study treatment during the DLT evaluation period  Time frame: Cycle 1 Day 1 through end of Cycle 3 and Cycle 6 Day 1 through end of Cycle 7 (Up to ~150 days from first dose of first combination regimen); Each cycle was 21 days  Results 1: Arm/Group Title: Cohort A: KNp / KAC ",
        "premise_nums": [
            "3 non-hematologic",
            "150 days from",
            "1 Day 1",
            "14 days due",
            "6 Day 1",
            "5 treatment-related adverse",
            "3 and Cycle"
        ]
    },
    {
        "id": "74a53536-bb9d-4c64-9280-679d7b660cdd",
        "primaryId": "NCT02162719",
        "statement_text": "the primary trial does not investigate the effects of its intervention on patient tpCR ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Progression Free Survival (PFS) PFS was defined as the time from randomization to the first occurrence of disease progression  as determined by investigator review of tumor assessments by RECIST  v1.1 or death on study (smaller than =30 days after the last dose of study treatment regimen) from any cause  whichever occurred first  Time frame: Baseline up to 30 days after the last dose of study drug administration (Clinical Cut Off Date: 07 June 2016) ",
        "premise_nums": [
            "07 June 2016)",
            "v1.1 or",
            "30 days after",
            "1 or death"
        ]
    },
    {
        "id": "6b35c306-a699-44f2-8606-a58d58fc18f3",
        "primaryId": "NCT00728949",
        "statement_text": "There were 6 adverse event categories for cohort 1 of the primary trial which recorded at least three cases ",
        "statement_nums": [
            "6 adverse event",
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 16/56 (28.57%) Pancytopenia 0/56 (0.00%) Pericarditis 0/56 (0.00%) Abdominal pain 1/56 (1.79%) Anal fissure 1/56 (1.79%) Ascites 1/56 (1.79%) Constipation 0/56 (0.00%) Diarrhoea 1/56 (1.79%) Nausea 0/56 (0.00%) Oesophageal pain 0/56 (0.00%) Vomiting 0/56 (0.00%) Disease progression 2/56 (3.57%) Infusion related reaction 1/56 (1.79%) Pain 0/56 (0.00%) ",
        "premise_nums": [
            "2/56 (3.57%)",
            "1/56 (1.79%)",
            "0/56 (0.00%)",
            "16/56 (28.57%)"
        ]
    },
    {
        "id": "62f50fe5-a83d-4f07-9dc7-8f495254d398",
        "primaryId": "NCT00784849",
        "secondaryId": "NCT02104895",
        "label": "Entailment",
        "statement_text": "Breast breast irradiation is used in some form for both cohorts of the secondary trial  but not at all in the primary trial ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Sentinel Lymph Node Biopsy With Radiolabeled Methylene Blue One arm diagnostic using 1 mCi of 125-I Methylene blue dye to find sentinel lymph nodes INTERVENTION 1: Whole Breast Irradiation (WBI) Conventional whole breast irradiation (WBI) Whole breast irradiation (WBI): Conventional whole breast irradiation (WBI) INTERVENTION 2: Partial Breast Irradiation (APBI) Accelerated partial breast irradiation (APBI) Accelerated partial breast irradiation (APBI): Accelerated partial breast irradiation (APBI) using intensity modulated radiotherapy (IMRT) ",
        "premise_nums": [
            "1 mCi of",
            "125-I Methylene"
        ]
    },
    {
        "id": "edcae553-8a0a-45d2-a0fa-4db68608ef03",
        "primaryId": "NCT00121134",
        "statement_text": "the primary trial requires participants to have a primary tumor greater than 5cm in longest dimension ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria: Patients must have completed definitive resection of primary tumor with adequate excision of gross disease  ",
        "premise_nums": []
    },
    {
        "id": "a1b3667f-bfa5-426a-975a-20ed350c12c0",
        "primaryId": "NCT00748553",
        "statement_text": "Patients in the primary trial receive 5 doses of Azacitidine (Vidaza) every month and 3 doses of Nab-paclitaxel (Abraxane) per month ",
        "statement_nums": [
            "5 doses of",
            "3 doses of"
        ],
        "label": "Entailment",
        "premise_text": "INTERVENTION 1: Phase 1 Azacitidine (Vidaza): 50mg/m2, 75mg/m2 or 100mg/m2 daily for 5 days for each 4-week cycle Nab-paclitaxel (Abraxane): 100mg/m2 weekly for 3 weeks of each 4-week cycle ",
        "premise_nums": [
            "3 weeks of",
            "2 weekly for",
            "1 Azacitidine (Vidaza):",
            "100mg/m2 daily",
            "50mg/m2,",
            "2 daily for",
            "5 days for",
            "75mg/m2 or",
            "4-week cycle",
            "100mg/m2 weekly"
        ]
    },
    {
        "id": "903617fa-7c40-45ac-a03c-498f51879408",
        "primaryId": "NCT02915744",
        "statement_text": "The difference in median  maximum and minimum Overall Survival (OS) of Patients between the two cohort of the primary trial was less than one month ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Overall Survival (OS) of Patients To compare Overall Survival (OS) of patients who receive 145 mg/m2 NKTR-102 given once every 21 days (q21d) with OS of patients who receive Treatment of Physician's Choice (TPC)  Overall survival is defined as the time from the date of randomization to the date of death from any cause  Patients will be followed until their date of death or until final database closure  Patients who are lost-to-follow-up or are alive at the time of analysis will be censored at the time they were last known to be alive or at the date of event cut-off for OS analysis  Time frame: Within 3 years from study start Results 1: Arm/Group Title: NKTR-102 ",
        "premise_nums": [
            "3 years from",
            "145 mg/m2 NKTR",
            "102 given once",
            "21 days (q21d)",
            "(q21d) with"
        ]
    },
    {
        "id": "903617fa-7c40-45ac-a03c-498f51879408",
        "primaryId": "NCT02915744",
        "statement_text": "The difference in median  maximum and minimum Overall Survival (OS) of Patients between the two cohort of the primary trial was less than one month ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Arm/Group Description: In Group A  NKTR-102 will be administered at a dose level of 145 mg/m2 on a q21d schedule as a 90-minute intravenous (IV) infusion on Day 1 of each treatment cycle Overall Number of Participants Analyzed: 92 Median (95% Confidence Interval) Unit of Measure: months 7.8 (6.1 to 10.2) Results 2: Arm/Group Title: Treatment of Physician's Choice (TPC) ",
        "premise_nums": [
            "145 mg/m2 on",
            "90-minute intravenous",
            "1 of each",
            "102 will be",
            "2 on a",
            "95% Confidence",
            "1 to 10.2)"
        ]
    },
    {
        "id": "903617fa-7c40-45ac-a03c-498f51879408",
        "primaryId": "NCT02915744",
        "statement_text": "The difference in median  maximum and minimum Overall Survival (OS) of Patients between the two cohort of the primary trial was less than one month ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Arm/Group Description: In Group B  TPC will be administered per standard of care  Patients randomized to TPC will receive single-agent IV chemotherapy  limited to choice of one of the following 7 agents: eribulin  ixabepilone  vinorelbine  gemcitabine  paclitaxel  docetaxel  or nab-paclitaxel Overall Number of Participants Analyzed: 86 Median (95% Confidence Interval) Unit of Measure: months 7.5 (5.8 to 10.4) ",
        "premise_nums": [
            "8 to 10.4)",
            "95% Confidence"
        ]
    },
    {
        "id": "9436e18a-a055-41c3-980f-bf451b4da7ee",
        "primaryId": "NCT00171314",
        "statement_text": "There are four types of adverse events in the primary trial  for which one occurence is recorded ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 47/254 (18.50%) Anaemia 1/254 (0.39%) Febrile neutropenia 1/254 (0.39%) Lymphadenopathy 1/254 (0.39%) Acute myocardial infarction 1/254 (0.39%) Angina pectoris 0/254 (0.00%) Angina unstable 0/254 (0.00%) Bundle branch block left 0/254 (0.00%) Cardiac failure 4/254 (1.57%) Coronary artery disease 0/254 (0.00%) Coronary artery stenosis 1/254 (0.39%) ",
        "premise_nums": [
            "1/254 (0.39%)",
            "47/254 (18.50%)",
            "0/254 (0.00%)",
            "4/254 (1.57%)"
        ]
    },
    {
        "id": "f57403d9-7278-481e-bcb9-066bf31b6158",
        "primaryId": "NCT01201265",
        "secondaryId": "NCT00932373",
        "label": "Contradiction",
        "statement_text": "1 patient in the primary trial was affected by Sepsis  and several were affected in the secondary trial ",
        "statement_nums": [
            "1 patient in"
        ],
        "premise_text": "Adverse Events 1: Total: 17/40 (42.50%) Anaemia 2/40 (5.00%) Febrile Neutropenia 3/40 (7.50%) Neutropenia 2/40 (5.00%) Thrombocytopenia 5/40 (12.50%) Pericardial Effusion 1/40 (2.50%) Abdominal Pain Lower 1/40 (2.50%) Disease Progression 6/40 (15.00%) Fatigue 1/40 (2.50%) Pyrexia 3/40 (7.50%) Septic Shock 1/40 (2.50%) Streptococcal Infection 1/40 (2.50%) Adverse Events 1: Total: 1/3 (33.33%) ",
        "premise_nums": [
            "2/40 (5.00%)",
            "3/40 (7.50%)",
            "1/3 (33.33%)",
            "1/40 (2.50%)",
            "17/40 (42.50%)",
            "5/40 (12.50%)",
            "6/40 (15.00%)"
        ]
    },
    {
        "id": "f57403d9-7278-481e-bcb9-066bf31b6158",
        "primaryId": "NCT01201265",
        "secondaryId": "NCT00932373",
        "label": "Contradiction",
        "statement_text": "1 patient in the primary trial was affected by Sepsis  and several were affected in the secondary trial ",
        "statement_nums": [
            "1 patient in"
        ],
        "premise_text": "Pain 0/3 (0.00%)Cellulitis 0/3 (0.00%) Influenza 0/3 (0.00%) Osteomyelitis 0/3 (0.00%) Pneumonia 0/3 (0.00%) Humerus Fracture 0/3 (0.00%) Brain Oedema 0/3 (0.00%) Cerebral Haemorrhage 0/3 (0.00%) Convulsion 0/3 (0.00%) Dysarthria 0/3 (0.00%) Hepatic Encephalopathy 0/3 (0.00%) Confusional State 0/3 (0.00%) Dyspnoea 1/3 (33.33%) Adverse Events 2: ",
        "premise_nums": [
            "1/3 (33.33%)",
            "0/3 (0.00%)Cellulitis"
        ]
    },
    {
        "id": "f57403d9-7278-481e-bcb9-066bf31b6158",
        "primaryId": "NCT01201265",
        "secondaryId": "NCT00932373",
        "label": "Contradiction",
        "statement_text": "1 patient in the primary trial was affected by Sepsis  and several were affected in the secondary trial ",
        "statement_nums": [
            "1 patient in"
        ],
        "premise_text": "Total: 1/1 (100.00%)Pain 0/1 (0.00%) Cellulitis 0/1 (0.00%) Influenza 0/1 (0.00%) Osteomyelitis 0/1 (0.00%) Pneumonia 0/1 (0.00%) Humerus Fracture 0/1 (0.00%) Brain Oedema 0/1 (0.00%) Cerebral Haemorrhage 0/1 (0.00%) Convulsion 0/1 (0.00%) Dysarthria 0/1 (0.00%) Hepatic Encephalopathy 0/1 (0.00%) Confusional State 0/1 (0.00%) ",
        "premise_nums": [
            "0/1 (0.00%)",
            "1/1 (100.00%)Pain"
        ]
    },
    {
        "id": "f57403d9-7278-481e-bcb9-066bf31b6158",
        "primaryId": "NCT01201265",
        "secondaryId": "NCT00932373",
        "label": "Contradiction",
        "statement_text": "1 patient in the primary trial was affected by Sepsis  and several were affected in the secondary trial ",
        "statement_nums": [
            "1 patient in"
        ],
        "premise_text": "Dyspnoea 0/1 (0.00%)",
        "premise_nums": [
            "0/1 (0.00%)"
        ]
    },
    {
        "id": "ec601f6b-6ce3-4df7-b7b3-fbde1a241e93",
        "primaryId": "NCT00688909",
        "secondaryId": "NCT00129376",
        "label": "Entailment",
        "statement_text": "Patients in the primary trial and the secondary trial did not suffer from any of the same adverse events ",
        "statement_nums": [],
        "premise_text": "Adverse Events 1: Total: 5/261 (1.92%) Cholecystitis chronic 1/261 (0.38%) Post procedural bile leak 1/261 (0.38%) Spinal column stenosis 1/261 (0.38%) Depression 1/261 (0.38%) Mania 1/261 (0.38%) Pulmonary embolism 1/261 (0.38%) Adverse Events 1: Total: 12/63 (19.05%) Febrile neutropenia * [1]4/63 (6.35%) Congestive heart failure * [2]1/63 (1.59%) Cardiac-ischemia/infarction * 1/63 (1.59%) ",
        "premise_nums": [
            "1/63 (1.59%)",
            "12/63 (19.05%)",
            "1/261 (0.38%)",
            "5/261 (1.92%)",
            "4/63 (6.35%)"
        ]
    },
    {
        "id": "ec601f6b-6ce3-4df7-b7b3-fbde1a241e93",
        "primaryId": "NCT00688909",
        "secondaryId": "NCT00129376",
        "label": "Entailment",
        "statement_text": "Patients in the primary trial and the secondary trial did not suffer from any of the same adverse events ",
        "statement_nums": [],
        "premise_text": "Vomiting * [1]1/63 (1.59%)Acute Pharyngitis * 1/63 (1.59%) Infection * 3/63 (4.76%) Neutrophil count decreased * [1]1/63 (1.59%) Pneumonitis/pulmonary infiltrates * [3]1/63 (1.59%) ",
        "premise_nums": [
            "1/63 (1.59%)Acute",
            "3/63 (4.76%)"
        ]
    },
    {
        "id": "0f0e5a8e-3972-46c2-84dd-7436e82a9787",
        "primaryId": "NCT00291135",
        "secondaryId": "NCT00291694",
        "label": "Contradiction",
        "statement_text": "The duration of treatment in the primary trial is half as long as in the secondary trial  but twice as frequent ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Letrozole Letrozole  2.5 mg daily for six months INTERVENTION 1: Celecoxib Randomized to receive celecoxib daily for 12 months INTERVENTION 2: Placebo Randomized to receive placebo daily for 12 months ",
        "premise_nums": [
            "12 months INTERVENTION",
            "5 mg daily"
        ]
    },
    {
        "id": "420e4977-ce75-4fab-99e0-3e7db837d521",
        "primaryId": "NCT00191152",
        "statement_text": "The longest Time to Disease Progression the primary trial was over 21 days in the Docetaxel Plus Capecitabine group ",
        "statement_nums": [
            "21 days in"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Time to Disease Progression (Initial Treatment) Time to disease progression (TTDP) at initial treatment was defined as the number of months between date of randomization and the date of first documented disease progression or the date of death due to disease under study  whichever came first  TTDP censored at earliest of: 1) date of death not due to disease; or 2) date of last contact for participants alive without disease progression; or 3) start date of other anti-tumor therapy; or 4) first dose date of crossover treatment  Time frame: Randomization date to the earliest date of first documented disease progression date or the date of death if the participant died due to study disease (up to 82 months) Results 1: Arm/Group Title: Gemcitabine Plus Docetaxel ",
        "premise_nums": []
    },
    {
        "id": "420e4977-ce75-4fab-99e0-3e7db837d521",
        "primaryId": "NCT00191152",
        "statement_text": "The longest Time to Disease Progression the primary trial was over 21 days in the Docetaxel Plus Capecitabine group ",
        "statement_nums": [
            "21 days in"
        ],
        "label": "Contradiction",
        "premise_text": "Arm/Group Description: gemcitabine 1000 milligrams per meter squared (mg/m2) intravenous  days 1 and 8 every 21 days plus docetaxel 75 mg/m2, intravenous  day 1 every 21 days Treatment continues until progression of disease at which time crossover treatment begins  Overall Number of Participants Analyzed: 239 Median (95% Confidence Interval) Unit of Measure: months 9.28 (7.73 to 10.79) Results 2: Arm/Group Title: Docetaxel Plus Capecitabine ",
        "premise_nums": [
            "1000 milligrams per",
            "75 mg/m2,",
            "1 every 21",
            "73 to 10.79)",
            "1 and 8",
            "95% Confidence",
            "21 days plus"
        ]
    },
    {
        "id": "420e4977-ce75-4fab-99e0-3e7db837d521",
        "primaryId": "NCT00191152",
        "statement_text": "The longest Time to Disease Progression the primary trial was over 21 days in the Docetaxel Plus Capecitabine group ",
        "statement_nums": [
            "21 days in"
        ],
        "label": "Contradiction",
        "premise_text": "Arm/Group Description: docetaxel 75 mg/m2, intravenous  day 1 every 21 days plus capecitabine 1000 mg/m2, by mouth twice a day  days 1-14 every 21 days  Treatment continues until progression of disease  at which time crossover treatment begins Overall Number of Participants Analyzed: 236 Median (95% Confidence Interval) Unit of Measure: months 8.88 (7.37 to 11.05) ",
        "premise_nums": [
            "14 every 21",
            "75 mg/m2,",
            "1 every 21",
            "37 to 11.05)",
            "95% Confidence",
            "1000 mg/m2,",
            "1-14 every"
        ]
    },
    {
        "id": "d07b4a30-e74f-468a-8420-7ade791d372d",
        "primaryId": "NCT00096356",
        "statement_text": "the primary trial results indicate that CoQ10 reduces the PFS of breast cancer patients compared to a placebo by about 8%",
        "statement_nums": [
            "10 reduces the",
            "CoQ10 reduces"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Effects of Coenzyme Q10 on Fatigue (as Measured by POMS-F) 24 Weeks Following Randomization POMS-F is the Profile of Mood States - fatigue scale  It ranges from 0 to 28; higher values indicate greater fatigue  Time frame: 24 weeks Results 1: Arm/Group Title: Arm 1 - CoQ10 & Vitamin E Arm/Group Description: CoQ10 100mg capsule combined with Vitamin E 100 IU taken orally three times per day  Overall Number of Participants Analyzed: 122 Least Squares Mean (Standard Error) Unit of Measure: units on a scale 6.96 (0.71) Results 2: Arm/Group Title: Arm 2 - Placebo & Vitamin E Arm/Group Description: Placebo-Vitamin E 100 mg/day in 3 doses Overall Number of Participants Analyzed: 114 ",
        "premise_nums": [
            "24 Weeks Following",
            "10 on Fatigue",
            "3 doses Overall",
            "100 IU taken",
            "Q10 on",
            "100 mg/day in",
            "122 Least Squares",
            "24 weeks Results",
            "0 to 28;"
        ]
    },
    {
        "id": "d07b4a30-e74f-468a-8420-7ade791d372d",
        "primaryId": "NCT00096356",
        "statement_text": "the primary trial results indicate that CoQ10 reduces the PFS of breast cancer patients compared to a placebo by about 8%",
        "statement_nums": [
            "10 reduces the",
            "CoQ10 reduces"
        ],
        "label": "Contradiction",
        "premise_text": "Least Squares Mean (Standard Error)Unit of Measure: units on a scale 8.33 (0.79) ",
        "premise_nums": []
    },
    {
        "id": "412b2743-8f76-494a-af97-f7bf9541a890",
        "primaryId": "NCT02536339",
        "secondaryId": "NCT00371345",
        "label": "Entailment",
        "statement_text": "At least one type of respiratory illness was observed in patients from both the primary trial and the secondary trial ",
        "statement_nums": [],
        "premise_text": "Adverse Events 1: Parainfluenzae virus infection 1/39 (2.56%) Adverse Events 1: PNEUMONIA 1/70 (1.43%) ",
        "premise_nums": [
            "1/70 (1.43%)",
            "1/39 (2.56%)"
        ]
    },
    {
        "id": "fd43feb6-4a55-4de6-b21d-25ff723b0959",
        "primaryId": "NCT00631852",
        "secondaryId": "NCT00193037",
        "label": "Contradiction",
        "statement_text": "Patients may be forced to take part in the secondary trial and the primary trial  even against their consent  as long as it is in their best interests ",
        "statement_nums": [],
        "premise_text": "Inclusion Criteria: ability and willingness to sign written consent Inclusion Criteria: Written informed consent ",
        "premise_nums": []
    },
    {
        "id": "e1fa68ac-42b4-4223-a362-a89c43562e06",
        "primaryId": "NCT01256567",
        "secondaryId": "NCT01926886",
        "label": "Contradiction",
        "statement_text": "The most common adverse event in the primary trial was Febrile neutropenia (14.29%), whereas in the secondary trial it was a decrease in Ejection fraction (4.95%).",
        "statement_nums": [],
        "premise_text": "Adverse Events 1: Total: 7/7 (100.00%) Febrile neutropenia 3/7 (42.86%) Cardiac failure 1/7 (14.29%) Neutrophil count decreased 1/7 (14.29%) Muscular weakness 1/7 (14.29%) Epistaxis 1/7 (14.29%) Interstitial lung disease 1/7 (14.29%) Pleural effusion 2/7 (28.57%) Adverse Events 1: Total: 8/101 (7.92%) Vertigo * 1/101 (0.99%) ",
        "premise_nums": [
            "3/7 (42.86%)",
            "2/7 (28.57%)",
            "1/7 (14.29%)",
            "7/7 (100.00%)",
            "8/101 (7.92%)",
            "1/101 (0.99%)"
        ]
    },
    {
        "id": "e1fa68ac-42b4-4223-a362-a89c43562e06",
        "primaryId": "NCT01256567",
        "secondaryId": "NCT01926886",
        "label": "Contradiction",
        "statement_text": "The most common adverse event in the primary trial was Febrile neutropenia (14.29%), whereas in the secondary trial it was a decrease in Ejection fraction (4.95%).",
        "statement_nums": [],
        "premise_text": "Infected lymphocele * 1/101 (0.99%)Ejection fraction decreased * 5/101 (4.95%) Lymphoedema * 1/101 (0.99%) ",
        "premise_nums": [
            "1/101 (0.99%)Ejection",
            "5/101 (4.95%)"
        ]
    },
    {
        "id": "6f5570c0-4114-47ee-9611-b2e4be91cf9a",
        "primaryId": "NCT03165955",
        "secondaryId": "NCT00912340",
        "label": "Contradiction",
        "statement_text": "2 patients in the primary trial suffer from DVT  0 in the secondary trial ",
        "statement_nums": [
            "0 in the",
            "2 patients in"
        ],
        "premise_text": "Deep vein thrombosis 1/28 (3.57%) Adverse Events 1: Total: 1/24 (4.17%) Pericardial effusion *1/24 (4.17%) Other cardiac disorder *0/24 (0.00%) Ejection fraction decrease *0/24 (0.00%) Hypertension *0/24 (0.00%) Salivary gland infection *0/24 (0.00%) Pleural effusion *0/24 (0.00%) Adverse Events 2: Total: 6/30 (20.00%) Pericardial effusion *1/30 (3.33%) Other cardiac disorder *1/30 (3.33%) Ejection fraction decrease *1/30 (3.33%) ",
        "premise_nums": [
            "1/24 (4.17%)",
            "6/30 (20.00%)",
            "1/28 (3.57%)",
            "1/30 (3.33%)",
            "0/24 (0.00%)"
        ]
    },
    {
        "id": "6f5570c0-4114-47ee-9611-b2e4be91cf9a",
        "primaryId": "NCT03165955",
        "secondaryId": "NCT00912340",
        "label": "Contradiction",
        "statement_text": "2 patients in the primary trial suffer from DVT  0 in the secondary trial ",
        "statement_nums": [
            "0 in the",
            "2 patients in"
        ],
        "premise_text": "Hypertension *1/30 (3.33%)Salivary gland infection *1/30 (3.33%) Pleural effusion *2/30 (6.67%) ",
        "premise_nums": [
            "1/30 (3.33%)Salivary",
            "2/30 (6.67%)"
        ]
    },
    {
        "id": "13b4a3c5-cf6e-4f65-9f94-be927c3ce5ef",
        "primaryId": "NCT01224678",
        "statement_text": "Intervention 2 of the primary trial resulted in a lower percentage change in tumor diameter than intervention 1.",
        "statement_nums": [
            "2 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Percent Change (Between Baseline and Month 12) in Mammographic Density by the Boyd Method Compared Between Arms To evaluate change in mammographic density using the Boyd method after one year of vitamin D supplementation compared to placebo in premenopausal women  The percent change in breast density will be reported here  Time frame: 12 months Results 1: Arm/Group Title: Placebo Arm/Group Description: Patients receive oral placebo once daily for 12 months  Overall Number of Participants Analyzed: 46 Mean (Standard Deviation) Unit of Measure: percent change -3.4 (7.1) Results 2: Arm/Group Title: Vitamin D Arm/Group Description: Patients receive oral vitamin D (2000 IU) once daily for 12 months  Overall Number of Participants Analyzed: 40 Mean (Standard Deviation) ",
        "premise_nums": [
            "46 Mean (Standard",
            "40 Mean (Standard",
            "12 months Results"
        ]
    },
    {
        "id": "13b4a3c5-cf6e-4f65-9f94-be927c3ce5ef",
        "primaryId": "NCT01224678",
        "statement_text": "Intervention 2 of the primary trial resulted in a lower percentage change in tumor diameter than intervention 1.",
        "statement_nums": [
            "2 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Unit of Measure: percent change -1.4 (11.9)",
        "premise_nums": []
    },
    {
        "id": "6495c223-f7d9-459f-8c57-66a2caac5ee4",
        "primaryId": "NCT02581839",
        "statement_text": "All participants in the primary trial had a Central Nervous System (CNS) Progression Free Survival (PFS) greater than or equal 16 weeks ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Percent of Participants With Central Nervous System (CNS) Progression Free Survival (PFS) The study team will assess the percent of participants without CNS progression at 3 months  The study team will generate a Kaplan- Meier curve of CNS PFS and estimate the PFS and 95% confidence interval (CI) of the PFS  Response and progression by MR were evaluated using WHO/modified McDonald's criteria  Time frame: At 12 weeks Results 1: Arm/Group Title: Eribulin Mesylate ",
        "premise_nums": [
            "95% confidence",
            "12 weeks Results"
        ]
    },
    {
        "id": "6495c223-f7d9-459f-8c57-66a2caac5ee4",
        "primaryId": "NCT02581839",
        "statement_text": "All participants in the primary trial had a Central Nervous System (CNS) Progression Free Survival (PFS) greater than or equal 16 weeks ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Arm/Group Description: The recommended starting dose of eribulin mesylate is 1.4 mg/m2 administered intravenously over 2 to 5 minutes on Days 1 and 8 of a 21-day cycle  An MRI will be completed at week 1, week 12 and every 12 weeks after cycles 4+ while on study eribulin mesylateEribulin Mesylate: Most subjects will begin eribulin mesylate at 1.4 mg/m2 administered intravenously over 2 to 5 minutes on Days 1 and 8 of a 21-day cycle  MRI: An MRI will be completed at week 1, week 12 and every 12 weeks after cycles 4+ while on study eribulin mesylate ",
        "premise_nums": [
            "is 1.4 mg/m2",
            "at 1.4 mg/m2",
            "2 to 5",
            "2 administered intravenously",
            "12 weeks after",
            "1 and 8",
            "12 and every",
            "21-day cycle"
        ]
    },
    {
        "id": "6495c223-f7d9-459f-8c57-66a2caac5ee4",
        "primaryId": "NCT02581839",
        "statement_text": "All participants in the primary trial had a Central Nervous System (CNS) Progression Free Survival (PFS) greater than or equal 16 weeks ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Pre-Medication: Zofran: Zofran at 8mg orally  Given at the discretion of the treating physicianPre-Medication: Decadron: decadron at 8mg orally  Given at the discretion of the treating physician Overall Number of Participants Analyzed: 9 Measure Type: Number Unit of Measure: percentage of participants 88.9 (51 to 99.7) ",
        "premise_nums": [
            "51 to 99.7)",
            "9 Measure Type:"
        ]
    },
    {
        "id": "eb61fee2-30fc-42f9-80bd-4d73d6af592c",
        "primaryId": "NCT01216319",
        "secondaryId": "NCT03346161",
        "label": "Entailment",
        "statement_text": "the secondary trial and the primary trial are evaluating interventions associated with breast reconstruction for patients that have had mastectomies ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Nipple Reconstruction Cylinder Nipple reconstruction: Biodesign® Nipple Reconstruction Cylinder INTERVENTION 1: Arm 1: BREASTChoice (Decision Tool) ",
        "premise_nums": []
    },
    {
        "id": "eb61fee2-30fc-42f9-80bd-4d73d6af592c",
        "primaryId": "NCT01216319",
        "secondaryId": "NCT03346161",
        "label": "Entailment",
        "statement_text": "the secondary trial and the primary trial are evaluating interventions associated with breast reconstruction for patients that have had mastectomies ",
        "statement_nums": [],
        "premise_text": "Investigators recruited patients scheduled for a plastic/reconstruction consult  Investigators identified patients who completed a mastectomy  or were scheduled for one  and considering reconstruction  but didn't have an appointment with a plastic/reconstructive surgeon  A study team member called the patient to determine their interest and offered for them to come to their scheduled appointment 30 minutes early to meet a coordinator or offered them the option to complete pre-appointment procedures at home  Patients randomized using computer random assignment  If the patient didn't have an appointment  she scheduled a convenient time to complete study procedures with research staff  Patients interacted with the decision tool  They were asked to answer a survey  After the appointment  the team collected information consult duration  decision process quality  and measures of shared decision making  Patient participation was approximately 30 minutes ",
        "premise_nums": [
            "30 minutes early"
        ]
    },
    {
        "id": "79c698bf-a756-4a73-8075-38c3c5eb7a04",
        "primaryId": "NCT00091832",
        "statement_text": "Both cohorts of the primary trial in a negative (mean) Percent Change From Baseline of Creatinine-adjusted Urinary N-telopeptide (uNTx/Cr) ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Percent Change From Baseline to Week 13 in Creatinine-adjusted Urinary N-telopeptide (uNTx/Cr) Percent change from Baseline to Week 13 in Urinary N-telopeptide corrected by creatinine (uNTx/Cr) calculated using ((Week 13 value - Baseline value) / Baseline value ) x 100. Time frame: Baseline and Week 13 Results 1: Arm/Group Title: Bisphosphonate IV Q4W Arm/Group Description: Open label bisphosphonate every 4 weeks (Q4W) by intravenous infusion Overall Number of Participants Analyzed: 38 Mean (Standard Deviation) ",
        "premise_nums": [
            "38 Mean (Standard",
            "4 weeks (Q4W)",
            "13 Results 1:",
            "13 in Creatinine",
            "13 in Urinary",
            "(Q4W) by"
        ]
    },
    {
        "id": "79c698bf-a756-4a73-8075-38c3c5eb7a04",
        "primaryId": "NCT00091832",
        "statement_text": "Both cohorts of the primary trial in a negative (mean) Percent Change From Baseline of Creatinine-adjusted Urinary N-telopeptide (uNTx/Cr) ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Unit of Measure: Percent change -10.19 (208.84)Results 2: Arm/Group Title: Denosumab 30 mg Q4W Arm/Group Description: Denosumab 30 mg by subcutaneous injection every 4 weeks (Q4W) Overall Number of Participants Analyzed: 40 Mean (Standard Deviation) Unit of Measure: Percent change -52.87 (95.14) ",
        "premise_nums": [
            "(Q4W) Overall",
            "30 mg by",
            "4 weeks (Q4W)",
            "40 Mean (Standard",
            "30 mg Q4W"
        ]
    },
    {
        "id": "f7be0a6e-6c63-473e-af00-df009f3d7d46",
        "primaryId": "NCT00571987",
        "statement_text": "Breast implants and Diffuse microcalcifications will not disqualify a patient from entry to the primary trial ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria: Female  18-100 years old Not pregnant or breastfeeding Pre-study radiologic documentation of: size 5 cm unicentric  unilateral suspicious mass or calcification BIRADS classification IV location of abnormality greater than 1 cm from skin Ductal or Infiltrating Ductal Carcinoma Grade I-III on final pathology Good general health Zubrod Performance Status of 0,1, or 2 No previous chemotherapy No palpable axillary or supraclavicular lymph nodes If prior non-breast malignancy  must have greater than 5 year disease-free survival Exclusion Criteria: Patient smaller than 18 y/o or greater than 100 y/o Pregnant or breastfeeding Male Breast implants Multicentric disease or bilateral disease ",
        "premise_nums": [
            "18 y/o or",
            "100 years old",
            "0,1, or",
            "5 year disease",
            "100 y/o Pregnant",
            "1 cm from",
            "18-100 years",
            "5 cm unicentric",
            "2 No previous"
        ]
    },
    {
        "id": "f7be0a6e-6c63-473e-af00-df009f3d7d46",
        "primaryId": "NCT00571987",
        "statement_text": "Breast implants and Diffuse microcalcifications will not disqualify a patient from entry to the primary trial ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Lesions greater than 5 cm in diameterLesions smaller than 1.0 cm from the skin Previous prior radiation to the breast Need for mastectomy Diffuse microcalcifications (as determined by the Investigator) ",
        "premise_nums": [
            "5 cm in",
            "than 1.0 cm from"
        ]
    },
    {
        "id": "6f686de9-f110-4be0-9cd8-1ceb0ce6f073",
        "primaryId": "NCT01376349",
        "secondaryId": "NCT01912612",
        "label": "Contradiction",
        "statement_text": "Cohort 2 subjects of the primary trial receive 3.25 mg of vaginal DHEA gel QD more than cohort 1 subjects  of the two cohorts in the secondary trial only the cohort without pain recieves Duloxetine 30 mg daily ",
        "statement_nums": [
            "receive 3.25 mg of",
            "2 subjects of",
            "30 mg daily"
        ],
        "premise_text": "INTERVENTION 1: Arm I Low Dose DHEA Participants apply a low dose (3.25 mg) of vaginal prasterone (dehydroepiandrosterone [DHEA]) gel once daily (QD)  at bed time  for 12 weeks  Treatment continues until unacceptable adverse events or patient refusal to continue participation on the study  INTERVENTION 2: Arm II High Dose DHEA Participants apply a high dose (6.5 mg) of vaginal DHEA gel QD  at bed time  for 12 weeks  Treatment continues until unacceptable adverse events or patient refusal to continue participation on the study  INTERVENTION 1: Arm 1 (Patients With Pain) ",
        "premise_nums": []
    },
    {
        "id": "6f686de9-f110-4be0-9cd8-1ceb0ce6f073",
        "primaryId": "NCT01376349",
        "secondaryId": "NCT01912612",
        "label": "Contradiction",
        "statement_text": "Cohort 2 subjects of the primary trial receive 3.25 mg of vaginal DHEA gel QD more than cohort 1 subjects  of the two cohorts in the secondary trial only the cohort without pain recieves Duloxetine 30 mg daily ",
        "statement_nums": [
            "receive 3.25 mg of",
            "2 subjects of",
            "30 mg daily"
        ],
        "premise_text": "Duloxetine 30 mg daily x 1 week  then 60 mg daily x 4 weeks  then 30 mg daily x 2 weeks Duloxetine: Subjects will receive 30 mg duloxetine orally for 7 days  then 60 mg duloxetine orally for 28 days  then 30 mg duloxetine orally x 14 days  INTERVENTION 2: Arm 2 (Patients Without Pain -- Control) Patient reported pain and symptoms assessment for comparison at baseline  ",
        "premise_nums": [
            "2 weeks Duloxetine:",
            "30 mg daily",
            "60 mg daily",
            "60 mg duloxetine",
            "30 mg duloxetine"
        ]
    },
    {
        "id": "2c602b4d-c8a5-4606-8e3a-a87ee7bbc480",
        "primaryId": "NCT01004744",
        "statement_text": "Patients must have a confirmed pregnancy by positive Hcg test  if they are to take part in the primary trial ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Postmenopausal status defined as cessation of menses for greater than 1 year or FSH greater than 20 mIU/mL (within the past month) ",
        "premise_nums": [
            "20 mIU/mL",
            "1 year or"
        ]
    },
    {
        "id": "ffa913b7-9875-458e-8a28-476f9e788bb0",
        "primaryId": "NCT02463032",
        "statement_text": "There was less than a 5% difference in the Percentage of Participants With Objective Response in the GTx-024 9 mg and GTx-024 18 mg group in the primary trial ",
        "statement_nums": [
            "18 mg group",
            "5% difference",
            "9 mg and"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Clinical Benefit Rate  in Centrally Confirmed Androgen Receptor (AR)+ Subjects ",
        "premise_nums": []
    },
    {
        "id": "ffa913b7-9875-458e-8a28-476f9e788bb0",
        "primaryId": "NCT02463032",
        "statement_text": "There was less than a 5% difference in the Percentage of Participants With Objective Response in the GTx-024 9 mg and GTx-024 18 mg group in the primary trial ",
        "statement_nums": [
            "18 mg group",
            "5% difference",
            "9 mg and"
        ],
        "label": "Contradiction",
        "premise_text": "To estimate the clinical benefit rate (defined as complete response  partial response  or stable disease) according to RECIST 1.1, in subjects with estrogen receptor positive/androgen receptor positive (ER+/AR+) BC who have centrally confirmed AR+ status  Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions assessed by CT or MRI: Complete Response (CR)  Disappearance of all target lesions; Partial Response (PR)  greater than or equal 30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR; Clinical Benefit Rate (CBR)= CR + PR + SD Time frame: 24 weeks Results 1: ",
        "premise_nums": [
            "30% decrease",
            "24 weeks Results"
        ]
    },
    {
        "id": "ffa913b7-9875-458e-8a28-476f9e788bb0",
        "primaryId": "NCT02463032",
        "statement_text": "There was less than a 5% difference in the Percentage of Participants With Objective Response in the GTx-024 9 mg and GTx-024 18 mg group in the primary trial ",
        "statement_nums": [
            "18 mg group",
            "5% difference",
            "9 mg and"
        ],
        "label": "Contradiction",
        "premise_text": "Arm/Group Title: GTx-024 9 mgArm/Group Description: Drug: GTx-024 GTx-024 softgel capsules will be administered once daily to a total dose of 9 mg GTx-024: To determine whether either or both doses result in an acceptable clinical benefit rate  Overall Number of Participants Analyzed: 50 Measure Type: Number Unit of Measure: participants 16 Results 2: Arm/Group Title: GTx-024 18 mg Arm/Group Description: Drug: GTx-024 GTx-024 softgel capsules will be administered once daily to a total dose of 18 mg ",
        "premise_nums": [
            "50 Measure Type:",
            "16 Results 2:",
            "18 mg Arm",
            "9 mg GTx",
            "024 softgel capsules",
            "9 mgArm/Group Description"
        ]
    },
    {
        "id": "ffa913b7-9875-458e-8a28-476f9e788bb0",
        "primaryId": "NCT02463032",
        "statement_text": "There was less than a 5% difference in the Percentage of Participants With Objective Response in the GTx-024 9 mg and GTx-024 18 mg group in the primary trial ",
        "statement_nums": [
            "18 mg group",
            "5% difference",
            "9 mg and"
        ],
        "label": "Contradiction",
        "premise_text": "GTx-024: To determine whether either or both doses result in an acceptable clinical benefit rate Overall Number of Participants Analyzed: 52 Measure Type: Number Unit of Measure: participants 15 ",
        "premise_nums": [
            "52 Measure Type:"
        ]
    },
    {
        "id": "5a4018ea-5d00-4d44-bfa3-a1dfb341b9e5",
        "primaryId": "NCT00193206",
        "statement_text": "the primary trial records a total of 7 different types of infections ",
        "statement_nums": [
            "7 different types"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 22/123 (17.89%) Cardiac Ischemia/Infarction [1]1/123 (0.81%) Pain - Chest 2/123 (1.63%) Dehydration 2/123 (1.63%) Death [2]1/123 (0.81%) Weakness 1/123 (0.81%) Pain - Liver 1/123 (0.81%) Infection - Skin [3]3/123 (2.44%) Infection - Gastrointestinal [4]1/123 (0.81%) Infection - Vein [5]2/123 (1.63%) Infection - Pneumonia 1/123 (0.81%) ",
        "premise_nums": [
            "3/123 (2.44%)",
            "1/123 (0.81%)",
            "2/123 (1.63%)",
            "22/123 (17.89%)"
        ]
    },
    {
        "id": "d8e47fe7-be41-4f74-881b-a80cd3a1e95f",
        "primaryId": "NCT03456427",
        "secondaryId": "NCT02685566",
        "label": "Entailment",
        "statement_text": "There are no details concerning the duration or frequency of administration in the intervention sections of the primary trial and the secondary trial",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: All Study Participants: Patient Assisted Compression All subjects will undergo standard of care imaging on one breast  The other breast will be imaged using Patient-Assisted Compression (PAC)  followed by Technologist-controlled (TC) Compression  Patient-Assisted Compression (PAC): The technologist will properly position the breast and apply minimum compression  The subject will be instructed to apply compression as the technologist ensures the breast tissue is in appropriate position and tautness  The technologist will then guide the subject to achieve appropriate compression level  sufficient but not excessive  and the image will be acquired  This will be done for both standard views CC & MLO  INTERVENTION 2: All Study Participants: Technologist Compression ",
        "premise_nums": []
    },
    {
        "id": "d8e47fe7-be41-4f74-881b-a80cd3a1e95f",
        "primaryId": "NCT03456427",
        "secondaryId": "NCT02685566",
        "label": "Entailment",
        "statement_text": "There are no details concerning the duration or frequency of administration in the intervention sections of the primary trial and the secondary trial",
        "statement_nums": [],
        "premise_text": "All subjects will undergo standard of care imaging on one breast  The other breast will be imaged using Patient-Assisted Compression (PAC)  followed by Technologist-controlled (TC) Compression Technologist-Controlled (TC) Compression: TC compression will be conducted per standard of care practices at the site  INTERVENTION 1: FFDM Plus DBT Breast Images with FFDM and DBT FFDM Plus DBT: FujiFilm Aspire Cristalle System  This endpoint will be evaluated qualitatively  The Pass Criteria require adequate performance in non-cancer cases (recall rate) and in cancer cases (detection rate)  INTERVENTION 2: Full-Field Digital Mammography (FFDM) ",
        "premise_nums": []
    },
    {
        "id": "d8e47fe7-be41-4f74-881b-a80cd3a1e95f",
        "primaryId": "NCT03456427",
        "secondaryId": "NCT02685566",
        "label": "Entailment",
        "statement_text": "There are no details concerning the duration or frequency of administration in the intervention sections of the primary trial and the secondary trial",
        "statement_nums": [],
        "premise_text": "Breast Images with FFDM alone FFDM: FujiFilm Aspire Cristalle System This endpoint will be evaluated qualitatively  The Pass Criteria require adequate performance in non-cancer cases (recall rate) and in cancer cases (detection rate)  ",
        "premise_nums": []
    },
    {
        "id": "e77e15a3-d851-4174-80c3-7b5156e7f987",
        "primaryId": "NCT00236899",
        "secondaryId": "NCT01153672",
        "label": "Entailment",
        "statement_text": "the primary trial and the secondary trial do not use any of the same drugs in their interventions ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Treatment Schedule (Weekly) Arm C  Docetaxel and Gemcitabine (Weekly): Docetaxel: 30 mg/m²  30-60 min IV infusion on Days 1, 8, and 15 to be given 30 minutes prior to Gemcitabine  repeated every 28 days (weekly) for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD  Gemcitabine: 800 mg/m²  30 min IV infusion on Days 1, 8, and 15 repeated every 28 days for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD  Arm D  Paclitaxel and Gemcitabine (Weekly): ",
        "premise_nums": [
            "28 days (weekly)",
            "28 days for",
            "60 min IV",
            "30-60 min",
            "800 mg/m²",
            "6 cycles for",
            "10 cycles for",
            "30 mg/m²",
            "15 repeated every",
            "30 min IV",
            "15 to be",
            "30 minutes prior"
        ]
    },
    {
        "id": "e77e15a3-d851-4174-80c3-7b5156e7f987",
        "primaryId": "NCT00236899",
        "secondaryId": "NCT01153672",
        "label": "Entailment",
        "statement_text": "the primary trial and the secondary trial do not use any of the same drugs in their interventions ",
        "statement_nums": [],
        "premise_text": "Paclitaxel: 80 mg/m²  IV infusion over approximately 1 hour  Days 1, 8, and 15, followed by Gemcitabine  repeated every 28 days (weekly) for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD Gemcitabine: 800 mg/m²  30 min IV infusion on Days 1, 8, and 15 repeated every 28 days for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD  INTERVENTION 2: Treatment Schedule (3 Weekly) Arm A  Docetaxel and Gemcitabine (3 Weekly): ",
        "premise_nums": [
            "28 days (weekly)",
            "80 mg/m²",
            "800 mg/m²",
            "6 cycles for",
            "10 cycles for",
            "15 repeated every",
            "30 min IV",
            "28 days for"
        ]
    },
    {
        "id": "e77e15a3-d851-4174-80c3-7b5156e7f987",
        "primaryId": "NCT00236899",
        "secondaryId": "NCT01153672",
        "label": "Entailment",
        "statement_text": "the primary trial and the secondary trial do not use any of the same drugs in their interventions ",
        "statement_nums": [],
        "premise_text": "Docetaxel: 75 mg/m²  60 min IV infusion on Day 1 only  to be given 30 min prior to Gemcitabine  repeated every 21 days (tri-weekly) for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD Gemcitabine: 1000 mg/m²  30 min IV infusion on Days 1 and 8, repeated every 21 days for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD  Arm B  Paclitaxel and Gemcitabine (3 Weekly): ",
        "premise_nums": [
            "60 min IV",
            "21 days for",
            "6 cycles for",
            "30 min prior",
            "75 mg/m²",
            "10 cycles for",
            "1000 mg/m²",
            "30 min IV",
            "1 and 8,"
        ]
    },
    {
        "id": "e77e15a3-d851-4174-80c3-7b5156e7f987",
        "primaryId": "NCT00236899",
        "secondaryId": "NCT01153672",
        "label": "Entailment",
        "statement_text": "the primary trial and the secondary trial do not use any of the same drugs in their interventions ",
        "statement_nums": [],
        "premise_text": "Paclitaxel: 175 mg/m²  IV infusion over approximately 3 hours followed by Gemcitabine  repeated every 21 days (tri-weekly) for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD Gemcitabine: 1250 mg/m²  30 min IV infusion on Days 1 and 8, repeated every 21 days for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD  INTERVENTION 1: Treatment (Enzyme Inhibitor Therapy  AI Sensitization Therapy) ",
        "premise_nums": [
            "21 days for",
            "6 cycles for",
            "3 hours followed",
            "10 cycles for",
            "175 mg/m²",
            "30 min IV",
            "1250 mg/m²",
            "1 and 8,"
        ]
    },
    {
        "id": "e77e15a3-d851-4174-80c3-7b5156e7f987",
        "primaryId": "NCT00236899",
        "secondaryId": "NCT01153672",
        "label": "Entailment",
        "statement_text": "the primary trial and the secondary trial do not use any of the same drugs in their interventions ",
        "statement_nums": [],
        "premise_text": "Patients receive vorinostat PO QD for 2 weeks followed by AI therapy comprising anastrozole PO QD  letrozole PO QD  OR exemestane PO QD for 6 weeks  Courses repeat every 8 weeks in the absence of disease progression or unacceptable toxicity vorinostat: Given PO laboratory biomarker analysis: Correlative studies biopsy: Optional correlative studies F-18 16 alpha-fluoroestradiol: Correlative studies positron emission tomography: Correlative studies anastrozole: Given PO letrozole: Given PO exemestane: Given PO gene expression analysis: Correlative studies ",
        "premise_nums": [
            "16 alpha-fluoroestradiol:",
            "8 weeks in",
            "2 weeks followed"
        ]
    },
    {
        "id": "c003dd08-af3b-44cc-b31c-6fbdadfa1d83",
        "primaryId": "NCT01806259",
        "statement_text": "In total Over 85% patient in the primary trial achieve Recurrence-free Survival after 3 years ",
        "statement_nums": [
            "85% patient"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Recurrence-free Survival 2 years for the primary analysis + 3 additional years for secondary analysis (From date of randomization until the date of first documented progression or date of death from any cause  whichever came first  assessed up to 5 years) Time frame: 5 years Results 1: Arm/Group Title: Ketorolac 30 mg Arm/Group Description: Active drug to be compared with placebo Ketorolac 30 mg IV Overall Number of Participants Analyzed: 96 Measure Type: Count of Participants Unit of Measure: Participants 80 83.3% Results 2: Arm/Group Title: NaCl 0.9% 3mL Arm/Group Description: Ketorolac 30 mg IV Overall Number of Participants Analyzed: 107 Measure Type: Count of Participants Unit of Measure: Participants 96 89.7% ",
        "premise_nums": [
            "96 Measure Type:",
            "30 mg Arm",
            "80 83.3% Results 2",
            "3 additional years",
            "2 years for",
            "30 mg IV",
            "107 Measure Type:",
            "5 years Results"
        ]
    },
    {
        "id": "8ddf49c7-316e-4c7c-b2dd-423182a37612",
        "primaryId": "NCT00455533",
        "secondaryId": "NCT00767520",
        "label": "Entailment",
        "statement_text": "Throughout both the secondary trial and the primary trial there was only one case of sudden and unexpected death  in cohort 1 of the secondary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Adverse Events 1: Total: 17/145 (11.72%) ANAEMIA 0/145 (0.00%) LEUKOPENIA 2/145 (1.38%) NEUTROPENIA 1/145 (0.69%) LEUKOCYTOSIS 1/145 (0.69%) THROMBOCYTOPENIA 1/145 (0.69%) FEBRILE NEUTROPENIA 1/145 (0.69%) THROMBOTIC THROMBOCYTOPENIC PURPURA 0/145 (0.00%) DISSEMINATED INTRAVASCULAR COAGULATION 0/145 (0.00%) CARDIAC FAILURE 1/145 (0.69%) ATRIAL FIBRILLATION 1/145 (0.69%) ",
        "premise_nums": [
            "1/145 (0.69%)",
            "2/145 (1.38%)",
            "17/145 (11.72%)",
            "0/145 (0.00%)"
        ]
    },
    {
        "id": "8ddf49c7-316e-4c7c-b2dd-423182a37612",
        "primaryId": "NCT00455533",
        "secondaryId": "NCT00767520",
        "label": "Entailment",
        "statement_text": "Throughout both the secondary trial and the primary trial there was only one case of sudden and unexpected death  in cohort 1 of the secondary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Adverse Events 2:Total: 11/144 (7.64%) ANAEMIA 1/144 (0.69%) LEUKOPENIA 0/144 (0.00%) NEUTROPENIA 0/144 (0.00%) LEUKOCYTOSIS 0/144 (0.00%) THROMBOCYTOPENIA 0/144 (0.00%) FEBRILE NEUTROPENIA 1/144 (0.69%) THROMBOTIC THROMBOCYTOPENIC PURPURA 1/144 (0.69%) DISSEMINATED INTRAVASCULAR COAGULATION 1/144 (0.69%) CARDIAC FAILURE 0/144 (0.00%) ATRIAL FIBRILLATION 0/144 (0.00%) ",
        "premise_nums": [
            "11/144 (7.64%)",
            "0/144 (0.00%)",
            "2:Total: 11/144",
            "1/144 (0.69%)"
        ]
    },
    {
        "id": "8ddf49c7-316e-4c7c-b2dd-423182a37612",
        "primaryId": "NCT00455533",
        "secondaryId": "NCT00767520",
        "label": "Entailment",
        "statement_text": "Throughout both the secondary trial and the primary trial there was only one case of sudden and unexpected death  in cohort 1 of the secondary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Adverse Events 1:Total: 22/79 (27.85%) Anaemia 0/79 (0.00%) Right ventricular dysfunction 1/79 (1.27%) Diarrhoea 1/79 (1.27%) Vomiting 2/79 (2.53%) Abdominal pain 0/79 (0.00%) Colonic obstruction 0/79 (0.00%) Dysphagia 1/79 (1.27%) Nausea 1/79 (1.27%) Mucosal inflammation 1/79 (1.27%) Performance status decreased 1/79 (1.27%) Sudden death 1/79 (1.27%) Adverse Events 2: ",
        "premise_nums": [
            "2/79 (2.53%)",
            "22/79 (27.85%)",
            "1:Total: 22/79",
            "0/79 (0.00%)",
            "1/79 (1.27%)"
        ]
    },
    {
        "id": "8ddf49c7-316e-4c7c-b2dd-423182a37612",
        "primaryId": "NCT00455533",
        "secondaryId": "NCT00767520",
        "label": "Entailment",
        "statement_text": "Throughout both the secondary trial and the primary trial there was only one case of sudden and unexpected death  in cohort 1 of the secondary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Total: 13/76 (17.11%)Anaemia 1/76 (1.32%) Right ventricular dysfunction 0/76 (0.00%) Diarrhoea 0/76 (0.00%) Vomiting 2/76 (2.63%) Abdominal pain 1/76 (1.32%) Colonic obstruction 1/76 (1.32%) Dysphagia 0/76 (0.00%) Nausea 1/76 (1.32%) Mucosal inflammation 0/76 (0.00%) Performance status decreased 0/76 (0.00%) Sudden death 0/76 (0.00%) ",
        "premise_nums": [
            "2/76 (2.63%)",
            "0/76 (0.00%)",
            "13/76 (17.11%)Anaemia",
            "1/76 (1.32%)"
        ]
    },
    {
        "id": "d9e41be5-1e37-4dff-b51a-166576f351d0",
        "primaryId": "NCT01498458",
        "statement_text": "For all adverse event types in the primary trial  at least one case was recorded ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 6/8 (75.00%) Thrombocytopenia 1/8 (12.50%) Hypertension 1/8 (12.50%) Hepatotoxicity 3/8 (37.50%) Pancreatectomy * 1/8 (12.50%) ",
        "premise_nums": [
            "6/8 (75.00%)",
            "1/8 (12.50%)",
            "3/8 (37.50%)"
        ]
    },
    {
        "id": "ee2287bd-af76-4232-9575-d371fe3257dc",
        "primaryId": "NCT00544167",
        "statement_text": "Every adverse event in the primary trial occurred once ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 7/45 (15.56%) Febrile neutropenia 1/45 (2.22%) Cardiac ischemia/infarction 1/45 (2.22%) Ventricular arrhythmia - left ventricular systolic dysfunction 1/45 (2.22%) Hemmorhage - GI 1/45 (2.22%) Pancreatitis 1/45 (2.22%) Infection - pneumonia 1/45 (2.22%) Infection - Streptococcus 1/45 (2.22%) Abcess of Bartholin's cyst 1/45 (2.22%) ",
        "premise_nums": [
            "7/45 (15.56%)",
            "1/45 (2.22%)"
        ]
    },
    {
        "id": "e5495b51-5f42-4e97-80ec-c215652bd3ab",
        "primaryId": "NCT00675259",
        "secondaryId": "NCT01875367",
        "label": "Contradiction",
        "statement_text": "Patients with an ImmunoHistoChemistry test result of 3+ are excluded from the primary trial and the secondary trial ",
        "statement_nums": [],
        "premise_text": "Exclusion: HER-2 neu overexpression either by IHC 3+ or FISH+ Inclusion Criteria: Breast cancer patients with tumors HER 2-negative. ",
        "premise_nums": [
            "2 neu overexpression"
        ]
    },
    {
        "id": "9b6bd158-a66d-42b6-8fe6-843ff05e0c8d",
        "primaryId": "NCT00612560",
        "statement_text": "children and illiterate adults are able to take part in the primary trial  unless they are can read and write in italian ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria: Age 18 and 85 years Exclusion Criteria: Inability to read and write English ",
        "premise_nums": [
            "18 and 85"
        ]
    },
    {
        "id": "9ae51f9c-8544-4764-b731-e4efe9ae0ba6",
        "primaryId": "NCT00452673",
        "statement_text": "1/7 patients in cohort 1 of the primary trial suffered dose-limiting toxicities ",
        "statement_nums": [
            "7 patients in",
            "1/7 patients",
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Number of Participants With Dose Limiting Toxicities Per Dose Level - Safety Population ",
        "premise_nums": []
    },
    {
        "id": "9ae51f9c-8544-4764-b731-e4efe9ae0ba6",
        "primaryId": "NCT00452673",
        "statement_text": "1/7 patients in cohort 1 of the primary trial suffered dose-limiting toxicities ",
        "statement_nums": [
            "7 patients in",
            "1/7 patients",
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Safety was assessed from first dose of study drug through at least 30 days after the last dose  until resolution of drug-related toxicity or when toxicity was deemed irreversible  whichever was longer  An adverse event (AE) was considered a dose limiting toxicity (DLT) if it occurred in the first 21 days and was at least possibly related to study drugs and were: Clinically-evident toxicity of Grade greater than or equal 3, or of Grade 2 which required interruption of treatment for greater than or equal 7 days (consecutive or non-consecutive); non-hematologic abnormal laboratory value of Grade greater than or equal 3, or hematologic toxicity of Grade 4, which persisted 7 days; any grade toxicity which in the judgment of the investigator required a dose reduction or removal from further study therapy Time frame: Day 1 to 30 days post last dose ",
        "premise_nums": [
            "21 days and",
            "2 which required",
            "30 days after",
            "1 to 30",
            "7 days (consecutive"
        ]
    },
    {
        "id": "9ae51f9c-8544-4764-b731-e4efe9ae0ba6",
        "primaryId": "NCT00452673",
        "statement_text": "1/7 patients in cohort 1 of the primary trial suffered dose-limiting toxicities ",
        "statement_nums": [
            "7 patients in",
            "1/7 patients",
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Results 1:Arm/Group Title: 50 mg Dasatinib + 825 mg/m^2Capecitabine ",
        "premise_nums": [
            "825 mg/m^2Capecitabine",
            "50 mg Dasatinib",
            "1:Arm/Group Title:"
        ]
    },
    {
        "id": "5b1915da-1819-4504-81bd-3f44a83b5e95",
        "primaryId": "NCT00320541",
        "statement_text": "Cohort 2 of the primary trial recorded three times as many cases of Leukopenia as cohort 1.",
        "statement_nums": [
            "2 of the"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Leukopenia 1/94 (1.06%) Adverse Events 2: Leukopenia 3/93 (3.23%) ",
        "premise_nums": [
            "1/94 (1.06%)",
            "3/93 (3.23%)"
        ]
    },
    {
        "id": "edb1e4c0-7669-4b8c-878b-ea8ca060c350",
        "primaryId": "NCT00074152",
        "statement_text": "Only 2 of the adverse event cases in the primary trial occurred in patients from cohort 1.",
        "statement_nums": [
            "2 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 0/77 (0.00%) Neutropenia [1]0/77 (0.00%) Left ventricular dysfunction 0/77 (0.00%) Cardiac ischemia 0/77 (0.00%) Gastrointestinal pain 0/77 (0.00%) Colitis 0/77 (0.00%) Febrile neutropenia 0/77 (0.00%) Pulmonary/upper respiratory infection 0/77 (0.00%) Diverticulitis 0/77 (0.00%) Motor neuropathy 0/77 (0.00%) Endometrial mucosa thinkening 0/77 (0.00%) Adverse Events 2: ",
        "premise_nums": [
            "0/77 (0.00%)"
        ]
    },
    {
        "id": "edb1e4c0-7669-4b8c-878b-ea8ca060c350",
        "primaryId": "NCT00074152",
        "statement_text": "Only 2 of the adverse event cases in the primary trial occurred in patients from cohort 1.",
        "statement_nums": [
            "2 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Total: 12/85 (14.12%)Neutropenia [1]1/85 (1.18%) Left ventricular dysfunction 1/85 (1.18%) Cardiac ischemia 2/85 (2.35%) Gastrointestinal pain 1/85 (1.18%) Colitis 1/85 (1.18%) Febrile neutropenia 3/85 (3.53%) Pulmonary/upper respiratory infection 1/85 (1.18%) Diverticulitis 1/85 (1.18%) Motor neuropathy 1/85 (1.18%) Endometrial mucosa thinkening 1/85 (1.18%) ",
        "premise_nums": [
            "12/85 (14.12%)Neutropenia",
            "2/85 (2.35%)",
            "3/85 (3.53%)",
            "1/85 (1.18%)"
        ]
    },
    {
        "id": "915939cf-7813-43e7-b503-e14a7eb4e568",
        "primaryId": "NCT00429299",
        "statement_text": "Only one cohort in the primary trial is administered trastuzumab 600 mg/m^2.",
        "statement_nums": [
            "600 mg/m^2."
        ],
        "label": "Contradiction",
        "premise_text": "INTERVENTION 1: CT Plus Trastuzumab ",
        "premise_nums": []
    },
    {
        "id": "126c1169-b375-4f89-95b2-52e971d19565",
        "primaryId": "NCT00856492",
        "statement_text": "Cohort 1 of the primary trial recorded no deaths and no cases of Enterocolitis infectious ",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 22/96 (22.92%) Anemia 1/96 (1.04%) Febrile neutropenia 4/96 (4.17%) Heart failure 1/96 (1.04%) Abdominal pain 1/96 (1.04%) Dysphagia 1/96 (1.04%) Mucositis oral 1/96 (1.04%) Nausea 1/96 (1.04%) Vomiting 2/96 (2.08%) Death NOS 0/96 (0.00%) Pain 1/96 (1.04%) Catheter related infection 1/96 (1.04%) Enterocolitis infectious 0/96 (0.00%) ",
        "premise_nums": [
            "1/96 (1.04%)",
            "0/96 (0.00%)",
            "22/96 (22.92%)",
            "2/96 (2.08%)",
            "4/96 (4.17%)"
        ]
    },
    {
        "id": "11235250-3627-427e-aae9-099507484456",
        "primaryId": "NCT00284180",
        "statement_text": "Across all three cohorts of the primary trial a total of two patients had low levels of oxygen in their body tissues ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 5/11 (45.45%) Diabetes insipidus [1]1/11 (9.09%) Nausea 0/11 (0.00%) Ileus 1/11 (9.09%) Dehydration 1/11 (9.09%) Vomiting 0/11 (0.00%) Pain NOS [2]2/11 (18.18%) Pain - abdomen 0/11 (0.00%) Fracture [3]0/11 (0.00%) Progressive Disease 1/11 (9.09%) CNS Ischemia 1/11 (9.09%) Respiratory Failure 0/11 (0.00%) Hypoxia 1/11 (9.09%) Adverse Events 2: ",
        "premise_nums": [
            "5/11 (45.45%)",
            "1/11 (9.09%)",
            "2/11 (18.18%)",
            "0/11 (0.00%)"
        ]
    },
    {
        "id": "11235250-3627-427e-aae9-099507484456",
        "primaryId": "NCT00284180",
        "statement_text": "Across all three cohorts of the primary trial a total of two patients had low levels of oxygen in their body tissues ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Total: 8/21 (38.10%)Diabetes insipidus [1]0/21 (0.00%) Nausea 1/21 (4.76%) Ileus 0/21 (0.00%) Dehydration 1/21 (4.76%) Vomiting 1/21 (4.76%) Pain NOS [2]0/21 (0.00%) Pain - abdomen 1/21 (4.76%) Fracture [3]1/21 (4.76%) Progressive Disease 1/21 (4.76%) CNS Ischemia 1/21 (4.76%) Respiratory Failure 1/21 (4.76%) Hypoxia 1/21 (4.76%) ",
        "premise_nums": [
            "0/21 (0.00%)",
            "8/21 (38.10%)Diabetes",
            "1/21 (4.76%)"
        ]
    },
    {
        "id": "8a9f2247-7c51-44be-910b-5091d9abb2ea",
        "primaryId": "NCT00236899",
        "secondaryId": "NCT01153672",
        "label": "Contradiction",
        "statement_text": "the primary trial and the secondary trial both administer Paclitaxel and Gemcitabine to their patients cohorts  but only the secondary trial utilises positron emission tomography ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Treatment Schedule (Weekly) Arm C  Docetaxel and Gemcitabine (Weekly): Docetaxel: 30 mg/m²  30-60 min IV infusion on Days 1, 8, and 15 to be given 30 minutes prior to Gemcitabine  repeated every 28 days (weekly) for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD  Gemcitabine: 800 mg/m²  30 min IV infusion on Days 1, 8, and 15 repeated every 28 days for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD  ",
        "premise_nums": [
            "28 days (weekly)",
            "28 days for",
            "60 min IV",
            "30-60 min",
            "800 mg/m²",
            "6 cycles for",
            "10 cycles for",
            "30 mg/m²",
            "15 repeated every",
            "30 min IV",
            "15 to be",
            "30 minutes prior"
        ]
    },
    {
        "id": "8a9f2247-7c51-44be-910b-5091d9abb2ea",
        "primaryId": "NCT00236899",
        "secondaryId": "NCT01153672",
        "label": "Contradiction",
        "statement_text": "the primary trial and the secondary trial both administer Paclitaxel and Gemcitabine to their patients cohorts  but only the secondary trial utilises positron emission tomography ",
        "statement_nums": [],
        "premise_text": "Arm D  Paclitaxel and Gemcitabine (Weekly):Paclitaxel: 80 mg/m²  IV infusion over approximately 1 hour  Days 1, 8, and 15, followed by Gemcitabine  repeated every 28 days (weekly) for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD  Gemcitabine: 800 mg/m²  30 min IV infusion on Days 1, 8, and 15 repeated every 28 days for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD  INTERVENTION 2: Treatment Schedule (3 Weekly) Arm A  Docetaxel and Gemcitabine (3 Weekly): ",
        "premise_nums": [
            "28 days (weekly)",
            "80 mg/m²",
            "800 mg/m²",
            "6 cycles for",
            "10 cycles for",
            "15 repeated every",
            "30 min IV",
            "28 days for"
        ]
    },
    {
        "id": "8a9f2247-7c51-44be-910b-5091d9abb2ea",
        "primaryId": "NCT00236899",
        "secondaryId": "NCT01153672",
        "label": "Contradiction",
        "statement_text": "the primary trial and the secondary trial both administer Paclitaxel and Gemcitabine to their patients cohorts  but only the secondary trial utilises positron emission tomography ",
        "statement_nums": [],
        "premise_text": "Docetaxel: 75 mg/m²  60 min IV infusion on Day 1 only  to be given 30 min prior to Gemcitabine  repeated every 21 days (tri-weekly) for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD Gemcitabine: 1000 mg/m²  30 min IV infusion on Days 1 and 8, repeated every 21 days for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD  Arm B  Paclitaxel and Gemcitabine (3 Weekly): ",
        "premise_nums": [
            "60 min IV",
            "21 days for",
            "6 cycles for",
            "30 min prior",
            "75 mg/m²",
            "10 cycles for",
            "1000 mg/m²",
            "30 min IV",
            "1 and 8,"
        ]
    },
    {
        "id": "8a9f2247-7c51-44be-910b-5091d9abb2ea",
        "primaryId": "NCT00236899",
        "secondaryId": "NCT01153672",
        "label": "Contradiction",
        "statement_text": "the primary trial and the secondary trial both administer Paclitaxel and Gemcitabine to their patients cohorts  but only the secondary trial utilises positron emission tomography ",
        "statement_nums": [],
        "premise_text": "Paclitaxel: 175 mg/m²  IV infusion over approximately 3 hours followed by Gemcitabine  repeated every 21 days (tri-weekly) for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD Gemcitabine: 1250 mg/m²  30 min IV infusion on Days 1 and 8, repeated every 21 days for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD  INTERVENTION 1: Treatment (Enzyme Inhibitor Therapy  AI Sensitization Therapy) ",
        "premise_nums": [
            "21 days for",
            "6 cycles for",
            "3 hours followed",
            "10 cycles for",
            "175 mg/m²",
            "30 min IV",
            "1250 mg/m²",
            "1 and 8,"
        ]
    },
    {
        "id": "8a9f2247-7c51-44be-910b-5091d9abb2ea",
        "primaryId": "NCT00236899",
        "secondaryId": "NCT01153672",
        "label": "Contradiction",
        "statement_text": "the primary trial and the secondary trial both administer Paclitaxel and Gemcitabine to their patients cohorts  but only the secondary trial utilises positron emission tomography ",
        "statement_nums": [],
        "premise_text": "Patients receive vorinostat PO QD for 2 weeks followed by AI therapy comprising anastrozole PO QD  letrozole PO QD  OR exemestane PO QD for 6 weeks  Courses repeat every 8 weeks in the absence of disease progression or unacceptable toxicity vorinostat: Given PO laboratory biomarker analysis: Correlative studies biopsy: Optional correlative studies F-18 16 alpha-fluoroestradiol: Correlative studies positron emission tomography: Correlative studies anastrozole: Given PO letrozole: Given PO exemestane: Given PO gene expression analysis: Correlative studies ",
        "premise_nums": [
            "16 alpha-fluoroestradiol:",
            "8 weeks in",
            "2 weeks followed"
        ]
    },
    {
        "id": "7e283897-4d9e-4353-8331-00f8db16cc7e",
        "primaryId": "NCT00038467",
        "statement_text": "The patient groups in the primary trial each receive different oral medication  either Tamoxifen or Exemestane ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "INTERVENTION 1: Exemestane Participants diagnosed with breast cancer who remained disease-free after previously receiving 2 to 3 years of tamoxifen 20 milligram (mg) or 30 mg tablet-in-capsule orally once daily as per standard medical practice  received exemestane (Aromasin) 25 mg tablet-in-capsule orally once daily for the remainder of 5-year period  INTERVENTION 2: Tamoxifen Participants diagnosed with breast cancer who remained disease-free after previously receiving 2 to 3 years of tamoxifen 20 mg or 30 mg tablet-in-capsule orally once daily as per standard medical practice  received the same dose of tamoxifen tablet-in-capsule orally once daily for the remainder of 5-year period  ",
        "premise_nums": [
            "25 mg tablet",
            "30 mg tablet",
            "5-year period",
            "2 to 3",
            "20 milligram (mg)",
            "20 mg or"
        ]
    },
    {
        "id": "54b15068-023b-4e60-bb82-2a22512fda62",
        "primaryId": "NCT00847171",
        "secondaryId": "NCT01764022",
        "label": "Contradiction",
        "statement_text": "Male patients with Systemic lupus erythematosus are excluded from the primary trial but may still be eligible for the secondary trial ",
        "statement_nums": [],
        "premise_text": "No prior or currently active autoimmune disease* requiring management with systemic immunosuppression  including any of the following: Systemic lupus erythematosus Inclusion Criteria: Written informed consent and ability to follow the Protocol procedures; Age from 18 years to 75 years inclusive; Female gender; Histologically confirmed breast cancer (BC); Metastatic BC (stage IV according to TNM classification version 6); Grade 3+ HER2 overexpression confirmed by immunohistochemical (IHC) staining or grade 2+ HER2 overexpression accompanied by HER2 gene amplification confirmed by fluorescent hybridization in situ (FISH) ; Documented results of oestrogen and progesterone receptors expression analysis; ",
        "premise_nums": [
            "75 years inclusive;",
            "2 overexpression confirmed",
            "2 gene amplification",
            "2 overexpression accompanied",
            "18 years to"
        ]
    },
    {
        "id": "54b15068-023b-4e60-bb82-2a22512fda62",
        "primaryId": "NCT00847171",
        "secondaryId": "NCT01764022",
        "label": "Contradiction",
        "statement_text": "Male patients with Systemic lupus erythematosus are excluded from the primary trial but may still be eligible for the secondary trial ",
        "statement_nums": [],
        "premise_text": "Eastern Cooperative Oncology Group (ECOG) status 0, 1 or 2, not increasing within 2 weeks prior to randomization;Life expectancy - 20 weeks or more from the moment of randomization; Presence of at least 1 tumour with a size not less than 1 cm (revealed with computed tomography (CT) slice thickness not more than 5 mm)  Patients having bone metastasis as the only measurable tumour are not eligible for the trial; Patients of childbearing potential must implement reliable contraceptive measures during the study treatment  starting 4 weeks prior to inclusion into the trial and until 6 months after the last administration of the study drug  Exclusion Criteria: ",
        "premise_nums": [
            "1 tumour with",
            "6 months after",
            "1 or 2,",
            "1 cm (revealed",
            "4 weeks prior",
            "20 weeks or",
            "2 weeks prior"
        ]
    },
    {
        "id": "54b15068-023b-4e60-bb82-2a22512fda62",
        "primaryId": "NCT00847171",
        "secondaryId": "NCT01764022",
        "label": "Contradiction",
        "statement_text": "Male patients with Systemic lupus erythematosus are excluded from the primary trial but may still be eligible for the secondary trial ",
        "statement_nums": [],
        "premise_text": "Previous anticancer therapy for metastatic BC  including cytotoxic chemotherapy  or previous anticancer therapy with signal transduction inhibitors (e.g  lapatinib)  biological drugs (e.g  trastuzumab  bevacizumab)  experimental (not approved for BC therapy) anticancer drugs  Any previous hormonal therapy is allowed;Disease progression within 6 months after adjuvant and/or neoadjuvant anti BC therapy; Surgery  radiation therapy  use of any experimental medications within 4 weeks (28 days) prior to randomization; ",
        "premise_nums": [
            "6 months after",
            "4 weeks (28"
        ]
    },
    {
        "id": "54b15068-023b-4e60-bb82-2a22512fda62",
        "primaryId": "NCT00847171",
        "secondaryId": "NCT01764022",
        "label": "Contradiction",
        "statement_text": "Male patients with Systemic lupus erythematosus are excluded from the primary trial but may still be eligible for the secondary trial ",
        "statement_nums": [],
        "premise_text": "Hypersensitivity to paclitaxel and all medications containing polyoxyethylated castor oil  hypersensitivity to dexamethasone  diphenhydramine  ranitidine/cimetidine  recombinant murine proteins  contrast agents or excipients of study medications;BC metastases in central nervous system  progressing or clinically manifested (e.g  cerebral oedema  spinal cord injury)  with exception of non-progressing metastases not requiring treatment with glucocorticosteroids and/or anticonvulsants within 4 weeks prior to randomization; ",
        "premise_nums": [
            "4 weeks prior"
        ]
    },
    {
        "id": "54b15068-023b-4e60-bb82-2a22512fda62",
        "primaryId": "NCT00847171",
        "secondaryId": "NCT01764022",
        "label": "Contradiction",
        "statement_text": "Male patients with Systemic lupus erythematosus are excluded from the primary trial but may still be eligible for the secondary trial ",
        "statement_nums": [],
        "premise_text": "Cardiovascular system pathology (congestive heart failure (CHF) stage III-IV according to New York Heart Association (NYHA) classification  unstable angina pectoris  myocardial infarction) within 12 months prior to randomization;Uncontrolled hypertension comprising all cases of arterial hypertension when no decrease in blood pressure could be achieved despite treatment with a combination of 3 antihypertensive drugs including one diuretic and non-medicamental correction methods (low salt diet  physical exercise); Left ventricular ejection fraction smaller than 50% according to electrocardiography; Neutrophils 1500/mm3; Platelets 100 000/mm3; Hemoglobin 90 g/L; ",
        "premise_nums": [
            "50% according",
            "000/mm3; Hemoglobin",
            "90 g/L;",
            "1500/mm3; Platelets",
            "12 months prior",
            "3 antihypertensive drugs"
        ]
    },
    {
        "id": "54b15068-023b-4e60-bb82-2a22512fda62",
        "primaryId": "NCT00847171",
        "secondaryId": "NCT01764022",
        "label": "Contradiction",
        "statement_text": "Male patients with Systemic lupus erythematosus are excluded from the primary trial but may still be eligible for the secondary trial ",
        "statement_nums": [],
        "premise_text": "Creatinine level 1.5 × upper limit of normal (ULN);Bilirubin level 1.5 × ULN; Asparagine transferase (AST) and alanine transferase (ALT) levels 2.5 × ULN (5 × ULN for patients with liver metastases); Alkaline phosphatase level 5 × ULN; Pregnancy or lactation; Any other concomitant cancer including contralateral breast cancer revealed within 5 years prior to screening  except curatively treated intraductal carcinoma in situ  curatively treated cervical carcinoma in situ or curatively treated basal cell or squamous cell carcinoma; ",
        "premise_nums": [
            "5 years prior"
        ]
    },
    {
        "id": "54b15068-023b-4e60-bb82-2a22512fda62",
        "primaryId": "NCT00847171",
        "secondaryId": "NCT01764022",
        "label": "Contradiction",
        "statement_text": "Male patients with Systemic lupus erythematosus are excluded from the primary trial but may still be eligible for the secondary trial ",
        "statement_nums": [],
        "premise_text": "Conditions limiting patient's adherence to protocol requirements (dementia  neurologic or psychiatric disorders  drug addiction  alcoholism and others);Stage II-IV neuropathy according to Common Terminology Criteria for Adverse Events (CTCAE) v.4.0; Concomitant participation in other clinical trials  previous participation in other clinical trials within 30 days before entering into the trial  previous participation in the same trial; Acute or active chronic infections; Hepatitis C virus  hepatitis B virus  HIV or syphilis infections; Obstacles in intravenous administration of study drugs ",
        "premise_nums": [
            "30 days before"
        ]
    },
    {
        "id": "78764961-52be-4235-a2b7-e581497d0099",
        "primaryId": "NCT00900627",
        "statement_text": "The two groups in the primary trial receive the same drug treatment  but different doses ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "INTERVENTION 1: AZD8931 160 mg bd Part A: AZD8931 160mg (bd) plus weekly paclitaxel of 90mg/m2 on days 1, 8 and 15 of each 28 day cycle INTERVENTION 2: AZD8931 120 mg bd Part A: AZD8931 120mg (bd) plus weekly paclitaxel of 90mg/m2 on days 1, 8 and 15 of each 28 day cycle ",
        "premise_nums": [
            "160 mg bd",
            "90mg/m2 on",
            "28 day cycle",
            "8 and 15",
            "2 on days",
            "120 mg bd"
        ]
    },
    {
        "id": "e09fe98c-ec5c-49cf-9f49-92ba8824e82e",
        "primaryId": "NCT03708393",
        "secondaryId": "NCT03456427",
        "label": "Contradiction",
        "statement_text": "The interventions in the primary trial and the secondary trial require active participation from the patient to apply the treatment ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: IUS Alone IUS alone imaging INTERVENTION 2: Imagio (IUS+OA) IUS+OA imaging INTERVENTION 1: All Study Participants: Patient Assisted Compression All subjects will undergo standard of care imaging on one breast  The other breast will be imaged using Patient-Assisted Compression (PAC)  followed by Technologist-controlled (TC) Compression  Patient-Assisted Compression (PAC): The technologist will properly position the breast and apply minimum compression  The subject will be instructed to apply compression as the technologist ensures the breast tissue is in appropriate position and tautness  The technologist will then guide the subject to achieve appropriate compression level  sufficient but not excessive  and the image will be acquired  This will be done for both standard views CC & MLO  ",
        "premise_nums": []
    },
    {
        "id": "a83d98c9-e3da-4449-878b-5fa2f3bee8cf",
        "primaryId": "NCT01277757",
        "statement_text": "the primary trial is not testing a novel Physiotherapy or radiotherapy intervention ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "INTERVENTION 1: Akt Inhibitor MK-2206 Akt Inhibitor MK-2206 orally once a week on days 1, 8, 15, and 22. Starting dose 200 mg  courses repeat every 28 days  ",
        "premise_nums": [
            "2206 Akt Inhibitor",
            "2206 orally once"
        ]
    },
    {
        "id": "41db854e-1565-4eda-8236-550556043b47",
        "primaryId": "NCT01027416",
        "statement_text": "To be eligible for the primary trial  patients must have an invasive carcinoma confirmed by core biopsy  and a -ive human chorionic gonadotropin urine test ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria: Core biopsy should definitively demonstrate invasive carcinoma  Negative serum or urine beta-hCG pregnancy test at screening for patients of child-bearing potential (this is routinely done if the patient is premenopausal and having surgery) ",
        "premise_nums": []
    },
    {
        "id": "f559cacb-30e7-47cf-9ac6-5929c1a508f7",
        "primaryId": "NCT00493649",
        "secondaryId": "NCT01201265",
        "label": "Entailment",
        "statement_text": "There were no MRSA infections in either the secondary trial or the primary trial ",
        "statement_nums": [],
        "premise_text": "Adverse Events 1: Total: 51/486 (10.49%) ANEMIA 1/486 (0.21%) NEUTROPENIA 4/486 (0.82%) FIBRILLATION ATRIAL 1/486 (0.21%) ABDOMINAL PAIN 2/486 (0.41%) BLOATING 1/486 (0.21%) BOWEL PERFORATION 1/486 (0.21%) COLITIS 1/486 (0.21%) DEHYDRATION 5/486 (1.03%) DIARRHEA 5/486 (1.03%) GASTRIC INFLAMMATION 1/486 (0.21%) NAUSEA 3/486 (0.62%) NAUSEA AND VOMITING 1/486 (0.21%) Adverse Events 1: ",
        "premise_nums": [
            "51/486 (10.49%)",
            "2/486 (0.41%)",
            "4/486 (0.82%)",
            "1/486 (0.21%)",
            "5/486 (1.03%)",
            "3/486 (0.62%)"
        ]
    },
    {
        "id": "f559cacb-30e7-47cf-9ac6-5929c1a508f7",
        "primaryId": "NCT00493649",
        "secondaryId": "NCT01201265",
        "label": "Entailment",
        "statement_text": "There were no MRSA infections in either the secondary trial or the primary trial ",
        "statement_nums": [],
        "premise_text": "Total: 17/40 (42.50%)Anaemia 2/40 (5.00%) Febrile Neutropenia 3/40 (7.50%) Neutropenia 2/40 (5.00%) Thrombocytopenia 5/40 (12.50%) Pericardial Effusion 1/40 (2.50%) Abdominal Pain Lower 1/40 (2.50%) Disease Progression 6/40 (15.00%) Fatigue 1/40 (2.50%) Pyrexia 3/40 (7.50%) Septic Shock 1/40 (2.50%) Streptococcal Infection 1/40 (2.50%) ",
        "premise_nums": [
            "2/40 (5.00%)",
            "3/40 (7.50%)",
            "17/40 (42.50%)Anaemia",
            "1/40 (2.50%)",
            "5/40 (12.50%)",
            "6/40 (15.00%)"
        ]
    },
    {
        "id": "79362f6d-ef2c-4b93-8719-be361d0b5acc",
        "primaryId": "NCT03096847",
        "secondaryId": "NCT01840163",
        "label": "Contradiction",
        "statement_text": "Female Patients recently prescribed Rapamycin are not eligible for the primary trial  but may be eligible for the secondary trial unless they have a stage 1 to 2 Ductal carcinoma in situ and can speak english ",
        "statement_nums": [
            "1 to 2"
        ],
        "premise_text": "Exclusion Criteria Patient who received any CDK4/6 inhibitor or any mTOR inhibitor  Inclusion Criteria: Stage 1-2 invasive breast cancer diagnosis  DCIS Ability to read English Exclusion Criteria: Male ",
        "premise_nums": [
            "CDK4/6 inhibitor",
            "6 inhibitor or",
            "2 invasive breast",
            "1-2 invasive"
        ]
    },
    {
        "id": "54918996-1b4d-48bd-a0ca-13d8e259767b",
        "primaryId": "NCT02650193",
        "secondaryId": "NCT00656669",
        "label": "Contradiction",
        "statement_text": "Patients with Class III obesity cannot be included in the primary trial  but can be entered into the secondary trial  even if they have uncontrolled Hypertension ",
        "statement_nums": [],
        "premise_text": "Inclusion Criteria: Body mass index (BMI) of 19 to 40 kg/m^2   inclusive Inclusion Criteria: Patients must have histologically-confirmed adenocarcinoma of the breast with operable or inoperable stage 1c (primary tumor greater than 1.0 cm)  II or III disease  Measurable disease by physical examinations or diagnostic breast imaging (mammography  ultrasonography or MR)  Pre-treatment core or incisional biopsy  Patients may not have had definitive primary surgery  Male or female  18 years of age or older  ECOG performance status 0 or 1. Adequate organ function as defined in the protocol  Exclusion Criteria: ",
        "premise_nums": [
            "19 to 40",
            "40 kg/m^2",
            "0 or 1.",
            "18 years of"
        ]
    },
    {
        "id": "54918996-1b4d-48bd-a0ca-13d8e259767b",
        "primaryId": "NCT02650193",
        "secondaryId": "NCT00656669",
        "label": "Contradiction",
        "statement_text": "Patients with Class III obesity cannot be included in the primary trial  but can be entered into the secondary trial  even if they have uncontrolled Hypertension ",
        "statement_nums": [],
        "premise_text": "Prior radiation therapy  cytotoxic therapy or systemic therapy for breast cancer  Prior use of tamoxifen or raloxifene as chemoprevention is allowed but must be discontinued prior to study entry Metastatic (Stage IV) breast cancer Patients who have had only a pre-treatment fine needle aspiration (FNA) are excluded  Current therapeutic treatment on another clinical trial with an investigational agent  Any of the following within the 6 months prior to starting study treatment: -myocardial infarction -severe/unstable angina -coronary/peripheral artery bypass graft -congestive heart failure -cerebrovascular accident including transient ischemic attack -pulmonary embolus ",
        "premise_nums": [
            "6 months prior"
        ]
    },
    {
        "id": "54918996-1b4d-48bd-a0ca-13d8e259767b",
        "primaryId": "NCT02650193",
        "secondaryId": "NCT00656669",
        "label": "Contradiction",
        "statement_text": "Patients with Class III obesity cannot be included in the primary trial  but can be entered into the secondary trial  even if they have uncontrolled Hypertension ",
        "statement_nums": [],
        "premise_text": "Ongoing cardiac dysrhythmias of NCI CTCAE grade greater than or equal 2, atrial fibrillation of any grade  or QTc interval greater than 450 msec for males or greater than 470 msec for females Hypertension that cannot be controlled by medications  Current treatment with therapeutic doses of any anti-coagulant  Prophylactic use of anticoagulants is allowed  Known human immunodeficiency virus (HIV) infection  Pregnancy or breastfeeding  All female patients with reproductive potential must have a negative pregnancy test prior to first day of study medication  ",
        "premise_nums": [
            "470 msec for",
            "450 msec for"
        ]
    },
    {
        "id": "54918996-1b4d-48bd-a0ca-13d8e259767b",
        "primaryId": "NCT02650193",
        "secondaryId": "NCT00656669",
        "label": "Contradiction",
        "statement_text": "Patients with Class III obesity cannot be included in the primary trial  but can be entered into the secondary trial  even if they have uncontrolled Hypertension ",
        "statement_nums": [],
        "premise_text": "Other severe acute or chronic medical or psychiatric condition  or laboratory abnormality that would impart  in the judgment of the investigator  excess risk associated with study participation or study drug administration  or which  in the judgment of the investigator  would make the patient inappropriate for entry into this study ",
        "premise_nums": []
    },
    {
        "id": "a5a1c7f1-92f4-4436-9dcb-ab222ff1c8a5",
        "primaryId": "NCT00679341",
        "secondaryId": "NCT00201851",
        "label": "Entailment",
        "statement_text": "Patients in the secondary trial and those in the primary trial did not share any of the same adverse events ",
        "statement_nums": [],
        "premise_text": "Adverse Events 1: Total: 14/69 (20.29%) Febrile neutropenia 0/69 (0.00%) Anaemia 0/69 (0.00%) Atrial fibrillation 1/69 (1.45%) Cardiopulmonary failure 0/69 (0.00%) Supraventricular extrasystoles 1/69 (1.45%) Abdominal pain 1/69 (1.45%) Intestinal obstruction 0/69 (0.00%) Vomiting 1/69 (1.45%) Chills 1/69 (1.45%) Oedema peripheral 0/69 (0.00%) Pyrexia 1/69 (1.45%) Adverse Events 2: ",
        "premise_nums": [
            "14/69 (20.29%)",
            "1/69 (1.45%)",
            "0/69 (0.00%)"
        ]
    },
    {
        "id": "a5a1c7f1-92f4-4436-9dcb-ab222ff1c8a5",
        "primaryId": "NCT00679341",
        "secondaryId": "NCT00201851",
        "label": "Entailment",
        "statement_text": "Patients in the secondary trial and those in the primary trial did not share any of the same adverse events ",
        "statement_nums": [],
        "premise_text": "Total: 17/66 (25.76%)Febrile neutropenia 6/66 (9.09%) Anaemia 1/66 (1.52%) Atrial fibrillation 1/66 (1.52%) Cardiopulmonary failure 1/66 (1.52%) Supraventricular extrasystoles 0/66 (0.00%) Abdominal pain 0/66 (0.00%) Intestinal obstruction 1/66 (1.52%) Vomiting 0/66 (0.00%) Chills 0/66 (0.00%) Oedema peripheral 1/66 (1.52%) Pyrexia 0/66 (0.00%) Adverse Events 1: ",
        "premise_nums": [
            "6/66 (9.09%)",
            "17/66 (25.76%)Febrile",
            "1/66 (1.52%)",
            "0/66 (0.00%)"
        ]
    },
    {
        "id": "a5a1c7f1-92f4-4436-9dcb-ab222ff1c8a5",
        "primaryId": "NCT00679341",
        "secondaryId": "NCT00201851",
        "label": "Entailment",
        "statement_text": "Patients in the secondary trial and those in the primary trial did not share any of the same adverse events ",
        "statement_nums": [],
        "premise_text": "Total: 0/244 (0.00%)Pregnancy *0/244 (0.00%) Endocervical cancer *0/244 (0.00%) Nosocomial pneumonia *0/244 (0.00%) Venous thrombosis *0/244 (0.00%) ",
        "premise_nums": [
            "0/244 (0.00%)Pregnancy"
        ]
    },
    {
        "id": "52c8361f-75dc-45f1-a35c-79180a22b931",
        "primaryId": "NCT02015676",
        "statement_text": "There are no recorded cases of thrombocytopenia in the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 26/69 (37.68%) Thrombophlebitis * 1/69 (1.45%) Anaemia NOS * 1/69 (1.45%) Acute febrile neutrophilic dermatosis * 1/69 (1.45%) Cardiac failure NOS * 2/69 (2.90%) Ejection fraction decreased * 1/69 (1.45%) Intestinal obstruction NOS * 1/69 (1.45%) Diarrhoea NOS * 2/69 (2.90%) Febrile neutropenia * 12/69 (17.39%) Mucosal inflammation NOS * 1/69 (1.45%) ",
        "premise_nums": [
            "26/69 (37.68%)",
            "12/69 (17.39%)",
            "1/69 (1.45%)",
            "2/69 (2.90%)"
        ]
    },
    {
        "id": "f2f05760-cc22-4fe8-a24f-f6d43f9c9a86",
        "primaryId": "NCT01091168",
        "statement_text": "Patients in the control group of the primary trial had a median Overall Survival of less than a year  however several patients in arm B survived longer than a year ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Overall Survival The main endpoint of this study is overall survival defined as the time from randomisation to the date of death or last follow-up  For patients who have not died  survival duration will be censored at the date of last contact or last follow-up or the date of last news  Time frame: From baseline up to 3 years 1 month Results 2: Arm/Group Title: Alkylating Agent Arm/Group Description: Patients randomised in the control arm (arm B) received an alkylating agent used as a single agent which was available in the investigational center and was approved for the treatment of cancer in the country  ",
        "premise_nums": [
            "3 years 1"
        ]
    },
    {
        "id": "f2f05760-cc22-4fe8-a24f-f6d43f9c9a86",
        "primaryId": "NCT01091168",
        "statement_text": "Patients in the control group of the primary trial had a median Overall Survival of less than a year  however several patients in arm B survived longer than a year ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Alkylating agent of physician choice registered in cancer: cyclophosphamide or melphalan or mitomycin C or thiotepa or cisplatin or carboplatinOverall Number of Participants Analyzed: 296 Median (95% Confidence Interval) Unit of Measure: Months 9.3 (7.5 to 10.9) ",
        "premise_nums": [
            "5 to 10.9)",
            "95% Confidence"
        ]
    },
    {
        "id": "db8ffa86-bf52-47bb-89f7-42e7ae47b84d",
        "primaryId": "NCT01271725",
        "statement_text": "In the primary trial The Percentage of Participants With Objective Response (OR) for the Afatinib Monotherapy was 18% lower than the Afatinib and Paclitaxel or Vinorelbine Combination Therapy group ",
        "statement_nums": [
            "18% lower"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Percentage of Participants With Objective Response (OR) Assessed by Response Evaluation Criteria in Solid Tumours Version (RECIST) 1.1 ",
        "premise_nums": []
    },
    {
        "id": "5a01d00f-8601-4c17-b814-be87e63b0d8a",
        "primaryId": "NCT02392611",
        "statement_text": "the primary trial cohorts are not seperated based on patient characteristics ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "INTERVENTION 1: Monotherapy: Alobresib 0.6 mg Participants with advanced solid tumors and lymphomas who had failed or were intolerant to standard therapy  or for whom no standard therapy existed received alobresib tablets at a dose of 0.6 mg orally once daily on Study Day 1 through C1D28 of 28 days cycle to determine the MTD  INTERVENTION 2: Monotherapy: Alobresib 1.4 mg Participants with advanced solid tumors and lymphomas who had failed or were intolerant to standard therapy  or for whom no standard therapy existed received alobresib tablets at a dose of 1.4 mg orally once daily on Study Day 1 through C1D28 of 28 days cycle to determine the MTD  ",
        "premise_nums": [
            "of 0.6 mg orally",
            "Alobresib 0.6 mg Participants",
            "Alobresib 1.4 mg Participants",
            "28 days cycle",
            "D28 of",
            "of 1.4 mg orally",
            "1 through C1D28"
        ]
    },
    {
        "id": "7577f05f-04e9-44de-9e00-b7411ff4010f",
        "primaryId": "NCT01351376",
        "statement_text": "Patients currently prescribed laxatives are not excluded from the primary trial ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Exclusion Criteria: medication(s) known to affect body fluid balance ",
        "premise_nums": []
    },
    {
        "id": "3b0440e6-cf85-4236-8a1d-2e3572143946",
        "primaryId": "NCT00191451",
        "statement_text": "Patients in the primary trial experienced a only one type of Oesophageal adverse events and several types of cardiac adverse events ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 10/50 (20.00%) Anaemia 0/50 (0.00%) Febrile neutropenia 0/50 (0.00%) Neutropenia 0/50 (0.00%) Thrombocytopenia 0/50 (0.00%) Diastolic dysfunction 0/50 (0.00%) Tachycardia 0/50 (0.00%) Intestinal obstruction 0/50 (0.00%) Nausea 1/50 (2.00%) Oesophageal spasm 0/50 (0.00%) Oesophagitis 0/50 (0.00%) Retching 0/50 (0.00%) ",
        "premise_nums": [
            "0/50 (0.00%)",
            "1/50 (2.00%)",
            "10/50 (20.00%)"
        ]
    },
    {
        "id": "3b0440e6-cf85-4236-8a1d-2e3572143946",
        "primaryId": "NCT00191451",
        "statement_text": "Patients in the primary trial experienced a only one type of Oesophageal adverse events and several types of cardiac adverse events ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Adverse Events 2:Total: 11/48 (22.92%) Anaemia 4/48 (8.33%) Febrile neutropenia 0/48 (0.00%) Neutropenia 2/48 (4.17%) Thrombocytopenia 2/48 (4.17%) Diastolic dysfunction 1/48 (2.08%) Tachycardia 1/48 (2.08%) Intestinal obstruction 0/48 (0.00%) Nausea 0/48 (0.00%) Oesophageal spasm 1/48 (2.08%) Oesophagitis 0/48 (0.00%) Retching 1/48 (2.08%) ",
        "premise_nums": [
            "1/48 (2.08%)",
            "4/48 (8.33%)",
            "2:Total: 11/48",
            "0/48 (0.00%)",
            "2/48 (4.17%)",
            "11/48 (22.92%)"
        ]
    },
    {
        "id": "6f342205-ef33-482a-b74a-74644537538b",
        "primaryId": "NCT00077857",
        "statement_text": "Patients must be older than 18, female  have one or more target lesions and more than 2 regiments of chemotherapy to participate in the primary trial ",
        "statement_nums": [
            "2 regiments of"
        ],
        "label": "Entailment",
        "premise_text": "Inclusion Criteria: women greater than or equal 18 years of age; greater than or equal 1 target lesion; greater than or equal 2 regimens of chemotherapy for advanced/metastatic disease  ",
        "premise_nums": [
            "1 target lesion;",
            "18 years of",
            "2 regimens of"
        ]
    },
    {
        "id": "5b63fffb-0a75-414f-8744-5fea78395f28",
        "primaryId": "NCT00950742",
        "statement_text": "100 participants in the Afatinib 20mg + Herceptin group of the primary trial suffer Dose Limiting Toxicities ",
        "statement_nums": [
            "100 participants in"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Number of Participants With Dose Limiting Toxicities (DLT) Number of participants with DLT in the first cycle (28 days) for the determination of the maximum tolerated dose (MTD)  Important Limitations and Caveats are provided in the respective section  Time frame: 28 days Results 1: Arm/Group Title: Afatinib 20mg + Herceptin Arm/Group Description: Patients received continuous daily dosing with Afatinib 20mg film-coated tablets and once weekly an intravenous infusion of Herceptin until disease progression or lack of clinical benefit  This group includes patients from the dose-escalation cohort and from the expansion cohort  Overall Number of Participants Analyzed: 13 Measure Type: Number Unit of Measure: Participants 4 ",
        "premise_nums": [
            "13 Measure Type:",
            "28 days Results"
        ]
    },
    {
        "id": "9e655973-7d1d-4528-8394-a9cbcf0b978f",
        "primaryId": "NCT02279108",
        "secondaryId": "NCT00943670",
        "label": "Entailment",
        "statement_text": "Adult Patients with Histologically proven HER2- infiltrating breast cancer that have had a Previous lumpectomy or same side mammary reduction are excluded from both the secondary trial and the primary trial ",
        "statement_nums": [],
        "premise_text": "Inclusion Criteria: Histologically proved infiltrating breast cancer (ductal  lobular carcinoma…) or a carcinoma in-situ with an elevated risk of micro-invasion  (High grade with necrosis  radiologically evaluated size more than 40mm, or immediate mastectomy…) Unifocal or multifocal but in same quarter Size smaller than 5cm clinically palpable or not Clinically or ultrasound axillary N0 Isotopic sentinel node detection Adult patient Signed informed consent by patient or legally responsable authority Patient registered to a social security system No surgical contra-indication Exclusion Criteria: Mammary carcinoma recurrence ",
        "premise_nums": [
            "0 Isotopic sentinel"
        ]
    },
    {
        "id": "9e655973-7d1d-4528-8394-a9cbcf0b978f",
        "primaryId": "NCT02279108",
        "secondaryId": "NCT00943670",
        "label": "Entailment",
        "statement_text": "Adult Patients with Histologically proven HER2- infiltrating breast cancer that have had a Previous lumpectomy or same side mammary reduction are excluded from both the secondary trial and the primary trial ",
        "statement_nums": [],
        "premise_text": "Previous same side mammary reductionPrevious lumpectomy Contra-indication to surgery Pregnant or breast feeding patient Denial of participation Inclusion Criteria: Histologically documented  locally advanced  or metastatic breast cancer; measurable and/or non-measureable but evaluable disease is permitted HER2-positive disease History of prior trastuzumab therapy Life expectancy 90 days as assessed by the investigator Negative urine pregnancy test 72 hours prior to Cycle 1 Day 1 for all women of childbearing potential ",
        "premise_nums": [
            "90 days as",
            "72 hours prior",
            "1 Day 1",
            "2-positive disease"
        ]
    },
    {
        "id": "9e655973-7d1d-4528-8394-a9cbcf0b978f",
        "primaryId": "NCT02279108",
        "secondaryId": "NCT00943670",
        "label": "Entailment",
        "statement_text": "Adult Patients with Histologically proven HER2- infiltrating breast cancer that have had a Previous lumpectomy or same side mammary reduction are excluded from both the secondary trial and the primary trial ",
        "statement_nums": [],
        "premise_text": "For patients of childbearing potential  agreement to use one highly effective form of contraception or two effective forms of contraception for the duration of the study treatment(s) and for 4 months after the last dose of T-DM1 or 6 months after the last dose of pertuzumab  if applicableExclusion Criteria: Any chemotherapy  hormonal therapy  radiotherapy  immunotherapy  or biologic therapy for the treatment of breast cancer within 2 weeks of the first study treatment Prior T-DM1 or pertuzumab therapy History of intolerance (such as Grade 3-4 infusion reaction) and/or adverse events related to trastuzumab ",
        "premise_nums": [
            "6 months after",
            "4 months after",
            "2 weeks of",
            "1 or pertuzumab",
            "3-4 infusion",
            "4 infusion reaction)",
            "1 or 6"
        ]
    },
    {
        "id": "9e655973-7d1d-4528-8394-a9cbcf0b978f",
        "primaryId": "NCT02279108",
        "secondaryId": "NCT00943670",
        "label": "Entailment",
        "statement_text": "Adult Patients with Histologically proven HER2- infiltrating breast cancer that have had a Previous lumpectomy or same side mammary reduction are excluded from both the secondary trial and the primary trial ",
        "statement_nums": [],
        "premise_text": "Grade 2 (based on National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE] v3) peripheral neuropathy at the time of or within 3 weeks prior to the first study treatmentBrain metastases that are untreated or progressive or have required any type of therapy  including radiation  surgery  and/or steroids  to control symptoms from brain metastases within 60 days prior to the first study treatment History of cardiac disease  unstable angina  symptomatic congestive heart failure (CHF) (Class II per the New York Heart Associate [NYHA] guidelines)  myocardial infarction  or ventricular arrhythmia 6 months prior to Cycle 1, Day 1 ",
        "premise_nums": [
            "3 weeks prior",
            "6 months prior",
            "60 days prior"
        ]
    },
    {
        "id": "9e655973-7d1d-4528-8394-a9cbcf0b978f",
        "primaryId": "NCT02279108",
        "secondaryId": "NCT00943670",
        "label": "Entailment",
        "statement_text": "Adult Patients with Histologically proven HER2- infiltrating breast cancer that have had a Previous lumpectomy or same side mammary reduction are excluded from both the secondary trial and the primary trial ",
        "statement_nums": [],
        "premise_text": "Implantable pacemaker or automatic implantable cardioverter defibrillatorCongenital long QT syndrome or family history of long QT syndrome Current uncontrolled hypertension Current treatment with medications that alter cardiac conduction (e.g.  digitalis  beta-blockers  or calcium channel blockers) or medications that are generally accepted to have a risk of causing torsades de pointes (TdP) Current known active infection with human immunodeficiency virus (HIV)  hepatitis B virus  or hepatitis C virus Major surgical procedure or significant traumatic injury within 28 days prior to first study treatment  or anticipation of the need for major surgery during the course of study treatment ",
        "premise_nums": [
            "28 days prior"
        ]
    },
    {
        "id": "ea62355f-aab9-4796-8658-746c0b669ca7",
        "primaryId": "NCT00073073",
        "secondaryId": "NCT00054028",
        "label": "Contradiction",
        "statement_text": "There is no placebo or control group in the primary trial  in the secondary trial  Suramin acts as placebo ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Exemestane exemestane 25 mg by mouth (PO) every day for two years taken with calcium carbonate 1200 mg PO every day and vitamin D 400 IU PO every day Initially patients were initially planned to receive Celecoxib but the study was amended prior to any subject going on and Celecoxib was never administered to any subjects  Exemestane: exemestane 25 mg by mouth (PO) every day for two years Calcium carbonate: calcium carbonate 1200 mg PO every day x 2 years Vitamin D: Vitamin D 400 international units PO every day x 2 years INTERVENTION 1: Suramin and Paclitaxel ",
        "premise_nums": [
            "400 IU PO",
            "25 mg by",
            "400 international units",
            "1200 mg PO",
            "2 years Vitamin",
            "2 years INTERVENTION"
        ]
    },
    {
        "id": "ea62355f-aab9-4796-8658-746c0b669ca7",
        "primaryId": "NCT00073073",
        "secondaryId": "NCT00054028",
        "label": "Contradiction",
        "statement_text": "There is no placebo or control group in the primary trial  in the secondary trial  Suramin acts as placebo ",
        "statement_nums": [],
        "premise_text": "Suramin will be infused weekly over 30 minutes  Four hours after the completion of the suramin infusion the 1 hour infusion of paclitaxel will begin ",
        "premise_nums": [
            "1 hour infusion"
        ]
    },
    {
        "id": "55eaae8d-611c-4dbb-b162-de664902e059",
        "primaryId": "NCT00454805",
        "statement_text": "In the primary trial there were more cases of Intestinal Obstruction in cohort 1 than in cohort 2.",
        "statement_nums": [
            "1 than in"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Small Intestinal Obstruction 1/31 (3.23%) Adverse Events 2: Small Intestinal Obstruction 0/31 (0.00%) ",
        "premise_nums": [
            "0/31 (0.00%)",
            "1/31 (3.23%)"
        ]
    },
    {
        "id": "c3438bb2-4a49-4f14-ae50-a46fb48d0208",
        "primaryId": "NCT00485953",
        "secondaryId": "NCT00068601",
        "label": "Entailment",
        "statement_text": "the cyclophosphamide dose in the secondary trial and the Placebo dose in the primary trial are not specified ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Active Medicine Group risedronate 35 mg weekly INTERVENTION 2: Placebo Group Received placebo medication once weekly INTERVENTION 1: Standard Chemotherapy Patients receive cyclophosphamide-containing chemotherapy alone  cyclophosphamide: Part of planned chemotherapy regimen INTERVENTION 2: Chemotherapy Plus Goserelin Patients receive goserelin subcutaneously once every 4 weeks beginning 1 week before start of cyclophosphamide-containing chemotherapy  Treatment continues until completion of chemotherapy in the absence of disease progression or unacceptable toxicity  cyclophosphamide: Part of planned chemotherapy regimen goserelin acetate: Given subcutaneously ",
        "premise_nums": [
            "35 mg weekly",
            "4 weeks beginning",
            "1 week before"
        ]
    },
    {
        "id": "8f505cec-6ad4-4142-a861-1771e3ae5cdd",
        "primaryId": "NCT00821964",
        "statement_text": "the primary trial participants apply topical imiquimod to cutaneous lesions once daily on days for a total of 13 days every 28 day cycle ",
        "statement_nums": [
            "13 days every",
            "28 day cycle"
        ],
        "label": "Entailment",
        "premise_text": "INTERVENTION 1: Treatment (Biological Therapy  Chemo) Patients receive Abraxane IV over 30 minutes on days 1, 8, and 15 and apply topical imiquimod to cutaneous lesions QD on days 1-4, 8-11, 15-18, and 22-25. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity  imiquimod: Given topically Abraxane: Given IV laboratory biomarker analysis: Correlative studies RNA analysis: Correlative studies immunoenzyme technique: Correlative studies ",
        "premise_nums": [
            "22-25. Treatment",
            "15 and apply",
            "30 minutes on",
            "15-18, and",
            "1-4, 8-11,",
            "3 cycles in",
            "28 days for"
        ]
    },
    {
        "id": "8f4f9793-041d-448b-9da8-b0c787a875bb",
        "primaryId": "NCT00478257",
        "statement_text": "Adequate Hematologic  Hepatic and renal function is not necessary for participating in the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Inclusion Criteria: stage I-III breast cancer adjuvant or neoadjuvant anthracycline-based chemotherapy Exclusion Criteria: under age 18 pregnancy metastatic or inoperable (including inflammatory) breast cancer confounding underlying medical illnesses history of mania history of other axis-I psychiatric disorder other physical or psychological impairments - ",
        "premise_nums": [
            "18 pregnancy metastatic"
        ]
    },
    {
        "id": "d13e5689-2a9e-4295-b3f8-e4a18fe42bf1",
        "primaryId": "NCT01735175",
        "secondaryId": "NCT01216319",
        "label": "Entailment",
        "statement_text": "the secondary trial is testing a surgical intervention  unlike the primary trial ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: LA-EP2006 During each chemotherapy cycle eligible patients receive LA-EP2006 s.c  post chemotherapy application  LA-EP2006: Eligible patients are scheduled to receive six cycles of chemotherapy every three weeks  During each chemotherapy cycle pegfilgrastim is injected s.c  post chemotherapy application  INTERVENTION 2: Neulasta® During each chemotherapy cycle eligible patients receive Neulasta® s.c  post chemotherapy application  Neulasta®: Eligible patients are scheduled to receive six cycles of chemotherapy every three weeks  During each chemotherapy cycle pegfilgrastim is injected s.c  post chemotherapy application  INTERVENTION 1: Nipple Reconstruction Cylinder Nipple reconstruction: Biodesign® Nipple Reconstruction Cylinder ",
        "premise_nums": [
            "EP2006 During",
            "2006 During each"
        ]
    },
    {
        "id": "61d56c2a-089f-4fa3-9e97-3a9007576077",
        "primaryId": "NCT00376597",
        "statement_text": "the primary trial do not receive any intervention by IV  orally or by surgery during the study ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "INTERVENTION 1: Arm I (Lymphedema Education) Six weeks after surgery  patients receive a brief initial post-operative care session describing lymphedema risk and prevention through oral instruction and written materials  Patients complete physical assessments and questionnaires at 6 weeks and at 6, 12, and 18 months  Patients are also contacted by telephone at 9 and 15 months  INTERVENTION 2: Arm II (Lymphedema Education  Physical Therapy) Patients receive lymphedema education and complete physical assessments and questionnaires as in Arm I  Patients also complete a personalized physical therapy intervention  receive a refrigerator magnet  and a 15-minute video that reinforces information and exercises  ",
        "premise_nums": [
            "9 and 15",
            "15-minute video",
            "6 weeks and"
        ]
    },
    {
        "id": "5b90b8de-97b9-4ed7-b5a4-e3724fd38c41",
        "primaryId": "NCT00411788",
        "statement_text": "If Hannah has been taking ketoconazole to treat athlete's foot for 6 weeks  until today  she will not be eligible for the primary trial for the next month ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Exclusion Criteria: Use of any of these medications within 4 weeks; cyclosporine  diltiazen  ketoconazole  rifampin  fluconazole  delavirdine  nicardipine  pioglitazone  and sulfonamides  erythromycin  clarithromycin  itraconazole  erythromycin  metoclopramide  nevirapine  phenobarbital  phenytoin  indinavir  fosamprenavir  nefazadone  St Johns Wort  ",
        "premise_nums": []
    },
    {
        "id": "bad4d3e7-a05a-44fd-937a-c94a23655c03",
        "primaryId": "NCT01712009",
        "secondaryId": "NCT00343382",
        "label": "Contradiction",
        "statement_text": "Cohort 2 patients in the primary trial receive naproxen at the same frequency and dosage as cohort 2 patients in the secondary trial receive Pilocarpine ",
        "statement_nums": [
            "2 patients in"
        ],
        "premise_text": "INTERVENTION 2: Naproxen 500 mg BID Participants received adjuvant or neoadjuvant chemotherapy and pegfilgrastim in addition to prophylactic naproxen 500 mg orally twice a day (BID) for 5 days in each of the 4 cycles  beginning on the day of pegfilgrastim administration  INTERVENTION 2: Pilocarpine 2 Times Per Day Patients receive 5mg of Pilocarpine 2 times per day for 6 weeks  ",
        "premise_nums": [
            "500 mg orally",
            "500 mg BID",
            "5 days in",
            "2 Times Per",
            "2 times per"
        ]
    },
    {
        "id": "b88eaf78-957d-4b3d-bcb2-d029b7d7b7e2",
        "primaryId": "NCT00499122",
        "secondaryId": "NCT00454805",
        "label": "Contradiction",
        "statement_text": "There were several cases of Multi-Organ Failure in both cohort 1 of the secondary trial and cohort 2 of the primary trial ",
        "statement_nums": [
            "2 of the",
            "1 of the"
        ],
        "premise_text": "Adverse Events 1: Total: 27/41 (65.85%) Febrile Neutropenia 4/41 (9.76%) Neutropenia 1/41 (2.44%) Deep Vein Thrombosis 1/41 (2.44%) Pulmonary embolism 1/41 (2.44%) Femoral Artery occlusion 1/41 (2.44%) Abdominal Pain 2/41 (4.88%) Constipation 1/41 (2.44%) Fatigue 2/41 (4.88%) Headache 1/41 (2.44%) Nausea 1/41 (2.44%) Cellulitis 1/41 (2.44%) Muscular Weakness 1/41 (2.44%) ",
        "premise_nums": [
            "27/41 (65.85%)",
            "2/41 (4.88%)",
            "4/41 (9.76%)",
            "1/41 (2.44%)"
        ]
    },
    {
        "id": "b88eaf78-957d-4b3d-bcb2-d029b7d7b7e2",
        "primaryId": "NCT00499122",
        "secondaryId": "NCT00454805",
        "label": "Contradiction",
        "statement_text": "There were several cases of Multi-Organ Failure in both cohort 1 of the secondary trial and cohort 2 of the primary trial ",
        "statement_nums": [
            "2 of the",
            "1 of the"
        ],
        "premise_text": "Adverse Events 1:Total: 15/31 (48.39%) Intracardiac Thrombus 1/31 (3.23%) Diarrhoea 2/31 (6.45%) Nausea 2/31 (6.45%) Vomiting 2/31 (6.45%) Ascites 0/31 (0.00%) Ileus 1/31 (3.23%) Small Intestinal Obstruction 1/31 (3.23%) Multi-Organ Failure 0/31 (0.00%) Sepsis 1/31 (3.23%) Weight Decreased 1/31 (3.23%) Dehydration 2/31 (6.45%) Hypokalaemia 0/31 (0.00%) ",
        "premise_nums": [
            "0/31 (0.00%)",
            "2/31 (6.45%)",
            "15/31 (48.39%)",
            "1:Total: 15/31",
            "1/31 (3.23%)"
        ]
    },
    {
        "id": "0c435231-a09c-4424-924a-13840c6b7068",
        "primaryId": "NCT00191789",
        "statement_text": "In the primary trial there was 1 case of jaundice ",
        "statement_nums": [
            "1 case of"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Jaundice 1/65 (1.54%) ",
        "premise_nums": [
            "1/65 (1.54%)"
        ]
    },
    {
        "id": "0812dcc1-eab5-4d5f-9d51-934f9b1f05ca",
        "primaryId": "NCT01217385",
        "secondaryId": "NCT01202591",
        "label": "Entailment",
        "statement_text": "Prior exposure to exemestane is not allowed for patients in the secondary trial  however  the primary trial may accept patients despite this ",
        "statement_nums": [],
        "premise_text": "Inclusion Criteria Pathologically confirmed diagnosis of invasive breast cancer  determined to be a candidate for primary systemic (neoadjuvant) therapy and for surgical resection of residual primary tumor following completion of neoadjuvant therapy; Tumor size greater than 2cm, measured on imaging or estimated by physical exam; No contraindications for primary chemotherapy; Planned definitive breast surgery (mastectomy or lumpectomy/breast conservation) following completion of neoadjuvant therapy; Age 18 years or older; ECOG Performance Status 2 (Karnofsky 60%; see Appendix II); Normal organ and marrow function as follows: leukocytes 3,000/μl; absolute neutrophil count 1,500/μl; platelets 100,000/μl; ",
        "premise_nums": [
            "3,000/μl; absolute",
            "1,500/μl; platelets",
            "18 years or"
        ]
    },
    {
        "id": "0812dcc1-eab5-4d5f-9d51-934f9b1f05ca",
        "primaryId": "NCT01217385",
        "secondaryId": "NCT01202591",
        "label": "Entailment",
        "statement_text": "Prior exposure to exemestane is not allowed for patients in the secondary trial  however  the primary trial may accept patients despite this ",
        "statement_nums": [],
        "premise_text": "total bilirubin within normal institutional limits;AST(SGOT)/ALT(SGPT) 2.5 times the institutional upper limit of normal; creatinine within normal institutional limits; OR creatinine clearance 30 mL/min/1.73 m2 for patients with creatinine levels above institutional normal; If female  postmenopausal for a minimum of one year  OR surgically sterile  OR not pregnant  confirmed by a pregnancy test as per institutional Standard of Care (SOC)  and willing to use adequate contraception (hormonal or barrier method of birth control; abstinence) for the duration of study participation; Able to understand and willing to sign a written informed consent document and a HIPAA authorization in accordance with institutional guidelines; Exclusion Criteria ",
        "premise_nums": [
            "2 for patients",
            "30 mL/min/1.73",
            "5 times the"
        ]
    },
    {
        "id": "0812dcc1-eab5-4d5f-9d51-934f9b1f05ca",
        "primaryId": "NCT01217385",
        "secondaryId": "NCT01202591",
        "label": "Entailment",
        "statement_text": "Prior exposure to exemestane is not allowed for patients in the secondary trial  however  the primary trial may accept patients despite this ",
        "statement_nums": [],
        "premise_text": "Previous treatment (chemotherapy  radiation  or surgery) to involved breast; including hormone therapy;Uncontrolled intercurrent illness including  but not limited to  ongoing or active infection  symptomatic congestive heart failure  unstable angina pectoris  cardiac arrhythmia  or psychiatric illness/social situations that would limit compliance with study requirements; Medically unstable; Under age 18; Pregnant or nursing; Previous malignancy  other than basal cell or squamous cell carcinoma of the skin or in situ carcinoma of the cervix  from which the patient has been disease free for less than 5 years  Exclusion Criteria: Prior exposure to exemestane (safety run-in) / fulvestrant (randomized phase IIa)  or any agent known to inhibit FGFRs  ",
        "premise_nums": []
    },
    {
        "id": "a29e6a86-65f3-4565-93e2-81f49fa837e4",
        "primaryId": "NCT01252290",
        "secondaryId": "NCT00479674",
        "label": "Contradiction",
        "statement_text": "Unlike the secondary trial  the primary trial does not record any instances of Anemia  Dyspepsia  Nausea or depression ",
        "statement_nums": [],
        "premise_text": "Adverse Events 1: Total: 2/35 (5.71%) Gastroesophageal reflux disease * 1/35 (2.86%) Ductal carcinoma in situ * 1/35 (2.86%) Adverse Events 1: Total: 22/41 (53.66%) Anemia 1/41 (2.44%) Dyspepsia 1/41 (2.44%) Mucositis oral 1/41 (2.44%) Nausea 3/41 (7.32%) Vomiting 1/41 (2.44%) Pain 3/41 (7.32%) Allergic reaction 1/41 (2.44%) Infections and infestations - Other  specify: [1]1/41 (2.44%) ",
        "premise_nums": [
            "2/35 (5.71%)",
            "1/41 (2.44%)",
            "22/41 (53.66%)",
            "1/35 (2.86%)",
            "3/41 (7.32%)"
        ]
    },
    {
        "id": "a29e6a86-65f3-4565-93e2-81f49fa837e4",
        "primaryId": "NCT01252290",
        "secondaryId": "NCT00479674",
        "label": "Contradiction",
        "statement_text": "Unlike the secondary trial  the primary trial does not record any instances of Anemia  Dyspepsia  Nausea or depression ",
        "statement_nums": [],
        "premise_text": "Vascular access complication 3/41 (7.32%)Alanine aminotransferase increased 1/41 (2.44%) ",
        "premise_nums": [
            "1/41 (2.44%)",
            "3/41 (7.32%)Alanine"
        ]
    },
    {
        "id": "2470d8d1-27cd-41a5-9e5d-f62d4bbdd049",
        "primaryId": "NCT00418457",
        "statement_text": "Scheduled flap reconstruction within 10 days prior to beginning is acceptable for patients entering the primary trial ",
        "statement_nums": [
            "10 days prior"
        ],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria: Primary breast cancer without known extension beyond the breast and axillary nodes (i.e  believed to be Tumor Stage 1-3, Nodes 0-2) Scheduled for unilateral or bilateral mastectomy with or without implant (isolated \"lumpectomy\" will not qualify) Isolated \"lumpectomy\" with axillary node dissection (anticipated removal of at least five nodes) Written informed consent  including willingness to be randomized to morphine or regional analgesia Exclusion Criteria: Previous surgery for breast cancer (except diagnostic biopsies) Inflammatory breast cancer Age smaller than 18 or greater than 85 years old Scheduled free flap reconstruction ASA Physical Status 4 Any contraindication to epidural or paravertebral anesthesia and analgesia (including coagulopathy  abnormal anatomy) ",
        "premise_nums": [
            "18 or greater",
            "85 years old",
            "0-2) Scheduled",
            "1-3, Nodes",
            "4 Any contraindication"
        ]
    },
    {
        "id": "2470d8d1-27cd-41a5-9e5d-f62d4bbdd049",
        "primaryId": "NCT00418457",
        "statement_text": "Scheduled flap reconstruction within 10 days prior to beginning is acceptable for patients entering the primary trial ",
        "statement_nums": [
            "10 days prior"
        ],
        "label": "Contradiction",
        "premise_text": "Any contraindication to midazolam  propofol  sevoflurane  fentanyl  or morphineOther cancer not believed by the attending surgeon to be in long-term remission Systemic disease believed by the attending surgeon to present 25% two-year mortality ",
        "premise_nums": [
            "25% two-year"
        ]
    },
    {
        "id": "34bb7f09-3b2b-464f-96df-c8d80b1206fc",
        "primaryId": "NCT03190083",
        "secondaryId": "NCT01805089",
        "label": "Contradiction",
        "statement_text": "All cancer stages are accepted for the primary trial and the secondary trial ",
        "statement_nums": [],
        "premise_text": "Inclusion Criteria: New diagnosis of breast cancer New diagnosis if a previous breast cancer patient with negative surgical margins Patients willing to sign a written informed consent form Inclusion Criteria: History of ductal carcinoma in situ  lobular carcinoma in situ or stages 1-3 breast cancer Not currently receiving chemotherapy or hormonal therapy Postmenopausal ",
        "premise_nums": [
            "1-3 breast",
            "3 breast cancer"
        ]
    },
    {
        "id": "e9824c27-bb70-4707-9599-ff20281f873e",
        "primaryId": "NCT00357110",
        "statement_text": "Less than 20% of patients in cohort 1 of the primary trial had Varicose Veins ",
        "statement_nums": [
            "20% of",
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Varicose Vein 1/6 (16.67%) ",
        "premise_nums": [
            "1/6 (16.67%)"
        ]
    },
    {
        "id": "43fcba9b-4edd-433d-86a7-370cbbf56853",
        "primaryId": "NCT00320385",
        "secondaryId": "NCT00075270",
        "label": "Entailment",
        "statement_text": "The median time from randomization until the first documented sign of disease progression or death due to any cause for all participants in the primary trial  was lower than the median time for patients in the secondary trial ",
        "statement_nums": [],
        "premise_text": "Outcome Measurement: Progression-Free Survival (PFS) PFS was defined as the time from randomization until the first documented sign of disease progression or death due to any cause  Time frame: Baseline to disease progression or death due to any cause or 30 days after last dose (up to 216 weeks) Results 1: Arm/Group Title: Trastuzumab + Lapatinib ",
        "premise_nums": [
            "30 days after"
        ]
    },
    {
        "id": "43fcba9b-4edd-433d-86a7-370cbbf56853",
        "primaryId": "NCT00320385",
        "secondaryId": "NCT00075270",
        "label": "Entailment",
        "statement_text": "The median time from randomization until the first documented sign of disease progression or death due to any cause for all participants in the primary trial  was lower than the median time for patients in the secondary trial ",
        "statement_nums": [],
        "premise_text": "Arm/Group Description: Participants received Lapatinib 1000 milligram (mg) tablets orally daily 1 hour before or after breakfast along with Trastuzumab infusion at a loading dose of 4 milligrams/kilogram (mg/kg) body weight intravenously (IV) over 90 minutes on Day 1, followed by 2 mg/kg IV over 30 minutes weekly  in a 4 week cycle Overall Number of Participants Analyzed: 146 Median (95% Confidence Interval) Unit of Measure: weeks 12.0 (8.1 to 16.0) Results 2: Arm/Group Title: Lapatinib Arm/Group Description: Participants received Lapatinib 1500 mg tablets orally daily 1 hour before or after breakfast  ",
        "premise_nums": [
            "30 minutes weekly",
            "1000 milligram (mg)",
            "4 week cycle",
            "1500 mg tablets",
            "1 hour before",
            "1 to 16.0)",
            "2 mg/kg IV",
            "95% Confidence",
            "4 milligrams/kilogram",
            "90 minutes on"
        ]
    },
    {
        "id": "43fcba9b-4edd-433d-86a7-370cbbf56853",
        "primaryId": "NCT00320385",
        "secondaryId": "NCT00075270",
        "label": "Entailment",
        "statement_text": "The median time from randomization until the first documented sign of disease progression or death due to any cause for all participants in the primary trial  was lower than the median time for patients in the secondary trial ",
        "statement_nums": [],
        "premise_text": "Overall Number of Participants Analyzed: 145Median (95% Confidence Interval) Unit of Measure: weeks 8.1 (7.6 to 9.0) Outcome Measurement: Time to Progression as Evaluated by the Investigator ",
        "premise_nums": [
            "6 to 9.0)",
            "95% Confidence"
        ]
    },
    {
        "id": "196c7a35-58a0-4d2d-a0a6-e9e3de077fb1",
        "primaryId": "NCT02555657",
        "statement_text": "The Median time from randomization to death due to any cause was higher in cohort 1 of the primary trial  compared to cohort 2.",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Overall Survival in Participants With Programmed Cell Death Ligand 1 (PD-L1) With Combined Positive Score (CPS) 10 Overall survival (OS) was defined as the time from randomization to death due to any cause  Time frame: Up to approximately 36 months (through Final Analysis database cutoff date of 11-April-2019) Results 1: Arm/Group Title: Pembrolizumab Arm/Group Description: Participants received pembrolizumab 200 mg IV every Q3W for up to 35 administrations (up to ~2 years)  Overall Number of Participants Analyzed: 96 Median (95% Confidence Interval) Unit of Measure: Months 12.7 (9.9 to 16.3) Results 2: ",
        "premise_nums": [
            "200 mg IV",
            "10 Overall survival",
            "35 administrations (up",
            "95% Confidence",
            "11-April-2019) Results",
            "36 months (through",
            "9 to 16.3)"
        ]
    },
    {
        "id": "196c7a35-58a0-4d2d-a0a6-e9e3de077fb1",
        "primaryId": "NCT02555657",
        "statement_text": "The Median time from randomization to death due to any cause was higher in cohort 1 of the primary trial  compared to cohort 2.",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Arm/Group Title: ChemotherapyArm/Group Description: Participants received capecitabine  eribulin  gemcitabine  or vinorelbine as single agent chemotherapy chosen by the treating physician (Treatment of Physician's Choice  TPC) in accordance with local regulations and guidelines  Overall Number of Participants Analyzed: 98 Median (95% Confidence Interval) Unit of Measure: Months 11.6 (8.3 to 13.7) ",
        "premise_nums": [
            "95% Confidence",
            "3 to 13.7)"
        ]
    },
    {
        "id": "27e0b995-b3d1-46a6-900a-d6e513504ff3",
        "primaryId": "NCT00398567",
        "statement_text": "3/4 patients in the primary trial did not suffer any adverse events ",
        "statement_nums": [
            "4 patients in",
            "3/4 patients"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 1/4 (25.00%) ",
        "premise_nums": [
            "1/4 (25.00%)"
        ]
    },
    {
        "id": "36a5357f-0c5f-4c64-a56a-a84aab165a16",
        "primaryId": "NCT01727011",
        "secondaryId": "NCT01420146",
        "label": "Entailment",
        "statement_text": "the primary trial and the secondary trial interventions involve a variety of scans  such as CT  PET and dosimetry",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: IPAS Once the patient recorded in the trial  and after completion of a post-implant dosimetry scanner to analyze the dose distribution within the target volume and organs at risk  the patient is treated by irradiation and partial accelerated breast brachytherapy using high dose rate  delivering a total dose of 16 Gy in one fraction IPAS INTERVENTION 1: Zr89-trastuzumab PET/CT Zr89-trastuzumab (trastuzumab labelled with zirconium 89) for PET/CT single arm ",
        "premise_nums": [
            "89-trastuzumab PET/CT",
            "16 Gy in"
        ]
    },
    {
        "id": "c876167f-fe1e-4c3b-9183-dd3c1069ed0b",
        "primaryId": "NCT00024102",
        "statement_text": "A patient in cohort 2 of the primary trial received a Packed red blood cell transfusion ",
        "statement_nums": [
            "2 of the"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 2: Transfusion: pRBCs 1/181 (0.55%) ",
        "premise_nums": [
            "1/181 (0.55%)"
        ]
    },
    {
        "id": "d6989b67-ae99-4c2a-a67d-c2285cc57058",
        "primaryId": "NCT00191152",
        "statement_text": "The longest Time to Disease Progression the primary trial was over 11 months in the Docetaxel Plus Capecitabine group ",
        "statement_nums": [
            "11 months in"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Time to Disease Progression (Initial Treatment) Time to disease progression (TTDP) at initial treatment was defined as the number of months between date of randomization and the date of first documented disease progression or the date of death due to disease under study  whichever came first  TTDP censored at earliest of: 1) date of death not due to disease; or 2) date of last contact for participants alive without disease progression; or 3) start date of other anti-tumor therapy; or 4) first dose date of crossover treatment  Time frame: Randomization date to the earliest date of first documented disease progression date or the date of death if the participant died due to study disease (up to 82 months) Results 1: Arm/Group Title: Gemcitabine Plus Docetaxel ",
        "premise_nums": []
    },
    {
        "id": "d6989b67-ae99-4c2a-a67d-c2285cc57058",
        "primaryId": "NCT00191152",
        "statement_text": "The longest Time to Disease Progression the primary trial was over 11 months in the Docetaxel Plus Capecitabine group ",
        "statement_nums": [
            "11 months in"
        ],
        "label": "Entailment",
        "premise_text": "Arm/Group Description: gemcitabine 1000 milligrams per meter squared (mg/m2) intravenous  days 1 and 8 every 21 days plus docetaxel 75 mg/m2, intravenous  day 1 every 21 days Treatment continues until progression of disease at which time crossover treatment begins  Overall Number of Participants Analyzed: 239 Median (95% Confidence Interval) Unit of Measure: months 9.28 (7.73 to 10.79) Results 2: Arm/Group Title: Docetaxel Plus Capecitabine ",
        "premise_nums": [
            "1000 milligrams per",
            "75 mg/m2,",
            "1 every 21",
            "73 to 10.79)",
            "1 and 8",
            "95% Confidence",
            "21 days plus"
        ]
    },
    {
        "id": "d6989b67-ae99-4c2a-a67d-c2285cc57058",
        "primaryId": "NCT00191152",
        "statement_text": "The longest Time to Disease Progression the primary trial was over 11 months in the Docetaxel Plus Capecitabine group ",
        "statement_nums": [
            "11 months in"
        ],
        "label": "Entailment",
        "premise_text": "Arm/Group Description: docetaxel 75 mg/m2, intravenous  day 1 every 21 days plus capecitabine 1000 mg/m2, by mouth twice a day  days 1-14 every 21 days  Treatment continues until progression of disease  at which time crossover treatment begins Overall Number of Participants Analyzed: 236 Median (95% Confidence Interval) Unit of Measure: months 8.88 (7.37 to 11.05) ",
        "premise_nums": [
            "14 every 21",
            "75 mg/m2,",
            "1 every 21",
            "37 to 11.05)",
            "95% Confidence",
            "1000 mg/m2,",
            "1-14 every"
        ]
    },
    {
        "id": "90dfb0bd-e0a0-47a9-945b-fd8ec8faaaa1",
        "primaryId": "NCT00320385",
        "secondaryId": "NCT00075270",
        "label": "Contradiction",
        "statement_text": "Both cohorts in the primary trial outperformed cohort 1 of the secondary trial in median PFS ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Outcome Measurement: Progression-Free Survival (PFS) PFS was defined as the time from randomization until the first documented sign of disease progression or death due to any cause  Time frame: Baseline to disease progression or death due to any cause or 30 days after last dose (up to 216 weeks) Results 1: Arm/Group Title: Trastuzumab + Lapatinib Arm/Group Description: Participants received Lapatinib 1000 milligram (mg) tablets orally daily 1 hour before or after breakfast along with Trastuzumab infusion at a loading dose of 4 milligrams/kilogram (mg/kg) body weight intravenously (IV) over 90 minutes on Day 1, followed by 2 mg/kg IV over 30 minutes weekly  in a 4 week cycle  ",
        "premise_nums": [
            "30 minutes weekly",
            "1000 milligram (mg)",
            "4 week cycle",
            "1 hour before",
            "2 mg/kg IV",
            "30 days after",
            "4 milligrams/kilogram",
            "90 minutes on"
        ]
    },
    {
        "id": "90dfb0bd-e0a0-47a9-945b-fd8ec8faaaa1",
        "primaryId": "NCT00320385",
        "secondaryId": "NCT00075270",
        "label": "Contradiction",
        "statement_text": "Both cohorts in the primary trial outperformed cohort 1 of the secondary trial in median PFS ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Overall Number of Participants Analyzed: 146Median (95% Confidence Interval) Unit of Measure: weeks 12.0 (8.1 to 16.0) Results 2: Arm/Group Title: Lapatinib Arm/Group Description: Participants received Lapatinib 1500 mg tablets orally daily 1 hour before or after breakfast  Overall Number of Participants Analyzed: 145 Median (95% Confidence Interval) Unit of Measure: weeks 8.1 (7.6 to 9.0) Outcome Measurement: Time to Progression as Evaluated by the Investigator ",
        "premise_nums": [
            "1500 mg tablets",
            "1 to 16.0)",
            "1 hour before",
            "95% Confidence",
            "6 to 9.0)"
        ]
    },
    {
        "id": "886d3280-bc44-4a58-a5ba-66b018210332",
        "primaryId": "NCT00076024",
        "statement_text": "The minimum period of time from start of study treatment to first documentation of objective tumor progression or death due to cancer for any patient in the primary trial  was just over a year ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Time to Tumor Progression (TTP) Time in days from start of study treatment to first documentation of objective tumor progression or death due to cancer  whichever comes first  TTP was calculated as first event date minus the date of first dose of study medication plus 1. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease [PD])  Time frame: Phase 2 double-blind baseline until tumor progression or death or discontinuation from study treatment  assessed every 9 weeks up to 129 weeks Results 1: Arm/Group Title: Axitinib + Docetaxel (Phase 2, Double-blind) ",
        "premise_nums": [
            "129 weeks Results",
            "9 weeks up",
            "2 double-blind baseline"
        ]
    },
    {
        "id": "886d3280-bc44-4a58-a5ba-66b018210332",
        "primaryId": "NCT00076024",
        "statement_text": "The minimum period of time from start of study treatment to first documentation of objective tumor progression or death due to cancer for any patient in the primary trial  was just over a year ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Arm/Group Description: Axitinib (AG-013736) 5 mg tablet orally BID starting from Day 1 of Cycle 1, in cycles of 3 weeks  Docetaxel 80 mg/m^2 1 hr IV infusion on Day 1 of each cycle  in cycles of 3 weeks  Treatment was continued until disease progression  intolerable toxicity  or for 2 cycles after complete response Overall Number of Participants Analyzed: 112 Median (95% Confidence Interval) Unit of Measure: days 247 (208 to 265) Results 2: Arm/Group Title: Docetaxel + Placebo (Phase 2, Double-blind) ",
        "premise_nums": [
            "1 hr IV",
            "80 mg/m^2",
            "208 to 265)",
            "1 of each",
            "1 of Cycle",
            "95% Confidence",
            "2 cycles after",
            "5 mg tablet"
        ]
    },
    {
        "id": "886d3280-bc44-4a58-a5ba-66b018210332",
        "primaryId": "NCT00076024",
        "statement_text": "The minimum period of time from start of study treatment to first documentation of objective tumor progression or death due to cancer for any patient in the primary trial  was just over a year ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Arm/Group Description: Placebo matched to axitinib (AG-013736) tablet orally BID starting from Day 1 of Cycle 1, in cycles of 3 weeks  Docetaxel 80 mg/m^2 1 hr IV infusion on Day 1 of each cycle  in cycles of 3 weeks  Treatment was continued until disease progression  intolerable toxicity  or for 2 cycles after complete response  Participants with disease progression after consent were continued to open-label phase Overall Number of Participants Analyzed: 55 Median (95% Confidence Interval) Unit of Measure: days 215 (191 to 247) ",
        "premise_nums": [
            "1 hr IV",
            "80 mg/m^2",
            "1 of each",
            "1 of Cycle",
            "95% Confidence",
            "191 to 247)",
            "2 cycles after"
        ]
    },
    {
        "id": "03dcb6d9-efae-40ec-87ee-68ef89424498",
        "primaryId": "NCT00323479",
        "secondaryId": "NCT03078751",
        "label": "Entailment",
        "statement_text": "There were more cases of deteriorating mental health in the primary trial than the secondary trial ",
        "statement_nums": [],
        "premise_text": "Adverse Events 1: Total: 6/110 (5.45%) Sudden death unexplained 1/110 (0.91%) General body pain 1/110 (0.91%) Lymphangitis 1/110 (0.91%) Femur fracture 1/110 (0.91%) Parathyroid adenoma 1/110 (0.91%) Depression worsened 1/110 (0.91%) Calculus urinary bladder 1/110 (0.91%) Pneumopathy 1/110 (0.91%) Adverse Events 1: Total: 4/26 (15.38%) Disseminated intravascular coagulation 1/26 (3.85%) Cardiac failure congestive 1/26 (3.85%) ",
        "premise_nums": [
            "1/110 (0.91%)",
            "4/26 (15.38%)",
            "6/110 (5.45%)",
            "1/26 (3.85%)"
        ]
    },
    {
        "id": "03dcb6d9-efae-40ec-87ee-68ef89424498",
        "primaryId": "NCT00323479",
        "secondaryId": "NCT03078751",
        "label": "Entailment",
        "statement_text": "There were more cases of deteriorating mental health in the primary trial than the secondary trial ",
        "statement_nums": [],
        "premise_text": "Breast cellulitis 1/26 (3.85%)Cellulitis 1/26 (3.85%) Acute myeloid leukaemia 1/26 (3.85%) Seizure 0/26 (0.00%) Pulmonary embolism 1/26 (3.85%) Adverse Events 2: Total: 2/24 (8.33%) Disseminated intravascular coagulation 0/24 (0.00%) Cardiac failure congestive 0/24 (0.00%) Breast cellulitis 0/24 (0.00%) Cellulitis 1/24 (4.17%) Acute myeloid leukaemia 0/24 (0.00%) Seizure 1/24 (4.17%) Pulmonary embolism 0/24 (0.00%) ",
        "premise_nums": [
            "2/24 (8.33%)",
            "1/24 (4.17%)",
            "0/26 (0.00%)",
            "1/26 (3.85%)Cellulitis",
            "0/24 (0.00%)"
        ]
    },
    {
        "id": "b881b717-1c8a-41b8-9554-6ed9e8ee7c77",
        "primaryId": "NCT00193206",
        "statement_text": "the primary trial records a total of 7 patients suffering from various infections ",
        "statement_nums": [
            "7 patients suffering"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 22/123 (17.89%) Cardiac Ischemia/Infarction [1]1/123 (0.81%) Pain - Chest 2/123 (1.63%) Dehydration 2/123 (1.63%) Death [2]1/123 (0.81%) Weakness 1/123 (0.81%) Pain - Liver 1/123 (0.81%) Infection - Skin [3]3/123 (2.44%) Infection - Gastrointestinal [4]1/123 (0.81%) Infection - Vein [5]2/123 (1.63%) Infection - Pneumonia 1/123 (0.81%) ",
        "premise_nums": [
            "3/123 (2.44%)",
            "1/123 (0.81%)",
            "2/123 (1.63%)",
            "22/123 (17.89%)"
        ]
    },
    {
        "id": "20530faf-addb-47bf-896d-b9666e149223",
        "primaryId": "NCT01439282",
        "statement_text": "In total cohort 1 of the primary trial recorded 20% more adverse events than cohort 2.",
        "statement_nums": [
            "20% more",
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 14/67 (20.90%) Adverse Events 2: Total: 1/10 (10.00%) ",
        "premise_nums": [
            "1/10 (10.00%)",
            "14/67 (20.90%)"
        ]
    },
    {
        "id": "52557c9f-f771-4f31-bb71-01f87f9f5821",
        "primaryId": "NCT00041067",
        "secondaryId": "NCT01273896",
        "label": "Contradiction",
        "statement_text": "Patients with ER positive  PR positive or HER2 positive stage 4 tumors may be eligible for the secondary trial or the primary trial ",
        "statement_nums": [
            "2 positive stage",
            "4 tumors may"
        ],
        "premise_text": "DISEASE CHARACTERISTICS: Histologically confirmed stage IV breast cancer Inclusion Criteria: Male and Female patients must be at least 18 years of age Pathologically confirmed diagnosis of breast cancer Metastatic or advanced stage breast cancer Prior treatment with at least one and no more than three lines of biologic and/or chemotherapy for metastatic breast cancer (excluding hormonal therapy) Patients with HER2+ disease must have received prior treatment with Trastuzumab Patients with ER and/or PR+ disease must have received prior treatment with hormonal therapy Off cytotoxic chemotherapy or biologic therapy (excluding Hormonal therapy) 3 weeks Measurable disease by RECIST 1.1 ",
        "premise_nums": [
            "18 years of",
            "3 weeks Measurable"
        ]
    },
    {
        "id": "52557c9f-f771-4f31-bb71-01f87f9f5821",
        "primaryId": "NCT00041067",
        "secondaryId": "NCT01273896",
        "label": "Contradiction",
        "statement_text": "Patients with ER positive  PR positive or HER2 positive stage 4 tumors may be eligible for the secondary trial or the primary trial ",
        "statement_nums": [
            "2 positive stage",
            "4 tumors may"
        ],
        "premise_text": "Central nervous system metastases are permitted if treated and radiographically and clinically stable for at least 4 weeks prior to first dose of STA-9090Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1 Life expectancy of at least 3 months Adequate hematologic function as defined by: Absolute neutrophil count 1,500 cells/μL Platelets 100,000/μL Hemoglobin 9.0g/dL Adequate hepatic function as defined by: Serum bilirubin 1.5 X upper limit of normal (ULN); Adequate renal function as defined by a serum creatinine 1.5 x ULN AST  ALT  and alkaline phosphatase 3 × ULN except for: ",
        "premise_nums": [
            "bilirubin 1.5 X upper",
            "0 or 1",
            "Hemoglobin 9.0g/dL",
            "creatinine 1.5 x ULN",
            "100,000/μL Hemoglobin",
            "1,500 cells/",
            "4 weeks prior",
            "3 months Adequate"
        ]
    },
    {
        "id": "52557c9f-f771-4f31-bb71-01f87f9f5821",
        "primaryId": "NCT00041067",
        "secondaryId": "NCT01273896",
        "label": "Contradiction",
        "statement_text": "Patients with ER positive  PR positive or HER2 positive stage 4 tumors may be eligible for the secondary trial or the primary trial ",
        "statement_nums": [
            "2 positive stage",
            "4 tumors may"
        ],
        "premise_text": "Patients with hepatic metastases: ALT and AST 5 × ULNPatients with hepatic and/or bone metastases: alkaline phosphatase 5 × ULN Patients with Gilbert's disease: serum bilirubin smaller than 5 mg/dL Willingness and ability to comply with scheduled visits  treatment plans  laboratory tests  and other study procedures Female subjects of childbearing potential and males must agree to use adequate contraception (e.g.  hormonal or barrier method of birth control; abstinence) for the duration of study treatment Female subjects of childbearing age must have a negative serum pregnancy test at study entry  Exclusion Criteria: Surgery  radiotherapy  or lesion ablative procedure to the only area of measurable disease ",
        "premise_nums": [
            "5 mg/dL Willingness"
        ]
    },
    {
        "id": "52557c9f-f771-4f31-bb71-01f87f9f5821",
        "primaryId": "NCT00041067",
        "secondaryId": "NCT01273896",
        "label": "Contradiction",
        "statement_text": "Patients with ER positive  PR positive or HER2 positive stage 4 tumors may be eligible for the secondary trial or the primary trial ",
        "statement_nums": [
            "2 positive stage",
            "4 tumors may"
        ],
        "premise_text": "Major surgery within 4 weeks prior to first dose of STA-9090Poor peripheral venous access for study drug administration  Study drug administration via indwelling catheters allowed only if the catheter is made of silicone material  History of severe (grade 3 or 4) allergic or hypersensitivity reactions to excipients (e.g.  Polyethylene glycol [PEG] 300 and Polysorbate 80) Baseline QTc greater than 470 msec Ventricular ejection fraction (EF) smaller than 50% at baseline Treatment with chronic immunosuppressants (e.g.  cyclosporine following transplantation) Women who are pregnant or lactating ",
        "premise_nums": [
            "4 weeks prior",
            "470 msec Ventricular",
            "50% at",
            "300 and Polysorbate",
            "3 or 4)"
        ]
    },
    {
        "id": "52557c9f-f771-4f31-bb71-01f87f9f5821",
        "primaryId": "NCT00041067",
        "secondaryId": "NCT01273896",
        "label": "Contradiction",
        "statement_text": "Patients with ER positive  PR positive or HER2 positive stage 4 tumors may be eligible for the secondary trial or the primary trial ",
        "statement_nums": [
            "2 positive stage",
            "4 tumors may"
        ],
        "premise_text": "Uncontrolled intercurrent illness including  but not limited to  human immunodeficiency virus (HIV)-positive subjects receiving combination antiretroviral therapy  ongoing or active infection  symptomatic congestive heart failure  unstable angina pectoris  ventricular arrhythmia  or psychiatric illness/social situations that would limit compliance with study requirementsOther medications  or severe acute/chronic medical or psychiatric condition  or laboratory abnormality that may increase the risk associated with study participation or study drug administration  or may interfere with the interpretation of study results in the judgment of the investigator Seizure disorder or requirement for seizure medication Prior treatment with an HSP90 inhibitor persistent adverse events of prior therapies that are greater than 1 grade 1 in severity ",
        "premise_nums": [
            "HSP90 inhibitor",
            "1 grade 1",
            "90 inhibitor persistent"
        ]
    },
    {
        "id": "52557c9f-f771-4f31-bb71-01f87f9f5821",
        "primaryId": "NCT00041067",
        "secondaryId": "NCT01273896",
        "label": "Contradiction",
        "statement_text": "Patients with ER positive  PR positive or HER2 positive stage 4 tumors may be eligible for the secondary trial or the primary trial ",
        "statement_nums": [
            "2 positive stage",
            "4 tumors may"
        ],
        "premise_text": "history of or current coronary artery disease  myocardial infarction  angina pectoris  angioplasty or coronary bypass surgeryhistory of or current uncontrolled dysrhythmias  or requirement for antiarrhythmic medications  or Grade 2 or greater left bundle branch block New York Heart Association class II/III/IV congestive heart failure with a history of dyspnea  orthopnea  or edema that requires current treatment with angiotensin converting enzyme inhibitors  angiotensin II receptor blockers  beta blockers or diuretics ",
        "premise_nums": [
            "2 or greater"
        ]
    },
    {
        "id": "11472413-533f-45f9-9aac-c46bca318aab",
        "primaryId": "NCT00373256",
        "statement_text": "Cohort 1 of the primary trial included over 200 patients being treated with Sunitinib and Paclitaxel for a duration of 18 months or until death  and the median PFS for this group was just under 7 and a half months ",
        "statement_nums": [
            "200 patients being",
            "18 months or",
            "1 of the",
            "7 and a"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Progression-Free Survival (PFS) Time from date of randomization to the date of the first documentation of objective tumor progression or death due to any cause  whichever occurred first  PFS = (first event date minus randomization date +1) divided by 30.4 Time frame: From date of randomization through Day 1 and every 8 weeks thereafter up to 18 months or death Results 1: Arm/Group Title: Sunitinib + Paclitaxel ",
        "premise_nums": [
            "1 and every",
            "4 Time frame:",
            "8 weeks thereafter",
            "by 30.4 Time frame",
            "18 months or"
        ]
    },
    {
        "id": "11472413-533f-45f9-9aac-c46bca318aab",
        "primaryId": "NCT00373256",
        "statement_text": "Cohort 1 of the primary trial included over 200 patients being treated with Sunitinib and Paclitaxel for a duration of 18 months or until death  and the median PFS for this group was just under 7 and a half months ",
        "statement_nums": [
            "200 patients being",
            "18 months or",
            "1 of the",
            "7 and a"
        ],
        "label": "Entailment",
        "premise_text": "Arm/Group Description: Starting sunitinib doses of 25 mg daily  After Cycle 1, escalation to 37.5 mg daily was permitted in the absence of complicated neutropenia and if all 3 Cycle 1 paclitaxel doses were successfully administered at 90 mg/m^2, at discretion of the investigator  Paclitaxel could have been reduced to 65 mg/m^2 based on tolerability; re-escalation to 80 or 90 mg/m^2 upon recovery was permitted Overall Number of Participants Analyzed: 242 Median (95% Confidence Interval) Unit of Measure: Months 7.4 (6.9 to 8.5) ",
        "premise_nums": [
            "to 37.5 mg daily",
            "80 or 90",
            "2 upon recovery",
            "2 based on",
            "9 to 8.5)",
            "3 Cycle 1",
            "95% Confidence",
            "90 mg/m^2,",
            "25 mg daily",
            "65 mg/m^2"
        ]
    },
    {
        "id": "3b8f5ef2-b0bb-42e8-a165-45a2d35780e0",
        "primaryId": "NCT00191854",
        "statement_text": "Patients do not need to have a Her2neu positive tumours or a measurable indicator lesion to be included in the primary trial",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Inclusion Criteria: Female patients with histological or cytological proven diagnosis of breast cancer Stage IV disease Performance Status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Scale Patients had to have previously received anthracycline based regimens as a adjuvant therapy or neo-adjuvant chemotherapy and then progressed and developed metastatic disease Adequate organ function Exclusion Criteria: Prior chemotherapy for metastatic disease Previous radiation therapy is allowed but must not have included whole pelvis radiation Known or suspected brain metastasis  Serious concomitant disorders that would compromise the safety of the patient or compromise the patient's ability to complete the study  at the discretion of the investigator ",
        "premise_nums": [
            "0 or 1"
        ]
    },
    {
        "id": "3b8f5ef2-b0bb-42e8-a165-45a2d35780e0",
        "primaryId": "NCT00191854",
        "statement_text": "Patients do not need to have a Her2neu positive tumours or a measurable indicator lesion to be included in the primary trial",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Concurrent administration of any other tumor therapy  including cytotoxic chemotherapy  hormonal therapy and immunotherapy (including trastuzumab (Herceptin))Peripheral neuropathy of Common Toxicity Criteria (CTC) Grade greater than 1. History of significant neurological or mental disorder  including seizures or dementia ",
        "premise_nums": []
    },
    {
        "id": "6446f085-c6b0-43ce-82ed-16d6952b549e",
        "primaryId": "NCT00880022",
        "secondaryId": "NCT00916578",
        "label": "Contradiction",
        "statement_text": "Only patients in cohort 2 of the primary trial undergo Trunk compression  However all patients in the secondary trial are treated with Trunk compression ",
        "statement_nums": [
            "2 of the"
        ],
        "premise_text": "INTERVENTION 1: Arm Compression Only [Not Specified] INTERVENTION 2: Arm  Trunck and Chest Compression [Not Specified] INTERVENTION 1: Single Arm Institution  Open Label  Phase II Patients will received 825 mg/m2 bid of capecitabine  One of the two daily doses of capecitabine will be taken 2 hours before receiving radiotherapy  Capecitabine will be administered when patients receives radiation therapy  Radiation therapy doses will be 50-57 Gy to the initial clinical target volume  ",
        "premise_nums": [
            "2 bid of",
            "2 hours before",
            "825 mg/m2 bid",
            "57 Gy to",
            "50-57 Gy"
        ]
    },
    {
        "id": "7348c2e8-9eb5-4ed6-9a5d-bcb02a5c3a0a",
        "primaryId": "NCT01104584",
        "statement_text": "the primary trial participants receive either 50mg/m2 trastuzumab  Tamoxifen or Exemestane ",
        "statement_nums": [
            "50mg/m2 trastuzumab"
        ],
        "label": "Contradiction",
        "premise_text": "INTERVENTION 1: CMRM Versus UMRM [Not Specified] ",
        "premise_nums": []
    },
    {
        "id": "db90c9d8-b289-48e2-a7df-f41620b3feab",
        "primaryId": "NCT00110084",
        "secondaryId": "NCT01961544",
        "label": "Entailment",
        "statement_text": "the primary trial and the secondary trial both reported cases of sepsis in their patients ",
        "statement_nums": [],
        "premise_text": "Adverse Events 1: Sepsis 1/50 (2.00%) Adverse Events 1: Pseudomonal sepsis * 1/101 (0.99%) ",
        "premise_nums": [
            "1/101 (0.99%)",
            "1/50 (2.00%)"
        ]
    },
    {
        "id": "f2533676-1e72-444e-8aef-1fa826ceb804",
        "primaryId": "NCT01419197",
        "statement_text": "There are no cases of agranulocytosis in the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Granulocytopenia 0/403 (0.00%) ",
        "premise_nums": [
            "0/403 (0.00%)"
        ]
    },
    {
        "id": "c15309b3-eb08-4d46-94ef-e4a504a111db",
        "primaryId": "NCT03708393",
        "secondaryId": "NCT03456427",
        "label": "Entailment",
        "statement_text": "The intervention in the primary trial is carried out by either a doctor  radiographer or a sonographer  whereas one of the interventions in the secondary trial requires active participation from the patient ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: IUS Alone IUS alone imaging INTERVENTION 2: Imagio (IUS+OA) IUS+OA imaging INTERVENTION 1: All Study Participants: Patient Assisted Compression All subjects will undergo standard of care imaging on one breast  The other breast will be imaged using Patient-Assisted Compression (PAC)  followed by Technologist-controlled (TC) Compression  Patient-Assisted Compression (PAC): The technologist will properly position the breast and apply minimum compression  The subject will be instructed to apply compression as the technologist ensures the breast tissue is in appropriate position and tautness  The technologist will then guide the subject to achieve appropriate compression level  sufficient but not excessive  and the image will be acquired  This will be done for both standard views CC & MLO  ",
        "premise_nums": []
    },
    {
        "id": "4885cd77-628c-4b8f-8345-6bce2165938c",
        "primaryId": "NCT02964234",
        "secondaryId": "NCT00246090",
        "label": "Contradiction",
        "statement_text": "Patients eligible for the primary trial and the secondary trial must live in the USA ",
        "statement_nums": [],
        "premise_text": "Inclusion Criteria: Age 52-75 years old; Identification as Latina/Hispanic/Chicana female; Residence in Pilsen  Little Village  East Side or South Chicago; Inclusion Criteria: Female patients with histologically or cytologically confirmed carcinoma of the breast  Every effort should be made to make paraffin embedded tissue or slides from the diagnostic biopsy or surgical specimen available for confirmation of diagnosis  Patients with locally advanced or metastatic disease who have received at least two (and not more than five) prior chemotherapeutic regimens for breast cancer  at least one of which was administered for treatment of locally advanced or metastatic disease  Prior therapy must be documented by the following criteria prior to entry onto study: ",
        "premise_nums": [
            "52-75 years",
            "75 years old;"
        ]
    },
    {
        "id": "4885cd77-628c-4b8f-8345-6bce2165938c",
        "primaryId": "NCT02964234",
        "secondaryId": "NCT00246090",
        "label": "Contradiction",
        "statement_text": "Patients eligible for the primary trial and the secondary trial must live in the USA ",
        "statement_nums": [],
        "premise_text": "Regimens must have included an anthracycline (eg  doxorubicin  epirubicin)  a taxane (eg  paclitaxel  docetaxel) and capecitabine in any combination or order One or two of these regimens may have been administered as adjuvant and/or neoadjuvant therapy  Patients with human epidermal growth factor receptor 2 (HER2/neu) over-expressing tumors must additionally have been treated with trastuzumab  Patients with estrogen receptor-expressing tumors may have additionally been treated with estrogen-specific therapy  ",
        "premise_nums": [
            "2/neu) over-expressing"
        ]
    },
    {
        "id": "4885cd77-628c-4b8f-8345-6bce2165938c",
        "primaryId": "NCT02964234",
        "secondaryId": "NCT00246090",
        "label": "Contradiction",
        "statement_text": "Patients eligible for the primary trial and the secondary trial must live in the USA ",
        "statement_nums": [],
        "premise_text": "Prior hormonal therapy  biological therapy  (eg  trastuzumab  bevacizumab)  or immunotherapy  is not to be counted as one of the 2 to 5 prior chemotherapy regimens allowed  However  hormonal therapy must be discontinued one week before administration of E7389, and biological therapy must be discontinued two weeks before E7389 administration Patients who are being treated with bisphosphonates when they enter the study are allowed to continue the medication as long as the dosing does not change  In case a change in dosing is deemed necessary  the case needs to be discussed with the Sponsor  Progression on or within six months of the last regimen for advanced disease  documented by the following: ",
        "premise_nums": [
            "E7389 administration",
            "7389 administration Patients",
            "2 to 5"
        ]
    },
    {
        "id": "4885cd77-628c-4b8f-8345-6bce2165938c",
        "primaryId": "NCT02964234",
        "secondaryId": "NCT00246090",
        "label": "Contradiction",
        "statement_text": "Patients eligible for the primary trial and the secondary trial must live in the USA ",
        "statement_nums": [],
        "premise_text": "The dates of treatment  doses  outcome of therapy and the reason for discontinuation of prior anthracycline  taxane  capecitabine  and trastuzumab therapy must be provided Prior to entry onto the study  information ensuring that the last therapy fulfills eligibility criteria is required  which includes progression while receiving this last prior chemotherapy regimen  or within six months of receiving that therapy  Chemotherapy medication administration sheets or other official medical/hospital records indicating type and dates of chemotherapy must be available for inspection  and one of the following as a reason for discontinuation of medication is required: radiographic evidence of progression  or doctor's office or hospitalization notes documenting radiologic progression  clinically documented increase in tumor burden  and/or increase in tumor-specific markers  ",
        "premise_nums": []
    },
    {
        "id": "4885cd77-628c-4b8f-8345-6bce2165938c",
        "primaryId": "NCT02964234",
        "secondaryId": "NCT00246090",
        "label": "Contradiction",
        "statement_text": "Patients eligible for the primary trial and the secondary trial must live in the USA ",
        "statement_nums": [],
        "premise_text": "Patients with measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria  defined as at least one lesion that can be accurately measured in at least one diameter (at least 10 mm in longest diameter [LD] by spiral computer tomography [CT] scan)  or at least 20 mm by standard techniques  If the only measurable lesion is a lymph node  it must measure at least 20 mm in LD  If a single lesion is identified as the target lesion  a biopsy or aspiration with cytological or histological confirmation of the diagnosis of breast carcinoma is required Resolution of all chemotherapy or radiation-related toxicities to less than Grade 2 severity  except for stable sensory neuropathy Grade 2 and alopecia  Age greater than or equal 18 years  ",
        "premise_nums": [
            "20 mm by",
            "2 and alopecia",
            "20 mm in",
            "10 mm in"
        ]
    },
    {
        "id": "4885cd77-628c-4b8f-8345-6bce2165938c",
        "primaryId": "NCT02964234",
        "secondaryId": "NCT00246090",
        "label": "Contradiction",
        "statement_text": "Patients eligible for the primary trial and the secondary trial must live in the USA ",
        "statement_nums": [],
        "premise_text": "Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2.Life expectancy of 3 months  Adequate renal function as evidenced by serum creatinine 2.0 mg/dL or calculated creatinine clearance 40 mL/minute (min) per the Cockcroft and Gault formula  Adequate bone marrow function as evidenced by absolute neutrophil count (ANC) 1.5 x 10^9/L hemoglobin 10.0 g/dL (acceptable if it is corrected by therapeutic intervention or transfusional support)  and platelet count 100 x 10^9/L. ",
        "premise_nums": [
            "40 mL/minute",
            "0 to 2.Life",
            "9/L hemoglobin",
            "100 x 10",
            "hemoglobin 10.0 g/dL",
            "creatinine 2.0 mg/dL"
        ]
    },
    {
        "id": "4885cd77-628c-4b8f-8345-6bce2165938c",
        "primaryId": "NCT02964234",
        "secondaryId": "NCT00246090",
        "label": "Contradiction",
        "statement_text": "Patients eligible for the primary trial and the secondary trial must live in the USA ",
        "statement_nums": [],
        "premise_text": "Adequate liver function as evidenced by bilirubin 1.5 mg/dL and alkaline phosphatase  alanine transaminase (ALT)  and aspartate transaminase (AST) 3 times the upper limits of normal (ULN) (in the case of liver metastases 5 x ULN)  unless there are bone metastases  in which case liver specific alkaline phosphatase must be separated from the total and used to assess the liver function instead of the total alkaline phosphatase Willing and able to complete the European Organization for Research on the Treatment of Cancer (EORTC) quality of life assessment  Analgesic Diary  and Pain Visual Analog Scale (VAS)  Willing and able to comply with the study protocol for the duration of the study  ",
        "premise_nums": [
            "bilirubin 1.5 mg/dL",
            "5 x ULN)",
            "3 times the"
        ]
    },
    {
        "id": "4885cd77-628c-4b8f-8345-6bce2165938c",
        "primaryId": "NCT02964234",
        "secondaryId": "NCT00246090",
        "label": "Contradiction",
        "statement_text": "Patients eligible for the primary trial and the secondary trial must live in the USA ",
        "statement_nums": [],
        "premise_text": "Written informed consent prior to any study-specific screening procedures with the understanding that the patient may withdraw consent at any time without prejudice Exclusion Criteria: Patients must not have received chemotherapy  radiation  or biologic therapy within two weeks  hormonal therapy within one week  or trastuzumab within three weeks  before E7389 treatment start  Patients must not have received radiation therapy encompassing greater than 30% of marrow (a lesion that has been irradiated cannot be used as a target lesion  unless it has progressed after the irradiation)  Patients must not have pre-existing neuropathy greater than Grade 2. Patients must not have participated in a prior E7389 clinical trial  ",
        "premise_nums": [
            "E7389 clinical",
            "E7389 treatment",
            "7389 treatment start",
            "7389 clinical trial",
            "30% of"
        ]
    },
    {
        "id": "8809cc5e-36d5-4f7e-b06d-b1915a421f71",
        "primaryId": "NCT00759785",
        "statement_text": "Only one adverse event  a Breast abscess  is observed in patients from cohort 1 of the primary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 1/25 (4.00%) Diarrhoea 0/25 (0.00%) Breast abscess 0/25 (0.00%) Breast cellulitis 0/25 (0.00%) Syncope 1/25 (4.00%) ",
        "premise_nums": [
            "0/25 (0.00%)",
            "1/25 (4.00%)"
        ]
    },
    {
        "id": "f0f7241c-0c2d-47cb-8b42-6e5d7494b2b1",
        "primaryId": "NCT00908791",
        "secondaryId": "NCT00297596",
        "label": "Contradiction",
        "statement_text": "Female patients over the age of 60, with Histologically confirmed breast cancer and advanced Alzheimer's disease are ineligible for both the secondary trial and the primary trial  unless they have an ECOGgreater than 2.",
        "statement_nums": [],
        "premise_text": "Inclusion Criteria: All study patients must have histologically confirmed invasive adenocarcinoma of the breast  Their breast cancer must be resectable clinical stage I or II breast cancer as defined by the current AJCC TNM Staging System (Greene FL  Page DL  Fleming ID  et al.: editors  AJCC cancer staging manual  6th edition  New York: Springer; 2002). All patients must be able to and give informed consent indicating they are aware of the investigational nature of this treatment  prior to entry into the study  All subjects must be Age greater than 18 years  ",
        "premise_nums": []
    },
    {
        "id": "f0f7241c-0c2d-47cb-8b42-6e5d7494b2b1",
        "primaryId": "NCT00908791",
        "secondaryId": "NCT00297596",
        "label": "Contradiction",
        "statement_text": "Female patients over the age of 60, with Histologically confirmed breast cancer and advanced Alzheimer's disease are ineligible for both the secondary trial and the primary trial  unless they have an ECOGgreater than 2.",
        "statement_nums": [],
        "premise_text": "All subject must have adequate hepatic and renal function documented prior to study entry to include: hepatic transaminases (AST or ALT) 1.5 times the upper limits of normal  total bilirubin 1.5 times the upper limits of normal  serum creatinine 1.5 times the upper limit of normal or eCRCl 60 mL/min Exclusion criteria: Patients who have received prior or be receiving radiation therapy for their breast cancer will be excluded  Patients who have received prior chemotherapy or receiving chemotherapy or hormonal therapy for their breast cancer will not be included  ",
        "premise_nums": [
            "bilirubin 1.5 times the",
            "60 mL/min Exclusion",
            "creatinine 1.5 times the"
        ]
    },
    {
        "id": "ca27db58-14c4-4889-95b1-69be9c10a07a",
        "primaryId": "NCT00623233",
        "secondaryId": "NCT01525589",
        "label": "Contradiction",
        "statement_text": "More patients with a Low Platelet Count where found in the primary trial than in the secondary trial ",
        "statement_nums": [],
        "premise_text": "Adverse Events 1: Total: 18/52 (34.62%) Anaemia 2/52 (3.85%) Febrile Neutropenia 1/52 (1.92%) Haemolytic Uraemic Syndrome 1/52 (1.92%) Leukopenia 1/52 (1.92%) Neutropenia 1/52 (1.92%) Thrombocytopenia 1/52 (1.92%) Cardiac Failure Congestive 1/52 (1.92%) Cardio-Respiratory Arrest 1/52 (1.92%) Abdominal Pain 1/52 (1.92%) Constipation 1/52 (1.92%) Diarrhoea 1/52 (1.92%) Adverse Events 1: ",
        "premise_nums": [
            "18/52 (34.62%)",
            "1/52 (1.92%)",
            "2/52 (3.85%)"
        ]
    },
    {
        "id": "ca27db58-14c4-4889-95b1-69be9c10a07a",
        "primaryId": "NCT00623233",
        "secondaryId": "NCT01525589",
        "label": "Contradiction",
        "statement_text": "More patients with a Low Platelet Count where found in the primary trial than in the secondary trial ",
        "statement_nums": [],
        "premise_text": "Total: 14/54 (25.93%)anaemia 2/54 (3.70%) Febrile neutropenia 7/54 (12.96%) Neutropenia 2/54 (3.70%) Thrombocytopenia 6/54 (11.11%) Atrial fibrillation 1/54 (1.85%) Cardiac failure congestive 1/54 (1.85%) Pericardial effusion 1/54 (1.85%) Nausea 2/54 (3.70%) Vomiting 3/54 (5.56%) Catheter site erythema 1/54 (1.85%) Chest discomfort 1/54 (1.85%) Adverse Events 2: Total: 5/20 (25.00%) ",
        "premise_nums": [
            "7/54 (12.96%)",
            "5/20 (25.00%)",
            "3/54 (5.56%)",
            "2/54 (3.70%)",
            "1/54 (1.85%)",
            "6/54 (11.11%)",
            "14/54 (25.93%)anaemia"
        ]
    },
    {
        "id": "ca27db58-14c4-4889-95b1-69be9c10a07a",
        "primaryId": "NCT00623233",
        "secondaryId": "NCT01525589",
        "label": "Contradiction",
        "statement_text": "More patients with a Low Platelet Count where found in the primary trial than in the secondary trial ",
        "statement_nums": [],
        "premise_text": "anaemia 0/20 (0.00%)Febrile neutropenia 2/20 (10.00%) Neutropenia 0/20 (0.00%) Thrombocytopenia 0/20 (0.00%) Atrial fibrillation 0/20 (0.00%) Cardiac failure congestive 0/20 (0.00%) Pericardial effusion 0/20 (0.00%) Nausea 0/20 (0.00%) Vomiting 0/20 (0.00%) Catheter site erythema 0/20 (0.00%) Chest discomfort 0/20 (0.00%) ",
        "premise_nums": [
            "0/20 (0.00%)Febrile",
            "2/20 (10.00%)"
        ]
    },
    {
        "id": "5147b171-b5dc-46d6-a153-1a6d9a062ef1",
        "primaryId": "NCT03190083",
        "statement_text": "All cancer stages are accepted for the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Inclusion Criteria: New diagnosis of breast cancer New diagnosis if a previous breast cancer patient with negative surgical margins Patients willing to sign a written informed consent form ",
        "premise_nums": []
    },
    {
        "id": "a5ed3500-1ea1-40b6-b1cb-3d5ae776f713",
        "primaryId": "NCT00656669",
        "statement_text": "the primary trial did not record any adverse events ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 0/23 (0.00%) ",
        "premise_nums": [
            "0/23 (0.00%)"
        ]
    },
    {
        "id": "3c482d5e-bfad-4a46-9e98-ba9967f2d900",
        "primaryId": "NCT00903162",
        "secondaryId": "NCT01674062",
        "label": "Contradiction",
        "statement_text": "Patients with BCC are excluded from the primary trial and the secondary trial ",
        "statement_nums": [],
        "premise_text": "Exclusion Criteria: History of cancer other than breast cancer within 5 years excluding basal/squamous cell skin carcinoma in situ of the cervix Exclusion Criteria: Any other malignancy in the last 5 years  except for basal cell cancer or cancer in situ of the cervix ",
        "premise_nums": [
            "5 years excluding"
        ]
    },
    {
        "id": "48ccd744-abf1-4e98-bc86-8ecd625e6279",
        "primaryId": "NCT00654836",
        "statement_text": "Patients with metastatic HER-2-negative adenocarcinoma of the breast may be eligible for the primary trial ",
        "statement_nums": [
            "2-negative adenocarcinoma"
        ],
        "label": "Entailment",
        "premise_text": "DISEASE CHARACTERISTICS: Histologically or cytologically confirmed primary adenocarcinoma of the breast Locally recurrent or metastatic disease Must have HER-2-negative breast cancer or  if HER-2-positive, must be unable to receive trastuzumab (Herceptin®) or have previously received trastuzumab in the past No known CNS disease ",
        "premise_nums": [
            "2-positive, must",
            "2-negative breast"
        ]
    },
    {
        "id": "dce5d9c8-7da6-4732-b969-c492c876cdca",
        "primaryId": "NCT01783444",
        "statement_text": "Women of any age can participate in the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Key Inclusion Criteria: - Women with locally advanced  recurrent  or metastatic breast cancer along with confirmation of estrogen-receptor positive (ER+)  Measurable disease defined as at least one lesion 10 mm by CT or MRI that can be accurately measured in at least one dimension (CT scan slice thickness 5 mm) OR Bone lesions: lytic or mixed (lytic + blastic) in the absence of measurable disease as defined above  Key Exclusion Criteria: - Patients who received more than one chemotherapy line  Patients with only non-measurable lesions other than lytic or mixed (lytic and blastic) bone metastasis.Previous treatment with exemestane  mTOR inhibitors  PI3K inhibitors or AKT inhibitors  ",
        "premise_nums": [
            "10 mm by"
        ]
    },
    {
        "id": "1882de62-2df2-4b73-a3d2-81811f85f661",
        "primaryId": "NCT01106898",
        "statement_text": "2% of the primary trial patients were diagnosed with Fatty Liver Disease after 3 years of Treatment with Chemotherapy or Maintenance Therapy ",
        "statement_nums": [
            "2% of",
            "3 years of"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Recurrence-free Survival Recurrence-free survival curves will be plotted for subjects treated with stage I and II disease  Time frame: Time from the start of treatment to recurrence  second malignancy  or death as a first event  assessed up to 3 years Results 1: Arm/Group Title: Treatment (Chemotherapy With or Without Maintenance Therapy) Arm/Group Description: SYSTEMIC CHEMOTHERAPY: Patients receive cyclophosphamide IV over 1 hour and paclitaxel IV over 3 hours on day 1. Treatment repeats every 14 days for 6 courses in the absence of disease progression or unacceptable toxicity  ",
        "premise_nums": [
            "3 hours on",
            "6 courses in",
            "1 hour and",
            "14 days for",
            "3 years Results"
        ]
    },
    {
        "id": "1882de62-2df2-4b73-a3d2-81811f85f661",
        "primaryId": "NCT01106898",
        "statement_text": "2% of the primary trial patients were diagnosed with Fatty Liver Disease after 3 years of Treatment with Chemotherapy or Maintenance Therapy ",
        "statement_nums": [
            "2% of",
            "3 years of"
        ],
        "label": "Contradiction",
        "premise_text": "MAINTENANCE THERAPY (Her-2 neu positive patients): Patients receive trastuzumab IV over 30 minutes on day 1. Treatment repeats every 14 days for 5 courses and then every 21 days for 14 courses in the absence of disease progression or unacceptable toxicity cyclophosphamide  paclitaxel  trastuzumab: Given IV Overall Number of Participants Analyzed: 100 Measure Type: Number Unit of Measure: percentage of subjects 98 (92.2 to 99.5) ",
        "premise_nums": [
            "21 days for",
            "2 to 99.5)",
            "14 days for",
            "30 minutes on",
            "5 courses and",
            "100 Measure Type:",
            "2 neu positive",
            "14 courses in"
        ]
    },
    {
        "id": "161c852e-a42c-47c2-ab6a-2b7bd6a4b934",
        "primaryId": "NCT00325234",
        "statement_text": "Patients wanting to participate in the primary trial  must discontinue any Antitumoral hormonal treatment  and must have a life expectancy of more than 3 months ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Inclusion Criteria: Antitumoral hormonal treatment must be discontinued prior to enrollment  Estimated life expectancy of at least 3 months  ",
        "premise_nums": []
    },
    {
        "id": "eb152d1b-a0d6-428c-8d1d-eb5d862a8147",
        "primaryId": "NCT01120184",
        "statement_text": "At least 1 patient in cohort 1 of the primary trial suffered from a Hemophilia  a rare coagulation disorder ",
        "statement_nums": [
            "1 patient in",
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 81/353 (22.95%) Febrile neutropenia * 13/353 (3.68%) Anaemia * 21/353 (0.28%) Neutropenia * 25/353 (1.42%) Thrombocytopenia * 20/353 (0.00%) Hypercoagulation * 21/353 (0.28%) Leukopenia * 21/353 (0.28%) Atrial fibrillation * 1/353 (0.28%) Cardiac failure * 0/353 (0.00%) Cardiac failure congestive * 0/353 (0.00%) ",
        "premise_nums": [
            "20/353 (0.00%)",
            "25/353 (1.42%)",
            "81/353 (22.95%)",
            "13/353 (3.68%)",
            "21/353 (0.28%)"
        ]
    },
    {
        "id": "eb152d1b-a0d6-428c-8d1d-eb5d862a8147",
        "primaryId": "NCT01120184",
        "statement_text": "At least 1 patient in cohort 1 of the primary trial suffered from a Hemophilia  a rare coagulation disorder ",
        "statement_nums": [
            "1 patient in",
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Myocardial infarction * 1/353 (0.28%)",
        "premise_nums": [
            "1/353 (0.28%)"
        ]
    },
    {
        "id": "0701ac32-45b3-4199-aa20-a71080ce9bf6",
        "primaryId": "NCT00546156",
        "secondaryId": "NCT00398567",
        "label": "Entailment",
        "statement_text": "There are no cases of Vertigo in the primary trial or the primary trial ",
        "statement_nums": [],
        "premise_text": "Adverse Events 1: Total: 4/104 (3.85%) Neutropenia 1/104 (0.96%) Leukopenia 2/104 (1.92%) paranasal sinus reaction 1/104 (0.96%) cellulitis 1/104 (0.96%) Adverse Events 1: Total: 1/4 (25.00%) Vertigo 0/4 (0.00%) Abdominal adhesions 0/4 (0.00%) Abdominal distension 0/4 (0.00%) Abdominal pain 0/4 (0.00%) Diarrhoea 0/4 (0.00%) Nausea 0/4 (0.00%) Vomiting 0/4 (0.00%) Disease progression 0/4 (0.00%) ",
        "premise_nums": [
            "2/104 (1.92%)",
            "0/4 (0.00%)",
            "1/104 (0.96%)",
            "1/4 (25.00%)",
            "4/104 (3.85%)"
        ]
    },
    {
        "id": "0701ac32-45b3-4199-aa20-a71080ce9bf6",
        "primaryId": "NCT00546156",
        "secondaryId": "NCT00398567",
        "label": "Entailment",
        "statement_text": "There are no cases of Vertigo in the primary trial or the primary trial ",
        "statement_nums": [],
        "premise_text": "Influenza 0/4 (0.00%)Nasopharyngitis 0/4 (0.00%) Lumbar vertebral fracture 0/4 (0.00%) Hyponatraemia 0/4 (0.00%) Ataxia 0/4 (0.00%) ",
        "premise_nums": [
            "0/4 (0.00%)Nasopharyngitis"
        ]
    },
    {
        "id": "866876f5-68de-44bd-b58a-e4b590aa4b39",
        "primaryId": "NCT03573804",
        "secondaryId": "NCT02781051",
        "label": "Entailment",
        "statement_text": "Participants of the primary trial must undergo at least one MRI during the intervention  in the secondary trial patients must use a fitbit ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Prone to Supine MRI Evaluated by Radiologist A Radiologist A  number of participants successfully segmented INTERVENTION 2: Prone to Supine MRI Evaluated by Radiologist B Radiologist B  number of participants successfully segmented INTERVENTION 1: Physical Activity Intervention Participants will participate in a multi-component physical activity intervention for 12 weeks with a 6 month follow up  Print-based education: Subjects were given a copy of Exercise for Health: An Exercise Guide for Breast Cancer Survivors  Topics covered within the book include benefits of exercise; recommendations on type  duration  frequency and intensity of exercise; goal-setting; and advice on overcoming barriers  Fitbit: Subjects were provided with a Fitbit and instructed to wear the device daily  ",
        "premise_nums": [
            "6 month follow",
            "12 weeks with"
        ]
    },
    {
        "id": "866876f5-68de-44bd-b58a-e4b590aa4b39",
        "primaryId": "NCT03573804",
        "secondaryId": "NCT02781051",
        "label": "Entailment",
        "statement_text": "Participants of the primary trial must undergo at least one MRI during the intervention  in the secondary trial patients must use a fitbit ",
        "statement_nums": [],
        "premise_text": "Active Living counseling: The Active Living counseling program consists of 12 weekly group educational sessions  These sessions involved discussion of topics related to increasing physical activity  including: identifying and overcoming barriers  setting goals  and time management Facility Access: Subjects will have access to the exercise lab in the UT Southwestern Depression Center consisting of equipment for aerobic exercise (treadmills  stationary bikes  etc.)  ",
        "premise_nums": [
            "12 weekly group"
        ]
    },
    {
        "id": "b4304362-1cb4-4606-9de4-03935ad509f1",
        "primaryId": "NCT00370552",
        "statement_text": "There 55 more Participants With Best Tumor Response of Partial Response (PR) or Complete Response (CR) in cohort 2 of the primary trial than in cohort 1.",
        "statement_nums": [
            "55 more Participants",
            "2 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Percentage of Participants With Best Tumor Response of Partial Response (PR) or Complete Response (CR) While On-study CR=Disappearance of all clinical and radiologic evidence of target lesions; PR=At least 30% reduction in the sum of the longest diameter of all target lesions  Time frame: Baseline visit and then every 8 weeks to 12 months  then every 3 months until disease progression Results 1: Arm/Group Title: Ixabepilone  16 mg/m^2 + Bevacizumab  10 mg/kg ",
        "premise_nums": [
            "8 weeks to",
            "3 months until",
            "30% reduction",
            "16 mg/m^2",
            "10 mg/kg"
        ]
    },
    {
        "id": "b4304362-1cb4-4606-9de4-03935ad509f1",
        "primaryId": "NCT00370552",
        "statement_text": "There 55 more Participants With Best Tumor Response of Partial Response (PR) or Complete Response (CR) in cohort 2 of the primary trial than in cohort 1.",
        "statement_nums": [
            "55 more Participants",
            "2 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Arm/Group Description: Ixabepilone,16 mg/m^2, administered as a 1-hour intravenous (IV) infusion on Days 1, 8, and 15 of a 28-day cycle until disease progression or unacceptable toxicity  Bevacizumab  10 mg/kg  administered after ixabepilone as IV infusion every 2 weeks  Bevacizumab to be infused over 90 minutes for the first dose  and if well tolerated for 60 minutes  for the second dose  Then if still tolerated  over 30 minutes for subsequent infusions  Bevacizumab was to be dosed until disease progression or unacceptable toxicity Overall Number of Participants Analyzed: 46 Measure Type: Number ",
        "premise_nums": [
            "46 Measure Type:",
            "1-hour intravenous",
            "15 of a",
            "10 mg/kg",
            "28-day cycle",
            "90 minutes for",
            "30 minutes for"
        ]
    },
    {
        "id": "b4304362-1cb4-4606-9de4-03935ad509f1",
        "primaryId": "NCT00370552",
        "statement_text": "There 55 more Participants With Best Tumor Response of Partial Response (PR) or Complete Response (CR) in cohort 2 of the primary trial than in cohort 1.",
        "statement_nums": [
            "55 more Participants",
            "2 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Unit of Measure: Percentage of participants 47.8 (32.9 to 63.1)Results 2: Arm/Group Title: Ixabepilone  40 mg/m^2 + Bevacizumab  15 mg/kg ",
        "premise_nums": [
            "9 to 63.1)Results",
            "15 mg/kg",
            "40 mg/m^2"
        ]
    },
    {
        "id": "b4304362-1cb4-4606-9de4-03935ad509f1",
        "primaryId": "NCT00370552",
        "statement_text": "There 55 more Participants With Best Tumor Response of Partial Response (PR) or Complete Response (CR) in cohort 2 of the primary trial than in cohort 1.",
        "statement_nums": [
            "55 more Participants",
            "2 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Arm/Group Description: Ixabepilone  40 mg/m^2, administered as a 3-hour IV infusion on Day 1 of a 21-day cycle until disease progression or unacceptable toxicity After Cycle 4, dose reduction to 32 mg/m^2 implemented for all subsequent cycles  Bevacizumab  15 mg/kg  administered after ixabepilone as IV infusion every 3 weeks  Bevacizumab to be infused over 90 minutes for the first dose  and if well tolerated for 60 minutes  for the second dose  Then if still tolerated  over 30 minutes for subsequent infusions  Bevacizumab was to be dosed until disease progression or unacceptable toxicity Overall Number of Participants Analyzed: 45 Measure Type: Number ",
        "premise_nums": [
            "15 mg/kg",
            "45 Measure Type:",
            "40 mg/m^2,",
            "32 mg/m^2",
            "2 implemented for",
            "3-hour IV",
            "1 of a",
            "90 minutes for",
            "30 minutes for",
            "21-day cycle"
        ]
    },
    {
        "id": "b4304362-1cb4-4606-9de4-03935ad509f1",
        "primaryId": "NCT00370552",
        "statement_text": "There 55 more Participants With Best Tumor Response of Partial Response (PR) or Complete Response (CR) in cohort 2 of the primary trial than in cohort 1.",
        "statement_nums": [
            "55 more Participants",
            "2 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Unit of Measure: Percentage of participants 71.1 (55.7 to 83.6)",
        "premise_nums": []
    },
    {
        "id": "9cddd86a-4340-4918-b000-7e6e593a3f7f",
        "primaryId": "NCT03097653",
        "secondaryId": "NCT00662129",
        "label": "Contradiction",
        "statement_text": "Females aged between 18-25 with stable angina cannot be included in either the secondary trial or the primary trial ",
        "statement_nums": [
            "18-25 with",
            "25 with stable"
        ],
        "premise_text": "Inclusion Criteria: Women aged 45-69, according to the target age of the screening centres involved; New invited women in mammography screening programme  Exclusion Criteria: None DISEASE CHARACTERISTICS: Histologically or cytologically confirmed infiltrating breast cancer Clinical evidence of metastatic disease Measurable disease  defined as at least one measurable lesion per RECIST criteria No non-measurable disease only  defined as all other lesions  including small lesions (longest diameter smaller than 2 cm) and truly non-measurable lesions  including any of the following: Bone lesions Leptomeningeal disease Ascites Pleural/pericardial effusion Inflammatory breast disease Lymphangitis cutis/pulmonis Abdominal masses that are not confirmed and followed by imaging techniques Cystic lesions ",
        "premise_nums": [
            "45-69, according"
        ]
    },
    {
        "id": "9cddd86a-4340-4918-b000-7e6e593a3f7f",
        "primaryId": "NCT03097653",
        "secondaryId": "NCT00662129",
        "label": "Contradiction",
        "statement_text": "Females aged between 18-25 with stable angina cannot be included in either the secondary trial or the primary trial ",
        "statement_nums": [
            "18-25 with",
            "25 with stable"
        ],
        "premise_text": "Patients with HER-2/neu positive tumors  must have received prior treatment with trastuzumab (Herceptin®) or have a contraindication for trastuzumabNo evidence of active brain metastasis  including leptomeningeal involvement  on MRI or CT scan CNS metastasis controlled by prior surgery and/or radiotherapy allowed Must be asymptomatic for 2 months with no evidence of progression prior to study entry Hormone receptor status not specified PATIENT CHARACTERISTICS: Menopausal status not specified Life expectancy 12 weeks ECOG performance status 0-1 ANC 1,500/mm³ Platelet count 100,000/mm³ Hemoglobin 9.0 g/dL ",
        "premise_nums": [
            "100,000/mm³ Hemoglobin",
            "2 months with",
            "Hemoglobin 9.0 g/dL",
            "0-1 ANC",
            "2/neu positive",
            "12 weeks ECOG",
            "1,500/mm³ Platelet"
        ]
    },
    {
        "id": "9cddd86a-4340-4918-b000-7e6e593a3f7f",
        "primaryId": "NCT03097653",
        "secondaryId": "NCT00662129",
        "label": "Contradiction",
        "statement_text": "Females aged between 18-25 with stable angina cannot be included in either the secondary trial or the primary trial ",
        "statement_nums": [
            "18-25 with",
            "25 with stable"
        ],
        "premise_text": "AST and ALT 2.5 times upper limit of normal (ULN)Alkaline phosphatase 2.5 times ULN Total bilirubin 1.5 times ULN Creatinine 1.5 mg/dL Urine protein:creatinine ratio smaller than 1 or urinalysis smaller than 1+ protein Patients discovered to have 1+ proteinuria at baseline must demonstrate 24-hour urine protein smaller than 1 g Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception during and for 30 days after completion of study therapy Able to complete questionnaires alone or with assistance No peripheral neuropathy greater than grade 1 ",
        "premise_nums": [
            "Creatinine 1.5 mg/dL",
            "bilirubin 1.5 times ULN",
            "30 days after",
            "phosphatase 2.5 times ULN",
            "24-hour urine",
            "ALT 2.5 times upper",
            "1 g Not",
            "1 or urinalysis"
        ]
    },
    {
        "id": "9cddd86a-4340-4918-b000-7e6e593a3f7f",
        "primaryId": "NCT03097653",
        "secondaryId": "NCT00662129",
        "label": "Contradiction",
        "statement_text": "Females aged between 18-25 with stable angina cannot be included in either the secondary trial or the primary trial ",
        "statement_nums": [
            "18-25 with",
            "25 with stable"
        ],
        "premise_text": "No history of allergy or hypersensitivity to albumin-bound paclitaxel  paclitaxel  gemcitabine hydrochloride  bevacizumab  albumin  drug product excipients  or chemically similar agentsNo stage III or IV invasive  non-breast malignancy within the past 5 years No other active malignancy  except nonmelanoma skin cancer or carcinoma in situ of the cervix Patient must not be receiving other specific treatment for a prior malignancy No uncontrolled hypertension (i.e.  blood pressure [BP] greater than 160/90 mm Hg on 2 occasions at least 5 minutes apart) ",
        "premise_nums": [
            "2 occasions at",
            "90 mm Hg",
            "160/90 mm",
            "5 minutes apart)",
            "5 years No"
        ]
    },
    {
        "id": "9cddd86a-4340-4918-b000-7e6e593a3f7f",
        "primaryId": "NCT03097653",
        "secondaryId": "NCT00662129",
        "label": "Contradiction",
        "statement_text": "Females aged between 18-25 with stable angina cannot be included in either the secondary trial or the primary trial ",
        "statement_nums": [
            "18-25 with",
            "25 with stable"
        ],
        "premise_text": "Patients who have recently started or adjusted antihypertensive medications are eligible providing that BP is smaller than 140/90 mm Hg on any new regimen for 3 different observations in 14 daysNo bleeding diathesis or uncontrolled coagulopathy No hemoptysis within the past 6 months No prior arterial or venous thrombosis within the past 12 months No history of cerebrovascular accident No history of hypertensive crisis or hypertensive encephalopathy No abdominal fistula or gastrointestinal perforation within the past 6 months No serious non-healing wound  ulcer  or fracture No clinically significant cardiac disease  defined as any of the following: Congestive heart failure Symptomatic coronary artery disease Unstable angina ",
        "premise_nums": [
            "90 mm Hg",
            "6 months No",
            "14 daysNo bleeding",
            "3 different observations",
            "12 months No",
            "140/90 mm"
        ]
    },
    {
        "id": "9cddd86a-4340-4918-b000-7e6e593a3f7f",
        "primaryId": "NCT03097653",
        "secondaryId": "NCT00662129",
        "label": "Contradiction",
        "statement_text": "Females aged between 18-25 with stable angina cannot be included in either the secondary trial or the primary trial ",
        "statement_nums": [
            "18-25 with",
            "25 with stable"
        ],
        "premise_text": "Cardiac arrhythmias not well controlled with medicationMyocardial infarction within the past 12 months No comorbid systemic illnesses or other severe concurrent disease which  in the judgment of the investigator  would make the patient inappropriate for study entry or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens PRIOR CONCURRENT THERAPY: See Disease Characteristics No prior chemotherapy for metastatic disease May have received one prior adjuvant chemotherapy regimen Prior neoadjuvant chemotherapy allowed More than 6 months since prior adjuvant or neoadjuvant taxane (i.e.  docetaxel or paclitaxel) therapy Prior hormonal therapy in either adjuvant or metastatic setting allowed ",
        "premise_nums": [
            "6 months since",
            "12 months No"
        ]
    },
    {
        "id": "9cddd86a-4340-4918-b000-7e6e593a3f7f",
        "primaryId": "NCT03097653",
        "secondaryId": "NCT00662129",
        "label": "Contradiction",
        "statement_text": "Females aged between 18-25 with stable angina cannot be included in either the secondary trial or the primary trial ",
        "statement_nums": [
            "18-25 with",
            "25 with stable"
        ],
        "premise_text": "More than 4 weeks since prior radiotherapy (except if to a non-target lesion only  or single dose radiation for palliation)Prior radiotherapy to a target lesion is allowed provided there has been clear progression of the lesion since radiotherapy was completed More than 4 weeks since prior cytotoxic chemotherapeutic agent or investigational drug More than 2 weeks since prior and no concurrent acetylsalicylic acid  anticoagulants  or thrombolytic agents (except for once-daily 81 mg acetylsalicylic acid) More than 6 weeks since prior major surgery  chemotherapy  or immunologic therapy More than 1 week since prior minor surgery (e.g.  core biopsy) Placement of a vascular access device within 7 days is allowed ",
        "premise_nums": [
            "2 weeks since",
            "6 weeks since",
            "4 weeks since",
            "81 mg acetylsalicylic",
            "7 days is",
            "1 week since"
        ]
    },
    {
        "id": "9cddd86a-4340-4918-b000-7e6e593a3f7f",
        "primaryId": "NCT03097653",
        "secondaryId": "NCT00662129",
        "label": "Contradiction",
        "statement_text": "Females aged between 18-25 with stable angina cannot be included in either the secondary trial or the primary trial ",
        "statement_nums": [
            "18-25 with",
            "25 with stable"
        ],
        "premise_text": "More than 3 months since prior neurosurgeryNo concurrent treatment in a different clinical study in which investigational procedures are performed or investigational therapies are administered Trials related to symptom management (Cancer Control) which do not employ hormonal treatments or treatments that may block the path of the targeted agents used in this study may be allowed ",
        "premise_nums": [
            "3 months since"
        ]
    },
    {
        "id": "c3f01101-2259-4677-add1-1b1f48a0202b",
        "primaryId": "NCT00528567",
        "secondaryId": "NCT01196052",
        "label": "Contradiction",
        "statement_text": "The total number of patients affected by adverse events in cohort 2 the primary trial is more than 1000.",
        "statement_nums": [
            "2 the primary"
        ],
        "premise_text": "Adverse Events 2: Total: 250/1271 (19.67%) Adverse Events 1: Total: 15/148 (10.14%) Febrile neutropenia 1/148 (0.68%) Atrial fibrillation 2/148 (1.35%) Abdominal pain 1/148 (0.68%) Diarrhoea 1/148 (0.68%) Pyrexia 2/148 (1.35%) Cellulitis 1/148 (0.68%) Device related infection 2/148 (1.35%) Gastroenteritis viral 1/148 (0.68%) Gastrointestinal infection 1/148 (0.68%) Upper respiratory tract infection 1/148 (0.68%) ",
        "premise_nums": [
            "2/148 (1.35%)",
            "15/148 (10.14%)",
            "1/148 (0.68%)",
            "250/1271 (19.67%)"
        ]
    },
    {
        "id": "33b827a0-ada5-4204-abb8-d5239ea16f0b",
        "primaryId": "NCT00143390",
        "statement_text": "In the primary trial There was less than 3 days difference between the maximum recorded TTP of the Exemestane group and the Anastrozole group ",
        "statement_nums": [
            "3 days difference"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Time to Progression (TTP) - Expert Evaluation Committee Assessment Time in months from randomization to first documentation of objective tumor progression or death due to breast cancer  whichever comes first  Tumor progression was determined by the expert evaluation committee using RECIST version 1.0 as an at least a 20% increase in the sum of the longest diameters (SLD) of the target lesions compared to the smallest SLD since the study treatment started  For participants with bone metastasis only  at least 25% increase in the measurable lesion according to General Rules for Clinical and Pathological Study of Breast Cancer (The 14th edition)  Time frame: Up to 2008 days of the treatment Results 1: Arm/Group Title: Exemestane ",
        "premise_nums": [
            "2008 days of",
            "25% increase",
            "version 1.0 as an",
            "20% increase"
        ]
    },
    {
        "id": "33b827a0-ada5-4204-abb8-d5239ea16f0b",
        "primaryId": "NCT00143390",
        "statement_text": "In the primary trial There was less than 3 days difference between the maximum recorded TTP of the Exemestane group and the Anastrozole group ",
        "statement_nums": [
            "3 days difference"
        ],
        "label": "Entailment",
        "premise_text": "Arm/Group Description: One tablet each of exemestane 25 mg and anastrozole placebo were orally administered once daily after a meal  The study treatment was continued until the disease progression or other discontinuation criteria were met Overall Number of Participants Analyzed: 147 Median (95% Confidence Interval) Unit of Measure: months 13.8 (10.8 to 16.5) Results 2: Arm/Group Title: Anastrozole Arm/Group Description: One tablet each of anastrozole 1 mg and exemestane placebo were orally administered once daily after a meal  The study treatment was continued until the disease progression or other discontinuation criteria were met  Overall Number of Participants Analyzed: 145 Median (95% Confidence Interval) ",
        "premise_nums": [
            "25 mg and",
            "95% Confidence",
            "8 to 16.5)",
            "1 mg and"
        ]
    },
    {
        "id": "33b827a0-ada5-4204-abb8-d5239ea16f0b",
        "primaryId": "NCT00143390",
        "statement_text": "In the primary trial There was less than 3 days difference between the maximum recorded TTP of the Exemestane group and the Anastrozole group ",
        "statement_nums": [
            "3 days difference"
        ],
        "label": "Entailment",
        "premise_text": "Unit of Measure: months 11.1 (10.8 to 16.6)",
        "premise_nums": []
    },
    {
        "id": "40f1d3ce-2ff8-4177-9b11-0bf10b7f6591",
        "primaryId": "NCT00259090",
        "statement_text": "the primary trial studies the impact of Fulvestrant  Anastrozole on Oestrogen Receptor H-score ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Percentage Change From Baseline to Time of Surgery in Oestrogen Receptor (ER) H-score: Antitumour Effects of Fulvestrant  Anastrozole and a Combination of Both as Measured by the ER H-score  ",
        "premise_nums": []
    },
    {
        "id": "22bff413-a1bd-419b-b19b-2157dedc9948",
        "primaryId": "NCT00802945",
        "secondaryId": "NCT01231659",
        "label": "Entailment",
        "statement_text": "Group 1 of the secondary trial has a higher ORR than both the NKTR-102 14 Day cohort of the primary trial and the NKTR-102 21 Days cohort ",
        "statement_nums": [
            "14 Day cohort",
            "21 Days cohort",
            "1 of the"
        ],
        "premise_text": "Outcome Measurement: Objective Response Rate (ORR) Per Response Evaluation Criteria In Solid Tumors (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR)  Disappearance of all target lesions; Partial Response (PR)  at least a 30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR  Time frame: Up to 2 years  Results 1: Arm/Group Title: NKTR-102 14 Day Arm/Group Description: NKTR-102: NKTR-102 given on a q14 day schedule Overall Number of Participants Analyzed: 35 Measure Type: Number Unit of Measure: percentage of subjects 28.6 (14.6 to 46.3) ",
        "premise_nums": [
            "30% decrease",
            "102 given on",
            "q14 day",
            "35 Measure Type:",
            "6 to 46.3)",
            "14 Day Arm",
            "14 day schedule"
        ]
    },
    {
        "id": "22bff413-a1bd-419b-b19b-2157dedc9948",
        "primaryId": "NCT00802945",
        "secondaryId": "NCT01231659",
        "label": "Entailment",
        "statement_text": "Group 1 of the secondary trial has a higher ORR than both the NKTR-102 14 Day cohort of the primary trial and the NKTR-102 21 Days cohort ",
        "statement_nums": [
            "14 Day cohort",
            "21 Days cohort",
            "1 of the"
        ],
        "premise_text": "Results 2:Arm/Group Title: NKTR-102 21 Days Arm/Group Description: NKTR-102: NKTR-102 given on a q21 day schedule Overall Number of Participants Analyzed: 35 Measure Type: Number Unit of Measure: percentage of subjects 35 (14.6 to 46.3) Outcome Measurement: Percentage of Participants With Overall Response Rate (ORR) ",
        "premise_nums": [
            "102 given on",
            "21 Days Arm",
            "2:Arm/Group Title:",
            "q21 day",
            "35 Measure Type:",
            "21 day schedule",
            "6 to 46.3)"
        ]
    },
    {
        "id": "22bff413-a1bd-419b-b19b-2157dedc9948",
        "primaryId": "NCT00802945",
        "secondaryId": "NCT01231659",
        "label": "Entailment",
        "statement_text": "Group 1 of the secondary trial has a higher ORR than both the NKTR-102 14 Day cohort of the primary trial and the NKTR-102 21 Days cohort ",
        "statement_nums": [
            "14 Day cohort",
            "21 Days cohort",
            "1 of the"
        ],
        "premise_text": "Overall Response Rate (ORR) was defined as the proportion of patients whose best overall response was either complete response (CR) or partial response (PR) according to RECIST 1.0 for target lesions and assessed by CT: Complete Response (CR)  disappearance of all target lesions for a period of at least one month; Partial Response (PR)  greater than or equal 30% decrease in the sum of the longest diameter of target lesions; Overall Response (ORR) = CR + PR  Only descriptive statistics Time frame: From the date of randomization until the date of the first documented disease progression or date of death from any cause whichever came first  assessed for approximately 15 months Results 1: ",
        "premise_nums": [
            "30% decrease",
            "15 months Results",
            "RECIST 1.0 for target"
        ]
    },
    {
        "id": "22bff413-a1bd-419b-b19b-2157dedc9948",
        "primaryId": "NCT00802945",
        "secondaryId": "NCT01231659",
        "label": "Entailment",
        "statement_text": "Group 1 of the secondary trial has a higher ORR than both the NKTR-102 14 Day cohort of the primary trial and the NKTR-102 21 Days cohort ",
        "statement_nums": [
            "14 Day cohort",
            "21 Days cohort",
            "1 of the"
        ],
        "premise_text": "Arm/Group Title: Everolimus + LetrozoleArm/Group Description: All patients received 2 tablets (5 mg each) of Everolimus (a total of 10 mg) + 1 tablet of Letrozole (2.5 mg) daily until disease progression or as described in the protocol  Overall Number of Participants Analyzed: 43 Measure Type: Number Unit of Measure: Percentage of Participants 37.2 ",
        "premise_nums": [
            "2 tablets (5",
            "43 Measure Type:",
            "1 tablet of"
        ]
    },
    {
        "id": "b64d6e41-7ec7-4e62-beda-c28559a6cee7",
        "primaryId": "NCT00880022",
        "statement_text": "Only patients in cohort 2 of the primary trial undergo Trunk compression ",
        "statement_nums": [
            "2 of the"
        ],
        "label": "Entailment",
        "premise_text": "INTERVENTION 1: Arm Compression Only [Not Specified] INTERVENTION 2: Arm  Trunck and Chest Compression [Not Specified] ",
        "premise_nums": []
    },
    {
        "id": "2ea80a50-0db3-4ff2-8ca0-71eb048649f7",
        "primaryId": "NCT01875367",
        "statement_text": "More than 3 patients in the primary trial had a common cold ",
        "statement_nums": [
            "3 patients in"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 2/81 (2.47%) Heart failure 0/81 (0.00%) Fever 1/81 (1.23%) Cold 0/81 (0.00%) Catheter related infection (Bacteriemia) 0/81 (0.00%) Lack of strength in left leg 0/81 (0.00%) Ostenecrosis produced by biphosphonates 0/81 (0.00%) Gastric cancer 0/81 (0.00%) Stroke 0/81 (0.00%) Hematuria 1/81 (1.23%) Nodule in left breast 0/81 (0.00%) Adverse Events 2: Total: 10/85 (11.76%) Heart failure 1/85 (1.18%) ",
        "premise_nums": [
            "1/85 (1.18%)",
            "0/81 (0.00%)",
            "2/81 (2.47%)",
            "1/81 (1.23%)",
            "10/85 (11.76%)"
        ]
    },
    {
        "id": "2ea80a50-0db3-4ff2-8ca0-71eb048649f7",
        "primaryId": "NCT01875367",
        "statement_text": "More than 3 patients in the primary trial had a common cold ",
        "statement_nums": [
            "3 patients in"
        ],
        "label": "Contradiction",
        "premise_text": "Fever 0/85 (0.00%)Cold 1/85 (1.18%) Catheter related infection (Bacteriemia) 1/85 (1.18%) Lack of strength in left leg 1/85 (1.18%) Ostenecrosis produced by biphosphonates 1/85 (1.18%) Gastric cancer 1/85 (1.18%) Stroke 1/85 (1.18%) Hematuria 0/85 (0.00%) Nodule in left breast 1/85 (1.18%) ",
        "premise_nums": [
            "0/85 (0.00%)Cold",
            "1/85 (1.18%)"
        ]
    },
    {
        "id": "20545360-b2a1-4be9-997a-97040866b239",
        "primaryId": "NCT00880464",
        "secondaryId": "NCT00458237",
        "label": "Contradiction",
        "statement_text": "Patients with AIDS are eligible for both the secondary trial and the primary trial ",
        "statement_nums": [],
        "premise_text": "Exclusion Criteria: Evidence of HIV infection Exclusion Criteria: HIV positive patients ",
        "premise_nums": []
    },
    {
        "id": "3b1bdc19-62cd-4ff1-9e30-424e124342f3",
        "primaryId": "NCT02425891",
        "secondaryId": "NCT00593827",
        "label": "Contradiction",
        "statement_text": "the secondary trial and the primary trial both measure PFS of their patient cohorts and use the same time frame ",
        "statement_nums": [],
        "premise_text": "Outcome Measurement: Progression Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (v1.1) in All Randomized Participants PFS was defined as the time from randomization to the occurrence of disease progression  as determined by investigators from tumor assessments per RECIST v1.1, or death from any cause  whichever occurred first  Time frame: Baseline up to approximately 34 months Outcome Measurement: Progression-Free Survival (PFS) at 6 Months (6-month PFS Rate): Proportion of Participants Progression Free at 6 Months PFS at 6 months was defined as proportion of participants who neither progressed nor died before 6 months  Computed using Kaplan-Meier estimates  Time frame: From the date of randomization to 6-months on study ",
        "premise_nums": [
            "(6-month PFS",
            "6-months on",
            "6 Months PFS",
            "34 months Outcome",
            "6 months was"
        ]
    },
    {
        "id": "a44cd0d1-92b3-4add-badf-b8dd5a324138",
        "primaryId": "NCT01466972",
        "secondaryId": "NCT01446159",
        "label": "Entailment",
        "statement_text": "the primary trial recorded one patient with congestive heart failure  the secondary trial did not record any ",
        "statement_nums": [],
        "premise_text": "Adverse Events 1: Heart Failure 1/30 (3.33%) Adverse Events 1: Cardiac failure 0/3 (0.00%) Adverse Events 2: Cardiac failure 0/3 (0.00%) ",
        "premise_nums": [
            "0/3 (0.00%)",
            "1/30 (3.33%)"
        ]
    },
    {
        "id": "291bb67e-f02f-49d4-b967-29cc9f5098c4",
        "primaryId": "NCT01738438",
        "secondaryId": "NCT00331552",
        "label": "Contradiction",
        "statement_text": "Cyclophosphamide  Cabozantinib and Trastuzumab were used in the secondary trial intervention  but not in the primary trial ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Cabozantinib Cabozantinib was given at a dose of 60 mg orally once per day for 21 day cycles  Treatment continued in the absence of disease progression or unacceptable toxicity  INTERVENTION 1: Phase I: Cyclophosphamide  Doxil  Trastuzumab Patients receive oral cyclophosphamide once daily on days 1-28 and pegylated doxorubicin HCl liposome IV over 90 minutes on day 1. Treatment repeats every 4-6 weeks in the absence of disease progression or unacceptable toxicity  Some patients with HER2/neu 3+ disease may also receive trastuzumab IV over 30-90 minutes weekly or every 3 weeks at the discretion of the treating physician  ",
        "premise_nums": [
            "90 minutes weekly",
            "2/neu 3+",
            "30-90 minutes",
            "3 weeks at",
            "28 and pegylated",
            "60 mg orally",
            "1-28 and",
            "6 weeks in",
            "4-6 weeks",
            "90 minutes on",
            "21 day cycles"
        ]
    },
    {
        "id": "291bb67e-f02f-49d4-b967-29cc9f5098c4",
        "primaryId": "NCT01738438",
        "secondaryId": "NCT00331552",
        "label": "Contradiction",
        "statement_text": "Cyclophosphamide  Cabozantinib and Trastuzumab were used in the secondary trial intervention  but not in the primary trial ",
        "statement_nums": [],
        "premise_text": "pegylated liposomal doxorubicin hydrochloride: Given IVcyclophosphamide: Given orally trastuzumab: Given IV ",
        "premise_nums": []
    },
    {
        "id": "55704a1f-eab2-44ea-a6de-8df508a28066",
        "primaryId": "NCT00274768",
        "secondaryId": "NCT00654836",
        "label": "Entailment",
        "statement_text": "Patients with stage 4 cancer are eligible for the secondary trial and the primary trial ",
        "statement_nums": [
            "4 cancer are"
        ],
        "premise_text": "Evidence of metastatic involvement (stage IV disease) Locally recurrent or metastatic disease ",
        "premise_nums": []
    },
    {
        "id": "6e1955b8-e6fa-42b2-a498-7ada9e733304",
        "primaryId": "NCT01593020",
        "secondaryId": "NCT00834678",
        "label": "Entailment",
        "statement_text": "Patients with aspartate aminotransferase more than 3 times the upper limit of normal are excluded from both the secondary trial and the primary trial ",
        "statement_nums": [
            "3 times the"
        ],
        "premise_text": "Exclusion Criteria: AST or ALT greater than 2.5 times the upper limit of normal (ULN) ALT and AST 2.5 times ULN ( 5 times ULN in the presence of documented liver metastases) ",
        "premise_nums": [
            "than 2.5 times the",
            "AST 2.5 times ULN"
        ]
    },
    {
        "id": "52337e14-7f51-40c1-b965-fb6aba8ae4e7",
        "primaryId": "NCT00821886",
        "statement_text": "Patients prescribed with bisoprolol or labetalol to treat CHF are eligible for the primary trial ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Exclusion Criteria: current use of medications (e.g.  digitalis  beta-blockers  calcium channel-blockers) that alter cardiac conduction  if these medications are administered for the management of cardiac arrhythmia  angina  or CHF  If these medications are administered for other reasons (e.g.  hypertension)  the patient may be eligible  ",
        "premise_nums": []
    },
    {
        "id": "8a6397e9-84cd-4a2e-ac6a-b56ee355d862",
        "primaryId": "NCT00004092",
        "statement_text": "Patients with Cancer that has spread from a breast tumor to their CNS are able to take part in the primary trial ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "No histologically proven bone marrow metastasis ",
        "premise_nums": []
    },
    {
        "id": "8b5f946c-71d9-42cd-aa9a-1d3a4845c460",
        "primaryId": "NCT01401959",
        "secondaryId": "NCT00852930",
        "label": "Entailment",
        "statement_text": "the primary trial designates specific interventions to its patients depending on their hormone status  Cohort A is TNBC patients and cohort B is ER/PR +HER2- BC Patients  in contrast the secondary trial assigns interventions randomly ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Cohort A: Triple-negative Breast Cancer Patients Patients with triple-negative breast cancer who do not have a pathological complete response following neoadjuvant therapy and surgery will receive eribulin 1.4 mg/m^2 on Days 1 and 8 every 21 days for 6 cycles via the intravenous (IV) route  INTERVENTION 2: Cohort B: ER/PR Positive/HER2-negative Breast Cancer Patients ",
        "premise_nums": [
            "21 days for",
            "2-negative Breast",
            "6 cycles via",
            "eribulin 1.4 mg/m",
            "1 and 8",
            "2 on Days"
        ]
    },
    {
        "id": "8b5f946c-71d9-42cd-aa9a-1d3a4845c460",
        "primaryId": "NCT01401959",
        "secondaryId": "NCT00852930",
        "label": "Entailment",
        "statement_text": "the primary trial designates specific interventions to its patients depending on their hormone status  Cohort A is TNBC patients and cohort B is ER/PR +HER2- BC Patients  in contrast the secondary trial assigns interventions randomly ",
        "statement_nums": [],
        "premise_text": "Patients with hormone receptor positive (ER and/or PR positive)  HER negative breast cancer breast cancer who do not have a pathological complete response following neoadjuvant therapy and surgery will receive eribulin 1.4 mg/m^2 on Days 1 and 8 every 21 days for 6 cycles via the intravenous (IV) route INTERVENTION 1: Laser Therapy Alone therapist administered laser treatment laser: therapist administered laser INTERVENTION 2: Mld Alone therapist administered manual lymphatic drainage manual lymphatic drainage: therapist administered massage therapy ",
        "premise_nums": [
            "21 days for",
            "6 cycles via",
            "eribulin 1.4 mg/m",
            "1 and 8",
            "2 on Days"
        ]
    },
    {
        "id": "8f0aff7f-0d9e-498b-bcb6-05e6d309724c",
        "primaryId": "NCT01852032",
        "secondaryId": "NCT01118624",
        "label": "Contradiction",
        "statement_text": "the secondary trial administers placebo tablets at twice the rate of the primary trial  but less than half the dose ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Breast Cancer Patients Tomosynthesis Breast Scanning is done and breast CT Scanning is done  INTERVENTION 1: Pralatrexate Study drug 190 mg/m^2 for 2 to 4 weeks  ",
        "premise_nums": [
            "2 for 2",
            "190 mg/m^2",
            "2 to 4"
        ]
    },
    {
        "id": "b7936bbc-f0c0-444c-a199-2db323c30396",
        "primaryId": "NCT00313170",
        "secondaryId": "NCT00305448",
        "label": "Contradiction",
        "statement_text": "Patients in the primary trial treated with Fulvestrant 250 mg had a 33% higher Objective response rate than those treated with Fulvestrant 250 mg + Loading Dose ",
        "statement_nums": [
            "250 mg had",
            "33% higher"
        ],
        "premise_text": "Outcome Measurement: Objective Response (ORR) Objective response rate was defined as percentage of patients with either complete response (CR - disappearance of all target lesions) or partial response (PR - at least 30% decrease in the sum of diameters of target lesions)  All patients were to be followed up every 12 weeks for progression  defined by response evaluation criteria in solid tumors (RECIST v1.1). Time frame: The planned data cut-off for this study was when all patients  except withdrawals  had been followed up for at least 24 weeks  Patients received treatment up to approximately 2 years  Results 1: Arm/Group Title: Fulvestrant 250 mg Arm/Group Description: Fulvestrant 250 mg Overall Number of Participants Analyzed: 47 Measure Type: Number ",
        "premise_nums": [
            "30% decrease",
            "12 weeks for",
            "250 mg Overall",
            "47 Measure Type:",
            "250 mg Arm"
        ]
    },
    {
        "id": "b7936bbc-f0c0-444c-a199-2db323c30396",
        "primaryId": "NCT00313170",
        "secondaryId": "NCT00305448",
        "label": "Contradiction",
        "statement_text": "Patients in the primary trial treated with Fulvestrant 250 mg had a 33% higher Objective response rate than those treated with Fulvestrant 250 mg + Loading Dose ",
        "statement_nums": [
            "250 mg had",
            "33% higher"
        ],
        "premise_text": "Unit of Measure: Percentage of patients 8.5 (2.4 to 20.4)Results 2: Arm/Group Title: Fulvestrant 250 mg + Loading Dose Arm/Group Description: Fulvestrant 250 mg + Loading Dose Overall Number of Participants Analyzed: 51 Measure Type: Number Unit of Measure: Percentage of patients 5.9 (1.2 to 16.2) Outcome Measurement: Objective Response Rate (ORR) ",
        "premise_nums": [
            "51 Measure Type:",
            "4 to 20.4)Results",
            "2 to 16.2)"
        ]
    },
    {
        "id": "b7936bbc-f0c0-444c-a199-2db323c30396",
        "primaryId": "NCT00313170",
        "secondaryId": "NCT00305448",
        "label": "Contradiction",
        "statement_text": "Patients in the primary trial treated with Fulvestrant 250 mg had a 33% higher Objective response rate than those treated with Fulvestrant 250 mg + Loading Dose ",
        "statement_nums": [
            "250 mg had",
            "33% higher"
        ],
        "premise_text": "An objective response (OR) is defined as a patient having a best overall response of either complete response (CR) or partial response (PR)  A patient has best overall response of CR if she had overall response of CR or PR on one visit and met the confirmation criteria per RECIST  ORR is defined as percentage of patients with objective response Each patient with measurable disease at baseline was assessed for OR from the sequence of Response Evaluation Criteria in Solid Tumors (RECIST) scan data up to data cut-off  RECIST scans were performed every 12 weeks (+/- 2weeks) from randomization ",
        "premise_nums": []
    },
    {
        "id": "b7936bbc-f0c0-444c-a199-2db323c30396",
        "primaryId": "NCT00313170",
        "secondaryId": "NCT00305448",
        "label": "Contradiction",
        "statement_text": "Patients in the primary trial treated with Fulvestrant 250 mg had a 33% higher Objective response rate than those treated with Fulvestrant 250 mg + Loading Dose ",
        "statement_nums": [
            "250 mg had",
            "33% higher"
        ],
        "premise_text": "Time frame: baseline and every 12 weeks (+/- 2weeks) from randomization data up to data cut-off (19th march 2008)Results 1: Arm/Group Title: Fulvestrant 250 mg Arm/Group Description: Fulvestrant 250 mg Overall Number of Participants Analyzed: 45 Measure Type: Number Unit of Measure: percentage of participants 11.1 Results 2: Arm/Group Title: Fulvestrant 250 mg + Loading Dose Arm/Group Description: Fulvestrant 250 mg + Loading Dose Overall Number of Participants Analyzed: 51 Measure Type: Number Unit of Measure: percentage of participants 17.6 ",
        "premise_nums": [
            "45 Measure Type:",
            "1 Results 2:",
            "250 mg Overall",
            "participants 11.1 Results 2",
            "51 Measure Type:",
            "250 mg Arm"
        ]
    },
    {
        "id": "6d6625ec-26b7-4157-a38c-87c770201323",
        "primaryId": "NCT01373671",
        "secondaryId": "NCT00686127",
        "label": "Entailment",
        "statement_text": "Lidoderm products are used in intervention arm 1 of the secondary trial  and a Siemens product is used in arm 1 of the primary trial",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "INTERVENTION 1: FFDM and DBT FFDM exam and DBT scan on Siemens MAMMOMAT Inspiration INTERVENTION 1: Lidocaine Patch Lidocaine patch 5% (Lidoderm®  Endo Pharmaceuticals Inc.): 1 patch was applied topically to the affected site(s) for 12 hours each day  ",
        "premise_nums": [
            "1 patch was",
            "12 hours each"
        ]
    },
    {
        "id": "e8b8c2b7-612d-4bab-b8a6-3dbc756cc210",
        "primaryId": "NCT01305941",
        "statement_text": "Patients must present IHC 3+ or FISH amplified results to participate in the primary trial  meaning their cancer is Histologically-confirmed as being triple-positive ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria Histologically-confirmed HER2-positive (IHC 3+ or fluorescence in situ hybridization (FISH) amplified; by clinical assay on either primary or metastatic tumor) adenocarcinoma of the breast with at least one progressive and/or new metastatic brain lesion (greater than /=5 mm on radiographic imaging) after receipt of intracranial radiation therapy (whole brain radiation therapy  stereotactic radiosurgery  gamma knife  or equivalent)  Patients in whom brain metastases (BM) are asymptomatic and detected during routine brain MRI screening per institutional protocols are eligible  ",
        "premise_nums": [
            "5 mm on"
        ]
    },
    {
        "id": "7e0259a3-073b-45f5-8e08-2cfaceecef0b",
        "primaryId": "NCT00606931",
        "statement_text": "the primary trial tests MRI scanning as a technique for guiding biopsies ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "INTERVENTION 1: PET Guided Biopsy No comparison group  All enrolled participants were expected to undergo PET guided biopsy  ",
        "premise_nums": []
    },
    {
        "id": "c94ad26b-1f5e-4446-a4fe-bb949c5dc561",
        "primaryId": "NCT00438100",
        "secondaryId": "NCT00662025",
        "label": "Contradiction",
        "statement_text": "Patients must have BUN smaller than 20 mg/dL  Platelet count: smaller than 90,000/mm3, Leukocyte count of 5,000/mm3 to 8,000/mm3 to be eligible for either the primary trial or the secondary trial ",
        "statement_nums": [
            "3 to be",
            "8,000/mm3 to",
            "20 mg/dL",
            "90,000/mm3, Leukocyte",
            "5,000/mm3 to"
        ],
        "premise_text": "Inclusion Criteria: Biopsy-diagnosed breast cancer with metastasis in multiple organs Performance Status (World Health Organization :WHO) 0-2 Functions below are maintained in major organs: Leukocyte count: 4,000/mm3 to 12,000/mm3 Neutrophil count: greater than 2,000/mm3 or more Platelet count: smaller than 100,000/mm3 or more Hemoglobin: greater than 9.5 g/dL Total bilirubin: greater than 1.5 mg/dL AST(GOT): within twice a normal upper value in an institution ",
        "premise_nums": [
            "2,000/mm3 or",
            "2 Functions below",
            "than 9.5 g/dL",
            "4,000/mm3 to",
            "12,000/mm3 Neutrophil",
            "3 Neutrophil count:",
            "100,000/mm3 or",
            "3 or more",
            "than 1.5 mg/dL",
            "0-2 Functions"
        ]
    },
    {
        "id": "c94ad26b-1f5e-4446-a4fe-bb949c5dc561",
        "primaryId": "NCT00438100",
        "secondaryId": "NCT00662025",
        "label": "Contradiction",
        "statement_text": "Patients must have BUN smaller than 20 mg/dL  Platelet count: smaller than 90,000/mm3, Leukocyte count of 5,000/mm3 to 8,000/mm3 to be eligible for either the primary trial or the secondary trial ",
        "statement_nums": [
            "3 to be",
            "8,000/mm3 to",
            "20 mg/dL",
            "90,000/mm3, Leukocyte",
            "5,000/mm3 to"
        ],
        "premise_text": "AST(GPT): within twice a normal upper value in an institutionBUN: smaller than 25 mg/dL Creatinine: within a normal upper value in the institution 24 hours creatinine clearance: greater than 50 mL/min (using the Cockcroft-Gault formula) Women's Ccr = Body weight x (140-Age)/(72 x Serum creatinine) x 0.85 Inclusion Criteria: Histologically- or cytologically-proven diagnosis of breast adenocarcinoma that is not amenable to surgery  radiation  or combined modality therapy with curative intent ",
        "premise_nums": [
            "72 x Serum",
            "25 mg/dL Creatinine",
            "x 0.85 Inclusion Criteria",
            "(140-Age)/(72 x",
            "24 hours creatinine",
            "85 Inclusion Criteria:",
            "50 mL/min"
        ]
    },
    {
        "id": "c94ad26b-1f5e-4446-a4fe-bb949c5dc561",
        "primaryId": "NCT00438100",
        "secondaryId": "NCT00662025",
        "label": "Contradiction",
        "statement_text": "Patients must have BUN smaller than 20 mg/dL  Platelet count: smaller than 90,000/mm3, Leukocyte count of 5,000/mm3 to 8,000/mm3 to be eligible for either the primary trial or the secondary trial ",
        "statement_nums": [
            "3 to be",
            "8,000/mm3 to",
            "20 mg/dL",
            "90,000/mm3, Leukocyte",
            "5,000/mm3 to"
        ],
        "premise_text": "Measurable disease as per RECIST  Measurable lesions that have been previously irradiated will not be considered target lesions unless increase in size has been observed following completion of radiation therapy Prior treatment with an anthracycline and a taxane in the neoadjuvant  adjuvant or metastatic disease settings  Exclusion Criteria: Histology of inflammatory carcinoma with no other measurable disease  Patients with histology of inflammatory carcinoma are allowed on study if they have measurable disease  Brain metastases  spinal cord compression  or carcinomatous meningitis  or leptomeningeal disease  ",
        "premise_nums": []
    },
    {
        "id": "c94ad26b-1f5e-4446-a4fe-bb949c5dc561",
        "primaryId": "NCT00438100",
        "secondaryId": "NCT00662025",
        "label": "Contradiction",
        "statement_text": "Patients must have BUN smaller than 20 mg/dL  Platelet count: smaller than 90,000/mm3, Leukocyte count of 5,000/mm3 to 8,000/mm3 to be eligible for either the primary trial or the secondary trial ",
        "statement_nums": [
            "3 to be",
            "8,000/mm3 to",
            "20 mg/dL",
            "90,000/mm3, Leukocyte",
            "5,000/mm3 to"
        ],
        "premise_text": "Prior treatment with 5-fluorouracil (5-FU) and 5-FU derivatives such as Furtulon (5'-DFUR), Futraful/ Sunfural (tegafur)  UFT/UFT-E (tegafur/uracil)  TS-1 (tegafur/gimeracil/oteracil) or Mifurol (carmofur) in metastatic disease setting",
        "premise_nums": [
            "(5-FU) and",
            "5-FU derivatives"
        ]
    },
    {
        "id": "4e31e4f8-a6da-49fc-8bfe-1309674ec2ee",
        "primaryId": "NCT00244881",
        "statement_text": "30% of the primary trial participants had an increased level of CECs after 42 days of treatment ",
        "statement_nums": [
            "30% of",
            "42 days of"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Fraction of Patients With Increased Levels of Circulating Endothelial Cells An exact 95% confidence interval (CI) will be calculated for the CEC response rate  With 26 patients  this CI will be no wider than 40% (e.g.  if 13 of 26 patients respond  the CI is 30% to 70%). Time frame: After 3 weeks of treatment Results 1: Arm/Group Title: Treatment (Cediranib Maleate) Arm/Group Description: Patients receive oral AZD2171 once daily for 42 days  Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity  Overall Number of Participants Analyzed: 26 Measure Type: Number Unit of Measure: percentage of participants 30 ",
        "premise_nums": [
            "3 weeks of",
            "42 days in",
            "26 Measure Type:",
            "AZD2171 once",
            "30% to",
            "2171 once daily",
            "95% confidence",
            "13 of 26"
        ]
    },
    {
        "id": "5c00f992-5066-42f2-88d7-566b8b9104b5",
        "primaryId": "NCT00089661",
        "statement_text": "On average cohort 1 participants in the primary trial had an increased Rate of Acute Toxicity   whereas those in cohort 2 did not experience any Acute Toxicities ",
        "statement_nums": [
            "2 did not",
            "1 participants in"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 12 Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry  Time frame: 12 months Results 1: Arm/Group Title: Denosumab 60 mg Q6M Arm/Group Description: [Not Specified] Overall Number of Participants Analyzed: 123 Least Squares Mean (95% Confidence Interval) Unit of Measure: Percent Change from Baseline 4.8 (4.3 to 5.4) Results 2: Arm/Group Title: Placebo Arm/Group Description: [Not Specified] Overall Number of Participants Analyzed: 122 Least Squares Mean (95% Confidence Interval) Unit of Measure: Percent Change from Baseline -.7 (-1.3 to -.1) ",
        "premise_nums": [
            "12 Bone Mineral",
            "12 months Results",
            "123 Least Squares",
            "95% Confidence",
            "122 Least Squares",
            "60 mg Q6M",
            "3 to 5.4)"
        ]
    },
    {
        "id": "4c0ffc50-5cb2-4574-b954-335d142edbe4",
        "primaryId": "NCT01527487",
        "statement_text": "Patients prescribed Citalopram as an ongoing treatment for depression are not eligible for the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Exclusion Criteria: Chronic use of drugs that cause QTc prolongation  Patients must discontinue use of these drugs 7 days prior to the start of study treatment  ",
        "premise_nums": [
            "7 days prior"
        ]
    },
    {
        "id": "4e3379b9-f971-4ab6-8846-c395f1162bf2",
        "primaryId": "NCT00810797",
        "secondaryId": "NCT00828074",
        "label": "Entailment",
        "statement_text": "Skin infections were more common in patients in cohort 1 of the secondary trial  than in cohort 1 of the primary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Adverse Events 1: Skin infection * 1/36 (2.78%) Adverse Events 1: Skin infection * 2/41 (4.88%) ",
        "premise_nums": [
            "2/41 (4.88%)",
            "1/36 (2.78%)"
        ]
    },
    {
        "id": "9872394c-18b7-4f88-849e-0e2831e6ebf0",
        "primaryId": "NCT00579826",
        "statement_text": "Participants of the primary trial cannot be currently receiving for treatment rheumatoid arthritis  experiencing poorly controlled migraines  receiving hormone replacement therapy or have any prior history of invasive breast cancer in the last 3 years ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria: On a stable dose of hormone replacement therapy Exclusion Criteria: Prior history of invasive breast cancer or other invasive cancer within five years from date of study entry  Receiving treatment for rheumatoid arthritis or fibromyalgia Current history of poorly controlled migraines or perimenopausal symptoms ",
        "premise_nums": []
    },
    {
        "id": "adf3bb50-ec36-467a-987a-f33c10380c60",
        "primaryId": "NCT01771666",
        "secondaryId": "NCT01256567",
        "label": "Contradiction",
        "statement_text": "Japanese participants with an ECOG of 2 are eligible for the secondary trial and the primary trial ",
        "statement_nums": [
            "2 are eligible"
        ],
        "premise_text": "Inclusion Criteria: Eastern Cooperative Oncology Group (ECOG) or Karnofsky Performance Status 0,1,2. Inclusion Criteria: The participant is Japanese The participant has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 ",
        "premise_nums": [
            "0,1,2. Inclusion",
            "0 or 1"
        ]
    },
    {
        "id": "2ef37a06-a1ed-47eb-b8f4-2f97f46293d1",
        "primaryId": "NCT01875367",
        "statement_text": "One patient in the primary trial suffered a cerebral infarction ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 2/81 (2.47%) Heart failure 0/81 (0.00%) Fever 1/81 (1.23%) Cold 0/81 (0.00%) Catheter related infection (Bacteriemia) 0/81 (0.00%) Lack of strength in left leg 0/81 (0.00%) Ostenecrosis produced by biphosphonates 0/81 (0.00%) Gastric cancer 0/81 (0.00%) Stroke 0/81 (0.00%) Hematuria 1/81 (1.23%) Nodule in left breast 0/81 (0.00%) Adverse Events 2: Total: 10/85 (11.76%) Heart failure 1/85 (1.18%) ",
        "premise_nums": [
            "1/85 (1.18%)",
            "0/81 (0.00%)",
            "2/81 (2.47%)",
            "1/81 (1.23%)",
            "10/85 (11.76%)"
        ]
    },
    {
        "id": "2ef37a06-a1ed-47eb-b8f4-2f97f46293d1",
        "primaryId": "NCT01875367",
        "statement_text": "One patient in the primary trial suffered a cerebral infarction ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Fever 0/85 (0.00%)Cold 1/85 (1.18%) Catheter related infection (Bacteriemia) 1/85 (1.18%) Lack of strength in left leg 1/85 (1.18%) Ostenecrosis produced by biphosphonates 1/85 (1.18%) Gastric cancer 1/85 (1.18%) Stroke 1/85 (1.18%) Hematuria 0/85 (0.00%) Nodule in left breast 1/85 (1.18%) ",
        "premise_nums": [
            "0/85 (0.00%)Cold",
            "1/85 (1.18%)"
        ]
    },
    {
        "id": "03cb39e4-1d21-47e5-9b09-ebe508eb2a17",
        "primaryId": "NCT00477464",
        "statement_text": "59 patients from Arm A of the primary trial achieved a best overall response  classified as a complete or partial (confirmed) tumor response or stable disease for at least 6 months ",
        "statement_nums": [
            "59 patients from"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Clinical Benefit Response (Independent Reviewer-assessed) CBR is defined as the percentage of participants receiving at least one dose of study medication who achieved a best overall response classified as a complete or partial (confirmed) tumor response or stable disease for at least 6 months (24 weeks)  A \"complete response\" is defined as the disappearance of all target or non-target lesions  \"partial response\" and \"disease progression\" as at least a 30% decrease and at least a 20% increase  respectively  in the sum of the longest diameter of target lesions  and \"stable disease\" as neither \"partial response\" nor \"disease progression.\" Time frame: Baseline  every 6 weeks until Week 24 and then every 12 weeks until disease progression (up to Week 119) Results 1: ",
        "premise_nums": [
            "30% decrease",
            "6 weeks until",
            "6 months (24",
            "12 weeks until",
            "24 and then",
            "20% increase"
        ]
    },
    {
        "id": "03cb39e4-1d21-47e5-9b09-ebe508eb2a17",
        "primaryId": "NCT00477464",
        "statement_text": "59 patients from Arm A of the primary trial achieved a best overall response  classified as a complete or partial (confirmed) tumor response or stable disease for at least 6 months ",
        "statement_nums": [
            "59 patients from"
        ],
        "label": "Contradiction",
        "premise_text": "Arm/Group Title: Lapatinib 1250 mg and Capecitabine 2000 mg/m^2Arm/Group Description: Participants took lapatinib and capecitabine  Lapatinib was orally administered at 1250 milligrams (mg) once daily  Capecitabine was orally administered at 1000 mg per square meter (mg/m^2) twice daily on the first day through the fourteenth day of each 21-day cycle  Overall Number of Participants Analyzed: 51 Measure Type: Number Unit of Measure: percentage of participants 59 ",
        "premise_nums": [
            "1250 milligrams (mg)",
            "1250 mg and",
            "1000 mg per",
            "2000 mg/m^2Arm/Group",
            "51 Measure Type:",
            "21-day cycle"
        ]
    },
    {
        "id": "dca6ba74-441e-482f-b667-6c45800ed8c1",
        "primaryId": "NCT00425672",
        "statement_text": "Patients receiving intervention 1 of the primary trial must undergo a 21 day treatment cycle  for a total of 6 courses  unless death occurs  ",
        "statement_nums": [
            "21 day treatment",
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "INTERVENTION 1: Arm I Patients receive ONTAK IV over 1 hour on days 1-5. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity  ONTAK: Given IV flow cytometry: Correlative studies immunohistochemistry staining method: Correlative studies enzyme-linked immunosorbent assay: Correlative studies laboratory biomarker analysis: Correlative studies protein expression analysis: Correlative studies ",
        "premise_nums": [
            "6 courses in",
            "1-5. Treatment",
            "21 days for",
            "1 hour on"
        ]
    },
    {
        "id": "aeecc244-13a9-4944-858e-27ef49585e90",
        "primaryId": "NCT01702571",
        "statement_text": "Patients with incurable and unresectable Locally Advanced Breast Cancer are eligible for the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Inclusion Criteria: Documented progression of incurable  unresectable  LABC  or mBC  defined by the investigator: progression must occur during or after most recent treatment for LABC/mBC or within 6 months of completing adjuvant therapy ",
        "premise_nums": [
            "6 months of"
        ]
    },
    {
        "id": "741ca5eb-4737-4a35-a9fd-4235d6552b4f",
        "primaryId": "NCT01256008",
        "secondaryId": "NCT00300781",
        "label": "Entailment",
        "statement_text": "the primary trial is investigating Cognitive behavioural therapy  a type of psychotherapy  in contrast the secondary trial studies Neratinib  a type of chemotherapy ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Stage 1 Clinical Management The group will receive clinical management treatment only each session  Clinical Management: Clinical management is a clear contrast method of psychological therapy  which is a half-structured interview and lasting for 20-25 minutes each session  Clinical management will be assigned to both experimental group and controlled group in the first stage of intervention  Following are major elements: Talk to the subjects to find their main problems; introduce knowledge and medication knowledge about cancer and depression; subjects reporting use of drugs for cancer and depression and a variety of signs and symptoms of the reaction  Encourage patients to adhere to drug treatment and to comply with this research program; The operation of CBT and clinical management should be conducted by the same person as far as possible  INTERVENTION 2: Stage 1 CBT The experimental group will receive CBT each session  ",
        "premise_nums": [
            "20-25 minutes",
            "1 Clinical Management",
            "1 CBT The",
            "25 minutes each"
        ]
    },
    {
        "id": "741ca5eb-4737-4a35-a9fd-4235d6552b4f",
        "primaryId": "NCT01256008",
        "secondaryId": "NCT00300781",
        "label": "Entailment",
        "statement_text": "the primary trial is investigating Cognitive behavioural therapy  a type of psychotherapy  in contrast the secondary trial studies Neratinib  a type of chemotherapy ",
        "statement_nums": [],
        "premise_text": "CBT and clinical management: The subjects will receive standardized CBT treatment regularly for 9 sessions(once per week in the first month and once half a month in the second and third months)  and each session will last for about 60 minutes.The treatment includes three steps:Concept stage (the first and second sessions): establishment of therapeutic relationships with the subjects; Skills acquisition and repeat stage (the third session to the 8th session): clarification of sources of stress  patients' cognitive and behavioral response to stress  Application and complete price segment (the 9th session): return visit to test efficacy of psychological intervention INTERVENTION 1: Neratinib 240, Prior Trastuzumab ",
        "premise_nums": []
    },
    {
        "id": "741ca5eb-4737-4a35-a9fd-4235d6552b4f",
        "primaryId": "NCT01256008",
        "secondaryId": "NCT00300781",
        "label": "Entailment",
        "statement_text": "the primary trial is investigating Cognitive behavioural therapy  a type of psychotherapy  in contrast the secondary trial studies Neratinib  a type of chemotherapy ",
        "statement_nums": [],
        "premise_text": "Neratinib: 80mg capsules and 40mg coated tablets taken orally in prescribed dose of 240mg daily  as long as tolerated and disease does not worsen in participants with prior trastuzumab treatment INTERVENTION 2: Neratinib 240, No Prior Trastuzumab Neratinib: 80mg capsules and 40mg coated tablets taken orally in prescribed dose of 240mg daily  as long as tolerated and disease does not worsen in participants with no prior trastuzumab treatment  ",
        "premise_nums": []
    },
    {
        "id": "b8e0458c-b834-42b5-b5fd-8791f89b0853",
        "primaryId": "NCT01881230",
        "statement_text": "The Gemcitabine group of the primary trial had a median Kaplan-Meier Estimate of Progression-Free Survival more than 2 months shorter than the Carboplatin group",
        "statement_nums": [
            "2 months shorter"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Kaplan-Meier Estimates of Progression-Free Survival (PFS) Based on Investigator Assessment  ",
        "premise_nums": []
    },
    {
        "id": "b8e0458c-b834-42b5-b5fd-8791f89b0853",
        "primaryId": "NCT01881230",
        "statement_text": "The Gemcitabine group of the primary trial had a median Kaplan-Meier Estimate of Progression-Free Survival more than 2 months shorter than the Carboplatin group",
        "statement_nums": [
            "2 months shorter"
        ],
        "label": "Entailment",
        "premise_text": "PFS was defined as the time from the date of randomization to the date of disease progression or death from any cause on or prior to the data cutoff date for the statistical analysis  whichever occurred earlier  Tumor responses were assessed every 6 weeks using  Response Evaluation Criteria in Solid Tumors (RECIST 1.1) and defined as: Complete response (CR) is the disappearance of all target lesions; Partial response (PR) occurs when at least a 30% decrease in the sum of diameters of target lesions from baseline; Stable disease is neither sufficient shrinkage to qualify for a PR nor sufficient increase of lesions to qualify for Progressive disease (PD); Progressive Disease- is at least a 20% increase in the sum of diameters of target lesions from nadir ",
        "premise_nums": [
            "30% decrease",
            "6 weeks using",
            "20% increase"
        ]
    },
    {
        "id": "b8e0458c-b834-42b5-b5fd-8791f89b0853",
        "primaryId": "NCT01881230",
        "statement_text": "The Gemcitabine group of the primary trial had a median Kaplan-Meier Estimate of Progression-Free Survival more than 2 months shorter than the Carboplatin group",
        "statement_nums": [
            "2 months shorter"
        ],
        "label": "Entailment",
        "premise_text": "Time frame: From date of randomization to data cut-off date of 16 December 2016; total length of time on study was 31 months for Arm A  34 months for Arm B and 35 months for Arm CResults 1: Arm/Group Title: Arm A: Nab-Paclitaxel + Gemcitabine ",
        "premise_nums": [
            "16 December 2016;",
            "31 months for",
            "35 months for",
            "34 months for"
        ]
    },
    {
        "id": "b8e0458c-b834-42b5-b5fd-8791f89b0853",
        "primaryId": "NCT01881230",
        "statement_text": "The Gemcitabine group of the primary trial had a median Kaplan-Meier Estimate of Progression-Free Survival more than 2 months shorter than the Carboplatin group",
        "statement_nums": [
            "2 months shorter"
        ],
        "label": "Entailment",
        "premise_text": "Arm/Group Description: Participants received nab-Paclitaxel 125 mg/m^2 on Days 1 and 8 by intravenous (IV) administration followed by gemcitabine 1000 mg/m^2 on Days 1 and 8 by IV administration of each 21-day treatment cycle  Participants continued treatment until progressive disease (PD)  unacceptable toxicity  required palliative radiotherapy or surgical intervention of lesion(s)  withdrawal from study treatment  withdrawal of study consent  participant refusal or the investigator felt it was no longer in the best interest of the participant to continue on treatmentOverall Number of Participants Analyzed: 61 Median (95% Confidence Interval) Unit of Measure: months 5.5 (4.1 to 7.0) ",
        "premise_nums": [
            "1 to 7.0)",
            "1000 mg/m^2",
            "1 and 8",
            "95% Confidence",
            "125 mg/m^2",
            "21-day treatment",
            "2 on Days"
        ]
    },
    {
        "id": "b8e0458c-b834-42b5-b5fd-8791f89b0853",
        "primaryId": "NCT01881230",
        "statement_text": "The Gemcitabine group of the primary trial had a median Kaplan-Meier Estimate of Progression-Free Survival more than 2 months shorter than the Carboplatin group",
        "statement_nums": [
            "2 months shorter"
        ],
        "label": "Entailment",
        "premise_text": "Results 2:Arm/Group Title: Arm B: Nab-Paclitaxel + Carboplatin Arm/Group Description: Participants received nab-Paclitaxel 125 mg/m^2 on Days 1 and 8 by IV administration followed by carboplatin area under the curve 2 (AUC 2) on Days 1 and 8 in each 21-day treatment cycle  Participants continued treatment until progressive disease (PD)  unacceptable toxicity  required palliative radiotherapy or surgical intervention of lesion(s)  withdrawal from study treatment  withdrawal of study consent  participant refusal or the investigator felt it was no longer in the best interest of the participant to continue on treatment  Overall Number of Participants Analyzed: 64 Median (95% Confidence Interval) ",
        "premise_nums": [
            "2:Arm/Group Title:",
            "1 and 8",
            "95% Confidence",
            "125 mg/m^2",
            "21-day treatment",
            "2 on Days"
        ]
    },
    {
        "id": "b8e0458c-b834-42b5-b5fd-8791f89b0853",
        "primaryId": "NCT01881230",
        "statement_text": "The Gemcitabine group of the primary trial had a median Kaplan-Meier Estimate of Progression-Free Survival more than 2 months shorter than the Carboplatin group",
        "statement_nums": [
            "2 months shorter"
        ],
        "label": "Entailment",
        "premise_text": "Unit of Measure: months 8.3 (5.7 to 10.6)",
        "premise_nums": []
    },
    {
        "id": "1a112ed3-8318-493b-8973-10de01794892",
        "primaryId": "NCT00382018",
        "secondaryId": "NCT03012477",
        "label": "Entailment",
        "statement_text": "Between the patients in the primary trial and the secondary trial  only a single one suffered from sepsis ",
        "statement_nums": [],
        "premise_text": "Adverse Events 1: Total: 0/161 (0.00%) Gastrointestinal-Other 0/161 (0.00%) Dehydration 0/161 (0.00%) Renal/Genitourinary-Other 0/161 (0.00%) Adverse Events 2: Total: 1/64 (1.56%) Gastrointestinal-Other 1/64 (1.56%) Dehydration 1/64 (1.56%) Renal/Genitourinary-Other 1/64 (1.56%) Sepsis 1/34 (2.94%) ",
        "premise_nums": [
            "1/64 (1.56%)",
            "0/161 (0.00%)",
            "1/34 (2.94%)"
        ]
    },
    {
        "id": "6044590d-0f89-4a6e-8be7-54ca0c0327d9",
        "primaryId": "NCT00003404",
        "secondaryId": "NCT00711529",
        "label": "Entailment",
        "statement_text": "the primary trial does not have a Hypnotherapy based intervention  and the secondary trial does not have a Radiotherapy intervention ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Adjuvant Radiotherapy Adjuvant radiation was started within 12 weeks of local excision or breast re-excision  Adjuvant Radiotherapy: Adjuvant radiation therapy INTERVENTION 1: Hypnotherapy Patients randomized to the hypnosis arm of the study will undergo individually three one-hour sessions with a certified hypnotherapist  These sessions will be one week apart  Patients will also be instructed on the use of self-hypnosis techniques to use at home  INTERVENTION 2: Gabapentin Patients randomized to the gabapentin arm will be prescribed 900mg of the drug daily (300 mg by mouth three times daily)  ",
        "premise_nums": [
            "12 weeks of",
            "300 mg by"
        ]
    },
    {
        "id": "8d3378f7-caaf-4654-b12a-382a0e911eb1",
        "primaryId": "NCT02429427",
        "statement_text": "Patients with a platelet count of 50 x 109/l are not eligible for the primary trial",
        "statement_nums": [
            "50 x 109",
            "109/l are"
        ],
        "label": "Entailment",
        "premise_text": "Inclusion Criteria: Pre-treatment haematology and biochemistry values within acceptable local limits: Haemoglobin  white blood cell greater or equal to 3.0 x 109/l or absolute neutrophil count greater or equal to 1.51 x 109/l, Platelets greater or equal to 100 x 109/l, Serum bilirubin less than 1.5 x upper normal limit   Alkaline phosphatase less or equal to 1.5 x upper normal limit   Serum creatinine less than 1.5 x upper normal limit ",
        "premise_nums": [
            "to 3.0 x 109",
            "than 1.5 x upper",
            "100 x 109",
            "to 1.5 x upper",
            "to 1.51 x 109",
            "109/l, Serum",
            "109/l or",
            "109/l, Platelets"
        ]
    },
    {
        "id": "f701473d-e034-4a06-9829-d20cc483162c",
        "primaryId": "NCT01516736",
        "secondaryId": "NCT00733408",
        "label": "Contradiction",
        "statement_text": "the primary trial and the secondary trial have non comparable results as the different in cohort size is too significant ",
        "statement_nums": [],
        "premise_text": "Outcome Measurement: Mean Duration of Severe Neutropenia (DSN) During Cycle 1 of Chemotherapy Mean duration of severe neutropenia  defined as number of consecutive days with ANC smaller than 0.5 × 10^9/l (grade 4 neutropenia)  Time frame: 21 days (Cycle 1 of chemotherapy treatment) Outcome Measurement: Progression-free Survival (PFS) ",
        "premise_nums": [
            "1 of Chemotherapy",
            "1 of chemotherapy",
            "21 days (Cycle"
        ]
    },
    {
        "id": "f701473d-e034-4a06-9829-d20cc483162c",
        "primaryId": "NCT01516736",
        "secondaryId": "NCT00733408",
        "label": "Contradiction",
        "statement_text": "the primary trial and the secondary trial have non comparable results as the different in cohort size is too significant ",
        "statement_nums": [],
        "premise_text": "Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions  or a measurable increase in a non-target lesion  or the appearance of new lesions  Kaplan-Meier survival curves will be used  A 95% confidence interval for the median PFS will be calculated  A lower bound greater than 8 months would be strong evidence that Nab-Paclitaxel- bevacizumab induction therapy followed by bevacizumab-erlotinib hydrochloride maintenance therapy is superior to paclitaxel and bevacizumab  However  a median PFS of 13 months or greater (regardless of whether the 95% confidence interval for the median extends below 8 months) could also indicate promising results ",
        "premise_nums": [
            "95% confidence",
            "8 months would",
            "13 months or",
            "20% increase"
        ]
    },
    {
        "id": "f701473d-e034-4a06-9829-d20cc483162c",
        "primaryId": "NCT01516736",
        "secondaryId": "NCT00733408",
        "label": "Contradiction",
        "statement_text": "the primary trial and the secondary trial have non comparable results as the different in cohort size is too significant ",
        "statement_nums": [],
        "premise_text": "Time frame: Time from date of registration to date of first documentation of progression or symptomatic deterioration or death due to any cause  assessed up to 8 years",
        "premise_nums": []
    },
    {
        "id": "3889cecd-aa2d-4f58-857e-11d7209f9cf4",
        "primaryId": "NCT00450866",
        "statement_text": "In the primary trial a cohort 1 has a higher percentage of patients with progression free survival at 3 months after treatment  than cohort 2.",
        "statement_nums": [
            "1 has a",
            "3 months after"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Central Nervous System (CNS) Progression-free Survival(PFS) The number of patients that are documented to have progression free survival at 3 months after treatment  Progression free is define as smaller than 25% increase in tumor area  PFS will be measured from the date of entry into the trial to the date of documented progression of brain metastases or death  Time frame: 3 months after treatment Results 1: Arm/Group Title: Epothilone B: Group A ",
        "premise_nums": [
            "25% increase",
            "3 months after"
        ]
    },
    {
        "id": "3889cecd-aa2d-4f58-857e-11d7209f9cf4",
        "primaryId": "NCT00450866",
        "statement_text": "In the primary trial a cohort 1 has a higher percentage of patients with progression free survival at 3 months after treatment  than cohort 2.",
        "statement_nums": [
            "1 has a",
            "3 months after"
        ],
        "label": "Entailment",
        "premise_text": "Arm/Group Description: Group A: Patients with progressive  radiographically measurable parenchymal brain metastases after whole brain radiation therapy (WBRT)  Patupilone will be administered as a single intravenous infusion over 20 minutes  once every 3 weeks  Patupilone will be administered at a dose of 10 mg/m2 (q3weeks) with actual body weight Overall Number of Participants Analyzed: 45 Measure Type: Number Unit of Measure: participants 12 Results 2: Arm/Group Title: Epothilone B: Group B ",
        "premise_nums": [
            "45 Measure Type:",
            "(q3weeks) with",
            "10 mg/m2",
            "12 Results 2:"
        ]
    },
    {
        "id": "3889cecd-aa2d-4f58-857e-11d7209f9cf4",
        "primaryId": "NCT00450866",
        "statement_text": "In the primary trial a cohort 1 has a higher percentage of patients with progression free survival at 3 months after treatment  than cohort 2.",
        "statement_nums": [
            "1 has a",
            "3 months after"
        ],
        "label": "Entailment",
        "premise_text": "Arm/Group Description: Group B: an exploratory cohort of patients  with either leptomeningeal metastases (LMD) or unirradiated  asymptomatic brain metastasis from breast cancer (BCBM).Patupilone will be administered as a single intravenous infusion over 20 minutes  once every 3 weeks  Patupilone will be administered at a dose of 10 mg/m2 (q3weeks) with actual body weight Overall Number of Participants Analyzed: 10 Measure Type: Number Unit of Measure: participants 2 ",
        "premise_nums": [
            "10 mg/m2",
            "(q3weeks) with",
            "10 Measure Type:"
        ]
    },
    {
        "id": "19d0c9de-02ad-4a8e-937b-e9d0f0cc8051",
        "primaryId": "NCT00338286",
        "statement_text": "No participants of the primary trial had a Progression Free Survival over 1 year ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Progression Free Survival Progression free survival was based in investigator-determined progressive disease (PD) and calculated from the date of randomization to the date of PD or the date of death  whichever occurred first  Participants who had not progressed and were still alive at the time of clinical cut off were censored at the last disease assessment prior to the clinical cutoff  For PD or death with a missing interval immediately preceding the event  progression-free survival (PFS) was censored at the last disease assessment prior to the missing interval  Participants who withdrew from the study (withdrawal of consent or lost to follow-up) without progression were censored at the time of the last disease assessment  Time frame: From the date of randomization to the date of disease progression (PD) or death  whichever occurred first (up to 8.4 years) Results 1: ",
        "premise_nums": []
    },
    {
        "id": "19d0c9de-02ad-4a8e-937b-e9d0f0cc8051",
        "primaryId": "NCT00338286",
        "statement_text": "No participants of the primary trial had a Progression Free Survival over 1 year ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Arm/Group Title: Standard of Care (SOC)Arm/Group Description: Participants received standard supportive care as packed red blood cells (RBC) transfusion as per Investigator's discretion  Overall Number of Participants Analyzed: 1048 Median (95% Confidence Interval) Unit of Measure: Months 7.4 (7.1 to 7.6) Results 2: Arm/Group Title: Epoetin Alfa Arm/Group Description: Participants received SOC plus epoetin alfa 40,000 international units (IU) subcutaneously (SC) once a week  Overall Number of Participants Analyzed: 1050 Median (95% Confidence Interval) Unit of Measure: Months 7.4 (6.9 to 7.6) ",
        "premise_nums": [
            "alfa 40,000 international units",
            "95% Confidence",
            "1 to 7.6)",
            "9 to 7.6)"
        ]
    },
    {
        "id": "cb023dbc-3e99-4c32-a857-7f8d49ef5a96",
        "primaryId": "NCT00789581",
        "secondaryId": "NCT02445586",
        "label": "Entailment",
        "statement_text": "the secondary trial reported more cases of Haematemesis  but the primary trial had more total cases of DIASTOLIC DYSFUNCTION across both its cohorts ",
        "statement_nums": [],
        "premise_text": "Adverse Events 1: Total: 58/305 (19.02%) FEBRILE NEUTROPENIA * 12/305 (3.93%) NEUTROPENIA * 4/305 (1.31%) ANAEMIA * 2/305 (0.66%) LEUKOPENIA * 1/305 (0.33%) PANCYTOPENIA * 1/305 (0.33%) THROMBOCYTOPENIA * 1/305 (0.33%) DISSEMINATED INTRAVASCULAR COAGULATION * 0/305 (0.00%) ATRIAL FIBRILLATION * 1/305 (0.33%) DIASTOLIC DYSFUNCTION * 1/305 (0.33%) ",
        "premise_nums": [
            "4/305 (1.31%)",
            "12/305 (3.93%)",
            "2/305 (0.66%)",
            "1/305 (0.33%)",
            "0/305 (0.00%)",
            "58/305 (19.02%)"
        ]
    },
    {
        "id": "cb023dbc-3e99-4c32-a857-7f8d49ef5a96",
        "primaryId": "NCT00789581",
        "secondaryId": "NCT02445586",
        "label": "Entailment",
        "statement_text": "the secondary trial reported more cases of Haematemesis  but the primary trial had more total cases of DIASTOLIC DYSFUNCTION across both its cohorts ",
        "statement_nums": [],
        "premise_text": "PERICARDIAL EFFUSION * 1/305 (0.33%)Adverse Events 2: Total: 50/304 (16.45%) FEBRILE NEUTROPENIA * 12/304 (3.95%) NEUTROPENIA * 1/304 (0.33%) ANAEMIA * 0/304 (0.00%) LEUKOPENIA * 0/304 (0.00%) PANCYTOPENIA * 0/304 (0.00%) THROMBOCYTOPENIA * 0/304 (0.00%) DISSEMINATED INTRAVASCULAR COAGULATION * 1/304 (0.33%) ATRIAL FIBRILLATION * 1/304 (0.33%) ",
        "premise_nums": [
            "0/304 (0.00%)",
            "50/304 (16.45%)",
            "12/304 (3.95%)",
            "1/304 (0.33%)",
            "1/305 (0.33%)Adverse"
        ]
    },
    {
        "id": "cb023dbc-3e99-4c32-a857-7f8d49ef5a96",
        "primaryId": "NCT00789581",
        "secondaryId": "NCT02445586",
        "label": "Entailment",
        "statement_text": "the secondary trial reported more cases of Haematemesis  but the primary trial had more total cases of DIASTOLIC DYSFUNCTION across both its cohorts ",
        "statement_nums": [],
        "premise_text": "DIASTOLIC DYSFUNCTION * 0/304 (0.00%)PERICARDIAL EFFUSION * 0/304 (0.00%) Adverse Events 1: Total: 31/52 (59.62%) Febrile neutropenia 2/52 (3.85%) Left ventricular dysfunction 2/52 (3.85%) Sinus tachycardia 1/52 (1.92%) Congenital arterial malformation 1/52 (1.92%) Diarrhoea 5/52 (9.62%) Salivary hypersecretion 1/52 (1.92%) Enteritis 1/52 (1.92%) ",
        "premise_nums": [
            "31/52 (59.62%)",
            "5/52 (9.62%)",
            "1/52 (1.92%)",
            "2/52 (3.85%)",
            "0/304 (0.00%)PERICARDIAL"
        ]
    },
    {
        "id": "cb023dbc-3e99-4c32-a857-7f8d49ef5a96",
        "primaryId": "NCT00789581",
        "secondaryId": "NCT02445586",
        "label": "Entailment",
        "statement_text": "the secondary trial reported more cases of Haematemesis  but the primary trial had more total cases of DIASTOLIC DYSFUNCTION across both its cohorts ",
        "statement_nums": [],
        "premise_text": "Abdominal pain 1/52 (1.92%)Vomiting 1/52 (1.92%) Stomatitis 1/52 (1.92%) Haematemesis 1/52 (1.92%) ",
        "premise_nums": [
            "1/52 (1.92%)Vomiting"
        ]
    },
    {
        "id": "1d0ce237-70eb-45b4-9c77-f0b70d410387",
        "primaryId": "NCT00193180",
        "statement_text": "A female patient over the age of 18 suffering from Cirrhosis cannot take part in the primary trial ",
        "statement_nums": [
            "18 suffering from"
        ],
        "label": "Entailment",
        "premise_text": "Inclusion Criteria: Age 18 years or older Exclusion Criteria: Known chronic liver disease ",
        "premise_nums": [
            "18 years or"
        ]
    },
    {
        "id": "93290529-38b1-444b-9ac8-fa32b98821c5",
        "primaryId": "NCT00256243",
        "secondaryId": "NCT00721630",
        "label": "Entailment",
        "statement_text": "Patients wanting to take part in the secondary trial must be at a specific location  this is not necessary for the primary trial ",
        "statement_nums": [],
        "premise_text": "Eligibility Criteria: Patients must be women with a histologically confirmed diagnosis of locally advanced or inflammatory breast carcinoma  Histologic confirmation shall be by either core needle biopsy or incisional biopsy  Punch biopsy is allowed if invasive breast cancer is documented  Patients must meet one of the criteria defined below (indicate one): a .Selected Stage IIB (T3, N0, M0) or IIIA (T3, N1-2, M0) disease judged primarily unresectable by an experienced breast surgeon; or otherwise deemed appropriate candidates for neoadjuvant treatment  b  Stage IIIB (T4, Any N  M0) or (Any T  N3, M0) disease  ",
        "premise_nums": [
            "1-2, M0"
        ]
    },
    {
        "id": "93290529-38b1-444b-9ac8-fa32b98821c5",
        "primaryId": "NCT00256243",
        "secondaryId": "NCT00721630",
        "label": "Entailment",
        "statement_text": "Patients wanting to take part in the secondary trial must be at a specific location  this is not necessary for the primary trial ",
        "statement_nums": [],
        "premise_text": "Physical examination  chest x-ray and any x-rays or scans needed for tumor assessment must be performed within 90 days prior to registration Patients with the clinical diagnosis of congestive heart failure or angina pectoris are NOT eligible  Patients with hypertension or age greater than 60 years must have a Multiple Gated Acquisition (MUGA) or echocardiogram scan performed within 90 days prior to registration (indicate not applicable (NA) if no MUGA required) and Left Ventricular Ejection Fraction (LVEF) % must be greater than the institutional lower limit of normal  ",
        "premise_nums": [
            "60 years must",
            "90 days prior"
        ]
    },
    {
        "id": "93290529-38b1-444b-9ac8-fa32b98821c5",
        "primaryId": "NCT00256243",
        "secondaryId": "NCT00721630",
        "label": "Entailment",
        "statement_text": "Patients wanting to take part in the secondary trial must be at a specific location  this is not necessary for the primary trial ",
        "statement_nums": [],
        "premise_text": "Patients must have a serum creatinine and bilirubin the institutional upper limit of normal  and an Serum glutamic oxaloacetic transaminase (SGOT) or Serum glutamic pyruvic transaminase (SGPT) 2x the institutional upper limit of normal  These tests must have been performed within 90 days prior to registration Patients must have an Absolute neutrophil count (ANC) of 1,500/μl and a platelet count of 100,000/μl. These tests must have been performed within 90 days prior to registration  Patients must have a performance status of 0-2 by Zubrod criteria ",
        "premise_nums": [
            "100,000/μl. These",
            "1,500/μl and",
            "90 days prior",
            "2 by Zubrod",
            "0-2 by"
        ]
    },
    {
        "id": "93290529-38b1-444b-9ac8-fa32b98821c5",
        "primaryId": "NCT00256243",
        "secondaryId": "NCT00721630",
        "label": "Entailment",
        "statement_text": "Patients wanting to take part in the secondary trial must be at a specific location  this is not necessary for the primary trial ",
        "statement_nums": [],
        "premise_text": "Pregnant or nursing women may not participate due to the possibility of fetal harm or of harm to nursing infants from this treatment regimen  Women of reproductive potential may not participate unless they have agreed to use an effective contraceptive method  A urine pregnancy test is required for women of childbearing potential All patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines  Inclusion Criteria: Patients with a diagnosis of invasive adenocarcinoma of the breast confirmed by histology or cytology at MSKCC  ",
        "premise_nums": []
    },
    {
        "id": "dad5ecc6-afcf-496c-8193-778a100c0318",
        "primaryId": "NCT00436917",
        "statement_text": "Patients with Scoliosis with a Cobb angle exceeding 20 degrees at the lumbar spine  or with a prior surgery at the lumbosacral spine are excluded from the primary trial  as these constitute contraindications to spine dual energy x-ray absorptiometry (DXA) ",
        "statement_nums": [
            "20 degrees at"
        ],
        "label": "Entailment",
        "premise_text": "No contraindication to spine dual energy x-ray absorptiometry (DXA) as defined by any of the following: History of surgery at the lumbosacral spine  with or without implantable devices Scoliosis with a Cobb angle greater than 15 degrees at the lumbar spine ",
        "premise_nums": [
            "15 degrees at"
        ]
    },
    {
        "id": "d0efe29c-1d76-4129-9cf5-2955564d1370",
        "primaryId": "NCT00976989",
        "statement_text": "Patients with LVEF greater than or equal to 60% are eligible for the primary trial ",
        "statement_nums": [
            "60% are"
        ],
        "label": "Entailment",
        "premise_text": "Inclusion Criteria: baseline left ventricular ejection fraction (LVEF) greater than /=55% ",
        "premise_nums": []
    },
    {
        "id": "63ec91be-7e12-431e-84b0-ca401bfb157b",
        "primaryId": "NCT01048099",
        "secondaryId": "NCT02502864",
        "label": "Entailment",
        "statement_text": "the primary trial recorded 2.38% more total adverse events than the secondary trial",
        "statement_nums": [
            "recorded 2.38% more total"
        ],
        "premise_text": "Adverse Events 1: Total: 5/14 (35.71%) Adverse Events 1: Total: 3/9 (33.33%) ",
        "premise_nums": [
            "3/9 (33.33%)",
            "5/14 (35.71%)"
        ]
    },
    {
        "id": "fd5af11f-7270-49d5-924a-755ff399c463",
        "primaryId": "NCT00373256",
        "statement_text": "Cohort 1 of the primary trial included 250 patients being treated with Sunitinib and Paclitaxel for a duration of 18 months or until death  and the mean PFS for this group was just under 7 and a half months ",
        "statement_nums": [
            "250 patients being",
            "18 months or",
            "1 of the",
            "7 and a"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Progression-Free Survival (PFS) Time from date of randomization to the date of the first documentation of objective tumor progression or death due to any cause  whichever occurred first  PFS = (first event date minus randomization date +1) divided by 30.4 Time frame: From date of randomization through Day 1 and every 8 weeks thereafter up to 18 months or death Results 1: Arm/Group Title: Sunitinib + Paclitaxel Overall Number of Participants Analyzed: 242 Median (95% Confidence Interval) Unit of Measure: Months 7.4 (6.9 to 8.5) ",
        "premise_nums": [
            "1 and every",
            "9 to 8.5)",
            "95% Confidence",
            "8 weeks thereafter",
            "4 Time frame:",
            "by 30.4 Time frame",
            "18 months or"
        ]
    },
    {
        "id": "f07e932e-1d79-4e1f-9ac2-ed9e2db1c276",
        "primaryId": "NCT02186015",
        "statement_text": "Women in cohort B of the primary trial with serum 25 (OH)D greater than or equal to 30 ng/ml did not receive weekly supplementation of cholecalciferol ",
        "statement_nums": [
            "30 ng/ml did"
        ],
        "label": "Entailment",
        "premise_text": "INTERVENTION 1: Cholecalciferol Enrolled women received 50,000 IUs weekly supplementation of cholecalciferol for 8 weeks  INTERVENTION 2: No Cholecalciferol Enrolled women with serum 25 (OH)D greater than or equal to 30 ng/ml received no intervention  ",
        "premise_nums": [
            "received 50,000 IUs weekly",
            "30 ng/ml received"
        ]
    },
    {
        "id": "6a5ee728-7db9-4ec0-b98c-0500e9a6187e",
        "primaryId": "NCT00924352",
        "statement_text": "One patient in the primary trial had abnormally low levels of AST  ALT and ANC ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 11/56 (19.64%) Febrile Neutropenia * 3/56 (5.36%) Neutropenia * 1/56 (1.79%) Pancytopenia * 1/56 (1.79%) Atrial Fibrillation * 1/56 (1.79%) Coronary Artery Disease * 1/56 (1.79%) Constipation * 1/56 (1.79%) Chest Pain * 1/56 (1.79%) Non-Cardiac Chest Pain * 1/56 (1.79%) Edema due to Cardiac Disease * 1/56 (1.79%) Cellulitis * 1/56 (1.79%) ",
        "premise_nums": [
            "3/56 (5.36%)",
            "1/56 (1.79%)",
            "11/56 (19.64%)"
        ]
    },
    {
        "id": "a495df61-260d-479c-8d5f-d586f295c672",
        "primaryId": "NCT02297412",
        "secondaryId": "NCT02667626",
        "label": "Contradiction",
        "statement_text": "Cohort 2 of the secondary trial and the primary trial are control groups  receiving a placebo tablet PO BID ",
        "statement_nums": [
            "2 of the"
        ],
        "premise_text": "INTERVENTION 1: Arm I (Minocycline Hydrochloride) Patients receive minocycline hydrochloride PO BID on days 1-7. Treatment repeats every 7 days for up to 12 courses in the absence of disease progression or unacceptable toxicity  INTERVENTION 2: Arm II (Placebo) Patients receive a placebo PO BID on days 1-7. Treatment repeats every 7 days for up to 12 courses in the absence of disease progression or unacceptable toxicity  INTERVENTION 1: SCPR Intervention Young breast cancer participants will receive their SCPR and access to additional web-based educational reproductive health information  including resource lists of helpful websites  followed by regular reproductive health prompts and study adherence reminders for 24 weeks  ",
        "premise_nums": [
            "12 courses in",
            "1-7. Treatment",
            "7 days for"
        ]
    },
    {
        "id": "a495df61-260d-479c-8d5f-d586f295c672",
        "primaryId": "NCT02297412",
        "secondaryId": "NCT02667626",
        "label": "Contradiction",
        "statement_text": "Cohort 2 of the secondary trial and the primary trial are control groups  receiving a placebo tablet PO BID ",
        "statement_nums": [
            "2 of the"
        ],
        "premise_text": "Reproductive Health Survivorship Care Plan (SCPR): The reproductive health survivorship care plan (SCPR) is a web-based educational tool that will include information on how to manage various reproductive health issues such as hot flashes  fertility concerns  contraception practices  and sexual function  The intervention also includes additional web-based information and resource lists  text-based reproductive health and study adherenceINTERVENTION 2: Control Young breast cancer participants randomized to the waitlist control arm will receive access to the web-based resources and study adherence reminders  At completion of the 24 weeks of follow up  they will have access to their SCPR  Control: Web-based resource lists and text-based study adherence reminders ",
        "premise_nums": [
            "24 weeks of"
        ]
    },
    {
        "id": "917afeec-5152-4424-89e3-7f3ffad6378f",
        "primaryId": "NCT01105650",
        "statement_text": "Participants in cohort 1 of the primary trial weighing less than 45 kg receive 4 million units/m^2 less of IL-2, than participants over 45 kg  but all participants will be administered IL-2 3 times per week for 6 doses ",
        "statement_nums": [
            "3 times per",
            "45 kg receive",
            "4 million units",
            "1 of the",
            "2 less of"
        ],
        "label": "Entailment",
        "premise_text": "INTERVENTION 1: Arm 1: CsA Fludarabine: Administered intravenously  25 mg/m^2, days -6 through -2 (5 days)  Cyclophosphamide: Administered intravenously  60 mg/kg  days -5 and -4. Cyclosporine (CsA): Administered intravenously  1.5 mg/kg for target dose range of 150-250 ng/mL day -3 through day +14 Natural Killer cells: Administered by infusion over less than 1 hour; no more than 8.0 x 10^7 cells/kg will be given  ",
        "premise_nums": [
            "10^7 cells",
            "60 mg/kg",
            "25 mg/m^2,",
            "14 Natural Killer",
            "1.5 mg/kg",
            "150-250 ng/mL",
            "than 8.0 x 10",
            "3 through day"
        ]
    },
    {
        "id": "917afeec-5152-4424-89e3-7f3ffad6378f",
        "primaryId": "NCT01105650",
        "statement_text": "Participants in cohort 1 of the primary trial weighing less than 45 kg receive 4 million units/m^2 less of IL-2, than participants over 45 kg  but all participants will be administered IL-2 3 times per week for 6 doses ",
        "statement_nums": [
            "3 times per",
            "45 kg receive",
            "4 million units",
            "1 of the",
            "2 less of"
        ],
        "label": "Entailment",
        "premise_text": "Interleukin- 2 (IL-2): Given subcutaneously at 9 million units 3 times a week for a total of 6 doses  beginning 4 hours after NK cell infusion  (For patients weighing less than 45 kilograms  IL-2 will be given at 5 million units/m^2 3 times per week for 6 doses) ",
        "premise_nums": [
            "3 times per",
            "2 will be",
            "3 times a",
            "9 million units",
            "5 million units",
            "4 hours after"
        ]
    },
    {
        "id": "19f84eca-6bb1-4d32-a9b0-b2dd7c3f22e6",
        "primaryId": "NCT01617668",
        "statement_text": "Patients must have healthy kidneys  liver and bone marrow to participate in the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Inclusion Criteria: Adequate bone marrow function Adequate liver function and serum transaminases Adequate renal function ",
        "premise_nums": []
    },
    {
        "id": "f5aa1aa3-7be3-4518-8cc5-df2394e70e96",
        "primaryId": "NCT02244580",
        "secondaryId": "NCT01901146",
        "label": "Contradiction",
        "statement_text": "Patients with undetermined estrogen receptor status can be accepted by both the primary trial and the secondary trial ",
        "statement_nums": [],
        "premise_text": "Inclusion Criteria: Estrogen receptor (ER)  PgR and HER2 expression have been determined Inclusion Criteria: HER2 positive disease Known estrogen receptor (ER) and progesterone receptor (PR) hormone receptor status at study entry ",
        "premise_nums": [
            "2 expression have",
            "2 positive disease"
        ]
    },
    {
        "id": "45338f7c-5aaa-40fb-8503-7c943e1f3a29",
        "primaryId": "NCT03584009",
        "statement_text": "Participants in the primary trial administered with Fulvestrant 500mg via intramuscular injection had a higher % of clinical benefit than participants who were administered an additional 800mg of Venetoclax orally ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Clinical Benefit Defined as Complete Response (CR)  Partial Response (PR) or Stable Disease (SD) Lasting greater than or equal 24 Weeks  as Determined by the Investigator According to RECIST v1.1 ",
        "premise_nums": []
    },
    {
        "id": "0964be32-f9e7-49ec-ad22-b030d483702a",
        "primaryId": "NCT00429507",
        "secondaryId": "NCT00038467",
        "label": "Entailment",
        "statement_text": "Unlike the secondary trial  the primary trial does not administer any medication orally ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Samarium 153-EDTMP + Stem Cell Transplant Samarium 153-EDTMP tracer dose = 30 millicurie (mCi) intravenous Day 1; or with study drug to bones  receive higher therapy dose of 153 Sm-EDTMP 7-14 days after tracer dose  Stem Cell Transplant Day 0, about 14-21 days after Samarium 153-EDTMP. INTERVENTION 1: Exemestane Participants diagnosed with breast cancer who remained disease-free after previously receiving 2 to 3 years of tamoxifen 20 milligram (mg) or 30 mg tablet-in-capsule orally once daily as per standard medical practice  received exemestane (Aromasin) 25 mg tablet-in-capsule orally once daily for the remainder of 5-year period  INTERVENTION 2: Tamoxifen ",
        "premise_nums": [
            "30 millicurie (mCi)",
            "153 Sm-EDTMP",
            "153-EDTMP. INTERVENTION",
            "14 days after",
            "14-21 days",
            "21 days after",
            "25 mg tablet",
            "7-14 days",
            "153-EDTMP +",
            "153-EDTMP tracer",
            "30 mg tablet",
            "5-year period",
            "2 to 3",
            "20 milligram (mg)"
        ]
    },
    {
        "id": "0964be32-f9e7-49ec-ad22-b030d483702a",
        "primaryId": "NCT00429507",
        "secondaryId": "NCT00038467",
        "label": "Entailment",
        "statement_text": "Unlike the secondary trial  the primary trial does not administer any medication orally ",
        "statement_nums": [],
        "premise_text": "Participants diagnosed with breast cancer who remained disease-free after previously receiving 2 to 3 years of tamoxifen 20 mg or 30 mg tablet-in-capsule orally once daily as per standard medical practice  received the same dose of tamoxifen tablet-in-capsule orally once daily for the remainder of 5-year period ",
        "premise_nums": [
            "30 mg tablet",
            "5-year period",
            "20 mg or",
            "2 to 3"
        ]
    },
    {
        "id": "73cfc4ea-afc0-465b-a403-c1bd771ded33",
        "primaryId": "NCT01527487",
        "statement_text": "Patients prescribed Citalopram as an ongoing treatment for depression are not eligible for the primary trial  as Psychological illnesses are not permitted ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria: Histologically confirmed invasive adenocarcinoma of the breast  Primary palpable disease confined to the breast and axilla on physical examination (clinical Stage II or III disease)  For patients without clinically suspicious axillary adenopathy  the primary must be greater than 2 cm in diameter by physical examination or imaging studies (clinical T2-3, N0-2, M0). For patients with clinically suspicious axillary adenopathy  the primary breast tumor can be any size (clinical T1-3, N1-2, M0). Patients who have had axillary node dissection and have pN3a (i.e  10 involved axillary nodes) are also eligible  ",
        "premise_nums": [
            "1-3, N1-2,",
            "2 cm in",
            "10 involved axillary",
            "2-3, N0-2,"
        ]
    },
    {
        "id": "73cfc4ea-afc0-465b-a403-c1bd771ded33",
        "primaryId": "NCT01527487",
        "statement_text": "Patients prescribed Citalopram as an ongoing treatment for depression are not eligible for the primary trial  as Psychological illnesses are not permitted ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Patients entering the trial after undergoing an axillary node dissection will be eligible if they meet other entry criteria Estrogen receptor (ER) and progesterone receptor (PR) status in the primary tumor known or pending at the time of study registration  Resolution of all acute effects of surgical procedures to grade 1. For patients who had or will have  a sentinel node and/or axillary node dissection  completion at least 1 week prior to the initiation of study treatment with a well-healed wound is required  Bilateral  synchronous breast cancer is allowed if both primary tumors are HER2-negative and at least one meets the specified qualifying tumor or nodal inclusion criteria  Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0-2. ",
        "premise_nums": [
            "2-negative and",
            "1 week prior"
        ]
    },
    {
        "id": "73cfc4ea-afc0-465b-a403-c1bd771ded33",
        "primaryId": "NCT01527487",
        "statement_text": "Patients prescribed Citalopram as an ongoing treatment for depression are not eligible for the primary trial  as Psychological illnesses are not permitted ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Patients entering this study must be willing to provide release of tumor tissue collected at baseline during a diagnostic procedure if available  and at the time of future surgical procedure(s) for correlative testing  If tissue is not available  the patient will still be eligible for enrollment to the study No evidence of metastatic disease  as documented by complete staging workup 8 weeks prior to initiation of study treatment  No prior treatment for this breast cancer with the exception of criterion #3. HER2-negative tumor status defined as: Immunohistochemical (IHC) 0-1+ or IHC 2+ or IHC 3+ confirmed as FISH (Fluorescence in situ hybridization) or SISH (Silver in situ hybridization) negative (defined by ratio smaller than 2.2) ",
        "premise_nums": [
            "2-negative tumor",
            "8 weeks prior",
            "0-1+ or"
        ]
    },
    {
        "id": "73cfc4ea-afc0-465b-a403-c1bd771ded33",
        "primaryId": "NCT01527487",
        "statement_text": "Patients prescribed Citalopram as an ongoing treatment for depression are not eligible for the primary trial  as Psychological illnesses are not permitted ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Adequate hematologic function defined as:Absolute neutrophil count (ANC) 1500/μL Hemoglobin (Hgb) 10 g/dL Platelets 100,000/uL Adequate liver function defined as: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) 2.5 x the upper limit of normal (ULN) Total bilirubin the institutional ULN Adequate renal function defined as: Serum creatinine 1.5 mg/dL x ULN OR calculated creatinine clearance 50 mL/min by the Cockcroft-Gault method: ",
        "premise_nums": [
            "creatinine 1.5 mg/dL",
            "10 g/dL Platelets",
            "50 mL/min by",
            "1500/μL Hemoglobin",
            "100,000/uL Adequate",
            "5 x the"
        ]
    },
    {
        "id": "73cfc4ea-afc0-465b-a403-c1bd771ded33",
        "primaryId": "NCT01527487",
        "statement_text": "Patients prescribed Citalopram as an ongoing treatment for depression are not eligible for the primary trial  as Psychological illnesses are not permitted ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "GRF =(140-age) x (weight/kg) x (0.85 if female) (72 x serum creatinine mg/dL)Other laboratory testing: Serum magnesium the institutional lower limit of normal (LLN) Serum potassium the institutional LLN Female and 18 years of age  Negative serum pregnancy test within smaller than 7 days prior to initial trial treatment  Female patients who are not of child-bearing potential  and female patients of child-bearing potential who agree to use adequate contraceptive measures that are approved by their study physician while receiving study treatment and continuing for 3 weeks after the last dose of study drug treatment  who are not breastfeeding  and who have a negative serum pregnancy test prior to start of dosing  Willingness and ability to comply with trial and follow-up procedures  ",
        "premise_nums": [
            "72 x serum",
            "3 weeks after",
            "85 if female)",
            "(140-age) x",
            "7 days prior",
            "18 years of"
        ]
    },
    {
        "id": "73cfc4ea-afc0-465b-a403-c1bd771ded33",
        "primaryId": "NCT01527487",
        "statement_text": "Patients prescribed Citalopram as an ongoing treatment for depression are not eligible for the primary trial  as Psychological illnesses are not permitted ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Ability to understand the nature of this trial and give written informed consent Exclusion Criteria: Clinical T4 lesions  including inflammatory breast cancer  Clinical N3 involvement (e.g.  ipsilateral  infraclavicular  supraclavicular  and internal mammary nodes)  Peripheral neuropathy (motor or sensory) greater than grade 1 according to Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v4.0). Patient has received radiotherapy for treatment of previous cancer that included 30% of major bone marrow containing areas (e.g.  pelvis  lumbar  spine)  ",
        "premise_nums": [
            "30% of",
            "1 according to",
            "3 involvement (e.g."
        ]
    },
    {
        "id": "73cfc4ea-afc0-465b-a403-c1bd771ded33",
        "primaryId": "NCT01527487",
        "statement_text": "Patients prescribed Citalopram as an ongoing treatment for depression are not eligible for the primary trial  as Psychological illnesses are not permitted ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Known or suspected allergy or hypersensitivity to any of the study drugs (i.e.  eribulin  cyclophosphamide  docetaxel) or known hypersensitivity to polysorbate 80.Patients with acute or chronic liver or renal disease or pancreatitis  Known diagnosis of human immunodeficiency virus (HIV)  Hepatitis B (HBV) or Hepatitis C (HCV)  ",
        "premise_nums": []
    },
    {
        "id": "73cfc4ea-afc0-465b-a403-c1bd771ded33",
        "primaryId": "NCT01527487",
        "statement_text": "Patients prescribed Citalopram as an ongoing treatment for depression are not eligible for the primary trial  as Psychological illnesses are not permitted ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Concurrent treatment with an ovarian hormonal replacement therapy or with hormonal agents such as raloxifene  tamoxifen or other selective estrogen receptor modulator (SERM)  Patients must have discontinued use of such agents prior to beginning study treatment  However  use of GNRH agonists for the purpose of fertility preservation or suppression of heavy menses is permitted (see Section 5.4.1).Patient has any of the following cardiac diseases currently or within the last 6 months: Left Ventricular Ejection Fraction (LVEF) smaller than 45% as determined by Multiple Gated acquisition (MUGA) scan or echocardiogram (ECHO) ",
        "premise_nums": [
            "45% as"
        ]
    },
    {
        "id": "73cfc4ea-afc0-465b-a403-c1bd771ded33",
        "primaryId": "NCT01527487",
        "statement_text": "Patients prescribed Citalopram as an ongoing treatment for depression are not eligible for the primary trial  as Psychological illnesses are not permitted ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Heart rate-corrected QT interval (QTc) greater than 480 ms on screening electrocardiogram (ECG) (using Bazett's formula)Unstable angina pectoris Congestive heart failure (New York Heart Association [NYHA] Grade 2 Acute myocardial infarction Conduction abnormality not controlled with pacemaker or medication Significant ventricular or supraventricular arrhythmias (Patients with chronic rate-controlled atrial fibrillation in the absence of other cardiac abnormalities are eligible)  Valvular disease with significant compromise in cardiac function Chronic use of drugs that cause QTc prolongation  Patients must discontinue use of these drugs 7 days prior to the start of study treatment  ",
        "premise_nums": [
            "2 Acute myocardial",
            "7 days prior",
            "480 ms on"
        ]
    },
    {
        "id": "73cfc4ea-afc0-465b-a403-c1bd771ded33",
        "primaryId": "NCT01527487",
        "statement_text": "Patients prescribed Citalopram as an ongoing treatment for depression are not eligible for the primary trial  as Psychological illnesses are not permitted ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Presence of other active cancers  or history of treatment for invasive cancer 5 years  Patients with stage I cancer who have received definitive local treatment at least 3 years previously  and are considered unlikely to recur are eligible  All patients with previously treated in situ carcinoma (i.e  non-invasive) are eligible  as are patients with history of non-melanoma skin cancer Patients may not receive any other investigational or anti-cancer treatments while participating in this trial  Psychological  familial  sociological  or geographical conditions that do not permit compliance with the protocol  Inability or unwillingness to comply with study and/or follow-up procedures outlined in the protocol  ",
        "premise_nums": [
            "3 years previously"
        ]
    },
    {
        "id": "75b67d63-9727-418d-afd5-c0fb867417b5",
        "primaryId": "NCT00876395",
        "statement_text": "Patients suffering from Ulcerative colitis are excluded from the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Exclusion Criteria: Impairment of gastrointestinal (GI) function or GI disease or active ulceration of the upper gastrointestinal tract  ",
        "premise_nums": []
    },
    {
        "id": "94cd9451-35a4-4035-a7de-2d385f771607",
        "primaryId": "NCT01671319",
        "statement_text": "1/42 patients in cohort 2 of the primary trial fainted ",
        "statement_nums": [
            "2 of the",
            "42 patients in",
            "1/42 patients"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 4/42 (9.52%) Perforation  GI 1/42 (2.38%) Febrile neutropenia 1/42 (2.38%) Syncope 1/42 (2.38%) Rash/desquamation 1/42 (2.38%) ",
        "premise_nums": [
            "1/42 (2.38%)",
            "4/42 (9.52%)"
        ]
    },
    {
        "id": "18310f83-54ca-4530-92f1-7c41419ab69e",
        "primaryId": "NCT00068341",
        "statement_text": "More patients in cohort 1 of the primary trial experienced febrile neutropenia than in cohort 2.",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 6/15 (40.00%) diarrhea and dehydration * 0/15 (0.00%) Severe Dehydration * 1/15 (6.67%) hypokalemia * 1/15 (6.67%) pain  swelling  mastectomy site cellulitis * 0/15 (0.00%) death progressive disease * 0/15 (0.00%) divetricular abscess * 0/15 (0.00%) fever * 1/15 (6.67%) febrile neutropenia * 3/15 (20.00%) Neutropenia * 0/15 (0.00%) Adverse Events 2: ",
        "premise_nums": [
            "0/15 (0.00%)",
            "3/15 (20.00%)",
            "1/15 (6.67%)",
            "6/15 (40.00%)"
        ]
    },
    {
        "id": "18310f83-54ca-4530-92f1-7c41419ab69e",
        "primaryId": "NCT00068341",
        "statement_text": "More patients in cohort 1 of the primary trial experienced febrile neutropenia than in cohort 2.",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Total: 4/14 (28.57%)diarrhea and dehydration * 0/14 (0.00%) Severe Dehydration * 0/14 (0.00%) hypokalemia * 0/14 (0.00%) pain  swelling  mastectomy site cellulitis * 0/14 (0.00%) death progressive disease * 1/14 (7.14%) divetricular abscess * 0/14 (0.00%) fever * 0/14 (0.00%) febrile neutropenia * 2/14 (14.29%) Neutropenia * 0/14 (0.00%) ",
        "premise_nums": [
            "2/14 (14.29%)",
            "1/14 (7.14%)",
            "0/14 (0.00%)",
            "4/14 (28.57%)diarrhea"
        ]
    },
    {
        "id": "4fa6b99e-0e70-465d-8b24-b728979b3689",
        "primaryId": "NCT00567190",
        "statement_text": "There was the same number of anemic patinets in both cohorts of the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Anaemia 3/396 (0.76%) Adverse Events 2: Anaemia 3/408 (0.74%) ",
        "premise_nums": [
            "3/396 (0.76%)",
            "3/408 (0.74%)"
        ]
    },
    {
        "id": "e0fac0a4-a5ab-4089-8986-f601586506af",
        "primaryId": "NCT00627978",
        "statement_text": "Women with leptomeningeal metastases are unfortunately excluded from the primary trial  as it would prevent them from giving informed consent to study entry ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Exclusion Criteria Patients with known and active brain and/or leptomeningeal metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events  ",
        "premise_nums": []
    },
    {
        "id": "85210693-996a-4ab9-92f4-62060571da21",
        "primaryId": "NCT01847001",
        "statement_text": "Spanish women with a heart rate of at most 50 beats per minute are eligible for the primary trial ",
        "statement_nums": [
            "50 beats per"
        ],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria: English or Spanish speaking women age 18 Heart Rate greater than 60 bpm ",
        "premise_nums": [
            "18 Heart Rate"
        ]
    },
    {
        "id": "f0fbdbf4-af12-4cde-a5f1-a56cc60658f4",
        "primaryId": "NCT00148668",
        "statement_text": "Cohort 1 and 2 of the primary trial recorded the same number of patients with Neutropenia ",
        "statement_nums": [
            "1 and 2"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 5/41 (12.20%) Neutropenia 4/41 (9.76%) Febrile Neutropenia 0/41 (0.00%) SGPT (ALT) 1/41 (2.44%) Adverse Events 2: Total: 5/40 (12.50%) Neutropenia 4/40 (10.00%) Febrile Neutropenia 1/40 (2.50%) SGPT (ALT) 0/40 (0.00%) ",
        "premise_nums": [
            "0/41 (0.00%)",
            "4/41 (9.76%)",
            "5/41 (12.20%)",
            "4/40 (10.00%)",
            "1/41 (2.44%)",
            "1/40 (2.50%)",
            "5/40 (12.50%)",
            "0/40 (0.00%)"
        ]
    },
    {
        "id": "6a37e999-4b7e-4654-b9ac-7776a0720040",
        "primaryId": "NCT01310231",
        "secondaryId": "NCT00093808",
        "label": "Entailment",
        "statement_text": "1 patient in the secondary trial developed an eating disorder  there were no cases of this happening in the primary trial ",
        "statement_nums": [
            "1 patient in"
        ],
        "premise_text": "Adverse Events 1: Total: 3/22 (13.64%) ascites with hyponatraemia 0/22 (0.00%) febrile neutropenia with respiratory infection 1/22 (4.55%) urosepsis 1/22 (4.55%) febrile neutropenia with urinary tract infection 0/22 (0.00%) dyspnoea 1/22 (4.55%) hypoxia 0/22 (0.00%) thromboembolism 0/22 (0.00%) Adverse Events 2: Total: 4/17 (23.53%) ascites with hyponatraemia 1/17 (5.88%) ",
        "premise_nums": [
            "4/17 (23.53%)",
            "3/22 (13.64%)",
            "0/22 (0.00%)",
            "1/17 (5.88%)",
            "1/22 (4.55%)"
        ]
    },
    {
        "id": "6a37e999-4b7e-4654-b9ac-7776a0720040",
        "primaryId": "NCT01310231",
        "secondaryId": "NCT00093808",
        "label": "Entailment",
        "statement_text": "1 patient in the secondary trial developed an eating disorder  there were no cases of this happening in the primary trial ",
        "statement_nums": [
            "1 patient in"
        ],
        "premise_text": "febrile neutropenia with respiratory infection 0/17 (0.00%)urosepsis 0/17 (0.00%) febrile neutropenia with urinary tract infection 1/17 (5.88%) dyspnoea 0/17 (0.00%) hypoxia 1/17 (5.88%) thromboembolism 1/17 (5.88%) Adverse Events 1: Total: 9/46 (19.57%) Febrile neutropenia 1/46 (2.17%) Cardiac disorder 1/46 (2.17%) Diarrhea 1/46 (2.17%) Upper gastrointestinal hemorrhage 1/46 (2.17%) ",
        "premise_nums": [
            "0/17 (0.00%)urosepsis",
            "9/46 (19.57%)",
            "1/46 (2.17%)",
            "1/17 (5.88%)"
        ]
    },
    {
        "id": "6a37e999-4b7e-4654-b9ac-7776a0720040",
        "primaryId": "NCT01310231",
        "secondaryId": "NCT00093808",
        "label": "Entailment",
        "statement_text": "1 patient in the secondary trial developed an eating disorder  there were no cases of this happening in the primary trial ",
        "statement_nums": [
            "1 patient in"
        ],
        "premise_text": "Chest pain 1/46 (2.17%)Fatigue 1/46 (2.17%) Neutrophil count decreased 2/46 (4.35%) Platelet count decreased 1/46 (2.17%) Anorexia 1/46 (2.17%) Dehydration 1/46 (2.17%) Serum potassium increased 1/46 (2.17%) ",
        "premise_nums": [
            "1/46 (2.17%)Fatigue",
            "2/46 (4.35%)"
        ]
    },
    {
        "id": "a625ff4b-9c91-4ab8-a78b-df833d15759a",
        "primaryId": "NCT00423917",
        "secondaryId": "NCT00082641",
        "label": "Contradiction",
        "statement_text": "the primary trial and the secondary trial both report cases of confusion in all their patient cohorts ",
        "statement_nums": [],
        "premise_text": "Adverse Events 1: Confusion 1/33 (3.03%) Adverse Events 1: Confusion 1/11 (9.09%) Adverse Events 2: Confusion 0/12 (0.00%) ",
        "premise_nums": [
            "0/12 (0.00%)",
            "1/11 (9.09%)",
            "1/33 (3.03%)"
        ]
    },
    {
        "id": "b25e7c40-a1db-4ae7-9613-0f65ddb4c040",
        "primaryId": "NCT00082641",
        "statement_text": "At least one patient in the primary trial suffered from a life threatening bone fracture ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 5/11 (45.45%) Nausea 1/11 (9.09%) Vomiting 1/11 (9.09%) Fever 1/11 (9.09%) skin infection [1]1/11 (9.09%) Hip fracture 0/11 (0.00%) Confusion 1/11 (9.09%) Adverse Events 2: Total: 1/12 (8.33%) Nausea 0/12 (0.00%) Vomiting 0/12 (0.00%) Fever 0/12 (0.00%) skin infection [1]0/12 (0.00%) Hip fracture 1/12 (8.33%) Confusion 0/12 (0.00%) ",
        "premise_nums": [
            "1/11 (9.09%)",
            "0/12 (0.00%)",
            "1/12 (8.33%)",
            "5/11 (45.45%)",
            "0/11 (0.00%)"
        ]
    },
    {
        "id": "25f1f3b8-15ed-4339-bf56-1cf1e0c2909f",
        "primaryId": "NCT00856492",
        "statement_text": "Cohort 1 of the primary trial recorded no deaths and no cases of Anemia ",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 22/96 (22.92%) Anemia 1/96 (1.04%) Febrile neutropenia 4/96 (4.17%) Heart failure 1/96 (1.04%) Abdominal pain 1/96 (1.04%) Dysphagia 1/96 (1.04%) Mucositis oral 1/96 (1.04%) Nausea 1/96 (1.04%) Vomiting 2/96 (2.08%) Death NOS 0/96 (0.00%) Pain 1/96 (1.04%) Catheter related infection 1/96 (1.04%) Enterocolitis infectious 0/96 (0.00%) ",
        "premise_nums": [
            "1/96 (1.04%)",
            "0/96 (0.00%)",
            "22/96 (22.92%)",
            "2/96 (2.08%)",
            "4/96 (4.17%)"
        ]
    },
    {
        "id": "c0ddffa9-4a88-4ee1-8525-a77e887c3d85",
        "primaryId": "NCT01268150",
        "statement_text": "The Eribulin Mesylate group in the primary trial had a higher proportion of patients with complete response (CR) or partial response (PR) than the control group ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Objective Response Rate (ORR) ",
        "premise_nums": []
    },
    {
        "id": "64ea58e5-e28f-42bc-818e-31bbf347080c",
        "primaryId": "NCT00129389",
        "secondaryId": "NCT00304096",
        "label": "Entailment",
        "statement_text": "Patients with permanent sensory loss  interfering with daily activities are excluded from the primary trial  but may still be eligible for the secondary trial ",
        "statement_nums": [],
        "premise_text": "Exclusion Criteria: Pre-existing grade greater than or equal 2 motor or sensorial neurotoxicity by the National Cancer Institute Common Toxicity Criteria (NCICTC) v-2.0. Histologically or cytologically confirmed adenocarcinoma of the breast Stage III or IV disease Primary or recurrent disease Invasive lobular carcinoma allowed HLA-A1, -A2, -A3, or -A31 positive Underwent and recovered from prior primary therapy Patients with no clinical or radiological evidence of disease who had a previous diagnosis of stage III or IV breast cancer must have undergone prior antineoplastic therapy including  but not limited to  surgery  chemotherapy  and radiotherapy within the past 36 months ",
        "premise_nums": [
            "31 positive Underwent",
            "2 motor or",
            "A31 positive"
        ]
    },
    {
        "id": "64ea58e5-e28f-42bc-818e-31bbf347080c",
        "primaryId": "NCT00129389",
        "secondaryId": "NCT00304096",
        "label": "Entailment",
        "statement_text": "Patients with permanent sensory loss  interfering with daily activities are excluded from the primary trial  but may still be eligible for the secondary trial ",
        "statement_nums": [],
        "premise_text": "Must have at least one undissected axillary and/or inguinal lymph node basinNo history of brain metastases Hormone receptor status Estrogen receptor-positive or -negative tumor PATIENT CHARACTERISTICS: ECOG performance status of 0 or 1 Body weight greater than 110 lbs (without clothes) Male or female Menopausal status not specified Absolute neutrophil count greater than 1000/mm^3 Platelet count greater than 100,000/mm^3 Hemoglobin greater than 9 g/dL Hemoglobin A1c smaller than 7% AST and ALT 2.5 x upper limit of normal (ULN) Bilirubin 2.5 x ULN Alkaline phosphatase 2.5 x ULN Creatinine 1.5 x ULN ",
        "premise_nums": [
            "110 lbs (without",
            "100,000/mm^3 Hemoglobin",
            "7% AST",
            "0 or 1",
            "Bilirubin 2.5 x ULN",
            "3 Platelet count",
            "1000/mm^3 Platelet",
            "3 Hemoglobin greater",
            "phosphatase 2.5 x ULN",
            "9 g/dL Hemoglobin",
            "Creatinine 1.5 x ULN",
            "ALT 2.5 x upper"
        ]
    },
    {
        "id": "64ea58e5-e28f-42bc-818e-31bbf347080c",
        "primaryId": "NCT00129389",
        "secondaryId": "NCT00304096",
        "label": "Entailment",
        "statement_text": "Patients with permanent sensory loss  interfering with daily activities are excluded from the primary trial  but may still be eligible for the secondary trial ",
        "statement_nums": [],
        "premise_text": "HIV negativeHepatitis C negative Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception No known or suspected allergies to any component of the vaccine No active infection requiring antibiotics No New York Heart Association class III or IV heart disease No autoimmune disorders requiring cytotoxic or immunosuppressive therapy or autoimmune disorders with visceral involvement  except the following: Laboratory evidence of autoimmune disease (e.g.  positive ANA titer) without symptoms Clinical evidence of vitiligo Other forms of depigmenting illness Mild arthritis requiring nonsteroidal antiinflammatory drugs No medical contraindication or potential problem that would preclude study participation PRIOR CONCURRENT THERAPY: More than 4 weeks since prior surgery ",
        "premise_nums": [
            "4 weeks since"
        ]
    },
    {
        "id": "64ea58e5-e28f-42bc-818e-31bbf347080c",
        "primaryId": "NCT00129389",
        "secondaryId": "NCT00304096",
        "label": "Entailment",
        "statement_text": "Patients with permanent sensory loss  interfering with daily activities are excluded from the primary trial  but may still be eligible for the secondary trial ",
        "statement_nums": [],
        "premise_text": "More than 4 weeks since prior and no concurrent chemotherapy and radiotherapyMore than 4 weeks since prior and no concurrent allergy desensitization injections More than 4 weeks since prior parenteral  oral  or inhaled corticosteroids No concurrent inhaled steroids (e.g.  Advair® or triamcinolone acetonide) Prior or concurrent topical corticosteroids allowed More than 4 weeks since prior and no concurrent growth factors (e.g.  epoetin alfa  darbepoetin alfa  or pegfilgrastim) More than 4 weeks since prior and no concurrent other investigational medication More than 4 weeks since prior and no concurrent other agents with putative immunomodulating activity except for non-steroidal anti-inflammatory agents ",
        "premise_nums": [
            "4 weeks since"
        ]
    },
    {
        "id": "64ea58e5-e28f-42bc-818e-31bbf347080c",
        "primaryId": "NCT00129389",
        "secondaryId": "NCT00304096",
        "label": "Entailment",
        "statement_text": "Patients with permanent sensory loss  interfering with daily activities are excluded from the primary trial  but may still be eligible for the secondary trial ",
        "statement_nums": [],
        "premise_text": "Prior and concurrent hormonal therapy (e.g.  tamoxifen  raloxifene  toremifene  fulvestrant  letrozole  anastrozole  or exemestane) allowedNo prior vaccination with any synthetic peptides in this protocol Vaccines for infectious disease (e.g.  influenza) allowed  provided they are administered 2 weeks prior to or 2 weeks after study vaccine Short term therapy for acute conditions not related to breast cancer allowed No concurrent illegal drugs ",
        "premise_nums": [
            "2 weeks prior",
            "2 weeks after"
        ]
    },
    {
        "id": "7a0f4365-9775-4f1d-a1c7-4630b41b43ea",
        "primaryId": "NCT01905592",
        "statement_text": "the primary trial only defines intervention dosage for cohort 2.",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "INTERVENTION 1: Physician's Choice Physician selection from 4 standard of care metastatic breast cancer chemotherapies (eribulin or vinorelbine or gemcitabine or capecitabine)  until progression or unacceptable toxicity develops  INTERVENTION 2: Niraparib Niraparib 300 mg (3x100 mg capsules) once daily until progression or unacceptable toxicity develops ",
        "premise_nums": [
            "x100 mg",
            "300 mg (3x100",
            "4 standard of"
        ]
    },
    {
        "id": "64dcb690-ef14-4cf2-85e5-670eb0645d7f",
        "primaryId": "NCT01073865",
        "statement_text": "Females over the age of 18, whose last period was 2 weeks prior are eligible for the primary trial ",
        "statement_nums": [
            "2 weeks prior"
        ],
        "label": "Entailment",
        "premise_text": "Inclusion Criteria: Female 20 years and pre-menopausal.Pre-menopausal defined as 1) last menses within 1 year of randomisation  and 2) E2 10 pg/mL and FSH 30 mIU/mL within 4 weeks of randomisation  ",
        "premise_nums": [
            "10 pg/mL and",
            "1 year of",
            "30 mIU/mL within",
            "4 weeks of",
            "20 years and"
        ]
    },
    {
        "id": "cacd1b1b-510e-421b-9adb-c5715f281794",
        "primaryId": "NCT01566721",
        "statement_text": "More patients in cohort 2 of the primary trial had At Least 1 Adverse Event (AE) During the Treatment Period than in cohort 1.",
        "statement_nums": [
            "2 of the",
            "1 Adverse Event"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Percentage of Participants With At Least 1 Adverse Event (AE) During the Treatment Period Participants were planned to receive a total of 18 cycles of SC Herceptin  An AE was defined as any untoward medical occurrence in a participant administered SC Herceptin  Examples included unfavorable/unintended signs and symptoms  new or exacerbated disease  recurrence of intermittent condition  deterioration in laboratory value or other clinical test  or adverse procedure-related events  The percentage of participants with at least 1 AE during the treatment period (regardless of severity or seriousness) was reported  Time frame: From Day 1 up to 19 cycles (cycle length 3 weeks) (approximately 1 year) Results 1: ",
        "premise_nums": [
            "19 cycles (cycle",
            "1 AE during",
            "18 cycles of",
            "1 up to",
            "1 Adverse Event"
        ]
    },
    {
        "id": "cacd1b1b-510e-421b-9adb-c5715f281794",
        "primaryId": "NCT01566721",
        "statement_text": "More patients in cohort 2 of the primary trial had At Least 1 Adverse Event (AE) During the Treatment Period than in cohort 1.",
        "statement_nums": [
            "2 of the",
            "1 Adverse Event"
        ],
        "label": "Contradiction",
        "premise_text": "Arm/Group Title: Cohort A: SC Herceptin by Needle/SyringeArm/Group Description: Participants received SC Herceptin by an assisted administration as 600 mg every 3 weeks for a total of 18 doses/cycles  Each dose of SC Herceptin was taken from a single-use vial and injected by needle/syringe  Overall Number of Participants Analyzed: 1864 Measure Type: Number Unit of Measure: percentage of participants 88.6 Results 2: Arm/Group Title: Cohort B: SC Herceptin by SID ",
        "premise_nums": [
            "1864 Measure Type:",
            "18 doses/cycles",
            "3 weeks for",
            "6 Results 2:",
            "600 mg every",
            "participants 88.6 Results 2"
        ]
    },
    {
        "id": "cacd1b1b-510e-421b-9adb-c5715f281794",
        "primaryId": "NCT01566721",
        "statement_text": "More patients in cohort 2 of the primary trial had At Least 1 Adverse Event (AE) During the Treatment Period than in cohort 1.",
        "statement_nums": [
            "2 of the",
            "1 Adverse Event"
        ],
        "label": "Contradiction",
        "premise_text": "Arm/Group Description: Participants received SC Herceptin as 600 mg every 3 weeks for a total of 18 doses/cycles  Each dose of SC Herceptin was administered from a pre-filled SID  The first administration was performed by an HCP  Subsequent doses were self-administered by participants who were willing and judged competent by the HCP Overall Number of Participants Analyzed: 709 Measure Type: Number Unit of Measure: percentage of participants 89.0 ",
        "premise_nums": [
            "18 doses/cycles",
            "3 weeks for",
            "600 mg every",
            "709 Measure Type:"
        ]
    },
    {
        "id": "c3e5a015-e8b5-4281-828c-deb1f7fc7e3a",
        "primaryId": "NCT02502864",
        "statement_text": "The maximum number of occurences for an adverse event in the primary trial was 3.",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 3/9 (33.33%) Fatigue * 1/9 (11.11%) Non-cardiac chest pain * 1/9 (11.11%) Sepsis * 1/9 (11.11%) Urinary tract infection * 1/9 (11.11%) Syncope * 1/9 (11.11%) Anxiety * 1/9 (11.11%) Thromboembolic event * 1/9 (11.11%) ",
        "premise_nums": [
            "1/9 (11.11%)",
            "3/9 (33.33%)"
        ]
    },
    {
        "id": "7926bfa3-cf49-4589-8143-0a0826336b67",
        "primaryId": "NCT01401166",
        "statement_text": "All patients in cohort 1 of the primary trial had a Preferred Method of Drug Administration ",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Percentage of Participants by Preferred Method of Drug Administration The preferred method of drug administration (IV or SC Herceptin) was assessed in trial-specific telephone interviews with each study participant  Participants were asked  \"All things considered  which method of administration did you prefer?\" at the end of the crossover period (Week 24). The percentage of participants who preferred each method of drug administration was reported  Time frame: Week 24 Results 1: Arm/Group Title: Cohort 1: SC (SID) Then IV Herceptin ",
        "premise_nums": [
            "24 Results 1:"
        ]
    },
    {
        "id": "7926bfa3-cf49-4589-8143-0a0826336b67",
        "primaryId": "NCT01401166",
        "statement_text": "All patients in cohort 1 of the primary trial had a Preferred Method of Drug Administration ",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Arm/Group Description: Participants received Herceptin on Day 1 of each 3-week cycle for 18 cycles  During Cycles 1 to 4 of the crossover period  SC Herceptin was administered via SID  and during Cycles 5 to 8, IV Herceptin was given  In the continuation period  participants received IV Herceptin for up to 10 remaining cycles  Administration was performed by HCP  Those with at least 2 treatment cycles remaining of the 18-cycle treatment course after the crossover period were offered the opportunity to self-administer SC Herceptin via SID under the direction of a trained HCP  The SC dose was 600 mg for all cycles where SC Herceptin was given  and the IV dose was 6 mg/kg for all cycles where IV Herceptin was given Overall Number of Participants Analyzed: 117 ",
        "premise_nums": [
            "5 to 8,",
            "1 of each",
            "1 to 4",
            "10 remaining cycles",
            "3-week cycle",
            "600 mg for",
            "2 treatment cycles",
            "6 mg/kg for",
            "18-cycle treatment"
        ]
    },
    {
        "id": "7926bfa3-cf49-4589-8143-0a0826336b67",
        "primaryId": "NCT01401166",
        "statement_text": "All patients in cohort 1 of the primary trial had a Preferred Method of Drug Administration ",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Measure Type: NumberUnit of Measure: percentage of participants SC Herceptin: 95.7 IV Herceptin: 4.3 No Preference: 0.0 ",
        "premise_nums": [
            "7 IV Herceptin:",
            "3 No Preference:"
        ]
    },
    {
        "id": "1e0da2b7-b91e-4b83-bcb6-7bfafff7e39b",
        "primaryId": "NCT00975676",
        "secondaryId": "NCT00632489",
        "label": "Entailment",
        "statement_text": "the primary trial does not explicitly state the dosage of Triptorelin for either of its patient cohorts  On the other hand  the secondary trial gives details of doses used for LBH589, Capecitabine and Lapatinib ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Triptorelin Plus Tamoxifen Determination of estrogen levels in blood samples from patients being treated with triptorelin plus tamoxifen for 5 years  INTERVENTION 2: Triptorelin Plus Exemestane Determination of estrogen levels in blood samples from patients being treated with triptorelin plus exemestane for 5 years  INTERVENTION 1: LBH589 With Capecitabine MTD  LBH589 with Capecitabine ",
        "premise_nums": [
            "LBH589 With",
            "589 With Capecitabine",
            "589 with Capecitabine",
            "LBH589 with"
        ]
    },
    {
        "id": "1e0da2b7-b91e-4b83-bcb6-7bfafff7e39b",
        "primaryId": "NCT00975676",
        "secondaryId": "NCT00632489",
        "label": "Entailment",
        "statement_text": "the primary trial does not explicitly state the dosage of Triptorelin for either of its patient cohorts  On the other hand  the secondary trial gives details of doses used for LBH589, Capecitabine and Lapatinib ",
        "statement_nums": [],
        "premise_text": "LBH589: LBH589 will be evaluated when administered twice weekly at the following possible dose levels: 20 mg  30 mg  45 mg  and 60 mg  Capecitabine will be paired with LBH589 and will range in dose from 825 mg/m2 to 1250 mg/m2 orally BID 14 of every 21 days  Treatment cycles will be 21 days in length  Once determined safe  10 additional patients will be treated at the determined MTD to further assess safety Capecitabine: Capecitabine will be administered orally twice daily for 14 days out of every 21 days  INTERVENTION 2: LBH589 and Lapatinib ",
        "premise_nums": [
            "589 will be",
            "21 days in",
            "2 to 1250",
            "10 additional patients",
            "589 and Lapatinib",
            "14 days out",
            "14 of every",
            "825 mg/m2 to",
            "589 and will",
            "LBH589 and",
            "1250 mg/m2 orally",
            "LBH589 will",
            "2 orally BID"
        ]
    },
    {
        "id": "1e0da2b7-b91e-4b83-bcb6-7bfafff7e39b",
        "primaryId": "NCT00975676",
        "secondaryId": "NCT00632489",
        "label": "Entailment",
        "statement_text": "the primary trial does not explicitly state the dosage of Triptorelin for either of its patient cohorts  On the other hand  the secondary trial gives details of doses used for LBH589, Capecitabine and Lapatinib ",
        "statement_nums": [],
        "premise_text": "LBH589 and LapatinibLBH589: LBH589 will be evaluated when administered twice weekly at the following possible dose levels: 20 mg  30 mg  45 mg  and 60 mg  Capecitabine will be paired with LBH589 and will range in dose from 825 mg/m2 to 1250 mg/m2 orally BID 14 of every 21 days  Treatment cycles will be 21 days in length  Once determined safe  10 additional patients will be treated at the determined MTD to further assess safety  Lapatinib: Lapatinib  1000 mg PO daily will be added to this combination  ",
        "premise_nums": [
            "1000 mg PO",
            "589 will be",
            "21 days in",
            "2 to 1250",
            "10 additional patients",
            "14 of every",
            "825 mg/m2 to",
            "589 and will",
            "589 and LapatinibLBH589:",
            "LBH589 will",
            "1250 mg/m2 orally",
            "LBH589 and",
            "2 orally BID"
        ]
    },
    {
        "id": "a81e4dbe-e9cf-4f2b-b2f7-b1bf6d630c42",
        "primaryId": "NCT00887575",
        "secondaryId": "NCT01610284",
        "label": "Contradiction",
        "statement_text": "Cohort 1 of the secondary trial had more than 50x the number of patients as cohort 1 of the primary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Adverse Events 1: Total: 3/41 (7.32%) Adverse Events 1: Total: 146/573 (25.48%) ",
        "premise_nums": [
            "146/573 (25.48%)",
            "3/41 (7.32%)"
        ]
    },
    {
        "id": "36957dd8-fe28-4b70-b651-8f6ea7d1d0e9",
        "primaryId": "NCT01269346",
        "secondaryId": "NCT01597193",
        "label": "Contradiction",
        "statement_text": "Cohort 1 of the primary trial and Cohort 1 of the secondary trial have the same total number of adverse events ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Adverse Events 1: Total: 15/52 (28.85%) Adverse Events 1: Total: 2/7 (28.57%) ",
        "premise_nums": [
            "15/52 (28.85%)",
            "2/7 (28.57%)"
        ]
    },
    {
        "id": "1aee22c7-96f2-4ea6-909a-48741f87ba07",
        "primaryId": "NCT01111825",
        "statement_text": "There were no observed cases of Constipation  Diarrhoea  Nausea or Febrile neutropenia within patient cohorts 1 and 2 of the primary trial ",
        "statement_nums": [
            "1 and 2"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 3/8 (37.50%) Anaemia 0/8 (0.00%) Febrile neutropenia 0/8 (0.00%) Polycythaemia 0/8 (0.00%) Acute coronary syndrome 0/8 (0.00%) Vertigo 0/8 (0.00%) Eyelid oedema 1/8 (12.50%) Constipation 0/8 (0.00%) Diarrhoea 0/8 (0.00%) Nausea 0/8 (0.00%) Stomatitis 0/8 (0.00%) ",
        "premise_nums": [
            "0/8 (0.00%)",
            "1/8 (12.50%)",
            "3/8 (37.50%)"
        ]
    },
    {
        "id": "1aee22c7-96f2-4ea6-909a-48741f87ba07",
        "primaryId": "NCT01111825",
        "statement_text": "There were no observed cases of Constipation  Diarrhoea  Nausea or Febrile neutropenia within patient cohorts 1 and 2 of the primary trial ",
        "statement_nums": [
            "1 and 2"
        ],
        "label": "Entailment",
        "premise_text": "Upper gastrointestinal haemorrhage 0/8 (0.00%)Vomiting 0/8 (0.00%) Chest pain 0/8 (0.00%) Adverse Events 2: Total: 2/6 (33.33%) Anaemia 0/6 (0.00%) Febrile neutropenia 0/6 (0.00%) Polycythaemia 0/6 (0.00%) Acute coronary syndrome 0/6 (0.00%) Vertigo 0/6 (0.00%) Eyelid oedema 0/6 (0.00%) Constipation 0/6 (0.00%) ",
        "premise_nums": [
            "2/6 (33.33%)",
            "0/8 (0.00%)Vomiting",
            "0/6 (0.00%)"
        ]
    },
    {
        "id": "1aee22c7-96f2-4ea6-909a-48741f87ba07",
        "primaryId": "NCT01111825",
        "statement_text": "There were no observed cases of Constipation  Diarrhoea  Nausea or Febrile neutropenia within patient cohorts 1 and 2 of the primary trial ",
        "statement_nums": [
            "1 and 2"
        ],
        "label": "Entailment",
        "premise_text": "Diarrhoea 0/6 (0.00%)Nausea 0/6 (0.00%) Stomatitis 0/6 (0.00%) Upper gastrointestinal haemorrhage 0/6 (0.00%) Vomiting 0/6 (0.00%) Chest pain 1/6 (16.67%) ",
        "premise_nums": [
            "0/6 (0.00%)Nausea",
            "1/6 (16.67%)"
        ]
    },
    {
        "id": "d677707e-9ca9-4801-8fcd-7960a9f4f30a",
        "primaryId": "NCT00513695",
        "statement_text": "paclitaxel is the only drug in the primary trial given by IV ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "INTERVENTION 1: Treatment (Neoadjuvant Chemotherapy Before Surgery) Patients receive neoadjuvant chemotherapy comprising sunitinib malate PO once daily and paclitaxel IV over 1 hour once weekly for 8-12 weeks in the absence of disease progression or unacceptable toxicity  Beginning within 3 weeks of completion of sunitinib malate and paclitaxel  patients receive doxorubicin IV once weekly for 15 weeks  cyclophosphamide PO once daily for 15 weeks  and filgrastim SC on days 2-7 for 16 weeks in the absence of disease progression or unacceptable toxicity  Beginning 3-6 weeks after completion of chemotherapy  patients undergo surgery  sunitinib malate: Given PO paclitaxel: Given IV ",
        "premise_nums": [
            "3 weeks of",
            "2-7 for",
            "3-6 weeks",
            "12 weeks in",
            "6 weeks after",
            "8-12 weeks",
            "1 hour once",
            "16 weeks in",
            "7 for 16"
        ]
    },
    {
        "id": "d677707e-9ca9-4801-8fcd-7960a9f4f30a",
        "primaryId": "NCT00513695",
        "statement_text": "paclitaxel is the only drug in the primary trial given by IV ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "doxorubicin hydrochloride: Given IVcyclophosphamide: Given PO filgrastim: Given SC therapeutic conventional surgery: Undergo surgery laboratory biomarker analysis: Correlative studies flow cytometry: Correlative studies ",
        "premise_nums": []
    },
    {
        "id": "5335a9c9-bae1-42e9-9428-eb0eded62d7f",
        "primaryId": "NCT03252145",
        "secondaryId": "NCT00904033",
        "label": "Entailment",
        "statement_text": "None of the subjects in the primary trial are required to injest any pills  whereas both cohorts of the secondary trial must take a weekly tablet ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Manual Lymph Drainage Manual lymph drainage (MLD) treatment 3 times a week for 4 weeks to the lymphedematous upper limb Manual Lymph Drainage (MLD): MLD is a practitioner-applied manual massage technique designed to decrease limb volume in patients with lymphedema by enhancing movement of lymph fluid  resulting in reductions in interstitial fluid  INTERVENTION 2: Negative Pressure PhysioTouch (negative pressure massage) treatment 3 times a week for 4 weeks to the lymphedematous upper limb ",
        "premise_nums": [
            "3 times a",
            "4 weeks to"
        ]
    },
    {
        "id": "5335a9c9-bae1-42e9-9428-eb0eded62d7f",
        "primaryId": "NCT03252145",
        "secondaryId": "NCT00904033",
        "label": "Entailment",
        "statement_text": "None of the subjects in the primary trial are required to injest any pills  whereas both cohorts of the secondary trial must take a weekly tablet ",
        "statement_nums": [],
        "premise_text": "PhysioTouch: The PhysioTouch is a hand-held device that administers negative pressure under the treatment head  and gently pulls the underlying skin and subcutaneous tissue into the suction cup  This suction produces a stretch to the skin and in the subcutaneous tissue space  This action is thought to facilitate lymphatic flow from the interstitium into the lymphatic vessels  and mobilizes the superficial fascia INTERVENTION 1: No Exercise Multivitamin Arm + Calcitriol Arm:Calcitriol pill taken once per week INTERVENTION 2: Exercise Exercise Arm: Exercise consisting of progressive walking and resistance band training Calcitriol+ Exercise Arm: Calcitriol pill taken once per week + Exercise ",
        "premise_nums": []
    },
    {
        "id": "e6c0f7af-b549-4aad-8f3c-15f367a04a50",
        "primaryId": "NCT01307891",
        "statement_text": "Abraxane + Tigatuzumab group of the primary trial has 10% more patients with either Complete Response (CR) disappearance of all target lesions; Partial Response (PR) at least a 30% decrease in the sum of the longest diameter of target lesions than the Abraxane Alone group ",
        "statement_nums": [
            "30% decrease",
            "10% more"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Objective Response Rate Patient response rates will be measured by the Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI  Responses include the following: Complete Response (CR) disappearance of all target lesions; Partial Response (PR) at least a 30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) best response from the start of treatment until disease progression  Time frame: Baseline to 6 months Results 1: Arm/Group Title: Abraxane + Tigatuzumab ",
        "premise_nums": [
            "30% decrease",
            "6 months Results"
        ]
    },
    {
        "id": "e6c0f7af-b549-4aad-8f3c-15f367a04a50",
        "primaryId": "NCT01307891",
        "statement_text": "Abraxane + Tigatuzumab group of the primary trial has 10% more patients with either Complete Response (CR) disappearance of all target lesions; Partial Response (PR) at least a 30% decrease in the sum of the longest diameter of target lesions than the Abraxane Alone group ",
        "statement_nums": [
            "30% decrease",
            "10% more"
        ],
        "label": "Entailment",
        "premise_text": "Arm/Group Description: Patients will receive Abraxane at 100 mg/m2 X 3 doses on Days 1, 8, and 15 at 28-day intervals and tigatuzumab to be administered as a 10 mg/kg loading dose followed by 5 mg/kg for the first cycle and then every other week on Days 1 and 15 for subsequent cycles  Patients will be evaluated for response every 8 weeks  Patients with disease progression will be taken off the study Overall Number of Participants Analyzed: 39 Measure Type: Number Unit of Measure: percentage of patients 28 (14.9 to 45.0) Results 2: ",
        "premise_nums": [
            "100 mg/m2 X",
            "9 to 45.0)",
            "2 X 3",
            "15 at 28",
            "1 and 15",
            "39 Measure Type:",
            "5 mg/kg for",
            "10 mg/kg loading",
            "3 doses on",
            "28-day intervals"
        ]
    },
    {
        "id": "e6c0f7af-b549-4aad-8f3c-15f367a04a50",
        "primaryId": "NCT01307891",
        "statement_text": "Abraxane + Tigatuzumab group of the primary trial has 10% more patients with either Complete Response (CR) disappearance of all target lesions; Partial Response (PR) at least a 30% decrease in the sum of the longest diameter of target lesions than the Abraxane Alone group ",
        "statement_nums": [
            "30% decrease",
            "10% more"
        ],
        "label": "Entailment",
        "premise_text": "Arm/Group Title: Abraxane AloneArm/Group Description: Patients will receive Abraxane at 100 mg/m2 weekly X 3 doses on Days 1, 8, and 15 at 28-day intervals  Abraxane will be administered on an outpatient basis by an IV infusion over 30 minutes  Patients will be evaluated for response every 2 cycles (every 8 weeks)  Overall Number of Participants Analyzed: 21 Measure Type: Number Unit of Measure: percentage of patients 38 (18 to 61.1) ",
        "premise_nums": [
            "2 weekly X",
            "18 to 61.1)",
            "2 cycles (every",
            "21 Measure Type:",
            "15 at 28",
            "100 mg/m2 weekly",
            "3 doses on",
            "28-day intervals"
        ]
    },
    {
        "id": "1fc3aeac-3bc0-4a47-8222-ea267a822804",
        "primaryId": "NCT00929240",
        "statement_text": "There are no cases of Febrile bone marrow aplasia in the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 78/284 (27.46%) Febrile neutropenia * 28/284 (9.86%) Neutropenia * 217/284 (5.99%) Leukopenia * 23/284 (1.06%) Anaemia * 22/284 (0.70%) Thrombocytopenia * 20/284 (0.00%) Myocardial infarction * 20/284 (0.00%) Arrhythmia * 21/284 (0.35%) Atrial fibrillation * 1/284 (0.35%) Coronary artery disease * 20/284 (0.00%) ",
        "premise_nums": [
            "217/284 (5.99%)",
            "21/284 (0.35%)",
            "20/284 (0.00%)",
            "78/284 (27.46%)",
            "23/284 (1.06%)",
            "22/284 (0.70%)",
            "28/284 (9.86%)"
        ]
    },
    {
        "id": "1fc3aeac-3bc0-4a47-8222-ea267a822804",
        "primaryId": "NCT00929240",
        "statement_text": "There are no cases of Febrile bone marrow aplasia in the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Left ventricular dysfunction * 21/284 (0.35%)Adverse Events 2: Total: 7/92 (7.61%) Febrile neutropenia * 0/92 (0.00%) Neutropenia * 20/92 (0.00%) Leukopenia * 20/92 (0.00%) Anaemia * 20/92 (0.00%) Thrombocytopenia * 20/92 (0.00%) Myocardial infarction * 20/92 (0.00%) Arrhythmia * 20/92 (0.00%) Atrial fibrillation * 0/92 (0.00%) Coronary artery disease * 20/92 (0.00%) ",
        "premise_nums": [
            "21/284 (0.35%)Adverse",
            "20/92 (0.00%)",
            "7/92 (7.61%)"
        ]
    },
    {
        "id": "1fc3aeac-3bc0-4a47-8222-ea267a822804",
        "primaryId": "NCT00929240",
        "statement_text": "There are no cases of Febrile bone marrow aplasia in the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Left ventricular dysfunction * 20/92 (0.00%)",
        "premise_nums": [
            "20/92 (0.00%)"
        ]
    },
    {
        "id": "9e664bcb-38cc-4ca6-9738-28d96248b7f2",
        "primaryId": "NCT00320411",
        "statement_text": "the primary trial participants must take 6 tablets of Lapatinib Monotherapy (1500g) PO once daily ",
        "statement_nums": [
            "(1500g) PO",
            "6 tablets of"
        ],
        "label": "Contradiction",
        "premise_text": "INTERVENTION 1: Lapatinib Monotherapy Lapatinib: 1500 mg (six 250 mg tablets) orally once daily ",
        "premise_nums": [
            "1500 mg (six",
            "250 mg tablets)"
        ]
    },
    {
        "id": "1b8403ac-7eb3-41cb-8b7e-a89af3492805",
        "primaryId": "NCT02924883",
        "statement_text": "In the primary trial  all cases of Enteritis  Vertigo and Anaemia occurred in cohort 2.",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 52/133 (39.10%) Thrombocytopenia 2/133 (1.50%) Anaemia 1/133 (0.75%) Disseminated intravascular coagulation 0/133 (0.00%) Atrial thrombosis 1/133 (0.75%) Cardiac failure 0/133 (0.00%) Vertigo 0/133 (0.00%) Vomiting 3/133 (2.26%) Nausea 1/133 (0.75%) Colitis 1/133 (0.75%) Constipation 1/133 (0.75%) Enteritis 0/133 (0.00%) Abdominal pain 0/133 (0.00%) Adverse Events 2: ",
        "premise_nums": [
            "0/133 (0.00%)",
            "52/133 (39.10%)",
            "2/133 (1.50%)",
            "3/133 (2.26%)",
            "1/133 (0.75%)"
        ]
    },
    {
        "id": "1b8403ac-7eb3-41cb-8b7e-a89af3492805",
        "primaryId": "NCT02924883",
        "statement_text": "In the primary trial  all cases of Enteritis  Vertigo and Anaemia occurred in cohort 2.",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Total: 16/67 (23.88%)Thrombocytopenia 0/67 (0.00%) Anaemia 0/67 (0.00%) Disseminated intravascular coagulation 1/67 (1.49%) Atrial thrombosis 0/67 (0.00%) Cardiac failure 1/67 (1.49%) Vertigo 1/67 (1.49%) Vomiting 0/67 (0.00%) Nausea 1/67 (1.49%) Colitis 0/67 (0.00%) Constipation 0/67 (0.00%) Enteritis 1/67 (1.49%) Abdominal pain 2/67 (2.99%) ",
        "premise_nums": [
            "2/67 (2.99%)",
            "1/67 (1.49%)",
            "0/67 (0.00%)",
            "16/67 (23.88%)Thrombocytopenia"
        ]
    },
    {
        "id": "ad853675-40ed-4a65-a401-d09ac3153570",
        "primaryId": "NCT03004534",
        "statement_text": "Participants with T2 N1 M0 breast carcinoma are eligible for the primary trial ",
        "statement_nums": [
            "0 breast carcinoma"
        ],
        "label": "Entailment",
        "premise_text": "Tumor must be confined to either the breast or to the breast and ipsilateral axilla (Note: patinets with multifocal/multicentric tumors are eligible)  Patient must have (according to TNM 7th edition rules): T1 with T 1.0cm, T2 or T3 by at least one radiographic or clinical measurement Either clinically positive (N1 only) or clinically negative axillary nodes (N0) M0 ",
        "premise_nums": [
            "2 or T3",
            "1 with T",
            "(N0) M"
        ]
    },
    {
        "id": "b43bee02-cc3f-4dc8-b13f-8a93de5dc422",
        "primaryId": "NCT00493636",
        "statement_text": "Cohort 1 of the primary trial had a longer median  maximum and minimum pfs than cohort 2.",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Progression Free Survival [Not Specified] Time frame: From the date of randomization to date of first documented disease progression (i.e.  the date on which a radiologic procedure or clinical evaluation was performed) or the date of death due to any cause  if before progression  assessed up to 39 months  Results 1: Arm/Group Title: A (Sorafenib + Gemcitabine or Capecitabine) ",
        "premise_nums": []
    },
    {
        "id": "b43bee02-cc3f-4dc8-b13f-8a93de5dc422",
        "primaryId": "NCT00493636",
        "statement_text": "Cohort 1 of the primary trial had a longer median  maximum and minimum pfs than cohort 2.",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Arm/Group Description: Sorafenib will be administered (400 mg; 2 tablets x 200 mg) orally twice daily (approximately every 12 hours); Gemcitabine will be administered 1000 mg/m2 pm Days 1 and 8 of a 21 day cycle; Capecitabine will be administered orally at a dose of 1,000 mg/m2 twice daily  within 30 minutes after a meal  for 14 days followed by a 7 day rest period (without capecitabine)Gemcitabine: Gemcitabine will be administered 1000 mg/m2 pm Days 1 and 8 of a 21 day cycle Sorafenib: Sorafenib will be administered (400 mg; 2 tablets x 200 mg) orally twice daily (approximately every 12 hours) ",
        "premise_nums": [
            "of 1,000 mg/m2",
            "14 days followed",
            "2 pm Days",
            "1000 mg/m2 pm",
            "1 and 8",
            "21 day cycle;",
            "2 tablets x",
            "2 twice daily",
            "30 minutes after",
            "7 day rest"
        ]
    },
    {
        "id": "b43bee02-cc3f-4dc8-b13f-8a93de5dc422",
        "primaryId": "NCT00493636",
        "statement_text": "Cohort 1 of the primary trial had a longer median  maximum and minimum pfs than cohort 2.",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Capecitabine: Capecitabine will be administered orally at a dose of 1,000 mg/m2 twice daily  within 30 minutes after a meal  for 14 days followed by a 7 day rest period (without capecitabine) Overall Number of Participants Analyzed: 81 Median (95% Confidence Interval) Unit of Measure: Days 103 (83 to 128) Results 2: Arm/Group Title: B (Placebo + Gemcitabine or Capecitabine) ",
        "premise_nums": [
            "of 1,000 mg/m2",
            "14 days followed",
            "95% Confidence",
            "2 twice daily",
            "30 minutes after",
            "7 day rest",
            "83 to 128)"
        ]
    },
    {
        "id": "b43bee02-cc3f-4dc8-b13f-8a93de5dc422",
        "primaryId": "NCT00493636",
        "statement_text": "Cohort 1 of the primary trial had a longer median  maximum and minimum pfs than cohort 2.",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Arm/Group Description: Placebo will be administered ( 2 tablets ) orally twice daily (approximately every 12 hours); Gemcitabine will be administered 1000 mg/m2 pm Days 1 and 8 of a 21 day cycle; Capecitabine will be administered orally at a dose of 1,000 mg/m2 twice daily  within 30 minutes after a meal  for 14 days followed by a 7 day rest period (without capecitabine)Gemcitabine: Gemcitabine will be administered 1000 mg/m2 pm Days 1 and 8 of a 21 day cycle Placebo: Placebo will be administered (400 mg; 2 tablets x 200 mg) orally twice daily (approximately every 12 hours) ",
        "premise_nums": [
            "of 1,000 mg/m2",
            "14 days followed",
            "2 pm Days",
            "1000 mg/m2 pm",
            "1 and 8",
            "21 day cycle;",
            "2 tablets x",
            "2 twice daily",
            "2 tablets )",
            "30 minutes after",
            "7 day rest"
        ]
    },
    {
        "id": "b43bee02-cc3f-4dc8-b13f-8a93de5dc422",
        "primaryId": "NCT00493636",
        "statement_text": "Cohort 1 of the primary trial had a longer median  maximum and minimum pfs than cohort 2.",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Capecitabine: Capecitabine will be administered orally at a dose of 1,000 mg/m2 twice daily  within 30 minutes after a meal  for 14 days followed by a 7 day rest period (without capecitabine) Overall Number of Participants Analyzed: 79 Median (95% Confidence Interval) Unit of Measure: Days 81 (48 to 95) ",
        "premise_nums": [
            "of 1,000 mg/m2",
            "14 days followed",
            "48 to 95)",
            "95% Confidence",
            "2 twice daily",
            "30 minutes after",
            "7 day rest"
        ]
    },
    {
        "id": "62258901-8207-413d-913f-a04682635add",
        "primaryId": "NCT00050011",
        "statement_text": "the primary trial results show that Zoledronic Acid Upfront is a better treatment than Zoledronic Acid Delayed-start for increasing Lumbar Spine (L1-L4) Bone Mineral Density (BMD) ",
        "statement_nums": [
            "1-L4) Bone"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Percent Change From Baseline in Lumbar Spine (L1-L4) Bone Mineral Density (BMD) ",
        "premise_nums": [
            "1-L4) Bone"
        ]
    },
    {
        "id": "62258901-8207-413d-913f-a04682635add",
        "primaryId": "NCT00050011",
        "statement_text": "the primary trial results show that Zoledronic Acid Upfront is a better treatment than Zoledronic Acid Delayed-start for increasing Lumbar Spine (L1-L4) Bone Mineral Density (BMD) ",
        "statement_nums": [
            "1-L4) Bone"
        ],
        "label": "Entailment",
        "premise_text": "Bone mineral density (BMD) measurements were assessed by dual energy x-ray absorptiometry (DXA)  The DXA devices of participating sites were cross-calibrated and the DXA results were compiled and analyzed by a central reader  Percent change = 100*((BMD at Month 12 - Baseline BMD)/Baseline BMD))  Missing data at month 12 were imputed by using the last observation carried forward (LOCF) method  Post-baseline non-missing data from month 6 were carried forward to month 12. Data prior to month 6 were not carried forward Time frame: Baseline  12 months Results 1: ",
        "premise_nums": [
            "6 were not",
            "12 were imputed",
            "6 were carried",
            "12 months Results"
        ]
    },
    {
        "id": "62258901-8207-413d-913f-a04682635add",
        "primaryId": "NCT00050011",
        "statement_text": "the primary trial results show that Zoledronic Acid Upfront is a better treatment than Zoledronic Acid Delayed-start for increasing Lumbar Spine (L1-L4) Bone Mineral Density (BMD) ",
        "statement_nums": [
            "1-L4) Bone"
        ],
        "label": "Entailment",
        "premise_text": "Arm/Group Title: Zoledronic Acid UpfrontArm/Group Description: Participants in the upfront arm received Zoledronic Acid 4 mg i.v  on Day 1 and every 6 months until disease progression (recurrence)or the end of study  Participants also received Letrozole 2.5 daily plus calcium (1000-1200 mg) and vitamin D (400-800 IU) daily  Letrozole : Participants received 2.5 mg daily  Zoledronic Acid : Participants received Zoledronic Acid 4 mg IV 15-minute infusion every 6 months  Overall Number of Participants Analyzed: 253 Mean (Standard Deviation) ",
        "premise_nums": [
            "4 mg i.v",
            "(1000-1200 mg",
            "1 and every",
            "15-minute infusion",
            "253 Mean (Standard",
            "(400-800 IU",
            "Letrozole 2.5 daily plus",
            "4 mg IV",
            "6 months until",
            "received 2.5 mg daily"
        ]
    },
    {
        "id": "62258901-8207-413d-913f-a04682635add",
        "primaryId": "NCT00050011",
        "statement_text": "the primary trial results show that Zoledronic Acid Upfront is a better treatment than Zoledronic Acid Delayed-start for increasing Lumbar Spine (L1-L4) Bone Mineral Density (BMD) ",
        "statement_nums": [
            "1-L4) Bone"
        ],
        "label": "Entailment",
        "premise_text": "Unit of Measure: Percentage of BMD 1.955 (3.3658)Results 2: Arm/Group Title: Zoledronic Acid Delayed-start ",
        "premise_nums": []
    },
    {
        "id": "62258901-8207-413d-913f-a04682635add",
        "primaryId": "NCT00050011",
        "statement_text": "the primary trial results show that Zoledronic Acid Upfront is a better treatment than Zoledronic Acid Delayed-start for increasing Lumbar Spine (L1-L4) Bone Mineral Density (BMD) ",
        "statement_nums": [
            "1-L4) Bone"
        ],
        "label": "Entailment",
        "premise_text": "Arm/Group Description: In lieu of a placebo arm  which was considered unethical for this trial  a delayed start arm was used  Participants who met certain clinical criteria indicating risk of lumbar spine or total hip fracture  or experienced clinical fracture unrelated to trauma or any asymptomatic fracture discovered at the Month 36 scheduled visit  were started on zoledronic acid 4 mg i.v  and for every 6 months until disease progression (recurrence) or end of study  Participants also received Letrozole 2.5 daily plus calcium (1000-1200 mg) and vitamin D (400-800 IU) daily Letrozole : Participants received 2.5 mg daily  ",
        "premise_nums": [
            "36 scheduled visit",
            "4 mg i.v",
            "(1000-1200 mg",
            "(400-800 IU",
            "Letrozole 2.5 daily plus",
            "6 months until",
            "received 2.5 mg daily"
        ]
    },
    {
        "id": "62258901-8207-413d-913f-a04682635add",
        "primaryId": "NCT00050011",
        "statement_text": "the primary trial results show that Zoledronic Acid Upfront is a better treatment than Zoledronic Acid Delayed-start for increasing Lumbar Spine (L1-L4) Bone Mineral Density (BMD) ",
        "statement_nums": [
            "1-L4) Bone"
        ],
        "label": "Entailment",
        "premise_text": "Zoledronic Acid : Participants received Zoledronic Acid 4 mg IV 15-minute infusion every 6 months Overall Number of Participants Analyzed: 256 Mean (Standard Deviation) Unit of Measure: Percentage of BMD -2.325 (3.9542) ",
        "premise_nums": [
            "6 months Overall",
            "4 mg IV",
            "256 Mean (Standard",
            "15-minute infusion"
        ]
    },
    {
        "id": "d23aee47-e80f-42fe-b095-9cd81f9e0ed3",
        "primaryId": "NCT02657889",
        "statement_text": "Both the primary trial cohorts reported identical results ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Phase 1: Number of Subjects Reporting Dose-Limiting Toxicities (DLTs) ",
        "premise_nums": []
    },
    {
        "id": "d23eb56e-c232-4754-94aa-903bc174cb35",
        "primaryId": "NCT00524303",
        "statement_text": "The Trastuzumab arm of the primary trial had 9% better results than the Lapatinib arm ",
        "statement_nums": [
            "9% better"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Percentage of Participants With Overall Pathological Complete Response (pCR) After 26 Weeks of Therapy A pCR in the breast was defined as no pathologic evidence of invasive disease (residual ductal carcinoma in situ [DCIS] or lobular carcinoma in situ [LCIS] was allowed)  A pCR in the axillary lymph node(s) was defined as no evidence of breast cancer cells in the lymph node (including subcapsular sinus)  Overall pCR was defined as the sum of pCR in the breast and pCR in the lymph nodes  26 weeks of therapy comprised the 2-week run-in phase  12 weeks of treatment with FEC  and 12 weeks of treatment with Paclitaxel  Time frame: Week 26 ",
        "premise_nums": [
            "26 Weeks of",
            "2-week run-in",
            "12 weeks of",
            "26 weeks of"
        ]
    },
    {
        "id": "d23eb56e-c232-4754-94aa-903bc174cb35",
        "primaryId": "NCT00524303",
        "statement_text": "The Trastuzumab arm of the primary trial had 9% better results than the Lapatinib arm ",
        "statement_nums": [
            "9% better"
        ],
        "label": "Entailment",
        "premise_text": "Results 1:Arm/Group Title: Trastuzumab ",
        "premise_nums": [
            "1:Arm/Group Title:"
        ]
    },
    {
        "id": "1c0dcd29-4a04-4b78-abbf-b047d4c29597",
        "primaryId": "NCT00562718",
        "statement_text": "Patients with breast implants are always excluded from the primary trial ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Patients having tissue expanders or implants placed prior to radiation may be enrolled at the physician's discretion ",
        "premise_nums": []
    },
    {
        "id": "b1a17048-dfe8-4173-ae80-6ec273244848",
        "primaryId": "NCT01298193",
        "statement_text": "More than 20% of patients in cohort 1 of the primary trial experienced adverse events ",
        "statement_nums": [
            "20% of",
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 31/185 (16.76%) ",
        "premise_nums": [
            "31/185 (16.76%)"
        ]
    },
    {
        "id": "33652443-0bb4-493e-adfe-f5032b96b13d",
        "primaryId": "NCT01808573",
        "statement_text": "the primary trial Patients receiving Neratinib Plus Capecitabine had a PFS much longer than the study time frame of 38 months ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Centrally Assessed Progression Free Survival ",
        "premise_nums": []
    },
    {
        "id": "74dba58a-8f5d-478b-a886-0e9758847fe3",
        "primaryId": "NCT00228943",
        "statement_text": "Clinically anxious patients are not able to participate in the primary trial ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Exclusion Criteria: Exclusion criteria are current depression  history of migraines or hepatitis  abnormal chemistry profile (e.g.  sodium  potassium  glucose)  or a positive urine drug screen for illegal substances  ",
        "premise_nums": []
    },
    {
        "id": "5344044c-127d-4a39-80dc-277538b5ad33",
        "primaryId": "NCT02131064",
        "statement_text": "less than 60 participants in the TCH + P group of the primary trial achieved Total Pathological Complete Response (tpCR) Assessed Based on Tumor Samples ",
        "statement_nums": [
            "60 participants in"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Percentage of Participants With Total Pathological Complete Response (tpCR) Assessed Based on Tumor Samples tpCR was assessed by local pathology review on samples taken at surgery following completion of neoadjuvant therapy  tpCR was defined as the absence of any residual invasive cancer on hematoxylin and eosin evaluation of the resected breast specimen and all sampled ipsilateral lymph nodes ( that is [i.e.]  ypT0/is, ypN0 in the American Joint Committee on Cancer [AJCC] staging system  7th edition)  Percentage of participants with tpCR was reported  Time frame: Pre-surgery (within 6 weeks after neoadjuvant therapy; up to approximately 6 months) Results 1: ",
        "premise_nums": [
            "6 weeks after",
            "0 in the",
            "0/is, ypN0"
        ]
    },
    {
        "id": "5344044c-127d-4a39-80dc-277538b5ad33",
        "primaryId": "NCT02131064",
        "statement_text": "less than 60 participants in the TCH + P group of the primary trial achieved Total Pathological Complete Response (tpCR) Assessed Based on Tumor Samples ",
        "statement_nums": [
            "60 participants in"
        ],
        "label": "Contradiction",
        "premise_text": "Arm/Group Title: TCH + P",
        "premise_nums": []
    },
    {
        "id": "ed43519d-9954-4e0f-9d42-39a3ed81e4a5",
        "primaryId": "NCT00820872",
        "statement_text": "Hyperglycemia was the most common adverse event in cohort 1 of the primary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 10/30 (33.33%) Hemoglobin decreased 2/30 (6.67%) Abdominal pain 1/30 (3.33%) Colitis 1/30 (3.33%) Diarrhea 7/30 (23.33%) Nausea 2/30 (6.67%) Rectal hemorrhage 1/30 (3.33%) Fatigue 1/30 (3.33%) Skin infection 1/30 (3.33%) Neutrophil count decreased 1/30 (3.33%) Platelet count decreased 3/30 (10.00%) Dehydration 1/30 (3.33%) ",
        "premise_nums": [
            "10/30 (33.33%)",
            "3/30 (10.00%)",
            "7/30 (23.33%)",
            "1/30 (3.33%)",
            "2/30 (6.67%)"
        ]
    },
    {
        "id": "8d2fde27-a5e8-40ee-a35d-3d4697198a4e",
        "primaryId": "NCT00929240",
        "statement_text": "There are no cases of Febrile neutropenia in the primary trial ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 78/284 (27.46%) Febrile neutropenia * 28/284 (9.86%) Neutropenia * 217/284 (5.99%) Leukopenia * 23/284 (1.06%) Anaemia * 22/284 (0.70%) Thrombocytopenia * 20/284 (0.00%) Myocardial infarction * 20/284 (0.00%) Arrhythmia * 21/284 (0.35%) Atrial fibrillation * 1/284 (0.35%) Coronary artery disease * 20/284 (0.00%) ",
        "premise_nums": [
            "217/284 (5.99%)",
            "21/284 (0.35%)",
            "20/284 (0.00%)",
            "78/284 (27.46%)",
            "23/284 (1.06%)",
            "22/284 (0.70%)",
            "28/284 (9.86%)"
        ]
    },
    {
        "id": "8d2fde27-a5e8-40ee-a35d-3d4697198a4e",
        "primaryId": "NCT00929240",
        "statement_text": "There are no cases of Febrile neutropenia in the primary trial ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Left ventricular dysfunction * 21/284 (0.35%)Adverse Events 2: Total: 7/92 (7.61%) Febrile neutropenia * 0/92 (0.00%) Neutropenia * 20/92 (0.00%) Leukopenia * 20/92 (0.00%) Anaemia * 20/92 (0.00%) Thrombocytopenia * 20/92 (0.00%) Myocardial infarction * 20/92 (0.00%) Arrhythmia * 20/92 (0.00%) Atrial fibrillation * 0/92 (0.00%) Coronary artery disease * 20/92 (0.00%) ",
        "premise_nums": [
            "21/284 (0.35%)Adverse",
            "20/92 (0.00%)",
            "7/92 (7.61%)"
        ]
    },
    {
        "id": "8d2fde27-a5e8-40ee-a35d-3d4697198a4e",
        "primaryId": "NCT00929240",
        "statement_text": "There are no cases of Febrile neutropenia in the primary trial ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Left ventricular dysfunction * 20/92 (0.00%)",
        "premise_nums": [
            "20/92 (0.00%)"
        ]
    },
    {
        "id": "fc0da76b-e5b5-44e3-abaf-6231fff493c3",
        "primaryId": "NCT00676663",
        "statement_text": "The the primary trial placebo group performed worse than the test group ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Progression-free Survival (PFS) PFS is defined as the number of months from the date of randomization to the earlier of progressive disease (PD) or death due to any cause  Time frame: From date of randomization to discontinuation due to disease progression or death up to primary completion date (Median follow-up 6 months) Results 1: Arm/Group Title: Exemestane 25 mg + Placebo Arm/Group Description: Exemestane (Aromasin ) 25 mg tablets orally once daily plus a placebo-matching entinostat tablet orally once per week on Days 1, 8, 15 and 22 of each 28-day treatment cycle until development of progressive disease (PD) or unacceptable toxicity or closure of the study by the Sponsor  whichever occurred first  Overall Number of Participants Analyzed: 66 Median (95% Confidence Interval) ",
        "premise_nums": [
            "15 and 22",
            "95% Confidence",
            "25 mg tablets",
            "28-day treatment"
        ]
    },
    {
        "id": "fc0da76b-e5b5-44e3-abaf-6231fff493c3",
        "primaryId": "NCT00676663",
        "statement_text": "The the primary trial placebo group performed worse than the test group ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Unit of Measure: months 2.27 (1.81 to 3.68)Results 2: Arm/Group Title: Exemestane 25 mg + Entinostat 5 mg Arm/Group Description: Exemestane (Aromasin ) 25 mg tablets orally once daily plus an entinostat 5 mg tablet orally once per week on Days 1, 8, 15 and 22 of each 28-day treatment cycle until development of progressive disease (PD) or unacceptable toxicity or closure of the study by the Sponsor  whichever occurred first  Overall Number of Participants Analyzed: 64 Median (95% Confidence Interval) Unit of Measure: months 4.28 (3.26 to 5.36) ",
        "premise_nums": [
            "81 to 3.68)Results",
            "95% Confidence",
            "26 to 5.36)",
            "15 and 22",
            "5 mg Arm",
            "25 mg tablets",
            "28-day treatment"
        ]
    },
    {
        "id": "1a32e1c1-31b1-40e5-bbb6-84041ef796fe",
        "primaryId": "NCT00119262",
        "statement_text": "cohorts 1 and 2 of the primary trial both had 3 patients that suffered from Congestive Heart Failure ",
        "statement_nums": [
            "1 and 2",
            "3 patients that"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Congestive Heart Failure Rate Clinical congestive heart failure includes patients with symptomatic decline in LVEF to at or below the lower limit of normal (LLN)  or symptomatic diastolic dysfunction  223 treated patients were included in the analysis  Time frame: assessed on day 1 of cycles 5, 9, 17 and 25, and at end of treatment  then every 3 months for smaller than 2 years and every 6 months for 2-3 years from study entry Results 1: Arm/Group Title: Arm A (ddBAC greater than BT greater than B) ",
        "premise_nums": [
            "3 years from",
            "2 years and",
            "17 and 25,",
            "6 months for",
            "3 months for",
            "223 treated patients",
            "2-3 years",
            "1 of cycles"
        ]
    },
    {
        "id": "1a32e1c1-31b1-40e5-bbb6-84041ef796fe",
        "primaryId": "NCT00119262",
        "statement_text": "cohorts 1 and 2 of the primary trial both had 3 patients that suffered from Congestive Heart Failure ",
        "statement_nums": [
            "1 and 2",
            "3 patients that"
        ],
        "label": "Entailment",
        "premise_text": "Arm/Group Description: Dose dense bevacizumab  cyclophosphamide and doxorubicin  followed by paclitaxel and bevacizumab  followed by bevacizumabOverall Number of Participants Analyzed: 103 Measure Type: Number Unit of Measure: percentage of participants 2.9 (0.6 to 8.3) Results 2: Arm/Group Title: Arm B (ddAC greater than BT greater than B) Arm/Group Description: Dose dense doxorubicin and cyclophosphamide  followed by paclitaxel and bevacizumab  followed by bevacizumab Overall Number of Participants Analyzed: 120 Measure Type: Number ",
        "premise_nums": [
            "120 Measure Type:",
            "6 to 8.3)",
            "103 Measure Type:"
        ]
    },
    {
        "id": "1a32e1c1-31b1-40e5-bbb6-84041ef796fe",
        "primaryId": "NCT00119262",
        "statement_text": "cohorts 1 and 2 of the primary trial both had 3 patients that suffered from Congestive Heart Failure ",
        "statement_nums": [
            "1 and 2",
            "3 patients that"
        ],
        "label": "Entailment",
        "premise_text": "Unit of Measure: percentage of participants 2.5 (0.5 to 7.1)",
        "premise_nums": []
    },
    {
        "id": "9a31db67-e28a-4114-a308-e899f9c22813",
        "primaryId": "NCT02291913",
        "statement_text": "One patient in the primary trial suffered from an inflammation of the esophagus ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 15/48 (31.25%) Anemia * 1/48 (2.08%) Cardiac failure congestive * 1/48 (2.08%) Constipation * 2/48 (4.17%) Esophagitis * 1/48 (2.08%) Gastrointestinal hemorrhage * 1/48 (2.08%) Non-Cardiac chest pain * 1/48 (2.08%) Pain * 1/48 (2.08%) Cholecystitis * 1/48 (2.08%) Diverticulitis * 1/48 (2.08%) Cellulitis * 1/48 (2.08%) Gastroenteritis * 1/48 (2.08%) ",
        "premise_nums": [
            "2/48 (4.17%)",
            "15/48 (31.25%)",
            "1/48 (2.08%)"
        ]
    },
    {
        "id": "f948a2d1-2e22-47c8-9345-0eb68569bd3f",
        "primaryId": "NCT00996632",
        "secondaryId": "NCT01644890",
        "label": "Entailment",
        "statement_text": "Emily has an Inoperable breast cancer  she is eligible for both the secondary trial and the primary trial ",
        "statement_nums": [],
        "premise_text": "Inclusion Criteria: Inoperable breast cancer Inclusion Criteria: Written informed consent of the patient signed by herself  Histologically confirmed metastatic or recurrent adenocarcinoma of the breast  Aged 20 to 74 at the time of informed consent  Exclusion Criteria: Prior systemic chemotherapy with taxane anticancer drugs for metastatic or recurrent breast cancer  ",
        "premise_nums": [
            "20 to 74"
        ]
    },
    {
        "id": "e3265040-8316-4f62-969c-27af396ba18c",
        "primaryId": "NCT00479674",
        "statement_text": "Patients that have previously been trated with bevacizumab are not eligible for the primary trial  unless they have also received carboplatin 2 weeks prior to study entry ",
        "statement_nums": [
            "2 weeks prior"
        ],
        "label": "Contradiction",
        "premise_text": "Exclusion Criteria: Prior treatment with Abraxane®  carboplatin or bevacizumab  or any taxane for metastatic breast cancer; ",
        "premise_nums": []
    },
    {
        "id": "6c25e195-47cd-48af-bb51-5b5c44772baa",
        "primaryId": "NCT00656019",
        "statement_text": "Candidates with hyperparathyroidism are automatically excluded from the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "EXCLUSION CRITERIA: History of parathyroid disease  hypercalcemia  or kidney stones  ",
        "premise_nums": []
    },
    {
        "id": "382747d3-69df-41be-a771-4218407ce5d3",
        "primaryId": "NCT00171340",
        "statement_text": "the primary trial results imply that Zoledronic Acid 4 mg Upfront causes a +ve Change in Bone Mineral Density  whereas Zoledronic Acid 4 mg Delayed causes a loss in Bone Mineral Density (within a certain patient demographic) ",
        "statement_nums": [
            "4 mg Delayed",
            "4 mg Upfront"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Percentage Change in Bone Mineral Density (BMD) of the Lumbar Spine (L2-L4) at 12 Months of Therapy  Bone Mineral Density (g/cm^2) of the Lumbar Spine (L2-L4) as measured by energy x-ray absorptiometry (DXA)  Time frame: Baseline  12 months Results 1: Arm/Group Title: Zoledronic Acid 4 mg Upfront ",
        "premise_nums": [
            "2-L4) at",
            "12 months Results",
            "2-L4) as",
            "12 Months of",
            "4 mg Upfront"
        ]
    },
    {
        "id": "382747d3-69df-41be-a771-4218407ce5d3",
        "primaryId": "NCT00171340",
        "statement_text": "the primary trial results imply that Zoledronic Acid 4 mg Upfront causes a +ve Change in Bone Mineral Density  whereas Zoledronic Acid 4 mg Delayed causes a loss in Bone Mineral Density (within a certain patient demographic) ",
        "statement_nums": [
            "4 mg Delayed",
            "4 mg Upfront"
        ],
        "label": "Entailment",
        "premise_text": "Arm/Group Description: Zolendronic acid 4 mg Intravenous (IV) 15 minute infusion every 6 months for 5 years beginning on Day 1. All participants took Letrozole tablets 2.5 mg/day for 5 years beginning on Day 1.Overall Number of Participants Analyzed: 423 Mean (Standard Deviation) Unit of Measure: Percentage change in BMD 2.208 (3.4194) Results 2: Arm/Group Title: Zoledronic Acid 4 mg Delayed ",
        "premise_nums": [
            "tablets 2.5 mg/day",
            "15 minute infusion",
            "423 Mean (Standard",
            "6 months for",
            "5 years beginning",
            "4 mg Delayed",
            "4 mg Intravenous"
        ]
    },
    {
        "id": "382747d3-69df-41be-a771-4218407ce5d3",
        "primaryId": "NCT00171340",
        "statement_text": "the primary trial results imply that Zoledronic Acid 4 mg Upfront causes a +ve Change in Bone Mineral Density  whereas Zoledronic Acid 4 mg Delayed causes a loss in Bone Mineral Density (within a certain patient demographic) ",
        "statement_nums": [
            "4 mg Delayed",
            "4 mg Upfront"
        ],
        "label": "Entailment",
        "premise_text": "Arm/Group Description: Zolendronic acid 4 mg Intravenous (IV) 15 minute infusion every 6 months beginning when one of the following occurred: BMD T-score smaller than = -2.0 SD at either the lumbar spine or total hip  any clinical fracture unrelated to trauma or an asymptomatic fracture discovered at the Month 36 visit  All participants took Letrozole tablets 2.5 mg/day for 5 years beginning on Day 1.Overall Number of Participants Analyzed: 418 Mean (Standard Deviation) Unit of Measure: Percentage change in BMD -3.617 (4.2151) ",
        "premise_nums": [
            "tablets 2.5 mg/day",
            "15 minute infusion",
            "5 years beginning",
            "6 months beginning",
            "418 Mean (Standard",
            "0 SD at",
            "4 mg Intravenous"
        ]
    },
    {
        "id": "d05ec90a-f267-44be-aaa6-3be960a0d50c",
        "primaryId": "NCT00376688",
        "statement_text": "Most the primary trial subjects experienced a complete response (CR)  partial response (PR)  or stable disease (SD) for at least 24 weeks ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Clinical Benefit Rate (Complete Response  Partial Response  or Stable Disease) Response evaluation criteria in solid tumors (RECIST) criteria version 1.0 was used for response evaluation  Clinical benefit rate is defined as the proportion of subjects experiencing a complete response (CR)  partial response (PR)  or stable disease (SD) for at least 24 weeks  Evaluation of target lesions: Complete Response (CR)-- Disappearance of all target lesions; Partial Response (PR)-- At least a 30% decrease in the sum of the LD of target lesions  taking as reference the baseline sum LD; Stable Disease (SD)-- Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD  taking as reference the smallest sum LD since the treatment started; ",
        "premise_nums": [
            "30% decrease",
            "version 1.0 was used"
        ]
    },
    {
        "id": "d05ec90a-f267-44be-aaa6-3be960a0d50c",
        "primaryId": "NCT00376688",
        "statement_text": "Most the primary trial subjects experienced a complete response (CR)  partial response (PR)  or stable disease (SD) for at least 24 weeks ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Evaluation of non-target lesions: Complete Response (CR)-- Disappearance of all non-target lesions and normalization of tumor marker level; Incomplete Response/ Stable Disease (SD)-- Persistence of one or more non-target lesion(s) or/and maintenance of tumor marker level above the normal limitsTime frame: Up to 24 months Results 1: Arm/Group Title: Treatment (Temsirolimus) Arm/Group Description: Patients receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity  Temsirolimus: Given IV Overall Number of Participants Analyzed: 31 Measure Type: Number Unit of Measure: percentage of participants 9.7 ",
        "premise_nums": [
            "28 days in",
            "30 minutes on",
            "31 Measure Type:",
            "24 months Results"
        ]
    },
    {
        "id": "37301690-9b68-48de-b280-6307e632043e",
        "primaryId": "NCT02301988",
        "secondaryId": "NCT00728949",
        "label": "Entailment",
        "statement_text": "The only types of adverse events recorded by both the secondary trial and the primary trial is Diarrhoea and various pains  ",
        "statement_nums": [],
        "premise_text": "Adverse Events 1: Total: 10/76 (13.16%) Sickle cell anaemia with crisis 1/76 (1.32%) Diarrhoea 1/76 (1.32%) Pyrexia 1/76 (1.32%) Chest pain 1/76 (1.32%) Complication associated with device 1/76 (1.32%) General physical health deterioration 0/76 (0.00%) Device related infection 2/76 (2.63%) Pneumonia 1/76 (1.32%) Atypical pneumonia 1/76 (1.32%) Dehydration 1/76 (1.32%) Adverse Events 2: Total: 3/75 (4.00%) ",
        "premise_nums": [
            "10/76 (13.16%)",
            "3/75 (4.00%)",
            "1/76 (1.32%)",
            "0/76 (0.00%)",
            "2/76 (2.63%)"
        ]
    },
    {
        "id": "37301690-9b68-48de-b280-6307e632043e",
        "primaryId": "NCT02301988",
        "secondaryId": "NCT00728949",
        "label": "Entailment",
        "statement_text": "The only types of adverse events recorded by both the secondary trial and the primary trial is Diarrhoea and various pains  ",
        "statement_nums": [],
        "premise_text": "Sickle cell anaemia with crisis 0/75 (0.00%)Diarrhoea 0/75 (0.00%) Pyrexia 1/75 (1.33%) Chest pain 0/75 (0.00%) Complication associated with device 0/75 (0.00%) General physical health deterioration 1/75 (1.33%) Device related infection 0/75 (0.00%) Pneumonia 1/75 (1.33%) Atypical pneumonia 0/75 (0.00%) Dehydration 0/75 (0.00%) Adverse Events 1: Total: 16/56 (28.57%) Pancytopenia 0/56 (0.00%) ",
        "premise_nums": [
            "0/75 (0.00%)Diarrhoea",
            "16/56 (28.57%)",
            "1/75 (1.33%)",
            "0/56 (0.00%)"
        ]
    },
    {
        "id": "37301690-9b68-48de-b280-6307e632043e",
        "primaryId": "NCT02301988",
        "secondaryId": "NCT00728949",
        "label": "Entailment",
        "statement_text": "The only types of adverse events recorded by both the secondary trial and the primary trial is Diarrhoea and various pains  ",
        "statement_nums": [],
        "premise_text": "Pericarditis 0/56 (0.00%)Abdominal pain 1/56 (1.79%) Anal fissure 1/56 (1.79%) Ascites 1/56 (1.79%) Constipation 0/56 (0.00%) Diarrhoea 1/56 (1.79%) Nausea 0/56 (0.00%) Oesophageal pain 0/56 (0.00%) Vomiting 0/56 (0.00%) Disease progression 2/56 (3.57%) Infusion related reaction 1/56 (1.79%) Pain 0/56 (0.00%) Adverse Events 2: Total: 11/37 (29.73%) ",
        "premise_nums": [
            "11/37 (29.73%)",
            "0/56 (0.00%)Abdominal",
            "1/56 (1.79%)",
            "2/56 (3.57%)"
        ]
    },
    {
        "id": "37301690-9b68-48de-b280-6307e632043e",
        "primaryId": "NCT02301988",
        "secondaryId": "NCT00728949",
        "label": "Entailment",
        "statement_text": "The only types of adverse events recorded by both the secondary trial and the primary trial is Diarrhoea and various pains  ",
        "statement_nums": [],
        "premise_text": "Pancytopenia 1/37 (2.70%)Pericarditis 1/37 (2.70%) Abdominal pain 2/37 (5.41%) Anal fissure 0/37 (0.00%) Ascites 0/37 (0.00%) Constipation 1/37 (2.70%) Diarrhoea 1/37 (2.70%) Nausea 2/37 (5.41%) Oesophageal pain 1/37 (2.70%) Vomiting 2/37 (5.41%) Disease progression 2/37 (5.41%) Infusion related reaction 0/37 (0.00%) Pain 1/37 (2.70%) ",
        "premise_nums": [
            "2/37 (5.41%)",
            "0/37 (0.00%)",
            "1/37 (2.70%)Pericarditis"
        ]
    },
    {
        "id": "b61e798c-d38f-4c72-91bb-4d3e28b6184c",
        "primaryId": "NCT00356148",
        "secondaryId": "NCT01856543",
        "label": "Entailment",
        "statement_text": "Women of any age can participate in the primary trial  but only adults can be eligible for the secondary trial ",
        "statement_nums": [],
        "premise_text": "Inclusion Criteria: Women at any age with early stage breast cancer (stage I-II) and American Society of Anesthesiologists (ASA) score of I-II  Inclusion Criteria: Age 18 years ",
        "premise_nums": []
    },
    {
        "id": "3ca27248-0728-4b10-b940-6e2603acef30",
        "primaryId": "NCT00201760",
        "secondaryId": "NCT00127933",
        "label": "Entailment",
        "statement_text": "Patients must have an infiltrating breast carcinoma to participate in the secondary trial or the primary trial ",
        "statement_nums": [],
        "premise_text": "Eligibility Criteria: Must have invasive metastatic breast cancer Inclusion Criteria: infiltrating (invasive) HER2-neu-negative or HER2-neu-positive breast cancer  ",
        "premise_nums": [
            "2-neu-negative or",
            "2-neu-positive breast"
        ]
    },
    {
        "id": "c2da6504-96a1-4669-b609-16731a5330d3",
        "primaryId": "NCT00248170",
        "secondaryId": "NCT01299038",
        "label": "Entailment",
        "statement_text": "Ae-Cha is a 32 year old Korean woman with an inoperable breast cancer  she is ineligible for both the secondary trial and the primary trial ",
        "statement_nums": [
            "32 year old"
        ],
        "premise_text": "Inclusion Criteria: Recent primary surgery for breast cancer Exclusion Criteria: Asian decent (including Filipino  Chinese  Japanese  Korean  Vietnamese or Asian-Indian origin) ",
        "premise_nums": []
    },
    {
        "id": "646959e4-25d0-4eb1-b7b0-2d7b1e02e132",
        "primaryId": "NCT01262027",
        "statement_text": "Less than 5% of patients in the primary trial suffered an adverse event ",
        "statement_nums": [
            "5% of"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 1/22 (4.55%) Blood bilirubin increased 1/22 (4.55%) Alkaline phosphatase increased 1/22 (4.55%) ",
        "premise_nums": [
            "1/22 (4.55%)"
        ]
    },
    {
        "id": "0e6eebe9-46c2-4fa5-b9ed-e0997044960b",
        "primaryId": "NCT01293032",
        "secondaryId": "NCT00849472",
        "label": "Contradiction",
        "statement_text": "None of the patients in the primary trial or the secondary trial are required to undergo radiotherapy or surgery ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Group 2 (RS 11-25) Patients with an intermediate RS (11-25) were assigned to Group 2. The subject was then randomized to treatment Arm 1, neoadjuvant hormonal therapy  or treatment Arm 2, neoadjuvant chemotherapy  INTERVENTION 1: AC  Followed by Weekly Paclitaxel and Concurrent Pazopanib ",
        "premise_nums": [
            "(11-25) were",
            "11-25) Patients"
        ]
    },
    {
        "id": "0e6eebe9-46c2-4fa5-b9ed-e0997044960b",
        "primaryId": "NCT01293032",
        "secondaryId": "NCT00849472",
        "label": "Contradiction",
        "statement_text": "None of the patients in the primary trial or the secondary trial are required to undergo radiotherapy or surgery ",
        "statement_nums": [],
        "premise_text": "Participants were treated with intravenous (IV) doxorubicin (60 milligrams per meters squared [mg/m^2]) and cyclophosphamide (AC) (600 mg/m^2) every 21 days for 4 cycles  This was followed by weekly paclitaxel (WP) 80 mg/m^2 IV on Days 1, 8, and 15 every 28 days for 4 cycles given concurrently with oral pazopanib 800 mg (2 tablets taken at the same time each day  either 1 hour before or 2 hours after a meal) taken daily and continuing until 7 days before surgery  Pazopanib was resumed at the same oral dose 4-6 weeks after surgery and was continued daily for 6 months ",
        "premise_nums": [
            "21 days for",
            "800 mg (2",
            "2 hours after",
            "80 mg/m^2",
            "1 hour before",
            "6 weeks after",
            "60 milligrams per",
            "4-6 weeks",
            "7 days before",
            "4 cycles given",
            "2 IV on",
            "15 every 28"
        ]
    },
    {
        "id": "a781374c-99e1-47ee-a266-bff9267c2ed1",
        "primaryId": "NCT00950742",
        "statement_text": "100% of participants in the Afatinib 30mg + Herceptin group of the primary trial suffer Dose Limiting Toxicities ",
        "statement_nums": [
            "100% of"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Number of Participants With Dose Limiting Toxicities (DLT) Number of participants with DLT in the first cycle (28 days) for the determination of the maximum tolerated dose (MTD)  Important Limitations and Caveats are provided in the respective section  Time frame: 28 days Results 2: Arm/Group Title: Afatinib 30mg + Herceptin Arm/Group Description: Patients received continuous daily dosing with Afatinib 30mg film-coated tablets and once weekly an intravenous infusion of Herceptin until disease progression or lack of clinical benefit  Overall Number of Participants Analyzed: 2 Measure Type: Number Unit of Measure: Participants 2 ",
        "premise_nums": [
            "2 Measure Type:",
            "28 days Results"
        ]
    },
    {
        "id": "9aea5a84-bced-4441-b8b8-154c307f5a03",
        "primaryId": "NCT01151046",
        "statement_text": "The placebo group in the primary trial had a much lower Median PFS than the MM-121 cohort ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Progression Free Survival (PFS) ",
        "premise_nums": []
    },
    {
        "id": "deb77d34-76a5-4e6e-bc9d-176cc30eca07",
        "primaryId": "NCT00917735",
        "statement_text": "One patient in cohort 2 of the primary trial died in a motorcycle crash ",
        "statement_nums": [
            "2 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 2: Total: 8/537 (1.49%) Hypertension 1/537 (0.19%) Acoustic Neuroma 0/537 (0.00%) Diarrhea 1/537 (0.19%) Colitis 0/537 (0.00%) Elevated ALT or AST enzyme 0/537 (0.00%) Diagnosis of Uterine Cancer 2/537 (0.37%) Motorcycle accident 1/537 (0.19%) Fall 1/537 (0.19%) Surgery 2/537 (0.37%) ",
        "premise_nums": [
            "8/537 (1.49%)",
            "1/537 (0.19%)",
            "2/537 (0.37%)",
            "0/537 (0.00%)"
        ]
    },
    {
        "id": "bfe97430-fcec-4c4a-9621-51f6ec05d8d3",
        "primaryId": "NCT00068341",
        "statement_text": "More patients in cohort 1 of the primary trial experienced death progressive disease than in cohort 2.",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 6/15 (40.00%) diarrhea and dehydration * 0/15 (0.00%) Severe Dehydration * 1/15 (6.67%) hypokalemia * 1/15 (6.67%) pain  swelling  mastectomy site cellulitis * 0/15 (0.00%) death progressive disease * 0/15 (0.00%) divetricular abscess * 0/15 (0.00%) fever * 1/15 (6.67%) febrile neutropenia * 3/15 (20.00%) Neutropenia * 0/15 (0.00%) Adverse Events 2: Total: 4/14 (28.57%) ",
        "premise_nums": [
            "3/15 (20.00%)",
            "0/15 (0.00%)",
            "6/15 (40.00%)",
            "4/14 (28.57%)",
            "1/15 (6.67%)"
        ]
    },
    {
        "id": "bfe97430-fcec-4c4a-9621-51f6ec05d8d3",
        "primaryId": "NCT00068341",
        "statement_text": "More patients in cohort 1 of the primary trial experienced death progressive disease than in cohort 2.",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "diarrhea and dehydration * 0/14 (0.00%)Severe Dehydration * 0/14 (0.00%) hypokalemia * 0/14 (0.00%) pain  swelling  mastectomy site cellulitis * 0/14 (0.00%) death progressive disease * 1/14 (7.14%) divetricular abscess * 0/14 (0.00%) fever * 0/14 (0.00%) febrile neutropenia * 2/14 (14.29%) Neutropenia * 0/14 (0.00%) ",
        "premise_nums": [
            "2/14 (14.29%)",
            "1/14 (7.14%)",
            "0/14 (0.00%)Severe"
        ]
    },
    {
        "id": "568beebd-b350-4ba1-b8fc-c43f4d6ed517",
        "primaryId": "NCT01421017",
        "statement_text": "the primary trial studies the effects of CTX/IMQ/RT and IMQ+RT on Systemic Tumor Response Rates 9 weeks after the start of treatment ",
        "statement_nums": [
            "9 weeks after"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Systemic Tumor Response Rates (Complete Response+Partial Response) The systemic tumor response refers to the response at the time of best overall response  The response criteria are specially adapted from Response Evaluation Criteria in Solid Tumor for Immunotherapies (Wolchok  et al.  2009). Time frame: 9 weeks from the start of the treatment of RT ",
        "premise_nums": [
            "9 weeks from"
        ]
    },
    {
        "id": "6bcc18b7-b063-49a1-8ab7-773636c02f1d",
        "primaryId": "NCT00076024",
        "statement_text": "The minimum number of days from start of study treatment to first documentation of objective tumor progression or death due to cancer for any patient in the primary trial  was 191.",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Time to Tumor Progression (TTP) Time in days from start of study treatment to first documentation of objective tumor progression or death due to cancer  whichever comes first  TTP was calculated as first event date minus the date of first dose of study medication plus 1. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease [PD])  Time frame: Phase 2 double-blind baseline until tumor progression or death or discontinuation from study treatment  assessed every 9 weeks up to 129 weeks Results 1: Arm/Group Title: Axitinib + Docetaxel (Phase 2, Double-blind) ",
        "premise_nums": [
            "129 weeks Results",
            "9 weeks up",
            "2 double-blind baseline"
        ]
    },
    {
        "id": "6bcc18b7-b063-49a1-8ab7-773636c02f1d",
        "primaryId": "NCT00076024",
        "statement_text": "The minimum number of days from start of study treatment to first documentation of objective tumor progression or death due to cancer for any patient in the primary trial  was 191.",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Arm/Group Description: Axitinib (AG-013736) 5 mg tablet orally BID starting from Day 1 of Cycle 1, in cycles of 3 weeks  Docetaxel 80 mg/m^2 1 hr IV infusion on Day 1 of each cycle  in cycles of 3 weeks  Treatment was continued until disease progression  intolerable toxicity  or for 2 cycles after complete response Overall Number of Participants Analyzed: 112 Median (95% Confidence Interval) Unit of Measure: days 247 (208 to 265) Results 2: Arm/Group Title: Docetaxel + Placebo (Phase 2, Double-blind) ",
        "premise_nums": [
            "1 hr IV",
            "80 mg/m^2",
            "208 to 265)",
            "1 of each",
            "1 of Cycle",
            "95% Confidence",
            "2 cycles after",
            "5 mg tablet"
        ]
    },
    {
        "id": "6bcc18b7-b063-49a1-8ab7-773636c02f1d",
        "primaryId": "NCT00076024",
        "statement_text": "The minimum number of days from start of study treatment to first documentation of objective tumor progression or death due to cancer for any patient in the primary trial  was 191.",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Arm/Group Description: Placebo matched to axitinib (AG-013736) tablet orally BID starting from Day 1 of Cycle 1, in cycles of 3 weeks  Docetaxel 80 mg/m^2 1 hr IV infusion on Day 1 of each cycle  in cycles of 3 weeks  Treatment was continued until disease progression  intolerable toxicity  or for 2 cycles after complete response  Participants with disease progression after consent were continued to open-label phase Overall Number of Participants Analyzed: 55 Median (95% Confidence Interval) Unit of Measure: days 215 (191 to 247) ",
        "premise_nums": [
            "1 hr IV",
            "80 mg/m^2",
            "1 of each",
            "1 of Cycle",
            "95% Confidence",
            "191 to 247)",
            "2 cycles after"
        ]
    },
    {
        "id": "dfa2ecee-96cf-4551-875e-aedd8aac5df9",
        "primaryId": "NCT01519700",
        "statement_text": "There was less than 24hrs difference in Mean Duration of Grade 4 Neutropenia During Cycle 1 of Chemotherapy for the two arms of the primary trial ",
        "statement_nums": [
            "1 of Chemotherapy",
            "4 Neutropenia During"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Mean Duration of Grade 4 Neutropenia During Cycle 1 of Chemotherapy Mean duration of severe neutropenia  defined as the mean number of consecutive days with Grade 4 neutropenia (ANC less than 0.5*10^9 cells/L) Time frame: 21 days (Cycle 1 of chemotherapy treatment) Results 1: Arm/Group Title: EP2006 + EP2006 & Neupogen Arm/Group Description: All subjects randomized to receive either EP2006 in Cycle 1 Overall Number of Participants Analyzed: 101 Mean (Standard Deviation) Unit of Measure: Days 1.17 (1.11) Results 2: Arm/Group Title: Neupogen + Neupogen & EP2006 ",
        "premise_nums": [
            "1 of Chemotherapy",
            "21 days (Cycle",
            "1 of chemotherapy",
            "4 Neutropenia During",
            "1 Overall Number",
            "2006 in Cycle",
            "EP2006 in",
            "101 Mean (Standard",
            "4 neutropenia (ANC"
        ]
    },
    {
        "id": "dfa2ecee-96cf-4551-875e-aedd8aac5df9",
        "primaryId": "NCT01519700",
        "statement_text": "There was less than 24hrs difference in Mean Duration of Grade 4 Neutropenia During Cycle 1 of Chemotherapy for the two arms of the primary trial ",
        "statement_nums": [
            "1 of Chemotherapy",
            "4 Neutropenia During"
        ],
        "label": "Entailment",
        "premise_text": "Arm/Group Description: All subjects randomized to receive Neupogen in Cycle 1Overall Number of Participants Analyzed: 103 Mean (Standard Deviation) Unit of Measure: Days 1.2 (1.02) ",
        "premise_nums": [
            "103 Mean (Standard"
        ]
    },
    {
        "id": "81c85a29-d449-4f79-a3b3-682ba5f288ca",
        "primaryId": "NCT00190671",
        "secondaryId": "NCT00455533",
        "label": "Entailment",
        "statement_text": "In the primary trial cohort 2 had more patients with Leukopenia than cohort 1, whereas in the secondary trial cohort 1 had more than cohort 2. Cohort 2 of the primary trial had the highest proportion of patients with leukopenia ",
        "statement_nums": [
            "1 had more",
            "2 of the",
            "2 had more"
        ],
        "premise_text": "Adverse Events 1: Leukopenia 0/42 (0.00%) Adverse Events 2: Leukopenia 2/61 (3.28%) Adverse Events 1: LEUKOPENIA 2/145 (1.38%) Adverse Events 2: LEUKOPENIA 0/144 (0.00%) ",
        "premise_nums": [
            "2/61 (3.28%)",
            "0/42 (0.00%)",
            "2/145 (1.38%)",
            "0/144 (0.00%)"
        ]
    },
    {
        "id": "9c48c5d6-83fd-42cc-aacc-2e888099bcdb",
        "primaryId": "NCT00338728",
        "statement_text": "Participants of the primary trial more Imatinib mesylate than Letrozole on a daily basis ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "INTERVENTION 1: Letrozole and Imatinib Mesylate Imatinib mesylate 400 mg by mouth twice a day daily for 28 days and Letrozole 2.5 mg once a day daily for 28 days cycle  ",
        "premise_nums": [
            "Letrozole 2.5 mg once",
            "400 mg by",
            "28 days and",
            "28 days cycle"
        ]
    },
    {
        "id": "79a3bb0d-315f-4c39-8786-2aa98e2e3f6f",
        "primaryId": "NCT00293540",
        "statement_text": "Males are not eligible for the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Inclusion Criteria: Estrogen receptor or progesterone receptor positive breast cancer Premenopausal with regular menstrual cycles Exclusion Criteria: Current oral contraceptives ",
        "premise_nums": []
    },
    {
        "id": "cea17554-6736-4b52-b76c-b3c5dc9ecb77",
        "primaryId": "NCT00503750",
        "statement_text": "All participants of the primary trial must have recently undergone either an echocardiography or a MUGA scan ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Inclusion Criteria: Normal (greater than 50%) left ventricular ejection fraction (LVEF) by MUGA scan or echocardiography  ",
        "premise_nums": []
    },
    {
        "id": "b250a17c-9d4d-405d-ba64-40f7eda16707",
        "primaryId": "NCT00368875",
        "statement_text": "the primary trial results indicate that the Recommended Phase II Dose for paclitaxel  as Assessed by NCI Common Terminology Criteria for Adverse Events  is 90 mg/m2  ",
        "statement_nums": [
            "90 mg/m2"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Recommended Phase II Dose as Assessed by NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 (Phase I) Dose-limiting toxcities (DLT) were defined as grade 3-4 febrile neutropenia  thrombocytopenia and non-hemtological toxicity attributed to therapy (nausea  vomiting and diarrhea would be considered dose limiting only if not adequately controlled with therapy)  Any toxicity occurring during cycle 1 that resulted in dose reduction of vorinostat or paclitaxel or failure to complete all protocol specificed doses in the first cycle was also considered a DLT Time frame: 28 days Results 1: Arm/Group Title: Phase I ",
        "premise_nums": [
            "4 febrile neutropenia",
            "1 that resulted",
            "3-4 febrile",
            "28 days Results"
        ]
    },
    {
        "id": "b250a17c-9d4d-405d-ba64-40f7eda16707",
        "primaryId": "NCT00368875",
        "statement_text": "the primary trial results indicate that the Recommended Phase II Dose for paclitaxel  as Assessed by NCI Common Terminology Criteria for Adverse Events  is 90 mg/m2  ",
        "statement_nums": [
            "90 mg/m2"
        ],
        "label": "Contradiction",
        "premise_text": "Arm/Group Description: Vorinostat dose (200 or 300 mg BID) was assigned at the time of registration  Vorinostat was administered orally twice daily on days 1-3, 8-10, and 15-17 of each 28-day cycle All patients also received paclitaxel at 90 mg/m2 as 1-hour infusion on days 2, 9, and 16 of every 28-day cycle  Bevacizumab was administered on day 2 and day 16 of the 28 day cycle at 10 mg/kg dose  Vorinostat dose escalation was carried out in the standard 3 + 3 phase I trial design based upon toxicity observed during the first cycle of therapy  Overall Number of Participants Analyzed: 6 Measure Type: Number Unit of Measure: mg 300 ",
        "premise_nums": [
            "2 and day",
            "16 of the",
            "1-hour infusion",
            "10 mg/kg dose",
            "90 mg/m2 as",
            "3 phase I",
            "200 or 300",
            "17 of each",
            "28 day cycle",
            "1-3, 8-10,",
            "28-day cycle",
            "16 of every",
            "6 Measure Type:",
            "300 mg BID",
            "15-17 of"
        ]
    },
    {
        "id": "698849c5-78fa-4c15-a1dc-f44eb9c970c2",
        "primaryId": "NCT00082641",
        "statement_text": "At least one patient in the primary trial suffered from impaired mobility ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Adverse Events 2: Hip fracture 1/12 (8.33%) ",
        "premise_nums": [
            "1/12 (8.33%)"
        ]
    },
    {
        "id": "4b4e6ac7-107c-46f4-adbb-c77c01f51935",
        "primaryId": "NCT00075764",
        "statement_text": "The most common adverse event in cohort 1 of the primary trial is low Hemoglobin levels ",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 21/337 (6.23%) Blood/Bone Marrow-Other 0/337 (0.00%) Febrile neutropenia 0/337 (0.00%) Hemoglobin 2/337 (0.59%) Atrioventricular block - 2nd degree Mobitz Type II 0/337 (0.00%) Cardiac-ischemia/infarction 1/337 (0.30%) Left ventricular diastolic dysfunction 0/337 (0.00%) Left ventricular systolic dysfunction 1/337 (0.30%) Restrictive cardiomyopathy 1/337 (0.30%) ",
        "premise_nums": [
            "0/337 (0.00%)",
            "1/337 (0.30%)",
            "2/337 (0.59%)",
            "21/337 (6.23%)"
        ]
    },
    {
        "id": "6b73dee4-0291-455e-90c2-786f0c2371d4",
        "primaryId": "NCT00579826",
        "statement_text": "Participants of the primary trial cannot be currently receiving treatment for rheumatoid arthritis  experiencing poorly controlled migraines or have any prior history of invasive breast cancer in the last 3 years ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Exclusion Criteria: Prior history of invasive breast cancer or other invasive cancer within five years from date of study entry  Receiving treatment for rheumatoid arthritis or fibromyalgia Current history of poorly controlled migraines or perimenopausal symptoms ",
        "premise_nums": []
    },
    {
        "id": "2a1d9064-fde9-4645-95ab-7ddaea4ad322",
        "primaryId": "NCT00324259",
        "statement_text": "Cohort 2 of the primary trial 3 had more patients with Complete response than cohort 1.",
        "statement_nums": [
            "2 of the",
            "3 had more"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Clinical Benefit Rate (CR Plus PR Plus SD) Complete response (CR) + partial response (PR) + stable disease (SD) using RECIST 1.0 CR = disappearance of all target lesions PR = at least a 30% decrease in the sum of the longest diameter of target lesions taking as reference the baseline sum longest diameter SD = neither sufficient shrinkage to quality for PR nor sufficient increase to qualify for progressive disease SD is defined as lack of disease progression by 24 weeks  Time frame: 24 weeks after start of treatment Results 1: Arm/Group Title: Arm 1 (6 mg Estradiol) Arm/Group Description: 6 mg of estradiol daily (2 mg tid)  Overall Number of Participants Analyzed: 34 Measure Type: Number ",
        "premise_nums": [
            "30% decrease",
            "0 CR =",
            "24 weeks after",
            "2 mg tid)",
            "34 Measure Type:",
            "6 mg of",
            "6 mg Estradiol)"
        ]
    },
    {
        "id": "2a1d9064-fde9-4645-95ab-7ddaea4ad322",
        "primaryId": "NCT00324259",
        "statement_text": "Cohort 2 of the primary trial 3 had more patients with Complete response than cohort 1.",
        "statement_nums": [
            "2 of the",
            "3 had more"
        ],
        "label": "Contradiction",
        "premise_text": "Unit of Measure: participants Complete response (CR): 0Partial response (PR): 3 Stable disease (SD): 7 CR+PR+SD: 10 Results 2: Arm/Group Title: Arm 2 (30 mg Estradiol) Arm/Group Description: 30 mg of estradiol  (10 mg tid) Overall Number of Participants Analyzed: 32 Measure Type: Number Unit of Measure: participants Complete response (CR): 0 Partial response (PR): 1 Stable disease (SD): 8 CR+PR+SD: 9 ",
        "premise_nums": [
            "30 mg Estradiol)",
            "1 Stable disease",
            "3 Stable disease",
            "0 Partial response",
            "32 Measure Type:",
            "30 mg of",
            "10 Results 2:",
            "10 mg tid)"
        ]
    },
    {
        "id": "847de3fe-b584-4d43-b82d-93263ce88830",
        "primaryId": "NCT00509587",
        "statement_text": "Patients in the primary trial receive 300 mg pazopanib once daily intravenously every day  continuing until disease progression or unacceptable toxicity ",
        "statement_nums": [
            "300 mg pazopanib"
        ],
        "label": "Contradiction",
        "premise_text": "INTERVENTION 1: Treatment (Pazopanib Hydrochloride) Patients receive oral pazopanib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity  pazopanib hydrochloride: Given orally pharmacological study: Correlative studies laboratory biomarker analysis: Correlative studies ",
        "premise_nums": [
            "28 days in",
            "1-28. Courses"
        ]
    },
    {
        "id": "3c798991-6366-43e2-94ca-0523629930c2",
        "primaryId": "NCT00149214",
        "secondaryId": "NCT01004744",
        "label": "Contradiction",
        "statement_text": "Prior use of Anthracycline drugs in the last 6 months for anticancer therapy is prohibted for patients in the primary trial  but not for patients in the secondary trial ",
        "statement_nums": [
            "6 months for"
        ],
        "premise_text": "Exclusion Criteria: Prior anthracyclines as part of prior anticancer therapy  Inclusion Criteria: No prior chemotherapy  radiation therapy  or surgery within 6 months of study entry ",
        "premise_nums": [
            "6 months of"
        ]
    },
    {
        "id": "64fe54a2-8897-4324-af88-f627c1c208ed",
        "primaryId": "NCT01764022",
        "statement_text": "Cohort 2 of the primary trial recorded multiple incidents of thrombocytopenia ",
        "statement_nums": [
            "2 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 2: Anemia with trombocytopenia 1/110 (0.91%) ",
        "premise_nums": [
            "1/110 (0.91%)"
        ]
    },
    {
        "id": "4eac6a2d-64cd-4289-a545-211eb835f0e9",
        "primaryId": "NCT01328249",
        "statement_text": "The Percentage of Participants With Feasibility was 70% higher in cohort 1 of the primary trial than in cohort 2.",
        "statement_nums": [
            "70% higher",
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Percentage of Participants With Feasibility ",
        "premise_nums": []
    },
    {
        "id": "3ee1c60e-46ce-4f25-af52-31d5c6d8eba1",
        "primaryId": "NCT02435680",
        "secondaryId": "NCT01743560",
        "label": "Contradiction",
        "statement_text": "the secondary trial and the primary trial use best Overall Response (OR) as their evaluation metrics  however they use significantly different time frames ",
        "statement_nums": [],
        "premise_text": "Outcome Measurement: Progression Free Survival (PFS) as Per RECIST v1.1 (by Local Investigator Assessment) PFS Results presented for all MCS110 treated patients (with and without day 8 dose)  in line with phase 2 study design  Time frame: 4 years Outcome Measurement: Best Overall Response of Everolimus and Exemestane Treatment in Postmenopausal Women With Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer ",
        "premise_nums": [
            "MCS110 treated",
            "2 study design",
            "110 treated patients",
            "4 years Outcome"
        ]
    },
    {
        "id": "3ee1c60e-46ce-4f25-af52-31d5c6d8eba1",
        "primaryId": "NCT02435680",
        "secondaryId": "NCT01743560",
        "label": "Contradiction",
        "statement_text": "the secondary trial and the primary trial use best Overall Response (OR) as their evaluation metrics  however they use significantly different time frames ",
        "statement_nums": [],
        "premise_text": "The best Overall Response (OR) for each patient is determined from the sequence of investigator overall lesion responses according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1.). To be assigned a best OR of Complete Responese (CR) at least two determinations of CR at least 4 weeks apart before progression are required  To be assigned a best OR of Partial Response (PR) at least two determinations of PR or better at least 4 weeks apart before progression (and not qualifying for a CR) are required.The Overall Response Rate (ORR) was defined as the proportion of patients with a best OR of confirmed CR or PR by week 48.Time frame: At 48 weeks ",
        "premise_nums": [
            "4 weeks apart"
        ]
    },
    {
        "id": "da1e1019-adb5-47bf-8093-e03352ca9e51",
        "primaryId": "NCT01340300",
        "secondaryId": "NCT00671918",
        "label": "Contradiction",
        "statement_text": "Patients cannot do more than half an hour of physical exercise in a day  if they are to participate in the primary trial  however  this is not a requirement for the secondary trial ",
        "statement_nums": [],
        "premise_text": "Inclusion Criteria: Less than 120 minutes of exercise per week Inclusion Criteria: The patient has provided written informed consent with HIPAA authorization before participating in the study  as has his/her responsible caregiver  if applicable  The patient is a candidate for surgical intervention  with lymph node mapping being a part of the surgical plan  The patient is at least 18 years of age at the time of consent  The patient has an ECOG performance status of Grade 0 - 2 [8]. The patient has a clinical negative node status at the time of study entry  If of child bearing potential  the patient has a negative pregnancy test within 72 hours prior to administration of Lymphoseek  has been surgically sterilized  or has been postmenopausal for at least 1 year  The patient is currently not participating in another investigational drug study  ",
        "premise_nums": [
            "120 minutes of",
            "72 hours prior",
            "18 years of"
        ]
    },
    {
        "id": "da1e1019-adb5-47bf-8093-e03352ca9e51",
        "primaryId": "NCT01340300",
        "secondaryId": "NCT00671918",
        "label": "Contradiction",
        "statement_text": "Patients cannot do more than half an hour of physical exercise in a day  if they are to participate in the primary trial  however  this is not a requirement for the secondary trial ",
        "statement_nums": [],
        "premise_text": "Melanoma PatientsThe patient has a diagnosis of primary melanoma  Breast Cancer Patients The patient has a diagnosis of primary breast cancer  Patients with pure ductal carcinoma in situ (DCIS) or non-invasive carcinoma if lymph node biopsy is part of the surgical plan  Exclusion Criteria: The patient is pregnant or lactating; The patient has clinical or radiological evidence of metastatic cancer including palpably abnormal or enlarged lymph nodes (i.e.  all patients should be any T,N0,M0); The patient has a known hypersensitivity to Lymphazurin or Patent Bleu V  Melanoma Patients The patient has a tumor with a Breslow depth less than 0.75mm.; ",
        "premise_nums": [
            "0,M0); The"
        ]
    },
    {
        "id": "da1e1019-adb5-47bf-8093-e03352ca9e51",
        "primaryId": "NCT01340300",
        "secondaryId": "NCT00671918",
        "label": "Contradiction",
        "statement_text": "Patients cannot do more than half an hour of physical exercise in a day  if they are to participate in the primary trial  however  this is not a requirement for the secondary trial ",
        "statement_nums": [],
        "premise_text": "Patients that have had preoperative chemotherapy  immunotherapy or radiation therapy;Patients diagnosed with a prior invasive melanoma that would occur on the same body region or potentially draining to the same nodal basin or patients with truncal or extremity primary melanoma who has had a prior breast cancer potentially draining to the same axillary nodal basin; Patients who have undergone node basin surgery of any type or radiation to the nodal basin(s) potentially draining the primary melanoma; Patients who have undergone a wide excision for their primary melanoma (greater than 1 cm in dimension) or complex reconstruction (rotation  free flap or skin graft of any type)  Breast Cancer Patients The patient has bilateral primary breast cancers or multiple tumors within their breast; ",
        "premise_nums": [
            "1 cm in"
        ]
    },
    {
        "id": "da1e1019-adb5-47bf-8093-e03352ca9e51",
        "primaryId": "NCT01340300",
        "secondaryId": "NCT00671918",
        "label": "Contradiction",
        "statement_text": "Patients cannot do more than half an hour of physical exercise in a day  if they are to participate in the primary trial  however  this is not a requirement for the secondary trial ",
        "statement_nums": [],
        "premise_text": "Patients that have had prior surgical procedures such as breast implants  reduction mammoplasty or axillary surgery;Patients scheduled for bilateral mastectomy for any reason; Patients that have had preoperative radiation therapy to the affected breast or axilla ",
        "premise_nums": []
    },
    {
        "id": "e7fb6490-1ec7-48ff-95b1-715d79faec92",
        "primaryId": "NCT01042938",
        "statement_text": "Patients must be english to participate in the primary trial ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria: Female with a diagnosis of  non-inflammatory breast adenocarcinoma and be referred for post-operative radiotherapy without concurrent chemotherapy  Participants must be at least 21 years of age  Participants must not be pregnant  Participants can be from any racial or ethnic origin  Breast adenocarcinoma could have been treated by either lumpectomy or mastectomy with or without adjuvant or neoadjuvant chemotherapy or hormonal treatment  Participants with in situ breast cancer are eligible  Participants who are prescribed concurrent hormone treatment with radiation treatment are eligible  Participants must be scheduled to receive five sessions of radiation therapy per week (1 session per day) for at least four weeks using standard (1.8-2.0 Gy per session)or Canadian (2.2-2.5 Gy per session)irradiation fractionation  ",
        "premise_nums": [
            "0 Gy per",
            "2-2.5 Gy",
            "8-2.0 Gy",
            "5 Gy per",
            "21 years of",
            "1 session per"
        ]
    },
    {
        "id": "e7fb6490-1ec7-48ff-95b1-715d79faec92",
        "primaryId": "NCT01042938",
        "statement_text": "Patients must be english to participate in the primary trial ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "A time period of three weeks must elapse after chemotherapy and surgery before beginning the study The total dose prescribed to the whole breast should be 50 Gy or greater  Participants must be able to understand English and able to complete assessment forms (all assessment forms are in English)  Participants must be able to swallow medication  Topical skin agents  e.g.  Aquaphor  Cetaphil  or other emollients  are allowed either PRN or prophylactically  Participant must give informed consent  Exclusion Criteria: Patients with bilateral breast cancer are not eligible  Patients who have had previous radiation therapy to the breast or chest are not eligible  Patients who are prescribed chemotherapy concurrently with radiation treatment are not eligible  ",
        "premise_nums": [
            "50 Gy or"
        ]
    },
    {
        "id": "e7fb6490-1ec7-48ff-95b1-715d79faec92",
        "primaryId": "NCT01042938",
        "statement_text": "Patients must be english to participate in the primary trial ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Patients who will be receiving treatment with Herceptin (trastuzumab)  anti-coagulants  or anti-human epidermal growth factor receptor (EGFR) drugs  e.g  Iressa (gefitinib)  Erbitux (cetuximab  C225), concurrently with their radiation therapy are not eligible Patients cannot have had breast reconstructions  implants  and/or expanders  Patients with known radiosensitivity syndromes (e.g.  Ataxia-telangiectasia) are not eligible  Patients with collagen vascular disease  vasculitis  unhealed surgical sites  or breast infections are not eligible  ",
        "premise_nums": []
    },
    {
        "id": "e7fb6490-1ec7-48ff-95b1-715d79faec92",
        "primaryId": "NCT01042938",
        "statement_text": "Patients must be english to participate in the primary trial ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Patients whose baseline blood tests meet the following criteria are not eligible: greater than or equal to Grade 2 change Hemoglobin (i.e.  25% decrease from baseline); greater than or equal to Grade 1 change in Platelets (i.e.  less than 75,000/mm3); greater than or equal to Grade 2 change in PT and PTT(i.e.  1.5-2x upper level normal (ULN)); greater than or equal to Grade 1 change in AST  ALT (i.e.  greater than 2.5x ULN); greater than or equal to Grade 1 change in Bilirubin (i.e.  greater than 1.5x ULN); greater than or equal to Grade 1 change in Creatinine (i.e.  greater than 2x ULN) ",
        "premise_nums": [
            "5-2x upper",
            "than 2.5x ULN",
            "25% decrease",
            "2 change Hemoglobin",
            "than 1.5x ULN",
            "1 change in",
            "75,000/mm3); greater",
            "2 change in"
        ]
    },
    {
        "id": "d5ea3443-103f-4d29-9be3-522210b84152",
        "primaryId": "NCT00618826",
        "secondaryId": "NCT02040857",
        "label": "Contradiction",
        "statement_text": "the primary trial and the secondary trial only record 2 of the same adverse events ",
        "statement_nums": [
            "2 of the"
        ],
        "premise_text": "Adverse Events 1: Lymphopenia 1/14 (7.14%) Diarrhea 1/14 (7.14%) Fatigue (asthenia  lethargy  malaise) 2/14 (14.29%) Hypertension 2/14 (14.29%) Adverse Events 1: Lymphocyte count decreased 2/162 (1.23%) Diarrhea 1/162 (0.62%) Fatigue 6/162 (3.70%) Hypertension 1/162 (0.62%) ",
        "premise_nums": [
            "2/14 (14.29%)",
            "6/162 (3.70%)",
            "2/162 (1.23%)",
            "1/162 (0.62%)",
            "1/14 (7.14%)"
        ]
    },
    {
        "id": "d54cae08-3ac9-4460-bf6d-7338b45d8cd7",
        "primaryId": "NCT00193050",
        "statement_text": "Patients must be over the age of 18 and have a life expectancy over 6 months to participate in the primary trial ",
        "statement_nums": [
            "6 months to",
            "18 and have"
        ],
        "label": "Entailment",
        "premise_text": "Inclusion Criteria: Female Patients greater than 18 years of age Exclusion Criteria: Life expectancy of smaller than than 6 months ",
        "premise_nums": [
            "18 years of"
        ]
    },
    {
        "id": "608c5521-c9a6-47de-9ebf-791ce317a02d",
        "primaryId": "NCT00086957",
        "statement_text": "All of the patients in cohort 1 of the primary trial experienced an adverse event ",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 2/2 (100.00%) Febrile neutropenia * 2/2 (100.00%) Haemorrhage NOS * 0/2 (0.00%) Abdominal pain * 0/2 (0.00%) Diarrhea * 0/2 (0.00%) Melaena * 0/2 (0.00%) Mucositis oral * 0/2 (0.00%) Nausea * 0/2 (0.00%) Vomiting * 0/2 (0.00%) Catheter related infection * 0/2 (0.00%) Infection NOS * 0/2 (0.00%) Leukopenia * 1/2 (50.00%) ",
        "premise_nums": [
            "1/2 (50.00%)",
            "0/2 (0.00%)",
            "2/2 (100.00%)"
        ]
    },
    {
        "id": "14a8e9e9-0a46-4537-bc07-53c786bcbe97",
        "primaryId": "NCT00593827",
        "secondaryId": "NCT00478257",
        "label": "Contradiction",
        "statement_text": "Patients with HER2 negative MBC are eligible for both the primary trial and the secondary trial ",
        "statement_nums": [
            "2 negative MBC"
        ],
        "premise_text": "Inclusion Criteria: Has MBC that is measurable by RECIST or has nonmeasurable disease with serum CA27.29 (or CA15.3) 50 Has Human Epidermal Growth Factor Receptor 2 (HER2) negative breast cancer Inclusion Criteria: stage I-III breast cancer adjuvant or neoadjuvant anthracycline-based chemotherapy Exclusion Criteria: under age 18 pregnancy metastatic or inoperable (including inflammatory) breast cancer confounding underlying medical illnesses history of mania history of other axis-I psychiatric disorder other physical or psychological impairments - ",
        "premise_nums": [
            "(HER2) negative",
            "18 pregnancy metastatic",
            "50 Has Human"
        ]
    },
    {
        "id": "2d97bfa0-336f-4976-95e5-1262327a730b",
        "primaryId": "NCT01048099",
        "secondaryId": "NCT02502864",
        "label": "Contradiction",
        "statement_text": "the primary trial recorded 2 more total adverse events than the secondary trial",
        "statement_nums": [
            "2 more total"
        ],
        "premise_text": "Adverse Events 1: Total: 5/14 (35.71%) Adverse Events 1: Total: 3/9 (33.33%) ",
        "premise_nums": [
            "3/9 (33.33%)",
            "5/14 (35.71%)"
        ]
    },
    {
        "id": "e68dddc8-ea04-49b2-ae91-ff7b4fcb1240",
        "primaryId": "NCT00003199",
        "statement_text": "The patient group with the highest percent of Event-free Survival in the primary trial was Stage IIIB patients  and the worst was Stage IV Disease patients ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Event-free Survival Event-free survival of patients treated for inflammatory (Stage IIIb) and responsive stage IV breast cancer with BUMELTT and PBSC support and low dose immunotherapy with IL2 and GM-CSF  Time frame: 11 years Results 1: Arm/Group Title: TX/Maintenance Therapy for Stage IIIB/IV Breast Cancer Arm/Group Description: See Detailed Description  tamoxifen citrate: Given orally busulfan: Given orally thiotepa: Given IV melphalan: Given IV aldesleukin: Given SC sargramostim: Given SC peripheral blood stem cell transplantation: Undergo autologous peripheral blood stem cell infusion ",
        "premise_nums": [
            "11 years Results"
        ]
    },
    {
        "id": "e68dddc8-ea04-49b2-ae91-ff7b4fcb1240",
        "primaryId": "NCT00003199",
        "statement_text": "The patient group with the highest percent of Event-free Survival in the primary trial was Stage IIIB patients  and the worst was Stage IV Disease patients ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "radiation therapy: May undergo radiotherapy after completion of IL-2/GM-CSFOverall Number of Participants Analyzed: 50 Measure Type: Count of Participants Unit of Measure: Participants Stage IIIB Disease: 18 participants 11 61.1% Stage IV Disease: 32 participants 9 28.1% ",
        "premise_nums": [
            "32 participants 9",
            "50 Measure Type:",
            "18 participants 11",
            "11 61.1% Stage IV",
            "2/GM-CSFOverall Number"
        ]
    },
    {
        "id": "8c83330f-f2f3-48e1-9905-dc2ba1970c54",
        "primaryId": "NCT03765996",
        "statement_text": "Participants in group 2 of the primary trial receive the same Complex Decongestive Physiotherapy as those in group 1, with the addition of applying taping to anastomosis regions ",
        "statement_nums": [
            "2 of the"
        ],
        "label": "Entailment",
        "premise_text": "INTERVENTION 1: Decongestive Physiotherapy This group received Complex Decongestive Physiotherapy  ",
        "premise_nums": []
    },
    {
        "id": "4613834d-c178-475c-b9fd-c9c66d5681eb",
        "primaryId": "NCT04080297",
        "secondaryId": "NCT02780713",
        "label": "Entailment",
        "statement_text": "Cohort 2 of the primary trial receives higher doses of Q-122 than either of the secondary trial cohorts receive of AZD9496 variants ",
        "statement_nums": [
            "2 of the",
            "AZD9496 variants",
            "122 than either"
        ],
        "premise_text": "INTERVENTION 2: 200 mg Q-122 Dosage was 200 mg Q-122 administered orally as four 50 mg capsules once daily for 28 days  INTERVENTION 1: Treatment Period 1 Participants received AZD9496 - Variant A (100 mg)  INTERVENTION 2: Treatment Period 2 Participants received AZD9496 - Reference (100 mg)  ",
        "premise_nums": [
            "122 administered orally",
            "2 Participants received",
            "200 mg Q",
            "50 mg capsules",
            "1 Participants received",
            "122 Dosage was"
        ]
    },
    {
        "id": "b4555685-6e25-4797-8616-bcab5b06a135",
        "primaryId": "NCT00259090",
        "statement_text": "the primary trial studies the impact of Fulvestrant  Docetaxel on Oestrogen Receptor H-score ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Percentage Change From Baseline to Time of Surgery in Oestrogen Receptor (ER) H-score: Antitumour Effects of Fulvestrant  Anastrozole and a Combination of Both as Measured by the ER H-score  ",
        "premise_nums": []
    },
    {
        "id": "c1b90c18-45f4-4e28-b50a-a00b0eadc523",
        "primaryId": "NCT00290732",
        "secondaryId": "NCT02748213",
        "label": "Contradiction",
        "statement_text": "Patients whose breast tumour is 0.1 cm across or less are eligible for the secondary trial  but not the primary trial ",
        "statement_nums": [
            "is 0.1 cm across"
        ],
        "premise_text": "T1-3, any N disease No inflammatory breast cancer or other T4 features Inclusion Criteria: Histologically confirmed  HER2-positive advanced and/or metastatic breast cancer not amenable to curative therapy ",
        "premise_nums": [
            "4 features Inclusion",
            "2-positive advanced",
            "1-3, any"
        ]
    },
    {
        "id": "33ef3abf-97c0-4d15-909d-258fb47ac54a",
        "primaryId": "NCT00232479",
        "statement_text": "Only patients with HER2 positive breast carcinoma are eligible for the primary trial ",
        "statement_nums": [
            "2 positive breast"
        ],
        "label": "Entailment",
        "premise_text": "Inclusion Criteria: HER-2 overexpressing breast cancer ",
        "premise_nums": [
            "2 overexpressing breast"
        ]
    },
    {
        "id": "a381e340-18b1-4baa-91ce-0c420bcb411c",
        "primaryId": "NCT01323530",
        "secondaryId": "NCT01106040",
        "label": "Contradiction",
        "statement_text": "the secondary trial and the primary trial results indicate that the PFS of participants is partially linked to age  cancer grade and ethnicity ",
        "statement_nums": [],
        "premise_text": "Outcome Measurement: Phase 1b: Number of Participants With Dose-limiting Toxicities (DLTs) as Per National Cancer Institute Common Terminology Criteria for Adverse Events Version 3.0 (NCI CTCAE v3.0) ",
        "premise_nums": []
    },
    {
        "id": "15e6b2b9-ba8f-4ca5-99d7-a1bbf9497b4b",
        "primaryId": "NCT00383500",
        "statement_text": "the primary trial is not testing a drug based intervention  it is testing a Medical device called Manual Lymphatic Drainage ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "INTERVENTION 1: Flexitouch Device Lymphedema management via Flexitouch device  an intermittent pneumatic compression device (aka  lymphedema pump) INTERVENTION 2: Manual Lymphatic Drainage (MLD) Lymphedema management via self-administered manual lymphatic drainage therapy ",
        "premise_nums": []
    },
    {
        "id": "8e246d8f-e063-4f2e-a382-5d201a946b87",
        "primaryId": "NCT00436566",
        "statement_text": "Not a single patient in the primary trial suffered from Congestive Heart Failure during active treatment with Trastuzumab and RAD001.",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Number of Patients With Congestive Heart Failure (CHF) While on Active Treatment [Not Specified] Time frame: 6 months Results 1: Arm/Group Title: AC/PTL ",
        "premise_nums": [
            "6 months Results"
        ]
    },
    {
        "id": "8e246d8f-e063-4f2e-a382-5d201a946b87",
        "primaryId": "NCT00436566",
        "statement_text": "Not a single patient in the primary trial suffered from Congestive Heart Failure during active treatment with Trastuzumab and RAD001.",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Arm/Group Description: Standard doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (80 mg/m^2) x 12 with concurrent standard dose trastuzumab (weekly x 12, then repeat 3 weeks for an additional 9 months) plus daily lapatinib (modified to 750 mg during Paclitaxel + Trastuzumab + Lapatinib (PTL) and 1000 mg during trastuzumab + lapatinib (TL)) for a total of 12 months Overall Number of Participants Analyzed: 109 Measure Type: Number Unit of Measure: participants 0 ",
        "premise_nums": [
            "1000 mg during",
            "3 weeks for",
            "12 with concurrent",
            "750 mg during",
            "12 months Overall",
            "109 Measure Type:"
        ]
    },
    {
        "id": "8154bd8c-90a2-4b2f-8090-fcc89aeae30c",
        "primaryId": "NCT00097721",
        "statement_text": "Patients of any ethnicity can participate in the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Inclusion Criteria: Female patients with histologically or cytologically confirmed carcinoma of the breast Patients with advanced/metastatic disease that is not amenable to curative therapy (either surgery or radiation therapy) Patients must have measurable disease by the RECIST criteria  defined as at least one lesion that can be accurately measured in at least one diameter (at least 10 mm in longest diameter (LD) by spiral computer tomography (CT) scan  or at least 20 mm by standard techniques; If the only measurable lesion is a lymph node  it must measure at least 20 mm in LD  If a single lesion is identified as the target lesion  a cytological or histological confirmation of breast carcinoma is required  ",
        "premise_nums": [
            "20 mm by",
            "20 mm in",
            "10 mm in"
        ]
    },
    {
        "id": "8154bd8c-90a2-4b2f-8090-fcc89aeae30c",
        "primaryId": "NCT00097721",
        "statement_text": "Patients of any ethnicity can participate in the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Patients must have had prior treatment with an anthracycline and a taxane (either sequential or in combination) and may have had prior treatment with other agents as well Patients must have progressed within six months of the last dose of chemotherapy  or experienced disease progression while receiving chemotherapy for advanced/metastatic disease  Resolution of all chemotherapy or radiation-related toxicities to less than grade 1 severity Age 18 years Eastern Cooperative Oncology Group (ECOG) Performance Status (APPENDIX 4) of 0 or 1 Life expectancy of 3 months Adequate renal function as evidenced by serum creatinine 1.5 mg/dL or calculated creatinine clearance 50 mL/minute (min) per the Cockcroft and Gault formula ",
        "premise_nums": [
            "creatinine 1.5 mg/dL",
            "0 or 1",
            "1 severity Age",
            "18 years Eastern",
            "50 mL/minute",
            "3 months Adequate"
        ]
    },
    {
        "id": "8154bd8c-90a2-4b2f-8090-fcc89aeae30c",
        "primaryId": "NCT00097721",
        "statement_text": "Patients of any ethnicity can participate in the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Adequate bone marrow function as evidenced by absolute neutrophil count (ANC) 1.5 x 10^9/L, hemoglobin 10.0 g/dL (a hemoglobin smaller than 10.0 g/dL would be acceptable if it can be corrected by growth factor or transfusion)  and platelet count 100 x 10^9/LAdequate liver function as evidenced by bilirubin 1.5 mg/dL and alkaline phosphatase  alanine transaminase (ALT)  and aspartate transaminase (AST) 3 times the upper limits of normal (ULN) (in the case of liver metastases 5 x ULN) Patients willing and able to complete the FACT-B questionnaire  Analgesic Diary  Pain VAS  and the tumor-related symptomatic assessment ",
        "premise_nums": [
            "than 10.0 g/dL",
            "9/L, hemoglobin",
            "bilirubin 1.5 mg/dL",
            "5 x ULN)",
            "100 x 10",
            "3 times the",
            "hemoglobin 10.0 g/dL",
            "9/LAdequate liver"
        ]
    },
    {
        "id": "8154bd8c-90a2-4b2f-8090-fcc89aeae30c",
        "primaryId": "NCT00097721",
        "statement_text": "Patients of any ethnicity can participate in the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Patients willing and able to comply with the study protocol for the duration of the studyA sample from the diagnostic biopsy (paraffin block) must be available Written informed consent prior to any study-specific screening procedures with the understanding that the patient may withdraw consent at any time without prejudice Exclusion Criteria: Patients who have received chemotherapy  radiation  hormonal therapy  or Herceptin within 2 weeks of E7389 treatment start Radiation therapy encompassing greater than 10% of marrow Failure to recover from any chemotherapy related or other therapy related toxicity at study entry that is deemed to be clinically significant by the study investigator Prior treatment with Mitomycin C or nitrosoureas Prior high dose chemotherapy with hematopoietic stem cell rescue in the past two years Pulmonary lymphangitic involvement that results in pulmonary dysfunction requiring active treatment  including the use of oxygen ",
        "premise_nums": [
            "7389 treatment start",
            "2 weeks of",
            "E7389 treatment",
            "10% of"
        ]
    },
    {
        "id": "8154bd8c-90a2-4b2f-8090-fcc89aeae30c",
        "primaryId": "NCT00097721",
        "statement_text": "Patients of any ethnicity can participate in the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Active symptomatic brain metastasis; Patients with central Nervous System (CNS) metastasis are considered eligible if they have completed local therapy and discontinued from corticosteroids for at least two weeks before starting treatment with E7389Patients with meningeal carcinomatosis Patients who require therapeutic anti-coagulant therapy with Warfarin or related compounds; Mini dose warfarin for catheter related thrombosis prophylaxis is permitted ",
        "premise_nums": []
    },
    {
        "id": "8154bd8c-90a2-4b2f-8090-fcc89aeae30c",
        "primaryId": "NCT00097721",
        "statement_text": "Patients of any ethnicity can participate in the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Women who are pregnant or breast-feeding; Women of childbearing potential with either a positive pregnancy test at Screening or no pregnancy test  Women of childbearing potential unless (1) surgically sterile or (2) using adequate measures of contraception in the opinion of the Investigator  Postmenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential Severe /uncontrolled intercurrent illness/infection Significant cardiovascular impairment (history of congestive heart failure greater than NYHA grade II  unstable angina or myocardial infarction within the past six months  or serious cardiac arrhythmia) Patients with organ allografts Patients with known positive HIV status ",
        "premise_nums": [
            "(1) surgically",
            "(2) using",
            "12 months to"
        ]
    },
    {
        "id": "8154bd8c-90a2-4b2f-8090-fcc89aeae30c",
        "primaryId": "NCT00097721",
        "statement_text": "Patients of any ethnicity can participate in the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Patients who have had a prior malignancy  other than carcinoma in situ of the cervix  or non-melanoma skin cancer  unless the prior malignancy was diagnosed and definitively treated 5 years previously with no subsequent evidence of recurrencePatients with pre-existing neuropathy greater than Grade 1 Patients with a hypersensitivity to halichondrin B and/or halichondrin B chemical derivative Patients who participated in a prior E7389 clinical trial Patients with other significant disease or disorders that  in the Investigator's opinion  would exclude the patient from the study ",
        "premise_nums": [
            "5 years previously",
            "1 Patients with",
            "7389 clinical trial",
            "E7389 clinical"
        ]
    },
    {
        "id": "537781f9-3693-479e-af22-824cdd827b9c",
        "primaryId": "NCT02657889",
        "statement_text": "the primary trial indicates that varying Pembrolizumab dosage has no effect on the Number of Subjects Reporting Dose-Limiting Toxicities (DLTs) ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Phase 1: Number of Subjects Reporting Dose-Limiting Toxicities (DLTs) ",
        "premise_nums": []
    },
    {
        "id": "5feefe8b-ddca-4eb8-af68-d1e211963d1f",
        "primaryId": "NCT02748213",
        "statement_text": "2 patients  in cohort 1 of the primary trial was recorded as having an overactive pituitary gland ",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 52/112 (46.43%) Febrile neutropenia * 16/112 (14.29%) Neutropenia * 7/112 (6.25%) Anaemia * 1/112 (0.89%) Cardiac failure * 1/112 (0.89%) Coronary artery disease * 1/112 (0.89%) Left ventricular dysfunction * 1/112 (0.89%) Pericardial effusion * 0/112 (0.00%) Hyperthyroidism * 1/112 (0.89%) Diarrhoea * 5/112 (4.46%) Vomiting * 3/112 (2.68%) Adverse Events 2: ",
        "premise_nums": [
            "0/112 (0.00%)",
            "16/112 (14.29%)",
            "7/112 (6.25%)",
            "1/112 (0.89%)",
            "3/112 (2.68%)",
            "52/112 (46.43%)",
            "5/112 (4.46%)"
        ]
    },
    {
        "id": "5feefe8b-ddca-4eb8-af68-d1e211963d1f",
        "primaryId": "NCT02748213",
        "statement_text": "2 patients  in cohort 1 of the primary trial was recorded as having an overactive pituitary gland ",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Total: 51/110 (46.36%)Febrile neutropenia * 26/110 (23.64%) Neutropenia * 7/110 (6.36%) Anaemia * 1/110 (0.91%) Cardiac failure * 0/110 (0.00%) Coronary artery disease * 0/110 (0.00%) Left ventricular dysfunction * 0/110 (0.00%) Pericardial effusion * 1/110 (0.91%) Hyperthyroidism * 0/110 (0.00%) Diarrhoea * 0/110 (0.00%) Vomiting * 1/110 (0.91%) ",
        "premise_nums": [
            "1/110 (0.91%)",
            "26/110 (23.64%)",
            "7/110 (6.36%)",
            "51/110 (46.36%)Febrile",
            "0/110 (0.00%)"
        ]
    },
    {
        "id": "2a5d8ca7-1608-4607-b996-490fc447b593",
        "primaryId": "NCT00956813",
        "statement_text": "All the primary trial subjects are required to take the intervention tablet PO daily ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "INTERVENTION 1: Flaxseed Patients receive 1 Nutrigrad™ flaxseed bar containing 7.5 grams flaxseed  410 mg lignans,once daily  INTERVENTION 2: Placebo Patients Identical looking bar with same calorie and total fat content but without flaxseed or lignans once daily  ",
        "premise_nums": [
            "containing 7.5 grams flaxseed",
            "410 mg lignans,once"
        ]
    },
    {
        "id": "178c50cc-49ee-4083-bc8e-b5832037498a",
        "primaryId": "NCT00258960",
        "statement_text": "4 patients in the primary trial experienced a grade 3 or above adverse event ",
        "statement_nums": [
            "4 patients in",
            "3 or above"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 16/48 (33.33%) Febrile neutropenia grade 3 3/48 (6.25%) Neutropenia grade 3 1/48 (2.08%) Holocraneal cephalea 1/48 (2.08%) Hypersensibility reaction grade 3 2/48 (4.17%) Palmoplantar erythrodysesthesia grade 3, stomatitis grade 3 1/48 (2.08%) Neutropenia grade 4, fever grade 1, oral mucositis grade 3 1/48 (2.08%) Catheter - related infection grade 3 1/48 (2.08%) ",
        "premise_nums": [
            "2/48 (4.17%)",
            "3/48 (6.25%)",
            "1/48 (2.08%)",
            "16/48 (33.33%)"
        ]
    },
    {
        "id": "92ace4fa-4426-4f34-af52-ee62913e60aa",
        "primaryId": "NCT01026142",
        "secondaryId": "NCT00846027",
        "label": "Contradiction",
        "statement_text": "There were 10% more patients with Left ventricular systolic dysfunction in cohort 1 of the primary trial than in the secondary trial ",
        "statement_nums": [
            "10% more",
            "1 of the"
        ],
        "premise_text": "Adverse Events 1: Left Ventricular Dysfunction 4/218 (1.83%) Adverse Events 2: Left Ventricular Dysfunction 13/228 (5.70%) Adverse Events 1: Left ventricular systolic dysfunction 1/82 (1.22%) ",
        "premise_nums": [
            "1/82 (1.22%)",
            "13/228 (5.70%)",
            "4/218 (1.83%)"
        ]
    },
    {
        "id": "7dbde84d-f1c9-4197-9d44-500fd337bebd",
        "primaryId": "NCT01823107",
        "statement_text": "At most 12 Patients implanted with a Meso BioMatrix Acellular Peritoneum Matrix suffered Breast Related Adverse Events ",
        "statement_nums": [
            "12 Patients implanted"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Rate of Breast Related Adverse Events Investigators evaluated each subject and each reconstructed breast for the occurrence of an adverse event from the first stage of reconstruction through the final follow-up visit  A breast related adverse event was defined as any untoward medical occurrence related to a reconstructed breast  Time frame: 18 months Results 1: Arm/Group Title: Meso BioMatrix Acellular Peritoneum Matrix Arm/Group Description: All subjects had the Meso BioMatrix Acellular Peritoneum Matrix implanted along with a tissue expander during the first stage of breast reconstruction  After tissue expansion  the tissue expander was replaced with a breast implant during the second stage of reconstruction  Overall Number of Participants Analyzed: 25 Overall Number of Units Analyzed ",
        "premise_nums": [
            "18 months Results",
            "25 Overall Number"
        ]
    },
    {
        "id": "7dbde84d-f1c9-4197-9d44-500fd337bebd",
        "primaryId": "NCT01823107",
        "statement_text": "At most 12 Patients implanted with a Meso BioMatrix Acellular Peritoneum Matrix suffered Breast Related Adverse Events ",
        "statement_nums": [
            "12 Patients implanted"
        ],
        "label": "Entailment",
        "premise_text": "Type of Units Analyzed: Reconstructed breasts Measure Type: NumberUnit of Measure: Reconstructed breasts affected: 12",
        "premise_nums": []
    },
    {
        "id": "824da29f-b2ff-440e-8b78-7a8291cbd6d2",
        "primaryId": "NCT02340221",
        "statement_text": "A total of 89 patients in the primary trial had Supraventricular tachycardia ",
        "statement_nums": [
            "89 patients in"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 19/213 (8.92%) Pancytopenia 0/213 (0.00%) Anaemia 1/213 (0.47%) Atrial fibrillation 0/213 (0.00%) Cardiac failure congestive 0/213 (0.00%) Myocardial infarction 0/213 (0.00%) Supraventricular tachycardia 0/213 (0.00%) Diarrhoea 0/213 (0.00%) Colitis 0/213 (0.00%) Vomiting 1/213 (0.47%) Nausea 1/213 (0.47%) Enterocolitis 0/213 (0.00%) Adverse Events 2: ",
        "premise_nums": [
            "0/213 (0.00%)",
            "1/213 (0.47%)",
            "19/213 (8.92%)"
        ]
    },
    {
        "id": "824da29f-b2ff-440e-8b78-7a8291cbd6d2",
        "primaryId": "NCT02340221",
        "statement_text": "A total of 89 patients in the primary trial had Supraventricular tachycardia ",
        "statement_nums": [
            "89 patients in"
        ],
        "label": "Contradiction",
        "premise_text": "Total: 133/416 (31.97%)Pancytopenia 1/416 (0.24%) Anaemia 0/416 (0.00%) Atrial fibrillation 2/416 (0.48%) Cardiac failure congestive 1/416 (0.24%) Myocardial infarction 1/416 (0.24%) Supraventricular tachycardia 1/416 (0.24%) Diarrhoea 32/416 (7.69%) Colitis 14/416 (3.37%) Vomiting 4/416 (0.96%) Nausea 3/416 (0.72%) Enterocolitis 2/416 (0.48%) ",
        "premise_nums": [
            "0/416 (0.00%)",
            "133/416 (31.97%)Pancytopenia",
            "32/416 (7.69%)",
            "4/416 (0.96%)",
            "3/416 (0.72%)",
            "2/416 (0.48%)",
            "1/416 (0.24%)",
            "14/416 (3.37%)"
        ]
    },
    {
        "id": "6cbac938-baf2-4f0b-b67b-9caeb7ea4fe1",
        "primaryId": "NCT02748213",
        "statement_text": "1 patient  in cohort 1 of the primary trial was recorded as having an overactive thyroid gland ",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 52/112 (46.43%) Febrile neutropenia * 16/112 (14.29%) Neutropenia * 7/112 (6.25%) Anaemia * 1/112 (0.89%) Cardiac failure * 1/112 (0.89%) Coronary artery disease * 1/112 (0.89%) Left ventricular dysfunction * 1/112 (0.89%) Pericardial effusion * 0/112 (0.00%) Hyperthyroidism * 1/112 (0.89%) Diarrhoea * 5/112 (4.46%) Vomiting * 3/112 (2.68%) Adverse Events 2: ",
        "premise_nums": [
            "0/112 (0.00%)",
            "16/112 (14.29%)",
            "7/112 (6.25%)",
            "1/112 (0.89%)",
            "3/112 (2.68%)",
            "52/112 (46.43%)",
            "5/112 (4.46%)"
        ]
    },
    {
        "id": "6cbac938-baf2-4f0b-b67b-9caeb7ea4fe1",
        "primaryId": "NCT02748213",
        "statement_text": "1 patient  in cohort 1 of the primary trial was recorded as having an overactive thyroid gland ",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Total: 51/110 (46.36%)Febrile neutropenia * 26/110 (23.64%) Neutropenia * 7/110 (6.36%) Anaemia * 1/110 (0.91%) Cardiac failure * 0/110 (0.00%) Coronary artery disease * 0/110 (0.00%) Left ventricular dysfunction * 0/110 (0.00%) Pericardial effusion * 1/110 (0.91%) Hyperthyroidism * 0/110 (0.00%) Diarrhoea * 0/110 (0.00%) Vomiting * 1/110 (0.91%) ",
        "premise_nums": [
            "1/110 (0.91%)",
            "26/110 (23.64%)",
            "7/110 (6.36%)",
            "51/110 (46.36%)Febrile",
            "0/110 (0.00%)"
        ]
    },
    {
        "id": "052ee533-7daa-4cbf-a64c-bc9a50444173",
        "primaryId": "NCT00244933",
        "statement_text": "the primary trial does not monitor the occurrence of Hemoglobin C Disease in its adverse events ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 5/19 (26.32%) Pain 3/19 (15.79%) White blood cells (WBC) 5/19 (26.32%) Hemoglobin (Hgb) 1/19 (5.26%) Absolute neutrophil count (ANC) 5/19 (26.32%) Platelets 3/19 (15.79%) Elevated Aspartate Aminotransferase (AST) 1/19 (5.26%) Elevated Alanine Aminotransferase (ALT) 1/19 (5.26%) Dyspnea 3/19 (15.79%) ",
        "premise_nums": [
            "1/19 (5.26%)",
            "5/19 (26.32%)",
            "3/19 (15.79%)"
        ]
    },
    {
        "id": "1d7dbb44-049d-4887-8bd6-6aefc77aa1e9",
        "primaryId": "NCT00444587",
        "statement_text": "A total of 7 patients in the primary trial were observed with either Leukopenia  Cardiopulmonary failure or Diarrhoea ",
        "statement_nums": [
            "7 patients in"
        ],
        "label": "Entailment",
        "premise_text": "Leukopenia 2/93 (2.15%) Cardiopulmonary failure 2/93 (2.15%) Diarrhoea 3/93 (3.23%) ",
        "premise_nums": [
            "2/93 (2.15%)",
            "3/93 (3.23%)"
        ]
    },
    {
        "id": "9b622b9b-3ad3-4cff-acb3-4127d0304de0",
        "primaryId": "NCT00571987",
        "statement_text": "occupational exposure to ionizing irradiation will not disqualify a patient from entry to the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Inclusion Criteria: Female  18-100 years old Not pregnant or breastfeeding Pre-study radiologic documentation of: size 5 cm unicentric  unilateral suspicious mass or calcification BIRADS classification IV location of abnormality greater than 1 cm from skin Ductal or Infiltrating Ductal Carcinoma Grade I-III on final pathology Good general health Zubrod Performance Status of 0,1, or 2 No previous chemotherapy No palpable axillary or supraclavicular lymph nodes If prior non-breast malignancy  must have greater than 5 year disease-free survival Exclusion Criteria: Patient smaller than 18 y/o or greater than 100 y/o Pregnant or breastfeeding Male Breast implants Multicentric disease or bilateral disease Lesions greater than 5 cm in diameter ",
        "premise_nums": [
            "18 y/o or",
            "5 cm in",
            "100 years old",
            "0,1, or",
            "5 year disease",
            "100 y/o Pregnant",
            "1 cm from",
            "18-100 years",
            "5 cm unicentric",
            "2 No previous"
        ]
    },
    {
        "id": "9b622b9b-3ad3-4cff-acb3-4127d0304de0",
        "primaryId": "NCT00571987",
        "statement_text": "occupational exposure to ionizing irradiation will not disqualify a patient from entry to the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Lesions smaller than 1.0 cm from the skinPrevious prior radiation to the breast Need for mastectomy Diffuse microcalcifications (as determined by the Investigator) ",
        "premise_nums": [
            "than 1.0 cm from"
        ]
    },
    {
        "id": "825ba6fd-8c08-49d2-941b-3338ef01e7fd",
        "primaryId": "NCT02673918",
        "secondaryId": "NCT01042938",
        "label": "Entailment",
        "statement_text": "African American patients are eligible for both the primary trial and the secondary trial ",
        "statement_nums": [],
        "premise_text": "Inclusion Criteria: Diagnosis of breast cancer Part 1 only: Surgery for breast cancer within the past eight weeks (mastectomy or lumpectomy with either sentinel or axillar dissection)  including those women with a history of previous surgery for breast cancer  radiation therapy or chemotherapy Part 2 only: Completion of surgery and radiation therapy for breast cancer within the past six weeks  Home access to internet from stationary computer  lab top or tablet Ability to use internet Ability to read and understand Danish Exclusion Criteria: Surgery for breast cancer with immediate breast reconstruction Diagnosis of primary lymphedema Metastatic or inflammatory breast cancer Planned use of chemotherapy within the next 6 weeks Surgical complications: infection  drainage issues  seroma  hematoma ",
        "premise_nums": [
            "6 weeks Surgical"
        ]
    },
    {
        "id": "825ba6fd-8c08-49d2-941b-3338ef01e7fd",
        "primaryId": "NCT02673918",
        "secondaryId": "NCT01042938",
        "label": "Entailment",
        "statement_text": "African American patients are eligible for both the primary trial and the secondary trial ",
        "statement_nums": [],
        "premise_text": "Severe physical  cognitive  or psychiatric illness causing inability to follow the study protocol: i.e  severe depression  anxiety  dementia  poor physical health with likely possibility of hospitalization within the next twelve weeks Planned hospitalization or surgery within the next twelve weeks Participation in another clinical trial with a rehabilitation or exercise intervention Inclusion Criteria: Participants can be from any racial or ethnic origin  ",
        "premise_nums": []
    },
    {
        "id": "0421750d-66c6-47be-bde7-0c41ee43a28b",
        "primaryId": "NCT01730729",
        "statement_text": "Patients with severe malabsorption disorders are ineligible for the primary trial  even if they are able to receive intravenous (IV) alimentation ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Patients with any of the following conditions or complications are NOT eligible for participation: Require intravenous (IV) alimentation Malabsorption syndrome ",
        "premise_nums": []
    },
    {
        "id": "95345dbe-446f-4999-8f3e-a429b77ea554",
        "primaryId": "NCT02872103",
        "secondaryId": "NCT02995980",
        "label": "Entailment",
        "statement_text": "Adequate renal  hepatic and blood work is required for entry to the primary trial  this includes the following criteria; hemoglobin 11.5 g/dL  aswell as ALT  AST  alkaline phosphatase and total bilirubin smaller than 2.5xULN, and Serum creatinine should be less than 1.7x ULN  These conditions are not explicitly required for the secondary trial ",
        "statement_nums": [
            "hemoglobin 11.5 g/dL",
            "than 1.7x ULN"
        ],
        "premise_text": "White Blood Cell count (WBC) 4.0 109/L, hemoglobin 11.5 g/dL and a platelet count 150 109/L. Demonstrate adequate renal  hepatic function (Liver function tests (ALT  AST  alkaline phosphatase and total bilirubin)) should be less than 2.5x upper limits of normal (ULN)  Serum creatinine should be less than 1.7x ULN  Inclusion Criteria: Signed informed consent ",
        "premise_nums": [
            "than 1.7x ULN",
            "than 2.5x upper",
            "109/L, hemoglobin",
            "hemoglobin 11.5 g/dL",
            "109/L. Demonstrate"
        ]
    },
    {
        "id": "95345dbe-446f-4999-8f3e-a429b77ea554",
        "primaryId": "NCT02872103",
        "secondaryId": "NCT02995980",
        "label": "Entailment",
        "statement_text": "Adequate renal  hepatic and blood work is required for entry to the primary trial  this includes the following criteria; hemoglobin 11.5 g/dL  aswell as ALT  AST  alkaline phosphatase and total bilirubin smaller than 2.5xULN, and Serum creatinine should be less than 1.7x ULN  These conditions are not explicitly required for the secondary trial ",
        "statement_nums": [
            "hemoglobin 11.5 g/dL",
            "than 1.7x ULN"
        ],
        "premise_text": "At least 19 years oldGlomerular filtration rategreater than 60 Heterogeneously or extremely dense breasts (BI-RADS category c or d)  Exclusion Criteria: History of iodinated contrast allergy Pregnant or lactating as determined by routine standard practice Personal history of breast cancer History of prior breast excisional biopsy (Patients with a history of core needle biopsy will not be excluded) History of prior breast reduction mammoplasty surgery History of prior breast augmentation surgery ",
        "premise_nums": [
            "60 Heterogeneously or",
            "19 years oldGlomerular"
        ]
    },
    {
        "id": "95345dbe-446f-4999-8f3e-a429b77ea554",
        "primaryId": "NCT02872103",
        "secondaryId": "NCT02995980",
        "label": "Entailment",
        "statement_text": "Adequate renal  hepatic and blood work is required for entry to the primary trial  this includes the following criteria; hemoglobin 11.5 g/dL  aswell as ALT  AST  alkaline phosphatase and total bilirubin smaller than 2.5xULN, and Serum creatinine should be less than 1.7x ULN  These conditions are not explicitly required for the secondary trial ",
        "statement_nums": [
            "hemoglobin 11.5 g/dL",
            "than 1.7x ULN"
        ],
        "premise_text": "Mental condition rendering the subject unable to understand the nature  scope  and possible consequences of the study ",
        "premise_nums": []
    },
    {
        "id": "b05fde86-4004-427f-8baf-2ea4a0a535c7",
        "primaryId": "NCT00376597",
        "statement_text": "the primary trial all undergo surgery twice  first at 2 weeks and then again a month later ",
        "statement_nums": [
            "2 weeks and"
        ],
        "label": "Contradiction",
        "premise_text": "INTERVENTION 1: Arm I (Lymphedema Education) Six weeks after surgery  patients receive a brief initial post-operative care session describing lymphedema risk and prevention through oral instruction and written materials  Patients complete physical assessments and questionnaires at 6 weeks and at 6, 12, and 18 months  Patients are also contacted by telephone at 9 and 15 months  INTERVENTION 2: Arm II (Lymphedema Education  Physical Therapy) Patients receive lymphedema education and complete physical assessments and questionnaires as in Arm I  Patients also complete a personalized physical therapy intervention  receive a refrigerator magnet  and a 15-minute video that reinforces information and exercises  ",
        "premise_nums": [
            "9 and 15",
            "15-minute video",
            "6 weeks and"
        ]
    },
    {
        "id": "21e24c6c-d282-48fb-8d68-3e723458794e",
        "primaryId": "NCT00825734",
        "statement_text": "Patients with any of the following conditions will be excluded from the primary trial; grade 3 infection  unstable angina or a grade 4 hemorrhage within the last month ",
        "statement_nums": [
            "4 hemorrhage within"
        ],
        "label": "Entailment",
        "premise_text": "Exclusion Criteria Uncontrolled intercurrent illness including (but not limited to) ongoing or active infection greater than grade 2. Unstable angina (anginal symptoms at rest) or new onset angina Pulmonary hemorrhage or bleeding event grade 2 within 4 weeks of the first dose of study treatment  or any other hemorrhage or bleeding event grade 3 within 4 weeks of the first dose of study treatment  ",
        "premise_nums": [
            "2 within 4",
            "3 within 4"
        ]
    },
    {
        "id": "d1e579e2-b057-43da-8a2f-64dad964b789",
        "primaryId": "NCT00821964",
        "statement_text": "the primary trial participants apply topical imiquimod to cutaneous lesions once daily every other day for a total of 14 days every 28 day cycle ",
        "statement_nums": [
            "14 days every",
            "28 day cycle"
        ],
        "label": "Contradiction",
        "premise_text": "INTERVENTION 1: Treatment (Biological Therapy  Chemo) Patients receive Abraxane IV over 30 minutes on days 1, 8, and 15 and apply topical imiquimod to cutaneous lesions QD on days 1-4, 8-11, 15-18, and 22-25. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity  imiquimod: Given topically Abraxane: Given IV laboratory biomarker analysis: Correlative studies RNA analysis: Correlative studies immunoenzyme technique: Correlative studies ",
        "premise_nums": [
            "22-25. Treatment",
            "15 and apply",
            "30 minutes on",
            "15-18, and",
            "1-4, 8-11,",
            "3 cycles in",
            "28 days for"
        ]
    },
    {
        "id": "5ac83a45-db7d-44d1-bf37-9cbf3c8fabb6",
        "primaryId": "NCT00093145",
        "secondaryId": "NCT00703326",
        "label": "Contradiction",
        "statement_text": "Heart-related adverse events were recorded in the secondary trial  but not the primary trial ",
        "statement_nums": [],
        "premise_text": "Adverse Events 1: Supraventricular tachycardia 1/32 (3.13%) Adverse Events 1: Atrial fibrillation 1/752 (0.13%) Atrial flutter 0/752 (0.00%) Cardiac failure congestive 1/752 (0.13%) Left ventricular dysfunction 0/752 (0.00%) ",
        "premise_nums": [
            "1/32 (3.13%)",
            "1/752 (0.13%)",
            "0/752 (0.00%)"
        ]
    },
    {
        "id": "d130c981-f602-4f17-b1cb-11a7ad632b92",
        "primaryId": "NCT01234402",
        "statement_text": "the primary trial more than 6 different types of cardiac related adverse events ",
        "statement_nums": [
            "6 different types"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Acute myocardial infarction 0/52 (0.00%) Atrial fibrillation 0/52 (0.00%) Cardiac failure 1/52 (1.92%) Cardiogenic shock 1/52 (1.92%) Palpitations 0/52 (0.00%) Pericardial effusion 0/52 (0.00%) Right ventricular failure 1/52 (1.92%) Adverse Events 2: Acute myocardial infarction 1/49 (2.04%) Atrial fibrillation 1/49 (2.04%) Cardiac failure 0/49 (0.00%) Cardiogenic shock 0/49 (0.00%) Palpitations 1/49 (2.04%) ",
        "premise_nums": [
            "1/49 (2.04%)",
            "0/49 (0.00%)",
            "1/52 (1.92%)",
            "0/52 (0.00%)"
        ]
    },
    {
        "id": "d130c981-f602-4f17-b1cb-11a7ad632b92",
        "primaryId": "NCT01234402",
        "statement_text": "the primary trial more than 6 different types of cardiac related adverse events ",
        "statement_nums": [
            "6 different types"
        ],
        "label": "Entailment",
        "premise_text": "Pericardial effusion 4/49 (8.16%)Right ventricular failure 0/49 (0.00%) ",
        "premise_nums": [
            "0/49 (0.00%)",
            "4/49 (8.16%)Right"
        ]
    },
    {
        "id": "c1f9982f-c4c9-48dc-887a-7ae05f508c21",
        "primaryId": "NCT03329937",
        "statement_text": "the primary trial Participants received niraparib 200 milligrams (mg) PO once daily for a 28 day cycle  for 2 cycles",
        "statement_nums": [
            "28 day cycle",
            "200 milligrams (mg)"
        ],
        "label": "Entailment",
        "premise_text": "INTERVENTION 1: Niraparib 200 mg Participants received niraparib 200 milligrams (mg) orally once daily in 28-day treatment cycles  After 2 cycles  participants either underwent surgery  received additional cycles of niraparib (maximum of 6 cycles total)  or received neoadjuvant chemotherapy  at physician's discretion  A breast magnetic resonance imaging (MRI) was performed at the end of cycle 2 and breast ultrasounds were performed at the end of each cycle  including any additional cycles beyond cycle 2. After completion of all neoadjuvant therapy participants proceeded to surgery  at which time pathological complete response (pCR) was assessed  ",
        "premise_nums": [
            "200 mg Participants",
            "6 cycles total)",
            "200 milligrams (mg)",
            "2 and breast",
            "28-day treatment"
        ]
    },
    {
        "id": "e966302f-9378-4681-b2c6-9d8b5b5f709f",
        "primaryId": "NCT00182793",
        "statement_text": "The majority of patients in the primary trial experienced an adverse event ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 24/32 (75.00%) ",
        "premise_nums": [
            "24/32 (75.00%)"
        ]
    },
    {
        "id": "75130da8-77be-45d1-bc32-dfc97c1a1dae",
        "primaryId": "NCT02441946",
        "secondaryId": "NCT00325598",
        "label": "Entailment",
        "statement_text": "the secondary trial has a much longer duration than the primary trial ",
        "statement_nums": [],
        "premise_text": "Outcome Measurement: Time frame: Baseline  2 Weeks Outcome Measurement: Time frame: Within 1 year of protocol registration ",
        "premise_nums": [
            "2 Weeks Outcome",
            "1 year of"
        ]
    },
    {
        "id": "c71cbcd6-3786-4b90-8991-b3c6e159ae77",
        "primaryId": "NCT00975676",
        "secondaryId": "NCT00632489",
        "label": "Contradiction",
        "statement_text": "the primary trial uses the same dosage of Triptorelin as the secondary trial uses for Capecitabine and Lapatinib ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Triptorelin Plus Tamoxifen Determination of estrogen levels in blood samples from patients being treated with triptorelin plus tamoxifen for 5 years  INTERVENTION 2: Triptorelin Plus Exemestane Determination of estrogen levels in blood samples from patients being treated with triptorelin plus exemestane for 5 years  INTERVENTION 1: LBH589 With Capecitabine MTD  LBH589 with Capecitabine ",
        "premise_nums": [
            "LBH589 With",
            "589 With Capecitabine",
            "589 with Capecitabine",
            "LBH589 with"
        ]
    },
    {
        "id": "c71cbcd6-3786-4b90-8991-b3c6e159ae77",
        "primaryId": "NCT00975676",
        "secondaryId": "NCT00632489",
        "label": "Contradiction",
        "statement_text": "the primary trial uses the same dosage of Triptorelin as the secondary trial uses for Capecitabine and Lapatinib ",
        "statement_nums": [],
        "premise_text": "LBH589: LBH589 will be evaluated when administered twice weekly at the following possible dose levels: 20 mg  30 mg  45 mg  and 60 mg  Capecitabine will be paired with LBH589 and will range in dose from 825 mg/m2 to 1250 mg/m2 orally BID 14 of every 21 days  Treatment cycles will be 21 days in length  Once determined safe  10 additional patients will be treated at the determined MTD to further assess safety Capecitabine: Capecitabine will be administered orally twice daily for 14 days out of every 21 days  INTERVENTION 2: LBH589 and Lapatinib LBH589 and Lapatinib ",
        "premise_nums": [
            "589 will be",
            "21 days in",
            "2 to 1250",
            "10 additional patients",
            "589 and Lapatinib",
            "14 days out",
            "14 of every",
            "825 mg/m2 to",
            "589 and will",
            "LBH589 and",
            "1250 mg/m2 orally",
            "LBH589 will",
            "2 orally BID"
        ]
    },
    {
        "id": "c71cbcd6-3786-4b90-8991-b3c6e159ae77",
        "primaryId": "NCT00975676",
        "secondaryId": "NCT00632489",
        "label": "Contradiction",
        "statement_text": "the primary trial uses the same dosage of Triptorelin as the secondary trial uses for Capecitabine and Lapatinib ",
        "statement_nums": [],
        "premise_text": "LBH589: LBH589 will be evaluated when administered twice weekly at the following possible dose levels: 20 mg  30 mg  45 mg  and 60 mg  Capecitabine will be paired with LBH589 and will range in dose from 825 mg/m2 to 1250 mg/m2 orally BID 14 of every 21 days  Treatment cycles will be 21 days in length  Once determined safe  10 additional patients will be treated at the determined MTD to further assess safety Lapatinib: Lapatinib  1000 mg PO daily will be added to this combination  ",
        "premise_nums": [
            "1000 mg PO",
            "589 will be",
            "21 days in",
            "2 to 1250",
            "10 additional patients",
            "14 of every",
            "825 mg/m2 to",
            "589 and will",
            "LBH589 and",
            "1250 mg/m2 orally",
            "LBH589 will",
            "2 orally BID"
        ]
    },
    {
        "id": "ed48936e-4933-437b-a7ba-e65b4c1fd276",
        "primaryId": "NCT03167359",
        "secondaryId": "NCT01385137",
        "label": "Contradiction",
        "statement_text": "Hypofractionated Simultaneous Integrated Boost Radiotherapy is used in the secondary trial  but not the primary trial ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Participants With Stage 0-III Breast Cancer Women with Stage 0-III breast cancer  treated with breast conserving surgery or mastectomy and clear margins  will receive 15 doses of radiation over three weeks  Hypofractionated Simultaneous Integrated Boost Radiotherapy: Participants will receive radiotherapy treatments to the whole breast or chest wall to a dose of 2.66 Gy per day x 15 fractions simultaneously with a boost treatment  The boost treatment will be given on the same days as the whole breast treatment  The lumpectomy cavity + scar (in lumpectomy patients) or chest wall scar (mastectomy patients) will receive 0.54 Gy per day x 15 fractions  INTERVENTION 1: Arm I (Omega-3-fatty Acid) ",
        "premise_nums": [
            "of 2.66 Gy per",
            "0-III Breast",
            "15 doses of",
            "receive 0.54 Gy per",
            "3-fatty Acid",
            "15 fractions simultaneously",
            "0-III breast"
        ]
    },
    {
        "id": "ed48936e-4933-437b-a7ba-e65b4c1fd276",
        "primaryId": "NCT03167359",
        "secondaryId": "NCT01385137",
        "label": "Contradiction",
        "statement_text": "Hypofractionated Simultaneous Integrated Boost Radiotherapy is used in the secondary trial  but not the primary trial ",
        "statement_nums": [],
        "premise_text": "Patients receive oral omega-3-fatty acid twice daily (BID) or three times daily (TID) for 24 weeks in the absence of disease progression or unacceptable toxicityINTERVENTION 2: Arm II (Placebo) Patients receive oral placebo BID or TID for 24 weeks in the absence of disease progression or unacceptable toxicity ",
        "premise_nums": [
            "3-fatty acid",
            "24 weeks in"
        ]
    },
    {
        "id": "b01e966e-6624-4740-b477-a8bbbd8eec50",
        "primaryId": "NCT02102490",
        "secondaryId": "NCT00768222",
        "label": "Entailment",
        "statement_text": "In contrast to the secondary trial  the primary trial did not record any cases of Skin lymphangitis  Bone marrow suppression or Allergic shock ",
        "statement_nums": [],
        "premise_text": "Adverse Events 1: Total: 33/132 (25.00%) Febrile neutropenia 1/132 (0.76%) Haematotoxicity 1/132 (0.76%) Neutropenia 1/132 (0.76%) Sinus bradycardia 1/132 (0.76%) Tachycardia 1/132 (0.76%) Abdominal pain 2/132 (1.52%) Abdominal pain upper 1/132 (0.76%) Constipation 1/132 (0.76%) Large intestinal obstruction 1/132 (0.76%) Nausea 3/132 (2.27%) Adverse Events 1: Total: 3/50 (6.00%) ",
        "premise_nums": [
            "1/132 (0.76%)",
            "3/50 (6.00%)",
            "3/132 (2.27%)",
            "33/132 (25.00%)",
            "2/132 (1.52%)"
        ]
    },
    {
        "id": "b01e966e-6624-4740-b477-a8bbbd8eec50",
        "primaryId": "NCT02102490",
        "secondaryId": "NCT00768222",
        "label": "Entailment",
        "statement_text": "In contrast to the secondary trial  the primary trial did not record any cases of Skin lymphangitis  Bone marrow suppression or Allergic shock ",
        "statement_nums": [],
        "premise_text": "Skin lymphangitis 1/50 (2.00%)Bone marrow suppression 0/50 (0.00%) Allergic shock 1/50 (2.00%) Deep incisional SSI 1/50 (2.00%) Adverse Events 2: Total: 1/51 (1.96%) Skin lymphangitis 0/51 (0.00%) Bone marrow suppression 1/51 (1.96%) Allergic shock 0/51 (0.00%) Deep incisional SSI 0/51 (0.00%) ",
        "premise_nums": [
            "1/51 (1.96%)",
            "0/50 (0.00%)",
            "0/51 (0.00%)",
            "1/50 (2.00%)Bone"
        ]
    },
    {
        "id": "92acd36d-ea44-4b98-acbc-e51382233089",
        "primaryId": "NCT00820872",
        "statement_text": "Diarrhea was the most common adverse event in cohort 1 of the primary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 10/30 (33.33%) Hemoglobin decreased 2/30 (6.67%) Abdominal pain 1/30 (3.33%) Colitis 1/30 (3.33%) Diarrhea 7/30 (23.33%) Nausea 2/30 (6.67%) Rectal hemorrhage 1/30 (3.33%) Fatigue 1/30 (3.33%) Skin infection 1/30 (3.33%) Neutrophil count decreased 1/30 (3.33%) Platelet count decreased 3/30 (10.00%) Dehydration 1/30 (3.33%) ",
        "premise_nums": [
            "10/30 (33.33%)",
            "3/30 (10.00%)",
            "7/30 (23.33%)",
            "1/30 (3.33%)",
            "2/30 (6.67%)"
        ]
    },
    {
        "id": "01280892-ca31-4e46-831b-a076426f65e5",
        "primaryId": "NCT01401062",
        "statement_text": "A patient who underwent T-cell transfer therapy in the past 6 months prior  and has fully recovered from the associated toxicities  would be excluded from the primary trial ",
        "statement_nums": [
            "6 months prior"
        ],
        "label": "Contradiction",
        "premise_text": "Must be 4 weeks since all of the following treatments (recovered from toxicity of prior treatment to Grade 1, excluding alopecia): immunotherapy; ",
        "premise_nums": [
            "4 weeks since"
        ]
    },
    {
        "id": "959bd67a-1b2a-48da-ae44-211cbab4b665",
        "primaryId": "NCT00393939",
        "statement_text": "Median (95% Confidence Interval) Progression-Free Survival (PFS) was over a month higher for patients in the Docetaxel + Sunitinib group of the primary trial than for the Docetaxel group ",
        "statement_nums": [
            "95% Confidence"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Progression-Free Survival (PFS) PFS defined as time from date of randomization to date of the first documentation of objective tumor progression or death due to any cause  whichever occurred first  PFS calculated as (Months) = (first event date minus randomization date plus 1) divided by 30.4. Time frame: Baseline up to Month 33 Results 1: Arm/Group Title: Docetaxel + Sunitinib ",
        "premise_nums": [
            "33 Results 1:"
        ]
    },
    {
        "id": "959bd67a-1b2a-48da-ae44-211cbab4b665",
        "primaryId": "NCT00393939",
        "statement_text": "Median (95% Confidence Interval) Progression-Free Survival (PFS) was over a month higher for patients in the Docetaxel + Sunitinib group of the primary trial than for the Docetaxel group ",
        "statement_nums": [
            "95% Confidence"
        ],
        "label": "Entailment",
        "premise_text": "Arm/Group Description: Sunitinib 37.5 milligrams (mg) daily by oral capsule for 2 weeks followed by a 1-week off-treatment period (Schedule 2/1) with docetaxel 75 milligrams per square meter (mg/m^2) every 3 weeks  or sunitinib 37.5 mg daily in continuous dosing (in absence of docetaxel)  or docetaxel 100 mg/m^2 every 3 weeks (in absence of sunitinib) Overall Number of Participants Analyzed: 296 Median (95% Confidence Interval) ",
        "premise_nums": [
            "2 every 3",
            "2 weeks followed",
            "75 milligrams per",
            "100 mg/m^2",
            "95% Confidence",
            "2/1) with",
            "sunitinib 37.5 mg daily",
            "1-week off-treatment",
            "5 milligrams (mg)"
        ]
    },
    {
        "id": "959bd67a-1b2a-48da-ae44-211cbab4b665",
        "primaryId": "NCT00393939",
        "statement_text": "Median (95% Confidence Interval) Progression-Free Survival (PFS) was over a month higher for patients in the Docetaxel + Sunitinib group of the primary trial than for the Docetaxel group ",
        "statement_nums": [
            "95% Confidence"
        ],
        "label": "Entailment",
        "premise_text": "Unit of Measure: months Independent radiology assessment: 8.6 (8.2 to 10.3)Investigator's assessment: 8.2 (7.3 to 8.6) Results 2: Arm/Group Title: Docetaxel Arm/Group Description: Docetaxel 100 mg/m^2 every 3 weeks Overall Number of Participants Analyzed: 297 Median (95% Confidence Interval) Unit of Measure: months Independent radiology assessment: 8.3 (7.7 to 9.6) Investigator's assessment: 6.9 (6.5 to 7.3) ",
        "premise_nums": [
            "2 every 3",
            "3 to 8.6)",
            "3 weeks Overall",
            "5 to 7.3)",
            "7 to 9.6)",
            "100 mg/m^2",
            "95% Confidence"
        ]
    },
    {
        "id": "92923765-76d4-4a27-a240-101690d9fea4",
        "primaryId": "NCT01432145",
        "statement_text": "the primary trial patients are administered cyclophosphamide more often and in higher dosages than Methotrexate and 6-Mercaptopurine.",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "INTERVENTION 1: 6-Mercaptopurine and Methotrexate (6MP/MTX) 6-Mercaptopurine: 6MP 75mg/m2 body surface area  administered orally (PO) once a day (od) in the morning 1 hour after eating  on a continuous schedule  One cycle is 28 days  Treatment is given continuously until disease progression  Methotrexate: Methotrexate 20mg/m2 will be taken orally  once a week  in the morning  One cycle is 28 days  Treatment is given continuously until disease progression  ",
        "premise_nums": [
            "1 hour after",
            "75mg/m2 body",
            "6-Mercaptopurine: 6MP",
            "2 will be",
            "2 body surface",
            "6-Mercaptopurine and",
            "20mg/m2 will"
        ]
    },
    {
        "id": "92923765-76d4-4a27-a240-101690d9fea4",
        "primaryId": "NCT01432145",
        "statement_text": "the primary trial patients are administered cyclophosphamide more often and in higher dosages than Methotrexate and 6-Mercaptopurine.",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Update: These original doses were reduced following an Urgent Safety Measure in August 2012 due to a large proportion of patients requiring a dose reduction or treatment delay due to incidences of myelo-suppression The reduced doses were 55mg/m2 of 6MP orally once a day  and 15mg/m2 of Methotrexate orally once a week  ",
        "premise_nums": [
            "2 of 6MP",
            "2 of Methotrexate",
            "2012 due to",
            "15mg/m2 of",
            "55mg/m2 of"
        ]
    },
    {
        "id": "437cb2c2-63e8-4d9b-a501-4b6a35db8d2b",
        "primaryId": "NCT00429507",
        "secondaryId": "NCT00038467",
        "label": "Contradiction",
        "statement_text": "Unlike the secondary trial  the primary trial does not administer any medication orally or intravenously ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Samarium 153-EDTMP + Stem Cell Transplant Samarium 153-EDTMP tracer dose = 30 millicurie (mCi) intravenous Day 1; or with study drug to bones  receive higher therapy dose of 153 Sm-EDTMP 7-14 days after tracer dose  Stem Cell Transplant Day 0, about 14-21 days after Samarium 153-EDTMP. INTERVENTION 1: Exemestane Participants diagnosed with breast cancer who remained disease-free after previously receiving 2 to 3 years of tamoxifen 20 milligram (mg) or 30 mg tablet-in-capsule orally once daily as per standard medical practice  received exemestane (Aromasin) 25 mg tablet-in-capsule orally once daily for the remainder of 5-year period  INTERVENTION 2: ",
        "premise_nums": [
            "30 millicurie (mCi)",
            "153 Sm-EDTMP",
            "153-EDTMP. INTERVENTION",
            "14 days after",
            "14-21 days",
            "21 days after",
            "25 mg tablet",
            "7-14 days",
            "153-EDTMP +",
            "153-EDTMP tracer",
            "30 mg tablet",
            "5-year period",
            "2 to 3",
            "20 milligram (mg)"
        ]
    },
    {
        "id": "437cb2c2-63e8-4d9b-a501-4b6a35db8d2b",
        "primaryId": "NCT00429507",
        "secondaryId": "NCT00038467",
        "label": "Contradiction",
        "statement_text": "Unlike the secondary trial  the primary trial does not administer any medication orally or intravenously ",
        "statement_nums": [],
        "premise_text": "TamoxifenParticipants diagnosed with breast cancer who remained disease-free after previously receiving 2 to 3 years of tamoxifen 20 mg or 30 mg tablet-in-capsule orally once daily as per standard medical practice  received the same dose of tamoxifen tablet-in-capsule orally once daily for the remainder of 5-year period  ",
        "premise_nums": [
            "30 mg tablet",
            "5-year period",
            "20 mg or",
            "2 to 3"
        ]
    },
    {
        "id": "5a5695e8-9b84-42ad-9f34-6dd043153943",
        "primaryId": "NCT02872103",
        "secondaryId": "NCT02995980",
        "label": "Contradiction",
        "statement_text": "Adequate renal  hepatic and blood work is required for entry to the primary trial and the secondary trial  this includes the following criteria; hemoglobin 11.5 g/dL  aswell as ALT  AST  alkaline phosphatase and total bilirubin smaller than 2.5xULN, and Serum creatinine should be less than 1.7x ULN ",
        "statement_nums": [
            "hemoglobin 11.5 g/dL",
            "than 1.7x ULN"
        ],
        "premise_text": "White Blood Cell count (WBC) 4.0 109/L, hemoglobin 11.5 g/dL and a platelet count 150 109/L. Demonstrate adequate renal  hepatic function (Liver function tests (ALT  AST  alkaline phosphatase and total bilirubin)) should be less than 2.5x upper limits of normal (ULN)  Serum creatinine should be less than 1.7x ULN  Inclusion Criteria: Signed informed consent At least 19 years old ",
        "premise_nums": [
            "than 1.7x ULN",
            "than 2.5x upper",
            "109/L, hemoglobin",
            "hemoglobin 11.5 g/dL",
            "109/L. Demonstrate",
            "19 years old"
        ]
    },
    {
        "id": "5a5695e8-9b84-42ad-9f34-6dd043153943",
        "primaryId": "NCT02872103",
        "secondaryId": "NCT02995980",
        "label": "Contradiction",
        "statement_text": "Adequate renal  hepatic and blood work is required for entry to the primary trial and the secondary trial  this includes the following criteria; hemoglobin 11.5 g/dL  aswell as ALT  AST  alkaline phosphatase and total bilirubin smaller than 2.5xULN, and Serum creatinine should be less than 1.7x ULN ",
        "statement_nums": [
            "hemoglobin 11.5 g/dL",
            "than 1.7x ULN"
        ],
        "premise_text": "Glomerular filtration rategreater than 60Heterogeneously or extremely dense breasts (BI-RADS category c or d)  Exclusion Criteria: History of iodinated contrast allergy Pregnant or lactating as determined by routine standard practice Personal history of breast cancer History of prior breast excisional biopsy (Patients with a history of core needle biopsy will not be excluded) History of prior breast reduction mammoplasty surgery History of prior breast augmentation surgery ",
        "premise_nums": []
    },
    {
        "id": "5a5695e8-9b84-42ad-9f34-6dd043153943",
        "primaryId": "NCT02872103",
        "secondaryId": "NCT02995980",
        "label": "Contradiction",
        "statement_text": "Adequate renal  hepatic and blood work is required for entry to the primary trial and the secondary trial  this includes the following criteria; hemoglobin 11.5 g/dL  aswell as ALT  AST  alkaline phosphatase and total bilirubin smaller than 2.5xULN, and Serum creatinine should be less than 1.7x ULN ",
        "statement_nums": [
            "hemoglobin 11.5 g/dL",
            "than 1.7x ULN"
        ],
        "premise_text": "Mental condition rendering the subject unable to understand the nature  scope  and possible consequences of the study ",
        "premise_nums": []
    },
    {
        "id": "33634c51-0fb9-4de1-966d-14784bca93f8",
        "primaryId": "NCT01847001",
        "statement_text": "Spanish women with a heart rate of at least 60 beats per minute are eligible for the primary trial ",
        "statement_nums": [
            "60 beats per"
        ],
        "label": "Entailment",
        "premise_text": "Inclusion Criteria: English or Spanish speaking women age 18 Heart Rate greater than 60 bpm ",
        "premise_nums": [
            "18 Heart Rate"
        ]
    },
    {
        "id": "8e46dc77-fa36-4231-a124-0ff6392891a1",
        "primaryId": "NCT02297412",
        "secondaryId": "NCT02667626",
        "label": "Entailment",
        "statement_text": "Cohort 2 of the secondary trial and the primary trial are control groups ",
        "statement_nums": [
            "2 of the"
        ],
        "premise_text": "INTERVENTION 1: Arm I (Minocycline Hydrochloride) Patients receive minocycline hydrochloride PO BID on days 1-7. Treatment repeats every 7 days for up to 12 courses in the absence of disease progression or unacceptable toxicity  INTERVENTION 2: Arm II (Placebo) Patients receive a placebo PO BID on days 1-7. Treatment repeats every 7 days for up to 12 courses in the absence of disease progression or unacceptable toxicity  INTERVENTION 1: SCPR Intervention Young breast cancer participants will receive their SCPR and access to additional web-based educational reproductive health information  including resource lists of helpful websites  followed by regular reproductive health prompts and study adherence reminders for 24 weeks  ",
        "premise_nums": [
            "12 courses in",
            "1-7. Treatment",
            "7 days for"
        ]
    },
    {
        "id": "8e46dc77-fa36-4231-a124-0ff6392891a1",
        "primaryId": "NCT02297412",
        "secondaryId": "NCT02667626",
        "label": "Entailment",
        "statement_text": "Cohort 2 of the secondary trial and the primary trial are control groups ",
        "statement_nums": [
            "2 of the"
        ],
        "premise_text": "Reproductive Health Survivorship Care Plan (SCPR): The reproductive health survivorship care plan (SCPR) is a web-based educational tool that will include information on how to manage various reproductive health issues such as hot flashes  fertility concerns  contraception practices  and sexual function  The intervention also includes additional web-based information and resource lists  text-based reproductive health and study adherenceINTERVENTION 2: Control Young breast cancer participants randomized to the waitlist control arm will receive access to the web-based resources and study adherence reminders  At completion of the 24 weeks of follow up  they will have access to their SCPR  Control: Web-based resource lists and text-based study adherence reminders ",
        "premise_nums": [
            "24 weeks of"
        ]
    },
    {
        "id": "d11b0673-42a9-46c0-887f-d5a9b038264f",
        "primaryId": "NCT00407888",
        "statement_text": "Arm 1 of the primary trial receive dose-intensive chemotherapy on a week long cycle up to 12 times in the absence of disease progression or unacceptable toxicity ",
        "statement_nums": [
            "12 times in",
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "INTERVENTION 1: Arm I ",
        "premise_nums": []
    },
    {
        "id": "d11b0673-42a9-46c0-887f-d5a9b038264f",
        "primaryId": "NCT00407888",
        "statement_text": "Arm 1 of the primary trial receive dose-intensive chemotherapy on a week long cycle up to 12 times in the absence of disease progression or unacceptable toxicity ",
        "statement_nums": [
            "12 times in",
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Patients receive dose-intensive chemotherapy comprising doxorubicin hydrochloride IV over 10-15 minutes on day 1, oral cyclophosphamide once daily on days 1-7, and filgrastim subcutaneously on days 2-7. Courses repeat every 7 days for up to 12 weeks in the absence of disease progression or unacceptable toxicity  Beginning 1 week later  patients then receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes once a week for 12 weeks in the absence of disease progression or unacceptable toxicity  Patients with HER-2/neu positive disease also receive trastuzumab IV over 30-90 minutes once a week for 1 year in the absence of disease progression or unacceptable toxicity ",
        "premise_nums": [
            "1 week later",
            "30 minutes once",
            "30-90 minutes",
            "7 days for",
            "90 minutes once",
            "15 minutes on",
            "12 weeks in",
            "2/neu positive",
            "2-7. Courses",
            "10-15 minutes",
            "1 year in",
            "1-7, and"
        ]
    },
    {
        "id": "d11b0673-42a9-46c0-887f-d5a9b038264f",
        "primaryId": "NCT00407888",
        "statement_text": "Arm 1 of the primary trial receive dose-intensive chemotherapy on a week long cycle up to 12 times in the absence of disease progression or unacceptable toxicity ",
        "statement_nums": [
            "12 times in",
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "doxorubicin hydrochloride: Given IVcyclophosphamide: Given orally filgrastim: Given SC paclitaxel albumin-stabilized nanoparticle formulation: Given IV trastuzumab: Given IV laboratory biomarker analysis: Correlative studies quality-of-life assessment: Ancillary studies ",
        "premise_nums": []
    },
    {
        "id": "e08c196a-e3f0-420b-a252-7e2818949038",
        "primaryId": "NCT03197389",
        "statement_text": "All women (regardless of Reproductive status) must use adequate methods of contraception to be eligible for the primary trial ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria: Female subjects of childbearing potential (Section 5.7.2) must be willing to use an adequate method of contraception as outlined in Section 5.7.2 - Contraception  for the course of the study through 120 days after receiving the study medication  Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject  Male subjects of childbearing potential (Section 5.7.1) must agree to use an adequate method of contraception as outlined in Section 5.7.1- Contraception  until 120 after receiving the study therapy  ",
        "premise_nums": [
            "120 days after",
            "120 after receiving"
        ]
    },
    {
        "id": "83511f04-e07c-438d-bf1e-f680fa49b384",
        "primaryId": "NCT01901146",
        "secondaryId": "NCT00209092",
        "label": "Entailment",
        "statement_text": "Cohort 1 of the primary trial recorded more instances of Neutropenic fever than Cohort 1 of the secondary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Adverse Events 1: Febrile neutropenia 3/364 (0.82%) Adverse Events 1: Febrile Neutropenia *0/25 (0.00%) ",
        "premise_nums": [
            "0/25 (0.00%)",
            "3/364 (0.82%)"
        ]
    },
    {
        "id": "c06a6571-6bc9-4bc1-b4f5-3e7aa71c8c94",
        "primaryId": "NCT00290758",
        "statement_text": "There was one genitourinary adverse events recorded in the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 6/62 (9.68%) Musculoskeletal * 1/62 (1.61%) Mood Alteration: Depression * 1/62 (1.61%) renal - Other * 1/62 (1.61%) Obstruction  GU: Uterus * 1/62 (1.61%) Sexual * 0/62 (0.00%) Pulmonary/Upper Respiratory: Dyspnea * 1/62 (1.61%) Ulceration * 1/62 (1.61%) Adverse Events 2: Total: 1/64 (1.56%) Musculoskeletal * 0/64 (0.00%) Mood Alteration: Depression * 0/64 (0.00%) ",
        "premise_nums": [
            "0/62 (0.00%)",
            "0/64 (0.00%)",
            "1/62 (1.61%)",
            "1/64 (1.56%)",
            "6/62 (9.68%)"
        ]
    },
    {
        "id": "c06a6571-6bc9-4bc1-b4f5-3e7aa71c8c94",
        "primaryId": "NCT00290758",
        "statement_text": "There was one genitourinary adverse events recorded in the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "renal - Other * 0/64 (0.00%)Obstruction  GU: Uterus * 0/64 (0.00%) Sexual * 1/64 (1.56%) Pulmonary/Upper Respiratory: Dyspnea * 0/64 (0.00%) Ulceration * 0/64 (0.00%) ",
        "premise_nums": [
            "1/64 (1.56%)",
            "0/64 (0.00%)Obstruction"
        ]
    },
    {
        "id": "72bb3c6e-66b0-4380-9da2-5a5867d715fd",
        "primaryId": "NCT00475670",
        "statement_text": "compared to cohort 1 of the primary trial  there are more cases of every observed adverse event in cohort 2.",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 0/3 (0.00%) Febrile Neutropenia * 0/3 (0.00%) Neutropenia * 0/3 (0.00%) Sudden Death * 0/3 (0.00%) Bacterial Infection * 0/3 (0.00%) Bronchitis * 0/3 (0.00%) Sepsis * 0/3 (0.00%) Lymphoedema * 0/3 (0.00%) Adverse Events 2: Total: 6/41 (14.63%) Febrile Neutropenia * 1/41 (2.44%) Neutropenia * 1/41 (2.44%) Sudden Death * 1/41 (2.44%) ",
        "premise_nums": [
            "0/3 (0.00%)",
            "6/41 (14.63%)",
            "1/41 (2.44%)"
        ]
    },
    {
        "id": "72bb3c6e-66b0-4380-9da2-5a5867d715fd",
        "primaryId": "NCT00475670",
        "statement_text": "compared to cohort 1 of the primary trial  there are more cases of every observed adverse event in cohort 2.",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Bacterial Infection * 1/41 (2.44%)Bronchitis * 1/41 (2.44%) Sepsis * 1/41 (2.44%) Lymphoedema * 1/41 (2.44%) ",
        "premise_nums": [
            "1/41 (2.44%)Bronchitis"
        ]
    },
    {
        "id": "1b433096-f36a-4205-b16e-f9a370be3d05",
        "primaryId": "NCT01365845",
        "statement_text": "More than 18 participants in the primary trial had radiation dermatitis ",
        "statement_nums": [
            "18 participants in"
        ],
        "label": "Contradiction",
        "premise_text": "Radiation dermatitis 2 [1]4/18 (22.22%) ",
        "premise_nums": [
            "4/18 (22.22%)"
        ]
    },
    {
        "id": "076ead15-ce03-4c33-9050-1f6eb13764a1",
        "primaryId": "NCT01490892",
        "secondaryId": "NCT02364388",
        "label": "Entailment",
        "statement_text": "The intervention in the primary trial requires an injection and two different imaging modalities  whereas the secondary trial provides almost no details in the intervention section ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: 3D HI and SHI of UCA Perflutren injection  suspension (IV)0.25 ml followed by 3D Harmonic imaging (HI) then (IV) 20 micro-l/kg followed by 3D subharmonic imaging (SHI) 3D HI and SHI of UCA: Perflutren injection  suspension (IV)0.25 ml followed by 3D Harmonic imaging (HI) then (IV) 20 micro-l/kg followed by 3D subharmonic imaging (SHI) INTERVENTION 1: MAESTRO Baseline ",
        "premise_nums": [
            "25 ml followed",
            "20 micro-l/kg"
        ]
    },
    {
        "id": "0d76e3b7-c6ed-48b2-a3c2-4857a9c02f76",
        "primaryId": "NCT00323479",
        "secondaryId": "NCT03078751",
        "label": "Contradiction",
        "statement_text": "There were more cases of Pulmonary embolisms in the primary trial than the secondary trial ",
        "statement_nums": [],
        "premise_text": "Adverse Events 1: Total: 6/110 (5.45%) Sudden death unexplained 1/110 (0.91%) General body pain 1/110 (0.91%) Lymphangitis 1/110 (0.91%) Femur fracture 1/110 (0.91%) Parathyroid adenoma 1/110 (0.91%) Depression worsened 1/110 (0.91%) Calculus urinary bladder 1/110 (0.91%) Pneumopathy 1/110 (0.91%) Adverse Events 1: Total: 4/26 (15.38%) Disseminated intravascular coagulation 1/26 (3.85%) Cardiac failure congestive 1/26 (3.85%) ",
        "premise_nums": [
            "1/110 (0.91%)",
            "4/26 (15.38%)",
            "6/110 (5.45%)",
            "1/26 (3.85%)"
        ]
    },
    {
        "id": "0d76e3b7-c6ed-48b2-a3c2-4857a9c02f76",
        "primaryId": "NCT00323479",
        "secondaryId": "NCT03078751",
        "label": "Contradiction",
        "statement_text": "There were more cases of Pulmonary embolisms in the primary trial than the secondary trial ",
        "statement_nums": [],
        "premise_text": "Breast cellulitis 1/26 (3.85%)Cellulitis 1/26 (3.85%) Acute myeloid leukaemia 1/26 (3.85%) Seizure 0/26 (0.00%) Pulmonary embolism 1/26 (3.85%) Adverse Events 2: Total: 2/24 (8.33%) Disseminated intravascular coagulation 0/24 (0.00%) Cardiac failure congestive 0/24 (0.00%) Breast cellulitis 0/24 (0.00%) Cellulitis 1/24 (4.17%) Acute myeloid leukaemia 0/24 (0.00%) Seizure 1/24 (4.17%) Pulmonary embolism 0/24 (0.00%) ",
        "premise_nums": [
            "2/24 (8.33%)",
            "1/24 (4.17%)",
            "0/26 (0.00%)",
            "1/26 (3.85%)Cellulitis",
            "0/24 (0.00%)"
        ]
    },
    {
        "id": "3e1037fd-cc1e-4229-892f-95d0987d9a68",
        "primaryId": "NCT01042535",
        "statement_text": "The Maximum Tolerated Dose (MTD) of of 1-methyl-d-tryptophan (indoximod) observed in the primary trial was 800 mg ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Phase 1 - Maximum Tolerated Dose (MTD) in Milligrams (mg) ",
        "premise_nums": []
    },
    {
        "id": "f25adbc7-c0a0-44ed-af93-02f4bced7208",
        "primaryId": "NCT00343382",
        "secondaryId": "NCT00798135",
        "label": "Contradiction",
        "statement_text": "Cohort 2 of the primary trial recieves the same dose of Pilocarpine as cohort 2 of the secondary trial recieves of oral itraconazole ",
        "statement_nums": [
            "2 of the"
        ],
        "premise_text": "INTERVENTION 2: Pilocarpine 2 Times Per Day Patients receive 5mg of Pilocarpine 2 times per day for 6 weeks  INTERVENTION 1: Itraconazole oral itraconazole 200mg a day until disease progression or unacceptable toxicities  ",
        "premise_nums": [
            "2 Times Per",
            "2 times per"
        ]
    },
    {
        "id": "99951bae-37c8-4299-8ec1-4577a97d0b81",
        "primaryId": "NCT00394082",
        "secondaryId": "NCT01033032",
        "label": "Contradiction",
        "statement_text": "the primary trial recorded cases of pleural effusion and Spinal compression fracture  neither of these were observed in the secondary trial ",
        "statement_nums": [],
        "premise_text": "Adverse Events 1: Total: 13/50 (26.00%) Febrile neutropenia 3/50 (6.00%) Neutropenia 1/50 (2.00%) Pancreatitis 1/50 (2.00%) Cholangitis 1/50 (2.00%) Cholelithiasis 1/50 (2.00%) Anaphylactic reaction [1]1/50 (2.00%) Pneumonia 1/50 (2.00%) Pneumonitis chemical 1/50 (2.00%) Spinal compression fracture 1/50 (2.00%) Dehydration 1/50 (2.00%) Electrolyte imbalance 1/50 (2.00%) Adverse Events 1: ",
        "premise_nums": [
            "3/50 (6.00%)",
            "13/50 (26.00%)",
            "1/50 (2.00%)"
        ]
    },
    {
        "id": "99951bae-37c8-4299-8ec1-4577a97d0b81",
        "primaryId": "NCT00394082",
        "secondaryId": "NCT01033032",
        "label": "Contradiction",
        "statement_text": "the primary trial recorded cases of pleural effusion and Spinal compression fracture  neither of these were observed in the secondary trial ",
        "statement_nums": [],
        "premise_text": "Total: 1/3 (33.33%)FEBRILE NEUTROPENIA 0/3 (0.00%) LYMPH NODE PAIN 0/3 (0.00%) NEUTROPHIL COUNT DECREASED 0/3 (0.00%) THROMBOCYTOPENIA 0/3 (0.00%) CHEST PAIN 0/3 (0.00%) DEHYDRATION 0/3 (0.00%) PLEURAL EFFUSION 1/3 (33.33%) PNEUMONITIS 0/3 (0.00%) PULMONARY INFILTERATES 0/3 (0.00%) ALOPECIA 0/3 (0.00%) ",
        "premise_nums": [
            "0/3 (0.00%)",
            "1/3 (33.33%)FEBRILE"
        ]
    },
    {
        "id": "b66b62c4-902d-4e19-929e-2086b349bd93",
        "primaryId": "NCT00149214",
        "statement_text": "Prior use of Anthracycline drugs for anticancer therapy is prohibted for patients in the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Exclusion Criteria: Prior anthracyclines as part of prior anticancer therapy  ",
        "premise_nums": []
    },
    {
        "id": "c789e79c-a254-4bb1-9d15-73d1726da8a6",
        "primaryId": "NCT00334802",
        "secondaryId": "NCT00167414",
        "label": "Contradiction",
        "statement_text": "There is no age limit for either the secondary trial or the primary trial  Patients simply need to be diagnosed with interstitial pneumonia or pulmonary fibrosis to be eligible ",
        "statement_nums": [],
        "premise_text": "Inclusion Criteria: Histologically and/or cytologically confirmed breast cancer Received adjuvant/neo-adjuvant chemotherapy for breast cancer with anthracycline regimen To have at least one measurable region Eastern Cooperative Oncology Group (ECOG) Performance Status: 0-1 To have adequate organ function (bone marrow  liver and renal function) Exclusion Criteria: To have interstitial pneumonia or pulmonary fibrosis To have inflammatory breast cancer Within 28 days after the latest chemotherapy or radiotherapy  14 days after the latest hormonal/immunotherapy or 7 days after surgery To have brain metastases with symptoms ",
        "premise_nums": [
            "14 days after",
            "0-1 To",
            "28 days after",
            "1 To have",
            "7 days after"
        ]
    },
    {
        "id": "c789e79c-a254-4bb1-9d15-73d1726da8a6",
        "primaryId": "NCT00334802",
        "secondaryId": "NCT00167414",
        "label": "Contradiction",
        "statement_text": "There is no age limit for either the secondary trial or the primary trial  Patients simply need to be diagnosed with interstitial pneumonia or pulmonary fibrosis to be eligible ",
        "statement_nums": [],
        "premise_text": "To have severe complication (cardiac infarction  infection  drug hypersensitivity or diabetes)Inclusion Criteria: Age: no limit ",
        "premise_nums": []
    },
    {
        "id": "2b182323-9357-486a-87aa-09ddc6230bf1",
        "primaryId": "NCT02481050",
        "statement_text": "There is only 1 adverse event in the primary trial that occurred more than once ",
        "statement_nums": [
            "1 adverse event"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 14/58 (24.14%) Constipation 1/58 (1.72%) Vomiting 1/58 (1.72%) Upper gastrointestinal haemorrhage 1/58 (1.72%) Asthenia 1/58 (1.72%) Chest pain 1/58 (1.72%) Pain 1/58 (1.72%) Sepsis 2/58 (3.45%) Fall 1/58 (1.72%) Spinal compression fracture 1/58 (1.72%) Neutrophil count decreased 1/58 (1.72%) Dehydration 1/58 (1.72%) Hypovolaemia 1/58 (1.72%) ",
        "premise_nums": [
            "14/58 (24.14%)",
            "2/58 (3.45%)",
            "1/58 (1.72%)"
        ]
    },
    {
        "id": "9681ec15-7545-455e-ac8c-1052fc199b11",
        "primaryId": "NCT02162667",
        "statement_text": "The Herceptin group in the primary trial had a higher number of Patients Achieving Pathological Complete Response than the CT-P6 group ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: The Percentage of Patients Achieving Pathological Complete Response Defined as the Absence of Invasion Tumor Cells in the Breast and in Axillary Lymph Nodes  Regardless of Ductal Carcinoma in Situ (DCIS) Subject who went through Neoadjuvant period completely (24 weeks)  will receive surgery within 3-6 weeks after last treatment of neoadjuvant period  The primary endpoint  Pathological complete response  will be assessed using resected bio-specimens collected in breast and axilla during a surgery  Time frame: After Neo-adjuvant therapy and Surgery (up to 30 weeks) Results 1: Arm/Group Title: CT-P6 ",
        "premise_nums": [
            "3-6 weeks",
            "6 weeks after"
        ]
    },
    {
        "id": "9681ec15-7545-455e-ac8c-1052fc199b11",
        "primaryId": "NCT02162667",
        "statement_text": "The Herceptin group in the primary trial had a higher number of Patients Achieving Pathological Complete Response than the CT-P6 group ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Arm/Group Description: Patient received CT-P6 at an initial dose of 8 mg/kg administered by a single IV infusion on Day 1 of Cycle 1, followed by 6 mg/kg on Day 1 of Cycles 2 through 8 (3-week cycles)  Patients also received docetaxel 75 mg/m^2 during cycles 1 through 4 and FEC (fluorouracil 500mg/m^2, epirubicin 75mg/m^2, and cyclophosphamide 500mg/m^2) during Cycles 5 through 8. After a total of 8 treatment cycles of the neoadjuvant treatment  surgery was performed within 3 to 6 weeks from the last dose of study Overall Number of Participants Analyzed: 248 Measure Type: Number ",
        "premise_nums": [
            "75mg/m^2,",
            "3 to 6",
            "500mg/m^2,",
            "2 through 8",
            "2 during cycles",
            "6 mg/kg on",
            "1 of Cycles",
            "500mg/m^2)",
            "75 mg/m^2",
            "1 through 4",
            "5 through 8.",
            "6 at an",
            "8 treatment cycles",
            "248 Measure Type:",
            "8 mg/kg administered",
            "(3-week cycles"
        ]
    },
    {
        "id": "9681ec15-7545-455e-ac8c-1052fc199b11",
        "primaryId": "NCT02162667",
        "statement_text": "The Herceptin group in the primary trial had a higher number of Patients Achieving Pathological Complete Response than the CT-P6 group ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Unit of Measure: percentage of responders 46.77 (40.43 to 53.19)Results 2: Arm/Group Title: Herceptin ",
        "premise_nums": [
            "43 to 53.19)Results"
        ]
    },
    {
        "id": "9681ec15-7545-455e-ac8c-1052fc199b11",
        "primaryId": "NCT02162667",
        "statement_text": "The Herceptin group in the primary trial had a higher number of Patients Achieving Pathological Complete Response than the CT-P6 group ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Arm/Group Description: Patient received Herceptin at an initial dose of 8 mg/kg administered by a single IV infusion on Day 1 of Cycle 1, followed by 6 mg/kg on Day 1 of Cycles 2 through 8 (3-week cycles)  Patients also received docetaxel 75 mg/m^2 during cycles 1 through 4 and FEC (fluorouracil 500mg/m^2, epirubicin 75mg/m^2, and cyclophosphamide 500mg/m^2) during Cycles 5 through 8. After a total of 8 treatment cycles of the neoadjuvant treatment  surgery was performed within 3 to 6 weeks from the last dose of study Overall Number of Participants Analyzed: 256 Measure Type: Number ",
        "premise_nums": [
            "75mg/m^2,",
            "3 to 6",
            "500mg/m^2,",
            "2 through 8",
            "2 during cycles",
            "6 mg/kg on",
            "1 of Cycles",
            "500mg/m^2)",
            "75 mg/m^2",
            "1 through 4",
            "5 through 8.",
            "8 treatment cycles",
            "8 mg/kg administered",
            "(3-week cycles",
            "256 Measure Type:"
        ]
    },
    {
        "id": "9681ec15-7545-455e-ac8c-1052fc199b11",
        "primaryId": "NCT02162667",
        "statement_text": "The Herceptin group in the primary trial had a higher number of Patients Achieving Pathological Complete Response than the CT-P6 group ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Unit of Measure: percentage of responders 50.39 (44.10 to 56.68)",
        "premise_nums": []
    },
    {
        "id": "8ca512c3-72d8-4179-a63e-51d83d76445f",
        "primaryId": "NCT00256243",
        "secondaryId": "NCT00721630",
        "label": "Contradiction",
        "statement_text": "the secondary trial and the primary trial are both taking place at the Memorial Sloan Kettering Cancer Center ",
        "statement_nums": [],
        "premise_text": "Eligibility Criteria: Patients must be women with a histologically confirmed diagnosis of locally advanced or inflammatory breast carcinoma  Histologic confirmation shall be by either core needle biopsy or incisional biopsy  Punch biopsy is allowed if invasive breast cancer is documented  Patients must meet one of the criteria defined below (indicate one): a .Selected Stage IIB (T3, N0, M0) or IIIA (T3, N1-2, M0) disease judged primarily unresectable by an experienced breast surgeon; or otherwise deemed appropriate candidates for neoadjuvant treatment  b  Stage IIIB (T4, Any N  M0) or (Any T  N3, M0) disease  Physical examination  chest x-ray and any x-rays or scans needed for tumor assessment must be performed within 90 days prior to registration  ",
        "premise_nums": [
            "1-2, M0",
            "90 days prior"
        ]
    },
    {
        "id": "8ca512c3-72d8-4179-a63e-51d83d76445f",
        "primaryId": "NCT00256243",
        "secondaryId": "NCT00721630",
        "label": "Contradiction",
        "statement_text": "the secondary trial and the primary trial are both taking place at the Memorial Sloan Kettering Cancer Center ",
        "statement_nums": [],
        "premise_text": "Patients with the clinical diagnosis of congestive heart failure or angina pectoris are NOT eligible  Patients with hypertension or age greater than 60 years must have a Multiple Gated Acquisition (MUGA) or echocardiogram scan performed within 90 days prior to registration (indicate not applicable (NA) if no MUGA required) and Left Ventricular Ejection Fraction (LVEF) % must be greater than the institutional lower limit of normal Patients must have a serum creatinine and bilirubin the institutional upper limit of normal  and an Serum glutamic oxaloacetic transaminase (SGOT) or Serum glutamic pyruvic transaminase (SGPT) 2x the institutional upper limit of normal  These tests must have been performed within 90 days prior to registration  ",
        "premise_nums": [
            "60 years must",
            "90 days prior"
        ]
    },
    {
        "id": "8ca512c3-72d8-4179-a63e-51d83d76445f",
        "primaryId": "NCT00256243",
        "secondaryId": "NCT00721630",
        "label": "Contradiction",
        "statement_text": "the secondary trial and the primary trial are both taking place at the Memorial Sloan Kettering Cancer Center ",
        "statement_nums": [],
        "premise_text": "Patients must have an Absolute neutrophil count (ANC) of 1,500/μl and a platelet count of 100,000/μl. These tests must have been performed within 90 days prior to registration Patients must have a performance status of 0-2 by Zubrod criteria Pregnant or nursing women may not participate due to the possibility of fetal harm or of harm to nursing infants from this treatment regimen  Women of reproductive potential may not participate unless they have agreed to use an effective contraceptive method  A urine pregnancy test is required for women of childbearing potential  All patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines  Inclusion Criteria: ",
        "premise_nums": [
            "100,000/μl. These",
            "1,500/μl and",
            "90 days prior",
            "2 by Zubrod",
            "0-2 by"
        ]
    },
    {
        "id": "8ca512c3-72d8-4179-a63e-51d83d76445f",
        "primaryId": "NCT00256243",
        "secondaryId": "NCT00721630",
        "label": "Contradiction",
        "statement_text": "the secondary trial and the primary trial are both taking place at the Memorial Sloan Kettering Cancer Center ",
        "statement_nums": [],
        "premise_text": "Patients with a diagnosis of invasive adenocarcinoma of the breast confirmed by histology or cytology at MSKCC ",
        "premise_nums": []
    },
    {
        "id": "171d0a20-8943-4994-a48a-7dff124e62ee",
        "primaryId": "NCT00046891",
        "statement_text": "cohort 1 of the primary trial recieves 60 mg of Ginkgo Biloba twice daily ",
        "statement_nums": [
            "60 mg of",
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "INTERVENTION 1: Ginkgo Biloba Ginkgo Biloba: Patients will take 120 mg per day (60 mg BID) ",
        "premise_nums": [
            "120 mg per",
            "60 mg BID)"
        ]
    },
    {
        "id": "25cc9a6e-656d-44ee-a301-93f5879407a0",
        "primaryId": "NCT01923168",
        "statement_text": "Intervention 1 of the primary trial require participants to take a total of 150 mg alpelisib every two days ",
        "statement_nums": [
            "150 mg alpelisib",
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "INTERVENTION 1: Alpelisib + Letrozole Participants took alpelisib 300 mg once daily plus letrozole 2.5 mg once daily  ",
        "premise_nums": [
            "300 mg once",
            "letrozole 2.5 mg once"
        ]
    },
    {
        "id": "d9b4d4aa-0094-405e-83a3-cf2978cfda38",
        "primaryId": "NCT00347919",
        "statement_text": "56.9% of the primary trial subjects treated with Lapatinib 1500 mg had no progressive Disease at Week 12.",
        "statement_nums": [
            "1500 mg had",
            "56.9% of"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Percentage of Participants With Progressive Disease at Week 12 in Cohort 1 The percentage of participants with progressive disease (PD) 12 weeks after randomization was measured  Per Response Evaluation Criteria In Solid Tumors (RECIST)  a response of PD is defined as a greater than or equal 20% increase in target lesions  Participants were also classified as having PD if their response at Week 12 was unknown or missing  Response was determined by an independent radiologist and by an investigator  Time frame: Week 12 Results 1: Arm/Group Title: Cohort 1: Lapatinib 1500 mg Arm/Group Description: Lapatinib 1500 milligrams (mg) administered orally once a day Overall Number of Participants Analyzed: 72 Measure Type: Number Unit of Measure: percentage of participants Independently Evaluated: 38.9 Investigator Evaluated: 43.1 ",
        "premise_nums": [
            "1500 milligrams (mg)",
            "72 Measure Type:",
            "12 Results 1:",
            "9 Investigator Evaluated:",
            "12 was unknown",
            "12 weeks after",
            "1500 mg Arm",
            "12 in Cohort",
            "1 The percentage",
            "20% increase"
        ]
    },
    {
        "id": "caa55802-329d-4a1f-a9a7-b99afc44fd67",
        "primaryId": "NCT00038467",
        "statement_text": "The patient groups in the primary trial each receive the same doses of different oral medication  either Tamoxifen or Exemestane ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "INTERVENTION 1: Exemestane Participants diagnosed with breast cancer who remained disease-free after previously receiving 2 to 3 years of tamoxifen 20 milligram (mg) or 30 mg tablet-in-capsule orally once daily as per standard medical practice  received exemestane (Aromasin) 25 mg tablet-in-capsule orally once daily for the remainder of 5-year period  INTERVENTION 2: Tamoxifen Participants diagnosed with breast cancer who remained disease-free after previously receiving 2 to 3 years of tamoxifen 20 mg or 30 mg tablet-in-capsule orally once daily as per standard medical practice  received the same dose of tamoxifen tablet-in-capsule orally once daily for the remainder of 5-year period  ",
        "premise_nums": [
            "25 mg tablet",
            "30 mg tablet",
            "5-year period",
            "2 to 3",
            "20 milligram (mg)",
            "20 mg or"
        ]
    },
    {
        "id": "6df9ec3b-43ba-442a-a4f5-4ce3cdb7a2a0",
        "primaryId": "NCT02525718",
        "secondaryId": "NCT02606708",
        "label": "Contradiction",
        "statement_text": "Patients in group 1 of the secondary trial and the primary trial receive the same dosage of oral placebo ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "INTERVENTION 1: Placebo Subjects will be randomly selected to receive saline (placebo)  administered to the breast area to cover the intercostal nerves supplying the breast tissue during surgery  Saline: If randomized to this arm  subjects will receive an intraoperative injection of saline  (2.5 mg/ml) INTERVENTION 1: Accelerated Intensity Modulated Radiation Therapy (AIMRT) All patients shall receive a total of 40.5 Gy to the entire breast in 2.7 Gy/fraction x 15 fractions  Monday to Friday for 3 weeks delivered prone in uniform daily doses through IMRT tangent fields  A concurrent boost to the original tumor bed of 0.50 Gy will be delivered  Accelerated intensity modulated radiation therapy (AIMRT) ",
        "premise_nums": [
            "of 40.5 Gy to",
            "3 weeks delivered",
            "in 2.7 Gy/fraction",
            "of 0.50 Gy will",
            "(2.5 mg/ml"
        ]
    },
    {
        "id": "0880bb0b-9e8d-4fce-8795-2ec6526d9bfb",
        "primaryId": "NCT00262834",
        "secondaryId": "NCT01106898",
        "label": "Entailment",
        "statement_text": "In the secondary trial Her-2 neu positive breast cancer patients receive additional maintenance therapy compared to other patients  Whereas all the primary trial participants receive the same treatment ",
        "statement_nums": [
            "2 neu positive"
        ],
        "premise_text": "INTERVENTION 1: Vorinostat Women in the vorinostat group were scheduled to receive 6 doses of oral vorinostat at 300 mg twice daily (bid)  with the last dose administered by study personnel approximately 2 hours before the scheduled breast surgery (or biopsy)  INTERVENTION 1: Treatment (Chemotherapy With or Without Maintenance Therapy) SYSTEMIC CHEMOTHERAPY: Patients receive cyclophosphamide IV over 1 hour and paclitaxel IV over 3 hours on day 1. Treatment repeats every 14 days for 6 courses in the absence of disease progression or unacceptable toxicity  ",
        "premise_nums": [
            "3 hours on",
            "2 hours before",
            "6 courses in",
            "1 hour and",
            "14 days for",
            "6 doses of",
            "300 mg twice"
        ]
    },
    {
        "id": "0880bb0b-9e8d-4fce-8795-2ec6526d9bfb",
        "primaryId": "NCT00262834",
        "secondaryId": "NCT01106898",
        "label": "Entailment",
        "statement_text": "In the secondary trial Her-2 neu positive breast cancer patients receive additional maintenance therapy compared to other patients  Whereas all the primary trial participants receive the same treatment ",
        "statement_nums": [
            "2 neu positive"
        ],
        "premise_text": "MAINTENANCE THERAPY (Her-2 neu positive patients): Patients receive trastuzumab IV over 30 minutes on day 1. Treatment repeats every 14 days for 5 courses and then every 21 days for 14 courses in the absence of disease progression or unacceptable toxicity cyclophosphamide  paclitaxel  trastuzumab: Given IV ",
        "premise_nums": [
            "21 days for",
            "14 days for",
            "30 minutes on",
            "5 courses and",
            "2 neu positive",
            "14 courses in"
        ]
    },
    {
        "id": "baea8eb9-a6e7-4473-9b4b-28a4fdb531ad",
        "primaryId": "NCT02780713",
        "statement_text": "Both cohorts of the primary trial are administered the same drugs in different doses  ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "INTERVENTION 1: Treatment Period 1 Participants received AZD9496 - Variant A (100 mg)  INTERVENTION 2: Treatment Period 2 Participants received AZD9496 - Reference (100 mg)  ",
        "premise_nums": [
            "1 Participants received",
            "2 Participants received"
        ]
    },
    {
        "id": "01f89936-1621-4dd5-93b7-8b0c64b397fd",
        "primaryId": "NCT00054275",
        "statement_text": "A patient with severe anginal syndrome but angiographically normal coronary arteries would be unable to participate in the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "No New York Heart Association class III or IV heart disease No unstable angina pectoris ",
        "premise_nums": []
    },
    {
        "id": "ee7fe82e-de91-45c7-bd12-bff5d6c887a3",
        "primaryId": "NCT00320411",
        "statement_text": "the primary trial participants must take 6 tablets of Lapatinib Monotherapy (250mg) PO once daily ",
        "statement_nums": [
            "(250mg) PO",
            "6 tablets of"
        ],
        "label": "Entailment",
        "premise_text": "INTERVENTION 1: Lapatinib Monotherapy Lapatinib: 1500 mg (six 250 mg tablets) orally once daily ",
        "premise_nums": [
            "1500 mg (six",
            "250 mg tablets)"
        ]
    },
    {
        "id": "888a8d39-3ad6-401e-acf2-cf5e01a73bf2",
        "primaryId": "NCT00266110",
        "secondaryId": "NCT00879086",
        "label": "Contradiction",
        "statement_text": "the primary trial had a much higher rate of adverse events than the secondary trial ",
        "statement_nums": [],
        "premise_text": "Adverse Events 1: Total: 2/17 (11.76%) Nausea * 1/17 (5.88%) Pain - Abdomen NOS * 1/17 (5.88%) Constipation * 1/17 (5.88%) Adverse Events 1: Total: 19/51 (37.25%) Febrile neutropenia 6/51 (11.76%) Anaemia 1/51 (1.96%) Leukopenia 1/51 (1.96%) Neutropenia 1/51 (1.96%) Thrombocytopenia 0/51 (0.00%) Pericarditis 1/51 (1.96%) Atrial flutter 0/51 (0.00%) Cardiac failure congestive 0/51 (0.00%) ",
        "premise_nums": [
            "6/51 (11.76%)",
            "1/51 (1.96%)",
            "0/51 (0.00%)",
            "19/51 (37.25%)",
            "1/17 (5.88%)",
            "2/17 (11.76%)"
        ]
    },
    {
        "id": "888a8d39-3ad6-401e-acf2-cf5e01a73bf2",
        "primaryId": "NCT00266110",
        "secondaryId": "NCT00879086",
        "label": "Contradiction",
        "statement_text": "the primary trial had a much higher rate of adverse events than the secondary trial ",
        "statement_nums": [],
        "premise_text": "Visual impairment 0/51 (0.00%)Dysphagia 1/51 (1.96%) Abdominal pain 0/51 (0.00%) Chills 1/51 (1.96%) Adverse Events 2: Total: 17/50 (34.00%) Febrile neutropenia 0/50 (0.00%) Anaemia 1/50 (2.00%) Leukopenia 0/50 (0.00%) Neutropenia 1/50 (2.00%) Thrombocytopenia 1/50 (2.00%) Pericarditis 0/50 (0.00%) Atrial flutter 1/50 (2.00%) Cardiac failure congestive 1/50 (2.00%) ",
        "premise_nums": [
            "1/51 (1.96%)",
            "1/50 (2.00%)",
            "0/50 (0.00%)",
            "0/51 (0.00%)Dysphagia",
            "17/50 (34.00%)"
        ]
    },
    {
        "id": "888a8d39-3ad6-401e-acf2-cf5e01a73bf2",
        "primaryId": "NCT00266110",
        "secondaryId": "NCT00879086",
        "label": "Contradiction",
        "statement_text": "the primary trial had a much higher rate of adverse events than the secondary trial ",
        "statement_nums": [],
        "premise_text": "Visual impairment 1/50 (2.00%)Dysphagia 0/50 (0.00%) Abdominal pain 1/50 (2.00%) Chills 0/50 (0.00%) ",
        "premise_nums": [
            "0/50 (0.00%)",
            "1/50 (2.00%)Dysphagia"
        ]
    },
    {
        "id": "13466cbb-9f78-46ff-a983-09e2e9ad5a2c",
        "primaryId": "NCT00679211",
        "statement_text": "1 patient in the primary trial presented a fever  in addition to either a cough or a sore throat ",
        "statement_nums": [
            "1 patient in"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Influenza like illness 1/110 (0.91%) ",
        "premise_nums": [
            "1/110 (0.91%)"
        ]
    },
    {
        "id": "0beaef44-a39a-462c-a084-d3f824857673",
        "primaryId": "NCT00374322",
        "statement_text": "the primary trial results show that Participants receiving lapatinib 1500 milligrams (mg) orally were more likely to achieve DFS at 5 years than placebo patients  however  there was less than a 30% difference in DFS rate between the two cohorts ",
        "statement_nums": [
            "5 years than",
            "1500 milligrams (mg)",
            "30% difference"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Number of Participants (Par.) With Any Recurrence of the Initial Disease  Second Primary Cancer  Contralateral Breast Cancer  or Death (Disease-free Survival [DFS]) ",
        "premise_nums": []
    },
    {
        "id": "8e45da73-f016-4ca0-b106-a3fabc960b36",
        "primaryId": "NCT01432145",
        "statement_text": "the primary trial patients are administered 6-Mercaptopurine more often and in higher dosages than Methotrexate ",
        "statement_nums": [
            "6-Mercaptopurine more"
        ],
        "label": "Entailment",
        "premise_text": "INTERVENTION 1: 6-Mercaptopurine and Methotrexate (6MP/MTX) 6-Mercaptopurine: 6MP 75mg/m2 body surface area  administered orally (PO) once a day (od) in the morning 1 hour after eating  on a continuous schedule  One cycle is 28 days  Treatment is given continuously until disease progression  Methotrexate: Methotrexate 20mg/m2 will be taken orally  once a week  in the morning  One cycle is 28 days  Treatment is given continuously until disease progression  Update: These original doses were reduced following an Urgent Safety Measure in August 2012 due to a large proportion of patients requiring a dose reduction or treatment delay due to incidences of myelo-suppression  ",
        "premise_nums": [
            "1 hour after",
            "75mg/m2 body",
            "6-Mercaptopurine: 6MP",
            "2 will be",
            "2012 due to",
            "2 body surface",
            "6-Mercaptopurine and",
            "20mg/m2 will"
        ]
    },
    {
        "id": "8e45da73-f016-4ca0-b106-a3fabc960b36",
        "primaryId": "NCT01432145",
        "statement_text": "the primary trial patients are administered 6-Mercaptopurine more often and in higher dosages than Methotrexate ",
        "statement_nums": [
            "6-Mercaptopurine more"
        ],
        "label": "Entailment",
        "premise_text": "The reduced doses were 55mg/m2 of 6MP orally once a day  and 15mg/m2 of Methotrexate orally once a week ",
        "premise_nums": [
            "2 of 6MP",
            "2 of Methotrexate",
            "15mg/m2 of",
            "55mg/m2 of"
        ]
    },
    {
        "id": "37dc56a4-4756-4ab0-8055-7637bf579740",
        "primaryId": "NCT01420146",
        "secondaryId": "NCT00077376",
        "label": "Entailment",
        "statement_text": "the primary trial and the secondary trial are both single arm clinical trials ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Zr89-trastuzumab PET/CT Zr89-trastuzumab (trastuzumab labelled with zirconium 89) for PET/CT single arm INTERVENTION 1: Trastuzumab/Ixabepilone/Carboplatin ",
        "premise_nums": [
            "89-trastuzumab PET/CT"
        ]
    },
    {
        "id": "37dc56a4-4756-4ab0-8055-7637bf579740",
        "primaryId": "NCT01420146",
        "secondaryId": "NCT00077376",
        "label": "Entailment",
        "statement_text": "the primary trial and the secondary trial are both single arm clinical trials ",
        "statement_nums": [],
        "premise_text": "During the induction phase  patients were treated with Ixabepilone (BMS-247550) 15mg/m2 intravenously (IV) followed by carboplatin (AUC=2 IV) on days 1, 8 and 15 of a 28-day cycle for a maximum of 6 cycles  Trastuzumab was administered weekly (4mg/kg loading dose then 2mg/kg IV) starting on day 1. Routine premedication included H1 blocker (diphenhydramine 50 mg orally (PO) or IV)  H2 blocker (ranitidine 150 mg PO or 50 mg IV or another equivalent H2 blocker)  and at least a 5-HT3 antagonist and dexamethasone ",
        "premise_nums": [
            "50 mg IV",
            "50 mg orally",
            "2mg/kg IV",
            "15mg/m2 intravenously",
            "150 mg PO",
            "2 intravenously (IV)",
            "2 blocker (ranitidine",
            "5-HT3 antagonist",
            "8 and 15",
            "3 antagonist and",
            "28-day cycle",
            "1 blocker (diphenhydramine"
        ]
    },
    {
        "id": "37dc56a4-4756-4ab0-8055-7637bf579740",
        "primaryId": "NCT01420146",
        "secondaryId": "NCT00077376",
        "label": "Entailment",
        "statement_text": "the primary trial and the secondary trial are both single arm clinical trials ",
        "statement_nums": [],
        "premise_text": "After completion of 24 weekly trastuzumab doses (induction therapy)  trastuzumab were given at a dose of 6 mg/kg IV every 3 weeks (maintenance therapy) beginning one week after the 24th weekly dose  Trastuzumab were repeated every 21 days until disease progression or prohibitive toxicity ",
        "premise_nums": [
            "21 days until",
            "24 weekly trastuzumab",
            "6 mg/kg IV",
            "3 weeks (maintenance"
        ]
    },
    {
        "id": "65e370b7-7726-477e-8730-8cea734d1609",
        "primaryId": "NCT02115607",
        "secondaryId": "NCT01823107",
        "label": "Contradiction",
        "statement_text": "Patients in the primary trial receive an Infusion of 3 ml Perflutren Lipid Microspheres at a rate of approximately 3ml/min, whereas in the secondary trial subjects are implanted with a permanent Meso BioMatrix Acellular Peritoneum Matrix ",
        "statement_nums": [
            "3 ml Perflutren",
            "3ml/min,"
        ],
        "premise_text": "INTERVENTION 1: Definity Infusion Infusion of Definity (Perflutren Lipid Microspheres) Definity infusion: 3 ml of Perflutren Lipid Microspheres (Definity) mixed in 50 ml of saline is infused at a rate of approximately 4ml/min INTERVENTION 1: Meso BioMatrix Acellular Peritoneum Matrix ",
        "premise_nums": [
            "3 ml of",
            "50 ml of",
            "4ml/min INTERVENTION"
        ]
    },
    {
        "id": "65e370b7-7726-477e-8730-8cea734d1609",
        "primaryId": "NCT02115607",
        "secondaryId": "NCT01823107",
        "label": "Contradiction",
        "statement_text": "Patients in the primary trial receive an Infusion of 3 ml Perflutren Lipid Microspheres at a rate of approximately 3ml/min, whereas in the secondary trial subjects are implanted with a permanent Meso BioMatrix Acellular Peritoneum Matrix ",
        "statement_nums": [
            "3 ml Perflutren",
            "3ml/min,"
        ],
        "premise_text": "All subjects had the Meso BioMatrix Acellular Peritoneum Matrix implanted along with a tissue expander during the first stage of breast reconstruction  After tissue expansion  the tissue expander was replaced with a breast implant during the second stage of reconstruction ",
        "premise_nums": []
    },
    {
        "id": "affdd551-15e2-4a47-8c20-209cc01570ec",
        "primaryId": "NCT03012477",
        "statement_text": "One patient in the primary trial experienced a thromboembolic event  a condition associated with a high degree of morbidity and mortality  However  the most common adverse event was Diarrhea ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 13/34 (38.24%) Anemia 3/34 (8.82%) Diarrhea 7/34 (20.59%) Nausea 2/34 (5.88%) Sepsis 1/34 (2.94%) Urinary tract infection 1/34 (2.94%) Alkaline phosphatase increased 1/34 (2.94%) Neutrophil count decreased 2/34 (5.88%) Dehydration 1/34 (2.94%) Headache 1/34 (2.94%) Thromboembolic event 1/34 (2.94%) ",
        "premise_nums": [
            "7/34 (20.59%)",
            "3/34 (8.82%)",
            "1/34 (2.94%)",
            "13/34 (38.24%)",
            "2/34 (5.88%)"
        ]
    },
    {
        "id": "2152f503-4fa4-4f32-b766-a05a4c69742f",
        "primaryId": "NCT02176083",
        "secondaryId": "NCT03061175",
        "label": "Contradiction",
        "statement_text": "Neither the primary trial or NCT0306117 use chemotherapy  adverse event management courses or radiotherapy in their intervention ",
        "statement_nums": [
            "0306117 use chemotherapy",
            "NCT0306117 use"
        ],
        "premise_text": "INTERVENTION 1: Intervention Text message management prompts: YBCS will receive text message prompts on how to manage hot flashes and vaginal dryness Text message management prompts INTERVENTION 2: Control Control YBCS will not receive text message prompts on managing hot flashes and vaginal dryness INTERVENTION 1: Arm I (Web-Based CPM-DA) Patients receive a website address  a secure username and password  and instructions for using the web-based CPM-DA  Internet-Based Intervention: Receive web-based CPM-DA Survey Administration: Ancillary studies INTERVENTION 2: Arm II (Usual Care) Patients undergo usual care available to patients considering CPM and receive information from a medical oncologist about CPM  Survey Administration: Ancillary studies ",
        "premise_nums": []
    },
    {
        "id": "a7903e59-9620-457a-8d83-eb6eb5dd8a2b",
        "primaryId": "NCT01300351",
        "statement_text": "At least 1 participant in each cohort of the primary trial showed signs of poor liver function ",
        "statement_nums": [
            "1 participant in"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Hepatic function abnormal * 1/109 (0.92%) ",
        "premise_nums": [
            "1/109 (0.92%)"
        ]
    },
    {
        "id": "dc7e7fbe-eed9-4307-b584-30ecaeb77c95",
        "primaryId": "NCT00186121",
        "statement_text": "Patients with E2 outside the premenopausal range are ineligible for the primary trial ",
        "statement_nums": [
            "2 outside the"
        ],
        "label": "Entailment",
        "premise_text": "If tamoxifen administered within the past 3 months  plasma estradiol must be in the premenopausal range ",
        "premise_nums": []
    },
    {
        "id": "a34c6194-b6d9-49c3-8ddb-72de10c8a18c",
        "primaryId": "NCT02006979",
        "statement_text": "Neither cohort of the primary trial need to perform low intensity exercise prior to each cycle of anthracyclines ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "INTERVENTION 1: Exercise an acute bout of exercise performed 24 hours prior to each cycle of anthracyclines and no exercise for 48 hours post exercise INTERVENTION 2: Usual Care no exercise for 72 hours prior or 48 hours post each cycle of anthracyclines ",
        "premise_nums": [
            "72 hours prior",
            "24 hours prior",
            "48 hours post"
        ]
    },
    {
        "id": "da00532d-57a8-4fe2-a2de-acc525161fd9",
        "primaryId": "NCT01120184",
        "statement_text": "At least 1 patient in cohort 1 of the primary trial suffered from a coagulation disorder ",
        "statement_nums": [
            "1 patient in",
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Hypercoagulation * 21/353 (0.28%) ",
        "premise_nums": [
            "21/353 (0.28%)"
        ]
    },
    {
        "id": "f90364e9-caee-4075-b444-2db1bf846d3a",
        "primaryId": "NCT02511730",
        "secondaryId": "NCT00193206",
        "label": "Contradiction",
        "statement_text": "Patients with prior chemotherapy are excluded from the secondary trial and the primary trial ",
        "statement_nums": [],
        "premise_text": "Inclusion Criteria: Female subjects participating in FMSU004A protocol with known clinical status Exclusion Criteria: Subjects with unknown clinical status not participating in FMSU004A protocol  Inclusion Criteria: No prior chemotherapy for breast cancer ",
        "premise_nums": []
    },
    {
        "id": "deb78676-8f04-44c4-a5f6-389740d8a268",
        "primaryId": "NCT01908101",
        "statement_text": "Prior exposure to doxatel is obligatory for patients in the primary trial ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria: Ability to provide written informed consent Prior exposure to taxane in the adjuvant  neoadjuvant or metastatic setting ",
        "premise_nums": []
    },
    {
        "id": "a06d1ca5-c890-4157-b1d2-0b70fd0092bd",
        "primaryId": "NCT00591851",
        "statement_text": "There were 4 different cardiac adverse events recorded in cohort 1 of the primary trial ",
        "statement_nums": [
            "4 different cardiac",
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 19/70 (27.14%) Febrile Neutropenia 24/70 (5.71%) Pericarditis 21/70 (1.43%) Sinus bradycardia 21/70 (1.43%) Abdominal Pain 2/70 (2.86%) Diarrhea 21/70 (1.43%) Lower gastrointestinal hemorrhage 21/70 (1.43%) Nausea 21/70 (1.43%) Non Cardiac-Chest pain 22/70 (2.86%) Fever 24/70 (5.71%) Skin infection 41/70 (1.43%) Neutrophil count decreased 31/70 (1.43%) ",
        "premise_nums": [
            "41/70 (1.43%)",
            "24/70 (5.71%)",
            "19/70 (27.14%)",
            "22/70 (2.86%)",
            "31/70 (1.43%)",
            "21/70 (1.43%)"
        ]
    },
    {
        "id": "5bc0d21d-a040-4d30-b0c7-8793cba6aba8",
        "primaryId": "NCT01091168",
        "statement_text": "Patients in the control group of the primary trial had a median Overall Survival of less than a year ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Overall Survival The main endpoint of this study is overall survival defined as the time from randomisation to the date of death or last follow-up  For patients who have not died  survival duration will be censored at the date of last contact or last follow-up or the date of last news  Time frame: From baseline up to 3 years 1 month Results 2: Arm/Group Title: Alkylating Agent Arm/Group Description: Patients randomised in the control arm (arm B) received an alkylating agent used as a single agent which was available in the investigational center and was approved for the treatment of cancer in the country  ",
        "premise_nums": [
            "3 years 1"
        ]
    },
    {
        "id": "5bc0d21d-a040-4d30-b0c7-8793cba6aba8",
        "primaryId": "NCT01091168",
        "statement_text": "Patients in the control group of the primary trial had a median Overall Survival of less than a year ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Alkylating agent of physician choice registered in cancer: cyclophosphamide or melphalan or mitomycin C or thiotepa or cisplatin or carboplatinOverall Number of Participants Analyzed: 296 Median (95% Confidence Interval) Unit of Measure: Months 9.3 (7.5 to 10.9) ",
        "premise_nums": [
            "5 to 10.9)",
            "95% Confidence"
        ]
    },
    {
        "id": "9bcbadcc-ae56-4254-ac8b-ab5d35e80eba",
        "primaryId": "NCT00952731",
        "secondaryId": "NCT00956813",
        "label": "Entailment",
        "statement_text": "Cohort 2 in the primary trial and the secondary trial but receive daily placebo doses ",
        "statement_nums": [
            "2 in the"
        ],
        "premise_text": "INTERVENTION 2: Placebo Gel + Oral Treatment Placebo gel applied to the breasts daily  20mg oral tamoxifen taken daily (taken as two (2) 10mg capsules)  tamoxifen citrate: 20mg oral tamoxifen taken daily (taken as two (2) 10mg capsules) for 4-10 weeks  placebo gel: Placebo gel applied to breasts daily for 4-10 weeks  INTERVENTION 2: Placebo Patients Identical looking bar with same calorie and total fat content but without flaxseed or lignans once daily  ",
        "premise_nums": [
            "4-10 weeks"
        ]
    },
    {
        "id": "5a1358af-f51b-49f8-b1c0-99a0b108b0a2",
        "primaryId": "NCT00091442",
        "statement_text": "There were more cases of Febrile neutropenia than leukopenia observed in the primary trial  but less cases of neutropenia than leukopenia ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Neutropenia 14/373 (3.75%) Febrile neutropenia 10/373 (2.68%) Leukopenia 1/373 (0.27%) ",
        "premise_nums": [
            "10/373 (2.68%)",
            "14/373 (3.75%)",
            "1/373 (0.27%)"
        ]
    },
    {
        "id": "ed0e1b04-aea7-4da0-922f-2be69c768c09",
        "primaryId": "NCT02635737",
        "statement_text": "Patients with implantable cardioverter defibrillators are excluded from the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Exclusion Criteria: Patients with a Pacemaker or implanted device; ",
        "premise_nums": []
    },
    {
        "id": "73d323e7-1a38-49d4-97f4-a15f1664fb3e",
        "primaryId": "NCT01439711",
        "statement_text": "One patient in the primary trial had a 0.98 cm3 increase in Total MRI Functional Tumor Volume (FTV) over 3 months  almost 1cm3 less than average ",
        "statement_nums": [
            "3 less than",
            "3 increase in"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Mean Total MRI Functional Tumor Volume (FTV) Change From Baseline to Month 3 (V3) Mean total MRI FTV change from baseline to month 3 (V3): For patients with more than one measureable lesion on the MRI  the sum over all measureable lesions on the MRI was calculated at each time point  V3 was calculated by subtracting the total MRI FTV measured (i.e  the sum over all lesions present with MRI FTV measurements) at 3 months from the total MRI FTV measured at baseline  For V3 the raw change in the volume will be calculated for each patient and a mean and 95% confidence interval will be constructed using two-sided t-tests  ",
        "premise_nums": [
            "3 months from",
            "(V3) Mean",
            "3 was calculated",
            "95% confidence",
            "3 the raw"
        ]
    },
    {
        "id": "73d323e7-1a38-49d4-97f4-a15f1664fb3e",
        "primaryId": "NCT01439711",
        "statement_text": "One patient in the primary trial had a 0.98 cm3 increase in Total MRI Functional Tumor Volume (FTV) over 3 months  almost 1cm3 less than average ",
        "statement_nums": [
            "3 less than",
            "3 increase in"
        ],
        "label": "Contradiction",
        "premise_text": "Time frame: up to 3 months from start of treatmentResults 1: Arm/Group Title: Letrozole + MRI Arm/Group Description: Protocol Therapy will consist of 6 months of letrozole  administered orally at a dose of 2.5 mg/day  Patients will have a bilateral MRI for disease evaluation at months 3 and 6. Overall Number of Participants Analyzed: 68 Mean (95% Confidence Interval) Unit of Measure: cubic centimeters -1.93 (-2.87 to -0.98) ",
        "premise_nums": [
            "3 months from",
            "of 2.5 mg/day",
            "6 months of",
            "95% Confidence",
            "3 and 6."
        ]
    },
    {
        "id": "02dea6a3-d94f-4650-bf4f-be8fdb0a382f",
        "primaryId": "NCT02010021",
        "statement_text": "A patient has recently had an oophorectomy,they are excluded from the primary trial ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Exclusion Criteria: Prior endocrine therapy for any histologically confirmed cancer is not allowed  Prior endocrine therapy that was administered 5 years ago for the prevention of breast cancer in patients with no history of breast cancer is allowed  ",
        "premise_nums": [
            "5 years ago"
        ]
    },
    {
        "id": "4c8a124b-f015-42e2-8ad3-6168f21fe705",
        "primaryId": "NCT00943670",
        "statement_text": "The Change From Baseline in Mean Duration of the QTcF Interval for patients in the primary trial was at its highest on Day 1 of the third cycle  before T-DM1 intravenous (IV) infusion ",
        "statement_nums": [
            "1 of the",
            "1 intravenous (IV)"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Change From Baseline in Mean Duration of the QTc Interval The QT interval is a measure of time between the start of the Q wave and the end of the T wave in the heart's electrical cycle  The corrected QT interval was calculated using Fridericia's correction (QTcF) from electrocardiogram (ECG) data  Each participant had triplicate QTcF intervals measured at each timepoint and the average was calculated for each patient at each timepoint  For each timepoint  a participant's corresponding baseline QTcF interval was subtracted from the average QTcF intervals to create a baseline-adjusted average QTcF interval  ",
        "premise_nums": []
    },
    {
        "id": "4c8a124b-f015-42e2-8ad3-6168f21fe705",
        "primaryId": "NCT00943670",
        "statement_text": "The Change From Baseline in Mean Duration of the QTcF Interval for patients in the primary trial was at its highest on Day 1 of the third cycle  before T-DM1 intravenous (IV) infusion ",
        "statement_nums": [
            "1 of the",
            "1 intravenous (IV)"
        ],
        "label": "Contradiction",
        "premise_text": "Time frame: Cycle 1 Day 1, pre-dose (Baseline); Cycle 1 Day 1, 15 and 60 minutes post-dose; Cycle 1 Day 8; and Cycle 3 Day 1, 15 minutes pre-dose and 15 and 60 minutes post-dose Results 1: Arm/Group Title: T-DM1 Arm/Group Description: Trastuzumab emtansine (T-DM1) was administered to participants by intravenous (IV) infusion on Day 1 of every 3 week cycle at a dose of 3.6 mg/kg  Overall Number of Participants Analyzed: 51 Mean (Standard Deviation) ",
        "premise_nums": [
            "1 Day 8;",
            "3 Day 1,",
            "51 Mean (Standard",
            "3 week cycle",
            "1 of every",
            "of 3.6 mg/kg",
            "15 and 60",
            "15 minutes pre",
            "1 Day 1,"
        ]
    },
    {
        "id": "4c8a124b-f015-42e2-8ad3-6168f21fe705",
        "primaryId": "NCT00943670",
        "statement_text": "The Change From Baseline in Mean Duration of the QTcF Interval for patients in the primary trial was at its highest on Day 1 of the third cycle  before T-DM1 intravenous (IV) infusion ",
        "statement_nums": [
            "1 of the",
            "1 intravenous (IV)"
        ],
        "label": "Contradiction",
        "premise_text": "Unit of Measure: milliseconds Cycle 1, Day 1, 15 minutes post-dose [N=44]: 1.2 (8.3)Cycle 1, Day 1, 60 minutes post-dose [N=45]: -1.0 (6.3) Cycle 1, Day 8 [N=43]: -4.0 (13.4) Cycle 3, Day 1, 15 minutes pre-dose [N=35]: -0.1 (10.1) Cycle 3, Day 1, 15 minutes post-dose [N=37]: 4.7 (9.6) ",
        "premise_nums": [
            "15 minutes post",
            "60 minutes post",
            "15 minutes pre"
        ]
    },
    {
        "id": "4c8a124b-f015-42e2-8ad3-6168f21fe705",
        "primaryId": "NCT00943670",
        "statement_text": "The Change From Baseline in Mean Duration of the QTcF Interval for patients in the primary trial was at its highest on Day 1 of the third cycle  before T-DM1 intravenous (IV) infusion ",
        "statement_nums": [
            "1 of the",
            "1 intravenous (IV)"
        ],
        "label": "Contradiction",
        "premise_text": "Cycle 3, Day 1, 60 minutes post-dose [N=37]: 4.7 (10.9)",
        "premise_nums": [
            "60 minutes post"
        ]
    },
    {
        "id": "fb43432d-6c1b-4ff7-aea8-72bc2519a12d",
        "primaryId": "NCT00130533",
        "statement_text": "Nobody in cohort 1 of the primary trial suffered from Hyperbilirrubinemia ",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Hyperbilirrubinemia [1]1/436 (0.23%) ",
        "premise_nums": [
            "1/436 (0.23%)"
        ]
    },
    {
        "id": "d6df95f5-472f-4b14-9cd4-5d5ef238175a",
        "primaryId": "NCT00005879",
        "statement_text": "There are criteria for PRIOR CONCURRENT THERAPY  PATIENT CHARACTERISTICS and DISEASE CHARACTERISTICS for entry to the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "DISEASE CHARACTERISTICS: Current random fine needle breast aspiration (FNA) evidence of 1 of the following: Hyperplasia with atypia Hyperplasia without atypia but with a 10-year modified Gail risk of at least 4% Hyperplasia without atypia but with a BRCAPRO risk of at least 25% Hyperplasia without atypia but with a known mutation in BRCA1 or BRCA2 Hyperplasia without atypia but with a history of contralateral ductal carcinoma in situ or invasive breast cancer FNA must have been taken during days 1-14 of the menstrual cycle for premenopausal women ",
        "premise_nums": [
            "25% Hyperplasia",
            "14 of the",
            "1 or BRCA2",
            "4% Hyperplasia",
            "10-year modified",
            "1-14 of",
            "1 of the"
        ]
    },
    {
        "id": "d6df95f5-472f-4b14-9cd4-5d5ef238175a",
        "primaryId": "NCT00005879",
        "statement_text": "There are criteria for PRIOR CONCURRENT THERAPY  PATIENT CHARACTERISTICS and DISEASE CHARACTERISTICS for entry to the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Classified as ACR class I-III on mammogram with stepwedge within past 6 months If intact uterus and/or ovaries  must have color doppler transvaginal pelvic sonogram within past 6 months showing endometrial thickening no greater than 13 mm premenopausal or no greater than 8 mm postmenopausalNo ovarian cysts felt to be possibly or probably non-physiologic that have not resolved to gynecologist's satisfaction on repeat sonogram Must agree to have or have had genetic counseling and genetic testing performed for BRCA1 and BRCA2 No active cancer (e.g.  detectable disease) Hormone receptor status: Not specified PATIENT CHARACTERISTICS: Age: 18 and over Sex: Female Menopausal status: Any Performance status: Not specified ",
        "premise_nums": [
            "13 mm premenopausal",
            "1 and BRCA2",
            "6 months showing",
            "8 mm postmenopausalNo",
            "6 months If",
            "18 and over"
        ]
    },
    {
        "id": "d6df95f5-472f-4b14-9cd4-5d5ef238175a",
        "primaryId": "NCT00005879",
        "statement_text": "There are criteria for PRIOR CONCURRENT THERAPY  PATIENT CHARACTERISTICS and DISEASE CHARACTERISTICS for entry to the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Life expectancy:At least 12 months Hematopoietic: Hemoglobin greater than 10 g/dL Granulocyte count greater than 1,000/mm^3 No deficiencies in protein C  protein S  or antithrombin III No activated protein C resistance Hepatic: Albumin greater than 3.0 g/dL Bilirubin less than 1.5 mg/dL AST less than 100 U/L Alkaline phosphatase less than 200 U/L Renal: Creatinine less than 1.5 mg/dL Cardiovascular: No history of deep venous thrombosis not related to trauma or pregnancy No severe coronary artery disease No history of prior stroke Other: Not pregnant or nursing Negative pregnancy test ",
        "premise_nums": [
            "10 g/dL Granulocyte",
            "1,000/mm^3 No",
            "3 No deficiencies",
            "than 3.0 g/dL",
            "200 U/L Renal",
            "12 months Hematopoietic:",
            "100 U/L Alkaline",
            "than 1.5 mg/dL"
        ]
    },
    {
        "id": "d6df95f5-472f-4b14-9cd4-5d5ef238175a",
        "primaryId": "NCT00005879",
        "statement_text": "There are criteria for PRIOR CONCURRENT THERAPY  PATIENT CHARACTERISTICS and DISEASE CHARACTERISTICS for entry to the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Fertile patients must use effective contraception during and for 3 months after studyNo other active cancer No retinal vein thrombosis No concurrent severe poorly controlled migraine No factor V Leiden mutation carrier PRIOR CONCURRENT THERAPY: Biologic therapy: At least 12 months since prior immunotherapy Chemotherapy: At least 3 months between completion of prior KUMC phase II difluoromethylornithine (DFMO) study and baseline aspiration At least 12 months since prior chemotherapy Endocrine therapy: Must not have started or stopped hormone replacement therapy or oral contraceptives within 6 months of baseline aspiration Must continue all hormone replacement therapy and/or oral contraceptives that were being taken at time of baseline aspiration ",
        "premise_nums": [
            "3 months between",
            "6 months of",
            "3 months after",
            "12 months since"
        ]
    },
    {
        "id": "d6df95f5-472f-4b14-9cd4-5d5ef238175a",
        "primaryId": "NCT00005879",
        "statement_text": "There are criteria for PRIOR CONCURRENT THERAPY  PATIENT CHARACTERISTICS and DISEASE CHARACTERISTICS for entry to the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "At least 12 months since prior tamoxifen  raloxifene  or other antihormonal therapyRadiotherapy: At least 3 months since prior radiotherapy Surgery: At least 6 months between prior oophorectomy and baseline aspiration Other: At least 2 weeks since the start of other new medication that would be ingested for 1 or more months ",
        "premise_nums": [
            "3 months since",
            "2 weeks since",
            "1 or more",
            "6 months between",
            "12 months since"
        ]
    },
    {
        "id": "bd8c39c6-96a3-40f8-80e6-6cbb6bdaecb5",
        "primaryId": "NCT00553410",
        "statement_text": "A 55 year old postmenopausal patient with sarcoidosis would be excluded from the primary trial due to her age ",
        "statement_nums": [
            "55 year old"
        ],
        "label": "Contradiction",
        "premise_text": "DISEASE CHARACTERISTICS: Confirmed diagnosis of prior operable  noninflammatory breast cancer meeting the following criteria: Steroid hormone receptor-positive tumors (estrogen receptor and/or progesterone receptor)  determined by immunohistochemistry  after primary surgery and before commencement of prior endocrine therapy Prior local treatment including surgery with or without radiotherapy for primary breast cancer with no known clinical residual loco-regional disease Following primary surgery  eligible patients must have had evidence of lymph node involvement either in the axillary or internal mammary nodes  but not supraclavicular nodes Clinically disease-free Must have completed 4-6 years of prior adjuvant selective estrogen receptor modulators (SERMs)  aromatase inhibitors (AIs)  or a sequential combination of both ",
        "premise_nums": [
            "4-6 years",
            "6 years of"
        ]
    },
    {
        "id": "bd8c39c6-96a3-40f8-80e6-6cbb6bdaecb5",
        "primaryId": "NCT00553410",
        "statement_text": "A 55 year old postmenopausal patient with sarcoidosis would be excluded from the primary trial due to her age ",
        "statement_nums": [
            "55 year old"
        ],
        "label": "Contradiction",
        "premise_text": "When calculating 4-6 years  neoadjuvant endocrine therapy should not be includedNo evidence of recurrent disease or distant metastatic disease No prior bilateral breast cancer PATIENT CHARACTERISTICS: Female Must be postmenopausal by any of the following criteria: Patients of any age who have had a bilateral oophorectomy (including radiation castration AND amenorrheic for greater than 3 months) Patients 56 years old or older with any evidence of ovarian function must have biochemical evidence of definite postmenopausal status (defined as estradiol  luteinizing hormone [LH]  and follicle-stimulating hormone [FSH] in the postmenopausal range) ",
        "premise_nums": [
            "4-6 years",
            "56 years old"
        ]
    },
    {
        "id": "bd8c39c6-96a3-40f8-80e6-6cbb6bdaecb5",
        "primaryId": "NCT00553410",
        "statement_text": "A 55 year old postmenopausal patient with sarcoidosis would be excluded from the primary trial due to her age ",
        "statement_nums": [
            "55 year old"
        ],
        "label": "Contradiction",
        "premise_text": "Patients 55 years old or younger must have biochemical evidence of definite postmenopausal status (defined as estradiol  LH  and FSH in the postmenopausal range)Patients who have received prior luteinizing-hormone releasing-hormone (LHRH) analogues within the last year are eligible if they have definite evidence of postmenopausal status as defined above Clinically adequate hepatic function No bone fracture due to osteoporosis at any time during the 4-6 years of prior therapy No prior or current malignancy except adequately treated basal cell or squamous cell carcinoma of the skin  in situ carcinoma of the cervix or bladder  or contra- or ipsilateral in situ breast carcinoma ",
        "premise_nums": [
            "4-6 years",
            "55 years old",
            "6 years of"
        ]
    },
    {
        "id": "bd8c39c6-96a3-40f8-80e6-6cbb6bdaecb5",
        "primaryId": "NCT00553410",
        "statement_text": "A 55 year old postmenopausal patient with sarcoidosis would be excluded from the primary trial due to her age ",
        "statement_nums": [
            "55 year old"
        ],
        "label": "Contradiction",
        "premise_text": "No other nonmalignant systemic diseases (cardiovascular  renal  lung  etc.) that would prevent prolonged follow-upNo psychiatric  addictive  or any other disorder that compromises compliance with protocol requirements PRIOR CONCURRENT THERAPY: See Disease Characteristics More than 12 months since prior and no other concurrent endocrine SERM/AI therapy Any type of prior adjuvant therapy allowed including  but not limited to  any of the following: Neoadjuvant chemotherapy Neoadjuvant endocrine therapy Adjuvant chemotherapy Trastuzumab (Herceptin®) Ovarian ablation Gonadotropin releasing hormone analogues Lapatinib ditosylate No concurrent hormone-replacement therapy  bisphosphonates (except for treatment of bone loss)  or any other investigational agent ",
        "premise_nums": [
            "12 months since"
        ]
    },
    {
        "id": "52ae415a-d8ab-48f5-abcb-9e8c5bb4fc83",
        "primaryId": "NCT00982319",
        "statement_text": "Only Post menopausal women can enter the primary trial  as long as they do not have prior hormone replacement therapy ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria: Female 18 + years of age Confirmed diagnosis of DCIS on core or excisional/incisional biopsy and scheduled for definitive surgery Pre or Post menopausal women reporting no use of hormone replacement therapy  tamoxifen or raloxifene within the prior 6 months to eligibility screening ",
        "premise_nums": [
            "6 months to"
        ]
    },
    {
        "id": "3bb3f3d5-e2e8-4cde-9d4f-dfc4b25c0b70",
        "primaryId": "NCT01425268",
        "secondaryId": "NCT01373671",
        "label": "Contradiction",
        "statement_text": "CO2 is utilised as part of the intervention in a single one of the study groups in the primary trial  and saline is used in both of the study groups in the secondary trial ",
        "statement_nums": [
            "2 is utilised"
        ],
        "premise_text": "INTERVENTION 1: AeroForm Tissue Expansion AeroForm Tissue Expansion inflation with carbon dioxide by remote control AeroForm Tissue Expansion: The AeroForm Patient Controlled Tissue Expander is a breast tissue expander implanted following mastectomy and activated by remote control to release small doses of carbon dioxide from an internal reservoir to fill and inflate the expander  INTERVENTION 1: FFDM and DBT FFDM exam and DBT scan on Siemens MAMMOMAT Inspiration INTERVENTION 2: FFDM Only FFDM exam only ",
        "premise_nums": []
    },
    {
        "id": "f820384b-0bf5-4f2e-96fd-2c8b13a4646c",
        "primaryId": "NCT01289353",
        "secondaryId": "NCT00429182",
        "label": "Entailment",
        "statement_text": "the primary trial and the secondary trial share at least one drug in their chemotherapy regiment ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Carboplatin: IV  weekly for 6 weeks  AUC of 2.0 INTERVENTION 1: Carboplatin + Cyclophosphamide + Thiotepa Carboplatin : Target AUC of 20, then divided into 4 doses given by vein (IV) days -6, -5, -4, -3 prior to stem cell infusion  ",
        "premise_nums": [
            "3 prior to",
            "of 2.0 INTERVENTION 1",
            "4 doses given",
            "0 INTERVENTION 1:"
        ]
    },
    {
        "id": "f7410166-82a7-4d15-8a04-47287ef6884c",
        "primaryId": "NCT00448591",
        "statement_text": "Only two types of adverse events occurred in more than 1% of patient in cohort 1 of the primary trial ",
        "statement_nums": [
            "1% of",
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Total: 672/2264 (29.68%) Febrile neutropenia * 117/2264 (5.17%) Neutropenia * 98/2264 (4.33%) Febrile bone marrow aplasia * 14/2264 (0.62%) Anaemia * 8/2264 (0.35%) Leukopenia * 8/2264 (0.35%) Thrombocytopenia * 6/2264 (0.27%) Disseminated intravascular coagulation * 3/2264 (0.13%) Agranulocytosis * 1/2264 (0.04%) Bone marrow failure * 1/2264 (0.04%) ",
        "premise_nums": [
            "14/2264 (0.62%)",
            "6/2264 (0.27%)",
            "117/2264 (5.17%)",
            "1/2264 (0.04%)",
            "8/2264 (0.35%)",
            "98/2264 (4.33%)",
            "3/2264 (0.13%)",
            "672/2264 (29.68%)"
        ]
    },
    {
        "id": "80726ab0-e8e4-4c42-860b-fdedad407517",
        "primaryId": "NCT00121836",
        "statement_text": "Patients that are not willing to sign and give written informed consent for participation of the primary trial will still be included ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria: Women greater than or equal 18 years of age HER2-negative metastatic breast cancer Previous adjuvant chemotherapy or hormonal treatment greater than or equal 1 measurable target lesion Exclusion Criteria: Previous treatment with chemotherapy  an anti-angiogenic agent  or a biologic therapy for advanced or metastatic cancer Radiation therapy within 4 weeks of study treatment start or insufficient recovery from the effects of prior radiation therapy Central nervous system metastases Other malignancy within last 5 years  except cured basal cell carcinoma of skin and carcinoma in situ of uterine cervix Serious concurrent infection ",
        "premise_nums": [
            "1 measurable target",
            "4 weeks of",
            "18 years of",
            "2-negative metastatic"
        ]
    },
    {
        "id": "f2e1c4f6-2f62-4a5e-b033-d798ba781d1d",
        "primaryId": "NCT02725801",
        "secondaryId": "NCT04030104",
        "label": "Entailment",
        "statement_text": "Neither the primary trial or the secondary trial have placebo groups ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: One-port intervention is placement of one-port tissue expander at time of reconstruction Allergen one-port tissue expander placement: patients will be randomized to receive a one port or two port tissue expander for breast reconstruction INTERVENTION 2: Two-port intervention is placement of two-port tissue expander at time of reconstruction AlloX2 two-port tissue expander placement: patients will be randomized to receive a one port or two port tissue expander for breast reconstruction INTERVENTION 1: IUS Alone IUS alone imaging INTERVENTION 2: Imagio (IUS+OA) IUS+OA imaging ",
        "premise_nums": []
    },
    {
        "id": "d42054cd-deb6-4436-941c-9e3a06c713cc",
        "primaryId": "NCT00036270",
        "statement_text": "In total Less than 10% of patients in the primary trial either had a disease relapse or died ",
        "statement_nums": [
            "10% of"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Disease Free Survival (DFS): Number of Events (Disease Relapse or Death) From Baseline up to 2.75 Years Number of events (disease relapse or death) to time of observation for DFS  DFS defined as time from randomization to earliest documentation of disease relapse or death from any cause in postmenopausal  receptor positive  node negative or node positive breast cancer patients for adjuvant treatment with exemestane compared with adjuvant tamoxifen therapy at 2.75 years  Disease relapse: primary tumor recurrence (locoregional or distant) and ipsilateral or contralateral breast cancer (CBC)  Intercurrent death: death without disease relapse  Time frame: Baseline (Month 0) up to 2.75 years Results 1: ",
        "premise_nums": [
            "to 2.75 years Results",
            "to 2.75 Years Number"
        ]
    },
    {
        "id": "d42054cd-deb6-4436-941c-9e3a06c713cc",
        "primaryId": "NCT00036270",
        "statement_text": "In total Less than 10% of patients in the primary trial either had a disease relapse or died ",
        "statement_nums": [
            "10% of"
        ],
        "label": "Contradiction",
        "premise_text": "Arm/Group Title: ExemestaneArm/Group Description: Exemestane (Aromasin ) 25 mg QD for 5 years  Overall Number of Participants Analyzed: 4898 Measure Type: Number Unit of Measure: Events (disease relapse or death) 352 Results 2: Arm/Group Title: Tamoxifen Followed by Exemestane Arm/Group Description: Tamoxifen 20 mg QD; upon completing 2.5 years to 3 years of tamoxifen  participants were to be switched to exemestane 25 mg QD and then were to complete a total of 5 years endocrine therapy  Overall Number of Participants Analyzed: 4868 Measure Type: Number Unit of Measure: Events (disease relapse or death) 388 ",
        "premise_nums": [
            "4868 Measure Type:",
            "completing 2.5 years to",
            "5 years endocrine",
            "20 mg QD;",
            "25 mg QD",
            "352 Results 2:",
            "4898 Measure Type:",
            "3 years of"
        ]
    },
    {
        "id": "0507fbf8-3557-4ace-b015-5e106b96f6a9",
        "primaryId": "NCT02041429",
        "secondaryId": "NCT00068588",
        "label": "Entailment",
        "statement_text": "the primary trial and the secondary trial use Maximum Tolerated Dose Determined by Dose-limiting Toxicities as their outcome measurements ",
        "statement_nums": [],
        "premise_text": "Outcome Measurement: Ruxolitinib Maximum Tolerated Dose (MTD) [Phase I] Ruxolitinib MTD in combination with paclitaxel 80 mg/m2 intravenously (IV) weekly is determined by the number of patients who have dose limiting toxicity (DLT)  See DLT primary outcome measure for definition Outcome Measurement: Maximum Tolerated Dose Determined by Dose-limiting Toxicities ",
        "premise_nums": [
            "2 intravenously (IV)",
            "80 mg/m2 intravenously"
        ]
    },
    {
        "id": "49ecc5a6-89be-48b6-85c5-c809c83f5baf",
        "primaryId": "NCT00825734",
        "statement_text": "Patients with any of the following conditions will be excluded from the primary trial; grade 1 infection  unstable angina or a grade 4 hemorrhage within the last month ",
        "statement_nums": [
            "4 hemorrhage within"
        ],
        "label": "Contradiction",
        "premise_text": "Exclusion Criteria Uncontrolled intercurrent illness including (but not limited to) ongoing or active infection greater than grade 2. Unstable angina (anginal symptoms at rest) or new onset angina Pulmonary hemorrhage or bleeding event grade 2 within 4 weeks of the first dose of study treatment  or any other hemorrhage or bleeding event grade 3 within 4 weeks of the first dose of study treatment  ",
        "premise_nums": [
            "2 within 4",
            "3 within 4"
        ]
    },
    {
        "id": "68792f63-d7b5-4570-bf8e-95e4cb8094e9",
        "primaryId": "NCT00343382",
        "secondaryId": "NCT00798135",
        "label": "Entailment",
        "statement_text": "Cohort 2 of the primary trial recieves a lower dose of Pilocarpine than cohort 2 of the secondary trial recieves of oral itraconazole ",
        "statement_nums": [
            "2 of the"
        ],
        "premise_text": "INTERVENTION 2: Pilocarpine 2 Times Per Day Patients receive 5mg of Pilocarpine 2 times per day for 6 weeks  INTERVENTION 1: Itraconazole oral itraconazole 200mg a day until disease progression or unacceptable toxicities  ",
        "premise_nums": [
            "2 Times Per",
            "2 times per"
        ]
    },
    {
        "id": "2ddd64c7-98ef-4b06-9f01-e59d3731e8ca",
        "primaryId": "NCT00483223",
        "secondaryId": "NCT00811135",
        "label": "Entailment",
        "statement_text": "There are more cases of Intestinal perforation  Chest pain  death  Erysipelas and Pneumonia in the secondary trial than in the primary trial",
        "statement_nums": [],
        "premise_text": "Adverse Events 1: Total: 8/86 (9.30%) Hypersensitivity reaction to Cisplatin 1/86 (1.16%) Infection with normal ANC 4/86 (4.65%) Neutrophil Count 1/86 (1.16%) Hyperglycemia 1/86 (1.16%) Hypertension 1/86 (1.16%) Adverse Events 1: Intestinal perforation * 1/88 (1.14%) Chest pain * 1/88 (1.14%) Death * 1/88 (1.14%) Erysipelas * 1/88 (1.14%) Pneumonia * 1/88 (1.14%) ",
        "premise_nums": [
            "1/86 (1.16%)",
            "8/86 (9.30%)",
            "4/86 (4.65%)",
            "1/88 (1.14%)"
        ]
    },
    {
        "id": "a1a5767f-07e7-4a33-a26f-586cf71a208d",
        "primaryId": "NCT01852032",
        "secondaryId": "NCT01118624",
        "label": "Entailment",
        "statement_text": "We cannot compare the doses and frequencies provided in the intervention sections of the secondary trial and the primary trial ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Breast Cancer Patients Tomosynthesis Breast Scanning is done and breast CT Scanning is done  INTERVENTION 1: Pralatrexate Study drug 190 mg/m^2 for 2 to 4 weeks  ",
        "premise_nums": [
            "2 for 2",
            "190 mg/m^2",
            "2 to 4"
        ]
    },
    {
        "id": "9c80fb61-66dc-4b3d-82b9-4fb62db89422",
        "primaryId": "NCT01326481",
        "statement_text": "Patients with Myocardial Infarction or Deep vein thrombosis within the last 3 months are excluded from the primary trial ",
        "statement_nums": [
            "3 months are"
        ],
        "label": "Entailment",
        "premise_text": "Exclusion Criteria: Angina  MI  symptomatic congestive heart failure  cerebrovascular accident  transient ischemic attack  arterial embolism  pulmonary embolism  DVT  PTCA or CABG within the past 6 months ",
        "premise_nums": []
    },
    {
        "id": "6755a378-08bf-4e9b-a6de-166733d0307b",
        "primaryId": "NCT00181363",
        "statement_text": "The only difference between the interventions used in the primary trial is the patients location ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "INTERVENTION 1: Prone Prone position INTERVENTION 2: Supine Supine position ",
        "premise_nums": []
    },
    {
        "id": "b7f3e657-638b-4463-9639-4fb0da2be042",
        "primaryId": "NCT00262834",
        "secondaryId": "NCT01106898",
        "label": "Contradiction",
        "statement_text": "In the secondary trial and the primary trial Her-2 neu positive breast cancer patients receive additional maintenance therapy compared to other patients ",
        "statement_nums": [
            "2 neu positive"
        ],
        "premise_text": "INTERVENTION 1: Vorinostat Women in the vorinostat group were scheduled to receive 6 doses of oral vorinostat at 300 mg twice daily (bid)  with the last dose administered by study personnel approximately 2 hours before the scheduled breast surgery (or biopsy)  INTERVENTION 1: Treatment (Chemotherapy With or Without Maintenance Therapy) SYSTEMIC CHEMOTHERAPY: Patients receive cyclophosphamide IV over 1 hour and paclitaxel IV over 3 hours on day 1. Treatment repeats every 14 days for 6 courses in the absence of disease progression or unacceptable toxicity  ",
        "premise_nums": [
            "3 hours on",
            "2 hours before",
            "6 courses in",
            "1 hour and",
            "14 days for",
            "6 doses of",
            "300 mg twice"
        ]
    },
    {
        "id": "b7f3e657-638b-4463-9639-4fb0da2be042",
        "primaryId": "NCT00262834",
        "secondaryId": "NCT01106898",
        "label": "Contradiction",
        "statement_text": "In the secondary trial and the primary trial Her-2 neu positive breast cancer patients receive additional maintenance therapy compared to other patients ",
        "statement_nums": [
            "2 neu positive"
        ],
        "premise_text": "MAINTENANCE THERAPY (Her-2 neu positive patients): Patients receive trastuzumab IV over 30 minutes on day 1. Treatment repeats every 14 days for 5 courses and then every 21 days for 14 courses in the absence of disease progression or unacceptable toxicity cyclophosphamide  paclitaxel  trastuzumab: Given IV ",
        "premise_nums": [
            "21 days for",
            "14 days for",
            "30 minutes on",
            "5 courses and",
            "2 neu positive",
            "14 courses in"
        ]
    },
    {
        "id": "5498a85b-a086-4d5d-b677-9ae44646a382",
        "primaryId": "NCT00546156",
        "secondaryId": "NCT00398567",
        "label": "Contradiction",
        "statement_text": "There are no cases of Vertigo  Abdominal distension or Neutropenia in the primary trial or the primary trial ",
        "statement_nums": [],
        "premise_text": "Adverse Events 1: Total: 4/104 (3.85%) Neutropenia 1/104 (0.96%) Leukopenia 2/104 (1.92%) paranasal sinus reaction 1/104 (0.96%) cellulitis 1/104 (0.96%) Adverse Events 1: Total: 1/4 (25.00%) Vertigo 0/4 (0.00%) Abdominal adhesions 0/4 (0.00%) Abdominal distension 0/4 (0.00%) Abdominal pain 0/4 (0.00%) Diarrhoea 0/4 (0.00%) Nausea 0/4 (0.00%) Vomiting 0/4 (0.00%) ",
        "premise_nums": [
            "2/104 (1.92%)",
            "0/4 (0.00%)",
            "1/104 (0.96%)",
            "1/4 (25.00%)",
            "4/104 (3.85%)"
        ]
    },
    {
        "id": "5498a85b-a086-4d5d-b677-9ae44646a382",
        "primaryId": "NCT00546156",
        "secondaryId": "NCT00398567",
        "label": "Contradiction",
        "statement_text": "There are no cases of Vertigo  Abdominal distension or Neutropenia in the primary trial or the primary trial ",
        "statement_nums": [],
        "premise_text": "Disease progression 0/4 (0.00%)Influenza 0/4 (0.00%) Nasopharyngitis 0/4 (0.00%) Lumbar vertebral fracture 0/4 (0.00%) Hyponatraemia 0/4 (0.00%) Ataxia 0/4 (0.00%) ",
        "premise_nums": [
            "0/4 (0.00%)Influenza"
        ]
    },
    {
        "id": "f3d2337e-6cd9-4e8c-b327-cbc48557b8dd",
        "primaryId": "NCT00418457",
        "statement_text": "antibiotics within 10 days prior to beginning is acceptable for patients entering the primary trial ",
        "statement_nums": [
            "10 days prior"
        ],
        "label": "Entailment",
        "premise_text": "Inclusion Criteria: Primary breast cancer without known extension beyond the breast and axillary nodes (i.e  believed to be Tumor Stage 1-3, Nodes 0-2) Scheduled for unilateral or bilateral mastectomy with or without implant (isolated \"lumpectomy\" will not qualify) Isolated \"lumpectomy\" with axillary node dissection (anticipated removal of at least five nodes) Written informed consent  including willingness to be randomized to morphine or regional analgesia Exclusion Criteria: Previous surgery for breast cancer (except diagnostic biopsies) Inflammatory breast cancer Age smaller than 18 or greater than 85 years old Scheduled free flap reconstruction ASA Physical Status 4 Any contraindication to epidural or paravertebral anesthesia and analgesia (including coagulopathy  abnormal anatomy) ",
        "premise_nums": [
            "18 or greater",
            "85 years old",
            "0-2) Scheduled",
            "1-3, Nodes",
            "4 Any contraindication"
        ]
    },
    {
        "id": "f3d2337e-6cd9-4e8c-b327-cbc48557b8dd",
        "primaryId": "NCT00418457",
        "statement_text": "antibiotics within 10 days prior to beginning is acceptable for patients entering the primary trial ",
        "statement_nums": [
            "10 days prior"
        ],
        "label": "Entailment",
        "premise_text": "Any contraindication to midazolam  propofol  sevoflurane  fentanyl  or morphineOther cancer not believed by the attending surgeon to be in long-term remission Systemic disease believed by the attending surgeon to present 25% two-year mortality ",
        "premise_nums": [
            "25% two-year"
        ]
    },
    {
        "id": "f25d63c8-9033-4db6-9c15-2151d82e2a6d",
        "primaryId": "NCT00068588",
        "statement_text": "between the two Arms of the primary trial  cohort 1 vastly outperformed cohort 2 in terms of the number of patients with complete tumor response ",
        "statement_nums": [
            "2 in terms",
            "1 vastly outperformed"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Maximum Tolerated Dose Determined by Dose-limiting Toxicities ",
        "premise_nums": []
    },
    {
        "id": "5ab5f2e8-d1cf-4789-86b4-e2f6dbf443ea",
        "primaryId": "NCT00209092",
        "secondaryId": "NCT00631852",
        "label": "Contradiction",
        "statement_text": "A patient with a Histologically confirmed breast cancer would be accepted for the primary trial and the secondary trial ",
        "statement_nums": [],
        "premise_text": "Inclusion Criteria: Histologically or cytologically confirmed breast carcinoma  Inclusion Criteria: Patients with cytologically confirmed breast cancer with biopsy showing invasive or non-invasive (DCIS) at least 1.0 cm greatest diameter on imaging ",
        "premise_nums": [
            "least 1.0 cm greatest"
        ]
    },
    {
        "id": "4fd10abc-81d1-44f4-825a-26e2eaeae979",
        "primaryId": "NCT02308020",
        "statement_text": "There were 23 participants in cohort 1 of the primary trial with a (CR) or (PR) based on the Response Assessment in Neuro-Oncology Brain Metastasis (RANO-BM) response criteria ",
        "statement_nums": [
            "1 of the",
            "23 participants in"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR): Objective Intracranial Response Rate (OIRR) ",
        "premise_nums": []
    },
    {
        "id": "a12a46de-9d3e-4c6a-becb-d43653040bf0",
        "primaryId": "NCT00089973",
        "statement_text": "the primary trial uses a 3 week cycle for SB-715992 administration  and the study lasts for 21 cycles ",
        "statement_nums": [
            "3 week cycle"
        ],
        "label": "Contradiction",
        "premise_text": "INTERVENTION 1: SB-715992 The eligible participants were administered Ispinesib  intravenously as a one-hour infusion on Day 1 of every 21-day treatment cycle  at a dose of 18 mg/m^2. The dosing was repeated for up to multiple cycles  until disease progression or removal from treatment due to an unacceptable toxicity or withdrawal of consent  ",
        "premise_nums": [
            "21-day treatment",
            "715992 The eligible",
            "1 of every",
            "18 mg/m^2."
        ]
    },
    {
        "id": "66ee10ac-1bfe-44d6-9b91-8a2bb1983606",
        "primaryId": "NCT01017549",
        "secondaryId": "NCT01390064",
        "label": "Contradiction",
        "statement_text": "the secondary trial has 5 more patients cohorts than the primary trial ",
        "statement_nums": [
            "5 more patients"
        ],
        "premise_text": "INTERVENTION 1: Electronic Brachytherapy Radiation therapy was delivered using the 510(k) cleared Xoft Axxent System  Accelerated partial breast irradiation is the method of radiation therapy administration that has been commonly used by physicians using Iridium-192, but was FDA cleared for use prior to commencing study enrollment using an electronic source  INTERVENTION 1: Initial Cohort Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG Subcutaneous administration 5 doses of 300 micrograms Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG: All research participants will receive the Mimotope P10s-PADRE/MONTANIDE ISA 51 VG vaccine via subcutaneous (SC) injection following the schedule INTERVENTION 2: ",
        "premise_nums": [
            "300 micrograms Vaccination",
            "5 doses of",
            "51 VG vaccine",
            "51 VG Subcutaneous"
        ]
    },
    {
        "id": "66ee10ac-1bfe-44d6-9b91-8a2bb1983606",
        "primaryId": "NCT01017549",
        "secondaryId": "NCT01390064",
        "label": "Contradiction",
        "statement_text": "the secondary trial has 5 more patients cohorts than the primary trial ",
        "statement_nums": [
            "5 more patients"
        ],
        "premise_text": "Escalation CohortVaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG Subcutaneous administration of 5 doses of 500 micrograms Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG: All research participants will receive the Mimotope P10s-PADRE/MONTANIDE ISA 51 VG vaccine via subcutaneous (SC) injection following the schedule ",
        "premise_nums": [
            "5 doses of",
            "51 VG vaccine",
            "500 micrograms Vaccination",
            "51 VG Subcutaneous"
        ]
    },
    {
        "id": "714c540c-1fa1-47c7-ac13-1e8f056d1e31",
        "primaryId": "NCT02115984",
        "statement_text": "A total of 3 patients in cohort 1 of the primary trial experience a Herpes related adverse event ",
        "statement_nums": [
            "3 patients in",
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 57/57 (100.00%) Dry eyes 13/33 (39.39%) Heartburn 9/33 (27.27%) Nausea after the CT (before day 7) 57/57 (100.00%) Herpetic eruption 0/33 (0.00%) Dry skin 15/33 (45.45%) Alopecia 57/57 (100.00%) Adverse Events 2: Total: 23/23 (100.00%) Dry eyes 2/11 (18.18%) Heartburn 2/11 (18.18%) Nausea after the CT (before day 7) 23/23 (100.00%) Herpetic eruption 3/11 (27.27%) Dry skin 9/11 (81.82%) ",
        "premise_nums": [
            "9/33 (27.27%)",
            "23/23 (100.00%)",
            "0/33 (0.00%)",
            "57/57 (100.00%)",
            "15/33 (45.45%)",
            "3/11 (27.27%)",
            "9/11 (81.82%)",
            "2/11 (18.18%)",
            "13/33 (39.39%)"
        ]
    },
    {
        "id": "714c540c-1fa1-47c7-ac13-1e8f056d1e31",
        "primaryId": "NCT02115984",
        "statement_text": "A total of 3 patients in cohort 1 of the primary trial experience a Herpes related adverse event ",
        "statement_nums": [
            "3 patients in",
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Alopecia 23/23 (100.00%)",
        "premise_nums": [
            "23/23 (100.00%)"
        ]
    },
    {
        "id": "3948b30d-934d-485c-b324-b3571e2957a3",
        "primaryId": "NCT00688740",
        "secondaryId": "NCT00191815",
        "label": "Entailment",
        "statement_text": "The most common adverse events in the primary trial and the secondary trial is Neutropenia with a total of 3 cases across all cohorts ",
        "statement_nums": [
            "3 cases across"
        ],
        "premise_text": "Adverse Events 1: Total: 267/744 (35.89%) Neutropenia *2/744 (0.27%) Anaemia *1/744 (0.13%) Leukopenia *1/744 (0.13%) Thrombocytopenia *1/744 (0.13%) Thrombotic thrombocytopenic purpura *1/744 (0.13%) Atrial flutter *1/744 (0.13%) Cardiac arrest *1/744 (0.13%) Myocardial ischaemia *1/744 (0.13%) Arrhythmia *0/744 (0.00%) ",
        "premise_nums": [
            "0/744 (0.00%)",
            "2/744 (0.27%)",
            "1/744 (0.13%)",
            "267/744 (35.89%)"
        ]
    },
    {
        "id": "3948b30d-934d-485c-b324-b3571e2957a3",
        "primaryId": "NCT00688740",
        "secondaryId": "NCT00191815",
        "label": "Entailment",
        "statement_text": "The most common adverse events in the primary trial and the secondary trial is Neutropenia with a total of 3 cases across all cohorts ",
        "statement_nums": [
            "3 cases across"
        ],
        "premise_text": "Cardiac failure congestive *0/744 (0.00%)Adverse Events 2: Total: 67/736 (9.10%) Neutropenia *1/736 (0.14%) Anaemia *0/736 (0.00%) Leukopenia *0/736 (0.00%) Thrombocytopenia *0/736 (0.00%) Thrombotic thrombocytopenic purpura *0/736 (0.00%) Atrial flutter *0/736 (0.00%) Cardiac arrest *0/736 (0.00%) Myocardial ischaemia *0/736 (0.00%) ",
        "premise_nums": [
            "0/744 (0.00%)Adverse",
            "0/736 (0.00%)",
            "1/736 (0.14%)",
            "67/736 (9.10%)"
        ]
    },
    {
        "id": "3948b30d-934d-485c-b324-b3571e2957a3",
        "primaryId": "NCT00688740",
        "secondaryId": "NCT00191815",
        "label": "Entailment",
        "statement_text": "The most common adverse events in the primary trial and the secondary trial is Neutropenia with a total of 3 cases across all cohorts ",
        "statement_nums": [
            "3 cases across"
        ],
        "premise_text": "Arrhythmia *2/736 (0.27%)Cardiac failure congestive *1/736 (0.14%) Adverse Events 1: Total: 6 Atrial fibrillation 1/67 (1.49%) Ventricular fibrillation 1/67 (1.49%) Gastrointestinal perforation 1/67 (1.49%) Periproctitis 1/67 (1.49%) General physical health deterioration 1/67 (1.49%) Escherichia sepsis 1/67 (1.49%) Pneumonia 1/67 (1.49%) Tumour pain 1/67 (1.49%) Renal failure acute 1/67 (1.49%) ",
        "premise_nums": [
            "6 Atrial fibrillation",
            "1/67 (1.49%)",
            "1/736 (0.14%)",
            "2/736 (0.27%)Cardiac"
        ]
    },
    {
        "id": "3948b30d-934d-485c-b324-b3571e2957a3",
        "primaryId": "NCT00688740",
        "secondaryId": "NCT00191815",
        "label": "Entailment",
        "statement_text": "The most common adverse events in the primary trial and the secondary trial is Neutropenia with a total of 3 cases across all cohorts ",
        "statement_nums": [
            "3 cases across"
        ],
        "premise_text": "Pleurisy 1/67 (1.49%)",
        "premise_nums": [
            "1/67 (1.49%)"
        ]
    },
    {
        "id": "45cf29ce-25f5-4719-8468-69d94893c9e7",
        "primaryId": "NCT01166763",
        "statement_text": "the primary trial recorded 4 life-threatening adverse events ",
        "statement_nums": [
            "4 life-threatening adverse"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 3/30 (10.00%) Cholecystitis * [1]1/30 (3.33%) Increase in diarrhea * [2]1/30 (3.33%) Flank pain * [3]1/30 (3.33%) ",
        "premise_nums": [
            "1/30 (3.33%)",
            "3/30 (10.00%)"
        ]
    },
    {
        "id": "7502090d-1bcb-4be9-9358-81afb9440a17",
        "primaryId": "NCT01823991",
        "statement_text": "Patients with metallic vascular clips placed to prevent bleeding from conditions such as intracranial aneurysms  are elligible for the primary trial ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Exclusion Criteria: Known claustrophobia  presence of pacemaker and/or ferromagnetic material in their body that would prohibit MRI imaging ",
        "premise_nums": []
    },
    {
        "id": "89f84928-82a9-413e-ab25-400657002c55",
        "primaryId": "NCT01840163",
        "secondaryId": "NCT02005549",
        "label": "Contradiction",
        "statement_text": "the primary trial and the secondary trial do not exclude patients with concurrent systemic antitumor therapy ",
        "statement_nums": [],
        "premise_text": "Inclusion Criteria: Stage 1-2 invasive breast cancer diagnosis  DCIS Ability to read English Exclusion Criteria: Male Inclusion Criteria: female patients  18-70years of age; histologically-proven invasive breast cancer; no prior or current neoplasm except for non-melanoma skin cancer  or in situ cancer of the cervix; no distant disease/secondary cancer  Exclusion Criteria: pregnant or lactating women; pre-operative local treatment for breast cancer; prior or concurrent systemic antitumor therapy; clinically significant cardiac disease  ",
        "premise_nums": [
            "18-70years of",
            "2 invasive breast",
            "1-2 invasive"
        ]
    },
    {
        "id": "79dbf7bf-e08d-4eae-a804-0daeb83d6f01",
        "primaryId": "NCT00930930",
        "statement_text": "The most frequent adverse event in cohort 1 of the primary trial was lymphopenia ",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 22/96 (22.92%) Anemia 1/96 (1.04%) lymphopenia 1/96 (1.04%) cardiac ischemia/infarction 1/96 (1.04%) sinus tachycardia 2/96 (2.08%) Dehydration 5/96 (5.21%) colitis 1/96 (1.04%) diarrhea 5/96 (5.21%) ileus 1/96 (1.04%) nausea 2/96 (2.08%) vomiting 1/96 (1.04%) distal small bowel obstruction 1/96 (1.04%) edema 1/96 (1.04%) ",
        "premise_nums": [
            "5/96 (5.21%)",
            "1/96 (1.04%)",
            "2/96 (2.08%)",
            "22/96 (22.92%)"
        ]
    },
    {
        "id": "79dbf7bf-e08d-4eae-a804-0daeb83d6f01",
        "primaryId": "NCT00930930",
        "statement_text": "The most frequent adverse event in cohort 1 of the primary trial was lymphopenia ",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "fatigue 2/96 (2.08%)Adverse Events 2: Total: 6/49 (12.24%) Anemia 0/49 (0.00%) lymphopenia 0/49 (0.00%) cardiac ischemia/infarction 0/49 (0.00%) sinus tachycardia 0/49 (0.00%) Dehydration 1/49 (2.04%) colitis 0/49 (0.00%) diarrhea 0/49 (0.00%) ileus 0/49 (0.00%) nausea 1/49 (2.04%) vomiting 1/49 (2.04%) distal small bowel obstruction 0/49 (0.00%) ",
        "premise_nums": [
            "1/49 (2.04%)",
            "0/49 (0.00%)",
            "2/96 (2.08%)Adverse",
            "6/49 (12.24%)"
        ]
    },
    {
        "id": "79dbf7bf-e08d-4eae-a804-0daeb83d6f01",
        "primaryId": "NCT00930930",
        "statement_text": "The most frequent adverse event in cohort 1 of the primary trial was lymphopenia ",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "edema 0/49 (0.00%)fatigue 0/49 (0.00%) ",
        "premise_nums": [
            "0/49 (0.00%)fatigue"
        ]
    },
    {
        "id": "c9ff5b91-cec7-4da7-b1cd-f08f3874e8ed",
        "primaryId": "NCT01381874",
        "statement_text": "The Exemestane group in the primary trial had a better median Progression-Free Survival than the Abiraterone Acetate + Prednisone group  however the patient with the maximum PFS was in the Abiraterone Acetate + Prednisone group ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Progression-Free Survival (PFS) Progression-free survival was defined as the time from randomization to first occurrence of disease progression (either radiographic or clinical)  or death from any cause  PFS was determined using radiographic progression defined by Response Evaluation Criteria in Solid Tumors (RECIST) on measurable lesions captured by computed tomography (CT) or magnetic resonance imaging (MRI)  Clinical disease progression was considered only when disease progression could not be confirmed by CT or MRI  such as when the disease site is skin  bone marrow  or central nervous system  Time frame: Approximately 2 years Results 1: Arm/Group Title: Exemestane ",
        "premise_nums": [
            "2 years Results"
        ]
    },
    {
        "id": "c9ff5b91-cec7-4da7-b1cd-f08f3874e8ed",
        "primaryId": "NCT01381874",
        "statement_text": "The Exemestane group in the primary trial had a better median Progression-Free Survival than the Abiraterone Acetate + Prednisone group  however the patient with the maximum PFS was in the Abiraterone Acetate + Prednisone group ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Arm/Group Description: Participants received exemestane tablet as oral dose of 25 milligram (mg) per day in 28-day treatment cycles until disease progression  unacceptable toxicity  or death (up to 3 years) Overall Number of Participants Analyzed: 102 Median (95% Confidence Interval) Unit of Measure: Months 3.68 (1.94 to 5.26) Results 2: Arm/Group Title: Abiraterone Acetate + Prednisone ",
        "premise_nums": [
            "94 to 5.26)",
            "25 milligram (mg)",
            "95% Confidence",
            "28-day treatment"
        ]
    },
    {
        "id": "c9ff5b91-cec7-4da7-b1cd-f08f3874e8ed",
        "primaryId": "NCT01381874",
        "statement_text": "The Exemestane group in the primary trial had a better median Progression-Free Survival than the Abiraterone Acetate + Prednisone group  however the patient with the maximum PFS was in the Abiraterone Acetate + Prednisone group ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Arm/Group Description: Participants received abiraterone acetate tablet at a total oral dose of 1000 milligram (mg) along with 5 mg capsule of prednisone/prednisolone per day in 28-day treatment cycles until disease progression  unacceptable toxicity  or death (up to 3 years) Overall Number of Participants Analyzed: 89 Median (95% Confidence Interval) Unit of Measure: Months 3.65 (2.73 to 5.59) ",
        "premise_nums": [
            "1000 milligram (mg)",
            "5 mg capsule",
            "95% Confidence",
            "73 to 5.59)",
            "28-day treatment"
        ]
    },
    {
        "id": "23040754-d1ad-4660-aacf-3298aefa5dae",
        "primaryId": "NCT00777101",
        "secondaryId": "NCT00559845",
        "label": "Contradiction",
        "statement_text": "There were no depressed patients in either the primary trial or the secondary trial  however there was one suicide attempt in cohort 2 of the secondary trial ",
        "statement_nums": [
            "2 of the"
        ],
        "premise_text": "Adverse Events 1: Total: 31/116 (26.72%) Neutropenia 1/116 (0.86%) Thrombocytopenia 1/116 (0.86%) Acute myocardial infarction 1/116 (0.86%) Myocardial infarction 0/116 (0.00%) Pericardial effusion 0/116 (0.00%) Abdominal pain 3/116 (2.59%) Ascites 1/116 (0.86%) Diarrhoea 3/116 (2.59%) Gingival bleeding 1/116 (0.86%) Intestinal haemorrhage 1/116 (0.86%) ",
        "premise_nums": [
            "1/116 (0.86%)",
            "31/116 (26.72%)",
            "3/116 (2.59%)",
            "0/116 (0.00%)"
        ]
    },
    {
        "id": "23040754-d1ad-4660-aacf-3298aefa5dae",
        "primaryId": "NCT00777101",
        "secondaryId": "NCT00559845",
        "label": "Contradiction",
        "statement_text": "There were no depressed patients in either the primary trial or the secondary trial  however there was one suicide attempt in cohort 2 of the secondary trial ",
        "statement_nums": [
            "2 of the"
        ],
        "premise_text": "Nausea 2/116 (1.72%)Adverse Events 2: Total: 24/115 (20.87%) Neutropenia 1/115 (0.87%) Thrombocytopenia 0/115 (0.00%) Acute myocardial infarction 0/115 (0.00%) Myocardial infarction 1/115 (0.87%) Pericardial effusion 1/115 (0.87%) Abdominal pain 0/115 (0.00%) Ascites 0/115 (0.00%) Diarrhoea 4/115 (3.48%) Gingival bleeding 0/115 (0.00%) ",
        "premise_nums": [
            "24/115 (20.87%)",
            "1/115 (0.87%)",
            "2/116 (1.72%)Adverse",
            "4/115 (3.48%)",
            "0/115 (0.00%)"
        ]
    },
    {
        "id": "23040754-d1ad-4660-aacf-3298aefa5dae",
        "primaryId": "NCT00777101",
        "secondaryId": "NCT00559845",
        "label": "Contradiction",
        "statement_text": "There were no depressed patients in either the primary trial or the secondary trial  however there was one suicide attempt in cohort 2 of the secondary trial ",
        "statement_nums": [
            "2 of the"
        ],
        "premise_text": "Intestinal haemorrhage 0/115 (0.00%)Nausea 3/115 (2.61%) Adverse Events 1: Total: 8/54 (14.81%) Anaemia 1/54 (1.85%) Febrile Neutropenia 1/54 (1.85%) Retinopathy Hypertensive 1/54 (1.85%) Febrile Infection 1/54 (1.85%) Postoperative Wound Complication 1/54 (1.85%) Cardiac Imaging Procedure Abnormal 1/54 (1.85%) Malignant Melanoma In Situ 1/54 (1.85%) Suicide Attempt 1/54 (1.85%) ",
        "premise_nums": [
            "3/115 (2.61%)",
            "8/54 (14.81%)",
            "1/54 (1.85%)",
            "0/115 (0.00%)Nausea"
        ]
    },
    {
        "id": "23040754-d1ad-4660-aacf-3298aefa5dae",
        "primaryId": "NCT00777101",
        "secondaryId": "NCT00559845",
        "label": "Contradiction",
        "statement_text": "There were no depressed patients in either the primary trial or the secondary trial  however there was one suicide attempt in cohort 2 of the secondary trial ",
        "statement_nums": [
            "2 of the"
        ],
        "premise_text": "Dyspnoea 1/54 (1.85%)",
        "premise_nums": [
            "1/54 (1.85%)"
        ]
    },
    {
        "id": "e3be834c-c311-4132-8529-d354b9e620b9",
        "primaryId": "NCT01033032",
        "statement_text": "The only adverse event recorded in the primary trial was one single case of pleural effusion ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 1/3 (33.33%) FEBRILE NEUTROPENIA 0/3 (0.00%) LYMPH NODE PAIN 0/3 (0.00%) NEUTROPHIL COUNT DECREASED 0/3 (0.00%) THROMBOCYTOPENIA 0/3 (0.00%) CHEST PAIN 0/3 (0.00%) DEHYDRATION 0/3 (0.00%) PLEURAL EFFUSION 1/3 (33.33%) PNEUMONITIS 0/3 (0.00%) PULMONARY INFILTERATES 0/3 (0.00%) ALOPECIA 0/3 (0.00%) ",
        "premise_nums": [
            "0/3 (0.00%)",
            "1/3 (33.33%)"
        ]
    },
    {
        "id": "8115b5e3-e178-433b-b114-09d97daaa8d7",
        "primaryId": "NCT01326481",
        "statement_text": "Patients with Myocardial Infarction,percutaneous transluminal coronary angioplasty or Deep vein thrombosis within the last 2 - 6 months are eligible for the primary trial ",
        "statement_nums": [
            "6 months are"
        ],
        "label": "Contradiction",
        "premise_text": "Exclusion Criteria: Angina  MI  symptomatic congestive heart failure  cerebrovascular accident  transient ischemic attack  arterial embolism  pulmonary embolism  DVT  PTCA or CABG within the past 6 months ",
        "premise_nums": []
    },
    {
        "id": "bbcfc019-2d60-413f-88f9-04cacec55e30",
        "primaryId": "NCT00333775",
        "secondaryId": "NCT00201864",
        "label": "Entailment",
        "statement_text": "There are several cardiac adverse events recorded in the primary trial  but not a single one in the secondary trial ",
        "statement_nums": [],
        "premise_text": "Adverse Events 1: Total: 82/217 (37.79%) Febrile neutropenia 21/217 (9.68%) Neutropenia 4/217 (1.84%) Leukopenia 0/217 (0.00%) Anaemia 1/217 (0.46%) Thrombocytopenia 0/217 (0.00%) Atrial fibrillation 0/217 (0.00%) Arrhythmia 1/217 (0.46%) Arteriospasm coronary 0/217 (0.00%) Atrioventricular block first degree 0/217 (0.00%) Cardiac failure 0/217 (0.00%) Adverse Events 2: Total: 106/252 (42.06%) ",
        "premise_nums": [
            "0/217 (0.00%)",
            "106/252 (42.06%)",
            "21/217 (9.68%)",
            "1/217 (0.46%)",
            "4/217 (1.84%)",
            "82/217 (37.79%)"
        ]
    },
    {
        "id": "bbcfc019-2d60-413f-88f9-04cacec55e30",
        "primaryId": "NCT00333775",
        "secondaryId": "NCT00201864",
        "label": "Entailment",
        "statement_text": "There are several cardiac adverse events recorded in the primary trial  but not a single one in the secondary trial ",
        "statement_nums": [],
        "premise_text": "Febrile neutropenia 29/252 (11.51%)Neutropenia 13/252 (5.16%) Leukopenia 3/252 (1.19%) Anaemia 0/252 (0.00%) Thrombocytopenia 1/252 (0.40%) Atrial fibrillation 1/252 (0.40%) Arrhythmia 0/252 (0.00%) Arteriospasm coronary 1/252 (0.40%) Atrioventricular block first degree 1/252 (0.40%) Cardiac failure 1/252 (0.40%) Adverse Events 1: Total: 6/40 (15.00%) Nausea 1/40 (2.50%) ",
        "premise_nums": [
            "0/252 (0.00%)",
            "1/40 (2.50%)",
            "3/252 (1.19%)",
            "13/252 (5.16%)",
            "6/40 (15.00%)",
            "29/252 (11.51%)Neutropenia",
            "1/252 (0.40%)"
        ]
    },
    {
        "id": "bbcfc019-2d60-413f-88f9-04cacec55e30",
        "primaryId": "NCT00333775",
        "secondaryId": "NCT00201864",
        "label": "Entailment",
        "statement_text": "There are several cardiac adverse events recorded in the primary trial  but not a single one in the secondary trial ",
        "statement_nums": [],
        "premise_text": "Vomiting 1/40 (2.50%)Chest pain 1/40 (2.50%) Hypercalcemia 1/40 (2.50%) Thromboembolism 2/40 (5.00%) ",
        "premise_nums": [
            "2/40 (5.00%)",
            "1/40 (2.50%)Chest"
        ]
    },
    {
        "id": "e7899445-9b80-4429-b4c3-d47bd36a2347",
        "primaryId": "NCT00232479",
        "statement_text": "Patients with HER2 positive breast or colon carcinoma are eligible for the primary trial ",
        "statement_nums": [
            "2 positive breast"
        ],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria: HER-2 overexpressing breast cancer ",
        "premise_nums": [
            "2 overexpressing breast"
        ]
    },
    {
        "id": "2a50cc2a-281b-4bc6-9f18-6bd9686c682d",
        "primaryId": "NCT00754845",
        "statement_text": "Patients who received over 5 years of anastrozole therapy  completed 2 years prior  are eligible for the primary trial ",
        "statement_nums": [
            "5 years of",
            "2 years prior"
        ],
        "label": "Entailment",
        "premise_text": "Must have received 4½ - 6 years of aromatase inhibitor therapy (e.g.  letrozole  anastrozole  or exemestane)  either as initial therapy or after prior tamoxifen citrate  including treatment received as part of clinical trial CAN-NCIC-MA17 Completed aromatase inhibitor therapy 2 years ago ",
        "premise_nums": [
            "6 years of",
            "17 Completed aromatase",
            "MA17 Completed",
            "2 years ago"
        ]
    },
    {
        "id": "26419cec-e256-46a7-9026-94dbe026c63d",
        "primaryId": "NCT01151046",
        "statement_text": "The placebo group in the primary trial had a much lower Median PFS than the MM-121 cohort ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Progression Free Survival (PFS) ",
        "premise_nums": []
    },
    {
        "id": "8ef93fe0-0a12-4a7e-93aa-c40af7154a57",
        "primaryId": "NCT02336737",
        "secondaryId": "NCT01432886",
        "label": "Contradiction",
        "statement_text": "the secondary trial is testing for the DLT of its interventions  whereas the primary trial is evaluating the dose limiting toxicity for SentiMag and SiennaXP ",
        "statement_nums": [],
        "premise_text": "Outcome Measurement: Number of Participants With Detected Lymph Nodes The proportion of lymph nodes detected intraoperatively by SentiMag and SiennaXP in relation the proportion of lymph nodes detected by the combination of Technetium Sulfur Colloid and Isosulfan blue dye Outcome Measurement: Number of Participants With Dose Limiting Toxicity (DLT) ",
        "premise_nums": []
    },
    {
        "id": "f5d50d87-b419-4537-87ec-7c9d23b765db",
        "primaryId": "NCT00171340",
        "statement_text": "the primary trial results imply that Zoledronic Acid 4 mg Upfront causes a +ve Change in Bone Mineral Density  whereas Zoledronic Acid 4 mg Delayed causes a smaller  but still positive change in Bone Mineral Density (within a certain patient demographic) ",
        "statement_nums": [
            "4 mg Delayed",
            "4 mg Upfront"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Percentage Change in Bone Mineral Density (BMD) of the Lumbar Spine (L2-L4) at 12 Months of Therapy  Bone Mineral Density (g/cm^2) of the Lumbar Spine (L2-L4) as measured by energy x-ray absorptiometry (DXA)  Time frame: Baseline  12 months Results 1: Arm/Group Title: Zoledronic Acid 4 mg Upfront ",
        "premise_nums": [
            "2-L4) at",
            "12 months Results",
            "2-L4) as",
            "12 Months of",
            "4 mg Upfront"
        ]
    },
    {
        "id": "f5d50d87-b419-4537-87ec-7c9d23b765db",
        "primaryId": "NCT00171340",
        "statement_text": "the primary trial results imply that Zoledronic Acid 4 mg Upfront causes a +ve Change in Bone Mineral Density  whereas Zoledronic Acid 4 mg Delayed causes a smaller  but still positive change in Bone Mineral Density (within a certain patient demographic) ",
        "statement_nums": [
            "4 mg Delayed",
            "4 mg Upfront"
        ],
        "label": "Contradiction",
        "premise_text": "Arm/Group Description: Zolendronic acid 4 mg Intravenous (IV) 15 minute infusion every 6 months for 5 years beginning on Day 1. All participants took Letrozole tablets 2.5 mg/day for 5 years beginning on Day 1.Overall Number of Participants Analyzed: 423 Mean (Standard Deviation) Unit of Measure: Percentage change in BMD 2.208 (3.4194) Results 2: Arm/Group Title: Zoledronic Acid 4 mg Delayed ",
        "premise_nums": [
            "tablets 2.5 mg/day",
            "15 minute infusion",
            "423 Mean (Standard",
            "6 months for",
            "5 years beginning",
            "4 mg Delayed",
            "4 mg Intravenous"
        ]
    },
    {
        "id": "f5d50d87-b419-4537-87ec-7c9d23b765db",
        "primaryId": "NCT00171340",
        "statement_text": "the primary trial results imply that Zoledronic Acid 4 mg Upfront causes a +ve Change in Bone Mineral Density  whereas Zoledronic Acid 4 mg Delayed causes a smaller  but still positive change in Bone Mineral Density (within a certain patient demographic) ",
        "statement_nums": [
            "4 mg Delayed",
            "4 mg Upfront"
        ],
        "label": "Contradiction",
        "premise_text": "Arm/Group Description: Zolendronic acid 4 mg Intravenous (IV) 15 minute infusion every 6 months beginning when one of the following occurred: BMD T-score smaller than = -2.0 SD at either the lumbar spine or total hip  any clinical fracture unrelated to trauma or an asymptomatic fracture discovered at the Month 36 visit  All participants took Letrozole tablets 2.5 mg/day for 5 years beginning on Day 1.Overall Number of Participants Analyzed: 418 Mean (Standard Deviation) Unit of Measure: Percentage change in BMD -3.617 (4.2151) ",
        "premise_nums": [
            "tablets 2.5 mg/day",
            "15 minute infusion",
            "5 years beginning",
            "6 months beginning",
            "418 Mean (Standard",
            "0 SD at",
            "4 mg Intravenous"
        ]
    },
    {
        "id": "f52ab54b-7a78-4449-9dfe-5fc67323e5c2",
        "primaryId": "NCT01797120",
        "statement_text": "Cohort 2 of the primary trial is only receiving placebo tablets  and no other medications ",
        "statement_nums": [
            "2 of the"
        ],
        "label": "Entailment",
        "premise_text": "INTERVENTION 2: Fulvestrant & Placebo Fulvestrant Day 1 & 15 of Cycle 1, then Day 1 of all subsequent cycles (every 28 days for 12 cycles) plus placebo daily x 12 cycles  Fulvestrant: Fulvestrant 500 mg Day 1 & 15 of Cycle 1, then 500 mg Day 1 of all subsequent cycles (every 28 days for 12 cycles)  If no evidence of disease progression after 12 cycles  unblind and continue same dose and schedule until progression or unacceptable toxicity  Placebo: Placebo for Everolimus (2 tablets) daily x 12 cycles  Placebo manufactured to mimic everolimus tablet  ",
        "premise_nums": [
            "15 of Cycle",
            "500 mg Day",
            "28 days for",
            "1 of all"
        ]
    },
    {
        "id": "c0277198-6eef-4cf3-9527-dea5d01a4000",
        "primaryId": "NCT00426556",
        "statement_text": "There were more than 3 cases of Febrile neutropenia  Leukopenia and Neutropenia across all cohorts in the primary trial ",
        "statement_nums": [
            "3 cases of"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 3/6 (50.00%) Febrile neutropenia 0/6 (0.00%) Leukopenia 0/6 (0.00%) Neutropenia 0/6 (0.00%) Adverse Events 2: Total: 6/17 (35.29%) Febrile neutropenia 0/17 (0.00%) Leukopenia 0/17 (0.00%) Neutropenia 0/17 (0.00%) ",
        "premise_nums": [
            "6/17 (35.29%)",
            "3/6 (50.00%)",
            "0/6 (0.00%)",
            "0/17 (0.00%)"
        ]
    },
    {
        "id": "fea87f74-c8ef-4efd-944a-053f5e5a752f",
        "primaryId": "NCT01582971",
        "statement_text": "In order to participate in the primary trial  participants must have 20/20 vision and a hiistologically confirmed  measurable  invasive breast carcinoma ",
        "statement_nums": [
            "20/20 vision",
            "20 vision and"
        ],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria: Age 21 Diagnosis of breast cancer  Stage III  IV  or Stage I or II with metastasis or recurrence Able to perform basic ADLs Undergoing chemotherapy and/or hormonal therapy for breast cancer Able to speak and understand English Have access to a telephone Able to hear normal conversation Cognitively oriented to time  place  and person (determined via nurse recruiter) Exclusion Criteria: Diagnosis of major mental illness on the medical record and verified by the recruiter Residing in a nursing home Bedridden Currently receiving regular reflexology Diagnosis of symptoms of deep vein thrombosis or painful foot neuropathy  which will require medical approval ",
        "premise_nums": [
            "21 Diagnosis of"
        ]
    },
    {
        "id": "43560d8e-0767-40ce-b2fb-1b8dda231bdf",
        "primaryId": "NCT00394251",
        "statement_text": "There were more cases of Cardiac failure than Pericardial effusion recorded in cohort 1.",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 30/98 (30.61%) Coagulopathy 1/98 (1.02%) Febrile neutropenia 7/98 (7.14%) Pancytopenia 2/98 (2.04%) Cardiac failure 0/98 (0.00%) Cardiac failure congestive 0/98 (0.00%) Pericardial effusion 0/98 (0.00%) Appendicitis perforated 1/98 (1.02%) Colitis 1/98 (1.02%) Ileus 1/98 (1.02%) Abdominal pain upper 1/98 (1.02%) Gastrointestinal haemorrhage 0/98 (0.00%) ",
        "premise_nums": [
            "1/98 (1.02%)",
            "7/98 (7.14%)",
            "0/98 (0.00%)",
            "30/98 (30.61%)",
            "2/98 (2.04%)"
        ]
    },
    {
        "id": "2417fea2-7c8e-4f03-a918-c3cfcbe97425",
        "primaryId": "NCT01998906",
        "statement_text": "The same number of cases of Neutropenia  Febrile neutropenia and Pancytopenia are observed in patients from cohort 1 of the primary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Febrile neutropenia * 7/115 (6.09%) Neutropenia * 1/115 (0.87%) Pancytopenia * 1/115 (0.87%) ",
        "premise_nums": [
            "1/115 (0.87%)",
            "7/115 (6.09%)"
        ]
    },
    {
        "id": "55391bc6-41a8-4686-82d6-6814166d32b8",
        "primaryId": "NCT01904903",
        "secondaryId": "NCT01663727",
        "label": "Entailment",
        "statement_text": "Patients must have LVEF smaller than 50% to be eligible for the primary trial ",
        "statement_nums": [
            "50% to"
        ],
        "premise_text": "LVEF smaller than 50% and 40% documented in echocardiogram done within the last 30 days Inclusion Criteria: Histologically or cytologically confirmed  HER2-negative adenocarcinoma of the breast  with measurable or non-measurable locally recurrent or metastatic disease  Locally recurrent disease must not be amenable to resection with curative intent  ECOG performance status of 0 or 1 For women of childbearing potential  use of an acceptable and effective method of non-hormonal contraception For patients who have received recent radiotherapy  recovery prior to randomization from any significant acute toxicity  and radiation treatments have to be completed more than 3 weeks from randomization Exclusion Criteria: Disease-Specific Exclusions: HER2-positive status Prior chemotherapy for locally recurrent or metastatic disease ",
        "premise_nums": [
            "40% documented",
            "2-negative adenocarcinoma",
            "0 or 1",
            "3 weeks from",
            "50% and",
            "2-positive status",
            "30 days Inclusion"
        ]
    },
    {
        "id": "55391bc6-41a8-4686-82d6-6814166d32b8",
        "primaryId": "NCT01904903",
        "secondaryId": "NCT01663727",
        "label": "Entailment",
        "statement_text": "Patients must have LVEF smaller than 50% to be eligible for the primary trial ",
        "statement_nums": [
            "50% to"
        ],
        "premise_text": "Prior hormonal therapy smaller than 2 weeks prior to randomizationPrior adjuvant or neo-adjuvant chemotherapy is allowed  provided its conclusion has been for at least 12 months prior to randomization Investigational therapy within 28 days of randomization General Medical Exclusions: Life expectancy of smaller than 12 weeks Inadequate organ function Uncontrolled serious medical or psychiatric illness Active infection requiring intravenous (IV) antibiotics at screening Pregnancy or lactation History of other malignancies within 5 years prior to screening  except for tumors with a negligible risk for metastasis or death ",
        "premise_nums": [
            "12 weeks Inadequate",
            "5 years prior",
            "28 days of",
            "12 months prior",
            "2 weeks prior"
        ]
    },
    {
        "id": "06d25b0a-ef0d-4b6e-a8ed-c91689bfa82b",
        "primaryId": "NCT00091832",
        "statement_text": "cohort 1 of the primary trial had a negative (median) Percent Change From Baseline of urea-adjusted Urinary N-telopeptide (uNTx/Ur) ",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Percent Change From Baseline to Week 13 in Creatinine-adjusted Urinary N-telopeptide (uNTx/Cr) Percent change from Baseline to Week 13 in Urinary N-telopeptide corrected by creatinine (uNTx/Cr) calculated using ((Week 13 value - Baseline value) / Baseline value ) x 100. Time frame: Baseline and Week 13 Results 1: Arm/Group Title: Bisphosphonate IV Q4W Arm/Group Description: Open label bisphosphonate every 4 weeks (Q4W) by intravenous infusion Overall Number of Participants Analyzed: 38 Mean (Standard Deviation) ",
        "premise_nums": [
            "38 Mean (Standard",
            "4 weeks (Q4W)",
            "13 Results 1:",
            "13 in Creatinine",
            "13 in Urinary",
            "(Q4W) by"
        ]
    },
    {
        "id": "06d25b0a-ef0d-4b6e-a8ed-c91689bfa82b",
        "primaryId": "NCT00091832",
        "statement_text": "cohort 1 of the primary trial had a negative (median) Percent Change From Baseline of urea-adjusted Urinary N-telopeptide (uNTx/Ur) ",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Unit of Measure: Percent change -10.19 (208.84)Results 2: Arm/Group Title: Denosumab 30 mg Q4W Arm/Group Description: Denosumab 30 mg by subcutaneous injection every 4 weeks (Q4W) Overall Number of Participants Analyzed: 40 Mean (Standard Deviation) Unit of Measure: Percent change -52.87 (95.14) ",
        "premise_nums": [
            "(Q4W) Overall",
            "30 mg by",
            "4 weeks (Q4W)",
            "40 Mean (Standard",
            "30 mg Q4W"
        ]
    },
    {
        "id": "15553950-e26b-4fbb-a576-8455e6bb7b23",
        "primaryId": "NCT02122796",
        "secondaryId": "NCT01575522",
        "label": "Contradiction",
        "statement_text": "The intervention section for the primary trial does not detail the type  dosage or duration of the intervention  unlike the secondary trial ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Patients Undergoing Mastectomy Surgery Number of individuals having mastectomy surgery who were approached for participation in the trial INTERVENTION 1: Treatment (Tivantinib) Patients receive tivantinib PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity  Patients undergo blood sample collection at baseline and periodically during study for c-Met expression  relevant markers (HGF and VEGF)  PTEN loss  and PI3K mutation analysis by FISH and IHC  Archived tumor tissue samples are also analyzed  Laboratory Biomarker Analysis: Correlative studies Tivantinib: Given PO ",
        "premise_nums": [
            "1-21. Courses",
            "21 days in"
        ]
    },
    {
        "id": "58838d25-bf87-44e7-a604-23468d67a1e3",
        "primaryId": "NCT02606708",
        "secondaryId": "NCT02504424",
        "label": "Entailment",
        "statement_text": "Only patients in the primary trial receive 40.5 Gy of Accelerated Intensity Modulated Radiation Therapy  patients in the secondary trial receive no radiotherapy whatsoever ",
        "statement_nums": [
            "receive 40.5 Gy of"
        ],
        "premise_text": "INTERVENTION 1: Accelerated Intensity Modulated Radiation Therapy (AIMRT) All patients shall receive a total of 40.5 Gy to the entire breast in 2.7 Gy/fraction x 15 fractions  Monday to Friday for 3 weeks delivered prone in uniform daily doses through IMRT tangent fields  A concurrent boost to the original tumor bed of 0.50 Gy will be delivered  Accelerated intensity modulated radiation therapy (AIMRT) INTERVENTION 1: AeroForm Tissue Expander AeroForm Tissue Expansion inflation with carbon dioxide by remote control AeroForm Tissue Expander: The AeroForm Tissue Expander is a breast tissue expander implanted following mastectomy and activated by remote control to release small doses of carbon dioxide from an internal reservoir to fill and inflate the expander  ",
        "premise_nums": [
            "of 40.5 Gy to",
            "3 weeks delivered",
            "in 2.7 Gy/fraction",
            "of 0.50 Gy will"
        ]
    },
    {
        "id": "02426c34-ebf9-4bd4-9d55-86fad89baf20",
        "primaryId": "NCT01959490",
        "statement_text": "In total only 20% of participants in the primary trial did not achieve Pathological Complete Response ",
        "statement_nums": [
            "20% of"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Number of Patients With a Pathological Complete Response (pCR) Who Received Targeted Therapy With Trastuzumab and Pertuzumab or Bevacizumab Predicted by Genomically-derived Molecular Subtypes  Number of patients with a pathological complete response (pCR) who received targeted therapy with trastuzumab and pertuzumab or bevacizumab predicted by genomically-derived molecular subtypes (HER2 positive or HER2 negative  pCR is defined as absence of invasive cancer in breast or lymph nodes after neoadjuvant chemotherapy  Time frame: Up to 30 days after last cycle of treatment Results 1: Arm/Group Title: Cohort 1P (HER2 Positive) ",
        "premise_nums": [
            "30 days after",
            "2 positive or"
        ]
    },
    {
        "id": "02426c34-ebf9-4bd4-9d55-86fad89baf20",
        "primaryId": "NCT01959490",
        "statement_text": "In total only 20% of participants in the primary trial did not achieve Pathological Complete Response ",
        "statement_nums": [
            "20% of"
        ],
        "label": "Contradiction",
        "premise_text": "Arm/Group Description: Patients receive a run-in Pertuzumab treatment of 840 mg IV over 60 minutes on day -14 followed by Trastuzumab IV over 30-60 minutes and Pertuzumab IV over 30-60 minutes  docetaxel IV  and carboplatin IV on day 1. Treatment repeats very 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity Overall Number of Participants Analyzed: 5 Measure Type: Count of Participants Unit of Measure: Participants 4 80.0% Results 2: Arm/Group Title: Cohort 1T (HER2 Positive) ",
        "premise_nums": [
            "840 mg IV",
            "4 80.0% Results 2",
            "60 minutes on",
            "6 courses in",
            "60 minutes and",
            "3 weeks for",
            "5 Measure Type:",
            "14 followed by",
            "30-60 minutes"
        ]
    },
    {
        "id": "02426c34-ebf9-4bd4-9d55-86fad89baf20",
        "primaryId": "NCT01959490",
        "statement_text": "In total only 20% of participants in the primary trial did not achieve Pathological Complete Response ",
        "statement_nums": [
            "20% of"
        ],
        "label": "Contradiction",
        "premise_text": "Arm/Group Description: Patients receive a run-in Trastuzumab treatment of 8 mg/kg IV over 90 minutes on day -14 followed by Trastuzumab IV over 30-60 minutes and Pertuzumab IV over 30-60 minutes  Docetaxel IV  and Carboplatin IV on day 1. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity Overall Number of Participants Analyzed: 6 Measure Type: Count of Participants Unit of Measure: Participants 6 100.0% ",
        "premise_nums": [
            "6 courses in",
            "60 minutes and",
            "3 weeks for",
            "8 mg/kg IV",
            "14 followed by",
            "6 Measure Type:",
            "30-60 minutes",
            "90 minutes on"
        ]
    },
    {
        "id": "9e28c807-8d88-4eea-87ee-48a42bd002ab",
        "primaryId": "NCT00618826",
        "secondaryId": "NCT02040857",
        "label": "Entailment",
        "statement_text": "the primary trial and the secondary trial only record 4 of the same adverse events ",
        "statement_nums": [
            "4 of the"
        ],
        "premise_text": "Adverse Events 1: Lymphopenia 1/14 (7.14%) Diarrhea 1/14 (7.14%) Fatigue (asthenia  lethargy  malaise) 2/14 (14.29%) Hypertension 2/14 (14.29%) Adverse Events 1: Lymphocyte count decreased 2/162 (1.23%) Diarrhea 1/162 (0.62%) Fatigue 6/162 (3.70%) Hypertension 1/162 (0.62%) ",
        "premise_nums": [
            "2/14 (14.29%)",
            "6/162 (3.70%)",
            "2/162 (1.23%)",
            "1/162 (0.62%)",
            "1/14 (7.14%)"
        ]
    },
    {
        "id": "80ac126e-c756-4031-9541-e50d51c18b38",
        "primaryId": "NCT02600923",
        "statement_text": "Patients with Leukemia  Hepatitis or Polycystic Kidney Disease cannot be included in the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Inclusion Criteria: Adequate bone marrow function  Adequate liver function Adequate renal function  ",
        "premise_nums": []
    },
    {
        "id": "1a1d7d1d-ec49-46db-b6bc-dfd94575e46c",
        "primaryId": "NCT02953860",
        "statement_text": "Patients in the primary trial receive less mg of Enzalutamide than Fulvestrant on a weekly basis ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Fulvestrant with Enzalutamide: 500mg of Fulvestrant will be given IM on days 1, 15, 28, then every 4 weeks as per standard of care (SOC) and 160mg of Enzalutamide will be given PO daily  Patients will receive a tumor biopsy at the start of treatment and 4 weeks after the start of treatment  with an optional 3rd biopsy at the end treatment  ",
        "premise_nums": [
            "4 weeks as",
            "4 weeks after"
        ]
    },
    {
        "id": "68a9f2f0-cf11-4cd4-847c-53b8befd6002",
        "primaryId": "NCT00717886",
        "statement_text": "Prior axillary surgery  axillary radiation  breast cancer and breast radiation are not permitted for entry to the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Exclusion Criteria: Prior ipsilateral axillary surgery Prior ipsilateral axillary radiation Prior ipsilateral breast cancer Prior ipsilateral breast radiation ",
        "premise_nums": []
    },
    {
        "id": "9bcd40cf-8221-4383-8891-76a4bcc5c766",
        "primaryId": "NCT00756717",
        "statement_text": "Patients with cytologically confirmed  non metastatic  early stage invasive breast cancer with an Allred score of 1 are excluded from the primary trial ",
        "statement_nums": [
            "1 are excluded"
        ],
        "label": "Entailment",
        "premise_text": "Inclusion Criteria: Patients must have histologically or cytologically confirmed early stage  ER-positive (Allred score 3), invasive breast cancer that is not either locally advanced by criteria other than size or inflammatory  and is not metastatic  - Patients must be candidates for surgical removal of the tumor by lumpectomy or mastectomy  ",
        "premise_nums": []
    },
    {
        "id": "341156fc-9cbd-492f-8e9e-8fbf98191625",
        "primaryId": "NCT00291577",
        "statement_text": "It is not possible for a participant of the primary trial to have a Time to Reach Maximum Plasma Concentration of 6, 24 or 12 hours ",
        "statement_nums": [
            "24 or 12"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Time to Reach Maximum Plasma Concentration (Tmax): Sunitinib (SU011248), Sunitinib Metabolite (SU012662), and Total Drug PK Parameters Median Tmax = time for maximum plasma concentration (Cmax) for SU011248, SU012662, and combined SU011248 and SU012662 (total drug); collected C1D2, C2D3. Paired observation  Time frame: 1, 2, 4, 6, 8, 12, 24 hours postdose ",
        "premise_nums": [
            "011248 and SU012662",
            "SU011248 and",
            "24 hours postdose"
        ]
    },
    {
        "id": "44ae021e-241b-4dbf-b88f-0b9d41eab555",
        "primaryId": "NCT00201851",
        "statement_text": "There were no cases of Oesophageal spasming observed in the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 0/244 (0.00%) Pregnancy *0/244 (0.00%) Endocervical cancer *0/244 (0.00%) Nosocomial pneumonia *0/244 (0.00%) Venous thrombosis *0/244 (0.00%) Adverse Events 2: Total: 5/255 (1.96%) Pregnancy *1/255 (0.39%) Endocervical cancer *1/255 (0.39%) Nosocomial pneumonia *2/255 (0.78%) Venous thrombosis *1/255 (0.39%) ",
        "premise_nums": [
            "5/255 (1.96%)",
            "2/255 (0.78%)",
            "1/255 (0.39%)",
            "0/244 (0.00%)"
        ]
    },
    {
        "id": "523a44a3-6b90-4be7-ab46-6b6addd7b5b9",
        "primaryId": "NCT00080301",
        "statement_text": "There were 5 more cases of THROMBOCYTOPENIA in cohort 2 of the primary trial  than in cohort 1.",
        "statement_nums": [
            "5 more cases",
            "2 of the"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: THROMBOCYTOPENIA 2/368 (0.54%) Adverse Events 2: THROMBOCYTOPENIA 7/369 (1.90%) ",
        "premise_nums": [
            "7/369 (1.90%)",
            "2/368 (0.54%)"
        ]
    },
    {
        "id": "258a51ca-e1f0-4d9a-88a6-8749f4822034",
        "primaryId": "NCT03475992",
        "secondaryId": "NCT03106077",
        "label": "Contradiction",
        "statement_text": "Participants in the primary trial receive different interventions depending on their cancer hormone status  so Triple-Negative patients are seperated from HER2+ patients for example  whereas all patients in the secondary trial took the same intervention ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Pre-diagnosed Breast Cancer - Biopsy Confirmed Low-power microwave breast imaging system  Core needle biopsy performed 14 days before the microwave breast investigation Low-power microwave breast imaging system: Investigate the capacity of microwave imaging to detect and characterise diagnosed palpable breast lump INTERVENTION 2: Pre-diagnosed Breast Cyst Low-power microwave breast imaging system  No prior biopsy Low-power microwave breast imaging system: Investigate the capacity of microwave imaging to detect and characterise diagnosed palpable breast lump INTERVENTION 1: Cohort A: Advanced Triple-Negative Breast Cancer (TNBC) 6 mg/kg IMGN853 IV Q3W ",
        "premise_nums": [
            "6 mg/kg IMGN",
            "IMGN853 IV",
            "14 days before",
            "853 IV Q3W"
        ]
    },
    {
        "id": "83bacd68-871a-4777-ba23-1f9a3df9227d",
        "primaryId": "NCT00057941",
        "secondaryId": "NCT01806259",
        "label": "Entailment",
        "statement_text": "Recurrence-free Survival  used as the outcome measurement in the secondary trial and Clinical Benefit Rate  used in the primary trial are not synonymous  and represent entirely different patient characteristics ",
        "statement_nums": [],
        "premise_text": "Outcome Measurement: Clinical Benefit Rate Clinical benefit = complete response (CR)  partial response (PR)  or stable disease (SD) lasting for at least 6 months  assessed per Response Evaluation Criteria of Solid Tumor (RECIST).CR=disappearance of all target and non-target lesions  PR= disappearance of or at least 30% decrease in the sum of the longest diameters of target lesions  with non-progressive disease in non-target lesions  SD= sum of the longest diameters of target lesions decrease smaller than 30% or increase smaller than 20%, with non-progressive disease in non-target lesions  141 eligible  treated patients were included  ",
        "premise_nums": [
            "30% decrease",
            "30% or"
        ]
    },
    {
        "id": "83bacd68-871a-4777-ba23-1f9a3df9227d",
        "primaryId": "NCT00057941",
        "secondaryId": "NCT01806259",
        "label": "Entailment",
        "statement_text": "Recurrence-free Survival  used as the outcome measurement in the secondary trial and Clinical Benefit Rate  used in the primary trial are not synonymous  and represent entirely different patient characteristics ",
        "statement_nums": [],
        "premise_text": "Time frame: assessed every 3 cycles while on treatment  assessed every 3 months when follow up smaller than 2 years  every 6 months between 2-3 years,no specific requirements after 3 yearsOutcome Measurement: Recurrence-free Survival 2 years for the primary analysis + 3 additional years for secondary analysis (From date of randomization until the date of first documented progression or date of death from any cause  whichever came first  assessed up to 5 years) Time frame: 5 years ",
        "premise_nums": [
            "2-3 years,no",
            "3 cycles while",
            "3 additional years",
            "2 years for",
            "3 months when",
            "6 months between",
            "3 yearsOutcome Measurement:"
        ]
    },
    {
        "id": "fedc0601-fd6b-4f9b-9ce7-6d9ee2e591e9",
        "primaryId": "NCT00369655",
        "secondaryId": "NCT00091832",
        "label": "Contradiction",
        "statement_text": "One patient in the primary trial had a Confirmed tumor partial response  in contrast thirty patients in the secondary trial had partial tumor response ",
        "statement_nums": [],
        "premise_text": "Outcome Measurement: Proportion of Patients With Confirmed Tumor Response Confirmed tumor response was defined as the total number of efficacy-evaluable patients who achieved a complete or partial response according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria on 2 consecutive evaluations at least 8 weeks apart  Time frame: Up to 5 years Results 1: Arm/Group Title: Treatment (Ziv-afibercept) Arm/Group Description: Patients receive VEGF Trap IV over 1 hour on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity  Overall Number of Participants Analyzed: 21 Measure Type: Number Unit of Measure: Participants Confirmed tumor partial response: 1 No Confirmed reponse: 20 Outcome Measurement: ",
        "premise_nums": [
            "14 days in",
            "1 No Confirmed",
            "20 Outcome Measurement:",
            "2 consecutive evaluations",
            "1 hour on",
            "5 years Results",
            "8 weeks apart",
            "21 Measure Type:"
        ]
    },
    {
        "id": "fedc0601-fd6b-4f9b-9ce7-6d9ee2e591e9",
        "primaryId": "NCT00369655",
        "secondaryId": "NCT00091832",
        "label": "Contradiction",
        "statement_text": "One patient in the primary trial had a Confirmed tumor partial response  in contrast thirty patients in the secondary trial had partial tumor response ",
        "statement_nums": [],
        "premise_text": "Percent Change From Baseline to Week 13 in Creatinine-adjusted Urinary N-telopeptide (uNTx/Cr)Percent change from Baseline to Week 13 in Urinary N-telopeptide corrected by creatinine (uNTx/Cr) calculated using ((Week 13 value - Baseline value) / Baseline value ) x 100. Time frame: Baseline and Week 13 ",
        "premise_nums": [
            "13 in Creatinine",
            "13 in Urinary"
        ]
    },
    {
        "id": "1a451f2e-0818-4a86-8808-0e4cce700aef",
        "primaryId": "NCT00391092",
        "statement_text": "In total there were 32 cases of Febrile neutropenia in the primary trial  and only one case of anemia ",
        "statement_nums": [
            "32 cases of"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Febrile neutropenia * 14/206 (6.80%) Anaemia * 1/206 (0.49%) Adverse Events 2: Febrile neutropenia * 18/215 (8.37%) Anaemia * 1/215 (0.47%) ",
        "premise_nums": [
            "1/206 (0.49%)",
            "14/206 (6.80%)",
            "18/215 (8.37%)",
            "1/215 (0.47%)"
        ]
    },
    {
        "id": "52333afb-0e7a-4823-ae9b-746e0ce57c8c",
        "primaryId": "NCT01325207",
        "secondaryId": "NCT02429427",
        "label": "Entailment",
        "statement_text": "Patients participating in the primary trial and the secondary trial experienced a variety of cardiac problems ",
        "statement_nums": [],
        "premise_text": "Pericardial effusion [1]0/3 (0.00%) Acute cardiac event * 1/1755 (0.06%) Aortic valve incompetence * 1/1755 (0.06%) Arrhythmia * 1/1755 (0.06%) Atrial fibrillation * 1/1755 (0.06%) Cardiac failure * 0/1755 (0.00%) Cardiac tamponade * 0/1755 (0.00%) ",
        "premise_nums": [
            "0/3 (0.00%)",
            "1/1755 (0.06%)",
            "0/1755 (0.00%)"
        ]
    },
    {
        "id": "4216b27f-4d3e-4029-9637-2e6dade15b73",
        "primaryId": "NCT00005908",
        "statement_text": "There was only one patient cohort in the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 29/30 (96.67%) Febrile neutropenia [1]3/30 (10.00%) Lymphatics 1/30 (3.33%) Diarrhea (without colostomy) 5/30 (16.67%) Abdominal pain or cramping 2/30 (6.67%) Colitis 1/30 (3.33%) Dehydration 1/30 (3.33%) Nausea 1/30 (3.33%) Stomatitis/pharyngitis (oral/pharyngeal/mucositis) 1/30 (3.33%) Vomiting 1/30 (3.33%) Adverse Events 2: ",
        "premise_nums": [
            "5/30 (16.67%)",
            "3/30 (10.00%)",
            "29/30 (96.67%)",
            "1/30 (3.33%)",
            "2/30 (6.67%)"
        ]
    },
    {
        "id": "14a32a42-424b-4b97-bae9-05f4bb2b415b",
        "primaryId": "NCT00246090",
        "secondaryId": "NCT00266799",
        "label": "Contradiction",
        "statement_text": "Cohort 1 of the primary trial 0.0015% less total adverse events than cohort 2 of the secondary trial ",
        "statement_nums": [
            "2 of the",
            "trial 0.0015% less total",
            "1 of the"
        ],
        "premise_text": "Adverse Events 1: Total: 88/291 (30.24%) Adverse Events 2: Total: 46/102 (45.10%) ",
        "premise_nums": [
            "88/291 (30.24%)",
            "46/102 (45.10%)"
        ]
    },
    {
        "id": "4d83c630-d767-40cf-9aec-c871c6fc7f38",
        "primaryId": "NCT00030823",
        "statement_text": "Patients with stage I  II  III or IV breast cancer may be eliglbe for the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Stage I  II  or III previously treated with adjuvant chemotherapy and clinically free of identifiable disease  but have rising CA 15-3 or CEA levels Stage IV that is free of all known disease after eradication by surgery  radiotherapy  or chemotherapy Stage IV that is stable on hormonal therapy ",
        "premise_nums": [
            "3 or CEA",
            "15-3 or"
        ]
    },
    {
        "id": "4fd230f2-caf1-44d6-81f2-4f51dda6da3a",
        "primaryId": "NCT03371732",
        "statement_text": "Any patients with Karnofsky Index smaller than 80 are eligible for the primary trial ",
        "statement_nums": [
            "80 are eligible"
        ],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria : women with primary breast cancer  without ongoing support for substance use  An AUDIT-C score greater than 1 or more than one cigarette smoked per day  Individuals able to consent to benefit of intervention focused on substance use  (Karnofsky Index greater than 70). ",
        "premise_nums": [
            "1 or more"
        ]
    },
    {
        "id": "7a3d1ca7-8776-4ace-bbc0-107635b93583",
        "primaryId": "NCT00764322",
        "statement_text": "The Ultra-rapid Metabolizers group of the primary trial had average increase of Endoxifen Concentration over 6 ng/mL over 4 months ",
        "statement_nums": [
            "6 ng/mL over"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Endoxifen Concentrations in Participants Receiving Tamoxifen Citrate Dose of 20 mg or 40 mg Stratified by the Metabolizing CYP2D6 Genotypes ",
        "premise_nums": [
            "40 mg Stratified",
            "20 mg or"
        ]
    },
    {
        "id": "7a3d1ca7-8776-4ace-bbc0-107635b93583",
        "primaryId": "NCT00764322",
        "statement_text": "The Ultra-rapid Metabolizers group of the primary trial had average increase of Endoxifen Concentration over 6 ng/mL over 4 months ",
        "statement_nums": [
            "6 ng/mL over"
        ],
        "label": "Entailment",
        "premise_text": "Measurements of plasma concentrations of the key active metabolite of tamoxifen  endoxifen  were measured at baseline and after 4 months of treatment; The most common CYP2D6 alleles have been grouped by functional activity classifications with descending activity: ultra-rapid (UM)  extensive (EM)  intermediate (IM) or poor (PM) metabolism  A given patient has two alleles  giving them 10 possible allelic combinations  or diplotypes (UM/UM  UM/EM  EM/EM  etc.)  These diplotypes are collapsed into four phenotypes  UM  EM  IM or PM Time frame: 4 months Results 1: Arm/Group Title: Ultra-rapid Metabolizers ",
        "premise_nums": [
            "6 alleles have",
            "4 months of",
            "10 possible allelic",
            "4 months Results"
        ]
    },
    {
        "id": "7a3d1ca7-8776-4ace-bbc0-107635b93583",
        "primaryId": "NCT00764322",
        "statement_text": "The Ultra-rapid Metabolizers group of the primary trial had average increase of Endoxifen Concentration over 6 ng/mL over 4 months ",
        "statement_nums": [
            "6 ng/mL over"
        ],
        "label": "Entailment",
        "premise_text": "Arm/Group Description: Those with the highest transformation of the CYP2D6 genotype to allelic activityOverall Number of Participants Analyzed: 5 Mean (Standard Deviation) Unit of Measure: ng/mL Baseline endoxifen concentration: 5 participants 8.4 (4.59) 4-Month endoxifen concentration: 4 participants 15.35 (5.48) ",
        "premise_nums": [
            "5 Mean (Standard",
            "6 genotype to",
            "4 participants 15.35",
            "5 participants 8.4",
            "4-Month endoxifen"
        ]
    },
    {
        "id": "e95902f1-bf4f-4bb5-8f48-4fa5ba6425d0",
        "primaryId": "NCT02040857",
        "statement_text": "Only men and postmenopausal women are eligible for the primary trial ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Men and both pre- and postmenopausal women are eligible  ",
        "premise_nums": []
    },
    {
        "id": "1196db61-0846-4185-afc9-dc4b2fccd059",
        "primaryId": "NCT01966471",
        "secondaryId": "NCT00981812",
        "label": "Contradiction",
        "statement_text": "A patient who had a breast-conserving surgery in the year prior to study entry would be excluded from both the primary trial and the secondary trial ",
        "statement_nums": [],
        "premise_text": "Inclusion Criteria: Known hormone receptor status of the primary tumor Adequately excised: participants must have undergone either breast-conserving surgery or mastectomy/nipple- or skin-sparing mastectomy Exclusion Criteria: subject has had surgery or radiation therapy on the study breast or has had chemotherapy within the past 12 months ",
        "premise_nums": []
    },
    {
        "id": "567ec6e3-87aa-4a4a-94b8-ebdf2e0cbf64",
        "primaryId": "NCT02005887",
        "secondaryId": "NCT00050011",
        "label": "Entailment",
        "statement_text": "All Participants in the primary trial and the secondary trial are receiving the same daily dose of oral Letrozole for the same duration of time ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Arm A: Triptorelin + Letrozol Arm A: Triptorelin 3.75 mg i.m  on day 1 every 28 days for 6 cycles + letrozole 2.5 mg/day orally for 6 cycles Triptorelin: Triptorelin 3.75 mg injected into the muscle on day 1 every 28 days for 6 cycles (1 cycle= 28 days) Letrozole: Letrozole 2.5 mg orally every day for 6 cycles INTERVENTION 1: Zoledronic Acid Upfront ",
        "premise_nums": [
            "6 cycles Triptorelin:",
            "1 every 28",
            "75 mg i.m",
            "letrozole 2.5 mg/day",
            "Triptorelin 3.75 mg injected",
            "6 cycles (1",
            "6 cycles INTERVENTION",
            "Letrozole 2.5 mg orally"
        ]
    },
    {
        "id": "567ec6e3-87aa-4a4a-94b8-ebdf2e0cbf64",
        "primaryId": "NCT02005887",
        "secondaryId": "NCT00050011",
        "label": "Entailment",
        "statement_text": "All Participants in the primary trial and the secondary trial are receiving the same daily dose of oral Letrozole for the same duration of time ",
        "statement_nums": [],
        "premise_text": "Participants in the upfront arm received Zoledronic Acid 4 mg i.v  on Day 1 and every 6 months until disease progression (recurrence)or the end of study  Participants also received Letrozole 2.5 daily plus calcium (1000-1200 mg) and vitamin D (400-800 IU) daily Letrozole : Participants received 2.5 mg daily  Zoledronic Acid : Participants received Zoledronic Acid 4 mg IV 15-minute infusion every 6 months  ",
        "premise_nums": [
            "4 mg i.v",
            "(1000-1200 mg",
            "1 and every",
            "15-minute infusion",
            "(400-800 IU",
            "Letrozole 2.5 daily plus",
            "4 mg IV",
            "6 months until",
            "received 2.5 mg daily"
        ]
    },
    {
        "id": "7e629f62-2981-4462-a4c1-f0cc9c24777a",
        "primaryId": "NCT00490646",
        "statement_text": "Cohort 1 of the primary trial had 25% more patients experiencing Cholecystitis than cohort 2.",
        "statement_nums": [
            "25% more",
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 13/24 (54.17%) FEBRILE NEUTROPENIA 5/24 (20.83%) HAEMATOTOXICITY 0/24 (0.00%) NEUTROPENIA 3/24 (12.50%) LYMPHADENOPATHY 0/24 (0.00%) PERICARDIAL EFFUSION 1/24 (4.17%) ATRIAL FIBRILLATION 1/24 (4.17%) APLASIA 0/24 (0.00%) NAUSEA 0/24 (0.00%) PYREXIA 1/24 (4.17%) EXTRAVASATION 0/24 (0.00%) CHOLECYSTITIS 1/24 (4.17%) ",
        "premise_nums": [
            "3/24 (12.50%)",
            "1/24 (4.17%)",
            "13/24 (54.17%)",
            "5/24 (20.83%)",
            "0/24 (0.00%)"
        ]
    },
    {
        "id": "7e629f62-2981-4462-a4c1-f0cc9c24777a",
        "primaryId": "NCT00490646",
        "statement_text": "Cohort 1 of the primary trial had 25% more patients experiencing Cholecystitis than cohort 2.",
        "statement_nums": [
            "25% more",
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "PATHOLOGICAL FRACTURE 1/24 (4.17%)Adverse Events 2: Total: 6/24 (25.00%) FEBRILE NEUTROPENIA 0/24 (0.00%) HAEMATOTOXICITY 1/24 (4.17%) NEUTROPENIA 0/24 (0.00%) LYMPHADENOPATHY 1/24 (4.17%) PERICARDIAL EFFUSION 0/24 (0.00%) ATRIAL FIBRILLATION 0/24 (0.00%) APLASIA 1/24 (4.17%) NAUSEA 1/24 (4.17%) PYREXIA 0/24 (0.00%) EXTRAVASATION 1/24 (4.17%) ",
        "premise_nums": [
            "1/24 (4.17%)Adverse",
            "6/24 (25.00%)",
            "0/24 (0.00%)"
        ]
    },
    {
        "id": "7e629f62-2981-4462-a4c1-f0cc9c24777a",
        "primaryId": "NCT00490646",
        "statement_text": "Cohort 1 of the primary trial had 25% more patients experiencing Cholecystitis than cohort 2.",
        "statement_nums": [
            "25% more",
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "CHOLECYSTITIS 0/24 (0.00%)PATHOLOGICAL FRACTURE 0/24 (0.00%) ",
        "premise_nums": [
            "0/24 (0.00%)PATHOLOGICAL"
        ]
    },
    {
        "id": "c660faec-58d8-4ba9-8e18-1775b1135819",
        "primaryId": "NCT00600340",
        "statement_text": "Cohorts 1 of the primary trial recieves Bevacizumab at a higher frequency than cohort 2.",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "INTERVENTION 1: Bevacizumab Plus Paclitaxel Bevacizumab 10 mg/kg intravenous (i.v.)  days 1 and 15, every 4 weeks  Paclitaxel 90 mg/m2, days 1, 8 and 15, every 4 weeks INTERVENTION 2: Bevacizumab Plus Capecitabine Bevacizumab 15 mg/kg i.v.  day 1, every 3 weeks  Capecitabine 1000 mg/m² twice-daily  days 1-14, every 3 weeks ",
        "premise_nums": [
            "4 weeks INTERVENTION",
            "8 and 15,",
            "1000 mg/m²",
            "10 mg/kg intravenous",
            "1-14, every",
            "90 mg/m2,",
            "1 and 15,",
            "15 mg/kg i"
        ]
    },
    {
        "id": "a6fcfea0-eacd-4a04-92a8-55a0c3c8bfb2",
        "primaryId": "NCT03078751",
        "statement_text": "Cohort 2 of the primary trial reported one case of AML ",
        "statement_nums": [
            "2 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 2: Total: 2/24 (8.33%) Disseminated intravascular coagulation 0/24 (0.00%) Cardiac failure congestive 0/24 (0.00%) Breast cellulitis 0/24 (0.00%) Cellulitis 1/24 (4.17%) Acute myeloid leukaemia 0/24 (0.00%) Seizure 1/24 (4.17%) Pulmonary embolism 0/24 (0.00%) ",
        "premise_nums": [
            "2/24 (8.33%)",
            "0/24 (0.00%)",
            "1/24 (4.17%)"
        ]
    },
    {
        "id": "3ee5742b-6bc3-400f-92eb-641384a75201",
        "primaryId": "NCT01830933",
        "secondaryId": "NCT01224678",
        "label": "Entailment",
        "statement_text": "Patients in the primary trial do not receive any extra medication for the study  whereas in the secondary trial they are given an oral medication ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Usual Care Usual Care is the comparison Clinic Patients  where there is no change in their standard or usual care  INTERVENTION 2: BreastCARE Intervention Intervention Clinic Patients: The participants will answer questions on the tablet-PC to calculate their breast cancer risk  Intervention Patient Report  Once the patient completes the BreastCare Computer survey  the program will immediately generate a personal feedback report containing information about her risk factors and recommendations to reduce her risk  This report will be printed and given to the patients before she meets with her doctor  BreastCARE : The physician will receive a physician report that contains information similar to the patient report  Patients receive oral vitamin D (2000 IU) once daily for 12 months  ",
        "premise_nums": []
    },
    {
        "id": "f6af788f-ee96-4308-8dec-12d0c46e957a",
        "primaryId": "NCT01823991",
        "statement_text": "Patients with irrational fear of confined spaces are not elligible for the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Exclusion Criteria: Known claustrophobia  presence of pacemaker and/or ferromagnetic material in their body that would prohibit MRI imaging ",
        "premise_nums": []
    },
    {
        "id": "2e09a2ec-149e-46b4-b60a-ed421fdbc9b3",
        "primaryId": "NCT00118157",
        "secondaryId": "NCT01401959",
        "label": "Contradiction",
        "statement_text": "Participants in the primary trial had a higher likelihood of achieving 2 Year Disease-Free Survival than those in either cohort of the secondary trial ",
        "statement_nums": [
            "2 Year Disease"
        ],
        "premise_text": "Outcome Measurement: Tumor Response Rate (Complete and Partial) Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) [Not Specified] Time frame: 4 weeks Results 1: Arm/Group Title: Arm 1 Arm/Group Description: Patients receive oral lapatinib and oral tamoxifen once daily on days 1-28. lapatinib ditosylate: Given orally tamoxifen citrate: Given orally Overall Number of Participants Analyzed: 17 Measure Type: Number Unit of Measure: participants 1 (1 to 27) Outcome Measurement: Percentage of Patients With a 2 Year Disease-Free Survival (DFS) as a Measure of Efficacy ",
        "premise_nums": [
            "1 Arm/Group Description",
            "1-28. lapatinib",
            "2 Year Disease",
            "17 Measure Type:",
            "1 to 27)",
            "4 weeks Results"
        ]
    },
    {
        "id": "2e09a2ec-149e-46b4-b60a-ed421fdbc9b3",
        "primaryId": "NCT00118157",
        "secondaryId": "NCT01401959",
        "label": "Contradiction",
        "statement_text": "Participants in the primary trial had a higher likelihood of achieving 2 Year Disease-Free Survival than those in either cohort of the secondary trial ",
        "statement_nums": [
            "2 Year Disease"
        ],
        "premise_text": "The percentage of patients that are without evidence of disease recurrence at the 2 year timepoint  as measured from date of first protocol treatment date to first documented disease progression date or date of death from any cause  whichever comes first  Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions  or a measurable increase in a non-target lesion  or the appearance of new lesions Time frame: Up to 2 years Results 1: Arm/Group Title: Cohort A: Triple-negative Breast Cancer Patients ",
        "premise_nums": [
            "2 year timepoint",
            "2 years Results",
            "20% increase"
        ]
    },
    {
        "id": "2e09a2ec-149e-46b4-b60a-ed421fdbc9b3",
        "primaryId": "NCT00118157",
        "secondaryId": "NCT01401959",
        "label": "Contradiction",
        "statement_text": "Participants in the primary trial had a higher likelihood of achieving 2 Year Disease-Free Survival than those in either cohort of the secondary trial ",
        "statement_nums": [
            "2 Year Disease"
        ],
        "premise_text": "Arm/Group Description: Patients with triple-negative breast cancer who do not have a pathological complete response following neoadjuvant therapy and surgery will receive eribulin 1.4 mg/m^2 on Days 1 and 8 every 21 days for 6 cycles via the intravenous (IV) route Overall Number of Participants Analyzed: 53 Measure Type: Number Unit of Measure: percentage of patients 56 (42 to 69) ",
        "premise_nums": [
            "21 days for",
            "6 cycles via",
            "42 to 69)",
            "eribulin 1.4 mg/m",
            "1 and 8",
            "2 on Days",
            "53 Measure Type:"
        ]
    },
    {
        "id": "e0b7a120-8735-413d-9a47-8508b2feffb3",
        "primaryId": "NCT01231659",
        "statement_text": "Less than 20 the primary trial participants achieved partial response (PR) ",
        "statement_nums": [
            "20 the primary"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Percentage of Participants With Overall Response Rate (ORR) Overall Response Rate (ORR) was defined as the proportion of patients whose best overall response was either complete response (CR) or partial response (PR) according to RECIST 1.0 for target lesions and assessed by CT: Complete Response (CR)  disappearance of all target lesions for a period of at least one month; Partial Response (PR)  greater than or equal 30% decrease in the sum of the longest diameter of target lesions; Overall Response (ORR) = CR + PR  Only descriptive statistics  Time frame: From the date of randomization until the date of the first documented disease progression or date of death from any cause whichever came first  assessed for approximately 15 months Results 1: Arm/Group Title: Everolimus + Letrozole ",
        "premise_nums": [
            "30% decrease",
            "15 months Results",
            "RECIST 1.0 for target"
        ]
    },
    {
        "id": "e0b7a120-8735-413d-9a47-8508b2feffb3",
        "primaryId": "NCT01231659",
        "statement_text": "Less than 20 the primary trial participants achieved partial response (PR) ",
        "statement_nums": [
            "20 the primary"
        ],
        "label": "Contradiction",
        "premise_text": "Arm/Group Description: All patients received 2 tablets (5 mg each) of Everolimus (a total of 10 mg) + 1 tablet of Letrozole (2.5 mg) daily until disease progression or as described in the protocol Overall Number of Participants Analyzed: 43 Measure Type: Number Unit of Measure: Percentage of Participants 37.2 ",
        "premise_nums": [
            "2 tablets (5",
            "43 Measure Type:",
            "1 tablet of"
        ]
    },
    {
        "id": "1393c5d9-d2be-433b-9abf-9449b46588c4",
        "primaryId": "NCT00981812",
        "statement_text": "Women who have undergone a breast enlargement procedure  and have since had the implants removed  are excluded from the primary trial ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria: female subject is 25-100 years of age subjects has at least one breast imaging finding on mammography and/or ultrasound which is assessed as highly suggestive of malignancy and recommended to biopsy subject is able to provide informed consent Exclusion Criteria: subject is pregnant subject is actively lactating or discontinued breastfeeding less than 2 months ago subject has breast implants subject is scheduled for sentinel node procedure using radioactive Tc-99m within 24 hours of the PEM study subject has contraindications for core biopsy and other invasive procedures subject has Type I diabetes mellitus or poorly controlled Type II diabetes mellitus subject has had surgery or radiation therapy on the study breast or has had chemotherapy within the past 12 months ",
        "premise_nums": [
            "25-100 years",
            "24 hours of",
            "2 months ago",
            "100 years of"
        ]
    },
    {
        "id": "1393c5d9-d2be-433b-9abf-9449b46588c4",
        "primaryId": "NCT00981812",
        "statement_text": "Women who have undergone a breast enlargement procedure  and have since had the implants removed  are excluded from the primary trial ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "subject has not fasted for 4-6 hours prior to the procedure and/or have a fasting blood glucose level greater than 140 mg/dl on day of PEM imaging",
        "premise_nums": [
            "6 hours prior",
            "4-6 hours",
            "140 mg/dl on"
        ]
    },
    {
        "id": "abfa5699-2863-4319-9386-4b359f2062f2",
        "primaryId": "NCT00195013",
        "secondaryId": "NCT00620373",
        "label": "Entailment",
        "statement_text": "Cohort 2 of the primary trial is a placebo group  the secondary trial does not have a placebo group ",
        "statement_nums": [
            "2 of the"
        ],
        "premise_text": "INTERVENTION 1: Glutamine 10 grams three times a day (orally) for four days and then stop glutamine: 10 grams three times a day (orally) for four days and then stop INTERVENTION 2: Placebo 10 grams three times a day (orally) for four days and then stop Placebo: 10 grams three times a day (orally) for four days and then stop INTERVENTION 1: Mammography Only For this reporting arm  the interpretation and analysis was done with mammography only  INTERVENTION 2: Gamma Imaging For this reporting arm  the interpretation and analysis was done with gamma imaging only  ",
        "premise_nums": [
            "10 grams three"
        ]
    },
    {
        "id": "4038f7c3-87e2-47d6-811b-fd2b21679577",
        "primaryId": "NCT01196052",
        "statement_text": "Participants in the primary trial must be willing to undergo anthracycline-based chemotherapy  or have previously received either cyclophosphamide or epirubicin ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Inclusion Criteria: Willingness to receive anthracycline-based chemotherapy or have received doxorubicin/cyclophosphamide (AC) OR 5-fluorouracil (FU)/epirubicin/ cyclophosphamide (FEC) in a similar dose and schedule as described in the protocol as part of neoadjuvant or adjuvant treatment  ",
        "premise_nums": []
    },
    {
        "id": "5097f4cd-9118-473d-a2a0-72f0cd12c7a5",
        "primaryId": "NCT01031446",
        "statement_text": "Sarah has been experiencing epileptic seizures from a brain tumor  This excludes her from participating in the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "No symptomatic brain metastases ",
        "premise_nums": []
    },
    {
        "id": "68e6a088-ab80-4a89-90d4-39308bccb1c2",
        "primaryId": "NCT00956813",
        "statement_text": "All the primary trial subjects are required to take the intervention PO daily ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "INTERVENTION 1: Flaxseed Patients receive 1 Nutrigrad™ flaxseed bar containing 7.5 grams flaxseed  410 mg lignans,once daily  INTERVENTION 2: Placebo Patients Identical looking bar with same calorie and total fat content but without flaxseed or lignans once daily  ",
        "premise_nums": [
            "containing 7.5 grams flaxseed",
            "410 mg lignans,once"
        ]
    },
    {
        "id": "a4c49b44-91b3-4a3c-bfbf-b3758cc398f1",
        "primaryId": "NCT00446030",
        "secondaryId": "NCT00975676",
        "label": "Contradiction",
        "statement_text": "the primary trial and the secondary trial have no overlap in the drugs they use for their interventions  however they both have placebo groups ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Stratum 1: TAC + Bevacizumab HER2 negative participants were administered chemotherapy with docetaxel  doxorubicin and cyclosphosphamide (TAC) + bevacizumab every 3 weeks for 6 cycles  and maintenance therapy with bevacizumab every 3 weeks for a total of 52 weeks  INTERVENTION 2: Stratum 2: TCH + Bevacizumab HER2 positive participants were administered chemotherapy with docetaxel  carboplatin and trastuzumab (TCH) + bevacizumab every 3 weeks for 6 cycles  and maintenance therapy with bevacizumab and trastuzumab every 3 weeks for a total of 52 weeks  ",
        "premise_nums": [
            "2 positive participants",
            "3 weeks for",
            "2 negative participants"
        ]
    },
    {
        "id": "a4c49b44-91b3-4a3c-bfbf-b3758cc398f1",
        "primaryId": "NCT00446030",
        "secondaryId": "NCT00975676",
        "label": "Contradiction",
        "statement_text": "the primary trial and the secondary trial have no overlap in the drugs they use for their interventions  however they both have placebo groups ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1:Triptorelin Plus Tamoxifen Determination of estrogen levels in blood samples from patients being treated with triptorelin plus tamoxifen for 5 years  INTERVENTION 2: Triptorelin Plus Exemestane Determination of estrogen levels in blood samples from patients being treated with triptorelin plus exemestane for 5 years  ",
        "premise_nums": [
            "1:Triptorelin Plus"
        ]
    },
    {
        "id": "08917306-11b0-44ad-8f45-9a67d7f6073e",
        "primaryId": "NCT00971737",
        "secondaryId": "NCT00392392",
        "label": "Entailment",
        "statement_text": "Patients with a positive FISH result are eligible for the secondary trial  but not for the primary trial ",
        "statement_nums": [],
        "premise_text": "DISEASE CHARACTERISTICS: Histologically confirmed adenocarcinoma of the breast Does not overexpress HER-2/neu, defined as FISH negative or 0, 1+, or 2+ by IHC Stage IV disease Inclusion Criteria: FISH+ HER2 gene amplified breast cancer ",
        "premise_nums": [
            "1+, or",
            "2 gene amplified",
            "2/neu, defined"
        ]
    },
    {
        "id": "9702cb6a-bdb1-415f-bb99-3b740728a4ea",
        "primaryId": "NCT00073073",
        "secondaryId": "NCT00054028",
        "label": "Entailment",
        "statement_text": "There are no placebo or control groups in the primary trial or the secondary trial ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Exemestane exemestane 25 mg by mouth (PO) every day for two years taken with calcium carbonate 1200 mg PO every day and vitamin D 400 IU PO every day Initially patients were initially planned to receive Celecoxib but the study was amended prior to any subject going on and Celecoxib was never administered to any subjects  Exemestane: exemestane 25 mg by mouth (PO) every day for two years Calcium carbonate: calcium carbonate 1200 mg PO every day x 2 years Vitamin D: Vitamin D 400 international units PO every day x 2 years INTERVENTION 1: Suramin and Paclitaxel ",
        "premise_nums": [
            "400 IU PO",
            "25 mg by",
            "400 international units",
            "1200 mg PO",
            "2 years Vitamin",
            "2 years INTERVENTION"
        ]
    },
    {
        "id": "9702cb6a-bdb1-415f-bb99-3b740728a4ea",
        "primaryId": "NCT00073073",
        "secondaryId": "NCT00054028",
        "label": "Entailment",
        "statement_text": "There are no placebo or control groups in the primary trial or the secondary trial ",
        "statement_nums": [],
        "premise_text": "Suramin will be infused weekly over 30 minutes  Four hours after the completion of the suramin infusion the 1 hour infusion of paclitaxel will begin ",
        "premise_nums": [
            "1 hour infusion"
        ]
    },
    {
        "id": "7afa2d1f-7922-4b09-b52a-43bd9a4788a9",
        "primaryId": "NCT00706030",
        "secondaryId": "NCT00171704",
        "label": "Contradiction",
        "statement_text": "participants from both cohorts of the primary trial had a drastically lower CNS Objective Response Rate than those in the secondary trial ",
        "statement_nums": [],
        "premise_text": "Outcome Measurement: Overall Response Rate Overall Response Rate (ORR)  subjects with CR or PR by independent review in subjects with ErbB-2-positive breast cancer treated at the MTD of neratinib in combination with vinorelbine per Response Evaluation Criteria In Solid Tumors Criteria (RECIST) v1.0: Complete Response (CR)  disappearance of all target lesions; Partial Response (PR)  greater than or equal 30% decrease in the sum of the longest diameter of target lesions; and Non-PD for non-target lesions  and no new lesions  Time frame: From first dose date to progression or last tumor assessment  up to four years and six months  Outcome Measurement: Percent Change From Baseline of Bone Mineral Density of the Lumbar Spine (L2-l4) ",
        "premise_nums": [
            "30% decrease",
            "2-positive breast"
        ]
    },
    {
        "id": "7afa2d1f-7922-4b09-b52a-43bd9a4788a9",
        "primaryId": "NCT00706030",
        "secondaryId": "NCT00171704",
        "label": "Contradiction",
        "statement_text": "participants from both cohorts of the primary trial had a drastically lower CNS Objective Response Rate than those in the secondary trial ",
        "statement_nums": [],
        "premise_text": "Lumbar spine (L2-L4) BMD measurements by dual energy X-ray absorptiometry (DXA) were performed after surgery and within 2 weeks prior to randomization and repeated every 6 months for the first 2 years and annually thereafter until 5 years after enrollment  The primary scanning site was the lumbar spine (L2 to L4) and the secondary scanning site was the total hip  All DXA scans were evaluated by a central reader Time frame: Baseline  24 months ",
        "premise_nums": [
            "2 years and",
            "5 years after",
            "6 months for",
            "2-L4) BMD",
            "2 to L4)",
            "2 weeks prior"
        ]
    },
    {
        "id": "dfd5acc2-6824-4b63-93ad-34e6a0a4c621",
        "primaryId": "NCT01299038",
        "statement_text": "Joe has had an alcohol addiction for 15 years  resulting in Cirrhosis therefore he is likely to be excluded from the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Inclusion Criteria: Metastatic adenocarcinoma of the breast (Stage IV) Actively receiving endocrine therapy for at least 6 weeks (with or without HER2 therapy) Minimum age 18 years ECOG Performance status of 0, 1 or 2 Normal organ and marrow function as defined in the protocol Exclusion Criteria: Participants may not be receiving any other study agents Actively receiving chemotherapy (exclusive of hormonal or HER2 therapy ) within last 5 weeks Any statin therapy within the last 3 weeks Asian decent (including Filipino  Chinese  Japanese  Korean  Vietnamese or Asian-Indian origin) ",
        "premise_nums": [
            "3 weeks Asian",
            "6 weeks (with",
            "2 therapy )",
            "5 weeks Any",
            "1 or 2",
            "18 years ECOG"
        ]
    },
    {
        "id": "dfd5acc2-6824-4b63-93ad-34e6a0a4c621",
        "primaryId": "NCT01299038",
        "statement_text": "Joe has had an alcohol addiction for 15 years  resulting in Cirrhosis therefore he is likely to be excluded from the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Concomitant use of the following drugs: cyclosporine  fibrates  niacin  gemfibrozil  ketaconazole  spironolactone  cimetidine  warfarin  erythromycin  or protease inhibitorsConditions predisposing to renal failure secondary to rhabdomyolysis Recent history of heavy alcohol use as judged by the treating physician Known to be pregnant (testing not required) or nursing History of rhabdomyolysis on statin therapy Known history of Hepatitis C or active hepatitis B infection (baseline testing not required) ",
        "premise_nums": []
    },
    {
        "id": "dfd5acc2-6824-4b63-93ad-34e6a0a4c621",
        "primaryId": "NCT01299038",
        "statement_text": "Joe has had an alcohol addiction for 15 years  resulting in Cirrhosis therefore he is likely to be excluded from the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Uncontrolled intercurrent illness including  but not limited to ongoing or active infection  hepatitis  symptomatic congestive heart failure  unstable angina pectoris  cardiac arrhythmia  or psychiatric illness/social situations that would limit compliance with study requirements",
        "premise_nums": []
    },
    {
        "id": "97e9967e-6525-4082-bd11-8c30e14d23fd",
        "primaryId": "NCT03273426",
        "secondaryId": "NCT01091168",
        "label": "Entailment",
        "statement_text": "Patients with Concurrent serious uncontrolled medical disorder may be eligible for the primary trial  but are always excluded from the secondary trial ",
        "statement_nums": [],
        "premise_text": "Inclusion Criteria: Patients with unilateral primary cancer pathologically confirmed before neoadjuvant chemotherapy (NAC) who received NAC with detectable lesion / clip marker on ultrasound with cT1-T3 tumors clinical and imaging complete or near-complete response on MRI with informed consent Exclusion Criteria: Multifocal cancer Residual microcalcification Contralateral breast cancer Concurrent serious uncontrolled medical disorder  ",
        "premise_nums": [
            "1-T3 tumors",
            "3 tumors clinical"
        ]
    },
    {
        "id": "d11dd4ae-28be-4ad2-a452-4374c48f08d1",
        "primaryId": "NCT00082433",
        "statement_text": "the primary trial results suggest that 40 mg/m2 administered as a 3-hour intravenous (IV) infusion on Day 1 of each cycle + Capecitabine  may increase OS  compared to Capecitabine alone ",
        "statement_nums": [
            "40 mg/m2 administered",
            "1 of each",
            "2 administered as",
            "3-hour intravenous"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Overall Survival (OS) Overall survival was defined as the time in months from randomization until the date of death  For those patients who had not died  survival duration was censored at the last date the patient was known to be alive  Median OS with 95% CI estimated using the Kaplan-Meier Product Limit Method  Time frame: from date of randomization until death Results 1: Arm/Group Title: Ixabepilone + Capecitabine ",
        "premise_nums": [
            "95% CI"
        ]
    },
    {
        "id": "d11dd4ae-28be-4ad2-a452-4374c48f08d1",
        "primaryId": "NCT00082433",
        "statement_text": "the primary trial results suggest that 40 mg/m2 administered as a 3-hour intravenous (IV) infusion on Day 1 of each cycle + Capecitabine  may increase OS  compared to Capecitabine alone ",
        "statement_nums": [
            "40 mg/m2 administered",
            "1 of each",
            "2 administered as",
            "3-hour intravenous"
        ],
        "label": "Entailment",
        "premise_text": "Arm/Group Description: Ixabepilone in combination with capecitabine (combination group): Ixabepilone 40 mg/m2 administered as a 3-hour intravenous (IV) infusion on Day 1 of each cycle only  plus oral capecitabine 1000 mg/m2 twice a day (BID) (2000 mg/m2 daily dose) x 14 days  followed by 1 week of rest Overall Number of Participants Analyzed: 609 Median (95% Confidence Interval) Unit of Measure: months 16.39 (14.95 to 17.91) Results 2: Arm/Group Title: Capecitabine ",
        "premise_nums": [
            "95 to 17.91)",
            "1 week of",
            "40 mg/m2 administered",
            "1000 mg/m2 twice",
            "1 of each",
            "2 daily dose)",
            "2 twice a",
            "95% Confidence",
            "2 administered as",
            "3-hour intravenous"
        ]
    },
    {
        "id": "d11dd4ae-28be-4ad2-a452-4374c48f08d1",
        "primaryId": "NCT00082433",
        "statement_text": "the primary trial results suggest that 40 mg/m2 administered as a 3-hour intravenous (IV) infusion on Day 1 of each cycle + Capecitabine  may increase OS  compared to Capecitabine alone ",
        "statement_nums": [
            "40 mg/m2 administered",
            "1 of each",
            "2 administered as",
            "3-hour intravenous"
        ],
        "label": "Entailment",
        "premise_text": "Arm/Group Description: Capecitabine alone: Capecitabine 1250 mg/m2 BID (2500 mg/m2 daily dose) x 14 days  followed by 1 week of rest Overall Number of Participants Analyzed: 612 Median (95% Confidence Interval) Unit of Measure: months 15.64 (13.86 to 17.02) ",
        "premise_nums": [
            "1 week of",
            "86 to 17.02)",
            "2 daily dose)",
            "95% Confidence",
            "1250 mg/m2 BID",
            "2 BID (2500"
        ]
    },
    {
        "id": "3b6229a9-00a1-4d26-9285-6d9f6a25fd77",
        "primaryId": "NCT02273973",
        "statement_text": "Twice as many patients in cohort 1 of the primary trial suffered from Erysipelas than diarrhoea ",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Diarrhoea 5/167 (2.99%) Erysipelas 2/167 (1.20%) ",
        "premise_nums": [
            "2/167 (1.20%)",
            "5/167 (2.99%)"
        ]
    },
    {
        "id": "9eab20ad-ffc6-473f-8087-c6c3f06f356f",
        "primaryId": "NCT00322348",
        "secondaryId": "NCT00429572",
        "label": "Entailment",
        "statement_text": "the primary trial and the secondary trial use different metrics to evaluate potential candidates' performance status ",
        "statement_nums": [],
        "premise_text": "World Health Organization (WHO) performance status of 0, 1, or 2 Zubrod performance status less than 2 ",
        "premise_nums": [
            "2 Zubrod performance"
        ]
    },
    {
        "id": "92680a4c-a1e0-47d2-9b7f-cacb20cd1fde",
        "primaryId": "NCT00368875",
        "statement_text": "the primary trial results indicate that the Recommended Phase II Dose for Vorinostat  as Assessed by NCI Common Terminology Criteria for Adverse Events  is 300 mg ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Recommended Phase II Dose as Assessed by NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 (Phase I) Dose-limiting toxcities (DLT) were defined as grade 3-4 febrile neutropenia  thrombocytopenia and non-hemtological toxicity attributed to therapy (nausea  vomiting and diarrhea would be considered dose limiting only if not adequately controlled with therapy)  Any toxicity occurring during cycle 1 that resulted in dose reduction of vorinostat or paclitaxel or failure to complete all protocol specificed doses in the first cycle was also considered a DLT Time frame: 28 days Results 1: Arm/Group Title: Phase I ",
        "premise_nums": [
            "4 febrile neutropenia",
            "1 that resulted",
            "3-4 febrile",
            "28 days Results"
        ]
    },
    {
        "id": "92680a4c-a1e0-47d2-9b7f-cacb20cd1fde",
        "primaryId": "NCT00368875",
        "statement_text": "the primary trial results indicate that the Recommended Phase II Dose for Vorinostat  as Assessed by NCI Common Terminology Criteria for Adverse Events  is 300 mg ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Arm/Group Description: Vorinostat dose (200 or 300 mg BID) was assigned at the time of registration  Vorinostat was administered orally twice daily on days 1-3, 8-10, and 15-17 of each 28-day cycle All patients also received paclitaxel at 90 mg/m2 as 1-hour infusion on days 2, 9, and 16 of every 28-day cycle  Bevacizumab was administered on day 2 and day 16 of the 28 day cycle at 10 mg/kg dose  Vorinostat dose escalation was carried out in the standard 3 + 3 phase I trial design based upon toxicity observed during the first cycle of therapy  Overall Number of Participants Analyzed: 6 Measure Type: Number Unit of Measure: mg 300 ",
        "premise_nums": [
            "2 and day",
            "16 of the",
            "1-hour infusion",
            "10 mg/kg dose",
            "90 mg/m2 as",
            "3 phase I",
            "200 or 300",
            "17 of each",
            "28 day cycle",
            "1-3, 8-10,",
            "28-day cycle",
            "16 of every",
            "6 Measure Type:",
            "300 mg BID",
            "15-17 of"
        ]
    },
    {
        "id": "b3dd4e23-f78c-4bf9-9268-d1018c966980",
        "primaryId": "NCT02550210",
        "statement_text": "Patients must have cancer that can be felt by touch to be eligible for the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Inclusion Criteria: Histologic diagnosis of palpable invasive breast cancer or ductal carcinoma in situ ",
        "premise_nums": []
    },
    {
        "id": "553d7721-289e-4ab1-a9b9-7b2c939f47c1",
        "primaryId": "NCT01997333",
        "statement_text": "The maximum Progression Free Survival for patients in cohort 1 the primary trial was 1 year ",
        "statement_nums": [
            "1 the primary"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Progression Free Survival (PFS) PFS is defined as the time from randomization to the earlier of disease progression or death due to any cause  Disease progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions  or progression in a non-target lesion  or the appearance of new lesions  The primary analysis of PFS was based on PFS events determined retrospectively by the central independent review committee  blinded to treatment assignment and investigator assessments according to RECIST 1.1 criteria  Time frame: Evaluated every 6 - 9 weeks following treatment initiation Results 1: Arm/Group Title: Capecitabine ",
        "premise_nums": [
            "9 weeks following",
            "20% increase"
        ]
    },
    {
        "id": "553d7721-289e-4ab1-a9b9-7b2c939f47c1",
        "primaryId": "NCT01997333",
        "statement_text": "The maximum Progression Free Survival for patients in cohort 1 the primary trial was 1 year ",
        "statement_nums": [
            "1 the primary"
        ],
        "label": "Contradiction",
        "premise_text": "Arm/Group Description: Capecitabine administered on Days 1 through 14 of each 21 day cycle until disease progression  discontinuation due to toxicity  withdrawal of consent  or end of study Overall Number of Participants Analyzed: 109 Median (95% Confidence Interval) Unit of Measure: months 2.8 (1.6 to 3.2) ",
        "premise_nums": [
            "6 to 3.2)",
            "1 through 14",
            "95% Confidence",
            "21 day cycle"
        ]
    },
    {
        "id": "01c6f82e-710d-4fa4-aa62-2d26e72f4533",
        "primaryId": "NCT00894504",
        "statement_text": "There were no adverse event in the primary trial which occurred more than 71 times ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 10/71 (14.08%) ATRIAL FIBRILLATION 1/71 (1.41%) CARDIAC TAMPONADE 1/71 (1.41%) PERICARDIAL EFFUSION 1/71 (1.41%) SUPRAVENTRICULAR TACHYCARDIA 1/71 (1.41%) DIARRHOEA 1/71 (1.41%) NAUSEA 1/71 (1.41%) VOMITING 1/71 (1.41%) CHEST PAIN 1/71 (1.41%) PNEUMONIA 1/71 (1.41%) MALIGNANT PLEURAL EFFUSION 1/71 (1.41%) HEPATIC ENCEPHALOPATHY 1/71 (1.41%) ",
        "premise_nums": [
            "1/71 (1.41%)",
            "10/71 (14.08%)"
        ]
    },
    {
        "id": "2e588ede-0ab8-4cb0-b03b-2c68a68bc5fc",
        "primaryId": "NCT02018458",
        "secondaryId": "NCT00895414",
        "label": "Entailment",
        "statement_text": "Patients with unexplained fever exceeding 39¬¨‚àûC are excluded from the primary trial but may be included in the secondary trial ",
        "statement_nums": [],
        "premise_text": "Exclusion Criteria: Active infection or unexplained fever greater than 38.5°C during screening  Inclusion Criteria: Tissue diagnosis of a breast carcinoma The oncologist must have prescribed doxorubicin as part of the planned chemotherapy regimen Have acceptable organ function within 14 days of enrollment defined as: liver function: total bilirubin  AST and ALT within normal institutional limits kidney function: estimated Creatinine Clearance greater than 60 ml/min calculated creatinine clearance (for females) - formula: (140 - age) x weight x .85 divided by (sCr x 72) At least 18 years old Patient must have given written informed consent indicating an understanding of the investigational nature of the study Agrees not to consume grapefruit juice while on the study Exclusion Criteria: ",
        "premise_nums": [
            "14 days of",
            "60 ml/min calculated",
            "85 divided by",
            "18 years old"
        ]
    },
    {
        "id": "2e588ede-0ab8-4cb0-b03b-2c68a68bc5fc",
        "primaryId": "NCT02018458",
        "secondaryId": "NCT00895414",
        "label": "Entailment",
        "statement_text": "Patients with unexplained fever exceeding 39¬¨‚àûC are excluded from the primary trial but may be included in the secondary trial ",
        "statement_nums": [],
        "premise_text": "Known allergy to enalaprilTaking any known P450 cytochrome inducers or inhibitors Taking any herbal supplements while on the study or the week prior to receiving doxorubicin Taking an ace-inhibitor or angiotensin receptor blocker Pregnant or lactating  Enalapril is Pregnancy Categories C (first trimester) and D (second and third trimesters) ",
        "premise_nums": [
            "450 cytochrome inducers",
            "P450 cytochrome"
        ]
    },
    {
        "id": "862c0bfe-10a6-453c-9ada-929dd00141a0",
        "primaryId": "NCT00295620",
        "secondaryId": "NCT03366428",
        "label": "Entailment",
        "statement_text": "the secondary trial and the primary trial employ non comparable outcome measures ",
        "statement_nums": [],
        "premise_text": "Outcome Measurement: Disease-free Survival After Prolonged Endocrine Treatment To determine whether 5 years of additional Anastrozole was more effective than 2 years of additional Anastrozole after 5 years of adjuvant endocrine therapy in terms of disease-free survival  Outcome Measurement: Changes in QTcF After Treatment With DS-8201a in Participants With HER2-expressing Metastatic and/or Unresectable Breast Cancer ",
        "premise_nums": [
            "2-expressing Metastatic",
            "5 years of",
            "2 years of"
        ]
    },
    {
        "id": "9ed5feb5-ab82-4f90-a6e4-5172dcd4d20f",
        "primaryId": "NCT01094184",
        "statement_text": "A patient who had an oophorectomy in the last month would not be eligible for the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Exclusion Criteria: Major surgery or significant traumatic injury within 28 days prior to enrollment or anticipation of the need for major surgery during study treatment ",
        "premise_nums": [
            "28 days prior"
        ]
    },
    {
        "id": "5501dae3-0d3c-4812-96c2-35ca863e24a5",
        "primaryId": "NCT00343863",
        "statement_text": "On day 1 Cohort 1 of the primary trial receive doxorubicin hydrochloride IV  oral cyclophosphamide  dexamethasone IV or orally and ondansetron IV ",
        "statement_nums": [
            "1 Cohort 1"
        ],
        "label": "Entailment",
        "premise_text": "INTERVENTION 1: Dexamethasone + Ondansetron IV All patients receive doxorubicin hydrochloride IV on day 1 and oral cyclophosphamide on days 1-7. Patients receive dexamethasone IV or orally and ondansetron IV on day 1 (prior to each dose of doxorubicin hydrochloride)  ",
        "premise_nums": [
            "1 and oral",
            "1-7. Patients"
        ]
    },
    {
        "id": "ece8e7df-790d-4e26-9c34-40cf66d2abf5",
        "primaryId": "NCT02005887",
        "secondaryId": "NCT00050011",
        "label": "Contradiction",
        "statement_text": "All Participants in the primary trial and the secondary trial are receiving the same daily dose of Degarelix injected into the muscle  for the same duration of time ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Arm A: Triptorelin + Letrozol Arm A: Triptorelin 3.75 mg i.m  on day 1 every 28 days for 6 cycles + letrozole 2.5 mg/day orally for 6 cycles Triptorelin: Triptorelin 3.75 mg injected into the muscle on day 1 every 28 days for 6 cycles (1 cycle= 28 days) Letrozole: Letrozole 2.5 mg orally every day for 6 cycles INTERVENTION 1: Zoledronic Acid Upfront ",
        "premise_nums": [
            "6 cycles Triptorelin:",
            "1 every 28",
            "75 mg i.m",
            "letrozole 2.5 mg/day",
            "Triptorelin 3.75 mg injected",
            "6 cycles (1",
            "6 cycles INTERVENTION",
            "Letrozole 2.5 mg orally"
        ]
    },
    {
        "id": "ece8e7df-790d-4e26-9c34-40cf66d2abf5",
        "primaryId": "NCT02005887",
        "secondaryId": "NCT00050011",
        "label": "Contradiction",
        "statement_text": "All Participants in the primary trial and the secondary trial are receiving the same daily dose of Degarelix injected into the muscle  for the same duration of time ",
        "statement_nums": [],
        "premise_text": "Participants in the upfront arm received Zoledronic Acid 4 mg i.v  on Day 1 and every 6 months until disease progression (recurrence)or the end of study  Participants also received Letrozole 2.5 daily plus calcium (1000-1200 mg) and vitamin D (400-800 IU) daily Letrozole : Participants received 2.5 mg daily  Zoledronic Acid : Participants received Zoledronic Acid 4 mg IV 15-minute infusion every 6 months  ",
        "premise_nums": [
            "4 mg i.v",
            "(1000-1200 mg",
            "1 and every",
            "15-minute infusion",
            "(400-800 IU",
            "Letrozole 2.5 daily plus",
            "4 mg IV",
            "6 months until",
            "received 2.5 mg daily"
        ]
    },
    {
        "id": "550a36e2-43bb-40af-b0c8-49498fbe2c8c",
        "primaryId": "NCT00077376",
        "secondaryId": "NCT01256008",
        "label": "Contradiction",
        "statement_text": "the primary trial investigates a novel radiotherapy treatment  whereas the secondary trial is testing a type of psychological therapy ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Trastuzumab/Ixabepilone/Carboplatin ",
        "premise_nums": []
    },
    {
        "id": "550a36e2-43bb-40af-b0c8-49498fbe2c8c",
        "primaryId": "NCT00077376",
        "secondaryId": "NCT01256008",
        "label": "Contradiction",
        "statement_text": "the primary trial investigates a novel radiotherapy treatment  whereas the secondary trial is testing a type of psychological therapy ",
        "statement_nums": [],
        "premise_text": "During the induction phase  patients were treated with Ixabepilone (BMS-247550) 15mg/m2 intravenously (IV) followed by carboplatin (AUC=2 IV) on days 1, 8 and 15 of a 28-day cycle for a maximum of 6 cycles  Trastuzumab was administered weekly (4mg/kg loading dose then 2mg/kg IV) starting on day 1. Routine premedication included H1 blocker (diphenhydramine 50 mg orally (PO) or IV)  H2 blocker (ranitidine 150 mg PO or 50 mg IV or another equivalent H2 blocker)  and at least a 5-HT3 antagonist and dexamethasone ",
        "premise_nums": [
            "50 mg IV",
            "50 mg orally",
            "2mg/kg IV",
            "15mg/m2 intravenously",
            "150 mg PO",
            "2 intravenously (IV)",
            "2 blocker (ranitidine",
            "5-HT3 antagonist",
            "8 and 15",
            "3 antagonist and",
            "28-day cycle",
            "1 blocker (diphenhydramine"
        ]
    },
    {
        "id": "550a36e2-43bb-40af-b0c8-49498fbe2c8c",
        "primaryId": "NCT00077376",
        "secondaryId": "NCT01256008",
        "label": "Contradiction",
        "statement_text": "the primary trial investigates a novel radiotherapy treatment  whereas the secondary trial is testing a type of psychological therapy ",
        "statement_nums": [],
        "premise_text": "After completion of 24 weekly trastuzumab doses (induction therapy)  trastuzumab were given at a dose of 6 mg/kg IV every 3 weeks (maintenance therapy) beginning one week after the 24th weekly dose  Trastuzumab were repeated every 21 days until disease progression or prohibitive toxicity INTERVENTION 1: Stage 1 Clinical Management The group will receive clinical management treatment only each session  Clinical Management: Clinical management is a clear contrast method of psychological therapy  which is a half-structured interview and lasting for 20-25 minutes each session  Clinical management will be assigned to both experimental group and controlled group in the first stage of intervention  Following are major elements: ",
        "premise_nums": [
            "1 Clinical Management",
            "25 minutes each",
            "21 days until",
            "24 weekly trastuzumab",
            "6 mg/kg IV",
            "3 weeks (maintenance",
            "20-25 minutes"
        ]
    },
    {
        "id": "550a36e2-43bb-40af-b0c8-49498fbe2c8c",
        "primaryId": "NCT00077376",
        "secondaryId": "NCT01256008",
        "label": "Contradiction",
        "statement_text": "the primary trial investigates a novel radiotherapy treatment  whereas the secondary trial is testing a type of psychological therapy ",
        "statement_nums": [],
        "premise_text": "Talk to the subjects to find their main problems; introduce knowledge and medication knowledge about cancer and depression; subjects reporting use of drugs for cancer and depression and a variety of signs and symptoms of the reaction  Encourage patients to adhere to drug treatment and to comply with this research program; The operation of CBT and clinical management should be conducted by the same person as far as possible ",
        "premise_nums": []
    },
    {
        "id": "95869347-6c3d-4de8-a325-a9a652f11edf",
        "primaryId": "NCT02102490",
        "secondaryId": "NCT00768222",
        "label": "Contradiction",
        "statement_text": "In contrast to the secondary trial  the primary trial did not record any cases of Sinus bradycardia  Bone marrow suppression or Constipation  ",
        "statement_nums": [],
        "premise_text": "Adverse Events 1: Total: 33/132 (25.00%) Febrile neutropenia 1/132 (0.76%) Haematotoxicity 1/132 (0.76%) Neutropenia 1/132 (0.76%) Sinus bradycardia 1/132 (0.76%) Tachycardia 1/132 (0.76%) Abdominal pain 2/132 (1.52%) Abdominal pain upper 1/132 (0.76%) Constipation 1/132 (0.76%) Large intestinal obstruction 1/132 (0.76%) Nausea 3/132 (2.27%) Adverse Events 1: Total: 3/50 (6.00%) ",
        "premise_nums": [
            "1/132 (0.76%)",
            "3/50 (6.00%)",
            "3/132 (2.27%)",
            "33/132 (25.00%)",
            "2/132 (1.52%)"
        ]
    },
    {
        "id": "95869347-6c3d-4de8-a325-a9a652f11edf",
        "primaryId": "NCT02102490",
        "secondaryId": "NCT00768222",
        "label": "Contradiction",
        "statement_text": "In contrast to the secondary trial  the primary trial did not record any cases of Sinus bradycardia  Bone marrow suppression or Constipation  ",
        "statement_nums": [],
        "premise_text": "Skin lymphangitis 1/50 (2.00%)Bone marrow suppression 0/50 (0.00%) Allergic shock 1/50 (2.00%) Deep incisional SSI 1/50 (2.00%) Adverse Events 2: Total: 1/51 (1.96%) Skin lymphangitis 0/51 (0.00%) Bone marrow suppression 1/51 (1.96%) Allergic shock 0/51 (0.00%) Deep incisional SSI 0/51 (0.00%) ",
        "premise_nums": [
            "1/51 (1.96%)",
            "0/50 (0.00%)",
            "0/51 (0.00%)",
            "1/50 (2.00%)Bone"
        ]
    },
    {
        "id": "8df8e2c0-a0ca-4ea2-ba83-494f250c4bef",
        "primaryId": "NCT00509769",
        "statement_text": "3/112 patients (2.68%) in the primary trial had Diabetes insipidus",
        "statement_nums": [
            "3/112 patients"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 30/112 (26.79%) Thrombocytopenia 1/112 (0.89%) Dysphagia 1/112 (0.89%) Haemorrhoidal haemorrhage 1/112 (0.89%) Oesophageal stenosis 1/112 (0.89%) Upper gastrointestinal haemorrhage 1/112 (0.89%) Asthenia 1/112 (0.89%) Disease progression 1/112 (0.89%) Hepatotoxicity 1/112 (0.89%) Cellulitis 3/112 (2.68%) Pneumonia 2/112 (1.79%) Osteomyelitis 1/112 (0.89%) ",
        "premise_nums": [
            "30/112 (26.79%)",
            "2/112 (1.79%)",
            "3/112 (2.68%)",
            "1/112 (0.89%)"
        ]
    },
    {
        "id": "1d4a385f-1c72-4c61-8d49-9ada0e3b716a",
        "primaryId": "NCT02556632",
        "statement_text": "Both cohorts the primary trial apply the same topical intervention for approximately every 4-6 hours every day for a week of the study ",
        "statement_nums": [
            "4-6 hours",
            "6 hours every"
        ],
        "label": "Contradiction",
        "premise_text": "INTERVENTION 1: Arm I (Curcumin-based Gel) Patients apply curcumin-based gel topically TID approximately every 4-6 hours beginning on the first day of radiation therapy and continuing until 1 week after completion of radiation therapy  Curcumin-based Gel: Applied topically Laboratory Biomarker Analysis: Correlative studies Questionnaire Administration: Ancillary studies INTERVENTION 2: Arm II (HPR Plus) Patients apply HPR Plus™ topically TID approximately every 4-6 hours beginning on the first day of radiation therapy and continuing until 1 week after completion of radiation therapy  Dermatologic Complications Management: Apply HPR Plus topically Laboratory Biomarker Analysis: Correlative studies Questionnaire Administration: Ancillary studies ",
        "premise_nums": [
            "1 week after",
            "6 hours beginning",
            "4-6 hours"
        ]
    },
    {
        "id": "b15aa13a-fbd9-4b2e-9dd2-b16628084d07",
        "primaryId": "NCT01091428",
        "statement_text": "The Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) for Alisertib in Combination With Paclitaxel  supported by results from cohort 2 of the primary trial  is 40 mg/m^2 orally  twice daily (BID) on Days 1-3, 8-10 and 15-17",
        "statement_nums": [
            "2 of the",
            "2 Dose (RP2D)",
            "40 mg/m^2",
            "1-3, 8-10",
            "(RP2D) for"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Phase 1: Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) for Alisertib in Combination With Paclitaxel ",
        "premise_nums": [
            "2 Dose (RP2D)",
            "(RP2D) for"
        ]
    },
    {
        "id": "c9214d06-2733-4c78-99e5-a42015908eae",
        "primaryId": "NCT00246571",
        "statement_text": "Renal cancer Patients from the primary trial receiving Standard of Care had a median PFS of 2.5 months by Core radiology laboratory assessment ",
        "statement_nums": [
            "of 2.5 months by"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Progression-Free Survival (PFS) Time in months from start of study treatment to first documentation of objective tumor progression (per RECIST) or death due to any cause  PFS was calculated as (first event date minus first randomization date plus 1) divided by 30.4. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease [PD])  or from adverse event (AE) data (where the outcome was \"Death\")  Time frame: Baseline  every 6 weeks until disease progression or death (up to 3 years from first dose) Results 1: Arm/Group Title: Sunitinib ",
        "premise_nums": [
            "3 years from",
            "6 weeks until"
        ]
    },
    {
        "id": "c9214d06-2733-4c78-99e5-a42015908eae",
        "primaryId": "NCT00246571",
        "statement_text": "Renal cancer Patients from the primary trial receiving Standard of Care had a median PFS of 2.5 months by Core radiology laboratory assessment ",
        "statement_nums": [
            "of 2.5 months by"
        ],
        "label": "Contradiction",
        "premise_text": "Arm/Group Description: SU011248 (Sutent [sunitinib malate  hereafter referred to as sunitinib]) oral capsules  37.5 milligrams (mg) once daily (QD) in a continuous regimen  expressed in 3-week cycles  1-week treatment rests and dose reductions allowed for dose-limiting toxicity (DLT)  Dose escalated to sunitinib 50 mg QD if minimal toxicities Overall Number of Participants Analyzed: 113 Median (95% Confidence Interval) Unit of Measure: Months Core radiology laboratory assessment: 2.0 (1.5 to 2.8) Investigator's assessment: 1.7 (1.5 to 2.6) Results 2: Arm/Group Title: Standard of Care ",
        "premise_nums": [
            "3-week cycles",
            "5 to 2.6)",
            "5 to 2.8)",
            "50 mg QD",
            "95% Confidence",
            "1-week treatment",
            "5 milligrams (mg)"
        ]
    },
    {
        "id": "a318fc31-4f28-4356-b09a-59741bb7c97a",
        "primaryId": "NCT02660788",
        "secondaryId": "NCT01490892",
        "label": "Entailment",
        "statement_text": "the primary trial is investigating different ways to communicate with women aged 51-73 years old   whereas the secondary trial is not ",
        "statement_nums": [
            "73 years old",
            "51-73 years"
        ],
        "premise_text": "INTERVENTION 1: Control Arm Mail Standard Reminder Postcard INTERVENTION 2: Family Physician Reminder Letter Arm Mail Standard Reminder Postcard Family Physician Reminder Letter INTERVENTION 1: 3D HI and SHI of UCA Perflutren injection  suspension (IV)0.25 ml followed by 3D Harmonic imaging (HI) then (IV) 20 micro-l/kg followed by 3D subharmonic imaging (SHI) 3D HI and SHI of UCA: Perflutren injection  suspension (IV)0.25 ml followed by 3D Harmonic imaging (HI) then (IV) 20 micro-l/kg followed by 3D subharmonic imaging (SHI) ",
        "premise_nums": [
            "25 ml followed",
            "20 micro-l/kg"
        ]
    },
    {
        "id": "70ec4bc8-f8fa-4901-aa7a-2388b53960c6",
        "primaryId": "NCT00206518",
        "statement_text": "The most common Chevalier grades for patients in the primary trial treated with Taxotere/Docetaxel were 3A and 3C.",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Pathological Tumor Response to Neoadjuvant Chemotherapy (Taxotere and AC) The patients' pathological response were assessed using Chevalier's system which graded the responses into Chevalier 1, 2, 3A, 3B, 3C, 3D, and 4, defined as: Disappearance of all tumor either on macroscopic or microscopic assessment in both the breast and LN (pCR) Presence of in situ carcinoma in the breast  No invasive tumor in breast and no tumor in LN (pCR) ",
        "premise_nums": []
    },
    {
        "id": "70ec4bc8-f8fa-4901-aa7a-2388b53960c6",
        "primaryId": "NCT00206518",
        "statement_text": "The most common Chevalier grades for patients in the primary trial treated with Taxotere/Docetaxel were 3A and 3C.",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Presence of invasive cancer with stromal alteration such as sclerosis or fibrosis (pPR) 3A: Subjectively greater than 75% therapeutic effect 3B: Subjectively between 50% - 75% therapeutic effect 3C: Subjectively between 25% - 50% therapeutic effect 3D: Subjectively smaller than 25% therapeutic effect OR Grade 4No or few modification of tumoral appearance (pNR)  Time frame: 10 years Results 1: Arm/Group Title: A: Taxotere/Docetaxel ",
        "premise_nums": [
            "75% therapeutic",
            "25% therapeutic",
            "50% therapeutic",
            "10 years Results"
        ]
    },
    {
        "id": "70ec4bc8-f8fa-4901-aa7a-2388b53960c6",
        "primaryId": "NCT00206518",
        "statement_text": "The most common Chevalier grades for patients in the primary trial treated with Taxotere/Docetaxel were 3A and 3C.",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Arm/Group Description: Chemotherapy In Arm A  patients will receive single agent Taxotere (100 mg/m2) every 3 weeks for 4 cycles before surgery  Primary surgery will then be conducted  if operable  following completion of neoadjuvant treatment  This will be followed by standard adjuvant AC (doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2, every 3 weeks) for 4 cycles  For patients whose BSA is greater than 2.0 m2, the Adriamycin dosage will be calculated using BSA = 2.0 m2. This is done in order to minimize Adriamycin-induced cardiotoxicity Taxotere/Docetaxel: Taxotere ",
        "premise_nums": [
            "60 mg/m2 and",
            "3 weeks for",
            "600 mg/m2,",
            "2 and cyclophosphamide",
            "4 cycles before"
        ]
    },
    {
        "id": "70ec4bc8-f8fa-4901-aa7a-2388b53960c6",
        "primaryId": "NCT00206518",
        "statement_text": "The most common Chevalier grades for patients in the primary trial treated with Taxotere/Docetaxel were 3A and 3C.",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "doxorubicin: AC (doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2, every 3 weeks) for 4 cycles before surgery Overall Number of Participants Analyzed: 83 Measure Type: Number Unit of Measure: participants 1: 3 2: 2 3A: 18 3B: 15 3C: 18 3D: 10 4: 3 N/A: 14 ",
        "premise_nums": [
            "83 Measure Type:",
            "60 mg/m2 and",
            "3 N/A:",
            "600 mg/m2,",
            "2 and cyclophosphamide",
            "4 cycles before"
        ]
    },
    {
        "id": "00dc0e37-1d0b-4f53-a037-86bf9799dae6",
        "primaryId": "NCT00570323",
        "secondaryId": "NCT00193180",
        "label": "Contradiction",
        "statement_text": "Female patients with a womb cannot take part in either the secondary trial or the primary trial ",
        "statement_nums": [],
        "premise_text": "Inclusion Criteria: All subjects must be female  Postmenopausal status  defined as any one of the following criteria: Documented history of bilateral oophorectomy  Age 60 years or more  Age 45 to 59 and satisfying one or more of the following criteria: Amenorrhea for at least 12 months and intact uterus  Amenorrhea for less than 12 months and a follicle stimulating hormone (FSH) and estradiol concentration within postmenopausal range including: patients who have had a hysterectomy and patients who have received hormone replacement  Patients must have histologically confirmed invasive breast cancer with a primary tumor of 3 cm or more in greatest dimension as measured by clinical examination  Estrogen receptor and/or progesterone receptor positive disease  Patients must not have received any prior treatment for current or newly diagnosed breast cancer  ",
        "premise_nums": [
            "12 months and",
            "3 cm or",
            "60 years or",
            "45 to 59"
        ]
    },
    {
        "id": "00dc0e37-1d0b-4f53-a037-86bf9799dae6",
        "primaryId": "NCT00570323",
        "secondaryId": "NCT00193180",
        "label": "Contradiction",
        "statement_text": "Female patients with a womb cannot take part in either the secondary trial or the primary trial ",
        "statement_nums": [],
        "premise_text": "Patients must have not received previous treatment with any of the study medications or similar drugs No use of selective estrogen receptor modulators (SERM) such as raloxifene or similar agents in the past 2 years  WHO performance status of 0, 1, or 2. Adequate organ function defined as follows: Adequate renal function  defined by a serum creatinine within 3 times the upper limits of normal  Adequate liver function  defined by total bilirubin  AST  ALT  and alkaline phosphatase within 3 times the upper limits of normal  Adequate bone marrow function  defined as a WBC greater than 3.0 ml  PLT greater than 75,000/ul, Hb greater than 9 gm/l  ",
        "premise_nums": [
            "75,000/ul, Hb",
            "3 times the",
            "9 gm/l"
        ]
    },
    {
        "id": "00dc0e37-1d0b-4f53-a037-86bf9799dae6",
        "primaryId": "NCT00570323",
        "secondaryId": "NCT00193180",
        "label": "Contradiction",
        "statement_text": "Female patients with a womb cannot take part in either the secondary trial or the primary trial ",
        "statement_nums": [],
        "premise_text": "Willing to undergo breast core biopsies as required by the study protocol  - Ability to understand and sign a written informed consent for participation in the trial Life expectancy of at least 1 year  Exclusion Criteria: Premenopausal status  Other coexisting malignancies with the exception of basal cell carcinoma or cervical cancer in situ  Patients with brain metastasis  WHO performance status of 3 or 4. Is judged by the investigator  uncontrolled intercurrent illness including  but not limited to  ongoing or active infection  symptomatic congestive heart failure  unstable angina pectoris  significant cardiac arrhythmia  or psychiatric illness/social situations that would limit compliance with study requirements  ",
        "premise_nums": [
            "3 or 4."
        ]
    },
    {
        "id": "00dc0e37-1d0b-4f53-a037-86bf9799dae6",
        "primaryId": "NCT00570323",
        "secondaryId": "NCT00193180",
        "label": "Contradiction",
        "statement_text": "Female patients with a womb cannot take part in either the secondary trial or the primary trial ",
        "statement_nums": [],
        "premise_text": "Evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the subject to participate in the clinical trial  - Concurrent treatment with estrogens or progestins  Patients must stop these drugs at least two weeks prior to study entry Treatment with a non-approved or investigational drug within 30 days before Day 1 of study treatment  Platelet count less than 75,000. In the opinion of the investigator  bleeding diathesis or anticoagulation therapy that would preclude intramuscular injections  History of hypersensitivity to castor oil  Any evidence of clinically active interstitial lung disease (patients with chronic stable radiographic changes who are asymptomatic need not be excluded) - Patients with recurrent breast cancer  Patients with contralateral second primary breast cancers are eligible  Inclusion Criteria: ",
        "premise_nums": [
            "75,000. In",
            "1 of study",
            "30 days before"
        ]
    },
    {
        "id": "00dc0e37-1d0b-4f53-a037-86bf9799dae6",
        "primaryId": "NCT00570323",
        "secondaryId": "NCT00193180",
        "label": "Contradiction",
        "statement_text": "Female patients with a womb cannot take part in either the secondary trial or the primary trial ",
        "statement_nums": [],
        "premise_text": "To be included in this study  you must meet the following criteria:Metastatic breast cancer confirmed by biopsy No more than one prior chemotherapy regimen for metastatic breast cancer Able to perform activities of daily living with minimal assistance Adequate bone marrow  liver and kidney function Age 18 years or older Give written informed consent Exclusion Criteria: You cannot participate in this study if any of the following apply to you: Moderate to severe peripheral neuropathy Uncontrolled blood pressure or uncontrolled heart beat irregularities Diabetes Mellitus with fasting blood sugar greater than 200 mg % Significant heart disease within the prior 6 months Severe or uncontrolled medical disease Active uncontrolled infection Known chronic liver disease Known diagnosis of HIV infection Pregnant or breast feeding females ",
        "premise_nums": [
            "6 months Severe",
            "18 years or"
        ]
    },
    {
        "id": "00dc0e37-1d0b-4f53-a037-86bf9799dae6",
        "primaryId": "NCT00570323",
        "secondaryId": "NCT00193180",
        "label": "Contradiction",
        "statement_text": "Female patients with a womb cannot take part in either the secondary trial or the primary trial ",
        "statement_nums": [],
        "premise_text": "Please note: There are additional inclusion/exclusion criteria  The study center will determine if you meet all of the criteria  If you do not qualify for the trial  study personnel will explain the reasons  If you do qualify  study personnel will explain the trial in detail and answer any questions you may have ",
        "premise_nums": []
    },
    {
        "id": "a1a421cc-01c9-4afb-8f09-6b10b0ff5094",
        "primaryId": "NCT01663727",
        "secondaryId": "NCT00072293",
        "label": "Contradiction",
        "statement_text": "Patients must be between the ages of 13 and 76 to participate in the primary trial or the secondary trial ",
        "statement_nums": [
            "13 and 76"
        ],
        "premise_text": "Inclusion Criteria: Histologically or cytologically confirmed  HER2-negative adenocarcinoma of the breast  with measurable or non-measurable locally recurrent or metastatic disease  Locally recurrent disease must not be amenable to resection with curative intent  ECOG performance status of 0 or 1 For women of childbearing potential  use of an acceptable and effective method of non-hormonal contraception For patients who have received recent radiotherapy  recovery prior to randomization from any significant acute toxicity  and radiation treatments have to be completed more than 3 weeks from randomization Exclusion Criteria: Disease-Specific Exclusions: HER2-positive status Prior chemotherapy for locally recurrent or metastatic disease Prior hormonal therapy smaller than 2 weeks prior to randomization ",
        "premise_nums": [
            "0 or 1",
            "2-negative adenocarcinoma",
            "3 weeks from",
            "2-positive status",
            "2 weeks prior"
        ]
    },
    {
        "id": "a1a421cc-01c9-4afb-8f09-6b10b0ff5094",
        "primaryId": "NCT01663727",
        "secondaryId": "NCT00072293",
        "label": "Contradiction",
        "statement_text": "Patients must be between the ages of 13 and 76 to participate in the primary trial or the secondary trial ",
        "statement_nums": [
            "13 and 76"
        ],
        "premise_text": "Prior adjuvant or neo-adjuvant chemotherapy is allowed  provided its conclusion has been for at least 12 months prior to randomizationInvestigational therapy within 28 days of randomization General Medical Exclusions: Life expectancy of smaller than 12 weeks Inadequate organ function Uncontrolled serious medical or psychiatric illness Active infection requiring intravenous (IV) antibiotics at screening Pregnancy or lactation History of other malignancies within 5 years prior to screening  except for tumors with a negligible risk for metastasis or death PATIENT CHARACTERISTICS: Age Any age ",
        "premise_nums": [
            "28 days of",
            "12 months prior",
            "12 weeks Inadequate",
            "5 years prior"
        ]
    },
    {
        "id": "9316ef0d-55b0-4547-88ae-887e0132a263",
        "primaryId": "NCT00246571",
        "statement_text": "Patients from the primary trial receiving Standard of Care had a median PFS of 2.7months by Core radiology laboratory assessment ",
        "statement_nums": [
            "of 2.7months by"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Progression-Free Survival (PFS) Time in months from start of study treatment to first documentation of objective tumor progression (per RECIST) or death due to any cause  PFS was calculated as (first event date minus first randomization date plus 1) divided by 30.4. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease [PD])  or from adverse event (AE) data (where the outcome was \"Death\")  Time frame: Baseline  every 6 weeks until disease progression or death (up to 3 years from first dose) Results 1: Arm/Group Title: Sunitinib ",
        "premise_nums": [
            "3 years from",
            "6 weeks until"
        ]
    },
    {
        "id": "9316ef0d-55b0-4547-88ae-887e0132a263",
        "primaryId": "NCT00246571",
        "statement_text": "Patients from the primary trial receiving Standard of Care had a median PFS of 2.7months by Core radiology laboratory assessment ",
        "statement_nums": [
            "of 2.7months by"
        ],
        "label": "Entailment",
        "premise_text": "Arm/Group Description: SU011248 (Sutent [sunitinib malate  hereafter referred to as sunitinib]) oral capsules  37.5 milligrams (mg) once daily (QD) in a continuous regimen  expressed in 3-week cycles  1-week treatment rests and dose reductions allowed for dose-limiting toxicity (DLT)  Dose escalated to sunitinib 50 mg QD if minimal toxicities Overall Number of Participants Analyzed: 113 Median (95% Confidence Interval) Unit of Measure: Months Core radiology laboratory assessment: 2.0 (1.5 to 2.8) Investigator's assessment: 1.7 (1.5 to 2.6) Results 2: Arm/Group Title: Standard of Care ",
        "premise_nums": [
            "3-week cycles",
            "5 to 2.6)",
            "5 to 2.8)",
            "50 mg QD",
            "95% Confidence",
            "1-week treatment",
            "5 milligrams (mg)"
        ]
    },
    {
        "id": "5d815fac-c66c-43fe-9ac8-a352b6e47a5b",
        "primaryId": "NCT01929395",
        "secondaryId": "NCT01857882",
        "label": "Contradiction",
        "statement_text": "the primary trial and the secondary trial are both utilising test and control groups in their interventions ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Phase 1: Addition of Supine MRI to Conventional Imaging Pre-operative supine MRI with intraoperative optical scanning and tracking (group MRI) INTERVENTION 1: Decision Support Workshop The decision support workshop will be 2 hours in duration on the morning of the consultation and will be facilitated by a dedicated social worker from psycho-oncology  Decision Support Workshop: Incorporates the key components of shared decision-making and decision support with the philosophy of delivering supportive care to cancer patients  Surgeon (30 mins): treatment options for breast reconstruction with indications/ contraindications  advantages / disadvantages  expected post-operative course  aesthetic result and complications with probabilities Registered nurse (30 mins): preparing for surgery  postoperative recovery and how to navigate the health care system Social worker (30 mins): values clarification exercise ",
        "premise_nums": [
            "2 hours in"
        ]
    },
    {
        "id": "5d815fac-c66c-43fe-9ac8-a352b6e47a5b",
        "primaryId": "NCT01929395",
        "secondaryId": "NCT01857882",
        "label": "Contradiction",
        "statement_text": "the primary trial and the secondary trial are both utilising test and control groups in their interventions ",
        "statement_nums": [],
        "premise_text": "Breast reconstruction patient volunteer (30 mins) questions and answers about her personal experienceINTERVENTION 2: Standard Care Routine pre-consultation education ",
        "premise_nums": []
    },
    {
        "id": "7b9fdeaa-5cb7-4453-b174-07b44bb58234",
        "primaryId": "NCT00127205",
        "statement_text": "More patients in the primary trial suffer from dysfunctions with ventricular contractions than ventricular relaxations ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Adverse Events 2: Left ventricular diastolic dysfunction 3/2186 (0.14%) Left ventricular systolic dysfunction 1/2186 (0.05%) ",
        "premise_nums": [
            "3/2186 (0.14%)",
            "1/2186 (0.05%)"
        ]
    },
    {
        "id": "c330f152-c64e-47ab-8568-5129a1a2099e",
        "primaryId": "NCT00875979",
        "statement_text": "None of the 60+ patients in cohort 2 the primary trial experienced any adverse events ",
        "statement_nums": [
            "2 the primary"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 0/3 (0.00%) Pericardial effusion 0/3 (0.00%) Tachycardia 0/3 (0.00%) Nausea 0/3 (0.00%) Vomiting 0/3 (0.00%) Abdominal pain 0/3 (0.00%) Colitis 0/3 (0.00%) Diarrhoea 0/3 (0.00%) Gastritis 0/3 (0.00%) Ileus 0/3 (0.00%) Fatigue 0/3 (0.00%) Pyrexia 0/3 (0.00%) Pain 0/3 (0.00%) Hepatic cirrhosis 0/3 (0.00%) ",
        "premise_nums": [
            "0/3 (0.00%)"
        ]
    },
    {
        "id": "c330f152-c64e-47ab-8568-5129a1a2099e",
        "primaryId": "NCT00875979",
        "statement_text": "None of the 60+ patients in cohort 2 the primary trial experienced any adverse events ",
        "statement_nums": [
            "2 the primary"
        ],
        "label": "Contradiction",
        "premise_text": "Cellulitis 0/3 (0.00%)Adverse Events 2: Total: 22/64 (34.38%) Pericardial effusion 1/64 (1.56%) Tachycardia 1/64 (1.56%) Nausea 2/64 (3.13%) Vomiting 2/64 (3.13%) Abdominal pain 2/64 (3.13%) Colitis 1/64 (1.56%) Diarrhoea 1/64 (1.56%) Gastritis 1/64 (1.56%) Ileus 1/64 (1.56%) Fatigue 1/64 (1.56%) Pyrexia 1/64 (1.56%) Pain 1/64 (1.56%) ",
        "premise_nums": [
            "1/64 (1.56%)",
            "22/64 (34.38%)",
            "0/3 (0.00%)Adverse",
            "2/64 (3.13%)"
        ]
    },
    {
        "id": "c330f152-c64e-47ab-8568-5129a1a2099e",
        "primaryId": "NCT00875979",
        "statement_text": "None of the 60+ patients in cohort 2 the primary trial experienced any adverse events ",
        "statement_nums": [
            "2 the primary"
        ],
        "label": "Contradiction",
        "premise_text": "Hepatic cirrhosis 1/64 (1.56%)Cellulitis 3/64 (4.69%) ",
        "premise_nums": [
            "3/64 (4.69%)",
            "1/64 (1.56%)Cellulitis"
        ]
    },
    {
        "id": "e3b88c8c-241d-4ead-8573-534a46210707",
        "primaryId": "NCT00811135",
        "statement_text": "The majority of patients in the primary trial did not experience Left ventricular dysfunction ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 20/88 (22.73%) ",
        "premise_nums": [
            "20/88 (22.73%)"
        ]
    },
    {
        "id": "e621f354-dea0-4d0f-a252-5480028c1712",
        "primaryId": "NCT00022516",
        "statement_text": "At least 1 patient in the primary trial suffered from a radiotherapy induced adverse event ",
        "statement_nums": [
            "1 patient in"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 0/0 Leukopenia 0/0 Neutropenia 0/0 Ocular-other 0/0 Elevated SGPT 0/0 Arthralgia 0/0 CNS hemorrhage 0/0 Neurologic-other 0/0 Radiation dermatitis 0/0 Adverse Events 2: Total: 11/473 (2.33%) Leukopenia 2/473 (0.42%) Neutropenia 5/473 (1.06%) Ocular-other 1/473 (0.21%) Elevated SGPT 1/473 (0.21%) Arthralgia 1/473 (0.21%) CNS hemorrhage 1/473 (0.21%) ",
        "premise_nums": [
            "0/0 Leukopenia",
            "1/473 (0.21%)",
            "0/0 Neurologic-other",
            "0/0 Radiation",
            "2/473 (0.42%)",
            "0 CNS hemorrhage",
            "0/0 Adverse",
            "0/0 Neutropenia",
            "0 Elevated SGPT",
            "0 Adverse Events",
            "11/473 (2.33%)",
            "0/0 Arthralgia",
            "0/0 Ocular-other",
            "0 Radiation dermatitis",
            "0/0 CNS",
            "0/0 Elevated",
            "5/473 (1.06%)"
        ]
    },
    {
        "id": "e621f354-dea0-4d0f-a252-5480028c1712",
        "primaryId": "NCT00022516",
        "statement_text": "At least 1 patient in the primary trial suffered from a radiotherapy induced adverse event ",
        "statement_nums": [
            "1 patient in"
        ],
        "label": "Entailment",
        "premise_text": "Neurologic-other 1/473 (0.21%)Radiation dermatitis 1/473 (0.21%) ",
        "premise_nums": [
            "1/473 (0.21%)Radiation"
        ]
    },
    {
        "id": "ee209156-74dc-475e-87af-ae51160982ef",
        "primaryId": "NCT00244881",
        "statement_text": "30% of the primary trial participants had an increased level of CECs after 3 weeks of Cediranib Maleate treatment ",
        "statement_nums": [
            "3 weeks of",
            "30% of"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Fraction of Patients With Increased Levels of Circulating Endothelial Cells An exact 95% confidence interval (CI) will be calculated for the CEC response rate  With 26 patients  this CI will be no wider than 40% (e.g.  if 13 of 26 patients respond  the CI is 30% to 70%). Time frame: After 3 weeks of treatment Results 1: Arm/Group Title: Treatment (Cediranib Maleate) Arm/Group Description: Patients receive oral AZD2171 once daily for 42 days  Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity  Overall Number of Participants Analyzed: 26 Measure Type: Number Unit of Measure: percentage of participants 30 ",
        "premise_nums": [
            "3 weeks of",
            "42 days in",
            "26 Measure Type:",
            "AZD2171 once",
            "30% to",
            "2171 once daily",
            "95% confidence",
            "13 of 26"
        ]
    },
    {
        "id": "edf813c0-2271-49ca-a040-a355bf71d8b4",
        "primaryId": "NCT01519700",
        "statement_text": "There was just over 36 hours difference in Median Duration of Grade 4 Neutropenia During Cycle 1 of Chemotherapy for the two arms of the primary trial ",
        "statement_nums": [
            "36 hours difference",
            "1 of Chemotherapy",
            "4 Neutropenia During"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Mean Duration of Grade 4 Neutropenia During Cycle 1 of Chemotherapy Mean duration of severe neutropenia  defined as the mean number of consecutive days with Grade 4 neutropenia (ANC less than 0.5*10^9 cells/L) Time frame: 21 days (Cycle 1 of chemotherapy treatment) Results 1: Arm/Group Title: EP2006 + EP2006 & Neupogen Arm/Group Description: All subjects randomized to receive either EP2006 in Cycle 1 Overall Number of Participants Analyzed: 101 Mean (Standard Deviation) Unit of Measure: Days 1.17 (1.11) Results 2: Arm/Group Title: Neupogen + Neupogen & EP2006 ",
        "premise_nums": [
            "1 of Chemotherapy",
            "21 days (Cycle",
            "1 of chemotherapy",
            "4 Neutropenia During",
            "1 Overall Number",
            "2006 in Cycle",
            "EP2006 in",
            "101 Mean (Standard",
            "4 neutropenia (ANC"
        ]
    },
    {
        "id": "edf813c0-2271-49ca-a040-a355bf71d8b4",
        "primaryId": "NCT01519700",
        "statement_text": "There was just over 36 hours difference in Median Duration of Grade 4 Neutropenia During Cycle 1 of Chemotherapy for the two arms of the primary trial ",
        "statement_nums": [
            "36 hours difference",
            "1 of Chemotherapy",
            "4 Neutropenia During"
        ],
        "label": "Contradiction",
        "premise_text": "Arm/Group Description: All subjects randomized to receive Neupogen in Cycle 1Overall Number of Participants Analyzed: 103 Mean (Standard Deviation) Unit of Measure: Days 1.2 (1.02) ",
        "premise_nums": [
            "103 Mean (Standard"
        ]
    },
    {
        "id": "352475ea-1b17-4d1a-a5e3-71f1b87cffd8",
        "primaryId": "NCT01827163",
        "statement_text": "Any patients with histologically confirmed stage 4 adenocarcinoma HER2/neu immunohistochemistry 3+, ECOG performance status smaller than 2 and a Negative HCG pregnancy test are eligible for the primary trial ",
        "statement_nums": [
            "4 adenocarcinoma HER2",
            "3+, ECOG",
            "2 and a",
            "2/neu immunohistochemistry"
        ],
        "label": "Contradiction",
        "premise_text": "Exclusion Criteria: Patients with stage IV breast cancer or undergoing chemotherapy  radiation therapy  immunotherapy  or biotherapy for current breast cancer  ",
        "premise_nums": []
    },
    {
        "id": "c7c745d6-03ee-4740-9ef4-641fb6546e46",
        "primaryId": "NCT00544167",
        "statement_text": "Every adverse event in the primary trial occurred more than 8 times ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 7/45 (15.56%) Febrile neutropenia 1/45 (2.22%) Cardiac ischemia/infarction 1/45 (2.22%) Ventricular arrhythmia - left ventricular systolic dysfunction 1/45 (2.22%) Hemmorhage - GI 1/45 (2.22%) Pancreatitis 1/45 (2.22%) Infection - pneumonia 1/45 (2.22%) Infection - Streptococcus 1/45 (2.22%) Abcess of Bartholin's cyst 1/45 (2.22%) ",
        "premise_nums": [
            "7/45 (15.56%)",
            "1/45 (2.22%)"
        ]
    },
    {
        "id": "c5c8ab0b-8062-4467-8ecd-bb15f35f54c0",
        "primaryId": "NCT00617942",
        "secondaryId": "NCT00388726",
        "label": "Entailment",
        "statement_text": "the primary trial had a lower total percentage of patients experiencing adverse events compared to the secondary trial ",
        "statement_nums": [],
        "premise_text": "Adverse Events 1: Total: 7/37 (18.92%) Adverse Events 1: Total: 130/503 (25.84%) ",
        "premise_nums": [
            "130/503 (25.84%)",
            "7/37 (18.92%)"
        ]
    },
    {
        "id": "601e9c47-ed82-4fa6-8a28-b3c71cc7c71b",
        "primaryId": "NCT01827787",
        "statement_text": "The Triple-Negative Breast Cancer cohort of the primary trial had a much lower ORR than the cohort receiving 1.4 mg/m2 of Eribulin ",
        "statement_nums": [
            "receiving 1.4 mg/m2",
            "2 of Eribulin"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Overall Response Rate (ORR) ORR was defined as the percentage of participants achieving complete response (CR) or partial response (PR) based on RECIST 1.1 criteria on treatment  Per RECIST 1.1 for target lesions: CR is complete disappearance of all target lesions and PR is at least a 30% decrease in the sum of longest diameter (LD) of target lesions  taking as reference baseline sum LD  PR or better overall response assumes at a minimum incomplete response/stable disease (SD) for the evaluation of non-target lesions and absence of new lesions  ",
        "premise_nums": [
            "30% decrease",
            "RECIST 1.1 criteria on",
            "RECIST 1.1 for target"
        ]
    },
    {
        "id": "601e9c47-ed82-4fa6-8a28-b3c71cc7c71b",
        "primaryId": "NCT01827787",
        "statement_text": "The Triple-Negative Breast Cancer cohort of the primary trial had a much lower ORR than the cohort receiving 1.4 mg/m2 of Eribulin ",
        "statement_nums": [
            "receiving 1.4 mg/m2",
            "2 of Eribulin"
        ],
        "label": "Contradiction",
        "premise_text": "Time frame: Disease was evaluated radiologically at baseline and every 9 weeks on treatment; Maximum treatment duration was 38 cycles/26 months (Cohort 1) and 17 cycles/12 months (Cohort 2)Results 1: Arm/Group Title: Cohort 1: HR+/HER2- Arm/Group Description: Eribulin: 1.4 mg/m2 administered intravenously over 2-5 minutes on days 1 and 8 of each 21 day cycle Participants remained on single agent eribulin until disease progression or withdrawal for other reasons  Overall Number of Participants Analyzed: 45 Measure Type: Number Unit of Measure: percentage of participants 35.6 (24 to 49) Results 2: ",
        "premise_nums": [
            "2-5 minutes",
            "17 cycles/12 months",
            "12 months (Cohort",
            "26 months (Cohort",
            "45 Measure Type:",
            "2 administered intravenously",
            "21 day cycle",
            "24 to 49)",
            "38 cycles/26 months",
            "1 and 8",
            "5 minutes on",
            "1.4 mg/m",
            "9 weeks on"
        ]
    },
    {
        "id": "601e9c47-ed82-4fa6-8a28-b3c71cc7c71b",
        "primaryId": "NCT01827787",
        "statement_text": "The Triple-Negative Breast Cancer cohort of the primary trial had a much lower ORR than the cohort receiving 1.4 mg/m2 of Eribulin ",
        "statement_nums": [
            "receiving 1.4 mg/m2",
            "2 of Eribulin"
        ],
        "label": "Contradiction",
        "premise_text": "Arm/Group Title: Cohort 2: TNBCArm/Group Description: Eribulin: 1.4 mg/m2 administered intravenously over 2-5 minutes on days 1 and 8 of each 21 day cycle Participants remained on single agent eribulin until disease progression or withdrawal for other reasons  Overall Number of Participants Analyzed: 38 Measure Type: Number Unit of Measure: percentage of participants 13.2 (5 to 26) ",
        "premise_nums": [
            "2-5 minutes",
            "2 administered intravenously",
            "5 to 26)",
            "1 and 8",
            "5 minutes on",
            "1.4 mg/m",
            "38 Measure Type:",
            "21 day cycle"
        ]
    },
    {
        "id": "8f1959e4-b93a-4112-9726-27a4034f0e07",
        "primaryId": "NCT00191854",
        "statement_text": "Patients must have a one bi-dimensional  measurable indicator lesion to be included in the primary trial",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria: Female patients with histological or cytological proven diagnosis of breast cancer Stage IV disease Performance Status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Scale Patients had to have previously received anthracycline based regimens as a adjuvant therapy or neo-adjuvant chemotherapy and then progressed and developed metastatic disease Adequate organ function Exclusion Criteria: Prior chemotherapy for metastatic disease Previous radiation therapy is allowed but must not have included whole pelvis radiation Known or suspected brain metastasis  Serious concomitant disorders that would compromise the safety of the patient or compromise the patient's ability to complete the study  at the discretion of the investigator ",
        "premise_nums": [
            "0 or 1"
        ]
    },
    {
        "id": "8f1959e4-b93a-4112-9726-27a4034f0e07",
        "primaryId": "NCT00191854",
        "statement_text": "Patients must have a one bi-dimensional  measurable indicator lesion to be included in the primary trial",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Concurrent administration of any other tumor therapy  including cytotoxic chemotherapy  hormonal therapy and immunotherapy (including trastuzumab (Herceptin))Peripheral neuropathy of Common Toxicity Criteria (CTC) Grade greater than 1. History of significant neurological or mental disorder  including seizures or dementia ",
        "premise_nums": []
    },
    {
        "id": "e1782960-8d44-4acc-aaae-bfa4f8e38de0",
        "primaryId": "NCT00254592",
        "statement_text": "Patients must have an ECOG score below 3 to participate in the primary trial ",
        "statement_nums": [
            "3 to participate"
        ],
        "label": "Entailment",
        "premise_text": "Inclusion Criteria: Patients must have a performance status of 0-2 by Zubrod criteria ",
        "premise_nums": [
            "0-2 by",
            "2 by Zubrod"
        ]
    },
    {
        "id": "61bd93b2-b38f-496d-acd9-f8b188d28a39",
        "primaryId": "NCT00365599",
        "secondaryId": "NCT01771666",
        "label": "Contradiction",
        "statement_text": "Black men with and ECOG smaller than =2, with ANC greater than 1.5 x 10^9/L,Bilirubin greater than 2.0 mg/dl  PLT greater than 100 x 10^9/L and no prior history of blood clots are eligible for the primary trial but excluded from the secondary trial",
        "statement_nums": [
            "9/L,Bilirubin greater",
            "than 2.0 mg/dl",
            "100 x 10",
            "than 1.5 x 10",
            "9/L and"
        ],
        "premise_text": "Inclusion Criteria: Patients must have Eastern Cooperative Oncology Group (ECOG) performance status 0-2. ",
        "premise_nums": []
    },
    {
        "id": "741c95c7-825c-4321-8d12-9037bb701ab8",
        "primaryId": "NCT02667626",
        "statement_text": "the primary trial is testing a web-based educational tool and the secondary trial is testing the effects of using Adjuvant Letrozole on Post-menopausal Women ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "INTERVENTION 1: SCPR Intervention Young breast cancer participants will receive their SCPR and access to additional web-based educational reproductive health information  including resource lists of helpful websites  followed by regular reproductive health prompts and study adherence reminders for 24 weeks  Reproductive Health Survivorship Care Plan (SCPR): The reproductive health survivorship care plan (SCPR) is a web-based educational tool that will include information on how to manage various reproductive health issues such as hot flashes  fertility concerns  contraception practices  and sexual function  The intervention also includes additional web-based information and resource lists  text-based reproductive health and study adherence INTERVENTION 2: Control ",
        "premise_nums": []
    },
    {
        "id": "741c95c7-825c-4321-8d12-9037bb701ab8",
        "primaryId": "NCT02667626",
        "statement_text": "the primary trial is testing a web-based educational tool and the secondary trial is testing the effects of using Adjuvant Letrozole on Post-menopausal Women ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Young breast cancer participants randomized to the waitlist control arm will receive access to the web-based resources and study adherence reminders  At completion of the 24 weeks of follow up  they will have access to their SCPR Control: Web-based resource lists and text-based study adherence reminders ",
        "premise_nums": [
            "24 weeks of"
        ]
    },
    {
        "id": "6ce047b6-c18f-4f63-90ec-8643f5145efe",
        "primaryId": "NCT00305448",
        "statement_text": "At least 11 patients in both cohorts of the primary trial achieved either complete response (CR) or partial response (PR) ",
        "statement_nums": [
            "11 patients in"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Objective Response Rate (ORR) An objective response (OR) is defined as a patient having a best overall response of either complete response (CR) or partial response (PR)  A patient has best overall response of CR if she had overall response of CR or PR on one visit and met the confirmation criteria per RECIST  ORR is defined as percentage of patients with objective response  Each patient with measurable disease at baseline was assessed for OR from the sequence of Response Evaluation Criteria in Solid Tumors (RECIST) scan data up to data cut-off  RECIST scans were performed every 12 weeks (+/- 2weeks) from randomization ",
        "premise_nums": []
    },
    {
        "id": "6ce047b6-c18f-4f63-90ec-8643f5145efe",
        "primaryId": "NCT00305448",
        "statement_text": "At least 11 patients in both cohorts of the primary trial achieved either complete response (CR) or partial response (PR) ",
        "statement_nums": [
            "11 patients in"
        ],
        "label": "Contradiction",
        "premise_text": "Time frame: baseline and every 12 weeks (+/- 2weeks) from randomization data up to data cut-off (19th march 2008)Results 1: Arm/Group Title: Fulvestrant 250 mg Arm/Group Description: Fulvestrant 250 mg Overall Number of Participants Analyzed: 45 Measure Type: Number Unit of Measure: percentage of participants 11.1 Results 2: Arm/Group Title: Fulvestrant 250 mg + Loading Dose Arm/Group Description: Fulvestrant 250 mg + Loading Dose Overall Number of Participants Analyzed: 51 Measure Type: Number Unit of Measure: percentage of participants 17.6 ",
        "premise_nums": [
            "45 Measure Type:",
            "1 Results 2:",
            "250 mg Overall",
            "participants 11.1 Results 2",
            "51 Measure Type:",
            "250 mg Arm"
        ]
    },
    {
        "id": "d647aad0-47f7-4b77-a265-e77dcf5e0983",
        "primaryId": "NCT02781051",
        "secondaryId": "NCT01067976",
        "label": "Contradiction",
        "statement_text": "The intervention for the primary trial requires participants to exercise for 12 weeks while wearing a fitbit  in contrast a full year of daily physical exercise is explicitly required for the secondary trial ",
        "statement_nums": [
            "12 weeks while"
        ],
        "premise_text": "INTERVENTION 1: Physical Activity Intervention Participants will participate in a multi-component physical activity intervention for 12 weeks with a 6 month follow up  Print-based education: Subjects were given a copy of Exercise for Health: An Exercise Guide for Breast Cancer Survivors  Topics covered within the book include benefits of exercise; recommendations on type  duration  frequency and intensity of exercise; goal-setting; and advice on overcoming barriers  Fitbit: Subjects were provided with a Fitbit and instructed to wear the device daily  Active Living counseling: The Active Living counseling program consists of 12 weekly group educational sessions  These sessions involved discussion of topics related to increasing physical activity  including: identifying and overcoming barriers  setting goals  and time management  ",
        "premise_nums": [
            "12 weekly group",
            "6 month follow",
            "12 weeks with"
        ]
    },
    {
        "id": "d647aad0-47f7-4b77-a265-e77dcf5e0983",
        "primaryId": "NCT02781051",
        "secondaryId": "NCT01067976",
        "label": "Contradiction",
        "statement_text": "The intervention for the primary trial requires participants to exercise for 12 weeks while wearing a fitbit  in contrast a full year of daily physical exercise is explicitly required for the secondary trial ",
        "statement_nums": [
            "12 weeks while"
        ],
        "premise_text": "Facility Access: Subjects will have access to the exercise lab in the UT Southwestern Depression Center consisting of equipment for aerobic exercise (treadmills  stationary bikes  etc.) INTERVENTION 1: CMRM vs UMRM [Not Specified] ",
        "premise_nums": []
    },
    {
        "id": "74fed085-3389-49c6-bdd2-a95c97071f2d",
        "primaryId": "NCT00841828",
        "secondaryId": "NCT01959490",
        "label": "Entailment",
        "statement_text": "All cohorts in the primary trial had lower percentage of participants with pCR compared to cohort 1 of the secondary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Outcome Measurement: Complete Pathological Response (pCR) Rate in Breast and Axilla According to the Miller&Payne Criteria (G5-A and G5-D). Within 3-4 weeks after last docetaxel dose the surgery was performed to evaluate pathological response  According to the Miller&Payne Criteria  pCR in node-negative patients is a grade 5-A and in node-positive patients is a grade 5-D. Time frame: Up to 16 weeks Results 1: Arm/Group Title: Arm 1: EC -greater than D + Lapatinib Arm/Group Description: EC -greater than D + Lapatinib Drugs plus Biological ",
        "premise_nums": [
            "5-D). Within",
            "5-A and",
            "5-D. Time",
            "3-4 weeks",
            "4 weeks after",
            "16 weeks Results"
        ]
    },
    {
        "id": "74fed085-3389-49c6-bdd2-a95c97071f2d",
        "primaryId": "NCT00841828",
        "secondaryId": "NCT01959490",
        "label": "Entailment",
        "statement_text": "All cohorts in the primary trial had lower percentage of participants with pCR compared to cohort 1 of the secondary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Epirubicin + Cyclophosphamide (EC) each 21 days for 4 cycles -greater than Docetaxel (D) + lapatinib each 21 days for 4 cycles)Overall Number of Participants Analyzed: 51 Measure Type: Number Unit of Measure: percentage of participants with pCR 23.5 (11.9 to 35.1) Results 2: Arm/Group Title: Arm 2: EC -greater than D + Trastuzumab Arm/Group Description: EC -greater than D + Trastuzumab Drug plus Biological ",
        "premise_nums": [
            "51 Measure Type:",
            "21 days for",
            "9 to 35.1)"
        ]
    },
    {
        "id": "74fed085-3389-49c6-bdd2-a95c97071f2d",
        "primaryId": "NCT00841828",
        "secondaryId": "NCT01959490",
        "label": "Entailment",
        "statement_text": "All cohorts in the primary trial had lower percentage of participants with pCR compared to cohort 1 of the secondary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Epirubicin + Cyclophosphamide (EC) each 21 days for 4 cycles -greater than Docetaxel (D) + Trastuzumab each 21 days for 4 cyclesOverall Number of Participants Analyzed: 48 Measure Type: Number Unit of Measure: percentage of participants with pCR 47.9 (33.8 to 62.0) Outcome Measurement: Number of Patients With a Pathological Complete Response (pCR) Who Received Targeted Therapy With Trastuzumab and Pertuzumab or Bevacizumab Predicted by Genomically-derived Molecular Subtypes  ",
        "premise_nums": [
            "21 days for",
            "4 cyclesOverall Number",
            "8 to 62.0)",
            "48 Measure Type:"
        ]
    },
    {
        "id": "74fed085-3389-49c6-bdd2-a95c97071f2d",
        "primaryId": "NCT00841828",
        "secondaryId": "NCT01959490",
        "label": "Entailment",
        "statement_text": "All cohorts in the primary trial had lower percentage of participants with pCR compared to cohort 1 of the secondary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Number of patients with a pathological complete response (pCR) who received targeted therapy with trastuzumab and pertuzumab or bevacizumab predicted by genomically-derived molecular subtypes (HER2 positive or HER2 negative  pCR is defined as absence of invasive cancer in breast or lymph nodes after neoadjuvant chemotherapy Time frame: Up to 30 days after last cycle of treatment Results 1: Arm/Group Title: Cohort 1P (HER2 Positive) ",
        "premise_nums": [
            "30 days after",
            "2 positive or"
        ]
    },
    {
        "id": "74fed085-3389-49c6-bdd2-a95c97071f2d",
        "primaryId": "NCT00841828",
        "secondaryId": "NCT01959490",
        "label": "Entailment",
        "statement_text": "All cohorts in the primary trial had lower percentage of participants with pCR compared to cohort 1 of the secondary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Arm/Group Description: Patients receive a run-in Pertuzumab treatment of 840 mg IV over 60 minutes on day -14 followed by Trastuzumab IV over 30-60 minutes and Pertuzumab IV over 30-60 minutes  docetaxel IV  and carboplatin IV on day 1. Treatment repeats very 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity Overall Number of Participants Analyzed: 5 Measure Type: Count of Participants Unit of Measure: Participants 4 80.0% Results 2: Arm/Group Title: Cohort 1T (HER2 Positive) ",
        "premise_nums": [
            "840 mg IV",
            "4 80.0% Results 2",
            "60 minutes on",
            "6 courses in",
            "60 minutes and",
            "3 weeks for",
            "5 Measure Type:",
            "14 followed by",
            "30-60 minutes"
        ]
    },
    {
        "id": "74fed085-3389-49c6-bdd2-a95c97071f2d",
        "primaryId": "NCT00841828",
        "secondaryId": "NCT01959490",
        "label": "Entailment",
        "statement_text": "All cohorts in the primary trial had lower percentage of participants with pCR compared to cohort 1 of the secondary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Arm/Group Description: Patients receive a run-in Trastuzumab treatment of 8 mg/kg IV over 90 minutes on day -14 followed by Trastuzumab IV over 30-60 minutes and Pertuzumab IV over 30-60 minutes  Docetaxel IV  and Carboplatin IV on day 1. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity Overall Number of Participants Analyzed: 6 Measure Type: Count of Participants Unit of Measure: Participants 6 100.0% ",
        "premise_nums": [
            "6 courses in",
            "60 minutes and",
            "3 weeks for",
            "8 mg/kg IV",
            "14 followed by",
            "6 Measure Type:",
            "30-60 minutes",
            "90 minutes on"
        ]
    },
    {
        "id": "986ffe33-8e8b-4cbf-8408-eb9489fb2314",
        "primaryId": "NCT00450723",
        "statement_text": "There are several types of surgical and therapeutic treatments  such as Appendectomies and radiotherapy  which are banned for patients wanting to take part in the primary trial ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "DISEASE CHARACTERISTICS: Histologically confirmed breast cancer Stage I or II disease (T1-T2, N0, M0/MX disease) No chest wall invasion by tumor (T3 disease) Medially or centrally located lesion No multicentric disease Multifocal disease allowed No clinically positive axillary nodes No enlarged internal mammary nodes by CT scan Hormone receptor status not specified PATIENT CHARACTERISTICS: Male or female Menopausal status not specified American Society of Anesthesiologists (ASA) physical status classification 1-2 Not pregnant or nursing Negative pregnancy test No other concurrent known  invasive malignancy No known chronic pulmonary disease No known allergy to methylene blue or isosulfan blue PRIOR CONCURRENT THERAPY: ",
        "premise_nums": [
            "2 Not pregnant",
            "1-2 Not",
            "0/MX disease",
            "1-T2, N0,"
        ]
    },
    {
        "id": "986ffe33-8e8b-4cbf-8408-eb9489fb2314",
        "primaryId": "NCT00450723",
        "statement_text": "There are several types of surgical and therapeutic treatments  such as Appendectomies and radiotherapy  which are banned for patients wanting to take part in the primary trial ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "No prior thoracic or cardiac surgeryNo prior ipsilateral chest tube placement Contralateral chest tube placement allowed No prior neoadjuvant chemotherapy No prior radiotherapy to the mediastinum ",
        "premise_nums": []
    },
    {
        "id": "aeac5b1c-26f9-44bc-b1c4-3bd0d498914e",
        "primaryId": "NCT00483223",
        "secondaryId": "NCT00811135",
        "label": "Contradiction",
        "statement_text": "There are more cases of Intestinal perforation  Chest pain  death  Hyperglycemia and Pneumonia in the secondary trial than in the primary trial",
        "statement_nums": [],
        "premise_text": "Adverse Events 1: Total: 8/86 (9.30%) Hypersensitivity reaction to Cisplatin 1/86 (1.16%) Infection with normal ANC 4/86 (4.65%) Neutrophil Count 1/86 (1.16%) Hyperglycemia 1/86 (1.16%) Hypertension 1/86 (1.16%) Adverse Events 1: Intestinal perforation * 1/88 (1.14%) Chest pain * 1/88 (1.14%) Death * 1/88 (1.14%) Erysipelas * 1/88 (1.14%) Pneumonia * 1/88 (1.14%) ",
        "premise_nums": [
            "1/86 (1.16%)",
            "8/86 (9.30%)",
            "4/86 (4.65%)",
            "1/88 (1.14%)"
        ]
    },
    {
        "id": "3f98cd71-ec28-4fd1-9ca0-2184eef3390a",
        "primaryId": "NCT02455453",
        "statement_text": "Patients with tumors that are HER2 +  PR and ER -  are eligible for the primary trial ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria: Patient must have any one of the following types of breast cancer (primary or metastatic): ER+/PgR+/HER2- or ER+/PgR-/HER2-. ",
        "premise_nums": []
    },
    {
        "id": "11138479-1666-4973-84c2-c6779b5444f5",
        "primaryId": "NCT01912612",
        "secondaryId": "NCT02392611",
        "label": "Contradiction",
        "statement_text": "In the primary trial only 1 cohort is administered the intervention  whereas in the secondary trial both cohorts receive the same intervention ",
        "statement_nums": [
            "1 cohort is"
        ],
        "premise_text": "INTERVENTION 1: Arm 1 (Patients With Pain) Duloxetine 30 mg daily x 1 week  then 60 mg daily x 4 weeks  then 30 mg daily x 2 weeks  Duloxetine: Subjects will receive 30 mg duloxetine orally for 7 days  then 60 mg duloxetine orally for 28 days  then 30 mg duloxetine orally x 14 days  INTERVENTION 2: Arm 2 (Patients Without Pain -- Control) Patient reported pain and symptoms assessment for comparison at baseline  INTERVENTION 1: Monotherapy: Alobresib 0.6 mg ",
        "premise_nums": [
            "60 mg daily",
            "60 mg duloxetine",
            "30 mg daily",
            "30 mg duloxetine"
        ]
    },
    {
        "id": "11138479-1666-4973-84c2-c6779b5444f5",
        "primaryId": "NCT01912612",
        "secondaryId": "NCT02392611",
        "label": "Contradiction",
        "statement_text": "In the primary trial only 1 cohort is administered the intervention  whereas in the secondary trial both cohorts receive the same intervention ",
        "statement_nums": [
            "1 cohort is"
        ],
        "premise_text": "Participants with advanced solid tumors and lymphomas who had failed or were intolerant to standard therapy  or for whom no standard therapy existed received alobresib tablets at a dose of 0.6 mg orally once daily on Study Day 1 through C1D28 of 28 days cycle to determine the MTD INTERVENTION 2: Monotherapy: Alobresib 1.4 mg Participants with advanced solid tumors and lymphomas who had failed or were intolerant to standard therapy  or for whom no standard therapy existed received alobresib tablets at a dose of 1.4 mg orally once daily on Study Day 1 through C1D28 of 28 days cycle to determine the MTD  ",
        "premise_nums": [
            "of 0.6 mg orally",
            "Alobresib 1.4 mg Participants",
            "28 days cycle",
            "D28 of",
            "of 1.4 mg orally",
            "1 through C1D28"
        ]
    },
    {
        "id": "35c62055-2832-4119-9080-5603beea1934",
        "primaryId": "NCT02402764",
        "secondaryId": "NCT00490646",
        "label": "Entailment",
        "statement_text": "There were no cases of Pneumopathy in either the primary trial or the secondary trial ",
        "statement_nums": [],
        "premise_text": "Adverse Events 1: Total: 3/10 (30.00%) Sinus tachycardia * 1/10 (10.00%) Blurred vision * 1/10 (10.00%) Memory impairment * 1/10 (10.00%) Dyspnea * 2/10 (20.00%) Adverse Events 1: Total: 13/24 (54.17%) FEBRILE NEUTROPENIA 5/24 (20.83%) HAEMATOTOXICITY 0/24 (0.00%) NEUTROPENIA 3/24 (12.50%) LYMPHADENOPATHY 0/24 (0.00%) PERICARDIAL EFFUSION 1/24 (4.17%) ATRIAL FIBRILLATION 1/24 (4.17%) ",
        "premise_nums": [
            "3/24 (12.50%)",
            "1/24 (4.17%)",
            "3/10 (30.00%)",
            "1/10 (10.00%)",
            "13/24 (54.17%)",
            "5/24 (20.83%)",
            "2/10 (20.00%)",
            "0/24 (0.00%)"
        ]
    },
    {
        "id": "35c62055-2832-4119-9080-5603beea1934",
        "primaryId": "NCT02402764",
        "secondaryId": "NCT00490646",
        "label": "Entailment",
        "statement_text": "There were no cases of Pneumopathy in either the primary trial or the secondary trial ",
        "statement_nums": [],
        "premise_text": "APLASIA 0/24 (0.00%)NAUSEA 0/24 (0.00%) PYREXIA 1/24 (4.17%) EXTRAVASATION 0/24 (0.00%) CHOLECYSTITIS 1/24 (4.17%) PATHOLOGICAL FRACTURE 1/24 (4.17%) Adverse Events 2: Total: 6/24 (25.00%) FEBRILE NEUTROPENIA 0/24 (0.00%) HAEMATOTOXICITY 1/24 (4.17%) NEUTROPENIA 0/24 (0.00%) LYMPHADENOPATHY 1/24 (4.17%) PERICARDIAL EFFUSION 0/24 (0.00%) ATRIAL FIBRILLATION 0/24 (0.00%) ",
        "premise_nums": [
            "6/24 (25.00%)",
            "0/24 (0.00%)NAUSEA",
            "1/24 (4.17%)"
        ]
    },
    {
        "id": "35c62055-2832-4119-9080-5603beea1934",
        "primaryId": "NCT02402764",
        "secondaryId": "NCT00490646",
        "label": "Entailment",
        "statement_text": "There were no cases of Pneumopathy in either the primary trial or the secondary trial ",
        "statement_nums": [],
        "premise_text": "APLASIA 1/24 (4.17%)NAUSEA 1/24 (4.17%) PYREXIA 0/24 (0.00%) EXTRAVASATION 1/24 (4.17%) CHOLECYSTITIS 0/24 (0.00%) PATHOLOGICAL FRACTURE 0/24 (0.00%) ",
        "premise_nums": [
            "1/24 (4.17%)NAUSEA",
            "0/24 (0.00%)"
        ]
    },
    {
        "id": "59ff0501-f6af-4739-bd07-71e12e8cd8a7",
        "primaryId": "NCT02244580",
        "secondaryId": "NCT01901146",
        "label": "Entailment",
        "statement_text": "Patients with undetermined human epidermal growth factor receptor 2 expression cannot be accepted by either the primary trial or the secondary trial ",
        "statement_nums": [
            "2 expression cannot"
        ],
        "premise_text": "Inclusion Criteria: Estrogen receptor (ER)  PgR and HER2 expression have been determined Inclusion Criteria: HER2 positive disease ",
        "premise_nums": [
            "2 expression have",
            "2 positive disease"
        ]
    },
    {
        "id": "ab52c559-5712-44ff-becd-1c491e107472",
        "primaryId": "NCT00605267",
        "statement_text": "Men are not eligible for the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Inclusion Criteria: Premenopausal  estrogen receptor positive women  aged 20 years and over  with operable and measurable breast cancer who have provided written informed consent Exclusion Criteria: Medical history of chemotherapy or endocrine therapy for breast cancer  or with treatment history of radiotherapy  Unwillingness to stop taking any drug known to affect sex hormone status (including hormone replacement therapy (HRT)  ",
        "premise_nums": [
            "20 years and"
        ]
    },
    {
        "id": "4619b957-3368-47b9-b949-01ec91208f96",
        "primaryId": "NCT01629615",
        "secondaryId": "NCT00320541",
        "label": "Contradiction",
        "statement_text": "the secondary trial recorded more cardiac related adverse events than the primary trial ",
        "statement_nums": [],
        "premise_text": "Adverse Events 1: Total: 17/50 (34.00%) Fatigue 4/50 (8.00%) Papulopustular rash 1/50 (2.00%) Alanine aminotransferase increased 5/50 (10.00%) Aspartate aminotransferase increased 4/50 (8.00%) Alkalosis 1/50 (2.00%) Anorexia 1/50 (2.00%) Hyperglycemia 2/50 (4.00%) Nervous system disorders - Other 1/50 (2.00%) Dry skin 1/50 (2.00%) Rash acneiform 1/50 (2.00%) Adverse Events 1: Total: 27/94 (28.72%) Anaemia 2/94 (2.13%) ",
        "premise_nums": [
            "4/50 (8.00%)",
            "27/94 (28.72%)",
            "1/50 (2.00%)",
            "5/50 (10.00%)",
            "2/94 (2.13%)",
            "17/50 (34.00%)",
            "2/50 (4.00%)"
        ]
    },
    {
        "id": "4619b957-3368-47b9-b949-01ec91208f96",
        "primaryId": "NCT01629615",
        "secondaryId": "NCT00320541",
        "label": "Contradiction",
        "statement_text": "the secondary trial recorded more cardiac related adverse events than the primary trial ",
        "statement_nums": [],
        "premise_text": "Febrile neutropenia 2/94 (2.13%)Leukopenia 1/94 (1.06%) Neutropenia 0/94 (0.00%) Thrombocytopenia 1/94 (1.06%) Arrhythmia 0/94 (0.00%) Atrial fibrillation 0/94 (0.00%) Cardiac failure congestive 0/94 (0.00%) Cardiomyopathy 0/94 (0.00%) Pericardial effusion 0/94 (0.00%) Tachycardia 0/94 (0.00%) Adverse Events 2: Total: 36/93 (38.71%) Anaemia 2/93 (2.15%) ",
        "premise_nums": [
            "1/94 (1.06%)",
            "2/94 (2.13%)Leukopenia",
            "2/93 (2.15%)",
            "36/93 (38.71%)",
            "0/94 (0.00%)"
        ]
    },
    {
        "id": "4619b957-3368-47b9-b949-01ec91208f96",
        "primaryId": "NCT01629615",
        "secondaryId": "NCT00320541",
        "label": "Contradiction",
        "statement_text": "the secondary trial recorded more cardiac related adverse events than the primary trial ",
        "statement_nums": [],
        "premise_text": "Febrile neutropenia 9/93 (9.68%)Leukopenia 3/93 (3.23%) Neutropenia 4/93 (4.30%) Thrombocytopenia 1/93 (1.08%) Arrhythmia 1/93 (1.08%) Atrial fibrillation 1/93 (1.08%) Cardiac failure congestive 3/93 (3.23%) Cardiomyopathy 2/93 (2.15%) Pericardial effusion 1/93 (1.08%) Tachycardia 1/93 (1.08%) ",
        "premise_nums": [
            "9/93 (9.68%)Leukopenia",
            "1/93 (1.08%)",
            "2/93 (2.15%)",
            "3/93 (3.23%)",
            "4/93 (4.30%)"
        ]
    },
    {
        "id": "5bb09d7b-622f-4bdd-8dfd-809ea014a278",
        "primaryId": "NCT00559754",
        "secondaryId": "NCT02924883",
        "label": "Entailment",
        "statement_text": "A higher percent of patients in cohort 1 of the secondary trial experienced adverse events  than in cohort 1 of the primary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Adverse Events 1: Total: 13/72 (18.06%) Adverse Events 1: Total: 52/133 (39.10%) ",
        "premise_nums": [
            "13/72 (18.06%)",
            "52/133 (39.10%)"
        ]
    },
    {
        "id": "07327b61-973b-48bb-b42b-dfde1efcfb7d",
        "primaryId": "NCT00435409",
        "secondaryId": "NCT00319254",
        "label": "Entailment",
        "statement_text": "The patient with the shortest PFS was in the secondary trial and the longest recorded PFS was in the primary trial ",
        "statement_nums": [],
        "premise_text": "Outcome Measurement: Progression Free Survival (PFS) Defined as the time from the date of randomization to the date of the first documentation of objective tumor progression or death due to any cause  whichever occurs first  If tumor progression data include more than 1 date  the first date will be used  PFS (in months) will be calculated as (first event date minus randomization date plus 1) divided by 30.4. Time frame: Baseline until disease progression (up to 3 years from first dose) Results 1: Arm/Group Title: Sunitinib + Capecitabine ",
        "premise_nums": [
            "3 years from"
        ]
    },
    {
        "id": "07327b61-973b-48bb-b42b-dfde1efcfb7d",
        "primaryId": "NCT00435409",
        "secondaryId": "NCT00319254",
        "label": "Entailment",
        "statement_text": "The patient with the shortest PFS was in the secondary trial and the longest recorded PFS was in the primary trial ",
        "statement_nums": [],
        "premise_text": "Arm/Group Description: Sunitinib administered orally at a starting dose of 37.5 mg once a day on a continuous regimen  Capecitabine administered orally at a starting dose of 2000 mg/m^2 per day (1000 mg/m^2 BID) from Days 1-14 every 3 weeks Overall Number of Participants Analyzed: 221 Median (95% Confidence Interval) Unit of Measure: months Independent radiology assessment: 5.5 (4.5 to 6.0) Investigator's assessment: 5.4 (4.4 to 5.8) Results 2: Arm/Group Title: Capecitabine ",
        "premise_nums": [
            "2 per day",
            "of 37.5 mg once",
            "3 weeks Overall",
            "4 to 5.8)",
            "14 every 3",
            "95% Confidence",
            "2000 mg/m^2",
            "5 to 6.0)",
            "1-14 every"
        ]
    },
    {
        "id": "07327b61-973b-48bb-b42b-dfde1efcfb7d",
        "primaryId": "NCT00435409",
        "secondaryId": "NCT00319254",
        "label": "Entailment",
        "statement_text": "The patient with the shortest PFS was in the secondary trial and the longest recorded PFS was in the primary trial ",
        "statement_nums": [],
        "premise_text": "Arm/Group Description: Capecitabine administered orally at a starting dose of 2500 mg/m^2 per day (1250 mg/m^2 BID) from Days 1-14 every 3 weeks  At the time of progression  participants could have been eligible to crossover to single agent sunitinib  administered orally at a starting dose of 37.5 mg daily continuously Overall Number of Participants Analyzed: 221 Median (95% Confidence Interval) Unit of Measure: months Independent radiology assessment: 5.9 (5.4 to 7.6) Investigator's assessment: 5.5 (4.3 to 6.8) Outcome Measurement: Progression-Free Survival (PFS) Rate ",
        "premise_nums": [
            "2 per day",
            "3 to 6.8)",
            "14 every 3",
            "95% Confidence",
            "4 to 7.6)",
            "2500 mg/m^2",
            "1-14 every",
            "of 37.5 mg daily"
        ]
    },
    {
        "id": "07327b61-973b-48bb-b42b-dfde1efcfb7d",
        "primaryId": "NCT00435409",
        "secondaryId": "NCT00319254",
        "label": "Entailment",
        "statement_text": "The patient with the shortest PFS was in the secondary trial and the longest recorded PFS was in the primary trial ",
        "statement_nums": [],
        "premise_text": "PFS was based on Kaplan-Meier estimates  PFS was defined as time in weeks from start of study treatment to first documentation of objective tumor progression or death due to any cause  PFS was calculated as (first event date minus the date of first dose of study medication plus 1) divided by 7. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease [PD])  or from death case report forms (CRFs)  Percentage of participants who had not experienced progression or death by Week 16 is reported Time frame: Baseline up to Week 16 Results 1: Arm/Group Title: Bosutinib ",
        "premise_nums": [
            "16 is reported",
            "16 Results 1:"
        ]
    },
    {
        "id": "07327b61-973b-48bb-b42b-dfde1efcfb7d",
        "primaryId": "NCT00435409",
        "secondaryId": "NCT00319254",
        "label": "Entailment",
        "statement_text": "The patient with the shortest PFS was in the secondary trial and the longest recorded PFS was in the primary trial ",
        "statement_nums": [],
        "premise_text": "Arm/Group Description: Four bosutinib 100 milligram (mg) capsules  equivalent to 400 mg bosutinib orally once daily for 48 weeks  or until disease progression  unacceptable toxicity or withdrawal of consent occurred Overall Number of Participants Analyzed: 73 Measure Type: Number Unit of Measure: percentage of participants 39.6 (28.1 to 50.8) ",
        "premise_nums": [
            "1 to 50.8)",
            "73 Measure Type:",
            "400 mg bosutinib",
            "100 milligram (mg)"
        ]
    },
    {
        "id": "3307a083-0c8a-47b8-94cb-0bf4095b9c3b",
        "primaryId": "NCT00633750",
        "statement_text": "Patients with Clinical stage II (T2 N2) invasive mammary carcinoma are not eligible for the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Inclusion Criteria: Clinical stage I or II (T1 or T2, N0 or N1) invasive mammary carcinoma Exclusion Criteria: Fixed axillary lymph node metastases (N2) ",
        "premise_nums": [
            "1 or T2,",
            "0 or N1)"
        ]
    },
    {
        "id": "bda2752e-082e-4d06-926a-04ade3f61c26",
        "primaryId": "NCT03165955",
        "secondaryId": "NCT00912340",
        "label": "Entailment",
        "statement_text": "11 patients in the primary trial suffer from a liver disease  0 in the secondary trial ",
        "statement_nums": [
            "0 in the",
            "11 patients in"
        ],
        "premise_text": "Hepatitis acute 1/28 (3.57%) Adverse Events 1: Total: 1/24 (4.17%) Pericardial effusion *1/24 (4.17%) Other cardiac disorder *0/24 (0.00%) Ejection fraction decrease *0/24 (0.00%) Hypertension *0/24 (0.00%) Salivary gland infection *0/24 (0.00%) Pleural effusion *0/24 (0.00%) Adverse Events 2: Total: 6/30 (20.00%) Pericardial effusion *1/30 (3.33%) Other cardiac disorder *1/30 (3.33%) Ejection fraction decrease *1/30 (3.33%) ",
        "premise_nums": [
            "1/24 (4.17%)",
            "6/30 (20.00%)",
            "1/28 (3.57%)",
            "1/30 (3.33%)",
            "0/24 (0.00%)"
        ]
    },
    {
        "id": "bda2752e-082e-4d06-926a-04ade3f61c26",
        "primaryId": "NCT03165955",
        "secondaryId": "NCT00912340",
        "label": "Entailment",
        "statement_text": "11 patients in the primary trial suffer from a liver disease  0 in the secondary trial ",
        "statement_nums": [
            "0 in the",
            "11 patients in"
        ],
        "premise_text": "Hypertension *1/30 (3.33%)Salivary gland infection *1/30 (3.33%) Pleural effusion *2/30 (6.67%) ",
        "premise_nums": [
            "1/30 (3.33%)Salivary",
            "2/30 (6.67%)"
        ]
    },
    {
        "id": "d4d73d33-4f71-46b2-b0c1-eac6741fd8f3",
        "primaryId": "NCT00118157",
        "statement_text": "Only one the primary trial patient treated with oral lapatinib and oral tamoxifen achieved either Complete and Partial tumour response ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Tumor Response Rate (Complete and Partial) Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) [Not Specified] Time frame: 4 weeks Results 1: Arm/Group Title: Arm 1 Arm/Group Description: Patients receive oral lapatinib and oral tamoxifen once daily on days 1-28. lapatinib ditosylate: Given orally tamoxifen citrate: Given orally Overall Number of Participants Analyzed: 17 Measure Type: Number Unit of Measure: participants 1 (1 to 27) ",
        "premise_nums": [
            "1 Arm/Group Description",
            "1-28. lapatinib",
            "17 Measure Type:",
            "1 to 27)",
            "4 weeks Results"
        ]
    },
    {
        "id": "f418c027-439a-4b19-bfb0-e1c1241886d8",
        "primaryId": "NCT01127763",
        "statement_text": "There were 4 more cases of Dyspnea than Dehydration in the primary trial ",
        "statement_nums": [
            "4 more cases"
        ],
        "label": "Contradiction",
        "premise_text": "Dehydration 1/25 (4.00%) Dyspnea (Shortness Of Breath) 2/25 (8.00%) ",
        "premise_nums": [
            "1/25 (4.00%)",
            "2/25 (8.00%)"
        ]
    },
    {
        "id": "4805e49a-b99e-46d8-b937-13ac2501c4a4",
        "primaryId": "NCT00009945",
        "statement_text": "Patients with a positive sentinel node biopsy must have surgery to remove lymph nodes from the groin or they will not be eligible for the primary trial ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Eligibility Patients must have undergone either a total mastectomy or a lumpectomy with either an axillary dissection or sentinel node biopsy  If any sentinel node is histologically positive by H & E  or histologically suspicious on H & E and confirmed positive by immunohistochemistry (IHC)  then the patient must have a completion axillary dissection  ",
        "premise_nums": []
    },
    {
        "id": "9a3cb836-66a8-4c68-980c-97e5841f331f",
        "primaryId": "NCT01091428",
        "statement_text": "The Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) for Alisertib in Combination With Paclitaxel  supported by the primary trial results  is 40 mg orally  twice daily (BID) on Days 1-3, 8-10 and 15-17",
        "statement_nums": [
            "40 mg orally",
            "1-3, 8-10",
            "(RP2D) for",
            "2 Dose (RP2D)"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Phase 1: Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) for Alisertib in Combination With Paclitaxel ",
        "premise_nums": [
            "2 Dose (RP2D)",
            "(RP2D) for"
        ]
    },
    {
        "id": "45d4f78f-04d4-434c-9679-fd92291e97b6",
        "primaryId": "NCT00553410",
        "statement_text": "A 55 year old postmenopausal patient with sarcoidosis would be excluded from the primary trial as it would prevent prevent prolonged follow-up ",
        "statement_nums": [
            "55 year old"
        ],
        "label": "Entailment",
        "premise_text": "DISEASE CHARACTERISTICS: Confirmed diagnosis of prior operable  noninflammatory breast cancer meeting the following criteria: Steroid hormone receptor-positive tumors (estrogen receptor and/or progesterone receptor)  determined by immunohistochemistry  after primary surgery and before commencement of prior endocrine therapy Prior local treatment including surgery with or without radiotherapy for primary breast cancer with no known clinical residual loco-regional disease Following primary surgery  eligible patients must have had evidence of lymph node involvement either in the axillary or internal mammary nodes  but not supraclavicular nodes Clinically disease-free ",
        "premise_nums": []
    },
    {
        "id": "45d4f78f-04d4-434c-9679-fd92291e97b6",
        "primaryId": "NCT00553410",
        "statement_text": "A 55 year old postmenopausal patient with sarcoidosis would be excluded from the primary trial as it would prevent prevent prolonged follow-up ",
        "statement_nums": [
            "55 year old"
        ],
        "label": "Entailment",
        "premise_text": "Must have completed 4-6 years of prior adjuvant selective estrogen receptor modulators (SERMs)  aromatase inhibitors (AIs)  or a sequential combination of bothWhen calculating 4-6 years  neoadjuvant endocrine therapy should not be included No evidence of recurrent disease or distant metastatic disease No prior bilateral breast cancer PATIENT CHARACTERISTICS: Female Must be postmenopausal by any of the following criteria: Patients of any age who have had a bilateral oophorectomy (including radiation castration AND amenorrheic for greater than 3 months) ",
        "premise_nums": [
            "4-6 years",
            "6 years of"
        ]
    },
    {
        "id": "45d4f78f-04d4-434c-9679-fd92291e97b6",
        "primaryId": "NCT00553410",
        "statement_text": "A 55 year old postmenopausal patient with sarcoidosis would be excluded from the primary trial as it would prevent prevent prolonged follow-up ",
        "statement_nums": [
            "55 year old"
        ],
        "label": "Entailment",
        "premise_text": "Patients 56 years old or older with any evidence of ovarian function must have biochemical evidence of definite postmenopausal status (defined as estradiol  luteinizing hormone [LH]  and follicle-stimulating hormone [FSH] in the postmenopausal range)Patients 55 years old or younger must have biochemical evidence of definite postmenopausal status (defined as estradiol  LH  and FSH in the postmenopausal range) Patients who have received prior luteinizing-hormone releasing-hormone (LHRH) analogues within the last year are eligible if they have definite evidence of postmenopausal status as defined above Clinically adequate hepatic function ",
        "premise_nums": [
            "56 years old",
            "55 years old"
        ]
    },
    {
        "id": "45d4f78f-04d4-434c-9679-fd92291e97b6",
        "primaryId": "NCT00553410",
        "statement_text": "A 55 year old postmenopausal patient with sarcoidosis would be excluded from the primary trial as it would prevent prevent prolonged follow-up ",
        "statement_nums": [
            "55 year old"
        ],
        "label": "Entailment",
        "premise_text": "No bone fracture due to osteoporosis at any time during the 4-6 years of prior therapyNo prior or current malignancy except adequately treated basal cell or squamous cell carcinoma of the skin  in situ carcinoma of the cervix or bladder  or contra- or ipsilateral in situ breast carcinoma No other nonmalignant systemic diseases (cardiovascular  renal  lung  etc.) that would prevent prolonged follow-up No psychiatric  addictive  or any other disorder that compromises compliance with protocol requirements PRIOR CONCURRENT THERAPY: See Disease Characteristics More than 12 months since prior and no other concurrent endocrine SERM/AI therapy Any type of prior adjuvant therapy allowed including  but not limited to  any of the following: ",
        "premise_nums": [
            "4-6 years",
            "6 years of",
            "12 months since"
        ]
    },
    {
        "id": "45d4f78f-04d4-434c-9679-fd92291e97b6",
        "primaryId": "NCT00553410",
        "statement_text": "A 55 year old postmenopausal patient with sarcoidosis would be excluded from the primary trial as it would prevent prevent prolonged follow-up ",
        "statement_nums": [
            "55 year old"
        ],
        "label": "Entailment",
        "premise_text": "Neoadjuvant chemotherapyNeoadjuvant endocrine therapy Adjuvant chemotherapy Trastuzumab (Herceptin®) Ovarian ablation Gonadotropin releasing hormone analogues Lapatinib ditosylate No concurrent hormone-replacement therapy  bisphosphonates (except for treatment of bone loss)  or any other investigational agent ",
        "premise_nums": []
    },
    {
        "id": "5338f894-aecb-4678-bb67-fe058653e12b",
        "primaryId": "NCT01365845",
        "statement_text": "Less than a quarter of participants in the primary trial had radiation dermatitis ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Radiation dermatitis 2 [1]4/18 (22.22%) ",
        "premise_nums": [
            "4/18 (22.22%)"
        ]
    },
    {
        "id": "2cebae78-f4a3-4e09-ac54-cd2388670274",
        "primaryId": "NCT01953003",
        "statement_text": "Patients receiving intervention 1 of the primary trial  will be administered medication topically and intraveinously ",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "INTERVENTION 1: Arm A : iv Vinflunine Plus Capecitabine Vinflunine dose 280 mg/m² on day 1 of each cycle every 3 weeks  Capecitabine 825 mg/m² twice daily orally for 14 consecutive days beginning on day 1 of each cycle followed by 1 week of rest  vinflunine: intraveinous administration day 1 once every 3 weeks  280 mg/m² Capecitabine: Arm A : 1650 mg/m² Arm B : 2500 mg/m² INTERVENTION 2: Arm B : Capecitabine 1250 mg/m² twice daily orally for 14 consecutive days beginning on day 1 of each cycle followed by 1 week of rest Capecitabine: Arm A : 1650 mg/m² Arm B : 2500 mg/m² ",
        "premise_nums": [
            "1 once every",
            "1 week of",
            "1 of each",
            "825 mg/m²",
            "2500 mg/m²",
            "14 consecutive days",
            "1650 mg/m²",
            "1250 mg/m²",
            "280 mg/m²"
        ]
    },
    {
        "id": "d8a98ace-009c-47e4-a812-3bc0df91ed2b",
        "primaryId": "NCT01516736",
        "secondaryId": "NCT00733408",
        "label": "Entailment",
        "statement_text": "the primary trial and the secondary trial have non comparable results as the metrics they records are completely different ",
        "statement_nums": [],
        "premise_text": "Outcome Measurement: Mean Duration of Severe Neutropenia (DSN) During Cycle 1 of Chemotherapy Mean duration of severe neutropenia  defined as number of consecutive days with ANC smaller than 0.5 × 10^9/l (grade 4 neutropenia)  Time frame: 21 days (Cycle 1 of chemotherapy treatment) Outcome Measurement: Progression-free Survival (PFS) ",
        "premise_nums": [
            "1 of Chemotherapy",
            "1 of chemotherapy",
            "21 days (Cycle"
        ]
    },
    {
        "id": "d8a98ace-009c-47e4-a812-3bc0df91ed2b",
        "primaryId": "NCT01516736",
        "secondaryId": "NCT00733408",
        "label": "Entailment",
        "statement_text": "the primary trial and the secondary trial have non comparable results as the metrics they records are completely different ",
        "statement_nums": [],
        "premise_text": "Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions  or a measurable increase in a non-target lesion  or the appearance of new lesions  Kaplan-Meier survival curves will be used  A 95% confidence interval for the median PFS will be calculated  A lower bound greater than 8 months would be strong evidence that Nab-Paclitaxel- bevacizumab induction therapy followed by bevacizumab-erlotinib hydrochloride maintenance therapy is superior to paclitaxel and bevacizumab  However  a median PFS of 13 months or greater (regardless of whether the 95% confidence interval for the median extends below 8 months) could also indicate promising results ",
        "premise_nums": [
            "95% confidence",
            "8 months would",
            "13 months or",
            "20% increase"
        ]
    },
    {
        "id": "d8a98ace-009c-47e4-a812-3bc0df91ed2b",
        "primaryId": "NCT01516736",
        "secondaryId": "NCT00733408",
        "label": "Entailment",
        "statement_text": "the primary trial and the secondary trial have non comparable results as the metrics they records are completely different ",
        "statement_nums": [],
        "premise_text": "Time frame: Time from date of registration to date of first documentation of progression or symptomatic deterioration or death due to any cause  assessed up to 8 years",
        "premise_nums": []
    },
    {
        "id": "c8cfd67e-5fac-4bff-9296-6e42dcb09f80",
        "primaryId": "NCT00300781",
        "statement_text": "Participants of the primary trial are assigned an intervention depending on their hormone recpetor status ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "INTERVENTION 1: Neratinib 240, Prior Trastuzumab Neratinib: 80mg capsules and 40mg coated tablets taken orally in prescribed dose of 240mg daily  as long as tolerated and disease does not worsen in participants with prior trastuzumab treatment  INTERVENTION 2: Neratinib 240, No Prior Trastuzumab Neratinib: 80mg capsules and 40mg coated tablets taken orally in prescribed dose of 240mg daily  as long as tolerated and disease does not worsen in participants with no prior trastuzumab treatment  ",
        "premise_nums": []
    },
    {
        "id": "57cf3760-1692-439f-bbe2-82a6bc8862ce",
        "primaryId": "NCT01376349",
        "secondaryId": "NCT01912612",
        "label": "Entailment",
        "statement_text": "Cohort 2 subjects of the primary trial receive 3.25 mg of vaginal DHEA gel QD more than cohort 1 subjects  of the two cohorts in the secondary trial only cohort 1 recieves Duloxetine 30 mg daily ",
        "statement_nums": [
            "1 recieves Duloxetine",
            "2 subjects of",
            "30 mg daily",
            "receive 3.25 mg of"
        ],
        "premise_text": "INTERVENTION 1: Arm I Low Dose DHEA Participants apply a low dose (3.25 mg) of vaginal prasterone (dehydroepiandrosterone [DHEA]) gel once daily (QD)  at bed time  for 12 weeks  Treatment continues until unacceptable adverse events or patient refusal to continue participation on the study  INTERVENTION 2: Arm II High Dose DHEA Participants apply a high dose (6.5 mg) of vaginal DHEA gel QD  at bed time  for 12 weeks  Treatment continues until unacceptable adverse events or patient refusal to continue participation on the study  INTERVENTION 1: Arm 1 (Patients With Pain) ",
        "premise_nums": []
    },
    {
        "id": "57cf3760-1692-439f-bbe2-82a6bc8862ce",
        "primaryId": "NCT01376349",
        "secondaryId": "NCT01912612",
        "label": "Entailment",
        "statement_text": "Cohort 2 subjects of the primary trial receive 3.25 mg of vaginal DHEA gel QD more than cohort 1 subjects  of the two cohorts in the secondary trial only cohort 1 recieves Duloxetine 30 mg daily ",
        "statement_nums": [
            "1 recieves Duloxetine",
            "2 subjects of",
            "30 mg daily",
            "receive 3.25 mg of"
        ],
        "premise_text": "Duloxetine 30 mg daily x 1 week  then 60 mg daily x 4 weeks  then 30 mg daily x 2 weeks Duloxetine: Subjects will receive 30 mg duloxetine orally for 7 days  then 60 mg duloxetine orally for 28 days  then 30 mg duloxetine orally x 14 days  INTERVENTION 2: Arm 2 (Patients Without Pain -- Control) Patient reported pain and symptoms assessment for comparison at baseline  ",
        "premise_nums": [
            "2 weeks Duloxetine:",
            "30 mg daily",
            "60 mg daily",
            "60 mg duloxetine",
            "30 mg duloxetine"
        ]
    },
    {
        "id": "7db1447c-b4e8-49c6-a125-8161bcd98560",
        "primaryId": "NCT00364611",
        "statement_text": "Patients with wounds that havent healed within five to eight weeks are ineligible for the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Presence of any non-healing wound  fracture  or ulcer  or the presence of clinically significant (greater than /= Grade 2) peripheral vascular disease ",
        "premise_nums": []
    },
    {
        "id": "626a05e9-2caf-4e73-a132-5432a5b2c7d9",
        "primaryId": "NCT00550771",
        "secondaryId": "NCT00143390",
        "label": "Contradiction",
        "statement_text": "over 20% of patients in the primary trial and the secondary trial Experienced myocardial infarction or arrhythmia  with the majority of those coming from the secondary trial ",
        "statement_nums": [
            "20% of"
        ],
        "premise_text": "Outcome Measurement: Number of Participants Who Experienced Cardiac Events (Level 1 or 2), or Inability to Administer Trastuzumab Either During the 8 Cycles of Chemotherapy or According to Package Insert for a Total Duration of 1 Year Cardiac events defined as: Level 1: Cardiac death due to heart failure (HF)  myocardial infarction or arrhythmia  or probable cardiac death defined as sudden  unexpected death within 24 hours of a definite or probable cardiac event  or severe symptomatic HF  concomitant with a left ventricular ejection fraction (LVEF) drop of greater than 10 percentage points from baseline and to 50% LVEF ",
        "premise_nums": [
            "8 Cycles of",
            "10 percentage points",
            "50% LVEF",
            "1 Year Cardiac",
            "1 or 2),",
            "24 hours of"
        ]
    },
    {
        "id": "626a05e9-2caf-4e73-a132-5432a5b2c7d9",
        "primaryId": "NCT00550771",
        "secondaryId": "NCT00143390",
        "label": "Contradiction",
        "statement_text": "over 20% of patients in the primary trial and the secondary trial Experienced myocardial infarction or arrhythmia  with the majority of those coming from the secondary trial ",
        "statement_nums": [
            "20% of"
        ],
        "premise_text": "Level 2: Asymptomatic systolic dysfunction or mildly symptomatic HF concomitant with an LVEF drop of greater than 10 percentage points from baseline and to smaller than 50% LVEF; the LVEF drop was to have been confirmed within 3-4 weeks Time frame: 8 cycles of chemotherapy and subsequently one year of planned trastuzumab treatment Results 1: Arm/Group Title: Pegylated Liposomal Doxorubicin (PLD) Based Regimen ",
        "premise_nums": [
            "8 cycles of",
            "4 weeks Time",
            "10 percentage points",
            "50% LVEF",
            "3-4 weeks"
        ]
    },
    {
        "id": "626a05e9-2caf-4e73-a132-5432a5b2c7d9",
        "primaryId": "NCT00550771",
        "secondaryId": "NCT00143390",
        "label": "Contradiction",
        "statement_text": "over 20% of patients in the primary trial and the secondary trial Experienced myocardial infarction or arrhythmia  with the majority of those coming from the secondary trial ",
        "statement_nums": [
            "20% of"
        ],
        "premise_text": "Arm/Group Description: PLD 35 mg/m^2 IV over 60 minutes + cyclophosphamide 600 mg/m^2 IV over 30-90 minutes given every 21 days + trastuzumab 2 mg/kg IV over 30 minutes (first dose 4 mg/kg IV over 90 minutes) given once weekly for 4 courses (12 weeks) followed by Paclitaxel 80 mg/m^2 IV over 60 minutes with trastuzumab 2 mg/kg IV over 30 minutes given weekly for 12 weeks (4 courses)Overall Number of Participants Analyzed: 120 Measure Type: Number Unit of Measure: Participants 5 Results 2: Arm/Group Title: Doxorubicin Based Regimen ",
        "premise_nums": [
            "80 mg/m^2",
            "2 IV over",
            "4 courses (12",
            "30 minutes (first",
            "120 Measure Type:",
            "600 mg/m^2",
            "30-90 minutes",
            "4 mg/kg IV",
            "5 Results 2:",
            "12 weeks (4",
            "35 mg/m^2",
            "60 minutes with",
            "90 minutes given",
            "30 minutes given",
            "2 mg/kg IV"
        ]
    },
    {
        "id": "626a05e9-2caf-4e73-a132-5432a5b2c7d9",
        "primaryId": "NCT00550771",
        "secondaryId": "NCT00143390",
        "label": "Contradiction",
        "statement_text": "over 20% of patients in the primary trial and the secondary trial Experienced myocardial infarction or arrhythmia  with the majority of those coming from the secondary trial ",
        "statement_nums": [
            "20% of"
        ],
        "premise_text": "Arm/Group Description: doxorubicin 60 mg/m^2 intravenous (IV) push + cyclophosphamide 600 mg/m^2 IV over 30-90 minutes given every 21 days for 4 courses (12 weeks) followed by Paclitaxel 80 mg/m^2 IV over 60 minutes with trastuzumab 2 mg/kg IV over 30 minutes (first administration 4 mg/kg IV over 90 minutes) given weekly for 12 weeks (4 courses)Overall Number of Participants Analyzed: 59 Measure Type: Number Unit of Measure: Participants 11 Outcome Measurement: Time to Progression (TTP) - Expert Evaluation Committee Assessment ",
        "premise_nums": [
            "60 mg/m^2",
            "80 mg/m^2",
            "2 IV over",
            "4 courses (12",
            "30 minutes (first",
            "600 mg/m^2",
            "30-90 minutes",
            "4 mg/kg IV",
            "59 Measure Type:",
            "12 weeks (4",
            "2 intravenous (IV)",
            "21 days for",
            "60 minutes with",
            "90 minutes given",
            "2 mg/kg IV",
            "11 Outcome Measurement:"
        ]
    },
    {
        "id": "626a05e9-2caf-4e73-a132-5432a5b2c7d9",
        "primaryId": "NCT00550771",
        "secondaryId": "NCT00143390",
        "label": "Contradiction",
        "statement_text": "over 20% of patients in the primary trial and the secondary trial Experienced myocardial infarction or arrhythmia  with the majority of those coming from the secondary trial ",
        "statement_nums": [
            "20% of"
        ],
        "premise_text": "Time in months from randomization to first documentation of objective tumor progression or death due to breast cancer  whichever comes first  Tumor progression was determined by the expert evaluation committee using RECIST version 1.0 as an at least a 20% increase in the sum of the longest diameters (SLD) of the target lesions compared to the smallest SLD since the study treatment started  For participants with bone metastasis only  at least 25% increase in the measurable lesion according to General Rules for Clinical and Pathological Study of Breast Cancer (The 14th edition) Time frame: Up to 2008 days of the treatment Results 1: Arm/Group Title: Exemestane ",
        "premise_nums": [
            "2008 days of",
            "25% increase",
            "version 1.0 as an",
            "20% increase"
        ]
    },
    {
        "id": "626a05e9-2caf-4e73-a132-5432a5b2c7d9",
        "primaryId": "NCT00550771",
        "secondaryId": "NCT00143390",
        "label": "Contradiction",
        "statement_text": "over 20% of patients in the primary trial and the secondary trial Experienced myocardial infarction or arrhythmia  with the majority of those coming from the secondary trial ",
        "statement_nums": [
            "20% of"
        ],
        "premise_text": "Arm/Group Description: One tablet each of exemestane 25 mg and anastrozole placebo were orally administered once daily after a meal  The study treatment was continued until the disease progression or other discontinuation criteria were met Overall Number of Participants Analyzed: 147 Median (95% Confidence Interval) Unit of Measure: months 13.8 (10.8 to 16.5) Results 2: Arm/Group Title: Anastrozole Arm/Group Description: One tablet each of anastrozole 1 mg and exemestane placebo were orally administered once daily after a meal  The study treatment was continued until the disease progression or other discontinuation criteria were met  Overall Number of Participants Analyzed: 145 Median (95% Confidence Interval) ",
        "premise_nums": [
            "25 mg and",
            "95% Confidence",
            "8 to 16.5)",
            "1 mg and"
        ]
    },
    {
        "id": "626a05e9-2caf-4e73-a132-5432a5b2c7d9",
        "primaryId": "NCT00550771",
        "secondaryId": "NCT00143390",
        "label": "Contradiction",
        "statement_text": "over 20% of patients in the primary trial and the secondary trial Experienced myocardial infarction or arrhythmia  with the majority of those coming from the secondary trial ",
        "statement_nums": [
            "20% of"
        ],
        "premise_text": "Unit of Measure: months 11.1 (10.8 to 16.6)",
        "premise_nums": []
    },
    {
        "id": "fe6f3faf-8be6-4ec6-8622-b4d36e8c2876",
        "primaryId": "NCT00066573",
        "secondaryId": "NCT01091454",
        "label": "Contradiction",
        "statement_text": "There were 0 cases of night blindness in the primary trial  and 1 in the secondary trial ",
        "statement_nums": [
            "1 in the",
            "0 cases of"
        ],
        "premise_text": "Adverse Events 1: Total: 19/3761 (0.51%) Cardiac ischemia/infarction 3/3761 (0.08%) Left ventricular systolic dysfunction 1/3761 (0.03%) Restrictive cardiomyopathy 1/3761 (0.03%) Supraven.arrhyth  Atrial flutter 1/3761 (0.03%) Ventric.arrhyth  Trigeminy 1/3761 (0.03%) Hypothyroidism 0/3761 (0.00%) Blurred vision 1/3761 (0.03%) Nyctalopia 0/3761 (0.00%) ",
        "premise_nums": [
            "19/3761 (0.51%)",
            "3/3761 (0.08%)",
            "0/3761 (0.00%)",
            "1/3761 (0.03%)"
        ]
    },
    {
        "id": "fe6f3faf-8be6-4ec6-8622-b4d36e8c2876",
        "primaryId": "NCT00066573",
        "secondaryId": "NCT01091454",
        "label": "Contradiction",
        "statement_text": "There were 0 cases of night blindness in the primary trial  and 1 in the secondary trial ",
        "statement_nums": [
            "1 in the",
            "0 cases of"
        ],
        "premise_text": "Ocular - Other 1/3761 (0.03%)Adverse Events 2: Total: 7/3759 (0.19%) Cardiac ischemia/infarction 0/3759 (0.00%) Left ventricular systolic dysfunction 0/3759 (0.00%) Restrictive cardiomyopathy 0/3759 (0.00%) Supraven.arrhyth  Atrial flutter 0/3759 (0.00%) Ventric.arrhyth  Trigeminy 0/3759 (0.00%) Hypothyroidism 1/3759 (0.03%) Blurred vision 0/3759 (0.00%) Nyctalopia 1/3759 (0.03%) ",
        "premise_nums": [
            "1/3759 (0.03%)",
            "0/3759 (0.00%)",
            "1/3761 (0.03%)Adverse",
            "7/3759 (0.19%)"
        ]
    },
    {
        "id": "fe6f3faf-8be6-4ec6-8622-b4d36e8c2876",
        "primaryId": "NCT00066573",
        "secondaryId": "NCT01091454",
        "label": "Contradiction",
        "statement_text": "There were 0 cases of night blindness in the primary trial  and 1 in the secondary trial ",
        "statement_nums": [
            "1 in the",
            "0 cases of"
        ],
        "premise_text": "Ocular - Other 0/3759 (0.00%)Adverse Events 1: Total: 29/48 (60.42%) Anemia 4/48 (8.33%) Febrile neutropenia 7/48 (14.58%) Atrial fibrillation 1/48 (2.08%) Pericardial effusion 1/48 (2.08%) Sinus bradycardia 1/48 (2.08%) Nausea 2/48 (4.17%) Vomiting 2/48 (4.17%) Death NOS 1/48 (2.08%) Fatigue 3/48 (6.25%) Allergic reaction 1/48 (2.08%) Lung infection 1/48 (2.08%) ",
        "premise_nums": [
            "29/48 (60.42%)",
            "7/48 (14.58%)",
            "3/48 (6.25%)",
            "4/48 (8.33%)",
            "2/48 (4.17%)",
            "1/48 (2.08%)",
            "0/3759 (0.00%)Adverse"
        ]
    },
    {
        "id": "fe6f3faf-8be6-4ec6-8622-b4d36e8c2876",
        "primaryId": "NCT00066573",
        "secondaryId": "NCT01091454",
        "label": "Contradiction",
        "statement_text": "There were 0 cases of night blindness in the primary trial  and 1 in the secondary trial ",
        "statement_nums": [
            "1 in the",
            "0 cases of"
        ],
        "premise_text": "Mucosal infection 1/48 (2.08%)",
        "premise_nums": [
            "1/48 (2.08%)"
        ]
    },
    {
        "id": "b1cd4818-9623-45e5-a2b3-4c80016e3c82",
        "primaryId": "NCT00186121",
        "statement_text": "Patients with E2 outside the premenopausal range are ineligible for the primary trial ",
        "statement_nums": [
            "2 outside the"
        ],
        "label": "Contradiction",
        "premise_text": "If tamoxifen administered within the past 3 months  plasma estradiol must be in the premenopausal range ",
        "premise_nums": []
    },
    {
        "id": "3050bca2-a8bc-412e-b679-5be1055e3749",
        "primaryId": "NCT03061175",
        "secondaryId": "NCT03098550",
        "label": "Contradiction",
        "statement_text": "Cohort 1 of the secondary trial does not receive the same doses of Daratumumab for the entire duration of the study  whereas Cohort 1 of the primary trial recieves a consistent dose of Daratumumab for the full study ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "INTERVENTION 1: Arm I (Web-Based CPM-DA) Patients receive a website address  a secure username and password  and instructions for using the web-based CPM-DA  Internet-Based Intervention: Receive web-based CPM-DA Survey Administration: Ancillary studies INTERVENTION 1: Nivolumab + Daratumumab (TNBC) ",
        "premise_nums": []
    },
    {
        "id": "3050bca2-a8bc-412e-b679-5be1055e3749",
        "primaryId": "NCT03061175",
        "secondaryId": "NCT03098550",
        "label": "Contradiction",
        "statement_text": "Cohort 1 of the secondary trial does not receive the same doses of Daratumumab for the entire duration of the study  whereas Cohort 1 of the primary trial recieves a consistent dose of Daratumumab for the full study ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Triple-negative breast cancer (TNBC) treated with Triple-negative breast cancer (TNBC) treated with Nivolumab IV 240 mg Q2W (weeks 3 to 24) + Daratumumab IV 16 mg/kg Q1W (weeks 1 to 8), Daratumumab IV 16 mg/kg Q2W (weeks 9-24)",
        "premise_nums": [
            "1 to 8),",
            "16 mg/kg Q",
            "3 to 24)",
            "240 mg Q2W"
        ]
    },
    {
        "id": "a49666fd-f278-4dcf-b6bf-287ace3969aa",
        "primaryId": "NCT02001974",
        "statement_text": "No cases of Metastasis to the CNS were recorded in the primary trial ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 2/4 (50.00%) Abdominal pain 0/4 (0.00%) Disease progression 0/4 (0.00%) Dehydration 2/4 (50.00%) Hyponatraemia 1/4 (25.00%) Metastasis to central nervous system 1/4 (25.00%) Oesophageal adenocarcinoma 0/4 (0.00%) Intracranial hypotension 0/4 (0.00%) Pneumothorax 0/4 (0.00%) Dyspnoea 0/4 (0.00%) Hypoxia 0/4 (0.00%) Adverse Events 2: Total: 1/3 (33.33%) ",
        "premise_nums": [
            "0/4 (0.00%)",
            "2/4 (50.00%)",
            "1/4 (25.00%)",
            "1/3 (33.33%)"
        ]
    },
    {
        "id": "a49666fd-f278-4dcf-b6bf-287ace3969aa",
        "primaryId": "NCT02001974",
        "statement_text": "No cases of Metastasis to the CNS were recorded in the primary trial ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Abdominal pain 0/3 (0.00%)Disease progression 0/3 (0.00%) Dehydration 0/3 (0.00%) Hyponatraemia 0/3 (0.00%) Metastasis to central nervous system 0/3 (0.00%) Oesophageal adenocarcinoma 0/3 (0.00%) Intracranial hypotension 0/3 (0.00%) Pneumothorax 1/3 (33.33%) Dyspnoea 0/3 (0.00%) Hypoxia 0/3 (0.00%) ",
        "premise_nums": [
            "0/3 (0.00%)Disease",
            "1/3 (33.33%)"
        ]
    },
    {
        "id": "f6c014af-63db-4578-9b2d-74ea95901842",
        "primaryId": "NCT00445458",
        "secondaryId": "NCT00950742",
        "label": "Contradiction",
        "statement_text": "the primary trial and the secondary trial measure the DLT of their respective interventions  using the same time frame and the same unit of measure ",
        "statement_nums": [],
        "premise_text": "Outcome Measurement: Dose Limiting Toxicity Incidence of Neratinib in Combination With Paclitaxel Dose Limiting Toxicity in subjects with solid tumors treated with neratinib  administered daily  in combination with paclitaxel 80 mg/m² IV on days 1, 8, and 15 of a 28 day cycle  Time frame: From first dose date through day 28 Outcome Measurement: Number of Participants With Dose Limiting Toxicities (DLT) Number of participants with DLT in the first cycle (28 days) for the determination of the maximum tolerated dose (MTD)  Important Limitations and Caveats are provided in the respective section  Time frame: 28 days ",
        "premise_nums": [
            "28 Outcome Measurement:",
            "80 mg/m²",
            "28 day cycle",
            "15 of a"
        ]
    },
    {
        "id": "c8ef1457-63a9-4eac-a98b-edb805afd35b",
        "primaryId": "NCT02660788",
        "secondaryId": "NCT01490892",
        "label": "Contradiction",
        "statement_text": "the primary trial is investigating different ways to communicate with women aged 51-73 years old   whereas the secondary trial is evaluating the impact of regular exercise and dieting ",
        "statement_nums": [
            "73 years old",
            "51-73 years"
        ],
        "premise_text": "INTERVENTION 1: Control Arm Mail Standard Reminder Postcard INTERVENTION 2: Family Physician Reminder Letter Arm Mail Standard Reminder Postcard Family Physician Reminder Letter INTERVENTION 1: 3D HI and SHI of UCA Perflutren injection  suspension (IV)0.25 ml followed by 3D Harmonic imaging (HI) then (IV) 20 micro-l/kg followed by 3D subharmonic imaging (SHI) 3D HI and SHI of UCA: Perflutren injection  suspension (IV)0.25 ml followed by 3D Harmonic imaging (HI) then (IV) 20 micro-l/kg followed by 3D subharmonic imaging (SHI) ",
        "premise_nums": [
            "25 ml followed",
            "20 micro-l/kg"
        ]
    },
    {
        "id": "515d0710-429b-4c28-b881-8a6531ee973e",
        "primaryId": "NCT03097653",
        "secondaryId": "NCT00662129",
        "label": "Entailment",
        "statement_text": "Females aged between 18-25 with Bone lesions or Leptomeningeal disease cannot be included in either the secondary trial or the primary trial ",
        "statement_nums": [
            "25 with Bone",
            "18-25 with"
        ],
        "premise_text": "Inclusion Criteria: Women aged 45-69, according to the target age of the screening centres involved; New invited women in mammography screening programme  Exclusion Criteria: None No non-measurable disease only  defined as all other lesions  including small lesions (longest diameter smaller than 2 cm) and truly non-measurable lesions  including any of the following: Bone lesions Leptomeningeal disease ",
        "premise_nums": [
            "45-69, according"
        ]
    },
    {
        "id": "b4d261a4-9b42-4158-9b21-159859b59e2a",
        "primaryId": "NCT02104895",
        "statement_text": "Neither cohorts of the primary trial receive any medication orally or by IV ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "INTERVENTION 1: Whole Breast Irradiation (WBI) Conventional whole breast irradiation (WBI) Whole breast irradiation (WBI): Conventional whole breast irradiation (WBI) INTERVENTION 2: Partial Breast Irradiation (APBI) Accelerated partial breast irradiation (APBI) Accelerated partial breast irradiation (APBI): Accelerated partial breast irradiation (APBI) using intensity modulated radiotherapy (IMRT) ",
        "premise_nums": []
    },
    {
        "id": "1c043d17-15a9-496c-a69b-9ec95a7ab8df",
        "primaryId": "NCT00293540",
        "statement_text": "Males are not eligible for the primary trial  because they do not produce oestrogen ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria: Estrogen receptor or progesterone receptor positive breast cancer Premenopausal with regular menstrual cycles Exclusion Criteria: Current oral contraceptives ",
        "premise_nums": []
    },
    {
        "id": "79c69498-7dd5-41fa-8946-36d452a5b9ec",
        "primaryId": "NCT00328783",
        "statement_text": "Patients with a COPD diagnosis through spirometry are ineligible for the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Inclusion Criteria: Adequate pulmonary function ",
        "premise_nums": []
    },
    {
        "id": "93fc76a9-5f3d-490b-8802-21d0fa806728",
        "primaryId": "NCT00633464",
        "statement_text": "Cohort 2 of the primary trial reported worse results than cohort 1.",
        "statement_nums": [
            "2 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Percentage of Participants With Objective Response (OR; Using Response Evaluation Criteria in Solid Tumors [RECIST]) The participant had an OR if her best overall response (BOR) during the study was either a complete response (CR) or a partial response (PR) according to the RECIST as determined by the investigator  CR: Disappearance of all evidence of target and non-target lesions  PR: At least 30% reduction from baseline in the sum of the longest diameter (LD) of all target lesions  Confidence interval (CI) was Computed using Clopper-Pearson method  Time frame: Assessed every 6 weeks for first 12 months from randomization thereafter every 3 months until disease progression (maximum participant objective response of 18.3 weeks) Results 1: Arm/Group Title: Ixabepilone 40 mg/m^2 ",
        "premise_nums": [
            "3 months until",
            "6 weeks for",
            "40 mg/m^2",
            "12 months from",
            "30% reduction"
        ]
    },
    {
        "id": "93fc76a9-5f3d-490b-8802-21d0fa806728",
        "primaryId": "NCT00633464",
        "statement_text": "Cohort 2 of the primary trial reported worse results than cohort 1.",
        "statement_nums": [
            "2 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Arm/Group Description: ixabepilone 40 mg/m^2 every 3 weeksOverall Number of Participants Analyzed: 40 Measure Type: Number Unit of Measure: percentage of participants 30.0 (16.6 to 46.5) Results 2: Arm/Group Title: Cetuximab 250 mg/m^2 + Ixabepilone 40 mg/m^2 Arm/Group Description: cetuximab 400 mg/m^2 loading dose then 250 mg/m^2 weekly + ixabepilone 40 mg/m^2 every 3 weeks Overall Number of Participants Analyzed: 39 Measure Type: Number Unit of Measure: percentage of participants 35.9 (21.2 to 52.8) ",
        "premise_nums": [
            "400 mg/m^2",
            "3 weeks Overall",
            "250 mg/m^2",
            "2 every 3",
            "40 Measure Type:",
            "40 mg/m^2",
            "39 Measure Type:",
            "3 weeksOverall Number",
            "2 to 52.8)",
            "6 to 46.5)",
            "2 loading dose"
        ]
    },
    {
        "id": "9f5e55af-8a94-4531-ab00-f16199795b64",
        "primaryId": "NCT02104895",
        "statement_text": "Neither cohorts of the primary trial receive any medication orally  by IV or by radiation ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "INTERVENTION 1: Whole Breast Irradiation (WBI) Conventional whole breast irradiation (WBI) Whole breast irradiation (WBI): Conventional whole breast irradiation (WBI) INTERVENTION 2: Partial Breast Irradiation (APBI) Accelerated partial breast irradiation (APBI) Accelerated partial breast irradiation (APBI): Accelerated partial breast irradiation (APBI) using intensity modulated radiotherapy (IMRT) ",
        "premise_nums": []
    },
    {
        "id": "ee85e355-3d0a-4e40-8a8d-6a0b71c77148",
        "primaryId": "NCT00945061",
        "statement_text": "patients with Multicentric breast cancer can be accepted for the primary trial ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria: Unifocal breast cancer recurrence ",
        "premise_nums": []
    },
    {
        "id": "c4a2ca0b-c4a7-4366-92c7-145dadd38af3",
        "primaryId": "NCT00629499",
        "statement_text": "Patients with peripheral neuropathy resulting in intolerable paresthesias  are excluded from the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Inclusion Criteria: Pre-existing peripheral neuropathy must be less than or equal to grade 1 by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v3.0 criteria  ",
        "premise_nums": [
            "1 by National",
            "v3.0 criteria"
        ]
    },
    {
        "id": "c6ca8c6a-7eae-4671-9eff-c44a1222fadb",
        "primaryId": "NCT00399529",
        "statement_text": "Women with rheumatoid arthritis that does not require systemic corticosteroids for treatement  are eligible for the primary trial ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "No prior or currently active autoimmune disease requiring management with systemic immunosuppression  This includes inflammatory bowel disease  systemic vasculitis  scleroderma  psoriasis  multiple sclerosis  hemolytic anemia or immune-mediated thrombocytopenia  rheumatoid arthritis  systemic lupus erythematosus  Sjogren's syndrome  sarcoidosis  or other rheumatologic disease  Asthma or chronic obstructive pulmonary disease that does not require daily systemic corticosteroids is acceptable  ",
        "premise_nums": []
    },
    {
        "id": "e591b3bb-0628-46e7-9d60-28989fd6a3d0",
        "primaryId": "NCT01674062",
        "statement_text": "One patient in the primary trial was observed vomiting blood ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Haematemesis * 1/66 (1.52%) ",
        "premise_nums": [
            "1/66 (1.52%)"
        ]
    },
    {
        "id": "75da6329-e8a1-4808-bb0f-78fd3a2dde9c",
        "primaryId": "NCT00463788",
        "statement_text": "Best Overall Response (BOR) was 10.3% higher in cohort 1 of the primary trial than in cohort 2.",
        "statement_nums": [
            "was 10.3% higher in",
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Best Overall Response (BOR) Percentage of participants with best overall (objective) response based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST)  Time frame: Evaluations were performed every 6 weeks until progression reported between day of first participant randomized  20 June 2007, until cut-off date  31 July 2009 Results 1: Arm/Group Title: Cisplatin and Cetuximab ",
        "premise_nums": [
            "6 weeks until",
            "31 July 2009",
            "20 June 2007,"
        ]
    },
    {
        "id": "75da6329-e8a1-4808-bb0f-78fd3a2dde9c",
        "primaryId": "NCT00463788",
        "statement_text": "Best Overall Response (BOR) was 10.3% higher in cohort 1 of the primary trial than in cohort 2.",
        "statement_nums": [
            "was 10.3% higher in",
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Arm/Group Description: Cisplatin 75 milligram per square meter (mg/m^2) intravenous (IV) infusion administered on Day 1 until every 3 weeks with a maximum of 6 cycles and cetuximab initially 400 mg/m^2 followed by 250 mg/m^2 IV infusion weekly  Participants who demonstrated at least stable disease (SD) up to 6 cycles of cisplatin continued treatment with cetuximab only until progressive disease (PD) or occurrence of unacceptable toxicity Overall Number of Participants Analyzed: 115 Measure Type: Number Unit of Measure: percentage of participants 20.0 (13.1 to 28.5) Results 2: Arm/Group Title: Cisplatin ",
        "premise_nums": [
            "3 weeks with",
            "1 until every",
            "2 IV infusion",
            "400 mg/m^2",
            "250 mg/m^2",
            "6 cycles of",
            "6 cycles and",
            "1 to 28.5)",
            "75 milligram per",
            "2 followed by",
            "115 Measure Type:"
        ]
    },
    {
        "id": "75da6329-e8a1-4808-bb0f-78fd3a2dde9c",
        "primaryId": "NCT00463788",
        "statement_text": "Best Overall Response (BOR) was 10.3% higher in cohort 1 of the primary trial than in cohort 2.",
        "statement_nums": [
            "was 10.3% higher in",
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Arm/Group Description: Cisplatin 75 mg/m^2 IV infusion administered on Day 1 until every 3 weeks with a maximum of 6 cycles until the first occurrence of PD  unacceptable toxicity or withdrawal of consent Overall Number of Participants Analyzed: 58 Measure Type: Number Unit of Measure: percentage of participants 10.3 (3.9 to 21.2) ",
        "premise_nums": [
            "3 weeks with",
            "1 until every",
            "6 cycles until",
            "2 IV infusion",
            "58 Measure Type:",
            "9 to 21.2)",
            "75 mg/m^2"
        ]
    },
    {
        "id": "dab9d582-eaf3-443f-bdb9-073aec304ee6",
        "primaryId": "NCT01629615",
        "secondaryId": "NCT00320541",
        "label": "Entailment",
        "statement_text": "the secondary trial recorded more cardiac related adverse events than the primary trial ",
        "statement_nums": [],
        "premise_text": "Adverse Events 1: Total: 17/50 (34.00%) Fatigue 4/50 (8.00%) Papulopustular rash 1/50 (2.00%) Alanine aminotransferase increased 5/50 (10.00%) Aspartate aminotransferase increased 4/50 (8.00%) Alkalosis 1/50 (2.00%) Anorexia 1/50 (2.00%) Hyperglycemia 2/50 (4.00%) Nervous system disorders - Other 1/50 (2.00%) Dry skin 1/50 (2.00%) Rash acneiform 1/50 (2.00%) Adverse Events 1: Total: 27/94 (28.72%) Anaemia 2/94 (2.13%) ",
        "premise_nums": [
            "4/50 (8.00%)",
            "27/94 (28.72%)",
            "1/50 (2.00%)",
            "5/50 (10.00%)",
            "2/94 (2.13%)",
            "17/50 (34.00%)",
            "2/50 (4.00%)"
        ]
    },
    {
        "id": "dab9d582-eaf3-443f-bdb9-073aec304ee6",
        "primaryId": "NCT01629615",
        "secondaryId": "NCT00320541",
        "label": "Entailment",
        "statement_text": "the secondary trial recorded more cardiac related adverse events than the primary trial ",
        "statement_nums": [],
        "premise_text": "Febrile neutropenia 2/94 (2.13%)Leukopenia 1/94 (1.06%) Neutropenia 0/94 (0.00%) Thrombocytopenia 1/94 (1.06%) Arrhythmia 0/94 (0.00%) Atrial fibrillation 0/94 (0.00%) Cardiac failure congestive 0/94 (0.00%) Cardiomyopathy 0/94 (0.00%) Pericardial effusion 0/94 (0.00%) Tachycardia 0/94 (0.00%) Adverse Events 2: Total: 36/93 (38.71%) Anaemia 2/93 (2.15%) ",
        "premise_nums": [
            "1/94 (1.06%)",
            "2/94 (2.13%)Leukopenia",
            "2/93 (2.15%)",
            "36/93 (38.71%)",
            "0/94 (0.00%)"
        ]
    },
    {
        "id": "dab9d582-eaf3-443f-bdb9-073aec304ee6",
        "primaryId": "NCT01629615",
        "secondaryId": "NCT00320541",
        "label": "Entailment",
        "statement_text": "the secondary trial recorded more cardiac related adverse events than the primary trial ",
        "statement_nums": [],
        "premise_text": "Febrile neutropenia 9/93 (9.68%)Leukopenia 3/93 (3.23%) Neutropenia 4/93 (4.30%) Thrombocytopenia 1/93 (1.08%) Arrhythmia 1/93 (1.08%) Atrial fibrillation 1/93 (1.08%) Cardiac failure congestive 3/93 (3.23%) Cardiomyopathy 2/93 (2.15%) Pericardial effusion 1/93 (1.08%) Tachycardia 1/93 (1.08%) ",
        "premise_nums": [
            "9/93 (9.68%)Leukopenia",
            "1/93 (1.08%)",
            "2/93 (2.15%)",
            "3/93 (3.23%)",
            "4/93 (4.30%)"
        ]
    },
    {
        "id": "8b9bb672-1de3-4220-956c-9e86ed78063d",
        "primaryId": "NCT00265759",
        "secondaryId": "NCT00866905",
        "label": "Entailment",
        "statement_text": "One case of hematolysis was recorded in the primary trial  none in the secondary trial ",
        "statement_nums": [],
        "premise_text": "Adverse Events 1: Total: 9/157 (5.73%) Blood disorder 1/157 (0.64%) Hemoglobin decreased 1/157 (0.64%) Hemolysis 0/157 (0.00%) Arrhythmia 0/157 (0.00%) Cardiac disorder 0/157 (0.00%) Myocardial ischemia 1/157 (0.64%) Hearing impaired 0/157 (0.00%) Tinnitus 0/157 (0.00%) Cataract 0/157 (0.00%) Diplopia 0/157 (0.00%) Glaucoma 0/157 (0.00%) Vision blurred 0/157 (0.00%) Adverse Events 2: Total: 14/157 (8.92%) ",
        "premise_nums": [
            "14/157 (8.92%)",
            "1/157 (0.64%)",
            "9/157 (5.73%)",
            "0/157 (0.00%)"
        ]
    },
    {
        "id": "8b9bb672-1de3-4220-956c-9e86ed78063d",
        "primaryId": "NCT00265759",
        "secondaryId": "NCT00866905",
        "label": "Entailment",
        "statement_text": "One case of hematolysis was recorded in the primary trial  none in the secondary trial ",
        "statement_nums": [],
        "premise_text": "Blood disorder 0/157 (0.00%)Hemoglobin decreased 2/157 (1.27%) Hemolysis 1/157 (0.64%) Arrhythmia 0/157 (0.00%) Cardiac disorder 0/157 (0.00%) Myocardial ischemia 0/157 (0.00%) Hearing impaired 2/157 (1.27%) Tinnitus 1/157 (0.64%) Cataract 1/157 (0.64%) Diplopia 0/157 (0.00%) Glaucoma 1/157 (0.64%) Vision blurred 1/157 (0.64%) Adverse Events 1: Total: 6/168 (3.57%) ",
        "premise_nums": [
            "6/168 (3.57%)",
            "0/157 (0.00%)Hemoglobin",
            "2/157 (1.27%)",
            "1/157 (0.64%)"
        ]
    },
    {
        "id": "8b9bb672-1de3-4220-956c-9e86ed78063d",
        "primaryId": "NCT00265759",
        "secondaryId": "NCT00866905",
        "label": "Entailment",
        "statement_text": "One case of hematolysis was recorded in the primary trial  none in the secondary trial ",
        "statement_nums": [],
        "premise_text": "FEBRILE NEUTROPENIA 3/168 (1.79%)ENTERITIS 1/168 (0.60%) PERIPHERAL NEUROPATHY 2/168 (1.19%) DEPRESSION 1/168 (0.60%) ",
        "premise_nums": [
            "3/168 (1.79%)ENTERITIS",
            "1/168 (0.60%)",
            "2/168 (1.19%)"
        ]
    },
    {
        "id": "3194a043-d156-49d6-97bb-81867ed188f0",
        "primaryId": "NCT00712985",
        "secondaryId": "NCT02038010",
        "label": "Contradiction",
        "statement_text": "Patients in the primary trial receive a lower dose of Zometa by IV than the secondary trial patients receive of PI3K inhibitor BYL719 by IV ",
        "statement_nums": [
            "BYL719 by",
            "719 by IV"
        ],
        "premise_text": "INTERVENTION 1: Zoledronic Acid 5 mg IV Zometa (Zoledronic Acid) 5 mg IV given over 15 minutes as a one time dose  Follow-up at month 1 & every 2 months to month 12 for serum & urine markers of bone destruction (NTx & CTx)  INTERVENTION 1: Cohort -1 (250mg BYL719, 3.6mg/kg T-DM1) ",
        "premise_nums": [
            "12 for serum",
            "5 mg IV",
            "2 months to",
            "15 minutes as",
            "3.6mg/kg"
        ]
    },
    {
        "id": "3194a043-d156-49d6-97bb-81867ed188f0",
        "primaryId": "NCT00712985",
        "secondaryId": "NCT02038010",
        "label": "Contradiction",
        "statement_text": "Patients in the primary trial receive a lower dose of Zometa by IV than the secondary trial patients receive of PI3K inhibitor BYL719 by IV ",
        "statement_nums": [
            "BYL719 by",
            "719 by IV"
        ],
        "premise_text": "Patients receive 250 mg PO daily PI3K inhibitor BYL719 on days 1-21 and 3.6mg/kg IV over 30-90 minutes on day 1 ado-trastuzumab emtansine (T-DM1). Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity PI3K inhibitor BYL719: Given PO Ado-trastuzumab emtansine: Given IV Pharmacological study: Correlative studies Laboratory biomarker analysis: Optional correlative studies ",
        "premise_nums": [
            "1-21 and",
            "250 mg PO",
            "21 days in",
            "30-90 minutes",
            "1 ado-trastuzumab emtansine",
            "and 3.6mg/kg",
            "719 on days",
            "BYL719 on",
            "90 minutes on"
        ]
    },
    {
        "id": "8c3ab1eb-c473-4399-b18c-512ef16e4a47",
        "primaryId": "NCT01027416",
        "statement_text": "To be eligible for the primary trial  patients must have an invasive carcinoma confirmed by core biopsy  and a -ive human chorionic gonadotropin urine test ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Inclusion Criteria: Core biopsy should definitively demonstrate invasive carcinoma  Negative serum or urine beta-hCG pregnancy test at screening for patients of child-bearing potential (this is routinely done if the patient is premenopausal and having surgery) ",
        "premise_nums": []
    },
    {
        "id": "aeac1009-91c3-40ad-8583-5b548e1f4b3b",
        "primaryId": "NCT00902330",
        "secondaryId": "NCT00952731",
        "label": "Contradiction",
        "statement_text": "the primary trial and the secondary trial only have test cohorts in their studies ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Arm I (Cranial Microcurrent Electrical Stimulation [CES]) Patients receive a CES unit (Alpha-Stim® 100 Microcurrent Stimulator) that passes microcurrent levels of biphasic electrical stimulation via ear-lobe electrodes  The CES unit is preset to provide 1 hour of 100 μA (sub-sensory level)  modified square-wave biphasic stimulation on a 50% duty cycle at .05 Hz  and to automatically turn off at the end of 1 hour  Patients use their CES unit once daily in weeks 1-18. energy-based therapy: Given once a day for 18 weeks INTERVENTION 2: Arm II (Sham CES) ",
        "premise_nums": [
            "1 hour of",
            "100 Microcurrent Stimulator)",
            "1-18. energy-based",
            "50% duty",
            "18 weeks INTERVENTION"
        ]
    },
    {
        "id": "aeac1009-91c3-40ad-8583-5b548e1f4b3b",
        "primaryId": "NCT00902330",
        "secondaryId": "NCT00952731",
        "label": "Contradiction",
        "statement_text": "the primary trial and the secondary trial only have test cohorts in their studies ",
        "statement_nums": [],
        "premise_text": "Patients receive a CES unit as in arm I  but the ear-lobe electrodes do not pass electrical current  Patients use their CES unit once daily in weeks 1-18.sham intervention: Given once a day for 18 weeks INTERVENTION 1: Treatment Gel + Oral Placebo 4-hydroxytamoxifen gel 2mg/breast applied daily  Oral placebo taken daily  oral placebo: Oral placebo taken daily for 4-10 weeks  afimoxifene: 2mg/breast applied daily in the form of a gel for 4-10 weeks  INTERVENTION 2: Placebo Gel + Oral Treatment Placebo gel applied to the breasts daily  20mg oral tamoxifen taken daily (taken as two (2) 10mg capsules)  ",
        "premise_nums": [
            "4-hydroxytamoxifen gel",
            "2mg/breast applied",
            "1-18.sham intervention:",
            "4-10 weeks",
            "18 weeks INTERVENTION"
        ]
    },
    {
        "id": "aeac1009-91c3-40ad-8583-5b548e1f4b3b",
        "primaryId": "NCT00902330",
        "secondaryId": "NCT00952731",
        "label": "Contradiction",
        "statement_text": "the primary trial and the secondary trial only have test cohorts in their studies ",
        "statement_nums": [],
        "premise_text": "tamoxifen citrate: 20mg oral tamoxifen taken daily (taken as two (2) 10mg capsules) for 4-10 weeks placebo gel: Placebo gel applied to breasts daily for 4-10 weeks  ",
        "premise_nums": [
            "10 weeks placebo",
            "4-10 weeks"
        ]
    },
    {
        "id": "3058d104-172e-41be-b641-9f0f9cb172be",
        "primaryId": "NCT00240071",
        "statement_text": "At least one participant of the primary trial survived over 200 days without documented disease progression ",
        "statement_nums": [
            "200 days without"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Progression Free Survival (PFS) Progression free survival is defined as time from date of registration until the date of first documented disease progression or date of death from any cause  whichever occurs first  Time frame: From date of registration until disease progression or death  whichever occurs first Results 1: Arm/Group Title: Avastin (Bevacizumab) Plus Hormone Arm/Group Description: All patients received Avastin (Bevacizumab) 15 mg/kg IV every three weeks as well as continuing with hormonal therapy they previously were taking  Overall Number of Participants Analyzed: 30 Median (95% Confidence Interval) Unit of Measure: days 125.5 (90 to 256) ",
        "premise_nums": [
            "90 to 256)",
            "95% Confidence",
            "15 mg/kg IV"
        ]
    },
    {
        "id": "bc845a3d-1f69-41a3-bf84-36a62e8127a4",
        "primaryId": "NCT01439282",
        "statement_text": "In total cohort 1 of the primary trial recorded more than 10 times the number of adverse events as cohort 2.",
        "statement_nums": [
            "1 of the",
            "10 times the"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 14/67 (20.90%) Adverse Events 2: Total: 1/10 (10.00%) ",
        "premise_nums": [
            "1/10 (10.00%)",
            "14/67 (20.90%)"
        ]
    },
    {
        "id": "69ced998-f3c9-460a-a272-b2c95421b89d",
        "primaryId": "NCT00570323",
        "secondaryId": "NCT00193180",
        "label": "Entailment",
        "statement_text": "Female patients over 6 months pregnant cannot take part in either the secondary trial or the primary trial",
        "statement_nums": [
            "6 months pregnant"
        ],
        "premise_text": "Inclusion Criteria: All subjects must be female  Postmenopausal status  defined as any one of the following criteria: Documented history of bilateral oophorectomy  Age 60 years or more  Age 45 to 59 and satisfying one or more of the following criteria: Amenorrhea for at least 12 months and intact uterus  Amenorrhea for less than 12 months and a follicle stimulating hormone (FSH) and estradiol concentration within postmenopausal range including: patients who have had a hysterectomy and patients who have received hormone replacement  Exclusion Criteria: Pregnant or breast feeding females ",
        "premise_nums": [
            "12 months and",
            "60 years or",
            "45 to 59"
        ]
    },
    {
        "id": "45fb84a3-674c-40f5-ac8c-26a3c7844e7b",
        "primaryId": "NCT00354640",
        "statement_text": "Patients taking Intervention 1 of the primary trial receive 4 times as much simvastatin as anastrozole ",
        "statement_nums": [
            "4 times as",
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "INTERVENTION 1: Anastrozole and Simvastatin adjuvant therapy : laboratory analysis pharmacological study : laboratory analysis simvastatin : 40 milligram tablet PO QD for 14 days anastrozole : 1 milligram tablet PO QD for 14 days ",
        "premise_nums": [
            "40 milligram tablet",
            "1 milligram tablet",
            "14 days anastrozole"
        ]
    },
    {
        "id": "c349cad6-8b63-4e5e-9b87-4fc08bb6fc30",
        "primaryId": "NCT00146172",
        "statement_text": "Cohort 1 of the primary trial recieves less than 60% of cohort 2's dose of Neratinb ",
        "statement_nums": [
            "60% of",
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "INTERVENTION 1: Neratinib 40 mg Neratinb 40 mg qd INTERVENTION 2: Neratinib 80 mg Neratinib 80 mg qd ",
        "premise_nums": [
            "80 mg Neratinib",
            "80 mg qd",
            "40 mg Neratinb",
            "40 mg qd"
        ]
    },
    {
        "id": "f4ce0687-a0b8-47e8-a3ba-dcf279c1dde9",
        "primaryId": "NCT00912340",
        "statement_text": "More patients in cohort 2 of the primary trial suffered from Pleural effusions than in cohort 1.",
        "statement_nums": [
            "2 of the"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Pleural effusion *0/24 (0.00%) Adverse Events 2: Pleural effusion *2/30 (6.67%) ",
        "premise_nums": [
            "2/30 (6.67%)",
            "0/24 (0.00%)"
        ]
    },
    {
        "id": "b3effb24-6ec0-4fa3-9c91-74a45bcc4602",
        "primaryId": "NCT01448447",
        "secondaryId": "NCT03252145",
        "label": "Contradiction",
        "statement_text": "the primary trial is testing a radiotherapy intervention whereas the secondary trial is testing a novel hand-held medical device  which patients must use themselves to drain their lymph vessels ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Sole Method patients will be treated with HDR brachytherapy using Mammosite ML as the sole method for radiation delivery after lumpectomy for breast cancer or DCIS Mammosite ML: 34 Gy / 10 fractions (3.4 Gy per fraction) 2 fractions / day (separated by at least 6 hours) Delivered in 5 consecutive working days INTERVENTION 2: Boost patients will be treated with HDR brachytherapy using Mammosite ML as a boost technique prior to standard external beam radiation after lumpectomy for breast cancer or DCIS ",
        "premise_nums": [
            "5 consecutive working",
            "10 fractions (3.4"
        ]
    },
    {
        "id": "b3effb24-6ec0-4fa3-9c91-74a45bcc4602",
        "primaryId": "NCT01448447",
        "secondaryId": "NCT03252145",
        "label": "Contradiction",
        "statement_text": "the primary trial is testing a radiotherapy intervention whereas the secondary trial is testing a novel hand-held medical device  which patients must use themselves to drain their lymph vessels ",
        "statement_nums": [],
        "premise_text": "Mammosite ML: 5-10.2 Gy / 2-3 fractions (3.4 Gy per fraction) 2 fractions / day (separated by at least 6 hours) Delivered in 1-2 days Followed by whole breast radiation (25-28 daily tx)INTERVENTION 1: Manual Lymph Drainage Manual lymph drainage (MLD) treatment 3 times a week for 4 weeks to the lymphedematous upper limb Manual Lymph Drainage (MLD): MLD is a practitioner-applied manual massage technique designed to decrease limb volume in patients with lymphedema by enhancing movement of lymph fluid  resulting in reductions in interstitial fluid  INTERVENTION 2: Negative Pressure ",
        "premise_nums": [
            "2-3 fractions",
            "2 days Followed",
            "3 fractions (3.4",
            "3 times a",
            "4 weeks to",
            "5-10.2 Gy",
            "28 daily tx)INTERVENTION",
            "(25-28 daily",
            "1-2 days"
        ]
    },
    {
        "id": "b3effb24-6ec0-4fa3-9c91-74a45bcc4602",
        "primaryId": "NCT01448447",
        "secondaryId": "NCT03252145",
        "label": "Contradiction",
        "statement_text": "the primary trial is testing a radiotherapy intervention whereas the secondary trial is testing a novel hand-held medical device  which patients must use themselves to drain their lymph vessels ",
        "statement_nums": [],
        "premise_text": "PhysioTouch (negative pressure massage) treatment 3 times a week for 4 weeks to the lymphedematous upper limbPhysioTouch: The PhysioTouch is a hand-held device that administers negative pressure under the treatment head  and gently pulls the underlying skin and subcutaneous tissue into the suction cup  This suction produces a stretch to the skin and in the subcutaneous tissue space  This action is thought to facilitate lymphatic flow from the interstitium into the lymphatic vessels  and mobilizes the superficial fascia  ",
        "premise_nums": [
            "3 times a",
            "4 weeks to"
        ]
    },
    {
        "id": "9026c2ff-2dd8-4aa9-b2fb-f6bef856189d",
        "primaryId": "NCT03106077",
        "statement_text": "Patients in the primary trial receive at least 150mg of IMGN853 by IV every 3 weeks ",
        "statement_nums": [
            "IMGN853 by",
            "853 by IV"
        ],
        "label": "Entailment",
        "premise_text": "INTERVENTION 1: Cohort A: Advanced Triple-Negative Breast Cancer (TNBC) 6 mg/kg IMGN853 IV Q3W ",
        "premise_nums": [
            "6 mg/kg IMGN",
            "853 IV Q3W",
            "IMGN853 IV"
        ]
    },
    {
        "id": "341c0861-b9a3-491d-8d49-aa61a8501a4f",
        "primaryId": "NCT00083174",
        "secondaryId": "NCT00190671",
        "label": "Contradiction",
        "statement_text": "The highest number of occurences for any adverse event in both the primary trial and the secondary trial was 39.",
        "statement_nums": [],
        "premise_text": "Adverse Events 1: Total: 39/2240 (1.74%) Supraven.arrhyth  Atrial fibrillation 1/2240 (0.04%) Cardiac ischemia/infarction 2/2240 (0.09%) Valvular heart disease 1/2240 (0.04%) Cardiac General - Other 2/2240 (0.09%) Endocrine - Other 1/2240 (0.04%) Ocular - Other 1/2240 (0.04%) Colitis 2/2240 (0.09%) Diarrhea 1/2240 (0.04%) Dysphagia 1/2240 (0.04%) Gastritis 1/2240 (0.04%) ",
        "premise_nums": [
            "2/2240 (0.09%)",
            "1/2240 (0.04%)",
            "39/2240 (1.74%)"
        ]
    },
    {
        "id": "341c0861-b9a3-491d-8d49-aa61a8501a4f",
        "primaryId": "NCT00083174",
        "secondaryId": "NCT00190671",
        "label": "Contradiction",
        "statement_text": "The highest number of occurences for any adverse event in both the primary trial and the secondary trial was 39.",
        "statement_nums": [],
        "premise_text": "Adverse Events 1:Total: 6 Agranulocytosis 0/42 (0.00%) Anaemia 2/42 (4.76%) Febrile neutropenia 1/42 (2.38%) Leukopenia 0/42 (0.00%) Neutropenia 1/42 (2.38%) Thrombocytopenia 1/42 (2.38%) Cardio-respiratory arrest 0/42 (0.00%) Pericardial effusion 1/42 (2.38%) Gastric ulcer haemorrhage 0/42 (0.00%) Melaena 0/42 (0.00%) Fatigue 1/42 (2.38%) ",
        "premise_nums": [
            "2/42 (4.76%)",
            "6 Agranulocytosis 0",
            "1:Total: 6",
            "0/42 (0.00%)",
            "1/42 (2.38%)"
        ]
    },
    {
        "id": "341c0861-b9a3-491d-8d49-aa61a8501a4f",
        "primaryId": "NCT00083174",
        "secondaryId": "NCT00190671",
        "label": "Contradiction",
        "statement_text": "The highest number of occurences for any adverse event in both the primary trial and the secondary trial was 39.",
        "statement_nums": [],
        "premise_text": "Multi-organ failure 0/42 (0.00%)Adverse Events 2: Total: 13 Agranulocytosis 1/61 (1.64%) Anaemia 1/61 (1.64%) Febrile neutropenia 0/61 (0.00%) Leukopenia 2/61 (3.28%) Neutropenia 2/61 (3.28%) Thrombocytopenia 1/61 (1.64%) Cardio-respiratory arrest 1/61 (1.64%) Pericardial effusion 0/61 (0.00%) Gastric ulcer haemorrhage 1/61 (1.64%) Melaena 1/61 (1.64%) ",
        "premise_nums": [
            "1/61 (1.64%)",
            "0/61 (0.00%)",
            "0/42 (0.00%)Adverse",
            "13 Agranulocytosis 1",
            "2/61 (3.28%)"
        ]
    },
    {
        "id": "341c0861-b9a3-491d-8d49-aa61a8501a4f",
        "primaryId": "NCT00083174",
        "secondaryId": "NCT00190671",
        "label": "Contradiction",
        "statement_text": "The highest number of occurences for any adverse event in both the primary trial and the secondary trial was 39.",
        "statement_nums": [],
        "premise_text": "Fatigue 1/61 (1.64%)Multi-organ failure 1/61 (1.64%) ",
        "premise_nums": [
            "1/61 (1.64%)Multi-organ"
        ]
    },
    {
        "id": "16d6e554-a1df-42f9-b051-947d70595cbb",
        "primaryId": "NCT00915018",
        "statement_text": "The only cases of Leukopenia in the primary trial occurred in cohort 1.",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 67/240 (27.92%) Anaemia 0/240 (0.00%) Febrile neutropenia 1/240 (0.42%) Leukopenia 2/240 (0.83%) Neutropenia 1/240 (0.42%) Thrombocytopenia 0/240 (0.00%) Atrial fibrillation 0/240 (0.00%) Cardiac failure congestive 2/240 (0.83%) Cardiac tamponade 1/240 (0.42%) Cardio-respiratory arrest 1/240 (0.42%) Left ventricular dysfunction 0/240 (0.00%) Adverse Events 2: Total: 56/234 (23.93%) ",
        "premise_nums": [
            "2/240 (0.83%)",
            "1/240 (0.42%)",
            "56/234 (23.93%)",
            "0/240 (0.00%)",
            "67/240 (27.92%)"
        ]
    },
    {
        "id": "16d6e554-a1df-42f9-b051-947d70595cbb",
        "primaryId": "NCT00915018",
        "statement_text": "The only cases of Leukopenia in the primary trial occurred in cohort 1.",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Anaemia 1/234 (0.43%)Febrile neutropenia 0/234 (0.00%) Leukopenia 0/234 (0.00%) Neutropenia 0/234 (0.00%) Thrombocytopenia 1/234 (0.43%) Atrial fibrillation 1/234 (0.43%) Cardiac failure congestive 0/234 (0.00%) Cardiac tamponade 0/234 (0.00%) Cardio-respiratory arrest 0/234 (0.00%) Left ventricular dysfunction 1/234 (0.43%) ",
        "premise_nums": [
            "1/234 (0.43%)Febrile",
            "0/234 (0.00%)"
        ]
    },
    {
        "id": "8f0159ce-1044-4f31-94b7-e394cf91d4e1",
        "primaryId": "NCT00316199",
        "statement_text": "Any women with stage 4 or Unresectable  locally recurrent cancer breast cancer are eligible for the primary trial ",
        "statement_nums": [
            "4 or Unresectable"
        ],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria: Female patients of Chinese origin with histologically or cytologically proven diagnosis of breast cancer  Unresectable  locally recurrent breast cancer or stage IV disease  ",
        "premise_nums": []
    },
    {
        "id": "ccc5e420-dda4-4fb9-8d68-82551d69017f",
        "primaryId": "NCT00688909",
        "secondaryId": "NCT00129376",
        "label": "Contradiction",
        "statement_text": "Patients in both the primary trial and the secondary trial suffered from Pulmonary embolisms ",
        "statement_nums": [],
        "premise_text": "Adverse Events 1: Total: 5/261 (1.92%) Cholecystitis chronic 1/261 (0.38%) Post procedural bile leak 1/261 (0.38%) Spinal column stenosis 1/261 (0.38%) Depression 1/261 (0.38%) Mania 1/261 (0.38%) Pulmonary embolism 1/261 (0.38%) Adverse Events 1: Total: 12/63 (19.05%) Febrile neutropenia * [1]4/63 (6.35%) Congestive heart failure * [2]1/63 (1.59%) Cardiac-ischemia/infarction * 1/63 (1.59%) ",
        "premise_nums": [
            "1/63 (1.59%)",
            "12/63 (19.05%)",
            "1/261 (0.38%)",
            "5/261 (1.92%)",
            "4/63 (6.35%)"
        ]
    },
    {
        "id": "ccc5e420-dda4-4fb9-8d68-82551d69017f",
        "primaryId": "NCT00688909",
        "secondaryId": "NCT00129376",
        "label": "Contradiction",
        "statement_text": "Patients in both the primary trial and the secondary trial suffered from Pulmonary embolisms ",
        "statement_nums": [],
        "premise_text": "Vomiting * [1]1/63 (1.59%)Acute Pharyngitis * 1/63 (1.59%) Infection * 3/63 (4.76%) Neutrophil count decreased * [1]1/63 (1.59%) Pneumonitis/pulmonary infiltrates * [3]1/63 (1.59%) ",
        "premise_nums": [
            "1/63 (1.59%)Acute",
            "3/63 (4.76%)"
        ]
    },
    {
        "id": "89f8ba8c-e626-4bd4-9994-3d0264018932",
        "primaryId": "NCT00429104",
        "statement_text": "Patients with end-stage liver disease are excluded from the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Exclusion Criteria: Chronic active hepatitis or cirrhosis  ",
        "premise_nums": []
    },
    {
        "id": "0bd8f61d-0b89-4c5d-89e0-9ba86e06b13d",
        "primaryId": "NCT00375505",
        "statement_text": "In the primary trial patients in the test group had better health outcomes than the control group ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Change in Bone Mineral Density (BMD) Measured by Dual (Energy) X-ray Absorptiometry (DXA) at Lumbar Spine (L2-L4) From Baseline to Month 24 Bone mineral density (BMD) by DXA at lumbar spine (L2-L4); DXA assessments of the BMD at dual hips  (BMD)  Two X-ray beams with different energy levels are aimed at the patient's bones  When soft tissue absorption is subtracted out  the BMD can be determined from the absorption of each beam by bone  Time frame: baseline  month 24 Results 1: Arm/Group Title: Placebo Arm/Group Description: Placebo as a 15-minute infusion every 3 months for a treatment period of 24 months (total of 8 infusions)  ",
        "premise_nums": [
            "24 months (total",
            "15-minute infusion",
            "3 months for",
            "24 Bone mineral",
            "2-L4) From",
            "24 Results 1:",
            "2-L4); DXA"
        ]
    },
    {
        "id": "0bd8f61d-0b89-4c5d-89e0-9ba86e06b13d",
        "primaryId": "NCT00375505",
        "statement_text": "In the primary trial patients in the test group had better health outcomes than the control group ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Overall Number of Participants Analyzed: 36Mean (Standard Deviation) Unit of Measure: Z-score -0.075 (0.041) Results 2: Arm/Group Title: Zometa Arm/Group Description: Zoledronic Acid 4mg as a 15-minute infusion every 3 months for a treatment period of 24 months (total of 8 infusions)  Overall Number of Participants Analyzed: 34 Mean (Standard Deviation) Unit of Measure: Z-score 0.037 (0.042) ",
        "premise_nums": [
            "3 months for",
            "24 months (total",
            "34 Mean (Standard",
            "15-minute infusion"
        ]
    },
    {
        "id": "57e6f0e1-6157-43bc-8bdf-c3649ed49133",
        "primaryId": "NCT01129336",
        "secondaryId": "NCT01945775",
        "label": "Contradiction",
        "statement_text": "More than half the participants of the primary trial are considered to be censored  the secondary trial used the same outcome measurement  but had no censored patients ",
        "statement_nums": [],
        "premise_text": "Outcome Measurement: Number of Participants With Progression Free Survival (PFS) ",
        "premise_nums": []
    },
    {
        "id": "300dbe96-0be8-4ca0-aa3b-41bc059bac7f",
        "primaryId": "NCT02725801",
        "secondaryId": "NCT04030104",
        "label": "Contradiction",
        "statement_text": "Neither the primary trial or the secondary trial have control groups ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: One-port intervention is placement of one-port tissue expander at time of reconstruction Allergen one-port tissue expander placement: patients will be randomized to receive a one port or two port tissue expander for breast reconstruction INTERVENTION 2: Two-port intervention is placement of two-port tissue expander at time of reconstruction AlloX2 two-port tissue expander placement: patients will be randomized to receive a one port or two port tissue expander for breast reconstruction INTERVENTION 1: IUS Alone IUS alone imaging INTERVENTION 2: Imagio (IUS+OA) IUS+OA imaging ",
        "premise_nums": []
    },
    {
        "id": "f40c8d92-2921-45fd-8389-15048b08e229",
        "primaryId": "NCT00670982",
        "statement_text": "Neutropenia was the most prevalent adverse event in the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 9/29 (31.03%) Neutropenia 5/29 (17.24%) Cataracts 1/29 (3.45%) Abdominal Pain 1/29 (3.45%) Perforated Appendix 1/29 (3.45%) Surgical Intervention 1/29 (3.45%) Deep Vein Thrombosis 1/29 (3.45%) Cerebrovascular Ischemia 1/29 (3.45%) ",
        "premise_nums": [
            "1/29 (3.45%)",
            "9/29 (31.03%)",
            "5/29 (17.24%)"
        ]
    },
    {
        "id": "31387af4-aad1-4f3c-bd81-641340ad4096",
        "primaryId": "NCT00256698",
        "secondaryId": "NCT03573804",
        "label": "Entailment",
        "statement_text": "the primary trial and the secondary trial use completely different drugs and techniques for their interventions ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Fulvestrant + Anastrozole Fulvestrant 250 mg Loading Dose Regimen + Anastrozole 1 mg INTERVENTION 2: Anastrozole Anastrozole 1 mg INTERVENTION 1: Prone to Supine MRI Evaluated by Radiologist A Radiologist A  number of participants successfully segmented INTERVENTION 2: Prone to Supine MRI Evaluated by Radiologist B Radiologist B  number of participants successfully segmented ",
        "premise_nums": [
            "1 mg INTERVENTION",
            "250 mg Loading"
        ]
    },
    {
        "id": "eabe9a78-965e-4984-82c2-25598b6b35da",
        "primaryId": "NCT00534417",
        "statement_text": "The median TTP in cohort one of the primary trial is just under 27 months ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Time to Progression (TTP) Time to progression is defined as the time from treatment start until objective tumor progression  Progression is defined per Response Evaluation Criteria in Solid Tumors (RECIST)v1.0 guidelines as a measurable increase in the smallest diameter of any target lesion  progression of existing non-target lesions  or the appearance of 1 or more new lesions  The median time to progression is the parameter used to describe TTP  Time frame: TTP was measured from day 1 of treatment until time of progression (assessed every 8 weeks)  up to 29 months  Results 1: Arm/Group Title: Capecitabine and Fulvestrant ",
        "premise_nums": [
            "v1.0 guidelines",
            "1 or more",
            "1 of treatment",
            "0 guidelines as"
        ]
    },
    {
        "id": "eabe9a78-965e-4984-82c2-25598b6b35da",
        "primaryId": "NCT00534417",
        "statement_text": "The median TTP in cohort one of the primary trial is just under 27 months ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Arm/Group Description: Capecitabine will be given on a continuous basis at a total dose of 1500 mg  given as 1000 mg po AM and 500 mg po PM in patients of body weight smaller than 80 kg  and at a total dose of 2000 mg given as 1000 mg po bid in patients with a body weight of 80 kg Fulvestrant will be given at 500 mg on Day 1 followed by 250 mg on Days 15 and 29, then 250 mg every 28 days  Overall Number of Participants Analyzed: 41 Median (95% Confidence Interval) Unit of Measure: Months 26.94 [1] (7.26 to NA) ",
        "premise_nums": [
            "80 kg Fulvestrant",
            "500 mg po",
            "1000 mg po",
            "500 mg on",
            "26 to NA)",
            "250 mg on",
            "95% Confidence",
            "1 followed by",
            "2000 mg given",
            "250 mg every",
            "15 and 29,"
        ]
    },
    {
        "id": "006f6b4e-6245-4f09-9786-327bbed3d766",
        "primaryId": "NCT01328249",
        "statement_text": "The Percentage of Participants With Feasibility was 10% higher in cohort 1 of the primary trial than in cohort 2.",
        "statement_nums": [
            "10% higher",
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Percentage of Participants With Feasibility ",
        "premise_nums": []
    },
    {
        "id": "88b13330-b937-4bbc-80ea-4bf8ccc17bd1",
        "primaryId": "NCT00699491",
        "statement_text": "3/4 participants in the primary trial suffered from Dose-limiting toxicities ",
        "statement_nums": [
            "4 participants in",
            "3/4 participants"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Recommended Dose Level for Phase II Testing (RPTD) (Phase I) The RPTD is defined as the highest dose level at which at most one of 6 patients develops a dose limiting toxicity (DLT) during the first course of treatment and the next highest dose level has 2 or more DLTs  The number of patients in each cohort reporting a DLT is reported  Dose-limiting toxicities (DLTs) are defined as any of the following adverse events (AEs) that are related to study agent with an attribution of possible  probably  or definite and fulfilling one of the following criteria: Any grade 4 hematologic toxicity Hyperglycemia that cannot be stably controlled with diabetic medication ",
        "premise_nums": [
            "4 hematologic toxicity",
            "2 or more",
            "6 patients develops"
        ]
    },
    {
        "id": "88b13330-b937-4bbc-80ea-4bf8ccc17bd1",
        "primaryId": "NCT00699491",
        "statement_text": "3/4 participants in the primary trial suffered from Dose-limiting toxicities ",
        "statement_nums": [
            "4 participants in",
            "3/4 participants"
        ],
        "label": "Entailment",
        "premise_text": "Any grade 3 or 4 non-hematologic toxicity (except asymptomatic medically manageable laboratory abnormalities such as hyperlipidemia  hypophosphatemia  and hypokalemia)Time frame: During first course Results 1: Arm/Group Title: Dose Level 1 Arm/Group Description: 25 mg temsirolimus IV over 30 minutes on days 1, 8, 15, and 22 3 mg/ks cixutumumab IV over 60 minutes on days 1, 8, 15, and 22 Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity  Overall Number of Participants Analyzed: 3 Measure Type: Number Unit of Measure: DLTs 2 Results 2: Arm/Group Title: Dose Level -1 ",
        "premise_nums": [
            "1 Arm/Group Description",
            "3 mg/ks cixutumumab",
            "3 or 4",
            "22 Courses repeat",
            "28 days in",
            "60 minutes on",
            "30 minutes on",
            "25 mg temsirolimus",
            "2 Results 2:",
            "3 Measure Type:",
            "4 non-hematologic toxicity"
        ]
    },
    {
        "id": "88b13330-b937-4bbc-80ea-4bf8ccc17bd1",
        "primaryId": "NCT00699491",
        "statement_text": "3/4 participants in the primary trial suffered from Dose-limiting toxicities ",
        "statement_nums": [
            "4 participants in",
            "3/4 participants"
        ],
        "label": "Entailment",
        "premise_text": "Arm/Group Description: 20 mg temsirolimus IV over 30 minutes on days 1, 8, 15, and 223 mg/ks cixutumumab IV over 60 minutes on days 1, 8, 15, and 22 Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity  Overall Number of Participants Analyzed: 1 Measure Type: Number Unit of Measure: DLTs 1 ",
        "premise_nums": [
            "1 Measure Type:",
            "28 days in",
            "22 Courses repeat",
            "60 minutes on",
            "30 minutes on",
            "223 mg/ks cixutumumab",
            "20 mg temsirolimus"
        ]
    },
    {
        "id": "e90e2368-808d-454d-8080-30427235b89d",
        "primaryId": "NCT01009918",
        "secondaryId": "NCT01688609",
        "label": "Entailment",
        "statement_text": "There are no racial criteria for entry into the primary trial  but there are for the secondary trial ",
        "statement_nums": [],
        "premise_text": "INCLUSION CRITERIA Males and Females 18 years old diagnosed with HER2 positive breast cancer Scheduled to receive neoadjuvant or adjuvant trastuzumab (Herceptin®) therapy (anthracycline-containing regimens are permitted)  Patients receiving Herceptin® with their chemotherapy are permitted for eligibility work-up  Taxanes are permitted  Trastuzumab (Herceptin®) therapy may be given with or after primary chemotherapy  Pertuzumab may be used in conjunction with trastuzumab  Left Ventricular Ejection Fraction (LVEF) 50% by MUGA scan or echocardiogram Adequate renal function for administration of trastuzumab-containing chemotherapy regimen  Sitting systolic blood pressure of greater than 90 mm Hg Pulse 60 beats/minute ",
        "premise_nums": [
            "2 positive breast",
            "90 mm Hg",
            "60 beats/minute",
            "18 years old",
            "50% by"
        ]
    },
    {
        "id": "e90e2368-808d-454d-8080-30427235b89d",
        "primaryId": "NCT01009918",
        "secondaryId": "NCT01688609",
        "label": "Entailment",
        "statement_text": "There are no racial criteria for entry into the primary trial  but there are for the secondary trial ",
        "statement_nums": [],
        "premise_text": "Not pregnant or breastfeedingFemale patients of childbearing potential  who are sexually active  must have a negative pregnancy test before starting the study Both men and women must be willing to use effective contraception during the study  Teratogenicity is documented for both active study agents Able to swallow capsules EXCLUSION CRITERIA: Patients with metastatic disease Prior treatment with trastuzumab or anthracyclines prior to this chemotherapy regimen Current treatment with angiotensin converting enzyme (ACE) inhibitors  angiotensin receptor blockers (ARBs)  such as losartan  β-blockers or digoxin Known cardiac history: heart failure  myocardial infarction  radiation-induced cardiac dysfunction Known allergy to either ACE inhibitors or β-blockers ",
        "premise_nums": []
    },
    {
        "id": "e90e2368-808d-454d-8080-30427235b89d",
        "primaryId": "NCT01009918",
        "secondaryId": "NCT01688609",
        "label": "Entailment",
        "statement_text": "There are no racial criteria for entry into the primary trial  but there are for the secondary trial ",
        "statement_nums": [],
        "premise_text": "History of bronchial asthma or related bronchospastic conditionsHereditary or idiopathic angioedema History of severe hypersensitivity reactions to drugs or other causes  i.e  bee stings This protocol does not exclude patients who are participating on other investigational studies  Refer to the local IRB guidelines  Only Japanese women are eligible for the trial ",
        "premise_nums": []
    },
    {
        "id": "d375ef3f-8b35-40eb-b9c0-3fc9592d9bec",
        "primaryId": "NCT00723398",
        "statement_text": "Patients with both type 1 and 2 Diabetes are not suitable for the primary trial ",
        "statement_nums": [
            "1 and 2"
        ],
        "label": "Entailment",
        "premise_text": "Exclusion Criteria: Diabetes mellitus ",
        "premise_nums": []
    },
    {
        "id": "2f2301cd-b8fa-47cc-94cc-e31150ce8f9e",
        "primaryId": "NCT00245219",
        "secondaryId": "NCT00038103",
        "label": "Contradiction",
        "statement_text": "the primary trial and the secondary trial only have test groups  so all patients are receiving novel (FDA approved) interventions ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Health Tracking (Control) Participants assigned to the health-tracking condition received usual care and did not attend any meetings  INTERVENTION 2: Peer Support The peer support group meetings focused on fostering purpose in life by providing participants with opportunities to support and care for one another  Patients completed a weekly diary of critical experiences or current life problems as homework  and were then encouraged to share these experiences in the group meetings  The group facilitator encouraged participants to help one another with these issues  and share how they had dealt with similar problems  INTERVENTION 1: Exemestane (Exemestane Alone) oral dose exemestane taken with food (25 mg tablet once daily) INTERVENTION 2: Combination (Exemestane + Celecoxib) ",
        "premise_nums": [
            "25 mg tablet"
        ]
    },
    {
        "id": "2f2301cd-b8fa-47cc-94cc-e31150ce8f9e",
        "primaryId": "NCT00245219",
        "secondaryId": "NCT00038103",
        "label": "Contradiction",
        "statement_text": "the primary trial and the secondary trial only have test groups  so all patients are receiving novel (FDA approved) interventions ",
        "statement_nums": [],
        "premise_text": "oral doses to be taken with food (25 mg tablet exemestane once daily; celecoxib 2 x 200 mg tablets twice daily)",
        "premise_nums": [
            "25 mg tablet",
            "2 x 200"
        ]
    },
    {
        "id": "eea73ae4-0985-4f74-957d-e2aad7ab453c",
        "primaryId": "NCT00248170",
        "secondaryId": "NCT01299038",
        "label": "Contradiction",
        "statement_text": "Ae-Cha is a 32 year old Korean woman with an inoperable breast cancer  she is too old to participate in both the secondary trial and the primary trial ",
        "statement_nums": [
            "32 year old"
        ],
        "premise_text": "Inclusion Criteria: Recent primary surgery for breast cancer Early stage breast cancer Postmenopausal Hormone receptor positive Positive lymph node involvement Exclusion Criteria: Metastatic disease Presence of contralateral breast cancer including DCIS Progression Other protocol-defined inclusion/exclusion criteria may apply  Inclusion Criteria: Metastatic adenocarcinoma of the breast (Stage IV) Actively receiving endocrine therapy for at least 6 weeks (with or without HER2 therapy) Minimum age 18 years ECOG Performance status of 0, 1 or 2 Normal organ and marrow function as defined in the protocol Exclusion Criteria: Participants may not be receiving any other study agents Actively receiving chemotherapy (exclusive of hormonal or HER2 therapy ) within last 5 weeks Any statin therapy within the last 3 weeks ",
        "premise_nums": [
            "6 weeks (with",
            "2 therapy )",
            "5 weeks Any",
            "1 or 2",
            "18 years ECOG"
        ]
    },
    {
        "id": "eea73ae4-0985-4f74-957d-e2aad7ab453c",
        "primaryId": "NCT00248170",
        "secondaryId": "NCT01299038",
        "label": "Contradiction",
        "statement_text": "Ae-Cha is a 32 year old Korean woman with an inoperable breast cancer  she is too old to participate in both the secondary trial and the primary trial ",
        "statement_nums": [
            "32 year old"
        ],
        "premise_text": "Asian decent (including Filipino  Chinese  Japanese  Korean  Vietnamese or Asian-Indian origin)Concomitant use of the following drugs: cyclosporine  fibrates  niacin  gemfibrozil  ketaconazole  spironolactone  cimetidine  warfarin  erythromycin  or protease inhibitors Conditions predisposing to renal failure secondary to rhabdomyolysis Recent history of heavy alcohol use as judged by the treating physician Known to be pregnant (testing not required) or nursing History of rhabdomyolysis on statin therapy Known history of Hepatitis C or active hepatitis B infection (baseline testing not required) ",
        "premise_nums": []
    },
    {
        "id": "eea73ae4-0985-4f74-957d-e2aad7ab453c",
        "primaryId": "NCT00248170",
        "secondaryId": "NCT01299038",
        "label": "Contradiction",
        "statement_text": "Ae-Cha is a 32 year old Korean woman with an inoperable breast cancer  she is too old to participate in both the secondary trial and the primary trial ",
        "statement_nums": [
            "32 year old"
        ],
        "premise_text": "Uncontrolled intercurrent illness including  but not limited to ongoing or active infection  hepatitis  symptomatic congestive heart failure  unstable angina pectoris  cardiac arrhythmia  or psychiatric illness/social situations that would limit compliance with study requirements",
        "premise_nums": []
    },
    {
        "id": "6550c068-14e6-4e93-8f98-756338c91e35",
        "primaryId": "NCT00313170",
        "statement_text": "Patients in the primary trial treated with Fulvestrant 250 mg had a higher Objective response rate than those treated with Fulvestrant 250 mg + Loading Dose ",
        "statement_nums": [
            "250 mg had"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Objective Response (ORR) Objective response rate was defined as percentage of patients with either complete response (CR - disappearance of all target lesions) or partial response (PR - at least 30% decrease in the sum of diameters of target lesions)  All patients were to be followed up every 12 weeks for progression  defined by response evaluation criteria in solid tumors (RECIST v1.1). Time frame: The planned data cut-off for this study was when all patients  except withdrawals  had been followed up for at least 24 weeks  Patients received treatment up to approximately 2 years  Results 1: Arm/Group Title: Fulvestrant 250 mg Arm/Group Description: Fulvestrant 250 mg Overall Number of Participants Analyzed: 47 Measure Type: Number ",
        "premise_nums": [
            "30% decrease",
            "12 weeks for",
            "250 mg Overall",
            "47 Measure Type:",
            "250 mg Arm"
        ]
    },
    {
        "id": "6550c068-14e6-4e93-8f98-756338c91e35",
        "primaryId": "NCT00313170",
        "statement_text": "Patients in the primary trial treated with Fulvestrant 250 mg had a higher Objective response rate than those treated with Fulvestrant 250 mg + Loading Dose ",
        "statement_nums": [
            "250 mg had"
        ],
        "label": "Entailment",
        "premise_text": "Unit of Measure: Percentage of patients 8.5 (2.4 to 20.4)Results 2: Arm/Group Title: Fulvestrant 250 mg + Loading Dose Arm/Group Description: Fulvestrant 250 mg + Loading Dose Overall Number of Participants Analyzed: 51 Measure Type: Number Unit of Measure: Percentage of patients 5.9 (1.2 to 16.2) ",
        "premise_nums": [
            "51 Measure Type:",
            "4 to 20.4)Results",
            "2 to 16.2)"
        ]
    },
    {
        "id": "0f5b81f0-b422-4000-8e0e-9f09c612ebc3",
        "primaryId": "NCT01293032",
        "secondaryId": "NCT00849472",
        "label": "Entailment",
        "statement_text": "None of the patients in the primary trial or the secondary trial are required to undergo radiotherapy or a support group course ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Group 2 (RS 11-25) Patients with an intermediate RS (11-25) were assigned to Group 2. The subject was then randomized to treatment Arm 1, neoadjuvant hormonal therapy  or treatment Arm 2, neoadjuvant chemotherapy  INTERVENTION 1: AC  Followed by Weekly Paclitaxel and Concurrent Pazopanib ",
        "premise_nums": [
            "(11-25) were",
            "11-25) Patients"
        ]
    },
    {
        "id": "0f5b81f0-b422-4000-8e0e-9f09c612ebc3",
        "primaryId": "NCT01293032",
        "secondaryId": "NCT00849472",
        "label": "Entailment",
        "statement_text": "None of the patients in the primary trial or the secondary trial are required to undergo radiotherapy or a support group course ",
        "statement_nums": [],
        "premise_text": "Participants were treated with intravenous (IV) doxorubicin (60 milligrams per meters squared [mg/m^2]) and cyclophosphamide (AC) (600 mg/m^2) every 21 days for 4 cycles  This was followed by weekly paclitaxel (WP) 80 mg/m^2 IV on Days 1, 8, and 15 every 28 days for 4 cycles given concurrently with oral pazopanib 800 mg (2 tablets taken at the same time each day  either 1 hour before or 2 hours after a meal) taken daily and continuing until 7 days before surgery  Pazopanib was resumed at the same oral dose 4-6 weeks after surgery and was continued daily for 6 months ",
        "premise_nums": [
            "21 days for",
            "800 mg (2",
            "2 hours after",
            "80 mg/m^2",
            "1 hour before",
            "6 weeks after",
            "60 milligrams per",
            "4-6 weeks",
            "7 days before",
            "4 cycles given",
            "2 IV on",
            "15 every 28"
        ]
    },
    {
        "id": "f6bba549-3d18-4a53-8685-96b4e321b1a7",
        "primaryId": "NCT00645333",
        "secondaryId": "NCT00006110",
        "label": "Entailment",
        "statement_text": "the primary trial records several immune system related adverse events in its patients  whereas the secondary trial does not ",
        "statement_nums": [],
        "premise_text": "Autoimmune disorder *1/30 (3.33%) Immune system disorder *1/30 (3.33%) Adverse Events 1: Total: 7/52 (13.46%) Febrile neutropenia (fever of unknown origin without clinically or microbiologically documented infe * 0/52 (0.00%) Atrial Fibrillation * 1/52 (1.92%) Sepsis * 1/52 (1.92%) Muscle weakness upper limb * 1/52 (1.92%) Dizziness * 1/52 (1.92%) Seizure * 1/52 (1.92%) Nervous system disorders - Other  specify * [1]1/52 (1.92%) ",
        "premise_nums": [
            "1/52 (1.92%)",
            "1/30 (3.33%)",
            "7/52 (13.46%)",
            "0/52 (0.00%)"
        ]
    },
    {
        "id": "1fe36432-40f8-4c53-ac2b-0f8e50e5743f",
        "primaryId": "NCT00602043",
        "secondaryId": "NCT01720602",
        "label": "Contradiction",
        "statement_text": "Several treatments in the secondary trial and the primary trial are administered by mouth ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Diagnostic FES: Average FES SUVmean greater than 1.5, no Negative Sites Patients undergo [^18F] FES PET scan  Patients also undergo standard clinical fludeoxyglucose F 18 (FDG)-PET or FDG-PET/CT scan up to 14 days prior to [^18F] FES PET scan  Patients begin clinically indicated endocrine therapy  Patients are followed-up to determine response on the therapy for 6 months using clinical exams  tumor marker assays  conventional imaging and standard clinical FDG PET/CT  This group represents patients who had positive FES uptake at all disease sites on the baseline diagnostic FES PET scan  laboratory biomarker analysis: Correlative studies INTERVENTION 2: Diagnostic FES: Patients With FES Negative Sites of Disease ",
        "premise_nums": [
            "6 months using",
            "14 days prior"
        ]
    },
    {
        "id": "1fe36432-40f8-4c53-ac2b-0f8e50e5743f",
        "primaryId": "NCT00602043",
        "secondaryId": "NCT01720602",
        "label": "Contradiction",
        "statement_text": "Several treatments in the secondary trial and the primary trial are administered by mouth ",
        "statement_nums": [],
        "premise_text": "Patients undergo [^18F] FES PET scan  Patients also undergo standard clinical fludeoxyglucose F 18 (FDG)-PET or FDG-PET/CT scan up to 14 days prior to [^18F] FES PET scan Patients begin clinically indicated endocrine therapy  Patients are followed-up to determine response on the therapy for 6 months using clinical exams  tumor marker assays  conventional imaging and standard clinical FDG PET/CT  This group represents patients who had some or all disease sites negative for FES uptake on the baseline diagnostic FES PET scan  INTERVENTION 1: Treatment (Vorinostat  AI Therapy) ",
        "premise_nums": [
            "6 months using",
            "14 days prior"
        ]
    },
    {
        "id": "1fe36432-40f8-4c53-ac2b-0f8e50e5743f",
        "primaryId": "NCT00602043",
        "secondaryId": "NCT01720602",
        "label": "Contradiction",
        "statement_text": "Several treatments in the secondary trial and the primary trial are administered by mouth ",
        "statement_nums": [],
        "premise_text": "Patients receive vorinostat PO 5 days a week for 3 weeks  Patients also receive AI therapy comprising either anastrozole PO daily  letrozole PO daily  or exemestane PO daily for 4 weeks  Courses repeat every 28 days in the absence of disease progression and unacceptable toxicity vorinostat: Given PO anastrozole: Given PO letrozole: Given PO exemestane: Given PO positron emission tomography: Correlative studies F-18 16 alpha-fluoroestradiol: Correlative studies fludeoxyglucose F 18: Correlative studies laboratory biomarker analysis: Correlative studies ",
        "premise_nums": [
            "16 alpha-fluoroestradiol:",
            "28 days in",
            "5 days a"
        ]
    },
    {
        "id": "3576f3e7-a1b9-4a75-934a-1ad2165b69dd",
        "primaryId": "NCT01091454",
        "secondaryId": "NCT00054275",
        "label": "Entailment",
        "statement_text": "There were more cases of Anemia and vomiting in the primary trial than the secondary trial ",
        "statement_nums": [],
        "premise_text": "Adverse Events 1: Total: 29/48 (60.42%) Anemia 4/48 (8.33%) Febrile neutropenia 7/48 (14.58%) Atrial fibrillation 1/48 (2.08%) Pericardial effusion 1/48 (2.08%) Sinus bradycardia 1/48 (2.08%) Nausea 2/48 (4.17%) Vomiting 2/48 (4.17%) Death NOS 1/48 (2.08%) Fatigue 3/48 (6.25%) Allergic reaction 1/48 (2.08%) Lung infection 1/48 (2.08%) Mucosal infection 1/48 (2.08%) Adverse Events 1: ",
        "premise_nums": [
            "1/48 (2.08%)",
            "29/48 (60.42%)",
            "7/48 (14.58%)",
            "3/48 (6.25%)",
            "4/48 (8.33%)",
            "2/48 (4.17%)"
        ]
    },
    {
        "id": "3576f3e7-a1b9-4a75-934a-1ad2165b69dd",
        "primaryId": "NCT01091454",
        "secondaryId": "NCT00054275",
        "label": "Entailment",
        "statement_text": "There were more cases of Anemia and vomiting in the primary trial than the secondary trial ",
        "statement_nums": [],
        "premise_text": "Total: 28/39 (71.79%)Anemia 1/39 (2.56%) Leukopenia 4/39 (10.26%) Neutropenia 4/39 (10.26%) Chest Pain 1/39 (2.56%) Pericarditis 1/39 (2.56%) Sinus Tach  1/39 (2.56%) Sinus Tachycardia 1/39 (2.56%) Eye tearing 1/39 (2.56%) Diarrhea 7/39 (17.95%) Mucositis 3/39 (7.69%) Nausea 2/39 (5.13%) Vomiting [1]1/39 (2.56%) Fatigue 6/39 (15.38%) ",
        "premise_nums": [
            "7/39 (17.95%)",
            "2/39 (5.13%)",
            "1/39 (2.56%)",
            "6/39 (15.38%)",
            "4/39 (10.26%)",
            "28/39 (71.79%)Anemia",
            "3/39 (7.69%)"
        ]
    },
    {
        "id": "de71f285-4382-465f-9e7e-d163662f6d9c",
        "primaryId": "NCT01446159",
        "statement_text": "the primary trial only had a total of 66 patients in across both its cohorts ",
        "statement_nums": [
            "66 patients in"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 2/3 (66.67%) Adverse Events 2: Total: 0/3 (0.00%) ",
        "premise_nums": [
            "0/3 (0.00%)",
            "2/3 (66.67%)"
        ]
    },
    {
        "id": "406247fb-003a-47b7-8fe4-b6b963b98f08",
        "primaryId": "NCT00281697",
        "statement_text": "the primary trial does not record any pain related adverse events ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 112/458 (24.45%) Febrile neutropenia 8/458 (1.75%) Neutropenia 6/458 (1.31%) Anaemia 3/458 (0.66%) Thrombocytopenia 3/458 (0.66%) Pancytopenia 2/458 (0.44%) Myocardial infarction 0/458 (0.00%) Pericardial effusion 0/458 (0.00%) Tachycardia 0/458 (0.00%) Acute myocardial infarction 1/458 (0.22%) Atrial fibrillation 0/458 (0.00%) Adverse Events 2: ",
        "premise_nums": [
            "112/458 (24.45%)",
            "3/458 (0.66%)",
            "0/458 (0.00%)",
            "8/458 (1.75%)",
            "6/458 (1.31%)",
            "2/458 (0.44%)",
            "1/458 (0.22%)"
        ]
    },
    {
        "id": "406247fb-003a-47b7-8fe4-b6b963b98f08",
        "primaryId": "NCT00281697",
        "statement_text": "the primary trial does not record any pain related adverse events ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Total: 39/221 (17.65%)Febrile neutropenia 5/221 (2.26%) Neutropenia 1/221 (0.45%) Anaemia 2/221 (0.90%) Thrombocytopenia 0/221 (0.00%) Pancytopenia 0/221 (0.00%) Myocardial infarction 2/221 (0.90%) Pericardial effusion 2/221 (0.90%) Tachycardia 2/221 (0.90%) Acute myocardial infarction 0/221 (0.00%) Atrial fibrillation 1/221 (0.45%) ",
        "premise_nums": [
            "5/221 (2.26%)",
            "0/221 (0.00%)",
            "1/221 (0.45%)",
            "2/221 (0.90%)",
            "39/221 (17.65%)Febrile"
        ]
    },
    {
        "id": "47553222-0aff-4394-bcfc-9f19c0863835",
        "primaryId": "NCT02441946",
        "secondaryId": "NCT00325598",
        "label": "Contradiction",
        "statement_text": "the secondary trial does not have a defined end date  whereas the primary trial lasted 2 weeks ",
        "statement_nums": [],
        "premise_text": "Outcome Measurement: Time frame: Baseline  2 Weeks Outcome Measurement: Time frame: Within 1 year of protocol registration ",
        "premise_nums": [
            "2 Weeks Outcome",
            "1 year of"
        ]
    },
    {
        "id": "e4756896-55c2-46e1-be19-14697ad3b39f",
        "primaryId": "NCT00201864",
        "statement_text": "One patient in the primary trial had blood calcium levels far above normal ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Hypercalcemia 1/40 (2.50%) ",
        "premise_nums": [
            "1/40 (2.50%)"
        ]
    },
    {
        "id": "594c9a79-d601-46b4-ae30-0b48a1117693",
        "primaryId": "NCT02447003",
        "secondaryId": "NCT00917735",
        "label": "Entailment",
        "statement_text": "The difference in cohort size between cohort 2 of the secondary trial and cohort 2 of the primary trial makes it impossible to make meaningful comparisons ",
        "statement_nums": [
            "2 of the"
        ],
        "premise_text": "Adverse Events 2: Total: 0/1 (0.00%) Anaemia 0/1 (0.00%) Febrile neutropenia 0/1 (0.00%) Cardiac tamponade 0/1 (0.00%) Myocarditis 0/1 (0.00%) Pericardial effusion 0/1 (0.00%) Pericarditis 0/1 (0.00%) Colitis 0/1 (0.00%) Constipation 0/1 (0.00%) Diarrhoea 0/1 (0.00%) Gastroenteritis eosinophilic 0/1 (0.00%) ",
        "premise_nums": [
            "0/1 (0.00%)"
        ]
    },
    {
        "id": "594c9a79-d601-46b4-ae30-0b48a1117693",
        "primaryId": "NCT02447003",
        "secondaryId": "NCT00917735",
        "label": "Entailment",
        "statement_text": "The difference in cohort size between cohort 2 of the secondary trial and cohort 2 of the primary trial makes it impossible to make meaningful comparisons ",
        "statement_nums": [
            "2 of the"
        ],
        "premise_text": "Intestinal obstruction 0/1 (0.00%)Nausea 0/1 (0.00%) Adverse Events 2: Total: 8/537 (1.49%) Hypertension 1/537 (0.19%) Acoustic Neuroma 0/537 (0.00%) Diarrhea 1/537 (0.19%) Colitis 0/537 (0.00%) Elevated ALT or AST enzyme 0/537 (0.00%) Diagnosis of Uterine Cancer 2/537 (0.37%) Motorcycle accident 1/537 (0.19%) Fall 1/537 (0.19%) Surgery 2/537 (0.37%) ",
        "premise_nums": [
            "2/537 (0.37%)",
            "1/537 (0.19%)",
            "0/1 (0.00%)Nausea",
            "0/537 (0.00%)",
            "8/537 (1.49%)"
        ]
    },
    {
        "id": "99e8ee0e-d72d-4e19-9424-20e5891bb2b6",
        "primaryId": "NCT02447003",
        "secondaryId": "NCT00917735",
        "label": "Contradiction",
        "statement_text": "It is appropriate to make clinical conclusions comparing cohort 2 of the secondary trial and cohort 2 the primary trial  despite the difference in cohort size ",
        "statement_nums": [
            "2 of the",
            "2 the primary"
        ],
        "premise_text": "Adverse Events 2: Total: 0/1 (0.00%) Anaemia 0/1 (0.00%) Febrile neutropenia 0/1 (0.00%) Cardiac tamponade 0/1 (0.00%) Myocarditis 0/1 (0.00%) Pericardial effusion 0/1 (0.00%) Pericarditis 0/1 (0.00%) Colitis 0/1 (0.00%) Constipation 0/1 (0.00%) Diarrhoea 0/1 (0.00%) Gastroenteritis eosinophilic 0/1 (0.00%) ",
        "premise_nums": [
            "0/1 (0.00%)"
        ]
    },
    {
        "id": "99e8ee0e-d72d-4e19-9424-20e5891bb2b6",
        "primaryId": "NCT02447003",
        "secondaryId": "NCT00917735",
        "label": "Contradiction",
        "statement_text": "It is appropriate to make clinical conclusions comparing cohort 2 of the secondary trial and cohort 2 the primary trial  despite the difference in cohort size ",
        "statement_nums": [
            "2 of the",
            "2 the primary"
        ],
        "premise_text": "Intestinal obstruction 0/1 (0.00%)Nausea 0/1 (0.00%) Adverse Events 2: Total: 8/537 (1.49%) Hypertension 1/537 (0.19%) Acoustic Neuroma 0/537 (0.00%) Diarrhea 1/537 (0.19%) Colitis 0/537 (0.00%) Elevated ALT or AST enzyme 0/537 (0.00%) Diagnosis of Uterine Cancer 2/537 (0.37%) Motorcycle accident 1/537 (0.19%) Fall 1/537 (0.19%) Surgery 2/537 (0.37%) ",
        "premise_nums": [
            "2/537 (0.37%)",
            "1/537 (0.19%)",
            "0/1 (0.00%)Nausea",
            "0/537 (0.00%)",
            "8/537 (1.49%)"
        ]
    },
    {
        "id": "f1b0653f-b5ce-4558-b325-56244940c0cd",
        "primaryId": "NCT01273896",
        "statement_text": "There was twice as many cases of Dyspnea as Cardiac adverse events in cohort 1 of the primary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Cardiac General  other1/22 (4.55%) Dyspnea (shortness of breath)2/22 (9.09%) ",
        "premise_nums": [
            "2/22 (9.09%)",
            "1/22 (4.55%)"
        ]
    },
    {
        "id": "24b24d36-2500-4841-99a3-13cba905d77d",
        "primaryId": "NCT01234402",
        "statement_text": "the primary trial at least 8 different types of cardiac related adverse events ",
        "statement_nums": [
            "8 different types"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Acute myocardial infarction 0/52 (0.00%) Atrial fibrillation 0/52 (0.00%) Cardiac failure 1/52 (1.92%) Cardiogenic shock 1/52 (1.92%) Palpitations 0/52 (0.00%) Pericardial effusion 0/52 (0.00%) Right ventricular failure 1/52 (1.92%) Adverse Events 2: Acute myocardial infarction 1/49 (2.04%) Atrial fibrillation 1/49 (2.04%) Cardiac failure 0/49 (0.00%) Cardiogenic shock 0/49 (0.00%) Palpitations 1/49 (2.04%) ",
        "premise_nums": [
            "1/49 (2.04%)",
            "0/49 (0.00%)",
            "1/52 (1.92%)",
            "0/52 (0.00%)"
        ]
    },
    {
        "id": "24b24d36-2500-4841-99a3-13cba905d77d",
        "primaryId": "NCT01234402",
        "statement_text": "the primary trial at least 8 different types of cardiac related adverse events ",
        "statement_nums": [
            "8 different types"
        ],
        "label": "Contradiction",
        "premise_text": "Pericardial effusion 4/49 (8.16%)Right ventricular failure 0/49 (0.00%) ",
        "premise_nums": [
            "0/49 (0.00%)",
            "4/49 (8.16%)Right"
        ]
    },
    {
        "id": "0797ff90-f847-4442-92fd-017c539bb38f",
        "primaryId": "NCT00546104",
        "statement_text": "1 patient in the primary trial suffered from a blood clot blocking their trachea ",
        "statement_nums": [
            "1 patient in"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 10/31 (32.26%) Edema  limb 1/31 (3.23%) Thrombosis1/31 (3.23%) diarrhea1/31 (3.23%) Pain 2/31 (6.45%) Pain  back1/31 (3.23%) Pain  extrimity limb 1/31 (3.23%) Syncope 1/31 (3.23%) Pain  chest/thorax1/31 (3.23%) hyponatremia 1/31 (3.23%) fever1/31 (3.23%) AST 1/31 (3.23%) infection1/31 (3.23%) Anorexia 1/31 (3.23%) ",
        "premise_nums": [
            "2/31 (6.45%)",
            "10/31 (32.26%)",
            "1/31 (3.23%)"
        ]
    },
    {
        "id": "0797ff90-f847-4442-92fd-017c539bb38f",
        "primaryId": "NCT00546104",
        "statement_text": "1 patient in the primary trial suffered from a blood clot blocking their trachea ",
        "statement_nums": [
            "1 patient in"
        ],
        "label": "Contradiction",
        "premise_text": "Dyspnea 2/31 (6.45%)",
        "premise_nums": [
            "2/31 (6.45%)"
        ]
    },
    {
        "id": "6b595151-7e51-4062-b587-3207ea251677",
        "primaryId": "NCT00606931",
        "statement_text": "the primary trial tests positron emission tomography as a technique for guiding a medical procedure ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "INTERVENTION 1: PET Guided Biopsy No comparison group  All enrolled participants were expected to undergo PET guided biopsy  ",
        "premise_nums": []
    },
    {
        "id": "e802b1f6-62fb-4759-b261-c69dbdc1d7ef",
        "primaryId": "NCT04080297",
        "secondaryId": "NCT02780713",
        "label": "Contradiction",
        "statement_text": "Both cohorts of the primary trial receive higher doses of Q-122 than either of the secondary trial cohorts receive of AZD9496 variants ",
        "statement_nums": [
            "AZD9496 variants",
            "122 than either"
        ],
        "premise_text": "INTERVENTION 1: 100 mg Q-122 Dosage was 100 mg Q-122 administered orally as two 50 mg capsules once daily for 28 days  INTERVENTION 2: 200 mg Q-122 Dosage was 200 mg Q-122 administered orally as four 50 mg capsules once daily for 28 days  INTERVENTION 1: Treatment Period 1 Participants received AZD9496 - Variant A (100 mg)  INTERVENTION 2: Treatment Period 2 Participants received AZD9496 - Reference (100 mg)  ",
        "premise_nums": [
            "100 mg Q",
            "122 administered orally",
            "2 Participants received",
            "122 Dosage was",
            "50 mg capsules",
            "1 Participants received",
            "200 mg Q"
        ]
    },
    {
        "id": "0a24a07e-2cb4-4591-aea4-a370f462cc49",
        "primaryId": "NCT00593346",
        "secondaryId": "NCT00902330",
        "label": "Entailment",
        "statement_text": "the primary trial treament last for a shorter period of time than the secondary trial treatment ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Accelerated Partial Breast Brachytherapy Each patient will receive accelerated partial breast brachytherapy with multiple plane implant  Patients will receive 3400 cGy delivered in 10 twice-daily fractions  Treatment is to be given over 5-7 days with a minimum of 6 hours separation between fractions  INTERVENTION 1: Arm I (Cranial Microcurrent Electrical Stimulation [CES]) ",
        "premise_nums": [
            "7 days with",
            "10 twice-daily fractions",
            "5-7 days",
            "3400 cGy delivered",
            "6 hours separation"
        ]
    },
    {
        "id": "0a24a07e-2cb4-4591-aea4-a370f462cc49",
        "primaryId": "NCT00593346",
        "secondaryId": "NCT00902330",
        "label": "Entailment",
        "statement_text": "the primary trial treament last for a shorter period of time than the secondary trial treatment ",
        "statement_nums": [],
        "premise_text": "Patients receive a CES unit (Alpha-Stim® 100 Microcurrent Stimulator) that passes microcurrent levels of biphasic electrical stimulation via ear-lobe electrodes  The CES unit is preset to provide 1 hour of 100 μA (sub-sensory level)  modified square-wave biphasic stimulation on a 50% duty cycle at .05 Hz  and to automatically turn off at the end of 1 hour  Patients use their CES unit once daily in weeks 1-18.energy-based therapy: Given once a day for 18 weeks ",
        "premise_nums": [
            "1 hour of",
            "100 Microcurrent Stimulator)",
            "50% duty",
            "1-18.energy-based therapy:"
        ]
    },
    {
        "id": "97d0bbf0-c2c5-409b-820b-6e14a6326b06",
        "primaryId": "NCT02322814",
        "secondaryId": "NCT00356148",
        "label": "Contradiction",
        "statement_text": "A patient with Histologically confirmed estrogen receptor-negative  progesterone receptor-negative  and human epidermal growth factor 2 positive breast cancer  with no known Brain metastases and no prior history of cardiac dysfunction  could be eligible for both the secondary trial and the primary trial ",
        "statement_nums": [
            "2 positive breast"
        ],
        "premise_text": "Inclusion Criteria: Histologically confirmed estrogen receptor (ER)-negative  progesterone receptor (PR)-negative  and human epidermal growth factor 2 (HER2)-negative adenocarcinoma of the breast with measurable metastatic or locally advanced disease History of autoimmune disease Brain metastases (symptomatic or nonsymptomatic) that have not been treated previously  are progressive  or require any type of therapy (e.g.  radiation  surgery  or steroids) to control symptoms from brain metastases within 30 days prior to first study treatment dose History of clinically significant cardiac dysfunction ",
        "premise_nums": [
            "30 days prior"
        ]
    },
    {
        "id": "97d0bbf0-c2c5-409b-820b-6e14a6326b06",
        "primaryId": "NCT02322814",
        "secondaryId": "NCT00356148",
        "label": "Contradiction",
        "statement_text": "A patient with Histologically confirmed estrogen receptor-negative  progesterone receptor-negative  and human epidermal growth factor 2 positive breast cancer  with no known Brain metastases and no prior history of cardiac dysfunction  could be eligible for both the secondary trial and the primary trial ",
        "statement_nums": [
            "2 positive breast"
        ],
        "premise_text": "Inclusion Criteria:Women at any age with early stage breast cancer (stage I-II) and American Society of Anesthesiologists (ASA) score of I-II  Exclusion Criteria: Ductal carcinoma in situ (DCIS; stage 0 cancer)  Advanced or distant metastatic stage  Receiving any neoadjuvant therapy  History of receiving any antibiotics within prior 3 months  History of immunodeficiency  Having a remote infection  History of reaction to study antibiotics  Denial of signing the consent form  ",
        "premise_nums": []
    },
    {
        "id": "bbb5ebc0-83c8-46cb-89b4-e1c67e042350",
        "primaryId": "NCT00859651",
        "statement_text": "Helen had stage III ovarian cancer 7 years prior  but has been disease-free for 5 years.  she is excluded from the primary trial ",
        "statement_nums": [
            "7 years prior"
        ],
        "label": "Contradiction",
        "premise_text": "Exclusion Criteria: Other prior malignancy  The following is allowed: adequately treated basal cell or squamous cell skin cancer  in situ cervical cancer  adequately treated stage I or II cancer from which the participant is currently in complete remission  or any other cancer (including breast cancer) for which the participant has been disease-free for 5 years  ",
        "premise_nums": []
    },
    {
        "id": "620106e8-2a7f-4078-80b6-d5f1840c66e1",
        "primaryId": "NCT00699491",
        "statement_text": "the primary trial results show that the Recommended Dose Level for Phase II Testing (RPTD) (Phase I) is 3 mg/ks cixutumumab ",
        "statement_nums": [
            "3 mg/ks cixutumumab"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Recommended Dose Level for Phase II Testing (RPTD) (Phase I) The RPTD is defined as the highest dose level at which at most one of 6 patients develops a dose limiting toxicity (DLT) during the first course of treatment and the next highest dose level has 2 or more DLTs  The number of patients in each cohort reporting a DLT is reported  Dose-limiting toxicities (DLTs) are defined as any of the following adverse events (AEs) that are related to study agent with an attribution of possible  probably  or definite and fulfilling one of the following criteria: Any grade 4 hematologic toxicity Hyperglycemia that cannot be stably controlled with diabetic medication ",
        "premise_nums": [
            "4 hematologic toxicity",
            "2 or more",
            "6 patients develops"
        ]
    },
    {
        "id": "620106e8-2a7f-4078-80b6-d5f1840c66e1",
        "primaryId": "NCT00699491",
        "statement_text": "the primary trial results show that the Recommended Dose Level for Phase II Testing (RPTD) (Phase I) is 3 mg/ks cixutumumab ",
        "statement_nums": [
            "3 mg/ks cixutumumab"
        ],
        "label": "Contradiction",
        "premise_text": "Any grade 3 or 4 non-hematologic toxicity (except asymptomatic medically manageable laboratory abnormalities such as hyperlipidemia  hypophosphatemia  and hypokalemia)Time frame: During first course Results 1: Arm/Group Title: Dose Level 1 Arm/Group Description: 25 mg temsirolimus IV over 30 minutes on days 1, 8, 15, and 22 3 mg/ks cixutumumab IV over 60 minutes on days 1, 8, 15, and 22 Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity  Overall Number of Participants Analyzed: 3 Measure Type: Number Unit of Measure: DLTs 2 Results 2: Arm/Group Title: Dose Level -1 ",
        "premise_nums": [
            "1 Arm/Group Description",
            "3 mg/ks cixutumumab",
            "3 or 4",
            "22 Courses repeat",
            "28 days in",
            "60 minutes on",
            "30 minutes on",
            "25 mg temsirolimus",
            "2 Results 2:",
            "3 Measure Type:",
            "4 non-hematologic toxicity"
        ]
    },
    {
        "id": "620106e8-2a7f-4078-80b6-d5f1840c66e1",
        "primaryId": "NCT00699491",
        "statement_text": "the primary trial results show that the Recommended Dose Level for Phase II Testing (RPTD) (Phase I) is 3 mg/ks cixutumumab ",
        "statement_nums": [
            "3 mg/ks cixutumumab"
        ],
        "label": "Contradiction",
        "premise_text": "Arm/Group Description: 20 mg temsirolimus IV over 30 minutes on days 1, 8, 15, and 223 mg/ks cixutumumab IV over 60 minutes on days 1, 8, 15, and 22 Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity  Overall Number of Participants Analyzed: 1 Measure Type: Number Unit of Measure: DLTs 1 ",
        "premise_nums": [
            "1 Measure Type:",
            "28 days in",
            "22 Courses repeat",
            "60 minutes on",
            "30 minutes on",
            "223 mg/ks cixutumumab",
            "20 mg temsirolimus"
        ]
    },
    {
        "id": "94a7b007-0332-4d01-979e-9677e5da4316",
        "primaryId": "NCT00513292",
        "statement_text": "In the primary trial the FEC-75 Then Paclitaxel/Trastuzumab group had more Invasive Tumor Remaining in the Breast than the Paclitaxel/Trastuzumab Then Trastuzumab/FEC-75 group ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: pCR Within the Breast  Defined as no Evidence of Invasive Tumor Remaining in the Breast at Surgery Following Completion of Chemotherapy Pathological complete response (pCR) rates will be based on institutional pathology reports  In the final analysis for publication  rates will be based on blinded central review of these institutional pathology reports  The Chi-squared test will be conducted at the two-sided 0.05 level  A 95% confidence interval will be computed for the difference in pCR rates  Time frame: Up to 5 years Results 1: Arm/Group Title: FEC-75 Then Paclitaxel/Trastuzumab ",
        "premise_nums": [
            "95% confidence",
            "5 years Results"
        ]
    },
    {
        "id": "2849d0ce-fed2-4c49-bec1-777c440caaeb",
        "primaryId": "NCT00127205",
        "statement_text": "More patients in the primary trial suffer from dysfunctions with ventricular contractions than ventricular systole ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Adverse Events 2: Left ventricular diastolic dysfunction 3/2186 (0.14%) Left ventricular systolic dysfunction 1/2186 (0.05%) ",
        "premise_nums": [
            "3/2186 (0.14%)",
            "1/2186 (0.05%)"
        ]
    },
    {
        "id": "aa6a20f8-ee49-42b7-9b9b-64caa8b22e35",
        "primaryId": "NCT00992225",
        "statement_text": "Only 2 of the 12 adverse event types recorded in the primary trial  occurred more than once ",
        "statement_nums": [
            "2 of the",
            "12 adverse event"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 10/33 (30.30%) Constipation 1/33 (3.03%) Dysphagia 1/33 (3.03%) Ileus 1/33 (3.03%) Nausea 1/33 (3.03%) Vomiting 1/33 (3.03%) Fatigue 1/33 (3.03%) Pain 1/33 (3.03%) Sepsis 2/33 (6.06%) Urinary tract infection 1/33 (3.03%) Alanine aminotransferase increased 1/33 (3.03%) Aspartate aminotransferase increased 1/33 (3.03%) Dehydration 2/33 (6.06%) ",
        "premise_nums": [
            "1/33 (3.03%)",
            "2/33 (6.06%)",
            "10/33 (30.30%)"
        ]
    },
    {
        "id": "01a57096-0278-4c70-be43-acd57010cd6f",
        "primaryId": "NCT01332630",
        "secondaryId": "NCT00121134",
        "label": "Entailment",
        "statement_text": "There were more patients with significantly elevated blood pressure in cohort 1 of the primary trial  than in cohort 1 of the secondary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Adverse Events 1: Total: 6/21 (28.57%) Hypertension 3/21 (14.29%) Edema 3/21 (14.29%) Nausea 2/21 (9.52%) Fracture 1/21 (4.76%) Dizziness 3/21 (14.29%) Syncope 2/21 (9.52%) Headache 2/21 (9.52%) Dyspnea 2/21 (9.52%) Hypoxia 3/21 (14.29%) Adverse Events 1: Total: 1/40 (2.50%) Hypertension 0/40 (0.00%) Lower GI bleed 1/40 (2.50%) ",
        "premise_nums": [
            "6/21 (28.57%)",
            "1/21 (4.76%)",
            "1/40 (2.50%)",
            "2/21 (9.52%)",
            "3/21 (14.29%)",
            "0/40 (0.00%)"
        ]
    },
    {
        "id": "01a57096-0278-4c70-be43-acd57010cd6f",
        "primaryId": "NCT01332630",
        "secondaryId": "NCT00121134",
        "label": "Entailment",
        "statement_text": "There were more patients with significantly elevated blood pressure in cohort 1 of the primary trial  than in cohort 1 of the secondary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Death 0/40 (0.00%)Headache 0/40 (0.00%) Dyspnea 0/40 (0.00%) Sinusitis 0/40 (0.00%) Wound Dehiscence 0/40 (0.00%) ",
        "premise_nums": [
            "0/40 (0.00%)Headache"
        ]
    },
    {
        "id": "49213077-0a5b-4368-a48a-282d2ca9d77a",
        "primaryId": "NCT02953860",
        "statement_text": "Patients in the primary trial receive more mg of Enzalutamide than Fulvestrant over the course of the study ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Fulvestrant with Enzalutamide: 500mg of Fulvestrant will be given IM on days 1, 15, 28, then every 4 weeks as per standard of care (SOC) and 160mg of Enzalutamide will be given PO daily  Patients will receive a tumor biopsy at the start of treatment and 4 weeks after the start of treatment  with an optional 3rd biopsy at the end treatment  ",
        "premise_nums": [
            "4 weeks as",
            "4 weeks after"
        ]
    },
    {
        "id": "426d3ecd-73e3-4226-83c6-cfcb9212ed62",
        "primaryId": "NCT00263588",
        "statement_text": "All the primary trial subjects either had Progressive disease  Complete CNS objective response rate or partial response rate ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: The Number of Participants With Central Nervous System (CNS) Best Overall Response Summary of CNS Objective Response (Lapatinib Monotherapy - MITT Population) Response to lapatinib in patients with progressive brain metastases from ErbB2-overexpressing breast cancer  The primary indicator of drug efficacy was CNS objective response rate  A CNS objective response was defined as either a Complete response (CR) or Partial response (PR)  as assessed by volumetric analysis of brain Magnetic resonance imaging (MRI)  provided there was no progression of systemic disease outside of the CNS  increasing steroid requirements  or worsening of Neurological signs and symptoms (NSS) ",
        "premise_nums": [
            "2-overexpressing breast"
        ]
    },
    {
        "id": "426d3ecd-73e3-4226-83c6-cfcb9212ed62",
        "primaryId": "NCT00263588",
        "statement_text": "All the primary trial subjects either had Progressive disease  Complete CNS objective response rate or partial response rate ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "A CNS objective response rate was defined as a 50% volumetric reduction in sum of CNS target lesions  with no new or progressive CNS or non-CNS lesions  no increases in tumor-related steroid requirements and no worsening of neurological signs or symptomsTime frame: time from baseline to data cutoff (25 Sept 2007); approximately 2 years Results 1: Arm/Group Title: Cohort A Arm/Group Description: 750mg lapatinib administered orally twice daily  Cohort A subjects had Eastern Cooperative Oncology Group (ECOG) performance status 0-1, and one or two prior trastuzumab-containing regimens  in total  for treatment of breast cancer in adjuvant and/or metastatic settings Overall Number of Participants Analyzed: 94 Measure Type: Count of Participants ",
        "premise_nums": [
            "94 Measure Type:",
            "50% volumetric",
            "0-1, and",
            "2 years Results",
            "25 Sept 2007);"
        ]
    },
    {
        "id": "426d3ecd-73e3-4226-83c6-cfcb9212ed62",
        "primaryId": "NCT00263588",
        "statement_text": "All the primary trial subjects either had Progressive disease  Complete CNS objective response rate or partial response rate ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Unit of Measure: Participants Complete response (CR): 0 0.0%Partial response (PR): 6 6.4% Stable disease (SD): 40 42.6% Progressive disease (PD): 40 42.6% Unknown: 8 8.5% Results 2: Arm/Group Title: Cohort B Arm/Group Description: 750mg lapatinib administered orally twice daily  Cohort B subjects had ECOG performance status 2 and/or more than 2 prior trastuzumab-containing regimens for treatment of breast cancer in the adjuvant and/or metastatic settings  Overall Number of Participants Analyzed: 143 Measure Type: Count of Participants Unit of Measure: Participants Complete response (CR): 0 0.0% Partial response (PR): 9 6.3% ",
        "premise_nums": [
            "2 and/or more",
            "2 prior trastuzumab",
            "0 0.0%Partial response",
            "8 8.5% Results 2",
            "6 6.4% Stable disease",
            "40 42.6% Progressive disease",
            "42.6% Unknown",
            "143 Measure Type:",
            "0 0.0% Partial response"
        ]
    },
    {
        "id": "426d3ecd-73e3-4226-83c6-cfcb9212ed62",
        "primaryId": "NCT00263588",
        "statement_text": "All the primary trial subjects either had Progressive disease  Complete CNS objective response rate or partial response rate ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Stable disease (SD): 46 32.2%Progressive disease (PD): 70 49.0% Unknown: 18 12.6% ",
        "premise_nums": [
            "46 32.2%Progressive disease",
            "49.0% Unknown"
        ]
    },
    {
        "id": "7c12676c-7973-4e9d-b1fc-3b14d241d0c8",
        "primaryId": "NCT00696072",
        "statement_text": "20 patients treated with Dasatinib and Letrozole in the primary trial had a Disease Free Interval (DFI) Greater Than 2 Years ",
        "statement_nums": [
            "20 patients treated"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Number of Participants With Clinical Benefit (CBR) and Number of Participants With CBR Having a Disease Free Interval (DFI) Greater Than 2 Years - Evaluable Population ",
        "premise_nums": []
    },
    {
        "id": "7c12676c-7973-4e9d-b1fc-3b14d241d0c8",
        "primaryId": "NCT00696072",
        "statement_text": "20 patients treated with Dasatinib and Letrozole in the primary trial had a Disease Free Interval (DFI) Greater Than 2 Years ",
        "statement_nums": [
            "20 patients treated"
        ],
        "label": "Entailment",
        "premise_text": "CBR=participants with complete response (CR) + participants with partial response (PR) + participants with stable disease (SD) for a length of time greater than  equal to 6 months  CR= Disappearance of all target lesions  No new lesions  PR= At least a 30% decrease in the sum of the longest diameter (LD) of target lesions taking as reference the baseline sum LD  SD= Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD) taking as reference the smallest sum LD since the treatment started  Physical examination,radiological assessment  and bone scans (if applicable) were used to assess outcome Time frame: First dose of study drug to last dose plus 7 days  up to study completion (approximately 6 years) Results 1: ",
        "premise_nums": [
            "30% decrease"
        ]
    },
    {
        "id": "7c12676c-7973-4e9d-b1fc-3b14d241d0c8",
        "primaryId": "NCT00696072",
        "statement_text": "20 patients treated with Dasatinib and Letrozole in the primary trial had a Disease Free Interval (DFI) Greater Than 2 Years ",
        "statement_nums": [
            "20 patients treated"
        ],
        "label": "Entailment",
        "premise_text": "Arm/Group Title: Dasatinib Plus LetrozoleArm/Group Description: Dasatinib + Letrozole: Tablets  Oral  once daily  up to 2 years Dasatinib 100 mg + Letrozole 2.5 mg Patients on letrozole plus dasatinib received both drugs until progressive disease (PD) or intolerable toxicity  If the intolerable toxicity was determined to be related to dasatinib  dasatinib was discontinued and the patient continued on single-agent letrozole  Although drugs were taken daily  cycle length was 28-days Overall Number of Participants Analyzed: 56 Measure Type: Number Unit of Measure: participants CBR (CR+PR+SD): 40 CBR  DFI smaller than = 2 Years: 20 ",
        "premise_nums": [
            "Letrozole 2.5 mg Patients",
            "2 years Dasatinib",
            "56 Measure Type:",
            "28-days Overall"
        ]
    },
    {
        "id": "7c12676c-7973-4e9d-b1fc-3b14d241d0c8",
        "primaryId": "NCT00696072",
        "statement_text": "20 patients treated with Dasatinib and Letrozole in the primary trial had a Disease Free Interval (DFI) Greater Than 2 Years ",
        "statement_nums": [
            "20 patients treated"
        ],
        "label": "Entailment",
        "premise_text": "CBR  DFI greater than 2 Years: 20",
        "premise_nums": []
    },
    {
        "id": "3419e901-5880-488d-912c-023e8d1b51c7",
        "primaryId": "NCT01466972",
        "secondaryId": "NCT01446159",
        "label": "Contradiction",
        "statement_text": "the primary trial recorded one patient with congestive Cardiac failure  the secondary trial recorded more ",
        "statement_nums": [],
        "premise_text": "Adverse Events 1: Heart Failure 1/30 (3.33%) Adverse Events 1: Cardiac failure 0/3 (0.00%) Adverse Events 2: Cardiac failure 0/3 (0.00%) ",
        "premise_nums": [
            "0/3 (0.00%)",
            "1/30 (3.33%)"
        ]
    },
    {
        "id": "cd645637-0a31-4f54-bc75-4a52349cf100",
        "primaryId": "NCT00748553",
        "statement_text": "Patients in the primary trial receive 50mg/m2, 75mg/m2 and 80mg/m2 daily every 5 days for each 4-week cycle",
        "statement_nums": [
            "80mg/m2 daily",
            "75mg/m2 and",
            "50mg/m2,",
            "5 days for",
            "2 daily every",
            "4-week cycle"
        ],
        "label": "Contradiction",
        "premise_text": "INTERVENTION 1: Phase 1 Azacitidine (Vidaza): 50mg/m2, 75mg/m2 or 100mg/m2 daily for 5 days for each 4-week cycle Nab-paclitaxel (Abraxane): 100mg/m2 weekly for 3 weeks of each 4-week cycle ",
        "premise_nums": [
            "3 weeks of",
            "2 weekly for",
            "1 Azacitidine (Vidaza):",
            "100mg/m2 daily",
            "50mg/m2,",
            "2 daily for",
            "5 days for",
            "75mg/m2 or",
            "4-week cycle",
            "100mg/m2 weekly"
        ]
    },
    {
        "id": "adfc79ba-2996-47ce-9986-7d287931df89",
        "primaryId": "NCT02115984",
        "statement_text": "A total of 3 patients in the primary trial experience a Herpes related adverse event ",
        "statement_nums": [
            "3 patients in"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 57/57 (100.00%) Dry eyes 13/33 (39.39%) Heartburn 9/33 (27.27%) Nausea after the CT (before day 7) 57/57 (100.00%) Herpetic eruption 0/33 (0.00%) Dry skin 15/33 (45.45%) Alopecia 57/57 (100.00%) Adverse Events 2: Total: 23/23 (100.00%) Dry eyes 2/11 (18.18%) Heartburn 2/11 (18.18%) Nausea after the CT (before day 7) 23/23 (100.00%) Herpetic eruption 3/11 (27.27%) Dry skin 9/11 (81.82%) ",
        "premise_nums": [
            "9/33 (27.27%)",
            "23/23 (100.00%)",
            "0/33 (0.00%)",
            "57/57 (100.00%)",
            "15/33 (45.45%)",
            "3/11 (27.27%)",
            "9/11 (81.82%)",
            "2/11 (18.18%)",
            "13/33 (39.39%)"
        ]
    },
    {
        "id": "adfc79ba-2996-47ce-9986-7d287931df89",
        "primaryId": "NCT02115984",
        "statement_text": "A total of 3 patients in the primary trial experience a Herpes related adverse event ",
        "statement_nums": [
            "3 patients in"
        ],
        "label": "Entailment",
        "premise_text": "Alopecia 23/23 (100.00%)",
        "premise_nums": [
            "23/23 (100.00%)"
        ]
    },
    {
        "id": "414ae027-b420-4f01-afd5-164cd8146a30",
        "primaryId": "NCT01129336",
        "secondaryId": "NCT01945775",
        "label": "Entailment",
        "statement_text": "16 participants of the primary trial are considered to be censored  the secondary trial used the same outcome measurement  but had no censored patients ",
        "statement_nums": [
            "16 participants of"
        ],
        "premise_text": "Outcome Measurement: Number of Participants With Progression Free Survival (PFS) ",
        "premise_nums": []
    },
    {
        "id": "45b2b9ec-ba58-4323-810a-4baed9c84a0e",
        "primaryId": "NCT00470847",
        "statement_text": "the primary trial participants will not receive any Lapatinib post WBRT ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "INTERVENTION 1: Lapatinib,Whole Brain Radiation,Herceptin Lapatinib before and during Whole Brain Radiation Therapy (WBRT)  then Herceptin 4mg/kg IV weekly ",
        "premise_nums": [
            "4mg/kg IV"
        ]
    },
    {
        "id": "72ffdfbf-aa72-4d44-814a-1d6ab8883898",
        "primaryId": "NCT00971945",
        "statement_text": "Patients must have already participated in a specific clinical study to participate in the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Inclusion Criteria: Subjects who were confirmed to have a response after receiving at least two courses of weekly paclitaxel therapy and considered to need to continue the therapy by the investigator/subinvestigator among the patients with advanced or recurrent breast cancer who had met the selection criteria and participated in the preceding phase II clinical study ",
        "premise_nums": []
    },
    {
        "id": "db613a72-e300-41a7-987f-788c306d94a4",
        "primaryId": "NCT00403130",
        "statement_text": "There were no cases of Leukopenia or Arrhythmia observed in patients participating in the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 18/26 (69.23%) Thrombocytopenia * 4/26 (15.38%) Neutropenia * 3/26 (11.54%) Epitasis * 1/26 (3.85%) Peripheral arterial ischemia * 1/26 (3.85%) Thrombosis * [1]1/26 (3.85%) Weakness * 1/26 (3.85%) Pain * [2]2/26 (7.69%) Febrile neutropenia * 1/26 (3.85%) Aspartate Aminotransferase * [3]1/26 (3.85%) Syncope * 1/26 (3.85%) ",
        "premise_nums": [
            "4/26 (15.38%)",
            "2/26 (7.69%)",
            "3/26 (11.54%)",
            "18/26 (69.23%)",
            "1/26 (3.85%)"
        ]
    },
    {
        "id": "2667d301-2efb-4d92-bc12-ccfc869e4835",
        "primaryId": "NCT02202252",
        "statement_text": "The difference between cohort 1 and 2 of the primary trial is the insertion of an additional negative pressure drain for patients in cohort 2.",
        "statement_nums": [
            "1 and 2"
        ],
        "label": "Entailment",
        "premise_text": "INTERVENTION 1: Single Drain Insertion of a single drain: A negative pressure drain will be inserted below the lower flap directing to the axilla in the single drain group  Ultrasonography after removal of the drains: One day after removal of the drains seroma under the flaps and in the axilla will be examined by ultrasonography  Insertion of a single drain: A negative pressure drain will be inserted below the lower flap directing to the axilla  Ultrasonography after removal of the drains: One day after removal of the drains seroma under the flaps and in the axilla will be examined by ultrasonography  INTERVENTION 2: Double Drain Insertion of double drains: Two negative pressure drains will be inserted into the axilla and below the lower flap in the double drains group  ",
        "premise_nums": []
    },
    {
        "id": "2667d301-2efb-4d92-bc12-ccfc869e4835",
        "primaryId": "NCT02202252",
        "statement_text": "The difference between cohort 1 and 2 of the primary trial is the insertion of an additional negative pressure drain for patients in cohort 2.",
        "statement_nums": [
            "1 and 2"
        ],
        "label": "Entailment",
        "premise_text": "Ultrasonography after removal of the drains: One day after removal of the drains seroma under the flaps and in the axilla will be examined by ultrasonography Insertion of double drains: Two drains will be inserted into the axilla and below the lower flap in the double drains group  Ultrasonography after removal of the drains: One day after removal of the drains seroma under the flaps and in the axilla will be examined by ultrasonography  ",
        "premise_nums": []
    },
    {
        "id": "60bff573-0251-4f05-b2b7-dec74c7363cc",
        "primaryId": "NCT00934856",
        "statement_text": "In total  across both cohorts of the primary trial  there was at least 2 fatigued patients ",
        "statement_nums": [
            "2 fatigued patients"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 2/6 (33.33%) Febrile neutropenia * 1/6 (16.67%) Neutropenia * 0/6 (0.00%) Thrombocytopenia * 1/6 (16.67%) Diarrhoea * 0/6 (0.00%) Pyrexia * 0/6 (0.00%) Thrombosis in device * 1/6 (16.67%) Fatigue * 0/6 (0.00%) Mucosal inflammation * 0/6 (0.00%) Device deployment issue * 0/6 (0.00%) Hepatocellular injury * 1/6 (16.67%) Cholecystitis * 1/6 (16.67%) ",
        "premise_nums": [
            "2/6 (33.33%)",
            "1/6 (16.67%)",
            "0/6 (0.00%)"
        ]
    },
    {
        "id": "60bff573-0251-4f05-b2b7-dec74c7363cc",
        "primaryId": "NCT00934856",
        "statement_text": "In total  across both cohorts of the primary trial  there was at least 2 fatigued patients ",
        "statement_nums": [
            "2 fatigued patients"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 2:Total: 2/6 (33.33%) Febrile neutropenia * 1/6 (16.67%) Neutropenia * 1/6 (16.67%) Thrombocytopenia * 0/6 (0.00%) Diarrhoea * 0/6 (0.00%) Pyrexia * 0/6 (0.00%) Thrombosis in device * 1/6 (16.67%) Fatigue * 0/6 (0.00%) Mucosal inflammation * 0/6 (0.00%) Device deployment issue * 0/6 (0.00%) Hepatocellular injury * 0/6 (0.00%) Cholecystitis * 0/6 (0.00%) ",
        "premise_nums": [
            "0/6 (0.00%)",
            "2/6 (33.33%)",
            "1/6 (16.67%)",
            "2:Total: 2/6"
        ]
    },
    {
        "id": "f6f8a0d3-6288-44cf-9b34-27444110dd10",
        "primaryId": "NCT01581619",
        "secondaryId": "NCT01008150",
        "label": "Entailment",
        "statement_text": "histologically confirmed extensive intraductal component of primary breast carcinoma would result in exclusion from the primary trial  but not from the secondary trial ",
        "statement_nums": [],
        "premise_text": "Exclusion Criteria: No histologic evidence of EIC Inclusion Criteria: Patients should have a life expectancy of at least 10 years  excluding their diagnosis of breast cancer  Submission of a block from the diagnostic biopsy sample and from the surgical sample  if gross residual disease greater than or equal to 1.0 cm was removed at the time of surgery  is required for all patients Patients of reproductive potential must agree to use an effective non-hormonal method of contraception during therapy and for at least 6 months after the last dose of study therapy  The Eastern Cooperative Oncology Group (ECOG) performance status must be 0 or 1. Patients must have the ability to swallow oral medication  The diagnosis of invasive adenocarcinoma of the breast must have been made by core needle biopsy or by limited incisional biopsy  ",
        "premise_nums": [
            "6 months after",
            "to 1.0 cm was",
            "0 or 1."
        ]
    },
    {
        "id": "f6f8a0d3-6288-44cf-9b34-27444110dd10",
        "primaryId": "NCT01581619",
        "secondaryId": "NCT01008150",
        "label": "Entailment",
        "statement_text": "histologically confirmed extensive intraductal component of primary breast carcinoma would result in exclusion from the primary trial  but not from the secondary trial ",
        "statement_nums": [],
        "premise_text": "Patients must have ER analysis performed on the primary tumor prior to randomization  If ER analysis is negative  then progesterone receptor (PgR) analysis must also be performed  (Patients are eligible with either hormone receptor-positive or hormone receptor-negative tumors.)Breast cancer must be determined to be HER2-positive prior to randomization  Assays using FISH or CISH require gene amplification  Assays using IHC require a strongly positive (3+) staining score  ",
        "premise_nums": [
            "2-positive prior",
            "(3+) staining"
        ]
    },
    {
        "id": "f6f8a0d3-6288-44cf-9b34-27444110dd10",
        "primaryId": "NCT01581619",
        "secondaryId": "NCT01008150",
        "label": "Entailment",
        "statement_text": "histologically confirmed extensive intraductal component of primary breast carcinoma would result in exclusion from the primary trial  but not from the secondary trial ",
        "statement_nums": [],
        "premise_text": "Clinical staging  based on the assessment by physical exam  must be American Joint Committee on Cancer (AJCC) stage IIB  IIIA  IIIB  or IIIC: cT2 and cN1; cT3 and cN0 or cN1; Any cT and cN2 or cN3; or cT4The patient must have a mass in the breast or axilla measuring greater than or equal to 2.0 cm by physical exam  unless the patient has inflammatory breast cancer  in which case measurable disease by physical exam is not required  ",
        "premise_nums": [
            "3 and cN0",
            "2 and cN1;",
            "2 or cN3;",
            "to 2.0 cm by"
        ]
    },
    {
        "id": "f6f8a0d3-6288-44cf-9b34-27444110dd10",
        "primaryId": "NCT01581619",
        "secondaryId": "NCT01008150",
        "label": "Entailment",
        "statement_text": "histologically confirmed extensive intraductal component of primary breast carcinoma would result in exclusion from the primary trial  but not from the secondary trial ",
        "statement_nums": [],
        "premise_text": "At the time of randomization  blood counts performed within 4 weeks prior to randomization must meet the following criteria: absolute neutrophil count (ANC) must be greater than or equal to 1200/mm3; Platelet count must be greater than or equal to 100,000/mm3; Hemoglobin must be greater than or equal to 10 g/dL",
        "premise_nums": [
            "100,000/mm3; Hemoglobin",
            "10 g/dL",
            "4 weeks prior",
            "1200/mm3; Platelet"
        ]
    },
    {
        "id": "f6f8a0d3-6288-44cf-9b34-27444110dd10",
        "primaryId": "NCT01581619",
        "secondaryId": "NCT01008150",
        "label": "Entailment",
        "statement_text": "histologically confirmed extensive intraductal component of primary breast carcinoma would result in exclusion from the primary trial  but not from the secondary trial ",
        "statement_nums": [],
        "premise_text": "The following criteria for evidence of adequate hepatic function performed within 4 weeks prior to randomization must be met: total bilirubin must be less than or equal to upper limit of normal (ULN) for the lab unless the patient has a bilirubin elevation greater than ULN to 1.5 x ULN due to Gilbert's disease or similar syndrome involving slow conjugation of bilirubin; and alkaline phosphatase must be less than or equal to 2.5 x ULN for the lab; and aspartate aminotransferase (AST) and ALT must be less than or equal to 1.5 x ULN for the lab ",
        "premise_nums": [
            "4 weeks prior",
            "to 2.5 x ULN",
            "to 1.5 x ULN"
        ]
    },
    {
        "id": "f6f8a0d3-6288-44cf-9b34-27444110dd10",
        "primaryId": "NCT01581619",
        "secondaryId": "NCT01008150",
        "label": "Entailment",
        "statement_text": "histologically confirmed extensive intraductal component of primary breast carcinoma would result in exclusion from the primary trial  but not from the secondary trial ",
        "statement_nums": [],
        "premise_text": "Patients with alkaline phosphatase greater than ULN but less than or equal to 2.5 x ULN are eligible for inclusion in the study if liver imaging (CT  MRI  PET  or PET-CT scan) performed within 4 weeks prior to randomization does not demonstrate metastatic disease and the requirements for adequate hepatic function are met ",
        "premise_nums": [
            "4 weeks prior",
            "to 2.5 x ULN"
        ]
    },
    {
        "id": "f6f8a0d3-6288-44cf-9b34-27444110dd10",
        "primaryId": "NCT01581619",
        "secondaryId": "NCT01008150",
        "label": "Entailment",
        "statement_text": "histologically confirmed extensive intraductal component of primary breast carcinoma would result in exclusion from the primary trial  but not from the secondary trial ",
        "statement_nums": [],
        "premise_text": "Patients with either unexplained skeletal pain or alkaline phosphatase that is greater than ULN but less than or equal to 2.5 x ULN are eligible for inclusion in the study if a bone scan  PET-CT scan  or PET scan performed within 4 weeks prior to randomization does not demonstrate metastatic disease  Patients with suspicious findings on bone scan or PET scan are eligible if suspicious findings are determined to be benign by x-ray  MRI  or biopsy Serum creatinine performed within 4 weeks prior to randomization must be less than or equal to 1.5 x ULN for the lab  ",
        "premise_nums": [
            "4 weeks prior",
            "to 2.5 x ULN",
            "to 1.5 x ULN"
        ]
    },
    {
        "id": "f6f8a0d3-6288-44cf-9b34-27444110dd10",
        "primaryId": "NCT01581619",
        "secondaryId": "NCT01008150",
        "label": "Entailment",
        "statement_text": "histologically confirmed extensive intraductal component of primary breast carcinoma would result in exclusion from the primary trial  but not from the secondary trial ",
        "statement_nums": [],
        "premise_text": "The left ventricular ejection fraction (LVEF) assessment by 2-D echocardiogram or multiple gated acquisition(MUGA) scan performed within 90 days prior to randomization must be greater than or equal to 50% regardless of the facility's LLN Exclusion Criteria: fine-needle aspiration (FNA) alone to diagnose the primary breast cancer  Excisional biopsy or lumpectomy performed prior to randomization  Surgical axillary staging procedure prior to randomization  (Procedures that are permitted prior to study entry include: 1) FNA or core biopsy of an axillary node for any patient  and 2) although not recommended  a pre-neoadjuvant therapy SN biopsy for patients with clinically negative axillary nodes.) ",
        "premise_nums": [
            "2-D echocardiogram",
            "50% regardless",
            "90 days prior"
        ]
    },
    {
        "id": "f6f8a0d3-6288-44cf-9b34-27444110dd10",
        "primaryId": "NCT01581619",
        "secondaryId": "NCT01008150",
        "label": "Entailment",
        "statement_text": "histologically confirmed extensive intraductal component of primary breast carcinoma would result in exclusion from the primary trial  but not from the secondary trial ",
        "statement_nums": [],
        "premise_text": "Definitive clinical or radiologic evidence of metastatic disease  (Note: Chest imaging [mandatory for all patients] and other imaging [if required] must have been performed within 90 days prior to randomization.)History of ipsilateral invasive breast cancer regardless of treatment or ipsilateral ductal carcinoma in situ (DCIS) treated with radiation therapy (RT)  (Patients with a history of LCIS are eligible.) Contralateral invasive breast cancer at any time  (Patients with contralateral DCIS or lobular carcinoma in situ (LCIS) are eligible.) ",
        "premise_nums": [
            "90 days prior"
        ]
    },
    {
        "id": "f6f8a0d3-6288-44cf-9b34-27444110dd10",
        "primaryId": "NCT01581619",
        "secondaryId": "NCT01008150",
        "label": "Entailment",
        "statement_text": "histologically confirmed extensive intraductal component of primary breast carcinoma would result in exclusion from the primary trial  but not from the secondary trial ",
        "statement_nums": [],
        "premise_text": "History of non-breast malignancies (except for in situ cancers treated only by local excision and basal cell and squamous cell carcinomas of the skin) within 5 years prior to randomization Known metastatic disease from any malignancy (solid tumor or hematologic)  Previous therapy with anthracyclines  taxanes  cyclophosphamide  trastuzumab  or neratinib for any malignancy  Treatment including RT  chemotherapy  and/or targeted therapy  administered for the currently diagnosed breast cancer prior to randomization  ",
        "premise_nums": [
            "5 years prior"
        ]
    },
    {
        "id": "f6f8a0d3-6288-44cf-9b34-27444110dd10",
        "primaryId": "NCT01581619",
        "secondaryId": "NCT01008150",
        "label": "Entailment",
        "statement_text": "histologically confirmed extensive intraductal component of primary breast carcinoma would result in exclusion from the primary trial  but not from the secondary trial ",
        "statement_nums": [],
        "premise_text": "Continued endocrine therapy such as raloxifene or tamoxifen (or other SERM) or an aromatase inhibitor  (Patients are eligible if these medications are discontinued prior to randomization.)Any continued sex hormonal therapy  e.g.  birth control pills and ovarian hormone replacement therapy  Patients are eligible if these medications are discontinued prior to randomization  Active hepatitis B or hepatitis C with abnormal liver function tests  Intrinsic lung disease resulting in dyspnea  Active infection or chronic infection requiring chronic suppressive antibiotics  Malabsorption syndrome  ulcerative colitis  inflammatory bowel disease  resection of the stomach or small bowel  or other disease or condition significantly affecting gastrointestinal function  ",
        "premise_nums": []
    },
    {
        "id": "f6f8a0d3-6288-44cf-9b34-27444110dd10",
        "primaryId": "NCT01581619",
        "secondaryId": "NCT01008150",
        "label": "Entailment",
        "statement_text": "histologically confirmed extensive intraductal component of primary breast carcinoma would result in exclusion from the primary trial  but not from the secondary trial ",
        "statement_nums": [],
        "premise_text": "Persistent greater than or equal to grade 2 diarrhea regardless of etiology Sensory or motor neuropathy greater than or equal to grade 2, as defined by the NCI Common Toxicity Criteria for Adverse Effects (CTCAE) v3.0. Conditions that would prohibit intermittent administration of corticosteroids for paclitaxel premedication  Chronic daily treatment with corticosteroids with a dose of greater than or equal to 10 mg/day methylprednisolone equivalent (excluding inhaled steroids)  ",
        "premise_nums": [
            "2 diarrhea regardless",
            "10 mg/day methylprednisolone"
        ]
    },
    {
        "id": "f6f8a0d3-6288-44cf-9b34-27444110dd10",
        "primaryId": "NCT01581619",
        "secondaryId": "NCT01008150",
        "label": "Entailment",
        "statement_text": "histologically confirmed extensive intraductal component of primary breast carcinoma would result in exclusion from the primary trial  but not from the secondary trial ",
        "statement_nums": [],
        "premise_text": "Uncontrolled hypertension defined as a systolic BP greater than 150 mmHg or diastolic BP greater than 90 mmHg  with or without anti-hypertensive medications  (Patients with hypertension that is well-controlled on medication are eligible.)",
        "premise_nums": [
            "150 mmHg or"
        ]
    },
    {
        "id": "8b0482c1-74d4-48ae-96bc-d80f8f1a0f50",
        "primaryId": "NCT00572728",
        "secondaryId": "NCT02472964",
        "label": "Contradiction",
        "statement_text": "Patients in the primary trial and the secondary trial will take Herceptin¬¨¬© (trastuzumab) or paclitaxel intravenously ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Diagnostic (18F-FLT) Patients undergo 18F-FLT PET/CT at baseline (prior to chemotherapy  FLT-1), early therapy (5-10 days after the initiation of the first course of chemotherapy  FLT-2), and post therapy (within 3 weeks prior to surgery  FLT-3). Patients undergo standard surgical resection of residual tumor following completion of neoadjuvant chemotherapy  Fluorothymidine F-18: Undergo 18F-FLT PET/CT Positron Emission Tomography: Undergo 18F-FLT PET/CT Computed Tomography: Undergo 18F-FLT PET/CT ",
        "premise_nums": [
            "(5-10 days",
            "10 days after",
            "3 weeks prior",
            "18F-FLT PET"
        ]
    },
    {
        "id": "8b0482c1-74d4-48ae-96bc-d80f8f1a0f50",
        "primaryId": "NCT00572728",
        "secondaryId": "NCT02472964",
        "label": "Contradiction",
        "statement_text": "Patients in the primary trial and the secondary trial will take Herceptin¬¨¬© (trastuzumab) or paclitaxel intravenously ",
        "statement_nums": [],
        "premise_text": "Laboratory Biomarker Analysis: Correlative studiesINTERVENTION 1: Herceptin© + Taxane Part 1: Herceptin© (trastuzumab) intravenously+ paclitaxel 80 mg/m2 weekly intravenously or docetaxel 75 mg/m2 intravenously once every three weeks (investigators choice) for 8 cycles then evaluate for primary endpoint  Part 2: If SD or PR  CR at cycle 9 (week 24) proceed to Herceptin© (trastuzumab) alone once every 3 weeks until DP or subject withdrawal   INTERVENTION 2: MYL-1401O Trastuzumab + Taxane ",
        "premise_nums": [
            "3 weeks until",
            "75 mg/m2 intravenously",
            "8 cycles then",
            "80 mg/m2 weekly",
            "2 intravenously once",
            "2 weekly intravenously"
        ]
    },
    {
        "id": "8b0482c1-74d4-48ae-96bc-d80f8f1a0f50",
        "primaryId": "NCT00572728",
        "secondaryId": "NCT02472964",
        "label": "Contradiction",
        "statement_text": "Patients in the primary trial and the secondary trial will take Herceptin¬¨¬© (trastuzumab) or paclitaxel intravenously ",
        "statement_nums": [],
        "premise_text": "Part 1:Myl 1401OTrastuzumab Intravenously + paclitaxel 80 mg/m2 weekly intravenously or docetaxel 75 mg/m2 intravenously once every three weeks (investigators choice) for 8 cycles then evaluate for primary endpoint Part 2: If SD or PR  CR at cycle 9 (week 24) proceed to Myl 1401O( Mylan Trastuzumab) alone once every 3 weeks until DP or subject withdrawal  ",
        "premise_nums": [
            "3 weeks until",
            "75 mg/m2 intravenously",
            "8 cycles then",
            "1:Myl 1401OTrastuzumab",
            "80 mg/m2 weekly",
            "2 intravenously once",
            "2 weekly intravenously"
        ]
    },
    {
        "id": "878dcfeb-c3db-4077-9a3e-8098efa80a99",
        "primaryId": "NCT00836186",
        "statement_text": "Patients cannot be excluded from the primary trial on the basis of race or ethnicity ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "INCLUSION CRITERIA: Women of all races and ethnic groups are eligible for this trial ",
        "premise_nums": []
    },
    {
        "id": "fc5dbfec-ba79-4c5d-9e38-3c97d0397570",
        "primaryId": "NCT04396665",
        "secondaryId": "NCT00493636",
        "label": "Contradiction",
        "statement_text": "Any patient can enter into the primary trial or the secondary trial; as long as they are willing to provide Informed consent and are capable of using the internet ",
        "statement_nums": [],
        "premise_text": "Inclusion Criteria: Informed consent signed Capability to use internet Exclusion Criteria: Breast cancer diagnosis duting the intervention Inclusion Criteria: Histologically or cytologically confirmed adenocarcinoma of the breast  Measurable or evaluable locally advanced or metastatic disease  Age 18 years  Disease progression during or after treatment with a bevacizumab-containing regimen in the adjuvant or first-line metastatic setting  Patients must have discontinued chemotherapy at least 3 weeks prior to randomization  No more than one prior chemotherapy regimen for locally advanced or metastatic disease  Prior hormonal therapy allowed provided it has been discontinued prior to randomization  Prior radiation therapy is allowed but must be completed at least 3 weeks prior to randomization  Previously radiated area(s) must not be the only site of disease  ",
        "premise_nums": [
            "3 weeks prior"
        ]
    },
    {
        "id": "fc5dbfec-ba79-4c5d-9e38-3c97d0397570",
        "primaryId": "NCT04396665",
        "secondaryId": "NCT00493636",
        "label": "Contradiction",
        "statement_text": "Any patient can enter into the primary trial or the secondary trial; as long as they are willing to provide Informed consent and are capable of using the internet ",
        "statement_nums": [],
        "premise_text": "ECOG Performance Status of 0 or 1.Adequate bone marrow  liver  and renal function Women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to randomization  and must agree to use adequate contraception prior to study entry  for the duration of study participation and 28 days after the last study drug dosing  Patients must be able and willing to sign a written informed consent  Patients must be able to swallow and retain oral medication  Exclusion Criteria: Patients with breast cancer over-expressing human epidermal growth factor receptor 2 (HER-2) (gene amplification by FISH or 3+ over-expression by immunohistochemistry)  Patients with unknown HER-2 status are not eligible  Patients with active brain metastases  ",
        "premise_nums": [
            "0 or 1.Adequate",
            "28 days after",
            "2 status are",
            "7 days prior"
        ]
    },
    {
        "id": "fc5dbfec-ba79-4c5d-9e38-3c97d0397570",
        "primaryId": "NCT04396665",
        "secondaryId": "NCT00493636",
        "label": "Contradiction",
        "statement_text": "Any patient can enter into the primary trial or the secondary trial; as long as they are willing to provide Informed consent and are capable of using the internet ",
        "statement_nums": [],
        "premise_text": "Major surgery  open biopsy  or significant traumatic injury within 4 weeks of randomization Prior use of gemcitabine/capecitabine or sorafenib  Evidence or history of bleeding diathesis or coagulopathy  Serious  non-healing wound  ulcer  or bone fracture  Substance abuse  or medical  psychological  or social condition that may interfere with the patient's participation in the study or evaluation of the study results  Use of cytochrome P450 enzyme-inducing anti-epileptic drugs is not allowed  Clinically significant cardiac disease Uncontrolled hypertension Thrombolic  embolic  venous  or arterial events such as a cerebrovascular accident including transient ischemic attacks within the past 6 months  ",
        "premise_nums": [
            "P450 enzyme-inducing",
            "4 weeks of"
        ]
    },
    {
        "id": "fc5dbfec-ba79-4c5d-9e38-3c97d0397570",
        "primaryId": "NCT04396665",
        "secondaryId": "NCT00493636",
        "label": "Contradiction",
        "statement_text": "Any patient can enter into the primary trial or the secondary trial; as long as they are willing to provide Informed consent and are capable of using the internet ",
        "statement_nums": [],
        "premise_text": "Pulmonary hemorrhage/bleeding event greater than NCI-CTCAE Grade 2 within 4 weeks of randomization Any other hemorrhage/bleeding event NCI-CTCAE Grade 3 within 4 weeks of randomization  Active clinically serious infection greater than NCI-CTCAE Grade 2. Known HIV infection or chronic hepatitis B or C (the safety and effectiveness of sorafenib in this patient population have not been studied)  Previous or concurrent cancer that is distinct in primary site or histology from breast cancer EXCEPT cervical cancer in-situ  treated basal cell carcinoma  superficial bladder tumors [Ta and Tis] or any cancer curatively treated greater than 5 years prior to randomization  ",
        "premise_nums": [
            "5 years prior",
            "2 within 4",
            "3 within 4"
        ]
    },
    {
        "id": "fc5dbfec-ba79-4c5d-9e38-3c97d0397570",
        "primaryId": "NCT04396665",
        "secondaryId": "NCT00493636",
        "label": "Contradiction",
        "statement_text": "Any patient can enter into the primary trial or the secondary trial; as long as they are willing to provide Informed consent and are capable of using the internet ",
        "statement_nums": [],
        "premise_text": "Known or suspected allergy to sorafenib or gemcitabine/capecitabine Prior or concurrent use of St  John's Wort or rifampin (rifampicin) within 3 weeks of randomization  Concurrent anti-cancer therapy other than gemcitabine/capecitabine and sorafenib/placebo  Prior treatment with any agent that targets VEGF or VEGFR (licensed or investigational)  except bevacizumab  Women who are pregnant or breast-feeding  Use of any investigational drug within 30 days or 5 half-lives  whichever is longer  preceding randomization  Inability to comply with protocol and/or not willing or not available for follow-up assessments  ",
        "premise_nums": [
            "3 weeks of",
            "30 days or",
            "5 half-lives"
        ]
    },
    {
        "id": "fc5dbfec-ba79-4c5d-9e38-3c97d0397570",
        "primaryId": "NCT04396665",
        "secondaryId": "NCT00493636",
        "label": "Contradiction",
        "statement_text": "Any patient can enter into the primary trial or the secondary trial; as long as they are willing to provide Informed consent and are capable of using the internet ",
        "statement_nums": [],
        "premise_text": "Any condition which in the investigator's opinion makes the patient unsuitable for the study participation ",
        "premise_nums": []
    },
    {
        "id": "a8514489-cb31-4c8a-abca-e1f7b3a8d4ce",
        "primaryId": "NCT01234337",
        "secondaryId": "NCT00217672",
        "label": "Entailment",
        "statement_text": "No cases of Anaphylaxis occurred in either the primary trial or the secondary trial ",
        "statement_nums": [],
        "premise_text": "Adverse Events 1: Total: 80/260 (30.77%) Anaemia * 2/260 (0.77%) Febrile neutropenia * 0/260 (0.00%) Neutropenia * 2/260 (0.77%) Thrombocytopenia * 0/260 (0.00%) Bundle branch block right * 0/260 (0.00%) Pericardial effusion * 0/260 (0.00%) Cardiopulmonary failure * 0/260 (0.00%) Aplasia * 0/260 (0.00%) Eye symptom * 1/260 (0.38%) Abdominal discomfort * 0/260 (0.00%) Adverse Events 2: ",
        "premise_nums": [
            "1/260 (0.38%)",
            "80/260 (30.77%)",
            "0/260 (0.00%)",
            "2/260 (0.77%)"
        ]
    },
    {
        "id": "a8514489-cb31-4c8a-abca-e1f7b3a8d4ce",
        "primaryId": "NCT01234337",
        "secondaryId": "NCT00217672",
        "label": "Entailment",
        "statement_text": "No cases of Anaphylaxis occurred in either the primary trial or the secondary trial ",
        "statement_nums": [],
        "premise_text": "Total: 71/267 (26.59%)Anaemia * 2/267 (0.75%) Febrile neutropenia * 1/267 (0.37%) Neutropenia * 0/267 (0.00%) Thrombocytopenia * 1/267 (0.37%) Bundle branch block right * 1/267 (0.37%) Pericardial effusion * 5/267 (1.87%) Cardiopulmonary failure * 1/267 (0.37%) Aplasia * 1/267 (0.37%) Eye symptom * 0/267 (0.00%) Abdominal discomfort * 1/267 (0.37%) Adverse Events 1: ",
        "premise_nums": [
            "1/267 (0.37%)",
            "2/267 (0.75%)",
            "71/267 (26.59%)Anaemia",
            "5/267 (1.87%)",
            "0/267 (0.00%)"
        ]
    },
    {
        "id": "a8514489-cb31-4c8a-abca-e1f7b3a8d4ce",
        "primaryId": "NCT01234337",
        "secondaryId": "NCT00217672",
        "label": "Entailment",
        "statement_text": "No cases of Anaphylaxis occurred in either the primary trial or the secondary trial ",
        "statement_nums": [],
        "premise_text": "Total: 13/74 (17.57%)neutropenia 1/74 (1.35%) left ventricular dysfunction 1/74 (1.35%) fistula enterovesical 1/74 (1.35%) constipation and hypokalemia 1/74 (1.35%) nausea  vomiting and burning abdominal pain 2/74 (2.70%) Infection 1/74 (1.35%) febrile neutropenia 3/74 (4.05%) speech impairment 1/74 (1.35%) dyspnea  pain 1/74 (1.35%) hemorrhage/bleeding 2/74 (2.70%) ",
        "premise_nums": [
            "13/74 (17.57%)neutropenia",
            "2/74 (2.70%)",
            "1/74 (1.35%)",
            "3/74 (4.05%)"
        ]
    },
    {
        "id": "64411610-090b-42d2-a176-d2b13ffef591",
        "primaryId": "NCT03210220",
        "secondaryId": "NCT00290745",
        "label": "Entailment",
        "statement_text": "Unlike the primary trial  the secondary trial has no control group ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Pecs Group Ultrasound guided pectoral nerve block is performed right after induction  before surgery  The needle is advanced to the tissue plane between the pectoralis major and pectoralis minor muscle at the vicinity of the pectoral branch of the acromiothoracic artery  and 10 mL of 0.5% ropivacaine deposited  In a similar manner  20 mL is deposited at the level of the third rib between the pectoralis minor muscle and the serratus anterior muscle   INTERVENTION 2: Control Group There is no block  INTERVENTION 1: Tamoxifen or Letrozole tamoxifen or letrozole work in treating women with ductal carcinoma in situ letrozole tamoxifen citrate conventional surgery neoadjuvant therapy ",
        "premise_nums": [
            "of 0.5% ropivacaine deposited",
            "10 mL of",
            "20 mL is"
        ]
    },
    {
        "id": "82bd50ac-9407-413b-9eb8-653cef49706c",
        "primaryId": "NCT02364388",
        "secondaryId": "NCT01425268",
        "label": "Contradiction",
        "statement_text": "warm saline solution is used in both the primary trial and the secondary trial ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: MAESTRO Baseline INTERVENTION 1: AeroForm Tissue Expansion AeroForm Tissue Expansion inflation with carbon dioxide by remote control AeroForm Tissue Expansion: The AeroForm Patient Controlled Tissue Expander is a breast tissue expander implanted following mastectomy and activated by remote control to release small doses of carbon dioxide from an internal reservoir to fill and inflate the expander  INTERVENTION 2: Saline Tissue Expansion Saline Tissue Expansion inflated by needle injections of saline Saline Tissue Expansion: A saline tissue expander is a breast tissue expander which is implanted following mastectomy and inflated over time using needle injections to fill and inflate the expander with saline  ",
        "premise_nums": []
    },
    {
        "id": "470611af-16b2-4094-ae2a-c9c6155e2672",
        "primaryId": "NCT02122796",
        "secondaryId": "NCT01575522",
        "label": "Entailment",
        "statement_text": "The intervention section for the primary trial does not detail the type or duration of the intervention  unlike the secondary trial ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Patients Undergoing Mastectomy Surgery Number of individuals having mastectomy surgery who were approached for participation in the trial INTERVENTION 1: Treatment (Tivantinib) Patients receive tivantinib PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity  Patients undergo blood sample collection at baseline and periodically during study for c-Met expression  relevant markers (HGF and VEGF)  PTEN loss  and PI3K mutation analysis by FISH and IHC  Archived tumor tissue samples are also analyzed  Laboratory Biomarker Analysis: Correlative studies Tivantinib: Given PO ",
        "premise_nums": [
            "1-21. Courses",
            "21 days in"
        ]
    },
    {
        "id": "f3a03aec-194d-4538-9be3-cea8281d995c",
        "primaryId": "NCT00693719",
        "statement_text": "the primary trial recorded less than 3 different Adverse Events  ",
        "statement_nums": [
            "3 different Adverse"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 4/31 (12.90%) Bleeding 1/31 (3.23%) Pain 2/31 (6.45%) Dehydration 1/31 (3.23%) Dyspnea 1/31 (3.23%) ",
        "premise_nums": [
            "4/31 (12.90%)",
            "2/31 (6.45%)",
            "1/31 (3.23%)"
        ]
    },
    {
        "id": "14a5e557-b223-4649-9867-0ff0e9001f5e",
        "primaryId": "NCT00911898",
        "secondaryId": "NCT02352779",
        "label": "Contradiction",
        "statement_text": "the primary trial and the secondary trial do not explain their interventions in the intervention section ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: MM-111 All participants INTERVENTION 1: Arm I (Low-dose Omega-3 Fatty Acid) Patients receive low-dose omega-3 fatty acid supplementation PO BID and placebo PO BID for 6 weeks  Omega-3 Fatty Acid: Given PO Placebo: Given PO Questionnaire Administration: Ancillary studies Laboratory Biomarker Analysis: Correlative studies INTERVENTION 2: Arm II (High-dose Omega-3 Fatty Acid) Patients receive high-dose omega-3 fatty acid supplementation PO BID for 6 weeks  Omega-3 Fatty Acid: Given PO Questionnaire Administration: Ancillary studies Laboratory Biomarker Analysis: Correlative studies ",
        "premise_nums": [
            "111 All participants",
            "3 Fatty Acid:",
            "3 Fatty Acid)",
            "3 fatty acid"
        ]
    },
    {
        "id": "c8df3461-4063-4fb0-ae48-f57062eb0a68",
        "primaryId": "NCT03329937",
        "statement_text": "the primary trial Participants received niraparib 200 milligrams (mg) PO once daily for a 28 day cycle  for 3 cycles  after which all participants undergo neoadjuvant chemotherapy ",
        "statement_nums": [
            "28 day cycle",
            "200 milligrams (mg)"
        ],
        "label": "Contradiction",
        "premise_text": "INTERVENTION 1: Niraparib 200 mg Participants received niraparib 200 milligrams (mg) orally once daily in 28-day treatment cycles  After 2 cycles  participants either underwent surgery  received additional cycles of niraparib (maximum of 6 cycles total)  or received neoadjuvant chemotherapy  at physician's discretion  A breast magnetic resonance imaging (MRI) was performed at the end of cycle 2 and breast ultrasounds were performed at the end of each cycle  including any additional cycles beyond cycle 2. After completion of all neoadjuvant therapy participants proceeded to surgery  at which time pathological complete response (pCR) was assessed  ",
        "premise_nums": [
            "200 mg Participants",
            "6 cycles total)",
            "200 milligrams (mg)",
            "2 and breast",
            "28-day treatment"
        ]
    },
    {
        "id": "1cd7cf90-bf66-480b-9227-2f7d2eccd647",
        "primaryId": "NCT01539317",
        "secondaryId": "NCT01323530",
        "label": "Contradiction",
        "statement_text": "the primary trial uses a topical intervention and the secondary trial exclusively uses intravenous treatments ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Topical Saline Topical liquid lidocaine: active intervention drug numbs the hypersensitive mucosa of the vulvar vestibule Topical saline: saline applied to the vestibule mucosa will not reverse the local tenderness INTERVENTION 2: Topical Liquid Lidocaine Topical liquid lidocaine: active intervention drug numbs the hypersensitive mucosa of the vulvar vestibule Topical saline: saline applied to the vestibule mucosa will not reverse the local tenderness INTERVENTION 1: Phase 1b (Schedule 1): Eribulin Mesilate (1.2 mg/m^2) ",
        "premise_nums": [
            "(1.2 mg/m"
        ]
    },
    {
        "id": "1cd7cf90-bf66-480b-9227-2f7d2eccd647",
        "primaryId": "NCT01539317",
        "secondaryId": "NCT01323530",
        "label": "Contradiction",
        "statement_text": "the primary trial uses a topical intervention and the secondary trial exclusively uses intravenous treatments ",
        "statement_nums": [],
        "premise_text": "Participants received eribulin mesilate 1.2 mg/m^2, injection  intravenously  once  on Day 1 and capecitabine 1000 mg/m^2, tablets  orally  twice daily from Day 1 to 14 in each 21-day treatment cycle for as long as the treatment was clinically appropriate according to the judgment of the investigator or until the occurrence of PD  undue toxicity  the presence of other medical conditions that prohibit continuation of therapy  pregnancy  a delay of more than 14 days in starting the next cycle during Phase 1b (Schedule 1).INTERVENTION 2: Phase 1b (Schedule 1): Eribulin Mesilate (1.6 mg/m^2) ",
        "premise_nums": [
            "mesilate 1.2 mg/m",
            "1 to 14",
            "14 days in",
            "1000 mg/m^2,",
            "1 and capecitabine",
            "21-day treatment",
            "(1.6 mg/m"
        ]
    },
    {
        "id": "1cd7cf90-bf66-480b-9227-2f7d2eccd647",
        "primaryId": "NCT01539317",
        "secondaryId": "NCT01323530",
        "label": "Contradiction",
        "statement_text": "the primary trial uses a topical intervention and the secondary trial exclusively uses intravenous treatments ",
        "statement_nums": [],
        "premise_text": "Participants received eribulin mesilate 1.6 mg/m^2, injection  intravenously  once  on Day 1 and capecitabine 1000 mg/m^2, tablets  orally  twice daily from Day 1 to 14 in each 21-day treatment cycle for as long as the treatment was clinically appropriate according to the judgment of the investigator or until the occurrence of PD  undue toxicity  the presence of other medical conditions that prohibit continuation of therapy  pregnancy  a delay of more than 14 days in starting the next cycle during Phase 1b (Schedule 1).",
        "premise_nums": [
            "mesilate 1.6 mg/m",
            "1 to 14",
            "14 days in",
            "1000 mg/m^2,",
            "1 and capecitabine",
            "21-day treatment"
        ]
    },
    {
        "id": "15f9d033-ebf7-44b3-94e2-3b8ee90b862b",
        "primaryId": "NCT00370552",
        "statement_text": "There over 20% difference in the Percentage of Participants With Best Tumor Response of Partial Response (PR) or Complete Response (CR) between the 2 cohorts of the primary trial ",
        "statement_nums": [
            "2 cohorts of",
            "20% difference"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Percentage of Participants With Best Tumor Response of Partial Response (PR) or Complete Response (CR) While On-study CR=Disappearance of all clinical and radiologic evidence of target lesions; PR=At least 30% reduction in the sum of the longest diameter of all target lesions  Time frame: Baseline visit and then every 8 weeks to 12 months  then every 3 months until disease progression Results 1: Arm/Group Title: Ixabepilone  16 mg/m^2 + Bevacizumab  10 mg/kg ",
        "premise_nums": [
            "8 weeks to",
            "3 months until",
            "30% reduction",
            "16 mg/m^2",
            "10 mg/kg"
        ]
    },
    {
        "id": "15f9d033-ebf7-44b3-94e2-3b8ee90b862b",
        "primaryId": "NCT00370552",
        "statement_text": "There over 20% difference in the Percentage of Participants With Best Tumor Response of Partial Response (PR) or Complete Response (CR) between the 2 cohorts of the primary trial ",
        "statement_nums": [
            "2 cohorts of",
            "20% difference"
        ],
        "label": "Entailment",
        "premise_text": "Arm/Group Description: Ixabepilone,16 mg/m^2, administered as a 1-hour intravenous (IV) infusion on Days 1, 8, and 15 of a 28-day cycle until disease progression or unacceptable toxicity  Bevacizumab  10 mg/kg  administered after ixabepilone as IV infusion every 2 weeks  Bevacizumab to be infused over 90 minutes for the first dose  and if well tolerated for 60 minutes  for the second dose  Then if still tolerated  over 30 minutes for subsequent infusions  Bevacizumab was to be dosed until disease progression or unacceptable toxicity Overall Number of Participants Analyzed: 46 Measure Type: Number ",
        "premise_nums": [
            "46 Measure Type:",
            "1-hour intravenous",
            "15 of a",
            "10 mg/kg",
            "28-day cycle",
            "90 minutes for",
            "30 minutes for"
        ]
    },
    {
        "id": "15f9d033-ebf7-44b3-94e2-3b8ee90b862b",
        "primaryId": "NCT00370552",
        "statement_text": "There over 20% difference in the Percentage of Participants With Best Tumor Response of Partial Response (PR) or Complete Response (CR) between the 2 cohorts of the primary trial ",
        "statement_nums": [
            "2 cohorts of",
            "20% difference"
        ],
        "label": "Entailment",
        "premise_text": "Unit of Measure: Percentage of participants 47.8 (32.9 to 63.1)Results 2: Arm/Group Title: Ixabepilone  40 mg/m^2 + Bevacizumab  15 mg/kg ",
        "premise_nums": [
            "9 to 63.1)Results",
            "15 mg/kg",
            "40 mg/m^2"
        ]
    },
    {
        "id": "15f9d033-ebf7-44b3-94e2-3b8ee90b862b",
        "primaryId": "NCT00370552",
        "statement_text": "There over 20% difference in the Percentage of Participants With Best Tumor Response of Partial Response (PR) or Complete Response (CR) between the 2 cohorts of the primary trial ",
        "statement_nums": [
            "2 cohorts of",
            "20% difference"
        ],
        "label": "Entailment",
        "premise_text": "Arm/Group Description: Ixabepilone  40 mg/m^2, administered as a 3-hour IV infusion on Day 1 of a 21-day cycle until disease progression or unacceptable toxicity After Cycle 4, dose reduction to 32 mg/m^2 implemented for all subsequent cycles  Bevacizumab  15 mg/kg  administered after ixabepilone as IV infusion every 3 weeks  Bevacizumab to be infused over 90 minutes for the first dose  and if well tolerated for 60 minutes  for the second dose  Then if still tolerated  over 30 minutes for subsequent infusions  Bevacizumab was to be dosed until disease progression or unacceptable toxicity Overall Number of Participants Analyzed: 45 Measure Type: Number ",
        "premise_nums": [
            "15 mg/kg",
            "45 Measure Type:",
            "40 mg/m^2,",
            "32 mg/m^2",
            "2 implemented for",
            "3-hour IV",
            "1 of a",
            "90 minutes for",
            "30 minutes for",
            "21-day cycle"
        ]
    },
    {
        "id": "15f9d033-ebf7-44b3-94e2-3b8ee90b862b",
        "primaryId": "NCT00370552",
        "statement_text": "There over 20% difference in the Percentage of Participants With Best Tumor Response of Partial Response (PR) or Complete Response (CR) between the 2 cohorts of the primary trial ",
        "statement_nums": [
            "2 cohorts of",
            "20% difference"
        ],
        "label": "Entailment",
        "premise_text": "Unit of Measure: Percentage of participants 71.1 (55.7 to 83.6)",
        "premise_nums": []
    },
    {
        "id": "ab6a9d30-eb92-4503-a69c-bdf3f3e6c38d",
        "primaryId": "NCT00266799",
        "statement_text": "None of the patients in cohort 1 of the primary trial had Acute coronary syndrome ",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 30/98 (30.61%) NEUTROPENIA 1/98 (1.02%) ATRIAL FIBRILLATION 1/98 (1.02%) CARDIAC FAILURE 1/98 (1.02%) TACHYCARDIA 0/98 (0.00%) ACUTE VESTIBULAR SYNDROME 1/98 (1.02%) VERTIGO 0/98 (0.00%) ABDOMINAL PAIN 0/98 (0.00%) COLITIS 0/98 (0.00%) DIARRHOEA 2/98 (2.04%) FEMORAL HERNIA 0/98 (0.00%) HAEMATEMESIS 0/98 (0.00%) ILEUS 0/98 (0.00%) ",
        "premise_nums": [
            "1/98 (1.02%)",
            "2/98 (2.04%)",
            "30/98 (30.61%)",
            "0/98 (0.00%)"
        ]
    },
    {
        "id": "ab6a9d30-eb92-4503-a69c-bdf3f3e6c38d",
        "primaryId": "NCT00266799",
        "statement_text": "None of the patients in cohort 1 of the primary trial had Acute coronary syndrome ",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "NAUSEA 0/98 (0.00%)",
        "premise_nums": [
            "0/98 (0.00%)"
        ]
    },
    {
        "id": "51cf1333-78b1-410a-82fe-aabfaa00a840",
        "primaryId": "NCT02995980",
        "statement_text": "A patient presenting Glomerular filtration rate of 63, a severe iodinated contrast allergy and with BI-RADS category c breast tissue would be eligilbe for the primary trial ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria: Glomerular filtration rategreater than 60 Heterogeneously or extremely dense breasts (BI-RADS category c or d)  Exclusion Criteria: History of iodinated contrast allergy ",
        "premise_nums": [
            "60 Heterogeneously or"
        ]
    },
    {
        "id": "d2e957c3-1e20-4ccd-9cf7-4cc2da63f74d",
        "primaryId": "NCT00662025",
        "statement_text": "on assessment 0 the primary trial Participants had a confirmed disappearance of all target and non-target lesions ",
        "statement_nums": [
            "0 the primary"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Number of Participants With Objective Response Based on Data Review Committee's Assessment Number of participants with objective response based on assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors version 1.0 (RECIST)  CR is defined as disappearance of all target and non-target lesions  PR is defined as 30% decrease in sum of the longest dimensions (LDs) of the target lesions taking as reference the baseline sum LD according to RECIST  Confirmed responses are those that persist on repeat evaluation 4 weeks after initial documentation of response  Time frame: Day 1 of Cycle 2, every 6 weeks after Cycle 2, and at the end of Cycle 8. Results 1: Arm/Group Title: SUNITINIB+CAPECITABINE ",
        "premise_nums": [
            "30% decrease",
            "6 weeks after",
            "1 of Cycle",
            "4 weeks after"
        ]
    },
    {
        "id": "d2e957c3-1e20-4ccd-9cf7-4cc2da63f74d",
        "primaryId": "NCT00662025",
        "statement_text": "on assessment 0 the primary trial Participants had a confirmed disappearance of all target and non-target lesions ",
        "statement_nums": [
            "0 the primary"
        ],
        "label": "Entailment",
        "premise_text": "Arm/Group Description: Sunitinib was administered orally from Day 1 at the starting dose of 37.5 mg/day on a continuous daily dosing schedule in 21-day cycles  Capecitabine was administered orally from Days 1 to 14 every 21 days at a starting dose of 2,000 mg/m^2/day. Participants were monitored for toxicity  and sunitinib and/or capecitabine dosing could be interrupted or reduced according to individual tolerance  Participants with progressive disease (PD) or intolerable toxicity were considered for discontinuation from the study Overall Number of Participants Analyzed: 63 Measure Type: Number Unit of Measure: participants Total Number of Participants with CR+PR: 19 Complete Response (CR): 0 Partial Response (PR): 19 ",
        "premise_nums": [
            "of 2,000 mg/m",
            "19 Complete Response",
            "1 to 14",
            "63 Measure Type:",
            "0 Partial Response",
            "21-day cycles",
            "2,000 mg/m^2/day",
            "21 days at",
            "1 at the",
            "of 37.5 mg/day"
        ]
    },
    {
        "id": "aef2367d-78a5-4dc7-a6f7-d96415082362",
        "primaryId": "NCT00570921",
        "secondaryId": "NCT00274456",
        "label": "Entailment",
        "statement_text": "There is one case of Cardiopulmonary failure in cohort 2 of the secondary trial  but none in cohort 1 of the primary trial ",
        "statement_nums": [
            "2 of the",
            "1 of the"
        ],
        "premise_text": "Adverse Events 1: Total: 5/33 (15.15%) Left Ventricular Thrombus * 1/33 (3.03%) Nausea * 1/33 (3.03%) Acute Cholecystitis * 1/33 (3.03%) Renal Failure * 1/33 (3.03%) Pneumonia * 1/33 (3.03%) Adverse Events 2: Total: 12/76 (15.79%) Neutropenia 2/76 (2.63%) Febrile neutropenia 1/76 (1.32%) Anaemia 0/76 (0.00%) Thrombocytopenia 0/76 (0.00%) ",
        "premise_nums": [
            "12/76 (15.79%)",
            "5/33 (15.15%)",
            "1/33 (3.03%)",
            "1/76 (1.32%)",
            "0/76 (0.00%)",
            "2/76 (2.63%)"
        ]
    },
    {
        "id": "aef2367d-78a5-4dc7-a6f7-d96415082362",
        "primaryId": "NCT00570921",
        "secondaryId": "NCT00274456",
        "label": "Entailment",
        "statement_text": "There is one case of Cardiopulmonary failure in cohort 2 of the secondary trial  but none in cohort 1 of the primary trial ",
        "statement_nums": [
            "2 of the",
            "1 of the"
        ],
        "premise_text": "Cardiopulmonary failure 1/76 (1.32%)Optic ischaemic neuropathy 1/76 (1.32%) Bowel peristalsis increased 0/76 (0.00%) Colitis 1/76 (1.32%) Diarrhoea 0/76 (0.00%) Gastritis 0/76 (0.00%) Nausea 1/76 (1.32%) ",
        "premise_nums": [
            "0/76 (0.00%)",
            "1/76 (1.32%)Optic"
        ]
    },
    {
        "id": "29ae75a2-d8d2-4427-bba3-ab2c411d5718",
        "primaryId": "NCT00201851",
        "statement_text": "There were no cases of Oesophageal spasming  Diastolic dysfunction or thrombosis observed in the primary trial ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 0/244 (0.00%) Pregnancy *0/244 (0.00%) Endocervical cancer *0/244 (0.00%) Nosocomial pneumonia *0/244 (0.00%) Venous thrombosis *0/244 (0.00%) Adverse Events 2: Total: 5/255 (1.96%) Pregnancy *1/255 (0.39%) Endocervical cancer *1/255 (0.39%) Nosocomial pneumonia *2/255 (0.78%) Venous thrombosis *1/255 (0.39%) ",
        "premise_nums": [
            "5/255 (1.96%)",
            "2/255 (0.78%)",
            "1/255 (0.39%)",
            "0/244 (0.00%)"
        ]
    },
    {
        "id": "985c4cb3-2684-4a67-a479-998602044a0d",
        "primaryId": "NCT00475670",
        "statement_text": "compared to cohort 1 of the primary trial  other than sudden death  there are more cases of every observed adverse event in cohort 2.",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 0/3 (0.00%) Febrile Neutropenia * 0/3 (0.00%) Neutropenia * 0/3 (0.00%) Sudden Death * 0/3 (0.00%) Bacterial Infection * 0/3 (0.00%) Bronchitis * 0/3 (0.00%) Sepsis * 0/3 (0.00%) Lymphoedema * 0/3 (0.00%) Adverse Events 2: Total: 6/41 (14.63%) Febrile Neutropenia * 1/41 (2.44%) Neutropenia * 1/41 (2.44%) ",
        "premise_nums": [
            "0/3 (0.00%)",
            "6/41 (14.63%)",
            "1/41 (2.44%)"
        ]
    },
    {
        "id": "985c4cb3-2684-4a67-a479-998602044a0d",
        "primaryId": "NCT00475670",
        "statement_text": "compared to cohort 1 of the primary trial  other than sudden death  there are more cases of every observed adverse event in cohort 2.",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Sudden Death * 1/41 (2.44%)Bacterial Infection * 1/41 (2.44%) Bronchitis * 1/41 (2.44%) Sepsis * 1/41 (2.44%) Lymphoedema * 1/41 (2.44%) ",
        "premise_nums": [
            "1/41 (2.44%)Bacterial"
        ]
    },
    {
        "id": "39e8a353-4eb0-4cf6-b0c2-f36c4bf589f3",
        "primaryId": "NCT00107276",
        "secondaryId": "NCT00232505",
        "label": "Contradiction",
        "statement_text": "Less than 5% of patients undergoing the intervention in the primary trial had adverse events  in comparison almost 10% patients in cohort 1 of the secondary trial experienced an adverse event  and less than a 1/3 of those in cohort 2 of the secondary trial had adverse events ",
        "statement_nums": [
            "2 of the",
            "5% of",
            "10% patients",
            "3 of those",
            "1/3 of",
            "1 of the"
        ],
        "premise_text": "Adverse Events 1: Total: 4/95 (4.21%) Adverse Events 1: Total: 3/31 (9.68%) Adverse Events 2: Total: 8/25 (32.00%) ",
        "premise_nums": [
            "8/25 (32.00%)",
            "3/31 (9.68%)",
            "4/95 (4.21%)"
        ]
    },
    {
        "id": "d695120e-db68-481d-9023-881e48654e29",
        "primaryId": "NCT00617539",
        "statement_text": "Patients with Extracranial metastases are still permited to enter in the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "DISEASE CHARACTERISTICS: Histologically or cytologically confirmed breast cancer with radiographically confirmed metastases to the brain Extracranial metastases allowed ",
        "premise_nums": []
    },
    {
        "id": "5319ac1a-07ae-4531-bf93-5fce83016c87",
        "primaryId": "NCT00941330",
        "statement_text": "Patients in cohort 1 of the primary trial receive Exemestane more often than cohort 2 patients receive Cytoxan ",
        "statement_nums": [
            "2 patients receive",
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "INTERVENTION 1: A: Exemestane ARM A: Patients will be treated with exemestane  Exemestane: 25 mg daily by mouth for 6 to 12 months  INTERVENTION 2: B: Docetaxel and Cytoxan ARM B: Patients will be treated with docetaxel and cytoxan  Docetaxel: Docetaxel (75 mg/m²) into a vein once every 3 weeks for 6 cycles (6 times in about 24 weeks)  Cytoxan: Cytoxan (600 mg/m²) into a vein once every 3 weeks for 6 cycles (6 times in about 24 weeks)  ",
        "premise_nums": [
            "6 cycles (6",
            "25 mg daily",
            "3 weeks for",
            "6 to 12"
        ]
    },
    {
        "id": "087aba29-40c6-4453-a44b-e63c3867e5b4",
        "primaryId": "NCT00388726",
        "statement_text": "A 75 year old female patient  with an ECOG of 3 and an estimated life expectancy of more than a year would be eligible for the primary trial ",
        "statement_nums": [
            "3 and an",
            "75 year old"
        ],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria: Age greater than or equal 18 years  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2. Life expectancy of greater than or equal 3 months  ",
        "premise_nums": [
            "0 to 2."
        ]
    },
    {
        "id": "c66f3e9e-f232-4035-b705-2785946d1542",
        "primaryId": "NCT03624972",
        "secondaryId": "NCT01216176",
        "label": "Entailment",
        "statement_text": "A 72 year old patient suffering from dementia would be excluded from both the secondary trial and the primary trial ",
        "statement_nums": [
            "72 year old"
        ],
        "premise_text": "Exclusion Criteria: Overt cognitive dysfunction or psychiatric disturbance or severe mental illness (e.g.  dementia  suicidal behavior  or psychosis)  as observed or judged by the researcher or referring source  Exclusion Criteria - Phase 2 (Cohort B): Any evidence of severe or uncontrolled systemic psychiatric or medical conditions (eg  Severe hepatic impairment  interstitial lung disease [bilateral  diffuse  parenchymal lung disease]) or current unstable or uncompensated respiratory or cardiac conditions which make it undesirable for the patient to participate in the study or which could jeopardize compliance with the protocol ",
        "premise_nums": []
    },
    {
        "id": "c679f426-b235-4ae9-ad6c-4f1a46a494d2",
        "primaryId": "NCT01390064",
        "secondaryId": "NCT00485953",
        "label": "Contradiction",
        "statement_text": "All Cohorts of the primary trial and the secondary trial receive their treatment via Subcutaneous administration ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Initial Cohort Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG Subcutaneous administration 5 doses of 300 micrograms Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG: All research participants will receive the Mimotope P10s-PADRE/MONTANIDE ISA 51 VG vaccine via subcutaneous (SC) injection following the schedule INTERVENTION 2: Escalation Cohort Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG Subcutaneous administration of 5 doses of 500 micrograms ",
        "premise_nums": [
            "300 micrograms Vaccination",
            "5 doses of",
            "51 VG vaccine",
            "51 VG Subcutaneous"
        ]
    },
    {
        "id": "c679f426-b235-4ae9-ad6c-4f1a46a494d2",
        "primaryId": "NCT01390064",
        "secondaryId": "NCT00485953",
        "label": "Contradiction",
        "statement_text": "All Cohorts of the primary trial and the secondary trial receive their treatment via Subcutaneous administration ",
        "statement_nums": [],
        "premise_text": "Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG: All research participants will receive the Mimotope P10s-PADRE/MONTANIDE ISA 51 VG vaccine via subcutaneous (SC) injection following the scheduleINTERVENTION 1: Active Medicine Group risedronate 35 mg weekly INTERVENTION 2: Placebo Group Received placebo medication once weekly ",
        "premise_nums": [
            "35 mg weekly",
            "51 VG vaccine"
        ]
    },
    {
        "id": "122b1aef-4506-464d-9852-47caa508b047",
        "primaryId": "NCT00879086",
        "statement_text": "Cohort 1 and 2 of the primary trial had the same number of patients with anaemia and Neutropenia  but Cohort 1 had 8 more cases of Leukopenia than cohort 2.",
        "statement_nums": [
            "1 and 2",
            "1 had 8"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Anaemia 1/51 (1.96%) Leukopenia 1/51 (1.96%) Neutropenia 1/51 (1.96%) Adverse Events 2: Anaemia 1/50 (2.00%) Leukopenia 0/50 (0.00%) Neutropenia 1/50 (2.00%) ",
        "premise_nums": [
            "0/50 (0.00%)",
            "1/51 (1.96%)",
            "1/50 (2.00%)"
        ]
    },
    {
        "id": "4a4f3e9e-6a29-4715-8000-2eec90e9bb5d",
        "primaryId": "NCT00841828",
        "secondaryId": "NCT01959490",
        "label": "Contradiction",
        "statement_text": "All cohorts in the primary trial had lower number of participants with pCR compared to cohort 1 of the secondary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Outcome Measurement: Complete Pathological Response (pCR) Rate in Breast and Axilla According to the Miller&Payne Criteria (G5-A and G5-D). Within 3-4 weeks after last docetaxel dose the surgery was performed to evaluate pathological response  According to the Miller&Payne Criteria  pCR in node-negative patients is a grade 5-A and in node-positive patients is a grade 5-D. Time frame: Up to 16 weeks Results 1: Arm/Group Title: Arm 1: EC -greater than D + Lapatinib Arm/Group Description: EC -greater than D + Lapatinib Drugs plus Biological ",
        "premise_nums": [
            "5-D). Within",
            "5-A and",
            "5-D. Time",
            "3-4 weeks",
            "4 weeks after",
            "16 weeks Results"
        ]
    },
    {
        "id": "4a4f3e9e-6a29-4715-8000-2eec90e9bb5d",
        "primaryId": "NCT00841828",
        "secondaryId": "NCT01959490",
        "label": "Contradiction",
        "statement_text": "All cohorts in the primary trial had lower number of participants with pCR compared to cohort 1 of the secondary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Epirubicin + Cyclophosphamide (EC) each 21 days for 4 cycles -greater than Docetaxel (D) + lapatinib each 21 days for 4 cycles)Overall Number of Participants Analyzed: 51 Measure Type: Number Unit of Measure: percentage of participants with pCR 23.5 (11.9 to 35.1) Results 2: Arm/Group Title: Arm 2: EC -greater than D + Trastuzumab Arm/Group Description: EC -greater than D + Trastuzumab Drug plus Biological ",
        "premise_nums": [
            "51 Measure Type:",
            "21 days for",
            "9 to 35.1)"
        ]
    },
    {
        "id": "4a4f3e9e-6a29-4715-8000-2eec90e9bb5d",
        "primaryId": "NCT00841828",
        "secondaryId": "NCT01959490",
        "label": "Contradiction",
        "statement_text": "All cohorts in the primary trial had lower number of participants with pCR compared to cohort 1 of the secondary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Epirubicin + Cyclophosphamide (EC) each 21 days for 4 cycles -greater than Docetaxel (D) + Trastuzumab each 21 days for 4 cyclesOverall Number of Participants Analyzed: 48 Measure Type: Number Unit of Measure: percentage of participants with pCR 47.9 (33.8 to 62.0) Outcome Measurement: Number of Patients With a Pathological Complete Response (pCR) Who Received Targeted Therapy With Trastuzumab and Pertuzumab or Bevacizumab Predicted by Genomically-derived Molecular Subtypes  ",
        "premise_nums": [
            "21 days for",
            "4 cyclesOverall Number",
            "8 to 62.0)",
            "48 Measure Type:"
        ]
    },
    {
        "id": "4a4f3e9e-6a29-4715-8000-2eec90e9bb5d",
        "primaryId": "NCT00841828",
        "secondaryId": "NCT01959490",
        "label": "Contradiction",
        "statement_text": "All cohorts in the primary trial had lower number of participants with pCR compared to cohort 1 of the secondary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Number of patients with a pathological complete response (pCR) who received targeted therapy with trastuzumab and pertuzumab or bevacizumab predicted by genomically-derived molecular subtypes (HER2 positive or HER2 negative  pCR is defined as absence of invasive cancer in breast or lymph nodes after neoadjuvant chemotherapy Time frame: Up to 30 days after last cycle of treatment Results 1: Arm/Group Title: Cohort 1P (HER2 Positive) ",
        "premise_nums": [
            "30 days after",
            "2 positive or"
        ]
    },
    {
        "id": "4a4f3e9e-6a29-4715-8000-2eec90e9bb5d",
        "primaryId": "NCT00841828",
        "secondaryId": "NCT01959490",
        "label": "Contradiction",
        "statement_text": "All cohorts in the primary trial had lower number of participants with pCR compared to cohort 1 of the secondary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Arm/Group Description: Patients receive a run-in Pertuzumab treatment of 840 mg IV over 60 minutes on day -14 followed by Trastuzumab IV over 30-60 minutes and Pertuzumab IV over 30-60 minutes  docetaxel IV  and carboplatin IV on day 1. Treatment repeats very 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity Overall Number of Participants Analyzed: 5 Measure Type: Count of Participants Unit of Measure: Participants 4 80.0% Results 2: Arm/Group Title: Cohort 1T (HER2 Positive) ",
        "premise_nums": [
            "840 mg IV",
            "4 80.0% Results 2",
            "60 minutes on",
            "6 courses in",
            "60 minutes and",
            "3 weeks for",
            "5 Measure Type:",
            "14 followed by",
            "30-60 minutes"
        ]
    },
    {
        "id": "4a4f3e9e-6a29-4715-8000-2eec90e9bb5d",
        "primaryId": "NCT00841828",
        "secondaryId": "NCT01959490",
        "label": "Contradiction",
        "statement_text": "All cohorts in the primary trial had lower number of participants with pCR compared to cohort 1 of the secondary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Arm/Group Description: Patients receive a run-in Trastuzumab treatment of 8 mg/kg IV over 90 minutes on day -14 followed by Trastuzumab IV over 30-60 minutes and Pertuzumab IV over 30-60 minutes  Docetaxel IV  and Carboplatin IV on day 1. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity Overall Number of Participants Analyzed: 6 Measure Type: Count of Participants Unit of Measure: Participants 6 100.0% ",
        "premise_nums": [
            "6 courses in",
            "60 minutes and",
            "3 weeks for",
            "8 mg/kg IV",
            "14 followed by",
            "6 Measure Type:",
            "30-60 minutes",
            "90 minutes on"
        ]
    },
    {
        "id": "9f7dc38b-1945-4035-a0ff-e08ead55145b",
        "primaryId": "NCT00297596",
        "secondaryId": "NCT00580333",
        "label": "Entailment",
        "statement_text": "Patients who completed a trastuzumab regiment  to treat the current breast cancer greater than 2 weeks before study entry are eligible for the primary trial but excluded from the secondary trial ",
        "statement_nums": [
            "2 weeks before"
        ],
        "premise_text": "Inclusion Criteria: Patients may have received one prior trastuzumab/chemotherapy containing regimen or prior single agent trastuzumab  All prior chemotherapy  trastuzumab and radiation therapy should be completed greater than 2 weeks before enrollment  Exclusion Criteria: Any prior cytotoxic chemotherapy or radiation for the current breast cancer ",
        "premise_nums": [
            "2 weeks before"
        ]
    },
    {
        "id": "b259774e-410a-49aa-b5d4-31b8d9505fc3",
        "primaryId": "NCT01525589",
        "statement_text": "People who inherit undamaged variants of the BReast CAncer gene 1 or 2 are eligible for the primary trial ",
        "statement_nums": [
            "1 or 2"
        ],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria: Known deleterious germline mutation of BRCA1/2 (Patients in Cohorts A and A1) ",
        "premise_nums": [
            "1/2 (Patients"
        ]
    },
    {
        "id": "e09a11e4-afc8-4351-a5bc-d847424c79ce",
        "primaryId": "NCT01565499",
        "secondaryId": "NCT01234402",
        "label": "Contradiction",
        "statement_text": "Some of the patients in the primary trial were recorded as having heart related adverse events  whereas many patients in the secondary trial experienced several different breathing related issues ",
        "statement_nums": [],
        "premise_text": "Adverse Events 1: Total: 6/81 (7.41%) Colitis [1]1/81 (1.23%) Multiple Sclerosis Relapse 1/81 (1.23%) Neurotoxicity [2]2/81 (2.47%) Community-acquired pneumonia 1/81 (1.23%) Local Infection Reservoir Area 1/81 (1.23%) Adverse Events 1: Total: 20/52 (38.46%) Anaemia 0/52 (0.00%) Pancytopenia 1/52 (1.92%) Acute myocardial infarction 0/52 (0.00%) Atrial fibrillation 0/52 (0.00%) ",
        "premise_nums": [
            "0/52 (0.00%)",
            "2/81 (2.47%)",
            "20/52 (38.46%)",
            "1/81 (1.23%)",
            "1/52 (1.92%)",
            "6/81 (7.41%)"
        ]
    },
    {
        "id": "e09a11e4-afc8-4351-a5bc-d847424c79ce",
        "primaryId": "NCT01565499",
        "secondaryId": "NCT01234402",
        "label": "Contradiction",
        "statement_text": "Some of the patients in the primary trial were recorded as having heart related adverse events  whereas many patients in the secondary trial experienced several different breathing related issues ",
        "statement_nums": [],
        "premise_text": "Cardiac failure 1/52 (1.92%)Cardiogenic shock 1/52 (1.92%) Palpitations 0/52 (0.00%) Pericardial effusion 0/52 (0.00%) Right ventricular failure 1/52 (1.92%) Abdominal pain 0/52 (0.00%) Ascites 3/52 (5.77%) Adverse Events 2: Total: 25/49 (51.02%) Anaemia 2/49 (4.08%) Pancytopenia 0/49 (0.00%) Acute myocardial infarction 1/49 (2.04%) Atrial fibrillation 1/49 (2.04%) ",
        "premise_nums": [
            "3/52 (5.77%)",
            "0/52 (0.00%)",
            "0/49 (0.00%)",
            "1/52 (1.92%)Cardiogenic",
            "25/49 (51.02%)",
            "1/49 (2.04%)",
            "2/49 (4.08%)"
        ]
    },
    {
        "id": "e09a11e4-afc8-4351-a5bc-d847424c79ce",
        "primaryId": "NCT01565499",
        "secondaryId": "NCT01234402",
        "label": "Contradiction",
        "statement_text": "Some of the patients in the primary trial were recorded as having heart related adverse events  whereas many patients in the secondary trial experienced several different breathing related issues ",
        "statement_nums": [],
        "premise_text": "Cardiac failure 0/49 (0.00%)Cardiogenic shock 0/49 (0.00%) Palpitations 1/49 (2.04%) Pericardial effusion 4/49 (8.16%) Right ventricular failure 0/49 (0.00%) Abdominal pain 1/49 (2.04%) Ascites 0/49 (0.00%) ",
        "premise_nums": [
            "1/49 (2.04%)",
            "0/49 (0.00%)Cardiogenic",
            "4/49 (8.16%)"
        ]
    },
    {
        "id": "d22f01f0-b2be-45b9-8996-11727750b91e",
        "primaryId": "NCT01720602",
        "secondaryId": "NCT00082810",
        "label": "Contradiction",
        "statement_text": "the primary trial participants receive more anastrozole  Fulvestrant and exemestane than patients in the secondary trial ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Treatment (Vorinostat  AI Therapy) Patients receive vorinostat PO 5 days a week for 3 weeks  Patients also receive AI therapy comprising either anastrozole PO daily  letrozole PO daily  or exemestane PO daily for 4 weeks  Courses repeat every 28 days in the absence of disease progression and unacceptable toxicity  vorinostat: Given PO anastrozole: Given PO letrozole: Given PO exemestane: Given PO positron emission tomography: Correlative studies F-18 16 alpha-fluoroestradiol: Correlative studies fludeoxyglucose F 18: Correlative studies laboratory biomarker analysis: Correlative studies INTERVENTION 1: ",
        "premise_nums": [
            "16 alpha-fluoroestradiol:",
            "28 days in",
            "5 days a"
        ]
    },
    {
        "id": "d22f01f0-b2be-45b9-8996-11727750b91e",
        "primaryId": "NCT01720602",
        "secondaryId": "NCT00082810",
        "label": "Contradiction",
        "statement_text": "the primary trial participants receive more anastrozole  Fulvestrant and exemestane than patients in the secondary trial ",
        "statement_nums": [],
        "premise_text": "Fulvestrant 250 mg + Tipifarnib 300 mgPatients receive fulvestrant 250 mg intramuscularly on day 1 and oral tipifarnib 300 mg twice daily on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity ",
        "premise_nums": [
            "250 mg intramuscularly",
            "28 days in",
            "1-21. Courses",
            "300 mgPatients receive",
            "1 and oral",
            "300 mg twice"
        ]
    },
    {
        "id": "893d5684-03f8-4acd-86e4-6d38eea3ce16",
        "primaryId": "NCT00129935",
        "statement_text": "There were 80% more cases of embolisms in cohort 2 of the primary trial than cohort 1.",
        "statement_nums": [
            "2 of the",
            "80% more"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 111/669 (16.59%) Leukocytes * [1]1/669 (0.15%) Hemoglobin * [1]1/669 (0.15%) Hemoglobin * [2]0/669 (0.00%) CNS cerebrovascular ischemia * [1]0/669 (0.00%) CNS cerebrovascular ischemia * [3]0/669 (0.00%) Heart Failure * [1]3/669 (0.45%) Thrombosis/embolism * [1]1/669 (0.15%) ",
        "premise_nums": [
            "0/669 (0.00%)",
            "3/669 (0.45%)",
            "111/669 (16.59%)",
            "1/669 (0.15%)"
        ]
    },
    {
        "id": "893d5684-03f8-4acd-86e4-6d38eea3ce16",
        "primaryId": "NCT00129935",
        "statement_text": "There were 80% more cases of embolisms in cohort 2 of the primary trial than cohort 1.",
        "statement_nums": [
            "2 of the",
            "80% more"
        ],
        "label": "Contradiction",
        "premise_text": "Thrombosis/embolism * [3]0/669 (0.00%)Adverse Events 2: Total: 138/715 (19.30%) Leukocytes * [1]0/715 (0.00%) Hemoglobin * [1]0/715 (0.00%) Hemoglobin * [2]1/715 (0.14%) CNS cerebrovascular ischemia * [1]1/715 (0.14%) CNS cerebrovascular ischemia * [3]1/715 (0.14%) Heart Failure * [1]1/715 (0.14%) ",
        "premise_nums": [
            "0/669 (0.00%)Adverse",
            "0/715 (0.00%)",
            "138/715 (19.30%)",
            "1/715 (0.14%)"
        ]
    },
    {
        "id": "893d5684-03f8-4acd-86e4-6d38eea3ce16",
        "primaryId": "NCT00129935",
        "statement_text": "There were 80% more cases of embolisms in cohort 2 of the primary trial than cohort 1.",
        "statement_nums": [
            "2 of the",
            "80% more"
        ],
        "label": "Contradiction",
        "premise_text": "Thrombosis/embolism * [1]3/715 (0.42%)Thrombosis/embolism * [3]2/715 (0.28%) ",
        "premise_nums": [
            "3/715 (0.42%)Thrombosis/embolism",
            "2/715 (0.28%)"
        ]
    },
    {
        "id": "4b46164d-a4c2-4738-be36-588ab231ceb1",
        "primaryId": "NCT01596751",
        "secondaryId": "NCT00193050",
        "label": "Entailment",
        "statement_text": "There were 0 patients with Dysphagia or Fever in the primary trial and the secondary trial cohorts ",
        "statement_nums": [
            "0 patients with"
        ],
        "premise_text": "Dysphagia 0/5 (0.00%) Fever 0/5 (0.00%) Adverse Events 1: Total: 17/110 (15.45%) Hemoglobin [1]1/110 (0.91%) Esophagitis 1/110 (0.91%) Dysphagia 1/110 (0.91%) Nausea/Vomiting 1/110 (0.91%) Nausea 1/110 (0.91%) Fever 1/110 (0.91%) Febrile Neutropenia 11/110 (10.00%) Infection - Other [2]1/110 (0.91%) Infection - Pneumonia 1/110 (0.91%) Dyspnea 2/110 (1.82%) ",
        "premise_nums": [
            "2/110 (1.82%)",
            "1/110 (0.91%)",
            "11/110 (10.00%)",
            "17/110 (15.45%)",
            "0/5 (0.00%)"
        ]
    },
    {
        "id": "4b46164d-a4c2-4738-be36-588ab231ceb1",
        "primaryId": "NCT01596751",
        "secondaryId": "NCT00193050",
        "label": "Entailment",
        "statement_text": "There were 0 patients with Dysphagia or Fever in the primary trial and the secondary trial cohorts ",
        "statement_nums": [
            "0 patients with"
        ],
        "premise_text": "Hypoxia 1/110 (0.91%)",
        "premise_nums": [
            "1/110 (0.91%)"
        ]
    },
    {
        "id": "d9236874-7f3d-4402-9699-2889db9f5c61",
        "primaryId": "NCT00320541",
        "statement_text": "Cohort 2 of the primary trial recorded 10% more cases of Leukopenia than cohort 1.",
        "statement_nums": [
            "2 of the",
            "10% more"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Leukopenia 1/94 (1.06%) Adverse Events 2: Leukopenia 3/93 (3.23%) ",
        "premise_nums": [
            "1/94 (1.06%)",
            "3/93 (3.23%)"
        ]
    },
    {
        "id": "e33825f1-45df-41f5-ba07-e9059636a146",
        "primaryId": "NCT00057941",
        "secondaryId": "NCT01806259",
        "label": "Contradiction",
        "statement_text": "DLT occurence  used as the outcome measurement in the secondary trial and Clinical Benefit Rate  used in the primary trial are not synonymous  and represent entirely different patient characteristics ",
        "statement_nums": [],
        "premise_text": "Outcome Measurement: Clinical Benefit Rate Clinical benefit = complete response (CR)  partial response (PR)  or stable disease (SD) lasting for at least 6 months  assessed per Response Evaluation Criteria of Solid Tumor (RECIST).CR=disappearance of all target and non-target lesions  PR= disappearance of or at least 30% decrease in the sum of the longest diameters of target lesions  with non-progressive disease in non-target lesions  SD= sum of the longest diameters of target lesions decrease smaller than 30% or increase smaller than 20%, with non-progressive disease in non-target lesions  141 eligible  treated patients were included  ",
        "premise_nums": [
            "30% decrease",
            "30% or"
        ]
    },
    {
        "id": "e33825f1-45df-41f5-ba07-e9059636a146",
        "primaryId": "NCT00057941",
        "secondaryId": "NCT01806259",
        "label": "Contradiction",
        "statement_text": "DLT occurence  used as the outcome measurement in the secondary trial and Clinical Benefit Rate  used in the primary trial are not synonymous  and represent entirely different patient characteristics ",
        "statement_nums": [],
        "premise_text": "Time frame: assessed every 3 cycles while on treatment  assessed every 3 months when follow up smaller than 2 years  every 6 months between 2-3 years,no specific requirements after 3 yearsOutcome Measurement: Recurrence-free Survival 2 years for the primary analysis + 3 additional years for secondary analysis (From date of randomization until the date of first documented progression or date of death from any cause  whichever came first  assessed up to 5 years) Time frame: 5 years ",
        "premise_nums": [
            "2-3 years,no",
            "3 cycles while",
            "3 additional years",
            "2 years for",
            "3 months when",
            "6 months between",
            "3 yearsOutcome Measurement:"
        ]
    },
    {
        "id": "5b0295e1-a322-40af-9acf-9cc1d55d3e64",
        "primaryId": "NCT00295620",
        "secondaryId": "NCT03366428",
        "label": "Contradiction",
        "statement_text": "the secondary trial and the primary trial use similar outcome measures  evaluating how long patients survive after treatment ",
        "statement_nums": [],
        "premise_text": "Outcome Measurement: Disease-free Survival After Prolonged Endocrine Treatment To determine whether 5 years of additional Anastrozole was more effective than 2 years of additional Anastrozole after 5 years of adjuvant endocrine therapy in terms of disease-free survival  Outcome Measurement: Changes in QTcF After Treatment With DS-8201a in Participants With HER2-expressing Metastatic and/or Unresectable Breast Cancer ",
        "premise_nums": [
            "2-expressing Metastatic",
            "5 years of",
            "2 years of"
        ]
    },
    {
        "id": "3658f2f7-a497-4abb-badb-c877036456f2",
        "primaryId": "NCT00077857",
        "statement_text": "Patients must be older than 18, female  have three or more target lesions and more than 1 regiment of chemotherapy to participate in the primary trial ",
        "statement_nums": [
            "1 regiment of"
        ],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria: women greater than or equal 18 years of age; greater than or equal 1 target lesion; greater than or equal 2 regimens of chemotherapy for advanced/metastatic disease  ",
        "premise_nums": [
            "1 target lesion;",
            "18 years of",
            "2 regimens of"
        ]
    },
    {
        "id": "37bc71d5-d9c0-4174-8da5-725d2d53a91b",
        "primaryId": "NCT00303108",
        "statement_text": "The Cohort of the primary trial which received D+C and Taxane Na‚àö√òve  produced marginally better results than the other cohort ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Objective Response Rate (ORR) Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR)  Disappearance of all target lesions; Partial Response (PR)  greater than or equal 30% decrease in the sum of the longest diameter of target lesions; Objective response (OR) = CR + PR  Time frame: From date of randomization until the date of first documented progression or date of intolerable toxicity  whichever came first  assessed up to 54 months  Results 1: Arm/Group Title: D+C and Taxane Naive Arm/Group Description: Doxil  Carboplatin and Taxane naive Overall Number of Participants Analyzed: 39 Measure Type: Number ",
        "premise_nums": [
            "30% decrease",
            "39 Measure Type:"
        ]
    },
    {
        "id": "37bc71d5-d9c0-4174-8da5-725d2d53a91b",
        "primaryId": "NCT00303108",
        "statement_text": "The Cohort of the primary trial which received D+C and Taxane Na‚àö√òve  produced marginally better results than the other cohort ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Unit of Measure: percentage of participants 30.8 (17.0 to 47.6)Results 2: Arm/Group Title: D+C and Taxane Pretreated Arm/Group Description: Doxil  Carboplatin and Taxane pretreated Overall Number of Participants Analyzed: 42 Measure Type: Number Unit of Measure: percentage of participants 31.0 (17.6 to 47.1) ",
        "premise_nums": [
            "0 to 47.6)Results",
            "42 Measure Type:",
            "6 to 47.1)"
        ]
    },
    {
        "id": "51ac9fe0-2bfa-42f5-aaec-69e0c5cdff7c",
        "primaryId": "NCT02781051",
        "secondaryId": "NCT01067976",
        "label": "Entailment",
        "statement_text": "The intervention for the primary trial requires participants to exercise for 12 weeks while wearing a fitbit  no physical activity is explicitly required for the secondary trial ",
        "statement_nums": [
            "12 weeks while"
        ],
        "premise_text": "INTERVENTION 1: Physical Activity Intervention Participants will participate in a multi-component physical activity intervention for 12 weeks with a 6 month follow up  Print-based education: Subjects were given a copy of Exercise for Health: An Exercise Guide for Breast Cancer Survivors  Topics covered within the book include benefits of exercise; recommendations on type  duration  frequency and intensity of exercise; goal-setting; and advice on overcoming barriers  Fitbit: Subjects were provided with a Fitbit and instructed to wear the device daily  Active Living counseling: The Active Living counseling program consists of 12 weekly group educational sessions  These sessions involved discussion of topics related to increasing physical activity  including: identifying and overcoming barriers  setting goals  and time management  ",
        "premise_nums": [
            "12 weekly group",
            "6 month follow",
            "12 weeks with"
        ]
    },
    {
        "id": "51ac9fe0-2bfa-42f5-aaec-69e0c5cdff7c",
        "primaryId": "NCT02781051",
        "secondaryId": "NCT01067976",
        "label": "Entailment",
        "statement_text": "The intervention for the primary trial requires participants to exercise for 12 weeks while wearing a fitbit  no physical activity is explicitly required for the secondary trial ",
        "statement_nums": [
            "12 weeks while"
        ],
        "premise_text": "Facility Access: Subjects will have access to the exercise lab in the UT Southwestern Depression Center consisting of equipment for aerobic exercise (treadmills  stationary bikes  etc.) INTERVENTION 1: CMRM vs UMRM [Not Specified] ",
        "premise_nums": []
    },
    {
        "id": "8bcc9fa3-0317-471a-a5b5-b115b5b72dea",
        "primaryId": "NCT01302379",
        "statement_text": "Both patient cohorts of the primary trial had a median Insulin change from baseline lower than -15%.",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Insulin Insulin measured as percent change from baseline Time frame: change from baseline to 6 months Results 1: Arm/Group Title: Metformin + Lifestyle Intervention Arm/Group Description: Metformin: Week 1: 500 mg at dinner time Weeks 2-4: 1000 mg at dinner time Weeks 5+: 500 mg in morning; 1000 mg at dinner time Lifestyle intervention: Telephone-based lifestyle intervention (dietary change and physical activity) for weight loss  Overall Number of Participants Analyzed: 83 Least Squares Mean (95% Confidence Interval) Unit of Measure: percent change from baseline -21.8 (-29.7 to -13.0) Results 2: Arm/Group Title: Placebo + Lifestyle Intervention ",
        "premise_nums": [
            "500 mg in",
            "500 mg at",
            "6 months Results",
            "83 Least Squares",
            "95% Confidence",
            "5+: 500",
            "2-4: 1000",
            "1000 mg at"
        ]
    },
    {
        "id": "8bcc9fa3-0317-471a-a5b5-b115b5b72dea",
        "primaryId": "NCT01302379",
        "statement_text": "Both patient cohorts of the primary trial had a median Insulin change from baseline lower than -15%.",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Arm/Group Description: Placebo: Week 1: 1 pill at dinner time Weeks 2-4: 2 pills at dinner time Weeks 5+: 1 pill in morning; 2 pills at dinner timeLifestyle intervention: Telephone-based lifestyle intervention (dietary change and physical activity) for weight loss  Overall Number of Participants Analyzed: 83 Least Squares Mean (95% Confidence Interval) Unit of Measure: percent change from baseline -17.7 (-25.9 to -8.6) ",
        "premise_nums": [
            "1 pill in",
            "2 pills at",
            "83 Least Squares",
            "95% Confidence",
            "2-4: 2",
            "1 pill at",
            "5+: 1"
        ]
    },
    {
        "id": "52610141-321d-4e3d-8660-ebc14b9f1696",
        "primaryId": "NCT00082433",
        "statement_text": "the primary trial results suggest that 40 mg/m2 administered as a 3-hour intravenous (IV) infusion on Day 1 of each cycle + Capecitabine  triples patient OS  compared to Capecitabine alone ",
        "statement_nums": [
            "40 mg/m2 administered",
            "1 of each",
            "2 administered as",
            "3-hour intravenous"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Overall Survival (OS) Overall survival was defined as the time in months from randomization until the date of death  For those patients who had not died  survival duration was censored at the last date the patient was known to be alive  Median OS with 95% CI estimated using the Kaplan-Meier Product Limit Method  Time frame: from date of randomization until death Results 1: Arm/Group Title: Ixabepilone + Capecitabine ",
        "premise_nums": [
            "95% CI"
        ]
    },
    {
        "id": "52610141-321d-4e3d-8660-ebc14b9f1696",
        "primaryId": "NCT00082433",
        "statement_text": "the primary trial results suggest that 40 mg/m2 administered as a 3-hour intravenous (IV) infusion on Day 1 of each cycle + Capecitabine  triples patient OS  compared to Capecitabine alone ",
        "statement_nums": [
            "40 mg/m2 administered",
            "1 of each",
            "2 administered as",
            "3-hour intravenous"
        ],
        "label": "Contradiction",
        "premise_text": "Arm/Group Description: Ixabepilone in combination with capecitabine (combination group): Ixabepilone 40 mg/m2 administered as a 3-hour intravenous (IV) infusion on Day 1 of each cycle only  plus oral capecitabine 1000 mg/m2 twice a day (BID) (2000 mg/m2 daily dose) x 14 days  followed by 1 week of rest Overall Number of Participants Analyzed: 609 Median (95% Confidence Interval) Unit of Measure: months 16.39 (14.95 to 17.91) Results 2: Arm/Group Title: Capecitabine ",
        "premise_nums": [
            "95 to 17.91)",
            "1 week of",
            "40 mg/m2 administered",
            "1000 mg/m2 twice",
            "1 of each",
            "2 daily dose)",
            "2 twice a",
            "95% Confidence",
            "2 administered as",
            "3-hour intravenous"
        ]
    },
    {
        "id": "52610141-321d-4e3d-8660-ebc14b9f1696",
        "primaryId": "NCT00082433",
        "statement_text": "the primary trial results suggest that 40 mg/m2 administered as a 3-hour intravenous (IV) infusion on Day 1 of each cycle + Capecitabine  triples patient OS  compared to Capecitabine alone ",
        "statement_nums": [
            "40 mg/m2 administered",
            "1 of each",
            "2 administered as",
            "3-hour intravenous"
        ],
        "label": "Contradiction",
        "premise_text": "Arm/Group Description: Capecitabine alone: Capecitabine 1250 mg/m2 BID (2500 mg/m2 daily dose) x 14 days  followed by 1 week of rest Overall Number of Participants Analyzed: 612 Median (95% Confidence Interval) Unit of Measure: months 15.64 (13.86 to 17.02) ",
        "premise_nums": [
            "1 week of",
            "86 to 17.02)",
            "2 daily dose)",
            "95% Confidence",
            "1250 mg/m2 BID",
            "2 BID (2500"
        ]
    },
    {
        "id": "90203158-6477-4486-b8d9-09dcaca63617",
        "primaryId": "NCT00570921",
        "secondaryId": "NCT00274456",
        "label": "Contradiction",
        "statement_text": "There is one case of Cardiopulmonary failure in cohort 1 of the secondary trial  but none in cohort 1 of the primary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Adverse Events 1: Total: 5/33 (15.15%) Left Ventricular Thrombus * 1/33 (3.03%) Nausea * 1/33 (3.03%) Acute Cholecystitis * 1/33 (3.03%) Renal Failure * 1/33 (3.03%) Pneumonia * 1/33 (3.03%) Adverse Events 1: Total: 14/76 (18.42%) Neutropenia 10/76 (13.16%) Febrile neutropenia 1/76 (1.32%) Anaemia 0/76 (0.00%) Thrombocytopenia 0/76 (0.00%) ",
        "premise_nums": [
            "5/33 (15.15%)",
            "10/76 (13.16%)",
            "1/33 (3.03%)",
            "1/76 (1.32%)",
            "0/76 (0.00%)",
            "14/76 (18.42%)"
        ]
    },
    {
        "id": "90203158-6477-4486-b8d9-09dcaca63617",
        "primaryId": "NCT00570921",
        "secondaryId": "NCT00274456",
        "label": "Contradiction",
        "statement_text": "There is one case of Cardiopulmonary failure in cohort 1 of the secondary trial  but none in cohort 1 of the primary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Cardiopulmonary failure 0/76 (0.00%)Optic ischaemic neuropathy 0/76 (0.00%) Bowel peristalsis increased 1/76 (1.32%) Colitis 0/76 (0.00%) Diarrhoea 0/76 (0.00%) Gastritis 0/76 (0.00%) Nausea 0/76 (0.00%) ",
        "premise_nums": [
            "0/76 (0.00%)Optic",
            "1/76 (1.32%)"
        ]
    },
    {
        "id": "03334f23-49ab-47e5-b420-a6753ce6e832",
        "primaryId": "NCT00574587",
        "secondaryId": "NCT00777049",
        "label": "Contradiction",
        "statement_text": "There were no cases of Myocardial ischaemia in the primary trial or the secondary trial ",
        "statement_nums": [],
        "premise_text": "Adverse Events 1: Total: 0/3 (0.00%) cardiac tamponade 0/3 (0.00%) congestive heart failure 0/3 (0.00%) pulmonary emobolism 0/3 (0.00%) Adverse Events 2: Total: 2/23 (8.70%) cardiac tamponade 0/23 (0.00%) congestive heart failure 1/23 (4.35%) pulmonary emobolism 1/23 (4.35%) Adverse Events 1: Total: 12/32 (37.50%) Anaemia 0/32 (0.00%) Neutropenia 1/32 (3.13%) Thrombocytopenia 4/32 (12.50%) ",
        "premise_nums": [
            "0/3 (0.00%)",
            "2/23 (8.70%)",
            "4/32 (12.50%)",
            "1/32 (3.13%)",
            "0/32 (0.00%)",
            "12/32 (37.50%)",
            "1/23 (4.35%)",
            "0/23 (0.00%)"
        ]
    },
    {
        "id": "03334f23-49ab-47e5-b420-a6753ce6e832",
        "primaryId": "NCT00574587",
        "secondaryId": "NCT00777049",
        "label": "Contradiction",
        "statement_text": "There were no cases of Myocardial ischaemia in the primary trial or the secondary trial ",
        "statement_nums": [],
        "premise_text": "Atrial fibrillation 1/32 (3.13%)Cardiac failure congestive 1/32 (3.13%) Myocardial ischaemia 1/32 (3.13%) Abdominal discomfort 0/32 (0.00%) Ascites 1/32 (3.13%) Constipation 0/32 (0.00%) Rectal haemorrhage 1/32 (3.13%) Vomiting 1/32 (3.13%) Fatigue 1/32 (3.13%) Adverse Events 2: Total: 8/20 (40.00%) Anaemia 1/20 (5.00%) Neutropenia 0/20 (0.00%) Thrombocytopenia 1/20 (5.00%) ",
        "premise_nums": [
            "8/20 (40.00%)",
            "1/20 (5.00%)",
            "0/32 (0.00%)",
            "0/20 (0.00%)",
            "1/32 (3.13%)Cardiac"
        ]
    },
    {
        "id": "03334f23-49ab-47e5-b420-a6753ce6e832",
        "primaryId": "NCT00574587",
        "secondaryId": "NCT00777049",
        "label": "Contradiction",
        "statement_text": "There were no cases of Myocardial ischaemia in the primary trial or the secondary trial ",
        "statement_nums": [],
        "premise_text": "Atrial fibrillation 0/20 (0.00%)Cardiac failure congestive 0/20 (0.00%) Myocardial ischaemia 0/20 (0.00%) Abdominal discomfort 1/20 (5.00%) Ascites 0/20 (0.00%) Constipation 2/20 (10.00%) Rectal haemorrhage 0/20 (0.00%) Vomiting 0/20 (0.00%) Fatigue 0/20 (0.00%) ",
        "premise_nums": [
            "0/20 (0.00%)Cardiac",
            "2/20 (10.00%)",
            "1/20 (5.00%)"
        ]
    },
    {
        "id": "a847cfc1-9556-4a55-9698-69c22696148f",
        "primaryId": "NCT02370238",
        "statement_text": "There were 2 cases of Angina in the primary trial ",
        "statement_nums": [
            "2 cases of"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 13/61 (21.31%) Anaemia 1/61 (1.64%) Febrile neutropenia 1/61 (1.64%) Cardiac failure congestive 0/61 (0.00%) Pericardial effusion 0/61 (0.00%) Constipation 1/61 (1.64%) Intestinal perforation 1/61 (1.64%) Stomatitis 0/61 (0.00%) Non-cardiac chest pain 2/61 (3.28%) Condition aggravated 1/61 (1.64%) General physical health deterioration 1/61 (1.64%) Adverse Events 2: Total: 12/60 (20.00%) ",
        "premise_nums": [
            "12/60 (20.00%)",
            "1/61 (1.64%)",
            "0/61 (0.00%)",
            "13/61 (21.31%)",
            "2/61 (3.28%)"
        ]
    },
    {
        "id": "a847cfc1-9556-4a55-9698-69c22696148f",
        "primaryId": "NCT02370238",
        "statement_text": "There were 2 cases of Angina in the primary trial ",
        "statement_nums": [
            "2 cases of"
        ],
        "label": "Contradiction",
        "premise_text": "Anaemia 1/60 (1.67%)Febrile neutropenia 0/60 (0.00%) Cardiac failure congestive 1/60 (1.67%) Pericardial effusion 1/60 (1.67%) Constipation 0/60 (0.00%) Intestinal perforation 0/60 (0.00%) Stomatitis 1/60 (1.67%) Non-cardiac chest pain 0/60 (0.00%) Condition aggravated 0/60 (0.00%) General physical health deterioration 1/60 (1.67%) ",
        "premise_nums": [
            "0/60 (0.00%)",
            "1/60 (1.67%)Febrile"
        ]
    },
    {
        "id": "fcbb7e0f-d106-44bd-a252-9b57adc6f071",
        "primaryId": "NCT01075100",
        "statement_text": "No mental health issues were observed in the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 10/48 (20.83%) NEUTROPENIA 1/48 (2.08%) THROMBOCYTOPENIA 0/48 (0.00%) VOLUME BLOOD DECREASED 1/48 (2.08%) FIBRILLATION ATRIAL 1/48 (2.08%) HYPOTENSION 1/48 (2.08%) ABDOMINAL PAIN 1/48 (2.08%) APPETITE DECREASED 0/48 (0.00%) DEHYDRATION 4/48 (8.33%) DIARRHEA 4/48 (8.33%) NAUSEA 3/48 (6.25%) VOMITING 2/48 (4.17%) FEVER 1/48 (2.08%) RIGORS 0/48 (0.00%) Adverse Events 2: ",
        "premise_nums": [
            "3/48 (6.25%)",
            "4/48 (8.33%)",
            "2/48 (4.17%)",
            "0/48 (0.00%)",
            "1/48 (2.08%)",
            "10/48 (20.83%)"
        ]
    },
    {
        "id": "fcbb7e0f-d106-44bd-a252-9b57adc6f071",
        "primaryId": "NCT01075100",
        "statement_text": "No mental health issues were observed in the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Total: 5/53 (9.43%)NEUTROPENIA 1/53 (1.89%) THROMBOCYTOPENIA 1/53 (1.89%) VOLUME BLOOD DECREASED 0/53 (0.00%) FIBRILLATION ATRIAL 0/53 (0.00%) HYPOTENSION 0/53 (0.00%) ABDOMINAL PAIN 0/53 (0.00%) APPETITE DECREASED 1/53 (1.89%) DEHYDRATION 0/53 (0.00%) DIARRHEA 0/53 (0.00%) NAUSEA 1/53 (1.89%) VOMITING 1/53 (1.89%) FEVER 1/53 (1.89%) RIGORS 1/53 (1.89%) ",
        "premise_nums": [
            "1/53 (1.89%)",
            "5/53 (9.43%)NEUTROPENIA",
            "0/53 (0.00%)"
        ]
    },
    {
        "id": "f82d94fe-c633-4bae-b28d-074196a08577",
        "primaryId": "NCT03584009",
        "statement_text": "Participants in the primary trial administered with Fulvestrant 500mg via intramuscular injection had a higher % of clinical benefit than participants who were administered an additional 160 mg of Neratinib ",
        "statement_nums": [
            "160 mg of"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Clinical Benefit Defined as Complete Response (CR)  Partial Response (PR) or Stable Disease (SD) Lasting greater than or equal 24 Weeks  as Determined by the Investigator According to RECIST v1.1 ",
        "premise_nums": []
    },
    {
        "id": "e5379a89-f880-44c1-bee0-a0d8ad2abfce",
        "primaryId": "NCT00659373",
        "secondaryId": "NCT02202252",
        "label": "Entailment",
        "statement_text": "the primary trial has a 5 year long intervention  the duration of the secondary trial is not specified in the intervention section ",
        "statement_nums": [
            "5 year long"
        ],
        "premise_text": "INTERVENTION 1: Tamoxifen Tamoxifen 20mg orally daily for 5 years INTERVENTION 2: Ovarian Function Suppression Tamoxifen 20mg orally daily or Exemestane 25mg orally daily for 5 years plus ovarian function suppression (OFS; triptorelin (GnRH analogue) 3.75 mg by im injection q28 days for 5 years; or surgical oophorectomy; or ovarian irradiation) Note: Data were collected separately for the T+OFS and E+OFS participants in the parent study  IBCSG 24-02 (SOFT)  The sample size for this Co-SOFT substudy was small  so the analysis plan was revised to pre-specify collective analysis for all patients receiving OFS  INTERVENTION 1: Single Drain ",
        "premise_nums": [
            "5 years INTERVENTION",
            "q28 days",
            "75 mg by",
            "5 years plus",
            "28 days for"
        ]
    },
    {
        "id": "e5379a89-f880-44c1-bee0-a0d8ad2abfce",
        "primaryId": "NCT00659373",
        "secondaryId": "NCT02202252",
        "label": "Entailment",
        "statement_text": "the primary trial has a 5 year long intervention  the duration of the secondary trial is not specified in the intervention section ",
        "statement_nums": [
            "5 year long"
        ],
        "premise_text": "Insertion of a single drain: A negative pressure drain will be inserted below the lower flap directing to the axilla in the single drain group Ultrasonography after removal of the drains: One day after removal of the drains seroma under the flaps and in the axilla will be examined by ultrasonography  Insertion of a single drain: A negative pressure drain will be inserted below the lower flap directing to the axilla  Ultrasonography after removal of the drains: One day after removal of the drains seroma under the flaps and in the axilla will be examined by ultrasonography  INTERVENTION 2: Double Drain Insertion of double drains: Two negative pressure drains will be inserted into the axilla and below the lower flap in the double drains group  ",
        "premise_nums": []
    },
    {
        "id": "e5379a89-f880-44c1-bee0-a0d8ad2abfce",
        "primaryId": "NCT00659373",
        "secondaryId": "NCT02202252",
        "label": "Entailment",
        "statement_text": "the primary trial has a 5 year long intervention  the duration of the secondary trial is not specified in the intervention section ",
        "statement_nums": [
            "5 year long"
        ],
        "premise_text": "Ultrasonography after removal of the drains: One day after removal of the drains seroma under the flaps and in the axilla will be examined by ultrasonography Insertion of double drains: Two drains will be inserted into the axilla and below the lower flap in the double drains group  Ultrasonography after removal of the drains: One day after removal of the drains seroma under the flaps and in the axilla will be examined by ultrasonography  ",
        "premise_nums": []
    },
    {
        "id": "d811aaec-b3bd-4376-a9d6-d14eacae875a",
        "primaryId": "NCT00717886",
        "statement_text": "Prior axillary surgery  axillary radiation  breast cancer and breast radiation are not permitted for entry to the primary trial  patients with prior High-dose chemotherapy can still enter if they satisfy all other inclusion criteria ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria: Females with Stage II invasive breast cancer and documented axillary metastases by core biopsy  clinical examination  or fine-needle aspiration who are scheduled to undergo an ALND  Females greater than 21 years of age Exclusion Criteria: Prior ipsilateral axillary surgery Prior ipsilateral axillary radiation Prior ipsilateral breast cancer Prior ipsilateral breast radiation Allergy to isosulfan blue dye History of ipsilateral upper extremity lymphedema Prior history of surgical excision of the upper outer quadrant of the ipsilateral breast Prior history of neoadjuvant chemotherapy for current breast cancer ",
        "premise_nums": [
            "21 years of"
        ]
    },
    {
        "id": "d811aaec-b3bd-4376-a9d6-d14eacae875a",
        "primaryId": "NCT00717886",
        "statement_text": "Prior axillary surgery  axillary radiation  breast cancer and breast radiation are not permitted for entry to the primary trial  patients with prior High-dose chemotherapy can still enter if they satisfy all other inclusion criteria ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Bulky axillary disease at presentation (N2)",
        "premise_nums": []
    },
    {
        "id": "99312d82-614c-4422-b6e6-104fe5a7fa54",
        "primaryId": "NCT00050167",
        "statement_text": "Only Patients with metastasis in less than 9 infraclavicular lymph nodes are eligible for the primary trial ",
        "statement_nums": [
            "9 infraclavicular lymph"
        ],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria: Patients with pN2a (metastasis in four to nine axillary lymph nodes) are eligible as are patients with pN3a (ten or more axillary lymph nodes)  Patients with infraclavicular lymph node involvement are NOT eligible  ",
        "premise_nums": []
    },
    {
        "id": "b02c99f3-70bd-4404-8d80-c57c6dfef7b7",
        "primaryId": "NCT02049957",
        "secondaryId": "NCT01506609",
        "label": "Contradiction",
        "statement_text": "There is are the same total number of patients in the primary trial as in the secondary trial ",
        "statement_nums": [],
        "premise_text": "Adverse Events 1: Total: 1/6 (16.67%) Angina pectoris 0/6 (0.00%) Pericardial effusion 0/6 (0.00%) Diplopia 0/6 (0.00%) Abdominal pain 0/6 (0.00%) Colitis 0/6 (0.00%) Gastritis 0/6 (0.00%) Nausea 0/6 (0.00%) Vomiting 0/6 (0.00%) Fatigue 0/6 (0.00%) General physical health deterioration 0/6 (0.00%) Generalised oedema 0/6 (0.00%) Hepatic failure [1]0/6 (0.00%) Adverse Events 2: ",
        "premise_nums": [
            "1/6 (16.67%)",
            "0/6 (0.00%)"
        ]
    },
    {
        "id": "b02c99f3-70bd-4404-8d80-c57c6dfef7b7",
        "primaryId": "NCT02049957",
        "secondaryId": "NCT01506609",
        "label": "Contradiction",
        "statement_text": "There is are the same total number of patients in the primary trial as in the secondary trial ",
        "statement_nums": [],
        "premise_text": "Total: 2/6 (33.33%)Angina pectoris 0/6 (0.00%) Pericardial effusion 0/6 (0.00%) Diplopia 0/6 (0.00%) Abdominal pain 0/6 (0.00%) Colitis 0/6 (0.00%) Gastritis 0/6 (0.00%) Nausea 0/6 (0.00%) Vomiting 0/6 (0.00%) Fatigue 0/6 (0.00%) General physical health deterioration 0/6 (0.00%) Generalised oedema 0/6 (0.00%) Hepatic failure [1]0/6 (0.00%) Adverse Events 1: ",
        "premise_nums": [
            "0/6 (0.00%)",
            "2/6 (33.33%)Angina"
        ]
    },
    {
        "id": "b02c99f3-70bd-4404-8d80-c57c6dfef7b7",
        "primaryId": "NCT02049957",
        "secondaryId": "NCT01506609",
        "label": "Contradiction",
        "statement_text": "There is are the same total number of patients in the primary trial as in the secondary trial ",
        "statement_nums": [],
        "premise_text": "Total: 0/2 (0.00%)ANAEMIA 0/2 (0.00%) FEBRILE NEUTROPENIA 0/2 (0.00%) LYMPHADENOPATHY 0/2 (0.00%) NEUTROPENIA 0/2 (0.00%) PANCYTOPENIA 0/2 (0.00%) THROMBOCYTOPENIA 0/2 (0.00%) ATRIAL FIBRILLATION 0/2 (0.00%) CARDIAC TAMPONADE 0/2 (0.00%) PERICARDIAL EFFUSION 0/2 (0.00%) TACHYCARDIA 0/2 (0.00%) ABDOMINAL PAIN 0/2 (0.00%) ABDOMINAL PAIN UPPER 0/2 (0.00%) ",
        "premise_nums": [
            "0/2 (0.00%)ANAEMIA"
        ]
    },
    {
        "id": "b02c99f3-70bd-4404-8d80-c57c6dfef7b7",
        "primaryId": "NCT02049957",
        "secondaryId": "NCT01506609",
        "label": "Contradiction",
        "statement_text": "There is are the same total number of patients in the primary trial as in the secondary trial ",
        "statement_nums": [],
        "premise_text": "Adverse Events 2:Total: 0/1 (0.00%) ANAEMIA 0/1 (0.00%) FEBRILE NEUTROPENIA 0/1 (0.00%) LYMPHADENOPATHY 0/1 (0.00%) NEUTROPENIA 0/1 (0.00%) PANCYTOPENIA 0/1 (0.00%) THROMBOCYTOPENIA 0/1 (0.00%) ATRIAL FIBRILLATION 0/1 (0.00%) CARDIAC TAMPONADE 0/1 (0.00%) PERICARDIAL EFFUSION 0/1 (0.00%) TACHYCARDIA 0/1 (0.00%) ABDOMINAL PAIN 0/1 (0.00%) ",
        "premise_nums": [
            "0/1 (0.00%)",
            "2:Total: 0/1"
        ]
    },
    {
        "id": "b02c99f3-70bd-4404-8d80-c57c6dfef7b7",
        "primaryId": "NCT02049957",
        "secondaryId": "NCT01506609",
        "label": "Contradiction",
        "statement_text": "There is are the same total number of patients in the primary trial as in the secondary trial ",
        "statement_nums": [],
        "premise_text": "ABDOMINAL PAIN UPPER 0/1 (0.00%)",
        "premise_nums": [
            "0/1 (0.00%)"
        ]
    },
    {
        "id": "3cbf2726-ddb0-460c-9dd2-082b8dda495d",
        "primaryId": "NCT00454532",
        "statement_text": "Less than half of patients in cohorts 1 in the primary trial experienced adverse events  but more than 45% of patients cohort 2 did experience adverse events ",
        "statement_nums": [
            "1 in the",
            "45% of",
            "2 did experience"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 5/11 (45.45%) Hemorrhage  GI-abdomen NOS 21/11 (9.09%) Pain-liver 21/11 (9.09%) Infection-ulcer 20/11 (0.00%) Hemoglobin 20/11 (0.00%) Hypoglycemia 20/11 (0.00%) Pain-rib cage due to vomiting 20/11 (0.00%) Obstruction-gu ureter 1/11 (9.09%) Hemorrhage gu-bladder 21/11 (9.09%) Pain-breast 21/11 (9.09%) ",
        "premise_nums": [
            "5/11 (45.45%)",
            "21/11 (9.09%)",
            "20/11 (0.00%)"
        ]
    },
    {
        "id": "3cbf2726-ddb0-460c-9dd2-082b8dda495d",
        "primaryId": "NCT00454532",
        "statement_text": "Less than half of patients in cohorts 1 in the primary trial experienced adverse events  but more than 45% of patients cohort 2 did experience adverse events ",
        "statement_nums": [
            "1 in the",
            "45% of",
            "2 did experience"
        ],
        "label": "Contradiction",
        "premise_text": "Pleural effusion 22/11 (18.18%)Adverse Events 2: Total: 0/6 (0.00%) ",
        "premise_nums": [
            "22/11 (18.18%)Adverse",
            "0/6 (0.00%)"
        ]
    },
    {
        "id": "e7741151-2b2c-4e78-a4df-fe998c580714",
        "primaryId": "NCT01912612",
        "secondaryId": "NCT02392611",
        "label": "Entailment",
        "statement_text": "In the primary trial only 1 cohort is administered the intervention  whereas in the secondary trial both cohorts receive the intervention  but cohort 2 recieves more than double the dose of cohort 1.",
        "statement_nums": [
            "1 cohort is",
            "2 recieves more"
        ],
        "premise_text": "INTERVENTION 1: Arm 1 (Patients With Pain) Duloxetine 30 mg daily x 1 week  then 60 mg daily x 4 weeks  then 30 mg daily x 2 weeks  Duloxetine: Subjects will receive 30 mg duloxetine orally for 7 days  then 60 mg duloxetine orally for 28 days  then 30 mg duloxetine orally x 14 days  INTERVENTION 2: Arm 2 (Patients Without Pain -- Control) Patient reported pain and symptoms assessment for comparison at baseline  INTERVENTION 1: Monotherapy: Alobresib 0.6 mg ",
        "premise_nums": [
            "60 mg daily",
            "60 mg duloxetine",
            "30 mg daily",
            "30 mg duloxetine"
        ]
    },
    {
        "id": "e7741151-2b2c-4e78-a4df-fe998c580714",
        "primaryId": "NCT01912612",
        "secondaryId": "NCT02392611",
        "label": "Entailment",
        "statement_text": "In the primary trial only 1 cohort is administered the intervention  whereas in the secondary trial both cohorts receive the intervention  but cohort 2 recieves more than double the dose of cohort 1.",
        "statement_nums": [
            "1 cohort is",
            "2 recieves more"
        ],
        "premise_text": "Participants with advanced solid tumors and lymphomas who had failed or were intolerant to standard therapy  or for whom no standard therapy existed received alobresib tablets at a dose of 0.6 mg orally once daily on Study Day 1 through C1D28 of 28 days cycle to determine the MTD INTERVENTION 2: Monotherapy: Alobresib 1.4 mg Participants with advanced solid tumors and lymphomas who had failed or were intolerant to standard therapy  or for whom no standard therapy existed received alobresib tablets at a dose of 1.4 mg orally once daily on Study Day 1 through C1D28 of 28 days cycle to determine the MTD  ",
        "premise_nums": [
            "of 0.6 mg orally",
            "Alobresib 1.4 mg Participants",
            "28 days cycle",
            "D28 of",
            "of 1.4 mg orally",
            "1 through C1D28"
        ]
    },
    {
        "id": "8cff36b0-a022-4469-8d14-7120be891cb1",
        "primaryId": "NCT00376688",
        "statement_text": "Less than 1/10 the primary trial subjects experienced a complete response (CR)  partial response (PR)  or stable disease (SD) for at least 24 weeks ",
        "statement_nums": [
            "10 the primary",
            "1/10 the"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Clinical Benefit Rate (Complete Response  Partial Response  or Stable Disease) Response evaluation criteria in solid tumors (RECIST) criteria version 1.0 was used for response evaluation  Clinical benefit rate is defined as the proportion of subjects experiencing a complete response (CR)  partial response (PR)  or stable disease (SD) for at least 24 weeks  ",
        "premise_nums": [
            "version 1.0 was used"
        ]
    },
    {
        "id": "8cff36b0-a022-4469-8d14-7120be891cb1",
        "primaryId": "NCT00376688",
        "statement_text": "Less than 1/10 the primary trial subjects experienced a complete response (CR)  partial response (PR)  or stable disease (SD) for at least 24 weeks ",
        "statement_nums": [
            "10 the primary",
            "1/10 the"
        ],
        "label": "Entailment",
        "premise_text": "Evaluation of target lesions: Complete Response (CR)-- Disappearance of all target lesions; Partial Response (PR)-- At least a 30% decrease in the sum of the LD of target lesions  taking as reference the baseline sum LD; Stable Disease (SD)-- Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD  taking as reference the smallest sum LD since the treatment started;Evaluation of non-target lesions: Complete Response (CR)-- Disappearance of all non-target lesions and normalization of tumor marker level; Incomplete Response/ Stable Disease (SD)-- Persistence of one or more non-target lesion(s) or/and maintenance of tumor marker level above the normal limits ",
        "premise_nums": [
            "30% decrease"
        ]
    },
    {
        "id": "8cff36b0-a022-4469-8d14-7120be891cb1",
        "primaryId": "NCT00376688",
        "statement_text": "Less than 1/10 the primary trial subjects experienced a complete response (CR)  partial response (PR)  or stable disease (SD) for at least 24 weeks ",
        "statement_nums": [
            "10 the primary",
            "1/10 the"
        ],
        "label": "Entailment",
        "premise_text": "Time frame: Up to 24 monthsResults 1: Arm/Group Title: Treatment (Temsirolimus) Arm/Group Description: Patients receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity  Temsirolimus: Given IV Overall Number of Participants Analyzed: 31 Measure Type: Number Unit of Measure: percentage of participants 9.7 ",
        "premise_nums": [
            "28 days in",
            "30 minutes on",
            "24 monthsResults 1:",
            "31 Measure Type:"
        ]
    },
    {
        "id": "4ce24508-3d12-499f-ab7f-4b437ea51366",
        "primaryId": "NCT00304096",
        "secondaryId": "NCT00876395",
        "label": "Contradiction",
        "statement_text": "A minimum bodyweight of 50kg is required to participate in either the primary trial or the secondary trial ",
        "statement_nums": [],
        "premise_text": "Body weight greater than 110 lbs (without clothes) Inclusion Criteria: Adult Women ( 18 years old)  Histologically or cytologically confirmed invasive breast carcinoma with local recurrence or radiological evidence of metastatic disease  Must have at least one lesion that can be accurately measured or bone lesions in the absence of measurable disease  HER2+ patients by local laboratory testing (IHC 3+ staining or in situ hybridization positive)  Prior trastuzumab and/or chemotherapy (taxanes included) as neo-adjuvant or adjuvant treatment is allowed but should be discontinued greater than 12 months prior to randomization  ",
        "premise_nums": [
            "18 years old)",
            "12 months prior",
            "110 lbs (without"
        ]
    },
    {
        "id": "4ce24508-3d12-499f-ab7f-4b437ea51366",
        "primaryId": "NCT00304096",
        "secondaryId": "NCT00876395",
        "label": "Contradiction",
        "statement_text": "A minimum bodyweight of 50kg is required to participate in either the primary trial or the secondary trial ",
        "statement_nums": [],
        "premise_text": "Prior treatment for breast cancer with endocrine therapy (adjuvant or metastatic settings) is allowed but should be discontinued at randomization  Patients treated with bisphosphonates at entry or who start bisphosphonates during study may continue this therapy during protocol treatment Documentation of negative pregnancy test  Organ functions at time of inclusion  Exclusion Criteria: Prior mTOR inhibitors for the treatment of cancer  Other anticancer therapy for locally advanced or metastatic breast cancer except for prior hormonal therapy  Patients with only non-measurable lesions other than bone metastasis (e.g  pleural effusion  ascites  etc)  Radiotherapy to 25% of the bone marrow within 4 weeks prior to randomization History of central nervous system metastasis  ",
        "premise_nums": [
            "4 weeks prior",
            "25% of"
        ]
    },
    {
        "id": "4ce24508-3d12-499f-ab7f-4b437ea51366",
        "primaryId": "NCT00304096",
        "secondaryId": "NCT00876395",
        "label": "Contradiction",
        "statement_text": "A minimum bodyweight of 50kg is required to participate in either the primary trial or the secondary trial ",
        "statement_nums": [],
        "premise_text": "Impairment of gastrointestinal (GI) function or GI disease or active ulceration of the upper gastrointestinal tract Serious peripheral neuropathy  Cardiac disease or dysfunction  Uncontrolled hypertension  HIV  Pregnant  ",
        "premise_nums": []
    },
    {
        "id": "2514da19-b30a-44bb-8853-4545e97295da",
        "primaryId": "NCT00633464",
        "statement_text": "The Ixabepilone 40 mg/m^2 group in the primary trial reported worse results than the Cetuximab 250 mg/m^2 + Ixabepilone 40 mg/m^2 group ",
        "statement_nums": [
            "40 mg/m^2",
            "250 mg/m^2",
            "2 group in"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Percentage of Participants With Objective Response (OR; Using Response Evaluation Criteria in Solid Tumors [RECIST]) The participant had an OR if her best overall response (BOR) during the study was either a complete response (CR) or a partial response (PR) according to the RECIST as determined by the investigator  CR: Disappearance of all evidence of target and non-target lesions  PR: At least 30% reduction from baseline in the sum of the longest diameter (LD) of all target lesions  Confidence interval (CI) was Computed using Clopper-Pearson method  ",
        "premise_nums": [
            "30% reduction"
        ]
    },
    {
        "id": "2514da19-b30a-44bb-8853-4545e97295da",
        "primaryId": "NCT00633464",
        "statement_text": "The Ixabepilone 40 mg/m^2 group in the primary trial reported worse results than the Cetuximab 250 mg/m^2 + Ixabepilone 40 mg/m^2 group ",
        "statement_nums": [
            "40 mg/m^2",
            "250 mg/m^2",
            "2 group in"
        ],
        "label": "Entailment",
        "premise_text": "Time frame: Assessed every 6 weeks for first 12 months from randomization thereafter every 3 months until disease progression (maximum participant objective response of 18.3 weeks)Results 1: Arm/Group Title: Ixabepilone 40 mg/m^2 Arm/Group Description: ixabepilone 40 mg/m^2 every 3 weeks Overall Number of Participants Analyzed: 40 Measure Type: Number Unit of Measure: percentage of participants 30.0 (16.6 to 46.5) Results 2: Arm/Group Title: Cetuximab 250 mg/m^2 + Ixabepilone 40 mg/m^2 ",
        "premise_nums": [
            "2 every 3",
            "3 months until",
            "250 mg/m^2",
            "3 weeks Overall",
            "40 Measure Type:",
            "6 weeks for",
            "40 mg/m^2",
            "12 months from",
            "6 to 46.5)"
        ]
    },
    {
        "id": "2514da19-b30a-44bb-8853-4545e97295da",
        "primaryId": "NCT00633464",
        "statement_text": "The Ixabepilone 40 mg/m^2 group in the primary trial reported worse results than the Cetuximab 250 mg/m^2 + Ixabepilone 40 mg/m^2 group ",
        "statement_nums": [
            "40 mg/m^2",
            "250 mg/m^2",
            "2 group in"
        ],
        "label": "Entailment",
        "premise_text": "Arm/Group Description: cetuximab 400 mg/m^2 loading dose then 250 mg/m^2 weekly + ixabepilone 40 mg/m^2 every 3 weeksOverall Number of Participants Analyzed: 39 Measure Type: Number Unit of Measure: percentage of participants 35.9 (21.2 to 52.8) ",
        "premise_nums": [
            "400 mg/m^2",
            "2 every 3",
            "250 mg/m^2",
            "40 mg/m^2",
            "39 Measure Type:",
            "3 weeksOverall Number",
            "2 to 52.8)",
            "2 loading dose"
        ]
    },
    {
        "id": "cb9f8a52-b88e-4b04-bb28-a0eabead1439",
        "primaryId": "NCT00728949",
        "statement_text": "There were 6 adverse event categories for cohort 1 of the primary trial which recorded at least one case ",
        "statement_nums": [
            "6 adverse event",
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 16/56 (28.57%) Pancytopenia 0/56 (0.00%) Pericarditis 0/56 (0.00%) Abdominal pain 1/56 (1.79%) Anal fissure 1/56 (1.79%) Ascites 1/56 (1.79%) Constipation 0/56 (0.00%) Diarrhoea 1/56 (1.79%) Nausea 0/56 (0.00%) Oesophageal pain 0/56 (0.00%) Vomiting 0/56 (0.00%) Disease progression 2/56 (3.57%) Infusion related reaction 1/56 (1.79%) Pain 0/56 (0.00%) ",
        "premise_nums": [
            "2/56 (3.57%)",
            "1/56 (1.79%)",
            "0/56 (0.00%)",
            "16/56 (28.57%)"
        ]
    },
    {
        "id": "c921d3a1-bd6e-41c9-b0e9-23babf7ead7c",
        "primaryId": "NCT02806544",
        "secondaryId": "NCT00605267",
        "label": "Entailment",
        "statement_text": "A patient with stage 2B   pathologically confirmed estrogen receptor-positive breast cancer is elgible for both the primary trial and the secondary trial ",
        "statement_nums": [],
        "premise_text": "Inclusion Criteria: Clinical locally advance breast cancer (Stage IIB or III) Pathologically confirmed diagnosis of estrogen receptor (ER)-positive or progesterone receptor (PR)-positive breast cancer with ER or PR Allred Score greater than 4 Inclusion Criteria: Premenopausal  estrogen receptor positive women  aged 20 years and over  with operable and measurable breast cancer who have provided written informed consent Exclusion Criteria: Medical history of chemotherapy or endocrine therapy for breast cancer  or with treatment history of radiotherapy  Unwillingness to stop taking any drug known to affect sex hormone status (including hormone replacement therapy (HRT)  ",
        "premise_nums": [
            "4 Inclusion Criteria:",
            "20 years and"
        ]
    },
    {
        "id": "358a1d3c-9ccc-48fc-badc-1644e326c8cb",
        "primaryId": "NCT02301988",
        "secondaryId": "NCT00728949",
        "label": "Contradiction",
        "statement_text": "The only type of adverse event recorded by both the secondary trial and the primary trial is Diarrhoea and Abdominal pain ",
        "statement_nums": [],
        "premise_text": "Adverse Events 1: Total: 10/76 (13.16%) Sickle cell anaemia with crisis 1/76 (1.32%) Diarrhoea 1/76 (1.32%) Pyrexia 1/76 (1.32%) Chest pain 1/76 (1.32%) Complication associated with device 1/76 (1.32%) General physical health deterioration 0/76 (0.00%) Device related infection 2/76 (2.63%) Pneumonia 1/76 (1.32%) Atypical pneumonia 1/76 (1.32%) Dehydration 1/76 (1.32%) Adverse Events 2: Total: 3/75 (4.00%) ",
        "premise_nums": [
            "10/76 (13.16%)",
            "3/75 (4.00%)",
            "1/76 (1.32%)",
            "0/76 (0.00%)",
            "2/76 (2.63%)"
        ]
    },
    {
        "id": "358a1d3c-9ccc-48fc-badc-1644e326c8cb",
        "primaryId": "NCT02301988",
        "secondaryId": "NCT00728949",
        "label": "Contradiction",
        "statement_text": "The only type of adverse event recorded by both the secondary trial and the primary trial is Diarrhoea and Abdominal pain ",
        "statement_nums": [],
        "premise_text": "Sickle cell anaemia with crisis 0/75 (0.00%)Diarrhoea 0/75 (0.00%) Pyrexia 1/75 (1.33%) Chest pain 0/75 (0.00%) Complication associated with device 0/75 (0.00%) General physical health deterioration 1/75 (1.33%) Device related infection 0/75 (0.00%) Pneumonia 1/75 (1.33%) Atypical pneumonia 0/75 (0.00%) Dehydration 0/75 (0.00%) Adverse Events 1: Total: 16/56 (28.57%) Pancytopenia 0/56 (0.00%) ",
        "premise_nums": [
            "0/75 (0.00%)Diarrhoea",
            "16/56 (28.57%)",
            "1/75 (1.33%)",
            "0/56 (0.00%)"
        ]
    },
    {
        "id": "358a1d3c-9ccc-48fc-badc-1644e326c8cb",
        "primaryId": "NCT02301988",
        "secondaryId": "NCT00728949",
        "label": "Contradiction",
        "statement_text": "The only type of adverse event recorded by both the secondary trial and the primary trial is Diarrhoea and Abdominal pain ",
        "statement_nums": [],
        "premise_text": "Pericarditis 0/56 (0.00%)Abdominal pain 1/56 (1.79%) Anal fissure 1/56 (1.79%) Ascites 1/56 (1.79%) Constipation 0/56 (0.00%) Diarrhoea 1/56 (1.79%) Nausea 0/56 (0.00%) Oesophageal pain 0/56 (0.00%) Vomiting 0/56 (0.00%) Disease progression 2/56 (3.57%) Infusion related reaction 1/56 (1.79%) Pain 0/56 (0.00%) Adverse Events 2: Total: 11/37 (29.73%) ",
        "premise_nums": [
            "11/37 (29.73%)",
            "0/56 (0.00%)Abdominal",
            "1/56 (1.79%)",
            "2/56 (3.57%)"
        ]
    },
    {
        "id": "358a1d3c-9ccc-48fc-badc-1644e326c8cb",
        "primaryId": "NCT02301988",
        "secondaryId": "NCT00728949",
        "label": "Contradiction",
        "statement_text": "The only type of adverse event recorded by both the secondary trial and the primary trial is Diarrhoea and Abdominal pain ",
        "statement_nums": [],
        "premise_text": "Pancytopenia 1/37 (2.70%)Pericarditis 1/37 (2.70%) Abdominal pain 2/37 (5.41%) Anal fissure 0/37 (0.00%) Ascites 0/37 (0.00%) Constipation 1/37 (2.70%) Diarrhoea 1/37 (2.70%) Nausea 2/37 (5.41%) Oesophageal pain 1/37 (2.70%) Vomiting 2/37 (5.41%) Disease progression 2/37 (5.41%) Infusion related reaction 0/37 (0.00%) Pain 1/37 (2.70%) ",
        "premise_nums": [
            "2/37 (5.41%)",
            "0/37 (0.00%)",
            "1/37 (2.70%)Pericarditis"
        ]
    },
    {
        "id": "60a86c87-7387-4eae-b5dd-6245f8bf541e",
        "primaryId": "NCT00045032",
        "secondaryId": "NCT00416572",
        "label": "Contradiction",
        "statement_text": "WOCBP that refuse to use contraception are excluded from the primary trial  but may be eligible for the secondary trial if they are a UK resident ",
        "statement_nums": [],
        "premise_text": "Women of childbearing potential or less than 1 year post-menopause unwilling to use adequate contraceptive measures INCLUSION CRITERIA (Disease Characteristics): Diagnosis of breast cancer Stage I or II disease No more than 10 positive lymph nodes First-time diagnosis Under the age of 50 at diagnosis Finished active treatment within the past 2 months English-speaking only Must live within 30 miles of Magee Women's Hospital  Pittsburgh  Pennsylvania INCLUSION CRITERIA (Patient Characteristics): Female patients only Must be able to communicate EXCLUSION CRITERIA (Patient Characteristics): Other prior malignancies except skin cancer PRIOR CONCURRENT THERAPY: See Disease Characteristics ",
        "premise_nums": [
            "10 positive lymph",
            "2 months English",
            "50 at diagnosis",
            "30 miles of",
            "1 year post"
        ]
    },
    {
        "id": "bd3055c6-09aa-47f0-89ed-67ad3798a580",
        "primaryId": "NCT00090857",
        "statement_text": "Candidates for the primary trial must have a bone density scan 1 month prior to study entry  if the results from this are more than 2 standard deviations below normal  they must be excluded ",
        "statement_nums": [
            "2 standard deviations",
            "1 month prior"
        ],
        "label": "Contradiction",
        "premise_text": "Bone density scan within 2 standard deviations from normal within the past 30 days Bone density scan 2 standard deviations below normal allowed if approved by the study physician ",
        "premise_nums": [
            "30 days Bone",
            "2 standard deviations"
        ]
    },
    {
        "id": "21d7d726-8557-459f-a307-fae3e08f45d8",
        "primaryId": "NCT00656019",
        "secondaryId": "NCT00328783",
        "label": "Contradiction",
        "statement_text": "Candidates with hyperparathyroidism are automatically excluded from the primary trial and the secondary trial ",
        "statement_nums": [],
        "premise_text": "EXCLUSION CRITERIA: History of parathyroid disease  hypercalcemia  or kidney stones  Inclusion Criteria: Requiring adjuvant or post mastectomy radiation therapy with tangential fields or 3-fields Adequate pulmonary function Presence of 5 cc of the heart or liver with the simulation fields Karnofsky Performance Status (KPS) equal to or greater than 70 Exclusion Criteria: Pregnant women Patients who have had previous ipsilateral breast or thoracic radiation therapy ",
        "premise_nums": [
            "3-fields Adequate",
            "5 cc of",
            "70 Exclusion Criteria:"
        ]
    },
    {
        "id": "9a8157a9-82fc-4d7e-9254-295123459430",
        "primaryId": "NCT00054132",
        "statement_text": "The majority of patients in the primary trial had an EGFR Expression level of 0, and 0 patients had an EGFR of 3 or above ",
        "statement_nums": [
            "0 patients had",
            "3 or above"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Level of EGFR Expression Estimated at the end of the trial Immunoreactivity will be evaluated qualitatively with regard to intensity as follows: Measured on a scale  ranging from 0-3+ 0=negative (no immunoreactivity) 1+ - 3+ = positive: faint immunoreactivity (weak staining) intense immunoreactivity (strong staining) Immunohistochemical studies will be performed on the tumor specimen to correlate the anti-tumor efficacy of OSI-774 and bevacizumab with pre-treatment molecular characteristics  Time frame: Up to 12 years Results 1: ",
        "premise_nums": [
            "0-3+ 0=negative",
            "12 years Results",
            "774 and bevacizumab"
        ]
    },
    {
        "id": "9a8157a9-82fc-4d7e-9254-295123459430",
        "primaryId": "NCT00054132",
        "statement_text": "The majority of patients in the primary trial had an EGFR Expression level of 0, and 0 patients had an EGFR of 3 or above ",
        "statement_nums": [
            "0 patients had",
            "3 or above"
        ],
        "label": "Entailment",
        "premise_text": "Arm/Group Title: Treatment (Erlotinib Hydrochloride  Bevacizumab)Arm/Group Description: Patients receive erlotinib hydrochloride PO QD on days 1-21 and bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity  Overall Number of Participants Analyzed: 38 Measure Type: Number Unit of Measure: participants EGFR 0: 24 EGFR 1+: 8 EGFR 2+: 4 EGFR 3+: 0 Insufficient tumor tissue: 2 ",
        "premise_nums": [
            "2+: 4",
            "3+: 0",
            "8 EGFR 2",
            "1-21 and",
            "4 EGFR 3",
            "21 days in",
            "0 Insufficient tumor",
            "30-90 minutes",
            "21 and bevacizumab",
            "24 EGFR 1",
            "38 Measure Type:",
            "1+: 8",
            "90 minutes on"
        ]
    },
    {
        "id": "ff37494d-2c61-4c06-86c1-d6bcfbe9e360",
        "primaryId": "NCT01856543",
        "secondaryId": "NCT00365599",
        "label": "Entailment",
        "statement_text": "Across all cohorts of the secondary trial and the primary trial there was only a single recorded case of Myocarditis and Pericarditis ",
        "statement_nums": [],
        "premise_text": "Adverse Events 1: Total: 3/73 (4.11%) Chest Pain - cardiac 1/73 (1.37%) Myocarditis 1/73 (1.37%) Pericarditis 1/73 (1.37%) Ventricular tachycardia 1/73 (1.37%) Skin infection 0/73 (0.00%) Dermatitis radiation 0/73 (0.00%) Dyspnea 1/73 (1.37%) Adverse Events 2: Total: 3/70 (4.29%) Chest Pain - cardiac 0/70 (0.00%) Myocarditis 0/70 (0.00%) Pericarditis 0/70 (0.00%) ",
        "premise_nums": [
            "0/73 (0.00%)",
            "0/70 (0.00%)",
            "3/70 (4.29%)",
            "3/73 (4.11%)",
            "1/73 (1.37%)"
        ]
    },
    {
        "id": "ff37494d-2c61-4c06-86c1-d6bcfbe9e360",
        "primaryId": "NCT01856543",
        "secondaryId": "NCT00365599",
        "label": "Entailment",
        "statement_text": "Across all cohorts of the secondary trial and the primary trial there was only a single recorded case of Myocarditis and Pericarditis ",
        "statement_nums": [],
        "premise_text": "Ventricular tachycardia 0/70 (0.00%)Skin infection 2/70 (2.86%) Dermatitis radiation 1/70 (1.43%) Dyspnea 0/70 (0.00%) Adverse Events 1: Total: 4/43 (9.30%) Hemoglobin [1]1/43 (2.33%) Hemorrhage/Bleeding [2]1/43 (2.33%) Neutrophils/granulocytes (ANC/AGC) [3]1/43 (2.33%) Platelets [4]1/43 (2.33%) Anorexia [5]1/43 (2.33%) ",
        "premise_nums": [
            "1/70 (1.43%)",
            "2/70 (2.86%)",
            "1/43 (2.33%)",
            "0/70 (0.00%)Skin",
            "4/43 (9.30%)"
        ]
    },
    {
        "id": "ff37494d-2c61-4c06-86c1-d6bcfbe9e360",
        "primaryId": "NCT01856543",
        "secondaryId": "NCT00365599",
        "label": "Entailment",
        "statement_text": "Across all cohorts of the secondary trial and the primary trial there was only a single recorded case of Myocarditis and Pericarditis ",
        "statement_nums": [],
        "premise_text": "Sodium  serum-low (hyponatremia) [1]1/43 (2.33%)Thrombosis/thrombus/embolism [6]2/43 (4.65%) ",
        "premise_nums": [
            "2/43 (4.65%)",
            "1/43 (2.33%)Thrombosis/thrombus/embolism"
        ]
    },
    {
        "id": "eb00b609-f17b-4595-87bd-d0843ec9e39a",
        "primaryId": "NCT01857882",
        "secondaryId": "NCT01439945",
        "label": "Contradiction",
        "statement_text": "the secondary trial administers 150 mg/Day more of Magnesium Oxide to its patients than the primary trial does ",
        "statement_nums": [
            "150 mg/Day more"
        ],
        "premise_text": "INTERVENTION 1: Decision Support Workshop The decision support workshop will be 2 hours in duration on the morning of the consultation and will be facilitated by a dedicated social worker from psycho-oncology  Decision Support Workshop: Incorporates the key components of shared decision-making and decision support with the philosophy of delivering supportive care to cancer patients  Surgeon (30 mins): treatment options for breast reconstruction with indications/ contraindications  advantages / disadvantages  expected post-operative course  aesthetic result and complications with probabilities Registered nurse (30 mins): preparing for surgery  postoperative recovery and how to navigate the health care system Social worker (30 mins): values clarification exercise Breast reconstruction patient volunteer (30 mins) questions and answers about her personal experience INTERVENTION 2: Standard Care Routine pre-consultation education INTERVENTION 1: ",
        "premise_nums": [
            "2 hours in"
        ]
    },
    {
        "id": "eb00b609-f17b-4595-87bd-d0843ec9e39a",
        "primaryId": "NCT01857882",
        "secondaryId": "NCT01439945",
        "label": "Contradiction",
        "statement_text": "the secondary trial administers 150 mg/Day more of Magnesium Oxide to its patients than the primary trial does ",
        "statement_nums": [
            "150 mg/Day more"
        ],
        "premise_text": "Low Dose Magnesium Oxide (800 mg/Day)Week 2: Patients take one 400 mg tablet of magnesium oxide orally (PO) daily (QD)  Week 3: Patients take two 400 mg tablet of magnesium oxide orally (PO) daily (QD)  Weeks 4-9: Patients take two 400 mg tablet of magnesium oxide orally (PO) daily (QD)  INTERVENTION 2: High Dose Magnesium Oxide (1200 mg/Day) Week 2: Patients take one 400 mg tablet of magnesium oxide orally (PO) daily (QD)  Week 3: Patients take two 400 mg tablet of magnesium oxide orally (PO) daily (QD)  Weeks 4-9: Patients take three 400 mg tablet of magnesium oxide orally (PO) daily (QD)  ",
        "premise_nums": [
            "400 mg tablet",
            "4-9: Patients"
        ]
    },
    {
        "id": "8bc9ea31-b731-4799-a1cc-a5ba63da00c1",
        "primaryId": "NCT00904033",
        "secondaryId": "NCT03592121",
        "label": "Contradiction",
        "statement_text": "Patients are not required to be sexually active to receive the primary trial intervention  this is however a requirement for the secondary trial where the intervention must be applied during sexual activity ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: No Exercise Multivitamin Arm + Calcitriol Arm:Calcitriol pill taken once per week INTERVENTION 2: Exercise Exercise Arm: Exercise consisting of progressive walking and resistance band training Calcitriol+ Exercise Arm: Calcitriol pill taken once per week + Exercise INTERVENTION 1: AB-101 Apply to both nipple/areola regions approximately 1 hour prior to sexual activity AB-101: Apply approximately 1 hour prior to sexual activity INTERVENTION 2: Placebo Apply to both nipple/areola regions approximately 1 hour prior to sexual activity Placebo: Apply approximately 1 hour prior to sexual activity ",
        "premise_nums": [
            "1 hour prior",
            "101 Apply to"
        ]
    },
    {
        "id": "0864493d-9f64-49d1-a585-21be71704c59",
        "primaryId": "NCT01684215",
        "statement_text": "In the primary trial there was no recorded difference in the Number/percentage of Participants With Dose Limiting Toxicities taking 100 mg vs 125 mg of oral PD-0332991, meaning 0% of patients in the primary trial suffered grade 4 or above thrombocytopenia ",
        "statement_nums": [
            "4 or above",
            "100 mg vs",
            "125 mg of",
            "0% of"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Number of Participants With Dose Limiting Toxicities (DLT): Part 1 Phase 1 ",
        "premise_nums": [
            "1 Phase 1"
        ]
    },
    {
        "id": "c49428a7-cc55-474e-a773-88ff2019de1b",
        "primaryId": "NCT02780713",
        "statement_text": "Both cohorts of the primary trial are administered the same doses of their respective drugs  ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "INTERVENTION 1: Treatment Period 1 Participants received AZD9496 - Variant A (100 mg)  INTERVENTION 2: Treatment Period 2 Participants received AZD9496 - Reference (100 mg)  ",
        "premise_nums": [
            "1 Participants received",
            "2 Participants received"
        ]
    },
    {
        "id": "78136809-c8de-4c40-9a7e-1d61d879ba27",
        "primaryId": "NCT00611624",
        "secondaryId": "NCT00600340",
        "label": "Entailment",
        "statement_text": "the primary trial and the secondary trial administer their interventions at different frequencies ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Five Days of Mammosite Therapy [Not Specified] INTERVENTION 1: Bevacizumab Plus Paclitaxel Bevacizumab 10 mg/kg intravenous (i.v.)  days 1 and 15, every 4 weeks  Paclitaxel 90 mg/m2, days 1, 8 and 15, every 4 weeks INTERVENTION 2: Bevacizumab Plus Capecitabine Bevacizumab 15 mg/kg i.v.  day 1, every 3 weeks  Capecitabine 1000 mg/m² twice-daily  days 1-14, every 3 weeks ",
        "premise_nums": [
            "4 weeks INTERVENTION",
            "8 and 15,",
            "1000 mg/m²",
            "10 mg/kg intravenous",
            "1-14, every",
            "90 mg/m2,",
            "1 and 15,",
            "15 mg/kg i"
        ]
    },
    {
        "id": "b430ea52-fa55-4280-9e23-8a7392afca58",
        "primaryId": "NCT00009945",
        "statement_text": "Patients with a positive sentinel node biopsy must have surgery to remove lymph nodes from the armpit (underarm or axilla) or they will not be eligible for the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Eligibility Patients must have undergone either a total mastectomy or a lumpectomy with either an axillary dissection or sentinel node biopsy  If any sentinel node is histologically positive by H & E  or histologically suspicious on H & E and confirmed positive by immunohistochemistry (IHC)  then the patient must have a completion axillary dissection  ",
        "premise_nums": []
    },
    {
        "id": "adfeff22-7bdd-4868-ab6e-90dd43d9621d",
        "primaryId": "NCT00038103",
        "statement_text": "There is no difference in the proportions of Subjects With Clinical Benefit in the Exemestane + Celecoxib cohort and in the Exemestane alone cohort of the primary trial ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Number of Subjects With Clinical Benefit Clinical benefit was based on objective tumor assessments made according to Response Evaluation Criteria (RECIST) system of unidimensional evaluation  Includes subjects with complete response (CR)  partial response (PR)  and long term disease stabilization (SD) for at least 24 weeks  Time frame: Baseline  Week 8, 16, 24, and every 12 weeks beyond 24 up to Week 108 and every 24 weeks thereafter until 9 months following last subject last visit (LSLV) Results 1: Arm/Group Title: Exemestane (Exemestane Alone) Arm/Group Description: oral dose exemestane taken with food (25 mg tablet once daily) Overall Number of Participants Analyzed: 49 ",
        "premise_nums": [
            "24 weeks thereafter",
            "25 mg tablet",
            "9 months following",
            "108 and every",
            "24 up to",
            "12 weeks beyond"
        ]
    },
    {
        "id": "adfeff22-7bdd-4868-ab6e-90dd43d9621d",
        "primaryId": "NCT00038103",
        "statement_text": "There is no difference in the proportions of Subjects With Clinical Benefit in the Exemestane + Celecoxib cohort and in the Exemestane alone cohort of the primary trial ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Measure Type: NumberUnit of Measure: participants 24 Results 2: Arm/Group Title: Combination (Exemestane + Celecoxib) Arm/Group Description: oral doses to be taken with food (25 mg tablet exemestane once daily; celecoxib 2 x 200 mg tablets twice daily) Overall Number of Participants Analyzed: 51 Measure Type: Number Unit of Measure: participants 24 ",
        "premise_nums": [
            "25 mg tablet",
            "24 Results 2:",
            "51 Measure Type:",
            "2 x 200"
        ]
    },
    {
        "id": "51b8964b-86b8-4e93-9fb1-cb4b6f7f3451",
        "primaryId": "NCT00371345",
        "secondaryId": "NCT00475670",
        "label": "Contradiction",
        "statement_text": "There only overlap between adverse events obeserved in the primary trial and the secondary trial is the several case of Sepsis which occurred in both trials ",
        "statement_nums": [],
        "premise_text": "Adverse Events 1: Total: 20/70 (28.57%) NAUSEA 2/70 (2.86%) VOMITING 1/70 (1.43%) DIARRHOEA 2/70 (2.86%) ABDOMINAL PAIN 1/70 (1.43%) ABDOMINAL PAIN LOWER 1/70 (1.43%) FATIGUE 2/70 (2.86%) PYREXIA 1/70 (1.43%) OEDEMA PERIPHERAL 1/70 (1.43%) GENERAL PHYSICAL HEALTH DETERIORATION 3/70 (4.29%) PNEUMONIA 1/70 (1.43%) SINUSITIS 1/70 (1.43%) LOBAR PNEUMONIA 1/70 (1.43%) Adverse Events 1: ",
        "premise_nums": [
            "2/70 (2.86%)",
            "20/70 (28.57%)",
            "1/70 (1.43%)",
            "3/70 (4.29%)"
        ]
    },
    {
        "id": "51b8964b-86b8-4e93-9fb1-cb4b6f7f3451",
        "primaryId": "NCT00371345",
        "secondaryId": "NCT00475670",
        "label": "Contradiction",
        "statement_text": "There only overlap between adverse events obeserved in the primary trial and the secondary trial is the several case of Sepsis which occurred in both trials ",
        "statement_nums": [],
        "premise_text": "Total: 0/3 (0.00%)Febrile Neutropenia * 0/3 (0.00%) Neutropenia * 0/3 (0.00%) Sudden Death * 0/3 (0.00%) Bacterial Infection * 0/3 (0.00%) Bronchitis * 0/3 (0.00%) Sepsis * 0/3 (0.00%) Lymphoedema * 0/3 (0.00%) ",
        "premise_nums": [
            "0/3 (0.00%)Febrile"
        ]
    },
    {
        "id": "276f5523-f45b-45b0-ad30-b737f2c1b1d0",
        "primaryId": "NCT00468585",
        "statement_text": "the primary trial recorded several skin infections in their patients ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 2/4 (50.00%) Atrial fibrillation 0/4 (0.00%) Dehydration 1/4 (25.00%) Fatigue (asthenia  lethargy  malaise) 1/4 (25.00%) Pain - Back 1/4 (25.00%) Urinary tract infection 0/4 (0.00%) Dyspnea (shortness of breath) 0/4 (0.00%) Pericardial effusion 0/4 (0.00%) Thrombosis 0/4 (0.00%) Skin infection 0/4 (0.00%) Rash: hand-foot skin reaction 0/4 (0.00%) Adverse Events 2: Total: 0/3 (0.00%) ",
        "premise_nums": [
            "0/4 (0.00%)",
            "2/4 (50.00%)",
            "1/4 (25.00%)",
            "0/3 (0.00%)"
        ]
    },
    {
        "id": "276f5523-f45b-45b0-ad30-b737f2c1b1d0",
        "primaryId": "NCT00468585",
        "statement_text": "the primary trial recorded several skin infections in their patients ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Atrial fibrillation 0/3 (0.00%)Dehydration 0/3 (0.00%) Fatigue (asthenia  lethargy  malaise) 0/3 (0.00%) Pain - Back 0/3 (0.00%) Urinary tract infection 0/3 (0.00%) Dyspnea (shortness of breath) 0/3 (0.00%) Pericardial effusion 0/3 (0.00%) Thrombosis 0/3 (0.00%) Skin infection 0/3 (0.00%) Rash: hand-foot skin reaction 0/3 (0.00%) ",
        "premise_nums": [
            "0/3 (0.00%)Dehydration"
        ]
    },
    {
        "id": "884ba067-d3fe-4837-ad2a-a802b671b53c",
        "primaryId": "NCT00295867",
        "statement_text": "Patients with an ECOG score between 3-5 are eligible for the primary trial ",
        "statement_nums": [
            "5 are eligible",
            "3-5 are"
        ],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria Women greater than 18 years of age with histologically or cytologically confirmed stage I  II or III breast cancer  If adjuvant chemotherapy is recommended  it must be completed before study start  Bone marrow aspirate positive by IC/FC assay a  Definition of positive: greater than 4 MM/ml b  Timing of bone marrow aspiration to determine study eligibility: i  If patient is to receive either no adjuvant therapy or hormonal therapy alone  the aspiration may be performed at diagnosis as part of the large MM study at University of California  San Francisco  or following diagnosis if the patient received initial surgery elsewhere  This is also true for patients who have surgery following neoadjuvant therapy for breast cancer  ",
        "premise_nums": [
            "4 MM/ml b",
            "18 years of"
        ]
    },
    {
        "id": "884ba067-d3fe-4837-ad2a-a802b671b53c",
        "primaryId": "NCT00295867",
        "statement_text": "Patients with an ECOG score between 3-5 are eligible for the primary trial ",
        "statement_nums": [
            "5 are eligible",
            "3-5 are"
        ],
        "label": "Contradiction",
        "premise_text": "ii  If the patient is to receive adjuvant chemotherapy  the aspiration will be performed at least three weeks after chemotherapy has been completed Adequate renal function as defined by: a  Creatinine must be smaller than upper limit of normal Normal liver function tests including total bilirubin  alkaline phosphatase  and aspartate aminotransferase (AST) / serum glutamic-oxaloacetic transaminase (SGOT) Ability to understand and sign informed consent  Concomitant hormonal therapy is allowed Concomitant radiation therapy is allowed Patients who have had surgery following neoadjuvant chemotherapy or hormonal therapy are eligible to participate in this trial Exclusion Criteria ",
        "premise_nums": []
    },
    {
        "id": "884ba067-d3fe-4837-ad2a-a802b671b53c",
        "primaryId": "NCT00295867",
        "statement_text": "Patients with an ECOG score between 3-5 are eligible for the primary trial ",
        "statement_nums": [
            "5 are eligible",
            "3-5 are"
        ],
        "label": "Contradiction",
        "premise_text": "History of allergy to bisphosphonates  Acute phase reactions occur in up to 24% of patients and disappear with subsequent dosing  An acute phase reaction does not qualify as an allergic reaction History of renal insufficiency  Renal insufficiency is defined by a serum creatinine greater than the upper limit of normal or a creatinine clearance smaller than 50 mL/min due to any underlying cause  Karnofsky Performance status smaller than 90%. Any significant medical condition that might interfere with treatment  Women participating in this study are not allowed to receive other bisphosphonate therapy during the study period  either oral or intravenous  Patients who are pregnant ",
        "premise_nums": [
            "50 mL/min due",
            "24% of"
        ]
    },
    {
        "id": "6619c75a-4073-47e9-8586-5070be1b3d39",
        "primaryId": "NCT02222337",
        "statement_text": "Participants for the primary trial must be in pairs  a breast cancer survivor and a caregiver  both must either be fluent in english or spanish ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Inclusion Criteria: Survivors: Latina  has been diagnosed with breast cancer  speaks English or Spanish  has a Caregiver who is willing to participate  Caregivers: a primary caregiver for a Latina breast cancer survivor  speak English or Spanish ",
        "premise_nums": []
    },
    {
        "id": "d81fafa4-1196-407b-a8c2-27d7b5da2f4f",
        "primaryId": "NCT01816594",
        "secondaryId": "NCT02222337",
        "label": "Contradiction",
        "statement_text": "Patients with histologically confirmed  newly diagnosed stage 0 breast cancer cannot take part in the primary trial  or the secondary trial  unless they present LVEF below 50%",
        "statement_nums": [
            "0 breast cancer"
        ],
        "premise_text": "Patient has bilateral breast cancer or metastatic disease or inflammatory breast cancer Inclusion Criteria: Survivors: Latina  has been diagnosed with breast cancer  speaks English or Spanish  has a Caregiver who is willing to participate  Caregivers: a primary caregiver for a Latina breast cancer survivor  speak English or Spanish Exclusion Criteria: Inability to understand spoken English and/or Spanish and/or Cognitive impairment that precludes informed consent (determined by the PIs or Co-Investigators who are mental health professionals)  ",
        "premise_nums": []
    },
    {
        "id": "6d8b4720-e600-47d7-b6c5-3b8627f2358f",
        "primaryId": "NCT00320710",
        "statement_text": "There was no adverse event in cohort 2 of the primary trial which occurred in more than 0.5% of patients ",
        "statement_nums": [
            "2 of the",
            "than 0.5% of patients"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 2: Anaemia 3/202 (1.49%) Febrile neutropenia 2/202 (0.99%) Leukocytosis 0/202 (0.00%) Leukopenia 0/202 (0.00%) Neutropenia 0/202 (0.00%) Pancytopenia 1/202 (0.50%) Atrial fibrillation 1/202 (0.50%) Cardiac failure congestive 1/202 (0.50%) Palpitations 1/202 (0.50%) Pericardial effusion 1/202 (0.50%) Supraventricular tachycardia 1/202 (0.50%) ",
        "premise_nums": [
            "3/202 (1.49%)",
            "2/202 (0.99%)",
            "1/202 (0.50%)",
            "0/202 (0.00%)"
        ]
    },
    {
        "id": "1b84007d-0002-4ab6-8e05-609e7de58684",
        "primaryId": "NCT01646346",
        "secondaryId": "NCT03283553",
        "label": "Entailment",
        "statement_text": "the secondary trial and the primary trial do not use topical medications in their studies ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: 4D Conformal Image-Guided Partial Breast RT This is a single arm trial designed to look at the results in women treated with partial breast irradiation twice daily for 5 days  4D Conformal Image-Guided Partial Breast RT: External beam partial breast radiation to target a portion of the breast twice a day for 5 days  INTERVENTION 1: Multicomponent Intervention 1.) A one-page paper-pencil agenda setting checklist completed immediately before a regularly scheduled medical oncology visit to elicit and align patient and companion perspectives regarding issues to discuss with the provider  and to stimulate discussion about the role of the companion in the visit  2.) facilitated registration for the patient portal (for patient and family member  as desired by the patient)  and 3.) education (as relevant) on access to doctor's electronic visit notes  INTERVENTION 2: Usual Care ",
        "premise_nums": []
    },
    {
        "id": "1b84007d-0002-4ab6-8e05-609e7de58684",
        "primaryId": "NCT01646346",
        "secondaryId": "NCT03283553",
        "label": "Entailment",
        "statement_text": "the secondary trial and the primary trial do not use topical medications in their studies ",
        "statement_nums": [],
        "premise_text": "Care as usual with the medical oncologist ",
        "premise_nums": []
    },
    {
        "id": "dc4f9c4a-ca42-4f4d-b93a-0e8dd627b009",
        "primaryId": "NCT00213980",
        "secondaryId": "NCT02536339",
        "label": "Contradiction",
        "statement_text": "Adequate hematologic  renal  and hepatic function are required to participate in the secondary trial and the primary trial  however  patients with severe loss in cognitive function are still eligible ",
        "statement_nums": [],
        "premise_text": "Inclusion Criteria: Postmenopausal women  Stage III or axillary node positive Currently disease free of breast cancer and other invasive malignancies at the time of registration No concurrent use of bisphosphonates Exclusion Criteria: Metastatic disease Inclusion Criteria: Pathologically confirmed HER2-positive MBC Progression of or new brain metastases after completion of whole-brain radiotherapy or stereotactic radiosurgery Completion of whole-brain radiotherapy or stereotactic radiosurgery more than 60 days prior to enrollment Stable systemic disease Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 LVEF at least 50% Adequate hematologic  renal  and hepatic function Life expectancy more than 12 weeks ",
        "premise_nums": [
            "2-positive MBC",
            "50% Adequate",
            "0 or 1",
            "60 days prior"
        ]
    },
    {
        "id": "dc4f9c4a-ca42-4f4d-b93a-0e8dd627b009",
        "primaryId": "NCT00213980",
        "secondaryId": "NCT02536339",
        "label": "Contradiction",
        "statement_text": "Adequate hematologic  renal  and hepatic function are required to participate in the secondary trial and the primary trial  however  patients with severe loss in cognitive function are still eligible ",
        "statement_nums": [],
        "premise_text": "Exclusion Criteria:Progression of systemic disease at Screening Leptomeningeal disease History of intolerance or hypersensitivity to study drug Use of certain investigational therapies within 21 days prior to enrollment Current anthracycline use Unwillingness to discontinue ado-trastuzumab emtansine or lapatinib use Active infection Pregnant or lactating women Significant history or risk of cardiac disease Symptomatic intrinsic lung disease or lung involvement History of other malignancy within the last 5 years ",
        "premise_nums": [
            "21 days prior"
        ]
    },
    {
        "id": "dc7c4409-32e5-4211-83fe-0a97b6176ca0",
        "primaryId": "NCT01007942",
        "statement_text": "Febrile neutropenia was in excess of 5 times more common in cohort 1 of the primary trial  than in cohort 2.",
        "statement_nums": [
            "5 times more",
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Febrile neutropenia 30/280 (10.71%) Adverse Events 2: Febrile neutropenia 4/282 (1.42%) ",
        "premise_nums": [
            "4/282 (1.42%)",
            "30/280 (10.71%)"
        ]
    },
    {
        "id": "73e7447b-a940-4126-a1d9-fffd7c56c900",
        "primaryId": "NCT00337103",
        "statement_text": "Several patients in the Eribulin Mesylate group in the primary trial survived less than a year ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Overall Survival (OS) OS was measured from the date of randomization until the date of death from any cause  or the last date the participant was known to be alive  Participants who were lost to follow-up or who were alive at the date of data cutoff were censored  The censoring rules for OS were as follows: 1) if the participant was still alive at data cutoff  the date of data cutoff was considered the end date  and 2) if the participant was lost to follow-up before data cutoff  the date they were last known to be alive was considered the end date  Participants who survived past the end of the study were counted as in the full study period  If death occurred after data cutoff  the end date was to be censored at the time of data cutoff  ",
        "premise_nums": []
    },
    {
        "id": "73e7447b-a940-4126-a1d9-fffd7c56c900",
        "primaryId": "NCT00337103",
        "statement_text": "Several patients in the Eribulin Mesylate group in the primary trial survived less than a year ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Time frame: From date of randomization until date of death from any cause  assessed up to data cutoff date of 12 Mar 2012, or up to approximately 6 yearsResults 1: Arm/Group Title: Eribulin Mesylate 1.4 mg/m^2 Arm/Group Description: Eribulin mesylate 1.4 mg/m^2 intravenous (IV) infusion given over 2-5 minutes on Days 1 and 8 every 21 days  Overall Number of Participants Analyzed: 554 Median (95% Confidence Interval) Unit of Measure: days 484 (462 to 536) ",
        "premise_nums": [
            "2-5 minutes",
            "462 to 536)",
            "Mesylate 1.4 mg/m",
            "mesylate 1.4 mg/m",
            "1 and 8",
            "95% Confidence",
            "12 Mar 2012,",
            "2 intravenous (IV)",
            "5 minutes on",
            "6 yearsResults 1:"
        ]
    },
    {
        "id": "c160ae6e-4dfe-47a4-ac9a-7497babbc2a2",
        "primaryId": "NCT00629499",
        "statement_text": "Patients with peripheral neuropathy  but no symptoms of neuropathy  are excluded from the primary trial ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria: Pre-existing peripheral neuropathy must be less than or equal to grade 1 by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v3.0 criteria  ",
        "premise_nums": [
            "1 by National",
            "v3.0 criteria"
        ]
    },
    {
        "id": "9f1afdf1-1ecf-4c8b-9b40-cc96cac0e063",
        "primaryId": "NCT00129389",
        "secondaryId": "NCT00304096",
        "label": "Contradiction",
        "statement_text": "Patients with permanent sensory loss  interfering with daily activities are excluded from the primary trial and the secondary trial ",
        "statement_nums": [],
        "premise_text": "Exclusion Criteria: Pre-existing grade greater than or equal 2 motor or sensorial neurotoxicity by the National Cancer Institute Common Toxicity Criteria (NCICTC) v-2.0. Histologically or cytologically confirmed adenocarcinoma of the breast Stage III or IV disease Primary or recurrent disease Invasive lobular carcinoma allowed HLA-A1, -A2, -A3, or -A31 positive Underwent and recovered from prior primary therapy Patients with no clinical or radiological evidence of disease who had a previous diagnosis of stage III or IV breast cancer must have undergone prior antineoplastic therapy including  but not limited to  surgery  chemotherapy  and radiotherapy within the past 36 months ",
        "premise_nums": [
            "31 positive Underwent",
            "2 motor or",
            "A31 positive"
        ]
    },
    {
        "id": "9f1afdf1-1ecf-4c8b-9b40-cc96cac0e063",
        "primaryId": "NCT00129389",
        "secondaryId": "NCT00304096",
        "label": "Contradiction",
        "statement_text": "Patients with permanent sensory loss  interfering with daily activities are excluded from the primary trial and the secondary trial ",
        "statement_nums": [],
        "premise_text": "Must have at least one undissected axillary and/or inguinal lymph node basinNo history of brain metastases Hormone receptor status Estrogen receptor-positive or -negative tumor PATIENT CHARACTERISTICS: ECOG performance status of 0 or 1 Body weight greater than 110 lbs (without clothes) Male or female Menopausal status not specified Absolute neutrophil count greater than 1000/mm^3 Platelet count greater than 100,000/mm^3 Hemoglobin greater than 9 g/dL Hemoglobin A1c smaller than 7% AST and ALT 2.5 x upper limit of normal (ULN) Bilirubin 2.5 x ULN Alkaline phosphatase 2.5 x ULN Creatinine 1.5 x ULN HIV negative ",
        "premise_nums": [
            "110 lbs (without",
            "100,000/mm^3 Hemoglobin",
            "7% AST",
            "0 or 1",
            "Bilirubin 2.5 x ULN",
            "3 Platelet count",
            "1000/mm^3 Platelet",
            "3 Hemoglobin greater",
            "phosphatase 2.5 x ULN",
            "9 g/dL Hemoglobin",
            "Creatinine 1.5 x ULN",
            "ALT 2.5 x upper"
        ]
    },
    {
        "id": "9f1afdf1-1ecf-4c8b-9b40-cc96cac0e063",
        "primaryId": "NCT00129389",
        "secondaryId": "NCT00304096",
        "label": "Contradiction",
        "statement_text": "Patients with permanent sensory loss  interfering with daily activities are excluded from the primary trial and the secondary trial ",
        "statement_nums": [],
        "premise_text": "Hepatitis C negativeNot pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception No known or suspected allergies to any component of the vaccine No active infection requiring antibiotics No New York Heart Association class III or IV heart disease No autoimmune disorders requiring cytotoxic or immunosuppressive therapy or autoimmune disorders with visceral involvement  except the following: Laboratory evidence of autoimmune disease (e.g.  positive ANA titer) without symptoms Clinical evidence of vitiligo Other forms of depigmenting illness Mild arthritis requiring nonsteroidal antiinflammatory drugs No medical contraindication or potential problem that would preclude study participation PRIOR CONCURRENT THERAPY: More than 4 weeks since prior surgery ",
        "premise_nums": [
            "4 weeks since"
        ]
    },
    {
        "id": "9f1afdf1-1ecf-4c8b-9b40-cc96cac0e063",
        "primaryId": "NCT00129389",
        "secondaryId": "NCT00304096",
        "label": "Contradiction",
        "statement_text": "Patients with permanent sensory loss  interfering with daily activities are excluded from the primary trial and the secondary trial ",
        "statement_nums": [],
        "premise_text": "More than 4 weeks since prior and no concurrent chemotherapy and radiotherapyMore than 4 weeks since prior and no concurrent allergy desensitization injections More than 4 weeks since prior parenteral  oral  or inhaled corticosteroids No concurrent inhaled steroids (e.g.  Advair® or triamcinolone acetonide) Prior or concurrent topical corticosteroids allowed More than 4 weeks since prior and no concurrent growth factors (e.g.  epoetin alfa  darbepoetin alfa  or pegfilgrastim) More than 4 weeks since prior and no concurrent other investigational medication More than 4 weeks since prior and no concurrent other agents with putative immunomodulating activity except for non-steroidal anti-inflammatory agents ",
        "premise_nums": [
            "4 weeks since"
        ]
    },
    {
        "id": "9f1afdf1-1ecf-4c8b-9b40-cc96cac0e063",
        "primaryId": "NCT00129389",
        "secondaryId": "NCT00304096",
        "label": "Contradiction",
        "statement_text": "Patients with permanent sensory loss  interfering with daily activities are excluded from the primary trial and the secondary trial ",
        "statement_nums": [],
        "premise_text": "Prior and concurrent hormonal therapy (e.g.  tamoxifen  raloxifene  toremifene  fulvestrant  letrozole  anastrozole  or exemestane) allowedNo prior vaccination with any synthetic peptides in this protocol Vaccines for infectious disease (e.g.  influenza) allowed  provided they are administered 2 weeks prior to or 2 weeks after study vaccine Short term therapy for acute conditions not related to breast cancer allowed No concurrent illegal drugs ",
        "premise_nums": [
            "2 weeks prior",
            "2 weeks after"
        ]
    },
    {
        "id": "a7106a35-36da-423a-a6b3-3da62fc0eea8",
        "primaryId": "NCT01908101",
        "statement_text": "Prior exposure to taxane is obligatory for patients in the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Inclusion Criteria: Ability to provide written informed consent Prior exposure to taxane in the adjuvant  neoadjuvant or metastatic setting ",
        "premise_nums": []
    },
    {
        "id": "f4f50a05-9d63-4006-9680-b7ef68dbb5fe",
        "primaryId": "NCT00952731",
        "secondaryId": "NCT00956813",
        "label": "Contradiction",
        "statement_text": "Cohort 2 in the primary trial and the secondary trial but receive daily placebo doses PO ",
        "statement_nums": [
            "2 in the"
        ],
        "premise_text": "INTERVENTION 2: Placebo Gel + Oral Treatment Placebo gel applied to the breasts daily  20mg oral tamoxifen taken daily (taken as two (2) 10mg capsules)  tamoxifen citrate: 20mg oral tamoxifen taken daily (taken as two (2) 10mg capsules) for 4-10 weeks  placebo gel: Placebo gel applied to breasts daily for 4-10 weeks  INTERVENTION 2: Placebo Patients Identical looking bar with same calorie and total fat content but without flaxseed or lignans once daily  ",
        "premise_nums": [
            "4-10 weeks"
        ]
    },
    {
        "id": "f34760f4-965e-4bbb-b88f-8b63a7045808",
        "primaryId": "NCT00741260",
        "statement_text": "Patients with HER2 positive tumors are ineligible for the primary trial ",
        "statement_nums": [
            "2 positive tumors"
        ],
        "label": "Contradiction",
        "premise_text": "INCLUSION CRITERIA erbB-2 gene amplified tumor (FISH or CISH) or erbB-2 overexpression (IHC 3+, or IHC2+ with FISH or CISH confirmation)  based on local testing  or based on centralized FISH testing prior to day 1. ",
        "premise_nums": [
            "2 gene amplified",
            "3+, or",
            "2 overexpression (IHC"
        ]
    },
    {
        "id": "f4a33395-7e6b-46b9-b222-af3bbfff1591",
        "primaryId": "NCT00866905",
        "statement_text": "Less than 2% of patients in the primary trial experienced an adverse event ",
        "statement_nums": [
            "2% of"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 6/168 (3.57%) ",
        "premise_nums": [
            "6/168 (3.57%)"
        ]
    },
    {
        "id": "e7d00591-381f-45e2-abdb-2ae1e568b193",
        "primaryId": "NCT01421472",
        "statement_text": "More than 3 patients in the primary trial suffered from adverse events associated with a low number of white blood cells ",
        "statement_nums": [
            "3 patients in"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Febrile Neutropenia * 5/67 (7.46%) ",
        "premise_nums": [
            "5/67 (7.46%)"
        ]
    },
    {
        "id": "59da1fb5-2636-4ca8-8970-6cb45dedbed3",
        "primaryId": "NCT00885755",
        "secondaryId": "NCT01075100",
        "label": "Contradiction",
        "statement_text": "Patients' appetites were not affected in the primary trial or the secondary trial ",
        "statement_nums": [],
        "premise_text": "Adverse Events 1: Total: 9/33 (27.27%) Febrile neutropenia * 1/33 (3.03%) Cardiac failure * 1/33 (3.03%) Pyrexia * 2/33 (6.06%) Chest pain * 1/33 (3.03%) Medical device complication * 1/33 (3.03%) Cellulitis * 1/33 (3.03%) Sepsis * 1/33 (3.03%) Hip fracture * 1/33 (3.03%) Back pain * 1/33 (3.03%) Menorrhagia * 1/33 (3.03%) Thrombosis * 1/33 (3.03%) Adverse Events 1: Total: 10/48 (20.83%) ",
        "premise_nums": [
            "9/33 (27.27%)",
            "1/33 (3.03%)",
            "2/33 (6.06%)",
            "10/48 (20.83%)"
        ]
    },
    {
        "id": "59da1fb5-2636-4ca8-8970-6cb45dedbed3",
        "primaryId": "NCT00885755",
        "secondaryId": "NCT01075100",
        "label": "Contradiction",
        "statement_text": "Patients' appetites were not affected in the primary trial or the secondary trial ",
        "statement_nums": [],
        "premise_text": "NEUTROPENIA 1/48 (2.08%)THROMBOCYTOPENIA 0/48 (0.00%) VOLUME BLOOD DECREASED 1/48 (2.08%) FIBRILLATION ATRIAL 1/48 (2.08%) HYPOTENSION 1/48 (2.08%) ABDOMINAL PAIN 1/48 (2.08%) APPETITE DECREASED 0/48 (0.00%) DEHYDRATION 4/48 (8.33%) DIARRHEA 4/48 (8.33%) NAUSEA 3/48 (6.25%) VOMITING 2/48 (4.17%) FEVER 1/48 (2.08%) RIGORS 0/48 (0.00%) Adverse Events 2: Total: 5/53 (9.43%) ",
        "premise_nums": [
            "3/48 (6.25%)",
            "4/48 (8.33%)",
            "1/48 (2.08%)THROMBOCYTOPENIA",
            "2/48 (4.17%)",
            "0/48 (0.00%)",
            "5/53 (9.43%)"
        ]
    },
    {
        "id": "59da1fb5-2636-4ca8-8970-6cb45dedbed3",
        "primaryId": "NCT00885755",
        "secondaryId": "NCT01075100",
        "label": "Contradiction",
        "statement_text": "Patients' appetites were not affected in the primary trial or the secondary trial ",
        "statement_nums": [],
        "premise_text": "NEUTROPENIA 1/53 (1.89%)THROMBOCYTOPENIA 1/53 (1.89%) VOLUME BLOOD DECREASED 0/53 (0.00%) FIBRILLATION ATRIAL 0/53 (0.00%) HYPOTENSION 0/53 (0.00%) ABDOMINAL PAIN 0/53 (0.00%) APPETITE DECREASED 1/53 (1.89%) DEHYDRATION 0/53 (0.00%) DIARRHEA 0/53 (0.00%) NAUSEA 1/53 (1.89%) VOMITING 1/53 (1.89%) FEVER 1/53 (1.89%) RIGORS 1/53 (1.89%) ",
        "premise_nums": [
            "1/53 (1.89%)THROMBOCYTOPENIA",
            "0/53 (0.00%)"
        ]
    },
    {
        "id": "f144c34b-9428-4836-bf01-5f7030eb579c",
        "primaryId": "NCT04030104",
        "secondaryId": "NCT02525718",
        "label": "Entailment",
        "statement_text": "Intervention 1 for the secondary trial and the primary trial are for the control groups ",
        "statement_nums": [
            "1 for the"
        ],
        "premise_text": "INTERVENTION 1: IUS Alone IUS alone imaging INTERVENTION 2: Imagio (IUS+OA) IUS+OA imaging INTERVENTION 1: Placebo Subjects will be randomly selected to receive saline (placebo)  administered to the breast area to cover the intercostal nerves supplying the breast tissue during surgery  Saline: If randomized to this arm  subjects will receive an intraoperative injection of saline  (2.5 mg/ml) INTERVENTION 2: 0.25 % Bupivacaine w/ Epinephrine & 4mg Dexamethasone ",
        "premise_nums": [
            "0.25 % Bupivacaine",
            "(2.5 mg/ml"
        ]
    },
    {
        "id": "f144c34b-9428-4836-bf01-5f7030eb579c",
        "primaryId": "NCT04030104",
        "secondaryId": "NCT02525718",
        "label": "Entailment",
        "statement_text": "Intervention 1 for the secondary trial and the primary trial are for the control groups ",
        "statement_nums": [
            "1 for the"
        ],
        "premise_text": "Subjects will be randomly selected to receive selective block with a local anesthetic solution containing 0.25 % bupivacaine (2.5 mg/ml) with 1:100,000 epinephrine and 4 mg dexamethasone  The injection will be performed in certain locations of the breast area to cover the intercostal nerves supplying the breast tissue Subjects will be randomly selected to receive the local anesthetic solution containing 0.25 % bupivacaine (2.5 mg/ml) with 1:100,000 epinephrine and 4 mg dexamethasoneadministered to the breast area to cover the intercostal nerves supplying the breast tissue during surgery  ",
        "premise_nums": [
            "0.25 % bupivacaine",
            "1:100,000 epinephrine",
            "000 epinephrine and",
            "4 mg dexamethasoneadministered",
            "(2.5 mg/ml"
        ]
    },
    {
        "id": "f144c34b-9428-4836-bf01-5f7030eb579c",
        "primaryId": "NCT04030104",
        "secondaryId": "NCT02525718",
        "label": "Entailment",
        "statement_text": "Intervention 1 for the secondary trial and the primary trial are for the control groups ",
        "statement_nums": [
            "1 for the"
        ],
        "premise_text": "0.25 % bupivacaine (2.5 mg/ml) w/ 1:100,000 epinephrine & 4 mg dexamethasone: If randomized to this arm  subjects will receive a selective block with a local anesthetic solution containing 0.25 % bupivacaine (2.5 mg/ml) with 1:100,000 epinephrine and 4 mg dexamethasone intraoperatively  ",
        "premise_nums": [
            "4 mg dexamethasone:",
            "0.25 % bupivacaine",
            "1:100,000 epinephrine",
            "000 epinephrine and",
            "(2.5 mg/ml"
        ]
    },
    {
        "id": "e7e87023-2227-4594-931a-0a3d89ec686e",
        "primaryId": "NCT02073487",
        "secondaryId": "NCT03371732",
        "label": "Contradiction",
        "statement_text": "Heavy smokers (more than 5 cigarettes smoked per day) and patients undergoing methadone or buprenorphine maintenance therapy for opiod addiction are eligible for the secondary trial and the primary trial ",
        "statement_nums": [
            "5 cigarettes smoked"
        ],
        "premise_text": "Inclusion Criteria: Female gender; Age 18 years; Performance Status- Eastern Cooperative Oncology Group (ECOG) 0-1 Histologically confirmed invasive breast cancer: Primary tumor greater than 1 cm diameter  measured by clinical examination and mammography or ultrasound  Any N  No evidence of metastasis (M0) (isolated supra-clavicular node involvement allowed); Over expression and/or amplification of HER2 in the invasive component of the primary tumor and confirmed by a certified laboratory prior to randomization  Known hormone receptor status  Hematopoietic status: ",
        "premise_nums": [
            "1 cm diameter",
            "1 Histologically confirmed",
            "0-1 Histologically",
            "2 in the"
        ]
    },
    {
        "id": "e7e87023-2227-4594-931a-0a3d89ec686e",
        "primaryId": "NCT02073487",
        "secondaryId": "NCT03371732",
        "label": "Contradiction",
        "statement_text": "Heavy smokers (more than 5 cigarettes smoked per day) and patients undergoing methadone or buprenorphine maintenance therapy for opiod addiction are eligible for the secondary trial and the primary trial ",
        "statement_nums": [
            "5 cigarettes smoked"
        ],
        "premise_text": "CBC not less than .75 of institutional lower limit  Absolute neutrophil count 1,5 x 10^9/L, Platelet count 100 x 10^9/L, Hemoglobin at least 9 g/dl Hepatic status: ",
        "premise_nums": [
            "75 of institutional",
            "count 1,5 x 10",
            "9 g/dl Hepatic",
            "100 x 10",
            "9/L, Hemoglobin",
            "9/L, Platelet"
        ]
    },
    {
        "id": "e7e87023-2227-4594-931a-0a3d89ec686e",
        "primaryId": "NCT02073487",
        "secondaryId": "NCT03371732",
        "label": "Contradiction",
        "statement_text": "Heavy smokers (more than 5 cigarettes smoked per day) and patients undergoing methadone or buprenorphine maintenance therapy for opiod addiction are eligible for the secondary trial and the primary trial ",
        "statement_nums": [
            "5 cigarettes smoked"
        ],
        "premise_text": "Serum total bilirubin 2 x upper limit of normal (ULN)  In the case of known Gilbert's syndrome  a higher serum total bilirubin (smaller than 1.5 x ULN) is allowed  Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) 3.5 times ULN  Alkaline phosphatase 2.5 times ULN  Renal status: Creatinine 1.5mg/dL,Cardiovascular: Baseline left ventricular ejection fraction (LVEF) ³ 50% measured by echocardiography (ECHO) or Multiple Gate Acquisition (MUGA) scan  ",
        "premise_nums": [
            "50% measured",
            "than 1.5 x ULN",
            "Creatinine 1.5mg/dL",
            "5 x ULN)",
            "phosphatase 2.5 times ULN",
            "2 x upper"
        ]
    },
    {
        "id": "e7e87023-2227-4594-931a-0a3d89ec686e",
        "primaryId": "NCT02073487",
        "secondaryId": "NCT03371732",
        "label": "Contradiction",
        "statement_text": "Heavy smokers (more than 5 cigarettes smoked per day) and patients undergoing methadone or buprenorphine maintenance therapy for opiod addiction are eligible for the secondary trial and the primary trial ",
        "statement_nums": [
            "5 cigarettes smoked"
        ],
        "premise_text": "Negative serum or urine β-hCG pregnancy test at screening for patients of childbearing potential within 2-weeks (preferably 7 days) prior to randomization Fertile patients must use effective contraception (barrier method - condoms  diaphragm - also in conjunction with spermicidal jelly  or total abstinence  Oral  injectable  or implant hormonal contraceptives are not allowed) Signed informed consent form (ICF) Patient accepts to make available tumor samples for submission to central laboratory to conduct translational studies as part of this protocol  Exclusion Criteria: ",
        "premise_nums": []
    },
    {
        "id": "e7e87023-2227-4594-931a-0a3d89ec686e",
        "primaryId": "NCT02073487",
        "secondaryId": "NCT03371732",
        "label": "Contradiction",
        "statement_text": "Heavy smokers (more than 5 cigarettes smoked per day) and patients undergoing methadone or buprenorphine maintenance therapy for opiod addiction are eligible for the secondary trial and the primary trial ",
        "statement_nums": [
            "5 cigarettes smoked"
        ],
        "premise_text": "Previous (less than 5 years) or current history of malignant neoplasms  except for curatively treated: Basal and squamous cell carcinoma of the skin; Carcinoma in situ of the cervix Patients with a prior malignancy diagnosed more than 5 years prior to randomization may enter the study  Preexisting peripheral neuropathy grade 2 Known history of uncontrolled or symptomatic angina  clinically significant arrhythmias  congestive heart failure  transmural myocardial infarction  uncontrolled hypertension ( 180/110), unstable diabetes mellitus  dyspnea at rest  or chronic therapy with oxygen; ",
        "premise_nums": [
            "180/110), unstable",
            "2 Known history",
            "5 years prior"
        ]
    },
    {
        "id": "e7e87023-2227-4594-931a-0a3d89ec686e",
        "primaryId": "NCT02073487",
        "secondaryId": "NCT03371732",
        "label": "Contradiction",
        "statement_text": "Heavy smokers (more than 5 cigarettes smoked per day) and patients undergoing methadone or buprenorphine maintenance therapy for opiod addiction are eligible for the secondary trial and the primary trial ",
        "statement_nums": [
            "5 cigarettes smoked"
        ],
        "premise_text": "Concurrent disease or condition that would make the subject inappropriate for study participation or any serious medical disorder that would interfere with the subject's safety;Unresolved or unstable  serious adverse events from prior administration of another investigational drug; Dementia  altered mental status  or any psychiatric condition that would prevent the understanding or rendering of ICF; Malabsorption syndrome  disease significantly affecting gastrointestinal function  or resection of the stomach or small bowel  Subjects with ulcerative colitis are also excluded; Concurrent neoadjuvant cancer therapy (chemotherapy  radiation therapy  immunotherapy  biologic therapy other than the trial therapies); Concurrent treatment with an investigational agent or participation in another therapeutic clinical trial; ",
        "premise_nums": []
    },
    {
        "id": "e7e87023-2227-4594-931a-0a3d89ec686e",
        "primaryId": "NCT02073487",
        "secondaryId": "NCT03371732",
        "label": "Contradiction",
        "statement_text": "Heavy smokers (more than 5 cigarettes smoked per day) and patients undergoing methadone or buprenorphine maintenance therapy for opiod addiction are eligible for the secondary trial and the primary trial ",
        "statement_nums": [
            "5 cigarettes smoked"
        ],
        "premise_text": "Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to trastuzumab Emtansine  trastuzumab  lapatinib  paclitaxel  abraxane or their components;Pregnant or lactating women; Concomitant use of CYP3A4 inhibitors or inducers Other concurrent severe and/or uncontrolled concomitant medical conditions (e.g  active or uncontrolled infection  uncontrolled diabetes) that could cause unacceptable safety risks or compromise compliance with the protocol Patients have an active infection and require IV or oral antibiotics  Pregnant or breast-feeding women Patients unwilling or unable to comply with the protocol ",
        "premise_nums": [
            "4 inhibitors or"
        ]
    },
    {
        "id": "e7e87023-2227-4594-931a-0a3d89ec686e",
        "primaryId": "NCT02073487",
        "secondaryId": "NCT03371732",
        "label": "Contradiction",
        "statement_text": "Heavy smokers (more than 5 cigarettes smoked per day) and patients undergoing methadone or buprenorphine maintenance therapy for opiod addiction are eligible for the secondary trial and the primary trial ",
        "statement_nums": [
            "5 cigarettes smoked"
        ],
        "premise_text": "Inclusion Criteria :women with primary breast cancer  without ongoing support for substance use  An AUDIT-C score greater than 1 or more than one cigarette smoked per day  ",
        "premise_nums": [
            "1 or more"
        ]
    },
    {
        "id": "ca4a190a-9007-4f8f-a199-b8fe4064e55b",
        "primaryId": "NCT02149524",
        "statement_text": "Several adverse events which occurred in the primary trial were not heart related ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 58/438 (13.24%) Febrile neutropenia 13/438 (2.97%) Neutropenia 5/438 (1.14%) Anaemia 0/438 (0.00%) Thrombocytopenia 0/438 (0.00%) Haemolytic anaemia 1/438 (0.23%) Leukopenia 1/438 (0.23%) Cardiac failure congestive 0/438 (0.00%) Supraventricular tachycardia 0/438 (0.00%) Myocardial infarction 1/438 (0.23%) Vertigo 0/438 (0.00%) Adverse Events 2: ",
        "premise_nums": [
            "58/438 (13.24%)",
            "1/438 (0.23%)",
            "5/438 (1.14%)",
            "0/438 (0.00%)",
            "13/438 (2.97%)"
        ]
    },
    {
        "id": "ca4a190a-9007-4f8f-a199-b8fe4064e55b",
        "primaryId": "NCT02149524",
        "statement_text": "Several adverse events which occurred in the primary trial were not heart related ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Total: 56/437 (12.81%)Febrile neutropenia 10/437 (2.29%) Neutropenia 7/437 (1.60%) Anaemia 2/437 (0.46%) Thrombocytopenia 1/437 (0.23%) Haemolytic anaemia 0/437 (0.00%) Leukopenia 0/437 (0.00%) Cardiac failure congestive 3/437 (0.69%) Supraventricular tachycardia 1/437 (0.23%) Myocardial infarction 0/437 (0.00%) Vertigo 1/437 (0.23%) ",
        "premise_nums": [
            "2/437 (0.46%)",
            "7/437 (1.60%)",
            "1/437 (0.23%)",
            "3/437 (0.69%)",
            "10/437 (2.29%)",
            "0/437 (0.00%)",
            "56/437 (12.81%)Febrile"
        ]
    },
    {
        "id": "4f790768-7fa4-4729-bcd6-cf7bcb44fa3c",
        "primaryId": "NCT00711529",
        "secondaryId": "NCT02835625",
        "label": "Contradiction",
        "statement_text": "the primary trial participants are treated with Cognitive behavioural therapy  this is not used at all in the secondary trial ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Hypnotherapy Patients randomized to the hypnosis arm of the study will undergo individually three one-hour sessions with a certified hypnotherapist  These sessions will be one week apart  Patients will also be instructed on the use of self-hypnosis techniques to use at home  INTERVENTION 2: Gabapentin Patients randomized to the gabapentin arm will be prescribed 900mg of the drug daily (300 mg by mouth three times daily)  INTERVENTION 1: Digital Breast Tomosynthesis Digital Breast Tomosynthesis + Synthetic Mammography (DBT) The DBT was independently read by two radiologists  A consensus meeting decided whether to recall the woman or not  Women selected for further assessment (positive screening exam) was recalled  ",
        "premise_nums": [
            "300 mg by"
        ]
    },
    {
        "id": "4f790768-7fa4-4729-bcd6-cf7bcb44fa3c",
        "primaryId": "NCT00711529",
        "secondaryId": "NCT02835625",
        "label": "Contradiction",
        "statement_text": "the primary trial participants are treated with Cognitive behavioural therapy  this is not used at all in the secondary trial ",
        "statement_nums": [],
        "premise_text": "Digital Breast Tomosynthesis + Synthetic Mammography: Two-view tomosynthesis performed with GE SenoClaire 3D Breast Tomosynthesis INTERVENTION 2: Digital Mammography The digital mammograms was independently read by two radiologists  A consensus meeting decided whether to recall the woman or not  Women selected for further assessment (positive screening exam) was recalled  Digital mammography: Two-view digital mammography performed with GE SenoClaire 3D Breast Tomosynthesis  ",
        "premise_nums": []
    },
    {
        "id": "cb133915-dc40-4f93-a6a7-076e4d7f07a1",
        "primaryId": "NCT02685566",
        "secondaryId": "NCT03076190",
        "label": "Entailment",
        "statement_text": "the primary trial and the secondary trial have the same number of study groups  but are testing different interventions ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: FFDM Plus DBT Breast Images with FFDM and DBT FFDM Plus DBT: FujiFilm Aspire Cristalle System  This endpoint will be evaluated qualitatively  The Pass Criteria require adequate performance in non-cancer cases (recall rate) and in cancer cases (detection rate)  INTERVENTION 2: Full-Field Digital Mammography (FFDM) Breast Images with FFDM alone FFDM: FujiFilm Aspire Cristalle System  This endpoint will be evaluated qualitatively  The Pass Criteria require adequate performance in non-cancer cases (recall rate) and in cancer cases (detection rate)  INTERVENTION 1: Active Control Group Health Education Active Control Group INTERVENTION 2: My Surgical Success Treatment Group My Surgical Success Intervention Group ",
        "premise_nums": []
    },
    {
        "id": "1f0825b6-8e32-44ff-96b7-ab082e24b493",
        "primaryId": "NCT00045032",
        "secondaryId": "NCT00416572",
        "label": "Entailment",
        "statement_text": "WOCBP that refuse to use contraception are excluded from the primary trial  but may be eligible for the secondary trial ",
        "statement_nums": [],
        "premise_text": "Women of childbearing potential or less than 1 year post-menopause unwilling to use adequate contraceptive measures INCLUSION CRITERIA (Disease Characteristics): Diagnosis of breast cancer Stage I or II disease No more than 10 positive lymph nodes First-time diagnosis Under the age of 50 at diagnosis Finished active treatment within the past 2 months English-speaking only Must live within 30 miles of Magee Women's Hospital  Pittsburgh  Pennsylvania INCLUSION CRITERIA (Patient Characteristics): Female patients only Must be able to communicate EXCLUSION CRITERIA (Patient Characteristics): Other prior malignancies except skin cancer PRIOR CONCURRENT THERAPY: See Disease Characteristics ",
        "premise_nums": [
            "10 positive lymph",
            "2 months English",
            "50 at diagnosis",
            "30 miles of",
            "1 year post"
        ]
    },
    {
        "id": "db96c4d6-ffcd-401a-8af3-807f665f16f7",
        "primaryId": "NCT00375427",
        "secondaryId": "NCT00579826",
        "label": "Contradiction",
        "statement_text": "Patients diagnosed with osteonecrosis are eligible for the primary trial but excluded from the secondary trial ",
        "statement_nums": [],
        "premise_text": "Inclusion criteria: Female patients 18 years of age  Written informed consent given  Histologically confirmed Stage IV breast cancer with at least one bone metastasis radiologically confirmed  Previous treatment with zoledronic acid every 3-4 weeks  for 9-12 infusions over no more than 15 months  Eastern Cooperative Oncology Group (ECOG) performance status 2   Life expectancy 1 year  Exclusion criteria: More than 3 months since last infusion of Zoledronic Acid (Zometa®)  Treatments with other bisphosphonate than Zoledronic Acid (Zometa®) at any time prior to study entry  ",
        "premise_nums": [
            "3 months since",
            "12 infusions over",
            "9-12 infusions",
            "3-4 weeks",
            "18 years of"
        ]
    },
    {
        "id": "db96c4d6-ffcd-401a-8af3-807f665f16f7",
        "primaryId": "NCT00375427",
        "secondaryId": "NCT00579826",
        "label": "Contradiction",
        "statement_text": "Patients diagnosed with osteonecrosis are eligible for the primary trial but excluded from the secondary trial ",
        "statement_nums": [],
        "premise_text": "Serum creatinine greater than 3 mg/dL (265 μmol/L) or calculated (Cockcroft-Gault formula) creatinine clearance (CLCr) smaller than 30 mL/min CrCl = ({[140-age (years)] x weight(kg)}/ [72 x serum creatinine (mg/dL)])x 0.85Corrected (adjusted for serum albumin) serum calcium smaller than 8 mg/dl (2 mmol/L) or greater than 12 mg/dL ( 3.0 mmol/L)  ",
        "premise_nums": [
            "72 x serum",
            "12 mg/dL",
            "3.0 mmol/L",
            "3 mg/dL",
            "8 mg/dl",
            "30 mL/min CrCl"
        ]
    },
    {
        "id": "db96c4d6-ffcd-401a-8af3-807f665f16f7",
        "primaryId": "NCT00375427",
        "secondaryId": "NCT00579826",
        "label": "Contradiction",
        "statement_text": "Patients diagnosed with osteonecrosis are eligible for the primary trial but excluded from the secondary trial ",
        "statement_nums": [],
        "premise_text": "Current active dental problem including infection of the teeth or jawbone (maxilla or mandibular); dental or fixture trauma  or a recurrent or prior diagnosis of osteonecrosis of the jaw (ONJ)  of exposed bone in the mouth  or of slow healing after dental procedures Recent (within 6 weeks) or planned dental or jaw surgery (e.g  extraction  implants)  Pregnant patients (with a positive pregnancy test prior to study entry) or lactating patients  Women of childbearing potential not using effective methods of birth control (e.g  abstinence  oral contraceptives or implants  IUD  vaginal diaphragm or sponge  or condom with spermicide)  History of non-compliance to medical regimens or potential unreliable behavior  Known sensitivity to study drug(s) or class of study drug(s)  ",
        "premise_nums": []
    },
    {
        "id": "db96c4d6-ffcd-401a-8af3-807f665f16f7",
        "primaryId": "NCT00375427",
        "secondaryId": "NCT00579826",
        "label": "Contradiction",
        "statement_text": "Patients diagnosed with osteonecrosis are eligible for the primary trial but excluded from the secondary trial ",
        "statement_nums": [],
        "premise_text": "Patients with severe medical condition(s) that in the view of the investigator prohibits participation in the studyUse of any other investigational agent in the last 30 days  Exclusion Criteria: Prior history of osteoporosis or osteoporotic fracture  ",
        "premise_nums": []
    },
    {
        "id": "b74dc1bc-76c3-4ce6-9735-634e7a507ff5",
        "primaryId": "NCT00976989",
        "statement_text": "Patients with LVEF equal to 53.5% are eligible for the primary trial ",
        "statement_nums": [
            "to 53.5% are eligible"
        ],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria: baseline left ventricular ejection fraction (LVEF) greater than /=55% ",
        "premise_nums": []
    },
    {
        "id": "f078c722-b879-40f2-ac72-c733001b93dd",
        "primaryId": "NCT01740323",
        "secondaryId": "NCT00127205",
        "label": "Contradiction",
        "statement_text": "the secondary trial and the primary trial only accept 18 year olds ",
        "statement_nums": [
            "18 year olds"
        ],
        "premise_text": "Inclusion Criteria: Female breast cancer patients over the age of 18 will be recruited for this study  Patients enrolled in the study will meet standard criteria for whole breast XRT  PATIENT CHARACTERISTICS: Age 18 and over ",
        "premise_nums": [
            "18 and over",
            "18 will be"
        ]
    },
    {
        "id": "c33d78e5-13be-4cde-b36e-7cc097f180a2",
        "primaryId": "NCT02041429",
        "secondaryId": "NCT00068588",
        "label": "Contradiction",
        "statement_text": "the primary trial and the secondary trial use the same outcome measurements  same drugs and the same cohort sizes ",
        "statement_nums": [],
        "premise_text": "Outcome Measurement: Ruxolitinib Maximum Tolerated Dose (MTD) [Phase I] Ruxolitinib MTD in combination with paclitaxel 80 mg/m2 intravenously (IV) weekly is determined by the number of patients who have dose limiting toxicity (DLT)  See DLT primary outcome measure for definition Outcome Measurement: Maximum Tolerated Dose Determined by Dose-limiting Toxicities ",
        "premise_nums": [
            "2 intravenously (IV)",
            "80 mg/m2 intravenously"
        ]
    },
    {
        "id": "58dbc33b-d32c-4e91-a940-ca1148bbdae4",
        "primaryId": "NCT00075270",
        "secondaryId": "NCT01781299",
        "label": "Entailment",
        "statement_text": "the primary trial is testing a chemotherapy treatment whereas the secondary trial is testing an implant ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Lapatinib With Paclitaxel Participants received lapatinib 1500 milligrams (mg) orally once daily (OD) with paclitaxel 175 mg/meters squared (m^2) intravenously (IV) over the course of 3 hours  every 3 weeks  The treatment group was stratified by sites of metastatic disease and stage of disease  Participants were treated until disease progression  unacceptable toxicity  or consent withdrawal  INTERVENTION 2: Placebo With Paclitaxel Participants received matching placebo orally OD with paclitaxel (175 mg/m^2 IV) over the course of 3 hours  every 3 weeks  The treatment group was stratified by sites of metastatic disease and stage of disease  Participants were treated until disease progression  unacceptable toxicity  or consent withdrawal  INTERVENTION 1: ",
        "premise_nums": [
            "1500 milligrams (mg)",
            "175 mg/meters squared"
        ]
    },
    {
        "id": "58dbc33b-d32c-4e91-a940-ca1148bbdae4",
        "primaryId": "NCT00075270",
        "secondaryId": "NCT01781299",
        "label": "Entailment",
        "statement_text": "the primary trial is testing a chemotherapy treatment whereas the secondary trial is testing an implant ",
        "statement_nums": [],
        "premise_text": "AlloDerm RTUParticipants within this arm will have the acellular dermal matrix AlloDerm RTU implanted at the time of tissue expander placement  AlloDerm RTU INTERVENTION 2: SurgiMend PRS Participants within this arm will have the acellular dermal matrix SurgiMend PRS implanted at the time of tissue expander placement  SurgiMend PRS ",
        "premise_nums": []
    },
    {
        "id": "fbbad9dc-58a9-4527-86c5-49cb0a3e7d0e",
        "primaryId": "NCT00602043",
        "secondaryId": "NCT01720602",
        "label": "Entailment",
        "statement_text": "Several treatments in the secondary trial are administered by mouth  none of the treatments in the primary trial are given via this route ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Diagnostic FES: Average FES SUVmean greater than 1.5, no Negative Sites Patients undergo [^18F] FES PET scan  Patients also undergo standard clinical fludeoxyglucose F 18 (FDG)-PET or FDG-PET/CT scan up to 14 days prior to [^18F] FES PET scan  Patients begin clinically indicated endocrine therapy  Patients are followed-up to determine response on the therapy for 6 months using clinical exams  tumor marker assays  conventional imaging and standard clinical FDG PET/CT  This group represents patients who had positive FES uptake at all disease sites on the baseline diagnostic FES PET scan  laboratory biomarker analysis: Correlative studies INTERVENTION 2: Diagnostic FES: Patients With FES Negative Sites of Disease ",
        "premise_nums": [
            "6 months using",
            "14 days prior"
        ]
    },
    {
        "id": "fbbad9dc-58a9-4527-86c5-49cb0a3e7d0e",
        "primaryId": "NCT00602043",
        "secondaryId": "NCT01720602",
        "label": "Entailment",
        "statement_text": "Several treatments in the secondary trial are administered by mouth  none of the treatments in the primary trial are given via this route ",
        "statement_nums": [],
        "premise_text": "Patients undergo [^18F] FES PET scan  Patients also undergo standard clinical fludeoxyglucose F 18 (FDG)-PET or FDG-PET/CT scan up to 14 days prior to [^18F] FES PET scan Patients begin clinically indicated endocrine therapy  Patients are followed-up to determine response on the therapy for 6 months using clinical exams  tumor marker assays  conventional imaging and standard clinical FDG PET/CT  This group represents patients who had some or all disease sites negative for FES uptake on the baseline diagnostic FES PET scan  INTERVENTION 1: Treatment (Vorinostat  AI Therapy) ",
        "premise_nums": [
            "6 months using",
            "14 days prior"
        ]
    },
    {
        "id": "fbbad9dc-58a9-4527-86c5-49cb0a3e7d0e",
        "primaryId": "NCT00602043",
        "secondaryId": "NCT01720602",
        "label": "Entailment",
        "statement_text": "Several treatments in the secondary trial are administered by mouth  none of the treatments in the primary trial are given via this route ",
        "statement_nums": [],
        "premise_text": "Patients receive vorinostat PO 5 days a week for 3 weeks  Patients also receive AI therapy comprising either anastrozole PO daily  letrozole PO daily  or exemestane PO daily for 4 weeks  Courses repeat every 28 days in the absence of disease progression and unacceptable toxicity vorinostat: Given PO anastrozole: Given PO letrozole: Given PO exemestane: Given PO positron emission tomography: Correlative studies F-18 16 alpha-fluoroestradiol: Correlative studies fludeoxyglucose F 18: Correlative studies laboratory biomarker analysis: Correlative studies ",
        "premise_nums": [
            "16 alpha-fluoroestradiol:",
            "28 days in",
            "5 days a"
        ]
    },
    {
        "id": "2c462296-35f5-482a-9ece-3b4ed4c2f53a",
        "primaryId": "NCT01216176",
        "statement_text": "Urosepsis was the only recorded adverse event in the primary trial ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 3/12 (25.00%) Atrial fibrillation 0/12 (0.00%) Cardiac ischemia/infarction [1]0/12 (0.00%) Congestive Heart Failure [2]0/12 (0.00%) Diverticulitis 0/12 (0.00%) Cholecystitis 0/12 (0.00%) Hyperbilirubinemia 0/12 (0.00%) Urosepsis 2/12 (16.67%) Brain hemorrhage complicating CNS metastasis 1/12 (8.33%) Rash [3]0/12 (0.00%) ",
        "premise_nums": [
            "0/12 (0.00%)",
            "3/12 (25.00%)",
            "2/12 (16.67%)",
            "1/12 (8.33%)"
        ]
    },
    {
        "id": "16358be6-3895-48f7-8006-4effeb3f74b3",
        "primaryId": "NCT01196052",
        "statement_text": "Participants in the primary trial must be willing to undergo cyclophosphamide-based chemotherapy ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria: Willingness to receive anthracycline-based chemotherapy or have received doxorubicin/cyclophosphamide (AC) OR 5-fluorouracil (FU)/epirubicin/ cyclophosphamide (FEC) in a similar dose and schedule as described in the protocol as part of neoadjuvant or adjuvant treatment  ",
        "premise_nums": []
    },
    {
        "id": "6d4ecb16-6586-4ea8-a1dc-f825e951e060",
        "primaryId": "NCT00703326",
        "secondaryId": "NCT00274768",
        "label": "Contradiction",
        "statement_text": "Participants with HER2- primary liver tumors  confirmed by fluorescence in-situ hybridization are eligible for the secondary trial and the primary trial ",
        "statement_nums": [],
        "premise_text": "Inclusion Criteria: Participant has histologically or cytologically confirmed adenocarcinoma of the breast that is now metastatic or locally-recurrent and inoperable with curative intent  Every effort should be made to make paraffin-embedded tissue or slides from the diagnostic biopsy or surgical specimen available for confirmation of diagnosis Participants' primary and/or metastatic tumor is human epidermal growth factor receptor 2 (HER2)-negative by fluorescence in-situ hybridization (FISH) or chromogenic in-situ hybridization (CISH) or 0, 1+ overexpression by immunohistochemistry (IHC) DISEASE CHARACTERISTICS: Histologically or cytologically confirmed diagnosis of adenocarcinoma of the breast ",
        "premise_nums": []
    },
    {
        "id": "6d4ecb16-6586-4ea8-a1dc-f825e951e060",
        "primaryId": "NCT00703326",
        "secondaryId": "NCT00274768",
        "label": "Contradiction",
        "statement_text": "Participants with HER2- primary liver tumors  confirmed by fluorescence in-situ hybridization are eligible for the secondary trial and the primary trial ",
        "statement_nums": [],
        "premise_text": "Hormone receptor status:Not specified ",
        "premise_nums": []
    },
    {
        "id": "5bb009f0-bc19-4a85-85b8-bd7bf0675f3f",
        "primaryId": "NCT01252290",
        "secondaryId": "NCT00479674",
        "label": "Entailment",
        "statement_text": "Unlike the secondary trial  the primary trial does not record any instances of Anemia  Dyspepsia  Nausea or vomiting ",
        "statement_nums": [],
        "premise_text": "Adverse Events 1: Total: 2/35 (5.71%) Gastroesophageal reflux disease * 1/35 (2.86%) Ductal carcinoma in situ * 1/35 (2.86%) Adverse Events 1: Total: 22/41 (53.66%) Anemia 1/41 (2.44%) Dyspepsia 1/41 (2.44%) Mucositis oral 1/41 (2.44%) Nausea 3/41 (7.32%) Vomiting 1/41 (2.44%) Pain 3/41 (7.32%) Allergic reaction 1/41 (2.44%) Infections and infestations - Other  specify: [1]1/41 (2.44%) ",
        "premise_nums": [
            "2/35 (5.71%)",
            "1/41 (2.44%)",
            "22/41 (53.66%)",
            "1/35 (2.86%)",
            "3/41 (7.32%)"
        ]
    },
    {
        "id": "5bb009f0-bc19-4a85-85b8-bd7bf0675f3f",
        "primaryId": "NCT01252290",
        "secondaryId": "NCT00479674",
        "label": "Entailment",
        "statement_text": "Unlike the secondary trial  the primary trial does not record any instances of Anemia  Dyspepsia  Nausea or vomiting ",
        "statement_nums": [],
        "premise_text": "Vascular access complication 3/41 (7.32%)Alanine aminotransferase increased 1/41 (2.44%) ",
        "premise_nums": [
            "1/41 (2.44%)",
            "3/41 (7.32%)Alanine"
        ]
    },
    {
        "id": "2731552d-195a-4f43-b6b5-02a3fbda81d9",
        "primaryId": "NCT01323530",
        "secondaryId": "NCT01106040",
        "label": "Entailment",
        "statement_text": "the secondary trial and the primary trial do not have comparable Outcome Measurements ",
        "statement_nums": [],
        "premise_text": "Outcome Measurement: Phase 1b: Number of Participants With Dose-limiting Toxicities (DLTs) as Per National Cancer Institute Common Terminology Criteria for Adverse Events Version 3.0 (NCI CTCAE v3.0) ",
        "premise_nums": []
    },
    {
        "id": "8fee5ce4-3e46-4731-842e-a5b1df451c7d",
        "primaryId": "NCT01231659",
        "statement_text": "Less than 40% of the primary trial participants achieved either complete response (CR) or partial response (PR) ",
        "statement_nums": [
            "40% of"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Percentage of Participants With Overall Response Rate (ORR) Overall Response Rate (ORR) was defined as the proportion of patients whose best overall response was either complete response (CR) or partial response (PR) according to RECIST 1.0 for target lesions and assessed by CT: Complete Response (CR)  disappearance of all target lesions for a period of at least one month; Partial Response (PR)  greater than or equal 30% decrease in the sum of the longest diameter of target lesions; Overall Response (ORR) = CR + PR  Only descriptive statistics  Time frame: From the date of randomization until the date of the first documented disease progression or date of death from any cause whichever came first  assessed for approximately 15 months Results 1: Arm/Group Title: Everolimus + Letrozole ",
        "premise_nums": [
            "30% decrease",
            "15 months Results",
            "RECIST 1.0 for target"
        ]
    },
    {
        "id": "8fee5ce4-3e46-4731-842e-a5b1df451c7d",
        "primaryId": "NCT01231659",
        "statement_text": "Less than 40% of the primary trial participants achieved either complete response (CR) or partial response (PR) ",
        "statement_nums": [
            "40% of"
        ],
        "label": "Entailment",
        "premise_text": "Arm/Group Description: All patients received 2 tablets (5 mg each) of Everolimus (a total of 10 mg) + 1 tablet of Letrozole (2.5 mg) daily until disease progression or as described in the protocol Overall Number of Participants Analyzed: 43 Measure Type: Number Unit of Measure: Percentage of Participants 37.2 ",
        "premise_nums": [
            "2 tablets (5",
            "43 Measure Type:",
            "1 tablet of"
        ]
    },
    {
        "id": "def4199f-a22d-4939-b15d-66fd073fb280",
        "primaryId": "NCT02518191",
        "statement_text": "Cohort 2 of the primary trial is the control group ",
        "statement_nums": [
            "2 of the"
        ],
        "label": "Entailment",
        "premise_text": "INTERVENTION 1: GnRHa (Gonadotrophin-releasing Hormone Analogues) Group Eligible patients with breast cancer treated with GnRHa (Gonadotrophin-releasing Hormone Analogues) while receiving chemotherapy  Goserelin 3.6mg, or leuprorelin 3.75mg subcutaneous injection every 28 days.Initiated 1-2 weeks before chemotherapy and ended 4-8 weeks after chemotherapy  INTERVENTION 2: None GnRHa (Gonadotrophin-releasing Hormone Analogues) Group Eligible patients with breast cancer treated without GnRHa (Gonadotrophin-releasing Hormone Analogues) while receiving chemotherapy  ",
        "premise_nums": [
            "2 weeks before",
            "leuprorelin 3.75mg subcutaneous",
            "1-2 weeks",
            "4-8 weeks",
            "8 weeks after"
        ]
    },
    {
        "id": "c16dcd52-f2f0-40b7-9b2b-af3fd7f438b2",
        "primaryId": "NCT00871858",
        "statement_text": "1 patient in the primary trial was diagnosed with a Clear cell renal cell carcinoma ",
        "statement_nums": [
            "1 patient in"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 2/60 (3.33%) Bronchial infection 0/60 (0.00%) Ankle fracture 1/60 (1.67%) Clear cell kidney cancer 0/60 (0.00%) Programmed peritoneal dialysis 1/60 (1.67%) Endometrial atrophy 0/60 (0.00%) Adverse Events 2: Total: 3/58 (5.17%) Bronchial infection 1/58 (1.72%) Ankle fracture 0/58 (0.00%) Clear cell kidney cancer 1/58 (1.72%) Programmed peritoneal dialysis 0/58 (0.00%) Endometrial atrophy 1/58 (1.72%) ",
        "premise_nums": [
            "2/60 (3.33%)",
            "3/58 (5.17%)",
            "1/60 (1.67%)",
            "0/60 (0.00%)",
            "1/58 (1.72%)",
            "0/58 (0.00%)"
        ]
    },
    {
        "id": "d97c3981-50f9-4221-aec6-60661b831c8e",
        "primaryId": "NCT03624972",
        "secondaryId": "NCT01216176",
        "label": "Contradiction",
        "statement_text": "A 56 year old patient presenting occasional memory loss would be excluded from both the secondary trial and the primary trial ",
        "statement_nums": [
            "56 year old"
        ],
        "premise_text": "Exclusion Criteria: Overt cognitive dysfunction or psychiatric disturbance or severe mental illness (e.g.  dementia  suicidal behavior  or psychosis)  as observed or judged by the researcher or referring source  Exclusion Criteria - Phase 2 (Cohort B): Any evidence of severe or uncontrolled systemic psychiatric or medical conditions (eg  Severe hepatic impairment  interstitial lung disease [bilateral  diffuse  parenchymal lung disease]) or current unstable or uncompensated respiratory or cardiac conditions which make it undesirable for the patient to participate in the study or which could jeopardize compliance with the protocol ",
        "premise_nums": []
    },
    {
        "id": "86c1430c-553b-4388-a034-b82f78afdc0d",
        "primaryId": "NCT01028352",
        "statement_text": "Patients with aromatase inhibitor associated musculoskeletal symptoms  such as Grade 1 or above musculoskeletal pain or grade 0 sensory neuropathy  are eligible for the primary trial ",
        "statement_nums": [
            "0 sensory neuropathy",
            "1 or above"
        ],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria: AI-associated musculoskeletal symptoms  defined as: Grade 1 or higher musculoskeletal pain that developed or worsened (6 or 7 on CGICS) during AI therapy or Grade 1 or higher sensory neuropathy that developed or worsened (6 or 7 on CGICS) during AI therapy; ",
        "premise_nums": [
            "6 or 7",
            "7 on CGICS",
            "1 or higher"
        ]
    },
    {
        "id": "b7cef0e1-7bd8-4c0e-a044-b11708cf927c",
        "primaryId": "NCT01905592",
        "statement_text": "both the primary trial cohorts receive Physician selection from 4 standard of care metastatic breast cancer chemotherapies ",
        "statement_nums": [
            "4 standard of"
        ],
        "label": "Contradiction",
        "premise_text": "INTERVENTION 1: Physician's Choice Physician selection from 4 standard of care metastatic breast cancer chemotherapies (eribulin or vinorelbine or gemcitabine or capecitabine)  until progression or unacceptable toxicity develops  INTERVENTION 2: Niraparib Niraparib 300 mg (3x100 mg capsules) once daily until progression or unacceptable toxicity develops ",
        "premise_nums": [
            "x100 mg",
            "300 mg (3x100",
            "4 standard of"
        ]
    },
    {
        "id": "0b55d5b7-5e71-497f-96ad-9dc2f872c4aa",
        "primaryId": "NCT00444587",
        "statement_text": "A total of 2/93 patients in the primary trial were observed with either Leukopenia  Cardiopulmonary failure or Diarrhoea ",
        "statement_nums": [
            "2/93 patients",
            "93 patients in"
        ],
        "label": "Contradiction",
        "premise_text": "Leukopenia 2/93 (2.15%) Cardiopulmonary failure 2/93 (2.15%) Diarrhoea 3/93 (3.23%) ",
        "premise_nums": [
            "2/93 (2.15%)",
            "3/93 (3.23%)"
        ]
    },
    {
        "id": "225f95a5-7c22-4cb7-a463-1c57d5b69d7a",
        "primaryId": "NCT01217385",
        "secondaryId": "NCT01202591",
        "label": "Contradiction",
        "statement_text": "Prior exposure to exemestane is not explicitly banned for patients in the secondary trial or the primary trial ",
        "statement_nums": [],
        "premise_text": "Inclusion Criteria Pathologically confirmed diagnosis of invasive breast cancer  determined to be a candidate for primary systemic (neoadjuvant) therapy and for surgical resection of residual primary tumor following completion of neoadjuvant therapy; Tumor size greater than 2cm, measured on imaging or estimated by physical exam; No contraindications for primary chemotherapy; Planned definitive breast surgery (mastectomy or lumpectomy/breast conservation) following completion of neoadjuvant therapy; Age 18 years or older; ECOG Performance Status 2 (Karnofsky 60%; see Appendix II); Normal organ and marrow function as follows: leukocytes 3,000/μl; absolute neutrophil count 1,500/μl; platelets 100,000/μl; ",
        "premise_nums": [
            "3,000/μl; absolute",
            "1,500/μl; platelets",
            "18 years or"
        ]
    },
    {
        "id": "225f95a5-7c22-4cb7-a463-1c57d5b69d7a",
        "primaryId": "NCT01217385",
        "secondaryId": "NCT01202591",
        "label": "Contradiction",
        "statement_text": "Prior exposure to exemestane is not explicitly banned for patients in the secondary trial or the primary trial ",
        "statement_nums": [],
        "premise_text": "total bilirubin within normal institutional limits;AST(SGOT)/ALT(SGPT) 2.5 times the institutional upper limit of normal; creatinine within normal institutional limits; OR creatinine clearance 30 mL/min/1.73 m2 for patients with creatinine levels above institutional normal; If female  postmenopausal for a minimum of one year  OR surgically sterile  OR not pregnant  confirmed by a pregnancy test as per institutional Standard of Care (SOC)  and willing to use adequate contraception (hormonal or barrier method of birth control; abstinence) for the duration of study participation; Able to understand and willing to sign a written informed consent document and a HIPAA authorization in accordance with institutional guidelines; Exclusion Criteria ",
        "premise_nums": [
            "2 for patients",
            "30 mL/min/1.73",
            "5 times the"
        ]
    },
    {
        "id": "225f95a5-7c22-4cb7-a463-1c57d5b69d7a",
        "primaryId": "NCT01217385",
        "secondaryId": "NCT01202591",
        "label": "Contradiction",
        "statement_text": "Prior exposure to exemestane is not explicitly banned for patients in the secondary trial or the primary trial ",
        "statement_nums": [],
        "premise_text": "Previous treatment (chemotherapy  radiation  or surgery) to involved breast; including hormone therapy;Uncontrolled intercurrent illness including  but not limited to  ongoing or active infection  symptomatic congestive heart failure  unstable angina pectoris  cardiac arrhythmia  or psychiatric illness/social situations that would limit compliance with study requirements; Medically unstable; Under age 18; Pregnant or nursing; Previous malignancy  other than basal cell or squamous cell carcinoma of the skin or in situ carcinoma of the cervix  from which the patient has been disease free for less than 5 years  Exclusion Criteria: Prior exposure to exemestane (safety run-in) / fulvestrant (randomized phase IIa)  or any agent known to inhibit FGFRs  ",
        "premise_nums": []
    },
    {
        "id": "5464e8a7-159c-4e00-8710-45a44ceaeda3",
        "primaryId": "NCT03061175",
        "secondaryId": "NCT03098550",
        "label": "Entailment",
        "statement_text": "Cohort 1 of the secondary trial does not receive the same doses of Daratumumab for the entire duration of the study  whereas Cohort 1 of the primary trial has the same intervention for the full study ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "INTERVENTION 1: Arm I (Web-Based CPM-DA) Patients receive a website address  a secure username and password  and instructions for using the web-based CPM-DA  Internet-Based Intervention: Receive web-based CPM-DA Survey Administration: Ancillary studies INTERVENTION 1: Nivolumab + Daratumumab (TNBC) ",
        "premise_nums": []
    },
    {
        "id": "5464e8a7-159c-4e00-8710-45a44ceaeda3",
        "primaryId": "NCT03061175",
        "secondaryId": "NCT03098550",
        "label": "Entailment",
        "statement_text": "Cohort 1 of the secondary trial does not receive the same doses of Daratumumab for the entire duration of the study  whereas Cohort 1 of the primary trial has the same intervention for the full study ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Triple-negative breast cancer (TNBC) treated with Triple-negative breast cancer (TNBC) treated with Nivolumab IV 240 mg Q2W (weeks 3 to 24) + Daratumumab IV 16 mg/kg Q1W (weeks 1 to 8), Daratumumab IV 16 mg/kg Q2W (weeks 9-24)",
        "premise_nums": [
            "1 to 8),",
            "16 mg/kg Q",
            "3 to 24)",
            "240 mg Q2W"
        ]
    },
    {
        "id": "98965d07-e2db-41bf-ac3e-a5c130513275",
        "primaryId": "NCT00382018",
        "secondaryId": "NCT03012477",
        "label": "Contradiction",
        "statement_text": "Between the patients in the primary trial and the secondary trial  only 1.56% suffered from sepsis ",
        "statement_nums": [
            "only 1.56% suffered from"
        ],
        "premise_text": "Adverse Events 1: Total: 0/161 (0.00%) Gastrointestinal-Other 0/161 (0.00%) Dehydration 0/161 (0.00%) Renal/Genitourinary-Other 0/161 (0.00%) Adverse Events 2: Total: 1/64 (1.56%) Gastrointestinal-Other 1/64 (1.56%) Dehydration 1/64 (1.56%) Renal/Genitourinary-Other 1/64 (1.56%) Sepsis 1/34 (2.94%) ",
        "premise_nums": [
            "1/64 (1.56%)",
            "0/161 (0.00%)",
            "1/34 (2.94%)"
        ]
    },
    {
        "id": "784cc905-937f-43fd-96a6-34ea8dce9e8d",
        "primaryId": "NCT00429104",
        "secondaryId": "NCT00878709",
        "label": "Contradiction",
        "statement_text": "Patients with end-stage liver disease are excluded from the primary trial and the secondary trial ",
        "statement_nums": [],
        "premise_text": "Exclusion Criteria: Chronic active hepatitis or cirrhosis  Inclusion Criteria: Stage II through IIIC HER-2/erbB-2 positive breast cancer with node positive disease  Been treated for early breast cancer with standard of care duration of trastuzumab  Could have been treated neoadjuvantly but have not reached pathologic complete response  Exclusion Criteria: Positive clinical and radiologic assessments for local or regional recurrence of disease at the time of study entry  History of heart disease  Corrected QT (QTc) interval greater than 0.45 seconds History of gastrointestinal disease with diarrhea as the major symptom  ",
        "premise_nums": [
            "2 positive breast",
            "2/erbB-2 positive",
            "than 0.45 seconds History"
        ]
    },
    {
        "id": "2e3f2fde-569e-46ef-958d-710599fec9a1",
        "primaryId": "NCT00706030",
        "secondaryId": "NCT00171704",
        "label": "Entailment",
        "statement_text": "the primary trial studies the interventions impact on target lesions and the secondary trial measures changes in Bone Mineral Density  the results from these two studies are therefore not directly comparable ",
        "statement_nums": [],
        "premise_text": "Outcome Measurement: Overall Response Rate Overall Response Rate (ORR)  subjects with CR or PR by independent review in subjects with ErbB-2-positive breast cancer treated at the MTD of neratinib in combination with vinorelbine per Response Evaluation Criteria In Solid Tumors Criteria (RECIST) v1.0: Complete Response (CR)  disappearance of all target lesions; Partial Response (PR)  greater than or equal 30% decrease in the sum of the longest diameter of target lesions; and Non-PD for non-target lesions  and no new lesions  Time frame: From first dose date to progression or last tumor assessment  up to four years and six months  Outcome Measurement: Percent Change From Baseline of Bone Mineral Density of the Lumbar Spine (L2-l4) ",
        "premise_nums": [
            "30% decrease",
            "2-positive breast"
        ]
    },
    {
        "id": "2e3f2fde-569e-46ef-958d-710599fec9a1",
        "primaryId": "NCT00706030",
        "secondaryId": "NCT00171704",
        "label": "Entailment",
        "statement_text": "the primary trial studies the interventions impact on target lesions and the secondary trial measures changes in Bone Mineral Density  the results from these two studies are therefore not directly comparable ",
        "statement_nums": [],
        "premise_text": "Lumbar spine (L2-L4) BMD measurements by dual energy X-ray absorptiometry (DXA) were performed after surgery and within 2 weeks prior to randomization and repeated every 6 months for the first 2 years and annually thereafter until 5 years after enrollment  The primary scanning site was the lumbar spine (L2 to L4) and the secondary scanning site was the total hip  All DXA scans were evaluated by a central reader Time frame: Baseline  24 months ",
        "premise_nums": [
            "2 years and",
            "5 years after",
            "6 months for",
            "2-L4) BMD",
            "2 to L4)",
            "2 weeks prior"
        ]
    },
    {
        "id": "d1080199-2591-44bd-bdad-0dea3830e657",
        "primaryId": "NCT00106002",
        "statement_text": "the primary trial participants are treated with 600 mg/m2 of Pemetrexed intravenously every 2 weeks until complete response or disease progression ",
        "statement_nums": [
            "2 weeks until",
            "600 mg/m2 of",
            "2 of Pemetrexed"
        ],
        "label": "Entailment",
        "premise_text": "INTERVENTION 1: Pemetrexed 600 mg/m2, intravenous (IV)  every 14 days until complete response or disease progression ",
        "premise_nums": [
            "600 mg/m2,",
            "14 days until"
        ]
    },
    {
        "id": "c37c21f5-19a0-4fcc-af92-89690fb64091",
        "primaryId": "NCT02352779",
        "secondaryId": "NCT00263588",
        "label": "Contradiction",
        "statement_text": "The differences between cohorts in the primary trial is once cohort recieves a 750mg Low-dose Omega-3 Fatty Acid and the other 500mg, in contrast the difference in the secondary trial is patient characteristics ",
        "statement_nums": [
            "3 Fatty Acid"
        ],
        "premise_text": "INTERVENTION 1: Arm I (Low-dose Omega-3 Fatty Acid) Patients receive low-dose omega-3 fatty acid supplementation PO BID and placebo PO BID for 6 weeks  Omega-3 Fatty Acid: Given PO Placebo: Given PO Questionnaire Administration: Ancillary studies Laboratory Biomarker Analysis: Correlative studies INTERVENTION 2: Arm II (High-dose Omega-3 Fatty Acid) Patients receive high-dose omega-3 fatty acid supplementation PO BID for 6 weeks  Omega-3 Fatty Acid: Given PO Questionnaire Administration: Ancillary studies Laboratory Biomarker Analysis: Correlative studies ",
        "premise_nums": [
            "3 fatty acid",
            "3 Fatty Acid:",
            "3 Fatty Acid)"
        ]
    },
    {
        "id": "c37c21f5-19a0-4fcc-af92-89690fb64091",
        "primaryId": "NCT02352779",
        "secondaryId": "NCT00263588",
        "label": "Contradiction",
        "statement_text": "The differences between cohorts in the primary trial is once cohort recieves a 750mg Low-dose Omega-3 Fatty Acid and the other 500mg, in contrast the difference in the secondary trial is patient characteristics ",
        "statement_nums": [
            "3 Fatty Acid"
        ],
        "premise_text": "INTERVENTION 1:Cohort A 750mg lapatinib administered orally twice daily  Cohort A subjects had Eastern Cooperative Oncology Group (ECOG) performance status 0-1, and one or two prior trastuzumab-containing regimens  in total  for treatment of breast cancer in adjuvant and/or metastatic settings INTERVENTION 2: Cohort B 750mg lapatinib administered orally twice daily  Cohort B subjects had ECOG performance status 2 and/or more than 2 prior trastuzumab-containing regimens for treatment of breast cancer in the adjuvant and/or metastatic settings  ",
        "premise_nums": [
            "2 and/or more",
            "2 prior trastuzumab",
            "0-1, and",
            "1:Cohort A"
        ]
    },
    {
        "id": "bea7f10e-09d6-42c3-9e89-dfd1112a33d5",
        "primaryId": "NCT01276041",
        "secondaryId": "NCT00688909",
        "label": "Contradiction",
        "statement_text": "0 patients in the primary trial or the secondary trial died ",
        "statement_nums": [
            "0 patients in"
        ],
        "premise_text": "Adverse Events 1: Total: 18/70 (25.71%) Cardiac arrest 1/70 (1.43%) Pericardial effusion 1/70 (1.43%) Ear pain 1/70 (1.43%) Blurred vision 1/70 (1.43%) Eye disorders - Other  specify 2/70 (2.86%) Abdominal Pain 5/70 (7.14%) Colitis 1/70 (1.43%) Diarrhea 2/70 (2.86%) Nausea 2/70 (2.86%) Death NOS 1/70 (1.43%) Edema limbs 1/70 (1.43%) Fatigue 3/70 (4.29%) Adverse Events 1: Total: 5/261 (1.92%) ",
        "premise_nums": [
            "5/70 (7.14%)",
            "1/70 (1.43%)",
            "2/70 (2.86%)",
            "5/261 (1.92%)",
            "3/70 (4.29%)",
            "18/70 (25.71%)"
        ]
    },
    {
        "id": "bea7f10e-09d6-42c3-9e89-dfd1112a33d5",
        "primaryId": "NCT01276041",
        "secondaryId": "NCT00688909",
        "label": "Contradiction",
        "statement_text": "0 patients in the primary trial or the secondary trial died ",
        "statement_nums": [
            "0 patients in"
        ],
        "premise_text": "Cholecystitis chronic 1/261 (0.38%)Post procedural bile leak 1/261 (0.38%) Spinal column stenosis 1/261 (0.38%) Depression 1/261 (0.38%) Mania 1/261 (0.38%) Pulmonary embolism 1/261 (0.38%) ",
        "premise_nums": [
            "1/261 (0.38%)Post"
        ]
    },
    {
        "id": "3d41d86b-f53f-4bf9-a4dd-eae2412c485e",
        "primaryId": "NCT00545077",
        "statement_text": "Only cohort 2 of the primary trial receive letrozole  but both cohorts undergo Endocrine Therapy  ",
        "statement_nums": [
            "2 of the"
        ],
        "label": "Contradiction",
        "premise_text": "INTERVENTION 1: Arm A: Endocrine Therapy (ET) Endocrine treatment consisting of either letrozole or fulvestrant  Patients will be randomized to receive bevacizumab 15mg/kg every 3 weeks plus endocrine treatment or endocrine treatment as a single agent  The patients will receive the assigned treatment until the progression of the disease  unacceptable toxicity or withdrawal of the consent  Letrozole Fulvestrant INTERVENTION 2: Arm B: ET With Bevacizumab (ET-B) ",
        "premise_nums": [
            "3 weeks plus",
            "15mg/kg every"
        ]
    },
    {
        "id": "3d41d86b-f53f-4bf9-a4dd-eae2412c485e",
        "primaryId": "NCT00545077",
        "statement_text": "Only cohort 2 of the primary trial receive letrozole  but both cohorts undergo Endocrine Therapy  ",
        "statement_nums": [
            "2 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Endocrine treatment consisting of either letrozole or fulvestrant  Patients will be randomized to receive bevacizumab 15mg/kg i.v  on day 1 every 3 weeks plus endocrine treatment or endocrine treatment as a single agent  The patients will receive the assigned treatment until the progression of the disease  unacceptable toxicity or withdrawal of the consent Letrozole Bevacizumab Fulvestrant ",
        "premise_nums": [
            "15mg/kg i",
            "1 every 3"
        ]
    },
    {
        "id": "0159bfb3-231e-4711-b3ee-2798c66f5f6a",
        "primaryId": "NCT01015131",
        "secondaryId": "NCT00312208",
        "label": "Contradiction",
        "statement_text": "Both the primary trial and the secondary trial record instances of Rectal Hemorrhage within their patient cohorts ",
        "statement_nums": [],
        "premise_text": "Adverse Events 1: Total: 8/44 (18.18%) Febrile neutropenia4/44 (9.09%) Rectal bleeding1/44 (2.27%) Chest pain2/44 (4.55%) Fever1/44 (2.27%) Catheter site infection1/44 (2.27%) Neutrophil count decreased1/44 (2.27%) Dizziness1/44 (2.27%) Adverse Events 1: Total: 331/1634 (20.26%) Anemia 3/1634 (0.18%) Coagulation disorders 1/1634 (0.06%) Hemorrhage Vaginal 1/1634 (0.06%) ",
        "premise_nums": [
            "1/1634 (0.06%)",
            "1/44 (2.27%)",
            "2/44 (4.55%)",
            "3/1634 (0.18%)",
            "331/1634 (20.26%)",
            "8/44 (18.18%)",
            "4/44 (9.09%)"
        ]
    },
    {
        "id": "0159bfb3-231e-4711-b3ee-2798c66f5f6a",
        "primaryId": "NCT01015131",
        "secondaryId": "NCT00312208",
        "label": "Contradiction",
        "statement_text": "Both the primary trial and the secondary trial record instances of Rectal Hemorrhage within their patient cohorts ",
        "statement_nums": [],
        "premise_text": "Leukopenia 18/1634 (1.10%)Lymphadenopathy 0/1634 (0.00%) Lymphedema 0/1634 (0.00%) Pancytopenia 0/1634 (0.00%) Thrombocytopenia 0/1634 (0.00%) Arrhythmia 3/1634 (0.18%) Arrhythmia Ventricular 0/1634 (0.00%) Cardiomyopathy 1/1634 (0.06%) ",
        "premise_nums": [
            "3/1634 (0.18%)",
            "1/1634 (0.06%)",
            "0/1634 (0.00%)",
            "18/1634 (1.10%)Lymphadenopathy"
        ]
    },
    {
        "id": "9e7628cd-931e-4b1f-b4c1-f03f0449ac27",
        "primaryId": "NCT00392392",
        "secondaryId": "NCT00503906",
        "label": "Contradiction",
        "statement_text": "the primary trial records two different types of pain in its adverse events  in the cranial and foot area  the secondary trial does not record any types of pain in its participants ",
        "statement_nums": [],
        "premise_text": "Adverse Events 1: Pain - Abdomen 1/29 (3.45%) Pain - Chest 1/29 (3.45%) Adverse Events 1: Total: 8/29 (27.59%) Leukopenia [1]1/29 (3.45%) Thrombocytopenia [1]1/29 (3.45%) Abscess [1]1/29 (3.45%) Breast Abscess 1/29 (3.45%) Fever/Sepsis [1]1/29 (3.45%) Neutropenic Fever [2]1/29 (3.45%) Peripheral Neuropathy [1]1/29 (3.45%) ",
        "premise_nums": [
            "1/29 (3.45%)",
            "8/29 (27.59%)"
        ]
    },
    {
        "id": "9e7628cd-931e-4b1f-b4c1-f03f0449ac27",
        "primaryId": "NCT00392392",
        "secondaryId": "NCT00503906",
        "label": "Contradiction",
        "statement_text": "the primary trial records two different types of pain in its adverse events  in the cranial and foot area  the secondary trial does not record any types of pain in its participants ",
        "statement_nums": [],
        "premise_text": "Seizure/Syncope [1]1/29 (3.45%)Hematuria [1]1/29 (3.45%) UTI [1]1/29 (3.45%) Shortness of breath [1]1/29 (3.45%) ",
        "premise_nums": [
            "1/29 (3.45%)Hematuria"
        ]
    },
    {
        "id": "f1108cbc-db27-431d-9154-1a267278bda4",
        "primaryId": "NCT00312208",
        "statement_text": "Cases of Cardiomyopathy and Leukopenia were only observed in cohort 1 of the primary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 331/1634 (20.26%) Anemia 3/1634 (0.18%) Coagulation disorders 1/1634 (0.06%) Hemorrhage Vaginal 1/1634 (0.06%) Leukopenia 18/1634 (1.10%) Lymphadenopathy 0/1634 (0.00%) Lymphedema 0/1634 (0.00%) Pancytopenia 0/1634 (0.00%) Thrombocytopenia 0/1634 (0.00%) Arrhythmia 3/1634 (0.18%) Arrhythmia Ventricular 0/1634 (0.00%) ",
        "premise_nums": [
            "1/1634 (0.06%)",
            "3/1634 (0.18%)",
            "331/1634 (20.26%)",
            "0/1634 (0.00%)",
            "18/1634 (1.10%)"
        ]
    },
    {
        "id": "f1108cbc-db27-431d-9154-1a267278bda4",
        "primaryId": "NCT00312208",
        "statement_text": "Cases of Cardiomyopathy and Leukopenia were only observed in cohort 1 of the primary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Cardiomyopathy 1/1634 (0.06%)Adverse Events 2: Total: 520/1635 (31.80%) Anemia 5/1635 (0.31%) Coagulation disorders 0/1635 (0.00%) Hemorrhage Vaginal 0/1635 (0.00%) Leukopenia 56/1635 (3.43%) Lymphadenopathy 1/1635 (0.06%) Lymphedema 2/1635 (0.12%) Pancytopenia 1/1635 (0.06%) Thrombocytopenia 1/1635 (0.06%) Arrhythmia 3/1635 (0.18%) ",
        "premise_nums": [
            "5/1635 (0.31%)",
            "520/1635 (31.80%)",
            "0/1635 (0.00%)",
            "2/1635 (0.12%)",
            "1/1635 (0.06%)",
            "56/1635 (3.43%)",
            "1/1634 (0.06%)Adverse",
            "3/1635 (0.18%)"
        ]
    },
    {
        "id": "f1108cbc-db27-431d-9154-1a267278bda4",
        "primaryId": "NCT00312208",
        "statement_text": "Cases of Cardiomyopathy and Leukopenia were only observed in cohort 1 of the primary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Arrhythmia Ventricular 1/1635 (0.06%)Cardiomyopathy 0/1635 (0.00%) ",
        "premise_nums": [
            "0/1635 (0.00%)",
            "1/1635 (0.06%)Cardiomyopathy"
        ]
    },
    {
        "id": "8eb69e3e-ac08-4e85-98be-211aecd4525d",
        "primaryId": "NCT04396665",
        "statement_text": "Any patient can enter into the primary trial as long as they are willing to provide Informed consent and are capable of using the internet ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Inclusion Criteria: Informed consent signed Capability to use internet Exclusion Criteria: Breast cancer diagnosis duting the intervention ",
        "premise_nums": []
    },
    {
        "id": "baf7e338-91fd-47d0-b766-a4e039efc5d7",
        "primaryId": "NCT01432886",
        "statement_text": "None of the patients in either cohort of the primary trial experienced DLT ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Results 1: Arm/Group Title: E7389 With Weekly Trastuzumab Arm/Group Description: Eribulin mesylate (E7389) was administered intravenously on Day 1 and Day 8 of each 3 week cycle  Trastuzumab was administered intravenously weekly  with an initial dose of 4 mg/kg followed by 2 mg/kg for the remaining doses  Overall Number of Participants Analyzed: 6 Measure Type: Number Unit of Measure: Participants 0 Results 2: Arm/Group Title: E7389 With Tri-weekly Trastuzumab ",
        "premise_nums": [
            "1 and Day",
            "2 mg/kg for",
            "3 week cycle",
            "E7389 With",
            "(E7389) was",
            "4 mg/kg followed",
            "7389 With Weekly",
            "6 Measure Type:",
            "0 Results 2:",
            "8 of each"
        ]
    },
    {
        "id": "baf7e338-91fd-47d0-b766-a4e039efc5d7",
        "primaryId": "NCT01432886",
        "statement_text": "None of the patients in either cohort of the primary trial experienced DLT ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Arm/Group Description: Eribulin mesylate (E7389) was administered intravenously on Day 1 and Day 8 of each 3 week cycle  Trastuzumab was administered intravenously tri-weekly  with an initial dose of 8 mg/kg followed by 6 mg/kg for the remaining doses Overall Number of Participants Analyzed: 6 Measure Type: Number Unit of Measure: Participants 0 ",
        "premise_nums": [
            "1 and Day",
            "3 week cycle",
            "(E7389) was",
            "8 mg/kg followed",
            "6 Measure Type:",
            "8 of each",
            "6 mg/kg for"
        ]
    },
    {
        "id": "9401b12d-3888-4a41-93a1-b2075930098b",
        "primaryId": "NCT00458237",
        "statement_text": "Patient who have undergone External beam radiation therapy and major surgery in the last two weeks are eligible for the primary trial ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria: Patients may have received prior radiation therapy Exclusion Criteria: Major surgery within 2 weeks before study entry ",
        "premise_nums": [
            "2 weeks before"
        ]
    },
    {
        "id": "c7aa030a-6b76-4bd7-a934-f02a4638a1ac",
        "primaryId": "NCT00908791",
        "secondaryId": "NCT00297596",
        "label": "Entailment",
        "statement_text": "Female patients over the age of 60, with Histologically confirmed breast cancer and advanced Alzheimer's disease are ineligible for both the secondary trial and the primary trial ",
        "statement_nums": [],
        "premise_text": "Inclusion Criteria: A serious uncontrolled medical disorder or active infection which would impair their ability to receive study treatment will be excluded  Significant cardiac disease  including uncontrolled high blood pressure  unstable angina  and congestive heart failure  myocardial infarction within the previous 3 months or serious cardiac arrhythmias will be excluded  Dementia or significantly altered mental status that would prohibit the understanding or rendering of informed consent and compliance with the requirements of this protocol will be excluded  Inclusion Criteria: Dementia or significantly altered mental status that would interfere with proper consenting  ",
        "premise_nums": [
            "3 months or"
        ]
    },
    {
        "id": "94f9a957-33bb-4409-8878-ba734d6b0d5c",
        "primaryId": "NCT01823107",
        "statement_text": "several Patients implanted with a Meso BioMatrix Acellular Peritoneum Matrix suffered Breast Related Adverse Events in both reconstructed breasts ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Rate of Breast Related Adverse Events Investigators evaluated each subject and each reconstructed breast for the occurrence of an adverse event from the first stage of reconstruction through the final follow-up visit  A breast related adverse event was defined as any untoward medical occurrence related to a reconstructed breast  Time frame: 18 months Results 1: Arm/Group Title: Meso BioMatrix Acellular Peritoneum Matrix Arm/Group Description: All subjects had the Meso BioMatrix Acellular Peritoneum Matrix implanted along with a tissue expander during the first stage of breast reconstruction  After tissue expansion  the tissue expander was replaced with a breast implant during the second stage of reconstruction  Overall Number of Participants Analyzed: 25 Overall Number of Units Analyzed ",
        "premise_nums": [
            "18 months Results",
            "25 Overall Number"
        ]
    },
    {
        "id": "94f9a957-33bb-4409-8878-ba734d6b0d5c",
        "primaryId": "NCT01823107",
        "statement_text": "several Patients implanted with a Meso BioMatrix Acellular Peritoneum Matrix suffered Breast Related Adverse Events in both reconstructed breasts ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Type of Units Analyzed: Reconstructed breasts Measure Type: NumberUnit of Measure: Reconstructed breasts affected: 12",
        "premise_nums": []
    },
    {
        "id": "04fd88c2-cf92-468d-bbc4-567cae19948d",
        "primaryId": "NCT00087152",
        "secondaryId": "NCT00203502",
        "label": "Entailment",
        "statement_text": "the primary trial recorded less patients with nausea than the secondary trial ",
        "statement_nums": [],
        "premise_text": "Adverse Events 1: Nausea 1/20 (5.00%) Adverse Events 1: Nausea/vomiting 4/39 (10.26%) ",
        "premise_nums": [
            "4/39 (10.26%)",
            "1/20 (5.00%)"
        ]
    },
    {
        "id": "8a0d98d1-3a04-4fe4-8dc9-a41fdad5acdd",
        "primaryId": "NCT00499122",
        "secondaryId": "NCT00454805",
        "label": "Entailment",
        "statement_text": "There were no cases of Multi-Organ Failure in both cohort 1 of the secondary trial and cohort 1 of the primary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Adverse Events 1: Total: 27/41 (65.85%) Febrile Neutropenia 4/41 (9.76%) Neutropenia 1/41 (2.44%) Deep Vein Thrombosis 1/41 (2.44%) Pulmonary embolism 1/41 (2.44%) Femoral Artery occlusion 1/41 (2.44%) Abdominal Pain 2/41 (4.88%) Constipation 1/41 (2.44%) Fatigue 2/41 (4.88%) Headache 1/41 (2.44%) Nausea 1/41 (2.44%) Cellulitis 1/41 (2.44%) Muscular Weakness 1/41 (2.44%) ",
        "premise_nums": [
            "27/41 (65.85%)",
            "2/41 (4.88%)",
            "4/41 (9.76%)",
            "1/41 (2.44%)"
        ]
    },
    {
        "id": "8a0d98d1-3a04-4fe4-8dc9-a41fdad5acdd",
        "primaryId": "NCT00499122",
        "secondaryId": "NCT00454805",
        "label": "Entailment",
        "statement_text": "There were no cases of Multi-Organ Failure in both cohort 1 of the secondary trial and cohort 1 of the primary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Adverse Events 1:Total: 15/31 (48.39%) Intracardiac Thrombus 1/31 (3.23%) Diarrhoea 2/31 (6.45%) Nausea 2/31 (6.45%) Vomiting 2/31 (6.45%) Ascites 0/31 (0.00%) Ileus 1/31 (3.23%) Small Intestinal Obstruction 1/31 (3.23%) Multi-Organ Failure 0/31 (0.00%) Sepsis 1/31 (3.23%) Weight Decreased 1/31 (3.23%) Dehydration 2/31 (6.45%) Hypokalaemia 0/31 (0.00%) ",
        "premise_nums": [
            "0/31 (0.00%)",
            "2/31 (6.45%)",
            "15/31 (48.39%)",
            "1:Total: 15/31",
            "1/31 (3.23%)"
        ]
    },
    {
        "id": "8074c35f-b74c-4250-94f1-9ad22fa315d7",
        "primaryId": "NCT00375427",
        "secondaryId": "NCT00579826",
        "label": "Entailment",
        "statement_text": "Patients diagnosed with osteoporosis are eligible for the primary trial but excluded from the secondary trial ",
        "statement_nums": [],
        "premise_text": "Inclusion criteria: Female patients 18 years of age  Written informed consent given  Histologically confirmed Stage IV breast cancer with at least one bone metastasis radiologically confirmed  Previous treatment with zoledronic acid every 3-4 weeks  for 9-12 infusions over no more than 15 months  Eastern Cooperative Oncology Group (ECOG) performance status 2   Life expectancy 1 year  Exclusion criteria: More than 3 months since last infusion of Zoledronic Acid (Zometa®)  Treatments with other bisphosphonate than Zoledronic Acid (Zometa®) at any time prior to study entry  ",
        "premise_nums": [
            "3 months since",
            "12 infusions over",
            "9-12 infusions",
            "3-4 weeks",
            "18 years of"
        ]
    },
    {
        "id": "8074c35f-b74c-4250-94f1-9ad22fa315d7",
        "primaryId": "NCT00375427",
        "secondaryId": "NCT00579826",
        "label": "Entailment",
        "statement_text": "Patients diagnosed with osteoporosis are eligible for the primary trial but excluded from the secondary trial ",
        "statement_nums": [],
        "premise_text": "Serum creatinine greater than 3 mg/dL (265 μmol/L) or calculated (Cockcroft-Gault formula) creatinine clearance (CLCr) smaller than 30 mL/min CrCl = ({[140-age (years)] x weight(kg)}/ [72 x serum creatinine (mg/dL)])x 0.85Corrected (adjusted for serum albumin) serum calcium smaller than 8 mg/dl (2 mmol/L) or greater than 12 mg/dL ( 3.0 mmol/L)  ",
        "premise_nums": [
            "72 x serum",
            "12 mg/dL",
            "3.0 mmol/L",
            "3 mg/dL",
            "8 mg/dl",
            "30 mL/min CrCl"
        ]
    },
    {
        "id": "8074c35f-b74c-4250-94f1-9ad22fa315d7",
        "primaryId": "NCT00375427",
        "secondaryId": "NCT00579826",
        "label": "Entailment",
        "statement_text": "Patients diagnosed with osteoporosis are eligible for the primary trial but excluded from the secondary trial ",
        "statement_nums": [],
        "premise_text": "Current active dental problem including infection of the teeth or jawbone (maxilla or mandibular); dental or fixture trauma  or a recurrent or prior diagnosis of osteonecrosis of the jaw (ONJ)  of exposed bone in the mouth  or of slow healing after dental procedures Recent (within 6 weeks) or planned dental or jaw surgery (e.g  extraction  implants)  Pregnant patients (with a positive pregnancy test prior to study entry) or lactating patients  Women of childbearing potential not using effective methods of birth control (e.g  abstinence  oral contraceptives or implants  IUD  vaginal diaphragm or sponge  or condom with spermicide)  History of non-compliance to medical regimens or potential unreliable behavior  Known sensitivity to study drug(s) or class of study drug(s)  ",
        "premise_nums": []
    },
    {
        "id": "8074c35f-b74c-4250-94f1-9ad22fa315d7",
        "primaryId": "NCT00375427",
        "secondaryId": "NCT00579826",
        "label": "Entailment",
        "statement_text": "Patients diagnosed with osteoporosis are eligible for the primary trial but excluded from the secondary trial ",
        "statement_nums": [],
        "premise_text": "Patients with severe medical condition(s) that in the view of the investigator prohibits participation in the studyUse of any other investigational agent in the last 30 days  Exclusion Criteria: Prior history of osteoporosis or osteoporotic fracture  ",
        "premise_nums": []
    },
    {
        "id": "afc4a45b-6592-4ca8-b174-033fb6a0624a",
        "primaryId": "NCT00580333",
        "secondaryId": "NCT00934856",
        "label": "Contradiction",
        "statement_text": "Candidates must have a life expectancy less than 12 weeks to particpate in the primary trial and the secondary trial ",
        "statement_nums": [
            "12 weeks to"
        ],
        "premise_text": "Exclusion Criteria: Life expectancy of less than 12 weeks Inclusion Criteria: Eastern Cooperative Oncology Group (ECOG) performance status 0-1 (ECOG performance status of 2 will be allowed if only due to debilitating bone disease) HER2-positive metastatic or locally advanced breast cancer For MBC participants: Documented metastatic or inoperable locally advanced (without meeting LABC criteria) disease  amenable for treatment with docetaxel History of disease progression within 3 months prior to study entry For LABC participants: Newly diagnosed locally advanced breast cancer  Stage IIA-IIIC (American Joint Committee on Cancer [AJCC] staging system) Exclusion Criteria: Significant cardiac disease Inadequate bone marrow  liver or renal function For MBC participants: ",
        "premise_nums": [
            "3 months prior",
            "12 weeks Inclusion",
            "2 will be",
            "2-positive metastatic"
        ]
    },
    {
        "id": "afc4a45b-6592-4ca8-b174-033fb6a0624a",
        "primaryId": "NCT00580333",
        "secondaryId": "NCT00934856",
        "label": "Contradiction",
        "statement_text": "Candidates must have a life expectancy less than 12 weeks to particpate in the primary trial and the secondary trial ",
        "statement_nums": [
            "12 weeks to"
        ],
        "premise_text": "Participants must not have received radiotherapy for the treatment of metastatic or locally recurrent/advanced disease other than for the relief of pain in progressing metastatic bone lesions and/or brain metastasesBrain metastases that are untreated  symptomatic or require therapy to control symptoms; or any radiation  surgery  or other therapy to control symptoms from brain metastasis within 2 months of the first study treatment  For LABC participants: Clinically or radiologically detectable metastasis (M1 disease) Participants for whom surgery as primary intent procedure is the best option to treat their disease Participants must not have received any systemic or loco-regional anti-cancer therapy for the treatment of locally advanced disease ",
        "premise_nums": [
            "2 months of"
        ]
    },
    {
        "id": "2e1d4811-ae58-4b81-b53a-dbcb8c980a08",
        "primaryId": "NCT00033514",
        "statement_text": "Elizabeth has HER2 positive breast cancer  she is eligible for the primary trial ",
        "statement_nums": [
            "2 positive breast"
        ],
        "label": "Entailment",
        "premise_text": "Inclusion Criteria: Women aged greater than 18 years Histologically documents metastatic breast cancer HER2 positive using Fluorescence In Situ Hybridization (FISH) ",
        "premise_nums": [
            "18 years Histologically",
            "2 positive using"
        ]
    },
    {
        "id": "d4f738c5-c99a-4d8d-b335-5821ce97fbd5",
        "primaryId": "NCT00568022",
        "secondaryId": "NCT01120184",
        "label": "Entailment",
        "statement_text": "Completely disabled patients  totally confined to bed or chair and unable to carry on any selfcare are eligible for the primary trial but excluded from the secondary trial ",
        "statement_nums": [],
        "premise_text": "Inclusion Criteria: Women 20 years Histologically or cytologically confirmed diagnosis of adenocarcinoma originating in the breast Exclusion Criteria: Number of prior chemotherapy lines of treatment in the metastatic setting 3 Inclusion Criteria: Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1 ",
        "premise_nums": [
            "3 Inclusion Criteria:",
            "20 years Histologically",
            "0 or 1"
        ]
    },
    {
        "id": "f27b25bd-c28e-4aac-8ad6-951fd7381ce4",
        "primaryId": "NCT01262027",
        "statement_text": "More than 1 patient in the primary trial suffered an adverse event ",
        "statement_nums": [
            "1 patient in"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 1/22 (4.55%) Blood bilirubin increased 1/22 (4.55%) Alkaline phosphatase increased 1/22 (4.55%) ",
        "premise_nums": [
            "1/22 (4.55%)"
        ]
    },
    {
        "id": "5311216c-94e0-4d04-acd2-b95b932ddc02",
        "primaryId": "NCT00127933",
        "secondaryId": "NCT00191789",
        "label": "Contradiction",
        "statement_text": "the primary trial recorded at least one patient with an infection  whereas in the secondary trial none where observed ",
        "statement_nums": [],
        "premise_text": "Catheter site cellulitis 1/122 (0.82%) Catheter site cellulitis 0/34 (0.00%) Adverse Events 1: Total: 17/65 (26.15%) Febrile neutropenia 3/65 (4.62%) Neutropenia 2/65 (3.08%) Pancytopenia 1/65 (1.54%) Thrombocytopenia 1/65 (1.54%) Cardiac arrest 2/65 (3.08%) Myocardial infarction 1/65 (1.54%) Diarrhoea 5/65 (7.69%) Stomatitis 1/65 (1.54%) Vomiting 2/65 (3.08%) ",
        "premise_nums": [
            "17/65 (26.15%)",
            "3/65 (4.62%)",
            "0/34 (0.00%)",
            "1/122 (0.82%)",
            "5/65 (7.69%)",
            "2/65 (3.08%)",
            "1/65 (1.54%)"
        ]
    },
    {
        "id": "5311216c-94e0-4d04-acd2-b95b932ddc02",
        "primaryId": "NCT00127933",
        "secondaryId": "NCT00191789",
        "label": "Contradiction",
        "statement_text": "the primary trial recorded at least one patient with an infection  whereas in the secondary trial none where observed ",
        "statement_nums": [],
        "premise_text": "Fatigue 1/65 (1.54%)Jaundice 1/65 (1.54%) Neutropenic infection 2/65 (3.08%) ",
        "premise_nums": [
            "1/65 (1.54%)Jaundice",
            "2/65 (3.08%)"
        ]
    },
    {
        "id": "01dfa37b-ce65-4e90-addc-395241c92f5f",
        "primaryId": "NCT00191451",
        "statement_text": "Patients in the primary trial experienced a variety of Oesophageal and cardiac adverse events ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 10/50 (20.00%) Anaemia 0/50 (0.00%) Febrile neutropenia 0/50 (0.00%) Neutropenia 0/50 (0.00%) Thrombocytopenia 0/50 (0.00%) Diastolic dysfunction 0/50 (0.00%) Tachycardia 0/50 (0.00%) Intestinal obstruction 0/50 (0.00%) Nausea 1/50 (2.00%) Oesophageal spasm 0/50 (0.00%) Oesophagitis 0/50 (0.00%) Retching 0/50 (0.00%) Adverse Events 2: ",
        "premise_nums": [
            "0/50 (0.00%)",
            "1/50 (2.00%)",
            "10/50 (20.00%)"
        ]
    },
    {
        "id": "01dfa37b-ce65-4e90-addc-395241c92f5f",
        "primaryId": "NCT00191451",
        "statement_text": "Patients in the primary trial experienced a variety of Oesophageal and cardiac adverse events ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Total: 11/48 (22.92%)Anaemia 4/48 (8.33%) Febrile neutropenia 0/48 (0.00%) Neutropenia 2/48 (4.17%) Thrombocytopenia 2/48 (4.17%) Diastolic dysfunction 1/48 (2.08%) Tachycardia 1/48 (2.08%) Intestinal obstruction 0/48 (0.00%) Nausea 0/48 (0.00%) Oesophageal spasm 1/48 (2.08%) Oesophagitis 0/48 (0.00%) Retching 1/48 (2.08%) ",
        "premise_nums": [
            "1/48 (2.08%)",
            "4/48 (8.33%)",
            "11/48 (22.92%)Anaemia",
            "0/48 (0.00%)",
            "2/48 (4.17%)"
        ]
    },
    {
        "id": "43588c50-7dc4-4d46-a53d-e94576e8ab55",
        "primaryId": "NCT03197389",
        "statement_text": "Both men and women of child bearing potential must use adequate methods of contraception to be eligible for the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Inclusion Criteria: Female subjects of childbearing potential (Section 5.7.2) must be willing to use an adequate method of contraception as outlined in Section 5.7.2 - Contraception  for the course of the study through 120 days after receiving the study medication  Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject  Male subjects of childbearing potential (Section 5.7.1) must agree to use an adequate method of contraception as outlined in Section 5.7.1- Contraception  until 120 after receiving the study therapy  ",
        "premise_nums": [
            "120 days after",
            "120 after receiving"
        ]
    },
    {
        "id": "f419f810-ca53-4168-86fd-d1d9a9154d3a",
        "primaryId": "NCT02683083",
        "statement_text": "sufferers of hyperthyroidism are excluded from the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Exclusion Criteria: Patients will not be included in the study if one of the following criteria applies: Pregnant patients Breast feeding patients Patients with occupational exposure to ionizing irradiation Patients with previous thyroid disorders ",
        "premise_nums": []
    },
    {
        "id": "630a8241-b776-4799-a7ca-b1fddf17686c",
        "primaryId": "NCT00206518",
        "statement_text": "The least common Chevalier grades for patients in the primary trial treated with Taxotere/Docetaxel were 1, 3D and 3C.",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Pathological Tumor Response to Neoadjuvant Chemotherapy (Taxotere and AC) The patients' pathological response were assessed using Chevalier's system which graded the responses into Chevalier 1, 2, 3A, 3B, 3C, 3D, and 4, defined as: Disappearance of all tumor either on macroscopic or microscopic assessment in both the breast and LN (pCR) Presence of in situ carcinoma in the breast  No invasive tumor in breast and no tumor in LN (pCR) ",
        "premise_nums": []
    },
    {
        "id": "630a8241-b776-4799-a7ca-b1fddf17686c",
        "primaryId": "NCT00206518",
        "statement_text": "The least common Chevalier grades for patients in the primary trial treated with Taxotere/Docetaxel were 1, 3D and 3C.",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Presence of invasive cancer with stromal alteration such as sclerosis or fibrosis (pPR) 3A: Subjectively greater than 75% therapeutic effect 3B: Subjectively between 50% - 75% therapeutic effect 3C: Subjectively between 25% - 50% therapeutic effect 3D: Subjectively smaller than 25% therapeutic effect OR Grade 4No or few modification of tumoral appearance (pNR)  Time frame: 10 years Results 1: Arm/Group Title: A: Taxotere/Docetaxel ",
        "premise_nums": [
            "75% therapeutic",
            "25% therapeutic",
            "50% therapeutic",
            "10 years Results"
        ]
    },
    {
        "id": "630a8241-b776-4799-a7ca-b1fddf17686c",
        "primaryId": "NCT00206518",
        "statement_text": "The least common Chevalier grades for patients in the primary trial treated with Taxotere/Docetaxel were 1, 3D and 3C.",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Arm/Group Description: Chemotherapy In Arm A  patients will receive single agent Taxotere (100 mg/m2) every 3 weeks for 4 cycles before surgery  Primary surgery will then be conducted  if operable  following completion of neoadjuvant treatment  This will be followed by standard adjuvant AC (doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2, every 3 weeks) for 4 cycles  For patients whose BSA is greater than 2.0 m2, the Adriamycin dosage will be calculated using BSA = 2.0 m2. This is done in order to minimize Adriamycin-induced cardiotoxicity Taxotere/Docetaxel: Taxotere ",
        "premise_nums": [
            "60 mg/m2 and",
            "3 weeks for",
            "600 mg/m2,",
            "2 and cyclophosphamide",
            "4 cycles before"
        ]
    },
    {
        "id": "630a8241-b776-4799-a7ca-b1fddf17686c",
        "primaryId": "NCT00206518",
        "statement_text": "The least common Chevalier grades for patients in the primary trial treated with Taxotere/Docetaxel were 1, 3D and 3C.",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "doxorubicin: AC (doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2, every 3 weeks) for 4 cycles before surgery Overall Number of Participants Analyzed: 83 Measure Type: Number Unit of Measure: participants 1: 3 2: 2 3A: 18 3B: 15 3C: 18 3D: 10 4: 3 N/A: 14 ",
        "premise_nums": [
            "83 Measure Type:",
            "60 mg/m2 and",
            "3 N/A:",
            "600 mg/m2,",
            "2 and cyclophosphamide",
            "4 cycles before"
        ]
    },
    {
        "id": "8f3fddf2-97ab-4456-bff7-8f83b27e3849",
        "primaryId": "NCT00675259",
        "secondaryId": "NCT01875367",
        "label": "Entailment",
        "statement_text": "Patients with an ImmunoHistoChemistry test result of 3+ are excluded from the primary trial but included in the secondary trial ",
        "statement_nums": [],
        "premise_text": "Exclusion: HER-2 neu overexpression either by IHC 3+ or FISH+ Inclusion Criteria: immuno-histochemistry (IHC) 3+ (greater than 10% of tumor cells with complete and intense membrane staining) ",
        "premise_nums": [
            "2 neu overexpression",
            "10% of"
        ]
    },
    {
        "id": "11617367-193f-4f6b-bc3e-e58ea76d1052",
        "primaryId": "NCT00485953",
        "secondaryId": "NCT00068601",
        "label": "Contradiction",
        "statement_text": "the cyclophosphamide dose in the secondary trial is 150mg once every 4 weeks and the Placebo dose in the primary trial is 12mg QD ",
        "statement_nums": [
            "4 weeks and"
        ],
        "premise_text": "INTERVENTION 1: Active Medicine Group risedronate 35 mg weekly INTERVENTION 2: Placebo Group Received placebo medication once weekly INTERVENTION 1: Standard Chemotherapy Patients receive cyclophosphamide-containing chemotherapy alone  cyclophosphamide: Part of planned chemotherapy regimen INTERVENTION 2: Chemotherapy Plus Goserelin Patients receive goserelin subcutaneously once every 4 weeks beginning 1 week before start of cyclophosphamide-containing chemotherapy  Treatment continues until completion of chemotherapy in the absence of disease progression or unacceptable toxicity  cyclophosphamide: Part of planned chemotherapy regimen goserelin acetate: Given subcutaneously ",
        "premise_nums": [
            "35 mg weekly",
            "4 weeks beginning",
            "1 week before"
        ]
    },
    {
        "id": "882f22f6-36d9-4c2f-8f49-52469d570977",
        "primaryId": "NCT01840163",
        "secondaryId": "NCT02005549",
        "label": "Entailment",
        "statement_text": "the primary trial and the secondary trial do not exclude patients with non-melanoma skin cancer ",
        "statement_nums": [],
        "premise_text": "Inclusion Criteria: Stage 1-2 invasive breast cancer diagnosis  DCIS Ability to read English Exclusion Criteria: Male Inclusion Criteria: female patients  18-70years of age; histologically-proven invasive breast cancer; no prior or current neoplasm except for non-melanoma skin cancer  or in situ cancer of the cervix; no distant disease/secondary cancer  Exclusion Criteria: pregnant or lactating women; pre-operative local treatment for breast cancer; prior or concurrent systemic antitumor therapy; clinically significant cardiac disease  ",
        "premise_nums": [
            "18-70years of",
            "2 invasive breast",
            "1-2 invasive"
        ]
    },
    {
        "id": "8f5423c9-17b5-4f66-aa9f-1fc9763958b2",
        "primaryId": "NCT01250379",
        "statement_text": "None of the patients in the primary trial had Thrombocytopenia  heart failure  Pancytopenia  Acute coronary syndrome or Atrial fibrillation ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Cardiac failure * 1/238 (0.42%) Thrombocytopenia * 0/238 (0.00%) Pancytopenia * 0/238 (0.00%) Acute coronary syndrome * 0/238 (0.00%) Atrial fibrillation * 0/238 (0.00%) Cardiac failure congestive * 0/238 (0.00%) ",
        "premise_nums": [
            "0/238 (0.00%)",
            "1/238 (0.42%)"
        ]
    },
    {
        "id": "0c45a782-1a3d-4e9b-a258-136ab080dbb6",
        "primaryId": "NCT00846027",
        "statement_text": "None of the adverse events recorded for the primary trial occurred less than twice ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 21/82 (25.61%) Neutrophils count decreased 1/82 (1.22%) Cardiac ischemia/infarction 1/82 (1.22%) Left ventricular systolic dysfunction 1/82 (1.22%) Hypertension 1/82 (1.22%) Supraventricular and nodal arrhythmia 1/82 (1.22%) Anorexia 1/82 (1.22%) Gastrointestinal perforation 1/82 (1.22%) Vomiting 1/82 (1.22%) Dehydration 1/82 (1.22%) Diarrhoea 1/82 (1.22%) ",
        "premise_nums": [
            "1/82 (1.22%)",
            "21/82 (25.61%)"
        ]
    },
    {
        "id": "4e42302d-2cd9-4a91-9338-8e3b0ffb9292",
        "primaryId": "NCT00654836",
        "statement_text": "Patients with metastatic HER-2 positive adenocarcinoma of the breast can never be eligible for the primary trial ",
        "statement_nums": [
            "2 positive adenocarcinoma"
        ],
        "label": "Contradiction",
        "premise_text": "DISEASE CHARACTERISTICS: Histologically or cytologically confirmed primary adenocarcinoma of the breast Locally recurrent or metastatic disease Must have HER-2-negative breast cancer or  if HER-2-positive, must be unable to receive trastuzumab (Herceptin®) or have previously received trastuzumab in the past No known CNS disease ",
        "premise_nums": [
            "2-positive, must",
            "2-negative breast"
        ]
    },
    {
        "id": "a5d5e6da-f3cd-49c7-92a7-f789468c4c4c",
        "primaryId": "NCT00270894",
        "statement_text": "60% of Subjects in the primary trial were able to Complete at least 85% of the Planned Dose on Schedule ",
        "statement_nums": [
            "60% of",
            "85% of"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Percentage of Subjects Able to Complete greater than 85% of the Planned Dose on Schedule Feasibility will be determined by evaluating the percentage of subjects able to complete the neoadjuvant portion of the study on time with greater than 85% of the protocol-specified dose  Time frame: From the start of treatment through the neoadjuvant treatment period (approximately 20 weeks) Results 1: Arm/Group Title: Neoadjuvant Therapy ",
        "premise_nums": [
            "85% of"
        ]
    },
    {
        "id": "a5d5e6da-f3cd-49c7-92a7-f789468c4c4c",
        "primaryId": "NCT00270894",
        "statement_text": "60% of Subjects in the primary trial were able to Complete at least 85% of the Planned Dose on Schedule ",
        "statement_nums": [
            "60% of",
            "85% of"
        ],
        "label": "Entailment",
        "premise_text": "Arm/Group Description: Neoadjuvant therapy will consist of epirubicin (100 mg/m^2) + cyclophosphamide (600 mg/m^2) every 2 weeks for 4 cycles; followed by a 3-week break; followed by docetaxel (75 mg/m^2) every 2 weeks for 4 cycles + trastuzumab (6 mg/kg [loading dose] once then 4 mg/kg [maintenance dose]) every 2 weeks for 4 treatments Overall Number of Participants Analyzed: 30 Measure Type: Number Unit of Measure: percentage of participants 60 ",
        "premise_nums": [
            "4 treatments Overall",
            "4 mg/kg",
            "30 Measure Type:",
            "2 weeks for",
            "3-week break"
        ]
    },
    {
        "id": "da2ea2e9-3109-433e-9033-9ae322c30c4b",
        "primaryId": "NCT00981812",
        "statement_text": "Women who have undergone a breast enlargement procedure in the last 2 years are excluded from the primary trial ",
        "statement_nums": [
            "2 years are"
        ],
        "label": "Entailment",
        "premise_text": "Exclusion Criteria: subject has breast implants ",
        "premise_nums": []
    },
    {
        "id": "c77c8e02-7abb-4b63-8917-01babe5cd372",
        "primaryId": "NCT00863655",
        "statement_text": "There were 5 more cases of Anaemia and 1 more case of Disseminated intravascular coagulation in cohort 1 of the primary trial compared to cohort 2.",
        "statement_nums": [
            "5 more cases",
            "1 of the",
            "1 more case"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 158/482 (32.78%) Anaemia 7/482 (1.45%) Disseminated intravascular coagulation 1/482 (0.21%) Adverse Events 2: Total: 37/238 (15.55%) Anaemia 2/238 (0.84%) Disseminated intravascular coagulation 0/238 (0.00%) ",
        "premise_nums": [
            "37/238 (15.55%)",
            "1/482 (0.21%)",
            "2/238 (0.84%)",
            "158/482 (32.78%)",
            "0/238 (0.00%)",
            "7/482 (1.45%)"
        ]
    },
    {
        "id": "f2b14720-6ff2-4ff7-a5bc-3841b93f647e",
        "primaryId": "NCT00911898",
        "statement_text": "the primary trial does not explain its intervention in the intervention section ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "INTERVENTION 1: MM-111 All participants ",
        "premise_nums": [
            "111 All participants"
        ]
    },
    {
        "id": "03e9368b-18a7-4643-a38b-a7b002403bf1",
        "primaryId": "NCT00568022",
        "secondaryId": "NCT01120184",
        "label": "Contradiction",
        "statement_text": "Completely disabled patients below the age of 20, totally confined to bed or chair and unable to carry on any selfcare are eligible for the primary trial but excluded from the secondary trial ",
        "statement_nums": [],
        "premise_text": "Inclusion Criteria: Women 20 years Histologically or cytologically confirmed diagnosis of adenocarcinoma originating in the breast Exclusion Criteria: Number of prior chemotherapy lines of treatment in the metastatic setting 3 Inclusion Criteria: Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1 ",
        "premise_nums": [
            "3 Inclusion Criteria:",
            "20 years Histologically",
            "0 or 1"
        ]
    },
    {
        "id": "c5dbd52d-01d4-4919-bfe9-2b7885490d6a",
        "primaryId": "NCT00422903",
        "statement_text": "Percentage of Participants With Clinical Objective Response (cOR) in the Breast  Evaluated by an Independent Radiological Evaluation Monitoring Committee was highest in cohort 2.",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Percentage of Participants With Clinical Objective Response (cOR) in the Breast  Evaluated by an Independent Radiological Evaluation Monitoring Committee ",
        "premise_nums": []
    },
    {
        "id": "c5dbd52d-01d4-4919-bfe9-2b7885490d6a",
        "primaryId": "NCT00422903",
        "statement_text": "Percentage of Participants With Clinical Objective Response (cOR) in the Breast  Evaluated by an Independent Radiological Evaluation Monitoring Committee was highest in cohort 2.",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "cOR is defined as the documented evidence of complete response (CR) and partial response (PR) as assessed by ultrasound examination using Response Evaluation Criteria In Solid Tumors (RECIST)  CR is defined as the disappearance of all target lesions (TLs) and non-TLs and the appearance of no new lesions (NLs)  PR for TLs is defined as a greater than or equal 30% decrease in the sum of the longest diameter (LD) of TLs  taking as a reference the Baseline sum LD  For non-TLs  it is defined as the persistence of greater than or equal 1 non-TL and no new TLs or non-TLs Time frame: From Baseline (Day 1) up to 6 months  evaluated every 12 weeks Results 1: ",
        "premise_nums": [
            "30% decrease",
            "1 non-TL and",
            "12 weeks Results"
        ]
    },
    {
        "id": "c5dbd52d-01d4-4919-bfe9-2b7885490d6a",
        "primaryId": "NCT00422903",
        "statement_text": "Percentage of Participants With Clinical Objective Response (cOR) in the Breast  Evaluated by an Independent Radiological Evaluation Monitoring Committee was highest in cohort 2.",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Arm/Group Title: Letrozole + PlaceboArm/Group Description: Letrozole tablets in the dose of 2.5 milligrams (mg) plus matching placebo were administered orally once daily for 6 months prior to surgery  Overall Number of Participants Analyzed: 48 Measure Type: Number Unit of Measure: percentage of participants CR: 2 PR: 58 Results 2: Arm/Group Title: Letrozole + Lapatinib Arm/Group Description: Letrozole tablets in the dose of 2.5 mg plus lapatinib ditosylate monohydrate tablets in the dose of 1500 mg were administered orally once daily for 6 months prior to surgery  Overall Number of Participants Analyzed: 41 Measure Type: Number ",
        "premise_nums": [
            "6 months prior",
            "58 Results 2:",
            "41 Measure Type:",
            "of 2.5 mg plus",
            "1500 mg were",
            "48 Measure Type:",
            "5 milligrams (mg)"
        ]
    },
    {
        "id": "c5dbd52d-01d4-4919-bfe9-2b7885490d6a",
        "primaryId": "NCT00422903",
        "statement_text": "Percentage of Participants With Clinical Objective Response (cOR) in the Breast  Evaluated by an Independent Radiological Evaluation Monitoring Committee was highest in cohort 2.",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Unit of Measure: percentage of participants CR: 12PR: 54 ",
        "premise_nums": []
    },
    {
        "id": "83115abd-1c07-4ee7-8ba5-b4575be2d50f",
        "primaryId": "NCT00630032",
        "secondaryId": "NCT00428922",
        "label": "Contradiction",
        "statement_text": "Patients with radiologically confirmed bone metatases are excluded from both the secondary trial and the primary trial ",
        "statement_nums": [],
        "premise_text": "Exclusion criteria: Clinically or radiologically detectable metastases (M0) Histologically confirmed breast cancer with evidence of metastatic disease HER2 3+ or FISH (fluorescent in situ hybridization)+ Age 18 years No prior trastuzumab  except as given in the adjuvant or neoadjuvant setting  No prior chemotherapy in the metastatic setting  Exclusion Criteria: CNS (central nervous system) metastases Prior radiation therapy within the last 4 weeks Pregnant (positive pregnancy test) or lactating women Major surgical procedure  open biopsy  non-healing wounds  or significant traumatic injury within 28 days prior to starting study or anticipation of need for major surgical procedure during the study Minor surgical procedures such as fine needle aspirations or core biopsies within 7 days prior to start of study  ",
        "premise_nums": [
            "18 years No",
            "(M0) Histologically",
            "28 days prior",
            "4 weeks Pregnant",
            "7 days prior"
        ]
    },
    {
        "id": "784872db-8ccf-4ddc-a432-6ee00fd0b0cc",
        "primaryId": "NCT01857882",
        "secondaryId": "NCT01439945",
        "label": "Entailment",
        "statement_text": "the secondary trial administers Magnesium Oxide to its patients whereas the primary trial tests an education intervention ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Decision Support Workshop The decision support workshop will be 2 hours in duration on the morning of the consultation and will be facilitated by a dedicated social worker from psycho-oncology  Decision Support Workshop: Incorporates the key components of shared decision-making and decision support with the philosophy of delivering supportive care to cancer patients  Surgeon (30 mins): treatment options for breast reconstruction with indications/ contraindications  advantages / disadvantages  expected post-operative course  aesthetic result and complications with probabilities Registered nurse (30 mins): preparing for surgery  postoperative recovery and how to navigate the health care system Social worker (30 mins): values clarification exercise Breast reconstruction patient volunteer (30 mins) questions and answers about her personal experience INTERVENTION 2: Standard Care Routine pre-consultation education INTERVENTION 1: ",
        "premise_nums": [
            "2 hours in"
        ]
    },
    {
        "id": "784872db-8ccf-4ddc-a432-6ee00fd0b0cc",
        "primaryId": "NCT01857882",
        "secondaryId": "NCT01439945",
        "label": "Entailment",
        "statement_text": "the secondary trial administers Magnesium Oxide to its patients whereas the primary trial tests an education intervention ",
        "statement_nums": [],
        "premise_text": "Low Dose Magnesium Oxide (800 mg/Day)Week 2: Patients take one 400 mg tablet of magnesium oxide orally (PO) daily (QD)  Week 3: Patients take two 400 mg tablet of magnesium oxide orally (PO) daily (QD)  Weeks 4-9: Patients take two 400 mg tablet of magnesium oxide orally (PO) daily (QD)  INTERVENTION 2: High Dose Magnesium Oxide (1200 mg/Day) Week 2: Patients take one 400 mg tablet of magnesium oxide orally (PO) daily (QD)  Week 3: Patients take two 400 mg tablet of magnesium oxide orally (PO) daily (QD)  Weeks 4-9: Patients take three 400 mg tablet of magnesium oxide orally (PO) daily (QD)  ",
        "premise_nums": [
            "400 mg tablet",
            "4-9: Patients"
        ]
    },
    {
        "id": "adae7d81-bc8e-48e4-b966-27c2633eb72d",
        "primaryId": "NCT02131064",
        "statement_text": "over 100 participants in the TCH + P group of the primary trial achieved Total Pathological Complete Response (tpCR) Assessed Based on Tumor Samples ",
        "statement_nums": [
            "100 participants in"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Percentage of Participants With Total Pathological Complete Response (tpCR) Assessed Based on Tumor Samples tpCR was assessed by local pathology review on samples taken at surgery following completion of neoadjuvant therapy  tpCR was defined as the absence of any residual invasive cancer on hematoxylin and eosin evaluation of the resected breast specimen and all sampled ipsilateral lymph nodes ( that is [i.e.]  ypT0/is, ypN0 in the American Joint Committee on Cancer [AJCC] staging system  7th edition)  Percentage of participants with tpCR was reported  Time frame: Pre-surgery (within 6 weeks after neoadjuvant therapy; up to approximately 6 months) Results 1: ",
        "premise_nums": [
            "6 weeks after",
            "0 in the",
            "0/is, ypN0"
        ]
    },
    {
        "id": "adae7d81-bc8e-48e4-b966-27c2633eb72d",
        "primaryId": "NCT02131064",
        "statement_text": "over 100 participants in the TCH + P group of the primary trial achieved Total Pathological Complete Response (tpCR) Assessed Based on Tumor Samples ",
        "statement_nums": [
            "100 participants in"
        ],
        "label": "Entailment",
        "premise_text": "Arm/Group Title: TCH + P",
        "premise_nums": []
    },
    {
        "id": "4ee4061e-a532-459e-8d03-3055bd92419c",
        "primaryId": "NCT00082810",
        "statement_text": "Throughout the duration of the primary trial  pariticpants receive tipifarnib more often than Fulvestrant ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "INTERVENTION 1: Fulvestrant 250 mg + Tipifarnib 300 mg Patients receive fulvestrant 250 mg intramuscularly on day 1 and oral tipifarnib 300 mg twice daily on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity ",
        "premise_nums": [
            "250 mg intramuscularly",
            "28 days in",
            "1-21. Courses",
            "300 mg Patients",
            "1 and oral",
            "300 mg twice"
        ]
    },
    {
        "id": "4cbb7f8f-ea60-453d-b4ab-e967944426d3",
        "primaryId": "NCT00992225",
        "statement_text": "Only 2 of the 16 adverse event types recorded in the primary trial  occurred more than once ",
        "statement_nums": [
            "2 of the",
            "16 adverse event"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 10/33 (30.30%) Constipation 1/33 (3.03%) Dysphagia 1/33 (3.03%) Ileus 1/33 (3.03%) Nausea 1/33 (3.03%) Vomiting 1/33 (3.03%) Fatigue 1/33 (3.03%) Pain 1/33 (3.03%) Sepsis 2/33 (6.06%) Urinary tract infection 1/33 (3.03%) Alanine aminotransferase increased 1/33 (3.03%) Aspartate aminotransferase increased 1/33 (3.03%) Dehydration 2/33 (6.06%) ",
        "premise_nums": [
            "1/33 (3.03%)",
            "2/33 (6.06%)",
            "10/33 (30.30%)"
        ]
    },
    {
        "id": "47f11df7-6c82-4c50-9249-5085313a5064",
        "primaryId": "NCT00209092",
        "secondaryId": "NCT00631852",
        "label": "Entailment",
        "statement_text": "A patient with a cytologically confirmed breast cancer with a 5 millimeter greatest diameter on imaging would be accepted for the primary trial  but not for the secondary trial ",
        "statement_nums": [
            "5 millimeter greatest"
        ],
        "premise_text": "Inclusion Criteria: Histologically or cytologically confirmed breast carcinoma  Inclusion Criteria: Patients with cytologically confirmed breast cancer with biopsy showing invasive or non-invasive (DCIS) at least 1.0 cm greatest diameter on imaging ",
        "premise_nums": [
            "least 1.0 cm greatest"
        ]
    },
    {
        "id": "3114ff0f-184c-48ba-b33d-631505cffeef",
        "primaryId": "NCT01961544",
        "statement_text": "the primary trial reported a combined total of 3 cases of Ascites  Asthenia and Gastritis in cohort 1.",
        "statement_nums": [
            "3 cases of"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Ascites * 1/101 (0.99%) Gastritis * 1/101 (0.99%) Asthenia * 1/101 (0.99%) ",
        "premise_nums": [
            "1/101 (0.99%)"
        ]
    },
    {
        "id": "edf31a43-a774-4f2a-8a02-89b84de941bb",
        "primaryId": "NCT02595372",
        "statement_text": "27.6% of Patients Who Have Fatty Acid Synthase (FASN) Expression in the primary trial treated with High Dose Omeprazole did not have Pathological Complete Response ",
        "statement_nums": [
            "27.6% of"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Percentage of Patients With Pathological Complete Response (pCR) in Patients Who Have Fatty Acid Synthase (FASN) Expression pCR is defined as no invasive disease in the breast of axilla at the time of definitive surgery  A patient is considered to have FASN expression if the positivity was greater than or equal 15% at the baseline or after 4-7 days of Omeprazole monotherapy  FASN expression is evaluated using immunohistochemistry in core biopsy samples  The percent of patients with FASN expression that have pCR will be calculated with an exact 95% confidence interval  Time frame: Up to 6 months Results 1: ",
        "premise_nums": [
            "95% confidence",
            "6 months Results",
            "4-7 days",
            "7 days of",
            "15% at"
        ]
    },
    {
        "id": "edf31a43-a774-4f2a-8a02-89b84de941bb",
        "primaryId": "NCT02595372",
        "statement_text": "27.6% of Patients Who Have Fatty Acid Synthase (FASN) Expression in the primary trial treated with High Dose Omeprazole did not have Pathological Complete Response ",
        "statement_nums": [
            "27.6% of"
        ],
        "label": "Entailment",
        "premise_text": "Arm/Group Title: High Dose Omeprazole TreatmentArm/Group Description: Patients will be treated with omeprazole 80 mg orally BID beginning 4-7 days prior to chemotherapy and continuing until surgery  Overall Number of Participants Analyzed: 29 Measure Type: Number Unit of Measure: percentage of participants 72.4 (52.8 to 87.3) ",
        "premise_nums": [
            "7 days prior",
            "4-7 days",
            "29 Measure Type:",
            "80 mg orally",
            "8 to 87.3)"
        ]
    },
    {
        "id": "ffdc4c5b-a091-4fa6-b2c1-49a131d7d109",
        "primaryId": "NCT01596751",
        "secondaryId": "NCT00193050",
        "label": "Contradiction",
        "statement_text": "There were at least 15 patients with Dysphagia or Fever between the primary trial and the secondary trial patient cohorts ",
        "statement_nums": [
            "15 patients with"
        ],
        "premise_text": "Dysphagia 0/5 (0.00%) Fever 0/5 (0.00%) Adverse Events 1: Total: 17/110 (15.45%) Hemoglobin [1]1/110 (0.91%) Esophagitis 1/110 (0.91%) Dysphagia 1/110 (0.91%) Nausea/Vomiting 1/110 (0.91%) Nausea 1/110 (0.91%) Fever 1/110 (0.91%) Febrile Neutropenia 11/110 (10.00%) Infection - Other [2]1/110 (0.91%) Infection - Pneumonia 1/110 (0.91%) Dyspnea 2/110 (1.82%) ",
        "premise_nums": [
            "2/110 (1.82%)",
            "1/110 (0.91%)",
            "11/110 (10.00%)",
            "17/110 (15.45%)",
            "0/5 (0.00%)"
        ]
    },
    {
        "id": "ffdc4c5b-a091-4fa6-b2c1-49a131d7d109",
        "primaryId": "NCT01596751",
        "secondaryId": "NCT00193050",
        "label": "Contradiction",
        "statement_text": "There were at least 15 patients with Dysphagia or Fever between the primary trial and the secondary trial patient cohorts ",
        "statement_nums": [
            "15 patients with"
        ],
        "premise_text": "Hypoxia 1/110 (0.91%)",
        "premise_nums": [
            "1/110 (0.91%)"
        ]
    },
    {
        "id": "df3e8e6b-fcfd-4909-bbb5-0d69df23f2c5",
        "primaryId": "NCT00632489",
        "statement_text": "the primary trial uses a set dosage of 1000 mg PO daily of Lapatinib  whereas the dose of Capecitabine changes with patients body weight ",
        "statement_nums": [
            "1000 mg PO"
        ],
        "label": "Contradiction",
        "premise_text": "INTERVENTION 1: LBH589 With Capecitabine MTD  LBH589 with Capecitabine LBH589: LBH589 will be evaluated when administered twice weekly at the following possible dose levels: 20 mg  30 mg  45 mg  and 60 mg  Capecitabine will be paired with LBH589 and will range in dose from 825 mg/m2 to 1250 mg/m2 orally BID 14 of every 21 days  Treatment cycles will be 21 days in length  Once determined safe  10 additional patients will be treated at the determined MTD to further assess safety  Capecitabine: Capecitabine will be administered orally twice daily for 14 days out of every 21 days  INTERVENTION 2: LBH589 and Lapatinib ",
        "premise_nums": [
            "LBH589 With",
            "10 additional patients",
            "589 and will",
            "589 with Capecitabine",
            "14 of every",
            "589 With Capecitabine",
            "589 will be",
            "589 and Lapatinib",
            "LBH589 with",
            "LBH589 and",
            "LBH589 will",
            "2 orally BID",
            "21 days in",
            "14 days out",
            "825 mg/m2 to",
            "2 to 1250",
            "1250 mg/m2 orally"
        ]
    },
    {
        "id": "df3e8e6b-fcfd-4909-bbb5-0d69df23f2c5",
        "primaryId": "NCT00632489",
        "statement_text": "the primary trial uses a set dosage of 1000 mg PO daily of Lapatinib  whereas the dose of Capecitabine changes with patients body weight ",
        "statement_nums": [
            "1000 mg PO"
        ],
        "label": "Contradiction",
        "premise_text": "LBH589 and LapatinibLBH589: LBH589 will be evaluated when administered twice weekly at the following possible dose levels: 20 mg  30 mg  45 mg  and 60 mg  Capecitabine will be paired with LBH589 and will range in dose from 825 mg/m2 to 1250 mg/m2 orally BID 14 of every 21 days  Treatment cycles will be 21 days in length  Once determined safe  10 additional patients will be treated at the determined MTD to further assess safety  Lapatinib: Lapatinib  1000 mg PO daily will be added to this combination  ",
        "premise_nums": [
            "1000 mg PO",
            "589 will be",
            "21 days in",
            "2 to 1250",
            "10 additional patients",
            "14 of every",
            "825 mg/m2 to",
            "589 and will",
            "589 and LapatinibLBH589:",
            "LBH589 will",
            "1250 mg/m2 orally",
            "LBH589 and",
            "2 orally BID"
        ]
    },
    {
        "id": "5a076708-c8d4-4341-9c1d-3ee762f57be5",
        "primaryId": "NCT03456427",
        "secondaryId": "NCT02685566",
        "label": "Contradiction",
        "statement_text": "There are no details concerning the types of imaging that are being used in the intervention sections of the primary trial and the secondary trial",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: All Study Participants: Patient Assisted Compression All subjects will undergo standard of care imaging on one breast  The other breast will be imaged using Patient-Assisted Compression (PAC)  followed by Technologist-controlled (TC) Compression  Patient-Assisted Compression (PAC): The technologist will properly position the breast and apply minimum compression  The subject will be instructed to apply compression as the technologist ensures the breast tissue is in appropriate position and tautness  The technologist will then guide the subject to achieve appropriate compression level  sufficient but not excessive  and the image will be acquired  This will be done for both standard views CC & MLO  INTERVENTION 2: All Study Participants: Technologist Compression ",
        "premise_nums": []
    },
    {
        "id": "5a076708-c8d4-4341-9c1d-3ee762f57be5",
        "primaryId": "NCT03456427",
        "secondaryId": "NCT02685566",
        "label": "Contradiction",
        "statement_text": "There are no details concerning the types of imaging that are being used in the intervention sections of the primary trial and the secondary trial",
        "statement_nums": [],
        "premise_text": "All subjects will undergo standard of care imaging on one breast  The other breast will be imaged using Patient-Assisted Compression (PAC)  followed by Technologist-controlled (TC) Compression Technologist-Controlled (TC) Compression: TC compression will be conducted per standard of care practices at the site  INTERVENTION 1: FFDM Plus DBT Breast Images with FFDM and DBT FFDM Plus DBT: FujiFilm Aspire Cristalle System  ",
        "premise_nums": []
    },
    {
        "id": "98a946b0-2be1-474c-b373-043f329ba261",
        "primaryId": "NCT02038010",
        "secondaryId": "NCT00764322",
        "label": "Entailment",
        "statement_text": "Neither the primary trial or the secondary trial are measuring Percentage of Participants With Overall Response Rate (ORR) Following Administration of Ispinesib ",
        "statement_nums": [],
        "premise_text": "Outcome Measurement: Dose Limiting Toxicity (DLT) of Dose-escalating BYL719 in Combination With T-DM1 DLTs of BYL719 in combination with T-DM1 will be assessed using National Cancer Institute's Common Toxicity Criteria for adverse events version 4.0 (except for hyperglycemia)  A DLT is described any grade 3 or higher  clinically significant toxicity (excluding alopecia) experienced during the first 21 days following first dose of BYL719 that is determined to be at least possibly related to study medication  Lower grades may also be considered DLTs if they lead to a dose interruption of more than 7 consecutive days of BYL719. In general adverse events (AEs) will be graded according to the following: ",
        "premise_nums": [
            "21 days following",
            "719 that is",
            "BYL719 that",
            "719 in Combination",
            "1 will be",
            "719 in combination",
            "BYL719 in",
            "7 consecutive days",
            "3 or higher",
            "1 DLTs of"
        ]
    },
    {
        "id": "98a946b0-2be1-474c-b373-043f329ba261",
        "primaryId": "NCT02038010",
        "secondaryId": "NCT00764322",
        "label": "Entailment",
        "statement_text": "Neither the primary trial or the secondary trial are measuring Percentage of Participants With Overall Response Rate (ORR) Following Administration of Ispinesib ",
        "statement_nums": [],
        "premise_text": "Grade 1 Mild AE Grade 2 Moderate AE Grade 3 Severe AE Grade 4 Life-threatening or disabling AE Grade 5 Death related to AETime frame: The 1st 21 days (Cycle 1) of treatment Outcome Measurement: Endoxifen Concentrations in Participants Receiving Tamoxifen Citrate Dose of 20 mg or 40 mg Stratified by the Metabolizing CYP2D6 Genotypes ",
        "premise_nums": [
            "4 Life-threatening or",
            "40 mg Stratified",
            "21 days (Cycle",
            "1 Mild AE",
            "3 Severe AE",
            "5 Death related",
            "2 Moderate AE",
            "20 mg or"
        ]
    },
    {
        "id": "98a946b0-2be1-474c-b373-043f329ba261",
        "primaryId": "NCT02038010",
        "secondaryId": "NCT00764322",
        "label": "Entailment",
        "statement_text": "Neither the primary trial or the secondary trial are measuring Percentage of Participants With Overall Response Rate (ORR) Following Administration of Ispinesib ",
        "statement_nums": [],
        "premise_text": "Measurements of plasma concentrations of the key active metabolite of tamoxifen  endoxifen  were measured at baseline and after 4 months of treatment; The most common CYP2D6 alleles have been grouped by functional activity classifications with descending activity: ultra-rapid (UM)  extensive (EM)  intermediate (IM) or poor (PM) metabolism  A given patient has two alleles  giving them 10 possible allelic combinations  or diplotypes (UM/UM  UM/EM  EM/EM  etc.)  These diplotypes are collapsed into four phenotypes  UM  EM  IM or PM Time frame: 4 months ",
        "premise_nums": [
            "6 alleles have",
            "4 months of",
            "10 possible allelic"
        ]
    },
    {
        "id": "b82e6861-3908-43e9-8e54-cf60c7d96a4e",
        "primaryId": "NCT00721409",
        "secondaryId": "NCT02413320",
        "label": "Entailment",
        "statement_text": "Patients with ER-positive tumours are eligible for the primary trial but not for the secondary trial ",
        "statement_nums": [],
        "premise_text": "Inclusion Criteria: Inoperable estrogen receptor positive and HER2 negative breast cancer  Inclusion Criteria: Patients with newly diagnosed stage I (Tgreater than 1cm), II or III triple negative breast cancer who have not had definitive breast surgery or received systemic chemotherapy ",
        "premise_nums": [
            "2 negative breast"
        ]
    },
    {
        "id": "b8e5baf7-ddc5-407f-84d3-4c93224477cd",
        "primaryId": "NCT02445586",
        "secondaryId": "NCT02115984",
        "label": "Entailment",
        "statement_text": "More than half of patients in the primary trial experienced adverse events  and there was not a single patient in either cohort of the secondary trial that did not experience an adverse event ",
        "statement_nums": [],
        "premise_text": "Adverse Events 1: Total: 31/52 (59.62%) Febrile neutropenia 2/52 (3.85%) Left ventricular dysfunction 2/52 (3.85%) Sinus tachycardia 1/52 (1.92%) Congenital arterial malformation 1/52 (1.92%) Diarrhoea 5/52 (9.62%) Salivary hypersecretion 1/52 (1.92%) Enteritis 1/52 (1.92%) Abdominal pain 1/52 (1.92%) Vomiting 1/52 (1.92%) Stomatitis 1/52 (1.92%) ",
        "premise_nums": [
            "5/52 (9.62%)",
            "2/52 (3.85%)",
            "1/52 (1.92%)",
            "31/52 (59.62%)"
        ]
    },
    {
        "id": "b8e5baf7-ddc5-407f-84d3-4c93224477cd",
        "primaryId": "NCT02445586",
        "secondaryId": "NCT02115984",
        "label": "Entailment",
        "statement_text": "More than half of patients in the primary trial experienced adverse events  and there was not a single patient in either cohort of the secondary trial that did not experience an adverse event ",
        "statement_nums": [],
        "premise_text": "Haematemesis 1/52 (1.92%)Adverse Events 1: Total: 57/57 (100.00%) Dry eyes 13/33 (39.39%) Heartburn 9/33 (27.27%) Nausea after the CT (before day 7) 57/57 (100.00%) Herpetic eruption 0/33 (0.00%) Dry skin 15/33 (45.45%) Alopecia 57/57 (100.00%) Adverse Events 2: Total: 23/23 (100.00%) Dry eyes 2/11 (18.18%) Heartburn 2/11 (18.18%) Nausea after the CT (before day 7) 23/23 (100.00%) ",
        "premise_nums": [
            "9/33 (27.27%)",
            "23/23 (100.00%)",
            "0/33 (0.00%)",
            "1/52 (1.92%)Adverse",
            "57/57 (100.00%)",
            "15/33 (45.45%)",
            "2/11 (18.18%)",
            "13/33 (39.39%)"
        ]
    },
    {
        "id": "b8e5baf7-ddc5-407f-84d3-4c93224477cd",
        "primaryId": "NCT02445586",
        "secondaryId": "NCT02115984",
        "label": "Entailment",
        "statement_text": "More than half of patients in the primary trial experienced adverse events  and there was not a single patient in either cohort of the secondary trial that did not experience an adverse event ",
        "statement_nums": [],
        "premise_text": "Herpetic eruption 3/11 (27.27%)Dry skin 9/11 (81.82%) Alopecia 23/23 (100.00%) ",
        "premise_nums": [
            "23/23 (100.00%)",
            "9/11 (81.82%)",
            "3/11 (27.27%)Dry"
        ]
    },
    {
        "id": "79c34b71-a90f-4ddb-9aee-5f61f71f0846",
        "primaryId": "NCT01277757",
        "statement_text": "the primary trial is not testing a novel Physiotherapy or chemotherapy intervention ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "INTERVENTION 1: Akt Inhibitor MK-2206 Akt Inhibitor MK-2206 orally once a week on days 1, 8, 15, and 22. Starting dose 200 mg  courses repeat every 28 days  ",
        "premise_nums": [
            "2206 Akt Inhibitor",
            "2206 orally once"
        ]
    },
    {
        "id": "e1f6d1b3-92eb-4ad8-8c00-e44b58650e62",
        "primaryId": "NCT02995980",
        "statement_text": "A patient presenting Glomerular filtration rate of 63 and with BI-RADS category c breast tissue would be eligilbe for the primary trial ",
        "statement_nums": [
            "63 and with"
        ],
        "label": "Entailment",
        "premise_text": "Inclusion Criteria: Glomerular filtration rategreater than 60 Heterogeneously or extremely dense breasts (BI-RADS category c or d)  ",
        "premise_nums": [
            "60 Heterogeneously or"
        ]
    },
    {
        "id": "02d5fe7a-60e2-422f-98c0-92461b8fa13f",
        "primaryId": "NCT00438659",
        "secondaryId": "NCT01271725",
        "label": "Contradiction",
        "statement_text": "the primary trial and the secondary trial have a topical intervention  to be applied to the breast or face ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Mometasone Patients apply 2.5 mL mometasone furoate cream once daily to the treatment area (breast or chest wall) for the duration of planned radiotherapy  INTERVENTION 2: Placebo Patients apply 2.5 mL of an identical-appearing placebo cream to the treatment area as in arm A  INTERVENTION 1: Afatinib Monotherapy Patient received Afatinib monotherapy orally once daily at a dose of 40 milligram (mg) film-coated tablets until progression of their disease  unacceptable adverse events or other reason necessitating withdrawal  Patients could have dose reduced if 40 mg was not tolerated  INTERVENTION 2: Afatinib and Paclitaxel or Vinorelbine Combination Therapy ",
        "premise_nums": [
            "apply 2.5 mL of",
            "40 mg was",
            "apply 2.5 mL mometasone",
            "40 milligram (mg)"
        ]
    },
    {
        "id": "02d5fe7a-60e2-422f-98c0-92461b8fa13f",
        "primaryId": "NCT00438659",
        "secondaryId": "NCT01271725",
        "label": "Contradiction",
        "statement_text": "the primary trial and the secondary trial have a topical intervention  to be applied to the breast or face ",
        "statement_nums": [],
        "premise_text": "Patient received Afatinib monotherapy orally once daily at a dose of 40 mg film-coated tablets until progression of their disease  unacceptable adverse events or other reason necessitating withdrawal (Patients could have dose reduced if 40 mg was not tolerated) and 80 mg/square meter (m2) Paclitaxel concentrate for intravenous infusion or 25 mg/m2 Vinorelbine concentrate for intravenous infusion once weekly starting after treatment failure on afatinib monotherapy",
        "premise_nums": [
            "40 mg film",
            "(m2) Paclitaxel",
            "80 mg/square meter",
            "25 mg/m2 Vinorelbine",
            "2 Vinorelbine concentrate",
            "40 mg was"
        ]
    },
    {
        "id": "869e413e-01c5-4a9e-8a4a-b6079f7ae300",
        "primaryId": "NCT00996632",
        "secondaryId": "NCT01644890",
        "label": "Contradiction",
        "statement_text": "Emily has an Inoperable non-metastatic breast cancer  she is eligible for both the secondary trial and the primary trial ",
        "statement_nums": [],
        "premise_text": "Inclusion Criteria: Inoperable breast cancer Inclusion Criteria: Written informed consent of the patient signed by herself  Histologically confirmed metastatic or recurrent adenocarcinoma of the breast  Aged 20 to 74 at the time of informed consent  Exclusion Criteria: Prior systemic chemotherapy with taxane anticancer drugs for metastatic or recurrent breast cancer  ",
        "premise_nums": [
            "20 to 74"
        ]
    },
    {
        "id": "c0b528ef-ae9f-4c01-8915-b47856f07c95",
        "primaryId": "NCT01142661",
        "statement_text": "the primary trial accepts patients with grade 3 neuropathy ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Exclusion Criteria Subjects who meet any of the following criteria will be excluded from participation in the treatment protocol: Existing anti-cancer therapy-related toxicities of Grade greater than /= 2, except that alopecia and Grade 2 neuropathy are acceptable  ",
        "premise_nums": [
            "2 neuropathy are"
        ]
    },
    {
        "id": "b6e484ff-d0c7-48bc-ab98-f0bd570d4b4e",
        "primaryId": "NCT01743560",
        "statement_text": "By week 48 of the primary trial the majority of patients had Stable Disease  none of them had complete or partial response ",
        "statement_nums": [
            "48 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Best Overall Response of Everolimus and Exemestane Treatment in Postmenopausal Women With Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer ",
        "premise_nums": []
    },
    {
        "id": "b6e484ff-d0c7-48bc-ab98-f0bd570d4b4e",
        "primaryId": "NCT01743560",
        "statement_text": "By week 48 of the primary trial the majority of patients had Stable Disease  none of them had complete or partial response ",
        "statement_nums": [
            "48 of the"
        ],
        "label": "Contradiction",
        "premise_text": "The best Overall Response (OR) for each patient is determined from the sequence of investigator overall lesion responses according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1.). To be assigned a best OR of Complete Responese (CR) at least two determinations of CR at least 4 weeks apart before progression are required  To be assigned a best OR of Partial Response (PR) at least two determinations of PR or better at least 4 weeks apart before progression (and not qualifying for a CR) are required.The Overall Response Rate (ORR) was defined as the proportion of patients with a best OR of confirmed CR or PR by week 48.Time frame: At 48 weeks Results 1: Arm/Group Title: Everolimus and Exemestane ",
        "premise_nums": [
            "4 weeks apart",
            "48 weeks Results"
        ]
    },
    {
        "id": "b6e484ff-d0c7-48bc-ab98-f0bd570d4b4e",
        "primaryId": "NCT01743560",
        "statement_text": "By week 48 of the primary trial the majority of patients had Stable Disease  none of them had complete or partial response ",
        "statement_nums": [
            "48 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Arm/Group Description: Postmenopausal women diagnosed with oestrogen receptor positive locally advanced or metastatic breast cancer will receive everolimus at a dose of 10mg daily p.o  and exemestane 25mg daily p.o Overall Number of Participants Analyzed: 49 Measure Type: Number Unit of Measure: participants Patients with measurable disease at baseline: 39 Patients with non-measurable disease at baseline: 10 Best at WK 48 - Complete Response (CR): 0 Best at WK 48 - Partial Response (PR): 7 Best at WK 48 - Stable Disease (SD): 18 Best at WK 48 - Progressive Disease (PD): 15 Unknown: 1 Missing: 8 ",
        "premise_nums": [
            "39 Patients with",
            "18 Best at",
            "49 Measure Type:",
            "7 Best at",
            "10 Best at"
        ]
    },
    {
        "id": "da15fae6-7fa1-4fe0-b61c-e043df3e9e74",
        "primaryId": "NCT01011946",
        "statement_text": "All patients in the primary trial must have a bilateral breast MRI prior to study entry ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Exclusion Criteria: Patients who have NOT undergone a standard of care bilateral breast MRI at UC  ",
        "premise_nums": []
    },
    {
        "id": "8ce665b5-20fb-44a3-b3c9-25493e8dd7ff",
        "primaryId": "NCT02455453",
        "statement_text": "Patients with tumors that are HER2 negative  PR and ER positive are eligible for the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Inclusion Criteria: Patient must have any one of the following types of breast cancer (primary or metastatic): ER+/PgR+/HER2- or ER+/PgR-/HER2-. ",
        "premise_nums": []
    },
    {
        "id": "01236718-14da-450c-8051-0207d31743a5",
        "primaryId": "NCT02555657",
        "statement_text": "The Median time from randomization to death due to any cause  was a month longer for patients in cohort 1 of the primary trial  compared to those in cohort 2.",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Overall Survival in Participants With Programmed Cell Death Ligand 1 (PD-L1) With Combined Positive Score (CPS) 10 Overall survival (OS) was defined as the time from randomization to death due to any cause  Time frame: Up to approximately 36 months (through Final Analysis database cutoff date of 11-April-2019) Results 1: Arm/Group Title: Pembrolizumab Arm/Group Description: Participants received pembrolizumab 200 mg IV every Q3W for up to 35 administrations (up to ~2 years)  Overall Number of Participants Analyzed: 96 Median (95% Confidence Interval) Unit of Measure: Months 12.7 (9.9 to 16.3) Results 2: ",
        "premise_nums": [
            "200 mg IV",
            "10 Overall survival",
            "35 administrations (up",
            "95% Confidence",
            "11-April-2019) Results",
            "36 months (through",
            "9 to 16.3)"
        ]
    },
    {
        "id": "01236718-14da-450c-8051-0207d31743a5",
        "primaryId": "NCT02555657",
        "statement_text": "The Median time from randomization to death due to any cause  was a month longer for patients in cohort 1 of the primary trial  compared to those in cohort 2.",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Arm/Group Title: ChemotherapyArm/Group Description: Participants received capecitabine  eribulin  gemcitabine  or vinorelbine as single agent chemotherapy chosen by the treating physician (Treatment of Physician's Choice  TPC) in accordance with local regulations and guidelines  Overall Number of Participants Analyzed: 98 Median (95% Confidence Interval) Unit of Measure: Months 11.6 (8.3 to 13.7) ",
        "premise_nums": [
            "95% Confidence",
            "3 to 13.7)"
        ]
    },
    {
        "id": "3419af1a-7923-419d-a673-2de96d41eabb",
        "primaryId": "NCT03719677",
        "statement_text": "Potential participants will be considered regardless of the hormone receptivity of their breast cancer  except if they are overexpressing ERBB2.",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Will not exclude participants based on hormone receptivity  one exception is that we will exclude HER2 positive BCS ",
        "premise_nums": [
            "2 positive BCS"
        ]
    },
    {
        "id": "2048912d-9e9f-4cbc-89cc-19020f20a976",
        "primaryId": "NCT01966471",
        "secondaryId": "NCT00981812",
        "label": "Entailment",
        "statement_text": "A patient who had a total bilateral mastectomy in the year prior to study entry would be excluded from both the primary trial and the secondary trial ",
        "statement_nums": [],
        "premise_text": "Inclusion Criteria: Known hormone receptor status of the primary tumor Adequately excised: participants must have undergone either breast-conserving surgery or mastectomy/nipple- or skin-sparing mastectomy Exclusion Criteria: subject has had surgery or radiation therapy on the study breast or has had chemotherapy within the past 12 months ",
        "premise_nums": []
    },
    {
        "id": "f5907902-d4d1-4d73-a196-7fbe0dcb44ad",
        "primaryId": "NCT00245219",
        "secondaryId": "NCT00038103",
        "label": "Entailment",
        "statement_text": "the primary trial and the secondary trial both have control groups ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Health Tracking (Control) Participants assigned to the health-tracking condition received usual care and did not attend any meetings  INTERVENTION 2: Peer Support The peer support group meetings focused on fostering purpose in life by providing participants with opportunities to support and care for one another  Patients completed a weekly diary of critical experiences or current life problems as homework  and were then encouraged to share these experiences in the group meetings  The group facilitator encouraged participants to help one another with these issues  and share how they had dealt with similar problems  INTERVENTION 1: Exemestane (Exemestane Alone) oral dose exemestane taken with food (25 mg tablet once daily) INTERVENTION 2: Combination (Exemestane + Celecoxib) oral doses to be taken with food (25 mg tablet exemestane once daily; celecoxib 2 x 200 mg tablets twice daily) ",
        "premise_nums": [
            "25 mg tablet",
            "2 x 200"
        ]
    },
    {
        "id": "93a8e018-ac25-48b2-81d2-fd5b01be8f37",
        "primaryId": "NCT01463007",
        "secondaryId": "NCT00965523",
        "label": "Entailment",
        "statement_text": "A higher number of patients in the secondary trial suffured from infection compared to those in the primary trial ",
        "statement_nums": [],
        "premise_text": "Adverse Events 1: Total: 1/41 (2.44%) Infection 1/41 (2.44%) Creatinine 1/41 (2.44%) Hypokalemia 1/41 (2.44%) Bicarbonate 1/41 (2.44%) SGOT 1/41 (2.44%) Alkaline Phosphatase value 1/41 (2.44%) Hyperbilirubineamia 1/41 (2.44%) Hypoalbuminemia 1/41 (2.44%) Leukocytes 1/41 (2.44%) Hemoglobin 1/41 (2.44%) Neutrophils 1/41 (2.44%) INR 1/41 (2.44%) ",
        "premise_nums": [
            "1/41 (2.44%)"
        ]
    },
    {
        "id": "93a8e018-ac25-48b2-81d2-fd5b01be8f37",
        "primaryId": "NCT01463007",
        "secondaryId": "NCT00965523",
        "label": "Entailment",
        "statement_text": "A higher number of patients in the secondary trial suffured from infection compared to those in the primary trial ",
        "statement_nums": [],
        "premise_text": "PTT 1/41 (2.44%)Adverse Events 1: Total: 14/81 (17.28%) Neutropenia1/81 (1.23%) Cataract1/81 (1.23%) Ascites1/81 (1.23%) Gastritis Hemorrhagic1/81 (1.23%) Nausea1/81 (1.23%) Stomatitis2/81 (2.47%) Malaise1/81 (1.23%) Oedema1/81 (1.23%) Pain1/81 (1.23%) Pyrexia1/81 (1.23%) Infection2/81 (2.47%) Upper Limb Fracture1/81 (1.23%) ",
        "premise_nums": [
            "1/41 (2.44%)Adverse",
            "2/81 (2.47%)",
            "14/81 (17.28%)",
            "1/81 (1.23%)"
        ]
    },
    {
        "id": "93a8e018-ac25-48b2-81d2-fd5b01be8f37",
        "primaryId": "NCT01463007",
        "secondaryId": "NCT00965523",
        "label": "Entailment",
        "statement_text": "A higher number of patients in the secondary trial suffured from infection compared to those in the primary trial ",
        "statement_nums": [],
        "premise_text": "Dehydration1/81 (1.23%)Hypercalcemia1/81 (1.23%) ",
        "premise_nums": [
            "1/81 (1.23%)Hypercalcemia1/81"
        ]
    },
    {
        "id": "d72c45e5-6654-4afe-91a0-1f47b0c13dc0",
        "primaryId": "NCT00464646",
        "statement_text": "Anna is a 57 year old female with an ECOG of 0, diagnosed with a HER2-positive invasive adenocarcinoma of the breast  with ipsilateral nodes pN2. She is eligible for the primary trial ",
        "statement_nums": [
            "2-positive invasive",
            "57 year old"
        ],
        "label": "Entailment",
        "premise_text": "Inclusion Criteria: Patients must be female  The patient must be greater than or equal to 18 years old  The patient's ECOG performance status must be 0 or 1. The tumor must be invasive adenocarcinoma of the breast on histologic examination  The breast cancer must be determined to be HER2-positive prior to study entry  Assays performed using FISH require gene amplification  Assays using IHC require a strongly positive (3+) staining score  By pathologic evaluation  ipsilateral nodes must be pN2 or pN3. ",
        "premise_nums": [
            "2-positive prior",
            "2 or pN3.",
            "(3+) staining",
            "18 years old",
            "0 or 1."
        ]
    },
    {
        "id": "e68b5690-11fd-4567-8dcc-dec91d1e4bb8",
        "primaryId": "NCT01033032",
        "statement_text": "The only adverse event recorded in the primary trial was one single case of spinal fracture ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 1/3 (33.33%) FEBRILE NEUTROPENIA 0/3 (0.00%) LYMPH NODE PAIN 0/3 (0.00%) NEUTROPHIL COUNT DECREASED 0/3 (0.00%) THROMBOCYTOPENIA 0/3 (0.00%) CHEST PAIN 0/3 (0.00%) DEHYDRATION 0/3 (0.00%) PLEURAL EFFUSION 1/3 (33.33%) PNEUMONITIS 0/3 (0.00%) PULMONARY INFILTERATES 0/3 (0.00%) ALOPECIA 0/3 (0.00%) ",
        "premise_nums": [
            "0/3 (0.00%)",
            "1/3 (33.33%)"
        ]
    },
    {
        "id": "e1417a26-2f40-4dd6-b598-e66e57312595",
        "primaryId": "NCT01931163",
        "secondaryId": "NCT00274469",
        "label": "Contradiction",
        "statement_text": "Less than 5% of cohort 1 of the primary trial had LACRIMAL DISORDER  0% of the secondary trial patients were recorded as having LACRIMAL DISORDER ",
        "statement_nums": [
            "5% of",
            "1 of the",
            "0% of"
        ],
        "premise_text": "Adverse Events 1: Total: 6/22 (27.27%) Thrombocytopenia 1/22 (4.55%) leucocytopenia 1/22 (4.55%) neutropenia 1/22 (4.55%) papilledema 1/22 (4.55%) Nausea 1/22 (4.55%) hyperglycemia 1/22 (4.55%) Adverse Events 1: Total: 24/101 (23.76%) LYMPHADENOPATHY 0/101 (0.00%) FEBRILE NEUTROPENIA 20/101 (0.00%) ATRIAL FIBRILLATION 1/101 (0.99%) ",
        "premise_nums": [
            "24/101 (23.76%)",
            "6/22 (27.27%)",
            "1/101 (0.99%)",
            "20/101 (0.00%)",
            "1/22 (4.55%)"
        ]
    },
    {
        "id": "e1417a26-2f40-4dd6-b598-e66e57312595",
        "primaryId": "NCT01931163",
        "secondaryId": "NCT00274469",
        "label": "Contradiction",
        "statement_text": "Less than 5% of cohort 1 of the primary trial had LACRIMAL DISORDER  0% of the secondary trial patients were recorded as having LACRIMAL DISORDER ",
        "statement_nums": [
            "5% of",
            "1 of the",
            "0% of"
        ],
        "premise_text": "ARRHYTHMIA 20/101 (0.00%)CARDIAC FAILURE 22/101 (1.98%) CARDIAC FAILURE CONGESTIVE 20/101 (0.00%) CORONARY OSTIAL STENOSIS 20/101 (0.00%) LACRIMAL DISORDER 0/101 (0.00%) BLINDNESS 21/101 (0.99%) GASTRIC ULCER 1/101 (0.99%) NAUSEA 1/101 (0.99%) Adverse Events 2: Total: 22/103 (21.36%) LYMPHADENOPATHY 1/103 (0.97%) FEBRILE NEUTROPENIA 21/103 (0.97%) ",
        "premise_nums": [
            "21/103 (0.97%)",
            "22/103 (21.36%)",
            "21/101 (0.99%)",
            "20/101 (0.00%)CARDIAC",
            "22/101 (1.98%)"
        ]
    },
    {
        "id": "e1417a26-2f40-4dd6-b598-e66e57312595",
        "primaryId": "NCT01931163",
        "secondaryId": "NCT00274469",
        "label": "Contradiction",
        "statement_text": "Less than 5% of cohort 1 of the primary trial had LACRIMAL DISORDER  0% of the secondary trial patients were recorded as having LACRIMAL DISORDER ",
        "statement_nums": [
            "5% of",
            "1 of the",
            "0% of"
        ],
        "premise_text": "ATRIAL FIBRILLATION 1/103 (0.97%)ARRHYTHMIA 21/103 (0.97%) CARDIAC FAILURE 20/103 (0.00%) CARDIAC FAILURE CONGESTIVE 21/103 (0.97%) CORONARY OSTIAL STENOSIS 21/103 (0.97%) LACRIMAL DISORDER 1/103 (0.97%) BLINDNESS 20/103 (0.00%) GASTRIC ULCER 0/103 (0.00%) NAUSEA 0/103 (0.00%) ",
        "premise_nums": [
            "21/103 (0.97%)",
            "1/103 (0.97%)ARRHYTHMIA",
            "20/103 (0.00%)"
        ]
    },
    {
        "id": "6ee89773-958b-4eb9-bc67-18fa98a70c2d",
        "primaryId": "NCT00365365",
        "statement_text": "the primary trial only recorded one type of acute adverse event ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 23/78 (29.49%) Febrile neutropenia * 4/78 (5.13%) Neutropenia * 1/78 (1.28%) Thrombocytopenia * 0/78 (0.00%) Acute coronary syndrome * 1/78 (1.28%) Cardiac failure congestive * 1/78 (1.28%) Myocardial infarction * 1/78 (1.28%) Cardiomyopathy * 0/78 (0.00%) Abdominal pain * 1/78 (1.28%) Diarrhoea * 1/78 (1.28%) Upper gastrointestinal haemorrhage * 1/78 (1.28%) ",
        "premise_nums": [
            "23/78 (29.49%)",
            "0/78 (0.00%)",
            "1/78 (1.28%)",
            "4/78 (5.13%)"
        ]
    },
    {
        "id": "4d776c28-8ed1-4f3f-9837-0821029d3775",
        "primaryId": "NCT00063570",
        "statement_text": "None of the patients in cohort 1 of the primary trial had a platlet deficiency  and none of the patients in cohort 2 were constipated ",
        "statement_nums": [
            "2 were constipated",
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 17 Anaemia 2/52 (3.85%) Febrile neutropenia 4/52 (7.69%) Pancytopenia 1/52 (1.92%) Thrombocytopenia 0/52 (0.00%) Abdominal pain 1/52 (1.92%) Constipation 1/52 (1.92%) Pyrexia 2/52 (3.85%) Hepatic failure 1/52 (1.92%) Hyperbilirubinaemia 1/52 (1.92%) Device related infection 1/52 (1.92%) Pneumonia 2/52 (3.85%) Sepsis 1/52 (1.92%) ",
        "premise_nums": [
            "0/52 (0.00%)",
            "4/52 (7.69%)",
            "17 Anaemia 2",
            "1/52 (1.92%)",
            "2/52 (3.85%)"
        ]
    },
    {
        "id": "4d776c28-8ed1-4f3f-9837-0821029d3775",
        "primaryId": "NCT00063570",
        "statement_text": "None of the patients in cohort 1 of the primary trial had a platlet deficiency  and none of the patients in cohort 2 were constipated ",
        "statement_nums": [
            "2 were constipated",
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 2:Total: 7 Anaemia 0/21 (0.00%) Febrile neutropenia 1/21 (4.76%) Pancytopenia 0/21 (0.00%) Thrombocytopenia 1/21 (4.76%) Abdominal pain 0/21 (0.00%) Constipation 0/21 (0.00%) Pyrexia 1/21 (4.76%) Hepatic failure 0/21 (0.00%) Hyperbilirubinaemia 0/21 (0.00%) Device related infection 0/21 (0.00%) Pneumonia 0/21 (0.00%) Sepsis 0/21 (0.00%) ",
        "premise_nums": [
            "7 Anaemia 0",
            "2:Total: 7",
            "0/21 (0.00%)",
            "1/21 (4.76%)"
        ]
    },
    {
        "id": "50e54a67-9cfb-4259-b810-2e9bc0b09b4c",
        "primaryId": "NCT00611624",
        "secondaryId": "NCT00600340",
        "label": "Contradiction",
        "statement_text": "the primary trial and the secondary trial require patients to undergo a minimum of two weeks of Mammosite Therapy ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Five Days of Mammosite Therapy [Not Specified] INTERVENTION 1: Bevacizumab Plus Paclitaxel Bevacizumab 10 mg/kg intravenous (i.v.)  days 1 and 15, every 4 weeks  Paclitaxel 90 mg/m2, days 1, 8 and 15, every 4 weeks INTERVENTION 2: Bevacizumab Plus Capecitabine Bevacizumab 15 mg/kg i.v.  day 1, every 3 weeks  Capecitabine 1000 mg/m² twice-daily  days 1-14, every 3 weeks ",
        "premise_nums": [
            "4 weeks INTERVENTION",
            "8 and 15,",
            "1000 mg/m²",
            "10 mg/kg intravenous",
            "1-14, every",
            "90 mg/m2,",
            "1 and 15,",
            "15 mg/kg i"
        ]
    },
    {
        "id": "9f23f617-b8ec-4665-ad0b-9a9bc8b19691",
        "primaryId": "NCT00688740",
        "secondaryId": "NCT00191815",
        "label": "Contradiction",
        "statement_text": "The most common adverse events in the primary trial and the secondary trial is Neutropenia with a total of 3 cases across all cohorts ",
        "statement_nums": [
            "3 cases across"
        ],
        "premise_text": "Adverse Events 1: Total: 267/744 (35.89%) Neutropenia *2/744 (0.27%) Anaemia *1/744 (0.13%) Leukopenia *1/744 (0.13%) Thrombocytopenia *1/744 (0.13%) Thrombotic thrombocytopenic purpura *1/744 (0.13%) Atrial flutter *1/744 (0.13%) Cardiac arrest *1/744 (0.13%) Myocardial ischaemia *1/744 (0.13%) Arrhythmia *0/744 (0.00%) ",
        "premise_nums": [
            "0/744 (0.00%)",
            "2/744 (0.27%)",
            "1/744 (0.13%)",
            "267/744 (35.89%)"
        ]
    },
    {
        "id": "9f23f617-b8ec-4665-ad0b-9a9bc8b19691",
        "primaryId": "NCT00688740",
        "secondaryId": "NCT00191815",
        "label": "Contradiction",
        "statement_text": "The most common adverse events in the primary trial and the secondary trial is Neutropenia with a total of 3 cases across all cohorts ",
        "statement_nums": [
            "3 cases across"
        ],
        "premise_text": "Cardiac failure congestive *0/744 (0.00%)Adverse Events 2: Total: 67/736 (9.10%) Neutropenia *1/736 (0.14%) Anaemia *0/736 (0.00%) Leukopenia *0/736 (0.00%) Thrombocytopenia *0/736 (0.00%) Thrombotic thrombocytopenic purpura *0/736 (0.00%) Atrial flutter *0/736 (0.00%) Cardiac arrest *0/736 (0.00%) Myocardial ischaemia *0/736 (0.00%) ",
        "premise_nums": [
            "0/744 (0.00%)Adverse",
            "0/736 (0.00%)",
            "1/736 (0.14%)",
            "67/736 (9.10%)"
        ]
    },
    {
        "id": "9f23f617-b8ec-4665-ad0b-9a9bc8b19691",
        "primaryId": "NCT00688740",
        "secondaryId": "NCT00191815",
        "label": "Contradiction",
        "statement_text": "The most common adverse events in the primary trial and the secondary trial is Neutropenia with a total of 3 cases across all cohorts ",
        "statement_nums": [
            "3 cases across"
        ],
        "premise_text": "Arrhythmia *2/736 (0.27%)Cardiac failure congestive *1/736 (0.14%) Adverse Events 1: Total: 6 Atrial fibrillation 1/67 (1.49%) Ventricular fibrillation 1/67 (1.49%) Gastrointestinal perforation 1/67 (1.49%) Periproctitis 1/67 (1.49%) General physical health deterioration 1/67 (1.49%) Escherichia sepsis 1/67 (1.49%) Pneumonia 1/67 (1.49%) Tumour pain 1/67 (1.49%) Renal failure acute 1/67 (1.49%) ",
        "premise_nums": [
            "6 Atrial fibrillation",
            "1/67 (1.49%)",
            "1/736 (0.14%)",
            "2/736 (0.27%)Cardiac"
        ]
    },
    {
        "id": "9f23f617-b8ec-4665-ad0b-9a9bc8b19691",
        "primaryId": "NCT00688740",
        "secondaryId": "NCT00191815",
        "label": "Contradiction",
        "statement_text": "The most common adverse events in the primary trial and the secondary trial is Neutropenia with a total of 3 cases across all cohorts ",
        "statement_nums": [
            "3 cases across"
        ],
        "premise_text": "Pleurisy 1/67 (1.49%)",
        "premise_nums": [
            "1/67 (1.49%)"
        ]
    },
    {
        "id": "b76c9c21-64f7-487b-bf08-e232a9da0174",
        "primaryId": "NCT01490892",
        "secondaryId": "NCT02364388",
        "label": "Contradiction",
        "statement_text": "The intervention in the primary trial requires an injection and two different imaging modalities  whereas the secondary trial firstly requires a consultation followed by an intensive radiotherapy treatment ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: 3D HI and SHI of UCA Perflutren injection  suspension (IV)0.25 ml followed by 3D Harmonic imaging (HI) then (IV) 20 micro-l/kg followed by 3D subharmonic imaging (SHI) 3D HI and SHI of UCA: Perflutren injection  suspension (IV)0.25 ml followed by 3D Harmonic imaging (HI) then (IV) 20 micro-l/kg followed by 3D subharmonic imaging (SHI) INTERVENTION 1: MAESTRO Baseline ",
        "premise_nums": [
            "25 ml followed",
            "20 micro-l/kg"
        ]
    },
    {
        "id": "66aaca41-f5f9-4ed4-b165-9510b7c64456",
        "primaryId": "NCT03136367",
        "secondaryId": "NCT00129935",
        "label": "Contradiction",
        "statement_text": "Only patients who identify as female are eligible for the secondary trial and the primary trial ",
        "statement_nums": [],
        "premise_text": "Inclusion Criteria: Assigned female at birth; Exclusion Criteria: Transgender men and women; Exclusion Criteria: Males  ",
        "premise_nums": []
    },
    {
        "id": "611317e3-83f9-4e8d-9a9d-3dcda62fb6cb",
        "primaryId": "NCT00206427",
        "statement_text": "A patient in the primary trial had a fungal infection of the mouth ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 3/49 (6.12%) Neutrophils/ANC *1/49 (2.04%) Leukocytes *1/49 (2.04%) Hypocalcemia *1/49 (2.04%) Febrile neutropenia *1/49 (2.04%) Left Ventricular Systolic Dysfunction *1/49 (2.04%) Constipation *1/49 (2.04%) Mucositis-oral *1/49 (2.04%) Infection-oral thrush *1/49 (2.04%) rash *1/49 (2.04%) ",
        "premise_nums": [
            "1/49 (2.04%)",
            "3/49 (6.12%)"
        ]
    },
    {
        "id": "d6b09c0f-979c-4151-87f9-830b964e275d",
        "primaryId": "NCT01216176",
        "statement_text": "Urosepsis was the most common adverse event in the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 3/12 (25.00%) Atrial fibrillation 0/12 (0.00%) Cardiac ischemia/infarction [1]0/12 (0.00%) Congestive Heart Failure [2]0/12 (0.00%) Diverticulitis 0/12 (0.00%) Cholecystitis 0/12 (0.00%) Hyperbilirubinemia 0/12 (0.00%) Urosepsis 2/12 (16.67%) Brain hemorrhage complicating CNS metastasis 1/12 (8.33%) Rash [3]0/12 (0.00%) ",
        "premise_nums": [
            "0/12 (0.00%)",
            "3/12 (25.00%)",
            "2/12 (16.67%)",
            "1/12 (8.33%)"
        ]
    },
    {
        "id": "92da8d30-a7e9-4fb4-95e4-484b53279ad7",
        "primaryId": "NCT01570036",
        "secondaryId": "NCT00021255",
        "label": "Entailment",
        "statement_text": "the primary trial and the secondary trial monitor the DFS of their patient cohorts  however the secondary trial reports the % of patients with DFS greater than or equal 5 years whereas the primary trial reports % of participants with DFS greater than or equal 2 years ",
        "statement_nums": [
            "5 years whereas"
        ],
        "premise_text": "Disease-free Survival (DFS) Disease-free survival (DFS) for all patients regardless of randomization will be determined by patients' own physicians at the individual study sites during routine follow-up screening  This will occur every three months for the first 24 months after completion of primary therapies and every six months thereafter with clinical exam  and laboratory and radiographic surveillance  The primary objective of the study is disease-free survival (DFS) at 24 months  Time frame: Disease-free survival at 24 months Outcome Measurement: Percentage of Participants With Disease Free Survival at 5 Years ",
        "premise_nums": [
            "24 months Outcome",
            "24 months after"
        ]
    },
    {
        "id": "92da8d30-a7e9-4fb4-95e4-484b53279ad7",
        "primaryId": "NCT01570036",
        "secondaryId": "NCT00021255",
        "label": "Entailment",
        "statement_text": "the primary trial and the secondary trial monitor the DFS of their patient cohorts  however the secondary trial reports the % of patients with DFS greater than or equal 5 years whereas the primary trial reports % of participants with DFS greater than or equal 2 years ",
        "statement_nums": [
            "5 years whereas"
        ],
        "premise_text": "Disease Free Survival was defined as the interval from the date of randomization to the date of local  regional or metastatic relapse or the date of second primary cancer (with the exception of curatively treated non-melanoma skin cancer or in situ carcinoma of the cervix) or death from any cause whichever occured first  Disease free survival was estimated using the Kaplan-Meier method Time frame: From randomization until relapse or death or up to 5 years ",
        "premise_nums": []
    },
    {
        "id": "762c3b23-547a-40cb-86c9-767294f4a142",
        "primaryId": "NCT02165605",
        "statement_text": "A 56 year old patient with a masectomy would not be eligible for the primary trial  due to her age ",
        "statement_nums": [
            "56 year old"
        ],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria: Female  age 18 or older Intact breast (not surgically absent) ",
        "premise_nums": [
            "18 or older"
        ]
    },
    {
        "id": "95a509d6-2990-49ac-b36c-aedf842f17ee",
        "primaryId": "NCT01111825",
        "statement_text": "There were no observed cases of Constipation  Diarrhoea  oedemas or Febrile neutropenia within patient cohorts 1 and 2 of the primary trial ",
        "statement_nums": [
            "1 and 2"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 3/8 (37.50%) Anaemia 0/8 (0.00%) Febrile neutropenia 0/8 (0.00%) Polycythaemia 0/8 (0.00%) Acute coronary syndrome 0/8 (0.00%) Vertigo 0/8 (0.00%) Eyelid oedema 1/8 (12.50%) Constipation 0/8 (0.00%) Diarrhoea 0/8 (0.00%) Nausea 0/8 (0.00%) Stomatitis 0/8 (0.00%) ",
        "premise_nums": [
            "0/8 (0.00%)",
            "1/8 (12.50%)",
            "3/8 (37.50%)"
        ]
    },
    {
        "id": "95a509d6-2990-49ac-b36c-aedf842f17ee",
        "primaryId": "NCT01111825",
        "statement_text": "There were no observed cases of Constipation  Diarrhoea  oedemas or Febrile neutropenia within patient cohorts 1 and 2 of the primary trial ",
        "statement_nums": [
            "1 and 2"
        ],
        "label": "Contradiction",
        "premise_text": "Upper gastrointestinal haemorrhage 0/8 (0.00%)Vomiting 0/8 (0.00%) Chest pain 0/8 (0.00%) Adverse Events 2: Total: 2/6 (33.33%) Anaemia 0/6 (0.00%) Febrile neutropenia 0/6 (0.00%) Polycythaemia 0/6 (0.00%) Acute coronary syndrome 0/6 (0.00%) Vertigo 0/6 (0.00%) Eyelid oedema 0/6 (0.00%) Constipation 0/6 (0.00%) ",
        "premise_nums": [
            "2/6 (33.33%)",
            "0/8 (0.00%)Vomiting",
            "0/6 (0.00%)"
        ]
    },
    {
        "id": "95a509d6-2990-49ac-b36c-aedf842f17ee",
        "primaryId": "NCT01111825",
        "statement_text": "There were no observed cases of Constipation  Diarrhoea  oedemas or Febrile neutropenia within patient cohorts 1 and 2 of the primary trial ",
        "statement_nums": [
            "1 and 2"
        ],
        "label": "Contradiction",
        "premise_text": "Diarrhoea 0/6 (0.00%)Nausea 0/6 (0.00%) Stomatitis 0/6 (0.00%) Upper gastrointestinal haemorrhage 0/6 (0.00%) Vomiting 0/6 (0.00%) Chest pain 1/6 (16.67%) ",
        "premise_nums": [
            "0/6 (0.00%)Nausea",
            "1/6 (16.67%)"
        ]
    },
    {
        "id": "9bdc9efc-89eb-4b6b-961c-ceb5d686ebe6",
        "primaryId": "NCT00258960",
        "statement_text": "One patient in the primary trial experienced a grade 4 adverse event ",
        "statement_nums": [
            "4 adverse event"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 16/48 (33.33%) Febrile neutropenia grade 3 3/48 (6.25%) Neutropenia grade 3 1/48 (2.08%) Holocraneal cephalea 1/48 (2.08%) Hypersensibility reaction grade 3 2/48 (4.17%) Palmoplantar erythrodysesthesia grade 3, stomatitis grade 3 1/48 (2.08%) Neutropenia grade 4, fever grade 1, oral mucositis grade 3 1/48 (2.08%) Catheter - related infection grade 3 1/48 (2.08%) ",
        "premise_nums": [
            "2/48 (4.17%)",
            "3/48 (6.25%)",
            "1/48 (2.08%)",
            "16/48 (33.33%)"
        ]
    },
    {
        "id": "19c2c2d7-4c33-4842-9ed4-02cfae663ce2",
        "primaryId": "NCT00066573",
        "secondaryId": "NCT01091454",
        "label": "Entailment",
        "statement_text": "There was 1 case of night blindness in the primary trial  and 0 in the secondary trial ",
        "statement_nums": [
            "1 case of",
            "0 in the"
        ],
        "premise_text": "Adverse Events 1: Total: 19/3761 (0.51%) Cardiac ischemia/infarction 3/3761 (0.08%) Left ventricular systolic dysfunction 1/3761 (0.03%) Restrictive cardiomyopathy 1/3761 (0.03%) Supraven.arrhyth  Atrial flutter 1/3761 (0.03%) Ventric.arrhyth  Trigeminy 1/3761 (0.03%) Hypothyroidism 0/3761 (0.00%) Blurred vision 1/3761 (0.03%) Nyctalopia 0/3761 (0.00%) ",
        "premise_nums": [
            "19/3761 (0.51%)",
            "3/3761 (0.08%)",
            "0/3761 (0.00%)",
            "1/3761 (0.03%)"
        ]
    },
    {
        "id": "19c2c2d7-4c33-4842-9ed4-02cfae663ce2",
        "primaryId": "NCT00066573",
        "secondaryId": "NCT01091454",
        "label": "Entailment",
        "statement_text": "There was 1 case of night blindness in the primary trial  and 0 in the secondary trial ",
        "statement_nums": [
            "1 case of",
            "0 in the"
        ],
        "premise_text": "Ocular - Other 1/3761 (0.03%)Adverse Events 2: Total: 7/3759 (0.19%) Cardiac ischemia/infarction 0/3759 (0.00%) Left ventricular systolic dysfunction 0/3759 (0.00%) Restrictive cardiomyopathy 0/3759 (0.00%) Supraven.arrhyth  Atrial flutter 0/3759 (0.00%) Ventric.arrhyth  Trigeminy 0/3759 (0.00%) Hypothyroidism 1/3759 (0.03%) Blurred vision 0/3759 (0.00%) Nyctalopia 1/3759 (0.03%) ",
        "premise_nums": [
            "1/3759 (0.03%)",
            "0/3759 (0.00%)",
            "1/3761 (0.03%)Adverse",
            "7/3759 (0.19%)"
        ]
    },
    {
        "id": "19c2c2d7-4c33-4842-9ed4-02cfae663ce2",
        "primaryId": "NCT00066573",
        "secondaryId": "NCT01091454",
        "label": "Entailment",
        "statement_text": "There was 1 case of night blindness in the primary trial  and 0 in the secondary trial ",
        "statement_nums": [
            "1 case of",
            "0 in the"
        ],
        "premise_text": "Ocular - Other 0/3759 (0.00%)Adverse Events 1: Total: 29/48 (60.42%) Anemia 4/48 (8.33%) Febrile neutropenia 7/48 (14.58%) Atrial fibrillation 1/48 (2.08%) Pericardial effusion 1/48 (2.08%) Sinus bradycardia 1/48 (2.08%) Nausea 2/48 (4.17%) Vomiting 2/48 (4.17%) Death NOS 1/48 (2.08%) Fatigue 3/48 (6.25%) Allergic reaction 1/48 (2.08%) Lung infection 1/48 (2.08%) ",
        "premise_nums": [
            "29/48 (60.42%)",
            "7/48 (14.58%)",
            "3/48 (6.25%)",
            "4/48 (8.33%)",
            "2/48 (4.17%)",
            "1/48 (2.08%)",
            "0/3759 (0.00%)Adverse"
        ]
    },
    {
        "id": "19c2c2d7-4c33-4842-9ed4-02cfae663ce2",
        "primaryId": "NCT00066573",
        "secondaryId": "NCT01091454",
        "label": "Entailment",
        "statement_text": "There was 1 case of night blindness in the primary trial  and 0 in the secondary trial ",
        "statement_nums": [
            "1 case of",
            "0 in the"
        ],
        "premise_text": "Mucosal infection 1/48 (2.08%)",
        "premise_nums": [
            "1/48 (2.08%)"
        ]
    },
    {
        "id": "1fdaafdc-766b-488e-9cc4-cbcad74ade97",
        "primaryId": "NCT01818063",
        "secondaryId": "NCT00559507",
        "label": "Contradiction",
        "statement_text": "In the primary trial and the secondary trial the only drugs administered orally are Doxorubicin and Veliparib ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Arm 1 (Paclitaxel  Carboplatin) Patients receive paclitaxel IV and carboplatin IV on day 1 (course 1 only) or day 2 (courses 2-12). Treatment repeats every 7 days for 12 courses in the absence of disease progression or unacceptable toxicity  Beginning 21 days after the last course  patients receive doxorubicin hydrochloride IV and cyclophosphamide IV on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity  Paclitaxel: Given IV Carboplatin: Given IV Doxorubicin: Given IV Cyclophosphamide: Given IV INTERVENTION 2: ",
        "premise_nums": [
            "21 days for",
            "21 days after",
            "7 days for",
            "12 courses in",
            "4 courses in",
            "2-12). Treatment"
        ]
    },
    {
        "id": "1fdaafdc-766b-488e-9cc4-cbcad74ade97",
        "primaryId": "NCT01818063",
        "secondaryId": "NCT00559507",
        "label": "Contradiction",
        "statement_text": "In the primary trial and the secondary trial the only drugs administered orally are Doxorubicin and Veliparib ",
        "statement_nums": [],
        "premise_text": "Arm 2 (Veliparib  Paclitaxel  Carboplatin)Patients receive veliparib PO BID on days 1-5. Patients also receive paclitaxel IV and carboplatin IV on day 3 (course 1 only) or day 4 (courses 2-12). Treatment repeats every 7 days for 12 courses in the absence of disease progression or unacceptable toxicity  Beginning 21 days after the last course  patients receive doxorubicin hydrochloride IV and cyclophosphamide IV on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity  Paclitaxel: Given IV Carboplatin: Given IV Doxorubicin: Given IV ",
        "premise_nums": [
            "21 days for",
            "21 days after",
            "7 days for",
            "12 courses in",
            "4 courses in",
            "1-5. Patients",
            "2-12). Treatment"
        ]
    },
    {
        "id": "1fdaafdc-766b-488e-9cc4-cbcad74ade97",
        "primaryId": "NCT01818063",
        "secondaryId": "NCT00559507",
        "label": "Contradiction",
        "statement_text": "In the primary trial and the secondary trial the only drugs administered orally are Doxorubicin and Veliparib ",
        "statement_nums": [],
        "premise_text": "Cyclophosphamide: Given IVVeliparib: Given PO INTERVENTION 1: Treatment (Enzyme Inhibitor Therapy) Patients receive saracatinib PO on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity  ",
        "premise_nums": [
            "1-28. Treatment",
            "28 days in"
        ]
    },
    {
        "id": "2e591059-5a3b-4a69-84c5-59d9604394a8",
        "primaryId": "NCT02040857",
        "statement_text": "All genders are eligible for the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Men and both pre- and postmenopausal women are eligible  ",
        "premise_nums": []
    },
    {
        "id": "94a54cdf-4c1c-4994-929a-ced7a33f2b43",
        "primaryId": "NCT00866905",
        "statement_text": "Less than 1% of patients in the primary trial became depressed ",
        "statement_nums": [
            "1% of"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: DEPRESSION 1/168 (0.60%) ",
        "premise_nums": [
            "1/168 (0.60%)"
        ]
    },
    {
        "id": "b217583e-2dbb-4951-8f73-cac08e365a7a",
        "primaryId": "NCT00562718",
        "statement_text": "Patients with pacemakers or stents may be allowed to participate in the primary trial at their physician's discretion ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Patients having tissue expanders or implants placed prior to radiation may be enrolled at the physician's discretion ",
        "premise_nums": []
    },
    {
        "id": "42086f11-1fb1-4041-8d1e-e150d4cc09ea",
        "primaryId": "NCT00304096",
        "statement_text": "A minimum bodyweight of 50kg is required to participate in the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Body weight greater than 110 lbs (without clothes) ",
        "premise_nums": [
            "110 lbs (without"
        ]
    },
    {
        "id": "0d75c493-58ce-4a45-8823-a9a1126751b3",
        "primaryId": "NCT00916578",
        "statement_text": "the primary trial is testing a combination of chemotherapy and radiotherapy ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "INTERVENTION 1: Single Arm Institution  Open Label  Phase II Patients will received 825 mg/m2 bid of capecitabine  One of the two daily doses of capecitabine will be taken 2 hours before receiving radiotherapy  Capecitabine will be administered when patients receives radiation therapy  Radiation therapy doses will be 50-57 Gy to the initial clinical target volume  ",
        "premise_nums": [
            "2 bid of",
            "2 hours before",
            "825 mg/m2 bid",
            "57 Gy to",
            "50-57 Gy"
        ]
    },
    {
        "id": "d0d4e184-0764-4c28-9af7-4535c7ed1aad",
        "primaryId": "NCT00303108",
        "statement_text": "Cohort 2 of the primary trial produced marginally better results than cohort 1.",
        "statement_nums": [
            "2 of the"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Objective Response Rate (ORR) Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR)  Disappearance of all target lesions; Partial Response (PR)  greater than or equal 30% decrease in the sum of the longest diameter of target lesions; Objective response (OR) = CR + PR  Time frame: From date of randomization until the date of first documented progression or date of intolerable toxicity  whichever came first  assessed up to 54 months  Results 1: Arm/Group Title: D+C and Taxane Naive Arm/Group Description: Doxil  Carboplatin and Taxane naive Overall Number of Participants Analyzed: 39 Measure Type: Number Unit of Measure: percentage of participants 30.8 (17.0 to 47.6) ",
        "premise_nums": [
            "30% decrease",
            "0 to 47.6)",
            "39 Measure Type:"
        ]
    },
    {
        "id": "d0d4e184-0764-4c28-9af7-4535c7ed1aad",
        "primaryId": "NCT00303108",
        "statement_text": "Cohort 2 of the primary trial produced marginally better results than cohort 1.",
        "statement_nums": [
            "2 of the"
        ],
        "label": "Entailment",
        "premise_text": "Results 2:Arm/Group Title: D+C and Taxane Pretreated Arm/Group Description: Doxil  Carboplatin and Taxane pretreated Overall Number of Participants Analyzed: 42 Measure Type: Number Unit of Measure: percentage of participants 31.0 (17.6 to 47.1) ",
        "premise_nums": [
            "42 Measure Type:",
            "2:Arm/Group Title:",
            "6 to 47.1)"
        ]
    },
    {
        "id": "e45886af-1edd-4987-a280-2609a86fd3dd",
        "primaryId": "NCT02413320",
        "statement_text": "Females over the age of 20 that have recieved chemotherapy in the last 4 weeks   are eligible for the primary trial ",
        "statement_nums": [
            "20 that have"
        ],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria: No prior chemotherapy  endocrine therapy or radiation therapy with therapeutic intent for this cancer Female subjects age 18 - 70 years ",
        "premise_nums": []
    },
    {
        "id": "c207ff16-b7d0-49e4-9177-0597044f3008",
        "primaryId": "NCT03374995",
        "statement_text": "Some the primary trial subjects receiving keratin are administered it topically twice daily for approximately 3-6 weeks  others participants may have it administered by ubcutaneous injection ",
        "statement_nums": [
            "3-6 weeks"
        ],
        "label": "Contradiction",
        "premise_text": "INTERVENTION 1: Group I (Topical Keratin) Patients receive topical keratin topically at least BID until the end of radiation therapy (approximately 3-6 weeks)  Quality-of-Life Assessment: Ancillary studies Topical Keratin: Given topically INTERVENTION 2: Group II (Standard of Care) Patients receive standard of care as directed by radiation oncologist until the end of radiation therapy (approximately 3-6 weeks)  Best Practice: Receive standard of care Quality-of-Life Assessment: Ancillary studies ",
        "premise_nums": [
            "3-6 weeks"
        ]
    },
    {
        "id": "35234f08-cf01-478f-b739-600b5a6ea3d9",
        "primaryId": "NCT00550771",
        "statement_text": "16/179 patients in the primary trial Experienced Cardiac Events  with the majority of those coming from cohort 2.",
        "statement_nums": [
            "16/179 patients",
            "179 patients in"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Number of Participants Who Experienced Cardiac Events (Level 1 or 2), or Inability to Administer Trastuzumab Either During the 8 Cycles of Chemotherapy or According to Package Insert for a Total Duration of 1 Year Cardiac events defined as: Level 1: Cardiac death due to heart failure (HF)  myocardial infarction or arrhythmia  or probable cardiac death defined as sudden  unexpected death within 24 hours of a definite or probable cardiac event  or severe symptomatic HF  concomitant with a left ventricular ejection fraction (LVEF) drop of greater than 10 percentage points from baseline and to 50% LVEF ",
        "premise_nums": [
            "8 Cycles of",
            "10 percentage points",
            "50% LVEF",
            "1 Year Cardiac",
            "1 or 2),",
            "24 hours of"
        ]
    },
    {
        "id": "35234f08-cf01-478f-b739-600b5a6ea3d9",
        "primaryId": "NCT00550771",
        "statement_text": "16/179 patients in the primary trial Experienced Cardiac Events  with the majority of those coming from cohort 2.",
        "statement_nums": [
            "16/179 patients",
            "179 patients in"
        ],
        "label": "Entailment",
        "premise_text": "Level 2: Asymptomatic systolic dysfunction or mildly symptomatic HF concomitant with an LVEF drop of greater than 10 percentage points from baseline and to smaller than 50% LVEF; the LVEF drop was to have been confirmed within 3-4 weeks Time frame: 8 cycles of chemotherapy and subsequently one year of planned trastuzumab treatment Results 1: Arm/Group Title: Pegylated Liposomal Doxorubicin (PLD) Based Regimen ",
        "premise_nums": [
            "8 cycles of",
            "4 weeks Time",
            "10 percentage points",
            "50% LVEF",
            "3-4 weeks"
        ]
    },
    {
        "id": "35234f08-cf01-478f-b739-600b5a6ea3d9",
        "primaryId": "NCT00550771",
        "statement_text": "16/179 patients in the primary trial Experienced Cardiac Events  with the majority of those coming from cohort 2.",
        "statement_nums": [
            "16/179 patients",
            "179 patients in"
        ],
        "label": "Entailment",
        "premise_text": "Arm/Group Description: PLD 35 mg/m^2 IV over 60 minutes + cyclophosphamide 600 mg/m^2 IV over 30-90 minutes given every 21 days + trastuzumab 2 mg/kg IV over 30 minutes (first dose 4 mg/kg IV over 90 minutes) given once weekly for 4 courses (12 weeks) followed by Paclitaxel 80 mg/m^2 IV over 60 minutes with trastuzumab 2 mg/kg IV over 30 minutes given weekly for 12 weeks (4 courses)Overall Number of Participants Analyzed: 120 Measure Type: Number Unit of Measure: Participants 5 Results 2: Arm/Group Title: Doxorubicin Based Regimen ",
        "premise_nums": [
            "80 mg/m^2",
            "2 IV over",
            "4 courses (12",
            "30 minutes (first",
            "120 Measure Type:",
            "600 mg/m^2",
            "30-90 minutes",
            "4 mg/kg IV",
            "5 Results 2:",
            "12 weeks (4",
            "35 mg/m^2",
            "60 minutes with",
            "90 minutes given",
            "30 minutes given",
            "2 mg/kg IV"
        ]
    },
    {
        "id": "35234f08-cf01-478f-b739-600b5a6ea3d9",
        "primaryId": "NCT00550771",
        "statement_text": "16/179 patients in the primary trial Experienced Cardiac Events  with the majority of those coming from cohort 2.",
        "statement_nums": [
            "16/179 patients",
            "179 patients in"
        ],
        "label": "Entailment",
        "premise_text": "Arm/Group Description: doxorubicin 60 mg/m^2 intravenous (IV) push + cyclophosphamide 600 mg/m^2 IV over 30-90 minutes given every 21 days for 4 courses (12 weeks) followed by Paclitaxel 80 mg/m^2 IV over 60 minutes with trastuzumab 2 mg/kg IV over 30 minutes (first administration 4 mg/kg IV over 90 minutes) given weekly for 12 weeks (4 courses)Overall Number of Participants Analyzed: 59 Measure Type: Number Unit of Measure: Participants 11 ",
        "premise_nums": [
            "21 days for",
            "60 mg/m^2",
            "80 mg/m^2",
            "60 minutes with",
            "2 IV over",
            "600 mg/m^2",
            "30-90 minutes",
            "4 mg/kg IV",
            "90 minutes given",
            "30 minutes (first",
            "12 weeks (4",
            "2 mg/kg IV",
            "2 intravenous (IV)",
            "4 courses (12",
            "59 Measure Type:"
        ]
    },
    {
        "id": "87adb323-6f56-4e1a-a04d-8437ac571eab",
        "primaryId": "NCT01805089",
        "statement_text": "Patients with Lactiferous duct carcinomas are eligible for the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Inclusion Criteria: History of ductal carcinoma in situ  lobular carcinoma in situ or stages 1-3 breast cancer ",
        "premise_nums": [
            "1-3 breast",
            "3 breast cancer"
        ]
    },
    {
        "id": "94410f2c-9c1c-4130-b479-738e343ba9f7",
        "primaryId": "NCT00194779",
        "secondaryId": "NCT04080297",
        "label": "Entailment",
        "statement_text": "There is a least one route of administration shared by the interventions used in the primary trial and the secondary trial ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Treatment (Neoadjuvant Therapy  Adjuvant Therapy) See Detailed Description  doxorubicin hydrochloride: Given IV cyclophosphamide: Given PO paclitaxel: Given IV filgrastim: Given SC capecitabine: Given PO methotrexate: Given IV vinorelbine tartrate: Given IV needle biopsy: Correlative studies therapeutic conventional surgery: Undergo definitive breast surgery immunohistochemistry staining method: Correlative studies trastuzumab: Given IV tamoxifen citrate: Given PO letrozole: Given PO laboratory biomarker analysis: Correlative studies INTERVENTION 1: 100 mg Q-122 ",
        "premise_nums": [
            "100 mg Q"
        ]
    },
    {
        "id": "94410f2c-9c1c-4130-b479-738e343ba9f7",
        "primaryId": "NCT00194779",
        "secondaryId": "NCT04080297",
        "label": "Entailment",
        "statement_text": "There is a least one route of administration shared by the interventions used in the primary trial and the secondary trial ",
        "statement_nums": [],
        "premise_text": "Dosage was 100 mg Q-122 administered orally as two 50 mg capsules once daily for 28 days ",
        "premise_nums": [
            "50 mg capsules",
            "100 mg Q",
            "122 administered orally"
        ]
    },
    {
        "id": "b811e872-90ef-4649-9c8d-f5488f316ccc",
        "primaryId": "NCT00671918",
        "secondaryId": "NCT00571987",
        "label": "Entailment",
        "statement_text": "Patients with pure ductal carcinoma in situ (DCIS) are eligible for both the secondary trial and the primary trial ",
        "statement_nums": [],
        "premise_text": "Inclusion Criteria: Patients with pure ductal carcinoma in situ (DCIS) or non-invasive carcinoma if lymph node biopsy is part of the surgical plan  Inclusion Criteria: Ductal or Infiltrating Ductal Carcinoma ",
        "premise_nums": []
    },
    {
        "id": "f66f4c30-2d39-4e29-876a-487bca9a8ccf",
        "primaryId": "NCT02835625",
        "secondaryId": "NCT00486525",
        "label": "Entailment",
        "statement_text": "the primary trial and the secondary trial do not use any chemotherapy or radiotherapy in their interventions",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Digital Breast Tomosynthesis Digital Breast Tomosynthesis + Synthetic Mammography (DBT) The DBT was independently read by two radiologists  A consensus meeting decided whether to recall the woman or not  Women selected for further assessment (positive screening exam) was recalled  Digital Breast Tomosynthesis + Synthetic Mammography: Two-view tomosynthesis performed with GE SenoClaire 3D Breast Tomosynthesis  INTERVENTION 2: Digital Mammography The digital mammograms was independently read by two radiologists  A consensus meeting decided whether to recall the woman or not  Women selected for further assessment (positive screening exam) was recalled  Digital mammography: Two-view digital mammography performed with GE SenoClaire 3D Breast Tomosynthesis  INTERVENTION 1: Arm I: Yoga Therapy ",
        "premise_nums": []
    },
    {
        "id": "f66f4c30-2d39-4e29-876a-487bca9a8ccf",
        "primaryId": "NCT02835625",
        "secondaryId": "NCT00486525",
        "label": "Entailment",
        "statement_text": "the primary trial and the secondary trial do not use any chemotherapy or radiotherapy in their interventions",
        "statement_nums": [],
        "premise_text": "Patients participated in a Hatha yoga session over 90 minutes twice weekly for 12 weeks  Patients were also encouraged to practice yoga at home  Patients recorded their total home/class practice time in weekly logs INTERVENTION 2: Arm II: Wait-List Wait-listed women were told to continue performing their usual activities  and to refrain from beginning any yoga practice  After their final assessment they were offered the yoga classes  ",
        "premise_nums": [
            "90 minutes twice"
        ]
    },
    {
        "id": "34f50f3f-d6a7-4e22-84cb-6a41f0b8c1f6",
        "primaryId": "NCT00452673",
        "statement_text": "7 patients in cohort 1 of the primary trial suffered dose-limiting toxicities ",
        "statement_nums": [
            "7 patients in",
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Number of Participants With Dose Limiting Toxicities Per Dose Level - Safety Population ",
        "premise_nums": []
    },
    {
        "id": "34f50f3f-d6a7-4e22-84cb-6a41f0b8c1f6",
        "primaryId": "NCT00452673",
        "statement_text": "7 patients in cohort 1 of the primary trial suffered dose-limiting toxicities ",
        "statement_nums": [
            "7 patients in",
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Safety was assessed from first dose of study drug through at least 30 days after the last dose  until resolution of drug-related toxicity or when toxicity was deemed irreversible  whichever was longer  An adverse event (AE) was considered a dose limiting toxicity (DLT) if it occurred in the first 21 days and was at least possibly related to study drugs and were: Clinically-evident toxicity of Grade greater than or equal 3, or of Grade 2 which required interruption of treatment for greater than or equal 7 days (consecutive or non-consecutive); non-hematologic abnormal laboratory value of Grade greater than or equal 3, or hematologic toxicity of Grade 4, which persisted 7 days; any grade toxicity which in the judgment of the investigator required a dose reduction or removal from further study therapy Time frame: Day 1 to 30 days post last dose Results 1: ",
        "premise_nums": [
            "21 days and",
            "2 which required",
            "30 days after",
            "1 to 30",
            "7 days (consecutive"
        ]
    },
    {
        "id": "34f50f3f-d6a7-4e22-84cb-6a41f0b8c1f6",
        "primaryId": "NCT00452673",
        "statement_text": "7 patients in cohort 1 of the primary trial suffered dose-limiting toxicities ",
        "statement_nums": [
            "7 patients in",
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Arm/Group Title: 50 mg Dasatinib + 825 mg/m^2Capecitabine",
        "premise_nums": [
            "825 mg/m^2Capecitabine",
            "50 mg Dasatinib"
        ]
    },
    {
        "id": "011991a5-724d-4b95-b9ab-9e1371d77368",
        "primaryId": "NCT00086957",
        "statement_text": "All of the patients in cohort 1 of the primary trial experienced Leukopenia and Febrile neutropenia ",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 2/2 (100.00%) Febrile neutropenia * 2/2 (100.00%) Haemorrhage NOS * 0/2 (0.00%) Abdominal pain * 0/2 (0.00%) Diarrhea * 0/2 (0.00%) Melaena * 0/2 (0.00%) Mucositis oral * 0/2 (0.00%) Nausea * 0/2 (0.00%) Vomiting * 0/2 (0.00%) Catheter related infection * 0/2 (0.00%) Infection NOS * 0/2 (0.00%) Leukopenia * 1/2 (50.00%) ",
        "premise_nums": [
            "1/2 (50.00%)",
            "0/2 (0.00%)",
            "2/2 (100.00%)"
        ]
    },
    {
        "id": "8421197a-3a35-4738-b1c8-83cce0ac4115",
        "primaryId": "NCT02896855",
        "secondaryId": "NCT00171314",
        "label": "Entailment",
        "statement_text": "the secondary trial recorded more total occurences of cardiac adverse events than the primary trial ",
        "statement_nums": [],
        "premise_text": "Adverse Events 1: Total: 23/120 (19.17%) Febrile neutropenia 4/120 (3.33%) Leukopenia 2/120 (1.67%) Neutropenia 8/120 (6.67%) Cardiac tamponade 0/120 (0.00%) Ventricular arrhythmia 1/120 (0.83%) Ascites 0/120 (0.00%) Oesophagitis 0/120 (0.00%) Large intestine polyp 0/120 (0.00%) Death 1/120 (0.83%) Liver injury 1/120 (0.83%) Pneumonia 3/120 (2.50%) Adverse Events 2: Total: 30/122 (24.59%) ",
        "premise_nums": [
            "23/120 (19.17%)",
            "0/120 (0.00%)",
            "3/120 (2.50%)",
            "8/120 (6.67%)",
            "2/120 (1.67%)",
            "4/120 (3.33%)",
            "30/122 (24.59%)",
            "1/120 (0.83%)"
        ]
    },
    {
        "id": "8421197a-3a35-4738-b1c8-83cce0ac4115",
        "primaryId": "NCT02896855",
        "secondaryId": "NCT00171314",
        "label": "Entailment",
        "statement_text": "the secondary trial recorded more total occurences of cardiac adverse events than the primary trial ",
        "statement_nums": [],
        "premise_text": "Febrile neutropenia 3/122 (2.46%)Leukopenia 3/122 (2.46%) Neutropenia 9/122 (7.38%) Cardiac tamponade 2/122 (1.64%) Ventricular arrhythmia 0/122 (0.00%) Ascites 1/122 (0.82%) Oesophagitis 1/122 (0.82%) Large intestine polyp 0/122 (0.00%) Death 1/122 (0.82%) Liver injury 0/122 (0.00%) Pneumonia 5/122 (4.10%) Adverse Events 1: Total: 47/254 (18.50%) Anaemia 1/254 (0.39%) ",
        "premise_nums": [
            "5/122 (4.10%)",
            "0/122 (0.00%)",
            "47/254 (18.50%)",
            "3/122 (2.46%)Leukopenia",
            "1/122 (0.82%)",
            "9/122 (7.38%)",
            "1/254 (0.39%)",
            "2/122 (1.64%)"
        ]
    },
    {
        "id": "8421197a-3a35-4738-b1c8-83cce0ac4115",
        "primaryId": "NCT02896855",
        "secondaryId": "NCT00171314",
        "label": "Entailment",
        "statement_text": "the secondary trial recorded more total occurences of cardiac adverse events than the primary trial ",
        "statement_nums": [],
        "premise_text": "Febrile neutropenia 1/254 (0.39%)Lymphadenopathy 1/254 (0.39%) Acute myocardial infarction 1/254 (0.39%) Angina pectoris 0/254 (0.00%) Angina unstable 0/254 (0.00%) Bundle branch block left 0/254 (0.00%) Cardiac failure 4/254 (1.57%) Coronary artery disease 0/254 (0.00%) Coronary artery stenosis 1/254 (0.39%) Adverse Events 2: Total: 56/269 (20.82%) Anaemia 1/269 (0.37%) Febrile neutropenia 0/269 (0.00%) ",
        "premise_nums": [
            "56/269 (20.82%)",
            "1/254 (0.39%)Lymphadenopathy",
            "0/269 (0.00%)",
            "1/269 (0.37%)",
            "0/254 (0.00%)",
            "4/254 (1.57%)"
        ]
    },
    {
        "id": "8421197a-3a35-4738-b1c8-83cce0ac4115",
        "primaryId": "NCT02896855",
        "secondaryId": "NCT00171314",
        "label": "Entailment",
        "statement_text": "the secondary trial recorded more total occurences of cardiac adverse events than the primary trial ",
        "statement_nums": [],
        "premise_text": "Lymphadenopathy 0/269 (0.00%)Acute myocardial infarction 0/269 (0.00%) Angina pectoris 3/269 (1.12%) Angina unstable 1/269 (0.37%) Bundle branch block left 1/269 (0.37%) Cardiac failure 1/269 (0.37%) Coronary artery disease 1/269 (0.37%) Coronary artery stenosis 0/269 (0.00%) ",
        "premise_nums": [
            "0/269 (0.00%)Acute",
            "3/269 (1.12%)",
            "1/269 (0.37%)"
        ]
    },
    {
        "id": "d09091f1-3fc5-498b-8c59-4678590c8464",
        "primaryId": "NCT03176238",
        "secondaryId": "NCT01498458",
        "label": "Contradiction",
        "statement_text": "Although there is a much higher percentage of patients with Enterocolitis in the secondary trial than in cohort 1 of the primary trial  no robust comparisons can be made due to the significant differences in cohort sizes ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Adverse Events 1: Total: 59/199 (29.65%) Anaemia 7/199 (3.52%) Thrombocytopenia 2/199 (1.01%) Acute myocardial infarction 0/199 (0.00%) Atrial fibrillation 1/199 (0.50%) Cardiac arrest 1/199 (0.50%) Cardiac failure 1/199 (0.50%) Cardiopulmonary failure 1/199 (0.50%) Left ventricular failure 1/199 (0.50%) Supraventricular tachycardia 0/199 (0.00%) ",
        "premise_nums": [
            "2/199 (1.01%)",
            "7/199 (3.52%)",
            "1/199 (0.50%)",
            "0/199 (0.00%)",
            "59/199 (29.65%)"
        ]
    },
    {
        "id": "d09091f1-3fc5-498b-8c59-4678590c8464",
        "primaryId": "NCT03176238",
        "secondaryId": "NCT01498458",
        "label": "Contradiction",
        "statement_text": "Although there is a much higher percentage of patients with Enterocolitis in the secondary trial than in cohort 1 of the primary trial  no robust comparisons can be made due to the significant differences in cohort sizes ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Ventricular tachycardia 1/199 (0.50%)Adverse Events 1: Total: 6/8 (75.00%) Thrombocytopenia 1/8 (12.50%) Hypertension 1/8 (12.50%) Hepatotoxicity 3/8 (37.50%) Pancreatectomy * 1/8 (12.50%) ",
        "premise_nums": [
            "6/8 (75.00%)",
            "1/199 (0.50%)Adverse",
            "1/8 (12.50%)",
            "3/8 (37.50%)"
        ]
    },
    {
        "id": "203a2e22-cae9-4bfe-b82d-6dc665a66ce6",
        "primaryId": "NCT00821886",
        "statement_text": "Patients prescribed with bisoprolol or labetalol to treat atrial fibrillation are excluded from the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Exclusion Criteria: current use of medications (e.g.  digitalis  beta-blockers  calcium channel-blockers) that alter cardiac conduction  if these medications are administered for the management of cardiac arrhythmia  angina  or CHF  If these medications are administered for other reasons (e.g.  hypertension)  the patient may be eligible  ",
        "premise_nums": []
    },
    {
        "id": "f4909215-5b14-42d9-bda4-4d112cf2a108",
        "primaryId": "NCT02574455",
        "statement_text": "More than 1/3 patients in cohort 1 of the primary trial experienced an adverse event ",
        "statement_nums": [
            "1/3 patients",
            "3 patients in",
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 69/258 (26.74%) ",
        "premise_nums": [
            "69/258 (26.74%)"
        ]
    },
    {
        "id": "9c27202c-7090-4be5-840e-351992aeb81c",
        "primaryId": "NCT00093808",
        "secondaryId": "NCT00394082",
        "label": "Entailment",
        "statement_text": "the primary trial and the secondary trial reported the same number of dehydrated patients during the studies ",
        "statement_nums": [],
        "premise_text": "Dehydration 1/46 (2.17%) Dehydration 1/50 (2.00%) ",
        "premise_nums": [
            "1/46 (2.17%)",
            "1/50 (2.00%)"
        ]
    },
    {
        "id": "fc7d8ffd-9896-4806-a095-d435cde83c88",
        "primaryId": "NCT00528567",
        "secondaryId": "NCT01196052",
        "label": "Entailment",
        "statement_text": "The total number of patients affected by adverse events in cohort 2 the primary trial  is larger than the cohort size of the secondary trial ",
        "statement_nums": [
            "2 the primary"
        ],
        "premise_text": "Adverse Events 2: Total: 250/1271 (19.67%) Adverse Events 1: Total: 15/148 (10.14%) Febrile neutropenia 1/148 (0.68%) Atrial fibrillation 2/148 (1.35%) Abdominal pain 1/148 (0.68%) Diarrhoea 1/148 (0.68%) Pyrexia 2/148 (1.35%) Cellulitis 1/148 (0.68%) Device related infection 2/148 (1.35%) Gastroenteritis viral 1/148 (0.68%) Gastrointestinal infection 1/148 (0.68%) Upper respiratory tract infection 1/148 (0.68%) ",
        "premise_nums": [
            "2/148 (1.35%)",
            "15/148 (10.14%)",
            "1/148 (0.68%)",
            "250/1271 (19.67%)"
        ]
    },
    {
        "id": "23116aca-0064-4426-b147-7af688a82443",
        "primaryId": "NCT00876395",
        "secondaryId": "NCT02287675",
        "label": "Contradiction",
        "statement_text": "Men suffering from Ulcerative colitis are excluded from the primary trial  but eligible for the secondary trial ",
        "statement_nums": [],
        "premise_text": "Exclusion Criteria: Impairment of gastrointestinal (GI) function or GI disease or active ulceration of the upper gastrointestinal tract  Inclusion Criteria: The subject must be female and 18 years of age or older  The subject must be a preoperative clinical Tis  T1, T2, T3, T4, as well as clinical N0 and clinical M0 breast cancer The subject must have a diagnosis of primary breast cancer  The subject must be a candidate for surgical intervention  either with lumpectomy and SLNB or with mastectomy and SLNB  as the treatment of her breast cancer  The subject must have an Eastern Cooperative Oncology Group (ECOG) performance status of Grade 0 - 2 ",
        "premise_nums": [
            "0 breast cancer",
            "18 years of",
            "0 and clinical"
        ]
    },
    {
        "id": "23116aca-0064-4426-b147-7af688a82443",
        "primaryId": "NCT00876395",
        "secondaryId": "NCT02287675",
        "label": "Contradiction",
        "statement_text": "Men suffering from Ulcerative colitis are excluded from the primary trial  but eligible for the secondary trial ",
        "statement_nums": [],
        "premise_text": "The subject must provide written informed consent with Health Insurance Portability and Accountability Act (HIPAA) authorization before participating in the studyExclusion Criteria: The subject has clinical or radiological or pathologic evidence of metastatic cancer  including any abnormal or enlarged clinical palpable lymph nodes or core biopsy/surgical biopsy/fine-needle-aspiration evidence of malignant cell within any lymph nodes  The subject has a known hypersensitivity to vital blue dye (VBD) in a case where vital blue dye was planned for use during SLNB  The subject has a positive pregnancy test or is lactating  The subject has had prior surgery to the indicated breast or axilla  ",
        "premise_nums": []
    },
    {
        "id": "7dd79595-4bdf-48e6-af94-fe39aa2e5fd4",
        "primaryId": "NCT00005879",
        "secondaryId": "NCT01217385",
        "label": "Contradiction",
        "statement_text": "The only criterias for entry to the primary trial and the secondary trial is that patients must be female  over the age of 21 and british ",
        "statement_nums": [
            "21 and british"
        ],
        "premise_text": "DISEASE CHARACTERISTICS: Current random fine needle breast aspiration (FNA) evidence of 1 of the following: Hyperplasia with atypia Hyperplasia without atypia but with a 10-year modified Gail risk of at least 4% Hyperplasia without atypia but with a BRCAPRO risk of at least 25% Hyperplasia without atypia but with a known mutation in BRCA1 or BRCA2 Hyperplasia without atypia but with a history of contralateral ductal carcinoma in situ or invasive breast cancer FNA must have been taken during days 1-14 of the menstrual cycle for premenopausal women ",
        "premise_nums": [
            "25% Hyperplasia",
            "14 of the",
            "1 or BRCA2",
            "4% Hyperplasia",
            "10-year modified",
            "1-14 of",
            "1 of the"
        ]
    },
    {
        "id": "7dd79595-4bdf-48e6-af94-fe39aa2e5fd4",
        "primaryId": "NCT00005879",
        "secondaryId": "NCT01217385",
        "label": "Contradiction",
        "statement_text": "The only criterias for entry to the primary trial and the secondary trial is that patients must be female  over the age of 21 and british ",
        "statement_nums": [
            "21 and british"
        ],
        "premise_text": "Classified as ACR class I-III on mammogram with stepwedge within past 6 months If intact uterus and/or ovaries  must have color doppler transvaginal pelvic sonogram within past 6 months showing endometrial thickening no greater than 13 mm premenopausal or no greater than 8 mm postmenopausalNo ovarian cysts felt to be possibly or probably non-physiologic that have not resolved to gynecologist's satisfaction on repeat sonogram Must agree to have or have had genetic counseling and genetic testing performed for BRCA1 and BRCA2 No active cancer (e.g.  detectable disease) Hormone receptor status: Not specified PATIENT CHARACTERISTICS: Age: 18 and over Sex: Female ",
        "premise_nums": [
            "13 mm premenopausal",
            "1 and BRCA2",
            "6 months showing",
            "8 mm postmenopausalNo",
            "6 months If",
            "18 and over"
        ]
    },
    {
        "id": "7dd79595-4bdf-48e6-af94-fe39aa2e5fd4",
        "primaryId": "NCT00005879",
        "secondaryId": "NCT01217385",
        "label": "Contradiction",
        "statement_text": "The only criterias for entry to the primary trial and the secondary trial is that patients must be female  over the age of 21 and british ",
        "statement_nums": [
            "21 and british"
        ],
        "premise_text": "Menopausal status:Any Performance status: Not specified Life expectancy: At least 12 months Hematopoietic: Hemoglobin greater than 10 g/dL Granulocyte count greater than 1,000/mm^3 No deficiencies in protein C  protein S  or antithrombin III No activated protein C resistance Hepatic: Albumin greater than 3.0 g/dL Bilirubin less than 1.5 mg/dL AST less than 100 U/L Alkaline phosphatase less than 200 U/L Renal: Creatinine less than 1.5 mg/dL Cardiovascular: No history of deep venous thrombosis not related to trauma or pregnancy No severe coronary artery disease ",
        "premise_nums": [
            "10 g/dL Granulocyte",
            "1,000/mm^3 No",
            "3 No deficiencies",
            "than 3.0 g/dL",
            "200 U/L Renal",
            "12 months Hematopoietic:",
            "100 U/L Alkaline",
            "than 1.5 mg/dL"
        ]
    },
    {
        "id": "7dd79595-4bdf-48e6-af94-fe39aa2e5fd4",
        "primaryId": "NCT00005879",
        "secondaryId": "NCT01217385",
        "label": "Contradiction",
        "statement_text": "The only criterias for entry to the primary trial and the secondary trial is that patients must be female  over the age of 21 and british ",
        "statement_nums": [
            "21 and british"
        ],
        "premise_text": "No history of prior strokeOther: Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception during and for 3 months after study No other active cancer No retinal vein thrombosis No concurrent severe poorly controlled migraine No factor V Leiden mutation carrier PRIOR CONCURRENT THERAPY: Biologic therapy: At least 12 months since prior immunotherapy Chemotherapy: At least 3 months between completion of prior KUMC phase II difluoromethylornithine (DFMO) study and baseline aspiration At least 12 months since prior chemotherapy Endocrine therapy: Must not have started or stopped hormone replacement therapy or oral contraceptives within 6 months of baseline aspiration ",
        "premise_nums": [
            "3 months between",
            "6 months of",
            "3 months after",
            "12 months since"
        ]
    },
    {
        "id": "7dd79595-4bdf-48e6-af94-fe39aa2e5fd4",
        "primaryId": "NCT00005879",
        "secondaryId": "NCT01217385",
        "label": "Contradiction",
        "statement_text": "The only criterias for entry to the primary trial and the secondary trial is that patients must be female  over the age of 21 and british ",
        "statement_nums": [
            "21 and british"
        ],
        "premise_text": "Must continue all hormone replacement therapy and/or oral contraceptives that were being taken at time of baseline aspirationAt least 12 months since prior tamoxifen  raloxifene  or other antihormonal therapy Radiotherapy: At least 3 months since prior radiotherapy Surgery: At least 6 months between prior oophorectomy and baseline aspiration Other: At least 2 weeks since the start of other new medication that would be ingested for 1 or more months Inclusion Criteria Pathologically confirmed diagnosis of invasive breast cancer  determined to be a candidate for primary systemic (neoadjuvant) therapy and for surgical resection of residual primary tumor following completion of neoadjuvant therapy; Tumor size greater than 2cm, measured on imaging or estimated by physical exam; ",
        "premise_nums": [
            "3 months since",
            "2 weeks since",
            "1 or more",
            "6 months between",
            "12 months since"
        ]
    },
    {
        "id": "7dd79595-4bdf-48e6-af94-fe39aa2e5fd4",
        "primaryId": "NCT00005879",
        "secondaryId": "NCT01217385",
        "label": "Contradiction",
        "statement_text": "The only criterias for entry to the primary trial and the secondary trial is that patients must be female  over the age of 21 and british ",
        "statement_nums": [
            "21 and british"
        ],
        "premise_text": "No contraindications for primary chemotherapy;Planned definitive breast surgery (mastectomy or lumpectomy/breast conservation) following completion of neoadjuvant therapy; Age 18 years or older; ECOG Performance Status 2 (Karnofsky 60%; see Appendix II); Normal organ and marrow function as follows: leukocytes 3,000/μl; absolute neutrophil count 1,500/μl; platelets 100,000/μl; total bilirubin within normal institutional limits; AST(SGOT)/ALT(SGPT) 2.5 times the institutional upper limit of normal; creatinine within normal institutional limits; OR ",
        "premise_nums": [
            "100,000/μl; total",
            "5 times the",
            "3,000/μl; absolute",
            "1,500/μl; platelets",
            "18 years or"
        ]
    },
    {
        "id": "7dd79595-4bdf-48e6-af94-fe39aa2e5fd4",
        "primaryId": "NCT00005879",
        "secondaryId": "NCT01217385",
        "label": "Contradiction",
        "statement_text": "The only criterias for entry to the primary trial and the secondary trial is that patients must be female  over the age of 21 and british ",
        "statement_nums": [
            "21 and british"
        ],
        "premise_text": "creatinine clearance 30 mL/min/1.73 m2 for patients with creatinine levels above institutional normal;If female  postmenopausal for a minimum of one year  OR surgically sterile  OR not pregnant  confirmed by a pregnancy test as per institutional Standard of Care (SOC)  and willing to use adequate contraception (hormonal or barrier method of birth control; abstinence) for the duration of study participation; Able to understand and willing to sign a written informed consent document and a HIPAA authorization in accordance with institutional guidelines; Exclusion Criteria Previous treatment (chemotherapy  radiation  or surgery) to involved breast; including hormone therapy; ",
        "premise_nums": [
            "2 for patients",
            "30 mL/min/1.73"
        ]
    },
    {
        "id": "7dd79595-4bdf-48e6-af94-fe39aa2e5fd4",
        "primaryId": "NCT00005879",
        "secondaryId": "NCT01217385",
        "label": "Contradiction",
        "statement_text": "The only criterias for entry to the primary trial and the secondary trial is that patients must be female  over the age of 21 and british ",
        "statement_nums": [
            "21 and british"
        ],
        "premise_text": "Uncontrolled intercurrent illness including  but not limited to  ongoing or active infection  symptomatic congestive heart failure  unstable angina pectoris  cardiac arrhythmia  or psychiatric illness/social situations that would limit compliance with study requirements;Medically unstable; Under age 18; Pregnant or nursing; Previous malignancy  other than basal cell or squamous cell carcinoma of the skin or in situ carcinoma of the cervix  from which the patient has been disease free for less than 5 years  ",
        "premise_nums": []
    },
    {
        "id": "98850daf-738c-4005-b476-8c5479ad3b79",
        "primaryId": "NCT00033514",
        "statement_text": "Mark has HER2 positive breast cancer  he is eligible for the primary trial ",
        "statement_nums": [
            "2 positive breast"
        ],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria: Women aged greater than 18 years Histologically documents metastatic breast cancer HER2 positive using Fluorescence In Situ Hybridization (FISH) ",
        "premise_nums": [
            "18 years Histologically",
            "2 positive using"
        ]
    },
    {
        "id": "fd8ddc92-4625-4392-b7ef-0ea218e2eb1c",
        "primaryId": "NCT00916578",
        "statement_text": "the primary trial is testing a combination of capecitabine once daily with radiotherapy ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "INTERVENTION 1: Single Arm Institution  Open Label  Phase II Patients will received 825 mg/m2 bid of capecitabine  One of the two daily doses of capecitabine will be taken 2 hours before receiving radiotherapy  Capecitabine will be administered when patients receives radiation therapy  Radiation therapy doses will be 50-57 Gy to the initial clinical target volume  ",
        "premise_nums": [
            "2 bid of",
            "2 hours before",
            "825 mg/m2 bid",
            "57 Gy to",
            "50-57 Gy"
        ]
    },
    {
        "id": "a4ed4cc0-9444-4a5d-863c-578fd42b8794",
        "primaryId": "NCT00425854",
        "statement_text": "Intervention of Cohort B is described as Afatinib 50 mg  taken orally  bi-weekly ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "INTERVENTION 1: Cohort B Patients with HER2-negative, ER-positive and/or PgR-positive tumours receiving oral dose of Afatinib 50 mg qd ",
        "premise_nums": [
            "50 mg qd",
            "2-negative, ER-positive"
        ]
    },
    {
        "id": "a4dcb9b6-7b6f-4467-a159-d6e770f6762f",
        "primaryId": "NCT01313039",
        "secondaryId": "NCT01031446",
        "label": "Entailment",
        "statement_text": "Nursing patients are not eligible for the primary trial or the secondary trial  due to potential harm to the nursing infant from the study interventions ",
        "statement_nums": [],
        "premise_text": "Patients who are pregnant or breast-feeding are excluded from the study due to potential harm to the fetus or nursing infant from the study therapy  Patients of reproductive potential must consent to use of contraception or abstinence to be eligible for the study  Not pregnant or nursing ",
        "premise_nums": []
    },
    {
        "id": "be1c82e6-200d-4bef-b723-c78655fa40e5",
        "primaryId": "NCT00291694",
        "statement_text": "the primary trial does not specificy the route of administration of its intervention ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "INTERVENTION 1: Celecoxib Randomized to receive celecoxib daily for 12 months INTERVENTION 2: Placebo Randomized to receive placebo daily for 12 months ",
        "premise_nums": [
            "12 months INTERVENTION"
        ]
    },
    {
        "id": "790047b1-43e3-486e-b41c-eaa89026eae7",
        "primaryId": "NCT02447328",
        "statement_text": "In the primary trial 11.1% of patients had serious adverse events  no patients had serious Adverse Drug Reactions  and over half of patients had Unexpected adverse events ",
        "statement_nums": [
            "trial 11.1% of patients"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Safety(Percentage of Participants With Adverse Events and/or Adverse Drug Reactions) Percentage of patients with AEs  Time frame: Adverse events were collected from treatment initiation to end of the study about 6 months for each patient  Results 1: Arm/Group Title: Single Arm Arm/Group Description: fulvestrant (Faslodex ) Overall Number of Participants Analyzed: 81 Measure Type: Number Unit of Measure: Percentage of participants Adverse Events(AE): 81.5 (71.3 to 89.3) ADR; based on current South Korea label.: 38.3 (27.7 to 49.7) Serious AE: 11.1 (5.2 to 20.1) Serious ADR: 0 (0 to 4.4) ",
        "premise_nums": [
            "7 to 49.7)",
            "6 months for",
            "81 Measure Type:",
            "2 to 20.1)",
            "3 to 89.3)",
            "0 to 4.4)"
        ]
    },
    {
        "id": "790047b1-43e3-486e-b41c-eaa89026eae7",
        "primaryId": "NCT02447328",
        "statement_text": "In the primary trial 11.1% of patients had serious adverse events  no patients had serious Adverse Drug Reactions  and over half of patients had Unexpected adverse events ",
        "statement_nums": [
            "trial 11.1% of patients"
        ],
        "label": "Entailment",
        "premise_text": "Unexpected AE: 71.6 (60.5 to 81.1)Unexpected ADR: 24.7 (15.8 to 35.5) ",
        "premise_nums": [
            "8 to 35.5)",
            "5 to 81.1)Unexpected"
        ]
    },
    {
        "id": "fc8ed290-e2b3-4eea-a837-d369dcd9b5da",
        "primaryId": "NCT00875979",
        "statement_text": "None of the 3 patients in cohort 1 of the primary trial experienced any adverse events ",
        "statement_nums": [
            "3 patients in",
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 0/3 (0.00%) Pericardial effusion 0/3 (0.00%) Tachycardia 0/3 (0.00%) Nausea 0/3 (0.00%) Vomiting 0/3 (0.00%) Abdominal pain 0/3 (0.00%) Colitis 0/3 (0.00%) Diarrhoea 0/3 (0.00%) Gastritis 0/3 (0.00%) Ileus 0/3 (0.00%) Fatigue 0/3 (0.00%) Pyrexia 0/3 (0.00%) Pain 0/3 (0.00%) Hepatic cirrhosis 0/3 (0.00%) ",
        "premise_nums": [
            "0/3 (0.00%)"
        ]
    },
    {
        "id": "fc8ed290-e2b3-4eea-a837-d369dcd9b5da",
        "primaryId": "NCT00875979",
        "statement_text": "None of the 3 patients in cohort 1 of the primary trial experienced any adverse events ",
        "statement_nums": [
            "3 patients in",
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Cellulitis 0/3 (0.00%)",
        "premise_nums": [
            "0/3 (0.00%)"
        ]
    },
    {
        "id": "207b0895-91de-4238-8d50-e2b8b7420fb0",
        "primaryId": "NCT00559845",
        "secondaryId": "NCT00426556",
        "label": "Entailment",
        "statement_text": "In total there were more adverse events in the secondary trial than in the primary trial ",
        "statement_nums": [],
        "premise_text": "Adverse Events 1: Total: 8/54 (14.81%) Anaemia 1/54 (1.85%) Febrile Neutropenia 1/54 (1.85%) Retinopathy Hypertensive 1/54 (1.85%) Febrile Infection 1/54 (1.85%) Postoperative Wound Complication 1/54 (1.85%) Cardiac Imaging Procedure Abnormal 1/54 (1.85%) Malignant Melanoma In Situ 1/54 (1.85%) Suicide Attempt 1/54 (1.85%) Dyspnoea 1/54 (1.85%) Adverse Events 1: Total: 3/6 (50.00%) Adverse Events 2: Total: 6/17 (35.29%) ",
        "premise_nums": [
            "8/54 (14.81%)",
            "6/17 (35.29%)",
            "3/6 (50.00%)",
            "1/54 (1.85%)"
        ]
    },
    {
        "id": "1340769c-b55c-480c-a4c4-130034e128ce",
        "primaryId": "NCT00317720",
        "statement_text": "Patients must have at least 1 prior treatment with trastuzumab to be eligible for the primary trial ",
        "statement_nums": [
            "1 prior treatment"
        ],
        "label": "Entailment",
        "premise_text": "Inclusion Criteria: History of trastuzumab resistance  defined as the development of progressive disease after trastuzumab-based therapy for metastatic breast cancer  Patient may not have received more than 2 prior trastuzumab-based regimens and one lapatinib-based regimen (either as single agent or in combination with chemotherapy)for metastatic breast cancer  Patients who develop metastatic disease during or after adjuvant or neoadjuvant trastuzumab are eligible  ",
        "premise_nums": [
            "2 prior trastuzumab"
        ]
    },
    {
        "id": "a4d6e27f-737b-4597-86e1-79b3f064cbee",
        "primaryId": "NCT02694029",
        "statement_text": "Candidates for the primary trial are expected to be capable of holding their breath underwater for 30 seconds ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria: Women with diagnosis of breast malignancy Women whom requires left chest wall post-mastectomy radiation with or without bolus Age 18 years  Performance status ECOG smaller than /=3 Women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry  for the duration of study participation  and for 90 days following completion of therapy  Should a woman become pregnant or suspect she is pregnant while participating in this study  she should inform her treating physician immediately Ability to understand and the willingness to sign a written informed consent  Patient must be able to maintain a 30 second breath hold  Conventional chest wall radiation delivery dose of 50.4 Gy/ 28 fractions with or without a boost (boost will not be evaluated for endpoints) Exclusion Criteria: ",
        "premise_nums": [
            "30 second breath",
            "90 days following",
            "28 fractions with",
            "3 Women of"
        ]
    },
    {
        "id": "a4d6e27f-737b-4597-86e1-79b3f064cbee",
        "primaryId": "NCT02694029",
        "statement_text": "Candidates for the primary trial are expected to be capable of holding their breath underwater for 30 seconds ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Uncontrolled intercurrent illness including  but not limited to  ongoing or active infection  symptomatic congestive heart failure  unstable angina pectoris  cardiac arrhythmia  or psychiatric illness/social situations that would limit compliance with study requirements Subjects must not be pregnant or nursing due to the potential for congenital abnormalities and the potential of this regimen to harm nursing infants  ",
        "premise_nums": []
    },
    {
        "id": "3edf0cf2-62ea-4ac6-82aa-2bb1566c6c43",
        "primaryId": "NCT00887575",
        "secondaryId": "NCT01610284",
        "label": "Entailment",
        "statement_text": "Cohort 1 of the secondary trial had more than 3x the cohort size of cohort 1 of the primary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Adverse Events 1: Total: 3/41 (7.32%) Adverse Events 1: Total: 146/573 (25.48%) ",
        "premise_nums": [
            "146/573 (25.48%)",
            "3/41 (7.32%)"
        ]
    },
    {
        "id": "030eded8-6513-4028-b1fe-fefd6dd388ad",
        "primaryId": "NCT02429427",
        "statement_text": "Patients with a platelet count of 50,0000 x 109/l are not eligible for the primary trial",
        "statement_nums": [
            "of 50,0000 x 109",
            "109/l are"
        ],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria: Pre-treatment haematology and biochemistry values within acceptable local limits: Haemoglobin  white blood cell greater or equal to 3.0 x 109/l or absolute neutrophil count greater or equal to 1.51 x 109/l, Platelets greater or equal to 100 x 109/l, Serum bilirubin less than 1.5 x upper normal limit   Alkaline phosphatase less or equal to 1.5 x upper normal limit   Serum creatinine less than 1.5 x upper normal limit ",
        "premise_nums": [
            "to 3.0 x 109",
            "than 1.5 x upper",
            "100 x 109",
            "to 1.5 x upper",
            "to 1.51 x 109",
            "109/l, Serum",
            "109/l or",
            "109/l, Platelets"
        ]
    },
    {
        "id": "412d3ee2-bbfb-4e24-b159-684ae144e742",
        "primaryId": "NCT00054275",
        "statement_text": "A patient with minimal symptoms but a severe obstruction of the left main coronary artery would be unable to participate in the primary trial ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "No New York Heart Association class III or IV heart disease No unstable angina pectoris ",
        "premise_nums": []
    },
    {
        "id": "d1d77877-9c85-41c8-9eca-6fd75b254a15",
        "primaryId": "NCT00768222",
        "statement_text": "Rachel is 19 years old and has skin ulcerations and allergic reactions to triclosan  she cannot take part in the primary trial due to her age ",
        "statement_nums": [
            "19 years old"
        ],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria: 18 years of age or older with written informed consent Exclusion Criteria: Has inflammatory cancers or skin ulceration Has known allergy or intolerance to triclosan ",
        "premise_nums": [
            "18 years of"
        ]
    },
    {
        "id": "c32d1b74-07ab-4afb-9db6-878e20727661",
        "primaryId": "NCT02279108",
        "statement_text": "Adult Patients with Histologically proven Unifocal HER2- infiltrating breast cancer that have not had Previous lumpectomy or same side mammary reduction and have no Contra-indication to surgery are excluded from the primary trial ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria: Histologically proved infiltrating breast cancer (ductal  lobular carcinoma…) or a carcinoma in-situ with an elevated risk of micro-invasion  (High grade with necrosis  radiologically evaluated size more than 40mm, or immediate mastectomy…) Unifocal or multifocal but in same quarter Size smaller than 5cm clinically palpable or not Clinically or ultrasound axillary N0 Isotopic sentinel node detection Adult patient Signed informed consent by patient or legally responsable authority Patient registered to a social security system No surgical contra-indication Exclusion Criteria: ",
        "premise_nums": [
            "0 Isotopic sentinel"
        ]
    },
    {
        "id": "c32d1b74-07ab-4afb-9db6-878e20727661",
        "primaryId": "NCT02279108",
        "statement_text": "Adult Patients with Histologically proven Unifocal HER2- infiltrating breast cancer that have not had Previous lumpectomy or same side mammary reduction and have no Contra-indication to surgery are excluded from the primary trial ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Mammary carcinoma recurrencePrevious same side mammary reduction Previous lumpectomy Contra-indication to surgery Pregnant or breast feeding patient Denial of participation ",
        "premise_nums": []
    },
    {
        "id": "ba0c0dc6-826b-426f-8738-eec23e47f6b0",
        "primaryId": "NCT03045653",
        "statement_text": "Sharone had a hip replacement 2 months prior  she is not elgible for the primary trial ",
        "statement_nums": [
            "2 months prior"
        ],
        "label": "Contradiction",
        "premise_text": "Exclusion Criteria: Major surgery (excluding placement of vascular access) within 4 weeks before study treatment Evidence of severe or uncontrolled systemic diseases  including uncontrolled hypertension  active bleeding diatheses  or active infection including hepatitis B  hepatitis C and HIV With the exception of alopecia  any unresolved toxicities from previous therapy greater than CTCAE grade 1 before study treatment Elevated ALP in absence of bone metastasis Evidence of dementia  altered mental status or any psychiatric condition that would prohibit understanding or rendering of informed consent Participation in another study with investigational product during last 30 days Inability or unwillingness to comply with study procedures  including inability to take regular oral medication ",
        "premise_nums": [
            "1 before study",
            "30 days Inability",
            "4 weeks before"
        ]
    },
    {
        "id": "77982c81-d147-48d9-909c-18b9a98224e9",
        "primaryId": "NCT01301729",
        "secondaryId": "NCT02129556",
        "label": "Contradiction",
        "statement_text": "Only 1 type of infection recorded across the duration of both the secondary trial and the primary trial ",
        "statement_nums": [
            "1 type of"
        ],
        "premise_text": "Adverse Events 1: Total: 5/32 (15.63%) Leukopenia 1/32 (3.13%) Neutropenia 1/32 (3.13%) Cataract 1/32 (3.13%) Infection 1/32 (3.13%) Upper respiratory tract infection 1/32 (3.13%) Completed suicide 1/32 (3.13%) Adverse Events 1: Total: 4/6 (66.67%) Anemia 0/6 (0.00%) Takotsubo cardiomyopathy 1/6 (16.67%) Pericardial effusion 0/6 (0.00%) Vertigo 1/6 (16.67%) Retinal vein occlusion 0/6 (0.00%) ",
        "premise_nums": [
            "5/32 (15.63%)",
            "1/32 (3.13%)",
            "1/6 (16.67%)",
            "4/6 (66.67%)",
            "0/6 (0.00%)"
        ]
    },
    {
        "id": "77982c81-d147-48d9-909c-18b9a98224e9",
        "primaryId": "NCT01301729",
        "secondaryId": "NCT02129556",
        "label": "Contradiction",
        "statement_text": "Only 1 type of infection recorded across the duration of both the secondary trial and the primary trial ",
        "statement_nums": [
            "1 type of"
        ],
        "premise_text": "Gastroenteritis 1/6 (16.67%)Vomiting 1/6 (16.67%) Diarrhea 0/6 (0.00%) Death 2/6 (33.33%) Bile duct dilatation 0/6 (0.00%) Hepatic hemorrhage 0/6 (0.00%) Adverse Events 2: Total: 25/52 (48.08%) Anemia 1/52 (1.92%) Takotsubo cardiomyopathy 0/52 (0.00%) Pericardial effusion 2/52 (3.85%) Vertigo 0/52 (0.00%) Retinal vein occlusion 1/52 (1.92%) ",
        "premise_nums": [
            "0/52 (0.00%)",
            "2/6 (33.33%)",
            "25/52 (48.08%)",
            "1/52 (1.92%)",
            "2/52 (3.85%)",
            "0/6 (0.00%)",
            "1/6 (16.67%)Vomiting"
        ]
    },
    {
        "id": "77982c81-d147-48d9-909c-18b9a98224e9",
        "primaryId": "NCT01301729",
        "secondaryId": "NCT02129556",
        "label": "Contradiction",
        "statement_text": "Only 1 type of infection recorded across the duration of both the secondary trial and the primary trial ",
        "statement_nums": [
            "1 type of"
        ],
        "premise_text": "Gastroenteritis 0/52 (0.00%)Vomiting 0/52 (0.00%) Diarrhea 1/52 (1.92%) Death 9/52 (17.31%) Bile duct dilatation 1/52 (1.92%) Hepatic hemorrhage 1/52 (1.92%) ",
        "premise_nums": [
            "0/52 (0.00%)Vomiting",
            "1/52 (1.92%)",
            "9/52 (17.31%)"
        ]
    },
    {
        "id": "7f1af51d-e22b-4285-aea4-3dc80c3ab2ec",
        "primaryId": "NCT00687440",
        "secondaryId": "NCT01307891",
        "label": "Contradiction",
        "statement_text": "Results from the primary trial and the secondary trial indicate Abraxane + Tigatuzumab produce better ORR than Caelyx  Docetaxe and Trastuzumab ",
        "statement_nums": [],
        "premise_text": "Outcome Measurement: Number of Participants Who Had a Tumor Response  According to Standard RECIST (Response Evaluation Criteria in Solid Tumors) Criteria Those who achieved either complete (disappearance of all target lesions) or partial (at least 30% decrease in the sum of the longest diameter (LD) of target lesions  taking as reference the baseline sum LD) response  Time frame: Week 09, Week 18, at the end of each patient's treatment  and at 3, 6, 9, and 12 months after end of treatment  Results 1: Arm/Group Title: Caelyx  Docetaxel  Trastuzumab ",
        "premise_nums": [
            "30% decrease",
            "12 months after"
        ]
    },
    {
        "id": "7f1af51d-e22b-4285-aea4-3dc80c3ab2ec",
        "primaryId": "NCT00687440",
        "secondaryId": "NCT01307891",
        "label": "Contradiction",
        "statement_text": "Results from the primary trial and the secondary trial indicate Abraxane + Tigatuzumab produce better ORR than Caelyx  Docetaxe and Trastuzumab ",
        "statement_nums": [],
        "premise_text": "Arm/Group Description: Stage 1: subjects will receive Caelyx one day every 3 weeks in combination with docetaxel one day every 3 weeks and trastuzumab once weekly during 6 cycles  At the end of this stage  based on the number of cardiac events  subjects will proceed to a second stage or restart with a lower dose of Caelyx Stage 2: subjects will be treated with the recommended dose of Caelyx (defined in the first stage) in combination with docetaxel and trastuzumab  Overall Number of Participants Analyzed: 26 Measure Type: Number Unit of Measure: Participants Participants who had a complete tumor response: 2 Participants who had a partial tumor response: 13 Participants who did not have a tumor response: 11 ",
        "premise_nums": [
            "26 Measure Type:",
            "2 Participants who",
            "3 weeks and",
            "13 Participants who",
            "3 weeks in"
        ]
    },
    {
        "id": "7f1af51d-e22b-4285-aea4-3dc80c3ab2ec",
        "primaryId": "NCT00687440",
        "secondaryId": "NCT01307891",
        "label": "Contradiction",
        "statement_text": "Results from the primary trial and the secondary trial indicate Abraxane + Tigatuzumab produce better ORR than Caelyx  Docetaxe and Trastuzumab ",
        "statement_nums": [],
        "premise_text": "Outcome Measurement:Objective Response Rate Patient response rates will be measured by the Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI  Responses include the following: Complete Response (CR) disappearance of all target lesions; Partial Response (PR) at least a 30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) best response from the start of treatment until disease progression  Time frame: Baseline to 6 months Results 1: Arm/Group Title: Abraxane + Tigatuzumab ",
        "premise_nums": [
            "30% decrease",
            "6 months Results"
        ]
    },
    {
        "id": "7f1af51d-e22b-4285-aea4-3dc80c3ab2ec",
        "primaryId": "NCT00687440",
        "secondaryId": "NCT01307891",
        "label": "Contradiction",
        "statement_text": "Results from the primary trial and the secondary trial indicate Abraxane + Tigatuzumab produce better ORR than Caelyx  Docetaxe and Trastuzumab ",
        "statement_nums": [],
        "premise_text": "Arm/Group Description: Patients will receive Abraxane at 100 mg/m2 X 3 doses on Days 1, 8, and 15 at 28-day intervals and tigatuzumab to be administered as a 10 mg/kg loading dose followed by 5 mg/kg for the first cycle and then every other week on Days 1 and 15 for subsequent cycles  Patients will be evaluated for response every 8 weeks  Patients with disease progression will be taken off the study Overall Number of Participants Analyzed: 39 Measure Type: Number Unit of Measure: percentage of patients 28 (14.9 to 45.0) Results 2: Arm/Group Title: Abraxane Alone ",
        "premise_nums": [
            "100 mg/m2 X",
            "9 to 45.0)",
            "2 X 3",
            "15 at 28",
            "1 and 15",
            "39 Measure Type:",
            "5 mg/kg for",
            "10 mg/kg loading",
            "3 doses on",
            "28-day intervals"
        ]
    },
    {
        "id": "7f1af51d-e22b-4285-aea4-3dc80c3ab2ec",
        "primaryId": "NCT00687440",
        "secondaryId": "NCT01307891",
        "label": "Contradiction",
        "statement_text": "Results from the primary trial and the secondary trial indicate Abraxane + Tigatuzumab produce better ORR than Caelyx  Docetaxe and Trastuzumab ",
        "statement_nums": [],
        "premise_text": "Arm/Group Description: Patients will receive Abraxane at 100 mg/m2 weekly X 3 doses on Days 1, 8, and 15 at 28-day intervals  Abraxane will be administered on an outpatient basis by an IV infusion over 30 minutes  Patients will be evaluated for response every 2 cycles (every 8 weeks) Overall Number of Participants Analyzed: 21 Measure Type: Number Unit of Measure: percentage of patients 38 (18 to 61.1) ",
        "premise_nums": [
            "2 weekly X",
            "18 to 61.1)",
            "2 cycles (every",
            "21 Measure Type:",
            "15 at 28",
            "100 mg/m2 weekly",
            "3 doses on",
            "28-day intervals"
        ]
    },
    {
        "id": "2e03f6f1-0d4f-4ebf-8781-20918d70d78f",
        "primaryId": "NCT02165605",
        "statement_text": "A 56 year old patient with a masectomy would not be eligible for the primary trial",
        "statement_nums": [
            "56 year old"
        ],
        "label": "Entailment",
        "premise_text": "Inclusion Criteria: Female  age 18 or older Intact breast (not surgically absent) ",
        "premise_nums": [
            "18 or older"
        ]
    },
    {
        "id": "57e74ef2-f170-47bd-a908-2a7b3cec150d",
        "primaryId": "NCT00482391",
        "statement_text": "Patients with No QT prolongation are excluded from the primary trial ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "No QT prolongation (greater than 500 ms) ",
        "premise_nums": []
    },
    {
        "id": "b5957a75-140f-445b-99dc-199b8182b8ed",
        "primaryId": "NCT01805089",
        "statement_text": "pre-menopausal patients with Lactiferous duct carcinomas are eligible for the primary trial ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria: History of ductal carcinoma in situ  lobular carcinoma in situ or stages 1-3 breast cancer Postmenopausal ",
        "premise_nums": [
            "1-3 breast",
            "3 breast cancer"
        ]
    },
    {
        "id": "142cc983-b0cc-4f9f-b3ef-4eb57e2a317b",
        "primaryId": "NCT00486525",
        "statement_text": "The difference between the two cohorts of the primary trial is that cohort 1 received higher doses of IMGN853, whereas cohort 2 received lower doses more frequently ",
        "statement_nums": [
            "1 received higher",
            "2 received lower"
        ],
        "label": "Contradiction",
        "premise_text": "INTERVENTION 1: Arm I: Yoga Therapy Patients participated in a Hatha yoga session over 90 minutes twice weekly for 12 weeks  Patients were also encouraged to practice yoga at home  Patients recorded their total home/class practice time in weekly logs  INTERVENTION 2: Arm II: Wait-List Wait-listed women were told to continue performing their usual activities  and to refrain from beginning any yoga practice  After their final assessment they were offered the yoga classes  ",
        "premise_nums": [
            "90 minutes twice"
        ]
    },
    {
        "id": "f57350c2-ac90-47ea-92b4-d903509bf07a",
        "primaryId": "NCT03252431",
        "statement_text": "patients from both arms of the primary trial experienced Grade 4 Neutropenia for the same amount of time  There was no recorded difference whatsoever ",
        "statement_nums": [
            "4 Neutropenia for"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Duration in Days of Grade 4 Neutropenia in Chemotherapy Cycle 1 ",
        "premise_nums": [
            "4 Neutropenia in"
        ]
    },
    {
        "id": "f57350c2-ac90-47ea-92b4-d903509bf07a",
        "primaryId": "NCT03252431",
        "statement_text": "patients from both arms of the primary trial experienced Grade 4 Neutropenia for the same amount of time  There was no recorded difference whatsoever ",
        "statement_nums": [
            "4 Neutropenia for"
        ],
        "label": "Contradiction",
        "premise_text": "Eligible subjects were randomized in a 1:1 ratio  Subjects were dosed with either the F 627 20 mg/dose PFS or Neulasta® 6 mg/dose as the study drug in each chemotherapy cycle  Subjects remained in their assigned treatment arm throughout the study  Subjects were dosed subcutaneously (SC) 24 to 28 hours after receiving TC chemotherapy (75 mg/m2 docetaxel + 600 mg/m2 cyclophosphamide) on Day 2 of each chemotherapy cycle that the subject underwent (up to 4 cycles)  Grade 4 (severe) neutropenia was defined as ANC smaller than 0.5 × 109/L within the first 12 days of chemotherapy ",
        "premise_nums": [
            "6 mg/dose as",
            "109/L within",
            "1:1 ratio",
            "12 days of",
            "24 to 28",
            "600 mg/m2 cyclophosphamide",
            "20 mg/dose PFS",
            "2 of each"
        ]
    },
    {
        "id": "f57350c2-ac90-47ea-92b4-d903509bf07a",
        "primaryId": "NCT03252431",
        "statement_text": "patients from both arms of the primary trial experienced Grade 4 Neutropenia for the same amount of time  There was no recorded difference whatsoever ",
        "statement_nums": [
            "4 Neutropenia for"
        ],
        "label": "Contradiction",
        "premise_text": "Time frame: The first of 4, 21-day chemotherapy cycles (average 3 weeks)Results 1: Arm/Group Title: F-627 Arm/Group Description: F-627, 20 mg fixed dose pre-filled syringe  administered on Day 2 of each of 4 chemotherapy cycles  F-627: single dose pre-filled syringe Overall Number of Participants Analyzed: 197 Mean (Standard Deviation) Unit of Measure: days 0.2 (0.51) Results 2: Arm/Group Title: Neulasta Arm/Group Description: 6 mg fixed dose Neulasta   administered on Day 2 of each of 4 chemotherapy cycles Neulasta: single dose pre-filled syringe Overall Number of Participants Analyzed: 196 Mean (Standard Deviation) ",
        "premise_nums": [
            "20 mg fixed",
            "197 Mean (Standard",
            "196 Mean (Standard",
            "6 mg fixed",
            "21-day chemotherapy",
            "4 chemotherapy cycles",
            "2 of each"
        ]
    },
    {
        "id": "f57350c2-ac90-47ea-92b4-d903509bf07a",
        "primaryId": "NCT03252431",
        "statement_text": "patients from both arms of the primary trial experienced Grade 4 Neutropenia for the same amount of time  There was no recorded difference whatsoever ",
        "statement_nums": [
            "4 Neutropenia for"
        ],
        "label": "Contradiction",
        "premise_text": "Unit of Measure: days 0.2 (0.45)",
        "premise_nums": []
    },
    {
        "id": "77c61307-567d-4ac2-a7f7-85feffd30473",
        "primaryId": "NCT00167414",
        "statement_text": "Patients do not need to have a known hormone receptor status to participate in the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Inclusion Criteria: Age: no limit Karnofsky performance status (KPS) 70 No more than 5 metastatic sites involving one or more different organs (liver  lung or bone)  The size of the lesion must be such that it can be safely treated to sterilizing radiation doses according to the rules in the protocol  Previously treated lesions are not eligible unless the prescribed dose can be safely delivered  Concurrent therapy is allowed and recommended  The chemotherapy protocol type and schedule are at the discretion of the medical oncologist  Informed consent must be obtained  Pregnancy test must be negative for women of child bearing potential Exclusion Criteria: Inability of patient to be followed longitudinally as specified by protocol  Technical inability to achieve required dose based on safe dose constraints required for radiosurgery  Women who are pregnant or nursing  Failure to meet requirements in Inclusion Criteria Contraindications to radiation  ",
        "premise_nums": [
            "70 No more",
            "5 metastatic sites"
        ]
    },
    {
        "id": "35dd977f-53d8-4400-b5cb-34caaa938e78",
        "primaryId": "NCT00764322",
        "statement_text": "The Ultra-rapid Metabolizers group of the primary trial had average increase of Endoxifen Concentration over 6 mg/m2 over 4 months ",
        "statement_nums": [
            "6 mg/m2 over",
            "2 over 4"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Endoxifen Concentrations in Participants Receiving Tamoxifen Citrate Dose of 20 mg or 40 mg Stratified by the Metabolizing CYP2D6 Genotypes ",
        "premise_nums": [
            "40 mg Stratified",
            "20 mg or"
        ]
    },
    {
        "id": "35dd977f-53d8-4400-b5cb-34caaa938e78",
        "primaryId": "NCT00764322",
        "statement_text": "The Ultra-rapid Metabolizers group of the primary trial had average increase of Endoxifen Concentration over 6 mg/m2 over 4 months ",
        "statement_nums": [
            "6 mg/m2 over",
            "2 over 4"
        ],
        "label": "Contradiction",
        "premise_text": "Measurements of plasma concentrations of the key active metabolite of tamoxifen  endoxifen  were measured at baseline and after 4 months of treatment; The most common CYP2D6 alleles have been grouped by functional activity classifications with descending activity: ultra-rapid (UM)  extensive (EM)  intermediate (IM) or poor (PM) metabolism  A given patient has two alleles  giving them 10 possible allelic combinations  or diplotypes (UM/UM  UM/EM  EM/EM  etc.)  These diplotypes are collapsed into four phenotypes  UM  EM  IM or PM Time frame: 4 months Results 1: Arm/Group Title: Ultra-rapid Metabolizers ",
        "premise_nums": [
            "6 alleles have",
            "4 months of",
            "10 possible allelic",
            "4 months Results"
        ]
    },
    {
        "id": "35dd977f-53d8-4400-b5cb-34caaa938e78",
        "primaryId": "NCT00764322",
        "statement_text": "The Ultra-rapid Metabolizers group of the primary trial had average increase of Endoxifen Concentration over 6 mg/m2 over 4 months ",
        "statement_nums": [
            "6 mg/m2 over",
            "2 over 4"
        ],
        "label": "Contradiction",
        "premise_text": "Arm/Group Description: Those with the highest transformation of the CYP2D6 genotype to allelic activityOverall Number of Participants Analyzed: 5 Mean (Standard Deviation) Unit of Measure: ng/mL Baseline endoxifen concentration: 5 participants 8.4 (4.59) 4-Month endoxifen concentration: 4 participants 15.35 (5.48) ",
        "premise_nums": [
            "5 Mean (Standard",
            "6 genotype to",
            "4 participants 15.35",
            "5 participants 8.4",
            "4-Month endoxifen"
        ]
    },
    {
        "id": "54554da5-e67f-4da5-819b-a85b7bc5d52c",
        "primaryId": "NCT00444535",
        "statement_text": "Less than 1/3 participants in the primary trial achieved Progression-free Survival Rate After 12 Weeks of Study Treatment ",
        "statement_nums": [
            "12 Weeks of",
            "1/3 participants",
            "3 participants in"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Investigator-evaluated Crude Progression-free Survival Rate After 12 Weeks of Study Treatment The PFS rate is defined as the percentage of subjects who have shown no evidence of disease progression or death from any cause following 12 weeks of treatment  Disease progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions  or a measurable increase in a non-target lesion  or the appearance of new lesions  Since there is no independent reviewer  only the investigator response was reported  Time frame: up to week 12 Results 1: Arm/Group Title: Lapatinib + Bevacizumab ",
        "premise_nums": [
            "12 Weeks of",
            "12 Results 1:",
            "12 weeks of",
            "20% increase"
        ]
    },
    {
        "id": "54554da5-e67f-4da5-819b-a85b7bc5d52c",
        "primaryId": "NCT00444535",
        "statement_text": "Less than 1/3 participants in the primary trial achieved Progression-free Survival Rate After 12 Weeks of Study Treatment ",
        "statement_nums": [
            "12 Weeks of",
            "1/3 participants",
            "3 participants in"
        ],
        "label": "Entailment",
        "premise_text": "Arm/Group Description: Lapatinib (1500 mg once daily taken orally) and bevacizumab (10 mg/kg intravenously [IV] every two weeks)Overall Number of Participants Analyzed: 52 Measure Type: Count of Participants Unit of Measure: Participants No disease progression by Week 12: 36 69.2% Disease progression or death by Week 12: 16 30.8% ",
        "premise_nums": [
            "36 69.2% Disease progression",
            "1500 mg once",
            "52 Measure Type:"
        ]
    },
    {
        "id": "592edd64-7841-4c19-ba75-583066308137",
        "primaryId": "NCT00343863",
        "statement_text": "On days 1-7 Cohort 1 of the primary trial receive doxorubicin hydrochloride IV  oral cyclophosphamide  dexamethasone IV or orally and ondansetron IV ",
        "statement_nums": [
            "7 Cohort 1",
            "1-7 Cohort",
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "INTERVENTION 1: Dexamethasone + Ondansetron IV All patients receive doxorubicin hydrochloride IV on day 1 and oral cyclophosphamide on days 1-7. Patients receive dexamethasone IV or orally and ondansetron IV on day 1 (prior to each dose of doxorubicin hydrochloride)  ",
        "premise_nums": [
            "1 and oral",
            "1-7. Patients"
        ]
    },
    {
        "id": "a1d207c8-2d57-4c49-89fa-60ceacf65829",
        "primaryId": "NCT00228943",
        "statement_text": "Clinically depressed patients are not able to participate in the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Exclusion Criteria: Exclusion criteria are current depression  history of migraines or hepatitis  abnormal chemistry profile (e.g.  sodium  potassium  glucose)  or a positive urine drug screen for illegal substances  ",
        "premise_nums": []
    },
    {
        "id": "4a8f0562-355b-4a68-8790-c283d93ce766",
        "primaryId": "NCT00093808",
        "secondaryId": "NCT00394082",
        "label": "Contradiction",
        "statement_text": "the primary trial and the secondary trial reported the same percentage of dehydrated patients during the studies ",
        "statement_nums": [],
        "premise_text": "Dehydration 1/46 (2.17%) Dehydration 1/50 (2.00%) ",
        "premise_nums": [
            "1/46 (2.17%)",
            "1/50 (2.00%)"
        ]
    },
    {
        "id": "04a9b8af-d01f-4090-97e2-0c0fcf8f7fe4",
        "primaryId": "NCT02491892",
        "secondaryId": "NCT00887575",
        "label": "Entailment",
        "statement_text": "Cohort 1 of the secondary trial recorded more cases of diarrhea and dyspepsia than cohort 1 of the primary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Adverse Events 1: Diarrhoea * 0/41 (0.00%) Dysphagia * 0/41 (0.00%) Adverse Events 1: DIARRHEA 1/41 (2.44%) DYSPEPSIA 1/41 (2.44%) ",
        "premise_nums": [
            "0/41 (0.00%)",
            "1/41 (2.44%)"
        ]
    },
    {
        "id": "3cd353ed-af0d-4356-8f45-efc1e91a2a0d",
        "primaryId": "NCT02878057",
        "statement_text": "Patients that are ambulatory and capable of all selfcare but unable to carry out any work activities  are excluded from the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Inclusion Criteria: Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. ",
        "premise_nums": []
    },
    {
        "id": "b8473ae8-11c9-4578-aab8-ee96e6287715",
        "primaryId": "NCT00580333",
        "secondaryId": "NCT00934856",
        "label": "Entailment",
        "statement_text": "Candidates must have a life expectancy exceeding 3 months to particpate in the primary trial  there is no mimimum life expectancy define for the secondary trial ",
        "statement_nums": [
            "3 months to"
        ],
        "premise_text": "Exclusion Criteria: Life expectancy of less than 12 weeks Inclusion Criteria: Eastern Cooperative Oncology Group (ECOG) performance status 0-1 (ECOG performance status of 2 will be allowed if only due to debilitating bone disease) HER2-positive metastatic or locally advanced breast cancer For MBC participants: Documented metastatic or inoperable locally advanced (without meeting LABC criteria) disease  amenable for treatment with docetaxel History of disease progression within 3 months prior to study entry For LABC participants: Newly diagnosed locally advanced breast cancer  Stage IIA-IIIC (American Joint Committee on Cancer [AJCC] staging system) Exclusion Criteria: Significant cardiac disease Inadequate bone marrow  liver or renal function For MBC participants: ",
        "premise_nums": [
            "3 months prior",
            "12 weeks Inclusion",
            "2 will be",
            "2-positive metastatic"
        ]
    },
    {
        "id": "b8473ae8-11c9-4578-aab8-ee96e6287715",
        "primaryId": "NCT00580333",
        "secondaryId": "NCT00934856",
        "label": "Entailment",
        "statement_text": "Candidates must have a life expectancy exceeding 3 months to particpate in the primary trial  there is no mimimum life expectancy define for the secondary trial ",
        "statement_nums": [
            "3 months to"
        ],
        "premise_text": "Participants must not have received radiotherapy for the treatment of metastatic or locally recurrent/advanced disease other than for the relief of pain in progressing metastatic bone lesions and/or brain metastasesBrain metastases that are untreated  symptomatic or require therapy to control symptoms; or any radiation  surgery  or other therapy to control symptoms from brain metastasis within 2 months of the first study treatment  For LABC participants: Clinically or radiologically detectable metastasis (M1 disease) Participants for whom surgery as primary intent procedure is the best option to treat their disease Participants must not have received any systemic or loco-regional anti-cancer therapy for the treatment of locally advanced disease ",
        "premise_nums": [
            "2 months of"
        ]
    },
    {
        "id": "4243dc45-5a64-486d-ae2a-11448db00dcf",
        "primaryId": "NCT00246090",
        "secondaryId": "NCT00266799",
        "label": "Entailment",
        "statement_text": "Cohort 1 of the primary trial 15% less total adverse events than cohort 2 of the secondary trial ",
        "statement_nums": [
            "2 of the",
            "15% less",
            "1 of the"
        ],
        "premise_text": "Adverse Events 1: Total: 88/291 (30.24%) Adverse Events 2: Total: 46/102 (45.10%) ",
        "premise_nums": [
            "88/291 (30.24%)",
            "46/102 (45.10%)"
        ]
    },
    {
        "id": "fb5fc14d-2bd9-4a02-9f6a-635c0055a8d5",
        "primaryId": "NCT00073528",
        "secondaryId": "NCT00191152",
        "label": "Contradiction",
        "statement_text": "cohort 1 of the secondary trial had a much longer median PFS than cohort 1 of the primary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Outcome Measurement: Number of Participants With Progression Free Survival (PFS) in the Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced or Metastatic Breast Cancer as Assessed by the Investigator PFS is defined as the time from randomization until the earliest date of disease progression (PD) or death due to any cause  if sooner  The date of documented PD is defined as the date of radiological PD as assessed by the investigator based on imaging data and also by the clinical assessment of symptomatic progression  Per Response Evaluation Criteria in Solid Tumors (RECIST 1.0), PD is defined as a 20% increase in the sum of the longest diameter (LD) of target lesions  taking as a reference the smallest sum LD recorded since the treatment started  or the appearance of 1 or more new lesions  ",
        "premise_nums": [
            "1 or more",
            "20% increase"
        ]
    },
    {
        "id": "fb5fc14d-2bd9-4a02-9f6a-635c0055a8d5",
        "primaryId": "NCT00073528",
        "secondaryId": "NCT00191152",
        "label": "Contradiction",
        "statement_text": "cohort 1 of the secondary trial had a much longer median PFS than cohort 1 of the primary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Time frame: From the date of randomization until the date of the first documented progression or date of death from any cause  whichever came first  assessed for up to 46 monthsResults 1: Arm/Group Title: Placebo + Letrozole 2.5 mg Arm/Group Description: Participants received 6 tablets of placebo  identical in appearance to lapatinib tablets  orally daily (approximately at the same time each day)  either 1 hour (or more) before breakfast or 1 hour (or more) after breakfast  Participants also received 1 tablet of letrozole 2.5 milligrams (mg) orally daily  preferably with the daily dose of lapatinib  Overall Number of Participants Analyzed: 108 Measure Type: Count of Participants Unit of Measure: Participants 89 82.4% Results 2: ",
        "premise_nums": [
            "1 tablet of",
            "89 82.4% Results 2",
            "6 tablets of",
            "1 hour (or",
            "46 monthsResults 1:",
            "108 Measure Type:",
            "Letrozole 2.5 mg Arm",
            "5 milligrams (mg)"
        ]
    },
    {
        "id": "fb5fc14d-2bd9-4a02-9f6a-635c0055a8d5",
        "primaryId": "NCT00073528",
        "secondaryId": "NCT00191152",
        "label": "Contradiction",
        "statement_text": "cohort 1 of the secondary trial had a much longer median PFS than cohort 1 of the primary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Arm/Group Title: Lapatinib 1500 mg + Letrozole 2.5 mgArm/Group Description: Participants received 6 tablets of Lapatinib orally daily (250 mg lapatinib/tablet for a total of 1500 mg of lapatinib/day; approximately at the same time each day)  either 1 hour (or more) before breakfast or 1 hour (or more) after breakfast  Participants also received 1 tablet of letrozole 2.5 mg orally daily  preferably with the daily dose of lapatinib  Overall Number of Participants Analyzed: 111 Measure Type: Count of Participants Unit of Measure: Participants 88 79.3% Outcome Measurement: Time to Disease Progression (Initial Treatment) ",
        "premise_nums": [
            "88 79.3% Outcome Measurement",
            "1 tablet of",
            "1500 mg of",
            "6 tablets of",
            "1 hour (or",
            "Letrozole 2.5 mgArm/Group",
            "111 Measure Type:",
            "letrozole 2.5 mg orally"
        ]
    },
    {
        "id": "fb5fc14d-2bd9-4a02-9f6a-635c0055a8d5",
        "primaryId": "NCT00073528",
        "secondaryId": "NCT00191152",
        "label": "Contradiction",
        "statement_text": "cohort 1 of the secondary trial had a much longer median PFS than cohort 1 of the primary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Time to disease progression (TTDP) at initial treatment was defined as the number of months between date of randomization and the date of first documented disease progression or the date of death due to disease under study  whichever came first  TTDP censored at earliest of: 1) date of death not due to disease; or 2) date of last contact for participants alive without disease progression; or 3) start date of other anti-tumor therapy; or 4) first dose date of crossover treatment Time frame: Randomization date to the earliest date of first documented disease progression date or the date of death if the participant died due to study disease (up to 82 months) Results 1: Arm/Group Title: Gemcitabine Plus Docetaxel ",
        "premise_nums": []
    },
    {
        "id": "fb5fc14d-2bd9-4a02-9f6a-635c0055a8d5",
        "primaryId": "NCT00073528",
        "secondaryId": "NCT00191152",
        "label": "Contradiction",
        "statement_text": "cohort 1 of the secondary trial had a much longer median PFS than cohort 1 of the primary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Arm/Group Description: gemcitabine 1000 milligrams per meter squared (mg/m2) intravenous  days 1 and 8 every 21 days plus docetaxel 75 mg/m2, intravenous  day 1 every 21 days Treatment continues until progression of disease at which time crossover treatment begins  Overall Number of Participants Analyzed: 239 Median (95% Confidence Interval) Unit of Measure: months 9.28 (7.73 to 10.79) ",
        "premise_nums": [
            "1000 milligrams per",
            "75 mg/m2,",
            "1 every 21",
            "73 to 10.79)",
            "1 and 8",
            "95% Confidence",
            "21 days plus"
        ]
    },
    {
        "id": "f616e3d8-6c1a-4b99-ac79-ea87895e37b7",
        "primaryId": "NCT00902330",
        "secondaryId": "NCT00952731",
        "label": "Entailment",
        "statement_text": "Cohort 2 of the primary trial is the control group and cohort 1 is the control group in the secondary trial ",
        "statement_nums": [
            "2 of the",
            "1 is the"
        ],
        "premise_text": "INTERVENTION 1: Arm I (Cranial Microcurrent Electrical Stimulation [CES]) Patients receive a CES unit (Alpha-Stim® 100 Microcurrent Stimulator) that passes microcurrent levels of biphasic electrical stimulation via ear-lobe electrodes  The CES unit is preset to provide 1 hour of 100 μA (sub-sensory level)  modified square-wave biphasic stimulation on a 50% duty cycle at .05 Hz  and to automatically turn off at the end of 1 hour  Patients use their CES unit once daily in weeks 1-18. energy-based therapy: Given once a day for 18 weeks INTERVENTION 2: Arm II (Sham CES) ",
        "premise_nums": [
            "1 hour of",
            "100 Microcurrent Stimulator)",
            "1-18. energy-based",
            "50% duty",
            "18 weeks INTERVENTION"
        ]
    },
    {
        "id": "f616e3d8-6c1a-4b99-ac79-ea87895e37b7",
        "primaryId": "NCT00902330",
        "secondaryId": "NCT00952731",
        "label": "Entailment",
        "statement_text": "Cohort 2 of the primary trial is the control group and cohort 1 is the control group in the secondary trial ",
        "statement_nums": [
            "2 of the",
            "1 is the"
        ],
        "premise_text": "Patients receive a CES unit as in arm I  but the ear-lobe electrodes do not pass electrical current  Patients use their CES unit once daily in weeks 1-18.sham intervention: Given once a day for 18 weeks INTERVENTION 1: Treatment Gel + Oral Placebo 4-hydroxytamoxifen gel 2mg/breast applied daily  Oral placebo taken daily  oral placebo: Oral placebo taken daily for 4-10 weeks  afimoxifene: 2mg/breast applied daily in the form of a gel for 4-10 weeks  INTERVENTION 2: Placebo Gel + Oral Treatment Placebo gel applied to the breasts daily  20mg oral tamoxifen taken daily (taken as two (2) 10mg capsules)  ",
        "premise_nums": [
            "4-hydroxytamoxifen gel",
            "2mg/breast applied",
            "1-18.sham intervention:",
            "4-10 weeks",
            "18 weeks INTERVENTION"
        ]
    },
    {
        "id": "f616e3d8-6c1a-4b99-ac79-ea87895e37b7",
        "primaryId": "NCT00902330",
        "secondaryId": "NCT00952731",
        "label": "Entailment",
        "statement_text": "Cohort 2 of the primary trial is the control group and cohort 1 is the control group in the secondary trial ",
        "statement_nums": [
            "2 of the",
            "1 is the"
        ],
        "premise_text": "tamoxifen citrate: 20mg oral tamoxifen taken daily (taken as two (2) 10mg capsules) for 4-10 weeks placebo gel: Placebo gel applied to breasts daily for 4-10 weeks  ",
        "premise_nums": [
            "10 weeks placebo",
            "4-10 weeks"
        ]
    },
    {
        "id": "2f700407-8baf-4e5f-8fc0-378a294512f5",
        "primaryId": "NCT01313039",
        "secondaryId": "NCT01031446",
        "label": "Contradiction",
        "statement_text": "Nursing patients are not eligible for the primary trial or the secondary trial  due to potential harm to the father from the study interventions ",
        "statement_nums": [],
        "premise_text": "Patients who are pregnant or breast-feeding are excluded from the study due to potential harm to the fetus or nursing infant from the study therapy  Patients of reproductive potential must consent to use of contraception or abstinence to be eligible for the study  Not pregnant or nursing ",
        "premise_nums": []
    },
    {
        "id": "cebee448-235d-49ff-8e87-56639399548b",
        "primaryId": "NCT02287675",
        "statement_text": "Informed consent is optional for entry in the primary trial ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria: The subject must provide written informed consent with Health Insurance Portability and Accountability Act (HIPAA) authorization before participating in the study ",
        "premise_nums": []
    },
    {
        "id": "d3f0dd2f-a5b9-4ff4-8a6b-65c9947cb710",
        "primaryId": "NCT01073865",
        "statement_text": "Females over the age of 18, whose last period was 2 years prior to randomisation are eligible for the primary trial ",
        "statement_nums": [
            "2 years prior"
        ],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria: Female 20 years and pre-menopausal.Pre-menopausal defined as 1) last menses within 1 year of randomisation  and 2) E2 10 pg/mL and FSH 30 mIU/mL within 4 weeks of randomisation  ",
        "premise_nums": [
            "10 pg/mL and",
            "1 year of",
            "30 mIU/mL within",
            "4 weeks of",
            "20 years and"
        ]
    },
    {
        "id": "7a981da3-dc7f-4e1f-ae5b-26e5399ba2a5",
        "primaryId": "NCT02187744",
        "statement_text": "sepsis  due to the presence of an implanted device was a common adverse event in the primary trial",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Device related sepsis 1/113 (0.88%) ",
        "premise_nums": [
            "1/113 (0.88%)"
        ]
    },
    {
        "id": "af677d94-a376-42ea-93fe-91963a071199",
        "primaryId": "NCT00676793",
        "secondaryId": "NCT01931163",
        "label": "Entailment",
        "statement_text": "Patients with dysphagia cannot participate in the secondary trial  but may be eligible for the primary trial ",
        "statement_nums": [],
        "premise_text": "Inclusion Criteria: Definitive biopsy demonstrating primary breast cancer Residual breast cancer requiring additional surgical resection Stage I  II or III disease Patient has ability to give signed informed consent Normal hepatic and renal function (creatininesmaller than 1.5, transaminases smaller than 1.5 times upper limit of normal)  ECOG Performance status of 0 or 1. Age 21 years and less than 75 Exclusion Criteria: Prior hormonal or surgical therapy for breast cancer Abnormal liver function test Liver or kidney problems that would interfere with metabolism of study drug Any condition that would hamper informed consent or ability to comply with study protocol Participation in another research study in the last three months Known malignancy at any site other than breast Recent consumption of green tea (5 or more cups per day  within one week prior to biopsy) ",
        "premise_nums": [
            "21 years and",
            "0 or 1.",
            "75 Exclusion Criteria:",
            "5 or more",
            "than 1.5 times upper"
        ]
    },
    {
        "id": "af677d94-a376-42ea-93fe-91963a071199",
        "primaryId": "NCT00676793",
        "secondaryId": "NCT01931163",
        "label": "Entailment",
        "statement_text": "Patients with dysphagia cannot participate in the secondary trial  but may be eligible for the primary trial ",
        "statement_nums": [],
        "premise_text": "Allergy or intolerance to any component of green teaInability or refusal to comply with definitive surgical therapy Inclusion Criteria: Able to swallow and retain oral medication  ",
        "premise_nums": []
    },
    {
        "id": "6579e25e-8dcf-44b5-a50d-7c84672cba89",
        "primaryId": "NCT00981305",
        "statement_text": "Only people who have previously been diagnosed with cancer and are currently receiving ongoing treatment for their primary tumor are eliglbe for the primary trial  as long as they are over the age of 20.",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria: breast cancer survivors over 20 years-old ",
        "premise_nums": [
            "20 years-old"
        ]
    },
    {
        "id": "1ac9c526-91e6-4e0d-8570-0a78e3ec78db",
        "primaryId": "NCT00451555",
        "statement_text": "Cohort 1 and 2 of the primary trial recorded exactly the same percentage of each type of adverse events ",
        "statement_nums": [
            "1 and 2"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 17/94 (18.09%) Anaemia 2/94 (2.13%) Lymphadenopathy 0/94 (0.00%) Angina pectoris 0/94 (0.00%) Ischaemic cardiomyopathy 0/94 (0.00%) Myocardial infarction 1/94 (1.06%) Haemorrhoids 1/94 (1.06%) Ileus 1/94 (1.06%) Nausea 1/94 (1.06%) Vomiting 1/94 (1.06%) Asthenia 1/94 (1.06%) Disease progression 0/94 (0.00%) Oedema peripheral 1/94 (1.06%) ",
        "premise_nums": [
            "1/94 (1.06%)",
            "17/94 (18.09%)",
            "0/94 (0.00%)",
            "2/94 (2.13%)"
        ]
    },
    {
        "id": "1ac9c526-91e6-4e0d-8570-0a78e3ec78db",
        "primaryId": "NCT00451555",
        "statement_text": "Cohort 1 and 2 of the primary trial recorded exactly the same percentage of each type of adverse events ",
        "statement_nums": [
            "1 and 2"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 2:Total: 9/39 (23.08%) Anaemia 2/39 (5.13%) Lymphadenopathy 0/39 (0.00%) Angina pectoris 0/39 (0.00%) Ischaemic cardiomyopathy 0/39 (0.00%) Myocardial infarction 1/39 (2.56%) Haemorrhoids 1/39 (2.56%) Ileus 1/39 (2.56%) Nausea 1/39 (2.56%) Vomiting 1/39 (2.56%) Asthenia 1/39 (2.56%) Disease progression 0/39 (0.00%) Oedema peripheral 1/39 (2.56%) ",
        "premise_nums": [
            "2/39 (5.13%)",
            "1/39 (2.56%)",
            "0/39 (0.00%)",
            "9/39 (23.08%)",
            "2:Total: 9/39"
        ]
    },
    {
        "id": "79c07f36-daf9-4844-ad8a-f362fbbaaf81",
        "primaryId": "NCT00767520",
        "statement_text": "Both cohorts of the primary trial reported the same precentage of patients vomiting during the trial ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Vomiting 2/79 (2.53%) Adverse Events 2: Vomiting 2/76 (2.63%) ",
        "premise_nums": [
            "2/79 (2.53%)",
            "2/76 (2.63%)"
        ]
    },
    {
        "id": "bced9c90-5ce0-416c-a168-f9e74359b332",
        "primaryId": "NCT01381874",
        "statement_text": "The Exemestane group in the primary trial had a better median Tumor Response than the Abiraterone Acetate + Prednisone group  however the patient with the maximum TR was in the Abiraterone Acetate + Prednisone group ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Progression-Free Survival (PFS) Progression-free survival was defined as the time from randomization to first occurrence of disease progression (either radiographic or clinical)  or death from any cause  PFS was determined using radiographic progression defined by Response Evaluation Criteria in Solid Tumors (RECIST) on measurable lesions captured by computed tomography (CT) or magnetic resonance imaging (MRI)  Clinical disease progression was considered only when disease progression could not be confirmed by CT or MRI  such as when the disease site is skin  bone marrow  or central nervous system  Time frame: Approximately 2 years Results 1: Arm/Group Title: Exemestane ",
        "premise_nums": [
            "2 years Results"
        ]
    },
    {
        "id": "bced9c90-5ce0-416c-a168-f9e74359b332",
        "primaryId": "NCT01381874",
        "statement_text": "The Exemestane group in the primary trial had a better median Tumor Response than the Abiraterone Acetate + Prednisone group  however the patient with the maximum TR was in the Abiraterone Acetate + Prednisone group ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Arm/Group Description: Participants received exemestane tablet as oral dose of 25 milligram (mg) per day in 28-day treatment cycles until disease progression  unacceptable toxicity  or death (up to 3 years) Overall Number of Participants Analyzed: 102 Median (95% Confidence Interval) Unit of Measure: Months 3.68 (1.94 to 5.26) Results 2: Arm/Group Title: Abiraterone Acetate + Prednisone ",
        "premise_nums": [
            "94 to 5.26)",
            "25 milligram (mg)",
            "95% Confidence",
            "28-day treatment"
        ]
    },
    {
        "id": "bced9c90-5ce0-416c-a168-f9e74359b332",
        "primaryId": "NCT01381874",
        "statement_text": "The Exemestane group in the primary trial had a better median Tumor Response than the Abiraterone Acetate + Prednisone group  however the patient with the maximum TR was in the Abiraterone Acetate + Prednisone group ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Arm/Group Description: Participants received abiraterone acetate tablet at a total oral dose of 1000 milligram (mg) along with 5 mg capsule of prednisone/prednisolone per day in 28-day treatment cycles until disease progression  unacceptable toxicity  or death (up to 3 years) Overall Number of Participants Analyzed: 89 Median (95% Confidence Interval) Unit of Measure: Months 3.65 (2.73 to 5.59) ",
        "premise_nums": [
            "1000 milligram (mg)",
            "5 mg capsule",
            "95% Confidence",
            "73 to 5.59)",
            "28-day treatment"
        ]
    },
    {
        "id": "ce88c763-0062-48dc-b5e1-f81af32f2628",
        "primaryId": "NCT00593827",
        "secondaryId": "NCT00478257",
        "label": "Entailment",
        "statement_text": "Patients with HER2 negative BC are eligible for both the primary trial and the secondary trial ",
        "statement_nums": [
            "2 negative BC"
        ],
        "premise_text": "Inclusion Criteria: Has MBC that is measurable by RECIST or has nonmeasurable disease with serum CA27.29 (or CA15.3) 50 Has Human Epidermal Growth Factor Receptor 2 (HER2) negative breast cancer Inclusion Criteria: stage I-III breast cancer adjuvant or neoadjuvant anthracycline-based chemotherapy Exclusion Criteria: under age 18 pregnancy metastatic or inoperable (including inflammatory) breast cancer confounding underlying medical illnesses history of mania history of other axis-I psychiatric disorder other physical or psychological impairments - ",
        "premise_nums": [
            "(HER2) negative",
            "18 pregnancy metastatic",
            "50 Has Human"
        ]
    },
    {
        "id": "982469a3-2fc1-40b4-92a9-d531b6c0ab5d",
        "primaryId": "NCT00296036",
        "statement_text": "the primary trial administers the Urea/Lactic Acid Cream topically  twice daily  and the placebo is administered orally once a day ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "INTERVENTION 1: Urea/Lactic Acid Cream Patients receive topical urea/lactic acid-based cream applied to palms and soles twice daily  INTERVENTION 2: Placebo Cream Patients receive placebo cream applied to palms and soles twice daily  ",
        "premise_nums": []
    },
    {
        "id": "71d16ba8-2cc9-4cb0-aa14-6b6adf0dd625",
        "primaryId": "NCT00334802",
        "secondaryId": "NCT00167414",
        "label": "Entailment",
        "statement_text": "There is no age limit for either the secondary trial or the primary trial ",
        "statement_nums": [],
        "premise_text": "Inclusion Criteria: Histologically and/or cytologically confirmed breast cancer Received adjuvant/neo-adjuvant chemotherapy for breast cancer with anthracycline regimen To have at least one measurable region Eastern Cooperative Oncology Group (ECOG) Performance Status: 0-1 To have adequate organ function (bone marrow  liver and renal function) Exclusion Criteria: To have interstitial pneumonia or pulmonary fibrosis To have inflammatory breast cancer Within 28 days after the latest chemotherapy or radiotherapy  14 days after the latest hormonal/immunotherapy or 7 days after surgery To have brain metastases with symptoms To have severe complication (cardiac infarction  infection  drug hypersensitivity or diabetes) Inclusion Criteria: Age: no limit ",
        "premise_nums": [
            "14 days after",
            "0-1 To",
            "28 days after",
            "1 To have",
            "7 days after"
        ]
    },
    {
        "id": "e6901a45-4c97-4618-bfcb-6f6dd046ef0c",
        "primaryId": "NCT00143390",
        "statement_text": "In the primary trial There was less than 3 months difference between the maximum and minimum recorded TTP of the Exemestane group ",
        "statement_nums": [
            "3 months difference"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Time to Progression (TTP) - Expert Evaluation Committee Assessment Time in months from randomization to first documentation of objective tumor progression or death due to breast cancer  whichever comes first  Tumor progression was determined by the expert evaluation committee using RECIST version 1.0 as an at least a 20% increase in the sum of the longest diameters (SLD) of the target lesions compared to the smallest SLD since the study treatment started  For participants with bone metastasis only  at least 25% increase in the measurable lesion according to General Rules for Clinical and Pathological Study of Breast Cancer (The 14th edition)  Time frame: Up to 2008 days of the treatment Results 1: Arm/Group Title: Exemestane ",
        "premise_nums": [
            "2008 days of",
            "25% increase",
            "version 1.0 as an",
            "20% increase"
        ]
    },
    {
        "id": "e6901a45-4c97-4618-bfcb-6f6dd046ef0c",
        "primaryId": "NCT00143390",
        "statement_text": "In the primary trial There was less than 3 months difference between the maximum and minimum recorded TTP of the Exemestane group ",
        "statement_nums": [
            "3 months difference"
        ],
        "label": "Contradiction",
        "premise_text": "Arm/Group Description: One tablet each of exemestane 25 mg and anastrozole placebo were orally administered once daily after a meal  The study treatment was continued until the disease progression or other discontinuation criteria were met Overall Number of Participants Analyzed: 147 Median (95% Confidence Interval) Unit of Measure: months 13.8 (10.8 to 16.5) ",
        "premise_nums": [
            "25 mg and",
            "95% Confidence",
            "8 to 16.5)"
        ]
    },
    {
        "id": "e94ea1b1-1816-4bac-b1ca-f6d66b95702a",
        "primaryId": "NCT00004888",
        "statement_text": "Most the primary trial participants suffered Grade 3 or above Cardiotoxicity Events After Cycle 8 of the study ",
        "statement_nums": [
            "8 of the",
            "3 or above"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Grades of Cardiotoxicity Events in the Subset of Patients Reporting a Cardiotoxicity Event This table summarizes the cardiotoxicity events of different grades  Grade 1 is a decline of left ventricular ejection fraction(LVEF) greater than or equal 10% but smaller than 20% of baseline value  Grade 2 is LVEF below LLN (50%) or decline of LVEF greater than or equal 20% of baseline value  Grade 3 is congestive heart failure responsive to treatment  Please note that only a subset of patients reported cardiotoxic events so the totals will not add up to the total number of participants  Time frame: Baseline  after cycle 4 (~84 days)  after cycle 8 (~168 days)  and 30 or more days after last cycle of induction therapy ",
        "premise_nums": [
            "10% but",
            "30 or more",
            "2 is LVEF",
            "1 is a",
            "3 is congestive",
            "(50%) or",
            "20% of"
        ]
    },
    {
        "id": "e94ea1b1-1816-4bac-b1ca-f6d66b95702a",
        "primaryId": "NCT00004888",
        "statement_text": "Most the primary trial participants suffered Grade 3 or above Cardiotoxicity Events After Cycle 8 of the study ",
        "statement_nums": [
            "8 of the",
            "3 or above"
        ],
        "label": "Contradiction",
        "premise_text": "Results 1:Arm/Group Title: Arm I: Doxorubicin and Taxotere Arm/Group Description: Patients received PLD 30 mg/m^2 IV followed by docetaxel 60 mg/m^2 IV  one hour after PLD completion  every 3 weeks for a total of 8 cycles  Dexamthasone 8 mg orally twice a day was administered the day before  the day of  and the day following docetaxel  The maximum allowed cumulative dose of PLD was 240 mg/m^2. Pyridoxine 200 mg PO daily started on Day 1 of Cycle 1 and continued daily while the patient was on PLD  Overall Number of Participants Analyzed: 16 Measure Type: Number Unit of Measure: participants Grade 1 After Cycle 4 (approx  84 days): 2 ",
        "premise_nums": [
            "200 mg PO",
            "60 mg/m^2",
            "30 mg/m^2",
            "3 weeks for",
            "1:Arm/Group Title:",
            "1 and continued",
            "1 of Cycle",
            "1 After Cycle",
            "16 Measure Type:",
            "240 mg/m^2.",
            "2 IV followed",
            "8 mg orally"
        ]
    },
    {
        "id": "e94ea1b1-1816-4bac-b1ca-f6d66b95702a",
        "primaryId": "NCT00004888",
        "statement_text": "Most the primary trial participants suffered Grade 3 or above Cardiotoxicity Events After Cycle 8 of the study ",
        "statement_nums": [
            "8 of the",
            "3 or above"
        ],
        "label": "Contradiction",
        "premise_text": "Grade 1 After Cycle 8 (approx  168 days): 4Grade 1 After 30 days or more after last cycle: 1 Grade 2 After Cycle 4 (approx 84 days): 3 Grade 2 After Cycle 8 (approx 168 days): 4 Grade 2 After 30 days or more after last cycle: 1 Grade 3 After Cycle 4 (approx 84 days): 1 Grade 3 After Cycle 8 (approx 168 days): 0 Grade 3 After 30 days or more after last cycle: 0 ",
        "premise_nums": [
            "4 Grade 2",
            "30 days or",
            "1 Grade 2",
            "1 After 30",
            "1 After Cycle",
            "3 Grade 2",
            "1 Grade 3",
            "0 Grade 3"
        ]
    },
    {
        "id": "0e3c62f7-a152-4370-9d09-b69a715c0a21",
        "primaryId": "NCT01216319",
        "secondaryId": "NCT03346161",
        "label": "Contradiction",
        "statement_text": "the secondary trial and the primary trial are evaluating surgical interventions for breast reconstruction for patients that have had mastectomies ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Nipple Reconstruction Cylinder Nipple reconstruction: Biodesign® Nipple Reconstruction Cylinder INTERVENTION 1: Arm 1: BREASTChoice (Decision Tool) ",
        "premise_nums": []
    },
    {
        "id": "0e3c62f7-a152-4370-9d09-b69a715c0a21",
        "primaryId": "NCT01216319",
        "secondaryId": "NCT03346161",
        "label": "Contradiction",
        "statement_text": "the secondary trial and the primary trial are evaluating surgical interventions for breast reconstruction for patients that have had mastectomies ",
        "statement_nums": [],
        "premise_text": "Investigators recruited patients scheduled for a plastic/reconstruction consult  Investigators identified patients who completed a mastectomy  or were scheduled for one  and considering reconstruction  but didn't have an appointment with a plastic/reconstructive surgeon  A study team member called the patient to determine their interest and offered for them to come to their scheduled appointment 30 minutes early to meet a coordinator or offered them the option to complete pre-appointment procedures at home  Patients randomized using computer random assignment  If the patient didn't have an appointment  she scheduled a convenient time to complete study procedures with research staff  Patients interacted with the decision tool  They were asked to answer a survey  After the appointment  the team collected information consult duration  decision process quality  and measures of shared decision making  Patient participation was approximately 30 minutes ",
        "premise_nums": [
            "30 minutes early"
        ]
    },
    {
        "id": "7191b5e9-4f29-4261-8a64-51653ee151fe",
        "primaryId": "NCT00410813",
        "statement_text": "In the primary trial  Dasatinib  70 mg  Twice Daily results in a better median PFS than Dasatinib  100 mg  Daily ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Progression-free Survival RECIST progression defined as 20% increase in the sum of longest diameters of target measurable lesions over the smallest sum observed  unequivocal progression of non-measurable disease  the appearance of any new lesion/site  death due to disease without prior documentation of progression and without symptomatic deterioration  development of one or more new bone lesions from baseline  or symptomatic deterioration related to disease progression  Time from date of registration to date of first documentation of progression or symptomatic deterioration  or death due to any cause  Patients last known to be alive and progression-free are censored at last date of contact  Time frame: Up to 2 years Results 1: Arm/Group Title: Dasatinib  100 mg  Daily ",
        "premise_nums": [
            "2 years Results",
            "20% increase"
        ]
    },
    {
        "id": "7191b5e9-4f29-4261-8a64-51653ee151fe",
        "primaryId": "NCT00410813",
        "statement_text": "In the primary trial  Dasatinib  70 mg  Twice Daily results in a better median PFS than Dasatinib  100 mg  Daily ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Arm/Group Description: Dasatinib  100 mg PO daily until progression of diseaseOverall Number of Participants Analyzed: 41 Median (95% Confidence Interval) Unit of Measure: weeks 10.3 (8.4 to 16.7) Results 2: Arm/Group Title: Dasatinib  70 mg  Twice Daily Arm/Group Description: Dasatinib  70 mg PO twice daily until progression of disease Overall Number of Participants Analyzed: 38 Median (95% Confidence Interval) Unit of Measure: weeks 15.3 (8.7 to 20.1) ",
        "premise_nums": [
            "7 to 20.1)",
            "100 mg PO",
            "95% Confidence",
            "4 to 16.7)",
            "70 mg PO"
        ]
    },
    {
        "id": "639ccada-370d-4709-bdd7-1b29bbcc8769",
        "primaryId": "NCT01597193",
        "statement_text": "ECOG greater than 1 and a life expectancy over 12 weeks are necessary to participate in the primary trial ",
        "statement_nums": [
            "1 and a",
            "12 weeks are"
        ],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria: Eastern Cooperative Oncology Group performance (ECOG) status of 0 or 1; Estimated life expectancy of at least 3 months ",
        "premise_nums": [
            "0 or 1;"
        ]
    },
    {
        "id": "8c6e6c06-c409-4c42-b195-e9d2a1065b97",
        "primaryId": "NCT02069093",
        "statement_text": "All of the patients in the primary trial had minimal Stomatitis symptoms and a normal diet ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Number of Participants With Stomatitis Grade 2 The incidence of grade 2 stomatitis was reported  Grade 1 = minimal symptoms  normal diet; grade 2 = symptomatic  but able to swallow a modified diet; grade 3 = symptomatic and unable to aliment or hydrate orally; and grade 4 = symptoms associated with life-threatening consequences  Time frame: 56 days Results 1: Arm/Group Title: Dexamethasone Based Mouthwash ",
        "premise_nums": [
            "2 The incidence",
            "2 stomatitis was",
            "56 days Results"
        ]
    },
    {
        "id": "8c6e6c06-c409-4c42-b195-e9d2a1065b97",
        "primaryId": "NCT02069093",
        "statement_text": "All of the patients in the primary trial had minimal Stomatitis symptoms and a normal diet ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Arm/Group Description: Participants swished and spat 10mL of 0.5mg/5mL dexamethasone steroid mouthwash (investigational treatment) 4 times daily (qid) orally for 2 minutes each for 8 weeks  Participants remained without food or drink (NPO) for one hour after administration of the mouthwash  Also  participants received everolimus 10 mg and exemstane 25 mg (study treatments) according to local regulations Overall Number of Participants Analyzed: 86 Measure Type: Number Unit of Measure: Participants Stomatitis grade greater than or equal 2: Yes: 2 Stomatitis grade greater than or equal 2: No: 83 Stomatitis grade greater than or equal 2: Not evaluable: 1 ",
        "premise_nums": [
            "2 Stomatitis grade",
            "10 mg and",
            "4 times daily",
            "83 Stomatitis grade",
            "of 0.5mg/5mL",
            "2 minutes each",
            "86 Measure Type:",
            "25 mg (study"
        ]
    },
    {
        "id": "b5183c1c-adb5-4877-b061-50a16d6a5b52",
        "primaryId": "NCT00191815",
        "secondaryId": "NCT01301729",
        "label": "Entailment",
        "statement_text": "None of the patients in the primary trial committed suicide  however there was one such case in the secondary trial ",
        "statement_nums": [],
        "premise_text": "Adverse Events 1: Total: 6 Atrial fibrillation 1/67 (1.49%) Ventricular fibrillation 1/67 (1.49%) Gastrointestinal perforation 1/67 (1.49%) Periproctitis 1/67 (1.49%) General physical health deterioration 1/67 (1.49%) Escherichia sepsis 1/67 (1.49%) Pneumonia 1/67 (1.49%) Tumour pain 1/67 (1.49%) Renal failure acute 1/67 (1.49%) Pleurisy 1/67 (1.49%) Adverse Events 1: Total: 5/32 (15.63%) Leukopenia 1/32 (3.13%) ",
        "premise_nums": [
            "5/32 (15.63%)",
            "1/67 (1.49%)",
            "1/32 (3.13%)",
            "6 Atrial fibrillation"
        ]
    },
    {
        "id": "b5183c1c-adb5-4877-b061-50a16d6a5b52",
        "primaryId": "NCT00191815",
        "secondaryId": "NCT01301729",
        "label": "Entailment",
        "statement_text": "None of the patients in the primary trial committed suicide  however there was one such case in the secondary trial ",
        "statement_nums": [],
        "premise_text": "Neutropenia 1/32 (3.13%)Cataract 1/32 (3.13%) Infection 1/32 (3.13%) Upper respiratory tract infection 1/32 (3.13%) Completed suicide 1/32 (3.13%) ",
        "premise_nums": [
            "1/32 (3.13%)Cataract"
        ]
    },
    {
        "id": "69f57cdb-22e9-4a3a-8f19-6095c66c6497",
        "primaryId": "NCT01855828",
        "secondaryId": "NCT00696072",
        "label": "Entailment",
        "statement_text": "the secondary trial uses Clinical Benefit (CBR) as outcome measurement  which is different from Proportion of Participants With a Pathologic Complete Response Rate which is used for the primary trial ",
        "statement_nums": [],
        "premise_text": "Outcome Measurement: Proportion of Participants With a Pathologic Complete Response Rate ",
        "premise_nums": []
    },
    {
        "id": "69f57cdb-22e9-4a3a-8f19-6095c66c6497",
        "primaryId": "NCT01855828",
        "secondaryId": "NCT00696072",
        "label": "Entailment",
        "statement_text": "the secondary trial uses Clinical Benefit (CBR) as outcome measurement  which is different from Proportion of Participants With a Pathologic Complete Response Rate which is used for the primary trial ",
        "statement_nums": [],
        "premise_text": "To estimate the pathologic complete response rate (pCR) when pertuzumab is added to weekly trastuzumab/paclitaxel followed by trastuzumab/5-fluorouracil, epirubicin and cyclophosphamide neoadjuvant chemotherapy in HER2-positive breast cancer  This study will assess pCR rates separately in ER+ and ER- cancers  Pathologic complete response is defined as no evidence of viable invasive tumor cells at the primary tumor site and axillary lymph nodes in the surgical specimen  Residual Disease (RD) is defined as: Any invasive cancer in the breast or axillary lymph nodes in the surgical specimen ",
        "premise_nums": [
            "2-positive breast",
            "5-fluorouracil, epirubicin"
        ]
    },
    {
        "id": "69f57cdb-22e9-4a3a-8f19-6095c66c6497",
        "primaryId": "NCT01855828",
        "secondaryId": "NCT00696072",
        "label": "Entailment",
        "statement_text": "the secondary trial uses Clinical Benefit (CBR) as outcome measurement  which is different from Proportion of Participants With a Pathologic Complete Response Rate which is used for the primary trial ",
        "statement_nums": [],
        "premise_text": "Time frame: 20 weeksOutcome Measurement: Number of Participants With Clinical Benefit (CBR) and Number of Participants With CBR Having a Disease Free Interval (DFI) Greater Than 2 Years - Evaluable Population ",
        "premise_nums": [
            "20 weeksOutcome Measurement:"
        ]
    },
    {
        "id": "69f57cdb-22e9-4a3a-8f19-6095c66c6497",
        "primaryId": "NCT01855828",
        "secondaryId": "NCT00696072",
        "label": "Entailment",
        "statement_text": "the secondary trial uses Clinical Benefit (CBR) as outcome measurement  which is different from Proportion of Participants With a Pathologic Complete Response Rate which is used for the primary trial ",
        "statement_nums": [],
        "premise_text": "CBR=participants with complete response (CR) + participants with partial response (PR) + participants with stable disease (SD) for a length of time greater than  equal to 6 months  CR= Disappearance of all target lesions  No new lesions  PR= At least a 30% decrease in the sum of the longest diameter (LD) of target lesions taking as reference the baseline sum LD  SD= Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD) taking as reference the smallest sum LD since the treatment started  Physical examination,radiological assessment  and bone scans (if applicable) were used to assess outcome ",
        "premise_nums": [
            "30% decrease"
        ]
    },
    {
        "id": "69f57cdb-22e9-4a3a-8f19-6095c66c6497",
        "primaryId": "NCT01855828",
        "secondaryId": "NCT00696072",
        "label": "Entailment",
        "statement_text": "the secondary trial uses Clinical Benefit (CBR) as outcome measurement  which is different from Proportion of Participants With a Pathologic Complete Response Rate which is used for the primary trial ",
        "statement_nums": [],
        "premise_text": "Time frame: First dose of study drug to last dose plus 7 days  up to study completion (approximately 6 years)",
        "premise_nums": []
    },
    {
        "id": "ea505463-c509-416e-ad88-11576764b734",
        "primaryId": "NCT01771666",
        "secondaryId": "NCT01256567",
        "label": "Entailment",
        "statement_text": "Japanese participants with an ECOG smaller than =1 are eligible for the secondary trial and the primary trial ",
        "statement_nums": [
            "1 are eligible"
        ],
        "premise_text": "Inclusion Criteria: Eastern Cooperative Oncology Group (ECOG) or Karnofsky Performance Status 0,1,2. Inclusion Criteria: The participant is Japanese The participant has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 ",
        "premise_nums": [
            "0,1,2. Inclusion",
            "0 or 1"
        ]
    },
    {
        "id": "81669281-db01-4493-a797-0d60f448f706",
        "primaryId": "NCT00930930",
        "statement_text": "The overall most frequent adverse event in the primary trial was Dehydration ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 22/96 (22.92%) Anemia 1/96 (1.04%) lymphopenia 1/96 (1.04%) cardiac ischemia/infarction 1/96 (1.04%) sinus tachycardia 2/96 (2.08%) Dehydration 5/96 (5.21%) colitis 1/96 (1.04%) diarrhea 5/96 (5.21%) ileus 1/96 (1.04%) nausea 2/96 (2.08%) vomiting 1/96 (1.04%) distal small bowel obstruction 1/96 (1.04%) edema 1/96 (1.04%) fatigue 2/96 (2.08%) ",
        "premise_nums": [
            "5/96 (5.21%)",
            "1/96 (1.04%)",
            "2/96 (2.08%)",
            "22/96 (22.92%)"
        ]
    },
    {
        "id": "81669281-db01-4493-a797-0d60f448f706",
        "primaryId": "NCT00930930",
        "statement_text": "The overall most frequent adverse event in the primary trial was Dehydration ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Adverse Events 2:Total: 6/49 (12.24%) Anemia 0/49 (0.00%) lymphopenia 0/49 (0.00%) cardiac ischemia/infarction 0/49 (0.00%) sinus tachycardia 0/49 (0.00%) Dehydration 1/49 (2.04%) colitis 0/49 (0.00%) diarrhea 0/49 (0.00%) ileus 0/49 (0.00%) nausea 1/49 (2.04%) vomiting 1/49 (2.04%) distal small bowel obstruction 0/49 (0.00%) edema 0/49 (0.00%) fatigue 0/49 (0.00%) ",
        "premise_nums": [
            "1/49 (2.04%)",
            "0/49 (0.00%)",
            "2:Total: 6/49",
            "6/49 (12.24%)"
        ]
    },
    {
        "id": "40dbf023-ead5-45fc-bdce-bf40e1955578",
        "primaryId": "NCT00382785",
        "secondaryId": "NCT00784849",
        "label": "Entailment",
        "statement_text": "Neither the primary trial or the secondary trial use Low Dose Magnesium Oxide  High Dose Magnesium Oxide or Mometasone in their intervention ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Moderated Group one 12-week online support group led by a professional healthcare provider INTERVENTION 2: Non-facilitated (Peer-led) 12-week online support in a peer-led format INTERVENTION 1: Sentinel Lymph Node Biopsy With Radiolabeled Methylene Blue One arm diagnostic using 1 mCi of 125-I Methylene blue dye to find sentinel lymph nodes ",
        "premise_nums": [
            "1 mCi of",
            "12-week online",
            "125-I Methylene"
        ]
    },
    {
        "id": "b64ae9c9-956a-421e-a41f-1886408fec2a",
        "primaryId": "NCT00003782",
        "statement_text": "One of the cohorts in the primary trial had more than 5% of patients experiencing side effects ",
        "statement_nums": [
            "5% of"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 66/1748 (3.78%) Adverse Events 2: Total: 43/1748 (2.46%) ",
        "premise_nums": [
            "43/1748 (2.46%)",
            "66/1748 (3.78%)"
        ]
    },
    {
        "id": "e0980234-0611-44de-9165-54bdd086663d",
        "primaryId": "NCT01539317",
        "secondaryId": "NCT01323530",
        "label": "Entailment",
        "statement_text": "the primary trial uses a topical intervention and the secondary trial uses a combination of oral and intravenous treatments ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Topical Saline Topical liquid lidocaine: active intervention drug numbs the hypersensitive mucosa of the vulvar vestibule Topical saline: saline applied to the vestibule mucosa will not reverse the local tenderness INTERVENTION 2: Topical Liquid Lidocaine Topical liquid lidocaine: active intervention drug numbs the hypersensitive mucosa of the vulvar vestibule Topical saline: saline applied to the vestibule mucosa will not reverse the local tenderness INTERVENTION 1: Phase 1b (Schedule 1): Eribulin Mesilate (1.2 mg/m^2) ",
        "premise_nums": [
            "(1.2 mg/m"
        ]
    },
    {
        "id": "e0980234-0611-44de-9165-54bdd086663d",
        "primaryId": "NCT01539317",
        "secondaryId": "NCT01323530",
        "label": "Entailment",
        "statement_text": "the primary trial uses a topical intervention and the secondary trial uses a combination of oral and intravenous treatments ",
        "statement_nums": [],
        "premise_text": "Participants received eribulin mesilate 1.2 mg/m^2, injection  intravenously  once  on Day 1 and capecitabine 1000 mg/m^2, tablets  orally  twice daily from Day 1 to 14 in each 21-day treatment cycle for as long as the treatment was clinically appropriate according to the judgment of the investigator or until the occurrence of PD  undue toxicity  the presence of other medical conditions that prohibit continuation of therapy  pregnancy  a delay of more than 14 days in starting the next cycle during Phase 1b (Schedule 1).INTERVENTION 2: Phase 1b (Schedule 1): Eribulin Mesilate (1.6 mg/m^2) ",
        "premise_nums": [
            "mesilate 1.2 mg/m",
            "1 to 14",
            "14 days in",
            "1000 mg/m^2,",
            "1 and capecitabine",
            "21-day treatment",
            "(1.6 mg/m"
        ]
    },
    {
        "id": "e0980234-0611-44de-9165-54bdd086663d",
        "primaryId": "NCT01539317",
        "secondaryId": "NCT01323530",
        "label": "Entailment",
        "statement_text": "the primary trial uses a topical intervention and the secondary trial uses a combination of oral and intravenous treatments ",
        "statement_nums": [],
        "premise_text": "Participants received eribulin mesilate 1.6 mg/m^2, injection  intravenously  once  on Day 1 and capecitabine 1000 mg/m^2, tablets  orally  twice daily from Day 1 to 14 in each 21-day treatment cycle for as long as the treatment was clinically appropriate according to the judgment of the investigator or until the occurrence of PD  undue toxicity  the presence of other medical conditions that prohibit continuation of therapy  pregnancy  a delay of more than 14 days in starting the next cycle during Phase 1b (Schedule 1).",
        "premise_nums": [
            "mesilate 1.6 mg/m",
            "1 to 14",
            "14 days in",
            "1000 mg/m^2,",
            "1 and capecitabine",
            "21-day treatment"
        ]
    },
    {
        "id": "3366c10a-3d41-48ae-bfa8-26b9e655761e",
        "primaryId": "NCT00005908",
        "statement_text": "There were 8 cases of pharyngitis in cohort 2 of the primary trial ",
        "statement_nums": [
            "2 of the",
            "8 cases of"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 29/30 (96.67%) Febrile neutropenia [1]3/30 (10.00%) Lymphatics 1/30 (3.33%) Diarrhea (without colostomy) 5/30 (16.67%) Abdominal pain or cramping 2/30 (6.67%) Colitis 1/30 (3.33%) Dehydration 1/30 (3.33%) Nausea 1/30 (3.33%) Stomatitis/pharyngitis (oral/pharyngeal/mucositis) 1/30 (3.33%) Vomiting 1/30 (3.33%) Adverse Events 2: ",
        "premise_nums": [
            "5/30 (16.67%)",
            "3/30 (10.00%)",
            "29/30 (96.67%)",
            "1/30 (3.33%)",
            "2/30 (6.67%)"
        ]
    },
    {
        "id": "be29030a-98e8-40ad-9138-90076fdb50d3",
        "primaryId": "NCT01572727",
        "statement_text": "Cohort 1 of the primary trial recorded more white blood cell related adversse events than cohort 2.",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 61/202 (30.20%) FEBRILE NEUTROPENIA 1/202 (0.50%) LEUKOPENIA 0/202 (0.00%) NEUTROPENIA 2/202 (0.99%) CARDIAC FAILURE CONGESTIVE 0/202 (0.00%) CARDIO-RESPIRATORY ARREST 1/202 (0.50%) PERICARDIAL EFFUSION 1/202 (0.50%) CATARACT 1/202 (0.50%) OPTIC NEUROPATHY 0/202 (0.00%) ABDOMINAL PAIN 0/202 (0.00%) CONSTIPATION 0/202 (0.00%) DIARRHOEA 5/202 (2.48%) Adverse Events 2: ",
        "premise_nums": [
            "2/202 (0.99%)",
            "61/202 (30.20%)",
            "5/202 (2.48%)",
            "1/202 (0.50%)",
            "0/202 (0.00%)"
        ]
    },
    {
        "id": "be29030a-98e8-40ad-9138-90076fdb50d3",
        "primaryId": "NCT01572727",
        "statement_text": "Cohort 1 of the primary trial recorded more white blood cell related adversse events than cohort 2.",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Total: 42/201 (20.90%)FEBRILE NEUTROPENIA 0/201 (0.00%) LEUKOPENIA 1/201 (0.50%) NEUTROPENIA 0/201 (0.00%) CARDIAC FAILURE CONGESTIVE 1/201 (0.50%) CARDIO-RESPIRATORY ARREST 0/201 (0.00%) PERICARDIAL EFFUSION 0/201 (0.00%) CATARACT 1/201 (0.50%) OPTIC NEUROPATHY 1/201 (0.50%) ABDOMINAL PAIN 1/201 (0.50%) CONSTIPATION 1/201 (0.50%) DIARRHOEA 3/201 (1.49%) ",
        "premise_nums": [
            "0/201 (0.00%)",
            "42/201 (20.90%)FEBRILE",
            "3/201 (1.49%)",
            "1/201 (0.50%)"
        ]
    },
    {
        "id": "a31298d5-20ae-4a3d-a57b-e97288fff6c0",
        "primaryId": "NCT01097460",
        "statement_text": "Every patient in the primary trial suffered at least 1 Treatment-emergent adverse event over a span of 2 years ",
        "statement_nums": [
            "1 Treatment-emergent adverse"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Incidence of Treatment-emergent AE's [Not Specified] Time frame: 2 years Results 1: Arm/Group Title: MM-111 + Herceptin Arm/Group Description: MM-111 will be combined with Herceptin MM-111 and Herceptin: For Phase 1: Dose escalation cohorts  MM-111 and Herceptin are administered weekly or bi-weekly via IV Overall Number of Participants Analyzed: 16 Measure Type: Number Unit of Measure: participants 16 ",
        "premise_nums": [
            "111 and Herceptin:",
            "16 Measure Type:",
            "2 years Results",
            "111 will be"
        ]
    },
    {
        "id": "54e93334-0f21-4ea2-b0f2-34473385da53",
        "primaryId": "NCT00003830",
        "statement_text": "The most common adverse event in both cohorts of the primary trial was Anaphylaxis  which affected less than 1% of patients ",
        "statement_nums": [
            "1% of"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 9/2788 (0.32%) Anaphylaxis 5/2788 (0.18%) Infections and infestations - Other  specify 2/2788 (0.07%) Nervous system disorders - Other  specify 0/2788 (0.00%) Respiratory  thoracic and mediastinal disorders - Other  specify 1/2788 (0.04%) Thromboembolic event 1/2788 (0.04%) Adverse Events 2: Total: 8/2800 (0.29%) Anaphylaxis 5/2800 (0.18%) Infections and infestations - Other  specify 0/2800 (0.00%) ",
        "premise_nums": [
            "0/2788 (0.00%)",
            "1/2788 (0.04%)",
            "2/2788 (0.07%)",
            "5/2800 (0.18%)",
            "8/2800 (0.29%)",
            "5/2788 (0.18%)",
            "0/2800 (0.00%)",
            "9/2788 (0.32%)"
        ]
    },
    {
        "id": "54e93334-0f21-4ea2-b0f2-34473385da53",
        "primaryId": "NCT00003830",
        "statement_text": "The most common adverse event in both cohorts of the primary trial was Anaphylaxis  which affected less than 1% of patients ",
        "statement_nums": [
            "1% of"
        ],
        "label": "Entailment",
        "premise_text": "Nervous system disorders - Other  specify 1/2800 (0.04%)Respiratory  thoracic and mediastinal disorders - Other  specify 1/2800 (0.04%) Thromboembolic event 2/2800 (0.07%) ",
        "premise_nums": [
            "2/2800 (0.07%)",
            "1/2800 (0.04%)Respiratory"
        ]
    },
    {
        "id": "fbedd8fc-05e8-4438-b780-d7483aed3b45",
        "primaryId": "NCT00404066",
        "statement_text": "Abnormal LVEF  Pregnancy or lactating automatically eliminates patients from participating in the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "EXCLUSION CRITERIA Congestive heart failure  abnormal left ventricular ejection fraction (LVEF)  angina pectoris  uncontrolled cardiac arrhythmias  or other significant heart disease  or who have had a myocardial infarction within the past year  Pregnant or lactating ",
        "premise_nums": []
    },
    {
        "id": "4bd9f061-6420-443d-8f84-b703733644ac",
        "primaryId": "NCT01202591",
        "statement_text": "100% of patients in the primary trial suffered life threatening adverse events ",
        "statement_nums": [
            "100% of"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Safety and Tolerability in Terms of Number of Patients With Adverse Events (Serious and Non-serious) [Not Specified] Time frame: 3 years  10 months (Adverse events recorded from patient screening to discontinuation plus 28 days safety follow-up)  Results 1: Arm/Group Title: AZD4547 80mg bd Cont + Ex 25mg Arm/Group Description: 80 mg AZD4547 BD continuous + 25 mg exemestane Overall Number of Participants Analyzed: 5 Measure Type: Number Unit of Measure: Participants 5 Results 2: Arm/Group Title: AZD4547 40mg Cont + Ex 25mg Arm/Group Description: 40 mg AZD4547 BD continuous + 25 mg exemestane Overall Number of Participants Analyzed: 5 Measure Type: Number Unit of Measure: Participants 5 ",
        "premise_nums": [
            "28 days safety",
            "5 Results 2:",
            "5 Measure Type:",
            "AZD4547 BD",
            "80 mg AZD4547",
            "10 months (Adverse",
            "25 mg exemestane",
            "40 mg AZD4547"
        ]
    },
    {
        "id": "e6d3354b-b36a-42b9-b406-61a9af594686",
        "primaryId": "NCT00046891",
        "statement_text": "cohort 1 of the primary trial recieves 120 mg of Ginkgo Biloba twice daily ",
        "statement_nums": [
            "120 mg of",
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "INTERVENTION 1: Ginkgo Biloba Ginkgo Biloba: Patients will take 120 mg per day (60 mg BID) ",
        "premise_nums": [
            "120 mg per",
            "60 mg BID)"
        ]
    },
    {
        "id": "62b3d09e-6b2a-4827-8ceb-96ccafca18d4",
        "primaryId": "NCT00896649",
        "statement_text": "prior hormonal treatment(s) in the metastatic or adjuvant setting is not necessary for patients in the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Inclusion criteria: DISEASE CHARACTERISTICS: Scheduled to undergo screening mammogram at one of the Boston Medical Center-affiliated primary care clinics and meets 1 of the following criteria: Dense breast tissue At high-risk for breast cancer PATIENT CHARACTERISTICS: Has 1 of the following racial or ethnic backgrounds based on the patient's country of birth or the mother and father's country of birth: Hispanic Haitian Creole African American Caucasian PRIOR CONCURRENT THERAPY: None specified Exclusion criteria: No history of breast cancer  palpable breast mass  abnormal nipple discharge  or other focal complaints warranting diagnostic mammogram ",
        "premise_nums": [
            "1 of the"
        ]
    },
    {
        "id": "065a6cfe-3991-4dd5-8a55-22b9b31d1fc3",
        "primaryId": "NCT00317603",
        "statement_text": "Participants of the primary trial must be older than 18, have histologically confirmed stage 3 or above breast cancer  ECOGsmaller than 2 and a life expectancy exceeding 6 months ",
        "statement_nums": [
            "3 or above",
            "2 and a"
        ],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria: Histologically confirmed Stage IV breast cancer ECOG performance status 0 or 1 Estimated life expectancy of greater than or equal to 6 months 18 years of age or older ",
        "premise_nums": [
            "6 months 18",
            "0 or 1"
        ]
    },
    {
        "id": "85c315e5-7ae4-4764-8b02-87d36f67a159",
        "primaryId": "NCT00278109",
        "secondaryId": "NCT01881230",
        "label": "Entailment",
        "statement_text": "Gemcitabine is not used in the primary trial  and used in only one of the arms of the secondary trial ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Experimental cyclophosphamide: chemotherapy doxorubicin hydrochloride: chemotherapy adjuvant therapy: chemotherapy radiation therapy: chemotherapy INTERVENTION 1: Arm A: Nab-Paclitaxel + Gemcitabine ",
        "premise_nums": []
    },
    {
        "id": "85c315e5-7ae4-4764-8b02-87d36f67a159",
        "primaryId": "NCT00278109",
        "secondaryId": "NCT01881230",
        "label": "Entailment",
        "statement_text": "Gemcitabine is not used in the primary trial  and used in only one of the arms of the secondary trial ",
        "statement_nums": [],
        "premise_text": "Participants received nab-Paclitaxel 125 mg/m^2 on Days 1 and 8 by intravenous (IV) administration followed by gemcitabine 1000 mg/m^2 on Days 1 and 8 by IV administration of each 21-day treatment cycle  Participants continued treatment until progressive disease (PD)  unacceptable toxicity  required palliative radiotherapy or surgical intervention of lesion(s)  withdrawal from study treatment  withdrawal of study consent  participant refusal or the investigator felt it was no longer in the best interest of the participant to continue on treatmentINTERVENTION 2: Arm B: Nab-Paclitaxel + Carboplatin ",
        "premise_nums": [
            "1000 mg/m^2",
            "1 and 8",
            "125 mg/m^2",
            "21-day treatment",
            "2 on Days"
        ]
    },
    {
        "id": "85c315e5-7ae4-4764-8b02-87d36f67a159",
        "primaryId": "NCT00278109",
        "secondaryId": "NCT01881230",
        "label": "Entailment",
        "statement_text": "Gemcitabine is not used in the primary trial  and used in only one of the arms of the secondary trial ",
        "statement_nums": [],
        "premise_text": "Participants received nab-Paclitaxel 125 mg/m^2 on Days 1 and 8 by IV administration followed by carboplatin area under the curve 2 (AUC 2) on Days 1 and 8 in each 21-day treatment cycle  Participants continued treatment until progressive disease (PD)  unacceptable toxicity  required palliative radiotherapy or surgical intervention of lesion(s)  withdrawal from study treatment  withdrawal of study consent  participant refusal or the investigator felt it was no longer in the best interest of the participant to continue on treatment ",
        "premise_nums": [
            "21-day treatment",
            "1 and 8",
            "125 mg/m^2",
            "2 on Days"
        ]
    },
    {
        "id": "497188e0-9d88-406f-b163-c154516cb12c",
        "primaryId": "NCT01560416",
        "statement_text": "There was over 10% more cases of adverse events in cohort 2 than in cohort 1 of the primary trial ",
        "statement_nums": [
            "2 than in",
            "10% more",
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 2/15 (13.33%) Adverse Events 2: Total: 11/35 (31.43%) ",
        "premise_nums": [
            "11/35 (31.43%)",
            "2/15 (13.33%)"
        ]
    },
    {
        "id": "abc437e1-9e38-4d68-ab9f-fdbaf37d20f3",
        "primaryId": "NCT00438100",
        "secondaryId": "NCT00662025",
        "label": "Entailment",
        "statement_text": "Patients with BUN smaller than 20 mg/dL  Platelet count: smaller than 90,000/mm3, Leukocyte count of 5,000/mm3 to 8,000/mm3 may be eligible for both the primary trial and the secondary trial ",
        "statement_nums": [
            "20 mg/dL",
            "90,000/mm3, Leukocyte",
            "3 may be",
            "8,000/mm3 may",
            "5,000/mm3 to"
        ],
        "premise_text": "Inclusion Criteria: Biopsy-diagnosed breast cancer with metastasis in multiple organs Performance Status (World Health Organization :WHO) 0-2 Functions below are maintained in major organs: Leukocyte count: 4,000/mm3 to 12,000/mm3 Neutrophil count: greater than 2,000/mm3 or more Platelet count: smaller than 100,000/mm3 or more Hemoglobin: greater than 9.5 g/dL Total bilirubin: greater than 1.5 mg/dL AST(GOT): within twice a normal upper value in an institution ",
        "premise_nums": [
            "2,000/mm3 or",
            "2 Functions below",
            "than 9.5 g/dL",
            "4,000/mm3 to",
            "12,000/mm3 Neutrophil",
            "3 Neutrophil count:",
            "100,000/mm3 or",
            "3 or more",
            "than 1.5 mg/dL",
            "0-2 Functions"
        ]
    },
    {
        "id": "abc437e1-9e38-4d68-ab9f-fdbaf37d20f3",
        "primaryId": "NCT00438100",
        "secondaryId": "NCT00662025",
        "label": "Entailment",
        "statement_text": "Patients with BUN smaller than 20 mg/dL  Platelet count: smaller than 90,000/mm3, Leukocyte count of 5,000/mm3 to 8,000/mm3 may be eligible for both the primary trial and the secondary trial ",
        "statement_nums": [
            "20 mg/dL",
            "90,000/mm3, Leukocyte",
            "3 may be",
            "8,000/mm3 may",
            "5,000/mm3 to"
        ],
        "premise_text": "AST(GPT): within twice a normal upper value in an institutionBUN: smaller than 25 mg/dL Creatinine: within a normal upper value in the institution 24 hours creatinine clearance: greater than 50 mL/min (using the Cockcroft-Gault formula) Women's Ccr = Body weight x (140-Age)/(72 x Serum creatinine) x 0.85 Inclusion Criteria: Histologically- or cytologically-proven diagnosis of breast adenocarcinoma that is not amenable to surgery  radiation  or combined modality therapy with curative intent ",
        "premise_nums": [
            "72 x Serum",
            "25 mg/dL Creatinine",
            "x 0.85 Inclusion Criteria",
            "(140-Age)/(72 x",
            "24 hours creatinine",
            "85 Inclusion Criteria:",
            "50 mL/min"
        ]
    },
    {
        "id": "abc437e1-9e38-4d68-ab9f-fdbaf37d20f3",
        "primaryId": "NCT00438100",
        "secondaryId": "NCT00662025",
        "label": "Entailment",
        "statement_text": "Patients with BUN smaller than 20 mg/dL  Platelet count: smaller than 90,000/mm3, Leukocyte count of 5,000/mm3 to 8,000/mm3 may be eligible for both the primary trial and the secondary trial ",
        "statement_nums": [
            "20 mg/dL",
            "90,000/mm3, Leukocyte",
            "3 may be",
            "8,000/mm3 may",
            "5,000/mm3 to"
        ],
        "premise_text": "Measurable disease as per RECIST  Measurable lesions that have been previously irradiated will not be considered target lesions unless increase in size has been observed following completion of radiation therapy Prior treatment with an anthracycline and a taxane in the neoadjuvant  adjuvant or metastatic disease settings  Exclusion Criteria: Histology of inflammatory carcinoma with no other measurable disease  Patients with histology of inflammatory carcinoma are allowed on study if they have measurable disease  Brain metastases  spinal cord compression  or carcinomatous meningitis  or leptomeningeal disease  ",
        "premise_nums": []
    },
    {
        "id": "abc437e1-9e38-4d68-ab9f-fdbaf37d20f3",
        "primaryId": "NCT00438100",
        "secondaryId": "NCT00662025",
        "label": "Entailment",
        "statement_text": "Patients with BUN smaller than 20 mg/dL  Platelet count: smaller than 90,000/mm3, Leukocyte count of 5,000/mm3 to 8,000/mm3 may be eligible for both the primary trial and the secondary trial ",
        "statement_nums": [
            "20 mg/dL",
            "90,000/mm3, Leukocyte",
            "3 may be",
            "8,000/mm3 may",
            "5,000/mm3 to"
        ],
        "premise_text": "Prior treatment with 5-fluorouracil (5-FU) and 5-FU derivatives such as Furtulon (5'-DFUR), Futraful/ Sunfural (tegafur)  UFT/UFT-E (tegafur/uracil)  TS-1 (tegafur/gimeracil/oteracil) or Mifurol (carmofur) in metastatic disease setting",
        "premise_nums": [
            "(5-FU) and",
            "5-FU derivatives"
        ]
    },
    {
        "id": "f26fb90b-a9a5-4614-9680-2e9f6f0ba649",
        "primaryId": "NCT01828021",
        "secondaryId": "NCT01326481",
        "label": "Contradiction",
        "statement_text": "Patients in the primary trial and the secondary trial did not have any of the same adverse events  except Supraventricular extrasystoles which was the most common event in both trials ",
        "statement_nums": [],
        "premise_text": "Adverse Events 1: Total: 6/25 (24.00%) Supraventricular extrasystoles 1/25 (4.00%) Ventricular extrasystoles 1/25 (4.00%) Ascites 2/25 (8.00%) Diarrhea 1/25 (4.00%) Nausea 1/25 (4.00%) Pancreatitis 1/25 (4.00%) Small intestinal obstruction 1/25 (4.00%) Vomiting 1/25 (4.00%) Bile duct obstruction 1/25 (4.00%) Portal hypertension 1/25 (4.00%) Adverse Events 1: ",
        "premise_nums": [
            "6/25 (24.00%)",
            "1/25 (4.00%)",
            "2/25 (8.00%)"
        ]
    },
    {
        "id": "f26fb90b-a9a5-4614-9680-2e9f6f0ba649",
        "primaryId": "NCT01828021",
        "secondaryId": "NCT01326481",
        "label": "Contradiction",
        "statement_text": "Patients in the primary trial and the secondary trial did not have any of the same adverse events  except Supraventricular extrasystoles which was the most common event in both trials ",
        "statement_nums": [],
        "premise_text": "Total: 6/19 (31.58%)Febrile neutropenia [1]1/19 (5.26%) Fatigue [1]1/19 (5.26%) Pyrexia [1]1/19 (5.26%) Fracture [1]1/19 (5.26%) Hip Fracture [1]1/19 (5.26%) Headache [2]1/19 (5.26%) ",
        "premise_nums": [
            "1/19 (5.26%)",
            "6/19 (31.58%)Febrile"
        ]
    },
    {
        "id": "90dd042b-c16c-4ea7-b360-625bd5e64590",
        "primaryId": "NCT00388726",
        "statement_text": "A 75 year old female patient  with an ECOG of 1 and an estimated life expectancy of more than a year would be eligible for the primary trial ",
        "statement_nums": [
            "1 and an",
            "75 year old"
        ],
        "label": "Entailment",
        "premise_text": "Inclusion Criteria: Age greater than or equal 18 years  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2. Life expectancy of greater than or equal 3 months  ",
        "premise_nums": [
            "0 to 2."
        ]
    },
    {
        "id": "9b03c9e7-ca64-4e9f-9c10-f8c2d64ff0b7",
        "primaryId": "NCT01271725",
        "statement_text": "In the primary trial The Percentage of Participants With Objective Response (OR) for the Afatinib Monotherapy was 13% lower than the Afatinib and Paclitaxel or Vinorelbine Combination Therapy group ",
        "statement_nums": [
            "13% lower"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Percentage of Participants With Objective Response (OR) Assessed by Response Evaluation Criteria in Solid Tumours Version (RECIST) 1.1 ",
        "premise_nums": []
    },
    {
        "id": "20cc98f8-a71a-466d-a39c-735899791613",
        "primaryId": "NCT00915603",
        "secondaryId": "NCT02511730",
        "label": "Entailment",
        "statement_text": "INR equal to or above 1.5 is mandatory for participation in the primary trial  it is not necessary for the secondary trial ",
        "statement_nums": [
            "above 1.5 is mandatory"
        ],
        "premise_text": "Inclusion Criteria: International normalized ratio (INR) smaller than =1.5 or prothrombin time (PT)/partial Inclusion Criteria: Female subjects participating in FMSU004A protocol with known clinical status Exclusion Criteria: Subjects with unknown clinical status not participating in FMSU004A protocol  ",
        "premise_nums": [
            "5 or prothrombin"
        ]
    },
    {
        "id": "fa1c6f63-ae37-4c18-918b-7b9ba445fd81",
        "primaryId": "NCT00391092",
        "statement_text": "In total there were 32 cases of Febrile neutropenia in the primary trial ",
        "statement_nums": [
            "32 cases of"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Febrile neutropenia * 14/206 (6.80%) Adverse Events 2: Febrile neutropenia * 18/215 (8.37%) ",
        "premise_nums": [
            "14/206 (6.80%)",
            "18/215 (8.37%)"
        ]
    },
    {
        "id": "6d0b2acc-11f4-479f-9a86-004e2f5f7599",
        "primaryId": "NCT00194779",
        "secondaryId": "NCT04080297",
        "label": "Contradiction",
        "statement_text": "IV is used as route of administration by the interventions in the primary trial and the secondary trial ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Treatment (Neoadjuvant Therapy  Adjuvant Therapy) See Detailed Description  doxorubicin hydrochloride: Given IV cyclophosphamide: Given PO paclitaxel: Given IV filgrastim: Given SC capecitabine: Given PO methotrexate: Given IV vinorelbine tartrate: Given IV needle biopsy: Correlative studies therapeutic conventional surgery: Undergo definitive breast surgery immunohistochemistry staining method: Correlative studies trastuzumab: Given IV tamoxifen citrate: Given PO letrozole: Given PO laboratory biomarker analysis: Correlative studies INTERVENTION 1: 100 mg Q-122 ",
        "premise_nums": [
            "100 mg Q"
        ]
    },
    {
        "id": "6d0b2acc-11f4-479f-9a86-004e2f5f7599",
        "primaryId": "NCT00194779",
        "secondaryId": "NCT04080297",
        "label": "Contradiction",
        "statement_text": "IV is used as route of administration by the interventions in the primary trial and the secondary trial ",
        "statement_nums": [],
        "premise_text": "Dosage was 100 mg Q-122 administered orally as two 50 mg capsules once daily for 28 days ",
        "premise_nums": [
            "50 mg capsules",
            "100 mg Q",
            "122 administered orally"
        ]
    },
    {
        "id": "7e9c3980-9f12-40c7-920e-76594db26fd1",
        "primaryId": "NCT02352779",
        "secondaryId": "NCT00263588",
        "label": "Entailment",
        "statement_text": "The differences between cohorts in the primary trial is once cohort recieves a placebo and the other Low-dose Omega-3 Fatty Acid  in contrast the difference in the secondary trial is patient characteristics ",
        "statement_nums": [
            "3 Fatty Acid"
        ],
        "premise_text": "INTERVENTION 1: Arm I (Low-dose Omega-3 Fatty Acid) Patients receive low-dose omega-3 fatty acid supplementation PO BID and placebo PO BID for 6 weeks  Omega-3 Fatty Acid: Given PO Placebo: Given PO Questionnaire Administration: Ancillary studies Laboratory Biomarker Analysis: Correlative studies INTERVENTION 2: Arm II (High-dose Omega-3 Fatty Acid) Patients receive high-dose omega-3 fatty acid supplementation PO BID for 6 weeks  Omega-3 Fatty Acid: Given PO Questionnaire Administration: Ancillary studies Laboratory Biomarker Analysis: Correlative studies INTERVENTION 1: Cohort A ",
        "premise_nums": [
            "3 fatty acid",
            "3 Fatty Acid:",
            "3 Fatty Acid)"
        ]
    },
    {
        "id": "7e9c3980-9f12-40c7-920e-76594db26fd1",
        "primaryId": "NCT02352779",
        "secondaryId": "NCT00263588",
        "label": "Entailment",
        "statement_text": "The differences between cohorts in the primary trial is once cohort recieves a placebo and the other Low-dose Omega-3 Fatty Acid  in contrast the difference in the secondary trial is patient characteristics ",
        "statement_nums": [
            "3 Fatty Acid"
        ],
        "premise_text": "750mg lapatinib administered orally twice daily  Cohort A subjects had Eastern Cooperative Oncology Group (ECOG) performance status 0-1, and one or two prior trastuzumab-containing regimens  in total  for treatment of breast cancer in adjuvant and/or metastatic settingsINTERVENTION 2: Cohort B 750mg lapatinib administered orally twice daily  Cohort B subjects had ECOG performance status 2 and/or more than 2 prior trastuzumab-containing regimens for treatment of breast cancer in the adjuvant and/or metastatic settings  ",
        "premise_nums": [
            "2 prior trastuzumab",
            "0-1, and",
            "2 and/or more"
        ]
    },
    {
        "id": "c83e003d-d12d-4f72-ab1f-c39f3a13326b",
        "primaryId": "NCT00499083",
        "secondaryId": "NCT03045653",
        "label": "Entailment",
        "statement_text": "In order to be eligible for both the secondary trial and the primary trial  patients must be female  over the age of 18, ECOG smaller than 2 and have Histologically confirmed HER2 negative breast cancer ",
        "statement_nums": [
            "2 negative breast",
            "2 and have"
        ],
        "premise_text": "HER2/neu-negative tumor by IHC Female ECOG performance status 0-1 Inclusion Criteria: ",
        "premise_nums": [
            "0-1 Inclusion",
            "1 Inclusion Criteria:",
            "2/neu-negative tumor"
        ]
    },
    {
        "id": "cae58656-76e7-447a-940e-dfcc78159173",
        "primaryId": "NCT00244933",
        "statement_text": "the primary trial monitors the occurrence of anemia in its adverse events ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 5/19 (26.32%) Pain 3/19 (15.79%) White blood cells (WBC) 5/19 (26.32%) Hemoglobin (Hgb) 1/19 (5.26%) Absolute neutrophil count (ANC) 5/19 (26.32%) Platelets 3/19 (15.79%) Elevated Aspartate Aminotransferase (AST) 1/19 (5.26%) Elevated Alanine Aminotransferase (ALT) 1/19 (5.26%) Dyspnea 3/19 (15.79%) ",
        "premise_nums": [
            "1/19 (5.26%)",
            "5/19 (26.32%)",
            "3/19 (15.79%)"
        ]
    },
    {
        "id": "94c4c3fc-7bcb-407b-86b5-6699305d3dbd",
        "primaryId": "NCT02481050",
        "statement_text": "There are no adverse events in the primary trial that occurred more than once ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 14/58 (24.14%) Constipation 1/58 (1.72%) Vomiting 1/58 (1.72%) Upper gastrointestinal haemorrhage 1/58 (1.72%) Asthenia 1/58 (1.72%) Chest pain 1/58 (1.72%) Pain 1/58 (1.72%) Sepsis 2/58 (3.45%) Fall 1/58 (1.72%) Spinal compression fracture 1/58 (1.72%) Neutrophil count decreased 1/58 (1.72%) Dehydration 1/58 (1.72%) Hypovolaemia 1/58 (1.72%) ",
        "premise_nums": [
            "14/58 (24.14%)",
            "2/58 (3.45%)",
            "1/58 (1.72%)"
        ]
    },
    {
        "id": "103fbaa8-1852-402a-9368-36bbf6c747b2",
        "primaryId": "NCT00022516",
        "statement_text": "At most 3 patients in the primary trial suffered from Neutropenia ",
        "statement_nums": [
            "3 patients in"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 0/0 Leukopenia 0/0 Neutropenia 0/0 Ocular-other 0/0 Elevated SGPT 0/0 Arthralgia 0/0 CNS hemorrhage 0/0 Neurologic-other 0/0 Radiation dermatitis 0/0 Adverse Events 2: Total: 11/473 (2.33%) Leukopenia 2/473 (0.42%) Neutropenia 5/473 (1.06%) Ocular-other 1/473 (0.21%) Elevated SGPT 1/473 (0.21%) Arthralgia 1/473 (0.21%) CNS hemorrhage 1/473 (0.21%) ",
        "premise_nums": [
            "0/0 Leukopenia",
            "1/473 (0.21%)",
            "0/0 Neurologic-other",
            "0/0 Radiation",
            "2/473 (0.42%)",
            "0 CNS hemorrhage",
            "0/0 Adverse",
            "0/0 Neutropenia",
            "0 Elevated SGPT",
            "0 Adverse Events",
            "11/473 (2.33%)",
            "0/0 Arthralgia",
            "0/0 Ocular-other",
            "0 Radiation dermatitis",
            "0/0 CNS",
            "0/0 Elevated",
            "5/473 (1.06%)"
        ]
    },
    {
        "id": "103fbaa8-1852-402a-9368-36bbf6c747b2",
        "primaryId": "NCT00022516",
        "statement_text": "At most 3 patients in the primary trial suffered from Neutropenia ",
        "statement_nums": [
            "3 patients in"
        ],
        "label": "Contradiction",
        "premise_text": "Neurologic-other 1/473 (0.21%)Radiation dermatitis 1/473 (0.21%) ",
        "premise_nums": [
            "1/473 (0.21%)Radiation"
        ]
    },
    {
        "id": "731dc36f-983d-4d4c-97ac-6e3eeee23a40",
        "primaryId": "NCT00581256",
        "statement_text": "Patients with left-sided breast cancer and an ECOG of 3 are excluded from the primary trial ",
        "statement_nums": [
            "3 are excluded"
        ],
        "label": "Entailment",
        "premise_text": "Inclusion Criteria: All patients must have left-sided breast cancer  Performance status should be 0-2 by ECOG criteria  Exclusion Criteria: Performance status greater than 2 by ECOG criteria ",
        "premise_nums": [
            "0-2 by",
            "2 by ECOG"
        ]
    },
    {
        "id": "b2883781-f4e9-405e-9231-7a07e46c35b0",
        "primaryId": "NCT00429299",
        "statement_text": "Only one cohort in the primary trial is administered trastuzumab at 4 milligrams per kilogram ",
        "statement_nums": [
            "4 milligrams per"
        ],
        "label": "Entailment",
        "premise_text": "INTERVENTION 1: CT Plus Trastuzumab ",
        "premise_nums": []
    },
    {
        "id": "932c2135-381a-4675-a782-e683eca8d935",
        "primaryId": "NCT00791037",
        "secondaryId": "NCT00606931",
        "label": "Contradiction",
        "statement_text": "the primary trial and the secondary trial both use vaccine based interventions  however this is done in different intervals and for a different duration of time ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Treatment (Vaccine Therapy+ex Vivo-expanded T Cells) Patients receive HER2/neu peptide vaccine admixed with sargramostim (GM-CSF) ID on days 1, 8, and 15. Beginning 2 weeks later  patients undergo leukapheresis to isolate and collect peripheral blood mononuclear cells for T-cell expansion  ",
        "premise_nums": [
            "2 weeks later",
            "2/neu peptide"
        ]
    },
    {
        "id": "932c2135-381a-4675-a782-e683eca8d935",
        "primaryId": "NCT00791037",
        "secondaryId": "NCT00606931",
        "label": "Contradiction",
        "statement_text": "the primary trial and the secondary trial both use vaccine based interventions  however this is done in different intervals and for a different duration of time ",
        "statement_nums": [],
        "premise_text": "Patients receive cyclophosphamide IV once on day -1 and autologous ex vivo-expanded HER2-specific T cell IV over 30 minutes on day 1. Treatment repeats every 7-10 days for up to three immunizations  Patients receive a booster HER2/neu peptide vaccine 1 month after the final T-cell infusion  followed by 2 additional booster vaccines at 2-month intervals HER-2/neu peptide vaccine: Given ID leukapheresis: Undergo leukapheresis ex vivo-expanded HER2-specific T cells: Given IV cyclophosphamide: Given IV sargramostim: Given ID laboratory biomarker analysis: Correlative study INTERVENTION 1: PET Guided Biopsy ",
        "premise_nums": [
            "2-month intervals",
            "1 month after",
            "1 and autologous",
            "30 minutes on",
            "2/neu peptide",
            "10 days for",
            "2 additional booster",
            "2-specific T",
            "7-10 days"
        ]
    },
    {
        "id": "932c2135-381a-4675-a782-e683eca8d935",
        "primaryId": "NCT00791037",
        "secondaryId": "NCT00606931",
        "label": "Contradiction",
        "statement_text": "the primary trial and the secondary trial both use vaccine based interventions  however this is done in different intervals and for a different duration of time ",
        "statement_nums": [],
        "premise_text": "No comparison group  All enrolled participants were expected to undergo PET guided biopsy ",
        "premise_nums": []
    },
    {
        "id": "6461007d-fc18-43e2-a797-11cb0a4512ce",
        "primaryId": "NCT01648322",
        "secondaryId": "NCT00436566",
        "label": "Entailment",
        "statement_text": "the primary trial has a shorter time frame than the secondary trial ",
        "statement_nums": [],
        "premise_text": "Outcome Measurement: Duration of Moderate Neurtopenia Post First Chemotherapy Administration Number of days In which the patient has had an absolute neutrophil count (ANC) Level smaller than 2.0 x 10^9/L after first cycle of chemotherapy Time frame: The first of 4, 21 Day Chemotherapy Cycles Outcome Measurement: Number of Patients With Congestive Heart Failure (CHF) While on Active Treatment [Not Specified] Time frame: 6 months ",
        "premise_nums": [
            "9/L after",
            "than 2.0 x 10",
            "21 Day Chemotherapy"
        ]
    },
    {
        "id": "819e85b0-2d4e-4535-b920-4e18868da883",
        "primaryId": "NCT00630032",
        "secondaryId": "NCT00428922",
        "label": "Entailment",
        "statement_text": "Patients with radiologically confirmed metatases in the CNS are excluded from both the secondary trial and the primary trial ",
        "statement_nums": [],
        "premise_text": "Exclusion criteria: Clinically or radiologically detectable metastases (M0) Exclusion Criteria: CNS (central nervous system) metastases ",
        "premise_nums": [
            "(M0) Exclusion"
        ]
    },
    {
        "id": "cc0d6fe8-69c4-49d3-b321-00e47c155db6",
        "primaryId": "NCT03098550",
        "statement_text": "There results from cohort 3 of the primary trial were inconclusive ",
        "statement_nums": [
            "3 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Number of Participants With Adverse Events (AEs) Number of participants with any grade of adverse events (AEs) graded by Common Terminology Criteria for Adverse Events (CTCAE v4.0) to determine the safety and tolerability of Nivolumab and Daratumumab Time frame: From first dose to 30 days post last dose (up to 34 months) Results 1: Arm/Group Title: Nivolumab + Daratumumab (TNBC) ",
        "premise_nums": [
            "30 days post"
        ]
    },
    {
        "id": "cc0d6fe8-69c4-49d3-b321-00e47c155db6",
        "primaryId": "NCT03098550",
        "statement_text": "There results from cohort 3 of the primary trial were inconclusive ",
        "statement_nums": [
            "3 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Arm/Group Description: Triple-negative breast cancer (TNBC) treated with Triple-negative breast cancer (TNBC) treated with Nivolumab IV 240 mg Q2W (weeks 3 to 24) + Daratumumab IV 16 mg/kg Q1W (weeks 1 to 8), Daratumumab IV 16 mg/kg Q2W (weeks 9-24)Overall Number of Participants Analyzed: 41 Measure Type: Count of Participants Unit of Measure: Participants 41 100.0% Results 2: Arm/Group Title: Nivolumab + Daratumumab (NSCLC) ",
        "premise_nums": [
            "1 to 8),",
            "41 100.0% Results 2",
            "16 mg/kg Q",
            "41 Measure Type:",
            "3 to 24)",
            "240 mg Q2W",
            "9-24)Overall Number"
        ]
    },
    {
        "id": "cc0d6fe8-69c4-49d3-b321-00e47c155db6",
        "primaryId": "NCT03098550",
        "statement_text": "There results from cohort 3 of the primary trial were inconclusive ",
        "statement_nums": [
            "3 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Arm/Group Description: Non-small cell lung cancer (NSCLC) treated with Nivolumab IV 240 mg Q2W (weeks 3 to 24) + Daratumumab IV 16 mg/kg Q1W (weeks 1 to 8), Daratumumab IV 16 mg/kg Q2W (weeks 9-24)Overall Number of Participants Analyzed: 21 Measure Type: Count of Participants Unit of Measure: Participants 21 100.0% ",
        "premise_nums": [
            "1 to 8),",
            "16 mg/kg Q",
            "3 to 24)",
            "240 mg Q2W",
            "21 Measure Type:",
            "9-24)Overall Number"
        ]
    },
    {
        "id": "0fbb4fb4-620b-4ee9-aaa8-956992026cef",
        "primaryId": "NCT00454532",
        "statement_text": "Less than half of patients in cohorts 1 and 2 in the primary trial experienced adverse events ",
        "statement_nums": [
            "1 and 2"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 5/11 (45.45%) Hemorrhage  GI-abdomen NOS 21/11 (9.09%) Pain-liver 21/11 (9.09%) Infection-ulcer 20/11 (0.00%) Hemoglobin 20/11 (0.00%) Hypoglycemia 20/11 (0.00%) Pain-rib cage due to vomiting 20/11 (0.00%) Obstruction-gu ureter 1/11 (9.09%) Hemorrhage gu-bladder 21/11 (9.09%) Pain-breast 21/11 (9.09%) Pleural effusion 22/11 (18.18%) Adverse Events 2: ",
        "premise_nums": [
            "22/11 (18.18%)",
            "20/11 (0.00%)",
            "5/11 (45.45%)",
            "21/11 (9.09%)"
        ]
    },
    {
        "id": "0fbb4fb4-620b-4ee9-aaa8-956992026cef",
        "primaryId": "NCT00454532",
        "statement_text": "Less than half of patients in cohorts 1 and 2 in the primary trial experienced adverse events ",
        "statement_nums": [
            "1 and 2"
        ],
        "label": "Entailment",
        "premise_text": "Total: 0/6 (0.00%)",
        "premise_nums": [
            "0/6 (0.00%)"
        ]
    },
    {
        "id": "69b12ff4-6bb4-4207-b400-67795709c3c8",
        "primaryId": "NCT02679755",
        "statement_text": "Every patient in the Palbociclib+Letrozole Australia Cohort of the primary trial experienced Treatment-Emergent Adverse Events ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Number of Participants With Treatment-Emergent Adverse Events (All Causalities) ",
        "premise_nums": []
    },
    {
        "id": "9c0b258d-1e66-4eaa-b4e7-a9098eaed1d7",
        "primaryId": "NCT00829166",
        "statement_text": "Female patients with Peripheral neuropathy grade 3 or 4 are excluded from the primary trial ",
        "statement_nums": [
            "3 or 4"
        ],
        "label": "Entailment",
        "premise_text": "Exclusion Criteria: Peripheral neuropathy of Grade greater than /= 3 per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE)  Version 3.0 ",
        "premise_nums": [
            "3 per National"
        ]
    },
    {
        "id": "9872cf9f-6f43-44d3-97ce-e205e0e5fc6c",
        "primaryId": "NCT00464646",
        "statement_text": "Anna is a 57 year old female with an ECOG of 0, diagnosed with an invasive adenocarcinoma of the breast  IHC results were 1+. She is eligible for the primary trial ",
        "statement_nums": [
            "57 year old",
            "1+. She"
        ],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria: Patients must be female  The patient must be greater than or equal to 18 years old  The patient's ECOG performance status must be 0 or 1. The tumor must be invasive adenocarcinoma of the breast on histologic examination  The breast cancer must be determined to be HER2-positive prior to study entry  Assays performed using FISH require gene amplification  Assays using IHC require a strongly positive (3+) staining score  By pathologic evaluation  ipsilateral nodes must be pN2 or pN3. ",
        "premise_nums": [
            "2-positive prior",
            "2 or pN3.",
            "(3+) staining",
            "18 years old",
            "0 or 1."
        ]
    },
    {
        "id": "efc15257-5e19-4b7e-8b51-da94840784d8",
        "primaryId": "NCT00623233",
        "secondaryId": "NCT01525589",
        "label": "Entailment",
        "statement_text": "the primary trial recorded 1 patient with a deficiency of platelets in the blood  whereas a total of 6 patients with a platelet deficiency where found in the secondary trial ",
        "statement_nums": [
            "6 patients with",
            "1 patient with"
        ],
        "premise_text": "Adverse Events 1: Total: 18/52 (34.62%) Anaemia 2/52 (3.85%) Febrile Neutropenia 1/52 (1.92%) Haemolytic Uraemic Syndrome 1/52 (1.92%) Leukopenia 1/52 (1.92%) Neutropenia 1/52 (1.92%) Thrombocytopenia 1/52 (1.92%) Cardiac Failure Congestive 1/52 (1.92%) Cardio-Respiratory Arrest 1/52 (1.92%) Abdominal Pain 1/52 (1.92%) Constipation 1/52 (1.92%) ",
        "premise_nums": [
            "18/52 (34.62%)",
            "1/52 (1.92%)",
            "2/52 (3.85%)"
        ]
    },
    {
        "id": "efc15257-5e19-4b7e-8b51-da94840784d8",
        "primaryId": "NCT00623233",
        "secondaryId": "NCT01525589",
        "label": "Entailment",
        "statement_text": "the primary trial recorded 1 patient with a deficiency of platelets in the blood  whereas a total of 6 patients with a platelet deficiency where found in the secondary trial ",
        "statement_nums": [
            "6 patients with",
            "1 patient with"
        ],
        "premise_text": "Diarrhoea 1/52 (1.92%)Adverse Events 1: Total: 14/54 (25.93%) anaemia 2/54 (3.70%) Febrile neutropenia 7/54 (12.96%) Neutropenia 2/54 (3.70%) Thrombocytopenia 6/54 (11.11%) Atrial fibrillation 1/54 (1.85%) Cardiac failure congestive 1/54 (1.85%) Pericardial effusion 1/54 (1.85%) Nausea 2/54 (3.70%) Vomiting 3/54 (5.56%) ",
        "premise_nums": [
            "7/54 (12.96%)",
            "1/52 (1.92%)Adverse",
            "3/54 (5.56%)",
            "2/54 (3.70%)",
            "14/54 (25.93%)",
            "1/54 (1.85%)",
            "6/54 (11.11%)"
        ]
    },
    {
        "id": "efc15257-5e19-4b7e-8b51-da94840784d8",
        "primaryId": "NCT00623233",
        "secondaryId": "NCT01525589",
        "label": "Entailment",
        "statement_text": "the primary trial recorded 1 patient with a deficiency of platelets in the blood  whereas a total of 6 patients with a platelet deficiency where found in the secondary trial ",
        "statement_nums": [
            "6 patients with",
            "1 patient with"
        ],
        "premise_text": "Catheter site erythema 1/54 (1.85%)Chest discomfort 1/54 (1.85%) Adverse Events 2: Total: 5/20 (25.00%) anaemia 0/20 (0.00%) Febrile neutropenia 2/20 (10.00%) Neutropenia 0/20 (0.00%) Thrombocytopenia 0/20 (0.00%) Atrial fibrillation 0/20 (0.00%) Cardiac failure congestive 0/20 (0.00%) Pericardial effusion 0/20 (0.00%) Nausea 0/20 (0.00%) ",
        "premise_nums": [
            "5/20 (25.00%)",
            "0/20 (0.00%)",
            "1/54 (1.85%)Chest",
            "2/20 (10.00%)"
        ]
    },
    {
        "id": "efc15257-5e19-4b7e-8b51-da94840784d8",
        "primaryId": "NCT00623233",
        "secondaryId": "NCT01525589",
        "label": "Entailment",
        "statement_text": "the primary trial recorded 1 patient with a deficiency of platelets in the blood  whereas a total of 6 patients with a platelet deficiency where found in the secondary trial ",
        "statement_nums": [
            "6 patients with",
            "1 patient with"
        ],
        "premise_text": "Vomiting 0/20 (0.00%)Catheter site erythema 0/20 (0.00%) Chest discomfort 0/20 (0.00%) ",
        "premise_nums": [
            "0/20 (0.00%)Catheter"
        ]
    },
    {
        "id": "0d4ea69b-5e78-48c2-ba3e-d51dc5336ee1",
        "primaryId": "NCT01310231",
        "secondaryId": "NCT00093808",
        "label": "Contradiction",
        "statement_text": "19.57% of patients in the secondary trial developed an eating disorder  there were no cases of this happening in the primary trial ",
        "statement_nums": [
            "19.57% of"
        ],
        "premise_text": "Adverse Events 1: Total: 3/22 (13.64%) ascites with hyponatraemia 0/22 (0.00%) febrile neutropenia with respiratory infection 1/22 (4.55%) urosepsis 1/22 (4.55%) febrile neutropenia with urinary tract infection 0/22 (0.00%) dyspnoea 1/22 (4.55%) hypoxia 0/22 (0.00%) thromboembolism 0/22 (0.00%) Adverse Events 2: Total: 4/17 (23.53%) ascites with hyponatraemia 1/17 (5.88%) ",
        "premise_nums": [
            "4/17 (23.53%)",
            "3/22 (13.64%)",
            "0/22 (0.00%)",
            "1/17 (5.88%)",
            "1/22 (4.55%)"
        ]
    },
    {
        "id": "0d4ea69b-5e78-48c2-ba3e-d51dc5336ee1",
        "primaryId": "NCT01310231",
        "secondaryId": "NCT00093808",
        "label": "Contradiction",
        "statement_text": "19.57% of patients in the secondary trial developed an eating disorder  there were no cases of this happening in the primary trial ",
        "statement_nums": [
            "19.57% of"
        ],
        "premise_text": "febrile neutropenia with respiratory infection 0/17 (0.00%)urosepsis 0/17 (0.00%) febrile neutropenia with urinary tract infection 1/17 (5.88%) dyspnoea 0/17 (0.00%) hypoxia 1/17 (5.88%) thromboembolism 1/17 (5.88%) Adverse Events 1: Total: 9/46 (19.57%) Febrile neutropenia 1/46 (2.17%) Cardiac disorder 1/46 (2.17%) Diarrhea 1/46 (2.17%) ",
        "premise_nums": [
            "0/17 (0.00%)urosepsis",
            "9/46 (19.57%)",
            "1/46 (2.17%)",
            "1/17 (5.88%)"
        ]
    },
    {
        "id": "0d4ea69b-5e78-48c2-ba3e-d51dc5336ee1",
        "primaryId": "NCT01310231",
        "secondaryId": "NCT00093808",
        "label": "Contradiction",
        "statement_text": "19.57% of patients in the secondary trial developed an eating disorder  there were no cases of this happening in the primary trial ",
        "statement_nums": [
            "19.57% of"
        ],
        "premise_text": "Upper gastrointestinal hemorrhage 1/46 (2.17%)Chest pain 1/46 (2.17%) Fatigue 1/46 (2.17%) Neutrophil count decreased 2/46 (4.35%) Platelet count decreased 1/46 (2.17%) Anorexia 1/46 (2.17%) Dehydration 1/46 (2.17%) Serum potassium increased 1/46 (2.17%) ",
        "premise_nums": [
            "1/46 (2.17%)Chest",
            "2/46 (4.35%)"
        ]
    },
    {
        "id": "7990b9bf-ac76-4f21-b9a1-5e0b4d91b9a9",
        "primaryId": "NCT02129556",
        "statement_text": "Cohort 1 of the primary trial had a much higher number of deaths than cohort 2.",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Death 2/6 (33.33%) Adverse Events 2: Death 9/52 (17.31%) ",
        "premise_nums": [
            "2/6 (33.33%)",
            "9/52 (17.31%)"
        ]
    },
    {
        "id": "e4961c1a-83e2-40ed-93ac-64d5cef1f84a",
        "primaryId": "NCT01819233",
        "statement_text": "All the primary trial participants must reduce the number of calories in their diets by a quarter throughout the duration of the study ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "INTERVENTION 1: Behavioral Dietary Intervention Beginning 2-4 weeks after completion of lumpectomy  patients receive food diaries to complete for 7-10 days  Dietary counselors then give patients guidelines for dietary modifications to reduce caloric intake by 25% of their normal diet  Patients follow caloric restricted diet for 10 weeks (2 weeks prior to radiation therapy  during 6 weeks of radiation therapy  and at least 2 weeks after radiation therapy)  Patients undergo radiation therapy QD 5 days a week for 6 weeks  Behavioral dietary intervention: Receive caloric restricted dietary intervention Therapeutic conventional surgery: Undergo definitive lumpectomy Radiation therapy: Undergo radiation therapy Counseling intervention: Receive dietary counseling Quality-of-life assessment: Ancillary studies ",
        "premise_nums": [
            "25% of",
            "2-4 weeks",
            "5 days a",
            "4 weeks after",
            "7-10 days",
            "10 weeks (2",
            "6 weeks of",
            "2 weeks after"
        ]
    },
    {
        "id": "9cb1c975-0d49-4437-af56-1a4f97e30aef",
        "primaryId": "NCT01663727",
        "secondaryId": "NCT00072293",
        "label": "Entailment",
        "statement_text": "There is no maximum or minimum age defined for participation in the primary trial or the secondary trial ",
        "statement_nums": [],
        "premise_text": "Inclusion Criteria: Histologically or cytologically confirmed  HER2-negative adenocarcinoma of the breast  with measurable or non-measurable locally recurrent or metastatic disease  Locally recurrent disease must not be amenable to resection with curative intent  ECOG performance status of 0 or 1 For women of childbearing potential  use of an acceptable and effective method of non-hormonal contraception For patients who have received recent radiotherapy  recovery prior to randomization from any significant acute toxicity  and radiation treatments have to be completed more than 3 weeks from randomization Exclusion Criteria: Disease-Specific Exclusions: HER2-positive status Prior chemotherapy for locally recurrent or metastatic disease Prior hormonal therapy smaller than 2 weeks prior to randomization ",
        "premise_nums": [
            "0 or 1",
            "2-negative adenocarcinoma",
            "3 weeks from",
            "2-positive status",
            "2 weeks prior"
        ]
    },
    {
        "id": "9cb1c975-0d49-4437-af56-1a4f97e30aef",
        "primaryId": "NCT01663727",
        "secondaryId": "NCT00072293",
        "label": "Entailment",
        "statement_text": "There is no maximum or minimum age defined for participation in the primary trial or the secondary trial ",
        "statement_nums": [],
        "premise_text": "Prior adjuvant or neo-adjuvant chemotherapy is allowed  provided its conclusion has been for at least 12 months prior to randomizationInvestigational therapy within 28 days of randomization General Medical Exclusions: Life expectancy of smaller than 12 weeks Inadequate organ function Uncontrolled serious medical or psychiatric illness Active infection requiring intravenous (IV) antibiotics at screening Pregnancy or lactation History of other malignancies within 5 years prior to screening  except for tumors with a negligible risk for metastasis or death PATIENT CHARACTERISTICS: Age Any age ",
        "premise_nums": [
            "28 days of",
            "12 months prior",
            "12 weeks Inadequate",
            "5 years prior"
        ]
    },
    {
        "id": "51699ae8-d297-4635-95c1-4ed38c8706c3",
        "primaryId": "NCT02732119",
        "statement_text": "Mark suffered Refractory ventricular fibrillation twice in the last month he is therefore excluded from the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Exclusion Criteria: Clinically significant  uncontrolled heart disease and/or recent cardiac events  ",
        "premise_nums": []
    },
    {
        "id": "c2c73b99-f89c-4dd3-8362-295f9a7965f3",
        "primaryId": "NCT02756364",
        "statement_text": "In order to meet the inclusion criteria for the primary trial patients must have had ineffective aromatase inhibitor (AI) therapy before study entry ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Inclusion Criteria: Progressive Disease (PD) during prior aromatase inhibitor (AI) therapy  ",
        "premise_nums": []
    },
    {
        "id": "180d7b66-9ee9-40fb-b4c7-a6060e6f67b7",
        "primaryId": "NCT02129556",
        "statement_text": "Cohort 1 of the primary trial had a much higher mortality rate than cohort 2.",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Death 2/6 (33.33%) Adverse Events 2: Death 9/52 (17.31%) ",
        "premise_nums": [
            "2/6 (33.33%)",
            "9/52 (17.31%)"
        ]
    },
    {
        "id": "949ac54b-a871-4134-a507-c98a4de55720",
        "primaryId": "NCT00394082",
        "secondaryId": "NCT01033032",
        "label": "Entailment",
        "statement_text": "the primary trial recorded cases of Anaphylaxis and Spinal compression fracture  neither of these were observed in the secondary trial ",
        "statement_nums": [],
        "premise_text": "Adverse Events 1: Total: 13/50 (26.00%) Febrile neutropenia 3/50 (6.00%) Neutropenia 1/50 (2.00%) Pancreatitis 1/50 (2.00%) Cholangitis 1/50 (2.00%) Cholelithiasis 1/50 (2.00%) Anaphylactic reaction [1]1/50 (2.00%) Pneumonia 1/50 (2.00%) Pneumonitis chemical 1/50 (2.00%) Spinal compression fracture 1/50 (2.00%) Dehydration 1/50 (2.00%) Electrolyte imbalance 1/50 (2.00%) Adverse Events 1: ",
        "premise_nums": [
            "3/50 (6.00%)",
            "13/50 (26.00%)",
            "1/50 (2.00%)"
        ]
    },
    {
        "id": "949ac54b-a871-4134-a507-c98a4de55720",
        "primaryId": "NCT00394082",
        "secondaryId": "NCT01033032",
        "label": "Entailment",
        "statement_text": "the primary trial recorded cases of Anaphylaxis and Spinal compression fracture  neither of these were observed in the secondary trial ",
        "statement_nums": [],
        "premise_text": "Total: 1/3 (33.33%)FEBRILE NEUTROPENIA 0/3 (0.00%) LYMPH NODE PAIN 0/3 (0.00%) NEUTROPHIL COUNT DECREASED 0/3 (0.00%) THROMBOCYTOPENIA 0/3 (0.00%) CHEST PAIN 0/3 (0.00%) DEHYDRATION 0/3 (0.00%) PLEURAL EFFUSION 1/3 (33.33%) PNEUMONITIS 0/3 (0.00%) PULMONARY INFILTERATES 0/3 (0.00%) ALOPECIA 0/3 (0.00%) ",
        "premise_nums": [
            "0/3 (0.00%)",
            "1/3 (33.33%)FEBRILE"
        ]
    },
    {
        "id": "02407f87-235d-4240-98fe-498b352cce75",
        "primaryId": "NCT00167414",
        "statement_text": "Patients must have Human epidermal growth factor receptor 2 (HER2) overexpressive tumors to participate in the primary trial ",
        "statement_nums": [
            "(HER2) overexpressive"
        ],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria: Age: no limit Karnofsky performance status (KPS) 70 No more than 5 metastatic sites involving one or more different organs (liver  lung or bone)  The size of the lesion must be such that it can be safely treated to sterilizing radiation doses according to the rules in the protocol  Previously treated lesions are not eligible unless the prescribed dose can be safely delivered  Concurrent therapy is allowed and recommended  The chemotherapy protocol type and schedule are at the discretion of the medical oncologist  Informed consent must be obtained  Pregnancy test must be negative for women of child bearing potential Exclusion Criteria: Inability of patient to be followed longitudinally as specified by protocol  Technical inability to achieve required dose based on safe dose constraints required for radiosurgery  Women who are pregnant or nursing  Failure to meet requirements in Inclusion Criteria Contraindications to radiation  ",
        "premise_nums": [
            "70 No more",
            "5 metastatic sites"
        ]
    },
    {
        "id": "61a524d4-1697-4a10-b36a-a0c6cda79526",
        "primaryId": "NCT00030823",
        "statement_text": "Patients with stage I  II  III or IV triple negative breast cancer are not eliglbe for the primary trial ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Hormone receptor status: Not specified ",
        "premise_nums": []
    },
    {
        "id": "304977b6-9742-4c3b-84fd-e5ef1737a143",
        "primaryId": "NCT01597193",
        "statement_text": "ECOG smaller than 2 and a life expectancy over 12 weeks are necessary to participate in the primary trial ",
        "statement_nums": [
            "2 and a",
            "12 weeks are"
        ],
        "label": "Entailment",
        "premise_text": "Inclusion Criteria: Eastern Cooperative Oncology Group performance (ECOG) status of 0 or 1; Estimated life expectancy of at least 3 months ",
        "premise_nums": [
            "0 or 1;"
        ]
    },
    {
        "id": "87c65217-85d9-4f05-87aa-f4dfacd9f25a",
        "primaryId": "NCT01790932",
        "statement_text": "patients with Phosphoinositide 3-kinase inhibitor based treatments are ineligible for the primary trial",
        "statement_nums": [
            "3-kinase inhibitor"
        ],
        "label": "Entailment",
        "premise_text": "Exclusion Criteria: Have received previous treatment with PI3K inhibitors ",
        "premise_nums": []
    },
    {
        "id": "19e89ebc-a417-47a8-bfa7-1778baead178",
        "primaryId": "NCT01385137",
        "secondaryId": "NCT00593346",
        "label": "Entailment",
        "statement_text": "Placebo treatment is used in the secondary trial  but there is only a test group in the primary trial ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Arm I (Omega-3-fatty Acid) Patients receive oral omega-3-fatty acid twice daily (BID) or three times daily (TID) for 24 weeks in the absence of disease progression or unacceptable toxicity INTERVENTION 2: Arm II (Placebo) Patients receive oral placebo BID or TID for 24 weeks in the absence of disease progression or unacceptable toxicity INTERVENTION 1: Accelerated Partial Breast Brachytherapy Each patient will receive accelerated partial breast brachytherapy with multiple plane implant  Patients will receive 3400 cGy delivered in 10 twice-daily fractions  Treatment is to be given over 5-7 days with a minimum of 6 hours separation between fractions  ",
        "premise_nums": [
            "7 days with",
            "3-fatty acid",
            "10 twice-daily fractions",
            "5-7 days",
            "3400 cGy delivered",
            "3-fatty Acid",
            "6 hours separation",
            "24 weeks in"
        ]
    },
    {
        "id": "561a0631-1eb3-48d1-baa2-81eb3fa79b98",
        "primaryId": "NCT00950300",
        "secondaryId": "NCT00615901",
        "label": "Entailment",
        "statement_text": "the primary trial recorded a patient with chest pain  whereas the secondary trial observed a patient with abdominal pain ",
        "statement_nums": [],
        "premise_text": "Adverse Events 1: Angina pectoris * 1/298 (0.34%) Adverse Events 1: Abdominal pain 1/38 (2.63%) ",
        "premise_nums": [
            "1/38 (2.63%)",
            "1/298 (0.34%)"
        ]
    },
    {
        "id": "bc617e84-a0c1-400b-9ad5-88b56d1805e8",
        "primaryId": "NCT01671319",
        "statement_text": "1/42 patients in cohort 1 of the primary trial fainted ",
        "statement_nums": [
            "42 patients in",
            "1 of the",
            "1/42 patients"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 4/42 (9.52%) Perforation  GI 1/42 (2.38%) Febrile neutropenia 1/42 (2.38%) Syncope 1/42 (2.38%) Rash/desquamation 1/42 (2.38%) ",
        "premise_nums": [
            "1/42 (2.38%)",
            "4/42 (9.52%)"
        ]
    },
    {
        "id": "8a8b7b19-9328-4cb3-b01c-8f4c358f4ac5",
        "primaryId": "NCT01097642",
        "statement_text": "Adult Patients with histologic confirmation of invasive bilateral breast carcinoma (T3 N1 M0) are eligible for the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Inclusion Criteria: Patients with histologic confirmation of invasive breast carcinoma  Patients greater than or equal to 18 years  Patients should have T1N1-3M0 or T2-4 N0-3M0. Patients with bilateral breast cancer are eligible  ",
        "premise_nums": [
            "1-3M0 or",
            "2-4 N0-3M0"
        ]
    },
    {
        "id": "bb4f69b0-0e2e-44e6-a3b6-049f4a8505fe",
        "primaryId": "NCT00354640",
        "statement_text": "Patients taking Intervention 1 of the primary trial receive higher doses of anastrozole than of simvastatin ",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "INTERVENTION 1: Anastrozole and Simvastatin adjuvant therapy : laboratory analysis pharmacological study : laboratory analysis simvastatin : 40 milligram tablet PO QD for 14 days anastrozole : 1 milligram tablet PO QD for 14 days ",
        "premise_nums": [
            "40 milligram tablet",
            "1 milligram tablet",
            "14 days anastrozole"
        ]
    },
    {
        "id": "b059e44b-9830-4c45-858e-ebd007fbaf69",
        "primaryId": "NCT00148668",
        "statement_text": "Cohort 1 and 2 of the primary trial recorded the same number of patients with Febrile Neutropenia ",
        "statement_nums": [
            "1 and 2"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 5/41 (12.20%) Neutropenia 4/41 (9.76%) Febrile Neutropenia 0/41 (0.00%) SGPT (ALT) 1/41 (2.44%) Adverse Events 2: Total: 5/40 (12.50%) Neutropenia 4/40 (10.00%) Febrile Neutropenia 1/40 (2.50%) SGPT (ALT) 0/40 (0.00%) ",
        "premise_nums": [
            "0/41 (0.00%)",
            "4/41 (9.76%)",
            "5/41 (12.20%)",
            "4/40 (10.00%)",
            "1/41 (2.44%)",
            "1/40 (2.50%)",
            "5/40 (12.50%)",
            "0/40 (0.00%)"
        ]
    },
    {
        "id": "fec065ca-fbde-476d-ab0d-7e7054e29858",
        "primaryId": "NCT00436917",
        "statement_text": "Patients with Scoliosis with a Cobb angle exceeding 20 degrees at the lumbar spine  or with a prior surgery at the lumbosacral spine are excluded from the primary trial  as these would interfere with the necessary CT and MRI scans for the study ",
        "statement_nums": [
            "20 degrees at"
        ],
        "label": "Contradiction",
        "premise_text": "No contraindication to spine dual energy x-ray absorptiometry (DXA) as defined by any of the following: History of surgery at the lumbosacral spine  with or without implantable devices Scoliosis with a Cobb angle greater than 15 degrees at the lumbar spine ",
        "premise_nums": [
            "15 degrees at"
        ]
    },
    {
        "id": "ea3bd229-001c-487f-9cda-edf2e699dbb2",
        "primaryId": "NCT01153672",
        "secondaryId": "NCT01432145",
        "label": "Contradiction",
        "statement_text": "Patients in the primary trial receive vorinostat at the same frequency  dosage and through the same route of administration as the secondary trial receive 6-Mercaptopurine.",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Treatment (Enzyme Inhibitor Therapy  AI Sensitization Therapy) Patients receive vorinostat PO QD for 2 weeks followed by AI therapy comprising anastrozole PO QD  letrozole PO QD  OR exemestane PO QD for 6 weeks  Courses repeat every 8 weeks in the absence of disease progression or unacceptable toxicity  vorinostat: Given PO laboratory biomarker analysis: Correlative studies biopsy: Optional correlative studies F-18 16 alpha-fluoroestradiol: Correlative studies positron emission tomography: Correlative studies anastrozole: Given PO letrozole: Given PO exemestane: Given PO ",
        "premise_nums": [
            "16 alpha-fluoroestradiol:",
            "8 weeks in",
            "2 weeks followed"
        ]
    },
    {
        "id": "ea3bd229-001c-487f-9cda-edf2e699dbb2",
        "primaryId": "NCT01153672",
        "secondaryId": "NCT01432145",
        "label": "Contradiction",
        "statement_text": "Patients in the primary trial receive vorinostat at the same frequency  dosage and through the same route of administration as the secondary trial receive 6-Mercaptopurine.",
        "statement_nums": [],
        "premise_text": "gene expression analysis: Correlative studiesINTERVENTION 1: 6-Mercaptopurine and Methotrexate (6MP/MTX) 6-Mercaptopurine: 6MP 75mg/m2 body surface area  administered orally (PO) once a day (od) in the morning 1 hour after eating  on a continuous schedule  One cycle is 28 days  Treatment is given continuously until disease progression  Methotrexate: Methotrexate 20mg/m2 will be taken orally  once a week  in the morning  One cycle is 28 days  Treatment is given continuously until disease progression  ",
        "premise_nums": [
            "1 hour after",
            "75mg/m2 body",
            "6-Mercaptopurine: 6MP",
            "2 will be",
            "2 body surface",
            "6-Mercaptopurine and",
            "20mg/m2 will"
        ]
    },
    {
        "id": "ea3bd229-001c-487f-9cda-edf2e699dbb2",
        "primaryId": "NCT01153672",
        "secondaryId": "NCT01432145",
        "label": "Contradiction",
        "statement_text": "Patients in the primary trial receive vorinostat at the same frequency  dosage and through the same route of administration as the secondary trial receive 6-Mercaptopurine.",
        "statement_nums": [],
        "premise_text": "Update: These original doses were reduced following an Urgent Safety Measure in August 2012 due to a large proportion of patients requiring a dose reduction or treatment delay due to incidences of myelo-suppression The reduced doses were 55mg/m2 of 6MP orally once a day  and 15mg/m2 of Methotrexate orally once a week  ",
        "premise_nums": [
            "2 of 6MP",
            "2 of Methotrexate",
            "2012 due to",
            "15mg/m2 of",
            "55mg/m2 of"
        ]
    },
    {
        "id": "576e519a-1ef3-43e5-a13c-6058ad71f388",
        "primaryId": "NCT00297596",
        "secondaryId": "NCT00580333",
        "label": "Contradiction",
        "statement_text": "Patients have received prior radiation treatment  to treat the current breast cancer  in the last two 2 weeks before study entry are eligible for the primary trial but excluded from the secondary trial ",
        "statement_nums": [
            "2 weeks before"
        ],
        "premise_text": "Inclusion Criteria: Patients may have received one prior trastuzumab/chemotherapy containing regimen or prior single agent trastuzumab  All prior chemotherapy  trastuzumab and radiation therapy should be completed greater than 2 weeks before enrollment  Exclusion Criteria: Any prior cytotoxic chemotherapy or radiation for the current breast cancer ",
        "premise_nums": [
            "2 weeks before"
        ]
    },
    {
        "id": "699d0cb5-1ebb-441d-aa7e-041a48923b00",
        "primaryId": "NCT03374995",
        "statement_text": "the primary trial subjects receiving keratin are administered it topically twice daily for approximately 3-6 weeks ",
        "statement_nums": [
            "3-6 weeks"
        ],
        "label": "Entailment",
        "premise_text": "INTERVENTION 1: Group I (Topical Keratin) Patients receive topical keratin topically at least BID until the end of radiation therapy (approximately 3-6 weeks)  Quality-of-Life Assessment: Ancillary studies Topical Keratin: Given topically INTERVENTION 2: Group II (Standard of Care) Patients receive standard of care as directed by radiation oncologist until the end of radiation therapy (approximately 3-6 weeks)  Best Practice: Receive standard of care Quality-of-Life Assessment: Ancillary studies ",
        "premise_nums": [
            "3-6 weeks"
        ]
    },
    {
        "id": "6ec27be7-aa61-4ba8-b92a-98dcaee1eb0b",
        "primaryId": "NCT01127373",
        "statement_text": "Patients with T1N1M0, T2N1M0, T3N1M0 and TxN1M0 tumors are eliglbe for the primary trial ",
        "statement_nums": [
            "0 and TxN1M0"
        ],
        "label": "Entailment",
        "premise_text": "Inclusion Criteria: Pathologic confirmation of metastatic disease in at least one regional lymph node  Regional lymph nodes are defined as the ipsilateral axillary lymph nodes  ipsilateral supraclavicular lymph nodes  and ipsilateral internal mammary lymph nodes  Thus  any T stage is allowed as long as the N stage is 1 and M stage is 0. ",
        "premise_nums": [
            "1 and M"
        ]
    },
    {
        "id": "6e882de6-e55f-40a4-95a1-bdb176e68a18",
        "primaryId": "NCT00266799",
        "statement_text": "None of the patients in cohort 1 of the primary trial had ACUTE VESTIBULAR or acute coronary syndrome ",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 30/98 (30.61%) NEUTROPENIA 1/98 (1.02%) ATRIAL FIBRILLATION 1/98 (1.02%) CARDIAC FAILURE 1/98 (1.02%) TACHYCARDIA 0/98 (0.00%) ACUTE VESTIBULAR SYNDROME 1/98 (1.02%) VERTIGO 0/98 (0.00%) ABDOMINAL PAIN 0/98 (0.00%) COLITIS 0/98 (0.00%) DIARRHOEA 2/98 (2.04%) FEMORAL HERNIA 0/98 (0.00%) HAEMATEMESIS 0/98 (0.00%) ILEUS 0/98 (0.00%) ",
        "premise_nums": [
            "1/98 (1.02%)",
            "2/98 (2.04%)",
            "30/98 (30.61%)",
            "0/98 (0.00%)"
        ]
    },
    {
        "id": "6e882de6-e55f-40a4-95a1-bdb176e68a18",
        "primaryId": "NCT00266799",
        "statement_text": "None of the patients in cohort 1 of the primary trial had ACUTE VESTIBULAR or acute coronary syndrome ",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "NAUSEA 0/98 (0.00%)",
        "premise_nums": [
            "0/98 (0.00%)"
        ]
    },
    {
        "id": "525ed182-07e9-4548-87b3-c831e0b7389e",
        "primaryId": "NCT00834678",
        "statement_text": "Patients with lymphopenia can participate in the primary trial ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "WBC greater than 1,500/mm³ ",
        "premise_nums": [
            "1,500/mm³"
        ]
    },
    {
        "id": "233d2ec1-1383-4088-90af-c5a948847631",
        "primaryId": "NCT00110084",
        "secondaryId": "NCT01961544",
        "label": "Contradiction",
        "statement_text": "the primary trial and the secondary trial both reported cases of Pseudomonal sepsis in their patients ",
        "statement_nums": [],
        "premise_text": "Adverse Events 1: Sepsis 1/50 (2.00%) Adverse Events 1: Pseudomonal sepsis * 1/101 (0.99%) ",
        "premise_nums": [
            "1/101 (0.99%)",
            "1/50 (2.00%)"
        ]
    },
    {
        "id": "8e3fe244-d47d-48ce-ab29-4a5226024aad",
        "primaryId": "NCT00426556",
        "statement_text": "There were an equal number of cases of Febrile neutropenia  Leukopenia and Neutropenia across cohorts in the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 3/6 (50.00%) Febrile neutropenia 0/6 (0.00%) Leukopenia 0/6 (0.00%) Neutropenia 0/6 (0.00%) Adverse Events 2: Total: 6/17 (35.29%) Febrile neutropenia 0/17 (0.00%) Leukopenia 0/17 (0.00%) Neutropenia 0/17 (0.00%) ",
        "premise_nums": [
            "6/17 (35.29%)",
            "3/6 (50.00%)",
            "0/6 (0.00%)",
            "0/17 (0.00%)"
        ]
    },
    {
        "id": "670443b0-89bf-4af4-a9ab-4cdff26d09a8",
        "primaryId": "NCT00005957",
        "statement_text": "T4 N3 M0 adenocarcinoma of the breast are eligible for the primary trial ",
        "statement_nums": [
            "0 adenocarcinoma of"
        ],
        "label": "Contradiction",
        "premise_text": "DISEASE CHARACTERISTICS: Histologically proven invasive carcinoma of the breast No evidence of T4, N2-3, or M1 disease prior to surgery Node positive or high-risk node negative ",
        "premise_nums": [
            "2-3, or",
            "1 disease prior"
        ]
    },
    {
        "id": "455748bf-8e12-4834-8126-ab77cab16200",
        "primaryId": "NCT00332709",
        "secondaryId": "NCT00659373",
        "label": "Entailment",
        "statement_text": "All the primary trial participants receive the same dose of Letrozole  only certain patients in the secondary trial are administered Exemestane ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Letrozole Letrozole 2.5 mg/day for 3 years INTERVENTION 2: Letrozole + Zoledronic Acid Letrozole 2.5mg/day for 3 years plus Zoledronic acid 4mg every 6 months INTERVENTION 1: Tamoxifen Tamoxifen 20mg orally daily for 5 years INTERVENTION 2: Ovarian Function Suppression Tamoxifen 20mg orally daily or Exemestane 25mg orally daily for 5 years plus ovarian function suppression (OFS; triptorelin (GnRH analogue) 3.75 mg by im injection q28 days for 5 years; or surgical oophorectomy; or ovarian irradiation) ",
        "premise_nums": [
            "3 years INTERVENTION",
            "5 years INTERVENTION",
            "q28 days",
            "Letrozole 2.5 mg/day",
            "3 years plus",
            "75 mg by",
            "Letrozole 2.5mg/day",
            "5 years plus",
            "28 days for",
            "6 months INTERVENTION"
        ]
    },
    {
        "id": "455748bf-8e12-4834-8126-ab77cab16200",
        "primaryId": "NCT00332709",
        "secondaryId": "NCT00659373",
        "label": "Entailment",
        "statement_text": "All the primary trial participants receive the same dose of Letrozole  only certain patients in the secondary trial are administered Exemestane ",
        "statement_nums": [],
        "premise_text": "Note: Data were collected separately for the T+OFS and E+OFS participants in the parent study  IBCSG 24-02 (SOFT)  The sample size for this Co-SOFT substudy was small  so the analysis plan was revised to pre-specify collective analysis for all patients receiving OFS ",
        "premise_nums": []
    },
    {
        "id": "d29bd9dd-b52e-4b18-82ea-e2914dfb9579",
        "primaryId": "NCT01808573",
        "statement_text": "the primary trial Patients receiving Neratinib Plus Capecitabine had a Mean (95% Confidence Interval) Progression Free Survival more than 2 months longer than patients administered with Lapatinib Plus Capecitabine ",
        "statement_nums": [
            "2 months longer",
            "95% Confidence"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Centrally Assessed Progression Free Survival ",
        "premise_nums": []
    },
    {
        "id": "2649c857-f98d-4529-9a4a-4f8b17813cb8",
        "primaryId": "NCT00337103",
        "statement_text": "The Median Overall Survival for cohort 1 patients was 44 days longer than for patients in cohort 2 of the primary trial ",
        "statement_nums": [
            "1 patients was",
            "2 of the",
            "44 days longer"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Overall Survival (OS) OS was measured from the date of randomization until the date of death from any cause  or the last date the participant was known to be alive  Participants who were lost to follow-up or who were alive at the date of data cutoff were censored  The censoring rules for OS were as follows: 1) if the participant was still alive at data cutoff  the date of data cutoff was considered the end date  and 2) if the participant was lost to follow-up before data cutoff  the date they were last known to be alive was considered the end date  Participants who survived past the end of the study were counted as in the full study period  If death occurred after data cutoff  the end date was to be censored at the time of data cutoff  ",
        "premise_nums": []
    },
    {
        "id": "2649c857-f98d-4529-9a4a-4f8b17813cb8",
        "primaryId": "NCT00337103",
        "statement_text": "The Median Overall Survival for cohort 1 patients was 44 days longer than for patients in cohort 2 of the primary trial ",
        "statement_nums": [
            "1 patients was",
            "2 of the",
            "44 days longer"
        ],
        "label": "Entailment",
        "premise_text": "Time frame: From date of randomization until date of death from any cause  assessed up to data cutoff date of 12 Mar 2012, or up to approximately 6 yearsResults 1: Arm/Group Title: Eribulin Mesylate 1.4 mg/m^2 Arm/Group Description: Eribulin mesylate 1.4 mg/m^2 intravenous (IV) infusion given over 2-5 minutes on Days 1 and 8 every 21 days  Overall Number of Participants Analyzed: 554 Median (95% Confidence Interval) Unit of Measure: days 484 (462 to 536) Results 2: Arm/Group Title: Capecitabine 2.5 g/m^2/Day ",
        "premise_nums": [
            "2-5 minutes",
            "462 to 536)",
            "Mesylate 1.4 mg/m",
            "mesylate 1.4 mg/m",
            "1 and 8",
            "95% Confidence",
            "12 Mar 2012,",
            "2 intravenous (IV)",
            "Capecitabine 2.5 g/m",
            "5 minutes on",
            "6 yearsResults 1:"
        ]
    },
    {
        "id": "2649c857-f98d-4529-9a4a-4f8b17813cb8",
        "primaryId": "NCT00337103",
        "statement_text": "The Median Overall Survival for cohort 1 patients was 44 days longer than for patients in cohort 2 of the primary trial ",
        "statement_nums": [
            "1 patients was",
            "2 of the",
            "44 days longer"
        ],
        "label": "Entailment",
        "premise_text": "Arm/Group Description: Capecitabine : Capecitabine 2.5 g/m^2/day administered orally twice daily in two equal doses on Days 1 to 14 every 21 days Overall Number of Participants Analyzed: 548 Median (95% Confidence Interval) Unit of Measure: days 440 (400 to 487) ",
        "premise_nums": [
            "21 days Overall",
            "1 to 14",
            "95% Confidence",
            "400 to 487)",
            "Capecitabine 2.5 g/m",
            "2/day administered"
        ]
    },
    {
        "id": "0a6e8720-ea47-4520-bd02-e0eb8fcd880f",
        "primaryId": "NCT00399802",
        "statement_text": "The Single IV Infusion of ZA 4 mg group of the primary trial had a smaller Percentage Change From Baseline in Urinary N-telopeptide of Type I Collagen than the Odanacatib 5 mg group",
        "statement_nums": [
            "5 mg group",
            "4 mg group"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Percentage Change From Baseline in Urinary N-telopeptide of Type I Collagen (u-NTx) at Week 4 u-NTx is a biochemical index of bone resorption  Participants provided urine specimens on Day 1 (baseline) and at Week 4 for measurement of u-NTx  Time frame: Baseline and Week 4 Results 1: Arm/Group Title: Single IV Infusion of ZA 4 mg Arm/Group Description: Participants received a single IV infusion of ZA 4 mg at the start of treatment and a once-daily odanacatib matching placebo tablet for 4 weeks  Overall Number of Participants Analyzed: 14 ",
        "premise_nums": [
            "4 mg at",
            "4 mg Arm",
            "4 u-NTx is",
            "4 for measurement",
            "4 Results 1:"
        ]
    },
    {
        "id": "0a6e8720-ea47-4520-bd02-e0eb8fcd880f",
        "primaryId": "NCT00399802",
        "statement_text": "The Single IV Infusion of ZA 4 mg group of the primary trial had a smaller Percentage Change From Baseline in Urinary N-telopeptide of Type I Collagen than the Odanacatib 5 mg group",
        "statement_nums": [
            "5 mg group",
            "4 mg group"
        ],
        "label": "Entailment",
        "premise_text": "Mean (95% Confidence Interval)Unit of Measure: Percentage change -73 (-80 to -62) Results 2: Arm/Group Title: Once-daily Odanacatib 5 mg Arm/Group Description: Participants received a once-daily odanacatib 5 mg tablet for 4 weeks and a single IV infusion of ZA matching placebo at the start of treatment  Overall Number of Participants Analyzed: 27 Mean (95% Confidence Interval) Unit of Measure: Percentage change -77 (-82 to -71) ",
        "premise_nums": [
            "5 mg Arm",
            "95% Confidence",
            "5 mg tablet",
            "4 weeks and"
        ]
    },
    {
        "id": "ce6630d3-d3b7-4870-a486-9b6284a454f0",
        "primaryId": "NCT02679755",
        "statement_text": "More patients in the Palbociclib+Letrozole Australia Cohort of the primary trial experienced Treatment-Emergent Adverse Events compared to patients in the Palbociclib+Letrozole India Cohort ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Results 1: Arm/Group Title: Palbociclib+Letrozole India Cohort Arm/Group Description: Participants received Palbociclib orally once a day at 125 mg for 21 days followed by 7 days off treatment ofr each 28-day cycle  Participants received Letrozole orally at 2.5 mg once daily as continuous daily dosing schedule according to product labeling and in compliance with its local prescribing information Overall Number of Participants Analyzed: 100 Measure Type: Count of Participants Unit of Measure: Participants Participants with adverse events: 92 92.0% Participants with serious adverse events: 18 18.0% ",
        "premise_nums": [
            "at 2.5 mg once",
            "92 92.0% Participants with",
            "100 Measure Type:",
            "28-day cycle",
            "7 days off",
            "125 mg for",
            "21 days followed"
        ]
    },
    {
        "id": "ce6630d3-d3b7-4870-a486-9b6284a454f0",
        "primaryId": "NCT02679755",
        "statement_text": "More patients in the Palbociclib+Letrozole Australia Cohort of the primary trial experienced Treatment-Emergent Adverse Events compared to patients in the Palbociclib+Letrozole India Cohort ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Participants with grade 3 or 4 adverse events: 69 69.0%Participants with grade 5 adverse events: 3 3.0% Participants discontinued due to adverse events: 2 2.0% Results 2: Arm/Group Title: Palbociclib+Letrozole Australia Cohort Arm/Group Description: Participants received Palbociclib orally once a day at 125 mg for 21 days followed by 7 days off treatment for each 28-day cycle  Participants received Letrozole orally at 2.5 mg once daily as continuous daily dosing schedule according to product labeling and in compliance with its local prescribing information ",
        "premise_nums": [
            "at 2.5 mg once",
            "3 or 4",
            "7 days off",
            "2 2.0% Results 2",
            "69 69.0%Participants with",
            "3 3.0% Participants discontinued",
            "5 adverse events:",
            "28-day cycle",
            "125 mg for",
            "21 days followed"
        ]
    },
    {
        "id": "ce6630d3-d3b7-4870-a486-9b6284a454f0",
        "primaryId": "NCT02679755",
        "statement_text": "More patients in the Palbociclib+Letrozole Australia Cohort of the primary trial experienced Treatment-Emergent Adverse Events compared to patients in the Palbociclib+Letrozole India Cohort ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Overall Number of Participants Analyzed: 152Measure Type: Count of Participants Unit of Measure: Participants Participants with adverse events: 152 100.0% Participants with serious adverse events: 45 29.6% Participants with grade 3 or 4 adverse events: 124 81.6% Participants with grade 5 adverse events: 7 4.6% Participants discontinued due to adverse events: 9 5.9% ",
        "premise_nums": [
            "3 or 4",
            "45 29.6% Participants with",
            "7 4.6% Participants discontinued",
            "124 81.6% Participants with",
            "152 100.0% Participants with",
            "5 adverse events:"
        ]
    },
    {
        "id": "27e31574-5a73-4a68-997d-daa84797a65a",
        "primaryId": "NCT00054028",
        "secondaryId": "NCT02162719",
        "label": "Entailment",
        "statement_text": "Both the primary trial and the secondary trial at least partly administer their interventions intravenously ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Suramin and Paclitaxel Suramin will be infused weekly over 30 minutes  Four hours after the completion of the suramin infusion the 1 hour infusion of paclitaxel will begin  INTERVENTION 1: Ipatasertib and Paclitaxel Participants randomised to receive paclitaxel 80 mg/m^2, intravenously on Days 1, 8, and 15 along with ipatasertib 400 mg  orally  once daily from Days 1-21 in each cycle of 28 days until disease progression  intolerable toxicity  elective withdrawal from the study  or study completion or termination  ",
        "premise_nums": [
            "80 mg/m^2,",
            "1-21 in",
            "1 hour infusion",
            "28 days until",
            "15 along with",
            "21 in each"
        ]
    },
    {
        "id": "e21171de-ad49-4fc5-9c5d-aa362ca61c8a",
        "primaryId": "NCT00014222",
        "statement_text": "Cohort one of the primary trial reported 2/680 patients experiecing eye-related adverse events  whereas cohort two recorded 41.",
        "statement_nums": [
            "680 patients experiecing",
            "2/680 patients"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 83/680 (12.21%) Hemoglobin 11/680 (1.62%) Transfusion: Platelets 0/680 (0.00%) Transfusion: pRBCs 0/680 (0.00%) Febrile neutropenia 49/680 (7.21%) Edema 1/680 (0.15%) Ischemia/infarction 0/680 (0.00%) Palpitations 0/680 (0.00%) Pericardial effusion 0/680 (0.00%) Keratitis 1/680 (0.15%) Double vision 1/680 (0.15%) Colitis 1/680 (0.15%) ",
        "premise_nums": [
            "49/680 (7.21%)",
            "11/680 (1.62%)",
            "83/680 (12.21%)",
            "0/680 (0.00%)",
            "1/680 (0.15%)"
        ]
    },
    {
        "id": "e21171de-ad49-4fc5-9c5d-aa362ca61c8a",
        "primaryId": "NCT00014222",
        "statement_text": "Cohort one of the primary trial reported 2/680 patients experiecing eye-related adverse events  whereas cohort two recorded 41.",
        "statement_nums": [
            "680 patients experiecing",
            "2/680 patients"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 2:Total: 86/688 (12.50%) Hemoglobin 15/688 (2.18%) Transfusion: Platelets 1/688 (0.15%) Transfusion: pRBCs 1/688 (0.15%) Febrile neutropenia 41/688 (5.96%) Edema 0/688 (0.00%) Ischemia/infarction 0/688 (0.00%) Palpitations 1/688 (0.15%) Pericardial effusion 1/688 (0.15%) Keratitis 0/688 (0.00%) Double vision 0/688 (0.00%) ",
        "premise_nums": [
            "1/688 (0.15%)",
            "0/688 (0.00%)",
            "41/688 (5.96%)",
            "86/688 (12.50%)",
            "2:Total: 86/688",
            "15/688 (2.18%)"
        ]
    },
    {
        "id": "e21171de-ad49-4fc5-9c5d-aa362ca61c8a",
        "primaryId": "NCT00014222",
        "statement_text": "Cohort one of the primary trial reported 2/680 patients experiecing eye-related adverse events  whereas cohort two recorded 41.",
        "statement_nums": [
            "680 patients experiecing",
            "2/680 patients"
        ],
        "label": "Contradiction",
        "premise_text": "Colitis 0/688 (0.00%)",
        "premise_nums": [
            "0/688 (0.00%)"
        ]
    },
    {
        "id": "5dcdeac8-1c4a-4c24-9074-bbe93fcf4d32",
        "primaryId": "NCT02518191",
        "statement_text": "Cohort 2 of the primary trial is the control group  as the Eligible patients with breast cancer treated with GnRHa every 28 days ",
        "statement_nums": [
            "2 of the"
        ],
        "label": "Contradiction",
        "premise_text": "INTERVENTION 1: GnRHa (Gonadotrophin-releasing Hormone Analogues) Group Eligible patients with breast cancer treated with GnRHa (Gonadotrophin-releasing Hormone Analogues) while receiving chemotherapy  Goserelin 3.6mg, or leuprorelin 3.75mg subcutaneous injection every 28 days.Initiated 1-2 weeks before chemotherapy and ended 4-8 weeks after chemotherapy  INTERVENTION 2: None GnRHa (Gonadotrophin-releasing Hormone Analogues) Group Eligible patients with breast cancer treated without GnRHa (Gonadotrophin-releasing Hormone Analogues) while receiving chemotherapy  ",
        "premise_nums": [
            "2 weeks before",
            "leuprorelin 3.75mg subcutaneous",
            "1-2 weeks",
            "4-8 weeks",
            "8 weeks after"
        ]
    },
    {
        "id": "38f47a03-f71d-4072-a005-b954fb6069da",
        "primaryId": "NCT00684983",
        "statement_text": "The Median length of time that a patient in Arm A of the primary trial lived with the disease without it getting worse was half a year ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Progression-free Survival (PFS) Analysis of the primary endpoint  PFS  will be performed using Cox regression with treatment group as a single covariate  Time frame: From randomization to the earliest date of documentation of disease progression  up to 5 years Results 1: Arm/Group Title: Arm A Arm/Group Description: Patients receive oral capecitabine twice daily on days 1-14 and oral lapatinib ditosylate once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity  lapatinib ditosylate: Given PO and capecitabine: Given PO Overall Number of Participants Analyzed: 19 Median (95% Confidence Interval) ",
        "premise_nums": [
            "14 and oral",
            "21 days in",
            "1-14 and",
            "1-21. Courses",
            "95% Confidence",
            "5 years Results"
        ]
    },
    {
        "id": "38f47a03-f71d-4072-a005-b954fb6069da",
        "primaryId": "NCT00684983",
        "statement_text": "The Median length of time that a patient in Arm A of the primary trial lived with the disease without it getting worse was half a year ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Unit of Measure: Median survival and CI in months 6.0 (4.3 to 8.6)",
        "premise_nums": []
    },
    {
        "id": "e41917b8-d921-4797-b845-0121a75104a4",
        "primaryId": "NCT00129376",
        "statement_text": "More than 2% of patients in the primary trial experienced a clinically significant inflammation of the back of the throat ",
        "statement_nums": [
            "2% of"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Acute Pharyngitis * 1/63 (1.59%) ",
        "premise_nums": [
            "1/63 (1.59%)"
        ]
    },
    {
        "id": "bcb2d4a9-f2da-4a51-861b-3d5a9fbb6541",
        "primaryId": "NCT02513472",
        "statement_text": "Cohort 1 patients in the primary trial surivied almost twice as long as those in cohort 2.",
        "statement_nums": [
            "1 patients in"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Objective Response Rate (ORR) ",
        "premise_nums": []
    },
    {
        "id": "3e56c28c-6d5c-49c4-aaf7-b4e2cb3ca2d7",
        "primaryId": "NCT02491892",
        "secondaryId": "NCT00887575",
        "label": "Contradiction",
        "statement_text": "Cohort 1 of the secondary trial recorded more cases of diarrhea and dyspepsia than cohort 1 of the primary trial  this is due to the significant difference in cohort size ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Adverse Events 1: Diarrhoea * 0/41 (0.00%) Dysphagia * 0/41 (0.00%) Adverse Events 1: DIARRHEA 1/41 (2.44%) DYSPEPSIA 1/41 (2.44%) ",
        "premise_nums": [
            "0/41 (0.00%)",
            "1/41 (2.44%)"
        ]
    },
    {
        "id": "27397dfc-b6cf-41a3-862c-a99ccd2ddd5d",
        "primaryId": "NCT01881230",
        "statement_text": "The Gemcitabine group of the primary trial had a median Kaplan-Meier Estimate of Progression-Free Survival more than 83% less than the Carboplatin group",
        "statement_nums": [
            "83% less"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Kaplan-Meier Estimates of Progression-Free Survival (PFS) Based on Investigator Assessment  ",
        "premise_nums": []
    },
    {
        "id": "27397dfc-b6cf-41a3-862c-a99ccd2ddd5d",
        "primaryId": "NCT01881230",
        "statement_text": "The Gemcitabine group of the primary trial had a median Kaplan-Meier Estimate of Progression-Free Survival more than 83% less than the Carboplatin group",
        "statement_nums": [
            "83% less"
        ],
        "label": "Contradiction",
        "premise_text": "PFS was defined as the time from the date of randomization to the date of disease progression or death from any cause on or prior to the data cutoff date for the statistical analysis  whichever occurred earlier  Tumor responses were assessed every 6 weeks using  Response Evaluation Criteria in Solid Tumors (RECIST 1.1) and defined as: Complete response (CR) is the disappearance of all target lesions; Partial response (PR) occurs when at least a 30% decrease in the sum of diameters of target lesions from baseline; Stable disease is neither sufficient shrinkage to qualify for a PR nor sufficient increase of lesions to qualify for Progressive disease (PD); Progressive Disease- is at least a 20% increase in the sum of diameters of target lesions from nadir ",
        "premise_nums": [
            "30% decrease",
            "6 weeks using",
            "20% increase"
        ]
    },
    {
        "id": "27397dfc-b6cf-41a3-862c-a99ccd2ddd5d",
        "primaryId": "NCT01881230",
        "statement_text": "The Gemcitabine group of the primary trial had a median Kaplan-Meier Estimate of Progression-Free Survival more than 83% less than the Carboplatin group",
        "statement_nums": [
            "83% less"
        ],
        "label": "Contradiction",
        "premise_text": "Time frame: From date of randomization to data cut-off date of 16 December 2016; total length of time on study was 31 months for Arm A  34 months for Arm B and 35 months for Arm CResults 1: Arm/Group Title: Arm A: Nab-Paclitaxel + Gemcitabine ",
        "premise_nums": [
            "16 December 2016;",
            "31 months for",
            "35 months for",
            "34 months for"
        ]
    },
    {
        "id": "27397dfc-b6cf-41a3-862c-a99ccd2ddd5d",
        "primaryId": "NCT01881230",
        "statement_text": "The Gemcitabine group of the primary trial had a median Kaplan-Meier Estimate of Progression-Free Survival more than 83% less than the Carboplatin group",
        "statement_nums": [
            "83% less"
        ],
        "label": "Contradiction",
        "premise_text": "Arm/Group Description: Participants received nab-Paclitaxel 125 mg/m^2 on Days 1 and 8 by intravenous (IV) administration followed by gemcitabine 1000 mg/m^2 on Days 1 and 8 by IV administration of each 21-day treatment cycle  Participants continued treatment until progressive disease (PD)  unacceptable toxicity  required palliative radiotherapy or surgical intervention of lesion(s)  withdrawal from study treatment  withdrawal of study consent  participant refusal or the investigator felt it was no longer in the best interest of the participant to continue on treatmentOverall Number of Participants Analyzed: 61 Median (95% Confidence Interval) Unit of Measure: months 5.5 (4.1 to 7.0) ",
        "premise_nums": [
            "1 to 7.0)",
            "1000 mg/m^2",
            "1 and 8",
            "95% Confidence",
            "125 mg/m^2",
            "21-day treatment",
            "2 on Days"
        ]
    },
    {
        "id": "27397dfc-b6cf-41a3-862c-a99ccd2ddd5d",
        "primaryId": "NCT01881230",
        "statement_text": "The Gemcitabine group of the primary trial had a median Kaplan-Meier Estimate of Progression-Free Survival more than 83% less than the Carboplatin group",
        "statement_nums": [
            "83% less"
        ],
        "label": "Contradiction",
        "premise_text": "Results 2:Arm/Group Title: Arm B: Nab-Paclitaxel + Carboplatin Arm/Group Description: Participants received nab-Paclitaxel 125 mg/m^2 on Days 1 and 8 by IV administration followed by carboplatin area under the curve 2 (AUC 2) on Days 1 and 8 in each 21-day treatment cycle  Participants continued treatment until progressive disease (PD)  unacceptable toxicity  required palliative radiotherapy or surgical intervention of lesion(s)  withdrawal from study treatment  withdrawal of study consent  participant refusal or the investigator felt it was no longer in the best interest of the participant to continue on treatment  Overall Number of Participants Analyzed: 64 Median (95% Confidence Interval) ",
        "premise_nums": [
            "2:Arm/Group Title:",
            "1 and 8",
            "95% Confidence",
            "125 mg/m^2",
            "21-day treatment",
            "2 on Days"
        ]
    },
    {
        "id": "27397dfc-b6cf-41a3-862c-a99ccd2ddd5d",
        "primaryId": "NCT01881230",
        "statement_text": "The Gemcitabine group of the primary trial had a median Kaplan-Meier Estimate of Progression-Free Survival more than 83% less than the Carboplatin group",
        "statement_nums": [
            "83% less"
        ],
        "label": "Contradiction",
        "premise_text": "Unit of Measure: months 8.3 (5.7 to 10.6)",
        "premise_nums": []
    },
    {
        "id": "6214280f-f665-48d3-b33f-9d798deff71f",
        "primaryId": "NCT01855828",
        "secondaryId": "NCT00696072",
        "label": "Contradiction",
        "statement_text": "the secondary trial uses Overall Survival (OS) as outcome measurement  which is different from Proportion of Participants With a Pathologic Complete Response Rate which is used for the primary trial ",
        "statement_nums": [],
        "premise_text": "Outcome Measurement: Proportion of Participants With a Pathologic Complete Response Rate ",
        "premise_nums": []
    },
    {
        "id": "6214280f-f665-48d3-b33f-9d798deff71f",
        "primaryId": "NCT01855828",
        "secondaryId": "NCT00696072",
        "label": "Contradiction",
        "statement_text": "the secondary trial uses Overall Survival (OS) as outcome measurement  which is different from Proportion of Participants With a Pathologic Complete Response Rate which is used for the primary trial ",
        "statement_nums": [],
        "premise_text": "To estimate the pathologic complete response rate (pCR) when pertuzumab is added to weekly trastuzumab/paclitaxel followed by trastuzumab/5-fluorouracil, epirubicin and cyclophosphamide neoadjuvant chemotherapy in HER2-positive breast cancer  This study will assess pCR rates separately in ER+ and ER- cancers  Pathologic complete response is defined as no evidence of viable invasive tumor cells at the primary tumor site and axillary lymph nodes in the surgical specimen  Residual Disease (RD) is defined as: Any invasive cancer in the breast or axillary lymph nodes in the surgical specimen ",
        "premise_nums": [
            "2-positive breast",
            "5-fluorouracil, epirubicin"
        ]
    },
    {
        "id": "6214280f-f665-48d3-b33f-9d798deff71f",
        "primaryId": "NCT01855828",
        "secondaryId": "NCT00696072",
        "label": "Contradiction",
        "statement_text": "the secondary trial uses Overall Survival (OS) as outcome measurement  which is different from Proportion of Participants With a Pathologic Complete Response Rate which is used for the primary trial ",
        "statement_nums": [],
        "premise_text": "Time frame: 20 weeksOutcome Measurement: Number of Participants With Clinical Benefit (CBR) and Number of Participants With CBR Having a Disease Free Interval (DFI) Greater Than 2 Years - Evaluable Population ",
        "premise_nums": [
            "20 weeksOutcome Measurement:"
        ]
    },
    {
        "id": "6214280f-f665-48d3-b33f-9d798deff71f",
        "primaryId": "NCT01855828",
        "secondaryId": "NCT00696072",
        "label": "Contradiction",
        "statement_text": "the secondary trial uses Overall Survival (OS) as outcome measurement  which is different from Proportion of Participants With a Pathologic Complete Response Rate which is used for the primary trial ",
        "statement_nums": [],
        "premise_text": "CBR=participants with complete response (CR) + participants with partial response (PR) + participants with stable disease (SD) for a length of time greater than  equal to 6 months  CR= Disappearance of all target lesions  No new lesions  PR= At least a 30% decrease in the sum of the longest diameter (LD) of target lesions taking as reference the baseline sum LD  SD= Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD) taking as reference the smallest sum LD since the treatment started  Physical examination,radiological assessment  and bone scans (if applicable) were used to assess outcome ",
        "premise_nums": [
            "30% decrease"
        ]
    },
    {
        "id": "6214280f-f665-48d3-b33f-9d798deff71f",
        "primaryId": "NCT01855828",
        "secondaryId": "NCT00696072",
        "label": "Contradiction",
        "statement_text": "the secondary trial uses Overall Survival (OS) as outcome measurement  which is different from Proportion of Participants With a Pathologic Complete Response Rate which is used for the primary trial ",
        "statement_nums": [],
        "premise_text": "Time frame: First dose of study drug to last dose plus 7 days  up to study completion (approximately 6 years)",
        "premise_nums": []
    },
    {
        "id": "108b54a9-b5cc-4f31-956f-e4e2e653d756",
        "primaryId": "NCT00089999",
        "statement_text": "In total more participants in the primary trial had no tumor Response  than partial response  and 0 participants had a complete response ",
        "statement_nums": [
            "0 participants had"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Number of Participants With a Best Overall Response (OR) of Confirmed Complete Response (CR) or Partial Response (PR)  as Assessed by the Independent Review Committee (IRC) ",
        "premise_nums": []
    },
    {
        "id": "662f4992-0155-4a82-926f-b1821539aab7",
        "primaryId": "NCT00723125",
        "secondaryId": "NCT00617942",
        "label": "Contradiction",
        "statement_text": "57% of patients in cohort 1 of the primary trial had Pathological Complete Response Rates at Surgery  compared to 60% in cohort 1 of the secondary trial ",
        "statement_nums": [
            "57% of",
            "60% in",
            "1 of the"
        ],
        "premise_text": "Outcome Measurement: Pathological Complete Response Rates at Surgery [Not Specified] Time frame: at surgery approximately 5 months after initial treatment Results 1: Arm/Group Title: Cohort 1 ",
        "premise_nums": [
            "5 months after"
        ]
    },
    {
        "id": "662f4992-0155-4a82-926f-b1821539aab7",
        "primaryId": "NCT00723125",
        "secondaryId": "NCT00617942",
        "label": "Contradiction",
        "statement_text": "57% of patients in cohort 1 of the primary trial had Pathological Complete Response Rates at Surgery  compared to 60% in cohort 1 of the secondary trial ",
        "statement_nums": [
            "57% of",
            "60% in",
            "1 of the"
        ],
        "premise_text": "Arm/Group Description: Avastin 10 mg/kg IV over 90 minutes day -14 Abraxane 100 mg/m2 IV over 30 minutes weekly x 12 weeks with Carboplatin at AUC 6 over 30 min IV and Avastin 15 mg/kg IV over 30-90 minutes weeks 1,4,7, and 10 Avastin 10 mg/kg IV over 30-60 minutes cycles 1-3 (omit dose with cycle 4) Doxorubicin 60 mg/m2* and Cyclophosphamide 600 mg/m2 IV q2weeks x 4 cycles Definitive surgery Avastin 10 mg/kg IV over 30-60 minutes q2weeks x 34 weeks",
        "premise_nums": [
            "100 mg/m2 IV",
            "60 minutes cycles",
            "2 IV over",
            "10 Avastin 10",
            "30 minutes weekly",
            "14 Abraxane 100",
            "30-90 minutes",
            "12 weeks with",
            "6 over 30",
            "30-60 minutes",
            "10 mg/kg IV",
            "60 minutes q2weeks",
            "90 minutes weeks",
            "60 mg/m2*",
            "15 mg/kg IV",
            "600 mg/m2 IV",
            "4 cycles Definitive",
            "1,4,7, and",
            "90 minutes day",
            "2 IV q2weeks"
        ]
    },
    {
        "id": "662f4992-0155-4a82-926f-b1821539aab7",
        "primaryId": "NCT00723125",
        "secondaryId": "NCT00617942",
        "label": "Contradiction",
        "statement_text": "57% of patients in cohort 1 of the primary trial had Pathological Complete Response Rates at Surgery  compared to 60% in cohort 1 of the secondary trial ",
        "statement_nums": [
            "57% of",
            "60% in",
            "1 of the"
        ],
        "premise_text": "Cohort 1 and Cohort 2: Abraxane 100 mg/m2 IV over 30 minutes weekly x 12 weeks with Carboplatin at AUC 6 over 30 min IV and Avastin 15 mg/kg IV over 30-90 minutes weeks 1,4,7, and 10 (in Cohort 2, omit dose of Avastin on week 10)Overall Number of Participants Analyzed: 28 Measure Type: Number Unit of Measure: participants 16 Outcome Measurement: Number of Patients With Complete Pathologic Response Rate  Observed Following Treatment With q3week Carboplatin  Weekly Abraxane and Weekly Trastuzumab in Resectable and Unresectable LABC; ",
        "premise_nums": [
            "30 minutes weekly",
            "100 mg/m2 IV",
            "1 and Cohort",
            "28 Measure Type:",
            "2 IV over",
            "16 Outcome Measurement:",
            "30-90 minutes",
            "1,4,7, and",
            "12 weeks with",
            "90 minutes weeks",
            "6 over 30",
            "15 mg/kg IV"
        ]
    },
    {
        "id": "662f4992-0155-4a82-926f-b1821539aab7",
        "primaryId": "NCT00723125",
        "secondaryId": "NCT00617942",
        "label": "Contradiction",
        "statement_text": "57% of patients in cohort 1 of the primary trial had Pathological Complete Response Rates at Surgery  compared to 60% in cohort 1 of the secondary trial ",
        "statement_nums": [
            "57% of",
            "60% in",
            "1 of the"
        ],
        "premise_text": "These numbers represent patients with a RCB score of zero (0). RCB stands for residual cancer burden Time frame: 1 year Results 1: Arm/Group Title: Cohort 1 Arm/Group Description: [Not Specified] Overall Number of Participants Analyzed: 37 Measure Type: Number Unit of Measure: participants 12 ",
        "premise_nums": [
            "1 Arm/Group Description",
            "37 Measure Type:",
            "1 year Results"
        ]
    },
    {
        "id": "398f744b-97cf-4f95-b162-99ec6652d327",
        "primaryId": "NCT01091454",
        "secondaryId": "NCT00054275",
        "label": "Contradiction",
        "statement_text": "There were more cases of Anemia and Leukopenia in the primary trial than the secondary trial ",
        "statement_nums": [],
        "premise_text": "Adverse Events 1: Total: 29/48 (60.42%) Anemia 4/48 (8.33%) Febrile neutropenia 7/48 (14.58%) Atrial fibrillation 1/48 (2.08%) Pericardial effusion 1/48 (2.08%) Sinus bradycardia 1/48 (2.08%) Nausea 2/48 (4.17%) Vomiting 2/48 (4.17%) Death NOS 1/48 (2.08%) Fatigue 3/48 (6.25%) Allergic reaction 1/48 (2.08%) Lung infection 1/48 (2.08%) Mucosal infection 1/48 (2.08%) Adverse Events 1: ",
        "premise_nums": [
            "1/48 (2.08%)",
            "29/48 (60.42%)",
            "7/48 (14.58%)",
            "3/48 (6.25%)",
            "4/48 (8.33%)",
            "2/48 (4.17%)"
        ]
    },
    {
        "id": "398f744b-97cf-4f95-b162-99ec6652d327",
        "primaryId": "NCT01091454",
        "secondaryId": "NCT00054275",
        "label": "Contradiction",
        "statement_text": "There were more cases of Anemia and Leukopenia in the primary trial than the secondary trial ",
        "statement_nums": [],
        "premise_text": "Total: 28/39 (71.79%)Anemia 1/39 (2.56%) Leukopenia 4/39 (10.26%) Neutropenia 4/39 (10.26%) Chest Pain 1/39 (2.56%) Pericarditis 1/39 (2.56%) Sinus Tach  1/39 (2.56%) Sinus Tachycardia 1/39 (2.56%) Eye tearing 1/39 (2.56%) Diarrhea 7/39 (17.95%) Mucositis 3/39 (7.69%) Nausea 2/39 (5.13%) Vomiting [1]1/39 (2.56%) Fatigue 6/39 (15.38%) ",
        "premise_nums": [
            "7/39 (17.95%)",
            "2/39 (5.13%)",
            "1/39 (2.56%)",
            "6/39 (15.38%)",
            "4/39 (10.26%)",
            "28/39 (71.79%)Anemia",
            "3/39 (7.69%)"
        ]
    },
    {
        "id": "43421f19-878e-46f7-b456-8031835af649",
        "primaryId": "NCT00632489",
        "statement_text": "the primary trial uses a set dosage of 1000 mg PO daily of Lapatinib  whereas the dose of Capecitabine changes with Body surface area ",
        "statement_nums": [
            "1000 mg PO"
        ],
        "label": "Entailment",
        "premise_text": "INTERVENTION 1: LBH589 With Capecitabine MTD  LBH589 with Capecitabine LBH589: LBH589 will be evaluated when administered twice weekly at the following possible dose levels: 20 mg  30 mg  45 mg  and 60 mg  Capecitabine will be paired with LBH589 and will range in dose from 825 mg/m2 to 1250 mg/m2 orally BID 14 of every 21 days  Treatment cycles will be 21 days in length  Once determined safe  10 additional patients will be treated at the determined MTD to further assess safety  Capecitabine: Capecitabine will be administered orally twice daily for 14 days out of every 21 days  INTERVENTION 2: LBH589 and Lapatinib ",
        "premise_nums": [
            "LBH589 With",
            "10 additional patients",
            "589 and will",
            "589 with Capecitabine",
            "14 of every",
            "589 With Capecitabine",
            "589 will be",
            "589 and Lapatinib",
            "LBH589 with",
            "LBH589 and",
            "LBH589 will",
            "2 orally BID",
            "21 days in",
            "14 days out",
            "825 mg/m2 to",
            "2 to 1250",
            "1250 mg/m2 orally"
        ]
    },
    {
        "id": "43421f19-878e-46f7-b456-8031835af649",
        "primaryId": "NCT00632489",
        "statement_text": "the primary trial uses a set dosage of 1000 mg PO daily of Lapatinib  whereas the dose of Capecitabine changes with Body surface area ",
        "statement_nums": [
            "1000 mg PO"
        ],
        "label": "Entailment",
        "premise_text": "LBH589 and LapatinibLBH589: LBH589 will be evaluated when administered twice weekly at the following possible dose levels: 20 mg  30 mg  45 mg  and 60 mg  Capecitabine will be paired with LBH589 and will range in dose from 825 mg/m2 to 1250 mg/m2 orally BID 14 of every 21 days  Treatment cycles will be 21 days in length  Once determined safe  10 additional patients will be treated at the determined MTD to further assess safety  Lapatinib: Lapatinib  1000 mg PO daily will be added to this combination  ",
        "premise_nums": [
            "1000 mg PO",
            "589 will be",
            "21 days in",
            "2 to 1250",
            "10 additional patients",
            "14 of every",
            "825 mg/m2 to",
            "589 and will",
            "589 and LapatinibLBH589:",
            "LBH589 will",
            "1250 mg/m2 orally",
            "LBH589 and",
            "2 orally BID"
        ]
    },
    {
        "id": "13fa44e7-38be-48fb-a0eb-6b212549f526",
        "primaryId": "NCT02260531",
        "statement_text": "the percentage of participants achieving complete response (CR) or partial response (PR) was much lower in the HER2-positive group in the primary trial,than in the ER+ and/or PR+ group ",
        "statement_nums": [
            "2-positive group"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: CNS Objective Response Rate (ORR) The central nervous system (CNS) ORR was defined as the percentage of participants achieving complete response (CR) or partial response (PR) based on RECIST 1.1 criteria in the evaluation CNS lesions on treatment: CR is complete disappearance of all target lesions and PR is at least a 30% decrease in the sum of longest diameter (LD) of target lesions  taking as reference baseline sum LD  PR or better overall response assumes at a minimum incomplete response/stable disease (SD) for the evaluation of non-target lesions and absence of new lesions  ",
        "premise_nums": [
            "30% decrease",
            "RECIST 1.1 criteria in"
        ]
    },
    {
        "id": "13fa44e7-38be-48fb-a0eb-6b212549f526",
        "primaryId": "NCT02260531",
        "statement_text": "the percentage of participants achieving complete response (CR) or partial response (PR) was much lower in the HER2-positive group in the primary trial,than in the ER+ and/or PR+ group ",
        "statement_nums": [
            "2-positive group"
        ],
        "label": "Entailment",
        "premise_text": "Time frame: Disease assessments occurred every 6 cycles  Patients with stable or responsive disease after completion of 6 cycles could reduce frequency of assessments to every 3 cycles  Response was evaluated up to 25 months Results 1: Arm/Group Title: Cohort 1 - Cabozantinib  Trastuzumab for HER2+ Arm/Group Description: HER2-positive Cabozantinib- orally administered daily per treatment cycle Trastuzumab- IV administered once per cycle MRI- Baseline  Cycle 2 Day 1, and every 2 cycles Magnetic Resonance Angiography (MRA )  Baseline  Cycle 2 Day 1, ",
        "premise_nums": [
            "6 cycles could",
            "2 Day 1,",
            "2 cycles Magnetic",
            "2-positive Cabozantinib-",
            "25 months Results"
        ]
    },
    {
        "id": "13fa44e7-38be-48fb-a0eb-6b212549f526",
        "primaryId": "NCT02260531",
        "statement_text": "the percentage of participants achieving complete response (CR) or partial response (PR) was much lower in the HER2-positive group in the primary trial,than in the ER+ and/or PR+ group ",
        "statement_nums": [
            "2-positive group"
        ],
        "label": "Entailment",
        "premise_text": "Cabozantinib: One  60 mg tablet daily of each 21 day cycle  Number of Cycles: until progression or unacceptable toxicity develops Trastuzumab: For HER2-Positive participants only  Administered by IV on day 1 of each 21 day cycle  Number of Cycles: until progression or unacceptable toxicity develops  Overall Number of Participants Analyzed: 21 Measure Type: Number Unit of Measure: percentage of participants 5 (.2 to 24) Results 2: Arm/Group Title: Cohort 2 - Cabozantinib for ER+ and/or PR+ Arm/Group Description: Hormone receptor-positive (ER+ and/or PR+) Cabozantinib- orally administered daily per treatment cycle ",
        "premise_nums": [
            "60 mg tablet",
            "1 of each",
            "2-Positive participants",
            "2 to 24)",
            "21 Measure Type:",
            "21 day cycle"
        ]
    },
    {
        "id": "13fa44e7-38be-48fb-a0eb-6b212549f526",
        "primaryId": "NCT02260531",
        "statement_text": "the percentage of participants achieving complete response (CR) or partial response (PR) was much lower in the HER2-positive group in the primary trial,than in the ER+ and/or PR+ group ",
        "statement_nums": [
            "2-positive group"
        ],
        "label": "Entailment",
        "premise_text": "MRI- Baseline  Cycle 2 Day 1, and every 2 cyclesMagnetic Resonance Angiography (MRA )  Baseline  Cycle 2 Day 1, Cabozantinib: One  60 mg tablet daily of each 21 day cycle  Number of Cycles: until progression or unacceptable toxicity develops  Overall Number of Participants Analyzed: 7 Measure Type: Number Unit of Measure: percentage of participants 14 (.4 to 58) ",
        "premise_nums": [
            "2 Day 1,",
            "4 to 58)",
            "60 mg tablet",
            "2 cyclesMagnetic Resonance",
            "7 Measure Type:",
            "21 day cycle"
        ]
    },
    {
        "id": "12ae2315-cc50-43ac-a595-762c85c1ec58",
        "primaryId": "NCT02308020",
        "statement_text": "There were no participants in cohort 1 of the primary trial with a (CR) or (PR) based on the Response Assessment in Neuro-Oncology Brain Metastasis (RANO-BM) response criteria ",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR): Objective Intracranial Response Rate (OIRR) ",
        "premise_nums": []
    },
    {
        "id": "11403f92-661b-4334-8dfb-098586610ec6",
        "primaryId": "NCT02536339",
        "secondaryId": "NCT00371345",
        "label": "Contradiction",
        "statement_text": "Respiratory illnesses were observed in most of the patients in the primary trial and the secondary trial ",
        "statement_nums": [],
        "premise_text": "Adverse Events 1: Total: 7/39 (17.95%) Gastroenteritis viral 1/39 (2.56%) Parainfluenzae virus infection 1/39 (2.56%) Seizure 4/39 (10.26%) Headache 1/39 (2.56%) Hydrocephalus 1/39 (2.56%) Hypertension 1/39 (2.56%) Adverse Events 1: Total: 20/70 (28.57%) NAUSEA 2/70 (2.86%) VOMITING 1/70 (1.43%) DIARRHOEA 2/70 (2.86%) ABDOMINAL PAIN 1/70 (1.43%) ABDOMINAL PAIN LOWER 1/70 (1.43%) FATIGUE 2/70 (2.86%) ",
        "premise_nums": [
            "7/39 (17.95%)",
            "1/70 (1.43%)",
            "1/39 (2.56%)",
            "2/70 (2.86%)",
            "20/70 (28.57%)",
            "4/39 (10.26%)"
        ]
    },
    {
        "id": "11403f92-661b-4334-8dfb-098586610ec6",
        "primaryId": "NCT02536339",
        "secondaryId": "NCT00371345",
        "label": "Contradiction",
        "statement_text": "Respiratory illnesses were observed in most of the patients in the primary trial and the secondary trial ",
        "statement_nums": [],
        "premise_text": "PYREXIA 1/70 (1.43%)OEDEMA PERIPHERAL 1/70 (1.43%) GENERAL PHYSICAL HEALTH DETERIORATION 3/70 (4.29%) PNEUMONIA 1/70 (1.43%) SINUSITIS 1/70 (1.43%) LOBAR PNEUMONIA 1/70 (1.43%) ",
        "premise_nums": [
            "3/70 (4.29%)",
            "1/70 (1.43%)OEDEMA"
        ]
    },
    {
        "id": "2823adfc-b3a4-4626-9690-0c292aa8da04",
        "primaryId": "NCT01422408",
        "statement_text": "the primary trial is a phase II trial in which all participants will recieve topical fluocinonide 0.05% face cream twice daily for two weeks ",
        "statement_nums": [
            "fluocinonide 0.05% face cream"
        ],
        "label": "Contradiction",
        "premise_text": "INTERVENTION 1: Supportive Care (Fluocinonide Cream) This is a single-arm  single-stage  open-label phase II trial of topical fluocinonide 0.05% cream to improve vaginal symptoms  All subjects will receive topical fluocinonide 0.05% cream to apply twice daily for two weeks and then once daily for two weeks to the vagina  The duration of treatment will be 4 weeks  ",
        "premise_nums": [
            "fluocinonide 0.05% cream to"
        ]
    },
    {
        "id": "1cda051f-27d0-4027-94cf-7b5340173ca2",
        "primaryId": "NCT02504424",
        "secondaryId": "NCT03708393",
        "label": "Entailment",
        "statement_text": "the primary trial and the secondary trial do not have the same number of study groups ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: AeroForm Tissue Expander AeroForm Tissue Expansion inflation with carbon dioxide by remote control AeroForm Tissue Expander: The AeroForm Tissue Expander is a breast tissue expander implanted following mastectomy and activated by remote control to release small doses of carbon dioxide from an internal reservoir to fill and inflate the expander  INTERVENTION 1: IUS Alone IUS alone imaging INTERVENTION 2: Imagio (IUS+OA) IUS+OA imaging ",
        "premise_nums": []
    },
    {
        "id": "2ca24749-7c1d-4697-a1aa-8bf5d13fb8c3",
        "primaryId": "NCT00435409",
        "secondaryId": "NCT00319254",
        "label": "Contradiction",
        "statement_text": "The patient with the shortest PFS was in the secondary trial  at only 5 days  and the longest recorded PFS was in the primary trial at 78 months ",
        "statement_nums": [],
        "premise_text": "Outcome Measurement: Progression Free Survival (PFS) Defined as the time from the date of randomization to the date of the first documentation of objective tumor progression or death due to any cause  whichever occurs first  If tumor progression data include more than 1 date  the first date will be used  PFS (in months) will be calculated as (first event date minus randomization date plus 1) divided by 30.4. Time frame: Baseline until disease progression (up to 3 years from first dose) Results 1: Arm/Group Title: Sunitinib + Capecitabine ",
        "premise_nums": [
            "3 years from"
        ]
    },
    {
        "id": "2ca24749-7c1d-4697-a1aa-8bf5d13fb8c3",
        "primaryId": "NCT00435409",
        "secondaryId": "NCT00319254",
        "label": "Contradiction",
        "statement_text": "The patient with the shortest PFS was in the secondary trial  at only 5 days  and the longest recorded PFS was in the primary trial at 78 months ",
        "statement_nums": [],
        "premise_text": "Arm/Group Description: Sunitinib administered orally at a starting dose of 37.5 mg once a day on a continuous regimen  Capecitabine administered orally at a starting dose of 2000 mg/m^2 per day (1000 mg/m^2 BID) from Days 1-14 every 3 weeks Overall Number of Participants Analyzed: 221 Median (95% Confidence Interval) Unit of Measure: months Independent radiology assessment: 5.5 (4.5 to 6.0) Investigator's assessment: 5.4 (4.4 to 5.8) Results 2: Arm/Group Title: Capecitabine ",
        "premise_nums": [
            "2 per day",
            "of 37.5 mg once",
            "3 weeks Overall",
            "4 to 5.8)",
            "14 every 3",
            "95% Confidence",
            "2000 mg/m^2",
            "5 to 6.0)",
            "1-14 every"
        ]
    },
    {
        "id": "2ca24749-7c1d-4697-a1aa-8bf5d13fb8c3",
        "primaryId": "NCT00435409",
        "secondaryId": "NCT00319254",
        "label": "Contradiction",
        "statement_text": "The patient with the shortest PFS was in the secondary trial  at only 5 days  and the longest recorded PFS was in the primary trial at 78 months ",
        "statement_nums": [],
        "premise_text": "Arm/Group Description: Capecitabine administered orally at a starting dose of 2500 mg/m^2 per day (1250 mg/m^2 BID) from Days 1-14 every 3 weeks  At the time of progression  participants could have been eligible to crossover to single agent sunitinib  administered orally at a starting dose of 37.5 mg daily continuously Overall Number of Participants Analyzed: 221 Median (95% Confidence Interval) Unit of Measure: months Independent radiology assessment: 5.9 (5.4 to 7.6) Investigator's assessment: 5.5 (4.3 to 6.8) Outcome Measurement: Progression-Free Survival (PFS) Rate ",
        "premise_nums": [
            "2 per day",
            "3 to 6.8)",
            "14 every 3",
            "95% Confidence",
            "4 to 7.6)",
            "2500 mg/m^2",
            "1-14 every",
            "of 37.5 mg daily"
        ]
    },
    {
        "id": "2ca24749-7c1d-4697-a1aa-8bf5d13fb8c3",
        "primaryId": "NCT00435409",
        "secondaryId": "NCT00319254",
        "label": "Contradiction",
        "statement_text": "The patient with the shortest PFS was in the secondary trial  at only 5 days  and the longest recorded PFS was in the primary trial at 78 months ",
        "statement_nums": [],
        "premise_text": "PFS was based on Kaplan-Meier estimates  PFS was defined as time in weeks from start of study treatment to first documentation of objective tumor progression or death due to any cause  PFS was calculated as (first event date minus the date of first dose of study medication plus 1) divided by 7. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease [PD])  or from death case report forms (CRFs)  Percentage of participants who had not experienced progression or death by Week 16 is reported Time frame: Baseline up to Week 16 Results 1: Arm/Group Title: Bosutinib ",
        "premise_nums": [
            "16 is reported",
            "16 Results 1:"
        ]
    },
    {
        "id": "2ca24749-7c1d-4697-a1aa-8bf5d13fb8c3",
        "primaryId": "NCT00435409",
        "secondaryId": "NCT00319254",
        "label": "Contradiction",
        "statement_text": "The patient with the shortest PFS was in the secondary trial  at only 5 days  and the longest recorded PFS was in the primary trial at 78 months ",
        "statement_nums": [],
        "premise_text": "Arm/Group Description: Four bosutinib 100 milligram (mg) capsules  equivalent to 400 mg bosutinib orally once daily for 48 weeks  or until disease progression  unacceptable toxicity or withdrawal of consent occurred Overall Number of Participants Analyzed: 73 Measure Type: Number Unit of Measure: percentage of participants 39.6 (28.1 to 50.8) ",
        "premise_nums": [
            "1 to 50.8)",
            "73 Measure Type:",
            "400 mg bosutinib",
            "100 milligram (mg)"
        ]
    },
    {
        "id": "1e91c023-96e8-459b-9070-02df13339617",
        "primaryId": "NCT00513292",
        "statement_text": "In the primary trial the FEC-75 Then Paclitaxel/Trastuzumab group produced better Pathological complete response (pCR) rates than the Paclitaxel/Trastuzumab Then Trastuzumab/FEC-75 group ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: pCR Within the Breast  Defined as no Evidence of Invasive Tumor Remaining in the Breast at Surgery Following Completion of Chemotherapy Pathological complete response (pCR) rates will be based on institutional pathology reports  In the final analysis for publication  rates will be based on blinded central review of these institutional pathology reports  The Chi-squared test will be conducted at the two-sided 0.05 level  A 95% confidence interval will be computed for the difference in pCR rates  Time frame: Up to 5 years Results 1: Arm/Group Title: FEC-75 Then Paclitaxel/Trastuzumab ",
        "premise_nums": [
            "95% confidence",
            "5 years Results"
        ]
    },
    {
        "id": "a15b4c0c-232b-4209-bf60-35d160e41d2c",
        "primaryId": "NCT03012477",
        "statement_text": "One patient in the primary trial experienced a thromboembolic event  a condition associated with a high degree of morbidity and mortality  However  the most common adverse event was Anemia ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 13/34 (38.24%) Anemia 3/34 (8.82%) Diarrhea 7/34 (20.59%) Nausea 2/34 (5.88%) Sepsis 1/34 (2.94%) Urinary tract infection 1/34 (2.94%) Alkaline phosphatase increased 1/34 (2.94%) Neutrophil count decreased 2/34 (5.88%) Dehydration 1/34 (2.94%) Headache 1/34 (2.94%) Thromboembolic event 1/34 (2.94%) ",
        "premise_nums": [
            "7/34 (20.59%)",
            "3/34 (8.82%)",
            "1/34 (2.94%)",
            "13/34 (38.24%)",
            "2/34 (5.88%)"
        ]
    },
    {
        "id": "795d634a-9f9c-49a2-a4e7-ec99bd3600f2",
        "primaryId": "NCT02667626",
        "statement_text": "the primary trial is testing a web-based educational tool and the secondary trial is testing a medical device on Post-menopausal Women ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "INTERVENTION 1: SCPR Intervention Young breast cancer participants will receive their SCPR and access to additional web-based educational reproductive health information  including resource lists of helpful websites  followed by regular reproductive health prompts and study adherence reminders for 24 weeks  Reproductive Health Survivorship Care Plan (SCPR): The reproductive health survivorship care plan (SCPR) is a web-based educational tool that will include information on how to manage various reproductive health issues such as hot flashes  fertility concerns  contraception practices  and sexual function  The intervention also includes additional web-based information and resource lists  text-based reproductive health and study adherence INTERVENTION 2: Control ",
        "premise_nums": []
    },
    {
        "id": "795d634a-9f9c-49a2-a4e7-ec99bd3600f2",
        "primaryId": "NCT02667626",
        "statement_text": "the primary trial is testing a web-based educational tool and the secondary trial is testing a medical device on Post-menopausal Women ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Young breast cancer participants randomized to the waitlist control arm will receive access to the web-based resources and study adherence reminders  At completion of the 24 weeks of follow up  they will have access to their SCPR Control: Web-based resource lists and text-based study adherence reminders ",
        "premise_nums": [
            "24 weeks of"
        ]
    },
    {
        "id": "e2d4c56c-a68f-4751-907d-9c2355c9528b",
        "primaryId": "NCT01463007",
        "secondaryId": "NCT00965523",
        "label": "Contradiction",
        "statement_text": "A significantly higher proportion of patients in the secondary trial suffured from infection compared to the primary trial ",
        "statement_nums": [],
        "premise_text": "Adverse Events 1: Total: 1/41 (2.44%) Infection 1/41 (2.44%) Creatinine 1/41 (2.44%) Hypokalemia 1/41 (2.44%) Bicarbonate 1/41 (2.44%) SGOT 1/41 (2.44%) Alkaline Phosphatase value 1/41 (2.44%) Hyperbilirubineamia 1/41 (2.44%) Hypoalbuminemia 1/41 (2.44%) Leukocytes 1/41 (2.44%) Hemoglobin 1/41 (2.44%) Neutrophils 1/41 (2.44%) INR 1/41 (2.44%) ",
        "premise_nums": [
            "1/41 (2.44%)"
        ]
    },
    {
        "id": "e2d4c56c-a68f-4751-907d-9c2355c9528b",
        "primaryId": "NCT01463007",
        "secondaryId": "NCT00965523",
        "label": "Contradiction",
        "statement_text": "A significantly higher proportion of patients in the secondary trial suffured from infection compared to the primary trial ",
        "statement_nums": [],
        "premise_text": "PTT 1/41 (2.44%)Adverse Events 1: Total: 14/81 (17.28%) Neutropenia1/81 (1.23%) Cataract1/81 (1.23%) Ascites1/81 (1.23%) Gastritis Hemorrhagic1/81 (1.23%) Nausea1/81 (1.23%) Stomatitis2/81 (2.47%) Malaise1/81 (1.23%) Oedema1/81 (1.23%) Pain1/81 (1.23%) Pyrexia1/81 (1.23%) Infection2/81 (2.47%) Upper Limb Fracture1/81 (1.23%) ",
        "premise_nums": [
            "1/41 (2.44%)Adverse",
            "2/81 (2.47%)",
            "14/81 (17.28%)",
            "1/81 (1.23%)"
        ]
    },
    {
        "id": "e2d4c56c-a68f-4751-907d-9c2355c9528b",
        "primaryId": "NCT01463007",
        "secondaryId": "NCT00965523",
        "label": "Contradiction",
        "statement_text": "A significantly higher proportion of patients in the secondary trial suffured from infection compared to the primary trial ",
        "statement_nums": [],
        "premise_text": "Dehydration1/81 (1.23%)Hypercalcemia1/81 (1.23%) ",
        "premise_nums": [
            "1/81 (1.23%)Hypercalcemia1/81"
        ]
    },
    {
        "id": "50f1c6c5-abe6-4178-93cf-32b5a8a3e9e9",
        "primaryId": "NCT00193050",
        "secondaryId": "NCT00232479",
        "label": "Contradiction",
        "statement_text": "Patients must be over the age of 18 and have a life expectancy over 6 months to participate in the primary trial or the secondary trial ",
        "statement_nums": [
            "6 months to",
            "18 and have"
        ],
        "premise_text": "Inclusion Criteria: Female Patients greater than 18 years of age Exclusion Criteria: Life expectancy of smaller than than 6 months Inclusion Criteria: HER-2 overexpressing breast cancer Clinical stage 2-3B Normal ejection fraction Exclusion Criteria: Metastatic disease Low ejection fraction ",
        "premise_nums": [
            "18 years of",
            "6 months Inclusion",
            "2-3B Normal",
            "2 overexpressing breast"
        ]
    },
    {
        "id": "9ad3444c-143d-4c28-a08a-e0c9cda44900",
        "primaryId": "NCT00243503",
        "secondaryId": "NCT00448279",
        "label": "Contradiction",
        "statement_text": "the primary trial and the secondary trial did not observe any of the same adverse events in their patients ",
        "statement_nums": [],
        "premise_text": "Adverse Events 1: Total: 25/60 (41.67%) Febrile neutropenia * 2/60 (3.33%) Adverse Events 1: Febrile neutropenia * 1/26 (3.85%) ",
        "premise_nums": [
            "2/60 (3.33%)",
            "1/26 (3.85%)",
            "25/60 (41.67%)"
        ]
    },
    {
        "id": "43061a8b-c1b2-4b5e-b935-73733d674fb4",
        "primaryId": "NCT01401959",
        "secondaryId": "NCT00852930",
        "label": "Contradiction",
        "statement_text": "the primary trial designates specific interventions to its patients depending on their tumour response  patients with complete response go to cohort A and all other in cohort B  in contrast the secondary trial assigns interventions randomly ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Cohort A: Triple-negative Breast Cancer Patients Patients with triple-negative breast cancer who do not have a pathological complete response following neoadjuvant therapy and surgery will receive eribulin 1.4 mg/m^2 on Days 1 and 8 every 21 days for 6 cycles via the intravenous (IV) route  INTERVENTION 2: Cohort B: ER/PR Positive/HER2-negative Breast Cancer Patients ",
        "premise_nums": [
            "21 days for",
            "2-negative Breast",
            "6 cycles via",
            "eribulin 1.4 mg/m",
            "1 and 8",
            "2 on Days"
        ]
    },
    {
        "id": "43061a8b-c1b2-4b5e-b935-73733d674fb4",
        "primaryId": "NCT01401959",
        "secondaryId": "NCT00852930",
        "label": "Contradiction",
        "statement_text": "the primary trial designates specific interventions to its patients depending on their tumour response  patients with complete response go to cohort A and all other in cohort B  in contrast the secondary trial assigns interventions randomly ",
        "statement_nums": [],
        "premise_text": "Patients with hormone receptor positive (ER and/or PR positive)  HER negative breast cancer breast cancer who do not have a pathological complete response following neoadjuvant therapy and surgery will receive eribulin 1.4 mg/m^2 on Days 1 and 8 every 21 days for 6 cycles via the intravenous (IV) route INTERVENTION 1: Laser Therapy Alone therapist administered laser treatment laser: therapist administered laser INTERVENTION 2: Mld Alone therapist administered manual lymphatic drainage manual lymphatic drainage: therapist administered massage therapy ",
        "premise_nums": [
            "21 days for",
            "6 cycles via",
            "eribulin 1.4 mg/m",
            "1 and 8",
            "2 on Days"
        ]
    },
    {
        "id": "fc7369dc-0fc5-4823-a8eb-5ac85188fd60",
        "primaryId": "NCT00416572",
        "statement_text": "Patients suffering from ovarian or lung cancer are excluded from the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "EXCLUSION CRITERIA (Patient Characteristics): Other prior malignancies except skin cancer ",
        "premise_nums": []
    },
    {
        "id": "25ec56f0-e472-4423-92ae-8d4840b067b5",
        "primaryId": "NCT03475992",
        "secondaryId": "NCT03106077",
        "label": "Entailment",
        "statement_text": "Participants in the primary trial receive different interventions depending on their pre-diagnosis  whereas all patients in the secondary trial took the same intervention ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Pre-diagnosed Breast Cancer - Biopsy Confirmed Low-power microwave breast imaging system  Core needle biopsy performed 14 days before the microwave breast investigation Low-power microwave breast imaging system: Investigate the capacity of microwave imaging to detect and characterise diagnosed palpable breast lump INTERVENTION 2: Pre-diagnosed Breast Cyst Low-power microwave breast imaging system  No prior biopsy Low-power microwave breast imaging system: Investigate the capacity of microwave imaging to detect and characterise diagnosed palpable breast lump INTERVENTION 1: Cohort A: Advanced Triple-Negative Breast Cancer (TNBC) 6 mg/kg IMGN853 IV Q3W ",
        "premise_nums": [
            "6 mg/kg IMGN",
            "IMGN853 IV",
            "14 days before",
            "853 IV Q3W"
        ]
    },
    {
        "id": "2c9e9407-e990-41bd-a87b-9d294c78f727",
        "primaryId": "NCT02286843",
        "statement_text": "the primary trial is testing a novel radiotracer called PET/CT to evaluate its use for visualization of HER2+ lesions ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "INTERVENTION 1: HER2-targeted PET/CT Pts with confirmed HER2- breast cancer will undergo HER2-targeted PET/CT  89Zr-trastuzumab is a novel radiotracer which allows excellent visualization of HER2+ lesions  89Zr-pertuzumab is a novel radiotracer which may allow for specific visualization of HER2+ lesions  PET/CT imaging with these novel radiotracers will allow evaluation of all identifiable malignant lesions  rather than evaluation of only single lesions by biopsy  ",
        "premise_nums": [
            "89Zr-pertuzumab is",
            "2-targeted PET/CT",
            "89Zr-trastuzumab is"
        ]
    },
    {
        "id": "f3cebdf7-be0c-45ad-85bd-bde827524e20",
        "primaryId": "NCT00693719",
        "statement_text": "the primary trial recorded less than 5 different Adverse Events  ",
        "statement_nums": [
            "5 different Adverse"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 4/31 (12.90%) Bleeding 1/31 (3.23%) Pain 2/31 (6.45%) Dehydration 1/31 (3.23%) Dyspnea 1/31 (3.23%) ",
        "premise_nums": [
            "4/31 (12.90%)",
            "2/31 (6.45%)",
            "1/31 (3.23%)"
        ]
    },
    {
        "id": "b5c7bfd2-d491-400c-8444-8bc424cd5dbf",
        "primaryId": "NCT01705691",
        "statement_text": "A patient in the primary trial suffered from Kidney stones ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Adverse Events 2: Nephrolithiasis 1/30 (3.33%) ",
        "premise_nums": [
            "1/30 (3.33%)"
        ]
    },
    {
        "id": "53c62057-d6ea-4639-adaf-98cb1544a394",
        "primaryId": "NCT00425672",
        "statement_text": "Patients receiving intervention 1 of the primary trial undergo a 21 day treatment cycle  up to a total of 6 times  but will stop earlier if they suffer disease progression or unacceptable toxicity occurs ",
        "statement_nums": [
            "21 day treatment",
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "INTERVENTION 1: Arm I Patients receive ONTAK IV over 1 hour on days 1-5. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity  ONTAK: Given IV flow cytometry: Correlative studies immunohistochemistry staining method: Correlative studies enzyme-linked immunosorbent assay: Correlative studies laboratory biomarker analysis: Correlative studies protein expression analysis: Correlative studies ",
        "premise_nums": [
            "6 courses in",
            "1-5. Treatment",
            "21 days for",
            "1 hour on"
        ]
    },
    {
        "id": "599b37cd-f380-48ac-864d-e766a7af963e",
        "primaryId": "NCT01570036",
        "secondaryId": "NCT00021255",
        "label": "Contradiction",
        "statement_text": "the primary trial and the secondary trial monitor the % of their patient cohorts with DFS smaller than 6years.",
        "statement_nums": [],
        "premise_text": "Disease-free Survival (DFS) Disease-free survival (DFS) for all patients regardless of randomization will be determined by patients' own physicians at the individual study sites during routine follow-up screening  This will occur every three months for the first 24 months after completion of primary therapies and every six months thereafter with clinical exam  and laboratory and radiographic surveillance  The primary objective of the study is disease-free survival (DFS) at 24 months  Time frame: Disease-free survival at 24 months Outcome Measurement: Percentage of Participants With Disease Free Survival at 5 Years ",
        "premise_nums": [
            "24 months Outcome",
            "24 months after"
        ]
    },
    {
        "id": "599b37cd-f380-48ac-864d-e766a7af963e",
        "primaryId": "NCT01570036",
        "secondaryId": "NCT00021255",
        "label": "Contradiction",
        "statement_text": "the primary trial and the secondary trial monitor the % of their patient cohorts with DFS smaller than 6years.",
        "statement_nums": [],
        "premise_text": "Disease Free Survival was defined as the interval from the date of randomization to the date of local  regional or metastatic relapse or the date of second primary cancer (with the exception of curatively treated non-melanoma skin cancer or in situ carcinoma of the cervix) or death from any cause whichever occured first  Disease free survival was estimated using the Kaplan-Meier method Time frame: From randomization until relapse or death or up to 5 years ",
        "premise_nums": []
    },
    {
        "id": "c428ec76-4d22-4d2d-8c06-1675bd431d41",
        "primaryId": "NCT02222337",
        "statement_text": "Participants for the primary trial must be in pairs  a breast cancer survivor and a caregiver  both must be ethnically Hispanic ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria: Survivors: Latina  has been diagnosed with breast cancer  speaks English or Spanish  has a Caregiver who is willing to participate  Caregivers: a primary caregiver for a Latina breast cancer survivor  speak English or Spanish ",
        "premise_nums": []
    },
    {
        "id": "6cbc1567-2b51-45c0-ab1b-cac0b5fc7c38",
        "primaryId": "NCT03283553",
        "statement_text": "the primary trial has two cohorts ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "INTERVENTION 1: Multicomponent Intervention 1.) A one-page paper-pencil agenda setting checklist completed immediately before a regularly scheduled medical oncology visit to elicit and align patient and companion perspectives regarding issues to discuss with the provider  and to stimulate discussion about the role of the companion in the visit  2.) facilitated registration for the patient portal (for patient and family member  as desired by the patient)  and 3.) education (as relevant) on access to doctor's electronic visit notes  INTERVENTION 2: Usual Care Care as usual with the medical oncologist  ",
        "premise_nums": []
    },
    {
        "id": "a9d5c664-896f-4bb1-95e7-1deaa88848ef",
        "primaryId": "NCT00089479",
        "secondaryId": "NCT02964234",
        "label": "Contradiction",
        "statement_text": "Agatha had her 53rd birthday last week  she has a histologically confirmed adenocarcinoma of the breast  with no evidence of metastatic disease  Agatha is of white british origin  she is eligible for the primary trial but not the secondary trial  due to her age ",
        "statement_nums": [],
        "premise_text": "Inclusion Criteria: female patients 18-70 years of age; adenocarcinoma of the breast; previous invasive breast cancer if diagnosed greater than 5 years before entering study; no evidence of metastatic disease  Exclusion Criteria: history of severe hypersensitivity reaction to Taxotere; previous treatment with anthracycline  anthracenedione (mitoxantrone)  or taxane; treatment with fluoropyrimidine (5-fluorouracil) within the last 5 years  Inclusion Criteria: Age 52-75 years old; Identification as Latina/Hispanic/Chicana female; ",
        "premise_nums": [
            "18-70 years",
            "(5-fluorouracil) within",
            "5 years before",
            "75 years old;",
            "52-75 years",
            "70 years of"
        ]
    },
    {
        "id": "62b5fe62-470d-46e3-82a6-d57cd6cab452",
        "primaryId": "NCT00471276",
        "secondaryId": "NCT00951665",
        "label": "Entailment",
        "statement_text": "Gastrointestinal haemorrhage was more common in patients from cohort 1 of the primary trial than cohort 1 of the secondary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Adverse Events 1: Total: 13/83 (15.66%) Cardiac failure congestive 1/83 (1.20%) Hypothyroidism 1/83 (1.20%) Nausea 2/83 (2.41%) Vomiting 2/83 (2.41%) Diarrhea 1/83 (1.20%) Gastrointestinal Haemorrhage 1/83 (1.20%) Asthenia 1/83 (1.20%) Hyperbilirubinaemia 1/83 (1.20%) Anal abscess 1/83 (1.20%) Dehydration 3/83 (3.61%) Decreased appetite 1/83 (1.20%) ",
        "premise_nums": [
            "2/83 (2.41%)",
            "13/83 (15.66%)",
            "3/83 (3.61%)",
            "1/83 (1.20%)"
        ]
    },
    {
        "id": "62b5fe62-470d-46e3-82a6-d57cd6cab452",
        "primaryId": "NCT00471276",
        "secondaryId": "NCT00951665",
        "label": "Entailment",
        "statement_text": "Gastrointestinal haemorrhage was more common in patients from cohort 1 of the primary trial than cohort 1 of the secondary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Adverse Events 1:Total: 7/26 (26.92%) Febrile neutropenia 1/26 (3.85%) Neutropenia 0/26 (0.00%) Thrombocytopenia 0/26 (0.00%) Cardiac failure congestive 0/26 (0.00%) Extrasystoles 0/26 (0.00%) Nausea 1/26 (3.85%) Abdominal pain 0/26 (0.00%) Constipation 0/26 (0.00%) Gastrointestinal haemorrhage 0/26 (0.00%) Death - unknown cause 1/26 (3.85%) ",
        "premise_nums": [
            "1:Total: 7/26",
            "0/26 (0.00%)",
            "1/26 (3.85%)",
            "7/26 (26.92%)"
        ]
    },
    {
        "id": "62b5fe62-470d-46e3-82a6-d57cd6cab452",
        "primaryId": "NCT00471276",
        "secondaryId": "NCT00951665",
        "label": "Entailment",
        "statement_text": "Gastrointestinal haemorrhage was more common in patients from cohort 1 of the primary trial than cohort 1 of the secondary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Thrombosis in device 0/26 (0.00%)",
        "premise_nums": [
            "0/26 (0.00%)"
        ]
    },
    {
        "id": "de349a2d-80ee-4c34-ab9f-38eb467c77d7",
        "primaryId": "NCT01106040",
        "secondaryId": "NCT01441596",
        "label": "Entailment",
        "statement_text": "the primary trial and the secondary trial are not studying patient PFS  ORR or DLTs ",
        "statement_nums": [],
        "premise_text": "Outcome Measurement: Concordance of Blue Dye and Lymphoseek The proportion of lymph nodes detected intraoperatively by blue dye that were also detected by Lymphoseek  Time frame: Surgery after injections of Lymphoseek and blue dye Outcome Measurement: Patient Benefit Rate at 12 Weeks Percentage of patients with patient benefit at week 12. Patient benefit was defined by the absence of central nervous system (CNS) disease progression according to Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1 in addition to no tumour-related worsening of the neurological signs and symptoms (NSS)  no tumour-related increase in corticosteroid dosage and no progression of extra CNS disease according to RECIST 1.1 Time frame: 12 weeks from randomisation ",
        "premise_nums": [
            "1 Time frame:",
            "RECIST 1.1 Time frame",
            "12 weeks from",
            "version 1.1 in addition",
            "12 Weeks Percentage"
        ]
    },
    {
        "id": "0d37bf26-bc74-4a01-9bc9-61e2fa3051da",
        "primaryId": "NCT00446030",
        "secondaryId": "NCT00975676",
        "label": "Entailment",
        "statement_text": "the primary trial and the secondary trial have no overlap in the drugs they use for their interventions ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Stratum 1: TAC + Bevacizumab HER2 negative participants were administered chemotherapy with docetaxel  doxorubicin and cyclosphosphamide (TAC) + bevacizumab every 3 weeks for 6 cycles  and maintenance therapy with bevacizumab every 3 weeks for a total of 52 weeks  INTERVENTION 2: Stratum 2: TCH + Bevacizumab HER2 positive participants were administered chemotherapy with docetaxel  carboplatin and trastuzumab (TCH) + bevacizumab every 3 weeks for 6 cycles  and maintenance therapy with bevacizumab and trastuzumab every 3 weeks for a total of 52 weeks  INTERVENTION 1: ",
        "premise_nums": [
            "2 positive participants",
            "3 weeks for",
            "2 negative participants"
        ]
    },
    {
        "id": "0d37bf26-bc74-4a01-9bc9-61e2fa3051da",
        "primaryId": "NCT00446030",
        "secondaryId": "NCT00975676",
        "label": "Entailment",
        "statement_text": "the primary trial and the secondary trial have no overlap in the drugs they use for their interventions ",
        "statement_nums": [],
        "premise_text": "Triptorelin Plus TamoxifenDetermination of estrogen levels in blood samples from patients being treated with triptorelin plus tamoxifen for 5 years  INTERVENTION 2: Triptorelin Plus Exemestane Determination of estrogen levels in blood samples from patients being treated with triptorelin plus exemestane for 5 years  ",
        "premise_nums": []
    },
    {
        "id": "69f7a93d-7134-40ec-aff3-50acd7119d2c",
        "primaryId": "NCT02425891",
        "secondaryId": "NCT00593827",
        "label": "Entailment",
        "statement_text": "the secondary trial and the primary trial both measure PFS of their patient cohorts ",
        "statement_nums": [],
        "premise_text": "Outcome Measurement: Progression Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (v1.1) in All Randomized Participants PFS was defined as the time from randomization to the occurrence of disease progression  as determined by investigators from tumor assessments per RECIST v1.1, or death from any cause  whichever occurred first  Time frame: Baseline up to approximately 34 months Outcome Measurement: Progression-Free Survival (PFS) at 6 Months (6-month PFS Rate): Proportion of Participants Progression Free at 6 Months PFS at 6 months was defined as proportion of participants who neither progressed nor died before 6 months  Computed using Kaplan-Meier estimates  Time frame: From the date of randomization to 6-months on study ",
        "premise_nums": [
            "(6-month PFS",
            "6-months on",
            "6 Months PFS",
            "34 months Outcome",
            "6 months was"
        ]
    },
    {
        "id": "8de31b0f-7127-4c8b-b5e0-060e7a83fae5",
        "primaryId": "NCT01299038",
        "statement_text": "Joe has a known history of Hepatitis  However as he is over the age of 18 is still eligible for the primary trial ",
        "statement_nums": [
            "18 is still"
        ],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria: Metastatic adenocarcinoma of the breast (Stage IV) Actively receiving endocrine therapy for at least 6 weeks (with or without HER2 therapy) Minimum age 18 years ECOG Performance status of 0, 1 or 2 Normal organ and marrow function as defined in the protocol Exclusion Criteria: Participants may not be receiving any other study agents Actively receiving chemotherapy (exclusive of hormonal or HER2 therapy ) within last 5 weeks Any statin therapy within the last 3 weeks Asian decent (including Filipino  Chinese  Japanese  Korean  Vietnamese or Asian-Indian origin) ",
        "premise_nums": [
            "3 weeks Asian",
            "6 weeks (with",
            "2 therapy )",
            "5 weeks Any",
            "1 or 2",
            "18 years ECOG"
        ]
    },
    {
        "id": "8de31b0f-7127-4c8b-b5e0-060e7a83fae5",
        "primaryId": "NCT01299038",
        "statement_text": "Joe has a known history of Hepatitis  However as he is over the age of 18 is still eligible for the primary trial ",
        "statement_nums": [
            "18 is still"
        ],
        "label": "Contradiction",
        "premise_text": "Concomitant use of the following drugs: cyclosporine  fibrates  niacin  gemfibrozil  ketaconazole  spironolactone  cimetidine  warfarin  erythromycin  or protease inhibitorsConditions predisposing to renal failure secondary to rhabdomyolysis Recent history of heavy alcohol use as judged by the treating physician Known to be pregnant (testing not required) or nursing History of rhabdomyolysis on statin therapy Known history of Hepatitis C or active hepatitis B infection (baseline testing not required) ",
        "premise_nums": []
    },
    {
        "id": "8de31b0f-7127-4c8b-b5e0-060e7a83fae5",
        "primaryId": "NCT01299038",
        "statement_text": "Joe has a known history of Hepatitis  However as he is over the age of 18 is still eligible for the primary trial ",
        "statement_nums": [
            "18 is still"
        ],
        "label": "Contradiction",
        "premise_text": "Uncontrolled intercurrent illness including  but not limited to ongoing or active infection  hepatitis  symptomatic congestive heart failure  unstable angina pectoris  cardiac arrhythmia  or psychiatric illness/social situations that would limit compliance with study requirements",
        "premise_nums": []
    },
    {
        "id": "207a1d82-a61b-4b5f-bebf-0706def6729d",
        "primaryId": "NCT01008150",
        "secondaryId": "NCT00375427",
        "label": "Entailment",
        "statement_text": "In total the secondary trial recorded only 1 more case of Mucosal inflammation than the primary trial ",
        "statement_nums": [
            "1 more case"
        ],
        "premise_text": "Adverse Events 1: Total: 7/42 (16.67%) Febrile neutropenia 1/42 (2.38%) Left venrticular dysfunction 1/42 (2.38%) Cardiac valve disease 1/42 (2.38%) Diarrhoea 0/42 (0.00%) Abdominal pain 1/42 (2.38%) Colitis 0/42 (0.00%) Nausea 0/42 (0.00%) Vomiting 0/42 (0.00%) Pyrexia 0/42 (0.00%) Influenza like illness 1/42 (2.38%) Oedema peripheral 1/42 (2.38%) Fatigue 0/42 (0.00%) Adverse Events 2: ",
        "premise_nums": [
            "1/42 (2.38%)",
            "0/42 (0.00%)",
            "7/42 (16.67%)"
        ]
    },
    {
        "id": "207a1d82-a61b-4b5f-bebf-0706def6729d",
        "primaryId": "NCT01008150",
        "secondaryId": "NCT00375427",
        "label": "Entailment",
        "statement_text": "In total the secondary trial recorded only 1 more case of Mucosal inflammation than the primary trial ",
        "statement_nums": [
            "1 more case"
        ],
        "premise_text": "Total: 7/42 (16.67%)Febrile neutropenia 0/42 (0.00%) Left venrticular dysfunction 1/42 (2.38%) Cardiac valve disease 0/42 (0.00%) Diarrhoea 0/42 (0.00%) Abdominal pain 0/42 (0.00%) Colitis 0/42 (0.00%) Nausea 0/42 (0.00%) Vomiting 0/42 (0.00%) Pyrexia 2/42 (4.76%) Influenza like illness 0/42 (0.00%) Oedema peripheral 0/42 (0.00%) Fatigue 0/42 (0.00%) Adverse Events 1: ",
        "premise_nums": [
            "2/42 (4.76%)",
            "0/42 (0.00%)",
            "1/42 (2.38%)",
            "7/42 (16.67%)Febrile"
        ]
    },
    {
        "id": "207a1d82-a61b-4b5f-bebf-0706def6729d",
        "primaryId": "NCT01008150",
        "secondaryId": "NCT00375427",
        "label": "Entailment",
        "statement_text": "In total the secondary trial recorded only 1 more case of Mucosal inflammation than the primary trial ",
        "statement_nums": [
            "1 more case"
        ],
        "premise_text": "Total: 21/209 (10.05%)Anaemia 0/209 (0.00%) Febrile neutropenia 0/209 (0.00%) Thrombocytopenia 0/209 (0.00%) Acute myocardial infarction 0/209 (0.00%) Cardiac failure 0/209 (0.00%) Diplopia 0/209 (0.00%) Gastric haemorrhage 0/209 (0.00%) Nausea 0/209 (0.00%) Oral pain 0/209 (0.00%) Vomiting 1/209 (0.48%) Mucosal inflammation 0/209 (0.00%) Pain 1/209 (0.48%) Adverse Events 2: ",
        "premise_nums": [
            "1/209 (0.48%)",
            "21/209 (10.05%)Anaemia",
            "0/209 (0.00%)"
        ]
    },
    {
        "id": "207a1d82-a61b-4b5f-bebf-0706def6729d",
        "primaryId": "NCT01008150",
        "secondaryId": "NCT00375427",
        "label": "Entailment",
        "statement_text": "In total the secondary trial recorded only 1 more case of Mucosal inflammation than the primary trial ",
        "statement_nums": [
            "1 more case"
        ],
        "premise_text": "Total: 29/216 (13.43%)Anaemia 2/216 (0.93%) Febrile neutropenia 2/216 (0.93%) Thrombocytopenia 2/216 (0.93%) Acute myocardial infarction 1/216 (0.46%) Cardiac failure 1/216 (0.46%) Diplopia 1/216 (0.46%) Gastric haemorrhage 1/216 (0.46%) Nausea 1/216 (0.46%) Oral pain 2/216 (0.93%) Vomiting 2/216 (0.93%) Mucosal inflammation 1/216 (0.46%) Pain 0/216 (0.00%) ",
        "premise_nums": [
            "2/216 (0.93%)",
            "1/216 (0.46%)",
            "0/216 (0.00%)",
            "29/216 (13.43%)Anaemia"
        ]
    },
    {
        "id": "968aeaf1-44b9-4454-8c99-e3c207037485",
        "primaryId": "NCT01491737",
        "statement_text": "There were 4 cases of Febrile neutropenia and heart failure in cohort 1 of the primary trial ",
        "statement_nums": [
            "4 cases of",
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Febrile neutropenia 4/127 (3.15%) Cardiac failure 0/127 (0.00%) ",
        "premise_nums": [
            "0/127 (0.00%)",
            "4/127 (3.15%)"
        ]
    },
    {
        "id": "2b79f9cc-4262-4353-ad28-91cda07a9b9a",
        "primaryId": "NCT02988986",
        "statement_text": "Patients must have AST  ALP and ALT smaller than 1.5 ULN to participate in the primary trial ",
        "statement_nums": [
            "than 1.5 ULN to"
        ],
        "label": "Entailment",
        "premise_text": "Inclusion Criteria: Hepatic status: Serum total bilirubin 1 x upper limit of normal (ULN; in the case of known Gilbert's syndrome  a higher serum total bilirubin [smaller than 1.5 x ULN] is allowed)  aspartate aminotransferase and alanine aminotransferase 1.5 x ULN  and alkaline phosphatase 1.5 x ULN; ",
        "premise_nums": [
            "5 x ULN;",
            "than 1.5 x ULN",
            "1 x upper",
            "phosphatase 1.5 x ULN",
            "aminotransferase 1.5 x ULN",
            "5 x ULN]"
        ]
    },
    {
        "id": "d56ffd81-4007-477b-b3c3-0fdb89806931",
        "primaryId": "NCT00723398",
        "statement_text": "Patients with diabetes insipidusare not suitable for the primary trial ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria: Postmenopausal status defined as history of at least 12 months without spontaneous menstrual bleeding or a documented hysterectomy and bilateral salpingo oophorectomy Breast density greater than 25% No hormone replacement therapy for at least six months prior to entry into this study Non-smokers  Exclusion Criteria: History of stroke  pulmonary embolism or deep vein thrombosis History of atherosclerotic heart disease Presence of any known hypercoagulable state either congenital (e.g.  protein S deficiency) or acquired (e.g.  corticosteroid treatment) Diabetes mellitus Uncontrolled hypertension (BP 140/90) Presence of a psychiatric condition that would interfere with adherence to the protocol  ",
        "premise_nums": [
            "140/90) Presence",
            "25% No",
            "12 months without"
        ]
    },
    {
        "id": "f62e6c20-862b-4ce3-9121-0d93ff050839",
        "primaryId": "NCT01373671",
        "secondaryId": "NCT00686127",
        "label": "Contradiction",
        "statement_text": "Lidoderm products are used in a intervention arm 1 of the secondary trial  and an FFDM product is used in arm 1 of the primary trial",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "INTERVENTION 1: FFDM and DBT FFDM exam and DBT scan on Siemens MAMMOMAT Inspiration INTERVENTION 1: Lidocaine Patch Lidocaine patch 5% (Lidoderm®  Endo Pharmaceuticals Inc.): 1 patch was applied topically to the affected site(s) for 12 hours each day  ",
        "premise_nums": [
            "1 patch was",
            "12 hours each"
        ]
    },
    {
        "id": "833eeb4b-4921-468a-947d-bacfc7816ae6",
        "primaryId": "NCT02162719",
        "secondaryId": "NCT02131064",
        "label": "Contradiction",
        "statement_text": "the primary trial and the secondary trial investigate the effects of their intervention on patient tpCR ",
        "statement_nums": [],
        "premise_text": "Outcome Measurement: Progression Free Survival (PFS) PFS was defined as the time from randomization to the first occurrence of disease progression  as determined by investigator review of tumor assessments by RECIST  v1.1 or death on study (smaller than =30 days after the last dose of study treatment regimen) from any cause  whichever occurred first  Time frame: Baseline up to 30 days after the last dose of study drug administration (Clinical Cut Off Date: 07 June 2016) Outcome Measurement: Percentage of Participants With Total Pathological Complete Response (tpCR) Assessed Based on Tumor Samples ",
        "premise_nums": [
            "07 June 2016)",
            "v1.1 or",
            "30 days after",
            "1 or death"
        ]
    },
    {
        "id": "6dea5ffa-066d-45bf-b7e5-df3ae5bca0b6",
        "primaryId": "NCT00006110",
        "secondaryId": "NCT00464646",
        "label": "Entailment",
        "statement_text": "the secondary trial records several gastrointestinal adverse events  whereas the primary trial doesn‚Äö√Ñ√¥t record any GI adverse events ",
        "statement_nums": [],
        "premise_text": "Adverse Events 1: Total: 7/52 (13.46%) Febrile neutropenia (fever of unknown origin without clinically or microbiologically documented infe * 0/52 (0.00%) Atrial Fibrillation * 1/52 (1.92%) Sepsis * 1/52 (1.92%) Muscle weakness upper limb * 1/52 (1.92%) Dizziness * 1/52 (1.92%) Seizure * 1/52 (1.92%) Nervous system disorders - Other  specify * [1]1/52 (1.92%) Adverse Events 2: Total: 1/30 (3.33%) ",
        "premise_nums": [
            "1/52 (1.92%)",
            "1/30 (3.33%)",
            "7/52 (13.46%)",
            "0/52 (0.00%)"
        ]
    },
    {
        "id": "6dea5ffa-066d-45bf-b7e5-df3ae5bca0b6",
        "primaryId": "NCT00006110",
        "secondaryId": "NCT00464646",
        "label": "Entailment",
        "statement_text": "the secondary trial records several gastrointestinal adverse events  whereas the primary trial doesn‚Äö√Ñ√¥t record any GI adverse events ",
        "statement_nums": [],
        "premise_text": "Febrile neutropenia (fever of unknown origin without clinically or microbiologically documented infe * 1/30 (3.33%)Atrial Fibrillation * 0/30 (0.00%) Sepsis * 0/30 (0.00%) Muscle weakness upper limb * 0/30 (0.00%) Dizziness * 0/30 (0.00%) Seizure * 0/30 (0.00%) Nervous system disorders - Other  specify * [1]0/30 (0.00%) Adverse Events 1: Hemorrhage  GI - stomach 0/76 (0.00%) Perforation  GI - colon 1/76 (1.32%) ",
        "premise_nums": [
            "1/30 (3.33%)Atrial",
            "0/76 (0.00%)",
            "0/30 (0.00%)",
            "1/76 (1.32%)"
        ]
    },
    {
        "id": "6dea5ffa-066d-45bf-b7e5-df3ae5bca0b6",
        "primaryId": "NCT00006110",
        "secondaryId": "NCT00464646",
        "label": "Entailment",
        "statement_text": "the secondary trial records several gastrointestinal adverse events  whereas the primary trial doesn‚Äö√Ñ√¥t record any GI adverse events ",
        "statement_nums": [],
        "premise_text": "Ulcer  GI - stomach 0/76 (0.00%)",
        "premise_nums": [
            "0/76 (0.00%)"
        ]
    },
    {
        "id": "c317750d-6ef7-494d-8040-2c7fa3d777fb",
        "primaryId": "NCT01129622",
        "secondaryId": "NCT01156987",
        "label": "Entailment",
        "statement_text": "the secondary trial and the primary trial both used MRI for their interventions ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Letrozole  Breast Enhancement  Safety Single arm of healthy postmenopausal women to have two breast MRI (baseline and post-treatment)  Letrozole of 12.5 mg/day is given for three successive days just prior to the second MRI  INTERVENTION 1: Healthy Volunteers Healthy women will be screened for Magnetic Resonance Imaging (MRI) contraindications  and then undergo contrast injection  and SWIFT acquisition  Magnetic resonance imaging: Patients and healthy volunteers will be first screened for MRI contraindications  The SWIFT MRI workflow will be performed as follows: ",
        "premise_nums": [
            "of 12.5 mg/day"
        ]
    },
    {
        "id": "87eca8d2-72fe-4285-9884-6d2ec7bae6df",
        "primaryId": "NCT00567190",
        "statement_text": "There was exactly the same proportion of anemic patinets in both cohorts of the primary trial ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Anaemia 3/396 (0.76%) Adverse Events 2: Anaemia 3/408 (0.74%) ",
        "premise_nums": [
            "3/396 (0.76%)",
            "3/408 (0.74%)"
        ]
    },
    {
        "id": "7a87c605-fc41-4d0a-9291-85e88f6eb510",
        "primaryId": "NCT01000662",
        "secondaryId": "NCT02413008",
        "label": "Entailment",
        "statement_text": "the secondary trial is testing a Gel which is applied inside the vagina  and the primary trial is testing an intervention which requires daily radiation of the breast(s) ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: ARM 1 Daily Boost Radiation Therapy Radiation Therapy: Arm 1= 15 daily radiation fractions of 2.7 Gy  Monday to Friday for 3 weeks  to the whole breast with a daily concomitant boost of 0.5 Gy to the tumor bed  for a total daily dose of 3.2 Gy to the tumor bed (2.7Gy+0.5 Gy)  The overall dose will be 40.5 Gy to the breast and 48.0 Gy to the tumor bed  ",
        "premise_nums": [
            "of 3.2 Gy to",
            "and 48.0 Gy to",
            "of 0.5 Gy to",
            "be 40.5 Gy to",
            "15 daily radiation",
            "1 Daily Boost"
        ]
    },
    {
        "id": "7a87c605-fc41-4d0a-9291-85e88f6eb510",
        "primaryId": "NCT01000662",
        "secondaryId": "NCT02413008",
        "label": "Entailment",
        "statement_text": "the secondary trial is testing a Gel which is applied inside the vagina  and the primary trial is testing an intervention which requires daily radiation of the breast(s) ",
        "statement_nums": [],
        "premise_text": "Arm 2= 15 daily radiation fractions of 2.7 Gy Monday to friday for three weeks to the entire breast with a Friday boost of 2.0 Gy to the tumor bed  for a total dose to the tumor bed on each friday of 4.7 Gy (2.7 Gy+ 2.0 Gy)  The overall dose will be 40.5 Gy to the breast and 46.5 gy to the tumor bed INTERVENTION 1: 0.005% Estriol Vaginal Gel ",
        "premise_nums": [
            "7 Gy (2.7",
            "of 2.7 Gy Monday",
            "0.005% Estriol",
            "15 daily radiation",
            "be 40.5 Gy to",
            "and 46.5 gy to",
            "of 2.0 Gy to"
        ]
    },
    {
        "id": "7a87c605-fc41-4d0a-9291-85e88f6eb510",
        "primaryId": "NCT01000662",
        "secondaryId": "NCT02413008",
        "label": "Entailment",
        "statement_text": "the secondary trial is testing a Gel which is applied inside the vagina  and the primary trial is testing an intervention which requires daily radiation of the breast(s) ",
        "statement_nums": [],
        "premise_text": "Route: Vaginal  Administration by an applicator inserted deep inside the vagina Dose: 1 g of gel  containing 50 Mcg of estriol Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: twice weekly administration",
        "premise_nums": [
            "4-12: twice",
            "1-3: single",
            "1 g of",
            "50 Mcg of"
        ]
    },
    {
        "id": "fbb853c9-bed4-4cde-a283-2d91b23d35bf",
        "primaryId": "NCT01964924",
        "secondaryId": "NCT00524303",
        "label": "Entailment",
        "statement_text": "the primary trial and the secondary trial both report results on pathologic evidence of invasive disease withing their patient cohorts after their interventions  using different outcome measurements ",
        "statement_nums": [],
        "premise_text": "Outcome Measurement: Objective Response Rate (ORR)  Defined as the Proportion of Patients Who Have Had a Partial Response (PR) or Complete Response (CR) (RECIST 1.1 Based) Within the First 6 Months After Initiation of Therapy With Trametinib Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR)  Disappearance of all target lesions; Partial Response (PR)  greater than or equal 30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR  Time frame: 6 months Outcome Measurement: Percentage of Participants With Overall Pathological Complete Response (pCR) After 26 Weeks of Therapy ",
        "premise_nums": [
            "30% decrease",
            "26 Weeks of",
            "6 months Outcome",
            "6 Months After"
        ]
    },
    {
        "id": "fbb853c9-bed4-4cde-a283-2d91b23d35bf",
        "primaryId": "NCT01964924",
        "secondaryId": "NCT00524303",
        "label": "Entailment",
        "statement_text": "the primary trial and the secondary trial both report results on pathologic evidence of invasive disease withing their patient cohorts after their interventions  using different outcome measurements ",
        "statement_nums": [],
        "premise_text": "A pCR in the breast was defined as no pathologic evidence of invasive disease (residual ductal carcinoma in situ [DCIS] or lobular carcinoma in situ [LCIS] was allowed)  A pCR in the axillary lymph node(s) was defined as no evidence of breast cancer cells in the lymph node (including subcapsular sinus)  Overall pCR was defined as the sum of pCR in the breast and pCR in the lymph nodes  26 weeks of therapy comprised the 2-week run-in phase  12 weeks of treatment with FEC  and 12 weeks of treatment with Paclitaxel Time frame: Week 26 ",
        "premise_nums": [
            "2-week run-in",
            "12 weeks of",
            "26 weeks of"
        ]
    },
    {
        "id": "c3cc3621-a8ce-4f0d-a150-7e627f36e7c5",
        "primaryId": "NCT00482391",
        "statement_text": "Patients with a QT interval longer than half a second are excluded from the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "No QT prolongation (greater than 500 ms) ",
        "premise_nums": []
    },
    {
        "id": "84aa97cf-efce-484e-825e-5af509e5988f",
        "primaryId": "NCT01441596",
        "statement_text": "Patients in cohort 1 of the primary trial may receive gradually increasing doses of Afatinib monotherapy  up to 160% of the starting dose ",
        "statement_nums": [
            "160% of",
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "INTERVENTION 1: Afatinib Mono Afatinib monotherapy administered orally: starting dose 40 mg per day  continuous treatment in a 3-weekly course  If well tolerated  the dose may be escalated to 50 mg  ",
        "premise_nums": [
            "40 mg per",
            "3-weekly course"
        ]
    },
    {
        "id": "a40e172a-8839-499d-896d-be71a7ca4905",
        "primaryId": "NCT03076190",
        "secondaryId": "NCT03196635",
        "label": "Contradiction",
        "statement_text": "Molecular Breast Imaging is not applied in either the primary trial or the secondary trial interventions  however all participants taking part in these studies will need to receive stem cell transplants ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Active Control Group Health Education Active Control Group INTERVENTION 2: My Surgical Success Treatment Group My Surgical Success Intervention Group INTERVENTION 1: All Study Participants  PA Compression Image Sets All image sets (30 patient-assisted compression image sets) were evaluated for acceptability of overall clinical image quality by two (2) readers  INTERVENTION 2: All Study Participants  TC Compression Image Sets All image sets (30 TC compression image sets) were evaluated for acceptability of overall clinical image quality by two (2) readers  ",
        "premise_nums": [
            "30 TC compression",
            "(2) readers"
        ]
    },
    {
        "id": "9e972e33-9ecd-4a8b-8337-7bee209f790b",
        "primaryId": "NCT02202252",
        "statement_text": "The difference between cohort 1 and 2 of the primary trial is assesment by ultrasonography and the insertion of an additional negative pressure drain for patients in cohort 2.",
        "statement_nums": [
            "1 and 2"
        ],
        "label": "Contradiction",
        "premise_text": "INTERVENTION 1: Single Drain Insertion of a single drain: A negative pressure drain will be inserted below the lower flap directing to the axilla in the single drain group  Ultrasonography after removal of the drains: One day after removal of the drains seroma under the flaps and in the axilla will be examined by ultrasonography  Insertion of a single drain: A negative pressure drain will be inserted below the lower flap directing to the axilla  Ultrasonography after removal of the drains: One day after removal of the drains seroma under the flaps and in the axilla will be examined by ultrasonography  INTERVENTION 2: Double Drain Insertion of double drains: Two negative pressure drains will be inserted into the axilla and below the lower flap in the double drains group  ",
        "premise_nums": []
    },
    {
        "id": "9e972e33-9ecd-4a8b-8337-7bee209f790b",
        "primaryId": "NCT02202252",
        "statement_text": "The difference between cohort 1 and 2 of the primary trial is assesment by ultrasonography and the insertion of an additional negative pressure drain for patients in cohort 2.",
        "statement_nums": [
            "1 and 2"
        ],
        "label": "Contradiction",
        "premise_text": "Ultrasonography after removal of the drains: One day after removal of the drains seroma under the flaps and in the axilla will be examined by ultrasonography Insertion of double drains: Two drains will be inserted into the axilla and below the lower flap in the double drains group  Ultrasonography after removal of the drains: One day after removal of the drains seroma under the flaps and in the axilla will be examined by ultrasonography  ",
        "premise_nums": []
    },
    {
        "id": "f29768ba-5d79-4528-839f-933ab13faaa1",
        "primaryId": "NCT01943916",
        "secondaryId": "NCT01653964",
        "label": "Contradiction",
        "statement_text": "All subjects in the primary trial and the secondary trial will be adminstered 4 mCi Tc-99m sestamibi and undergo Molecular breast imaging ",
        "statement_nums": [
            "4 mCi Tc"
        ],
        "premise_text": "INTERVENTION 1: Overall Population Each subject served as her own control  with imaging of each mass by both the test and control modalities  Specificity difference is a single measure for the overall ITD population  INTERVENTION 1: Molecular Breast Imaging Molecular breast imaging performed after injection of 4 mCi Tc-99m sestamibi and again after 8 mCi Tc-99m sestamibi  ",
        "premise_nums": [
            "4 mCi Tc",
            "8 mCi Tc"
        ]
    },
    {
        "id": "343e0a32-aebe-4bbb-97c0-b2c597c36802",
        "primaryId": "NCT00392392",
        "secondaryId": "NCT00503906",
        "label": "Entailment",
        "statement_text": "the primary trial records two different types of pain in its adverse events  in the abdomen and chest area  the secondary trial does not record any types of pain in its participants ",
        "statement_nums": [],
        "premise_text": "Adverse Events 1: Pain - Abdomen 1/29 (3.45%) Pain - Chest 1/29 (3.45%) Adverse Events 1: Total: 8/29 (27.59%) Leukopenia [1]1/29 (3.45%) Thrombocytopenia [1]1/29 (3.45%) Abscess [1]1/29 (3.45%) Breast Abscess 1/29 (3.45%) Fever/Sepsis [1]1/29 (3.45%) Neutropenic Fever [2]1/29 (3.45%) Peripheral Neuropathy [1]1/29 (3.45%) ",
        "premise_nums": [
            "1/29 (3.45%)",
            "8/29 (27.59%)"
        ]
    },
    {
        "id": "343e0a32-aebe-4bbb-97c0-b2c597c36802",
        "primaryId": "NCT00392392",
        "secondaryId": "NCT00503906",
        "label": "Entailment",
        "statement_text": "the primary trial records two different types of pain in its adverse events  in the abdomen and chest area  the secondary trial does not record any types of pain in its participants ",
        "statement_nums": [],
        "premise_text": "Seizure/Syncope [1]1/29 (3.45%)Hematuria [1]1/29 (3.45%) UTI [1]1/29 (3.45%) Shortness of breath [1]1/29 (3.45%) ",
        "premise_nums": [
            "1/29 (3.45%)Hematuria"
        ]
    },
    {
        "id": "4d51608c-b0d8-4019-9b9a-34cf1c3d5087",
        "primaryId": "NCT00558103",
        "statement_text": "All participants in the primary trial are administered with Lapatinib 1500 mg PO QD and Pazopanib 800 mg ",
        "statement_nums": [
            "1500 mg PO"
        ],
        "label": "Contradiction",
        "premise_text": "INTERVENTION 1: Cohort 1: Lapatinib 1500 mg + Pazopanib Placebo Participants received oral lapatinib 1500 milligrams (mg) (6 x 250 mg tablets) in combination with placebo (matching to pazopanib; 2 tablets) once daily (QD)  INTERVENTION 2: Cohort 1: Lapatinib 1500 mg + Pazopanib 800 mg Participants received oral lapatinib 1500 mg (6 x 250 mg tablets) in combination with pazopanib 800 mg (2 x 400 mg tablets) QD  ",
        "premise_nums": [
            "800 mg (2",
            "1500 milligrams (mg)",
            "6 x 250",
            "1500 mg (6",
            "800 mg Participants",
            "250 mg tablets)",
            "400 mg tablets)"
        ]
    },
    {
        "id": "7bb88699-1536-4fdc-9cb2-c5ef350d559b",
        "primaryId": "NCT00331552",
        "secondaryId": "NCT01306942",
        "label": "Entailment",
        "statement_text": "trastuzumab was used for the interventions in the primary trial and the secondary trial ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Phase I: Cyclophosphamide  Doxil  Trastuzumab Patients receive oral cyclophosphamide once daily on days 1-28 and pegylated doxorubicin HCl liposome IV over 90 minutes on day 1. Treatment repeats every 4-6 weeks in the absence of disease progression or unacceptable toxicity  Some patients with HER2/neu 3+ disease may also receive trastuzumab IV over 30-90 minutes weekly or every 3 weeks at the discretion of the treating physician  pegylated liposomal doxorubicin hydrochloride: Given IV cyclophosphamide: Given orally trastuzumab: Given IV INTERVENTION 1: ",
        "premise_nums": [
            "90 minutes weekly",
            "2/neu 3+",
            "30-90 minutes",
            "3 weeks at",
            "28 and pegylated",
            "1-28 and",
            "6 weeks in",
            "4-6 weeks",
            "90 minutes on"
        ]
    },
    {
        "id": "7bb88699-1536-4fdc-9cb2-c5ef350d559b",
        "primaryId": "NCT00331552",
        "secondaryId": "NCT01306942",
        "label": "Entailment",
        "statement_text": "trastuzumab was used for the interventions in the primary trial and the secondary trial ",
        "statement_nums": [],
        "premise_text": "Phase I: Dasatinib 100mg/Trastuzumab 2mg/kg/Paclitaxel 80mg/m2Cohort 1: Eligible patients were enrolled and treated with 4-week cycles of trastuzumab 2 mg/kg IV weekly (following a loading dose of 4 mg/kg in cycle 1) and paclitaxel 80 mg/m2 weekly x 3 weeks followed by a rest period of 7 days  Dasatinib 100mg was administered orally once daily (QD)  Treatment was repeated on Day 1 of a 28-day cycle until radiographic or symptomatic progression or unacceptable toxicity occured  Only in the phase I  the first cycle lasted 38 days  ",
        "premise_nums": [
            "1 of a",
            "2mg/kg/Paclitaxel",
            "80mg/m2Cohort",
            "3 weeks followed",
            "2 weekly x",
            "4-week cycles",
            "2 mg/kg IV",
            "80 mg/m2 weekly",
            "4 mg/kg in",
            "28-day cycle",
            "100mg/Trastuzumab"
        ]
    },
    {
        "id": "c86ef61b-7565-465a-82ba-25e7ac050ccc",
        "primaryId": "NCT02139358",
        "secondaryId": "NCT02574455",
        "label": "Entailment",
        "statement_text": "There was one case of hemorrhaging in the primary trial  and no recorded cases in the secondary trial ",
        "statement_nums": [],
        "premise_text": "Adverse Events 1: Total: 7/15 (46.67%) Cardiac arrest * 1/15 (6.67%) Chest pain - cardiac * 1/15 (6.67%) Diarrhea * 1/15 (6.67%) Duodenal hemorrhage * 1/15 (6.67%) Fatigue * 1/15 (6.67%) Fever * 1/15 (6.67%) Sudden death NOS * 1/15 (6.67%) Sepsis * 1/15 (6.67%) Skin infection * 1/15 (6.67%) Neutrophil count decreased * 1/15 (6.67%) Platelet count decreased * 1/15 (6.67%) Adverse Events 1: ",
        "premise_nums": [
            "7/15 (46.67%)",
            "1/15 (6.67%)"
        ]
    },
    {
        "id": "c86ef61b-7565-465a-82ba-25e7ac050ccc",
        "primaryId": "NCT02139358",
        "secondaryId": "NCT02574455",
        "label": "Entailment",
        "statement_text": "There was one case of hemorrhaging in the primary trial  and no recorded cases in the secondary trial ",
        "statement_nums": [],
        "premise_text": "Total: 69/258 (26.74%)Anaemia 3/258 (1.16%) Febrile neutropenia 13/258 (5.04%) Neutropenia 5/258 (1.94%) Thrombocytopenia 1/258 (0.39%) Atrial fibrillation 0/258 (0.00%) Mitral valve incompetence 1/258 (0.39%) Pericardial effusion 0/258 (0.00%) Sinus tachycardia 0/258 (0.00%) Abdominal pain 3/258 (1.16%) Abdominal pain upper 1/258 (0.39%) Colitis 1/258 (0.39%) Adverse Events 2: ",
        "premise_nums": [
            "1/258 (0.39%)",
            "13/258 (5.04%)",
            "3/258 (1.16%)",
            "0/258 (0.00%)",
            "5/258 (1.94%)",
            "69/258 (26.74%)Anaemia"
        ]
    },
    {
        "id": "c86ef61b-7565-465a-82ba-25e7ac050ccc",
        "primaryId": "NCT02139358",
        "secondaryId": "NCT02574455",
        "label": "Entailment",
        "statement_text": "There was one case of hemorrhaging in the primary trial  and no recorded cases in the secondary trial ",
        "statement_nums": [],
        "premise_text": "Total: 64/224 (28.57%)Anaemia 2/224 (0.89%) Febrile neutropenia 4/224 (1.79%) Neutropenia 1/224 (0.45%) Thrombocytopenia 0/224 (0.00%) Atrial fibrillation 1/224 (0.45%) Mitral valve incompetence 0/224 (0.00%) Pericardial effusion 2/224 (0.89%) Sinus tachycardia 1/224 (0.45%) Abdominal pain 3/224 (1.34%) Abdominal pain upper 0/224 (0.00%) Colitis 0/224 (0.00%) ",
        "premise_nums": [
            "2/224 (0.89%)",
            "1/224 (0.45%)",
            "4/224 (1.79%)",
            "64/224 (28.57%)Anaemia",
            "3/224 (1.34%)",
            "0/224 (0.00%)"
        ]
    },
    {
        "id": "58dec898-e0af-41c1-96f9-7163d3e3e855",
        "primaryId": "NCT02019277",
        "secondaryId": "NCT00863655",
        "label": "Entailment",
        "statement_text": "the primary trial and the secondary trial recorded three of the same types of adverse events",
        "statement_nums": [],
        "premise_text": "Adverse Events 1: Total: 27/50 (54.00%) Febrile neutropenia * 4/50 (8.00%) Anaemia * 1/50 (2.00%) Neutropenia * 1/50 (2.00%) Cardiac failure * 1/50 (2.00%) Diarrhoea * 1/50 (2.00%) Gastritis * 1/50 (2.00%) Nausea * 1/50 (2.00%) Oesophagitis * 1/50 (2.00%) Pyrexia * 7/50 (14.00%) Mucosal inflammation * 1/50 (2.00%) Drug hypersensitivity * 1/50 (2.00%) ",
        "premise_nums": [
            "27/50 (54.00%)",
            "4/50 (8.00%)",
            "7/50 (14.00%)",
            "1/50 (2.00%)"
        ]
    },
    {
        "id": "58dec898-e0af-41c1-96f9-7163d3e3e855",
        "primaryId": "NCT02019277",
        "secondaryId": "NCT00863655",
        "label": "Entailment",
        "statement_text": "the primary trial and the secondary trial recorded three of the same types of adverse events",
        "statement_nums": [],
        "premise_text": "Cellulitis * 2/50 (4.00%)Adverse Events 1: Total: 158/482 (32.78%) Anaemia 7/482 (1.45%) Disseminated intravascular coagulation 1/482 (0.21%) Lymphadenopathy 0/482 (0.00%) Neutropenia 0/482 (0.00%) Thrombocytopenia 2/482 (0.41%) Anaemia 28/482 (1.66%) Disseminated intravascular coagulation 21/482 (0.21%) Febrile neutropenia 21/482 (0.21%) Lymphadenopathy 20/482 (0.00%) ",
        "premise_nums": [
            "20/482 (0.00%)",
            "21/482 (0.21%)",
            "158/482 (32.78%)",
            "28/482 (1.66%)",
            "2/482 (0.41%)",
            "2/50 (4.00%)Adverse",
            "7/482 (1.45%)"
        ]
    },
    {
        "id": "58dec898-e0af-41c1-96f9-7163d3e3e855",
        "primaryId": "NCT02019277",
        "secondaryId": "NCT00863655",
        "label": "Entailment",
        "statement_text": "the primary trial and the secondary trial recorded three of the same types of adverse events",
        "statement_nums": [],
        "premise_text": "Neutropenia 20/482 (0.00%)",
        "premise_nums": [
            "20/482 (0.00%)"
        ]
    },
    {
        "id": "5cf74526-9f91-498d-a13a-6393dcd45b7b",
        "primaryId": "NCT02291913",
        "statement_text": "One patient in the primary trial suffered from an inflammation of the liver ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 15/48 (31.25%) Anemia * 1/48 (2.08%) Cardiac failure congestive * 1/48 (2.08%) Constipation * 2/48 (4.17%) Esophagitis * 1/48 (2.08%) Gastrointestinal hemorrhage * 1/48 (2.08%) Non-Cardiac chest pain * 1/48 (2.08%) Pain * 1/48 (2.08%) Cholecystitis * 1/48 (2.08%) Diverticulitis * 1/48 (2.08%) Cellulitis * 1/48 (2.08%) Gastroenteritis * 1/48 (2.08%) ",
        "premise_nums": [
            "2/48 (4.17%)",
            "15/48 (31.25%)",
            "1/48 (2.08%)"
        ]
    },
    {
        "id": "154caa20-3be1-4cee-a838-2d90b44566c4",
        "primaryId": "NCT00191269",
        "statement_text": "the primary trial did not use PFS to evaluate the performance of its interventions ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Tumor Response Best response recorded from the start of treatment until disease progression/recurrence using Response Evaluation Criteria In Solid Tumors (RECIST) criteria that defines when participants improve (\"respond\")  stay the same (\"stable\")  or worsen (\"progression\") during treatment  Time frame: baseline to measured progressive disease ",
        "premise_nums": []
    },
    {
        "id": "c40d8532-4e66-4eef-9644-91f20a02066d",
        "primaryId": "NCT02001974",
        "statement_text": "No cases of Oesophageal adenocarcinoma were recorded in the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 2/4 (50.00%) Abdominal pain 0/4 (0.00%) Disease progression 0/4 (0.00%) Dehydration 2/4 (50.00%) Hyponatraemia 1/4 (25.00%) Metastasis to central nervous system 1/4 (25.00%) Oesophageal adenocarcinoma 0/4 (0.00%) Intracranial hypotension 0/4 (0.00%) Pneumothorax 0/4 (0.00%) Dyspnoea 0/4 (0.00%) Hypoxia 0/4 (0.00%) Adverse Events 2: Total: 1/3 (33.33%) ",
        "premise_nums": [
            "0/4 (0.00%)",
            "2/4 (50.00%)",
            "1/4 (25.00%)",
            "1/3 (33.33%)"
        ]
    },
    {
        "id": "c40d8532-4e66-4eef-9644-91f20a02066d",
        "primaryId": "NCT02001974",
        "statement_text": "No cases of Oesophageal adenocarcinoma were recorded in the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Abdominal pain 0/3 (0.00%)Disease progression 0/3 (0.00%) Dehydration 0/3 (0.00%) Hyponatraemia 0/3 (0.00%) Metastasis to central nervous system 0/3 (0.00%) Oesophageal adenocarcinoma 0/3 (0.00%) Intracranial hypotension 0/3 (0.00%) Pneumothorax 1/3 (33.33%) Dyspnoea 0/3 (0.00%) Hypoxia 0/3 (0.00%) ",
        "premise_nums": [
            "0/3 (0.00%)Disease",
            "1/3 (33.33%)"
        ]
    },
    {
        "id": "3d450be5-4587-48e5-ae2e-745623606631",
        "primaryId": "NCT01289353",
        "secondaryId": "NCT00429182",
        "label": "Contradiction",
        "statement_text": "the primary trial and the secondary trial both administer bi-weekly oral Carboplatin to their test groups ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Carboplatin: IV  weekly for 6 weeks  AUC of 2.0 INTERVENTION 1: Carboplatin + Cyclophosphamide + Thiotepa Carboplatin : Target AUC of 20, then divided into 4 doses given by vein (IV) days -6, -5, -4, -3 prior to stem cell infusion  ",
        "premise_nums": [
            "3 prior to",
            "of 2.0 INTERVENTION 1",
            "4 doses given",
            "0 INTERVENTION 1:"
        ]
    },
    {
        "id": "fa28753a-aa3b-4642-9fd4-a2414fd8a472",
        "primaryId": "NCT00943670",
        "statement_text": "The Change From Baseline in Mean Duration of the QTcF Interval for patients in the primary trial was at its highest on Day 1 of the third cycle  post T-DM1 intravenous (IV) infusion ",
        "statement_nums": [
            "1 of the",
            "1 intravenous (IV)"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Change From Baseline in Mean Duration of the QTc Interval The QT interval is a measure of time between the start of the Q wave and the end of the T wave in the heart's electrical cycle  The corrected QT interval was calculated using Fridericia's correction (QTcF) from electrocardiogram (ECG) data  Each participant had triplicate QTcF intervals measured at each timepoint and the average was calculated for each patient at each timepoint  For each timepoint  a participant's corresponding baseline QTcF interval was subtracted from the average QTcF intervals to create a baseline-adjusted average QTcF interval  ",
        "premise_nums": []
    },
    {
        "id": "fa28753a-aa3b-4642-9fd4-a2414fd8a472",
        "primaryId": "NCT00943670",
        "statement_text": "The Change From Baseline in Mean Duration of the QTcF Interval for patients in the primary trial was at its highest on Day 1 of the third cycle  post T-DM1 intravenous (IV) infusion ",
        "statement_nums": [
            "1 of the",
            "1 intravenous (IV)"
        ],
        "label": "Entailment",
        "premise_text": "Time frame: Cycle 1 Day 1, pre-dose (Baseline); Cycle 1 Day 1, 15 and 60 minutes post-dose; Cycle 1 Day 8; and Cycle 3 Day 1, 15 minutes pre-dose and 15 and 60 minutes post-dose Results 1: Arm/Group Title: T-DM1 Arm/Group Description: Trastuzumab emtansine (T-DM1) was administered to participants by intravenous (IV) infusion on Day 1 of every 3 week cycle at a dose of 3.6 mg/kg  Overall Number of Participants Analyzed: 51 Mean (Standard Deviation) ",
        "premise_nums": [
            "1 Day 8;",
            "3 Day 1,",
            "51 Mean (Standard",
            "3 week cycle",
            "1 of every",
            "of 3.6 mg/kg",
            "15 and 60",
            "15 minutes pre",
            "1 Day 1,"
        ]
    },
    {
        "id": "fa28753a-aa3b-4642-9fd4-a2414fd8a472",
        "primaryId": "NCT00943670",
        "statement_text": "The Change From Baseline in Mean Duration of the QTcF Interval for patients in the primary trial was at its highest on Day 1 of the third cycle  post T-DM1 intravenous (IV) infusion ",
        "statement_nums": [
            "1 of the",
            "1 intravenous (IV)"
        ],
        "label": "Entailment",
        "premise_text": "Unit of Measure: milliseconds Cycle 1, Day 1, 15 minutes post-dose [N=44]: 1.2 (8.3)Cycle 1, Day 1, 60 minutes post-dose [N=45]: -1.0 (6.3) Cycle 1, Day 8 [N=43]: -4.0 (13.4) Cycle 3, Day 1, 15 minutes pre-dose [N=35]: -0.1 (10.1) Cycle 3, Day 1, 15 minutes post-dose [N=37]: 4.7 (9.6) ",
        "premise_nums": [
            "15 minutes post",
            "60 minutes post",
            "15 minutes pre"
        ]
    },
    {
        "id": "fa28753a-aa3b-4642-9fd4-a2414fd8a472",
        "primaryId": "NCT00943670",
        "statement_text": "The Change From Baseline in Mean Duration of the QTcF Interval for patients in the primary trial was at its highest on Day 1 of the third cycle  post T-DM1 intravenous (IV) infusion ",
        "statement_nums": [
            "1 of the",
            "1 intravenous (IV)"
        ],
        "label": "Entailment",
        "premise_text": "Cycle 3, Day 1, 60 minutes post-dose [N=37]: 4.7 (10.9)",
        "premise_nums": [
            "60 minutes post"
        ]
    },
    {
        "id": "5e700303-cd26-4024-a260-62f6a1c297ed",
        "primaryId": "NCT01000662",
        "secondaryId": "NCT02413008",
        "label": "Contradiction",
        "statement_text": "the secondary trial is testing a Gel which is applied to the breast  whereas the primary trial is testing an intervention which requires daily radiation of the breast ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: ARM 1 Daily Boost Radiation Therapy Radiation Therapy: Arm 1= 15 daily radiation fractions of 2.7 Gy  Monday to Friday for 3 weeks  to the whole breast with a daily concomitant boost of 0.5 Gy to the tumor bed  for a total daily dose of 3.2 Gy to the tumor bed (2.7Gy+0.5 Gy)  The overall dose will be 40.5 Gy to the breast and 48.0 Gy to the tumor bed  ",
        "premise_nums": [
            "of 3.2 Gy to",
            "and 48.0 Gy to",
            "of 0.5 Gy to",
            "be 40.5 Gy to",
            "15 daily radiation",
            "1 Daily Boost"
        ]
    },
    {
        "id": "5e700303-cd26-4024-a260-62f6a1c297ed",
        "primaryId": "NCT01000662",
        "secondaryId": "NCT02413008",
        "label": "Contradiction",
        "statement_text": "the secondary trial is testing a Gel which is applied to the breast  whereas the primary trial is testing an intervention which requires daily radiation of the breast ",
        "statement_nums": [],
        "premise_text": "Arm 2= 15 daily radiation fractions of 2.7 Gy Monday to friday for three weeks to the entire breast with a Friday boost of 2.0 Gy to the tumor bed  for a total dose to the tumor bed on each friday of 4.7 Gy (2.7 Gy+ 2.0 Gy)  The overall dose will be 40.5 Gy to the breast and 46.5 gy to the tumor bed INTERVENTION 1: 0.005% Estriol Vaginal Gel Route: Vaginal  Administration by an applicator inserted deep inside the vagina Dose: 1 g of gel  containing 50 Mcg of estriol Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: twice weekly administration ",
        "premise_nums": [
            "1-3: single",
            "7 Gy (2.7",
            "of 2.7 Gy Monday",
            "0.005% Estriol",
            "15 daily radiation",
            "4-12: twice",
            "1 g of",
            "be 40.5 Gy to",
            "50 Mcg of",
            "and 46.5 gy to",
            "of 2.0 Gy to"
        ]
    },
    {
        "id": "4c4c191c-de68-44c8-a23c-2455acc43d46",
        "primaryId": "NCT00371345",
        "secondaryId": "NCT00475670",
        "label": "Entailment",
        "statement_text": "There is no overlap between adverse events obeserved in the primary trial and the secondary trial ",
        "statement_nums": [],
        "premise_text": "Adverse Events 1: Total: 20/70 (28.57%) NAUSEA 2/70 (2.86%) VOMITING 1/70 (1.43%) DIARRHOEA 2/70 (2.86%) ABDOMINAL PAIN 1/70 (1.43%) ABDOMINAL PAIN LOWER 1/70 (1.43%) FATIGUE 2/70 (2.86%) PYREXIA 1/70 (1.43%) OEDEMA PERIPHERAL 1/70 (1.43%) GENERAL PHYSICAL HEALTH DETERIORATION 3/70 (4.29%) PNEUMONIA 1/70 (1.43%) SINUSITIS 1/70 (1.43%) LOBAR PNEUMONIA 1/70 (1.43%) Adverse Events 1: Total: 0/3 (0.00%) ",
        "premise_nums": [
            "1/70 (1.43%)",
            "2/70 (2.86%)",
            "20/70 (28.57%)",
            "3/70 (4.29%)",
            "0/3 (0.00%)"
        ]
    },
    {
        "id": "4c4c191c-de68-44c8-a23c-2455acc43d46",
        "primaryId": "NCT00371345",
        "secondaryId": "NCT00475670",
        "label": "Entailment",
        "statement_text": "There is no overlap between adverse events obeserved in the primary trial and the secondary trial ",
        "statement_nums": [],
        "premise_text": "Febrile Neutropenia * 0/3 (0.00%)Neutropenia * 0/3 (0.00%) Sudden Death * 0/3 (0.00%) Bacterial Infection * 0/3 (0.00%) Bronchitis * 0/3 (0.00%) Sepsis * 0/3 (0.00%) Lymphoedema * 0/3 (0.00%) ",
        "premise_nums": [
            "0/3 (0.00%)Neutropenia"
        ]
    },
    {
        "id": "e5a4cb11-2a00-4144-93ba-f5462d7efbf0",
        "primaryId": "NCT01818063",
        "secondaryId": "NCT00559507",
        "label": "Entailment",
        "statement_text": "In the primary trial and the secondary trial the only drugs administered orally are saracatinib and Veliparib ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Arm 1 (Paclitaxel  Carboplatin) Patients receive paclitaxel IV and carboplatin IV on day 1 (course 1 only) or day 2 (courses 2-12). Treatment repeats every 7 days for 12 courses in the absence of disease progression or unacceptable toxicity  Beginning 21 days after the last course  patients receive doxorubicin hydrochloride IV and cyclophosphamide IV on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity  Paclitaxel: Given IV Carboplatin: Given IV Doxorubicin: Given IV Cyclophosphamide: Given IV INTERVENTION 2: ",
        "premise_nums": [
            "21 days for",
            "21 days after",
            "7 days for",
            "12 courses in",
            "4 courses in",
            "2-12). Treatment"
        ]
    },
    {
        "id": "e5a4cb11-2a00-4144-93ba-f5462d7efbf0",
        "primaryId": "NCT01818063",
        "secondaryId": "NCT00559507",
        "label": "Entailment",
        "statement_text": "In the primary trial and the secondary trial the only drugs administered orally are saracatinib and Veliparib ",
        "statement_nums": [],
        "premise_text": "Arm 2 (Veliparib  Paclitaxel  Carboplatin)Patients receive veliparib PO BID on days 1-5. Patients also receive paclitaxel IV and carboplatin IV on day 3 (course 1 only) or day 4 (courses 2-12). Treatment repeats every 7 days for 12 courses in the absence of disease progression or unacceptable toxicity  Beginning 21 days after the last course  patients receive doxorubicin hydrochloride IV and cyclophosphamide IV on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity  Paclitaxel: Given IV Carboplatin: Given IV Doxorubicin: Given IV ",
        "premise_nums": [
            "21 days for",
            "21 days after",
            "7 days for",
            "12 courses in",
            "4 courses in",
            "1-5. Patients",
            "2-12). Treatment"
        ]
    },
    {
        "id": "e5a4cb11-2a00-4144-93ba-f5462d7efbf0",
        "primaryId": "NCT01818063",
        "secondaryId": "NCT00559507",
        "label": "Entailment",
        "statement_text": "In the primary trial and the secondary trial the only drugs administered orally are saracatinib and Veliparib ",
        "statement_nums": [],
        "premise_text": "Cyclophosphamide: Given IVVeliparib: Given PO INTERVENTION 1: Treatment (Enzyme Inhibitor Therapy) Patients receive saracatinib PO on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity  ",
        "premise_nums": [
            "1-28. Treatment",
            "28 days in"
        ]
    },
    {
        "id": "03d72e5f-b921-4aeb-802c-4dc4ee1a7e4c",
        "primaryId": "NCT01720602",
        "secondaryId": "NCT00082810",
        "label": "Entailment",
        "statement_text": "the primary trial participants receive more anastrozole  letrozole and exemestane than patients in the secondary trial ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Treatment (Vorinostat  AI Therapy) Patients receive vorinostat PO 5 days a week for 3 weeks  Patients also receive AI therapy comprising either anastrozole PO daily  letrozole PO daily  or exemestane PO daily for 4 weeks  Courses repeat every 28 days in the absence of disease progression and unacceptable toxicity  vorinostat: Given PO anastrozole: Given PO letrozole: Given PO exemestane: Given PO positron emission tomography: Correlative studies F-18 16 alpha-fluoroestradiol: Correlative studies fludeoxyglucose F 18: Correlative studies laboratory biomarker analysis: Correlative studies INTERVENTION 1: ",
        "premise_nums": [
            "16 alpha-fluoroestradiol:",
            "28 days in",
            "5 days a"
        ]
    },
    {
        "id": "03d72e5f-b921-4aeb-802c-4dc4ee1a7e4c",
        "primaryId": "NCT01720602",
        "secondaryId": "NCT00082810",
        "label": "Entailment",
        "statement_text": "the primary trial participants receive more anastrozole  letrozole and exemestane than patients in the secondary trial ",
        "statement_nums": [],
        "premise_text": "Fulvestrant 250 mg + Tipifarnib 300 mgPatients receive fulvestrant 250 mg intramuscularly on day 1 and oral tipifarnib 300 mg twice daily on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity ",
        "premise_nums": [
            "250 mg intramuscularly",
            "28 days in",
            "1-21. Courses",
            "300 mgPatients receive",
            "1 and oral",
            "300 mg twice"
        ]
    },
    {
        "id": "27a4d1a8-185b-4483-85ce-0fbb3d323b99",
        "primaryId": "NCT01945775",
        "statement_text": "The shortest PFS in the Talazoparib group of the primary trial was over a month longer than the study duration ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Progression-Free Survival (PFS): Independent Radiological Facility (IRF) Assessment ",
        "premise_nums": []
    },
    {
        "id": "ff797dd4-0b4d-42fc-808d-27c439563ce2",
        "primaryId": "NCT01743560",
        "statement_text": "By week 48 of the primary trial none of the patients had Complete Response  7 had partial response and 15 had progressive disease ",
        "statement_nums": [
            "48 of the",
            "7 had partial",
            "15 had progressive"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Best Overall Response of Everolimus and Exemestane Treatment in Postmenopausal Women With Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer ",
        "premise_nums": []
    },
    {
        "id": "ff797dd4-0b4d-42fc-808d-27c439563ce2",
        "primaryId": "NCT01743560",
        "statement_text": "By week 48 of the primary trial none of the patients had Complete Response  7 had partial response and 15 had progressive disease ",
        "statement_nums": [
            "48 of the",
            "7 had partial",
            "15 had progressive"
        ],
        "label": "Entailment",
        "premise_text": "The best Overall Response (OR) for each patient is determined from the sequence of investigator overall lesion responses according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1.). To be assigned a best OR of Complete Responese (CR) at least two determinations of CR at least 4 weeks apart before progression are required  To be assigned a best OR of Partial Response (PR) at least two determinations of PR or better at least 4 weeks apart before progression (and not qualifying for a CR) are required.The Overall Response Rate (ORR) was defined as the proportion of patients with a best OR of confirmed CR or PR by week 48.Time frame: At 48 weeks Results 1: Arm/Group Title: Everolimus and Exemestane ",
        "premise_nums": [
            "4 weeks apart",
            "48 weeks Results"
        ]
    },
    {
        "id": "ff797dd4-0b4d-42fc-808d-27c439563ce2",
        "primaryId": "NCT01743560",
        "statement_text": "By week 48 of the primary trial none of the patients had Complete Response  7 had partial response and 15 had progressive disease ",
        "statement_nums": [
            "48 of the",
            "7 had partial",
            "15 had progressive"
        ],
        "label": "Entailment",
        "premise_text": "Arm/Group Description: Postmenopausal women diagnosed with oestrogen receptor positive locally advanced or metastatic breast cancer will receive everolimus at a dose of 10mg daily p.o  and exemestane 25mg daily p.o Overall Number of Participants Analyzed: 49 Measure Type: Number Unit of Measure: participants Patients with measurable disease at baseline: 39 Patients with non-measurable disease at baseline: 10 Best at WK 48 - Complete Response (CR): 0 Best at WK 48 - Partial Response (PR): 7 Best at WK 48 - Stable Disease (SD): 18 Best at WK 48 - Progressive Disease (PD): 15 Unknown: 1 Missing: 8 ",
        "premise_nums": [
            "39 Patients with",
            "18 Best at",
            "49 Measure Type:",
            "7 Best at",
            "10 Best at"
        ]
    },
    {
        "id": "9f666667-0fde-4d79-b53c-33c0ffbbed90",
        "primaryId": "NCT00494481",
        "statement_text": "Paula recently had fell down a flight of stairs and fractured her hip  she is excluded from the primary trial ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria: Females with histological/cytological confirmation of breast cancer  Subjects with a measurable lesion or bone lesions Exclusion Criteria: Previous radiotherapy within 6 weeks Significant cardiac events  arrhythmias or other cardiac conditions ",
        "premise_nums": [
            "6 weeks Significant"
        ]
    },
    {
        "id": "47084742-d031-4e59-865c-d8687282c782",
        "primaryId": "NCT00494481",
        "statement_text": "Paula recently had a heart attack  she is excluded from the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Exclusion Criteria: Previous radiotherapy within 6 weeks Significant cardiac events  arrhythmias or other cardiac conditions ",
        "premise_nums": [
            "6 weeks Significant"
        ]
    },
    {
        "id": "ae583ea3-36a5-472c-acda-825cd7d513b6",
        "primaryId": "NCT00454805",
        "statement_text": "In the primary trial there were no cases of subendocardial myocardial infarction in cohort 1 or 2.",
        "statement_nums": [
            "1 or 2"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 15/31 (48.39%) Intracardiac Thrombus 1/31 (3.23%) Diarrhoea 2/31 (6.45%) Nausea 2/31 (6.45%) Vomiting 2/31 (6.45%) Ascites 0/31 (0.00%) Ileus 1/31 (3.23%) Small Intestinal Obstruction 1/31 (3.23%) Multi-Organ Failure 0/31 (0.00%) Sepsis 1/31 (3.23%) Weight Decreased 1/31 (3.23%) Dehydration 2/31 (6.45%) ",
        "premise_nums": [
            "15/31 (48.39%)",
            "2/31 (6.45%)",
            "0/31 (0.00%)",
            "1/31 (3.23%)"
        ]
    },
    {
        "id": "ae583ea3-36a5-472c-acda-825cd7d513b6",
        "primaryId": "NCT00454805",
        "statement_text": "In the primary trial there were no cases of subendocardial myocardial infarction in cohort 1 or 2.",
        "statement_nums": [
            "1 or 2"
        ],
        "label": "Entailment",
        "premise_text": "Hypokalaemia 0/31 (0.00%)Adverse Events 2: Total: 4/31 (12.90%) Intracardiac Thrombus 0/31 (0.00%) Diarrhoea 0/31 (0.00%) Nausea 0/31 (0.00%) Vomiting 0/31 (0.00%) Ascites 1/31 (3.23%) Ileus 0/31 (0.00%) Small Intestinal Obstruction 0/31 (0.00%) Multi-Organ Failure 1/31 (3.23%) Sepsis 0/31 (0.00%) Weight Decreased 0/31 (0.00%) ",
        "premise_nums": [
            "1/31 (3.23%)",
            "0/31 (0.00%)Adverse",
            "4/31 (12.90%)"
        ]
    },
    {
        "id": "ae583ea3-36a5-472c-acda-825cd7d513b6",
        "primaryId": "NCT00454805",
        "statement_text": "In the primary trial there were no cases of subendocardial myocardial infarction in cohort 1 or 2.",
        "statement_nums": [
            "1 or 2"
        ],
        "label": "Entailment",
        "premise_text": "Dehydration 0/31 (0.00%)Hypokalaemia 1/31 (3.23%) ",
        "premise_nums": [
            "0/31 (0.00%)Hypokalaemia",
            "1/31 (3.23%)"
        ]
    },
    {
        "id": "a18c447b-de08-48ef-8e65-0ecaa775c2b0",
        "primaryId": "NCT00206427",
        "statement_text": "A patient in the primary trial had a vaginal fungal infection ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 3/49 (6.12%) Neutrophils/ANC *1/49 (2.04%) Leukocytes *1/49 (2.04%) Hypocalcemia *1/49 (2.04%) Febrile neutropenia *1/49 (2.04%) Left Ventricular Systolic Dysfunction *1/49 (2.04%) Constipation *1/49 (2.04%) Mucositis-oral *1/49 (2.04%) Infection-oral thrush *1/49 (2.04%) rash *1/49 (2.04%) ",
        "premise_nums": [
            "1/49 (2.04%)",
            "3/49 (6.12%)"
        ]
    },
    {
        "id": "18b900fb-b071-43df-b37d-c68a89ef78c0",
        "primaryId": "NCT00050167",
        "statement_text": "Patients with metastasis in four or more axillary lymph nodes are eligible for the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Inclusion Criteria: Patients with pN2a (metastasis in four to nine axillary lymph nodes) are eligible as are patients with pN3a (ten or more axillary lymph nodes)  Patients with infraclavicular lymph node involvement are NOT eligible  ",
        "premise_nums": []
    },
    {
        "id": "ebdf2841-b5e0-431a-8dc7-e100c5d27ccf",
        "primaryId": "NCT00932373",
        "statement_text": "Patients with Grade III peripheral neuropathy or above are eliminated from participation in the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Exclusion Criteria: Grade 2 peripheral neuropathy ",
        "premise_nums": [
            "2 peripheral neuropathy"
        ]
    },
    {
        "id": "d56745c3-ba0b-4b42-b3cf-ac060f658d83",
        "primaryId": "NCT00670982",
        "statement_text": "Acute coronary syndrome was the most prevalent adverse event in the primary trial  other than Thrombocytopenia  ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 9/29 (31.03%) Neutropenia 5/29 (17.24%) Cataracts 1/29 (3.45%) Abdominal Pain 1/29 (3.45%) Perforated Appendix 1/29 (3.45%) Surgical Intervention 1/29 (3.45%) Deep Vein Thrombosis 1/29 (3.45%) Cerebrovascular Ischemia 1/29 (3.45%) ",
        "premise_nums": [
            "1/29 (3.45%)",
            "9/29 (31.03%)",
            "5/29 (17.24%)"
        ]
    },
    {
        "id": "0ef77b5d-684a-4a87-bf61-8d4bc9975b7f",
        "primaryId": "NCT01446159",
        "statement_text": "the primary trial only had a total of 6 patients in across both its cohorts ",
        "statement_nums": [
            "6 patients in"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 2/3 (66.67%) Adverse Events 2: Total: 0/3 (0.00%) ",
        "premise_nums": [
            "0/3 (0.00%)",
            "2/3 (66.67%)"
        ]
    },
    {
        "id": "03c7f31f-788c-4edb-a885-b6cb0fca05da",
        "primaryId": "NCT00375505",
        "statement_text": "In the primary trial patients in control group had a Z-score of 0.037, higher than the test group score ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Change in Bone Mineral Density (BMD) Measured by Dual (Energy) X-ray Absorptiometry (DXA) at Lumbar Spine (L2-L4) From Baseline to Month 24 Bone mineral density (BMD) by DXA at lumbar spine (L2-L4); DXA assessments of the BMD at dual hips  (BMD)  Two X-ray beams with different energy levels are aimed at the patient's bones  When soft tissue absorption is subtracted out  the BMD can be determined from the absorption of each beam by bone  Time frame: baseline  month 24 Results 1: Arm/Group Title: Placebo ",
        "premise_nums": [
            "24 Bone mineral",
            "2-L4) From",
            "24 Results 1:",
            "2-L4); DXA"
        ]
    },
    {
        "id": "03c7f31f-788c-4edb-a885-b6cb0fca05da",
        "primaryId": "NCT00375505",
        "statement_text": "In the primary trial patients in control group had a Z-score of 0.037, higher than the test group score ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Arm/Group Description: Placebo as a 15-minute infusion every 3 months for a treatment period of 24 months (total of 8 infusions) Overall Number of Participants Analyzed: 36 Mean (Standard Deviation) Unit of Measure: Z-score -0.075 (0.041) Results 2: Arm/Group Title: Zometa Arm/Group Description: Zoledronic Acid 4mg as a 15-minute infusion every 3 months for a treatment period of 24 months (total of 8 infusions)  Overall Number of Participants Analyzed: 34 Mean (Standard Deviation) Unit of Measure: Z-score 0.037 (0.042) ",
        "premise_nums": [
            "24 months (total",
            "15-minute infusion",
            "36 Mean (Standard",
            "3 months for",
            "34 Mean (Standard"
        ]
    },
    {
        "id": "e43c01e9-20a2-4435-a32b-224d5f460d7c",
        "primaryId": "NCT01997333",
        "statement_text": "The minimum Progression Free Survival for patients in cohort 1 the primary trial was 1.6 months ",
        "statement_nums": [
            "1 the primary"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Progression Free Survival (PFS) PFS is defined as the time from randomization to the earlier of disease progression or death due to any cause  Disease progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions  or progression in a non-target lesion  or the appearance of new lesions  The primary analysis of PFS was based on PFS events determined retrospectively by the central independent review committee  blinded to treatment assignment and investigator assessments according to RECIST 1.1 criteria  Time frame: Evaluated every 6 - 9 weeks following treatment initiation Results 1: Arm/Group Title: Capecitabine ",
        "premise_nums": [
            "9 weeks following",
            "20% increase"
        ]
    },
    {
        "id": "e43c01e9-20a2-4435-a32b-224d5f460d7c",
        "primaryId": "NCT01997333",
        "statement_text": "The minimum Progression Free Survival for patients in cohort 1 the primary trial was 1.6 months ",
        "statement_nums": [
            "1 the primary"
        ],
        "label": "Entailment",
        "premise_text": "Arm/Group Description: Capecitabine administered on Days 1 through 14 of each 21 day cycle until disease progression  discontinuation due to toxicity  withdrawal of consent  or end of study Overall Number of Participants Analyzed: 109 Median (95% Confidence Interval) Unit of Measure: months 2.8 (1.6 to 3.2) ",
        "premise_nums": [
            "6 to 3.2)",
            "1 through 14",
            "95% Confidence",
            "21 day cycle"
        ]
    },
    {
        "id": "c55f34ab-b883-465e-89dc-75bbeb8afa77",
        "primaryId": "NCT00369655",
        "secondaryId": "NCT00091832",
        "label": "Entailment",
        "statement_text": "One patient in the primary trial had a Confirmed tumor partial response  No patients in the secondary trial were evaluated for tumor response ",
        "statement_nums": [],
        "premise_text": "Outcome Measurement: Proportion of Patients With Confirmed Tumor Response Confirmed tumor response was defined as the total number of efficacy-evaluable patients who achieved a complete or partial response according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria on 2 consecutive evaluations at least 8 weeks apart  Time frame: Up to 5 years Results 1: Arm/Group Title: Treatment (Ziv-afibercept) Arm/Group Description: Patients receive VEGF Trap IV over 1 hour on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity  Overall Number of Participants Analyzed: 21 Measure Type: Number Unit of Measure: Participants Confirmed tumor partial response: 1 No Confirmed reponse: 20 Outcome Measurement: ",
        "premise_nums": [
            "14 days in",
            "1 No Confirmed",
            "20 Outcome Measurement:",
            "2 consecutive evaluations",
            "1 hour on",
            "5 years Results",
            "8 weeks apart",
            "21 Measure Type:"
        ]
    },
    {
        "id": "c55f34ab-b883-465e-89dc-75bbeb8afa77",
        "primaryId": "NCT00369655",
        "secondaryId": "NCT00091832",
        "label": "Entailment",
        "statement_text": "One patient in the primary trial had a Confirmed tumor partial response  No patients in the secondary trial were evaluated for tumor response ",
        "statement_nums": [],
        "premise_text": "Percent Change From Baseline to Week 13 in Creatinine-adjusted Urinary N-telopeptide (uNTx/Cr)Percent change from Baseline to Week 13 in Urinary N-telopeptide corrected by creatinine (uNTx/Cr) calculated using ((Week 13 value - Baseline value) / Baseline value ) x 100. Time frame: Baseline and Week 13 ",
        "premise_nums": [
            "13 in Creatinine",
            "13 in Urinary"
        ]
    },
    {
        "id": "0ee36ceb-5790-440e-b6ad-10a0b7a23f43",
        "primaryId": "NCT01925170",
        "secondaryId": "NCT00324259",
        "label": "Entailment",
        "statement_text": "Participant in cohort 1 of the primary trial undergo a Mammography  whereas patients in cohort 1 of the secondary trial receive 6 mg Estradiol  and no Mammography ",
        "statement_nums": [
            "6 mg Estradiol",
            "1 of the"
        ],
        "premise_text": "INTERVENTION 1: Mammography Only For this reporting arm  the interpretation and analysis was done with mammography only  INTERVENTION 1: Arm 1 (6 mg Estradiol) 6 mg of estradiol daily (2 mg tid)  ",
        "premise_nums": [
            "2 mg tid)",
            "6 mg Estradiol)",
            "6 mg of"
        ]
    },
    {
        "id": "2535da13-e0f7-44df-aa02-89765d8d51cb",
        "primaryId": "NCT02419807",
        "secondaryId": "NCT00777101",
        "label": "Contradiction",
        "statement_text": "Patients with HER2 + breast cancer stage 1-4 are eligible for both the primary trial and the secondary trial ",
        "statement_nums": [
            "1-4 are",
            "4 are eligible"
        ],
        "premise_text": "Inclusion Criteria: Participants with a confirmed diagnosis of clinical stage 1 or 2 breast cancer Inclusion Criteria: Stage IIIB  IIIC  or IV erbB2 (HER2) positive breast cancer ",
        "premise_nums": [
            "1 or 2",
            "(HER2) positive"
        ]
    },
    {
        "id": "94fc6e05-8a73-43d9-a48c-531d36dfbbcd",
        "primaryId": "NCT00548184",
        "statement_text": "The majority of breast cancer patients in the primary trial treated with Lapatinib + Trastuzumab experienced at least Near Complete Pathologic Response  or better  after 12 weeks ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Pathologic Assessment After Study Treatment Pathologic Assessment After 12 weeks of lapatinib and trastuzumab with or without endocrine therapy  Pathologic complete response: no invasive cancer in the residual breast  Near pathologic complete response: residual disease of less than 1 cm in breast  Time frame: 12 weeks Results 1: Arm/Group Title: Lapatinib + Trastuzumab Arm/Group Description: All study participants received lapatinib 1000mg daily and trauzumab 4mg/kg loading dose and then 2mg/kg every week Overall Number of Participants Analyzed: 64 Measure Type: Number Unit of Measure: participants Complete Pathologic Response: 18 Near Complete Pathologic Response: 16 ",
        "premise_nums": [
            "12 weeks Results",
            "12 weeks of",
            "2mg/kg every",
            "4mg/kg loading",
            "64 Measure Type:",
            "1 cm in",
            "18 Near Complete"
        ]
    },
    {
        "id": "94fc6e05-8a73-43d9-a48c-531d36dfbbcd",
        "primaryId": "NCT00548184",
        "statement_text": "The majority of breast cancer patients in the primary trial treated with Lapatinib + Trastuzumab experienced at least Near Complete Pathologic Response  or better  after 12 weeks ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Not Pathologic response: 30",
        "premise_nums": []
    },
    {
        "id": "0057172f-d019-401b-a516-993a7b46a67b",
        "primaryId": "NCT01306942",
        "statement_text": "Participants of cohort 1 in the primary trial received more Dasatinib than those in cohort 2.",
        "statement_nums": [
            "1 in the"
        ],
        "label": "Entailment",
        "premise_text": "INTERVENTION 1: Phase I: Dasatinib 100mg/Trastuzumab 2mg/kg/Paclitaxel 80mg/m2 Cohort 1: Eligible patients were enrolled and treated with 4-week cycles of trastuzumab 2 mg/kg IV weekly (following a loading dose of 4 mg/kg in cycle 1) and paclitaxel 80 mg/m2 weekly x 3 weeks followed by a rest period of 7 days  Dasatinib 100mg was administered orally once daily (QD)  Treatment was repeated on Day 1 of a 28-day cycle until radiographic or symptomatic progression or unacceptable toxicity occured  Only in the phase I  the first cycle lasted 38 days  INTERVENTION 2: ",
        "premise_nums": [
            "1 of a",
            "2mg/kg/Paclitaxel",
            "2 Cohort 1:",
            "3 weeks followed",
            "2 weekly x",
            "4-week cycles",
            "2 mg/kg IV",
            "80 mg/m2 weekly",
            "4 mg/kg in",
            "28-day cycle",
            "100mg/Trastuzumab",
            "80mg/m2 Cohort"
        ]
    },
    {
        "id": "0057172f-d019-401b-a516-993a7b46a67b",
        "primaryId": "NCT01306942",
        "statement_text": "Participants of cohort 1 in the primary trial received more Dasatinib than those in cohort 2.",
        "statement_nums": [
            "1 in the"
        ],
        "label": "Entailment",
        "premise_text": "Phase I: Dasatinib 140mg/Trastuzumab 2mg/kg/Paclitaxel 80mg/m2Cohort 2: Eligible patients were enrolled and treated with 4-week cycles of trastuzumab 2 mg/kg IV weekly (following a loading dose of 4 mg/kg in cycle 1) and paclitaxel 80 mg/m2 weekly x 3 weeks followed by a rest period of 7 days  Dasatinib 140mg was administered orally once daily (QD)  Treatment was repeated on Day 1 of a 28-day cycle until radiographic or symptomatic progression or unacceptable toxicity occured  Only in the phase I  the first cycle lasted 38 days  ",
        "premise_nums": [
            "1 of a",
            "2mg/kg/Paclitaxel",
            "80mg/m2Cohort",
            "3 weeks followed",
            "2 weekly x",
            "4-week cycles",
            "2 mg/kg IV",
            "80 mg/m2 weekly",
            "4 mg/kg in",
            "140mg/Trastuzumab",
            "28-day cycle"
        ]
    },
    {
        "id": "bb23e8b8-c7d6-4e58-80a2-0555db5645e9",
        "primaryId": "NCT03096847",
        "secondaryId": "NCT01840163",
        "label": "Entailment",
        "statement_text": "Female Patients recently prescribed Rapamycin are not eligible for the primary trial  but may be eligible for the secondary trial as long as they have a stage 1 to 2 Ductal carcinoma in situ and can speak english ",
        "statement_nums": [
            "1 to 2"
        ],
        "premise_text": "Exclusion Criteria Patient who received any CDK4/6 inhibitor or any mTOR inhibitor  Inclusion Criteria: Stage 1-2 invasive breast cancer diagnosis  DCIS Ability to read English Exclusion Criteria: Male ",
        "premise_nums": [
            "CDK4/6 inhibitor",
            "6 inhibitor or",
            "2 invasive breast",
            "1-2 invasive"
        ]
    },
    {
        "id": "c4588d2c-b0d4-428d-a958-29787b9d4ec5",
        "primaryId": "NCT00545077",
        "statement_text": "Only cohort 2 of the primary trial receive Bevacizumab  but both cohorts undergo Endocrine Therapy  ",
        "statement_nums": [
            "2 of the"
        ],
        "label": "Entailment",
        "premise_text": "INTERVENTION 1: Arm A: Endocrine Therapy (ET) Endocrine treatment consisting of either letrozole or fulvestrant  Patients will be randomized to receive bevacizumab 15mg/kg every 3 weeks plus endocrine treatment or endocrine treatment as a single agent  The patients will receive the assigned treatment until the progression of the disease  unacceptable toxicity or withdrawal of the consent  Letrozole Fulvestrant INTERVENTION 2: Arm B: ET With Bevacizumab (ET-B) ",
        "premise_nums": [
            "3 weeks plus",
            "15mg/kg every"
        ]
    },
    {
        "id": "c4588d2c-b0d4-428d-a958-29787b9d4ec5",
        "primaryId": "NCT00545077",
        "statement_text": "Only cohort 2 of the primary trial receive Bevacizumab  but both cohorts undergo Endocrine Therapy  ",
        "statement_nums": [
            "2 of the"
        ],
        "label": "Entailment",
        "premise_text": "Endocrine treatment consisting of either letrozole or fulvestrant  Patients will be randomized to receive bevacizumab 15mg/kg i.v  on day 1 every 3 weeks plus endocrine treatment or endocrine treatment as a single agent  The patients will receive the assigned treatment until the progression of the disease  unacceptable toxicity or withdrawal of the consent Letrozole Bevacizumab Fulvestrant ",
        "premise_nums": [
            "15mg/kg i",
            "1 every 3"
        ]
    },
    {
        "id": "ee1f81d1-7e99-44dc-bb6a-ed002a78c9f6",
        "primaryId": "NCT00364611",
        "statement_text": "Patients with clinically significant grade 3 PVD are eligible for the primary trial ",
        "statement_nums": [
            "3 PVD are"
        ],
        "label": "Contradiction",
        "premise_text": "Presence of any non-healing wound  fracture  or ulcer  or the presence of clinically significant (greater than /= Grade 2) peripheral vascular disease ",
        "premise_nums": []
    },
    {
        "id": "00466f98-52b8-41f3-9bf1-2edaad950be9",
        "primaryId": "NCT02504424",
        "secondaryId": "NCT03708393",
        "label": "Contradiction",
        "statement_text": "the primary trial and the secondary trial both require the patients to activate the interventions by remote control ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: AeroForm Tissue Expander AeroForm Tissue Expansion inflation with carbon dioxide by remote control AeroForm Tissue Expander: The AeroForm Tissue Expander is a breast tissue expander implanted following mastectomy and activated by remote control to release small doses of carbon dioxide from an internal reservoir to fill and inflate the expander  INTERVENTION 1: IUS Alone IUS alone imaging INTERVENTION 2: Imagio (IUS+OA) IUS+OA imaging ",
        "premise_nums": []
    },
    {
        "id": "50a524ae-2135-45f7-ae9b-515fd4e2e404",
        "primaryId": "NCT02445586",
        "secondaryId": "NCT02115984",
        "label": "Contradiction",
        "statement_text": "More than half of patients in the primary trial experienced adverse events  and 100% of patients in the secondary trial did not experience an adverse event ",
        "statement_nums": [
            "100% of"
        ],
        "premise_text": "Adverse Events 1: Total: 31/52 (59.62%) Febrile neutropenia 2/52 (3.85%) Left ventricular dysfunction 2/52 (3.85%) Sinus tachycardia 1/52 (1.92%) Congenital arterial malformation 1/52 (1.92%) Diarrhoea 5/52 (9.62%) Salivary hypersecretion 1/52 (1.92%) Enteritis 1/52 (1.92%) Abdominal pain 1/52 (1.92%) Vomiting 1/52 (1.92%) Stomatitis 1/52 (1.92%) ",
        "premise_nums": [
            "5/52 (9.62%)",
            "2/52 (3.85%)",
            "1/52 (1.92%)",
            "31/52 (59.62%)"
        ]
    },
    {
        "id": "50a524ae-2135-45f7-ae9b-515fd4e2e404",
        "primaryId": "NCT02445586",
        "secondaryId": "NCT02115984",
        "label": "Contradiction",
        "statement_text": "More than half of patients in the primary trial experienced adverse events  and 100% of patients in the secondary trial did not experience an adverse event ",
        "statement_nums": [
            "100% of"
        ],
        "premise_text": "Haematemesis 1/52 (1.92%)Adverse Events 1: Total: 57/57 (100.00%) Dry eyes 13/33 (39.39%) Heartburn 9/33 (27.27%) Nausea after the CT (before day 7) 57/57 (100.00%) Herpetic eruption 0/33 (0.00%) Dry skin 15/33 (45.45%) Alopecia 57/57 (100.00%) Adverse Events 2: Total: 23/23 (100.00%) Dry eyes 2/11 (18.18%) Heartburn 2/11 (18.18%) Nausea after the CT (before day 7) 23/23 (100.00%) ",
        "premise_nums": [
            "9/33 (27.27%)",
            "23/23 (100.00%)",
            "0/33 (0.00%)",
            "1/52 (1.92%)Adverse",
            "57/57 (100.00%)",
            "15/33 (45.45%)",
            "2/11 (18.18%)",
            "13/33 (39.39%)"
        ]
    },
    {
        "id": "50a524ae-2135-45f7-ae9b-515fd4e2e404",
        "primaryId": "NCT02445586",
        "secondaryId": "NCT02115984",
        "label": "Contradiction",
        "statement_text": "More than half of patients in the primary trial experienced adverse events  and 100% of patients in the secondary trial did not experience an adverse event ",
        "statement_nums": [
            "100% of"
        ],
        "premise_text": "Herpetic eruption 3/11 (27.27%)Dry skin 9/11 (81.82%) Alopecia 23/23 (100.00%) ",
        "premise_nums": [
            "23/23 (100.00%)",
            "9/11 (81.82%)",
            "3/11 (27.27%)Dry"
        ]
    },
    {
        "id": "b2062e01-0ea6-4ee8-94a1-b59dc40901d3",
        "primaryId": "NCT01688609",
        "statement_text": "Patients must have histologically or cytologically confirmed ERBB2+ invasive breast cancer  with Primary tumor greater than 2 cm in diameter to participate in the primary trial ",
        "statement_nums": [
            "2 cm in"
        ],
        "label": "Entailment",
        "premise_text": "Inclusion Criteria: Patients must have histologically or cytologically confirmed primary invasive breast cancer Primary tumor is larger than 2 cm in diameter (T2) as measured by caliper or ultrasound Overexpression and/or amplification of HER2 is confirmed by immunohistochemistry (IHC) 3+ or fluorescence in situ hybridization (FISH) + when IHC 2+ ",
        "premise_nums": [
            "2 is confirmed",
            "2 cm in",
            "(T2) as"
        ]
    },
    {
        "id": "4dbce51b-1cfc-4d5f-82bb-ce9319ace3af",
        "primaryId": "NCT00826267",
        "statement_text": "Cohort 1 and 2 of the primary trial receive different quantities of different drugs ",
        "statement_nums": [
            "1 and 2"
        ],
        "label": "Entailment",
        "premise_text": "INTERVENTION 1: Afatinib 50 mg Patients received continuous daily dosing with Afatinib 50 mg orally from Day 1 to Day 21 of each treatment course  2 treatment courses were to be given in the trial  INTERVENTION 2: Lapatinib 1500 mg Patients received continuous daily dosing with Lapatinib 1500 mg orally from Day 1 to Day 21 of each treatment course  2 treatment courses were to be given in the trial  ",
        "premise_nums": [
            "50 mg orally",
            "50 mg Patients",
            "21 of each",
            "2 treatment courses",
            "1500 mg Patients",
            "1 to Day",
            "1500 mg orally"
        ]
    },
    {
        "id": "43a9cc96-4020-459c-8fa4-4bbde7173f7a",
        "primaryId": "NCT02447328",
        "statement_text": "In the primary trial 11 patients had serious adverse events  no patients had serious Adverse Drug Reactions  and over half of patients passed away from Unexpected adverse events ",
        "statement_nums": [
            "11 patients had"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Safety(Percentage of Participants With Adverse Events and/or Adverse Drug Reactions) Percentage of patients with AEs  Time frame: Adverse events were collected from treatment initiation to end of the study about 6 months for each patient  Results 1: Arm/Group Title: Single Arm Arm/Group Description: fulvestrant (Faslodex ) Overall Number of Participants Analyzed: 81 Measure Type: Number Unit of Measure: Percentage of participants Adverse Events(AE): 81.5 (71.3 to 89.3) ADR; based on current South Korea label.: 38.3 (27.7 to 49.7) Serious AE: 11.1 (5.2 to 20.1) Serious ADR: 0 (0 to 4.4) ",
        "premise_nums": [
            "7 to 49.7)",
            "6 months for",
            "81 Measure Type:",
            "2 to 20.1)",
            "3 to 89.3)",
            "0 to 4.4)"
        ]
    },
    {
        "id": "43a9cc96-4020-459c-8fa4-4bbde7173f7a",
        "primaryId": "NCT02447328",
        "statement_text": "In the primary trial 11 patients had serious adverse events  no patients had serious Adverse Drug Reactions  and over half of patients passed away from Unexpected adverse events ",
        "statement_nums": [
            "11 patients had"
        ],
        "label": "Contradiction",
        "premise_text": "Unexpected AE: 71.6 (60.5 to 81.1)Unexpected ADR: 24.7 (15.8 to 35.5) ",
        "premise_nums": [
            "8 to 35.5)",
            "5 to 81.1)Unexpected"
        ]
    },
    {
        "id": "ff319fa6-89b6-4f1a-871d-456edb91b69b",
        "primaryId": "NCT03045653",
        "statement_text": "Sharone had a hip replacement 3 weeks prior  she is not elgible for the primary trial ",
        "statement_nums": [
            "3 weeks prior"
        ],
        "label": "Entailment",
        "premise_text": "Exclusion Criteria: Major surgery (excluding placement of vascular access) within 4 weeks before study treatment Evidence of severe or uncontrolled systemic diseases  including uncontrolled hypertension  active bleeding diatheses  or active infection including hepatitis B  hepatitis C and HIV With the exception of alopecia  any unresolved toxicities from previous therapy greater than CTCAE grade 1 before study treatment Elevated ALP in absence of bone metastasis Evidence of dementia  altered mental status or any psychiatric condition that would prohibit understanding or rendering of informed consent Participation in another study with investigational product during last 30 days Inability or unwillingness to comply with study procedures  including inability to take regular oral medication ",
        "premise_nums": [
            "1 before study",
            "30 days Inability",
            "4 weeks before"
        ]
    },
    {
        "id": "a321acf0-2296-4588-bf96-85b22bf1420f",
        "primaryId": "NCT00274456",
        "statement_text": "There are a total of 14 cases of neutropenia related adverse events in the primary trial across both cohorts ",
        "statement_nums": [
            "14 cases of"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 14/76 (18.42%) Neutropenia 10/76 (13.16%) Febrile neutropenia 1/76 (1.32%) Anaemia 0/76 (0.00%) Thrombocytopenia 0/76 (0.00%) Cardiopulmonary failure 0/76 (0.00%) Optic ischaemic neuropathy 0/76 (0.00%) Bowel peristalsis increased 1/76 (1.32%) Colitis 0/76 (0.00%) Diarrhoea 0/76 (0.00%) Gastritis 0/76 (0.00%) Nausea 0/76 (0.00%) ",
        "premise_nums": [
            "1/76 (1.32%)",
            "0/76 (0.00%)",
            "10/76 (13.16%)",
            "14/76 (18.42%)"
        ]
    },
    {
        "id": "a321acf0-2296-4588-bf96-85b22bf1420f",
        "primaryId": "NCT00274456",
        "statement_text": "There are a total of 14 cases of neutropenia related adverse events in the primary trial across both cohorts ",
        "statement_nums": [
            "14 cases of"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 2:Total: 12/76 (15.79%) Neutropenia 2/76 (2.63%) Febrile neutropenia 1/76 (1.32%) Anaemia 0/76 (0.00%) Thrombocytopenia 0/76 (0.00%) Cardiopulmonary failure 1/76 (1.32%) Optic ischaemic neuropathy 1/76 (1.32%) Bowel peristalsis increased 0/76 (0.00%) Colitis 1/76 (1.32%) Diarrhoea 0/76 (0.00%) Gastritis 0/76 (0.00%) Nausea 1/76 (1.32%) ",
        "premise_nums": [
            "12/76 (15.79%)",
            "1/76 (1.32%)",
            "2:Total: 12/76",
            "0/76 (0.00%)",
            "2/76 (2.63%)"
        ]
    },
    {
        "id": "b841dfd8-4676-4d3c-a57d-6ba1055b8597",
        "primaryId": "NCT02027376",
        "statement_text": "A patient was treated with Pertuzumab for 6 months  and this treatment was discontinued 2 months prior to study entry and the patient has fully recovered from the entailing side effects  hence this patient is eligible for the primary trial ",
        "statement_nums": [
            "2 months prior"
        ],
        "label": "Entailment",
        "premise_text": "Exclusion Criteria: Patients who have received biologic therapy (e.g  antibodies) 4 weeks prior to starting study drug or who have not recovered from the side effects of such therapy  ",
        "premise_nums": [
            "4 weeks prior"
        ]
    },
    {
        "id": "1dd4acd1-657c-40c0-b5ab-9c7adbe4ebf4",
        "primaryId": "NCT01042535",
        "statement_text": "The Maximum Tolerated Dose (MTD) of of 1-Pemetrexed-d-tryptophan (indoximod) observed in the primary trial was 800 mg ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Phase 1 - Maximum Tolerated Dose (MTD) in Milligrams (mg) ",
        "premise_nums": []
    },
    {
        "id": "48d40c7e-3514-43c3-a31a-7b391727f012",
        "primaryId": "NCT01209195",
        "statement_text": "Lower doses of MM-121 are utilised in cohort1 of the primary trial than in cohort 2, Paclitaxel doses are the same for both cohorts ",
        "statement_nums": [
            "121 are utilised",
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "INTERVENTION 1: Part 1: Dose Escalation: Cohort 1 MM-121 - 20 mg/kg loading dose followed by 12 mg/kg weekly IV Paclitaxel - 80mg/m2 weekly IV INTERVENTION 2: Part 1: Dose Escalation: Cohort 2 MM-121 - 40 mg/kg loading dose followed by 20 mg/kg weekly IV Paclitaxel - 80mg/m2 weekly IV ",
        "premise_nums": [
            "2 MM-121",
            "80mg/m2 weekly",
            "2 weekly IV",
            "40 mg/kg loading",
            "20 mg/kg weekly",
            "12 mg/kg weekly",
            "1 MM-121",
            "20 mg/kg loading"
        ]
    },
    {
        "id": "dd98fca1-27a7-41c2-ba0c-3ff90aceab54",
        "primaryId": "NCT01305941",
        "statement_text": "Patients must present IHC 3+ or FISH amplified results to participate in the primary trial  meaning their cancer is Histologically-confirmed as being HER2-positive.",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Inclusion Criteria Histologically-confirmed HER2-positive (IHC 3+ or fluorescence in situ hybridization (FISH) amplified; by clinical assay on either primary or metastatic tumor) adenocarcinoma of the breast with at least one progressive and/or new metastatic brain lesion (greater than /=5 mm on radiographic imaging) after receipt of intracranial radiation therapy (whole brain radiation therapy  stereotactic radiosurgery  gamma knife  or equivalent)  Patients in whom brain metastases (BM) are asymptomatic and detected during routine brain MRI screening per institutional protocols are eligible  ",
        "premise_nums": [
            "5 mm on"
        ]
    },
    {
        "id": "b975dc12-757e-4ef5-af33-83dfce12e6cc",
        "primaryId": "NCT01989676",
        "statement_text": "the primary trial only records GI adverse events ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 67/349 (19.20%) Anaemia * 3/349 (0.86%) Leukopenia * 1/349 (0.29%) Neutropenia * 3/349 (0.86%) Thrombocytopenia * 1/349 (0.29%) Atrial fibrillation * 2/349 (0.57%) Cardiac arrest * 1/349 (0.29%) Cardiac failure * 0/349 (0.00%) Cardiac failure acute * 0/349 (0.00%) Cardio-respiratory arrest * 2/349 (0.57%) Cardiovascular insufficiency * 0/349 (0.00%) ",
        "premise_nums": [
            "0/349 (0.00%)",
            "2/349 (0.57%)",
            "1/349 (0.29%)",
            "67/349 (19.20%)",
            "3/349 (0.86%)"
        ]
    },
    {
        "id": "2c4254c9-9c40-492f-aa45-2a9ab47579b3",
        "primaryId": "NCT02658734",
        "secondaryId": "NCT02073487",
        "label": "Entailment",
        "statement_text": "Female Patients with LVEF greater than 50%, who have previously undergone treatment with trastuzumab emtansine or lapatinib are still eligible for the secondary trial but are excluded from the primary trial ",
        "statement_nums": [],
        "premise_text": "Exclusion Criteria: Prior treatment with trastuzumab emtansine Prior treatment with lapatinib or lapatinib with capecitabine or non-comparable biologic or biosimilar of trastuzumab Inclusion Criteria: Female gender; Age 18 years; Performance Status- Eastern Cooperative Oncology Group (ECOG) 0-1 Histologically confirmed invasive breast cancer: Primary tumor greater than 1 cm diameter  measured by clinical examination and mammography or ultrasound  Any N  No evidence of metastasis (M0) (isolated supra-clavicular node involvement allowed); ",
        "premise_nums": [
            "1 cm diameter",
            "1 Histologically confirmed",
            "0-1 Histologically"
        ]
    },
    {
        "id": "2c4254c9-9c40-492f-aa45-2a9ab47579b3",
        "primaryId": "NCT02658734",
        "secondaryId": "NCT02073487",
        "label": "Entailment",
        "statement_text": "Female Patients with LVEF greater than 50%, who have previously undergone treatment with trastuzumab emtansine or lapatinib are still eligible for the secondary trial but are excluded from the primary trial ",
        "statement_nums": [],
        "premise_text": "Over expression and/or amplification of HER2 in the invasive component of the primary tumor and confirmed by a certified laboratory prior to randomization Known hormone receptor status  Hematopoietic status: CBC not less than .75 of institutional lower limit  Absolute neutrophil count 1,5 x 10^9/L, Platelet count 100 x 10^9/L, Hemoglobin at least 9 g/dl  Hepatic status: ",
        "premise_nums": [
            "75 of institutional",
            "count 1,5 x 10",
            "2 in the",
            "100 x 10",
            "9/L, Hemoglobin",
            "9/L, Platelet",
            "9 g/dl"
        ]
    },
    {
        "id": "2c4254c9-9c40-492f-aa45-2a9ab47579b3",
        "primaryId": "NCT02658734",
        "secondaryId": "NCT02073487",
        "label": "Entailment",
        "statement_text": "Female Patients with LVEF greater than 50%, who have previously undergone treatment with trastuzumab emtansine or lapatinib are still eligible for the secondary trial but are excluded from the primary trial ",
        "statement_nums": [],
        "premise_text": "Serum total bilirubin 2 x upper limit of normal (ULN)  In the case of known Gilbert's syndrome  a higher serum total bilirubin (smaller than 1.5 x ULN) is allowed  Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) 3.5 times ULN  Alkaline phosphatase 2.5 times ULN  Renal status: Creatinine 1.5mg/dL,Cardiovascular: Baseline left ventricular ejection fraction (LVEF) ³ 50% measured by echocardiography (ECHO) or Multiple Gate Acquisition (MUGA) scan  ",
        "premise_nums": [
            "50% measured",
            "than 1.5 x ULN",
            "Creatinine 1.5mg/dL",
            "5 x ULN)",
            "phosphatase 2.5 times ULN",
            "2 x upper"
        ]
    },
    {
        "id": "2c4254c9-9c40-492f-aa45-2a9ab47579b3",
        "primaryId": "NCT02658734",
        "secondaryId": "NCT02073487",
        "label": "Entailment",
        "statement_text": "Female Patients with LVEF greater than 50%, who have previously undergone treatment with trastuzumab emtansine or lapatinib are still eligible for the secondary trial but are excluded from the primary trial ",
        "statement_nums": [],
        "premise_text": "Negative serum or urine β-hCG pregnancy test at screening for patients of childbearing potential within 2-weeks (preferably 7 days) prior to randomization Fertile patients must use effective contraception (barrier method - condoms  diaphragm - also in conjunction with spermicidal jelly  or total abstinence  Oral  injectable  or implant hormonal contraceptives are not allowed) Signed informed consent form (ICF) Patient accepts to make available tumor samples for submission to central laboratory to conduct translational studies as part of this protocol  Exclusion Criteria: ",
        "premise_nums": []
    },
    {
        "id": "2c4254c9-9c40-492f-aa45-2a9ab47579b3",
        "primaryId": "NCT02658734",
        "secondaryId": "NCT02073487",
        "label": "Entailment",
        "statement_text": "Female Patients with LVEF greater than 50%, who have previously undergone treatment with trastuzumab emtansine or lapatinib are still eligible for the secondary trial but are excluded from the primary trial ",
        "statement_nums": [],
        "premise_text": "Previous (less than 5 years) or current history of malignant neoplasms  except for curatively treated: Basal and squamous cell carcinoma of the skin; Carcinoma in situ of the cervix Patients with a prior malignancy diagnosed more than 5 years prior to randomization may enter the study  Preexisting peripheral neuropathy grade 2 ",
        "premise_nums": [
            "5 years prior"
        ]
    },
    {
        "id": "2c4254c9-9c40-492f-aa45-2a9ab47579b3",
        "primaryId": "NCT02658734",
        "secondaryId": "NCT02073487",
        "label": "Entailment",
        "statement_text": "Female Patients with LVEF greater than 50%, who have previously undergone treatment with trastuzumab emtansine or lapatinib are still eligible for the secondary trial but are excluded from the primary trial ",
        "statement_nums": [],
        "premise_text": "Known history of uncontrolled or symptomatic angina  clinically significant arrhythmias  congestive heart failure  transmural myocardial infarction  uncontrolled hypertension ( 180/110), unstable diabetes mellitus  dyspnea at rest  or chronic therapy with oxygen;Concurrent disease or condition that would make the subject inappropriate for study participation or any serious medical disorder that would interfere with the subject's safety; Unresolved or unstable  serious adverse events from prior administration of another investigational drug; Dementia  altered mental status  or any psychiatric condition that would prevent the understanding or rendering of ICF; ",
        "premise_nums": [
            "180/110), unstable"
        ]
    },
    {
        "id": "2c4254c9-9c40-492f-aa45-2a9ab47579b3",
        "primaryId": "NCT02658734",
        "secondaryId": "NCT02073487",
        "label": "Entailment",
        "statement_text": "Female Patients with LVEF greater than 50%, who have previously undergone treatment with trastuzumab emtansine or lapatinib are still eligible for the secondary trial but are excluded from the primary trial ",
        "statement_nums": [],
        "premise_text": "Malabsorption syndrome  disease significantly affecting gastrointestinal function  or resection of the stomach or small bowel  Subjects with ulcerative colitis are also excluded;Concurrent neoadjuvant cancer therapy (chemotherapy  radiation therapy  immunotherapy  biologic therapy other than the trial therapies); Concurrent treatment with an investigational agent or participation in another therapeutic clinical trial; Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to trastuzumab Emtansine  trastuzumab  lapatinib  paclitaxel  abraxane or their components; Pregnant or lactating women; ",
        "premise_nums": []
    },
    {
        "id": "2c4254c9-9c40-492f-aa45-2a9ab47579b3",
        "primaryId": "NCT02658734",
        "secondaryId": "NCT02073487",
        "label": "Entailment",
        "statement_text": "Female Patients with LVEF greater than 50%, who have previously undergone treatment with trastuzumab emtansine or lapatinib are still eligible for the secondary trial but are excluded from the primary trial ",
        "statement_nums": [],
        "premise_text": "Concomitant use of CYP3A4 inhibitors or inducersOther concurrent severe and/or uncontrolled concomitant medical conditions (e.g  active or uncontrolled infection  uncontrolled diabetes) that could cause unacceptable safety risks or compromise compliance with the protocol Patients have an active infection and require IV or oral antibiotics  Pregnant or breast-feeding women Patients unwilling or unable to comply with the protocol ",
        "premise_nums": [
            "4 inhibitors or"
        ]
    },
    {
        "id": "e140b055-b7fc-4802-a79b-9dfe7d136876",
        "primaryId": "NCT01575522",
        "secondaryId": "NCT00181363",
        "label": "Entailment",
        "statement_text": "the primary trial and the secondary trial are testing completely different modalities of interventions ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Treatment (Tivantinib) Patients receive tivantinib PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity  Patients undergo blood sample collection at baseline and periodically during study for c-Met expression  relevant markers (HGF and VEGF)  PTEN loss  and PI3K mutation analysis by FISH and IHC  Archived tumor tissue samples are also analyzed  Laboratory Biomarker Analysis: Correlative studies Tivantinib: Given PO INTERVENTION 1: Prone Prone position INTERVENTION 2: Supine Supine position ",
        "premise_nums": [
            "1-21. Courses",
            "21 days in"
        ]
    },
    {
        "id": "0a6418c8-63a6-4900-bfc9-1659acbe1ad7",
        "primaryId": "NCT02581839",
        "statement_text": "At least 8 participants in the primary trial had a Central Nervous System (CNS) Progression Free Survival (PFS) greater than or equal 3 months ",
        "statement_nums": [
            "8 participants in"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Percent of Participants With Central Nervous System (CNS) Progression Free Survival (PFS) The study team will assess the percent of participants without CNS progression at 3 months  The study team will generate a Kaplan- Meier curve of CNS PFS and estimate the PFS and 95% confidence interval (CI) of the PFS  Response and progression by MR were evaluated using WHO/modified McDonald's criteria  Time frame: At 12 weeks Results 1: Arm/Group Title: Eribulin Mesylate ",
        "premise_nums": [
            "95% confidence",
            "12 weeks Results"
        ]
    },
    {
        "id": "0a6418c8-63a6-4900-bfc9-1659acbe1ad7",
        "primaryId": "NCT02581839",
        "statement_text": "At least 8 participants in the primary trial had a Central Nervous System (CNS) Progression Free Survival (PFS) greater than or equal 3 months ",
        "statement_nums": [
            "8 participants in"
        ],
        "label": "Entailment",
        "premise_text": "Arm/Group Description: The recommended starting dose of eribulin mesylate is 1.4 mg/m2 administered intravenously over 2 to 5 minutes on Days 1 and 8 of a 21-day cycle  An MRI will be completed at week 1, week 12 and every 12 weeks after cycles 4+ while on study eribulin mesylateEribulin Mesylate: Most subjects will begin eribulin mesylate at 1.4 mg/m2 administered intravenously over 2 to 5 minutes on Days 1 and 8 of a 21-day cycle  MRI: An MRI will be completed at week 1, week 12 and every 12 weeks after cycles 4+ while on study eribulin mesylate ",
        "premise_nums": [
            "is 1.4 mg/m2",
            "at 1.4 mg/m2",
            "2 to 5",
            "2 administered intravenously",
            "12 weeks after",
            "1 and 8",
            "12 and every",
            "21-day cycle"
        ]
    },
    {
        "id": "0a6418c8-63a6-4900-bfc9-1659acbe1ad7",
        "primaryId": "NCT02581839",
        "statement_text": "At least 8 participants in the primary trial had a Central Nervous System (CNS) Progression Free Survival (PFS) greater than or equal 3 months ",
        "statement_nums": [
            "8 participants in"
        ],
        "label": "Entailment",
        "premise_text": "Pre-Medication: Zofran: Zofran at 8mg orally  Given at the discretion of the treating physicianPre-Medication: Decadron: decadron at 8mg orally  Given at the discretion of the treating physician Overall Number of Participants Analyzed: 9 Measure Type: Number Unit of Measure: percentage of participants 88.9 (51 to 99.7) ",
        "premise_nums": [
            "51 to 99.7)",
            "9 Measure Type:"
        ]
    },
    {
        "id": "2db9e0c7-d94b-47d2-a61f-55a0896d714e",
        "primaryId": "NCT00789581",
        "secondaryId": "NCT02445586",
        "label": "Contradiction",
        "statement_text": "the secondary trial reported more cases of Haematemesis  but the primary trial had more cases of Sinus tachycardia ",
        "statement_nums": [],
        "premise_text": "Adverse Events 1: Total: 58/305 (19.02%) FEBRILE NEUTROPENIA * 12/305 (3.93%) NEUTROPENIA * 4/305 (1.31%) ANAEMIA * 2/305 (0.66%) LEUKOPENIA * 1/305 (0.33%) PANCYTOPENIA * 1/305 (0.33%) THROMBOCYTOPENIA * 1/305 (0.33%) DISSEMINATED INTRAVASCULAR COAGULATION * 0/305 (0.00%) ATRIAL FIBRILLATION * 1/305 (0.33%) DIASTOLIC DYSFUNCTION * 1/305 (0.33%) ",
        "premise_nums": [
            "4/305 (1.31%)",
            "12/305 (3.93%)",
            "2/305 (0.66%)",
            "1/305 (0.33%)",
            "0/305 (0.00%)",
            "58/305 (19.02%)"
        ]
    },
    {
        "id": "2db9e0c7-d94b-47d2-a61f-55a0896d714e",
        "primaryId": "NCT00789581",
        "secondaryId": "NCT02445586",
        "label": "Contradiction",
        "statement_text": "the secondary trial reported more cases of Haematemesis  but the primary trial had more cases of Sinus tachycardia ",
        "statement_nums": [],
        "premise_text": "PERICARDIAL EFFUSION * 1/305 (0.33%)Adverse Events 2: Total: 50/304 (16.45%) FEBRILE NEUTROPENIA * 12/304 (3.95%) NEUTROPENIA * 1/304 (0.33%) ANAEMIA * 0/304 (0.00%) LEUKOPENIA * 0/304 (0.00%) PANCYTOPENIA * 0/304 (0.00%) THROMBOCYTOPENIA * 0/304 (0.00%) DISSEMINATED INTRAVASCULAR COAGULATION * 1/304 (0.33%) ATRIAL FIBRILLATION * 1/304 (0.33%) ",
        "premise_nums": [
            "0/304 (0.00%)",
            "50/304 (16.45%)",
            "12/304 (3.95%)",
            "1/304 (0.33%)",
            "1/305 (0.33%)Adverse"
        ]
    },
    {
        "id": "2db9e0c7-d94b-47d2-a61f-55a0896d714e",
        "primaryId": "NCT00789581",
        "secondaryId": "NCT02445586",
        "label": "Contradiction",
        "statement_text": "the secondary trial reported more cases of Haematemesis  but the primary trial had more cases of Sinus tachycardia ",
        "statement_nums": [],
        "premise_text": "DIASTOLIC DYSFUNCTION * 0/304 (0.00%)PERICARDIAL EFFUSION * 0/304 (0.00%) Adverse Events 1: Total: 31/52 (59.62%) Febrile neutropenia 2/52 (3.85%) Left ventricular dysfunction 2/52 (3.85%) Sinus tachycardia 1/52 (1.92%) Congenital arterial malformation 1/52 (1.92%) Diarrhoea 5/52 (9.62%) Salivary hypersecretion 1/52 (1.92%) Enteritis 1/52 (1.92%) Abdominal pain 1/52 (1.92%) ",
        "premise_nums": [
            "31/52 (59.62%)",
            "5/52 (9.62%)",
            "1/52 (1.92%)",
            "2/52 (3.85%)",
            "0/304 (0.00%)PERICARDIAL"
        ]
    },
    {
        "id": "2db9e0c7-d94b-47d2-a61f-55a0896d714e",
        "primaryId": "NCT00789581",
        "secondaryId": "NCT02445586",
        "label": "Contradiction",
        "statement_text": "the secondary trial reported more cases of Haematemesis  but the primary trial had more cases of Sinus tachycardia ",
        "statement_nums": [],
        "premise_text": "Vomiting 1/52 (1.92%)Stomatitis 1/52 (1.92%) Haematemesis 1/52 (1.92%) ",
        "premise_nums": [
            "1/52 (1.92%)Stomatitis"
        ]
    },
    {
        "id": "3129e58d-0c16-42a5-90b4-f26e048dfe58",
        "primaryId": "NCT01644890",
        "statement_text": "Throughout the primary trial  one patient in cohort 1 developed issues with their vision ",
        "statement_nums": [
            "1 developed issues"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 34/214 (15.89%) Leukocytosis 0/214 (0.00%) Atrial fibrillation 0/214 (0.00%) Cardiac failure congestive 0/214 (0.00%) Pericardial effusion 1/214 (0.47%) Cataract 0/214 (0.00%) Macular fibrosis 0/214 (0.00%) Constipation 2/214 (0.93%) Diarrhoea 2/214 (0.93%) Enterocolitis 0/214 (0.00%) Ileus 1/214 (0.47%) Nausea 3/214 (1.40%) Adverse Events 2: Total: 27/213 (12.68%) ",
        "premise_nums": [
            "27/213 (12.68%)",
            "2/214 (0.93%)",
            "1/214 (0.47%)",
            "34/214 (15.89%)",
            "3/214 (1.40%)",
            "0/214 (0.00%)"
        ]
    },
    {
        "id": "3129e58d-0c16-42a5-90b4-f26e048dfe58",
        "primaryId": "NCT01644890",
        "statement_text": "Throughout the primary trial  one patient in cohort 1 developed issues with their vision ",
        "statement_nums": [
            "1 developed issues"
        ],
        "label": "Contradiction",
        "premise_text": "Leukocytosis 1/213 (0.47%)Atrial fibrillation 1/213 (0.47%) Cardiac failure congestive 1/213 (0.47%) Pericardial effusion 0/213 (0.00%) Cataract 1/213 (0.47%) Macular fibrosis 1/213 (0.47%) Constipation 1/213 (0.47%) Diarrhoea 1/213 (0.47%) Enterocolitis 1/213 (0.47%) Ileus 0/213 (0.00%) Nausea 0/213 (0.00%) ",
        "premise_nums": [
            "0/213 (0.00%)",
            "1/213 (0.47%)Atrial"
        ]
    },
    {
        "id": "7be7cecb-d265-4098-9969-a40555702573",
        "primaryId": "NCT00679211",
        "statement_text": "1 patient in the primary trial was diangosed with Influenza ",
        "statement_nums": [
            "1 patient in"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Influenza like illness 1/110 (0.91%) ",
        "premise_nums": [
            "1/110 (0.91%)"
        ]
    },
    {
        "id": "5b0d3709-7879-4dea-96c3-29178cd9f162",
        "primaryId": "NCT00767520",
        "statement_text": "Both cohorts of the primary trial reported the same number of patients vomiting during the trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Vomiting 2/79 (2.53%) Adverse Events 2: Vomiting 2/76 (2.63%) ",
        "premise_nums": [
            "2/79 (2.53%)",
            "2/76 (2.63%)"
        ]
    },
    {
        "id": "af70a3a9-d2d0-4d65-81fe-15a1becb5e95",
        "primaryId": "NCT01420146",
        "secondaryId": "NCT00077376",
        "label": "Contradiction",
        "statement_text": "the primary trial and the secondary trial both have a control arm  and several test arms ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Zr89-trastuzumab PET/CT Zr89-trastuzumab (trastuzumab labelled with zirconium 89) for PET/CT single arm INTERVENTION 1: Trastuzumab/Ixabepilone/Carboplatin ",
        "premise_nums": [
            "89-trastuzumab PET/CT"
        ]
    },
    {
        "id": "af70a3a9-d2d0-4d65-81fe-15a1becb5e95",
        "primaryId": "NCT01420146",
        "secondaryId": "NCT00077376",
        "label": "Contradiction",
        "statement_text": "the primary trial and the secondary trial both have a control arm  and several test arms ",
        "statement_nums": [],
        "premise_text": "During the induction phase  patients were treated with Ixabepilone (BMS-247550) 15mg/m2 intravenously (IV) followed by carboplatin (AUC=2 IV) on days 1, 8 and 15 of a 28-day cycle for a maximum of 6 cycles  Trastuzumab was administered weekly (4mg/kg loading dose then 2mg/kg IV) starting on day 1. Routine premedication included H1 blocker (diphenhydramine 50 mg orally (PO) or IV)  H2 blocker (ranitidine 150 mg PO or 50 mg IV or another equivalent H2 blocker)  and at least a 5-HT3 antagonist and dexamethasone ",
        "premise_nums": [
            "50 mg IV",
            "50 mg orally",
            "2mg/kg IV",
            "15mg/m2 intravenously",
            "150 mg PO",
            "2 intravenously (IV)",
            "2 blocker (ranitidine",
            "5-HT3 antagonist",
            "8 and 15",
            "3 antagonist and",
            "28-day cycle",
            "1 blocker (diphenhydramine"
        ]
    },
    {
        "id": "af70a3a9-d2d0-4d65-81fe-15a1becb5e95",
        "primaryId": "NCT01420146",
        "secondaryId": "NCT00077376",
        "label": "Contradiction",
        "statement_text": "the primary trial and the secondary trial both have a control arm  and several test arms ",
        "statement_nums": [],
        "premise_text": "After completion of 24 weekly trastuzumab doses (induction therapy)  trastuzumab were given at a dose of 6 mg/kg IV every 3 weeks (maintenance therapy) beginning one week after the 24th weekly dose  Trastuzumab were repeated every 21 days until disease progression or prohibitive toxicity ",
        "premise_nums": [
            "21 days until",
            "24 weekly trastuzumab",
            "6 mg/kg IV",
            "3 weeks (maintenance"
        ]
    },
    {
        "id": "a378f448-eef0-465a-abc0-8b4dd1156bb5",
        "primaryId": "NCT00372424",
        "secondaryId": "NCT00041067",
        "label": "Entailment",
        "statement_text": "Patients with HER2 positive breast tumors are eligible for the primary trial and the secondary trial ",
        "statement_nums": [
            "2 positive breast"
        ],
        "premise_text": "Inclusion Criteria: Breast cancer with evidence of unresectable  locally recurrent  or metastatic disease  Tumors over-expressing Her-2 Candidate for treatment with docetaxel/trastuzumab HER2-positive by fluorescence in situ hybridization (FISH) or immunohistochemistry 3+ staining confirmed in the adjuvant or metastatic setting ",
        "premise_nums": [
            "2-positive by",
            "2 Candidate for"
        ]
    },
    {
        "id": "f30182a1-b82a-497c-885c-9bd2e805db62",
        "primaryId": "NCT01487954",
        "statement_text": "All patients in the primary trial had to drink 237 ml of water  either Alkaline Water or Distilled  depending on which cohort they are in ",
        "statement_nums": [
            "237 ml of"
        ],
        "label": "Entailment",
        "premise_text": "INTERVENTION 1: Arm I: Alkaline Water Patients undergo external beam radiation therapy QD  5 days a week for 6 weeks  Patients drink 8 ounces of alkaline water within 30 minutes immediately prior to and after undergoing radiation therapy  alkaline water: Patients drink 8 ounces of alkaline water within 30 minutes immediately prior to and after undergoing radiation therapy  external beam radiation therapy (EBRT): Patients undergo external beam radiation therapy QD  5 days a week for 6 weeks  INTERVENTION 2: Arm II: Distilled Water Patients undergo external beam radiation therapy as in arm I  Patients also drink 8 ounces of distilled water within 30 minutes immediately prior to and after undergoing radiation therapy ",
        "premise_nums": [
            "30 minutes immediately",
            "5 days a",
            "8 ounces of"
        ]
    },
    {
        "id": "f30182a1-b82a-497c-885c-9bd2e805db62",
        "primaryId": "NCT01487954",
        "statement_text": "All patients in the primary trial had to drink 237 ml of water  either Alkaline Water or Distilled  depending on which cohort they are in ",
        "statement_nums": [
            "237 ml of"
        ],
        "label": "Entailment",
        "premise_text": "distilled water: Patients also drink 8 ounces of distilled water within 30 minutes immediately prior to and after undergoing radiation therapy external beam radiation therapy (EBRT): Patients undergo external beam radiation therapy QD  5 days a week for 6 weeks  ",
        "premise_nums": [
            "30 minutes immediately",
            "5 days a",
            "8 ounces of"
        ]
    },
    {
        "id": "ae87e5a3-fdd8-4003-ae80-4b370cade158",
        "primaryId": "NCT01106898",
        "statement_text": "2% of the primary trial patients had Recurrence-free Survival smaller than 3 years ",
        "statement_nums": [
            "2% of"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Recurrence-free Survival Recurrence-free survival curves will be plotted for subjects treated with stage I and II disease  Time frame: Time from the start of treatment to recurrence  second malignancy  or death as a first event  assessed up to 3 years Results 1: Arm/Group Title: Treatment (Chemotherapy With or Without Maintenance Therapy) Arm/Group Description: SYSTEMIC CHEMOTHERAPY: Patients receive cyclophosphamide IV over 1 hour and paclitaxel IV over 3 hours on day 1. Treatment repeats every 14 days for 6 courses in the absence of disease progression or unacceptable toxicity  ",
        "premise_nums": [
            "3 hours on",
            "6 courses in",
            "1 hour and",
            "14 days for",
            "3 years Results"
        ]
    },
    {
        "id": "ae87e5a3-fdd8-4003-ae80-4b370cade158",
        "primaryId": "NCT01106898",
        "statement_text": "2% of the primary trial patients had Recurrence-free Survival smaller than 3 years ",
        "statement_nums": [
            "2% of"
        ],
        "label": "Entailment",
        "premise_text": "MAINTENANCE THERAPY (Her-2 neu positive patients): Patients receive trastuzumab IV over 30 minutes on day 1. Treatment repeats every 14 days for 5 courses and then every 21 days for 14 courses in the absence of disease progression or unacceptable toxicity cyclophosphamide  paclitaxel  trastuzumab: Given IV Overall Number of Participants Analyzed: 100 Measure Type: Number Unit of Measure: percentage of subjects 98 (92.2 to 99.5) ",
        "premise_nums": [
            "21 days for",
            "2 to 99.5)",
            "14 days for",
            "30 minutes on",
            "5 courses and",
            "100 Measure Type:",
            "2 neu positive",
            "14 courses in"
        ]
    },
    {
        "id": "9f3062db-16fb-41b8-ac10-f205f66070c8",
        "primaryId": "NCT00696072",
        "statement_text": "Most patients treated with Dasatinib and Letrozole in the primary trial had a Disease Free Interval (DFI) Greater Than 2 Years ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Number of Participants With Clinical Benefit (CBR) and Number of Participants With CBR Having a Disease Free Interval (DFI) Greater Than 2 Years - Evaluable Population ",
        "premise_nums": []
    },
    {
        "id": "9f3062db-16fb-41b8-ac10-f205f66070c8",
        "primaryId": "NCT00696072",
        "statement_text": "Most patients treated with Dasatinib and Letrozole in the primary trial had a Disease Free Interval (DFI) Greater Than 2 Years ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "CBR=participants with complete response (CR) + participants with partial response (PR) + participants with stable disease (SD) for a length of time greater than  equal to 6 months  CR= Disappearance of all target lesions  No new lesions  PR= At least a 30% decrease in the sum of the longest diameter (LD) of target lesions taking as reference the baseline sum LD  SD= Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD) taking as reference the smallest sum LD since the treatment started  Physical examination,radiological assessment  and bone scans (if applicable) were used to assess outcome Time frame: First dose of study drug to last dose plus 7 days  up to study completion (approximately 6 years) Results 1: ",
        "premise_nums": [
            "30% decrease"
        ]
    },
    {
        "id": "9f3062db-16fb-41b8-ac10-f205f66070c8",
        "primaryId": "NCT00696072",
        "statement_text": "Most patients treated with Dasatinib and Letrozole in the primary trial had a Disease Free Interval (DFI) Greater Than 2 Years ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Arm/Group Title: Dasatinib Plus LetrozoleArm/Group Description: Dasatinib + Letrozole: Tablets  Oral  once daily  up to 2 years Dasatinib 100 mg + Letrozole 2.5 mg Patients on letrozole plus dasatinib received both drugs until progressive disease (PD) or intolerable toxicity  If the intolerable toxicity was determined to be related to dasatinib  dasatinib was discontinued and the patient continued on single-agent letrozole  Although drugs were taken daily  cycle length was 28-days Overall Number of Participants Analyzed: 56 Measure Type: Number Unit of Measure: participants CBR (CR+PR+SD): 40 CBR  DFI smaller than = 2 Years: 20 ",
        "premise_nums": [
            "Letrozole 2.5 mg Patients",
            "2 years Dasatinib",
            "56 Measure Type:",
            "28-days Overall"
        ]
    },
    {
        "id": "9f3062db-16fb-41b8-ac10-f205f66070c8",
        "primaryId": "NCT00696072",
        "statement_text": "Most patients treated with Dasatinib and Letrozole in the primary trial had a Disease Free Interval (DFI) Greater Than 2 Years ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "CBR  DFI greater than 2 Years: 20",
        "premise_nums": []
    },
    {
        "id": "a1c5685a-8e6e-4733-aa8b-7040bac1a397",
        "primaryId": "NCT00022672",
        "statement_text": "There were no patients in either cohort of the primary trial with a PFS exceeding 6 months ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Progression Free Survival (PFS) ",
        "premise_nums": []
    },
    {
        "id": "d58683e2-d276-4184-a8e9-c9df6ffd8047",
        "primaryId": "NCT00559507",
        "statement_text": "the primary trial participants are given saracatinib PO for a maximum of 28 days ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "INTERVENTION 1: Treatment (Enzyme Inhibitor Therapy) Patients receive saracatinib PO on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity  ",
        "premise_nums": [
            "1-28. Treatment",
            "28 days in"
        ]
    },
    {
        "id": "28d8f88a-e8cb-40c0-a12b-ef555f83ff59",
        "primaryId": "NCT01904903",
        "secondaryId": "NCT01663727",
        "label": "Contradiction",
        "statement_text": "Patients must have LVEF smaller than 50% to be eligible for the primary trial and the secondary trial ",
        "statement_nums": [
            "50% to"
        ],
        "premise_text": "LVEF smaller than 50% and 40% documented in echocardiogram done within the last 30 days Inclusion Criteria: Histologically or cytologically confirmed  HER2-negative adenocarcinoma of the breast  with measurable or non-measurable locally recurrent or metastatic disease  Locally recurrent disease must not be amenable to resection with curative intent  ECOG performance status of 0 or 1 For women of childbearing potential  use of an acceptable and effective method of non-hormonal contraception For patients who have received recent radiotherapy  recovery prior to randomization from any significant acute toxicity  and radiation treatments have to be completed more than 3 weeks from randomization Exclusion Criteria: Disease-Specific Exclusions: HER2-positive status Prior chemotherapy for locally recurrent or metastatic disease ",
        "premise_nums": [
            "40% documented",
            "2-negative adenocarcinoma",
            "0 or 1",
            "3 weeks from",
            "50% and",
            "2-positive status",
            "30 days Inclusion"
        ]
    },
    {
        "id": "28d8f88a-e8cb-40c0-a12b-ef555f83ff59",
        "primaryId": "NCT01904903",
        "secondaryId": "NCT01663727",
        "label": "Contradiction",
        "statement_text": "Patients must have LVEF smaller than 50% to be eligible for the primary trial and the secondary trial ",
        "statement_nums": [
            "50% to"
        ],
        "premise_text": "Prior hormonal therapy smaller than 2 weeks prior to randomizationPrior adjuvant or neo-adjuvant chemotherapy is allowed  provided its conclusion has been for at least 12 months prior to randomization Investigational therapy within 28 days of randomization General Medical Exclusions: Life expectancy of smaller than 12 weeks Inadequate organ function Uncontrolled serious medical or psychiatric illness Active infection requiring intravenous (IV) antibiotics at screening Pregnancy or lactation History of other malignancies within 5 years prior to screening  except for tumors with a negligible risk for metastasis or death ",
        "premise_nums": [
            "12 weeks Inadequate",
            "5 years prior",
            "28 days of",
            "12 months prior",
            "2 weeks prior"
        ]
    },
    {
        "id": "0ee4c935-18bd-4807-a2af-041a3d84e125",
        "primaryId": "NCT02721147",
        "statement_text": "Stephanie has been living with her boyfriend for 2 months  she is eligible for the primary trial ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria: Has a partner or spouse who is greater than 21 Lives with a romantic partner greater than 6 months ",
        "premise_nums": [
            "21 Lives with"
        ]
    },
    {
        "id": "355fb813-cbe0-44f5-b04a-87813e060d54",
        "primaryId": "NCT00371254",
        "statement_text": "Patients must have eceptorsestrogen receptor (ER) -  progesterone receptor (PR) - and human epidermal growth factor receptor 2 (HER2) - breast cancer  aswell as not having Dysphagia ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Inclusion Criteria: recurrent or progressive locally advanced  or 'triple negative' metastatic breast cancer Exclusion Criteria: Unable to take oral medication ",
        "premise_nums": []
    },
    {
        "id": "274d9d2b-9227-4496-a525-d5477b0003ce",
        "primaryId": "NCT00796978",
        "secondaryId": "NCT01276041",
        "label": "Contradiction",
        "statement_text": "More patients in cohort 1 of the secondary trial suffered from oedema in their limbs  compared to patients in cohort 2 of the primary trial ",
        "statement_nums": [
            "2 of the",
            "1 of the"
        ],
        "premise_text": "Adverse Events 1: Total: 8/56 (14.29%) Platelets * 1/56 (1.79%) Heart failure * 1/56 (1.79%) Left ventricular systolic dysfunction * 1/56 (1.79%) Dehydration * 1/56 (1.79%) Diarrhea * 1/56 (1.79%) Infection with normal ANC or Grade 1 or 2 neutrophils - Bladder (urinary) * 1/56 (1.79%) Sodium  serum-low (hyponatremia) * 1/56 (1.79%) Fracture * 2/56 (3.57%) Adverse Events 1: ",
        "premise_nums": [
            "1 or 2",
            "1/56 (1.79%)",
            "8/56 (14.29%)",
            "2/56 (3.57%)"
        ]
    },
    {
        "id": "274d9d2b-9227-4496-a525-d5477b0003ce",
        "primaryId": "NCT00796978",
        "secondaryId": "NCT01276041",
        "label": "Contradiction",
        "statement_text": "More patients in cohort 1 of the secondary trial suffered from oedema in their limbs  compared to patients in cohort 2 of the primary trial ",
        "statement_nums": [
            "2 of the",
            "1 of the"
        ],
        "premise_text": "Total: 18/70 (25.71%)Cardiac arrest 1/70 (1.43%) Pericardial effusion 1/70 (1.43%) Ear pain 1/70 (1.43%) Blurred vision 1/70 (1.43%) Eye disorders - Other  specify 2/70 (2.86%) Abdominal Pain 5/70 (7.14%) Colitis 1/70 (1.43%) Diarrhea 2/70 (2.86%) Nausea 2/70 (2.86%) Death NOS 1/70 (1.43%) Edema limbs 1/70 (1.43%) Fatigue 3/70 (4.29%) ",
        "premise_nums": [
            "5/70 (7.14%)",
            "18/70 (25.71%)Cardiac",
            "1/70 (1.43%)",
            "2/70 (2.86%)",
            "3/70 (4.29%)"
        ]
    },
    {
        "id": "3ab9c66c-06fc-4bc5-b504-d9193efa8701",
        "primaryId": "NCT00290745",
        "statement_text": "in the primary trial participants from different ethnicities receive different interventions ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "INTERVENTION 1: Tamoxifen or Letrozole tamoxifen or letrozole work in treating women with ductal carcinoma in situ letrozole tamoxifen citrate conventional surgery neoadjuvant therapy ",
        "premise_nums": []
    },
    {
        "id": "d39078d9-9bc3-4b91-a012-e95f14813c9a",
        "primaryId": "NCT01252277",
        "statement_text": "Fiona's step sister  who is 34 years old was diagnosed with a ductal carcinoma  therefore fiona may be eligible for the primary trial ",
        "statement_nums": [
            "34 years old"
        ],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria A first degree relative with breast cancer under the age of 60 or multiple second degree relatives with breast cancer  ",
        "premise_nums": [
            "60 or multiple"
        ]
    },
    {
        "id": "02538194-97ac-4749-9301-83f108927478",
        "primaryId": "NCT00041067",
        "secondaryId": "NCT01273896",
        "label": "Entailment",
        "statement_text": "Patients with ER positive  PR positive or HER2 positive tumors may be eligible for the secondary trial or the primary trial ",
        "statement_nums": [
            "2 positive tumors"
        ],
        "premise_text": "DISEASE CHARACTERISTICS: Histologically confirmed stage IV breast cancer Metastasis to the ipsilateral supraclavicular lymph nodes allowed HER2-positive by fluorescence in situ hybridization (FISH) or immunohistochemistry 3+ staining confirmed in the adjuvant or metastatic setting No effusions or ascites as only sites of disease No primary or metastatic brain or central nervous system tumor Hormone receptor status: Not specified PATIENT CHARACTERISTICS: Age: 18 and over Sex: Female Menopausal status: Not specified Performance status: Zubrod 0-2 Life expectancy: Not specified Hematopoietic: Absolute neutrophil count at least 1,500/mm^3 Platelet count at least 100,000/mm^3 Hepatic: ",
        "premise_nums": [
            "18 and over",
            "3 Platelet count",
            "100,000/mm^3 Hepatic:",
            "2-positive by",
            "0-2 Life",
            "2 Life expectancy:",
            "1,500/mm^3 Platelet"
        ]
    },
    {
        "id": "02538194-97ac-4749-9301-83f108927478",
        "primaryId": "NCT00041067",
        "secondaryId": "NCT01273896",
        "label": "Entailment",
        "statement_text": "Patients with ER positive  PR positive or HER2 positive tumors may be eligible for the secondary trial or the primary trial ",
        "statement_nums": [
            "2 positive tumors"
        ],
        "premise_text": "Bilirubin normalaspartate aminotransferase or Alanine aminotranferease no greater than 1.5 times upper limit of normal (ULN) Alkaline phosphatase no greater than 2.5 times ULN Renal: Not specified Cardiovascular: left ventricular ejection fraction normal by multigated radionuclide angiography or echocardiogram (patients who have received prior anthracycline therapy) No clinical evidence or history of cardiomyopathy Other: No pre-existing grade 2 or greater motor or sensory peripheral neuropathy except abnormalities due to cancer No prior severe hypersensitivity reaction to docetaxel or other drugs formulated with Polysorbate 80 ",
        "premise_nums": [
            "than 2.5 times ULN",
            "2 or greater",
            "than 1.5 times upper"
        ]
    },
    {
        "id": "02538194-97ac-4749-9301-83f108927478",
        "primaryId": "NCT00041067",
        "secondaryId": "NCT01273896",
        "label": "Entailment",
        "statement_text": "Patients with ER positive  PR positive or HER2 positive tumors may be eligible for the secondary trial or the primary trial ",
        "statement_nums": [
            "2 positive tumors"
        ],
        "premise_text": "No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer  carcinoma in situ of the cervix  or other adequately treated stage I or II cancer currently in complete remissionNo known sensitivity to E  coli-derived proteins Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: At least 6 months since prior chemotherapy Prior anthracycline as adjuvant therapy allowed No prior cumulative dose of doxorubicin more than 360 mg/m^2 No prior cumulative dose of epirubicin more than 720 mg/m^2 No more than 1 prior adjuvant or neoadjuvant chemotherapy regimen for primary disease No prior docetaxel ",
        "premise_nums": [
            "2 No more",
            "720 mg/m^2",
            "5 years except",
            "2 No prior",
            "360 mg/m^2",
            "1 prior adjuvant",
            "6 months since"
        ]
    },
    {
        "id": "02538194-97ac-4749-9301-83f108927478",
        "primaryId": "NCT00041067",
        "secondaryId": "NCT01273896",
        "label": "Entailment",
        "statement_text": "Patients with ER positive  PR positive or HER2 positive tumors may be eligible for the secondary trial or the primary trial ",
        "statement_nums": [
            "2 positive tumors"
        ],
        "premise_text": "No prior vinorelbinePrior paclitaxel allowed Endocrine therapy: Prior hormonal therapy as adjuvant therapy or for metastatic breast cancer allowed No concurrent hormonal therapy Radiotherapy: At least 3 weeks since prior radiotherapy Surgery: At least 2 weeks since prior surgery and recovered Inclusion Criteria: Male and Female patients must be at least 18 years of age Pathologically confirmed diagnosis of breast cancer Metastatic or advanced stage breast cancer Prior treatment with at least one and no more than three lines of biologic and/or chemotherapy for metastatic breast cancer (excluding hormonal therapy) Patients with HER2+ disease must have received prior treatment with Trastuzumab Patients with ER and/or PR+ disease must have received prior treatment with hormonal therapy ",
        "premise_nums": [
            "2 weeks since",
            "18 years of",
            "3 weeks since"
        ]
    },
    {
        "id": "02538194-97ac-4749-9301-83f108927478",
        "primaryId": "NCT00041067",
        "secondaryId": "NCT01273896",
        "label": "Entailment",
        "statement_text": "Patients with ER positive  PR positive or HER2 positive tumors may be eligible for the secondary trial or the primary trial ",
        "statement_nums": [
            "2 positive tumors"
        ],
        "premise_text": "Off cytotoxic chemotherapy or biologic therapy (excluding Hormonal therapy) 3 weeksMeasurable disease by RECIST 1.1 Central nervous system metastases are permitted if treated and radiographically and clinically stable for at least 4 weeks prior to first dose of STA-9090 Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1 Life expectancy of at least 3 months Adequate hematologic function as defined by: Absolute neutrophil count 1,500 cells/μL Platelets 100,000/μL Hemoglobin 9.0g/dL Adequate hepatic function as defined by: Serum bilirubin 1.5 X upper limit of normal (ULN); ",
        "premise_nums": [
            "bilirubin 1.5 X upper",
            "RECIST 1.1 Central nervous",
            "0 or 1",
            "Hemoglobin 9.0g/dL",
            "100,000/μL Hemoglobin",
            "1,500 cells/",
            "3 weeksMeasurable disease",
            "9090 Eastern Cooperative",
            "4 weeks prior",
            "3 months Adequate"
        ]
    },
    {
        "id": "02538194-97ac-4749-9301-83f108927478",
        "primaryId": "NCT00041067",
        "secondaryId": "NCT01273896",
        "label": "Entailment",
        "statement_text": "Patients with ER positive  PR positive or HER2 positive tumors may be eligible for the secondary trial or the primary trial ",
        "statement_nums": [
            "2 positive tumors"
        ],
        "premise_text": "Adequate renal function as defined by a serum creatinine 1.5 x ULNAST  ALT  and alkaline phosphatase 3 × ULN except for: Patients with hepatic metastases: ALT and AST 5 × ULN Patients with hepatic and/or bone metastases: alkaline phosphatase 5 × ULN Patients with Gilbert's disease: serum bilirubin smaller than 5 mg/dL Willingness and ability to comply with scheduled visits  treatment plans  laboratory tests  and other study procedures Female subjects of childbearing potential and males must agree to use adequate contraception (e.g.  hormonal or barrier method of birth control; abstinence) for the duration of study treatment ",
        "premise_nums": [
            "creatinine 1.5 x ULNAST",
            "5 mg/dL Willingness"
        ]
    },
    {
        "id": "02538194-97ac-4749-9301-83f108927478",
        "primaryId": "NCT00041067",
        "secondaryId": "NCT01273896",
        "label": "Entailment",
        "statement_text": "Patients with ER positive  PR positive or HER2 positive tumors may be eligible for the secondary trial or the primary trial ",
        "statement_nums": [
            "2 positive tumors"
        ],
        "premise_text": "Female subjects of childbearing age must have a negative serum pregnancy test at study entry Exclusion Criteria: Surgery  radiotherapy  or lesion ablative procedure to the only area of measurable disease Major surgery within 4 weeks prior to first dose of STA-9090 Poor peripheral venous access for study drug administration  Study drug administration via indwelling catheters allowed only if the catheter is made of silicone material  History of severe (grade 3 or 4) allergic or hypersensitivity reactions to excipients (e.g.  Polyethylene glycol [PEG] 300 and Polysorbate 80) Baseline QTc greater than 470 msec Ventricular ejection fraction (EF) smaller than 50% at baseline ",
        "premise_nums": [
            "9090 Poor peripheral",
            "4 weeks prior",
            "470 msec Ventricular",
            "50% at",
            "300 and Polysorbate",
            "3 or 4)"
        ]
    },
    {
        "id": "02538194-97ac-4749-9301-83f108927478",
        "primaryId": "NCT00041067",
        "secondaryId": "NCT01273896",
        "label": "Entailment",
        "statement_text": "Patients with ER positive  PR positive or HER2 positive tumors may be eligible for the secondary trial or the primary trial ",
        "statement_nums": [
            "2 positive tumors"
        ],
        "premise_text": "Treatment with chronic immunosuppressants (e.g.  cyclosporine following transplantation)Women who are pregnant or lactating Uncontrolled intercurrent illness including  but not limited to  human immunodeficiency virus (HIV)-positive subjects receiving combination antiretroviral therapy  ongoing or active infection  symptomatic congestive heart failure  unstable angina pectoris  ventricular arrhythmia  or psychiatric illness/social situations that would limit compliance with study requirements Other medications  or severe acute/chronic medical or psychiatric condition  or laboratory abnormality that may increase the risk associated with study participation or study drug administration  or may interfere with the interpretation of study results in the judgment of the investigator Seizure disorder or requirement for seizure medication Prior treatment with an HSP90 inhibitor ",
        "premise_nums": [
            "HSP90 inhibitor"
        ]
    },
    {
        "id": "02538194-97ac-4749-9301-83f108927478",
        "primaryId": "NCT00041067",
        "secondaryId": "NCT01273896",
        "label": "Entailment",
        "statement_text": "Patients with ER positive  PR positive or HER2 positive tumors may be eligible for the secondary trial or the primary trial ",
        "statement_nums": [
            "2 positive tumors"
        ],
        "premise_text": "persistent adverse events of prior therapies that are greater than 1 grade 1 in severityhistory of or current coronary artery disease  myocardial infarction  angina pectoris  angioplasty or coronary bypass surgery history of or current uncontrolled dysrhythmias  or requirement for antiarrhythmic medications  or Grade 2 or greater left bundle branch block New York Heart Association class II/III/IV congestive heart failure with a history of dyspnea  orthopnea  or edema that requires current treatment with angiotensin converting enzyme inhibitors  angiotensin II receptor blockers  beta blockers or diuretics ",
        "premise_nums": [
            "2 or greater",
            "1 grade 1"
        ]
    },
    {
        "id": "6d9113b4-9d18-4a1b-bc78-cc3ac1150876",
        "primaryId": "NCT01572038",
        "secondaryId": "NCT00826267",
        "label": "Entailment",
        "statement_text": "Each patient in the primary trial receives 3 different drugs  whereas in the secondary trial patients receive 1 of 2 possible drugs ",
        "statement_nums": [
            "1 of 2",
            "3 different drugs"
        ],
        "premise_text": "INTERVENTION 1: Pertuzumab + Trastuzumab + Taxane Participants received pertuzumab and trastuzumab intravenously (IV) plus taxane chemotherapy once of every 3 weeks per treatment cycle until predefined study end  unacceptable toxicity  withdrawal of consent  disease progression  or death  whichever occurred first  Taxane chemotherapy was docetaxel  paclitaxel  or nab-paclitaxel  per the investigator's choice  INTERVENTION 1: Afatinib 50 mg Patients received continuous daily dosing with Afatinib 50 mg orally from Day 1 to Day 21 of each treatment course  2 treatment courses were to be given in the trial  INTERVENTION 2: Lapatinib 1500 mg ",
        "premise_nums": [
            "50 mg orally",
            "50 mg Patients",
            "21 of each",
            "3 weeks per",
            "2 treatment courses",
            "1 to Day"
        ]
    },
    {
        "id": "6d9113b4-9d18-4a1b-bc78-cc3ac1150876",
        "primaryId": "NCT01572038",
        "secondaryId": "NCT00826267",
        "label": "Entailment",
        "statement_text": "Each patient in the primary trial receives 3 different drugs  whereas in the secondary trial patients receive 1 of 2 possible drugs ",
        "statement_nums": [
            "1 of 2",
            "3 different drugs"
        ],
        "premise_text": "Patients received continuous daily dosing with Lapatinib 1500 mg orally from Day 1 to Day 21 of each treatment course  2 treatment courses were to be given in the trial ",
        "premise_nums": [
            "21 of each",
            "1500 mg orally",
            "2 treatment courses",
            "1 to Day"
        ]
    },
    {
        "id": "99599b71-85d7-4c15-8d23-4294732f87cf",
        "primaryId": "NCT00558103",
        "statement_text": "All participants in the primary trial are administered with Lapatinib 1500 mg PO QD ",
        "statement_nums": [
            "1500 mg PO"
        ],
        "label": "Entailment",
        "premise_text": "INTERVENTION 1: Cohort 1: Lapatinib 1500 mg + Pazopanib Placebo Participants received oral lapatinib 1500 milligrams (mg) (6 x 250 mg tablets) in combination with placebo (matching to pazopanib; 2 tablets) once daily (QD)  INTERVENTION 2: Cohort 1: Lapatinib 1500 mg + Pazopanib 800 mg Participants received oral lapatinib 1500 mg (6 x 250 mg tablets) in combination with pazopanib 800 mg (2 x 400 mg tablets) QD  ",
        "premise_nums": [
            "800 mg (2",
            "1500 milligrams (mg)",
            "6 x 250",
            "1500 mg (6",
            "800 mg Participants",
            "250 mg tablets)",
            "400 mg tablets)"
        ]
    },
    {
        "id": "adbc193f-ffd6-49ce-9acd-7b1675adf0c0",
        "primaryId": "NCT00768222",
        "statement_text": "Rachel is 19 years old and has skin ulcerations and allergic reactions to triclosan  she cannot take part in the primary trial ",
        "statement_nums": [
            "19 years old"
        ],
        "label": "Entailment",
        "premise_text": "Inclusion Criteria: 18 years of age or older with written informed consent Exclusion Criteria: Has inflammatory cancers or skin ulceration Has known allergy or intolerance to triclosan ",
        "premise_nums": [
            "18 years of"
        ]
    },
    {
        "id": "c476f92a-a450-4e5c-9688-6557ff3d822b",
        "primaryId": "NCT01617668",
        "statement_text": "Patients must have healthy kidneys  liver and ovaries to participate in the primary trial ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria: Histologically confirmed diagnosis of invasive triple negative breast cancer Known status for the LCL161 predictive gene expression signature as determined during molecular pre-screening Candidates for mastectomy or breast-conserving surgery Primary tumor of greater than 20 mm and less than or equal to 50 mm diameter measured by imaging (previous Amendment #3 was tumor size greater than 10 mm) Regional nodes N0-N2 Absence of distant metastatic disease ECOG performance status 0-1 Adequate bone marrow function Adequate liver function and serum transaminases Adequate renal function Exclusion Criteria: Bilateral or inflammatory breast cancer (bilateral mammography is required during Screening/baseline); locally recurrent breast cancer Patients currently receiving systemic therapy for any other malignancy  or having received systemic therapy for a malignancy in the preceding 3 months ",
        "premise_nums": [
            "LCL161 predictive",
            "0-N2 Absence",
            "2 Absence of",
            "50 mm diameter",
            "161 predictive gene",
            "3 was tumor",
            "0-1 Adequate",
            "1 Adequate bone",
            "20 mm and"
        ]
    },
    {
        "id": "c476f92a-a450-4e5c-9688-6557ff3d822b",
        "primaryId": "NCT01617668",
        "statement_text": "Patients must have healthy kidneys  liver and ovaries to participate in the primary trial ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Uncontrolled cardiac diseasePatients who are currently receiving chronic treatment (greater than 3 months) with corticosteroids at a dose 10 mg of prednisone (or its glucocorticoid equivalent) per day (inhaled and topical steroids are allowed)  or any other chronic immunosuppressive treatment that cannot be discontinued prior to starting study drug Impaired GI function that may affect the absorption of LCL161 Pregnant or breast feeding (lactating) women Women of child-bearing potential  defined as all women physiologically capable of becoming pregnant  unless they are using highly effective methods of contraception during dosing and for 180 days after study treatment Other protocol-defined inclusion/exclusion criteria may apply ",
        "premise_nums": [
            "10 mg of",
            "180 days after",
            "LCL161 Pregnant",
            "161 Pregnant or"
        ]
    },
    {
        "id": "39d685a4-b179-4687-a273-2a44e675f2c6",
        "primaryId": "NCT00900627",
        "statement_text": "The two groups in the primary trial receive the same drug treatment  but group 2 gets double the dose ",
        "statement_nums": [
            "2 gets double"
        ],
        "label": "Contradiction",
        "premise_text": "INTERVENTION 1: AZD8931 160 mg bd Part A: AZD8931 160mg (bd) plus weekly paclitaxel of 90mg/m2 on days 1, 8 and 15 of each 28 day cycle INTERVENTION 2: AZD8931 120 mg bd Part A: AZD8931 120mg (bd) plus weekly paclitaxel of 90mg/m2 on days 1, 8 and 15 of each 28 day cycle ",
        "premise_nums": [
            "160 mg bd",
            "90mg/m2 on",
            "28 day cycle",
            "8 and 15",
            "2 on days",
            "120 mg bd"
        ]
    },
    {
        "id": "c66963b9-19e0-4c0f-bb65-2fec15e60b8f",
        "primaryId": "NCT00965523",
        "statement_text": "The most common adverse events in the primary trial where Infection and Stomatitis  affecting a total of 14 patients ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 14/81 (17.28%) Neutropenia1/81 (1.23%) Cataract1/81 (1.23%) Ascites1/81 (1.23%) Gastritis Hemorrhagic1/81 (1.23%) Nausea1/81 (1.23%) Stomatitis2/81 (2.47%) Malaise1/81 (1.23%) Oedema1/81 (1.23%) Pain1/81 (1.23%) Pyrexia1/81 (1.23%) Infection2/81 (2.47%) Upper Limb Fracture1/81 (1.23%) Dehydration1/81 (1.23%) ",
        "premise_nums": [
            "14/81 (17.28%)",
            "2/81 (2.47%)",
            "1/81 (1.23%)"
        ]
    },
    {
        "id": "c66963b9-19e0-4c0f-bb65-2fec15e60b8f",
        "primaryId": "NCT00965523",
        "statement_text": "The most common adverse events in the primary trial where Infection and Stomatitis  affecting a total of 14 patients ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Hypercalcemia1/81 (1.23%)",
        "premise_nums": [
            "1/81 (1.23%)"
        ]
    },
    {
        "id": "f541ce25-c43e-496b-98e6-8470fe23f840",
        "primaryId": "NCT00559845",
        "secondaryId": "NCT00426556",
        "label": "Contradiction",
        "statement_text": "In total there were more adverse events in cohort 1 of the secondary trial than in cohort 2 of the primary trial ",
        "statement_nums": [
            "2 of the",
            "1 of the"
        ],
        "premise_text": "Adverse Events 1: Total: 8/54 (14.81%) Anaemia 1/54 (1.85%) Febrile Neutropenia 1/54 (1.85%) Retinopathy Hypertensive 1/54 (1.85%) Febrile Infection 1/54 (1.85%) Postoperative Wound Complication 1/54 (1.85%) Cardiac Imaging Procedure Abnormal 1/54 (1.85%) Malignant Melanoma In Situ 1/54 (1.85%) Suicide Attempt 1/54 (1.85%) Dyspnoea 1/54 (1.85%) Adverse Events 1: Total: 3/6 (50.00%) Adverse Events 2: ",
        "premise_nums": [
            "8/54 (14.81%)",
            "3/6 (50.00%)",
            "1/54 (1.85%)"
        ]
    },
    {
        "id": "f541ce25-c43e-496b-98e6-8470fe23f840",
        "primaryId": "NCT00559845",
        "secondaryId": "NCT00426556",
        "label": "Contradiction",
        "statement_text": "In total there were more adverse events in cohort 1 of the secondary trial than in cohort 2 of the primary trial ",
        "statement_nums": [
            "2 of the",
            "1 of the"
        ],
        "premise_text": "Total: 6/17 (35.29%)",
        "premise_nums": [
            "6/17 (35.29%)"
        ]
    },
    {
        "id": "dafe9dce-420e-46dc-a8ed-ac2f4c84b49b",
        "primaryId": "NCT01224678",
        "statement_text": "Intervention 2 of the primary trial resulted in a lower percentage in Mammographic Density than intervention 1.",
        "statement_nums": [
            "2 of the"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Percent Change (Between Baseline and Month 12) in Mammographic Density by the Boyd Method Compared Between Arms To evaluate change in mammographic density using the Boyd method after one year of vitamin D supplementation compared to placebo in premenopausal women  The percent change in breast density will be reported here  Time frame: 12 months Results 1: Arm/Group Title: Placebo Arm/Group Description: Patients receive oral placebo once daily for 12 months  Overall Number of Participants Analyzed: 46 Mean (Standard Deviation) Unit of Measure: percent change -3.4 (7.1) Results 2: Arm/Group Title: Vitamin D Arm/Group Description: Patients receive oral vitamin D (2000 IU) once daily for 12 months  Overall Number of Participants Analyzed: 40 Mean (Standard Deviation) ",
        "premise_nums": [
            "46 Mean (Standard",
            "40 Mean (Standard",
            "12 months Results"
        ]
    },
    {
        "id": "dafe9dce-420e-46dc-a8ed-ac2f4c84b49b",
        "primaryId": "NCT01224678",
        "statement_text": "Intervention 2 of the primary trial resulted in a lower percentage in Mammographic Density than intervention 1.",
        "statement_nums": [
            "2 of the"
        ],
        "label": "Entailment",
        "premise_text": "Unit of Measure: percent change -1.4 (11.9)",
        "premise_nums": []
    },
    {
        "id": "24d81b18-ce9c-4927-9386-9ebef969a159",
        "primaryId": "NCT00291135",
        "secondaryId": "NCT00291694",
        "label": "Entailment",
        "statement_text": "The duration of treatment in the primary trial is half as long as in the secondary trial ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Letrozole Letrozole  2.5 mg daily for six months INTERVENTION 1: Celecoxib Randomized to receive celecoxib daily for 12 months INTERVENTION 2: Placebo Randomized to receive placebo daily for 12 months ",
        "premise_nums": [
            "12 months INTERVENTION",
            "5 mg daily"
        ]
    },
    {
        "id": "0046e113-8ac5-4725-a285-e78b8c26f825",
        "primaryId": "NCT02756364",
        "statement_text": "In order to meet the inclusion criteria for the primary trial patients must have had aromatase inhibitor (AI) therapy before study entry  resulting in complete tumor response ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria: Progressive Disease (PD) during prior aromatase inhibitor (AI) therapy  ",
        "premise_nums": []
    },
    {
        "id": "e90f7748-f4b4-4822-8768-586c3f2f9980",
        "primaryId": "NCT00499083",
        "secondaryId": "NCT03045653",
        "label": "Contradiction",
        "statement_text": "In order to be eligible for both the secondary trial and the primary trial  patients must be female  over the age of 18, ECOG smaller than 2 and have Histologically confirmed HER2 + breast cancer ",
        "statement_nums": [
            "2 and have"
        ],
        "premise_text": "HER2/neu-negative tumor by IHC Female ECOG performance status 0-1 Inclusion Criteria: ",
        "premise_nums": [
            "0-1 Inclusion",
            "1 Inclusion Criteria:",
            "2/neu-negative tumor"
        ]
    },
    {
        "id": "fb8f09d6-c393-4943-bc67-fa0f0a6bdd86",
        "primaryId": "NCT00429572",
        "secondaryId": "NCT02455453",
        "label": "Contradiction",
        "statement_text": "post-menopausal patients are excluded from the secondary trial  but eligible for the primary trial ",
        "statement_nums": [],
        "premise_text": "Inclusion Criteria: Recurrent or residual metastatic breast carcinoma Zubrod performance status less than 2 18-60 years old Related donor human leukocyte antigen (HLA)-compatible for allogeneic transplantation or unrelated HLA-compatible donor  No major organ dysfunction or active infection Exclusion Criteria: None Inclusion Criteria: Patient must be postmenopausal defined as meeting one or more of the following: ",
        "premise_nums": [
            "60 years old",
            "2 18-60 years"
        ]
    },
    {
        "id": "3c3fb5e3-1994-455a-bae4-6d267c5c89d7",
        "primaryId": "NCT00932373",
        "statement_text": "Patients with Grade I peripheral neuropathy or above are eliminated from participation in the primary trial ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Exclusion Criteria: Grade 2 peripheral neuropathy ",
        "premise_nums": [
            "2 peripheral neuropathy"
        ]
    },
    {
        "id": "2ecd62df-f5ea-417d-8783-2174a6d77087",
        "primaryId": "NCT03573804",
        "secondaryId": "NCT02781051",
        "label": "Contradiction",
        "statement_text": "Participants of the primary trial must undergo at least one MRI during the intervention and a strict chemotherapy regiment  whereas in the secondary trial patients must use a fitbit ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Prone to Supine MRI Evaluated by Radiologist A Radiologist A  number of participants successfully segmented INTERVENTION 2: Prone to Supine MRI Evaluated by Radiologist B Radiologist B  number of participants successfully segmented INTERVENTION 1: Physical Activity Intervention Participants will participate in a multi-component physical activity intervention for 12 weeks with a 6 month follow up  Print-based education: Subjects were given a copy of Exercise for Health: An Exercise Guide for Breast Cancer Survivors  Topics covered within the book include benefits of exercise; recommendations on type  duration  frequency and intensity of exercise; goal-setting; and advice on overcoming barriers  Fitbit: Subjects were provided with a Fitbit and instructed to wear the device daily  ",
        "premise_nums": [
            "6 month follow",
            "12 weeks with"
        ]
    },
    {
        "id": "2ecd62df-f5ea-417d-8783-2174a6d77087",
        "primaryId": "NCT03573804",
        "secondaryId": "NCT02781051",
        "label": "Contradiction",
        "statement_text": "Participants of the primary trial must undergo at least one MRI during the intervention and a strict chemotherapy regiment  whereas in the secondary trial patients must use a fitbit ",
        "statement_nums": [],
        "premise_text": "Active Living counseling: The Active Living counseling program consists of 12 weekly group educational sessions  These sessions involved discussion of topics related to increasing physical activity  including: identifying and overcoming barriers  setting goals  and time management Facility Access: Subjects will have access to the exercise lab in the UT Southwestern Depression Center consisting of equipment for aerobic exercise (treadmills  stationary bikes  etc.)  ",
        "premise_nums": [
            "12 weekly group"
        ]
    },
    {
        "id": "b43c02bf-c4b0-495f-b7ba-879f409cb685",
        "primaryId": "NCT01781299",
        "statement_text": "all subjects in the primary trial must commit to a regular exercise schedule ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "INTERVENTION 1: AlloDerm RTU Participants within this arm will have the acellular dermal matrix AlloDerm RTU implanted at the time of tissue expander placement  AlloDerm RTU INTERVENTION 2: SurgiMend PRS Participants within this arm will have the acellular dermal matrix SurgiMend PRS implanted at the time of tissue expander placement  SurgiMend PRS ",
        "premise_nums": []
    },
    {
        "id": "fdff0cf1-a0a2-4516-bdf7-109ac7adb266",
        "primaryId": "NCT03136367",
        "secondaryId": "NCT00129935",
        "label": "Entailment",
        "statement_text": "Only patients which have been assigned as female at birth are eligible for the secondary trial and the primary trial ",
        "statement_nums": [],
        "premise_text": "Inclusion Criteria: Assigned female at birth; Exclusion Criteria: Transgender men and women; Exclusion Criteria: Males  ",
        "premise_nums": []
    },
    {
        "id": "6babfc60-5043-4f2b-9605-3e44744265e9",
        "primaryId": "NCT00398567",
        "statement_text": "80% of patients in the primary trial did not suffer any adverse events ",
        "statement_nums": [
            "80% of"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 1/4 (25.00%) ",
        "premise_nums": [
            "1/4 (25.00%)"
        ]
    },
    {
        "id": "5ca02204-6120-4b02-bf3b-fba94d6fac4f",
        "primaryId": "NCT00274469",
        "statement_text": "No more than 1% of either cohorts of the primary trial felt nauseous ",
        "statement_nums": [
            "1% of"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: NAUSEA 1/101 (0.99%) Adverse Events 2: NAUSEA 0/103 (0.00%) ",
        "premise_nums": [
            "0/103 (0.00%)",
            "1/101 (0.99%)"
        ]
    },
    {
        "id": "625c2690-ec9e-4ecc-85c0-9b5ca8467848",
        "primaryId": "NCT00836186",
        "statement_text": "Patients cannot be excluded from the primary trial on the basis of gender or ethnicity ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "INCLUSION CRITERIA: Women of all races and ethnic groups are eligible for this trial ",
        "premise_nums": []
    },
    {
        "id": "c28ad685-4c91-492a-85ab-180f37d9cef5",
        "primaryId": "NCT00290758",
        "statement_text": "There was one GU and three GI adverse events recorded in the primary trial ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 6/62 (9.68%) Musculoskeletal * 1/62 (1.61%) Mood Alteration: Depression * 1/62 (1.61%) renal - Other * 1/62 (1.61%) Obstruction  GU: Uterus * 1/62 (1.61%) Sexual * 0/62 (0.00%) Pulmonary/Upper Respiratory: Dyspnea * 1/62 (1.61%) Ulceration * 1/62 (1.61%) Adverse Events 2: Total: 1/64 (1.56%) Musculoskeletal * 0/64 (0.00%) Mood Alteration: Depression * 0/64 (0.00%) ",
        "premise_nums": [
            "0/62 (0.00%)",
            "0/64 (0.00%)",
            "1/62 (1.61%)",
            "1/64 (1.56%)",
            "6/62 (9.68%)"
        ]
    },
    {
        "id": "c28ad685-4c91-492a-85ab-180f37d9cef5",
        "primaryId": "NCT00290758",
        "statement_text": "There was one GU and three GI adverse events recorded in the primary trial ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "renal - Other * 0/64 (0.00%)Obstruction  GU: Uterus * 0/64 (0.00%) Sexual * 1/64 (1.56%) Pulmonary/Upper Respiratory: Dyspnea * 0/64 (0.00%) Ulceration * 0/64 (0.00%) ",
        "premise_nums": [
            "1/64 (1.56%)",
            "0/64 (0.00%)Obstruction"
        ]
    },
    {
        "id": "52e8d676-1744-4fdb-bab4-a553874329bd",
        "primaryId": "NCT00829166",
        "statement_text": "Female patients with Peripheral neuropathy greater than 0 are excluded from the primary trial ",
        "statement_nums": [
            "0 are excluded"
        ],
        "label": "Contradiction",
        "premise_text": "Exclusion Criteria: Peripheral neuropathy of Grade greater than /= 3 per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE)  Version 3.0 ",
        "premise_nums": [
            "3 per National"
        ]
    },
    {
        "id": "beff8878-9405-412d-af3a-0f2720275bf3",
        "primaryId": "NCT00068601",
        "secondaryId": "NCT01684215",
        "label": "Contradiction",
        "statement_text": "the primary trial and the secondary trial both use subcutaneous injections as the route of administration for their interventions ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Standard Chemotherapy Patients receive cyclophosphamide-containing chemotherapy alone  cyclophosphamide: Part of planned chemotherapy regimen INTERVENTION 2: Chemotherapy Plus Goserelin Patients receive goserelin subcutaneously once every 4 weeks beginning 1 week before start of cyclophosphamide-containing chemotherapy  Treatment continues until completion of chemotherapy in the absence of disease progression or unacceptable toxicity  cyclophosphamide: Part of planned chemotherapy regimen goserelin acetate: Given subcutaneously INTERVENTION 1: PD-0332991 100 mg: Dose Escalation Cohort ",
        "premise_nums": [
            "4 weeks beginning",
            "1 week before"
        ]
    },
    {
        "id": "beff8878-9405-412d-af3a-0f2720275bf3",
        "primaryId": "NCT00068601",
        "secondaryId": "NCT01684215",
        "label": "Contradiction",
        "statement_text": "the primary trial and the secondary trial both use subcutaneous injections as the route of administration for their interventions ",
        "statement_nums": [],
        "premise_text": "In Phase 1-Part 1, participants received single oral dose of PD-0332991 100 mg capsule in lead-in period (7 days prior to Cycle 1 Day 1), followed by PD-0332991 100 mg capsule orally once daily continuously for 21 days followed by 7 days off treatment in each cycle of 28 days  unless participants experienced disease progression or unacceptable toxicity or withdrew consent INTERVENTION 2: PD-0332991 125 mg: Dose Escalation Cohort ",
        "premise_nums": [
            "1-Part 1,",
            "7 days prior",
            "7 days off",
            "1 Day 1),",
            "21 days followed",
            "100 mg capsule"
        ]
    },
    {
        "id": "beff8878-9405-412d-af3a-0f2720275bf3",
        "primaryId": "NCT00068601",
        "secondaryId": "NCT01684215",
        "label": "Contradiction",
        "statement_text": "the primary trial and the secondary trial both use subcutaneous injections as the route of administration for their interventions ",
        "statement_nums": [],
        "premise_text": "In Phase 1-Part 1, participants received single oral dose of PD-0332991 125 mg capsule in lead-in period (7 days prior to Cycle 1 Day 1), followed by PD-0332991 125 mg capsule orally once daily continuously for 21 days followed by 7 days off treatment in each cycle of 28 days  unless participants experienced disease progression or unacceptable toxicity or withdrew consent ",
        "premise_nums": [
            "1-Part 1,",
            "125 mg capsule",
            "7 days prior",
            "7 days off",
            "1 Day 1),",
            "21 days followed"
        ]
    },
    {
        "id": "96f41881-6ba5-4688-8471-9462fc727919",
        "primaryId": "NCT00089661",
        "statement_text": "On average cohort 1 participants in the primary trial had an increased Lumbar Spine Bone Mineral Density  whereas those in cohort 2 lost mineral density ",
        "statement_nums": [
            "2 lost mineral",
            "1 participants in"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 12 Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry  Time frame: 12 months Results 1: Arm/Group Title: Denosumab 60 mg Q6M Arm/Group Description: [Not Specified] Overall Number of Participants Analyzed: 123 Least Squares Mean (95% Confidence Interval) Unit of Measure: Percent Change from Baseline 4.8 (4.3 to 5.4) Results 2: Arm/Group Title: Placebo Arm/Group Description: [Not Specified] Overall Number of Participants Analyzed: 122 Least Squares Mean (95% Confidence Interval) Unit of Measure: Percent Change from Baseline -.7 (-1.3 to -.1) ",
        "premise_nums": [
            "12 Bone Mineral",
            "12 months Results",
            "123 Least Squares",
            "95% Confidence",
            "122 Least Squares",
            "60 mg Q6M",
            "3 to 5.4)"
        ]
    },
    {
        "id": "9dbf55d5-6af3-4250-b5cb-97799cdf778a",
        "primaryId": "NCT02370238",
        "statement_text": "There were no cases of Intracranial hemorrhage in the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 13/61 (21.31%) Anaemia 1/61 (1.64%) Febrile neutropenia 1/61 (1.64%) Cardiac failure congestive 0/61 (0.00%) Pericardial effusion 0/61 (0.00%) Constipation 1/61 (1.64%) Intestinal perforation 1/61 (1.64%) Stomatitis 0/61 (0.00%) Non-cardiac chest pain 2/61 (3.28%) Condition aggravated 1/61 (1.64%) General physical health deterioration 1/61 (1.64%) Adverse Events 2: Total: 12/60 (20.00%) ",
        "premise_nums": [
            "12/60 (20.00%)",
            "1/61 (1.64%)",
            "0/61 (0.00%)",
            "13/61 (21.31%)",
            "2/61 (3.28%)"
        ]
    },
    {
        "id": "9dbf55d5-6af3-4250-b5cb-97799cdf778a",
        "primaryId": "NCT02370238",
        "statement_text": "There were no cases of Intracranial hemorrhage in the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Anaemia 1/60 (1.67%)Febrile neutropenia 0/60 (0.00%) Cardiac failure congestive 1/60 (1.67%) Pericardial effusion 1/60 (1.67%) Constipation 0/60 (0.00%) Intestinal perforation 0/60 (0.00%) Stomatitis 1/60 (1.67%) Non-cardiac chest pain 0/60 (0.00%) Condition aggravated 0/60 (0.00%) General physical health deterioration 1/60 (1.67%) ",
        "premise_nums": [
            "0/60 (0.00%)",
            "1/60 (1.67%)Febrile"
        ]
    },
    {
        "id": "e8ce8686-8d5f-4d31-b442-0cb52b7b2bec",
        "primaryId": "NCT00338728",
        "statement_text": "Participants of the primary trial higher doses of Imatinib mesylate than Letrozole  but are administered Letrozole twice as often ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "INTERVENTION 1: Letrozole and Imatinib Mesylate Imatinib mesylate 400 mg by mouth twice a day daily for 28 days and Letrozole 2.5 mg once a day daily for 28 days cycle  ",
        "premise_nums": [
            "Letrozole 2.5 mg once",
            "400 mg by",
            "28 days and",
            "28 days cycle"
        ]
    },
    {
        "id": "d72709fd-e94e-4c27-bf56-3f028c0bbd3f",
        "primaryId": "NCT01118624",
        "statement_text": "The majority of the primary trial participants achieved CR or PR ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Objective Response Rate (ORR) Tumor response evaluation was performed using RECIST 1.0 using CT/MRI  Proportion of patients achieving a CR or PR is considered in the overall response  Time frame: Assessed at the end of each even-numbered cycle (every 8 weeks)  or per standard of care but no less than 4 weeks and nor more than every 12 weeks (+/- 1 week) if treatment has ended  Results 1: Arm/Group Title: Pralatrexate Arm/Group Description: Study drug 190 mg/m^2 for 2 to 4 weeks  Overall Number of Participants Analyzed: 22 Measure Type: Number Unit of Measure: participants 1 ",
        "premise_nums": [
            "4 weeks and",
            "2 for 2",
            "22 Measure Type:",
            "RECIST 1.0 using CT",
            "190 mg/m^2",
            "2 to 4"
        ]
    },
    {
        "id": "bdf078ad-37b0-4f8f-80a3-35fa8e59fd2b",
        "primaryId": "NCT00463788",
        "statement_text": "Best Overall Response (BOR) was less than 10% higher in cohort 1 of the primary trial than in cohort 2.",
        "statement_nums": [
            "10% higher",
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Best Overall Response (BOR) Percentage of participants with best overall (objective) response based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST)  Time frame: Evaluations were performed every 6 weeks until progression reported between day of first participant randomized  20 June 2007, until cut-off date  31 July 2009 Results 1: Arm/Group Title: Cisplatin and Cetuximab ",
        "premise_nums": [
            "6 weeks until",
            "31 July 2009",
            "20 June 2007,"
        ]
    },
    {
        "id": "bdf078ad-37b0-4f8f-80a3-35fa8e59fd2b",
        "primaryId": "NCT00463788",
        "statement_text": "Best Overall Response (BOR) was less than 10% higher in cohort 1 of the primary trial than in cohort 2.",
        "statement_nums": [
            "10% higher",
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Arm/Group Description: Cisplatin 75 milligram per square meter (mg/m^2) intravenous (IV) infusion administered on Day 1 until every 3 weeks with a maximum of 6 cycles and cetuximab initially 400 mg/m^2 followed by 250 mg/m^2 IV infusion weekly  Participants who demonstrated at least stable disease (SD) up to 6 cycles of cisplatin continued treatment with cetuximab only until progressive disease (PD) or occurrence of unacceptable toxicity Overall Number of Participants Analyzed: 115 Measure Type: Number Unit of Measure: percentage of participants 20.0 (13.1 to 28.5) Results 2: Arm/Group Title: Cisplatin ",
        "premise_nums": [
            "3 weeks with",
            "1 until every",
            "2 IV infusion",
            "400 mg/m^2",
            "250 mg/m^2",
            "6 cycles of",
            "6 cycles and",
            "1 to 28.5)",
            "75 milligram per",
            "2 followed by",
            "115 Measure Type:"
        ]
    },
    {
        "id": "bdf078ad-37b0-4f8f-80a3-35fa8e59fd2b",
        "primaryId": "NCT00463788",
        "statement_text": "Best Overall Response (BOR) was less than 10% higher in cohort 1 of the primary trial than in cohort 2.",
        "statement_nums": [
            "10% higher",
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Arm/Group Description: Cisplatin 75 mg/m^2 IV infusion administered on Day 1 until every 3 weeks with a maximum of 6 cycles until the first occurrence of PD  unacceptable toxicity or withdrawal of consent Overall Number of Participants Analyzed: 58 Measure Type: Number Unit of Measure: percentage of participants 10.3 (3.9 to 21.2) ",
        "premise_nums": [
            "3 weeks with",
            "1 until every",
            "6 cycles until",
            "2 IV infusion",
            "58 Measure Type:",
            "9 to 21.2)",
            "75 mg/m^2"
        ]
    },
    {
        "id": "49f44497-2382-4658-b716-38e66c5c52b7",
        "primaryId": "NCT00425854",
        "statement_text": "Intervention of Cohort B is described as Afatinib 50 mg  taken orally  for every day of the study ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "INTERVENTION 1: Cohort B Patients with HER2-negative, ER-positive and/or PgR-positive tumours receiving oral dose of Afatinib 50 mg qd ",
        "premise_nums": [
            "50 mg qd",
            "2-negative, ER-positive"
        ]
    },
    {
        "id": "4a6dc84a-3afd-4060-b8c5-981895f31099",
        "primaryId": "NCT00312208",
        "statement_text": "Cases of Cardiomyopathy and Coagulation disorders were only observed in cohort 1 of the primary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 331/1634 (20.26%) Anemia 3/1634 (0.18%) Coagulation disorders 1/1634 (0.06%) Hemorrhage Vaginal 1/1634 (0.06%) Leukopenia 18/1634 (1.10%) Lymphadenopathy 0/1634 (0.00%) Lymphedema 0/1634 (0.00%) Pancytopenia 0/1634 (0.00%) Thrombocytopenia 0/1634 (0.00%) Arrhythmia 3/1634 (0.18%) Arrhythmia Ventricular 0/1634 (0.00%) ",
        "premise_nums": [
            "1/1634 (0.06%)",
            "3/1634 (0.18%)",
            "331/1634 (20.26%)",
            "0/1634 (0.00%)",
            "18/1634 (1.10%)"
        ]
    },
    {
        "id": "4a6dc84a-3afd-4060-b8c5-981895f31099",
        "primaryId": "NCT00312208",
        "statement_text": "Cases of Cardiomyopathy and Coagulation disorders were only observed in cohort 1 of the primary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Cardiomyopathy 1/1634 (0.06%)Adverse Events 2: Total: 520/1635 (31.80%) Anemia 5/1635 (0.31%) Coagulation disorders 0/1635 (0.00%) Hemorrhage Vaginal 0/1635 (0.00%) Leukopenia 56/1635 (3.43%) Lymphadenopathy 1/1635 (0.06%) Lymphedema 2/1635 (0.12%) Pancytopenia 1/1635 (0.06%) Thrombocytopenia 1/1635 (0.06%) Arrhythmia 3/1635 (0.18%) ",
        "premise_nums": [
            "5/1635 (0.31%)",
            "520/1635 (31.80%)",
            "0/1635 (0.00%)",
            "2/1635 (0.12%)",
            "1/1635 (0.06%)",
            "56/1635 (3.43%)",
            "1/1634 (0.06%)Adverse",
            "3/1635 (0.18%)"
        ]
    },
    {
        "id": "4a6dc84a-3afd-4060-b8c5-981895f31099",
        "primaryId": "NCT00312208",
        "statement_text": "Cases of Cardiomyopathy and Coagulation disorders were only observed in cohort 1 of the primary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Arrhythmia Ventricular 1/1635 (0.06%)Cardiomyopathy 0/1635 (0.00%) ",
        "premise_nums": [
            "0/1635 (0.00%)",
            "1/1635 (0.06%)Cardiomyopathy"
        ]
    },
    {
        "id": "11e84dc4-6573-4ad7-b2d9-cfc66b626e1c",
        "primaryId": "NCT02574455",
        "statement_text": "More than a quarter of patients in cohort 1 of the primary trial experienced an adverse event ",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 69/258 (26.74%) ",
        "premise_nums": [
            "69/258 (26.74%)"
        ]
    },
    {
        "id": "f1f2e066-a016-422f-8627-d0e477933352",
        "primaryId": "NCT00193063",
        "statement_text": "In the primary trial patient cohort  3 different types of infections are observed ",
        "statement_nums": [
            "3 different types"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 14/41 (34.15%) Cardiac ischemia/infarction 2/41 (4.88%) Duodenal ulcer 1/41 (2.44%) Vomiting 2/41 (4.88%) Fever 2/41 (4.88%) Death NOS 1/41 (2.44%) Liver failure 1/41 (2.44%) Infection - pneumonia 2/41 (4.88%) Infection - port site 2/41 (4.88%) Infection - urinary tract 1/41 (2.44%) Disease progression 3/41 (7.32%) Confusion 1/41 (2.44%) ",
        "premise_nums": [
            "2/41 (4.88%)",
            "14/41 (34.15%)",
            "1/41 (2.44%)",
            "3/41 (7.32%)"
        ]
    },
    {
        "id": "efbd87d7-f8ac-42c6-ac9a-e3a35d354885",
        "primaryId": "NCT00295867",
        "statement_text": "Patients with a Karnofsky status of 94% are eligible for the primary trial ",
        "statement_nums": [
            "94% are"
        ],
        "label": "Entailment",
        "premise_text": "Exclusion Criteria Karnofsky Performance status smaller than 90%. ",
        "premise_nums": []
    },
    {
        "id": "a604244f-789f-4c12-8c5a-96c86d1b976e",
        "primaryId": "NCT00558272",
        "statement_text": "The biggest change in Change From Baseline in Serum Beta C-terminal Cross-linking Telopeptide of Type I Collagen (betaCTX) at Week 4 observed in the primary trial was a patient in the AZD0530 175 mg group  with a -75.9 % change from baseline ",
        "statement_nums": [
            "75.9 % change",
            "4 observed in",
            "175 mg group"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Percentage Change From Baseline in Serum Beta C-terminal Cross-linking Telopeptide of Type I Collagen (betaCTX) at Week 4 Result at Week 4 minus result at baseline as a percentage of the result at baseline  based on log transformed data  Back transformation of the least squares (LS) mean  Time frame: Baseline to Week 4 Results 1: Arm/Group Title: AZD0530 175 mg Arm/Group Description: AZD0530 (saracatinib) 175 mg once daily Overall Number of Participants Analyzed: 46 Geometric Mean (95% Confidence Interval) ",
        "premise_nums": [
            "175 mg Arm",
            "95% Confidence",
            "175 mg once",
            "4 Results 1:",
            "46 Geometric Mean",
            "4 minus result",
            "4 Result at"
        ]
    },
    {
        "id": "a604244f-789f-4c12-8c5a-96c86d1b976e",
        "primaryId": "NCT00558272",
        "statement_text": "The biggest change in Change From Baseline in Serum Beta C-terminal Cross-linking Telopeptide of Type I Collagen (betaCTX) at Week 4 observed in the primary trial was a patient in the AZD0530 175 mg group  with a -75.9 % change from baseline ",
        "statement_nums": [
            "75.9 % change",
            "4 observed in",
            "175 mg group"
        ],
        "label": "Entailment",
        "premise_text": "Unit of Measure: Percentage change in betaCTX -71.1 (-75.9 to -65.4)Results 2: Arm/Group Title: Zoledronic Acid 4 mg Arm/Group Description: Zoledronic Acid 4 mg on Day 1 of the 4-week treatment period Overall Number of Participants Analyzed: 65 Geometric Mean (95% Confidence Interval) Unit of Measure: Percentage change in betaCTX -68.4 (-73.0 to -63.2) ",
        "premise_nums": [
            "65 Geometric Mean",
            "4 mg Arm",
            "4-week treatment",
            "95% Confidence",
            "4 mg on",
            "1 of the"
        ]
    },
    {
        "id": "2b543cc7-e295-4dc6-ad04-a2e43e9b3d97",
        "primaryId": "NCT01565083",
        "statement_text": "Two different types of tachycardia occurred to patients in cohort 2 of the primary trial ",
        "statement_nums": [
            "2 of the"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 2: Supraventricular tachycardia * 1/107 (0.93%) Tachycardia * 1/107 (0.93%) ",
        "premise_nums": [
            "1/107 (0.93%)"
        ]
    },
    {
        "id": "987b1da5-0276-417d-a659-8e298529ccac",
        "primaryId": "NCT01684215",
        "statement_text": "In the primary trial there was no recorded difference in the Number/percentage of Participants With Dose Limiting Toxicities taking 100 mg vs 125 mg of oral PD-0332991.",
        "statement_nums": [
            "100 mg vs",
            "125 mg of"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Number of Participants With Dose Limiting Toxicities (DLT): Part 1 Phase 1 ",
        "premise_nums": [
            "1 Phase 1"
        ]
    },
    {
        "id": "b9e8a0b3-574f-4079-9191-214af99e97a8",
        "primaryId": "NCT01176916",
        "secondaryId": "NCT00186121",
        "label": "Contradiction",
        "statement_text": "postmenopausal women with T1-4N1-3M1 Early invasive breast cancer are eligible for the primary trial  and Premenopausal women with T4-4N1-3M1 Early invasive breast cancerare eligible for the secondary trial ",
        "statement_nums": [
            "1-4N1-3M1 Early",
            "4-4N1-3M1 Early",
            "1 Early invasive"
        ],
        "premise_text": "Inclusion Criteria: The patient must be postmenopausal woman  INCLUSION CRITERIA Premenopausal  defined as any of: ",
        "premise_nums": []
    },
    {
        "id": "0151d1fa-05c8-45a0-b21e-f08478ea5110",
        "primaryId": "NCT01697345",
        "secondaryId": "NCT00513292",
        "label": "Contradiction",
        "statement_text": "Fluorouracil  testosterone  and cyclophosphamide (FEC) are used in both cohorts of the secondary trial  but not in cohort 1 of the primary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "INTERVENTION 1: FSFI Total Score (Pretest) Administered to participants prior to starting vaginal testosterone therapy  INTERVENTION 1: FEC-75 Then Paclitaxel/Trastuzumab ",
        "premise_nums": []
    },
    {
        "id": "b4b3ebdf-0e46-48fd-a57d-7d2a6c8a48de",
        "primaryId": "NCT01075100",
        "secondaryId": "NCT00290758",
        "label": "Contradiction",
        "statement_text": "several different mental health issues were observed in the primary trial and the secondary trial ",
        "statement_nums": [],
        "premise_text": "Adverse Events 1: Total: 10/48 (20.83%) NEUTROPENIA 1/48 (2.08%) THROMBOCYTOPENIA 0/48 (0.00%) VOLUME BLOOD DECREASED 1/48 (2.08%) FIBRILLATION ATRIAL 1/48 (2.08%) HYPOTENSION 1/48 (2.08%) ABDOMINAL PAIN 1/48 (2.08%) APPETITE DECREASED 0/48 (0.00%) DEHYDRATION 4/48 (8.33%) DIARRHEA 4/48 (8.33%) NAUSEA 3/48 (6.25%) VOMITING 2/48 (4.17%) FEVER 1/48 (2.08%) RIGORS 0/48 (0.00%) Adverse Events 2: ",
        "premise_nums": [
            "3/48 (6.25%)",
            "4/48 (8.33%)",
            "2/48 (4.17%)",
            "0/48 (0.00%)",
            "1/48 (2.08%)",
            "10/48 (20.83%)"
        ]
    },
    {
        "id": "b4b3ebdf-0e46-48fd-a57d-7d2a6c8a48de",
        "primaryId": "NCT01075100",
        "secondaryId": "NCT00290758",
        "label": "Contradiction",
        "statement_text": "several different mental health issues were observed in the primary trial and the secondary trial ",
        "statement_nums": [],
        "premise_text": "Total: 5/53 (9.43%)NEUTROPENIA 1/53 (1.89%) THROMBOCYTOPENIA 1/53 (1.89%) VOLUME BLOOD DECREASED 0/53 (0.00%) FIBRILLATION ATRIAL 0/53 (0.00%) HYPOTENSION 0/53 (0.00%) ABDOMINAL PAIN 0/53 (0.00%) APPETITE DECREASED 1/53 (1.89%) DEHYDRATION 0/53 (0.00%) DIARRHEA 0/53 (0.00%) NAUSEA 1/53 (1.89%) VOMITING 1/53 (1.89%) FEVER 1/53 (1.89%) RIGORS 1/53 (1.89%) Adverse Events 1: ",
        "premise_nums": [
            "1/53 (1.89%)",
            "5/53 (9.43%)NEUTROPENIA",
            "0/53 (0.00%)"
        ]
    },
    {
        "id": "b4b3ebdf-0e46-48fd-a57d-7d2a6c8a48de",
        "primaryId": "NCT01075100",
        "secondaryId": "NCT00290758",
        "label": "Contradiction",
        "statement_text": "several different mental health issues were observed in the primary trial and the secondary trial ",
        "statement_nums": [],
        "premise_text": "Total: 6/62 (9.68%)Musculoskeletal * 1/62 (1.61%) Mood Alteration: Depression * 1/62 (1.61%) renal - Other * 1/62 (1.61%) Obstruction  GU: Uterus * 1/62 (1.61%) Sexual * 0/62 (0.00%) Pulmonary/Upper Respiratory: Dyspnea * 1/62 (1.61%) Ulceration * 1/62 (1.61%) Adverse Events 2: Total: 1/64 (1.56%) Musculoskeletal * 0/64 (0.00%) Mood Alteration: Depression * 0/64 (0.00%) renal - Other * 0/64 (0.00%) ",
        "premise_nums": [
            "0/62 (0.00%)",
            "0/64 (0.00%)",
            "6/62 (9.68%)Musculoskeletal",
            "1/62 (1.61%)",
            "1/64 (1.56%)"
        ]
    },
    {
        "id": "b4b3ebdf-0e46-48fd-a57d-7d2a6c8a48de",
        "primaryId": "NCT01075100",
        "secondaryId": "NCT00290758",
        "label": "Contradiction",
        "statement_text": "several different mental health issues were observed in the primary trial and the secondary trial ",
        "statement_nums": [],
        "premise_text": "Obstruction  GU: Uterus * 0/64 (0.00%)Sexual * 1/64 (1.56%) Pulmonary/Upper Respiratory: Dyspnea * 0/64 (0.00%) Ulceration * 0/64 (0.00%) ",
        "premise_nums": [
            "1/64 (1.56%)",
            "0/64 (0.00%)Sexual"
        ]
    },
    {
        "id": "b838a265-99e4-42f0-bd72-b4f72d7eb16e",
        "primaryId": "NCT02027376",
        "statement_text": "A patient was treated with Pertuzumab for 6 months  and this treatment was discontinued less than 1 month prior to study entry and the patient has not fully recovered from the entailing side effects  hence this patient is eligible for the primary trial ",
        "statement_nums": [
            "1 month prior"
        ],
        "label": "Contradiction",
        "premise_text": "Exclusion Criteria: Patients who have received biologic therapy (e.g  antibodies) 4 weeks prior to starting study drug or who have not recovered from the side effects of such therapy  ",
        "premise_nums": [
            "4 weeks prior"
        ]
    },
    {
        "id": "240e9cb0-3e40-4478-9d2c-fb4ff22e1e21",
        "primaryId": "NCT00676793",
        "secondaryId": "NCT01931163",
        "label": "Contradiction",
        "statement_text": "Patients suffering from vomiting are still eligible for both the secondary trial and the primary trial ",
        "statement_nums": [],
        "premise_text": "Inclusion Criteria: Definitive biopsy demonstrating primary breast cancer Residual breast cancer requiring additional surgical resection Stage I  II or III disease Patient has ability to give signed informed consent Normal hepatic and renal function (creatininesmaller than 1.5, transaminases smaller than 1.5 times upper limit of normal)  ECOG Performance status of 0 or 1. Age 21 years and less than 75 Exclusion Criteria: Prior hormonal or surgical therapy for breast cancer Abnormal liver function test Liver or kidney problems that would interfere with metabolism of study drug Any condition that would hamper informed consent or ability to comply with study protocol Participation in another research study in the last three months Known malignancy at any site other than breast Recent consumption of green tea (5 or more cups per day  within one week prior to biopsy) ",
        "premise_nums": [
            "21 years and",
            "0 or 1.",
            "75 Exclusion Criteria:",
            "5 or more",
            "than 1.5 times upper"
        ]
    },
    {
        "id": "240e9cb0-3e40-4478-9d2c-fb4ff22e1e21",
        "primaryId": "NCT00676793",
        "secondaryId": "NCT01931163",
        "label": "Contradiction",
        "statement_text": "Patients suffering from vomiting are still eligible for both the secondary trial and the primary trial ",
        "statement_nums": [],
        "premise_text": "Allergy or intolerance to any component of green teaInability or refusal to comply with definitive surgical therapy Inclusion Criteria: Able to swallow and retain oral medication  ",
        "premise_nums": []
    },
    {
        "id": "a1644573-fba8-4598-8353-a40d3ef1968c",
        "primaryId": "NCT00428922",
        "secondaryId": "NCT00499083",
        "label": "Entailment",
        "statement_text": "Patients with prior chemotherapy for the treatment of stage 4 cancer are not eligible for either the primary trial or the secondary trial ",
        "statement_nums": [
            "4 cancer are"
        ],
        "premise_text": "Inclusion Criteria: No prior chemotherapy in the metastatic setting  No prior chemotherapy or radiotherapy ",
        "premise_nums": []
    },
    {
        "id": "ba533122-db9d-49e1-a2d1-936c8fdfdd00",
        "primaryId": "NCT01298193",
        "statement_text": "More than 15 patients in cohort 1 of the primary trial experienced adverse events ",
        "statement_nums": [
            "15 patients in",
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 31/185 (16.76%) ",
        "premise_nums": [
            "31/185 (16.76%)"
        ]
    },
    {
        "id": "f20cd859-7159-457a-a1cb-56bdb01d521b",
        "primaryId": "NCT00274456",
        "statement_text": "There are a total of 7 cases of Gastritis in the primary trial across both cohorts ",
        "statement_nums": [
            "7 cases of"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 14/76 (18.42%) Neutropenia 10/76 (13.16%) Febrile neutropenia 1/76 (1.32%) Anaemia 0/76 (0.00%) Thrombocytopenia 0/76 (0.00%) Cardiopulmonary failure 0/76 (0.00%) Optic ischaemic neuropathy 0/76 (0.00%) Bowel peristalsis increased 1/76 (1.32%) Colitis 0/76 (0.00%) Diarrhoea 0/76 (0.00%) Gastritis 0/76 (0.00%) Nausea 0/76 (0.00%) Adverse Events 2: ",
        "premise_nums": [
            "1/76 (1.32%)",
            "0/76 (0.00%)",
            "10/76 (13.16%)",
            "14/76 (18.42%)"
        ]
    },
    {
        "id": "f20cd859-7159-457a-a1cb-56bdb01d521b",
        "primaryId": "NCT00274456",
        "statement_text": "There are a total of 7 cases of Gastritis in the primary trial across both cohorts ",
        "statement_nums": [
            "7 cases of"
        ],
        "label": "Contradiction",
        "premise_text": "Total: 12/76 (15.79%)Neutropenia 2/76 (2.63%) Febrile neutropenia 1/76 (1.32%) Anaemia 0/76 (0.00%) Thrombocytopenia 0/76 (0.00%) Cardiopulmonary failure 1/76 (1.32%) Optic ischaemic neuropathy 1/76 (1.32%) Bowel peristalsis increased 0/76 (0.00%) Colitis 1/76 (1.32%) Diarrhoea 0/76 (0.00%) Gastritis 0/76 (0.00%) Nausea 1/76 (1.32%) ",
        "premise_nums": [
            "1/76 (1.32%)",
            "0/76 (0.00%)",
            "12/76 (15.79%)Neutropenia",
            "2/76 (2.63%)"
        ]
    },
    {
        "id": "d33df923-6c12-4135-b339-5cefdd240985",
        "primaryId": "NCT00003782",
        "statement_text": "Neither of the cohorts in the primary trial had more than 5% of patients experiencing side effects ",
        "statement_nums": [
            "5% of"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 66/1748 (3.78%) Adverse Events 2: Total: 43/1748 (2.46%) ",
        "premise_nums": [
            "43/1748 (2.46%)",
            "66/1748 (3.78%)"
        ]
    },
    {
        "id": "0f49a1ec-ed73-465b-be20-b70fe990b1f0",
        "primaryId": "NCT00333775",
        "secondaryId": "NCT00201864",
        "label": "Contradiction",
        "statement_text": "There are several coagulative adverse events recorded in the primary trial  but not a single one in the secondary trial ",
        "statement_nums": [],
        "premise_text": "Adverse Events 1: Total: 82/217 (37.79%) Febrile neutropenia 21/217 (9.68%) Neutropenia 4/217 (1.84%) Leukopenia 0/217 (0.00%) Anaemia 1/217 (0.46%) Thrombocytopenia 0/217 (0.00%) Atrial fibrillation 0/217 (0.00%) Arrhythmia 1/217 (0.46%) Arteriospasm coronary 0/217 (0.00%) Atrioventricular block first degree 0/217 (0.00%) Cardiac failure 0/217 (0.00%) Adverse Events 2: Total: 106/252 (42.06%) ",
        "premise_nums": [
            "0/217 (0.00%)",
            "106/252 (42.06%)",
            "21/217 (9.68%)",
            "1/217 (0.46%)",
            "4/217 (1.84%)",
            "82/217 (37.79%)"
        ]
    },
    {
        "id": "0f49a1ec-ed73-465b-be20-b70fe990b1f0",
        "primaryId": "NCT00333775",
        "secondaryId": "NCT00201864",
        "label": "Contradiction",
        "statement_text": "There are several coagulative adverse events recorded in the primary trial  but not a single one in the secondary trial ",
        "statement_nums": [],
        "premise_text": "Febrile neutropenia 29/252 (11.51%)Neutropenia 13/252 (5.16%) Leukopenia 3/252 (1.19%) Anaemia 0/252 (0.00%) Thrombocytopenia 1/252 (0.40%) Atrial fibrillation 1/252 (0.40%) Arrhythmia 0/252 (0.00%) Arteriospasm coronary 1/252 (0.40%) Atrioventricular block first degree 1/252 (0.40%) Cardiac failure 1/252 (0.40%) Adverse Events 1: Total: 6/40 (15.00%) Nausea 1/40 (2.50%) ",
        "premise_nums": [
            "0/252 (0.00%)",
            "1/40 (2.50%)",
            "3/252 (1.19%)",
            "13/252 (5.16%)",
            "6/40 (15.00%)",
            "29/252 (11.51%)Neutropenia",
            "1/252 (0.40%)"
        ]
    },
    {
        "id": "0f49a1ec-ed73-465b-be20-b70fe990b1f0",
        "primaryId": "NCT00333775",
        "secondaryId": "NCT00201864",
        "label": "Contradiction",
        "statement_text": "There are several coagulative adverse events recorded in the primary trial  but not a single one in the secondary trial ",
        "statement_nums": [],
        "premise_text": "Vomiting 1/40 (2.50%)Chest pain 1/40 (2.50%) Hypercalcemia 1/40 (2.50%) Thromboembolism 2/40 (5.00%) ",
        "premise_nums": [
            "2/40 (5.00%)",
            "1/40 (2.50%)Chest"
        ]
    },
    {
        "id": "7370c10d-f6e7-4153-9649-9d2598ce1ed7",
        "primaryId": "NCT03196635",
        "secondaryId": "NCT01943916",
        "label": "Entailment",
        "statement_text": "the primary trial and the secondary trial are both evaluating imaging techniques ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: All Study Participants  PA Compression Image Sets All image sets (30 patient-assisted compression image sets) were evaluated for acceptability of overall clinical image quality by two (2) readers  INTERVENTION 2: All Study Participants  TC Compression Image Sets All image sets (30 TC compression image sets) were evaluated for acceptability of overall clinical image quality by two (2) readers  INTERVENTION 1: Overall Population Each subject served as her own control  with imaging of each mass by both the test and control modalities  Specificity difference is a single measure for the overall ITD population  ",
        "premise_nums": [
            "30 TC compression",
            "(2) readers"
        ]
    },
    {
        "id": "3f89537a-479e-4314-b9de-4caf845850fc",
        "primaryId": "NCT00558272",
        "statement_text": "The biggest change in Change From Baseline in Serum Beta C-terminal Cross-linking Telopeptide of Type I Collagen (betaCTX) at Week 4 observed in the primary trial was a patient in the Zoledronic Acid 4 mg group  with a -73.0 % change from baseline ",
        "statement_nums": [
            "73.0 % change",
            "4 observed in",
            "4 mg group"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Percentage Change From Baseline in Serum Beta C-terminal Cross-linking Telopeptide of Type I Collagen (betaCTX) at Week 4 Result at Week 4 minus result at baseline as a percentage of the result at baseline  based on log transformed data  Back transformation of the least squares (LS) mean  Time frame: Baseline to Week 4 Results 1: Arm/Group Title: AZD0530 175 mg Arm/Group Description: AZD0530 (saracatinib) 175 mg once daily Overall Number of Participants Analyzed: 46 Geometric Mean (95% Confidence Interval) ",
        "premise_nums": [
            "175 mg Arm",
            "95% Confidence",
            "175 mg once",
            "4 Results 1:",
            "46 Geometric Mean",
            "4 minus result",
            "4 Result at"
        ]
    },
    {
        "id": "3f89537a-479e-4314-b9de-4caf845850fc",
        "primaryId": "NCT00558272",
        "statement_text": "The biggest change in Change From Baseline in Serum Beta C-terminal Cross-linking Telopeptide of Type I Collagen (betaCTX) at Week 4 observed in the primary trial was a patient in the Zoledronic Acid 4 mg group  with a -73.0 % change from baseline ",
        "statement_nums": [
            "73.0 % change",
            "4 observed in",
            "4 mg group"
        ],
        "label": "Contradiction",
        "premise_text": "Unit of Measure: Percentage change in betaCTX -71.1 (-75.9 to -65.4)Results 2: Arm/Group Title: Zoledronic Acid 4 mg Arm/Group Description: Zoledronic Acid 4 mg on Day 1 of the 4-week treatment period Overall Number of Participants Analyzed: 65 Geometric Mean (95% Confidence Interval) Unit of Measure: Percentage change in betaCTX -68.4 (-73.0 to -63.2) ",
        "premise_nums": [
            "65 Geometric Mean",
            "4 mg Arm",
            "4-week treatment",
            "95% Confidence",
            "4 mg on",
            "1 of the"
        ]
    },
    {
        "id": "8e9f417a-dc0f-4c20-9cf7-5f8586c23df2",
        "primaryId": "NCT01985971",
        "secondaryId": "NCT03273426",
        "label": "Contradiction",
        "statement_text": "Patients will have to undergo an MRI scan of the spine for before entry for both the secondary trial and the primary trial  for the primary trial patients will also need to have a brain MR and PET imaging  after study entry ",
        "statement_nums": [],
        "premise_text": "Inclusion Criteria: Ability to undergo brain MR and PET imaging Subjects with prior resection of brain metastases with progressions on brain MRI  Inclusion Criteria: clinical and imaging complete or near-complete response on MRI ",
        "premise_nums": []
    },
    {
        "id": "8ba451be-606a-4a57-a85e-82b5e5b286fc",
        "primaryId": "NCT03366428",
        "statement_text": "3/49 the primary trial Participants With HER2-expressing Metastatic and/or Unresectable Breast Cancer had a Maximum change from baseline in QTcF of over 30 ms ",
        "statement_nums": [
            "3/49 the",
            "2-expressing Metastatic",
            "49 the primary"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Changes in QTcF After Treatment With DS-8201a in Participants With HER2-expressing Metastatic and/or Unresectable Breast Cancer The number of participants with notable electrocardiogram changes meeting predefined criteria is being reported  Time frame: Screening (within 7 days before enrollment) up to Cycle 3 Day 15 (each cycle is 21 days) Results 1: Arm/Group Title: DS-8201a Arm/Group Description: Participants who received 6.4 mg/kg of DS-8201a as an intravenous (IV) infusion once every 3 weeks on Day 1 of each 21-day cycle  Overall Number of Participants Analyzed: 49 Measure Type: Count of Participants ",
        "premise_nums": [
            "1 of each",
            "3 Day 15",
            "2-expressing Metastatic",
            "received 6.4 mg/kg",
            "7 days before",
            "3 weeks on",
            "49 Measure Type:",
            "21-day cycle"
        ]
    },
    {
        "id": "8ba451be-606a-4a57-a85e-82b5e5b286fc",
        "primaryId": "NCT03366428",
        "statement_text": "3/49 the primary trial Participants With HER2-expressing Metastatic and/or Unresectable Breast Cancer had a Maximum change from baseline in QTcF of over 30 ms ",
        "statement_nums": [
            "3/49 the",
            "2-expressing Metastatic",
            "49 the primary"
        ],
        "label": "Entailment",
        "premise_text": "Unit of Measure: Participants Maximum change from baseline in QTcF: greater than 30 ms: 3 6.1%Maximum change from baseline in QTcF: greater than 60 ms: 0 0.0% ",
        "premise_nums": [
            "3 6.1%Maximum change"
        ]
    },
    {
        "id": "46906361-5133-4db9-b9e5-b9b7f80a8666",
        "primaryId": "NCT00721630",
        "secondaryId": "NCT00364611",
        "label": "Contradiction",
        "statement_text": "the primary trial and the secondary trial recorded the same proportion of patients experiencing nausea ",
        "statement_nums": [],
        "premise_text": "Adverse Events 1: Nausea 1/23 (4.35%) Adverse Events 1: Nausea * 1/52 (1.92%) ",
        "premise_nums": [
            "1/23 (4.35%)",
            "1/52 (1.92%)"
        ]
    },
    {
        "id": "ab17f223-3f70-4b63-bfc5-1fca5d6ec05d",
        "primaryId": "NCT00121992",
        "statement_text": "In order to be eligible for the primary trial  patients must not have prior radiation  anthracycline or systemic anticancer therapy   and must have T1-3, N0 and M0 breast cancer ",
        "statement_nums": [
            "1-3, N0",
            "0 and M0"
        ],
        "label": "Entailment",
        "premise_text": "Exclusion Criteria: Prior systemic anticancer therapy for breast cancer (immunotherapy  hormonotherapy  chemotherapy)  Prior anthracycline therapy or taxoids (paclitaxel  docetaxel) for any malignancy  Prior radiation therapy for breast cancer  Any T4 or N1-3 or M1 breast cancer  ",
        "premise_nums": [
            "N1-3 or",
            "3 or M1"
        ]
    },
    {
        "id": "3320983d-55cb-49f9-9265-ca4e77acf62a",
        "primaryId": "NCT01094184",
        "statement_text": "A patient who had a Joint injection in the last month would not be eligible for the primary trial ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria: Histologically confirmed triple-negative (estrogen  progesterone  and HER-2 receptor negative) adenocarcinoma of the breast in pre- or post-menopausal women with measurable or non-measurable metastatic disease Participant who in the Investigator's opinion requires combination therapy for their disease Life expectancy of greater than or equal to (greater than /=)12 weeks Exclusion Criteria: Previous chemotherapy for metastatic breast cancer Participants currently undergoing radiation therapy for the treatment of metastatic disease (apart from the relief of metastatic bone pain) Major surgery or significant traumatic injury within 28 days prior to enrollment or anticipation of the need for major surgery during study treatment ",
        "premise_nums": [
            "2 receptor negative)",
            "12 weeks Exclusion",
            "28 days prior"
        ]
    },
    {
        "id": "6c57e451-a706-4b32-ae71-254e9d0e04de",
        "primaryId": "NCT01250379",
        "statement_text": "None of the patients in the primary trial had Thrombocytopenia  congestive Cardiac failure  Pancytopenia  Acute coronary syndrome or Atrial fibrillation ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Thrombocytopenia * 0/238 (0.00%) Pancytopenia * 0/238 (0.00%) Acute coronary syndrome * 0/238 (0.00%) Atrial fibrillation * 0/238 (0.00%) Cardiac failure congestive * 0/238 (0.00%) ",
        "premise_nums": [
            "0/238 (0.00%)"
        ]
    },
    {
        "id": "73a5f715-6d4c-43f3-ace4-9f1217d3d0c4",
        "primaryId": "NCT00383500",
        "statement_text": "the primary trial is not testing a drug based intervention  it is testing a Medical device called the Flexitouch ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "INTERVENTION 1: Flexitouch Device Lymphedema management via Flexitouch device  an intermittent pneumatic compression device (aka  lymphedema pump) INTERVENTION 2: Manual Lymphatic Drainage (MLD) Lymphedema management via self-administered manual lymphatic drainage therapy ",
        "premise_nums": []
    },
    {
        "id": "83883edd-ea16-4b20-8a97-2a545f957add",
        "primaryId": "NCT00006110",
        "secondaryId": "NCT00464646",
        "label": "Contradiction",
        "statement_text": "the secondary trial records only gastrointestinal adverse events  whereas the primary trial doesn‚Äö√Ñ√¥t record any GI adverse events ",
        "statement_nums": [],
        "premise_text": "Adverse Events 1: Total: 7/52 (13.46%) Febrile neutropenia (fever of unknown origin without clinically or microbiologically documented infe * 0/52 (0.00%) Atrial Fibrillation * 1/52 (1.92%) Sepsis * 1/52 (1.92%) Muscle weakness upper limb * 1/52 (1.92%) Dizziness * 1/52 (1.92%) Seizure * 1/52 (1.92%) Nervous system disorders - Other  specify * [1]1/52 (1.92%) Adverse Events 2: Total: 1/30 (3.33%) ",
        "premise_nums": [
            "1/52 (1.92%)",
            "1/30 (3.33%)",
            "7/52 (13.46%)",
            "0/52 (0.00%)"
        ]
    },
    {
        "id": "83883edd-ea16-4b20-8a97-2a545f957add",
        "primaryId": "NCT00006110",
        "secondaryId": "NCT00464646",
        "label": "Contradiction",
        "statement_text": "the secondary trial records only gastrointestinal adverse events  whereas the primary trial doesn‚Äö√Ñ√¥t record any GI adverse events ",
        "statement_nums": [],
        "premise_text": "Febrile neutropenia (fever of unknown origin without clinically or microbiologically documented infe * 1/30 (3.33%)Atrial Fibrillation * 0/30 (0.00%) Sepsis * 0/30 (0.00%) Muscle weakness upper limb * 0/30 (0.00%) Dizziness * 0/30 (0.00%) Seizure * 0/30 (0.00%) Nervous system disorders - Other  specify * [1]0/30 (0.00%) Adverse Events 1: Total: 16/76 (21.05%) Hemoglobin 0/76 (0.00%) Left ventricular systolic function 1/76 (1.32%) ",
        "premise_nums": [
            "0/30 (0.00%)",
            "1/30 (3.33%)Atrial",
            "1/76 (1.32%)",
            "16/76 (21.05%)",
            "0/76 (0.00%)"
        ]
    },
    {
        "id": "83883edd-ea16-4b20-8a97-2a545f957add",
        "primaryId": "NCT00006110",
        "secondaryId": "NCT00464646",
        "label": "Contradiction",
        "statement_text": "the secondary trial records only gastrointestinal adverse events  whereas the primary trial doesn‚Äö√Ñ√¥t record any GI adverse events ",
        "statement_nums": [],
        "premise_text": "Hypertension 0/76 (0.00%)Dehydration 1/76 (1.32%) Diarrhea 1/76 (1.32%) Hemorrhage  GI - stomach 0/76 (0.00%) Perforation  GI - colon 1/76 (1.32%) Ulcer  GI - stomach 0/76 (0.00%) Pain- head/headache 3/76 (3.95%) Pain- back 2/76 (2.63%) ",
        "premise_nums": [
            "3/76 (3.95%)",
            "1/76 (1.32%)",
            "0/76 (0.00%)Dehydration",
            "2/76 (2.63%)"
        ]
    },
    {
        "id": "ad0628ef-be51-4d54-a5c6-7608df258629",
        "primaryId": "NCT00895414",
        "statement_text": "Orange juice is banned for patients undertaking the primary trial ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria: Agrees not to consume grapefruit juice while on the study ",
        "premise_nums": []
    },
    {
        "id": "619d88fd-cef5-4f1a-83dc-3cc710c1c93d",
        "primaryId": "NCT00203502",
        "statement_text": "Less than 30% of patients in the primary trial experienced at least 1 adverse event ",
        "statement_nums": [
            "1 adverse event",
            "30% of"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 39/39 (100.00%) ",
        "premise_nums": [
            "39/39 (100.00%)"
        ]
    },
    {
        "id": "42d6a15e-fa43-4ebc-b627-70f4dd0233f8",
        "primaryId": "NCT00322374",
        "statement_text": "Cohort 2 of the primary trial receive a higher dose of Ixabepilone than cohort 1, but the same dose of Epirubicin ",
        "statement_nums": [
            "2 of the"
        ],
        "label": "Entailment",
        "premise_text": "INTERVENTION 1: Ixabepilone 25 mg^m2 + Epirubicin 75 mg^m2 Participants received 25 mg/m^2 Ixabepilone as a 3-hour IV infusion following a 3- to 5-minute IV infusion of 75 mg/m^2 epirubicin every 21 days  INTERVENTION 2: Ixabepilone 30 mg^m2 + Epirubicin 75 mg^m2 Participants received 30 mg/m^2 Ixabepilone as a 3-hour IV infusion following a 3- to 5-minute IV infusion of 75 mg/m^2 epirubicin every 21 days  ",
        "premise_nums": [
            "30 mg/m^2",
            "2 Ixabepilone as",
            "25 mg/m^2",
            "75 mg^m2 Participants",
            "30 mg^m2",
            "2 Participants received",
            "25 mg^m2",
            "2 epirubicin every",
            "3-hour IV",
            "5-minute IV",
            "75 mg/m^2"
        ]
    },
    {
        "id": "fc60c272-ceeb-47b5-b25b-dca832a2a57e",
        "primaryId": "NCT02203565",
        "secondaryId": "NCT00194779",
        "label": "Contradiction",
        "statement_text": "laboratory biomarker analysis and questionnaires are used in the secondary trial and the primary trial ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: Supportive Care (Dakin's Solution  Radiation Therapy) Patients apply Dakin's solution topically daily over 10 minutes within 60 minutes of radiation therapy for up to 6 weeks  Dakin's solution: Applied topically radiation therapy: Undergo radiation therapy questionnaire administration: Ancillary studies laboratory biomarker analysis: Optional correlative studies INTERVENTION 1: Treatment (Neoadjuvant Therapy  Adjuvant Therapy) See Detailed Description  doxorubicin hydrochloride: Given IV cyclophosphamide: Given PO paclitaxel: Given IV filgrastim: Given SC capecitabine: Given PO methotrexate: Given IV vinorelbine tartrate: Given IV needle biopsy: Correlative studies ",
        "premise_nums": [
            "60 minutes of",
            "10 minutes within"
        ]
    },
    {
        "id": "fc60c272-ceeb-47b5-b25b-dca832a2a57e",
        "primaryId": "NCT02203565",
        "secondaryId": "NCT00194779",
        "label": "Contradiction",
        "statement_text": "laboratory biomarker analysis and questionnaires are used in the secondary trial and the primary trial ",
        "statement_nums": [],
        "premise_text": "therapeutic conventional surgery: Undergo definitive breast surgeryimmunohistochemistry staining method: Correlative studies trastuzumab: Given IV tamoxifen citrate: Given PO letrozole: Given PO laboratory biomarker analysis: Correlative studies ",
        "premise_nums": []
    },
    {
        "id": "dfe1236f-ac29-4c1c-a287-6f46abb7703d",
        "primaryId": "NCT00810797",
        "secondaryId": "NCT00828074",
        "label": "Contradiction",
        "statement_text": "Skin infections were more common in patients in cohort 2 of the secondary trial  than in cohort 1 of the primary trial ",
        "statement_nums": [
            "2 of the",
            "1 of the"
        ],
        "premise_text": "Adverse Events 1: Skin infection * 1/36 (2.78%) Adverse Events 2: Skin infection * 0/5 (0.00%) ",
        "premise_nums": [
            "0/5 (0.00%)",
            "1/36 (2.78%)"
        ]
    },
    {
        "id": "b1060434-0f7c-4c4a-bcff-53c3124bb51e",
        "primaryId": "NCT02513472",
        "statement_text": "Cohort 1 of the primary trial produced better Objective Response Rate results than cohort 2.",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Objective Response Rate (ORR) ",
        "premise_nums": []
    },
    {
        "id": "e2862bbf-562f-4c96-abf1-fc9f07655b46",
        "primaryId": "NCT00627978",
        "statement_text": "Women with leptomeningeal metastases are unfortunately excluded from the primary trial  as this would complicate the evaluation of neurologic and other adverse events ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Exclusion Criteria Patients with known and active brain and/or leptomeningeal metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events  ",
        "premise_nums": []
    },
    {
        "id": "aed75656-1594-4d99-be42-7097f7926c18",
        "primaryId": "NCT00240071",
        "statement_text": "At least one participant of the primary trial died in under a 100 days ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Progression Free Survival (PFS) Progression free survival is defined as time from date of registration until the date of first documented disease progression or date of death from any cause  whichever occurs first  Time frame: From date of registration until disease progression or death  whichever occurs first Results 1: Arm/Group Title: Avastin (Bevacizumab) Plus Hormone Arm/Group Description: All patients received Avastin (Bevacizumab) 15 mg/kg IV every three weeks as well as continuing with hormonal therapy they previously were taking  Overall Number of Participants Analyzed: 30 Median (95% Confidence Interval) Unit of Measure: days 125.5 (90 to 256) ",
        "premise_nums": [
            "90 to 256)",
            "95% Confidence",
            "15 mg/kg IV"
        ]
    },
    {
        "id": "6ce5a9d7-5793-43b0-92ed-980cca3be02b",
        "primaryId": "NCT01961544",
        "statement_text": "the primary trial reported a combined total of 3 cases of Pericardial effusion  Asthenia and Gastritis in cohort 1.",
        "statement_nums": [
            "3 cases of"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Pericardial effusion * 2/101 (1.98%) Gastritis * 1/101 (0.99%) Asthenia * 1/101 (0.99%) ",
        "premise_nums": [
            "2/101 (1.98%)",
            "1/101 (0.99%)"
        ]
    },
    {
        "id": "b2a4f905-c6b5-4977-95de-5aa6424a5bb6",
        "primaryId": "NCT00217399",
        "statement_text": "To be included in the primary trial  patients must have at least 1 unidimensionally measurable lesion  there are no size boundaries for eligibility ",
        "statement_nums": [
            "1 unidimensionally measurable"
        ],
        "label": "Contradiction",
        "premise_text": "Measurable disease  defined as greater than or equal 1 unidimensionally measurable lesion  including greater than or equal 1 of the following: Lesion greater than or equal 10 mm on CT scan (5 mm sections) Lesion greater than or equal 20 mm on CT scan or MRI (10 mm sections) Lesion greater than or equal 10 mm on physical exam ",
        "premise_nums": [
            "1 unidimensionally measurable",
            "10 mm on",
            "10 mm sections)",
            "20 mm on",
            "5 mm sections)",
            "1 of the"
        ]
    },
    {
        "id": "a611e8dd-cafc-46dd-b8ed-3fa7c5f5a7b4",
        "primaryId": "NCT00591851",
        "statement_text": "There were 4 different Gastrointestinal adverse events recorded in cohort 1 of the primary trial ",
        "statement_nums": [
            "4 different Gastrointestinal",
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Abdominal Pain 2/70 (2.86%) Diarrhea 21/70 (1.43%) Lower gastrointestinal hemorrhage 21/70 (1.43%) Nausea 21/70 (1.43%) ",
        "premise_nums": [
            "2/70 (2.86%)",
            "21/70 (1.43%)"
        ]
    },
    {
        "id": "4db02d9b-d96e-4ced-947c-71cebcccc933",
        "primaryId": "NCT00847171",
        "secondaryId": "NCT01764022",
        "label": "Entailment",
        "statement_text": "Sufferers of Systemic lupus erythematosus are excluded from the primary trial but may still be eligible for the secondary trial ",
        "statement_nums": [],
        "premise_text": "No prior or currently active autoimmune disease* requiring management with systemic immunosuppression  including any of the following: Systemic lupus erythematosus Inclusion Criteria: Written informed consent and ability to follow the Protocol procedures; Age from 18 years to 75 years inclusive; Female gender; Histologically confirmed breast cancer (BC); Metastatic BC (stage IV according to TNM classification version 6); Grade 3+ HER2 overexpression confirmed by immunohistochemical (IHC) staining or grade 2+ HER2 overexpression accompanied by HER2 gene amplification confirmed by fluorescent hybridization in situ (FISH) ; Documented results of oestrogen and progesterone receptors expression analysis; ",
        "premise_nums": [
            "75 years inclusive;",
            "2 overexpression confirmed",
            "2 gene amplification",
            "2 overexpression accompanied",
            "18 years to"
        ]
    },
    {
        "id": "4db02d9b-d96e-4ced-947c-71cebcccc933",
        "primaryId": "NCT00847171",
        "secondaryId": "NCT01764022",
        "label": "Entailment",
        "statement_text": "Sufferers of Systemic lupus erythematosus are excluded from the primary trial but may still be eligible for the secondary trial ",
        "statement_nums": [],
        "premise_text": "Eastern Cooperative Oncology Group (ECOG) status 0, 1 or 2, not increasing within 2 weeks prior to randomization;Life expectancy - 20 weeks or more from the moment of randomization; Presence of at least 1 tumour with a size not less than 1 cm (revealed with computed tomography (CT) slice thickness not more than 5 mm)  Patients having bone metastasis as the only measurable tumour are not eligible for the trial; Patients of childbearing potential must implement reliable contraceptive measures during the study treatment  starting 4 weeks prior to inclusion into the trial and until 6 months after the last administration of the study drug  Exclusion Criteria: ",
        "premise_nums": [
            "1 tumour with",
            "6 months after",
            "1 or 2,",
            "1 cm (revealed",
            "4 weeks prior",
            "20 weeks or",
            "2 weeks prior"
        ]
    },
    {
        "id": "4db02d9b-d96e-4ced-947c-71cebcccc933",
        "primaryId": "NCT00847171",
        "secondaryId": "NCT01764022",
        "label": "Entailment",
        "statement_text": "Sufferers of Systemic lupus erythematosus are excluded from the primary trial but may still be eligible for the secondary trial ",
        "statement_nums": [],
        "premise_text": "Previous anticancer therapy for metastatic BC  including cytotoxic chemotherapy  or previous anticancer therapy with signal transduction inhibitors (e.g  lapatinib)  biological drugs (e.g  trastuzumab  bevacizumab)  experimental (not approved for BC therapy) anticancer drugs  Any previous hormonal therapy is allowed;Disease progression within 6 months after adjuvant and/or neoadjuvant anti BC therapy; Surgery  radiation therapy  use of any experimental medications within 4 weeks (28 days) prior to randomization; ",
        "premise_nums": [
            "6 months after",
            "4 weeks (28"
        ]
    },
    {
        "id": "4db02d9b-d96e-4ced-947c-71cebcccc933",
        "primaryId": "NCT00847171",
        "secondaryId": "NCT01764022",
        "label": "Entailment",
        "statement_text": "Sufferers of Systemic lupus erythematosus are excluded from the primary trial but may still be eligible for the secondary trial ",
        "statement_nums": [],
        "premise_text": "Hypersensitivity to paclitaxel and all medications containing polyoxyethylated castor oil  hypersensitivity to dexamethasone  diphenhydramine  ranitidine/cimetidine  recombinant murine proteins  contrast agents or excipients of study medications;BC metastases in central nervous system  progressing or clinically manifested (e.g  cerebral oedema  spinal cord injury)  with exception of non-progressing metastases not requiring treatment with glucocorticosteroids and/or anticonvulsants within 4 weeks prior to randomization; ",
        "premise_nums": [
            "4 weeks prior"
        ]
    },
    {
        "id": "4db02d9b-d96e-4ced-947c-71cebcccc933",
        "primaryId": "NCT00847171",
        "secondaryId": "NCT01764022",
        "label": "Entailment",
        "statement_text": "Sufferers of Systemic lupus erythematosus are excluded from the primary trial but may still be eligible for the secondary trial ",
        "statement_nums": [],
        "premise_text": "Cardiovascular system pathology (congestive heart failure (CHF) stage III-IV according to New York Heart Association (NYHA) classification  unstable angina pectoris  myocardial infarction) within 12 months prior to randomization;Uncontrolled hypertension comprising all cases of arterial hypertension when no decrease in blood pressure could be achieved despite treatment with a combination of 3 antihypertensive drugs including one diuretic and non-medicamental correction methods (low salt diet  physical exercise); Left ventricular ejection fraction smaller than 50% according to electrocardiography; Neutrophils 1500/mm3; Platelets 100 000/mm3; Hemoglobin 90 g/L; ",
        "premise_nums": [
            "50% according",
            "000/mm3; Hemoglobin",
            "90 g/L;",
            "1500/mm3; Platelets",
            "12 months prior",
            "3 antihypertensive drugs"
        ]
    },
    {
        "id": "4db02d9b-d96e-4ced-947c-71cebcccc933",
        "primaryId": "NCT00847171",
        "secondaryId": "NCT01764022",
        "label": "Entailment",
        "statement_text": "Sufferers of Systemic lupus erythematosus are excluded from the primary trial but may still be eligible for the secondary trial ",
        "statement_nums": [],
        "premise_text": "Creatinine level 1.5 × upper limit of normal (ULN);Bilirubin level 1.5 × ULN; Asparagine transferase (AST) and alanine transferase (ALT) levels 2.5 × ULN (5 × ULN for patients with liver metastases); Alkaline phosphatase level 5 × ULN; Pregnancy or lactation; Any other concomitant cancer including contralateral breast cancer revealed within 5 years prior to screening  except curatively treated intraductal carcinoma in situ  curatively treated cervical carcinoma in situ or curatively treated basal cell or squamous cell carcinoma; ",
        "premise_nums": [
            "5 years prior"
        ]
    },
    {
        "id": "4db02d9b-d96e-4ced-947c-71cebcccc933",
        "primaryId": "NCT00847171",
        "secondaryId": "NCT01764022",
        "label": "Entailment",
        "statement_text": "Sufferers of Systemic lupus erythematosus are excluded from the primary trial but may still be eligible for the secondary trial ",
        "statement_nums": [],
        "premise_text": "Conditions limiting patient's adherence to protocol requirements (dementia  neurologic or psychiatric disorders  drug addiction  alcoholism and others);Stage II-IV neuropathy according to Common Terminology Criteria for Adverse Events (CTCAE) v.4.0; Concomitant participation in other clinical trials  previous participation in other clinical trials within 30 days before entering into the trial  previous participation in the same trial; Acute or active chronic infections; Hepatitis C virus  hepatitis B virus  HIV or syphilis infections; Obstacles in intravenous administration of study drugs ",
        "premise_nums": [
            "30 days before"
        ]
    },
    {
        "id": "cfb07772-e485-491c-8ae3-9009e3d04415",
        "primaryId": "NCT00201864",
        "statement_text": "One patient in the primary trial had a WBC count far below normal ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 6/40 (15.00%) Nausea 1/40 (2.50%) Vomiting 1/40 (2.50%) Chest pain 1/40 (2.50%) Hypercalcemia 1/40 (2.50%) Thromboembolism 2/40 (5.00%) ",
        "premise_nums": [
            "2/40 (5.00%)",
            "6/40 (15.00%)",
            "1/40 (2.50%)"
        ]
    },
    {
        "id": "a283b69c-0f36-4773-a711-9e6088a8ee63",
        "primaryId": "NCT01712009",
        "secondaryId": "NCT00343382",
        "label": "Entailment",
        "statement_text": "Cohort 2 patients in the primary trial receive naproxen at the same frequency as cohort 2 patients in the secondary trial receive Pilocarpine ",
        "statement_nums": [
            "2 patients in"
        ],
        "premise_text": "INTERVENTION 2: Naproxen 500 mg BID Participants received adjuvant or neoadjuvant chemotherapy and pegfilgrastim in addition to prophylactic naproxen 500 mg orally twice a day (BID) for 5 days in each of the 4 cycles  beginning on the day of pegfilgrastim administration  INTERVENTION 2: Pilocarpine 2 Times Per Day Patients receive 5mg of Pilocarpine 2 times per day for 6 weeks  ",
        "premise_nums": [
            "500 mg orally",
            "500 mg BID",
            "5 days in",
            "2 Times Per",
            "2 times per"
        ]
    },
    {
        "id": "8d90d538-3b56-48dd-bd58-007d266c923c",
        "primaryId": "NCT00915018",
        "statement_text": "The only cases of cardiac problems in the primary trial occurred in cohort 1.",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 67/240 (27.92%) Anaemia 0/240 (0.00%) Febrile neutropenia 1/240 (0.42%) Leukopenia 2/240 (0.83%) Neutropenia 1/240 (0.42%) Thrombocytopenia 0/240 (0.00%) Atrial fibrillation 0/240 (0.00%) Cardiac failure congestive 2/240 (0.83%) Cardiac tamponade 1/240 (0.42%) Cardio-respiratory arrest 1/240 (0.42%) Left ventricular dysfunction 0/240 (0.00%) Adverse Events 2: Total: 56/234 (23.93%) ",
        "premise_nums": [
            "2/240 (0.83%)",
            "1/240 (0.42%)",
            "56/234 (23.93%)",
            "0/240 (0.00%)",
            "67/240 (27.92%)"
        ]
    },
    {
        "id": "8d90d538-3b56-48dd-bd58-007d266c923c",
        "primaryId": "NCT00915018",
        "statement_text": "The only cases of cardiac problems in the primary trial occurred in cohort 1.",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Anaemia 1/234 (0.43%)Febrile neutropenia 0/234 (0.00%) Leukopenia 0/234 (0.00%) Neutropenia 0/234 (0.00%) Thrombocytopenia 1/234 (0.43%) Atrial fibrillation 1/234 (0.43%) Cardiac failure congestive 0/234 (0.00%) Cardiac tamponade 0/234 (0.00%) Cardio-respiratory arrest 0/234 (0.00%) Left ventricular dysfunction 1/234 (0.43%) ",
        "premise_nums": [
            "1/234 (0.43%)Febrile",
            "0/234 (0.00%)"
        ]
    },
    {
        "id": "fa0fe1a0-2b89-4b78-8fdb-04dee84b4421",
        "primaryId": "NCT00904033",
        "secondaryId": "NCT03592121",
        "label": "Entailment",
        "statement_text": "Patients are not required to be sexually active to receive the primary trial intervention  this is however a requirement for the secondary trial ",
        "statement_nums": [],
        "premise_text": "INTERVENTION 1: No Exercise Multivitamin Arm + Calcitriol Arm:Calcitriol pill taken once per week INTERVENTION 2: Exercise Exercise Arm: Exercise consisting of progressive walking and resistance band training Calcitriol+ Exercise Arm: Calcitriol pill taken once per week + Exercise INTERVENTION 1: AB-101 Apply to both nipple/areola regions approximately 1 hour prior to sexual activity AB-101: Apply approximately 1 hour prior to sexual activity INTERVENTION 2: Placebo Apply to both nipple/areola regions approximately 1 hour prior to sexual activity Placebo: Apply approximately 1 hour prior to sexual activity ",
        "premise_nums": [
            "1 hour prior",
            "101 Apply to"
        ]
    },
    {
        "id": "8502cb9e-e382-41bc-b547-02d2d7beb381",
        "primaryId": "NCT00620373",
        "statement_text": "the primary trial tests two different breast imaging modalities  namely X-ray and gamma imaging ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "INTERVENTION 1: Mammography Only For this reporting arm  the interpretation and analysis was done with mammography only  INTERVENTION 2: Gamma Imaging For this reporting arm  the interpretation and analysis was done with gamma imaging only  ",
        "premise_nums": []
    },
    {
        "id": "f6c64bb3-1836-4685-8541-8856f003524b",
        "primaryId": "NCT01105312",
        "statement_text": "Patients with non-measurable diseases are only eligible for phase I of the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Measurable or non-measurable disease for phase I study (The Phase I portion of this study closed and the Phase II portion of the study opened as per NCCTG Addendum 6, effective January 23, 2012.) Measurable disease only for phase II study ",
        "premise_nums": []
    },
    {
        "id": "79272218-91b9-4331-ba44-6a3709a13f62",
        "primaryId": "NCT00073528",
        "secondaryId": "NCT00191152",
        "label": "Entailment",
        "statement_text": "the secondary trial and the primary trial study the Progression Free Survival (PFS) of their participants  however they use different Units of Measure ",
        "statement_nums": [],
        "premise_text": "Outcome Measurement: Number of Participants With Progression Free Survival (PFS) in the Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced or Metastatic Breast Cancer as Assessed by the Investigator Measure Type: Count of Participants Unit of Measure: Participants 89 82.4% Outcome Measurement: Time to Disease Progression (Initial Treatment) Median (95% Confidence Interval) Unit of Measure: months 9.28 (7.73 to 10.79) ",
        "premise_nums": [
            "73 to 10.79)",
            "95% Confidence",
            "89 82.4% Outcome Measurement"
        ]
    },
    {
        "id": "97e3b0d7-3320-4eb5-bc42-5031db87692e",
        "primaryId": "NCT01964924",
        "secondaryId": "NCT00524303",
        "label": "Contradiction",
        "statement_text": "the primary trial and the secondary trial both report Objective Response Rate (ORR) of their patients ",
        "statement_nums": [],
        "premise_text": "Outcome Measurement: Objective Response Rate (ORR)  Defined as the Proportion of Patients Who Have Had a Partial Response (PR) or Complete Response (CR) (RECIST 1.1 Based) Within the First 6 Months After Initiation of Therapy With Trametinib Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR)  Disappearance of all target lesions; Partial Response (PR)  greater than or equal 30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR  Time frame: 6 months Outcome Measurement: Percentage of Participants With Overall Pathological Complete Response (pCR) After 26 Weeks of Therapy ",
        "premise_nums": [
            "30% decrease",
            "26 Weeks of",
            "6 months Outcome",
            "6 Months After"
        ]
    },
    {
        "id": "97e3b0d7-3320-4eb5-bc42-5031db87692e",
        "primaryId": "NCT01964924",
        "secondaryId": "NCT00524303",
        "label": "Contradiction",
        "statement_text": "the primary trial and the secondary trial both report Objective Response Rate (ORR) of their patients ",
        "statement_nums": [],
        "premise_text": "A pCR in the breast was defined as no pathologic evidence of invasive disease (residual ductal carcinoma in situ [DCIS] or lobular carcinoma in situ [LCIS] was allowed)  A pCR in the axillary lymph node(s) was defined as no evidence of breast cancer cells in the lymph node (including subcapsular sinus)  Overall pCR was defined as the sum of pCR in the breast and pCR in the lymph nodes  26 weeks of therapy comprised the 2-week run-in phase  12 weeks of treatment with FEC  and 12 weeks of treatment with Paclitaxel Time frame: Week 26 ",
        "premise_nums": [
            "2-week run-in",
            "12 weeks of",
            "26 weeks of"
        ]
    },
    {
        "id": "83251670-803e-4fec-a5cf-50f052932752",
        "primaryId": "NCT00708214",
        "statement_text": "All Participants with disease progression (After 16 Weeks of Treatment) in the primary trial were in the Afatinib 50 mg With Letrozole group ",
        "statement_nums": [
            "50 mg With",
            "16 Weeks of"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Percentage of Progression Free Participants After 16 Weeks of Treatment Progression was defined according to 1 of the following criteria: New bone lesion(s) on bone scan or on magnetic resonance imaging; Progression or occurrence of new lesion(s) according to the Response Evaluation Criteria In Solid Tumours version 1.0 (RECIST); an increase in tumour marker CA 15.3 of more than 20 percent,compared with baseline  at 2 consecutive examinations; occurrence of disease-related skeletal events  If a patient did not fulfil any criteria and was withdrawn because of clinical deterioration amounting to PD according to the Investigator  they were considered as having PD  Time frame: 16 weeks Results 1: Arm/Group Title: Afatinib 50 mg With Letrozole ",
        "premise_nums": [
            "CA 15.3 of more",
            "16 Weeks of",
            "50 mg With",
            "2 consecutive examinations;",
            "1 of the",
            "16 weeks Results"
        ]
    },
    {
        "id": "83251670-803e-4fec-a5cf-50f052932752",
        "primaryId": "NCT00708214",
        "statement_text": "All Participants with disease progression (After 16 Weeks of Treatment) in the primary trial were in the Afatinib 50 mg With Letrozole group ",
        "statement_nums": [
            "50 mg With",
            "16 Weeks of"
        ],
        "label": "Contradiction",
        "premise_text": "Arm/Group Description: Patients received continuous daily dosing with Afatinib 50 mg therapy with letrozole 2.5 mg over 28-day treatment cycles until further disease progression Overall Number of Participants Analyzed: 7 Measure Type: Number Unit of Measure: Percentage of participants 28.57 (3.67 to 70.96) Results 2: Arm/Group Title: Afatinib 40 mg With Letrozole Arm/Group Description: Patients received continuous daily dosing with Afatinib 40 mg therapy with letrozole 2.5 mg over 28-day treatment cycles until further disease progression  Overall Number of Participants Analyzed: 13 Measure Type: Number Unit of Measure: Percentage of participants 0.00 (0.00 to 24.71) ",
        "premise_nums": [
            "50 mg therapy",
            "40 mg With",
            "13 Measure Type:",
            "67 to 70.96)",
            "letrozole 2.5 mg over",
            "00 to 24.71)",
            "40 mg therapy",
            "7 Measure Type:",
            "28-day treatment"
        ]
    },
    {
        "id": "efd950a8-ae79-4d4a-9ce7-3f1d0a37e6de",
        "primaryId": "NCT01610284",
        "statement_text": "1 patient in the primary trial had an abrupt loss of heart function ",
        "statement_nums": [
            "1 patient in"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 146/573 (25.48%) Anaemia 4/573 (0.70%) Disseminated intravascular coagulation 0/573 (0.00%) Neutropenia 1/573 (0.17%) Thrombocytopenia 0/573 (0.00%) Acute coronary syndrome 1/573 (0.17%) Angina pectoris 1/573 (0.17%) Atrial fibrillation 2/573 (0.35%) Atrial flutter 0/573 (0.00%) Cardiac arrest 1/573 (0.17%) Cardiac failure 0/573 (0.00%) Adverse Events 2: Total: 101/570 (17.72%) ",
        "premise_nums": [
            "0/573 (0.00%)",
            "1/573 (0.17%)",
            "146/573 (25.48%)",
            "2/573 (0.35%)",
            "101/570 (17.72%)",
            "4/573 (0.70%)"
        ]
    },
    {
        "id": "efd950a8-ae79-4d4a-9ce7-3f1d0a37e6de",
        "primaryId": "NCT01610284",
        "statement_text": "1 patient in the primary trial had an abrupt loss of heart function ",
        "statement_nums": [
            "1 patient in"
        ],
        "label": "Entailment",
        "premise_text": "Anaemia 3/570 (0.53%)Disseminated intravascular coagulation 1/570 (0.18%) Neutropenia 1/570 (0.18%) Thrombocytopenia 1/570 (0.18%) Acute coronary syndrome 0/570 (0.00%) Angina pectoris 1/570 (0.18%) Atrial fibrillation 0/570 (0.00%) Atrial flutter 1/570 (0.18%) Cardiac arrest 0/570 (0.00%) Cardiac failure 1/570 (0.18%) ",
        "premise_nums": [
            "1/570 (0.18%)",
            "3/570 (0.53%)Disseminated",
            "0/570 (0.00%)"
        ]
    },
    {
        "id": "e00b0ccc-e53b-44ba-9555-b6f8d6d5e55a",
        "primaryId": "NCT01256567",
        "secondaryId": "NCT01926886",
        "label": "Entailment",
        "statement_text": "The most common adverse event in the primary trial was Febrile neutropenia (42.86%), whereas in the secondary trial it was a decrease in Ejection fraction (4.95%).",
        "statement_nums": [],
        "premise_text": "Adverse Events 1: Total: 7/7 (100.00%) Febrile neutropenia 3/7 (42.86%) Cardiac failure 1/7 (14.29%) Neutrophil count decreased 1/7 (14.29%) Muscular weakness 1/7 (14.29%) Epistaxis 1/7 (14.29%) Interstitial lung disease 1/7 (14.29%) Pleural effusion 2/7 (28.57%) Adverse Events 1: Total: 8/101 (7.92%) Vertigo * 1/101 (0.99%) ",
        "premise_nums": [
            "3/7 (42.86%)",
            "2/7 (28.57%)",
            "1/7 (14.29%)",
            "7/7 (100.00%)",
            "8/101 (7.92%)",
            "1/101 (0.99%)"
        ]
    },
    {
        "id": "e00b0ccc-e53b-44ba-9555-b6f8d6d5e55a",
        "primaryId": "NCT01256567",
        "secondaryId": "NCT01926886",
        "label": "Entailment",
        "statement_text": "The most common adverse event in the primary trial was Febrile neutropenia (42.86%), whereas in the secondary trial it was a decrease in Ejection fraction (4.95%).",
        "statement_nums": [],
        "premise_text": "Infected lymphocele * 1/101 (0.99%)Ejection fraction decreased * 5/101 (4.95%) Lymphoedema * 1/101 (0.99%) ",
        "premise_nums": [
            "1/101 (0.99%)Ejection",
            "5/101 (4.95%)"
        ]
    },
    {
        "id": "97812fde-57f3-4299-be34-dd436757adde",
        "primaryId": "NCT00093795",
        "statement_text": "Patients with cancer cells in lymph nodes above the collarbone cannot enter the primary trial ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "Inclusion Criteria: By pathologic evaluation  ipsilateral nodes must be pN1 (pN1mi, pN1a, pN1b, pN1c), pN2a, pN3a, or pN3b (only if due to microscopic involvement of internal mammary node detected by sentinel lymph node dissection and with more than 3 positive axillary lymph nodes)  ",
        "premise_nums": [
            "3 positive axillary"
        ]
    },
    {
        "id": "f37774f4-db96-4aa6-b3a1-626953faeecf",
        "primaryId": "NCT00213980",
        "secondaryId": "NCT02536339",
        "label": "Entailment",
        "statement_text": "Adequate blood  kidney  and hepatic function are required to participate in the secondary trial  however this condition is not specified in the primary trial ",
        "statement_nums": [],
        "premise_text": "Inclusion Criteria: Postmenopausal women  Stage III or axillary node positive Currently disease free of breast cancer and other invasive malignancies at the time of registration No concurrent use of bisphosphonates Exclusion Criteria: Metastatic disease Inclusion Criteria: Adequate hematologic  renal  and hepatic function ",
        "premise_nums": []
    },
    {
        "id": "4fef4cdf-53bf-4239-9d31-4710fd3edc6f",
        "primaryId": "NCT01605396",
        "statement_text": "The Ridaforolimus + Dalotuzumab + Exemestane group of the primary trial had a median PFS of over 38.43 months ",
        "statement_nums": [],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: 1. Progression-free Survival (PFS) According to Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Based on Blinded Independent Central Review (BICR) ",
        "premise_nums": []
    },
    {
        "id": "331affb2-f8e9-4a55-ac4c-62d2ecc4f80b",
        "primaryId": "NCT00181363",
        "statement_text": "The only difference between the interventions used in the primary trial is the patients position ",
        "statement_nums": [],
        "label": "Entailment",
        "premise_text": "INTERVENTION 1: Prone Prone position INTERVENTION 2: Supine Supine position ",
        "premise_nums": []
    },
    {
        "id": "a577e819-c928-4217-8743-f4809e852919",
        "primaryId": "NCT00834678",
        "statement_text": "Patients must have a white blood cell count above 1,500/mm¬¨‚â• to participate in the primary trial ",
        "statement_nums": [
            "1,500/mm¬¨‚â• to"
        ],
        "label": "Entailment",
        "premise_text": "WBC greater than 1,500/mm³ ",
        "premise_nums": [
            "1,500/mm³"
        ]
    },
    {
        "id": "bd073d05-3ba2-4898-9d86-a51951a7ad1f",
        "primaryId": "NCT01004172",
        "secondaryId": "NCT00802945",
        "label": "Contradiction",
        "statement_text": "the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions ",
        "statement_nums": [],
        "premise_text": "Outcome Measurement: Central Nervous System (CNS) Objective Response Rate Outcome Measurement: Objective Response Rate (ORR) ",
        "premise_nums": []
    }
]